

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

4 nucleic - nucleic search, using sw model

on on: February 5, 2004, 22:17:43 ; Search time 576 Seconds
(without alignments)
10240.056 Million cell updates/sec

itle: US-09-989-279-228
irect score: 2185
quence: 1 gttctccttcgcgcaaa.....aaagacaaaagtcacaaaca 2185

oring table: OLIGO NUC
Gapop 60.0 , Gapext 60.0

arched: 2552756 seqs, 1349719017 residues

rd size : 10

real number of hits satisfying chosen parameters: 1659446

imum DB seq length: 0

aximum DB seq length: 2000000000

ost-processing: Listing first 150 summaries

atabase : N Geneseq 19Jun03:*

```
1: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1980.DAT:*
2: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1981.DAT:*
3: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1982.DAT:*
4: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1983.DAT:*
5: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1984.DAT:*
6: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1985.DAT:*
7: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1986.DAT:*
8: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1987.DAT:*
9: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1988.DAT:*
10: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1989.DAT:*
11: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1990.DAT:*
12: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1991.DAT:*
13: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1992.DAT:*
14: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1993.DAT:*
15: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1994.DAT:*
16: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1995.DAT:*
17: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1996.DAT:*
18: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1997.DAT:*
19: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1998.DAT:*
20: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA1999.DAT:*
21: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2000.DAT:*
22: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT:*
23: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT:*
24: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2002.DAT:*
25: /SIDSI/gcgdata/geneseq/geneseq-emb1/NA2003.DAT:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

result No.	Score	Query Match	Length	ID	Description
1	2185	100.0	2185	21	Human PRO1111 nucl
2	2185	100.0	2185	21	Membrane-bound pro
3	2185	100.0	2185	22	Human cDNA sequenc
4	2185	100.0	2185	22	Human PRO1111 (UNQ
5	2185	100.0	2185	25	cDNA encoding huma
6	2185	100.0	2185	25	Human cDNA encodin
7	2185	100.0	2185	25	DNA encoding novel
8	2185	100.0	2185	25	Novel human secret

9	2185	100.0	2185	25	ABX80774	Human secreted/tra
10	2185	100.0	2185	25	ABX81157	Novel human secret
11	2185	100.0	2185	25	ABX90247	Human secreted/tra
12	2185	100.0	2185	25	ABX77858	Human PRO polynuci
13	2185	100.0	2185	25	ABX79454	Human secreted/tr
14	2185	100.0	2185	25	ABX64093	cDNA encoding huma
15	2185	100.0	2185	25	ABX17057	Human PRO polynuci
16	1982	90.7	2324	22	AAS28823	Human immunoglobul
17	1911	87.4	1962	22	RAA16345	Human sbgPRO331a g
18	1910	87.5	2360	20	AAK90848	cDNA clone cc359.4
19	1826	83.6	2341	21	AAA93620	Human SLIT protein
20	1778	81.4	2159	22	ABA06571	Human cDNA SEQ ID
21	1778	81.4	2159	24	ABV83908	Human polynucleoti
22	1440	65.9	2607	21	AAA93621	Human SLIT protein
23	1351	61.8	1805	21	AAC77300	Human ORFX ORF2855
24	1178	53.9	1356	21	AAA93631	Human SLIT protein
25	758	34.7	1168	22	ABA06744	Human cDNA SEQ ID
26	758	34.7	1168	22	AAS28872	Human immunoglobul
27	758	34.7	1168	24	ABV84081	Human polynucleoti
28	259	11.9	274	20	AAV88338	EST clone FX353.
29	193	8.8	257	20	AAV89165	EST clone CC359.
30	60	2.7	60	24	ABN40900	Human spliced tran
31	50	2.3	50	21	AAC58254	Human PRO1111 hybr
32	50	2.3	50	21	AAZ65183	Probe specific for
33	50	2.3	50	22	AAF44340	Human PRO1111 hybr
34	50	2.3	50	25	ABX80286	Novel human secret
35	50	2.3	50	25	ABX80790	Human secreted/tra
36	50	2.3	50	25	ABX81173	Novel human secret
37	50	2.3	50	25	ABX90263	Human secreted/tra
38	50	2.3	50	25	ABX77874	Human PRO probe #2
39	50	2.3	50	25	ABX79470	Human secreted/tr
40	50	2.3	50	25	ABX64109	Human PRO DNA prob
41	50	2.3	50	25	ABX17073	Human PRO probe #2
42	31	1.4	31	21	AAZ58323	Human PRO1111 hybr
43	31	1.4	31	22	AAF44427	Human PRO1111 hybr
44	31	1.4	31	25	ABX80436	Human secreted or
45	31	1.4	31	25	ABX80340	Human secreted/tra
46	31	1.4	31	25	ABX81323	Human secreted or
47	31	1.4	31	25	ABX90413	Human secreted/tra
48	31	1.4	31	25	ABX78024	Human PRO probe #5
49	31	1.4	31	25	ABX79620	Human secreted/tr
50	31	1.4	31	25	ABX64259	Human PRO DNA prob
51	31	1.4	31	25	ABX17223	Human PRO probe #5
52	29	1.3	39	21	AAA93644	Human mature SECK
53	29	1.3	757	21	AA43881	Human secreted exp
54	29	1.3	973	21	AAZ98019	Human secreted pro
55	29	1.3	973	22	AAZ11632	Human secreted pro
56	29	1.3	973	24	ABK69728	Human secreted pro
57	29	1.3	973	25	ACC50741	Human secreted pro
58	29	1.3	984	21	AAZ98088	Human secreted pro
59	29	1.3	984	22	AAZ11701	Human secreted pro
60	29	1.3	984	24	ABK69797	Human secreted pro
61	29	1.3	984	25	ACC50742	Human secreted pro
62	29	1.3	1002	25	ACC50471	Human secreted pro
63	29	1.3	1869	24	ABK34766	Human cDNA for nov
64	29	1.3	2083	24	ABX03572	Human nervous syst
65	29	1.3	2090	24	AAS62318	cDNA sequence #105
66	29	1.3	2316	25	ABX70472	DNA encoding human
67	29	1.3	2337	24	ABK62093	Human cDNA encodin
68	29	1.3	2450	24	ABX03571	Human leucine-rich
69	29	1.3	2493	22	AAZ21287	DNA encoding human
70	29	1.3	2756	24	ABX03577	Human cDNA encodin
71	29	1.3	3027	24	ABK62087	Human SECK 3352358
72	27	1.2	27	21	AAZ93653	Human PRO1111 reve
73	27	1.2	29	20	AAK90858	Human PRO1111 reve
74	26	1.2	26	21	AAC58322	Human secreted or
75	26	1.2	26	22	AAF44426	Human secreted/tra
76	26	1.2	26	25	ABX80435	Human secreted or
77	26	1.2	26	25	ABX80939	Human secreted/tra
78	26	1.2	26	25	ABX81322	Human secreted or
79	26	1.2	26	25	ABX90412	Human secreted/tra
80	26	1.2	26	25	ABX78023	Human PRO PCR prim
81	26	1.2	26	25	ABX79619	Human secreted/tr

C 82	26	1-2	26	25	ABX64258
C 83	26	1-2	26	25	ABX17222
C 84	24	1-1	20623	23	ABX109022
C 85	21	1-0	21	21	AAA93661
C 86	21	1-0	21	21	AAA93662
C 87	21	1-0	1593	23	ABX12811
C 88	21	1-0	3747	23	ABX12810
C 89	21	1-0	15572	22	AA57074
C 90	21	1-0	15572	23	ABX03268
C 91	20	0-9	20	21	AA58321
C 92	20	0-9	20	21	AAA93645
C 93	20	0-9	20	21	AAA93646
C 94	20	0-9	20	21	AAA93647
C 95	20	0-9	20	21	AAA93648
C 96	20	0-9	20	22	AAF44425
C 97	20	0-9	20	25	ABX80434
C 98	20	0-9	20	25	ABX80938
C 99	20	0-9	20	25	ABX81321
C 100	20	0-9	20	25	ABX81321
C 101	20	0-9	20	25	ABX78022
C 102	20	0-9	20	25	ABX79618
C 103	20	0-9	20	25	ABX64257
C 104	20	0-9	20	25	ABX17221
C 105	20	0-9	511	22	AAH29455
C 106	20	0-9	601	22	AAH10618
C 107	20	0-9	789	22	AAH08433
C 108	20	0-9	827	22	AAH08674
C 109	20	0-9	925	22	AAH32483
C 110	20	0-9	948	22	AAH17028
C 111	20	0-9	1050	24	AAF88593
C 112	20	0-9	1153	22	AAH159333
C 113	20	0-9	1178	25	ABX05231
C 114	20	0-9	1260	23	ABX20461
C 115	20	0-9	1370	23	ABX15803
C 116	20	0-9	1739	22	AAH16813
C 117	20	0-9	1748	22	AAH158821
C 118	20	0-9	1757	22	AAH64800
C 119	20	0-9	2012	24	ABX56721
C 120	20	0-9	2574	23	ABX16161
C 121	20	0-9	2656	23	ABX08375
C 122	20	0-9	2919	23	ABX16370
C 123	20	0-9	3170	23	ABX19730
C 124	20	0-9	3401	23	ABX20460
C 125	20	0-9	3434	23	ABX15802
C 126	20	0-9	3679	23	ABX04099
C 127	20	0-9	4203	24	ABX37119
C 128	20	0-9	4656	23	ABX08374
C 129	20	0-9	4888	23	ABX07063
C 130	20	0-9	4934	23	ABX18314
C 131	20	0-9	5418	23	ABX16891
C 132	20	0-9	6359	23	ABX04098
C 133	20	0-9	5565	23	ABX01922
C 134	20	0-9	7138	24	ABX28455
C 135	20	0-9	8363	23	ABX07062
C 136	20	0-9	8489	24	ABX59483
C 137	20	0-9	9044	23	ABX10014
C 138	20	0-9	10425	23	ABX13480
C 139	20	0-9	10426	23	ABX19870
C 140	20	0-9	10515	24	ABX10772
C 141	20	0-9	12099	23	ABX16890
C 142	20	0-9	13555	22	ABX18329
C 143	20	0-9	24999	22	AAK65622
C 144	20	0-9	43671	23	ABX16160
C 145	20	0-9	134525	11	AAQ04525
C 146	19	0-9	132	22	AAK65652
C 147	19	0-9	198	21	AAQ05957
C 148	19	0-9	209	21	AAQ15152
C 149	19	0-9	244	21	AAQ03719
C 150	19	0-9	248	22	AAI98905

ALIGNMENTS

Human PRO DNA PCR	RESULT 1
Human PRO PCR Prim	AAC58383
Drosophila melanog	ID AAC58383 standard; cDNA; 2185 BP.
Human SECX 3352358	XX AAC58383;
Human SECX 3352358	AC AAC58383;
Drosophila melanog	XX 29-JAN-2001 (first entry)
Drosophila melanog	XX Human PRO1111 nucleotide sequence SEQ ID NO:45.
DNA encoding Dros	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	DE XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human PRO1111 forw	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human mature SECX	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human mature SECX	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human mature SECX	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human mature SECX	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human PRO1111 forw	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human secreted or	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human secreted or	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human secreted or	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human secreted or	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human PRO PCR prim	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human secreted/tr	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human PRO DNA PCR	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human PRO PCR prim	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human breast cauce	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human neuroblastom	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human cDNA clone (XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human olfactory re	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
G-protein coupled-	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human GRC-14 cDN	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human polynucleoti	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human novel polynu	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human cDNA sequenc	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human polynucleoti	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human secreted pro	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Nucleotide sequenc	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
DNA transcription	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Nucleotide sequenc	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human small induci	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human nervous syst	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human immune/haema	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Drosophila melanog	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Total base sequenc	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human immune/haema	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human secreted pro	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human secreted pro	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human secreted pro	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
Human excretory re	XX Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;

Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth; proliferation; tumorigenesis; identification; cancer; cytostatic; neoplastic; neuroprotective; antineoplastic; immunosuppressive; immunostimulant; antiangiogenic; leukaemia; lymphoid malignancy; neuronal disorder; glioma disorder; astrocytoma disorder; angiogenic; hypothalamic disorder; glandular disorder; macrophagal disorder; epithelial disorder; stromal disorder; blastocoele disorder; inflammatory disorder; immunologic disorder; ss. Homo sapiens. WO200053755-A2. 14-SEP-2000. 06-JAN-2000; 2000WO-US00376. 08-MAR-1999; 99WO-US05028. 02-JUN-1999; 99WO-US12252. 23-JUN-1999; 99US-0141037. 07-JUL-1999; 99US-0143048. 26-JUL-1999; 99US-0145698. 30-NOV-1999; 99WO-US28313. 20-DEC-1999; 99WO-US30911. 05-JAN-2000; 2000WO-US00219. (GETH) GENENTECH INC. Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hillan KJ, Roy MA; Watanabe CK, Wood WI; WPI; 2000-572270/53. P-PSDB; AAB24073. Thirty PRO polynucleotides encoding PRO polypeptides, useful in the treatment, diagnosis and prevention of cancer - Claim 50; Fig 33; 286pp; English. The present invention describes an isolated antibody that binds to one of the human PRO proteins designated PRO212, PRO290, PRO341, PRO335, PRO619, PRO717, PRO809, PRO830, PRO848, PRO943, PRO1005, PRO1009, PRO1025, PRO1030, PRO1097, PRO1107, PRO1111, PRO1153, PRO1182, PRO1184, PRO1187, PRO1231, PRO23, PRO39, PRO334, PRO1317, PRO1710, PRO2094, PRO2145 OR PRO2198. PRO antagonists can be used to inhibit tumour cell growth. The PRO polypeptides and nucleotides are useful in the treatment, diagnosis and prevention of cancer. The antibodies and other anti-tumour compounds may be used to treat various conditions, including those characterised by overexpression and/or activation of the amplified PRO genes. Exemplary conditions or disorders to be treated with such antibodies and other compounds include benign or malignant tumours (e.g., renal, liver, kidney, pancreatic, lung, vulva, thyroid, hepatic colorectal, prostate, glioblastomas, and various head and neck tumours), leukemias and lymphoid malignancies, other disorders such as neuronal, glioma, astrocytoma, sarcomas, glioblastomas, and other glandular, macrophagal, epithelial, stromal and blastocoele disorders, and inflammatory, angiogenic and immunologic disorders. AAC58366 represent PCR primers and hybridisation probes used in the isolation of the human PRO sequences. AAC58367 to AAC58396 and AAB24057 to AAB24089 represent human PRO polynucleotide and protein sequences given in the exemplification of the present invention.

OY 2101 TTCTGTATATGCTTATATATTAAGTCTATGGCTGGTTAAAAACACAGATTATATAA 2160
 DB 2101 TTCTGTATATGCTTATATATTAAGTCTATGGCTGGTTAAAAACACAGATTATATAA 2160
 OY 2161 AATTTAAGACAAAAGTCAAAACA 2185
 DB 2161 AATTTAAGACAAAAGTCAAAACA 2185

RESULT 2
 AAZ65033
 ID AAZ65033 standard; cDNA; 2185 BP.
 XX AC AAZ65033;
 XX DT 05-APR-2000 (first entry)
 XX DE Membrane-bound protein PRO1111 encoding cDNA.
 XX KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
 KW pharmaceutical; receptor immunoadhesin; gene mapping; ss.
 XX OS Homo sapiens.
 XX PN WO9963088-A2.
 XX PD 09-DEC-1999.
 XX PF 02-JUN-1999; 99WO-US12252.
 XX PR 02-JUN-1998; 98US-0087607.
 PR 02-JUN-1998; 98US-0087609.
 PR 03-JUN-1998; 98US-0087759.
 PR 04-JUN-1998; 98US-0087827.
 PR 04-JUN-1998; 98US-0088021.
 PR 04-JUN-1998; 98US-0088025.
 PR 04-JUN-1998; 98US-0088028.
 PR 04-JUN-1998; 98US-0088029.
 PR 04-JUN-1998; 98US-0088030.
 PR 04-JUN-1998; 98US-0088033.
 PR 04-JUN-1998; 98US-0088326.
 PR 05-JUN-1998; 98US-0088167.
 PR 05-JUN-1998; 98US-0088202.
 PR 05-JUN-1998; 98US-0088212.
 PR 05-JUN-1998; 98US-0088217.
 PR 05-JUN-1998; 98US-0088655.
 PR 10-JUN-1998; 98US-0088722.
 PR 10-JUN-1998; 98US-0088730.
 PR 10-JUN-1998; 98US-0088734.
 PR 10-JUN-1998; 98US-0088738.
 PR 10-JUN-1998; 98US-0088740.
 PR 10-JUN-1998; 98US-0088741.
 PR 10-JUN-1998; 98US-0088742.
 PR 10-JUN-1998; 98US-0088810.
 PR 10-JUN-1998; 98US-0088811.
 PR 10-JUN-1998; 98US-0088824.
 PR 10-JUN-1998; 98US-0088825.
 PR 10-JUN-1998; 98US-0088826.
 PR 11-JUN-1998; 98US-0088858.
 PR 11-JUN-1998; 98US-0088861.
 PR 11-JUN-1998; 98US-0088863.
 PR 11-JUN-1998; 98US-0088876.
 PR 12-JUN-1998; 98US-0089090.
 PR 12-JUN-1998; 98US-0089105.
 PR 16-JUN-1998; 98US-0089440.
 PR 16-JUN-1998; 98US-0089512.
 PR 17-JUN-1998; 98US-0089514.
 PR 17-JUN-1998; 98US-0089532.
 PR 17-JUN-1998; 98US-0089538.
 PR 17-JUN-1998; 98US-0089598.
 PR 17-JUN-1998; 98US-0089599.
 PR 17-JUN-1998; 98US-0089600.

PR 17-JUN-1998; 98US-0089653.
 PR 18-JUN-1998; 98US-0089801.
 PR 18-JUN-1998; 98US-0089907.
 PR 18-JUN-1998; 98US-0089908.
 PR 19-JUN-1998; 98US-0089947.
 PR 19-JUN-1998; 98US-0089948.
 PR 19-JUN-1998; 98US-0089952.
 PR 22-JUN-1998; 98US-0090246.
 PR 22-JUN-1998; 98US-0090252.
 PR 22-JUN-1998; 98US-0090254.
 PR 23-JUN-1998; 98US-0090349.
 PR 23-JUN-1998; 98US-0090355.
 PR 24-JUN-1998; 98US-0090429.
 PR 24-JUN-1998; 98US-0090431.
 PR 24-JUN-1998; 98US-0090435.
 PR 24-JUN-1998; 98US-0090444.
 PR 24-JUN-1998; 98US-0090445.
 PR 24-JUN-1998; 98US-0090461.
 PR 24-JUN-1998; 98US-0090472.
 PR 24-JUN-1998; 98US-0090535.
 PR 24-JUN-1998; 98US-0090538.
 PR 24-JUN-1998; 98US-0090540.
 PR 25-JUN-1998; 98US-0090557.
 PR 25-JUN-1998; 98US-0090676.
 PR 25-JUN-1998; 98US-0090678.
 PR 25-JUN-1998; 98US-0090688.
 PR 25-JUN-1998; 98US-0090690.
 PR 25-JUN-1998; 98US-0090691.
 PR 25-JUN-1998; 98US-0090694.
 PR 25-JUN-1998; 98US-0090695.
 PR 25-JUN-1998; 98US-0090696.
 PR 26-JUN-1998; 98US-0090862.
 PR 01-JUL-1998; 98US-0091358.
 PR 01-JUL-1998; 98US-0091360.
 PR 01-JUL-1998; 98US-0091544.
 PR 02-JUL-1998; 98US-0091478.
 PR 02-JUL-1998; 98US-0091486.
 PR 02-JUL-1998; 98US-0091519.
 PR 02-JUL-1998; 98US-0091626.
 PR 02-JUL-1998; 98US-0091633.
 PR 02-JUL-1998; 98US-0091646.
 PR 02-JUL-1998; 98US-0091673.
 PR 07-JUL-1998; 98US-0091978.
 PR 07-JUL-1998; 98US-0091982.
 PR 10-JUL-1998; 98US-0092182.
 PR 20-JUL-1998; 98US-0093339.
 PR 30-JUL-1998; 98US-0094651.
 PR 04-AUG-1998; 98US-0095282.
 PR 04-AUG-1998; 98US-0095285.
 PR 04-AUG-1998; 98US-0095301.
 PR 04-AUG-1998; 98US-0095302.
 PR 04-AUG-1998; 98US-0095318.
 PR 04-AUG-1998; 98US-0095321.
 PR 04-AUG-1998; 98US-0095325.
 PR 10-AUG-1998; 98US-0095916.
 PR 10-AUG-1998; 98US-0095929.
 PR 10-AUG-1998; 98US-0096012.
 PR 11-AUG-1998; 98US-0096143.
 PR 11-AUG-1998; 98US-0096146.
 PR 12-AUG-1998; 98US-0096329.
 PR 17-AUG-1998; 98US-0096757.
 PR 17-AUG-1998; 98US-0096766.
 PR 17-AUG-1998; 98US-0096768.
 PR 17-AUG-1998; 98US-0096773.
 PR 17-AUG-1998; 98US-0096791.
 PR 17-AUG-1998; 98US-0096867.
 PR 17-AUG-1998; 98US-0096891.
 PR 17-AUG-1998; 98US-0096894.
 PR 17-AUG-1998; 98US-0096895.
 PR 17-AUG-1998; 98US-0096897.

R 18-AUG-1998; 98US-0096949.
R 18-AUG-1998; 98US-0096950.
R 18-AUG-1998; 98US-0096959.
R 18-AUG-1998; 98US-0096960.
R 18-AUG-1998; 98US-0097022.
R 18-AUG-1998; 98US-0097141.
R 20-AUG-1998; 98US-0097218.
R 24-AUG-1998; 98US-0097661.
R 24-AUG-1998; 98US-0097951.
R 26-AUG-1998; 98US-0097952.
R 26-AUG-1998; 98US-0097954.
R 26-AUG-1998; 98US-0097955.
R 26-AUG-1998; 98US-0097971.
R 26-AUG-1998; 98US-0097974.
R 26-AUG-1998; 98US-0097973.
R 26-AUG-1998; 98US-0097979.
R 26-AUG-1998; 98US-0097986.
R 26-AUG-1998; 98US-0098014.
R 31-AUG-1998; 98US-0098525.
R 16-SEP-1998; 98US-0100634.
R 12-JAN-1999; 99US-0115565.

(GETH) GENENTECH INC.

Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK,
Wood WI, Yuan J;

WPI; 2000-072883/06.

P-PSDB; AAY66694.

Membrane-bound proteins and related nucleotide sequences -

Claim 2; Fig 156; 822pp; English.

The invention provides membrane-bound PRO polypeptides and polynucleotides encoding them. The PRO sequences of the invention were identified based on extracellular domain homology screening. The PRO sequences have homology with proteins including LDL receptors, TIE ligands and various enzymes. The membrane-bound proteins and receptor molecules are useful as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be used as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. The PRO encoding sequences are useful as hybridization probes, in chromosome and gene mapping and in the generation of antisense RNA and DNA. PRO nucleic acid sequences will also be useful for the preparation of PRO polypeptides, especially by recombinant techniques.

Sequence 2185 BP; 527 A; 666 C; 519 G; 473 T; 0 other;

Query Match 100.0%; Score 2185; DB 21; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Y 1 GTTCTCTTCCAGGCAAAATCCAGGCGATGGTGAATTATGACGTGCCACACATGA 60
b 1 GTTCTCTTCCAGGCAAAATCCAGGCGATGGTGAATTATGACGTGCCACACATGA 60
Y 61 AGCTCTTGTGGCAGGTAATGTGCAACAACACCTGGAAATGCCATCTGCTCCGTTTCG 120
b 61 AGCTCTTGTGGCAGGTAATGTGCAACAACACCTGGAAATGCCATCTGCTCCGTTTCG 120
Y 121 TCTACCTCAGCGCGCAAGTGTGATCTGTGTGACGCCATCGTCTGCGGCTCAGCGG 180
b 121 TCTACCTCAGCGCGCAAGTGTGATCTGTGTGACGCCATCGTCTGCGGCTCAGCGG 180
Y 181 GGGCCCAAGAACTGCCCTCCGTTTGTCTGTGCAAGTAACAGTTCAGAGGTGTGCA 240
b 181 GGGCCCAAGAACTGCCCTCCGTTTGTCTGTGCAAGTAACAGTTCAGAGGTGTGCA 240
Y 241 CCGCGCGGCGCTCTCGAGGTCCCGAGGTAATTCCTTCGACACCCCGGTACTCAACC 300

Db 241 CGCGCGGCGGCTCTCCGAGGTCCCGAGGGTATTTCCCTCGAACACCCCGGTACCTCAACC 300
Qy 301 TCATGGAGAACACATCCAGATCATCCAGCGCGACACCTTCCGCGACCTCCACACCTGG 360
Db 301 TCATGGAGAACACATCCAGATCATCCAGCGCGACACCTTCCGCGACCTCCACACCTGG 360
Qy 361 AGGTCTCTGAGTTGGCGAGAACTCCATCCGCGAGATTGAGTGGGGGCTTCAACGGCC 420
Db 361 AGGTCTCTGAGTTGGCGAGAACTCCATCCGCGAGATTGAGTGGGGGCTTCAACGGCC 420
Qy 421 TGGCGAGCTCAACACCTCGAGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480
Db 421 TGGCGAGCTCAACACCTCGAGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480
Qy 481 CTTTGAATAACCTGTCCAAAGCTCGCGGAGCTCTGGCTTCGCAACACCCCATCGAAAGCA 540
Db 481 CTTTGAATAACCTGTCCAAAGCTCGCGGAGCTCTGGCTTCGCAACACCCCATCGAAAGCA 540
Qy 541 TCCCTCTTACGCTTCAACCGGCTGCTCCTCATGCGCTGAGCTTTGGGGGAGCTCA 600
Db 541 TCCCTCTTACGCTTCAACCGGCTGCTCCTCATGCGCTGAGCTTTGGGGGAGCTCA 600
Qy 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGGGGGCTTTCAACCTCAAGTATCTCA 660
Db 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGGGGGCTTTCAACCTCAAGTATCTCA 660
Qy 661 ACTTGGGCATGTGCAACATTAAGACATGCCCAATCTCACCCCCTCTGTGGGGCTGGAGG 720
Db 661 ACTTGGGCATGTGCAACATTAAGACATGCCCAATCTCACCCCCTCTGTGGGGCTGGAGG 720
Qy 721 AGCTGGAGATGTGAGGGAACCACTTCCCTGAGATCAGGCTCGGCTCTTCCATGGCTCA 780
Db 721 AGCTGGAGATGTGAGGGAACCACTTCCCTGAGATCAGGCTCGGCTCTTCCATGGCTCA 780
Qy 781 GCTCCCTCAAGAGCTCTGGTTCATGAATCAAGTCAAGTCAAGTCAAGTCAAGTCAAGT 840
Db 781 GCTCCCTCAAGAGCTCTGGTTCATGAATCAAGTCAAGTCAAGTCAAGTCAAGTCAAGT 840
Qy 841 TTGACGGGCTGGCTTCACTTGTGGAATCACTTGGCCCAATACCTCTCTCTTTTCG 900
Db 841 TTGACGGGCTGGCTTCACTTGTGGAATCACTTGGCCCAATACCTCTCTCTTTTCG 900
Qy 901 CCATGACCTCTTTTACCCGCTGAGTACCTCTGTGGAGTTGATCTTACACCAACCTTT 960
Db 901 CCATGACCTCTTTTACCCGCTGAGTACCTCTGTGGAGTTGATCTTACACCAACCTTT 960
Qy 961 GGAATGTGATGTGACATCTCTGCTAGCTTCCATGCAATGCGAGGCGCTACCTCGTGG 1020
Db 961 GGAATGTGATGTGACATCTCTGCTAGCTTCCATGCAATGCGAGGCGCTACCTCGTGG 1020
Qy 1021 ATTCCACCTCTGCTGGCGCTGTCATGCTCCCATGCAATGCGAGGCGCTACCTCGTGG 1080
Db 1021 ATTCCACCTCTGCTGGCGCTGTCATGCTCCCATGCAATGCGAGGCGCTACCTCGTGG 1080
Qy 1081 AGTGGACCAAGGCTCTCTTCCAGTGTCTGCGCCCTTTCATGATGAGCGACCTCGAGAC 1140
Db 1081 AGTGGACCAAGGCTCTCTTCCAGTGTCTGCGCCCTTTCATGATGAGCGACCTCGAGAC 1140
Qy 1141 TCACATTTCTGAGGGTGGAGTGGAGTAAAGTGTGCGACTCCCTCTATGTCTCTCG 1200
Db 1141 TCACATTTCTGAGGGTGGAGTGGAGTAAAGTGTGCGACTCCCTCTATGTCTCTCG 1200
Qy 1201 TGAAGTGGTTGCTGCCCAATGGGACAGTCTCAGCCACGCTCCCGCCACCAAGATCT 1260
Db 1201 TGAAGTGGTTGCTGCCCAATGGGACAGTCTCAGCCACGCTCCCGCCACCAAGATCT 1260
Qy 1261 CTGTCTCAAGCGAGGCACTTGAACCTTTCCAGCTGTGCTTTCAGACACTGGGGTGT 1320
Db 1261 CTGTCTCAAGCGAGGCACTTGAACCTTTCCAGCTGTGCTTTCAGACACTGGGGTGT 1320
Qy 1321 ACACATGCAATGTGTGACCAATGTTGACAGGCAACTCCAAACGCTCTCGGCTTCAATGTGA 1380
Db 1321 ACACATGCAATGTGTGACCAATGTTGACAGGCAACTCCAAACGCTCTCGGCTTCAATGTGA 1380

QY 1381 GCACGGCTGAGCTTAACACCTCCAACTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1440
DB |||||
QY 1381 GCACGGCTGAGCTTAACACCTCCAACTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1440
DB |||||
QY 1441 CGGAGATCTCGCTGAGGACACACAGGGAAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1500
DB |||||
QY 1441 CGGAGATCTCGCTGAGGACACACAGGGAAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1500
DB |||||
QY 1501 GTTACACGCGGACATATACACCTCTTACACGGTGTCTCATTTACAGACTACCGGTGTGCCCA 1560
DB |||||
QY 1501 GTTACACGCGGACATATACACCTCTTACACGGTGTCTCATTTACAGACTACCGGTGTGCCCA 1560
DB |||||
QY 1561 AGCAGTGGCAGTACCGGACACACACCTTGTGAGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1620
DB |||||
QY 1561 AGCAGTGGCAGTACCGGACACACACCTTGTGAGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1620
DB |||||
QY 1621 TCATGAAGACACACCAAGATCATCTTGTGAGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1680
DB |||||
QY 1621 TCATGAAGACACCAAGATCATCTTGTGAGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1680
DB |||||
QY 1681 CCATGTTGATGCTTCTTATTAACCTTGTGAGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1740
DB |||||
QY 1681 CCATGTTGATGCTTCTTATTAACCTTGTGAGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1740
DB |||||
QY 1741 CGCCCGGAGCTGTTGAGATATATCCAGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1800
DB |||||
QY 1741 CGCCCGGAGCTGTTGAGATATATCCAGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1800
DB |||||
QY 1801 CAGCAACAGAGCTCCGCTCGGAGTATACAGTGGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1860
DB |||||
QY 1801 CAGCAACAGAGCTCCGCTCGGAGTATACAGTGGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1860
DB |||||
QY 1861 ATGACCATATTAACATACACACCTTACAAACAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1920
DB |||||
QY 1861 ATGACCATATTAACATACACACCTTACAAACAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1920
DB |||||
QY 1921 GCCTGGGAACCTCTGACCCCGGAGTATACAGTGGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1980
DB |||||
QY 1921 GCCTGGGAACCTCTGACCCCGGAGTATACAGTGGGAGTACAGCTTCTTCCACACAGTAACTAGTGAGACCA 1980
DB |||||
QY 1981 CCATACCAAGACAGTACAGGAACTCAAAATGATGCTTCTTCCACACAGTAACTAGTGAGACCA 2040
DB |||||
QY 1981 CCATACCAAGACAGTACAGGAACTCAAAATGATGCTTCTTCCACACAGTAACTAGTGAGACCA 2040
DB |||||
QY 2041 TAAATGCAATAGATGACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
DB |||||
QY 2041 TAAATGCAATAGATGACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
DB |||||
QY 2101 TTCCTGTATGCTTATATATTAAGTCTATGGCTGTTTAAATAAAGACAGATATATTA 2160
DB |||||
QY 2101 TTCCTGTATGCTTATATATTAAGTCTATGGCTGTTTAAATAAAGACAGATATATTA 2160
DB |||||
QY 2161 AATTTAAAGACAAAAGTCAAAACA 2185
DB |||||
QY 2161 AATTTAAAGACAAAAGTCAAAACA 2185
DB |||||

RESULT 3
AAS21462
ID AAS21462 standard; cDNA; 2185 BP.
XX
AC AAS21462;
XX
DT 24-OCT-2001 (first entry)
XX
DE Human cDNA sequence encoding for PRO1111 polypeptide.
XX
KW Human secretory and transmembrane; PRO; mammalian; cancer; lung;
KW breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
KW cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
KW adipocyte; A-peptide; factor VIIA; gene therapy; ss.
XX

OS Homo sapiens.
XX WO200140466-A2.
PN
XX
PD 07-JUN-2001.
PF
XX 01-DEC-2000; 2000WO-US32678.
XX
PF 01-DEC-1999; 99WO-US28301.
XX 01-DEC-1999; 99WO-US28634.
XX 02-DEC-1999; 99WO-US28551.
XX 02-DEC-1999; 99WO-US28564.
XX 02-DEC-1999; 99WO-US28565.
XX 09-DEC-1999; 99US-0170262.
XX 16-DEC-1999; 99WO-US30095.
XX 20-DEC-1999; 99WO-US30911.
XX 20-DEC-1999; 99WO-US30999.
XX 30-DEC-1999; 99WO-US31243.
XX 06-JAN-2000; 2000WO-US00277.
XX 06-JAN-2000; 2000WO-US00376.
XX 11-FEB-2000; 2000WO-US03565.
XX 18-FEB-2000; 2000WO-US04341.
XX 18-FEB-2000; 2000WO-US04342.
XX 22-FEB-2000; 2000WO-US04414.
XX 24-FEB-2000; 2000WO-US04914.
XX 24-FEB-2000; 2000WO-US05004.
XX 01-MAR-2000; 2000WO-US05601.
XX 20-MAR-2000; 2000WO-US07377.
XX 21-MAR-2000; 2000WO-US07532.
XX 30-MAR-2000; 2000WO-US08439.
XX 17-MAY-2000; 2000WO-US13705.
XX 22-MAY-2000; 2000WO-US14042.
XX 30-MAY-2000; 2000WO-US14941.
XX 02-JUN-2000; 2000WO-US15264.
XX 10-NOV-2000; 2000WO-US30873.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2001-408281/43.
DR P-PSDB; AUI2390.
XX
XX Isolated, secretory and transmembrane PRO polypeptide used to detect
PT other PRO polypeptides, link bioactive molecules to cells expressing
PT PRO polypeptides, and detect the presence of mammalian tumours e.g.
PT lung, breast, prostate, cervical
XX
PS Claim 3; Fig 437; 813pp; English.
XX
XX AAS21244-AAS21518 encode for novel human secretory and transmembrane
CC PRO polypeptides. The PRO polypeptides are useful to detect other
CC PRO polypeptides, to link bioactive molecules to cells expressing
CC PRO polypeptides, to modulate biological activities of cells expressing
CC PRO polypeptides, and to detect the presence of mammalian lung, colon,
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC polypeptide expression in a cell sample to that in a control sample.
CC Some of the 275 sequences are also useful to stimulate the release of
CC tumour necrosis factor-alpha (TNF-alpha) from human blood, the
CC proliferation or differentiation of chondrocytes, the proliferation or
CC gene expression in pericyte cells, the release of proteoglycans from
CC cartilage, the proliferation of inner ear utricular supporting cells or
CC of T-lymphocytes, the release of a cytokine from peripheral blood
CC monocytes (PBMCs), or the proliferation of endothelial cells. Some of
CC the PRO polypeptides may modulate glucose or free fatty acid uptake by
CC skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide
CC to factor VIIA. The PRO polypeptides can be used in assays to identify
CC molecules involved in binding interactions. The polynucleotides encoding
CC PRO polypeptides can be used to generate probes, antisense RNA/DNA,
CC transgenic or knock out animals and can be used in gene therapy.
XX

3Q Sequence 2185 BP; 527 A; 666 C; 519 G; 473 T; 0 other;
 Query Match 100.0%; Score 2185; DB 22; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 GTTCTCTTTCCGAGCCAAATCCAGCCGATGGTGAATATGAAGCTGCCACACCTGA 60
 1 GTTCTCTTTCCGAGCCAAATCCAGCCGATGGTGAATATGAAGCTGCCACACCTGA 60

61 AGCTCTTGTGCGAGTAAGTGTGACCAACACACCTGGAAATGCACTCTGCTCCCGTTGG 120
 61 AGCTCTTGTGCGAGTAAGTGTGACCAACACACCTGGAAATGCACTCTGCTCCCGTTGG 120

121 TCTACCTCAAGCGCAAGTGTGATCTGTGTGAGCAGATCGTGTGCGGCTCAGCGG 180
 121 TCTACCTCAAGCGCAAGTGTGATCTGTGTGAGCAGATCGTGTGCGGCTCAGCGG 180

181 GGCCCCAGAACTGCCCTCCGTTGTGCTGTCAGTAAACAGTTTCAAGAGGTGGTGTGA 240
 181 GGCCCCAGAACTGCCCTCCGTTGTGCTGTCAGTAAACAGTTTCAAGAGGTGGTGTGA 240

241 CGGCGCGGGCTCTCCGAGGTCCGAGGATTCCTCTCGAAACACCCGGTACCTCAACC 300
 241 CGGCGCGGGCTCTCCGAGGTCCGAGGATTCCTCTCGAAACACCCGGTACCTCAACC 300

301 TCATGGAGAACATCATCAGATGATCCAGSCCAGACACCTTCGSCACCTCCACCCCTGG 360
 301 TCATGGAGAACATCATCAGATGATCCAGSCCAGACACCTTCGSCACCTCCACCCCTGG 360

361 AGTTCCTGAGTTGGGAGGAACTCCATCCGAGATTCAGGTGGGGGCTTCAACGGCC 420
 361 AGTTCCTGAGTTGGGAGGAACTCCATCCGAGATTCAGGTGGGGGCTTCAACGGCC 420

421 TGCCAGCTTCAACCCCTGGAGCTTTCAGAACTGCTGACAGTCACTCCCTAGGGGG 480
 421 TGCCAGCTTCAACCCCTGGAGCTTTCAGAACTGCTGACAGTCACTCCCTAGGGGG 480

481 CTTTGAATACCTGTCTCAAGCTCGGGAGCTCTGGCTTCGCAACACCCCATCGAAAGCA 540
 481 CTTTGAATACCTGTCTCAAGCTCGGGAGCTCTGGCTTCGCAACACCCCATCGAAAGCA 540

541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTGGAGCTTGGGGGAGCTCA 600
 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTGGAGCTTGGGGGAGCTCA 600

601 AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGGGGGCTTCAACCTCAAGTATCTGA 660
 601 AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGGGGGCTTCAACCTCAAGTATCTGA 660

661 ACTTGGGCATGTGCAATTAAGACATGCCAAATCTCAACCCCTGGTGGGGCTGGAGG 720
 661 ACTTGGGCATGTGCAATTAAGACATGCCAAATCTCAACCCCTGGTGGGGCTGGAGG 720

721 AGCTGGAGATGTGAGGAACTCTGAGGAGCTTTTGGGGGCTTCAACCTCAAGTATCTGA 780
 721 AGCTGGAGATGTGAGGAACTCTGAGGAGCTTTTGGGGGCTTCAACCTCAAGTATCTGA 780

781 GCTCCCTCAAGAGCTCTGGGTCAATGAATCAAGCTCAGCTGATGGAGCGGATGCTT 840
 781 GCTCCCTCAAGAGCTCTGGGTCAATGAATCAAGCTCAGCTGATGGAGCGGATGCTT 840

841 TTGACGGGCTGGCTTCACTGTGGAACTCACTGGAGTGGAGTGGAGTGGAGTGGAGTGG 900
 841 TTGACGGGCTGGCTTCACTGTGGAACTCACTGGAGTGGAGTGGAGTGGAGTGGAGTGG 900

901 CCCATGACCTCTTTACCCGCTGAGTACCTGGTGGAGTGGAGTGGAGTGGAGTGGAGTGG 960
 901 CCCATGACCTCTTTACCCGCTGAGTACCTGGTGGAGTGGAGTGGAGTGGAGTGGAGTGG 960

961 GGAAGCTGTGATGTGACATTTCTGTGGCTAGCTGGTGGTGGTGGTGGTGGTGGTGGTGG 1020
 961 GGAAGCTGTGATGTGACATTTCTGTGGCTAGCTGGTGGTGGTGGTGGTGGTGGTGGTGG 1020

QY 1021 ATTCCACTGTGTGGCCGCTGTATGCTCCCATGCAATGCCAGGCGCTACTCTGTGG 1080
 DB 1021 ATTCCACTGTGTGGCCGCTGTATGCTCCCATGCAATGCCAGGCGCTACTCTGTGG 1080

QY 1081 AGGTGGACCAAGGCTCTCCAGTGTCTGCCCCCTTTCATATGGAAGCGACCTCGAGACC 1140
 DB 1081 AGGTGGACCAAGGCTCTCCAGTGTCTGCCCCCTTTCATATGGAAGCGACCTCGAGACC 1140

QY 1141 TCAACATTTCTGAGGTCGGATGCGAGAACTTAAGTGTGCGACTCCCCCTATGCTCTCG 1200
 DB 1141 TCAACATTTCTGAGGTCGGATGCGAGAACTTAAGTGTGCGACTCCCCCTATGCTCTCG 1200

QY 1201 TGAAGTGGTGTGCTGCCCAATGGGACAGTGTGAGCCAGGCTCCCGCCACCCAGGATCT 1260
 DB 1201 TGAAGTGGTGTGCTGCCCAATGGGACAGTGTGAGCCAGGCTCCCGCCACCCAGGATCT 1260

QY 1261 CTGTCTCTCAACGACGCGACCTTGAACCTTTTCCACGCTGCTGCTTTTTCAGACACTGGGGTGT 1320
 DB 1261 CTGTCTCTCAACGACGCGACCTTGAACCTTTTCCACGCTGCTGCTTTTTCAGACACTGGGGTGT 1320

QY 1321 ACATATGATGTTGACCAATGTTTGGAGGAACTCCAAAGGCTCGGCTTACCTCAATGTGA 1380
 DB 1321 ACATATGATGTTGACCAATGTTTGGAGGAACTCCAAAGGCTCGGCTTACCTCAATGTGA 1380

QY 1381 GCAGGCTGAGCTTAAACACCTTCCAACTACAGCTTCTTCCACAGTAAACAGTGGAGACCA 1440
 DB 1381 GCAGGCTGAGCTTAAACACCTTCCAACTACAGCTTCTTCCACAGTAAACAGTGGAGACCA 1440

QY 1441 CGGAGATCTCGCTGAGGACCAACCGGAAAGTAAAGCTGTTTCTAGCACTCCACTG 1500
 DB 1441 CGGAGATCTCGCTGAGGACCAACCGGAAAGTAAAGCTGTTTCTAGCACTCCACTG 1500

QY 1501 GTTACAGAGCGGATATACCACTTCTACACGCTGCTCATTCAGAGTACCGGTGCCCCA 1560
 DB 1501 GTTACAGAGCGGATATACCACTTCTACACGCTGCTCATTCAGAGTACCGGTGCCCCA 1560

QY 1561 AGCAGGTGGAGTACCCGCGACAGACACCACTGACAGAGTGCAGACCGCTGGATGAAG 1620
 DB 1561 AGCAGGTGGAGTACCCGCGACAGACACCACTGACAGAGTGCAGACCGCTGGATGAAG 1620

QY 1621 TCATGAAGACCAAGATCATCATTTGGCTGTTTGGGAGTGTCTGTAGTGGCTGG 1680
 DB 1621 TCATGAAGACCAAGATCATCATTTGGCTGTTTGGGAGTGTCTGTAGTGGCTGG 1680

QY 1681 CCATGTTGATGTTCTTATAAACTTCTGTAAGCGCACCGACGAGCGAGTACAGTCAAG 1740
 DB 1681 CCATGTTGATGTTCTTATAAACTTCTGTAAGCGCACCGACGAGCGAGTACAGTCAAG 1740

QY 1741 CCGCCCGGACTGTGTGAGTAAATCCAGGTGGAAGAGATCCCGAGCAATCCGCGAG 1800
 DB 1741 CCGCCCGGACTGTGTGAGTAAATCCAGGTGGAAGAGATCCCGAGCAATCCGCGAG 1800

QY 1801 CAGCAACAGCAGCTCCGCTCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC 1860
 DB 1801 CAGCAACAGCAGCTCCGCTCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC 1860

QY 1861 ATGACCAATTAATCAACACCTCAAAACAGCAATGGGGCCCACTGGACAGAAAAA 1920
 DB 1861 ATGACCAATTAATCAACACCTCAAAACAGCAATGGGGCCCACTGGACAGAAAAA 1920

QY 1921 GCTTGGGAGTCTCTGCAACCCAGTCACTATCTCTGAACTTATATTAATTCAGA 1980
 DB 1921 GCTTGGGAGTCTCTGCAACCCAGTCACTATCTCTGAACTTATATTAATTCAGA 1980

QY 1981 CCATATCCAGGACCAAGGTACAGGAACTCAAAATATGACTCCCTCCCTCCCAAACTTA 2040
 DB 1981 CCATATCCAGGACCAAGGTACAGGAACTCAAAATATGACTCCCTCCCTCCCAAACTTA 2040

QY 2041 TAAATGCAATAGAAATGCAACAAAGACAGCAACTTTTGTACAGAGTGGGAGACTTT 2100
 DB 2041 TAAATGCAATAGAAATGCAACAAAGACAGCAACTTTTGTACAGAGTGGGAGACTTT 2100

QY 2101 TTCTTGATATGCTATATATTAAGTCTATGGCTGGTTAAACACAGATTATATTA 2160
 Db 2101 TTCTTGATATGCTATATATTAAGTCTATGGCTGGTTAAACACAGATTATATTA 2160
 QY 2161 AATTAAACACAAAAGTCAAAACA 2185
 Db 2161 AATTAAACACAAAAGTCAAAACA 2185

RESULT 4

ID AAF44179 standard; cDNA; 2185 BP.

XX AAF44179;

XX AAF44179;

DT 02-APR-2001 (first entry)

XX Human PRO1111 (UNQ554) nucleotide sequence SEQ ID NO:228.

XX Human; secreted and transmembrane protein; PRO; cytostatic;
 KW cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
 KW diagnostic assay; ss.

XX Homo sapiens.

XX WO200073454-A1.

PN 07-DEC-2000.

PD 30-MAR-2000; 2000WO-US08439.

PP 02-JUN-1999; 99WO-US12252.

PR 23-JUN-1999; 99US-0141037.

PR 07-JUL-1999; 99US-0143048.

PR 26-JUL-1999; 99US-0144758.

PR 28-JUL-1999; 99US-0145698.

PR 17-AUG-1999; 99US-0148222.

PR 15-SEP-1999; 99US-0149396.

PR 15-SEP-1999; 99WO-US21090.

PR 08-OCT-1999; 99US-0153663.

PR 01-DEC-1999; 99WO-US28313.

PR 16-DEC-1999; 99WO-US28301.

PR 20-DEC-1999; 99WO-US30095.

PR 05-JAN-2000; 99WO-US30911.

PR 06-JAN-2000; 2000WO-US06219.

PR 11-FEB-2000; 2000WO-US03576.

PR 18-FEB-2000; 2000WO-US04341.

PR 22-FEB-2000; 2000WO-US04414.

PR 24-FEB-2000; 2000WO-US04914.

PR 02-MAR-2000; 2000WO-US05004.

PR 15-MAR-2000; 2000WO-US05841.

PR 20-MAR-2000; 2000WO-US06884.

PR 20-MAR-2000; 2000WO-US07377.

XX (GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

PI Ferrera N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi CJ, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;

PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;

PI Zhang Z;

XX WPI; 2001-032160/04.

DR P-PSDB; AAB65217.

XX PRO polynucleotides used to produce polypeptides used to target

PT bioactive molecules such as toxins, radiolabels or antibodies, to

PT specific cells, to cause targeted cell death -

XX Claim 2; Fig 156; 935pp; English.

PS

XX

CC The present invention describes human secreted and transmembrane PRO
 CC proteins. The PRO proteins have cytostatic activity. The PRO proteins
 CC can be used for targeted delivery of bioactive molecules, such as
 CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
 CC sequences, and their fragments, can be used as hybridisation probes, in
 CC chromosomal and gene mapping, and in the generation of anti-sense RNA
 CC and DNA. They may also be used to produce transgenic animals which are
 CC used to develop and screen therapeutically useful reagents. The PRO
 CC nucleotide and protein sequence can be used for tissue typing and in
 CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
 CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
 CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and
 CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein
 CC sequences given in the exemplification of the present invention.

XX Sequence 2185 BP; 527 A; 666 C; 519 G; 473 T; 0 other;

QY Query Match 100.0%; Score 2185; DB 22; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTCTCTCTTCCGAGCCAAATCCGAGCGGATGTGAATTATGACGTGCACACCATGA 60

Db 1 GTCTCTCTTCCGAGCCAAATCCGAGCGGATGTGAATTATGACGTGCACACCATGA 60

QY 61 AGCTCTTGTGCGAGGTAACTGTGCACACCATGCACACCATCTGGAATGCCATCTCCCGTTGG 120

Db 61 AGCTCTTGTGCGAGGTAACTGTGCACACCATGCACACCATCTGGAATGCCATCTCCCGTTGG 120

QY 121 TCTACTCAGCGCGCAAGTGTGGATTCTGTGTGAGCCATCGCTGTCGCCCTCAGCGG 180

Db 121 TCTACTCAGCGCGCAAGTGTGGATTCTGTGTGAGCCATCGCTGTCGCCCTCAGCGG 180

QY 181 GGCCCCAGAACTGCCCTCCGTTCTGTGAGTAACTGACAGTTCAGCAAGTGTGTGCA 240

Db 181 GGCCCCAGAACTGCCCTCCGTTCTGTGAGTAACTGACAGTTCAGCAAGTGTGTGCA 240

QY 241 CGCGCGGGGGCTCTCCGAGTCCGCGAGGGTATTCCTCGAACAACCCCGTACCTCAACC 300

Db 241 CGCGCGGGGGCTCTCCGAGTCCGCGAGGGTATTCCTCGAACAACCCCGTACCTCAACC 300

QY 301 TCATGAGAACCAATCCAGATGATCCAGGCGGACACCTCCGCGACCTCCACACCTGG 360

Db 301 TCATGAGAACCAATCCAGATGATCCAGGCGGACACCTCCGCGACCTCCACACCTGG 360

QY 361 AGTCTCTGCAAGTGTGGGAGGAACTCCATCCGCGAGATTGAGTGGGGGCTTCAACGGCC 420

Db 361 AGTCTCTGCAAGTGTGGGAGGAACTCCATCCGCGAGATTGAGTGGGGGCTTCAACGGCC 420

QY 421 TGGCCAGCTCAACACCTGGAGCTGTTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480

Db 421 TGGCCAGCTCAACACCTGGAGCTGTTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480

QY 481 CCTTTGAATACCTGTCCAAAGCTGCGGAGCTCTGGCTTCGCAACAAACCCCATCGAAAGCA 540

Db 481 CCTTTGAATACCTGTCCAAAGCTGCGGAGCTCTGGCTTCGCAACAAACCCCATCGAAAGCA 540

QY 541 TCCCTCTTACGCTTCAACCGGGTGCCTCTCTCTATCGGCTGGAATTGGGGAGCTCA 600

Db 541 TCCCTCTTACGCTTCAACCGGGTGCCTCTCTCTATCGGCTGGAATTGGGGAGCTCA 600

QY 601 AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGGAGGGCTGTTCAACCTCAAGTATCTGA 660

Db 601 AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGGAGGGCTGTTCAACCTCAAGTATCTGA 660

QY 661 ACTTGGGATGTGAAACATTAAGACATGCGCAATCTCACCCCTGGTGGGCTGGAGG 720

Db 661 ACTTGGGATGTGAAACATTAAGACATGCGCAATCTCACCCCTGGTGGGCTGGAGG 720

QY 721 AGCTGGAGATGTGAGGAAACCACTTCCCTGAGATGAGGCTGGCTCTTCCATGGCCTGA 780

Db 721 AGCTGGAGATGTGAGGAAACCACTTCCCTGAGATGAGGCTGGCTCTTCCATGGCCTGA 780

781 GCTCCCTCAAGAGCTCTGGGTCTAGCACTCAGGTCAGCTGATGAGCGGATGCTT 840
 781 GCTCCCTCAAGAGCTCTGGGTCTAGCACTCAGGTCAGCTGATGAGCGGATGCTT 840
 841 TTGACGGGTGGCTTCACTTTGGAAGTCAACTTGGCCCAATAAATCTCTCTTTTC 900
 841 TTGACGGGTGGCTTCACTTTGGAAGTCAACTTGGCCCAATAAATCTCTCTTTTC 900
 901 CCATGACCTCTTTACCCCGCTGAGTACCTGAGTGTGATCTACACCAACCCCTT 960
 901 CCATGACCTCTTTACCCCGCTGAGTACCTGAGTGTGATCTACACCAACCCCTT 960
 961 GGAATCTGATGATGATCTCTGCTGCTAGCTGCTGCTGCTGCTGCTGCTGCTGCT 1020
 961 GGAATCTGATGATGATCTCTGCTGCTAGCTGCTGCTGCTGCTGCTGCTGCTGCT 1020
 1021 ATTCCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1080
 1021 ATTCCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1080
 1081 AGGTGACACGAGGCTCTCTCCAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
 1081 AGGTGACACGAGGCTCTCTCCAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
 1141 TCAACATTTCTGAGGCTCGATGAGCAAACTTAAGTGTGAGTCTCCCTCTATGCTCTCG 1200
 1141 TCAACATTTCTGAGGCTCGATGAGCAAACTTAAGTGTGAGTCTCCCTCTATGCTCTCG 1200
 1201 TGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
 1201 TGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
 1261 CTGCTCTCAACGAGGCTCTGAACTTTTCCAGTGTGCTGCTTTCAGACACTGCGGTGT 1320
 1261 CTGCTCTCAACGAGGCTCTGAACTTTTCCAGTGTGCTGCTTTCAGACACTGCGGTGT 1320
 1321 ACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1380
 1321 ACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1380
 1381 GCAGGCTGAGCTTAACCTCTCACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1440
 1381 GCAGGCTGAGCTTAACCTCTCACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1440
 1441 CGGAGATCTCGCTGAGGACACAAACGCGAAGTACAGCTGCTTCTTACCACTGCTCACTG 1500
 1441 CGGAGATCTCGCTGAGGACACAAACGCGAAGTACAGCTGCTTCTTACCACTGCTCACTG 1500
 1501 GTTACGACGCGGATATACCTCTTACCACTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1560
 1501 GTTACGACGCGGATATACCTCTTACCACTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1560
 1561 AGCAGGTGCGAGTACCCGCGACAGACACCACTGCAAGATGAGACCAAGCTGATGAAG 1620
 1561 AGCAGGTGCGAGTACCCGCGACAGACACCACTGCAAGATGAGACCAAGCTGATGAAG 1620
 1621 TCAATGAAGACCAAGATATACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1680
 1621 TCAATGAAGACCAAGATATACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1680
 1681 CCAATGTTGATGCTTCTATATAAATCTGTAAGCGGACACAGAGGAGTACAGTCAAG 1740
 1681 CCAATGTTGATGCTTCTATATAAATCTGTAAGCGGACACAGAGGAGTACAGTCAAG 1740
 1741 CCGCCCGGACTGTTGAGATATATCCAGGTGAGAGAGATATCCAGACGAAATCCCGGAG 1800
 1741 CCGCCCGGACTGTTGAGATATATCCAGGTGAGAGAGATATCCAGACGAAATCCCGGAG 1800
 1801 CAGCAACAGAGCTCGCTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1860
 1801 CAGCAACAGAGCTCGCTCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1860
 1861 ATGACCATTAATCAACACCTTACAAACCGAGCATGGGCGCCCACTGGACAGAAAACA 1920

1861 ATGACCATTAATCAACACCTTACAAACCGAGCATGGGCGCCCACTGGACAGAAAACA 1920
 1921 GCCTGGGAACTCTCTGCAACCCACAGTCACTATCTCTGAACTTATATAATTCAGA 1980
 1921 GCCTGGGAACTCTCTGCAACCCACAGTCACTATCTCTGAACTTATATAATTCAGA 1980
 1981 CCATACCAAGGAGGAGTACAGGAACTCAATATGACTCCCTCCCTCCCTCCCTCCCT 2040
 1981 CCATACCAAGGAGGAGTACAGGAACTCAATATGACTCCCTCCCTCCCTCCCTCCCT 2040
 2041 TAAATGCAATGAAATGCAACACACACACACACACACACACACACACACACACAC 2100
 2041 TAAATGCAATGAAATGCAACACACACACACACACACACACACACACACACACAC 2100
 2101 TTCTTTATATGCTTATATATTAATGCTATGCTGCTGCTGCTGCTGCTGCTGCTGCT 2160
 2101 TTCTTTATATGCTTATATATTAATGCTATGCTGCTGCTGCTGCTGCTGCTGCTGCT 2160
 2161 AATTAAAGACAAAAGTCAAAAACA 2185
 2161 AATTAAAGACAAAAGTCAAAAACA 2185

RESULT 5
 ACA03821
 ID ACA03821 standard; cDNA; 2185 BP.
 XX ACA03821;
 AC ACA03821;
 XX 23-MAY-2003 (first entry)
 XX cDNA encoding human PRO polypeptide #219.
 XX Human, PRO polypeptide; secreted and transmembrane protein;
 XX tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
 XX differentiation; chondrocyte; tumour; genetic disorder;
 XX cytosolic; gene; ss.
 OS Homo sapiens.
 XX US2003036180-A1.
 XX 20-FEB-2003.
 XX 09-MAY-2002; 2002US-0143114.
 XX 31-MAR-1997; 97WO-US05230.
 XX 12-JUN-1998; 98WO-US12456.
 XX 14-JUL-1998; 98WO-US14552.
 XX 28-AUG-1998; 98WO-US17888.
 XX 10-SEP-1998; 98WO-US18824.
 XX 14-SEP-1998; 98WO-US19093.
 XX 14-SEP-1998; 98WO-US19177.
 XX 16-SEP-1998; 98WO-US19330.
 XX 17-SEP-1998; 98WO-US19437.
 XX 07-OCT-1998; 98WO-US21141.
 XX 29-OCT-1998; 98WO-US22991.
 XX 20-NOV-1998; 98WO-US24855.
 XX 01-DEC-1998; 98WO-US25108.
 XX 05-JAN-1999; 99WO-US010106.
 XX 08-MAR-1999; 99WO-US05028.
 XX 10-MAR-1999; 99WO-US05190.
 XX 20-APR-1999; 99WO-US10733.
 XX 14-MAY-1999; 99WO-US12252.
 XX 02-JUN-1999; 99WO-US20111.
 XX 01-SEP-1999; 99WO-US20594.
 XX 08-SEP-1999; 99WO-US20944.
 XX 13-SEP-1999; 99WO-US21090.
 XX 15-SEP-1999; 99WO-US21547.

PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 30-NOV-1999; 99WO-US28409.
PR 01-DEC-1999; 99WO-US28501.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 12-MAY-2000; 2000WO-US11705.
PR 17-MAY-2000; 2000WO-US114042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 06-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US13692.
PR 29-JUN-2001; 2001WO-US21016.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.

XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood MI, Zhang Z;
XX WPI; 2003-332040/31.
XX P-PSDB; ABU66788.
XX New secreted and transmembrane PRO nucleic acids, useful for gene
XX therapy, in chromosome and gene mapping as chromosome markers, in
XX tissue typing, and in chromosome identification
XX Claim 2; Fig 437; 660pp; English.

XX The present invention relates to the isolation of novel human PRO
XX polypeptides, and the polynucleotide sequences encoding them. The
XX PRO polypeptides are secreted and transmembrane proteins. The PRO
XX polypeptides are useful for detecting other PRO polypeptides, for
XX linking bioactive molecules to cells expressing PRO polypeptides, for
XX for modulating biological activities of cells expressing PRO
XX polypeptides, and for identifying agonists or antagonists.
XX The PRO polypeptides are useful for stimulating the release of
XX tumour necrosis factor (TNF)-alpha from human blood, for stimulating the
XX the proliferation or differentiation of chondrocytes, and detecting the
XX presence of tumours. The polynucleotide sequences encoding PRO
XX polypeptides are useful as hybridisation probes, in chromosome and
XX gene mapping, in the generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptides, for generating transgenic animals or
XX knockout animals, for the genetic analysis of individuals with genetic
XX disorders, and in gene therapy. ACA03603-ACA03877 represent cDNAs
XX encoding the human PRO polypeptides of the invention.
XX Note: The sequence data for this patent was obtained in electronic
XX format directly from the USPTO web site at
XX seqdata.uspto.gov/psipdsIDentry.html.

SQ Sequence 2185 BP; 527 A; 666 C; 519 G; 473 T; 0 other;

Query Match 100.0%; Score 2185; DB 25; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTCTCTTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAACGTGCCACACCATGA 60
DB 1 GTTCTCTTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAACGTGCCACACCATGA 60
QY 61 AGCTCTTGTGGCAGGTAATCTGTCACACACACACATGGAATCCATCTGCTCCGGTTCG 120
DB 61 AGCTCTTGTGGCAGGTAATCTGTCACACACACACATGGAATCCATCTGCTCCGGTTCG 120
QY 121 TCTACTCTACGCGCGCAAGTGTGGATTCTGTGTGAGCCATCGCTGCTCGCGCTCAGCG 180
DB 121 TCTACTCTACGCGCGCAAGTGTGGATTCTGTGTGAGCCATCGCTGCTCGCGCTCAGCG 180
QY 181 GGGCCCGAGAACTGCCCTTCGGTTGCTGTCGATTAACCAAGTTCCAGAGTGGTGTGCA 240
DB 181 GGGCCCGAGAACTGCCCTTCGGTTGCTGTCGATTAACCAAGTTCCAGAGTGGTGTGCA 240
QY 241 CGCGCGCGGGCTCTCCGAGGTCCGCGAGGATTCCTCTCGAACACCGGTACCTCAACC 300
DB 241 CGCGCGCGGGCTCTCCGAGGTCCGCGAGGATTCCTCTCGAACACCGGTACCTCAACC 300
QY 301 TCATGGAGAAACAATCCAGATGATTCAGGCGCGACACTTCCGCGCACTCCACCACTGG 360
DB 301 TCATGGAGAAACAATCCAGATGATTCAGGCGCGACACTTCCGCGCACTCCACCACTGG 360
QY 361 AGGTCTCTCAGTTGGGCGAGGAACCTCCATCCGGCAGATTAGTGGGGGCTTCAACGGCC 420
DB 361 AGGTCTCTCAGTTGGGCGAGGAACCTCCATCCGGCAGATTAGTGGGGGCTTCAACGGCC 420
QY 421 TGGCCAGCTCAACACCTCGAGTGTTCGACAACTGGTGAAGTATCATCCGCGAGATTAGTGGGGGCTTCAACGGGG 480

421 TGGCCAGCCTCAACCCCTGGAGCTGTTGCAAACTGGCTGACAGTCATCCCTAGCGGG 480
481 CTTTGAATACCTCTCAAGCTGGGAGCTCTGGCTTGGCAACACCCCATCGAAGCA 540
481 CTTTGAATACCTCTCAAGCTGGGAGCTCTGGCTTGGCAACACCCCATCGAAGCA 540
541 TCCCTCTTAGCCTTCAACCGGGTCCCTCCCTCATGGCCTTGGAATTGGGGGAGCTCA 600
541 TCCCTCTTAGCCTTCAACCGGGTCCCTCCCTCATGGCCTTGGAATTGGGGGAGCTCA 600
601 AGAAGCTGAGTATATCTCTGAGGGAGCTTTTGGGGGCTGTTCAACCTCAAGTATCTGA 660
601 AGAAGCTGAGTATATCTCTGAGGGAGCTTTTGGGGGCTGTTCAACCTCAAGTATCTGA 660
661 ACTTGGGCTATGTGCAACATTAAGACATGCCAATCTCAACCCCTGGTGGGCTGGAG 720
661 ACTTGGGCTATGTGCAACATTAAGACATGCCAATCTCAACCCCTGGTGGGCTGGAG 720
721 AGCTGGAGATGTGAGGAAACCACTTCCCTCAGATCAGGCTGGCTCCTCCATGGCCTGA 780
721 AGCTGGAGATGTGAGGAAACCACTTCCCTCAGATCAGGCTGGCTCCTCCATGGCCTGA 780
781 GCTCCCTCAAGAGCTCTGGGTATGAATCTCAAGGTCAAGCTGATTTGAGCGGAATGCTT 840
781 GCTCCCTCAAGAGCTCTGGGTATGAATCTCAAGGTCAAGCTGATTTGAGCGGAATGCTT 840
841 TTGAGCGGCTGGCTTCACTTGTGGAACTGAACTTGGGCCCAATTAACCTCTCTCTTTC 900
841 TTGAGCGGCTGGCTTCACTTGTGGAACTGAACTTGGGCCCAATTAACCTCTCTCTTTC 900
901 CCATGACCTCTTACCCCGCTGAGTACCTGGTGGAGTTGCATCTACACCAACACCTTT 960
901 CCATGACCTCTTACCCCGCTGAGTACCTGGTGGAGTTGCATCTACACCAACACCTTT 960
961 GGAATGTGATGTGCAATCTGTGGCTACCTGGTGGCTTGGAGATATACCAACCA 1020
961 GGAATGTGATGTGCAATCTGTGGCTACCTGGTGGCTTGGAGATATATACCAACCA 1020
1021 ATTCACCTCTGGGCGCTGTCATGCTCCCATGACATGGAGCGCGCTACCTCGTGG 1080
1021 ATTCACCTCTGGGCGCTGTCATGCTCCCATGACATGGAGCGCGCTACCTCGTGG 1080
1081 AGTGGACCAAGGCTCTTCCAGTGTCTGCCCTTCATCATGGAGCGACCTGGAGACC 1140
1081 AGTGGACCAAGGCTCTTCCAGTGTCTGCCCTTCATCATGGAGCGACCTGGAGACC 1140
1141 TCACATTTCTGAGGCTGGATGGCAACCTTAAGTGTGGACTCCCTCATGTCTCTCG 1200
1141 TCACATTTCTGAGGCTGGATGGCAACCTTAAGTGTGGACTCCCTCATGTCTCTCG 1200
1201 TGAAGTGTGCTGCTGCCCAATGGGACAGTGTCTGAGCCACGCTCCCGCCACCCAGGATCT 1260
1201 TGAAGTGTGCTGCTGCCCAATGGGACAGTGTCTGAGCCACGCTCCCGCCACCCAGGATCT 1260
1261 CTGTCTCAACGACGACCTTGAACTTTTCCCAAGTGTCTGCTTTCAGACACTGGGGTGT 1320
1261 CTGTCTCAACGACGACCTTGAACTTTTCCCAAGTGTCTGCTTTCAGACACTGGGGTGT 1320
1321 ACACATGATGTGACCAATGTTGAGGCAACTTCAACGCTCTGGCTACCTCAATGTGA 1380
1321 ACACATGATGTGACCAATGTTGAGGCAACTTCAACGCTCTGGCTACCTCAATGTGA 1380
1381 GCACGGCTGAGCTTAAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAAC 1440
1381 GCACGGCTGAGCTTAAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAAC 1440
1441 CGGAGATCTCGCTGAGGACACACGCGGAAGTACAGCTGTTCTTACCACTGCTCACTG 1500
1441 CGGAGATCTCGCTGAGGACACACGCGGAAGTACAGCTGTTCTTACCACTGCTCACTG 1500
1501 GTTACACGCGGATATACCACTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAAC 1560
1501 GTTACACGCGGATATACCACTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAAC 1560

RESULT 6

AC04242

ID AC04242 standard; cDNA; 2185 BP.

XX ACA04242;

XX AC

XX 27-MAY-2003 (first entry)

XX Human cDNA encoding a secreted/transmembrane protein, SEQ ID 437.

XX Human; ss; gene; secreted protein; transmembrane protein; PRO;
XX inflammatory disease; organ failure; atherosclerosis; cardiac injury;
XX infertility; birth defects; premature aging; AIDS; biosensor;
XX acquired immunodeficiency syndrome; cancer; diabetic complication;
XX bioresactor; tumour.

XX Homo sapiens.

XX OS

XX PN

XX US2003032155-A1.

XX 13-FEB-2003.

XX 03-MAY-2002; 2002US-0137865.

XX 31-MAR-1997; 97WO-US05230.

XX 12-JUN-1998; 98WO-US12456.

XX 14-JUL-1998; 98WO-US14552.

PR 28-AUG-1998; 98WO-US17888.
 PR 10-SEP-1998; 98WO-US18824.
 PR 14-SEP-1998; 98WO-US19093.
 PR 14-SEP-1998; 98WO-US19094.
 PR 14-SEP-1998; 98WO-US19177.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US11141.
 PR 29-OCT-1998; 98WO-US22991.
 PR 29-OCT-1998; 98WO-US22992.
 PR 29-OCT-1998; 98WO-US24855.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 98WO-US00106.
 PR 08-MAR-1999; 98WO-US05028.
 PR 10-MAR-1999; 98WO-US05190.
 PR 20-APR-1999; 98WO-US06615.
 PR 14-MAY-1999; 98WO-US10733.
 PR 02-JUN-1999; 98WO-US12252.
 PR 01-SEP-1999; 98WO-US20111.
 PR 08-SEP-1999; 98WO-US20594.
 PR 13-SEP-1999; 98WO-US20944.
 PR 15-SEP-1999; 98WO-US21090.
 PR 15-SEP-1999; 98WO-US21547.
 PR 05-OCT-1999; 98WO-US23089.
 PR 29-NOV-1999; 98WO-US28214.
 PR 30-NOV-1999; 98WO-US28313.
 PR 30-NOV-1999; 98WO-US28409.
 PR 01-DEC-1999; 98WO-US28301.
 PR 01-DEC-1999; 98WO-US28634.
 PR 02-DEC-1999; 98WO-US28551.
 PR 02-DEC-1999; 98WO-US28564.
 PR 02-DEC-1999; 98WO-US28565.
 PR 16-DEC-1999; 98WO-US30095.
 PR 20-DEC-1999; 98WO-US30911.
 PR 20-DEC-1999; 98WO-US30999.
 PR 22-DEC-1999; 98WO-US30720.
 PR 30-DEC-1999; 98WO-US31243.
 PR 30-DEC-1999; 98WO-US31274.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00277.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US01565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 18-FEB-2000; 2000WO-US04342.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 01-MAR-2000; 2000WO-US05601.
 PR 02-MAR-2000; 2000WO-US05745.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 21-MAR-2000; 2000WO-US07532.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 17-MAY-2000; 2000WO-US11705.
 PR 22-MAY-2000; 2000WO-US11402.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 10-NOV-2000; 2000WO-US30873.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 20-DEC-2000; 2000WO-US34956.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-MAR-2001; 2001WO-US06666.
 PR 25-MAY-2001; 2001WO-US17092.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US18692.
 PR 22-JUN-2001; 2001WO-US20116.

PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 20-DEC-2000; 2000US-0747259.
 PR 28-FEB-2001; 2001US-0796496.
 PR 09-MAR-2001; 2001US-0802706.
 PR 14-MAR-2001; 2001US-0808689.
 PR 22-MAR-2001; 2001US-0816744.
 PR 05-APR-2001; 2001US-0828366.
 PR 10-MAY-2001; 2001US-0854208.
 PR 10-MAY-2001; 2001US-0854280.
 PR 18-MAY-2001; 2001US-0860216.
 PR 25-MAY-2001; 2001US-0866028.
 PR 25-MAY-2001; 2001US-0866034.
 PR 01-JUN-2001; 2001US-0872035.
 PR 05-JUN-2001; 2001US-0874503.
 PR 14-JUN-2001; 2001US-0882636.
 PR 19-JUN-2001; 2001US-0886342.
 PR 21-JUN-2001; 2001US-0887879.
 PR 18-JUL-2001; 2001US-0908827.
 PR 06-AUG-2001; 2001US-0924419.
 PR 09-AUG-2001; 2001US-0927796.
 PR 16-AUG-2001; 2001US-0931836.
 PR 19-DEC-2001; 2001US-0028072.
 XX
 PR (GETH) GENENTECH INC.
 PA Baker KP, Bezesini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-331925/31.
 DR P-PSDB; AB067064.
 XX
 PT New secreted and transmembrane nucleic acids and polypeptides,
 PT designated as PRO, useful for treating inflammation, organ failure,
 PT atherosclerosis, cardiac injury, infertility, birth defects, premature
 PT aging, AIDS, or cancer
 XX
 PS Claim 2; Fig 437; 659pp; English.
 XX
 CC The invention relates to an isolated nucleic acid comprising, or which is
 CC at least 80% identical to, or the full-length coding sequence of, any of
 CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
 CC (one of 275 secreted or transmembrane proteins). The nucleic acid
 CC further comprises the full-length coding sequence of the DNA deposited
 CC under American Type Culture Collection (ATCC) accession number in a list
 CC given in the specification. Also included are vectors and host
 CC cells for producing PRO proteins, PRO fusion proteins, anti-PRO
 CC antibodies, PRO extracellular domains and mature sequences, methods
 CC of detecting PRO proteins, methods for stimulating the release of
 CC TNF-alpha (tumour necrosis factor alpha) from human blood,
 CC (and the proliferation of differentiation of chondrocyte cells, the
 CC proliferation of, or gene expression in pericyte cells, the release or
 CC proteoglycans from cartilage, proliferation of inner ear articular
 CC supporting cells, the proliferation of T-lymphocyte cells, the release
 CC of a cytokine from peripheral blood mononuclear cells (PBMC), or the
 CC proliferation of endothelial cells), a method for modulating the uptake
 CC of glucose or free fatty acid (FFA) by skeletal muscle cells,
 CC a method for inhibiting the binding of A-peptide to factor VIIA,
 CC or the differentiation of adipocyte cells, a method for detecting the
 CC presence of a tumour in a mammal and an oligonucleotide probe derived
 CC from any of the nucleotide sequences cited above. The nucleic acids and
 CC polypeptides are useful for treating inflammatory diseases, organ
 CC failure, atherosclerosis, cardiac injury, infertility, birth defects,
 CC premature aging, AIDS (acquired immunodeficiency syndrome), cancer, or
 CC diabetic complications. The nucleic acids are useful as hybridisation
 CC probes, in chromosome and gene mapping, and in generating antisense RNA
 CC or DNA. The polypeptides are useful as pharmaceuticals, diagnostics,
 CC biosensors or bioreactors. Both are useful in tissue typing.
 CC The present sequence encodes a PRO protein of the invention.
 XX
 SQ Sequence 2185 BP; 527 A; 666 C; 519 G; 473 T; 0 other;

Query Match		100.0%	Score 2185;	DB 25;	Length 2185;		
Best Local Similarity		100.0%	Pred. No. 0;				
Matches 2185; Conservative		0;	Mismatches	0;	Indels	0;	Gaps
		0;					
1	GTCTCTCTTCCAGAGCCAAATCCAGAGCGATGGTGAATATGACGGCCACACCATGA	60					
b	1 GTCTCTCTTCCAGAGCCAAATCCAGAGCGATGGTGAATATGACGGCCACACCATGA	60					
y	61 AGCTCTTGTGGCAGAGTAAGTGTGACACACACACACCTGGAAATGCCATCTCTGCTCCGTTGG	120					
b	61 AGCTCTTGTGGCAGAGTAAGTGTGACACACACACACCTGGAAATGCCATCTCTGCTCCGTTGG	120					
y	121 TGTACCTACAGGCGAGAGTGTGATCTGTGTGACAGCCATCTCTGCTGCGCTCAGCGG	180					
b	121 TGTACCTACAGGCGAGAGTGTGATCTGTGTGACAGCCATCTCTGCTGCGCTCAGCGG	180					
y	181 GGCCCCAGAACTGCCCTCCGTTTGTCTGTGAGTAACAGATTCAAGAGGTGGTGTGCA	240					
b	181 GGCCCCAGAACTGCCCTCCGTTTGTCTGTGAGTAACAGATTCAAGAGGTGGTGTGCA	240					
y	241 CGCGCGGGGCTCTCTCGAGGTCCCGAGAGTATTCCTCTGAAACACCGGTACCTCAACC	300					
b	241 CGCGCGGGGCTCTCTCGAGGTCCCGAGAGTATTCCTCTGAAACACCGGTACCTCAACC	300					
y	301 TCATGAGAAACATCCAGATGATCCAGGCGACACCTTCGCGCACTCCACACCTGG	360					
b	301 TCATGAGAAACATCCAGATGATCCAGGCGACACCTTCGCGCACTCCACACCTGG	360					
y	361 AGTCTCTGAGTTGGGAGGAACTCCATCCGCGAGATGAGGTGGGGCTTCAACGGCC	420					
b	361 AGTCTCTGAGTTGGGAGGAACTCCATCCGCGAGATGAGGTGGGGCTTCAACGGCC	420					
y	421 TGGCGAGCTCAGACCTCGAGAGCTGTTCGAACTGCTGAGTCACTCCCTAGCGGG	480					
b	421 TGGCGAGCTCAGACCTCGAGAGCTGTTCGAACTGCTGAGTCACTCCCTAGCGGG	480					
y	481 CTTTGAATACCTGTCCAGCTCGGAGGCTCTGCTTCGAAACACCCCATCGAAAGCA	540					
b	481 CTTTGAATACCTGTCCAGCTCGGAGGCTCTGCTTCGAAACACCCCATCGAAAGCA	540					
y	541 TCGCTCTTACGGCTTCAACCGGGGCTCTCTCTGAGATCAGGCTGCTGCTGAGGAGCTCA	600					
b	541 TCGCTCTTACGGCTTCAACCGGGGCTCTCTCTGAGATCAGGCTGCTGCTGAGGAGCTCA	600					
y	601 AGAAGCTGAGTATATCTGAGGAGCTTTTGGGGGCTTTCAACCTCAAGTATCTGA	660					
b	601 AGAAGCTGAGTATATCTGAGGAGCTTTTGGGGGCTTTCAACCTCAAGTATCTGA	660					
y	661 ACTTGGGATGTGCAATTAAGACATGCCCCAATCTCAACCCCTGTGGGGCTGGAGG	720					
b	661 ACTTGGGATGTGCAATTAAGACATGCCCCAATCTCAACCCCTGTGGGGCTGGAGG	720					
y	721 AGCTGGAGATGTGAGGAACTCTCCCTGAGATCAGGCTGCTCTTCCATGGCCTGA	780					
b	721 AGCTGGAGATGTGAGGAACTCTCCCTGAGATCAGGCTGCTCTTCCATGGCCTGA	780					
y	781 GCTCCCTCAAGAGCTCTGGGTATGAATCAAGGTCAAGCTGATTTGAGCGGAATGCTT	840					
b	781 GCTCCCTCAAGAGCTCTGGGTATGAATCAAGGTCAAGCTGATTTGAGCGGAATGCTT	840					
y	841 TTGAGGGGCTGGCTTCACTTGTGGAACTCACTTGGCGGCAATTAACCTCTCTTTCG	900					
b	841 TTGAGGGGCTGGCTTCACTTGTGGAACTCACTTGGCGGCAATTAACCTCTCTTTCG	900					
y	901 CCCATGACCTCTTACCCCGCTGAGTACCTGGTGGAGTTGCATCTACACCAACCCCTT	960					
b	901 CCCATGACCTCTTACCCCGCTGAGTACCTGGTGGAGTTGCATCTACACCAACCCCTT	960					
y	961 GGAAGCTGATGTGACATCTCTGGGTAGCTGTGGCTGTGAGGTATATACCCACA	1020					
b	961 GGAAGCTGATGTGACATCTCTGGGTAGCTGTGGCTGTGAGGTATATACCCACA	1020					
y	1021 ATTCCACCTGCTGGGCGCTGTCATGCTCCCATGACATGCGAGGCGCTACCTCGTGG	1080					

Db	1021	ATTCCACCTGCTGTCGCGCTGTCATGCTCCCATGACATGCGAGGCGCTACCTCGTGG	1080
Qy	1081	AGGTGACACAGGCTCTCTTCCAGTGTCTGCCCCCTTCAATCATGAGCAGCACTCGAGACC	1140
Db	1081	AGGTGACACAGGCTCTCTTCCAGTGTCTGCCCCCTTCAATCATGAGCAGCACTCGAGACC	1140
Qy	1141	TCAACATTTCTGAGGGTGGATGGAGAACTTAAGTGTGGATCTCCCTATATGTCTCGG	1200
Db	1141	TCAACATTTCTGAGGGTGGATGGAGAACTTAAGTGTGGATCTCCCTATATGTCTCGG	1200
Qy	1201	TGAAGTGTGCTGCTGCCCAATGGGACAGTGTCTAGCCACGCTCCCGCCACCAAGATCT	1260
Db	1201	TGAAGTGTGCTGCTGCCCAATGGGACAGTGTCTAGCCACGCTCCCGCCACCAAGATCT	1260
Qy	1261	CTGTCTCTCAACGAGCGGACCTTGAACTTTTCCGACGCTGCTTTTTCAGACACTGGGGTGT	1320
Db	1261	CTGTCTCTCAACGAGCGGACCTTGAACTTTTCCGACGCTGCTTTTTCAGACACTGGGGTGT	1320
Qy	1321	ACACATGATGCTGACCAATGTTGCAAGGCAACTCCAAACGCTCGGCTACCTCAATGTGA	1380
Db	1321	ACACATGATGCTGACCAATGTTGCAAGGCAACTCCAAACGCTCGGCTACCTCAATGTGA	1380
Qy	1381	GCACGGCTGAGCTTAAACACCTCCAACTACAGCTTTCTTCCACAGTAAACAGTGGAGACA	1440
Db	1381	GCACGGCTGAGCTTAAACACCTCCAACTACAGCTTTCTTCCACAGTAAACAGTGGAGACA	1440
Qy	1441	CGAGATCTCGCTGAGGACACAGCGGAAAGTACAGGCTTTCTTCCACAGTAAACAGTGGAG	1500
Db	1441	CGAGATCTCGCTGAGGACACAGCGGAAAGTACAGGCTTTCTTCCACAGTAAACAGTGGAG	1500
Qy	1501	GTTACACAGCGGCAATATACCACTTACCAAGCTGCTCAATCAGACTACCCGCTGCCCCA	1560
Db	1501	GTTACACAGCGGCAATATACCACTTACCAAGCTGCTCAATCAGACTACCCGCTGCCCCA	1560
Qy	1561	AGCAGTGGGAGTACCGCGGACAGACACCACTGACAGTACAGGACCGCTGGATGAG	1620
Db	1561	AGCAGTGGGAGTACCGCGGACAGACACCACTGACAGTACAGGACCGCTGGATGAG	1620
Qy	1621	TCATGAGACACCAAGATCATATTTGGCTGCTTTTGGCAGTGACTCTGTAGCTGCGG	1680
Db	1621	TCATGAGACACCAAGATCATATTTGGCTGCTTTTGGCAGTGACTCTGTAGCTGCGG	1680
Qy	1681	CCATGTTGATGTTCTTCTATAAATCTTCTAAGCGGACCCAGCAGCGGAGTACAGTACAG	1740
Db	1681	CCATGTTGATGTTCTTCTATAAATCTTCTAAGCGGACCCAGCAGCGGAGTACAGTACAG	1740
Qy	1741	CCGCCGAGCTGTTGAGTAACTCCAGTGGAGACACATCCAGCAGCAACATCCGAG	1800
Db	1741	CCGCCGAGCTGTTGAGTAACTCCAGTGGAGACACATCCAGCAGCAACATCCGAG	1800
Qy	1801	CAGCAACAGCAGCTCCGTCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC	1860
Db	1801	CAGCAACAGCAGCTCCGTCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC	1860
Qy	1861	ATGACCATATTAATCAACACCTACAGGACAGCAATCCAGGCGGCTGAGCAGGAGAAACA	1920
Db	1861	ATGACCATATTAATCAACACCTACAGGACAGCAATCCAGGCGGCTGAGCAGGAGAAACA	1920
Qy	1921	GCCTGGGGAATCTCTGACCCCAAGTACCACTATCTCTGAACCTTATATAATTCAGA	1980
Db	1921	GCCTGGGGAATCTCTGACCCCAAGTACCACTATCTCTGAACCTTATATAATTCAGA	1980
Qy	1981	CCCATACCAAGGACAGGTACAGGAACTCAATATGATCTCCCTCCCAAAACCTTA	2040
Db	1981	CCCATACCAAGGACAGGTACAGGAACTCAATATGATCTCCCTCCCAAAACCTTA	2040
Qy	2041	TAAATGCAATAGATGACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGCTTT	2100
Db	2041	TAAATGCAATAGATGACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGCTTT	2100
Qy	2101	TTCTGTGATATGCTTATATATTAAGTCTATGGCTGGTGTAAAAAAGAGATTTATTTAA	2160

Db 2101 TTCCTGTATATCTATATATTAAGTCTCTATGGCTGGTTAAATAAAACAGATTATATTA 2160
Qy 2161 AATTTAAAGACAAAGTCAAAACA 2185
Db 2161 AATTTAAAGACAAAGTCAAAACA 2185

RESULT 7

ID ABX89359 standard; cDNA; 2185 BP.

AC ABX89359;

XX 13-MAY-2003 (first entry)

XX DNA encoding novel secreted and transmembrane protein PRO1111.

XX Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumor; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; Gene; ss.

XX Homo sapiens.

XX US2003017563-A1.

XX 23-JAN-2003.

XX 07-MAY-2002; 2002US-0140808.

XX 31-MAR-1997; 97WO-US05230.
PR 12-JUN-1998; 98WO-US12455.
PR 14-JUL-1998; 98WO-US14552.
PR 28-AUG-1998; 98WO-US17886.
PR 10-SEP-1998; 98WO-US18824.
PR 14-SEP-1998; 98WO-US19093.
PR 14-SEP-1998; 98WO-US19094.
PR 16-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 29-OCT-1998; 98WO-US22991.
PR 20-NOV-1998; 98WO-US22992.
PR 01-DEC-1998; 98WO-US24855.
PR 05-JAN-1999; 98WO-US25108.
PR 08-MAR-1999; 98WO-US05028.
PR 10-MAR-1999; 98WO-US05190.
PR 20-APR-1999; 98WO-US08615.
PR 14-MAY-1999; 98WO-US10733.
PR 02-JUN-1999; 98WO-US12252.
PR 01-SEP-1999; 98WO-US20111.
PR 08-SEP-1999; 98WO-US20594.
PR 13-SEP-1999; 98WO-US20944.
PR 15-SEP-1999; 98WO-US21090.
PR 15-SEP-1999; 98WO-US21547.
PR 29-OCT-1999; 98WO-US23089.
PR 29-NOV-1999; 98WO-US28214.
PR 30-NOV-1999; 98WO-US28313.
PR 30-NOV-1999; 98WO-US28409.
PR 01-DEC-1999; 98WO-US28301.
PR 01-DEC-1999; 98WO-US28634.
PR 02-DEC-1999; 98WO-US28551.
PR 02-DEC-1999; 98WO-US28564.
PR 02-DEC-1999; 98WO-US28565.
PR 16-DEC-1999; 98WO-US30095.
PR 20-DEC-1999; 98WO-US30911.

PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUN-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 23-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-148238/14.
DR P-PSDB; ABUS9869.

XX Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT

T and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
T are therapeutically useful for enhancing immune response and in cancer
T treatments -
X
S Claim 2; Fig 437; 659pp; English.
X
C The invention describes an isolated human PRO polypeptide. The PRO
C polypeptides are useful in detecting PRO polypeptides in a sample, in
C linking a bioactive molecule to a cell expressing a PRO polypeptide, and
C in modulating at least one biological activity of a cell expressing a PRO
C polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
C useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
C stimulate adrenal cortical capillary endothelial growth, and PRO536,
C PRO943, PRO828, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
C PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
C useful for treating conditions or disorders where angiogenesis would be
C beneficial, e.g. wound healing and antagonist of this polypeptide are
C useful for treating cancerous tumours. PRO812 inhibits vascular
C endothelial growth factor (VEGF) stimulated proliferation of endothelial
C cells and is thus useful for inhibiting endothelial cell growth in
C mammals which would be beneficial in inhibiting tumour growth. PRO826,
C PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
C stimulated T-lymphocytes and are therapeutically useful for enhancing
C immune response. PRO828, PRO826, PRO1068 or PRO132 enhance survival of
C retinal neurons cells (PRO1132 is also enhances survival/proliferation of
C rod photoreceptor cells) and therefore are useful for treating retinal
C disorders of injuries, e.g. retinitis pigmentosa, AMD, PRO819, PRO813
C and PRO1066 induce proliferation of mammalian kidney mesangial cells,
C and therefore are useful for treating kidney disorders associated with
C decreased mesangial cell function such as Berger disease or Crohn's
C nephropathies associated with dermatitis, herpeticiformis or Crohn's
C disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
C proliferation and/or redifferentiation of chondrocytes in culture and
C are thus useful for treating sports injuries, and arthritis. This
C sequence encodes a novel human PRO protein.

X Q Sequence 2185 BP; 527 A; 666 C; 519 G; 473 T; 0 other;

Query Match 100.0%; Score 2185; DB 25; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Y 1 GTTCTCTTCCAGGCAAAATCCAGGGGATGGTGAATTATGACGTGCGACACCATGA 60
b 1 GTTCTCTTCCAGGCAAAATCCAGGGGATGGTGAATTATGACGTGCGACACCATGA 60
Y 61 AGCTCTTGTGCGAGTAACCTGTCACACACACCTGGAATGCCATCTGCTCCCGTTGCG 120
b 61 AGCTCTTGTGCGAGTAACCTGTCACACACACCTGGAATGCCATCTGCTCCCGTTGCG 120
Y 121 TCTACTCTACGGCGCAAGTGTGATTTCTGTGTCAGCCATGCTGCTGCCCTCAGCGG 180
b 121 TCTACTCTACGGCGCAAGTGTGATTTCTGTGTCAGCCATGCTGCTGCCCTCAGCGG 180
Y 181 GCGCCAGAGACTGCCCTCGCTTGTGTCGAGTAACAGTTCAGCAGGTGGTGTGCA 240
b 181 GCGCCAGAGACTGCCCTCGCTTGTGTCGAGTAACAGTTCAGCAGGTGGTGTGCA 240
Y 241 CGCGCGCGGGCCCTCTCGAGGTCGCGAGGGATTTCCCTCGAACACCGGTACTCAACC 300
b 241 CGCGCGCGGGCCCTCTCGAGGTCGCGAGGGATTTCCCTCGAACACCGGTACTCAACC 300
Y 301 TCATGGAGAACATCATCCAGATGATCCAGGCGAGACCTTCGCGACCTCCAGACCTGG 360
b 301 TCATGGAGAACATCATCCAGATGATCCAGGCGAGACCTTCGCGACCTCCAGACCTGG 360
Y 361 AGGTCTCTGAGTTGGGAGGAACTCCATCCGGCAGATTGAGGTGGGGGCTTCAACGGCC 420
b 361 AGGTCTCTGAGTTGGGAGGAACTCCATCCGGCAGATTGAGGTGGGGGCTTCAACGGCC 420
Y 421 TGCGCAGCCTCAACACCTCGAGCTGTTCGAACCTGGCTGACAGTCATCCCTAGCGGG 480
b 421 TGCGCAGCCTCAACACCTCGAGCTGTTCGAACCTGGCTGACAGTCATCCCTAGCGGG 480

Qy 481 CTTTCAATACCTGTCCAAAGCTGCGGAGCTCTGCTTCGCAACAAACCCCATCGAAAGCA 540
Db 481 CTTTCAATACCTGTCCAAAGCTGCGGAGCTCTGCTTCGCAACAAACCCCATCGAAAGCA 540
Qy 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCTCATGCGCTGAGCTTGGGGAGCTCA 600
Db 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCTCATGCGCTGAGCTTGGGGAGCTCA 600
Qy 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGAAGGGCTGTGTCAACCTCAAGTATCTGA 660
Db 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGAAGGGCTGTGTCAACCTCAAGTATCTGA 660
Qy 661 ACTTGGGCTGTGCAACATTAAGCATGCCCAATCTACCCCTCTGGTGGGGCTGGAGG 720
Db 661 ACTTGGGCTGTGCAACATTAAGCATGCCCAATCTACCCCTCTGGTGGGGCTGGAGG 720
Qy 721 AGCTGAGATGTCAAGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGAGCTGA 780
Db 721 AGCTGAGATGTCAAGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGAGCTGA 780
Qy 781 GCTCCCTCAAGAGCTCTGGGTATGAACTCAGAGTCAAGCTGATGAGCGGAATGCTT 840
Db 781 GCTCCCTCAAGAGCTCTGGGTATGAACTCAGAGTCAAGCTGATGAGCGGAATGCTT 840
Qy 841 TTGACGGGCTGGCTTCACTTGTGGAACTCAAATTGGCCCAATAAACCCTCTCTTTTGC 900
Db 841 TTGACGGGCTGGCTTCACTTGTGGAACTCAAATTGGCCCAATAAACCCTCTCTTTTGC 900
Qy 901 CCATGACCTCTTTACCCGCTGAGTACTCTGGTGGAGTGTGATACACCAACCTT 960
Db 901 CCATGACCTCTTTACCCGCTGAGTACTCTGGTGGAGTGTGATACACCAACCTT 960
Qy 961 GGAACCTGTGATGTGACATTTCTGTGCTAGCTGAGCTGGTGGCTTGGAGATATATACCA 1020
Db 961 GGAACCTGTGATGTGACATTTCTGTGCTAGCTGAGCTGGTGGCTTGGAGATATATACCA 1020
Qy 1021 ATTCCACCTGTGCTGGCGCTGTCATGCTCCCATGCAATGAGAGCGCTACCTGCTGG 1080
Db 1021 ATTCCACCTGTGCTGGCGCTGTCATGCTCCCATGCAATGAGAGCGCTACCTGCTGG 1080
Qy 1081 AGGTGACAGGGCTCTTCCAGTGTCTGCGCCCTTTCATCATGAGCGCACCTCGAGACC 1140
Db 1081 AGGTGACAGGGCTCTTCCAGTGTCTGCGCCCTTTCATCATGAGCGCACCTCGAGACC 1140
Qy 1141 TCAACATTTCTGAGGGTGGATGCGAGAACTTAAAGTGTGCGACTCCCTATGTCCTCG 1200
Db 1141 TCAACATTTCTGAGGGTGGATGCGAGAACTTAAAGTGTGCGACTCCCTATGTCCTCG 1200
Qy 1201 TGAAGTGTGCTGCCAATGGGACAGTGTGAGCCAGCGCTCCGCGACCAAGATCT 1260
Db 1201 TGAAGTGTGCTGCCAATGGGACAGTGTGAGCCAGCGCTCCGCGACCAAGATCT 1260
Qy 1261 CTGTCTCAACAGCGCACCTTGAACCTTTTCCACCTGCTGCTTTTTCAGACACTGGGGTGT 1320
Db 1261 CTGTCTCAACAGCGCACCTTGAACCTTTTCCACCTGCTGCTTTTTCAGACACTGGGGTGT 1320
Qy 1321 ACATGATGATGAGCAATGTTGAGGCAACCTTCAACCGCTCGGCTTACCTCAATGTGA 1380
Db 1321 ACATGATGATGAGCAATGTTGAGGCAACCTTCAACCGCTCGGCTTACCTCAATGTGA 1380
Qy 1381 GCGGCTGAGCTTAAACCTTCCAACTGAGCTTTCACCAAGTAAAGTGGAGACCA 1440
Db 1381 GCGGCTGAGCTTAAACCTTCCAACTGAGCTTTCACCAAGTAAAGTGGAGACCA 1440
Qy 1441 CGGAGATCTCGCTGAGGACACCAACCGGAAAGTACAAAGCTGTTCCTACAGTCCACTG 1500
Db 1441 CGGAGATCTCGCTGAGGACACCAACCGGAAAGTACAAAGCTGTTCCTACAGTCCACTG 1500
Qy 1501 GTTACGAGCGGATATACCACTTACCAAGTGTCTTACAGTACCTACCTGCTGCCCA 1560
Db 1501 GTTACGAGCGGATATACCACTTACCAAGTGTCTTACAGTACCTACCTGCTGCCCA 1560

QY 1561 AGCAGTGGCAGTACCCGCGACGACACACTGCAAGCATGCAGCCAGCTCGATGAAG 1620
DB |||||
QY 1561 AGCAGTGGCAGTACCCGCGACGACACACTGCAAGCATGCAGCCAGCTCGATGAAG 1620
DB |||||
QY 1621 TCATGAAGACCAACCAAGATCATCATTTGGCTGCTTTGTGGCAGTACCTGCTAGCTCCG 1680
DB |||||
QY 1621 TCATGAAGACCAACCAAGATCATCATTTGGCTGCTTTGTGGCAGTACCTGCTAGCTCCG 1680
DB |||||
QY 1681 CCATGTTGATTTCTCTTATTAACCTTCGTAGCGGCACACGAGGAGTACAGTCAAG 1740
DB |||||
QY 1681 CCATGTTGATTTCTCTTATTAACCTTCGTAGCGGCACACGAGGAGTACAGTCAAG 1740
DB |||||
QY 1741 CGCGCCGACTGTTGAGATAATCCAGGTGGACGAGACATCCAGCAGCAATCCCGAG 1800
DB |||||
QY 1801 CAGCAACAGCAGCTCGCTCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC 1860
DB |||||
QY 1801 CAGCAACAGCAGCTCGCTCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC 1860
DB |||||
QY 1861 ATGACCATATTAACTACAACTTACAAACGACATGCGGGGCGACATGGGCGGCAAGAAAACA 1920
DB |||||
QY 1861 ATGACCATATTAACTACAACTTACAAACGACATGCGGGGCGACATGGGCGGCAAGAAAACA 1920
DB |||||
QY 1921 GCCTGGGAACCTCTGTGACCCCAAGTCAACATCTCTGAACTTTATTAATTGAGA 1980
DB |||||
QY 1921 GCCTGGGAACCTCTGTGACCCCAAGTCAACATCTCTGAACTTTATTAATTGAGA 1980
DB |||||
QY 1981 CCCATACCAAGCAGCAGGTPACAGGAACTCAAAATGACTCCCTCCCGGCAAGAACTTA 2040
DB |||||
QY 1981 CCCATACCAAGCAGCAGGTPACAGGAACTCAAAATGACTCCCTCCCGGCAAGAACTTA 2040
DB |||||
QY 2041 TAAATGCAATGAATGCAACAAAGACAGCAACTTTTGTACAGTGGGAGAGACTTT 2100
DB |||||
QY 2041 TAAATGCAATGAATGCAACAAAGACAGCAACTTTTGTACAGTGGGAGAGACTTT 2100
DB |||||
QY 2101 TTCTTGATATGCTTATATTAATTAAGTCTATGCTGCTGCTTAAABAAACAGATTATATA 2160
DB |||||
QY 2101 TTCTTGATATGCTTATATTAATTAAGTCTATGCTGCTGCTTAAABAAACAGATTATATA 2160
DB |||||
QY 2161 AATTTAAAGACAAAAGTCAAAAACA 2185
DB |||||
QY 2161 AATTTAAAGACAAAAGTCAAAAACA 2185
DB |||||

RESULT 8
ABX80270
ID ABX80270 standard; DNA; 2185 BP.
XX
AC ABX80270;
XX
DT 28-APR-2003 (first entry)
DE
DE Novel human secreted or transmembrane protein PRO1344 DNA.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; gene; ds.
XX
OS Homo sapiens.
XX
XX US2002132252-A1.
PN
XX
PD 19-SEP-2002.
XX
XX 14-NOV-2001; 2001US-0990442.
PF

10-JUN-1998; 98US-088742P.
 10-JUN-1998; 98US-088810P.
 10-JUN-1998; 98US-088824P.
 10-JUN-1998; 98US-088826P.
 11-JUN-1998; 98US-088858P.
 11-JUN-1998; 98US-088861P.
 11-JUN-1998; 98US-088876P.
 12-JUN-1998; 98US-089105P.
 16-JUN-1998; 98US-089440P.
 16-JUN-1998; 98US-089512P.
 16-JUN-1998; 98US-089514P.
 17-JUN-1998; 98US-089532P.
 17-JUN-1998; 98US-089538P.
 17-JUN-1998; 98US-089598P.
 17-JUN-1998; 98US-089599P.
 17-JUN-1998; 98US-089600P.
 17-JUN-1998; 98US-089653P.
 18-JUN-1998; 98US-089801P.
 18-JUN-1998; 98US-089907P.
 18-JUN-1998; 98US-089908P.
 28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH INC.

Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL, Ferrara N, Fong S, Gerber H, Gerritsen MB, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams EM, Wood WI, Zhang Z;

WPI; 2003-247083/24.
 P-PSDB; ABUS9111.

Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346 and PRO1375, which stimulate proliferation of stimulated T-lymphocytes are therapeutically useful for enhancing immune response and in cancer treatments

Claim 2; Fig 158; 648pp; English.

The invention describes an isolated human PRO polypeptide. The PRO polypeptides are useful in detecting PRO polypeptides in a sample, in linking a bioactive molecule to a cell expressing a PRO polypeptide, and in modulating at least one biological activity of a cell expressing a PRO polypeptide. PRO132 stimulates hypertrophy of neonatal heart and is thus useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186 stimulate adrenal cortical capillary endothelial growth, and PRO536, PRO943, PRO828, PRO1068 or PRO535, PRO826, PRO819, PRO1126, PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus useful for treating conditions or disorders where angiogenesis would be beneficial, e.g. wound healing and antagonist of this polypeptide are useful for treating cancerous tumours. PRO812 inhibits vascular endothelial growth factor (VEGF) stimulated proliferation of endothelial cells and is thus useful for inhibiting endothelial cell growth in mammals which would be beneficial in inhibiting tumour growth. PRO826, PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of stimulated T-lymphocytes and are therapeutically useful for enhancing immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of retinal neurons cells (PRO1132 is also enhances survival/proliferation of rod photoreceptor cells) and therefore are useful for treating retinal disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO813, PRO813 and PRO1066 induce proliferation of mammalian kidney mesangial cells, and therefore are useful for treating kidney disorders associated with decreased mesangial cell function such as Berger disease or other nephropathies associated with dermatitis, herpeticiformis or Crohn's disease. PRO310, PRO844, PRO1312, PRO1192 and PRO1387 induce the proliferation and/or redifferentiation of chondrocytes in culture and are thus useful for treating sports injuries, and arthritis. This sequence represents a novel human PRO protein polynucleotide.

Sequence 2185 BP; 527 A; 666 C; 519 G; 473 T; 0 other;

Query Match 100.0%; Score 2185; DB 25; Length 2185;

	Best Local Similarity	100.0%;	Pred. No. 0;	Mismatches	0;	Indels	0;	Gaps	0;
	Matches	2185;	Conservative	0;					
QY	1	GTCTCTCTTCCGAGCCAAATCCAGGCGATGGTGAATATGAAGTGCACACCATGA	60						
DB	1	GTCTCTCTTCCGAGCCAAATCCAGGCGATGGTGAATATGAAGTGCACACCATGA	60						
QY	61	AGCTCTTGTGGCAGGTAACTGTGTCACCCACCACTTGGAAATCCATCTCTCCGCTTCG	120						
DB	61	AGCTCTTGTGGCAGGTAACTGTGTCACCCACCACTTGGAAATCCATCTCTCCGCTTCG	120						
QY	121	TCTACCTCAGGGCGCAAGTGTGATCTGTGTGACGCCATCGCTGCTCGGCTCAGCG	180						
DB	121	TCTACCTCAGGGCGCAAGTGTGATCTGTGTGACGCCATCGCTGCTCGGCTCAGCG	180						
QY	181	GGCCCCAGAACTGCCCTTCGTTGCTGTCAGTAAACCAAGTTCAGCAAGTGTGTGCA	240						
DB	181	GGCCCCAGAACTGCCCTTCGTTGCTGTCAGTAAACCAAGTTCAGCAAGTGTGTGCA	240						
QY	241	CGCGCGGGGCTCTCCGAGTCCCGAGGTTTCCTCGAACAACCCGGTACTCAACC	300						
DB	241	CGCGCGGGGCTCTCCGAGTCCCGAGGTTTCCTCGAACAACCCGGTACTCAACC	300						
QY	301	TCATGGAGAACCAATCCAGATGATCCAGCCGACACTTCCGCACTCCACACCTGG	360						
DB	301	TCATGGAGAACCAATCCAGATGATCCAGCCGACACTTCCGCACTCCACACCTGG	360						
QY	361	AGCTCTCTGAGTGTGGCAGGAATCTCAATCCGCGCAGATGAGTGGGGGCTTCAAGGCC	420						
DB	361	AGCTCTCTGAGTGTGGCAGGAATCTCAATCCGCGCAGATGAGTGGGGGCTTCAAGGCC	420						
QY	421	TGGCCAGCTCAACACCTCGAGCTGTTCCGACAACTGGCTGACAGTCACTCCCTAGCGGG	480						
DB	421	TGGCCAGCTCAACACCTCGAGCTGTTCCGACAACTGGCTGACAGTCACTCCCTAGCGGG	480						
QY	481	CCTTTGATATCTCTCAAGCTCGGGAGCTCTGGCTTCGCAACAACTCCATCGAAAGCA	540						
DB	481	CCTTTGATATCTCTCAAGCTCGGGAGCTCTGGCTTCGCAACAACTCCATCGAAAGCA	540						
QY	541	TCCCTCTTACGCTTCAACCGGGTGGCTCCCTCATGCGCTGGACTTGGGGGAGCTCA	600						
DB	541	TCCCTCTTACGCTTCAACCGGGTGGCTCCCTCATGCGCTGGACTTGGGGGAGCTCA	600						
QY	601	AGAACTGGAGTATCTCTGAGGGAGCTTTGAGGGGCTGTTCAACTCAAGTATCTGA	660						
DB	601	AGAACTGGAGTATCTCTGAGGGAGCTTTGAGGGGCTGTTCAACTCAAGTATCTGA	660						
QY	661	ACTTGGGCAATGTGCAACATTAAGACATGCCATCTCACCCCTGGTGGGGCTGAGG	720						
DB	661	ACTTGGGCAATGTGCAACATTAAGACATGCCATCTCACCCCTGGTGGGGCTGAGG	720						
QY	721	AGCTGGAGATCTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTCCATGGGCTGA	780						
DB	721	AGCTGGAGATCTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTCCATGGGCTGA	780						
QY	781	GCTCCCTCAAGAACTCTGGGCTCATGAATCAGAGTCAAGCTGATGAGGGAATGCTT	840						
DB	781	GCTCCCTCAAGAACTCTGGGCTCATGAATCAGAGTCAAGCTGATGAGGGAATGCTT	840						
QY	841	TGAGGGGCTGGCTTCACTGTGGAATCAACTTGGGCCCAATAACTCTCTCTTTTC	900						
DB	841	TGAGGGGCTGGCTTCACTGTGGAATCAACTTGGGCCCAATAACTCTCTCTTTTC	900						
QY	901	CCCATGACTCTTTTACCCCGCTGAGGTACCTGTGGAGTTGCAATACCAACACCTT	960						
DB	901	CCCATGACTCTTTTACCCCGCTGAGGTACCTGTGGAGTTGCAATACCAACACCTT	960						
QY	961	GGAACTGTGATGTGACATTTCTGTGGCTAGCTGGCTGGCTGGAGTATATACCAACA	1020						
DB	961	GGAACTGTGATGTGACATTTCTGTGGCTAGCTGGCTGGCTGGAGTATATACCAACA	1020						
QY	1021	ATTCACCTGCTGTGGCGCTGTCTCATCTCCCATGCACATGCGAGGCGCTACTCTGTGG	1080						

1021 ATTCCACCTGCTGTGCGCGCTGTCTATGCTCCCATGCAATGCGAGCGCGCTACCTCGTGG 1080
 1081 AGGTGACACAGGCTCTCTCCAGTCTCTGCGCCCTTCTATCATGACGACCTCTGAGACC 1140
 1081 AGTGGACAGGCTCTCTCCAGTCTCTGCGCCCTTCTATCATGACGACCTCTGAGACC 1140
 1141 TCAACATTTCTGAGGTCGAGTGGCAGAACTTAAAGTGTGCGACTCCCTATGCTCTCG 1200
 1141 TCAACATTTCTGAGGTCGAGTGGCAGAACTTAAAGTGTGCGACTCCCTATGCTCTCG 1200
 1201 TGAAGTGTGCTGCTGCGCAATGGACAGTCTCAGACAGCGCTCCCGCCACCAAGGATCT 1260
 1201 TGAAGTGTGCTGCTGCGCAATGGACAGTCTCAGACAGCGCTCCCGCCACCAAGGATCT 1260
 1261 CTGTCTCTCAACGACGCGACCTTTGAATTTTCCACAGTCTGCTTTTTCAGACACTGCGGTGT 1320
 1261 CTGTCTCTCAACGACGCGACCTTTGAATTTTCCACAGTCTGCTTTTTCAGACACTGCGGTGT 1320
 1321 ACATGATGTCGATGACCAATGTCAGGCAATCTCCACGCTCGGCTACTCTCATGTGA 1380
 1321 ACATGATGTCGATGACCAATGTCAGGCAATCTCCACGCTCGGCTACTCTCATGTGA 1380
 1381 GCAAGCTGAGCTTTAACAATCTCAACTCAGCTTTCTTCCACAGTAACTGAGGACCA 1440
 1381 GCAAGCTGAGCTTTAACAATCTCAACTCAGCTTTCTTCCACAGTAACTGAGGACCA 1440
 1441 CGAGATCTCGCTGAGGACCAACGCGAAAGTCAAGCTGTTCTTACACAGCTCCACTG 1500
 1441 CGAGATCTCGCTGAGGACCAACGCGAAAGTCAAGCTGTTCTTACACAGCTCCACTG 1500
 1501 GTTACAGCGCGGATATACACTCTTACCACTGCTCTTCACTCAGACTACCGTGTGCCCA 1560
 1501 GTTACAGCGCGGATATACACTCTTACCACTGCTCTTCACTCAGACTACCGTGTGCCCA 1560
 1561 AGCAGTGTGAGTACCGCGAGACACCACTGACAAAGTGCAGACGAGCTGTGATGAAG 1620
 1561 AGCAGTGTGAGTACCGCGAGACACCACTGACAAAGTGCAGACGAGCTGTGATGAAG 1620
 1621 TCATGAAGACCCAGAGTATCATTTGGCTGCTTTGTCGAGTACTCTGTAGTGTGCG 1680
 1621 TCATGAAGACCCAGAGTATCATTTGGCTGCTTTGTCGAGTACTCTGTAGTGTGCG 1680
 1681 CCATGTGTGATTTCTTCTATAACTTCGTAAGCGGCAACAGCGGAGTACAGTCAAG 1740
 1681 CCATGTGTGATTTCTTCTATAACTTCGTAAGCGGCAACAGCGGAGTACAGTCAAG 1740
 1741 CCGCCCGGACTGTGAGTAAATCCAGGTGGAAGAGACATCCAGCAGCAATCCCGAG 1800
 1741 CCGCCCGGACTGTGAGTAAATCCAGGTGGAAGAGACATCCAGCAGCAATCCCGAG 1800
 1801 CAGCAACAGCAGCTCGCTCGGCTGTATCAGGTGAGGGGGCAGTGTGCTGCCCAATTC 1860
 1801 CAGCAACAGCAGCTCGCTCGGCTGTATCAGGTGAGGGGGCAGTGTGCTGCCCAATTC 1860
 1861 ATGACCATTTAATCAACACCTTCAAAACGAGACATGCGGCGGACCTGGACAGAAACA 1920
 1861 ATGACCATTTAATCAACACCTTCAAAACGAGACATGCGGCGGACCTGGACAGAAACA 1920
 1921 GCTGTGGGAACTCTCTGCAACCCACAGTCAACCTATCTCTGAACCTTATATTCAGA 1980
 1921 GCTGTGGGAACTCTCTGCAACCCACAGTCAACCTATCTCTGAACCTTATATTCAGA 1980
 1981 CCATACCAAGGACAGGTTACAGGAACTCAAAATATGACTCCCTCCCGCAAAACTTA 2040
 1981 CCATACCAAGGACAGGTTACAGGAACTCAAAATATGACTCCCTCCCGCAAAACTTA 2040
 2041 TAAATGCAATGAAATGCAACAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
 2041 TAAATGCAATGAAATGCAACAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
 2101 TTCCTGTATATGCTTATATTAAGTCTATGGCTGTTTAAATAAAGACAGATTATTA 2160
 2101 TTCCTGTATATGCTTATATTAAGTCTATGGCTGTTTAAATAAAGACAGATTATTA 2160

QY 2161 AATTAAAGACAAAAGTCAAAACA 2185
 |||||
 Db 2161 AATTAAAGACAAAAGTCAAAACA 2185

RESULT 9
 ABX80774
 ID ABX80774 standard; cDNA; 2185 BP.
 XX
 AC ABX80774;
 XX
 DT 22-APR-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein cDNA, #93.

XX Human; gene; ss; PRO; secreted; transmembrane; pharmaceutical;
 KW diagnostic; biosensor; bioreactor; tumour; therapeutic;
 KW gene therapy; tumour-associated antigenic target; TAT; ADEPT;
 KW antibody-dependent enzyme mediated prodrug therapy; cytostatic.

XX Homo sapiens.

XX US2003027162-A1.

XX 06-FEB-2003.

XX 15-NOV-2001; 2001US-0997428.

XX 05-NOV-1997; 97WO-US20069.

XX 16-SEP-1998; 98WO-US19330.

XX 17-SEP-1998; 98WO-US19437.

XX 07-OCT-1998; 98WO-US21141.

XX 01-DEC-1998; 98WO-US21108.

XX 03-JAN-1999; 99WO-US00106.

XX 08-MAR-1999; 99WO-US05028.

XX 02-JUN-1999; 99WO-US12252.

XX 15-SEP-1999; 99WO-US21090.

XX 30-NOV-1999; 99WO-US28313.

XX 01-DEC-1999; 99WO-US28301.

XX 01-DEC-1999; 99WO-US28634.

XX 16-DEC-1999; 99WO-US30095.

XX 20-DEC-1999; 99WO-US30911.

XX 05-JAN-2000; 2000WO-US00219.

XX 06-JAN-2000; 2000WO-US00376.

XX 11-FEB-2000; 2000WO-US03565.

XX 18-FEB-2000; 2000WO-US04341.

XX 22-FEB-2000; 2000WO-US04414.

XX 24-FEB-2000; 2000WO-US04914.

XX 24-FEB-2000; 2000WO-US05004.

XX 10-MAR-2000; 2000WO-US06319.

XX 15-MAR-2000; 2000WO-US06884.

XX 20-MAR-2000; 2000WO-US07377.

XX 30-MAR-2000; 2000WO-US08439.

XX 15-MAY-2000; 2000WO-US13358.

XX 17-MAY-2000; 2000WO-US13705.

XX 22-MAY-2000; 2000WO-US14042.

XX 30-MAY-2000; 2000WO-US14941.

XX 02-JUN-2000; 2000WO-US15264.

XX 28-JUL-2000; 2000WO-US20710.

XX 11-AUG-2000; 2000WO-US22031.

XX 23-AUG-2000; 2000WO-US23522.

XX 24-AUG-2000; 2000WO-US23528.

XX 08-NOV-2000; 2000WO-US30952.

XX 01-DEC-2000; 2000WO-US32678.

XX 28-FEB-2001; 2001WO-US06520.

XX 01-JUN-2001; 2001WO-US17800.

XX 20-JUN-2001; 2001WO-US19692.

XX 29-JUN-2001; 2001WO-US21066.

XX 09-JUL-2001; 2001WO-US21735.

XX 16-JUN-1997; 97US-049787P.

R	17-OCT-1997;	97US-062250P.	PR	26-JUN-1998;	98US-050863P.
R	12-NOV-1997;	97US-065186P.	PR	01-JUL-1998;	98US-051360P.
R	13-NOV-1997;	97US-065311P.	PR	01-JUL-1998;	98US-091544P.
R	24-NOV-1997;	97US-066770P.	PR	02-JUL-1998;	98US-091478P.
R	25-FEB-1998;	98US-075945P.	PR	02-JUL-1998;	98US-091519P.
R	20-MAR-1998;	98US-078910P.	PR	02-JUL-1998;	98US-091626P.
R	28-APR-1998;	98US-083322P.	PR	02-JUL-1998;	98US-091628P.
R	07-MAY-1998;	98US-084600P.	PR	02-JUL-1998;	98US-091633P.
R	28-MAY-1998;	98US-087106P.	PR	02-JUL-1998;	98US-091646P.
R	02-JUN-1998;	98US-087607P.	PR	02-JUL-1998;	98US-091673P.
R	02-JUN-1998;	98US-087609P.	PR	07-JUL-1998;	98US-091978P.
R	02-JUN-1998;	98US-087759P.	PR	07-JUL-1998;	98US-091982P.
R	02-JUN-1998;	98US-087827P.	PR	09-JUL-1998;	98US-092182P.
R	04-JUN-1998;	98US-088021P.	PR	10-JUL-1998;	98US-092472P.
R	04-JUN-1998;	98US-088025P.	PR	20-JUL-1998;	98US-093339P.
R	04-JUN-1998;	98US-088026P.	PR	30-JUL-1998;	98US-094651P.
R	04-JUN-1998;	98US-088028P.	PR	04-AUG-1998;	98US-095282P.
R	04-JUN-1998;	98US-088029P.	PR	04-AUG-1998;	98US-095285P.
R	04-JUN-1998;	98US-088030P.	PR	04-AUG-1998;	98US-095301P.
R	04-JUN-1998;	98US-088033P.	PR	04-AUG-1998;	98US-095302P.
R	04-JUN-1998;	98US-088326P.	PR	04-AUG-1998;	98US-095318P.
R	05-JUN-1998;	98US-088167P.	PR	04-AUG-1998;	98US-095321P.
R	05-JUN-1998;	98US-088202P.	PR	04-AUG-1998;	98US-095325P.
R	05-JUN-1998;	98US-088212P.	PR	10-AUG-1998;	98US-095916P.
R	05-JUN-1998;	98US-088217P.	PR	10-AUG-1998;	98US-095929P.
R	09-JUN-1998;	98US-088655P.	PR	11-AUG-1998;	98US-096012P.
R	10-JUN-1998;	98US-088734P.	PR	11-AUG-1998;	98US-096143P.
R	10-JUN-1998;	98US-088738P.	PR	11-AUG-1998;	98US-096146P.
R	10-JUN-1998;	98US-088742P.	PR	12-AUG-1998;	98US-096323P.
R	10-JUN-1998;	98US-088810P.	PR	17-AUG-1998;	98US-096757P.
R	10-JUN-1998;	98US-088824P.	PR	17-AUG-1998;	98US-096766P.
R	10-JUN-1998;	98US-088826P.	PR	17-AUG-1998;	98US-096773P.
R	11-JUN-1998;	98US-088858P.	PR	17-AUG-1998;	98US-096779P.
R	11-JUN-1998;	98US-088861P.	PR	17-AUG-1998;	98US-096791P.
R	11-JUN-1998;	98US-088876P.	PR	17-AUG-1998;	98US-096857P.
R	12-JUN-1998;	98US-089105P.	PR	17-AUG-1998;	98US-096891P.
R	16-JUN-1998;	98US-089440P.	PR	17-AUG-1998;	98US-096894P.
R	16-JUN-1998;	98US-089512P.	PR	17-AUG-1998;	98US-096895P.
R	16-JUN-1998;	98US-089514P.	PR	17-AUG-1998;	98US-096897P.
R	17-JUN-1998;	98US-089532P.	PR	18-AUG-1998;	98US-096949P.
R	17-JUN-1998;	98US-089538P.	PR	18-AUG-1998;	98US-096950P.
R	17-JUN-1998;	98US-089598P.	PR	18-AUG-1998;	98US-096959P.
R	17-JUN-1998;	98US-089599P.	PR	18-AUG-1998;	98US-096960P.
R	17-JUN-1998;	98US-089600P.	PR	18-AUG-1998;	98US-097022P.
R	17-JUN-1998;	98US-089653P.	PR	18-AUG-1998;	98US-097141P.
R	18-JUN-1998;	98US-089801P.	PR	20-AUG-1998;	98US-097218P.
R	18-JUN-1998;	98US-089907P.	PR	24-AUG-1998;	98US-097661P.
R	18-JUN-1998;	98US-089908P.	PR	26-AUG-1998;	98US-097952P.
R	19-JUN-1998;	98US-089947P.	PR	26-AUG-1998;	98US-097954P.
R	19-JUN-1998;	98US-089948P.	PR	26-AUG-1998;	98US-097972P.
R	19-JUN-1998;	98US-089952P.	PR	26-AUG-1998;	98US-097974P.
R	22-JUN-1998;	98US-090246P.	PR	26-AUG-1998;	98US-097978P.
R	22-JUN-1998;	98US-090252P.	PR	26-AUG-1998;	98US-097979P.
R	22-JUN-1998;	98US-090254P.	PR	26-AUG-1998;	98US-097986P.
R	23-JUN-1998;	98US-090349P.	PR	26-AUG-1998;	98US-098014P.
R	23-JUN-1998;	98US-090355P.	PR	31-AUG-1998;	98US-098525P.
R	24-JUN-1998;	98US-090429P.	PR	16-SEP-1998;	98US-100634P.
R	24-JUN-1998;	98US-090431P.	PR	17-SEP-1998;	98US-100858P.
R	24-JUN-1998;	98US-090435P.	PR	22-DEC-1998;	98US-113296P.
R	24-JUN-1998;	98US-090444P.	PR	12-MAR-1999;	99US-123957P.
R	24-JUN-1998;	98US-090445P.	PR	23-JUN-1999;	99US-141037P.
R	24-JUN-1998;	98US-090472P.			
R	24-JUN-1998;	98US-090535P.			
R	24-JUN-1998;	98US-090540P.			
R	24-JUN-1998;	98US-090542P.			
R	24-JUN-1998;	98US-090557P.			
R	25-JUN-1998;	98US-090676P.			
R	25-JUN-1998;	98US-090678P.			
R	25-JUN-1998;	98US-090690P.			
R	25-JUN-1998;	98US-090694P.			
R	25-JUN-1998;	98US-090695P.			
R	25-JUN-1998;	98US-090696P.			
R	26-JUN-1998;	98US-090862P.			

Query Match 100.0%; Score 2185; DB 25; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTCTCTTTCCGAGCCAAAATCCGAGCGGATGGTGAATTATGAACGTGCCACCATGA 60
|||||
Db 1 GTTCTCTTTCCGAGCCAAAATCCGAGCGGATGGTGAATTATGAACGTGCCACCATGA 60
|||||
Qy 61 AGCTCTGGCGAGGTAAGTGTGCACCAACCTGGGAATGCCATCTGCTCCGTTGG 120
|||||

Db 61 AGCTCTTGGCAGGTAACCTGTGCAACACCACTGGAAATGCCATCTGCTCCGGTTGC 120
 Qy 121 TCTACCTCAGCGCGCAAGTGTGATTTCTGTGTGAGCCATGCTGCTCGCGCTCAGCGG 180
 Db 121 TCTACCTCAGCGCGCAAGTGTGATTTCTGTGTGAGCCATGCTGCTCGCGCTCAGCGG 180
 Qy 181 GGGCCAGAACTGCCCCCTCGTTTGTCTGTGAGTAAACAGTTCAGAGGTGTGTGTGCA 240
 Db 181 GGGCCAGAACTGCCCCCTCGTTTGTCTGTGAGTAAACAGTTCAGAGGTGTGTGTGCA 240
 Qy 241 CGCGCGCGGCGCTCTCCGAGGTCGCGAGGATTCCTCTGAAACACCGGCTACCTCAACC 300
 Db 241 CGCGCGCGGCGCTCTCCGAGGTCGCGAGGATTCCTCTGAAACACCGGCTACCTCAACC 300
 Qy 301 TCATGAGAACAAATPCAGATGATCCAGGCGGACACTTTCGGCCCACTCTCAACACCTTGG 360
 Db 301 TCATGAGAACAAATPCAGATGATCCAGGCGGACACTTTCGGCCCACTCTCAACACCTTGG 360
 Qy 361 AGTCTCTGAGTTGGGACGAACTCCATCCGCGAGATTCAGGTGGGGGCTTCAACGGCC 420
 Db 361 AGTCTCTGAGTTGGGACGAACTCCATCCGCGAGATTCAGGTGGGGGCTTCAACGGCC 420
 Qy 421 TGGCCAGCCTCAACACCTCGAGCTGTTCGACAACTGCTGACAGTCACTTACCGGG 480
 Db 421 TGGCCAGCCTCAACACCTCGAGCTGTTCGACAACTGCTGACAGTCACTTACCGGG 480
 Qy 481 CTTTGAATACCTGTCAGAGCTGCGGAGCTCTGCTTCGAAACACCCATCGAAGCA 540
 Db 481 CTTTGAATACCTGTCAGAGCTGCGGAGCTCTGCTTCGAAACACCCATCGAAGCA 540
 Qy 541 TCCCTCTTACGCTTCAACCGGGTGCCTCCCTCATGCGCTGAGCTTGGGGAGCTCA 600
 Db 541 TCCCTCTTACGCTTCAACCGGGTGCCTCCCTCATGCGCTGAGCTTGGGGAGCTCA 600
 Qy 601 AGAAGCTGAGATATCTCTGAGGAGCTTTTGGGGGCTGTTCAGCTCAAGTATCTGA 660
 Db 601 AGAAGCTGAGATATCTCTGAGGAGCTTTTGGGGGCTGTTCAGCTCAAGTATCTGA 660
 Qy 661 ACTTGGGCACTGCAACATTAAGACATGCCAAATCTCAACCCCTGCTGGGGCTGGAGG 720
 Db 661 ACTTGGGCACTGCAACATTAAGACATGCCAAATCTCAACCCCTGCTGGGGCTGGAGG 720
 Qy 721 AGTGGAGATGTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTCTTCCATGGCCTGA 780
 Db 721 AGTGGAGATGTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTCTTCCATGGCCTGA 780
 Qy 781 GCTCCCTCAAGAGCTCTGGGTGATGAACTCAGAGTCAAGCTGAGTGGGAGTCTT 840
 Db 781 GCTCCCTCAAGAGCTCTGGGTGATGAACTCAGAGTCAAGCTGAGTGGGAGTCTT 840
 Qy 841 TTGAACGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCACTTCTCTTCTTTC 900
 Db 841 TTGAACGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCACTTCTCTTCTTTC 900
 Qy 901 CCATGACCTCTTACCCGCTGAGTACTGCTGGAGTGGATGATCTACACCAACCTT 960
 Db 901 CCATGACCTCTTACCCGCTGAGTACTGCTGGAGTGGATGATCTACACCAACCTT 960
 Qy 961 GGAATCTGATTTGATCATTCTCTGCTGAGCTTGGCTTGGAGTATATACCCCA 1020
 Db 961 GGAATCTGATTTGATCATTCTCTGCTGAGCTTGGCTTGGAGTATATACCCCA 1020
 Qy 1021 ATTCCACCTGCTGTGGCGGTGATCTGCTCCATGCAATGGAGGCGCTACCTCTGG 1080
 Db 1021 ATTCCACCTGCTGTGGCGGTGATCTGCTCCATGCAATGGAGGCGCTACCTCTGG 1080
 Qy 1081 AGTGGACAGGCTCTCTTCCAGTGTCTGCGCCCTTCAATGAGCAGCTCTCGAGACC 1140
 Db 1081 AGTGGACAGGCTCTCTTCCAGTGTCTGCGCCCTTCAATGAGCAGCTCTCGAGACC 1140
 Qy 1141 TCAACATTTCTGAGGTCGAGTGGAGAACTTAAGTGTGCGACTCCCTGATGCTCTCG 1200
 Db 1141 TCAACATTTCTGAGGTCGAGTGGAGAACTTAAGTGTGCGACTCCCTGATGCTCTCG 1200

RESULT 10
 ABX81157
 ID ABX81157 standard; DNA; 2185 BP.

Qy 1201 TGAAGTGTGTGCTGCCCAATGGGACAGTGTCTCAGCAACGCTCCCGCCACCCCAAGGATCT 1260
 Db 1201 TGAAGTGTGTGCTGCCCAATGGGACAGTGTCTCAGCAACGCTCCCGCCACCCCAAGGATCT 1260
 Qy 1261 CTGTCTCAACGAGCGCACTGTGAACTTTCCAGTGTGCTTTCCAGACTCTGGGGTGT 1320
 Db 1261 CTGTCTCAACGAGCGCACTGTGAACTTTCCAGTGTGCTTTCCAGACTCTGGGGTGT 1320
 Qy 1321 ACACATGCAATGGTGTGACCAATGTTGCAGGCAACTCCAAAGCTTCCGCTTACCTCAATGTGA 1380
 Db 1321 ACACATGCAATGGTGTGACCAATGTTGCAGGCAACTCCAAAGCTTCCGCTTACCTCAATGTGA 1380
 Qy 1381 GCAAGCTGAGCTTAAACCTTCAACTTCTTCCACACAGTAAAGTGGAGCA 1440
 Db 1381 GCAAGCTGAGCTTAAACCTTCAACTTCTTCCACACAGTAAAGTGGAGCA 1440
 Qy 1441 CGGAGATCTCGCTGAGGACACCAACGCGAAAGTACAAGCTTCTTACCAGCTCCACTG 1500
 Db 1441 CGGAGATCTCGCTGAGGACACCAACGCGAAAGTACAAGCTTCTTACCAGCTCCACTG 1500
 Qy 1501 GTTACAGCGCGGATATACCACTCTACCAAGTGTCTATTTCAGACTACCTGTGCGCA 1560
 Db 1501 GTTACAGCGCGGATATACCACTCTACCAAGTGTCTATTTCAGACTACCTGTGCGCA 1560
 Qy 1561 AGCAGTGTGAGTACCGCGACAGACACCACTGCAAGTGCAGACCAAGCTTGAATGAAG 1620
 Db 1561 AGCAGTGTGAGTACCGCGACAGACACCACTGCAAGTGCAGACCAAGCTTGAATGAAG 1620
 Qy 1621 TCATGAAGACCAACCAAGATCATATTGGTGTGCTTTGTGGCTGCTCTGTAGTGGCG 1680
 Db 1621 TCATGAAGACCAACCAAGATCATATTGGTGTGCTTTGTGGCTGCTCTGTAGTGGCG 1680
 Qy 1681 CCAATGTGATGCTCTTCTATAAATTCGTAAGCGCACACAGCGGAGTACAGTCAAG 1740
 Db 1681 CCAATGTGATGCTCTTCTATAAATTCGTAAGCGCACACAGCGGAGTACAGTCAAG 1740
 Qy 1741 CGCCCGGAGTGTGAGATAATCCAGGTGGAGAGACATCCAGCAACAATCCGCGAG 1800
 Db 1741 CGCCCGGAGTGTGAGATAATCCAGGTGGAGAGACATCCAGCAACAATCCGCGAG 1800
 Qy 1801 CAGCAACAGAGCTCGCTCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCACAATTC 1860
 Db 1801 CAGCAACAGAGCTCGCTCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCACAATTC 1860
 Qy 1861 ATGACCATTAATTAACATAACACTTCAAAACAGACACATGGGGCCCACTGGAGAGAAACA 1920
 Db 1861 ATGACCATTAATTAACATAACACTTCAAAACAGACACATGGGGCCCACTGGAGAGAAACA 1920
 Qy 1921 GCTTGGGAACTCTCTGCAACCCCAAGTCAACACTATCTCTGAACCTTATATATTCAGA 1980
 Db 1921 GCTTGGGAACTCTCTGCAACCCCAAGTCAACACTATCTCTGAACCTTATATATTCAGA 1980
 Qy 1981 CCATACCAAGCAAGGTACAGGAACTCAAAATATGACTCCCTCCCGCCCAAACTTA 2040
 Db 1981 CCATACCAAGCAAGGTACAGGAACTCAAAATATGACTCCCTCCCGCCCAAACTTA 2040
 Qy 2041 TAAATGCAATGAGATGACACAAAGACAGCAACTTTGTACAGAGTGGGAGAGACTTT 2100
 Db 2041 TAAATGCAATGAGATGACACAAAGACAGCAACTTTGTACAGAGTGGGAGAGACTTT 2100
 Qy 2101 TTCTTCTATATCTTATATTAAGTCTATGGCTGTGTTAAAAAACAAGATTAATTA 2160
 Db 2101 TTCTTCTATATCTTATATTAAGTCTATGGCTGTGTTAAAAAACAAGATTAATTA 2160
 Qy 2161 AATTTAAGACAAAAGTCAAAACA 2185
 Db 2161 AATTTAAGACAAAAGTCAAAACA 2185

X C AX801157;
X T 22-APR-2003 (first entry)
X E Novel human secreted or transmembrane protein PRO1344 DNA.
X X Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
W cardiac insufficiency disorder; cancer; tumour; immune response;
W adrenal cortical capillary endothelial growth; c-fos induction;
W vascular endothelial growth factor inhibition; VEGF inhibition;
W endothelial cell growth inhibitor; T-lymphocytes stimulation;
W retinal neurons cell survival; rod photoreceptor cell survival;
W retinal disorder; retinitis pigmentosa; kidney disorder;
W mammalian kidney mesangial cell proliferation; Berger disease;
W dermatitis; herpesiformis; Cronn's disease; chondrocyte proliferation;
W chondrocyte redifferentiation; sports injury; arthritis; gene; ds.
X X Homo sapiens.
S US2003027985-A1.
N 06-FEB-2003.
X 14-NOV-2001; 2001US-0990562.
D 05-NOV-1997; 97WO-US20069.
X 16-SEP-1998; 98WO-US19330.
R 17-SEP-1998; 98WO-US19437.
R 07-OCT-1998; 98WO-US21141.
R 01-DEC-1998; 98WO-US25108.
R 05-JAN-1999; 99WO-US00106.
R 08-MAR-1999; 99WO-US05028.
R 02-JUN-1999; 99WO-US12252.
R 15-SEP-1999; 99WO-US21090.
R 15-SEP-1999; 99WO-US21547.
R 30-NOV-1999; 99WO-US28313.
R 01-DEC-1999; 99WO-US28301.
R 01-DEC-1999; 99WO-US28634.
R 16-DEC-1999; 99WO-US30095.
R 20-DEC-1999; 99WO-US31031.
R 05-JAN-2000; 2000WO-US00219.
R 06-JAN-2000; 2000WO-US00376.
R 11-FEB-2000; 2000WO-US03565.
R 18-FEB-2000; 2000WO-US04341.
R 22-FEB-2000; 2000WO-US04414.
R 24-FEB-2000; 2000WO-US04914.
R 24-FEB-2000; 2000WO-US05004.
R 02-MAR-2000; 2000WO-US05841.
R 10-MAR-2000; 2000WO-US06319.
R 15-MAR-2000; 2000WO-US06884.
R 20-MAR-2000; 2000WO-US07377.
R 30-MAR-2000; 2000WO-US08439.
R 15-MAY-2000; 2000WO-US13358.
R 17-MAY-2000; 2000WO-US13705.
R 22-MAY-2000; 2000WO-US14042.
R 30-MAY-2000; 2000WO-US14941.
R 02-JUN-2000; 2000WO-US15284.
R 28-JUL-2000; 2000WO-US20710.
R 11-AUG-2000; 2000WO-US22031.
R 23-AUG-2000; 2000WO-US23522.
R 24-AUG-2000; 2000WO-US23328.
R 08-NOV-2000; 2000WO-US30952.
R 01-DEC-2000; 2000WO-US32678.
R 28-FEB-2001; 2001WO-US06520.
R 01-JUN-2001; 2001WO-US17800.
R 20-JUN-2001; 2001WO-US19692.
R 29-JUN-2001; 2001WO-US21066.
R 09-JUL-2001; 2001WO-US21735.
R 16-JUN-1997; 97US-0457872.
R 17-OCT-1997; 97US-0622502.
R 12-NOV-1997; 97US-065186F.
R 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089947P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 23-JUN-1998; 98US-090349P.
PR 23-JUN-1998; 98US-090355P.
PR 23-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090431P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090445P.
PR 24-JUN-1998; 98US-090472P.
PR 24-JUN-1998; 98US-090555P.
PR 24-JUN-1998; 98US-090540P.
PR 24-JUN-1998; 98US-090542P.
PR 24-JUN-1998; 98US-090557P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.

PR	02-JUL-1998;	98US-091478P.
PR	02-JUL-1998;	98US-091519P.
PR	02-JUL-1998;	98US-091626P.
PR	02-JUL-1998;	98US-091628P.
PR	02-JUL-1998;	98US-091633P.
PR	02-JUL-1998;	98US-091646P.
PR	02-JUL-1998;	98US-091673P.
PR	07-JUL-1998;	98US-091978P.
PR	07-JUL-1998;	98US-091982P.
PR	09-JUL-1998;	98US-092182P.
PR	10-JUL-1998;	98US-092472P.
PR	20-JUL-1998;	98US-093339P.
PR	30-JUL-1998;	98US-094651P.
PR	04-AUG-1998;	98US-095282P.
PR	04-AUG-1998;	98US-095288P.
PR	04-AUG-1998;	98US-095301P.
PR	04-AUG-1998;	98US-095302P.
PR	04-AUG-1998;	98US-095318P.
PR	04-AUG-1998;	98US-095321P.
PR	10-AUG-1998;	98US-095325P.
PR	10-AUG-1998;	98US-095915P.
PR	10-AUG-1998;	98US-095929P.
PR	10-AUG-1998;	98US-096012P.
PR	11-AUG-1998;	98US-096143P.
PR	11-AUG-1998;	98US-096146P.
PR	12-AUG-1998;	98US-096329P.
PR	17-AUG-1998;	98US-096757P.
PR	17-AUG-1998;	98US-096766P.
PR	17-AUG-1998;	98US-096768P.
PR	17-AUG-1998;	98US-096773P.
PR	17-AUG-1998;	98US-096791P.
PR	17-AUG-1998;	98US-096867P.
PR	17-AUG-1998;	98US-096891P.
PR	17-AUG-1998;	98US-096894P.
PR	17-AUG-1998;	98US-096895P.
PR	17-AUG-1998;	98US-096897P.
PR	18-AUG-1998;	98US-096949P.
PR	18-AUG-1998;	98US-096950P.
PR	18-AUG-1998;	98US-096959P.
PR	18-AUG-1998;	98US-096960P.
PR	18-AUG-1998;	98US-097022P.
PR	19-AUG-1998;	98US-097141P.
PR	20-AUG-1998;	98US-097218P.
PR	24-AUG-1998;	98US-097661P.
PR	24-AUG-1998;	98US-097952P.
PR	26-AUG-1998;	98US-097954P.
PR	26-AUG-1998;	98US-097955P.
PR	26-AUG-1998;	98US-097971P.
PR	26-AUG-1998;	98US-097974P.
PR	26-AUG-1998;	98US-097978P.
PR	26-AUG-1998;	98US-097979P.
PR	26-AUG-1998;	98US-097986P.
PR	26-AUG-1998;	98US-098014P.
Query Match 100.0%; Score 2185; DB 25; Length 2185;		
Best Local Similarity 100.0%; Pred. No. 0;		
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	1	GTCTCTCTTTCGAGCCAAAATCCAGCGCATGGTGAATTATGAAGTGCACACCATGA 60
Db	1	GTCTCTCTTTCGAGCCAAAATCCAGCGCATGGTGAATTATGAAGTGCACACCATGA 60
QY	61	ACGTCCTGTGGCAGTAACTGTGCACACCACTTGGATGGCATCTCTGCTCCGGTTGG 120
Db	61	ACGTCCTGTGGCAGTAACTGTGCACACCACTTGGATGGCATCTCTGCTCCGGTTGG 120
QY	121	TCTACTCTACGGCGCAAGTGTGGATTCTGTGTGCAGCCATCGCTGCTGCCGCTCAGCG 180
Db	121	TCTACTCTACGGCGCAAGTGTGGATTCTGTGTGCAGCCATCGCTGCTGCCGCTCAGCG 180
QY	181	GGCCCCAGAACTGCCCCCTCCGTTTGTCTGTGCGAGTACCAAGTGTGTTGTGCA 240
Db	181	GGCCCCAGAACTGCCCCCTCCGTTTGTCTGTGCGAGTACCAAGTGTGTTGTGCA 240

QY	241	CGCGCGGGCGCTCTCGAGGTC	CCGACGGGTATTCCTCGAACACCGGTACCTCAACC	300
DB	241	CGCGCGGGGCGCTCTCGAGGTC	CCGACGGGTATTCCTCGAACACCGGTACCTCAACC	300
QY	301	TCATGGAGAACAACTCCAGATGAT	CCAGSCCGACACCTTCGCGCACTCCACCACTCG	360
DB	301	TCATGGAGAACAACTCCAGATGAT	CCAGSCCGACACCTTCGCGCACTCCACCACTCG	360
QY	361	AGGTCTCGAGTTGGCGCGGA	CTCATCGCGCAGATTGAGTGGGGGCTTCACACGCC	420
DB	361	AGGTCTCGAGTTGGCGCGGA	CTCATCGCGCAGATTGAGTGGGGGCTTCACACGCC	420
QY	421	TGGCCAGCCTCAACACCCCTGGAG	CTGTCGACAACTGGCTGACAGTCACTCCCTAGCGGGG	480
DB	421	TGGCCAGCCTCAACACCCCTGGAG	CTGTCGACAACTGGCTGACAGTCACTCCCTAGCGGGG	480
QY	481	CCTTTGAAATACCTGTCCAGCT	TCGGGAGCTCTGGCTTCGACAACTGCATCAAGTAGCA	540
DB	481	CCTTTGAAATACCTGTCCAGCT	TCGGGAGCTCTGGCTTCGACAACTGCATCAAGTAGCA	540
QY	541	TCGCCTCTTAGCGCTTCAAC	CCGGGTGCCCTCCCTCATGCGCTGACCTGGGGGAGTCA	600
DB	541	TCGCCTCTTAGCGCTTCAAC	CCGGGTGCCCTCCCTCATGCGCTGACCTGGGGGAGTCA	600
QY	601	AGAACTGGAGTATATCTCTG	AGGAGCTTTTGAAGGGCTGTTCAACTCAAGTATCTGA	660
DB	601	AGAACTGGAGTATATCTCTG	AGGAGCTTTTGAAGGGCTGTTCAACTCAAGTATCTGA	660
QY	661	ACTTGGGCATGTGCAACAT	TAAGAATGCCAAATCTCAACCCCTGTGTGGGGCTGGAGG	720
DB	661	ACTTGGGCATGTGCAACAT	TAAGAATGCCAAATCTCAACCCCTGTGTGGGGCTGGAGG	720
QY	721	AGCTGGAGATCTCAGGGAAC	CACTTCCCTGAGATCAGGCGTGGCTTCCATGAGCCCTGA	780
DB	721	AGCTGGAGATCTCAGGGAAC	CACTTCCCTGAGATCAGGCGTGGCTTCCATGAGCCCTGA	780
QY	781	GCTCCCTCAAGAAGCTCTG	GGTCAAGAACTCAAGCTCAAGCTGAGTTGAGCGGAATGCTT	840
DB	781	GCTCCCTCAAGAAGCTCTG	GGTCAAGAACTCAAGCTCAAGCTGAGTTGAGCGGAATGCTT	840
QY	841	TTGACGGGCTGGCTTCACTT	GTGGAATCAACTTGGSCCAAAATACCTCTCTCTTTTC	900
DB	841	TTGACGGGCTGGCTTCACTT	GTGGAATCAACTTGGSCCAAAATACCTCTCTCTTTTC	900
QY	901	CCCATGACCTCTTTAC	CCCGCTGAGTACTGGTGGAGTTGCATCAACCAACCCCTT	960
DB	901	CCCATGACCTCTTTAC	CCCGCTGAGTACTGGTGGAGTTGCATCAACCAACCCCTT	960
QY	961	GGAACTGATTTGACATTTCT	GTGCTAGCTGGCTTCAGAGTATATACCCACCA	1020
DB	961	GGAACTGATTTGACATTTCT	GTGCTAGCTGGCTTCAGAGTATATACCCACCA	1020
QY	1021	ATTCACCTGTGTGGCGCTG	TCATGCTCCCATGCAATGCGAGCGCGCTACTCTGTGG	1080
DB	1021	ATTCACCTGTGTGGCGCTG	TCATGCTCCCATGCAATGCGAGCGCGCTACTCTGTGG	1080
QY	1081	AGGTGGACCGGCTCTCCAG	TGCTCCGCTTCATATGGAAGCAGCTCTCGAGACC	1140
DB	1081	AGGTGGACCGGCTCTCCAG	TGCTCCGCTTCATATGGAAGCAGCTCTCGAGACC	1140
QY	1141	TCACAATTTCTGAGGTT	CGGAATTAAGTGTGCGAACTCCCGCTATGTCTCTCG	1200
DB	1141	TCACAATTTCTGAGGTT	CGGAATTAAGTGTGCGAACTCCCGCTATGTCTCTCG	1200
QY	1201	TGAAGTGTGTCTCCCAAT	TGGACAGTGTCTAGCCAACGCTCCCGCCACCAAGGATCT	1260
DB	1201	TGAAGTGTGTCTCCCAAT	TGGACAGTGTCTAGCCAACGCTCCCGCCACCAAGGATCT	1260
QY	1261	CTGTCTCTCAACGACGG	CACTTTTTCACACCTGTGCTTTTCAGACCTGGGGTGT	1320
DB	1261	CTGTCTCTCAACGACGG	CACTTTTTCAGACCTGTGCTTTTCAGACCTGGGGTGT	1320

```

1321 ACACATGATGCTGAGCAATGTTGAGGCAATCCAAAGCCTCGGCTACCTCAATGTGA 1380
1321 ACACATGATGCTGAGCAATGTTGAGGCAATCCAAAGCCTCGGCTACCTCAATGTGA 1380
1381 GCACGGCTGAGCTTAACACCTCCAACTACAGCTTCTTACACACAGTAAACAGTGGAGACA 1440
1381 GCACGGCTGAGCTTAACACCTCCAACTACAGCTTCTTACACACAGTAAACAGTGGAGACA 1440
1441 CGAGATCTCGCTGAGGACACAAACCGAAAGTAAAGCTGTCTCTACCACTCCAGTCCACTG 1500
1441 CGAGATCTCGCTGAGGACACAAACCGAAAGTAAAGCTGTCTCTACCACTCCAGTCCACTG 1500
1501 GTTACACAGCGGATATACACCTCTACACAGGCTCTATTCAGACTACCGTGTGGCCA 1560
1501 GTTACACAGCGGATATACACCTCTACACAGGCTCTATTCAGACTACCGTGTGGCCA 1560
1561 AGCAGGTGGCAGTACCGGACAGACACCACTGACAAAGTACAGACCCAGCTGTGATGAAG 1620
1561 AGCAGGTGGCAGTACCGGACAGACACCACTGACAAAGTACAGACCCAGCTGTGATGAAG 1620
1621 TCATGAGACCAACAGATCATATGCTGTCTTGTGTCAGTACTGTCTAGCTGCGG 1680
1621 TCATGAGACCAACAGATCATATGCTGTCTTGTGTCAGTACTGTCTAGCTGCGG 1680
1681 CCATGTTGATGCTTCTATAAACTTCGTAAGCGGCACAGCAGCGGAGTACAGTCAAG 1740
1681 CCATGTTGATGCTTCTATAAACTTCGTAAGCGGCACAGCAGCGGAGTACAGTCAAG 1740
1741 CCGCCCGGACTGTTGAGATAATCCAGGTGAGCAAGACATCCAGCAGCAACATCCGAG 1800
1741 CCGCCCGGACTGTTGAGATAATCCAGGTGAGCAAGACATCCAGCAGCAACATCCGAG 1800
1801 CAGCAACAGCAGCTCCGTCGGGTGATCAGGTGAGGCGGAGTGTGCTGCCCAATTC 1860
1801 CAGCAACAGCAGCTCCGTCGGGTGATCAGGTGAGGCGGAGTGTGCTGCCCAATTC 1860
1861 ATGACCATATTAATCAACACCTACAAACAGCAGCATATGCTGACCTTATATATTCAGA 1920
1861 ATGACCATATTAATCAACACCTACAAACAGCAGCATATGCTGACCTTATATATTCAGA 1920
1921 GCCTGGGGACTCTGTCACCCACAGTCAACCTATCTGACCTTATATATTCAGA 1980
1921 GCCTGGGGACTCTGTCACCCACAGTCAACCTATCTGACCTTATATATTCAGA 1980
1981 CCATACCAAGGACAGGTACAGGAACCTCAATATGACTCCCTCCCTCCCAAAACTTA 2040
1981 CCATACCAAGGACAGGTACAGGAACCTCAATATGACTCCCTCCCTCCCAAAACTTA 2040
2041 TAAATGCAATAGATGACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
2041 TAAATGCAATAGATGACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
2101 TTCTTGTATATGCTTATATATTAAGTCTATGGCTGTTAAAAAACAAGATTATATAA 2160
2101 TTCTTGTATATGCTTATATATTAAGTCTATGGCTGTTAAAAAACAAGATTATATAA 2160
2161 ANTTTAAAGCAAAAGTCAAAACA 2185
2161 ANTTTAAAGCAAAAGTCAAAACA 2185

```

RESULT 11

EX90247 standard; cDNA; 2185 BP.

D X

C X

X X

T 01-MAY-2003 (first entry)

X Human secreted/transmembrane protein cDNA, #93.

E Human; gene; ss; PRO; secreted; transmembrane; signal peptide;

X pharmaceutical; diagnostic; therapeutic; gene therapy.

W

```

XX OS Homo sapiens.
XX PN US2002160384-A1.
XX ED 31-OCT-2002.
XX PF 14-NOV-2001; 2001US-0992598.
XX XX 05-NOV-1997; 97WO-US20069.
XX PR 16-SEP-1998; 98WO-US19330.
XX PR 17-SEP-1998; 98WO-US19437.
XX PR 07-OCT-1998; 98WO-US21141.
XX PR 01-DEC-1998; 98WO-US25108.
XX PR 05-JAN-1999; 99WO-US00106.
XX PR 08-MAR-1999; 99WO-US05028.
XX PR 02-JUN-1999; 99WO-US12252.
XX PR 15-SEP-1999; 99WO-US21090.
XX PR 15-SEP-1999; 99WO-US21547.
XX PR 30-NOV-1999; 99WO-US28113.
XX PR 01-DEC-1999; 99WO-US28301.
XX PR 01-DEC-1999; 99WO-US28634.
XX PR 16-DEC-1999; 99WO-US30095.
XX PR 20-DEC-1999; 99WO-US30911.
XX PR 05-JAN-2000; 2000WO-US00219.
XX PR 06-JAN-2000; 2000WO-US00376.
XX PR 11-FEB-2000; 2000WO-US03565.
XX PR 18-FEB-2000; 2000WO-US04341.
XX PR 22-FEB-2000; 2000WO-US04414.
XX PR 24-FEB-2000; 2000WO-US04914.
XX PR 24-FEB-2000; 2000WO-US05004.
XX PR 02-MAR-2000; 2000WO-US05841.
XX PR 10-MAR-2000; 2000WO-US06319.
XX PR 15-MAR-2000; 2000WO-US06884.
XX PR 20-MAR-2000; 2000WO-US07377.
XX PR 30-MAR-2000; 2000WO-US08439.
XX PR 15-MAY-2000; 2000WO-US13358.
XX PR 17-MAY-2000; 2000WO-US13705.
XX PR 22-MAY-2000; 2000WO-US14042.
XX PR 30-MAY-2000; 2000WO-US14941.
XX PR 02-JUN-2000; 2000WO-US15264.
XX PR 28-JUL-2000; 2000WO-US20710.
XX PR 11-AUG-2000; 2000WO-US22031.
XX PR 23-AUG-2000; 2000WO-US23522.
XX PR 24-AUG-2000; 2000WO-US23328.
XX PR 08-NOV-2000; 2000WO-US30952.
XX PR 01-DEC-2000; 2000WO-US32678.
XX PR 28-FEB-2001; 2001WO-US06520.
XX PR 01-JUN-2001; 2001WO-US17800.
XX PR 20-JUN-2001; 2001WO-US19692.
XX PR 29-JUN-2001; 2001WO-US21066.
XX PR 09-JUL-2001; 2001WO-US21735.
XX PR 16-JUN-1997; 97US-049787P.
XX PR 17-OCT-1997; 97US-062250P.
XX PR 12-NOV-1997; 97US-065186P.
XX PR 13-NOV-1997; 97US-065311P.
XX PR 24-NOV-1997; 97US-066770P.
XX PR 25-FEB-1998; 98US-075945P.
XX PR 20-MAR-1998; 98US-078910P.
XX PR 28-APR-1998; 98US-083322P.
XX PR 07-MAY-1998; 98US-084600P.
XX PR 28-MAY-1998; 98US-087106P.
XX PR 02-JUN-1998; 98US-087607P.
XX PR 02-JUN-1998; 98US-087609P.
XX PR 02-JUN-1998; 98US-087759P.
XX PR 04-JUN-1998; 98US-088021P.
XX PR 04-JUN-1998; 98US-088025P.
XX PR 04-JUN-1998; 98US-088026P.
XX PR 04-JUN-1998; 98US-088028P.
XX PR 04-JUN-1998; 98US-088029P.
XX PR 04-JUN-1998; 98US-088030P.
XX PR 04-JUN-1998; 98US-088033P.

```


1081 AGGTGGACAGGCGCTCTTCCAGTGTCTGCGCCCTTTCATCATGAGCGCACTCCAGACC 1140
1141 TCACATTTCTGAGGGTGGGATGCGAGAACTTAAGTGTGGAGCTCCCTCCCTATGCTCTCG 1200
1141 TCACATTTCTGAGGGTGGGATGCGAGAACTTAAGTGTGGAGCTCCCTCCCTATGCTCTCG 1200
1201 TGAAGTGGTGTCTGCGCAATGGGACAGTGTCTAGCAAGCTCCCGCCCAAGGATCT 1260
1201 TGAAGTGGTGTCTGCGCAATGGGACAGTGTCTAGCAAGCTCCCGCCCAAGGATCT 1260
1261 CTGTCTCTCAACGACGCGCACCTTGAATCTTTTCCACGCTGTCTTTTTCAGACACTGGGGTGT 1320
1261 CTGTCTCTCAACGACGCGCACCTTGAATCTTTTCCACGCTGTCTTTTTCAGACACTGGGGTGT 1320
1321 ACACATGCTGTTGTCACCAATGTTGAGGCACTTCCAAAGCTCCCGCTCCCTCAATGTGA 1380
1321 ACACATGCTGTTGTCACCAATGTTGAGGCACTTCCAAAGCTCCCGCTCCCTCAATGTGA 1380
1381 GCACGGCTGAGCTTAAACCTTCAACCTTACAGCTTCTTCCACAGTAAACAGTGGAGACCA 1440
1381 GCACGGCTGAGCTTAAACCTTCAACCTTACAGCTTCTTCCACAGTAAACAGTGGAGACCA 1440
1441 CGGAGATCTCGCTGAGGAACAACGCGAAGTACAAAGCTGTCTTCTACAGTCTCACTG 1500
1441 CGGAGATCTCGCTGAGGAACAACGCGAAGTACAAAGCTGTCTTCTACAGTCTCACTG 1500
1501 GTTACACGCGCGCATATACCACTTACACGCTGTCTTCTTACAGTCTACCGTGTGCCA 1560
1501 GTTACACGCGCGCATATACCACTTACACGCTGTCTTCTTACAGTCTACCGTGTGCCA 1560
1561 AGCAGTGGCAGTACCGCGACAGACACCACTGCAAGATGCAAGCTGAGTGAAG 1620
1561 AGCAGTGGCAGTACCGCGACAGACACCACTGCAAGATGCAAGCTGAGTGAAG 1620
1621 TCATGAGACCAACAGATCATATGCTGTCTTGTGGAGTGTCTGCTAGCTGCG 1680
1621 TCATGAGACCAACAGATCATATGCTGTCTTGTGGAGTGTCTGCTAGCTGCG 1680
1681 CCATGTTGATGTTCTTCTATAAATCTTGAAGCGGACACAGCGAGTACAGTCAACAG 1740
1681 CCATGTTGATGTTCTTCTATAAATCTTGAAGCGGACACAGCGAGTACAGTCAACAG 1740
1741 CGCGCGGACTGTTGAGATTAATCAGGTGCAAGAACATCCAGCAGCAACATCCGAG 1800
1741 CGCGCGGACTGTTGAGATTAATCAGGTGCAAGAACATCCAGCAGCAACATCCGAG 1800
1801 CAGCAACAGCAGCTCCCTCGGTGTATCAGTTCAGGCGGAGTGTCTGCTGCTCAATTC 1860
1801 CAGCAACAGCAGCTCCCTCGGTGTATCAGTTCAGGCGGAGTGTCTGCTGCTCAATTC 1860
1861 ATGACCATATTAATCAACACCTTACAAACAGCAGATGGGGCCCACTGGACAGAAACA 1920
1861 ATGACCATATTAATCAACACCTTACAAACAGCAGATGGGGCCCACTGGACAGAAACA 1920
1921 GCCTGGGAGCTCTGCGCCACAGTCACTACTCTCTGACCTTATATATTCAGA 1980
1921 GCCTGGGAGCTCTGCGCCACAGTCACTACTCTCTGACCTTATATATTCAGA 1980
1981 CCCATCAAGGACAGGTACAGGAACTCAATATGACTTCCCTCCCTCCCAAAACTTAA 2040
1981 CCCATCAAGGACAGGTACAGGAACTCAATATGACTTCCCTCCCTCCCAAAACTTAA 2040
2041 TAAATGCAATGATGACACAAAGACAGCACTTTTGTACAGTGGGAGAGCTTT 2100
2041 TAAATGCAATGATGACACAAAGACAGCACTTTTGTACAGTGGGAGAGCTTT 2100
2101 TTTCTGATATGCTTATATTAAGTCTATGCTGTGTTAAAAAACAAGATTAATTA 2160
2101 TTTCTGATATGCTTATATTAAGTCTATGCTGTGTTAAAAAACAAGATTAATTA 2160
2161 AATTAAAGACAAAGTCAAAACA 2185
2161 AATTAAAGACAAAGTCAAAACA 2185

RESULT 12

ABX77858

ID ABX77858 standard; cDNA; 2185 BP.

XX AC ABX77858;

XX DT 14-APR-2003 (first entry)

XX Human PRO polynucleotide #64.

Human; PRO; gene; ss; cytosolic; tumour; cancer; breast; lung; stomach;
liver; horse; cow; dog; cat; sheep; pig; goat; rabbit; ADPRT;
antibody-dependent enzyme mediated prodrug therapy.

XX OS Homo sapiens.

XX PN US2003027163-A1.

XX PD 06-FEB-2003.

XX PF 15-NOV-2001; 2001US-0997666.

XX PR 05-NOV-1997; 97WO-US20069.

XX PR 16-SEP-1998; 98WO-US19330.

XX PR 17-SEP-1998; 98WO-US19437.

XX PR 07-OCT-1998; 98WO-US21141.

XX PR 01-DEC-1998; 98WO-US25108.

XX PR 05-JAN-1999; 99WO-US00106.

XX PR 08-MAR-1999; 99WO-US05028.

XX PR 15-SEP-1999; 99WO-US12252.

XX PR 15-SEP-1999; 99WO-US21090.

XX PR 15-SEP-1999; 99WO-US21547.

XX PR 30-NOV-1999; 99WO-US28313.

XX PR 01-DEC-1999; 99WO-US28301.

XX PR 16-DEC-1999; 99WO-US28634.

XX PR 20-DEC-1999; 99WO-US30095.

XX PR 05-JAN-2000; 2000WO-US30911.

XX PR 06-JAN-2000; 2000WO-US00376.

XX PR 11-FEB-2000; 2000WO-US03565.

XX PR 18-FEB-2000; 2000WO-US04341.

XX PR 22-FEB-2000; 2000WO-US04414.

XX PR 24-FEB-2000; 2000WO-US04914.

XX PR 24-FEB-2000; 2000WO-US05004.

XX PR 02-MAR-2000; 2000WO-US05841.

XX PR 10-MAR-2000; 2000WO-US06319.

XX PR 15-MAR-2000; 2000WO-US06884.

XX PR 20-MAR-2000; 2000WO-US07377.

XX PR 30-MAR-2000; 2000WO-US08439.

XX PR 15-MAY-2000; 2000WO-US13358.

XX PR 17-MAY-2000; 2000WO-US13705.

XX PR 22-MAY-2000; 2000WO-US14042.

XX PR 02-JUN-2000; 2000WO-US14941.

XX PR 28-JUL-2000; 2000WO-US15264.

XX PR 11-AUG-2000; 2000WO-US22031.

XX PR 23-AUG-2000; 2000WO-US23522.

XX PR 24-AUG-2000; 2000WO-US23328.

XX PR 08-NOV-2000; 2000WO-US30952.

XX PR 01-DEC-2000; 2000WO-US32678.

XX PR 28-FEB-2001; 2001WO-US06520.

XX PR 01-JUN-2001; 2001WO-US17800.

XX PR 20-JUN-2001; 2001WO-US19692.

XX PR 29-JUN-2001; 2001WO-US21066.

XX PR 09-JUL-2001; 2001WO-US21735.

XX PR 16-JUN-1997; 97US-049787P.

XX PR 17-OCT-1997; 97US-062250P.

XX PR 12-NOV-1997; 97US-065186P.

XX PR 13-NOV-1997; 97US-065311P.

XX PR 24-NOV-1997; 97US-066770P.

XX PR 25-FEB-1998; 98US-075945P.

PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088036P.
PR 04-JUN-1998; 98US-088126P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088022P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088555P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 11-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 11-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089807P.
PR 18-JUN-1998; 98US-089808P.
PR 19-JUN-1998; 98US-089947P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 23-JUN-1998; 98US-090349P.
PR 23-JUN-1998; 98US-090355P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090431P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090445P.
PR 24-JUN-1998; 98US-090472P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 24-JUN-1998; 98US-090542P.
PR 25-JUN-1998; 98US-090557P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091519P.

PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091633P.
PR 02-JUL-1998; 98US-091646P.
PR 02-JUL-1998; 98US-091673P.
PR 07-JUL-1998; 98US-091978P.
PR 07-JUL-1998; 98US-091982P.
PR 09-JUL-1998; 98US-092182P.
PR 10-JUL-1998; 98US-092472P.
PR 20-JUL-1998; 98US-093339P.
PR 30-JUL-1998; 98US-094651P.
PR 04-AUG-1998; 98US-095282P.
PR 04-AUG-1998; 98US-095285P.
PR 04-AUG-1998; 98US-095301P.
PR 04-AUG-1998; 98US-095302P.
PR 04-AUG-1998; 98US-095318P.
PR 04-AUG-1998; 98US-095321P.
PR 04-AUG-1998; 98US-095325P.
PR 10-AUG-1998; 98US-095916P.
PR 10-AUG-1998; 98US-095929P.
PR 10-AUG-1998; 98US-096012P.
PR 11-AUG-1998; 98US-096143P.
PR 11-AUG-1998; 98US-096146P.
PR 12-AUG-1998; 98US-096329P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096768P.
PR 17-AUG-1998; 98US-096773P.
PR 17-AUG-1998; 98US-096791P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096894P.
PR 17-AUG-1998; 98US-096895P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096950P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-096960P.
PR 19-AUG-1998; 98US-097022P.
PR 19-AUG-1998; 98US-097141P.
PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 26-AUG-1998; 98US-098014P.
PR 31-AUG-1998; 98US-098525P.
PR 16-SEP-1998; 98US-100634P.
PR 17-SEP-1998; 98US-100858P.
PR 22-DEC-1998; 98US-113296P.
PR 12-MAR-1999; 98US-123957P.
PR 23-JUN-1999; 98US-141037P.
PR 07-JUL-1999; 98US-143048P.

Query Match 100.0%; Score 2185; DB 25; Length 2185;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTCTCTTTCGAGCCAAATCCAGCGATGGTGAATTATGAACGTGCCACCATGA 60
|||||
DB 1 GTTCTCTTTCGAGCCAAATCCAGCGATGGTGAATTATGAACGTGCCACCATGA 60
|||||
QY 61 AGCTCTTGTGCGAGTAACTGTGCACCAACACACACTGGAATGCCATCTGCTCCGTTGC 120
|||||
DB 61 AGCTCTTGTGCGAGTAACTGTGCACCAACACACACTGGAATGCCATCTGCTCCGTTGC 120
|||||
QY 121 TCTACTCAGCGCGAGTGGATTCTGTGTGAGCATGCTGTGCGGCTCAGCG 180
|||||

XX DE Human secreted/transmembrane protein cDNA, #93.
 XX KW Human; gene; ss; PRO; secreted; transmembrane; signal peptide;
 KW pharmacological; diagnostic; biosensor; bioreactor; tumour; therapeutic;
 XX colon cancer; lung cancer; breast cancer; cancer; gene therapy.
 OS Homo sapiens.
 XX US2002142961-A1.
 XX 03-OCT-2002.
 XX 19-NOV-2001; 2001US-0989721.
 XX 05-NOV-1997; 97WO-US20069.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 16-DEC-1999; 99WO-US28634.
 PR 20-DEC-1999; 99WO-US30095.
 PR 05-JAN-2000; 99WO-US30911.
 PR 06-JAN-2000; 2000WO-US00219.
 PR 18-FEB-2000; 2000WO-US03565.
 PR 22-FEB-2000; 2000WO-US04341.
 PR 24-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 02-MAR-2000; 2000WO-US05004.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 13-NOV-1997; 97US-063486P.
 PR 12-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084500P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.

PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gerber H, Gerritsen WE, Goddard A, Godowski PU;
 PI Grimaldi JC, Gurney AJ, Kijavini IJ, Napier MA, Pan J, Paoni NP;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 PI Zhang Z;

WPI: 2003-155950/15.

P-PSDB; ABUS8963.

PT New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
 PT PRO361 or PRO846) useful as targets for therapeutic intervention in
 PT cancers (e.g. lung or breast cancers), or for diagnosing these cancers

Claim 2; Fig 156; 647pp; English.

CC The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC comprising a sequence without signal peptide and the nucleic acid
 CC encoding them. The polypeptides can be used to raise antibodies that
 CC specifically bind to the PRO polypeptide, for linking a bioactive
 CC molecule to a cell expressing a PRO protein and for modulating at least
 CC one biological activity of a cell. The PRO polypeptides or
 CC polynucleotides are also useful as pharmaceuticals, diagnostics,
 CC biosensors or bioreactors, for detecting or treating e.g. tumours in
 CC mammals, e.g. humans, dogs, cats, cattle, horses, sheep, goats or
 CC rabbits as targets for therapeutic intervention in certain cancers (e.g.
 CC colon, lung or breast cancers) and diagnostic determination of the
 CC presence of these cancers. The PRO polypeptides are also useful as
 CC molecular weight markers or for chromosome identification. The PRO genes
 CC are useful as hybridisation probes or for screening libraries of human
 CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
 CC therapy, particularly for replacing a defective gene. The sequences
 CC presented in ABX79290-ABX79675 are the genes encoding, the primers
 CC amplifying and the probes detecting the PRO polynucleotides of the
 CC invention.

CC Note: The sequence data for this patent is also available in electronic

1C format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 2185 BP; 527 A; 666 C; 519 G; 473 T; 0 other;

Query Match	100.0%;	Score 2185;	DB 25;	Length 2185;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 2185;	Conservative	0;	Mismatches	0;
			Indels	0;

1	GTTCCTCTTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAAACGTGCCACACATGA	60	1	GTTCCTCTTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAAACGTGCCACACATGA	60
1y			1y		
1b			1b		
61	AGCTCTTTGGCAGGTAACGTGCAACACACACCTTGGAAAGCCATCTGCTCCCGTTCG	120	61	AGCTCTTTGGCAGGTAACGTGCAACACACACCTTGGAAAGCCATCTGCTCCCGTTCG	120
61y			61y		
61b			61b		
121	TCTACCTCAACGGCGCAAGTGTGGAAATCTGTGTGCAAGCCATCGGCTGTCGGCGCTCAGCG	180	121	TCTACCTCAACGGCGCAAGTGTGGAAATCTGTGTGCAAGCCATCGGCTGTCGGCGCTCAGCG	180
121y			121y		
121b			121b		
181	GGCCCCAGAACTGCCCCCTCCGCTTTCGTCGTCAGTAACACAGTTTCAGCAAGGTGGTGTGCA	240	181	GGCCCCAGAACTGCCCCCTCCGCTTTCGTCGTCAGTAACACAGTTTCAGCAAGGTGGTGTGCA	240
181y			181y		
181b			181b		
241	CGCGCGGGGCGCTCTCGAGGTCGCGCAGGGTAATTCCTCGAACAACCGGTACTCTCAACC	300	241	CGCGCGGGGCGCTCTCGAGGTCGCGCAGGGTAATTCCTCGAACAACCGGTACTCTCAACC	300
241y			241y		
241b			241b		
301	TCATGGAGAAACAAATCCAGATGATCCAGGCCAGACACTTCCGCCACACTCCCAACCTGG	360	301	TCATGGAGAAACAAATCCAGATGATCCAGGCCAGACACTTCCGCCACACTCCCAACCTGG	360
301y			301y		
301b			301b		
361	AGGTCCTCGAGTTGGGCAGGAATCCATCCGCGCAGATTGAGTTGSGGGGCTTCAACGGCC	420	361	AGGTCCTCGAGTTGGGCAGGAATCCATCCGCGCAGATTGAGTTGSGGGGCTTCAACGGCC	420
361y			361y		
361b			361b		
421	TGGCCAGCCTCAACACACCTCGAGCTGTTTCGACAACTGGCTGCACAGTCATCCCTAGCGGG	480	421	TGGCCAGCCTCAACACACCTCGAGCTGTTTCGACAACTGGCTGCACAGTCATCCCTAGCGGG	480
421y			421y		
421b			421b		
481	CTTTTGAATACCTGTPCCAAGCTGCGGAGCTGTGGCTTCGCAACAACCCATCGAAAGCA	540	481	CTTTTGAATACCTGTPCCAAGCTGCGGAGCTGTGGCTTCGCAACAACCCATCGAAAGCA	540
481y			481y		
481b			481b		
541	TCCCTCTTTAGCCTTCAACCGGGTCCCTCCCTCATGCGCTTGAATTTGGGGAGCTCA	600	541	TCCCTCTTTAGCCTTCAACCGGGTCCCTCCCTCATGCGCTTGAATTTGGGGAGCTCA	600
541y			541y		
541b			541b		
601	AGAAGCTGGAGTATATCTCTCAGGGAGCTTTGAGGGCTGTTCACCTCAAGTATCTGA	660	601	AGAAGCTGGAGTATATCTCTCAGGGAGCTTTGAGGGCTGTTCACCTCAAGTATCTGA	660
601y			601y		
601b			601b		
661	ACTTGGGCATGTGCAACAATTAAGACATGCCATCTCAACCCCTGGTGGGGCTGGAG	720	661	ACTTGGGCATGTGCAACAATTAAGACATGCCATCTCAACCCCTGGTGGGGCTGGAG	720
661y			661y		
661b			661b		
721	AGCTGGAGATGTCAAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGCTGA	780	721	AGCTGGAGATGTCAAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGCTGA	780
721y			721y		
721b			721b		
781	GCTCCCTCAAGAGCTCTGGGTCTATGAACCTCAGAGGTCAAGCTGATTTGAGCGGAATGCTT	840	781	GCTCCCTCAAGAGCTCTGGGTCTATGAACCTCAGAGGTCAAGCTGATTTGAGCGGAATGCTT	840
781y			781y		
781b			781b		
841	TTGAGGGCTGGCTTTCACTTTGTGGAACTCAACTTGGGCCCAATAAACCCTCTCTTTTCG	900	841	TTGAGGGCTGGCTTTCACTTTGTGGAACTCAACTTGGGCCCAATAAACCCTCTCTTTTCG	900
841y			841y		
841b			841b		
901	CCCATGAACCTCTTTACCCGGCTGAGGTACTGTGTGGAGTTGCACTTACACCAACACCTT	960	901	CCCATGAACCTCTTTACCCGGCTGAGGTACTGTGTGGAGTTGCACTTACACCAACACCTT	960
901y			901y		
901b			901b		
961	GGAACTGTGATTGTGACATTTCTGTGGCTTAGCCTGGTGGCTTCGAGAGTATATATCCACCA	1020	961	GGAACTGTGATTGTGACATTTCTGTGGCTTAGCCTGGTGGCTTCGAGAGTATATATCCACCA	1020
961y			961y		
961b			961b		

Db	961	GGAACTGTGATTGTGACATTTCTGTGGCTAGCTGGTGGCTTGGAGATATATACCAACA	1021
Qy	1021	ATTCCACCTCTGTGGCCGGTGTCATGCTCCCATGCAATGGAGCCGGTACTCTGGTGG	1080
Db	1021	ATTCCACCTCTGTGGCCGGTGTCATGCTCCCATGCAATGGAGCCGGTACTCTGGTGG	1080
Qy	1081	AGTGGACGAGGCTCTCTTCCAGTGTCTTGGCCCTTTCATCATGGACGACCTTCGAGACC	1140
Db	1081	AGTGGACGAGGCTCTCTTCCAGTGTCTTGGCCCTTTCATCATGGACGACCTTCGAGACC	1140
Qy	1141	TCAACATTTCTGAGGGTTCGATGGCAAGAACTTAAGTGTGGACTTCCCTCATGTCTCTCG	1200
Db	1141	TCAACATTTCTGAGGGTTCGATGGCAAGAACTTAAGTGTGGACTTCCCTCATGTCTCTCG	1200
Qy	1201	TGAAGTGTGTCTGGCCCATGGGACAGTGTCTAGCCAGCCAGCTCCGCCACCCCAAGATCT	1260
Db	1201	TGAAGTGTGTCTGGCCCATGGGACAGTGTCTAGCCAGCCAGCTCCGCCACCCCAAGATCT	1260
Qy	1261	CTGTCTCAACGACGGCACCTTGAACTTTTCCCACTGTGTCTTTTCAGACACATGGGGTGT	1320
Db	1261	CTGTCTCAACGACGGCACCTTGAACTTTTCCCACTGTGTCTTTTCAGACACATGGGGTGT	1320
Qy	1321	ACAATGCAATGTGACCAATGTTGZAGGAACTTCCAAAGCTCTGGCTACTCTCAATGTGA	1380
Db	1321	ACAATGCAATGTGACCAATGTTGZAGGAACTTCCAAAGCTCTGGCTACTCTCAATGTGA	1380
Qy	1381	GCACGGCTGAGCTTAAACACTTCCAACTGATGCTTCTTCAACAGTAAACAGTGGAGACCA	1440
Db	1381	GCACGGCTGAGCTTAAACACTTCCAACTGATGCTTCTTCAACAGTAAACAGTGGAGACCA	1440
Qy	1441	CGGAGATCTCGCTGAGGACACAACCGGAAAGTACAAGCTTGTTCCTTACAGCTCCACTG	1500
Db	1441	CGGAGATCTCGCTGAGGACACAACCGGAAAGTACAAGCTTGTTCCTTACAGCTCCACTG	1500
Qy	1501	GTTTACGACGGGCATATACCACTCTTACACAGTGTCTTTCATTCAGATACCCGTGTGCCA	1560
Db	1501	GTTTACGACGGGCATATACCACTCTTACACAGTGTCTTTCATTCAGATACCCGTGTGCCA	1560
Qy	1561	AGCAGTGTGGAGTACCCGCGACAGACCACTGCAAGAATGACAGCCAGCTCGATGAAG	1620
Db	1561	AGCAGTGTGGAGTACCCGCGACAGACCACTGCAAGAATGACAGCCAGCTCGATGAAG	1620
Qy	1621	TCATGAGACCAACAGATCATCATTTGGCTGTCTTTGGCAGTGAATCTGTAGCTAGCTGCC	1680
Db	1621	TCATGAGACCAACAGATCATCATTTGGCTGTCTTTGGCAGTGAATCTGTAGCTAGCTGCC	1680
Qy	1681	CCATGTTGATGTCTTCTATAAACTTCGTAAGCGGACCCAGACGGAGTACAGTCAACAG	1740
Db	1681	CCATGTTGATGTCTTCTATAAACTTCGTAAGCGGACCCAGACGGAGTACAGTCAACAG	1740
Qy	1741	CCGCCCGGACTGTGAGATTAATCCAGGTGACGAAGATATCCAGAGCAATATCCGACAG	1800
Db	1741	CCGCCCGGACTGTGAGATTAATCCAGGTGACGAAGATATCCAGAGCAATATCCGACAG	1800
Qy	1801	CAGCAACAGCAGCTCCGTCCGGTGTATCAGTTCAGGGGGCAGTGTCTGCCCACAATTC	1860
Db	1801	CAGCAACAGCAGCTCCGTCCGGTGTATCAGTTCAGGGGGCAGTGTCTGCCCACAATTC	1860
Qy	1861	ATGACCATATTAACCTACAACCTTACAAACCCAGCACAATGGGGCCCATGAGCAGAAAACA	1920
Db	1861	ATGACCATATTAACCTACAACCTTACAAACCCAGCACAATGGGGCCCATGAGCAGAAAACA	1920
Qy	1921	GCCTGGGGAATCTCTGCACCCACAGTCACTACTCTGTGAACCTTATATATTTTCTAGA	1980
Db	1921	GCCTGGGGAATCTCTCTGCACCCACAGTCACTACTCTGTGAACCTTATATATTTTCTAGA	1980
Qy	1981	CCCATACCAAGGACAGGTACAGGAACTCAAAATATGACTCTCCCTCCCCCAAAAACTTTA	2040
Db	1981	CCCATACCAAGGACAGGTACAGGAACTCAAAATATGACTCTCCCTCCCCCAAAAACTTTA	2040
Qy	2041	TAAATGCCAATAGATGCAACAAGACCAACTTTTGTACAGATGGGGAGAGACTTTT	2100

Db 2041 TAAATGCAATAGATGACACAAAGACAGCAACTTTTGTACAGAGTGGGAGAGACTTT 2100
 Qy 2101 TTCTGTATATGCTTATATATTAAGTCTATGGCTGCTTAAAAAACAAGATTATATAA 2160
 Db 2101 TTCTGTATATGCTTATATATTAAGTCTATGGCTGCTTAAAAAACAAGATTATATAA 2160
 Qy 2161 AATTTAAACAAAAAGTCAAAACA 2185
 Db 2161 AATTTAAACAAAAAGTCAAAACA 2185

RESULT 14
 ABX64093
 ID ABX64093 standard; cDNA; 2185 BP.
 XX
 AC ABX64093;
 XX
 DT 26-FEB-2003 (first entry)
 XX
 DE cDNA encoding human PRO1111 polypeptide.
 XX
 KW Human; PRO polypeptide; secreted protein; transmembrane protein;
 KW genetic disorder; antibacterial; immunosuppressive; transgenic;
 KW gene therapy; gens; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002103125-A1.
 XX
 PD 01-AUG-2002.
 XX
 PF 20-NOV-2001; 2001US-0989731.
 XX
 PR 05-NOV-1997; 97WO-US20069.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 06-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.

PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088367P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 18-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.
 PA (GETH) GENENTECH LTD.
 XX Ashkenazi AJ, Baker KP, Borstein D, Desnoyers L, Eaton DL,
 XX Ferrara N, Fong S, Gerber H, Gerritsen MF, Goddard A, Godowski PJ,
 XX Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF,
 XX Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI,
 XX Zhang Z;
 XX WFI; 2003-102117/09.
 DR P-PSDB; ABU13923.
 DR
 XX Novel secreted and transmembrane polypeptide for modulating biological
 PT activity of cell expressing the polypeptide, identifying agonists or
 PT antagonists of polypeptide, and as molecular weight markers -
 XX
 PS Claim 2; Fig 156; 649pp; English.
 XX The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The

PRO polypeptides are secreted and transmembrane proteins. The PRO polypeptides are useful for detecting other PRO polypeptides, for linking bioactive molecules to cells expressing PRO polypeptides, for modulating biological activities of cells expressing PRO polypeptides, and for identifying agonists or antagonists. The polynucleotide sequences encoding PRO polypeptides are useful as hybridisation probes, in chromosome and gene mapping, in the generation of antisense RNA and DNA, in the preparation of PRO polypeptides, for generating transgenic animals or knockout animals, to construct hybridisation probes for mapping the gene which encodes the PRO polypeptide, and for the genetic analysis of individuals with genetic disorders, in gene therapy, for chromosome identification, as chromosome markers, and for generating probes for PCR, Northern analysis, Southern analysis and Western analysis. The present sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent was obtained in electronic format directly from the USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html.

Sequence 2185 BP; 527 A; 666 C; 519 G; 473 T; 0 other;

Query Match 100.0%; Score 2185; DB 25; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 1 GTCTCTCTTCGAGCCAAATCCAGGCGATGGTGAATATGAACGTGCCACCATGA 60
 b 1 GTCTCTCTTCGAGCCAAATCCAGGCGATGGTGAATATGAACGTGCCACCATGA 60
 Y 61 AGCTCTTTGGGAGGTAACCTGTGCACACACACACCTGGAAATGCCATCTGCTCCCGTTCG 120
 b 61 AGCTCTTTGGGAGGTAACCTGTGCACACACACACCTGGAAATGCCATCTGCTCCCGTTCG 120
 Y 121 TCTACCTCAGCGGCAAGTGTGGAATCTGTGTGAGCCATCTGCTGCTGCTGCTGCTGCTGCTG 180
 b 121 TCTACCTCAGCGGCAAGTGTGGAATCTGTGTGAGCCATCTGCTGCTGCTGCTGCTGCTGCTG 180
 Y 181 GGCCCGCAGAACTCCCTCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
 b 181 GGCCCGCAGAACTCCCTCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240
 Y 241 CGCGCGGGGCTCTCCGAGGTCGCGAGGTCGCGAGGTCGCGAGGTCGCGAGGTCGCGAGGTCGCGAGG 300
 b 241 CGCGCGGGGCTCTCCGAGGTCGCGAGGTCGCGAGGTCGCGAGGTCGCGAGGTCGCGAGGTCGCGAGG 300
 Y 301 TCAATGAGAACACATCCAGATGATCCAGGCGACACCTTCGCGACCTCCACACCTCGG 360
 b 301 TCAATGAGAACACATCCAGATGATCCAGGCGACACCTTCGCGACCTCCACACCTCGG 360
 Y 361 AGTCTCTGAGTTGGGAGGAACTCCATCCGCGAGATTCAGTGGGGGCTTCACACGGCC 420
 b 361 AGTCTCTGAGTTGGGAGGAACTCCATCCGCGAGATTCAGTGGGGGCTTCACACGGCC 420
 Y 421 TGGCGAGCTCAACACCTGGAGCTCTGACACACCTGGGCTGAGTCACTCCCTAGCGGG 480
 b 421 TGGCGAGCTCAACACCTGGAGCTCTGACACACCTGGGCTGAGTCACTCCCTAGCGGG 480
 Y 481 CTTTGAATACCTGTCCAACTCCGAGCTCTGGCTTCGCAACACCTCCATCGAAGCA 540
 b 481 CTTTGAATACCTGTCCAACTCCGAGCTCTGGCTTCGCAACACCTCCATCGAAGCA 540
 Y 541 TCCGCTTACGCTTCAACCGGGTGCCTTCTCATGCGCTGAGCTTGGGGGAGCTCA 600
 b 541 TCCGCTTACGCTTCAACCGGGTGCCTTCTCATGCGCTGAGCTTGGGGGAGCTCA 600
 Y 601 AGAAGCTGGAGTATCTCTGAGGAGCTTTTTCAGGGGCTGTTCAACCTCAAGTATCTGA 660
 b 601 AGAAGCTGGAGTATCTCTGAGGAGCTTTTTCAGGGGCTGTTCAACCTCAAGTATCTGA 660
 Y 661 ACTTGGGCAATGCAACATTAAGACATGCCCAATCTCAACCTCTGCTGGGCTGGAGG 720
 b 661 ACTTGGGCAATGCAACATTAAGACATGCCCAATCTCAACCTCTGCTGGGCTGGAGG 720

QY 721 AGCTGGAGATGTCCAGGAAACCACTTCCCTGAGATCAGGCTCGCTCTTCCATGSCCTGA 780
 DB 721 AGCTGGAGATGTCCAGGAAACCACTTCCCTGAGATCAGGCTCGCTCTTCCATGSCCTGA 780
 QY 781 GCTCCCTCAAGAGCTCTGGGTGATGAACTCAGAGTCAAGCTGAGCTGATGAGCGGATGTT 840
 DB 781 GCTCCCTCAAGAGCTCTGGGTGATGAACTCAGAGTCAAGCTGAGCTGATGAGCGGATGTT 840
 QY 841 TTGACGGGCTGGCTTCACTCTGTGGAACTCAACTTGGCCCAATAAACCCTCTCTTTTTCG 900
 DB 841 TTGACGGGCTGGCTTCACTCTGTGGAACTCAACTTGGCCCAATAAACCCTCTCTTTTTCG 900
 QY 901 CCATGACCTCTTTTACCCGCTGAGGTACTCGTGGTGGAGTGTGATCTACACCAACCCCTT 960
 DB 901 CCATGACCTCTTTTACCCGCTGAGGTACTCGTGGTGGAGTGTGATCTACACCAACCCCTT 960
 QY 961 GGAACGTGATGTGTGACATCTCTGTGGCTAGCTGCTGGTGGCTTGGAGGTATATACCCACCA 1020
 DB 961 GGAACGTGATGTGTGACATCTCTGTGGCTAGCTGCTGGTGGCTTGGAGGTATATACCCACCA 1020
 QY 1021 ATTCCACCTGCTGTGGCGCTGTCACTGCTCCATGCAATGAGGCGCTACCTCTGCTGG 1080
 DB 1021 ATTCCACCTGCTGTGGCGCTGTCACTGCTCCATGCAATGAGGCGCTACCTCTGCTGG 1080
 QY 1081 AGCTGGACGAGGCTCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140
 DB 1081 AGCTGGACGAGGCTCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140
 QY 1141 TCAACATTTCTGAGGCTGGATGGCAGAACTTAAAGTGTGGAGTCTCCCTCTATGTCTCGG 1200
 DB 1141 TCAACATTTCTGAGGCTGGATGGCAGAACTTAAAGTGTGGAGTCTCCCTCTATGTCTCGG 1200
 QY 1201 TGAAGTGTGCTGCCCAATGGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGT 1260
 DB 1201 TGAAGTGTGCTGCCCAATGGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGT 1260
 QY 1261 CTGTCTCTCAACGAGGAGCTTGAACCTTTTCCACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
 DB 1261 CTGTCTCTCAACGAGGAGCTTGAACCTTTTCCACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
 QY 1321 ACATGCTGATGTGAGCAATGTGGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGT 1380
 DB 1321 ACATGCTGATGTGAGCAATGTGGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGT 1380
 QY 1381 GCACGGCTGAGCTTAAACCTCCACCTGAGCTTCTTCAACACAGTAACTGAGGAGGAGCA 1440
 DB 1381 GCACGGCTGAGCTTAAACCTCCACCTGAGCTTCTTCAACACAGTAACTGAGGAGGAGCA 1440
 QY 1441 CGGAGTCTGCTGAGGAGGAGCAACCGGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGT 1500
 DB 1441 CGGAGTCTGCTGAGGAGGAGCAACCGGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGTCTGAGGAGTGT 1500
 QY 1501 GTTACAGGCGGCTATACCACTCTTACCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1560
 DB 1501 GTTACAGGCGGCTATACCACTCTTACCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1560
 QY 1561 AGCAGTGGCAGTACCGGAGGAGCAACCTGAGGAGTGTGAGGAGTGTGAGGAGTGTGAGGAGTGT 1620
 DB 1561 AGCAGTGGCAGTACCGGAGGAGCAACCTGAGGAGTGTGAGGAGTGTGAGGAGTGTGAGGAGTGT 1620
 QY 1621 TCATGAGACCAACAGATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1680
 DB 1621 TCATGAGACCAACAGATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1680
 QY 1681 CCATGTTGATGCTTCTATAACTTCGTAAGCGGCAACCGAGGAGGAGTACAGTCAACAG 1740
 DB 1681 CCATGTTGATGCTTCTATAACTTCGTAAGCGGCAACCGAGGAGGAGTACAGTCAACAG 1740
 QY 1741 CCAGCGGAGCTGTGAGATATCCAGGTCGAGGAGTGTGAGGAGTGTGAGGAGTGTGAGGAGTGT 1800
 DB 1741 CCAGCGGAGCTGTGAGATATCCAGGTCGAGGAGTGTGAGGAGTGTGAGGAGTGTGAGGAGTGT 1800
 QY 1801 CAGCAACAGCAGCTCCGCTCGGTGTATCAGGTGAGGAGGAGTGTGCTGCTGCTGCTGCTGCTGCTGCTG 1860

```

Db      1801  CAGCAACAGCAGCTCCGTCGGTGATCAGGTGAGGGGCGAGTAGTCTGCCCAATTC 1860
Qy      1861  ATGACCATATTAACATCAACACCTACAAACCCAGACACATGGGGCCCACTGGACAGAAAACA 1920
Db      1861  ATGACCATATTAACATCAACACCTACAAACCCAGACACATGGGGCCCACTGGACAGAAAACA 1920
Qy      1921  GCCTGGGAACCTCTGCACCCGACAGTCACACATCTCTGAACCTTATATTAATTCAGA 1980
Db      1921  GCCTGGGAACCTCTGCACCCGACAGTCACACATCTCTGAACCTTATATTAATTCAGA 1980
Qy      1981  CCATACCAAGGACAGAGGTACAGGAACTCAATATGACTCCCTCCCAAAAACCTTA 2040
Db      1981  CCATACCAAGGACAGAGGTACAGGAACTCAATATGACTCCCTCCCAAAAACCTTA 2040
Qy      2041  TAAATGCAATAGATGACACAAAGACGCAACTTTTGTACAGATGGGGAGAGCTTT 2100
Db      2041  TAAATGCAATAGATGACACAAAGACGCAACTTTTGTACAGATGGGGAGAGCTTT 2100
Qy      2101  TTCCTGTATATGCTTATATATTAATTAAGTCTATGGGCTGGTTAAAAAACAAGATATATA 2160
Db      2101  TTCCTGTATATGCTTATATATTAATTAAGTCTATGGGCTGGTTAAAAAACAAGATATATA 2160
Qy      2161  AATTTAAAGACAAAAGTCAAAAACA 2185
Db      2161  AATTTAAAGACAAAAGTCAAAAACA 2185

```

```

RESULT 15
ABX17057
ID ABX17057 standard; cDNA; 2185 BP.
AC ABX17057;
XX
XX
DT 04-FEB-2003 (first entry)
DE Human PRO polynucleotide #64.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW toxin; radiolabel; cell death; gene mapping; chromosome mapping;
KW protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
KW antibacterial.
XX
OS Homo sapiens.
XX
PN US2002123463-A1.
XX
XX
PD 05-SEP-2002.
XX
XX
PF 19-NOV-2001; 2001US-0989732.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 06-JAN-2000; 2000WO-US00219.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.

```

```

PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUN-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23222.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062505P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
XX
PA (GETH ) GENENTECH INC.

```

X Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 Y Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Gowski PJ;
 I Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;
 I Roy MA, Stewart TA, Tumas D, Watanabe CX, Williams PM, Wood WI;
 I Zhang Z;
 X WPI: 2003-066810/06.
 R P-PSDB; ABU10879.
 X Novel secreted and transmembrane polypeptide for modulating biological
 T activity of cell expressing the polypeptide, identifying agonists or
 T antagonists of polypeptide, and as molecular weight markers -
 X Claim 2; Fig 156; 655pp; English.
 X The invention relates to a secreted and transmembrane polypeptide, termed
 C PRO polypeptide, and the polynucleotide encoding it. The polypeptide is
 C useful for detecting PRO polypeptides and for linking a bioactive
 C molecule to a cell expressing the above polypeptides, where the bioactive
 C molecule is a toxin, radiolabel or an antibody. The bioactive material
 C causes the death of the cell. The polypeptide is useful for identifying
 C agonists or antagonists of the PRO polypeptide, for preparing variants of
 C PRO, as a molecular weight marker for protein electrophoresis purposes
 C and the PRO polynucleotide is useful for recombinantly expressing those
 C markers. The polynucleotide is also useful as a hybridisation probe, in
 C chromosome and gene mapping, in generation of antisense RNA and DNA, in
 C the preparation of PRO polypeptide, for generating transgenic animals or
 C knockout animals which in turn are useful in the development and
 C screening of therapeutically useful reagents, to construct hybridisation
 C probes for mapping the gene which encodes PRO and for the genetic
 C analysis of individuals with genetic disorders, in gene therapy, for
 C chromosome identification, as a chromosome marker and for generating
 C probes for PCR, Northern analysis, Southern analysis and Western
 C analysis. This sequence represents a human PRO polynucleotide of the
 C invention.
 X Sequence 2185 BP; 527 A; 666 C; 519 G; 473 T; 0 other;
 Query Match 100.0%; Score 2185; DB 25; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185, Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Y 1 GTTCTCTTCCGAGCCAAATCCAGCGGATGGTGAATATGAACTGCGCCACCATGA 60
 Y 1 GTTCTCTTCCGAGCCAAATCCAGCGGATGGTGAATATGAACTGCGCCACCATGA 60
 Y 61 AGCTCTGTGCGAGTAACGTGTCACACACACACCTGGAATGCTGCTCCGCTCG 120
 Y 61 AGCTCTGTGCGAGTAACGTGTCACACACACACCTGGAATGCTGCTCCGCTCG 120
 Y 121 TCTACCTCAGCGGCAAGTGTGGATCTGTGTGAGCCATGCTGCTGCGGCTCAGCG 180
 Y 121 TCTACCTCAGCGGCAAGTGTGGATCTGTGTGAGCCATGCTGCTGCGGCTCAGCG 180
 Y 181 GGCCCGAAGTCCCTCCGTTGCTGTCGAGTAACCACTTACAGAGTGGTGTGCA 240
 Y 181 GGCCCGAAGTCCCTCCGTTGCTGTCGAGTAACCACTTACAGAGTGGTGTGCA 240
 Y 241 CGCCCGCGGGCTCTCCGAGGTCCCGAGGATATTCCTCGAACACCGGTACCTCAAC 300
 Y 241 CGCCCGCGGGCTCTCCGAGGTCCCGAGGATATTCCTCGAACACCGGTACCTCAAC 300
 Y 301 TCATGGAGAACACATCCAGATGATCCAGCCGACACCTTCGCGCACCCTCGACCTGG 360
 Y 301 TCATGGAGAACACATCCAGATGATCCAGCCGACACCTTCGCGCACCCTCGACCTGG 360
 Y 361 AGGTCCTGAGTGGGAGCAATCCATCCGAGATTTAGGTGGGGGCTTCAACGGGC 420
 Y 361 AGGTCCTGAGTGGGAGCAATCCATCCGAGATTTAGGTGGGGGCTTCAACGGGC 420
 Y 421 TGGCCAGCCTCAACACCTCGAGCTGTTCGAACTGGCTGACAGTCACTCCCTAGCGGG 480

Db 421 TGGCCAGCCTCAACACCTCGAGCTGTTGCAACACTGGCTGACAGTCACTCCCTAGCGGG 480
 QY 481 CTTTGAATACCTGTCAAGCTCGGGAGCTCTGGCTTGCACAAACCCCTCGAAAGCA 540
 Db 481 CTTTGAATACCTGTCAAGCTCGGGAGCTCTGGCTTGCACAAACCCCTCGAAAGCA 540
 QY 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTCGAGCTTGGGGAGCTCA 600
 Db 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTCGAGCTTGGGGAGCTCA 600
 QY 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGGGGGCTGTTCACCTCAAGTATCTGA 660
 Db 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGGGGGCTGTTCACCTCAAGTATCTGA 660
 QY 661 ACTTGGGCTGTCACATTAAGACATGCCCAATCTCACCCCTCGTGGGGCTGGAGG 720
 Db 661 ACTTGGGCTGTCACATTAAGACATGCCCAATCTCACCCCTCGTGGGGCTGGAGG 720
 QY 721 AGCTGGAGATGTCAAGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGCTGA 780
 Db 721 AGCTGGAGATGTCAAGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGCTGA 780
 QY 781 GCTCCCTCAAGAGCTCTGGGTATGAACTCAGCTCAGCTCAGCTGATGAGCGAATGCTT 840
 Db 781 GCTCCCTCAAGAGCTCTGGGTATGAACTCAGCTCAGCTCAGCTGATGAGCGAATGCTT 840
 QY 841 TTGACGGGCTGGCTTCACTTGTGAACTCAACTTGGCCCAATAACCTCTCTTCTTTGC 900
 Db 841 TTGACGGGCTGGCTTCACTTGTGAACTCAACTTGGCCCAATAACCTCTCTTCTTTGC 900
 QY 901 CCCATGACCTTTTACCCCTGAGTACCTGTGTGAGTGTGATCTACACCAACCTT 960
 Db 901 CCCATGACCTTTTACCCCTGAGTACCTGTGTGAGTGTGATCTACACCAACCTT 960
 QY 961 GGAAGTGTGATGACATCTGTGGCTAGCTGCTGCTGAGAGTATATACCCACCA 1020
 Db 961 GGAAGTGTGATGACATCTGTGGCTAGCTGCTGCTGAGAGTATATACCCACCA 1020
 QY 1021 ATTCCACCTGCTGTGGCGCTGTCTCCATGACATGACATGACGAGCGCTACCTCGTGG 1080
 Db 1021 ATTCCACCTGCTGTGGCGCTGTCTCCATGACATGACATGACGAGCGCTACCTCGTGG 1080
 QY 1081 AGGTGACAGGCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
 Db 1081 AGGTGACAGGCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
 QY 1141 TCAACATTTCTGAGGGTGGATGCGAGAACTTAAGTGTGCGACTCCCTCTGCTGCTGCT 1200
 Db 1141 TCAACATTTCTGAGGGTGGATGCGAGAACTTAAGTGTGCGACTCCCTCTGCTGCTGCT 1200
 QY 1201 TGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
 Db 1201 TGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
 QY 1261 CTGTCTCTCAACGAGCGCACTTCAACTTTTCCCACTGCTGCTGCTGCTGCTGCTGCTGCT 1320
 Db 1261 CTGTCTCTCAACGAGCGCACTTCAACTTTTCCCACTGCTGCTGCTGCTGCTGCTGCTGCT 1320
 QY 1321 ACACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1380
 Db 1321 ACACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1380
 QY 1381 GCAGGCTGAGCTTAAACCTCTCAACTTCTTCAACAGTAAACAGTGGAGCA 1440
 Db 1381 GCAGGCTGAGCTTAAACCTCTCAACTTCTTCAACAGTAAACAGTGGAGCA 1440
 QY 1441 CGGAGATCTCGCTGAGGACCAACCGGAAAGTAAAGGCTGTTCCTACCGTCCACTG 1500
 Db 1441 CGGAGATCTCGCTGAGGACCAACCGGAAAGTAAAGGCTGTTCCTACCGTCCACTG 1500
 QY 1501 GTTACAGCGCGGATATACCACTCTACCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1560
 Db 1501 GTTACAGCGCGGATATACCACTCTACCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1560

2y	1561	ACGAGTGGCAGTACCGCGACACACACCACTGACAGATGACAGCAGCCTGATGAAG	1620	PR	02-MAR-2000;	2000US-0186350.
2y	1561	ACGAGTGGCAGTACCGCGACACACACCACTGACAGATGACAGCAGCCTGATGAAG	1620	PR	16-MAR-2000;	2000US-0189874.
2y	1561	ACGAGTGGCAGTACCGCGACACACACCACTGACAGATGACAGCAGCCTGATGAAG	1620	PR	17-MAR-2000;	2000US-0190076.
2y	1621	TCATGAAGACCAACCAAGATCATCTGGCTGCTTTGTGGCAGTGACTCTGCTAGCTGCCG	1680	PR	18-APR-2000;	2000US-0198123.
2y	1621	TCATGAAGACCAACCAAGATCATCTGGCTGCTTTGTGGCAGTGACTCTGCTAGCTGCCG	1680	PR	19-MAY-2000;	2000US-0205515.
2y	1681	CCATGTTGATGTTCTTCTATATAAATTCGTAAGCGGCACGAGCGAGTACAGTACACAG	1740	PR	07-JUN-2000;	2000US-0209467.
2y	1681	CCATGTTGATGTTCTTCTATATAAATTCGTAAGCGGCACGAGCGAGTACAGTACACAG	1740	PR	28-JUN-2000;	2000US-0214886.
2y	1741	CCGCCCCGAGCTGTTGAGATATATCAGGTGACGAGCAATCCAGCAGCAATCCCGCAG	1800	PR	30-JUN-2000;	2000US-0215135.
2y	1741	CCGCCCCGAGCTGTTGAGATATATCAGGTGACGAGCAATCCAGCAGCAATCCCGCAG	1800	PR	07-JUL-2000;	2000US-0216647.
2y	1801	CAGCAACAGCAGCTCCGTCGGGTGATCAGGTGAGGGGGCAGTAGTCTGCCCAATTC	1860	PR	07-JUL-2000;	2000US-0216880.
2y	1801	CAGCAACAGCAGCTCCGTCGGGTGATCAGGTGAGGGGGCAGTAGTCTGCCCAATTC	1860	PR	11-JUL-2000;	2000US-0217487.
2y	1861	ATGACCATATTAATACAAACACCTACAAACAGCAGCAATGGGGCCCACTGGACAGAAAAA	1920	PR	11-JUL-2000;	2000US-0217496.
2y	1861	ATGACCATATTAATACAAACACCTACAAACAGCAGCAATGGGGCCCACTGGACAGAAAAA	1920	PR	14-JUL-2000;	2000US-0218290.
2y	1921	GCCTGGGGAATCTCTGCAACCCACAGTACCACTATCTCTGAACTTATATTAATTCAGA	1980	PR	26-JUL-2000;	2000US-0220963.
2y	1921	GCCTGGGGAATCTCTGCAACCCACAGTACCACTATCTCTGAACTTATATTAATTCAGA	1980	PR	26-JUL-2000;	2000US-0220964.
2y	1981	CCCATACCAAGGACAGTACGAGAACTCAATATGACTCCCTCCCCCAAAACTTTA	2040	PR	14-AUG-2000;	2000US-0224518.
2y	1981	CCCATACCAAGGACAGTACGAGAACTCAATATGACTCCCTCCCCCAAAACTTTA	2040	PR	14-AUG-2000;	2000US-0224519.
2y	2041	TAAATGCAATAGATGACACAAAGACAGCAATTTGTACAGAGTGGGGAGAGACTTT	2100	PR	14-AUG-2000;	2000US-0225213.
2y	2041	TAAATGCAATAGATGACACAAAGACAGCAATTTGTACAGAGTGGGGAGAGACTTT	2100	PR	14-AUG-2000;	2000US-0225214.
2y	2101	TTCCTGTATATGCTTATATATTAATTAAGTCTATGGCTGTTTAAATAAACAAGATTATTA	2160	PR	14-AUG-2000;	2000US-0225266.
2y	2101	TTCCTGTATATGCTTATATATTAATTAAGTCTATGGCTGTTTAAATAAACAAGATTATTA	2160	PR	14-AUG-2000;	2000US-0225267.
2y	2161	AATTTAAGACAAAAAGTCAAAACA	2185	PR	14-AUG-2000;	2000US-0225270.
2y	2161	AATTTAAGACAAAAAGTCAAAACA	2185	PR	14-AUG-2000;	2000US-0225447.

RESULT 16
AAS28823
ID AAS28823 standard; cDNA; 2324 BP.
AC AAS28823;
XX
DT 07-NOV-2001 (first entry)
DE Human immunoglobulin encoding cDNA SEQ ID No 69.
XX
KW Immunoglobulin; primer; signal transduction pathway protein; cancer; ss;
KW antisense therapy; gene therapy; neurological disorder; renal disorder;
KW cardiovascular disorder; gastrointestinal disorder; pulmonary disorder;
KW reproductive disorder; immune system disorder; proliferative disorder;
KW muscular disorder.
XX
OS Homo sapiens.
XX
PN WC20015315-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01326.
XX
XX 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR

02-OCT-2000; 2000US-0237040.
13-OCT-2000; 2000US-0239935.
13-OCT-2000; 2000US-0239937.
20-OCT-2000; 2000US-0240960.
20-OCT-2000; 2000US-0241221.
20-OCT-2000; 2000US-0241785.
20-OCT-2000; 2000US-0241786.
20-OCT-2000; 2000US-0241787.
20-OCT-2000; 2000US-0241808.
20-OCT-2000; 2000US-0241809.
20-OCT-2000; 2000US-0241826.
01-NOV-2000; 2000US-0244617.
08-NOV-2000; 2000US-0246474.
08-NOV-2000; 2000US-0246475.
08-NOV-2000; 2000US-0246476.
08-NOV-2000; 2000US-0246477.
08-NOV-2000; 2000US-0246478.
08-NOV-2000; 2000US-0246523.
08-NOV-2000; 2000US-0246524.
08-NOV-2000; 2000US-0246525.
08-NOV-2000; 2000US-0246526.
08-NOV-2000; 2000US-0246527.
08-NOV-2000; 2000US-0246528.
08-NOV-2000; 2000US-0246528.
08-NOV-2000; 2000US-0246532.
08-NOV-2000; 2000US-0246609.
08-NOV-2000; 2000US-0246610.
08-NOV-2000; 2000US-0246611.
08-NOV-2000; 2000US-0246613.
17-NOV-2000; 2000US-0249207.
17-NOV-2000; 2000US-0249208.
17-NOV-2000; 2000US-0249209.
17-NOV-2000; 2000US-0249210.
17-NOV-2000; 2000US-0249211.
17-NOV-2000; 2000US-0249212.
17-NOV-2000; 2000US-0249213.
17-NOV-2000; 2000US-0249214.
17-NOV-2000; 2000US-0249215.
17-NOV-2000; 2000US-0249216.
17-NOV-2000; 2000US-0249217.
17-NOV-2000; 2000US-0249218.
17-NOV-2000; 2000US-0249244.
17-NOV-2000; 2000US-0249245.
17-NOV-2000; 2000US-0249264.
17-NOV-2000; 2000US-0249265.
17-NOV-2000; 2000US-0249297.
17-NOV-2000; 2000US-0249299.
17-NOV-2000; 2000US-0249300.
01-DEC-2000; 2000US-0250160.
01-DEC-2000; 2000US-0250391.
05-DEC-2000; 2000US-0251030.
05-DEC-2000; 2000US-0251988.
05-DEC-2000; 2000US-0256719.
06-DEC-2000; 2000US-0251479.
08-DEC-2000; 2000US-0251856.
08-DEC-2000; 2000US-0251868.
08-DEC-2000; 2000US-0251869.
08-DEC-2000; 2000US-0251989.
08-DEC-2000; 2000US-0251990.
11-DEC-2000; 2000US-0254097.
05-JUN-2001; 2001US-0259678.

(HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Barash SC, Ruben SM;

WPI; 2001-457725/49.

P-PSDB; AAU18035.

Isolated novel immunoglobulin polypeptide for monitoring the presence and progression of diseases and for diagnosis -

Claim 1; SEQ ID No 69; 551pp; English.

CC Sequences AAS28765-AAS28877 represent cDNA molecules, which encode the
CC immunoglobulin polypeptides of the invention, and primers for the
CC polynucleotides. The polynucleotides and polypeptides can be used to
CC diagnose a pathological condition or a susceptibility to a pathological
CC condition in a subject by determining the presence or absence of a
CC mutation in a DNA sequence or determining the presence or amount of a
CC expression of the protein. Alternatively the identification of a binding
CC partner to a sequence allows determination of changes in protein
CC activity. The sequences can be used as research tools for receptors or
CC other signal transduction pathway proteins that interact with the
CC polypeptides of the invention and can be used to treat, prevent or
CC diagnose various types of disorders such as neurological disorders,
CC cardiovascular disorders, gastrointestinal disorders, reproductive,
CC disorders, immune system disorders, renal disorders, muscular disorders,
CC pulmonary disorders, proliferative disorders and cancer.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 2324 BP; 604 A; 647 C; 552 G; 521 T; 0 other;

Query Match 90.7%; Score 1982; DB 22; Length 2324;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1982; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 204 TGCTGTGCAAGTAACCAAGTTCAGCAAGGTGGTGTCTCAGCGCGCGGGGCTCTCCAGGTC 263
DB 8 TGCTGTGCAAGTAACCAAGTTCAGCAAGGTGGTGTCTCAGCGCGCGGGGCTCTCCAGGTC 67
QY 264 CCGCAGGTTATTCCTCGAGACACCGGTACCTCAACCTCATGAGAAACAACATCCAGATG 323
DB 68 CCGCAGGTTATTCCTCGAGACACCGGTACCTCAACCTCATGAGAAACAACATCCAGATG 127
QY 324 ATCCAGGCGGACACCTTCCGCGCACCTCCACACCTCGAGGTCTCTCAGTTGGGCGAGAAC 383
DB 128 ATCCAGGCGGACACCTTCCGCGCACCTCCACACCTCGAGGTCTCTCAGTTGGGCGAGAAC 187
QY 384 TCATCCGCGCAATTCAGTGGGGGCTTCACGGCTTGGCGAGCTCAACACCTCGAG 443
DB 188 TCATCCGCGCAATTCAGTGGGGGCTTCACGGCTTGGCGAGCTCAACACCTCGAG 247
QY 444 CTGTTGCAACATTCGCTGACAGTCACTCCCTAGCGGGGCTTTGAATACCTGTCACAGTG 503
DB 248 CTGTTGCAACATTCGCTGACAGTCACTCCCTAGCGGGGCTTTGAATACCTGTCACAGTG 307
QY 504 CGGAGCTCTGGCTTGGCAACAAACCCCAACGATCCCTCTTAAGCTTCAACCGG 563
DB 308 CGGAGCTCTGGCTTGGCAACAAACCCCAACGATCCCTCTTAAGCTTCAACCGG 367
QY 564 GTGCGCTCCCTCATGCGCTGAGCTTGGGGAGCTCAAGAGCTGAGTATATCTCTGAG 623
DB 368 GTGCGCTCCCTCATGCGCTGAGCTTGGGGAGCTCAAGAGCTGAGTATATCTCTGAG 427
QY 624 GGAGCTTTTGAGGGGCTGTTCAACCTCAAGTATCTGAATTTGGGCAATGTCACATTTAA 683
DB 428 GGAGCTTTTGAGGGGCTGTTCAACCTCAAGTATCTGAATTTGGGCAATGTCACATTTAA 487
QY 684 GACATGCCCAATCTACCCCTCTGTTGGGGCTGAGAGCTGAGATGTCAGGGACAC 743
DB 488 GACATGCCCAATCTACCCCTCTGTTGGGGCTGAGAGCTGAGATGTCAGGGACAC 547
QY 744 TTCCCTGAGATCAGGCTGGCTCTTCCATGCGCTGAGCTCCCTCAAGAGCTCTGGGTC 803
DB 548 TTCCCTGAGATCAGGCTGGCTCTTCCATGCGCTGAGCTCCCTCAAGAGCTCTGGGTC 607
QY 804 ATGAACTCAGCTCAGCTGATTTGGGGATGCTTTTTCAGGGCTGGCTTCAGCTTGG 863
DB 608 ATGAACTCAGCTCAGCTGATTTGGGGATGCTTTTTCAGGGCTGGCTTCAGCTTGG 667
QY 864 GAACCTCAACTTGGCCCAACAATAACCTCTCTTCTTGGCCCATGACCTCTTTACCCCGCTG 923
DB 668 GAACCTCAACTTGGCCCAACAATAACCTCTCTTCTTGGCCCATGACCTCTTTACCCCGCTG 727

924 AGGTACCTGGTGGAGTTGCAATCTACACCAACCCCTTGGAACTGTGATGTGACATTCG 983
728 AGGTACCTGGTGGAGTTGCAATCTACACCAACCCCTTGGAACTGTGATGTGACATTCG 787
984 TGGTACCTGGTGGAGTTGCAATCTACACCAACCCCTTGGAACTGTGATGTGACATTCG 1043
788 TGGTACCTGGTGGAGTTGCAATCTACACCAACCCCTTGGAACTGTGATGTGACATTCG 847
1044 CATGCTCCCATGCAATGCGAGGCGGCTACTCTGAGAGTGGACAGGCGCTCTTCGAG 1103
848 CATGCTCCCATGCAATGCGAGGCGGCTACTCTGAGAGTGGACAGGCGCTCTTCGAG 907
1104 TGCTTGCCCTTCATCATGAGAGGAGCTGAGACCTGACATTTCTGAGGCTGGATG 1163
908 TGCTTGCCCTTCATCATGAGAGGAGCTGAGACCTGACATTTCTGAGGCTGGATG 967
1164 GCAGAACTTAAGTGTGAGTCTCCCTTATGCTCTCCCTGAAGTGTGCTGCGCAATGGG 1223
968 GCAGAACTTAAGTGTGAGTCTCCCTTATGCTCTCCCTGAAGTGTGCTGCGCAATGGG 1027
1224 ACAGTGTGAGCAGCGCTCCGCGCACCCAGAGTCTCTGCTCAACGAGCGACCTTG 1283
1028 ACAGTGTGAGCAGCGCTCCGCGCACCCAGAGTCTCTGCTCAACGAGCGACCTTG 1087
1284 AACCTTTCCACGCTGCTCTTTTACAGACCTGGGCTGTACATGCTGCTGACCAATGTT 1343
1088 AACCTTTCCACGCTGCTCTTTTACAGACCTGGGCTGTACATGCTGCTGACCAATGTT 1147
1344 GCAGCAACTCCAGCGCTCCGCGCACCCAGAGTCTCTGCTCAACGAGCGACCTTG 1403
1148 GCAGCAACTCCAGCGCTCCGCGCACCCAGAGTCTCTGCTCAACGAGCGACCTTG 1207
1404 AACCTTTCCACGCTGCTCTTTTACAGACCTGGGCTGTACATGCTGCTGACCAATGTT 1463
1208 AACCTTTCCACGCTGCTCTTTTACAGACCTGGGCTGTACATGCTGCTGACCAATGTT 1267
1464 ACAGCAACTCCAGCGCTCCGCGCACCCAGAGTCTCTGCTCAACGAGCGACCTTG 1523
1268 ACAGCAACTCCAGCGCTCCGCGCACCCAGAGTCTCTGCTCAACGAGCGACCTTG 1327
1524 TCTACAGCGTGTCTTACAGCTACCGTGTGCGGAGGAGTGGAGTGGAGTGGAGTGGAG 1583
1328 TCTACAGCGTGTCTTACAGCTACCGTGTGCGGAGGAGTGGAGTGGAGTGGAGTGGAG 1387
1584 GACACCACTGACAGATGACAGCAGCGCTGATGAGTGTGAGTGTGAGTGTGAGTGTGAG 1643
1388 GACACCACTGACAGATGACAGCAGCGCTGATGAGTGTGAGTGTGAGTGTGAGTGTGAG 1447
1644 ATGCTGCTTTTGGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1703
1448 ATGCTGCTTTTGGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1507
1704 CTTCGTAAGCGGACAGCAGCGGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1763
1508 CTTCGTAAGCGGACAGCAGCGGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1567
1764 CAGGTGGAGAGATCCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 1823
1568 CAGGTGGAGAGATCCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 1627
1824 GTATCAGGTGAGGCGGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1883
1628 GTATCAGGTGAGGCGGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1687
1884 TACAAACCAAGCAGTGGGCGGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1943
1688 TACAAACCAAGCAGTGGGCGGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAG 1747
1944 ACAGTCAACCAATCTCTGAGCTTATATATATATATATATATATATATATATATATATAT 2003
1748 ACAGTCAACCAATCTCTGAGCTTATATATATATATATATATATATATATATATATATAT 1807
2004 GAACTCAAAATATGATCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCT 2063

Db 1808 GAACTCAAAATATGATCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCC 1867
Qy 2064 AAGACAGCAACTTTTGTACAGAGTGGGAGAGACTTTTCTTGTATATGCTTATATATTA 2123
Db 1868 AAGACAGCAACTTTTGTACAGAGTGGGAGAGACTTTTCTTGTATATGCTTATATATTA 1927
Qy 2124 AGTATATGCTGCTTTTAAACCAACAGATTTATATATATATATATATATATATATTA 2183
Db 1928 AGTATATGCTGCTTTTAAACCAACAGATTTATATATATATATATATATATATTA 1987
Qy 2184 CA 2185
Db 1988 CA 1989
RESULT 17
AAD16345
ID AAD16345 standard; DNA; 1962 BP.
XX
AC AAD16345;
XX 19-NOV-2001 (first entry)
XX Human sbgPRO331a gene.
XX
KW Human; Alzheimer's disease; amyotrophic lateral sclerosis;
KW ALS; Zollinger-Ellison syndrome; immune system disease; schizophrenia;
KW inflammation; haematopoietic disease; anxiety; feeding disorder; aging;
KW anorexia; depression; cardiovascular disease; sleep disorder; seizure;
KW memory alteration; migraine; stroke; asthma; neuropathy; hypoglycaemia;
KW sexual disorder; growth abnormality; infection; autoimmune disease;
KW rheumatoid arthritis; cataractogenesis; angiogenesis; atherosclerosis;
KW cerebral ischaemia; cirrhosis; Huntington's disease; Hodgson's disease;
KW hypercholesterolaemia; headache; amnesia; cardiac arrhythmia; obesity;
KW diabetes mellitus; glomerulonephritis; renovascular hypertension;
KW cancer; vaccine; gene therapy; sbgPRO331a gene; ds.
XX Homo sapiens.
XX
FH Key Location/Qualifiers
FT 1..1962
FT CDS /tag= a
FT /product= "Human sbgPRO331a protein"
XX WO200150850-A1.
XX 23-AUG-2001.
XX 14-FEB-2001; 2001WO-US04703.
XX 14-FEB-2000; 2000US-0182172.
XX 29-FEB-2000; 2000US-0186084.
XX 18-APR-2000; 2000US-0198583.
XX 04-OCT-2000; 2000US-0237963.
XX (SMIK) SMITHKLINE BEECHAM CORP.
XX (SMIK) SMITHKLINE BEECHAM PLC.
XX Agarwal P, Kabnick KS, Murdoch PR, Rizvi SK, Smith RP, Xiang Z;
XX WPI; 2001-536566/59.
XX P-PSDB; AAE09438.
XX New secreted and membrane associated polypeptides for treating
XX Alzheimer's disease, psoriasis, cancer, enterocolitis, sleep and sexual
XX disorders, stroke, and asthma -
XX Claim 2; Page 37-38; 94pp; English.
XX The present sequence is a gene encoding human sbgPRO331a protein,
XX a membrane bound protein of the invention.
XX The invention relates to secreted and membrane associated polypeptides

C and nucleic acid molecules encoding such polypeptides. Sequences of the
C invention are useful for treating diseases such as Alzheimer's disease,
C amyotrophic lateral sclerosis (ALS), Zollinger-Ellison syndrome, diseases
C of the immune system, haematopoietic disease, inflammation, anxiety,
C schizophrenia, feeding disorders, anorexia, depression, social, sexual
C and memory behaviour, cardiovascular disease, sleep disorder, learning
C cancer, stroke, asthma, neuropathy, aging, sexual disorders, treatment
C of transsexuals, growth abnormalities, obesity, infections, autoimmune
C diseases (e.g. rheumatoid arthritis), cataractogenesis, angiogenesis,
C disorders associated with healthy maintenance of gastric mucosa and
C repair of acute and chronic mucosal lesion, lung carcinoma, cerebral
C ischaemia, atherosclerosis, cirrhosis, Huntington's disease, headache,
C anesmia, multiple sclerosis, Hodgson's disease, dilated cardiomyopathy,
C congestive heart failure, cardiac arrhythmias, hypercholesterolaemia,
C viral and non-viral hepatitis, type I and type II diabetes mellitus,
C glomerulonephritis, renovascular hypertension, hypoglycaemia, periodic
C paralyses, tendinitis and malignant hyperthermia. Polypeptides of the
C invention are used to identify membrane bound and soluble receptors.
C They are also useful as vaccines for inducing an immunological response
C in a mammal. Polynucleotides of the invention are used in gene therapy.
C They are also valuable for chromosome localisation studies and tissue
C expression studies.

X Sequence 1962 BP; 444 A; 622 C; 482 G; 414 T; 0 other;

Query Match 87.5%; Score 1911; DB 22; Length 1962;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 1962; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

57 ATGAAGCTCTTGTGGAGGTAACCTGTCACACACACACCTGGATGCTGCTCCG 116
1 ATGAAGCTCTTGTGGAGGTAACCTGTCACACACACACCTGGATGCTGCTCCG 60
117 TTGCTCTACTCTCAGCGCAAGTGTGATCTCTGTGACGACCATGCTGCTCGGCTCA 176
61 TTGCTCTACTCTCAGCGCAAGTGTGATCTCTGTGACGACCATGCTGCTCGGCTCA 120
177 GCGGGGCCCCAGAACTGCGGCTCGTGTGTCGAGGTAACTGTCAGAGTGTGTTG 236
121 GCGGGGCCCCAGAACTGCGGCTCGTGTGTCGAGGTAACTGTCAGAGTGTGTTG 180
237 TGCAAGCGCGCGGGGCTCTCGAGGTCCCGAGGTATTCCTCGAACACCCGGTACCTC 296
181 TGCAAGCGCGCGGGGCTCTCGAGGTCCCGAGGTATTCCTCGAACACCCGGTACCTC 240
297 AACCTCATGAGAACACATCCAGATATCCAGCCGACACCTTCCGCCACCTCCACAC 356
241 AACCTCATGAGAACACATCCAGATATCCAGCCGACACCTTCCGCCACCTCCACAC 300
357 CTGAGGTCTCGAGTTGGGCGAACTCCATCCGCGAGATTGAGTGGGGGCTTCAAC 416
301 CTGAGGTCTCGAGTTGGGCGAACTCCATCCGCGAGATTGAGTGGGGGCTTCAAC 360
417 GCGCTGGCGAGCTCAACACCTGGAGCTGTTCGACAACTGGCTGACGTATCCCTAGC 476
361 GCGCTGGCGAGCTCAACACCTGGAGCTGTTCGACAACTGGCTGACGTATCCCTAGC 420
477 GGGGCTTTGAAATCTGTCAAGCTGGGAGCTCTGGCTTTCGACAACTGGCTGACGT 536
421 GGGGCTTTGAAATCTGTCAAGCTGGGAGCTCTGGCTTTCGACAACTGGCTGACGT 480
537 AGCATCCCTCTTACGCTTCAACCGGGTGCCTTCCCTCATGGGCTGAGACTTGGGGGAG 596
481 AGCATCCCTCTTACGCTTCAACCGGGTGCCTTCCCTCATGGGCTGAGACTTGGGGGAG 540
597 CTCAGAGAGCTGGAGTATCTCTGAGGAGCTTTTGGGGGCTTTTCAACCTCAAGTAT 556
541 CTCAGAGAGCTGGAGTATCTCTGAGGAGCTTTTGGGGGCTTTTCAACCTCAAGTAT 600
657 CTGAACTTGGGCACTGCAACATTAAGACATGCCCAATCTCAACCTTGGTGGGGCTG 716
601 CTGAACTTGGGCACTGCAACATTAAGACATGCCCAATCTCAACCTTGGTGGGGCTG 660

QY 717 GAGGAGCTGGAGATGTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTTCTTCATGCG 776
DB 661 GAGGAGCTGGAGATGTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTTCTTCATGCG 720
QY 777 CTGAGCTTCCCTCAAGAGCTCTGGTTCATGAATCAAGTCAAGTCAAGTCAAGTCAAGT 836
DB 721 CTGAGCTTCCCTCAAGAGCTCTGGTTCATGAATCAAGTCAAGTCAAGTCAAGTCAAGT 780
QY 837 GCTTTTGAAGGCTGGCTTCACTTGTGGAACTCAACTTGGGCCCCACAAATACCTTCTTCT 896
DB 781 GCTTTTGAAGGCTGGCTTCACTTGTGGAACTCAACTTGGGCCCCACAAATACCTTCTTCT 840
QY 897 TTGCCCCATGACCTCTTTTACCCCGCTGAGTACCTGCTGGCTTCGAGAGTATATACCC 956
DB 841 TTGCCCCATGACCTCTTTTACCCCGCTGAGTACCTGCTGGCTTCGAGAGTATATACCC 900
QY 957 CTTTGGAACTGTGATTTGTGACATTTCTGGCTAGCTGCTGGCTTCGAGAGTATATACCC 960
DB 901 CTTTGGAACTGTGATTTGTGACATTTCTGGCTAGCTGCTGGCTTCGAGAGTATATACCC 960
QY 1017 ACCAATTCACCTGCTGCTGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1076
DB 961 ACCAATTCACCTGCTGCTGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1020
QY 1077 GTGAGGTGAGACGAGGCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1136
DB 1021 GTGAGGTGAGACGAGGCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1080
QY 1137 GACCTCAACATTTCTGAGGCTCGGATGGGAGAACTTAAAGTGTGAGTGTGCTGCTGCTGCT 1196
DB 1081 GACCTCAACATTTCTGAGGCTCGGATGGGAGAACTTAAAGTGTGAGTGTGCTGCTGCTGCT 1140
QY 1197 TCCGTGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1256
DB 1141 TCCGTGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1200
QY 1257 ATCTCTGCTCTCAAGACGAGGCTTGAACCTTTTCCCACTGCTGCTGCTGCTGCTGCTGCT 1316
DB 1201 ATCTCTGCTCTCAAGACGAGGCTTGAACCTTTTCCCACTGCTGCTGCTGCTGCTGCTGCT 1260
QY 1317 GTGTACACATGATGTGACCAATTTGAGGAGCACTCCCAAGCTGCTGCTGCTGCTGCTGCTGCT 1376
DB 1261 GTGTACACATGATGTGACCAATTTGAGGAGCACTCCCAAGCTGCTGCTGCTGCTGCTGCTGCT 1320
QY 1377 GTGAGCAAGCTGAGCTTAACTCACTCACTCACTCACTCACTCACTCACTCACTCACTCACT 1436
DB 1321 GTGAGCAAGCTGAGCTTAACTCACTCACTCACTCACTCACTCACTCACTCACTCACTCACT 1380
QY 1437 ACCACGAGATCTCGCTGAGGACAAACCGGAAAGTAAAGCTGCTTCTTACACGCTCC 1496
DB 1381 ACCACGAGATCTCGCTGAGGACAAACCGGAAAGTAAAGCTGCTTCTTACACGCTCC 1440
QY 1497 ACTGTTTACGAGCGGCTATACCACTCTTACCAAGCTGCTCACTTACAGCTTACCGCTGCTG 1556
DB 1441 ACTGTTTACGAGCGGCTATACCACTCTTACCAAGCTGCTCACTTACAGCTTACCGCTGCTG 1500
QY 1557 CCCAAGCAGTGGCAGTACCCCGGAGACACCACTGACAAAGTACGAGACGAGCTGGAT 1616
DB 1501 CCCAAGCAGTGGCAGTACCCCGGAGACACCACTGACAAAGTACGAGACGAGCTGGAT 1560
QY 1617 GAAGTCAAGAGACCAACCAAGATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1676
DB 1561 GAAGTCAAGAGACCAACCAAGATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1620
QY 1677 GCGGCACTGTTGATGTTCTTCTTAAACTTCTGTAAGCGGCAACGAGCGAGGTACAGTC 1736
DB 1621 GCGGCACTGTTGATGTTCTTCTTAAACTTCTGTAAGCGGCAACGAGCGAGGTACAGTC 1680
QY 1737 ACAGCGCGCGGAGCTGTTGAGATATCCAGGTGGAACGAGATATCCAGCAGCAACATCC 1796
DB 1681 ACAGCGCGCGGAGCTGTTGAGATATCCAGGTGGAACGAGATATCCAGCAGCAACATCC 1740

QY 1797 GCAGCAGCAACAGCAGCTCCGTCGGTGTATCATAGTGGGGGAGTAGTGTGCCCCACA 1856
 Db 1741 GCAGCAGCAACAGCAGCTCCGTCGGTGTATCATAGTGGGGGAGTAGTGTGCCCCACA 1800
 QY 1857 ATTATGACCATATTAATACACACCTACAAACAGCAGCATGGGCCCACTGGACAGAA 1916
 Db 1801 ATTATGACCATATTAATACACACCTACAAACAGCAGCATGGGCCCACTGGACAGAA 1860
 QY 1917 AACAGCCTGGGAACTCTTGACACCCCACTGACCTACCTATCTCTGAACCTTATATTAATT 1976
 Db 1861 AACAGCCTGGGAACTCTTGACACCCCACTGACCTACCTATCTCTGAACCTTATATTAATT 1920
 QY 1977 CAGACCCATACCAAGCAAGGACAGGACAGCAAACTCAATATGA 2018
 Db 1921 CAGACCCATACCAAGCAAGGACAGGACAGCAAACTCAATATGA 1962

RESULT 18

AAK90848

ID AAX90848 standard; DNA; 2360 BP.

XX AAX90848;

17-JAN-2000 (first entry)

cDNA clone cc359_4.

clone cc359_4; cc359_4 protein; human adult brain cDNA library;
 secreted protein; H23117; human cDNA clone 51970 3'; gene therapy;
 cytokine; nutritional activity; cell proliferation; immune stimulation;
 immune suppression; hematopoiesis regulation; tissue growth;
 tumour inhibition; ds.

OS Homo sapiens.

Key Location/Qualifiers
 CDS 216..2177
 FT /tag= a
 FT /product= "cc359_4 protein"
 FT 216..338
 FT /tag= b
 FT 339..2177
 FT /tag= c
 FT /note= "Mature cc359_4 protein"

W09950405-A1.

PN XX

XX 07-OCT-1999.

30-MAR-1999; 99MO-US06946.

31-MAR-1998; 98US-0080110.

29-MAR-1999; 99US-0280591.

(GEM) GENETICS INST INC.

Jacobs K, McCoy JM, LaVallie ER, Collins-Racie LA, Evans C;

Merberg D, Treacy M, Agostino MJ, Steininger RJ;

WPI; 1999-610849/52.

P-PSDB; AAY28806.

Polynucleotides encoding secreted human proteins, derived from human

adult brain, human fetal brain, human fetal kidney, and human adult

blood cDNA libraries

Claim 1; Page 96-97; 122pp; English.

The present nucleotide sequence comprises the full-length protein-coding

sequence of clone cc359_4. cc359_4 was isolated from a human adult brain

cDNA library using methods specific for secreted protein cDNAs. This

demonstrates some similarity with AAH23117 of human cDNA clone 51970 3'.

This can be used in gene therapy. The polynucleotide and protein may

CC effect nutritional activity, cytokine and cell proliferation, immune
 CC stimulation or suppression, hematopoiesis regulation, tissue growth,
 CC tumour inhibition etc.

XX Sequence 2360 BP; 582 A; 707 C; 562 G; 508 T; 1 other;

Query Match 87.4%; Score 1910; DB 20; Length 2360;

Best Local Similarity 99.8%; Pred. No. 0;

Matches 2180; Conservative 0; Mismatches 3; Indels 1; Gaps 1;

QY 1 GTTCTCTTTCCGAGCCAAATCCAGGCGATGTGAATTATTAATGAACCTGCCACACCATGA 60

Db 160 GTTCTCTTTCCGAGCCAAATCCAGGCGATGTGAATTATTAATGAACCTGCCACACCATGA 219

QY 61 AGCTCTTGTGCGAGGTAACTGTGCACCAACACCTGGAATGCCATCTGCTCCCGTTGG 120

Db 220 AGCTCTTGTGCGAGGTAACTGTGCACCAACACCTGGAATGCCATCTGCTCCCGTTGG 279

QY 121 TCTACCTCACGCGCAAGTGTGGATTCTGTGTGAGCCATCGTGTGCGGCTCAGCG 180

Db 280 TCTACCTCACGCGCAAGTGTGGATTCTGTGTGAGCCATCGTGTGCGGCTCAGCG 339

QY 181 GGCCCCAGAACTGCCCTCCGTTTGTCTGTCAGTAACTGAGTTCAGCAAGTGTGTGCA 240

Db 340 GGCCCCAGAACTGCCCTCCGTTTGTCTGTCAGTAACTGAGTTCAGCAAGTGTGTGCA 399

QY 241 CGCGCGGGGCTCTCCGAGGTCCCGCAGGGTATTCCCTCGAAACACCGGTACCTCAACC 300

Db 400 CGCGCGGGGCTCTCCGAGGTCCCGCAGGGTATTCCCTCGAAACACCGGTACCTCAACC 459

QY 301 TCATGGAGAAACAAATCCAGATGATCCAGGCGGACCTCCGCGACCTCCACACCTGG 360

Db 460 TCATGGAGAAACAAATCCAGATGATCCAGGCGGACCTCCGCGACCTCCACACCTGG 519

QY 361 AGTCTCTGAGTTGGCGAGGAATCCATCCCGCAGATTGAGTGGGGGCTTCAACGGCC 420

Db 520 AGTCTCTGAGTTGGCGAGGAATCCATCCCGCAGATTGAGTGGGGGCTTCAACGGCC 579

QY 421 TGGCCAGCTCAACACCTGGAGCTGTTTCGAACAATGGCTGACAGTCAATCCCTAGCGGG 480

Db 580 TGGCCAGCTCAACACCTGGAGCTGTTTCGAACAATGGCTGACAGTCAATCCCTAGCGGG 639

QY 481 CTTTGTGATACCTGTCCAAAGCTGGCGGAGCTCTGGCTTCGCAACAAACCCCATCGAAAGCA 540

Db 640 CTTTGTGATACCTGTCCAAAGCTGGCGGAGCTCTGGCTTCGCAACAAACCCCATCGAAAGCA 699

QY 541 TCCCTCTTTACGCTTTCAAACCGGTCCTCCCTCANGCGCTGGACTTTGGGGGAGCTCA 600

Db 700 TCCCTCTTTACGCTTTCAAACCGGTCCTCCCTCANGCGCTGGACTTTGGGGGAGCTCA 759

QY 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGAAGGGCTGTTCAACCTCAAGTATCTGA 660

Db 760 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGAAGGGCTGTTCAACCTCAAGTATCTGA 819

QY 661 ACTTGGGCATGTGCAACATTAAGACATGCCCAATCTCACCCCTTGGTGGGCTGGAGG 720

Db 820 ACTTGGGCATGTGCAACATTAAGACATGCCCAATCTCACCCCTTGGTGGGCTGGAGG 879

QY 721 AGCTGAGATGTACAGGAACCACTTCCCTGAGATCAGGCTGGCTTCTTCCATGSCCTGA 780

Db 880 AGCTGAGATGTACAGGAACCACTTCCCTGAGATCAGGCTGGCTTCTTCCATGSCCTGA 939

QY 781 GCTTCCCTCAAGAAGCTCTGGGTCATGAATCACAGGTCAAGTATTGAGGGGATGCTT 840

Db 940 GCTTCCCTCAAGAAGCTCTGGGTCATGAATCACAGGTCAAGTATTGAGGGGATGCTT 999

QY 841 TTGAOCCGCTGGCTTCACTTTGTGGAACTCAACTTGGCCCAATTAACCTCTCTTTTTCG 900

Db 1000 TTGAOCCGCTGGCTTCACTTTGTGGAACTCAACTTGGCCCAATTAACCTCTCTTTTTCG 1059

QY 901 CCATGACCTTTTACCCCGCTGAGTACCTGGTGGAGTTGCTATCTACACCAACCCCTT 960

Db 1060 CCATGACCTTTTACCCCGCTGAGTACCTGGTGGAGTTGCTATCTACACCAACCCCTT 1119

961 GAACTGTGATTTGACATTCCTGTCGCTAGCTTGTGTGCTTCGAGGTATATATACCCACCA 1020
 1120 GAACTGTGATTTGACATTCCTGTCGCTAGCTTGTGTGCTTCGAGGTATATATACCCACCA 1179
 1021 ATTCCACCTGCTGTGCGCTGCTATGCTCCATGCATATGCGAGCGCTACCTCGTGG 1080
 1180 ATTCCACCTGCTGTGCGCTGCTATGCTCCATGCATATGCGAGCGCTACCTCGTGG 1239
 1081 AGGTGGACAGGCTTCCTTCCAGTCTCTGCGCTTCATATGAGACGACCTCGAGAC 1140
 1240 AGGTGGACAGGCTTCCTTCCAGTCTCTGCGCTTCATATGAGACGACCTCGAGAC 1299
 1141 TCACATTTCTGAGGTCGATGCGAGCACTTAAAGTCTGAGTCTCCCTCTATGCTCCG 1200
 1300 TCACATTTCTGAGGTCGATGCGAGCACTTAAAGTCTGAGTCTCCCTCTATGCTCCG 1359
 1201 TGAAGTGTGTGCTGCGCTTCATGAGCACTTTCACAGTCTGCTTCACAGTCTGGGT 1260
 1360 TGAAGTGTGTGCTGCGCTTCATGAGCACTTTCACAGTCTGCTTCACAGTCTGGGT 1419
 1261 CTGTCTCAAGAGGCACTTGAAGTCTTTCACAGTCTGCTTCACAGTCTGGGT 1320
 1420 CTGTCTCAAGAGGCACTTGAAGTCTTTCACAGTCTGCTTCACAGTCTGGGT 1479
 1321 ACACATGCTGTGACCAATGTTGAGGCACTTTCACAGTCTGCTTCACAGTCTGGGT 1380
 1480 ACACATGCTGTGACCAATGTTGAGGCACTTTCACAGTCTGCTTCACAGTCTGGGT 1539
 1381 GCACGCTGAGTTAACAATGCTTCAAGTCTTTCACAGTCTGCTTCACAGTCTGGGT 1440
 1540 GCACGCTGAGTTAACAATGCTTCAAGTCTTTCACAGTCTGCTTCACAGTCTGGGT 1599
 1441 CGAGATCTGCTGAGGACCAAGTCTTTCACAGTCTGCTTCACAGTCTGGGT 1500
 1600 CGAGATCTGCTGAGGACCAAGTCTTTCACAGTCTGCTTCACAGTCTGGGT 1659
 1501 GTTACAGCGCGCATATACCACTTACACGCTGCTTTCACAGTCTGCTTCACAGTCTGGGT 1560
 1660 GTTACAGCGCGCATATACCACTTACACGCTGCTTTCACAGTCTGCTTCACAGTCTGGGT 1719
 1561 AGCAGTGGCTGACCGGACGACGACCACTTTCACAGTCTGCTTTCACAGTCTGGGT 1620
 1720 AGCAGTGGCTGACCGGACGACGACCACTTTCACAGTCTGCTTTCACAGTCTGGGT 1779
 1621 TCATGAGACCAACCAAGATCATCATTTGCTGCTTTCACAGTCTGCTTTCACAGTCTGGGT 1680
 1780 TCATGAGACCAACCAAGATCATCATTTGCTGCTTTCACAGTCTGCTTTCACAGTCTGGGT 1839
 1681 CCATGTTGATTTCTTATTAACCTTTCACAGTCTGCTTTCACAGTCTGGGT 1740
 1840 CCATGTTGATTTCTTATTAACCTTTCACAGTCTGCTTTCACAGTCTGGGT 1899
 1741 CCAGCGGCTGTTGAGATATCCAGTGTGAGCAATCCAGTGTGAGCAATCCAGTGTGAGCA 1800
 1900 CCAGCGGCTGTTGAGATATCCAGTGTGAGCAATCCAGTGTGAGCAATCCAGTGTGAGCA 1959
 1801 CAGCAACAGCAGTCTCGTCTGCTGCTTTCAGTGTGAGGCGCAGTGTGCTGCCCAATTC 1860
 1960 CAGCAACAGCAGTCTCGTCTGCTGCTTTCAGTGTGAGGCGCAGTGTGCTGCCCAATTC 2019
 1861 ATGACCATATTAACCACTTACCAACCTTACCAACCTTACCAACCTTACCAACCTTACCAAC 1920
 2020 ATGACCATATTAACCACTTACCAACCTTACCAACCTTACCAACCTTACCAACCTTACCAAC 2079
 1921 GCCTGGGGAATCTCTGACCCCAACAGTCACTATCTCTGACCTTATATATATATATATATAT 1980
 2080 GCCTGGGGAATCTCTGACCCCAACAGTCACTATCTCTGACCTTATATATATATATATATAT 2139
 1981 CCATACCAAGGACAGTACAGGAACTCAATATGATCTCCCTCCCAAAACTTA 2040
 2140 CCATACCAAGGACAGTACAGGAACTCAATATGATCTCCCTCCCAAAACTTA 2198

2041 TAAATGCAATAGATGACACACACACACACAACTTTTGTACAGAGTGGGAGACATTT 2100
 2199 TAAATGCAATAGATGACACACACACACAACTTTTGTACAGAGTGGGAGACATTT 2258
 2101 TTCTTGTATATCTTAT 2160
 2259 TTCTTGTATATCTTAT 2318
 2161 AATTTAAAGACAAAGTCAAAAC 2184
 2319 AATTTAAAGACAAAGTCAAAAC 2342

RESULT 19
 AAA93620
 ID AAA93620 standard; DNA; 2341 BP.
 XX
 AC AAA93620;
 AC
 XX
 DT 16-JAN-2001 (first entry)
 XX
 DE Human SLIT protein-like splice variant SECX 3352358-1 DNA.
 XX
 KW SECX protein; human; secreted; membrane-associated; cancer;
 KW proliferation regulator; differentiation regulator; non-malignant tumour;
 KW immune disorder; autoimmune disease; transplant rejection; allergy; AIDS;
 KW infection; inflammatory disorder; arthritis; haematopoietic disorder;
 KW skin disorder; cardiovascular disorder; atherosclerosis; restenosis;
 KW neurological disease; Alzheimer's disease; trauma; wound;
 KW spinal cord injury; skeletal disorder; cytostatic; immunosuppressive;
 KW anti-HIV; antiinflammatory; antiaerthritic; antiarteriosclerotic;
 KW neuroprotective; vulnery; antiallergic; antimicrobial; cardiant;
 KW dermatological; gene therapy; da.
 XX
 OS Homo sapiens.
 XX
 XX
 PH Key Location/Qualifiers
 CDS 214..2299
 FT /*tag= a
 FT /product= "Human SECX 3352358-1 protein"
 FT /transl_except= (pos:2174..2176, aa:Xaa)
 FT /note= "Xaa = unknown. Base 2174-2176 correspond to an
 in-frame stop codon"
 XX
 FN MO200053742-A2.
 XX
 PD 14-SEP-2000.
 XX
 PP 09-MAR-2000; 2000MO-US06280.
 XX
 PR 09-MAR-1999; 99US-0123667.
 PR 08-MAR-2000; 2000US-0123667.
 XX
 XX (CURA-) CURAGEN CORP.
 XX
 XX Shimketa RA;
 XX
 DR WPI; 2000-594318/56.
 DR P-PSDB; AAB23033.
 XX
 PT Novel human membrane associated or secreted polypeptides and
 PT polynucleotides useful for diagnosis, prevention and treatment of
 PT pathological states such as cancer, immune, cardiovascular and
 PT neurological disorders
 XX
 PS Claim 3; Fig 5; 151pp; English.
 XX
 CC Sequences AAA93616-A93631 and AAA93673-A93676 represent nucleic acids
 CC which encode human SECX proteins (AAB23029-B23048). The SECX proteins
 CC of the invention are either secreted or membrane-associated proteins
 CC and act as regulator of cellular proliferation and differentiation. SECX
 CC proteins or nucleotides are useful for diagnosing the presence of, or
 CC predisposition to, a disease associated with altered levels of SECX

CC proteins and nucleotides. The SECK proteins are also useful to screen
 CC compounds that modulate SECK activity or expression. The interaction of
 CC a SECK protein with other cellular proteins may be useful to modulate
 CC the activity of a partner protein, cellular proliferation, cellular
 CC differentiation and cell survival. SECK nucleotides are useful for the
 CC recombinant expression of SECK protein, and may be used to detect SECK mRNA
 CC or genetic lesions in the SECK gene. They may also be used to modulate
 CC SECK expression (e.g., using antisense oligonucleotides). SECK nucleic
 CC acid sequences are also useful for identifying a cell or tissue type in
 CC a biological sample, and in forensic biology. SECK primers or probes are
 CC useful for detecting the presence of SECK nucleotides and for screening
 CC tissue cultures for contamination. Diseases that may be treated or
 CC prevented using SECK proteins or nucleotides include cancer (e.g.,
 CC colorectal carcinoma, prostate cancer), benign tumors, immune disorders
 CC (including autoimmune diseases, transplant rejection, allergies, AIDS),
 CC infections, inflammatory disorders, arthritis, hematopoietic disorders,
 CC skin disorders, cardiovascular disorders, atherosclerosis, restenosis,
 CC neurological diseases (e.g., Alzheimer's disease), trauma (e.g.,
 CC surgical or traumatic wounds, spinal cord injury), and skeletal
 CC disorders.

XX Sequence 2341 BP; 565 A; 768 C; 565 G; 503 T; 0 other;

Query Match		83.6%	Score 1826;	DB 21;	Length 2341;
Best Local Similarity		99.7%	Pred. No. 0;		
Matches 2176;		Conservative	0;	Mismatches	7;
				Indels	0;
				Gaps	0;
QY	1	GTCTCTCTTCGAGCCAAATCCAGCGAGTGTGAATATGAACTGTCACACCAATGA	60		
DB	159	GTCTCTCTTCGAGCCAAATCCAGCGAGTGTGAATATGAACTGTCACACCAATGA	218		
QY	61	AGCTCTGTGGCAGTAACTGTGACACCAACCTGGAATGACCTCTCTCCCGTTTC	120		
DB	219	AGCTCTGTGGCAGTAACTGTGACACCAACCTGGAATGACCTCTCTCCCGTTTC	278		
QY	121	TCTACTCTACGCGCGCAAGTGTGATTTCTGTGTGACGCAACCTGCTGCCGCTCAG	180		
DB	279	TCTACTCTACGCGCGCAAGTGTGATTTCTGTGTGACGCAACCTGCTGCCGCTCAG	338		
QY	181	GGCCCCAGAACTGCCCTCCCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	240		
DB	339	GGCCCCAGAACTGCCCTCCCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	398		
QY	241	CGCGCGCGGCGCTCTCCGAGTCCGCGAGGTATTCCTCGAAACACCGCGTACCTCA	300		
DB	399	CGCGCGGCGGCTCTCCGAGTCCGCGAGGTATTCCTCGAAACACCGCGTACCTCA	458		
QY	301	TGATGAGAAACAATCCAGATGATCCAGCGGACCTTCGGGACCTCCACACCTGG	360		
DB	459	TGATGAGAAACAATCCAGATGATCCAGCGGACCTTCGGGACCTCCACACCTGG	518		
QY	361	AGGTCTCTGAGTGGGCGAGAACTCCATCCGCGCAGATTGAGTGGGCGCTTCAAC	420		
DB	519	AGGTCTCTGAGTGGGCGAGAACTCCATCCGCGCAGATTGAGTGGGCGCTTCAAC	578		
QY	421	TGGCAGGCTTCAACCTCGAGCTGTTGCAACAATGCTGCTGCTGCTGCTGCTGCT	480		
DB	579	TGGCAGGCTTCAACCTCGAGCTGTTGCAACAATGCTGCTGCTGCTGCTGCTGCT	638		
QY	481	CTTTTGAATACCTGTCGAGCTCGGAGCTCTGCTTGGCAACAACCCCAATCGAA	540		
DB	639	CTTTTGAATACCTGTCGAGCTCGGAGCTCTGCTTGGCAACAACCCCAATCGAA	698		
QY	541	TCCCTCTTTCACCTGTCACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	600		
DB	699	TCCCTCTTTCACCTGTCACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	758		
QY	601	AGAGCTGAGTATATCTCTGAGGAGCTTTTGGGAGCTGTTCAACTCAAGTATCTGA	660		
DB	759	AGAGCTGAGTATATCTCTGAGGAGCTTTTGGGAGCTGTTCAACTCAAGTATCTGA	818		
QY	661	ACTTGGGCAATGTCACCAATTAAGACATGCCCAATCTCACCCCTCTGCTGGGCTGG	720		

DB	819	ACTTGGGCAATGTCACCAATTAAGACATGCCCAATCTCAACCCCTGGTGGGCTGGAG	878		
QY	721	AGCTGGAGATGTCAGGGAACCACTCTCCCTGAGATCAGGCTTGGCTCTTCCATGGCTGA	780		
DB	879	AGCTGGAGATGTCAGGGAACCACTCTCCCTGAGATCAGGCTTGGCTCTTCCATGGCTGA	938		
QY	781	GCTCCCTCAAGAACTCTGGGTCAATGAACTCAGCTCAGCTGATGAGGGAATGCTT	840		
DB	939	GCTCCCTCAAGAACTCTGGGTCAATGAACTCAGCTCAGCTGATGAGGGAATGCTT	998		
QY	841	TTGACGGGCTGGCTTCACTTGTGGAATCAACTTGGGCCCAATAAATCTCTCTTTTGC	900		
DB	999	TTGACGGGCTGGCTTCACTTGTGGAATCAACTTGGGCCCAATAAATCTCTCTTTTGC	1058		
QY	901	CCATGAGCTCTTTACCCCGCTGAGGTACCTGTTGGAGTTGTCATCTACACCAACCTT	960		
DB	1059	CCATGAGCTCTTTACCCCGCTGAGGTACCTGTTGGAGTTGTCATCTACACCAACCTT	1118		
QY	961	GGAACTGTGATTTGACATTTCTGTGGCTAGCTTGGCTTGGCTTGGAGTATATACCA	1020		
DB	1119	GGAACTGTGATTTGACATTTCTGTGGCTAGCTTGGCTTGGCTTGGAGTATATACCA	1178		
QY	1021	ATTCCACCTGTGGGCGCTGTATGCTCCATGACATGCGAGGCGCTTACCTGTGG	1080		
DB	1179	ATTCCACCTGTGGGCGCTGTATGCTCCATGACATGCGAGGCGCTTACCTGTGG	1238		
QY	1081	AGGTGGACCGAGGCTCTTCCAGTGTCTGCCCTTCAATCATGAGACGACCTCGAGAC	1140		
DB	1239	AGGTGGACCGAGGCTCTTCCAGTGTCTGCCCTTCAATCATGAGACGACCTCGAGAC	1298		
QY	1141	TCACATTTCTGAGGCTCGGATGTCAGAACTTAAGTGTGCGACTCCCTTATGCTCTCG	1200		
DB	1299	TCACATTTCTGAGGCTCGGATGTCAGAACTTAAGTGTGCGACTCCCTTATGCTCTCG	1358		
QY	1201	TGAAGTGTGCTGCCCAATGGGACGTGTCCAGCGGCTCCCGCCACCCAGGATCT	1260		
DB	1359	TGAAGTGTGCTGCCCAATGGGACGTGTCCAGCGGCTCCCGCCACCCAGGATCT	1418		
QY	1261	CTGTCTCTCAACGAGGACCTTTTCCACGTGTCTCTTTCAGACACTGGGGTGT	1320		
DB	1419	CTGTCTCTCAACGAGGACCTTTTCCACGTGTCTCTTTCAGACACTGGGGTGT	1478		
QY	1321	ACACATGATGTTGACCAATGTTGAGGCACTCCAGGCTCGGCTTACCTCAATGGA	1380		
DB	1479	ACACATGATGTTGAGGCACTTGTGAGGCACTCCAGGCTCGGCTTACCTCAATGGA	1538		
QY	1381	GCACGGCTGAGCTTAAACACCTTCAACTACAGCTTCTTCCACAGTAACTGAGACCA	1440		
DB	1539	GCACGGCTGAGCTTAAACACCTTCAACTACAGCTTCTTCCACAGTAACTGAGACCA	1598		
QY	1441	CGGAGATCTGGCTGAGGACCAACGGGAAAGTCAAGCTTCTTCCAGACTACCGTGTGCCA	1500		
DB	1599	CGGAGATCTGGCTGAGGACCAACGGGAAAGTCAAGCTTCTTCCAGACTACCGTGTGCCA	1658		
QY	1501	GTTCACCGCGCATATACCACTTACCGGTGCTCAATTCAGACTACCGTGTGCCA	1560		
DB	1659	GTTCACCGCGCATATACCACTTACCGGTGCTCAATTCAGACTACCGTGTGCCA	1718		
QY	1561	AGCAGTGGGAGTACCCCGGACAGACCACTGACAGATGACAGCCAGCTTACCTGAG	1620		
DB	1719	AGCAGTGGGAGTACCCCGGACAGACCACTGACAGATGACAGCCAGCTTACCTGAG	1778		
QY	1621	TCATCAAGACCAACCAAGATCATATGCTTGTGGAGTGAATCTGCTAGCTGCG	1680		
DB	1779	TCATCAAGACCAACCAAGATCATATGCTTGTGGAGTGAATCTGCTAGCTGCG	1838		
QY	1681	CCATGTTGATTTCTTTTATAAACTTGTAAAGCGGACCCAGAGCGGAGTACAGTCA	1740		
DB	1839	CCATGTTGATTTCTTTTATAAACTTGTAAAGCGGACCCAGAGCGGAGTACAGTCA	1898		
QY	1741	CGGCGGAGCTGTTGAGTATCCAGGTGACAGACATCCAGGACCAATCCCGAG	1800		
DB	1899	CGGCGGAGCTGTTGAGTATCCAGGTGACAGACATCCCGGAGCAATCCCGAG	1958		

1801 CAGCAACAGCAGCTCGTCCGCTGTATCAGGTGAGGGGCAAGTAGTCTGCCCAATTC 1860
1959 CAGCAACAGCAGCTCGTCCGCTGTATCAGGTGAGGGGCAAGTAGTCTGCCCAATTC 2018
1861 ATGACCATATTAACTACCAACACTTACAAACAGCAGCATGGGGCCCACTGGACAGAAAACA 1920
2019 ATGACCATATTAACTACCAACACTTACAAACAGCAGCATGGGGCCCACTGGACAGAAAACA 2078
1921 GCTGGGGAACTCTCTGACCCCAAGTCAGTCACCACTATCTCTGAACCTTATATTTTCA 1980
2079 GCTGGGGAACTCTCTGACCCCAAGTCAGTCACCACTATCTCTGAACCTTATATTTTCA 2138
1981 CCCATACCAAGGACAGGATGACAGGAACTCAAAATGACTCCCTCCGCCCAAAACTTA 2040
2139 CCATACCAAGGACAGGATGACAGGAACTCAAAATGACTCCCTCCGCCCAAAACTTA 2198
2041 TAAATGCAATAGATGACACAAAGACAGCAACTTTTGTACAGGTGGGGAGAGACTTT 2100
2199 TAAATGCAATAGATGACACAAAGACAGCAACTTTTGTACAGGTGGGGAGAGACTTT 2258
2101 TTCTTGTATATCTTATATATTAAGTCTATGGCTGTTAAAAAACAAGATTATATTA 2160
2259 TTCTTGTATATCTTATATATTAAGTCTATGGCTGTTAAAAAACAAGATTATATTA 2318
2161 AATTTAAAGACAAAAGTCAAAA 2183
2319 AATTTAAAGACAAAAGTCAAAA 2341
RESULT 20
BA06571
D ABA06571 standard; cdNA; 2159 BP.
C ABA06571;
X
T 10-JAN-2002 (first entry)
E Human cDNA SEQ ID NO: 237.
X Human; gene therapy; neural disorder; immune system disorder;
W muscular disorder; reproductive disorder; gastrointestinal disorder;
W pulmonary disorder; cardiovascular disorder; renal disorder;
W proliferative disorder; inflammation; ss.
X Homo sapiens.
S WO200154474-A2.
N 02-AUG-2001.
X
D
X
F 17-JAN-2001; 2001WO-US01349.
X
R 31-JAN-2000; 2000US-179065P.
R 04-FEB-2000; 2000US-180628P.
R 24-FEB-2000; 2000US-184664P.
R 02-MAR-2000; 2000US-186350P.
R 16-MAR-2000; 2000US-189874P.
R 17-MAR-2000; 2000US-190076P.
R 18-APR-2000; 2000US-198123P.
R 19-MAY-2000; 2000US-205515P.
R 07-JUN-2000; 2000US-209467P.
R 28-JUN-2000; 2000US-214886P.
R 30-JUN-2000; 2000US-215135P.
R 07-JUL-2000; 2000US-216647P.
R 07-JUL-2000; 2000US-216880P.
R 11-JUL-2000; 2000US-217487P.
R 11-JUL-2000; 2000US-217496P.
R 14-JUL-2000; 2000US-218290P.
R 26-JUL-2000; 2000US-220963P.
R 26-JUL-2000; 2000US-220964P.
R 14-AUG-2000; 2000US-224518P.
R 14-AUG-2000; 2000US-224519P.

14-AUG-2000; 2000US-225213P.
14-AUG-2000; 2000US-225214P.
14-AUG-2000; 2000US-225266P.
14-AUG-2000; 2000US-225267P.
14-AUG-2000; 2000US-225268P.
14-AUG-2000; 2000US-225270P.
14-AUG-2000; 2000US-225271P.
14-AUG-2000; 2000US-225275P.
14-AUG-2000; 2000US-225278P.
14-AUG-2000; 2000US-225279P.
18-AUG-2000; 2000US-226799P.
22-AUG-2000; 2000US-226861P.
22-AUG-2000; 2000US-226868P.
23-AUG-2000; 2000US-227009P.
30-AUG-2000; 2000US-228924P.
01-SEP-2000; 2000US-229287P.
01-SEP-2000; 2000US-229343P.
01-SEP-2000; 2000US-229344P.
01-SEP-2000; 2000US-229345P.
05-SEP-2000; 2000US-229509P.
06-SEP-2000; 2000US-229513P.
06-SEP-2000; 2000US-230437P.
08-SEP-2000; 2000US-231242P.
08-SEP-2000; 2000US-231243P.
08-SEP-2000; 2000US-231244P.
08-SEP-2000; 2000US-231413P.
08-SEP-2000; 2000US-231414P.
08-SEP-2000; 2000US-232080P.
08-SEP-2000; 2000US-232081P.
12-SEP-2000; 2000US-231968P.
14-SEP-2000; 2000US-232397P.
14-SEP-2000; 2000US-232398P.
14-SEP-2000; 2000US-232399P.
14-SEP-2000; 2000US-232400P.
14-SEP-2000; 2000US-232401P.
14-SEP-2000; 2000US-233063P.
14-SEP-2000; 2000US-233064P.
14-SEP-2000; 2000US-233065P.
21-SEP-2000; 2000US-234223P.
21-SEP-2000; 2000US-234274P.
25-SEP-2000; 2000US-234997P.
25-SEP-2000; 2000US-234998P.
26-SEP-2000; 2000US-235484P.
27-SEP-2000; 2000US-235834P.
27-SEP-2000; 2000US-235836P.
29-SEP-2000; 2000US-236327P.
29-SEP-2000; 2000US-236367P.
29-SEP-2000; 2000US-236369P.
29-SEP-2000; 2000US-236370P.
02-OCT-2000; 2000US-236802P.
02-OCT-2000; 2000US-237037P.
02-OCT-2000; 2000US-237038P.
02-OCT-2000; 2000US-237039P.
13-OCT-2000; 2000US-237040P.
13-OCT-2000; 2000US-239935P.
20-OCT-2000; 2000US-240960P.
20-OCT-2000; 2000US-241221P.
20-OCT-2000; 2000US-241785P.
20-OCT-2000; 2000US-241786P.
20-OCT-2000; 2000US-241787P.
20-OCT-2000; 2000US-241808P.
20-OCT-2000; 2000US-241809P.
20-OCT-2000; 2000US-241826P.
01-NOV-2000; 2000US-244617P.
08-NOV-2000; 2000US-246474P.
08-NOV-2000; 2000US-246475P.
08-NOV-2000; 2000US-246476P.
08-NOV-2000; 2000US-246477P.
08-NOV-2000; 2000US-246478P.

PR 08-NOV-2000; 2000US-246523P.
PR 08-NOV-2000; 2000US-246524P.
PR 08-NOV-2000; 2000US-246525P.
PR 08-NOV-2000; 2000US-246526P.
PR 08-NOV-2000; 2000US-246527P.
PR 08-NOV-2000; 2000US-246528P.
PR 08-NOV-2000; 2000US-246532P.
PR 08-NOV-2000; 2000US-246509P.
PR 08-NOV-2000; 2000US-246610P.
PR 08-NOV-2000; 2000US-246611P.
PR 08-NOV-2000; 2000US-246613P.
PR 17-NOV-2000; 2000US-249207P.
PR 17-NOV-2000; 2000US-249208P.
PR 17-NOV-2000; 2000US-249209P.
PR 17-NOV-2000; 2000US-249210P.
PR 17-NOV-2000; 2000US-249211P.
PR 17-NOV-2000; 2000US-249212P.
PR 17-NOV-2000; 2000US-249213P.
PR 17-NOV-2000; 2000US-249214P.
PR 17-NOV-2000; 2000US-249215P.
PR 17-NOV-2000; 2000US-249216P.
PR 17-NOV-2000; 2000US-249217P.
PR 17-NOV-2000; 2000US-249218P.
PR 17-NOV-2000; 2000US-249244P.
PR 17-NOV-2000; 2000US-249245P.
PR 17-NOV-2000; 2000US-249264P.
PR 17-NOV-2000; 2000US-249265P.
PR 17-NOV-2000; 2000US-249297P.
PR 17-NOV-2000; 2000US-249299P.
PR 17-NOV-2000; 2000US-249300P.
PR 01-DEC-2000; 2000US-250160P.
PR 01-DEC-2000; 2000US-250391P.
PR 05-DEC-2000; 2000US-251030P.
PR 05-DEC-2000; 2000US-251988P.
PR 05-DEC-2000; 2000US-256719P.
PR 06-DEC-2000; 2000US-251479P.
PR 08-DEC-2000; 2000US-251856P.
PR 08-DEC-2000; 2000US-251868P.
PR 08-DEC-2000; 2000US-251869P.
PR 08-DEC-2000; 2000US-251989P.
PR 11-DEC-2000; 2000US-251990P.
PR 05-JAN-2001; 2001US-259678P.
XX (HUMA-) HUMAN GENOME SCI INC.
PA Rosen CR, Barash SC, Ruben SM;
XX WPI: 2001-476161/51.
XX P-PSDB; ABB10349.
XX Isolated nucleic acid molecule encoding an inflammation-associated
XX polypeptide is used in preventing, treating or ameliorating a medical
XX condition -
XX Claim 1; SEQ ID NO: 237; 859pp + Sequence Listing; English.
XX The present invention provides human cDNAs, proteins and related genomic
XX DNAs. These can be used in the treatment of neural, immune system,
XX muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,
XX renal and proliferative disorders and inflammation. The present sequence
XX is a cDNA of the invention.
XX Sequence 2159 BP; 569 A; 585 C; 512 G; 493 T; 0 other;
SQ
Query Match 81.4%; Score 1778; DB 22; Length 2159;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 1828; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 357 CTGGAGGCTCTGCACTTGGGAGGAACTCCATCCGGAGATTGAGTGGGGGCTTCAAC 416
DB 1 CTGGAGGCTCTGCACTTGGGAGGAACTCCATCCGGAGATTGAGTGGGGGCTTCAAC 60

QY 417 GSCCTGGCCAGCCTCAACACCCCTGGAGCTGTTTCGAACTGGCTGACAGTCATCCCTAGC 476
DB 61 GGCCTGGCCAGCCTCAACACCCCTGGAGCTGTTTCGAACTGGCTGACAGTCATCCCTAGC 120
QY 477 GGGGCTTTGAATACCTGTCCAGCTGGGAGCTCTGGCTTCGACAAACCCCATCGAA 536
DB 121 GGGGCTTTGAATACCTGTCCAAAGCTGGGAGCTCTGGCTTCGAAACCCCATCGAA 180
QY 537 AGCATCCCTCTTACGGCTTCAACCCGGTGCCTCCCTCATCGCCCTGGAGCTTGGGGGAG 596
DB 181 AGCATCCCTCTTACGGCTTCAACCCGGTGCCTCCCTCATCGCCCTGGAGCTTGGGGGAG 240
QY 597 CTCAGAAGCTGGAGTATATCTCTGAGGGAGCTTTGAGGGGCTGTTCAACCTCAAGTAT 656
DB 241 CTCAGAAGCTGGAGTATATCTCTGAGGGAGCTTTGAGGGGCTGTTCAACCTCAAGTAT 300
QY 657 CTGACTTTGGGCTGTGCAACATTAAAGACATGCCAATCTCACCCCTGGTGGGGCTG 716
DB 301 CTGAACTTTGGGCTGTGCAACATTAAAGACATGCCAATCTCACCCCTGGTGGGGCTG 360
QY 717 GAGGAGCTGGAGATGTCAAGGAAACACTTCCCTGAGATCAGGCTGGCTCCCTCATGGC 776
DB 361 GAGGAGCTGGAGATGTCAAGGAAACACTTCCCTGAGATCAGGCTGGCTCCCTCATGGC 420
QY 777 CTGAGCTCCCTCAAGAGCTCTGGGTCAATGAATCAAGGTACGCTGATTGAGCGGAAT 836
DB 421 CTGAGCTCCCTCAAGAGCTCTGGGTCAATGAATCAAGGTACGCTGATTGAGCGGAAT 480
QY 837 GCTTTTGAAGGCTGGCTTCACTTTGTGGAATCAACTTGGCCCAATAAACCCTCTTCT 896
DB 481 GCTTTTGAAGGCTGGCTTCACTTTGTGGAATCAACTTGGCCCAATAAACCCTCTTCT 540
QY 897 TTGCCCCATGACCTTTTACCCCGCTGAGCTACCTGCTGGAGTGCATCTACACCAAC 956
DB 541 TTGCCCCATGACCTTTTACCCCGCTGAGCTACCTGCTGGAGTGCATCTACACCAAC 600
QY 957 CCTTGGAACTGTGATTGTGACATCTGTGGCTAGCTGTGGCTTCGAGAGTATATACCC 1016
DB 601 CCTTGGAACTGTGATTGTGACATCTGTGGCTAGCTGTGGCTTCGAGAGTATATACCC 660
QY 1017 ACCAATTCACCTGTGTGGGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1076
DB 661 ACCAATTCACCTGTGTGGGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 720
QY 1077 GTGGAGGTGGACAGGCTCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1136
DB 721 GTGGAGGTGGACAGGCTCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 780
QY 1137 GACCTCAACATTTCTGAGGTCGGATGGAGCAACTTAAGTGTGGAATCTTCCCTATGTCC 1196
DB 781 GACCTCAACATTTCTGAGGTCGGATGGAGCAACTTAAGTGTGGAATCTTCCCTATGTCC 840
QY 1197 TCGGTGAGGTGGTGTGCTGCCAAATGGGACAGTGTCTGAGCCAGCTCCCGCCACCCAGG 1256
DB 841 TCGGTGAGGTGGTGTGCTGCCAAATGGGACAGTGTCTGAGCCAGCTCCCGCCACCCAGG 900
QY 1257 ATCTCTGTCTCAACAGCGGCACTTTGAACTTTTCCACGCTGCTGCTTTCAGACACTGGG 1316
DB 901 ATCTCTGTCTCAACAGCGGCACTTTGATCTTTTCCACGCTGCTGCTTTCAGACACTGGG 960
QY 1317 GTGTACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1376
DB 961 GTGTACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1020
QY 1377 GTGAGCAAGCTGAGCTTAAACACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAAC 1436
DB 1021 GTGAGCAAGCTGAGCTTAAACACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAAC 1080
QY 1437 ACCAGGAGATCTGCTGAGGAGCAACAGGAGGAGTACAGCTTCTTCCCTACACGTC 1496
DB 1081 ACCAGGAGATCTGCTGAGGAGCAACAGGAGGAGTACAGCTTCTTCCCTACACGTC 1140
QY 1497 ACTGGTTACAGCCGGCATATACCACTCTTACCAAGGCTGCTCAATTCAGACTACCGGTG 1556

b 1141 ACTGGTTACAGCGGCATATACCACTCTACACGGTGTCTATTGAGACTACCGGTGTG 1200
 y 1557 CCCAAGCAGGTGGCAGTACCCGGGAGAGACACCACTGACCAAGATGACAGACCGCTGGAT 1616
 b 1201 CCCAAGCAGGTGGCAGTACCCGGGAGAGACACCACTGACCAAGATGACAGACCGCTGGAT 1260
 y 1617 GAAGTCATGAAGACCAACCAAGATCATCTATGGCTGCTTTGGGAGTGAATCTGTAGCT 1676
 b 1261 GAAGTCATGAAGACCAACCAAGATCATCTATGGCTGCTTTGGGAGTGAATCTGTAGCT 1320
 y 1677 GCGGCCATGTTGATGCTTCTTATATAAATCTGTAAGCGGCACAGCGGAGTACAGTC 1736
 b 1321 GCGGCCATGTTGATGCTTCTTATATAAATCTGTAAGCGGCACAGCGGAGTACAGTC 1380
 y 1737 ACAGCCGCGGAGTGTGAGATAATCCAGGTGGAGAGACATCCGAGCAGCAACATCC 1796
 b 1381 ACAGCCGCGGAGTGTGAGATAATCCAGGTGGAGAGACATCCGAGCAGCAACATCC 1440
 y 1797 GCAGCAGCAACAGCAGCTCCGTCGGTGTATCAGGTGAGGGGGCAGTGTGCTGCCACA 1856
 b 1441 GCAGCAGCAACAGCAGCTCCGTCGGTGTATCAGGTGAGGGGGCAGTGTGCTGCCACA 1500
 y 1857 ATTCTAGCACCATTAACTAACACACTTACAAACCCAGCAGCATGCGGCCCACTGGACAGAA 1916
 b 1501 ATTCTAGCACCATTAACTAACACACTTACAAACCCAGCAGCATGCGGCCCACTGGACAGAA 1560
 y 1917 AACAGCCTGGGGAATCTCTGCAACCCAGTCACCACTATCTCTGAACCTTATATATT 1976
 b 1561 AACAGCCTGGGGAATCTCTGCAACCCAGTCACCACTATCTCTGAACCTTATATATT 1620
 y 1977 CAGACCCATACCAAGGACCAAGGTACAGGAATCTCAAAATGACTCCCTCCGCCCAAAAAA 2036
 b 1621 CAGACCCATACCAAGGACCAAGGTACAGGAATCTCAAAATGACTCCCTCCGCCCAAAAAA 1680
 y 2037 CTTATAAATGCAATGAGATGACACAAAGACAGCAACTTTTGTGACAGTGGGGAGAGA 2096
 b 1681 CTTATAAATGCAATGAGATGACACAAAGACAGCAACTTTTGTGACAGTGGGGAGAGA 1740
 y 2097 CTTTTCCTGTATGCTTATATATTAAAGTCTATGGCTGTTAAAAAACAAGATTATA 2156
 b 1741 CTTTTCCTGTATGCTTATATATTAAAGTCTATGGCTGTTAAAAAACAAGATTATA 1800
 y 2157 TTAATAATTTAAGACAAAAAGTCAAAAAA 2185
 b 1801 TTAATAATTTAAGACAAAAAGTCAAAAAA 1829

RESULT 21
 BV83908
 D ABV83908 standard; cDNA; 2159 BP.
 X C
 X C ABV83908;
 X T
 X T 09-DEC-2002 (first entry)
 X E Human polynucleotide SEQ ID NO 237.

X Human; nontropic; neuroprotective; cytostatic; dermatological; virucide;
 W immunosuppressive; anti-inflammatory; anti-HIV; antibacterial; vulnerary;
 W antiparkinsonian; antisickling; antianemic; antiarthritic; cancer;
 W antirheumatic; hepatotropic; cerebrotective; antiinflammatory;
 W antiallergic; antidiabetic; antilucer; anticonvulsant; antifungal;
 W antiparasitic; cardiant; immune disorder; cardiovascular disorder;
 W neurological disease; infection; nephrotropic; gene therapy; vaccine;
 W gene; ss.

X S Homo sapiens.
 X S
 X X US2002090672-A1.
 X X
 X D 11-JUL-2002.
 X X

PF 17-JAN-2001; 2001US-0764853.
 XX 31-JAN-2000; 2000US-179065P.
 PR 04-FEB-2000; 2000US-180628P.
 PR 28-JUN-2000; 2000US-214886P.
 PR 07-JUL-2000; 2000US-216647P.
 PR 07-JUL-2000; 2000US-216880P.
 PR 11-JUL-2000; 2000US-217487P.
 PR 11-JUL-2000; 2000US-217496P.
 PR 14-JUL-2000; 2000US-218290P.
 PR 26-JUL-2000; 2000US-220963P.
 PR 26-JUL-2000; 2000US-220964P.
 PR 14-AUG-2000; 2000US-224518P.
 PR 14-AUG-2000; 2000US-224519P.
 PR 14-AUG-2000; 2000US-225267P.
 PR 14-AUG-2000; 2000US-225268P.
 PR 14-AUG-2000; 2000US-225270P.
 PR 14-AUG-2000; 2000US-225447P.
 PR 14-AUG-2000; 2000US-225757P.
 PR 14-AUG-2000; 2000US-225758P.
 PR 22-AUG-2000; 2000US-226888P.
 PR 30-AUG-2000; 2000US-228944P.
 PR 01-SEP-2000; 2000US-229287P.
 PR 01-SEP-2000; 2000US-229343P.
 PR 01-SEP-2000; 2000US-229344P.
 PR 05-SEP-2000; 2000US-229509P.
 PR 05-SEP-2000; 2000US-229513P.
 PR 08-SEP-2000; 2000US-231413P.
 PR 21-SEP-2000; 2000US-234223P.
 PR 21-SEP-2000; 2000US-234274P.
 PR 25-SEP-2000; 2000US-234997P.
 PR 27-SEP-2000; 2000US-235834P.
 PR 29-SEP-2000; 2000US-236327P.
 PR 29-SEP-2000; 2000US-236367P.
 PR 29-SEP-2000; 2000US-236368P.
 PR 29-SEP-2000; 2000US-236369P.
 PR 29-SEP-2000; 2000US-236370P.
 PR 02-OCT-2000; 2000US-236802P.
 PR 02-OCT-2000; 2000US-237037P.
 PR 02-OCT-2000; 2000US-237038P.
 PR 02-OCT-2000; 2000US-237039P.
 PR 02-OCT-2000; 2000US-237040P.
 PR 13-OCT-2000; 2000US-239935P.
 PR 20-OCT-2000; 2000US-240960P.
 PR 20-OCT-2000; 2000US-241785P.
 PR 20-OCT-2000; 2000US-241809P.
 PR 01-NOV-2000; 2000US-244617P.
 PR 17-NOV-2000; 2000US-249299P.
 PR 08-DEC-2000; 2000US-251856P.
 PR 08-DEC-2000; 2000US-251868P.
 PR 08-DEC-2000; 2000US-251869P.
 XX (ROSE/) ROSEN C A.
 PA (RUBE/) RUBEN S M.
 PA (BARA/) BARASH S C.
 XX Rosen CA, Ruben SM, Barash SC;
 PI WPI; 2002-681727/73.
 XX P-PSDB; ABP66936.
 XX Novel polypeptide useful for diagnosis, prognosis, prevention, and
 PT treatment of immune, hyperproliferative, renal, respiratory, and
 PT cardiovascular, reproductive, endocrine, gastrointestinal and
 PT neurological disorders
 XX Claim 1; SEQ ID NO 237; 369pp + Sequence Listing; English.
 PS The invention relates to novel genes (ABV83682-ABV84101) and proteins
 XX (ABP6710-ABP67129) useful for preventing, treating or ameliorating
 CC medical conditions e.g. by protein or gene therapy. The genes are
 CC isolated from a range of human tissues disclosed in the specification.
 CC

CC The nucleic acids, proteins, antibodies and (ant)agonists are useful
 CC in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
 CC and ovarian cancer and other cancers of the adrenal gland, bone, bone
 CC marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
 CC (b) immune disorders e.g. Addison's disease, allergies, autoimmune
 CC haemolytic anemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
 CC disease, multiple sclerosis, rheumatoid arthritis and ulcerative
 CC colitis; (c) cardiovascular disorders such as myocardial ischaemias;
 CC (d) wound healing; (e) neurological diseases e.g. cerebral anoxia and
 CC epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
 CC and parasitic infections.
 CC Note: The sequence data for this patent did not form part of the
 CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pat_sequences.
 XX
 SQ Sequence 2159 BP; 569 A; 585 C; 512 G; 493 T; 0 other;
 Query Match 81.4%; Score 1778; DB 24; Length 2159;
 Best Local Similarity 99.9%; Pred. No. 0;
 Matches 1828; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 357 CTGGAGGCTCTGCACTTGGGAGGAACTCCATCCGGGAGATGAGTGGGGCCCTTCAAC 416
 DB 1 CTGGAGGCTCTGCACTTGGGAGGAACTCCATCCGGGAGATGAGTGGGGCCCTTCAAC 60
 417 GSCCTGGCCAGCTCAACACCTCGAGCTGTTCGAACCTGGCTGACAGTCACTCCCTAGC 476
 DB 61 GSCCTGGCCAGCTCAACACCTCGAGCTGTTCGAACCTGGCTGACAGTCACTCCCTAGC 120
 477 GGGGCTTTTGAATACCTGTCGAAGTGGGGAGCTCTGGCTTGGCAACACCCCATGAA 536
 DB 121 GGGGCTTTTGAATACCTGTCGAAGTGGGGAGCTCTGGCTTGGCAACACCCCATGAA 180
 537 AGCATCCCTCTTACGCTTCAACCGGCTGCTCCCTCATGCGCTGGCTGAGCTGGGGAG 596
 DB 181 AGCATCCCTCTTACGCTTCAACCGGCTGCTCCCTCATGCGCTGGCTGAGCTGGGGAG 240
 597 CTCAGAACTGGAGTATCTCTGAGGAGCTTTTGAAGGCTGTTCAACTCAAGTAT 656
 DB 241 CTCAGAACTGGAGTATCTCTGAGGAGCTTTTGAAGGCTGTTCAACTCAAGTAT 300
 657 CTGAACCTGGGCAATGCAACATTAAGACATGCCAATCTCACCCCTGGTGGGGCTG 716
 DB 301 CTGAACCTGGGCAATGCAACATTAAGACATGCCAATCTCACCCCTGGTGGGGCTG 360
 717 GAGGAGCTGAGATGTCAGGAGACCACTTCCCTGAGATCAGGCTGGCTTCCATGGC 776
 DB 361 GAGGAGCTGAGATGTCAGGAGACCACTTCCCTGAGATCAGGCTGGCTTCCATGGC 420
 777 CTGAGCTCCCTCAAGAGCTTGGGTATGAACTCACAGGTGAGCTGATGAGGGAT 836
 DB 421 CTGAGCTCCCTCAAGAGCTTGGGTATGAACTCACAGGTGAGCTGATGAGGGAT 480
 837 GCTTTTGAAGGCTGCTTCACTTGTGGAATCACTTGGCCCAATAAATCTCTCTT 896
 DB 481 GCTTTTGAAGGCTGCTTCACTTGTGGAATCACTTGGCCCAATAAATCTCTCTT 540
 897 TTGCCCATGACTCTTTTACCCCGCTGAGGTACCTGGTGGAGTTCATCTACACCAAC 956
 DB 541 TTGCCCATGACTCTTTTACCCCGCTGAGGTACCTGGTGGAGTTCATCTACACCAAC 600
 957 CTTTGAATGTGATGTGACATCTCTGCTGAGCTTGGTGGCTTTCGAGAGTATATACC 1016
 DB 601 CTTTGAATGTGATGTGACATCTCTGCTGAGCTTGGTGGCTTTCGAGAGTATATACC 660
 1017 ACCAATTCACCTGTGTGGCGCTGTATGCTGCCATGCAATGCGAGGCGCTTACCTC 1076
 DB 661 ACCAATTCACCTGTGTGGCGCTGTATGCTGCCATGCAATGCGAGGCGCTTACCTC 720
 1077 GTGGAGTGGACAGGCTCTCTTCCAGTGTCTGCTGCCCTTCAATGATGAGCACTCGA 1136
 DB 721 GTGGAGTGGACAGGCTCTCTTCCAGTGTCTGCTGCCCTTCAATGATGAGCACTCGA 780

QY 1137 GACCTCAACATTTCTGAGGGTGGATGCGAGAACTTAAGTGTGGACTCCCTCTATGTCC 1196
 DB 781 GACCTCAACATTTCTGAGGGTGGATGCGAGAACTTAAGTGTGGACTCCCTCTATGTCC 840
 QY 1197 TCCGTGAAGTGGTGTCTGTCGCCAATGGGACAGTGTCTAGCAAGCTCCCGCCACCAAGG 1256
 DB 841 TCCGTGAAGTGGTGTCTGTCGCCAATGGGACAGTGTCTAGCAAGCTCCCGCCACCAAGG 900
 QY 1257 ATCTCTGTCTCTCAAGGCGGCACTTGAACCTTTTCCACCTGCTGCTTTCAGACACTGGG 1316
 DB 901 ATCTCTGTCTCTCAAGGCGGCACTTGAACCTTTTCCACCTGCTGCTTTCAGACACTGGG 960
 QY 1317 GTGTACACATGATGCTGACCAATGTTTGGAGCAACTCCAAAGCTCGGCTACCTCAAT 1376
 DB 961 GTGTACACATGATGCTGACCAATGTTTGGAGCAACTCCAAAGCTCGGCTACCTCAAT 1020
 QY 1377 GTGAGCAGGCTGAGCTTAAACCTCTCAACTACAGCTTCTTCCACAGTAACAGTGGAG 1436
 DB 1021 GTGAGCAGGCTGAGCTTAAACCTCTCAACTACAGCTTCTTCCACAGTAACAGTGGAG 1080
 QY 1437 ACCACGGAGATCTGCGCTGAGGACACCAAGCGAAGTACAAAGCTGTTCCTTACCAAGTCC 1496
 DB 1081 ACCACGGAGATCTGCGCTGAGGACACCAAGCGAAGTACAAAGCTGTTCCTTACCAAGTCC 1140
 QY 1497 ACTGTTTACAGCGCGCATATACACCTCTTACAGCTGTCTTATTCAGACTACCGGTGG 1556
 DB 1141 ACTGTTTACAGCGCGCATATACACCTCTTACAGCTGTCTTATTCAGACTACCGGTGG 1200
 QY 1557 CCAAGCAGGCTGAGTACCGCGGACAGACACCACTGCAAGAGTGCAGACAGGCTTGGAT 1616
 DB 1201 CCAAGCAGGCTGAGTACCGCGGACAGACACCACTGCAAGAGTGCAGACAGGCTTGGAT 1260
 QY 1617 GAAGTATGAAGACCAACCAAGATCATCTTGGCTGTCTTGTGGAGTGAATCTGTAGCT 1676
 DB 1261 GAAGTATGAAGACCAACCAAGATCATCTTGGCTGTCTTGTGGAGTGAATCTGTAGCT 1320
 QY 1677 GCGGCTATGATGTCTTCTATAAATCTTGTAAAGCGGACCAAGAGTGTAGTGTGCTGCTG 1736
 DB 1321 GCGGCTATGATGTCTTCTATAAATCTTGTAAAGCGGACCAAGAGTGTAGTGTGCTGCTG 1380
 QY 1737 ACAGCGCCCGGACTGTTGAGATAATCCAGGTGGAAGAGCAATCCAGCAGCAACATCC 1796
 DB 1381 ACAGCGCCCGGACTGTTGAGATAATCCAGGTGGAAGAGCAATCCAGCAGCAACATCC 1440
 QY 1797 GAGGAGCAAGCAGGCTCCGTCCGTGTATCAGGTGAGGGGCGAGTGTGCTGCCACA 1856
 DB 1441 GAGGAGCAAGCAGGCTCCGTCCGTGTATCAGGTGAGGGGCGAGTGTGCTGCCACA 1500
 QY 1857 ATTCAATGACCATATTAATTAACCTTACAACTTACAACTTACAACTTACAACTTACAA 1916
 DB 1501 ATTCAATGACCATATTAATTAACCTTACAACTTACAACTTACAACTTACAACTTACAA 1560
 QY 1917 AACAGCTGGGAACTCTCTGACCCGACAGTCACTATCTCTGAACTTATATTAAT 1976
 DB 1561 AACAGCTGGGAACTCTCTGACCCGACAGTCACTATCTCTGAACTTATATTAAT 1620
 QY 1977 CAGACCATACCAAGGACAAAGGTACAGGAACTCAATATGACTCCCTCCCTCCCAAAAA 2036
 DB 1621 CAGACCATACCAAGGACAAAGGTACAGGAACTCAATATGACTCCCTCCCTCCCAAAAA 1680
 QY 2037 CTTTAAATGCAATAGATGACCAAGAGCAAGCACTTTTGTACAGAGTGGGAGAGA 2096
 DB 1681 CTTTAAATGCAATAGATGACCAAGAGCAAGCACTTTTGTACAGAGTGGGAGAGA 1740
 QY 2097 CTTTTCCTGTATGCTTATATATTAAGTCTATGCTGGTGGTAAAAAAGAGAGATTATA 2156
 DB 1741 CTTTTCCTGTATGCTTATATATTAAGTCTATGCTGGTGGTAAAAAAGAGAGATTATA 1800
 QY 2157 TTTAAAAATTTAAAGACAAAAGTCAAAACA 2185
 DB 1801 TTTAAAAATTTAAAGACAAAAGTCAAAACA 1829

RESULT 22	SQ	Sequence 2607 BP; 681 A; 752 C; 619 G; 555 T; 0 other;
AA93621	Query Match	65.9%; Score 1440; DB 21; Length 2607;
AAA93621 standard; DNA; 2607 BP.	Best Local Similarity	99.7%; Pred. No. 0;
AAA93621;	Matches 1740; Conservative	0; Mismatches 6; Indels 0; Gaps 0;
P 16-JAN-2001 (first entry)		
Human SLIT protein-like splice variant SECX 3552359-2 DNA.		
SECX protein; human; secreted; membrane-associated; cancer;	QY	1 GTTCTCTTTCCGAGCCAAATCCGAGCGGATGGTGAATTAAGACGTCACACCATGA 60
proliferation regulator; differentiation regulator; non-malignant tumour;	DB	159 GTTCTCTTTCCGAGCCAAATCCGAGCGGATGGTGAATTAAGACGTCACACCATGA 218
immune disorder; autoimmune disease; transplant rejection; allergy; AIDS;	QY	61 AGCTCTTGTGGCAGGTAATCTGTGACACCAACACCTGGAATGCCATCTCTCTCCGTTGG 120
infection; inflammatory disorder; arthritis; haematopoietic disorder;	DB	219 AGCTCTTGTGGCAGGTAATCTGTGACACCAACACCTGGAATGCCATCTCTCTCCGTTGG 278
skin disorder; cardiovascular disorder; atherosclerosis; restenosis;	QY	121 TCTACTCTACGCGCAAGTGTGATCTGTGTGACGACCATCGCTGTCTGCGGCTCAGCGG 180
neurological disease; Alzheimer's disease; trauma; wounding;	DB	279 TCTACTCTACGCGCAAGTGTGATCTGTGTGACGACCATCGCTGTCTGCGGCTCAGCGG 338
spinal cord injury; skeletal disorder; cytostatic; immunosuppressive;	QY	181 GGCCCCAGAACTGCCCCCTCCGTTTCTGCTGTCAGTAAACAGTTCAGCAAGGTGGTGTGCA 240
anti-HIV; antiinflammatory; antiarthritis; antiarteriosclerotic;	DB	339 GGCCCCAGAACTGCCCCCTCCGTTTCTGCTGTCAGTAAACAGTTCAGCAAGGTGGTGTGCA 398
neuroprotective; vulnery; antiallergic; antimicrobial; cardiant;	QY	241 CGCGCGGCGGCTCTCCGAGGTCCGCGAGGATTCCTCTCGAAACACCGGTAACCTCAACC 300
dermatological; gene therapy; ds.	DB	399 CGCGCGGCGGCTCTCCGAGGTCCGCGAGGATTCCTCTCGAAACACCGGTAACCTCAACC 458
Homo sapiens.	QY	301 TCATGGAGAACAAATCCAGATATCCAGGCGGACACCTCCGCGACCTCCACACCATGG 360
WO200053742-A2.	DB	459 TCATGGAGAACAAATCCAGATATCCAGGCGGACACCTCCGCGACCTCCACACCATGG 518
14-SEP-2000.	QY	361 AGGTCTCTCAGTTCGGCAGGAATCCATTCGCGCAGATTTAGTGGGGGCTTCGAAGGCC 420
09-MAR-2000; 2000WO-US06280.	DB	519 AGGTCTCTCAGTTCGGCAGGAATCCATTCGCGCAGATTTAGTGGGGGCTTCGAAGGCC 578
09-MAR-1999; 99US-0123667.	QY	421 TGGCAGGCTCAACACCTGAGGCTGTTCGACAACTGGCTGACAGTCACTCCCTGAGCGGG 480
08-MAR-2000; 2000US-0123667.	DB	579 TGGCAGGCTCAACACCTGAGGCTGTTCGACAACTGGCTGACAGTCACTCCCTGAGCGGG 638
(CURA-) CURAGEN CORP.	QY	481 CTTTGAATACCTGTCCAAAGCTGGCGGAGCTCTGCTTCGCAACAAACCCCAACGAAAGCA 540
Shinketsu RA;	DB	639 CTTTGAATACCTGTCCAAAGCTGGCGGAGCTCTGCTTCGCAACAAACCCCAACGAAAGCA 698
WPI; 2000-594318/56.	QY	541 TCCCTCTTACGCTTCAACCGGCTGCTCCCTCATGCGGCTGAGCTTGGGGGAGCTCA 600
P-PSDB; AAB23034.	DB	699 TCCCTCTTACGCTTCAACCGGCTGCTCCCTCATGCGGCTGAGCTTGGGGGAGCTCA 758
Novel human membrane associated or secreted polypeptides and	QY	601 AGAAGCTGAGTATATCTCTCAGGAGCTTTTGGGGGCTGTTCAACCTCAAGTATCTGA 660
polynucleotides useful for diagnosis, prevention and treatment of	DB	759 AGAAGCTGAGTATATCTCTCAGGAGCTTTTGGGGGCTGTTCAACCTCAAGTATCTGA 818
pathological states such as cancer, immune, cardiovascular and	QY	661 ACTTGGGATGTGCAAAATTAAGACATGCCAAATCTCAACCCCTCGTGGGGCTGGAGG 720
neurological disorders	DB	819 ACTTGGGATGTGCAAAATTAAGACATGCCAAATCTCAACCCCTCGTGGGGCTGGAGG 878
Claim 3; Fig 6; 15ipp; English.	QY	721 AGCTGAGATGTGAGGAAACCACTTCCTCGAGATCAGGCTGGCTCTCTTCATGGCTGA 780
Sequences AAA93616-A93631 and AAA93673-A93676 represent nucleic acids	DB	879 AGCTGAGATGTGAGGAAACCACTTCCTCGAGATCAGGCTGGCTCTCTTCATGGCTGA 938
which encode human SECX proteins (AAB23029-B23048). The SECX proteins	QY	781 GCTCCTCAAGAAGCTCTGGGTATGAATCACTCAGGTCAGCTGATTAAGCGGAATGCTT 840
of the invention are either secreted or membrane-associated proteins	DB	939 GCTCCTCAAGAAGCTCTGGGTATGAATCACTCAGGTCAGCTGATTAAGCGGAATGCTT 998
and act as regulator of cellular proliferation and differentiation. SECX	QY	841 TTGAGGGGCTGGCTTCACTTCTGGAATCTCAACTTGGCCCACTAACTCTCTCTCTTTCG 900
proteins or nucleotides are useful for diagnosing the presence of, or	DB	999 TTGAGGGGCTGGCTTCACTTCTGGAATCTCAACTTGGCCCACTAACTCTCTCTCTTTCG 1058
predisposition to, a disease associated with altered levels of SECX	QY	901 CCATGAGCTCTTTTACCCCGCTGAGGTACCTCTGGTGGATTTGCATCTACACCAACACCTT 960
proteins and nucleotides. The SECX proteins are also useful to screen	DB	1059 CCATGAGCTCTTTTACCCCGCTGAGGTACCTCTGGTGGATTTGCATCTACACCAACACCTT 1118
compounds that modulate SECX activity or expression. The interaction of	QY	961 GGAATCTGATTTGACATTTCTGTGGCTAGCTGGTGGCTTGGAGATATATACCCACCA 1020
a SECX protein with other cellular proteins may be useful to modulate	DB	1119 GGAATCTGATTTGACATTTCTGTGGCTAGCTGGTGGCTTGGAGATATATACCCACCA 1178
the activity of a partner protein, cellular proliferation, cellular		
differentiation and cell survival. SECX nucleotides are useful for the		
recombinant expression of SECX protein, and may be used to detect SECX mRNA		
or genetic lesions in the SECX gene. They may also be used to modulate		
SECX expression (e.g., using antisense oligonucleotides). SECX nucleic		
acid sequences are also useful for identifying a cell or tissue type in		
a biological sample, and in forensic biology. SECX primers or probes are		
useful for detecting the presence of SECX nucleotides and for screening		
tissue cultures for contamination. Diseases that may be treated or		
prevented using SECX proteins or nucleotides include cancer (e.g.,		
colorectal carcinoma, prostate cancer), benign tumours, immune disorders		
(including autoimmune diseases, transplant rejection, allergies, AIDS),		
infections, inflammatory disorders, arthritis, haematopoietic disorders,		
skin disorders, cardiovascular disorders, atherosclerosis, restenosis,		
neurological diseases (e.g., Alzheimer's disease), trauma (e.g.,		
surgical or traumatic wounds, spinal cord injury), and skeletal		
disorders.		

1021	ATTCCACCTGCTGTGGCCGCTGTCAATGCTCCCATGCAATGCGAGGCGCTACTCTGTTGG	1080
1179	ATTCCACCTGCTGTGGCCGCTGTCAATGCTCCCATGCAATGCGAGGCGCTACTCTGTTGG	1238
1081	AGGTGGACAGAGCCTCTTTCCAGTGTCTGCGCCCTTCATCATGTGACGACGCACTTCGAGACC	1140
1239	AGTGGACAGAGCCTCTTTCCAGTGTCTGCGCCCTTCATCATGTGACGACGCACTTCGAGACC	1298
1141	TCAACATTTCTGAGGGTCCGATGGCAGAACTTAAAGTGTCCGACATCCCTCTATGTCTCTCG	1200
1299	TCAACATTTCTGAGGGTCCGATGGCAGAACTTAAAGTGTCCGACATCCCTCTATGTCTCTCG	1358
1201	TGAAGTGTGTGTCGCCCAATGGGACAGTGTCTAGGCCAGCGCTCCGCCACCCCAAGATCT	1260
1359	TGAAGTGTGTGTGTCGCCCAATGGGACAGTGTCTAGGCCAGCGCTCCGCCACCCCAAGATCT	1418
1261	CTGTCTCTCAAGACGGCACCTTGAATCTTTCCACGTGTCTCTTTCAGACACACTGGGGTGT	1320
1419	CTGTCTCTCAAGACGGCACCTTGAATCTTTCCACGTGTCTCTTTCAGACACACTGGGGTGT	1478
1321	ACACATGCAATGTGTACCAATGTTGCAGGCAACTCTCAACGGCTTCGGCTTACTCTCAATGTGA	1380
1479	ACACATGCAATGTGTACCAATGTTGCAGGCAACTCTCAACGGCTTCGGCTTACTCTCAATGTGA	1538
1381	GCACGGCTCAGCTTAAACCTCCAACTACAGCTTCTTCAACACAGTAACAGTGGAGACCA	1440
1539	GCACGGCTCAGCTTAAACCTCCAACTACAGCTTCTTCAACACAGTAACAGTGGAGACCA	1598
1441	CGGAGATCTCGCTGTAGGACACAACCGGAAAGTACAAGCTGTCTTCTACCAAGTCCACTG	1500
1599	CGGAGATCTCGCTGTAGGACACAACCGGAAAGTACAAGCTGTCTTCTACCAAGTCCACTG	1658
1501	GTTTACACGCGGGATATACCACTCTTACCACGGTGCTCATTTACAGACTACCGTGTGCCCA	1560
1659	GTTTACACGCGGGATATACCACTCTTACCACGGTGCTCATTTACAGACTACCGTGTGCCCA	1718
1561	AGCAGTGGCAGTACCCCGGACAGACCACTGACAAGATGCACACAGAGCTGGATGAAG	1620
1719	AGCAGTGGCAGTACCCCGGACAGACCACTGACAAGATGCACACAGAGCTGGATGAAG	1778
1621	TGATGAAGACCAACAGATCATCTTGGCTGTCTTTGTGGAGTGACTCTGTACTGTCGG	1680
1779	TGATGAAGACCAACAGATCATCTTGGCTGTCTTTGTGGAGTGACTCTGTACTGTCGG	1838
1681	CCATGTTGATGTCTTCTATAAATCTGTAACGGCACACAGCAGCGGAGTACAGTCAAG	1740
1839	CCAATGTTGATGTCTTCTATAAATCTGTAACGGCACACAGCAGCGGAGTACAGTCAAG	1898
1741	CCGCCC	1746
1899	CCGCCC	1904

RESULT 23	
AAAC77300	
XX	AAAC77300 standard; cDNA, 1805 BP.
XX	
XX	AAC77300;
XX	
DT	08-FEB-2001 (first entry)
XX	
XX	Human ORFX ORF2855 polynucleotide sequence SEQ ID NO:5709.
XX	
XX	Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;
XX	vulnary; antiproliferatic; antiparkinsonian; nootropic; neuroprotective;
XX	anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;
XX	immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
XX	hypotensive; dermatological; immunosuppressive; antinflammatory;
XX	antiviral; antibacterial; antifungal; antineumatic; antichyroid;
XX	antianemic; gene therapy; cancer; proliferative disorder; hypertension;
XX	cardiogenenerative disorder; osteoarthritis; graft vs host disease;
XX	cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
XX	

KW	cholesterol ester storage; systemic lupus erythematosus; infection;
KW	severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
KW	allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
KW	bone damage; cartilage damage; antiinflammatory disease; coagulation;
KW	thrombosis; contraceptive; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200058473-A2.
XX	
PD	05-OCT-2000.
XX	
PF	31-MAR-2000; 2000WO-US08621.
PR	21-MAR-1999; 99US-0127607.
PR	02-APR-1999; 99US-0127636.
PR	05-APR-1999; 99US-0127728.
PR	30-MAR-2000; 2000US-0540763.
XX	
XX	
PA	(CURA-) CURAGEN CORP.
XX	
PI	Shimkets RA, Leach M;
XX	
DR	WPI; 2000-502362/57.
DR	P-PSDB; AAB43091.
XX	
PT	Novel nucleic acids and peptides derived from open reading frame X,
PT	useful for treating e.g. cancers, proliferative disorders,
PT	neurodegenerative disorders and cardiovascular disease -
XX	
PS	Claim 5; Page 4876-4877; 5507pp; English.
XX	
CC	AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,
CC	which represent the human ORF open reading frames 1 to 3161. The ORF
CC	sequences have activities such as: cytostatic; hepatotropic; vulnery;
CC	antiparasitic; antiparkinsonian; nootropic; neuroprotective;
CC	osteopathic; anticonvulsant; antiarthritic; immunosuppressant;
CC	immunostimulant; cardiant; thrombolytic; coagulant; vasotropic;
CC	antidiabetic; hypotensive; dermatological; immunosuppressive;
CC	antiinflammatory; antibacterial; antiviral; antifungal; antirheumatic;
CC	antithyroid; and antianemic. The sequences can be used for determining
CC	the presence of or predisposition to, or preventing or treating
CC	pathological conditions associated with an ORF-associated disorder. The
CC	nucleic acids can be used to express ORF proteins in gene therapy
CC	vectors. The proteins and nucleic acids may be used to treat cancers,
CC	proliferative disorders, neurodegenerative disorders, osteoarthritis,
CC	graft vs host disease, cardiovascular disease, diabetes mellitus,
CC	hypertension, hypothyroidism, cholesterol ester storage, systemic lupus
CC	erythematosus, severe combined immunodeficiency (SCID), AIDS, viral,
CC	bacterial or fungal infection, malaria, autoimmune disorders, asthma,
CC	allergies, aplastic anaemia, burns, wounds, bone and cartilage damage,
CC	nocturnal haemoglobinuria, antiinflammatory disease, to enhance
CC	coagulation; to inhibit thrombosis; and as a contraceptive.

XX	SQ	Sequence	1805 BP;	484 A;	486 C;	416 G;	419 T;	0 other;
		Query Match	61.8%;	Score	1351;	DB	21;	Length
		Best Local Similarity	99.9%;	Pred. No.	0;			1805;
		Matches 1471;	Conservative	0;	Mismatches	0;	Indels	1;
		Gaps						1;
QY	715	TTGAGGAGCTGGAGATGTCAGGGAACCACTTCCTCGAGATCAGGCTGGCTGCTCTTCATG	774					
DB	23	TTGAGGAGCTGGAGATGTCAGGGAACCACTTCCTCGAGATCAGGCTGGCTGCTCTTCATG	82					
QY	775	GCTCGAGCTCCCTCAAGAAGCTCTGGGTCATGAACCTCACAGGTCAGCTGATGTGAGCGGA	834					
DB	83	GCTCGAGCTCCCTCAAGAAGCTCTGGGTCATGAACCTCACAGGTCAGCTGATGTGAGCGGA	142					
QY	835	ATGCTTTTGA CGGGTGGCTTCAGCTCTGGAACATCAACTTGGCCCAATAACCTCTCTT	894					
DB	143	ATGCTTTTGA CGGGTGGCTTCAGCTCTGGAACATCAACTTGGCCCAATAACCTCTCTT	202					
QY	895	CTTTGGCCCAATGACCTCTTTTATCCCGCTGAGGTACCTGCTGGAGTTGCTATACACCA	954					

or genetic lesions in the SECK gene. They may also be used to modulate SECK expression (e.g., using antisense oligonucleotides). SECK nucleic acid sequences are also useful for identifying a cell or tissue type in a biological sample, and in forensic biology. SECK primers or probes are useful for detecting the presence of SECK nucleotides and for screening tissue cultures for contamination. Diseases that may be treated or prevented using SECK proteins or nucleotides include cancer (e.g., colorectal carcinoma, prostate cancer), benign tumours, immune disorders (including autoimmune diseases, transplant rejection, allergies, AIDS), infections, inflammatory disorders, arthritis, haematopoietic disorders, skin disorders, cardiovascular disorders, atherosclerosis, retinosis, neurological diseases (e.g., Alzheimer's disease), trauma (e.g., surgical or traumatic wounds, spinal cord injury), and skeletal disorders.

Sequence 1356 BP; 283 A; 437 C; 339 G; 297 T; 0 other;

Query Match 53.9%; Score 1178; DB 21; Length 1356;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 1328; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

204 TGCTGTCAGTAACCAAGTTCAGCAAGGTGGTGTGCAAGCGCGGGGCTCTCCGAGGTC 263
22 TGCTGTCAGTAACCAAGTTCAGCAAGGTGGTGTGCAAGCGCGGGGCTCTCCGAGGTC 81
264 CGCAGGAGTATTCCTCGAACAACCGGTGACTCAACCTCATGTGAGAGAACATCCAGATG 323
82 CGCAGGAGTATTCCTCGAACAACCGGTGACTCAACCTCATGTGAGAGAACATCCAGATG 141
324 ATCCAGGCGGACACCTCCGCGACCTCCACCACTGGAGGTCTCTGCAAGTGGGCGAGAAC 383
142 ATCCAGGCGGACACCTCCGCGACCTCCACCACTGGAGGTCTCTGCAAGTGGGCGAGAAC 201
384 TCCATCCGCGAGATTGAGTGGGGGCTTCAACCGGCTGGCGAGCTTCAACCACTCGGAG 443
202 TCCATCCGCGAGATTGAGTGGGGGCTTCAACCGGCTGGCGAGCTTCAACCACTCGGAG 261
444 CTGTTTCGACACTGCTGCAAGTATCCCTAGCGGGGCTTTGAATACCTGTCTCAAGCTG 503
262 CTGTTTCGACACTGCTGCAAGTATCCCTAGCGGGGCTTTGAATACCTGTCTCAAGCTG 321
504 CGGAGGCTCTGGCTTCGCAACACCCCACTCAAGTATCTGAACCTGGGCGATGTGCAACATTA 563
322 CGGAGGCTCTGGCTTCGCAACACCCCACTCAAGTATCTGAACCTGGGCGATGTGCAACATTA 381
564 GTGCGCTCTGCTCATGCTGCAAGTATCTGGGAGCTCAAGAGCTGGAGTATCTCTGAG 623
382 GTGCGCTCTGCTCATGCTGCAAGTATCTGGGAGCTCAAGAGCTGGAGTATCTCTGAG 441
624 GGAGCTTTTGAGGGCTGTTCACCTCAAGTATCTGAACCTGGGCGATGTGCAACATTA 683
442 GGAGCTTTTGAGGGCTGTTCACCTCAAGTATCTGAACCTGGGCGATGTGCAACATTA 501
684 GACATGCCAATCTCACCCCTGCTGGGCTGGAGGCTGGAGAGCTCAGGGAGCCAC 743
502 GACATGCCAATCTCACCCCTGCTGGGCTGGAGGCTGGAGAGCTCAGGGAGCCAC 561
744 TTCCCTGAGATCAGGCTGGGCTCTTCCATGCGCTGAGCTCCCTCAAGAGCTCTGGGTC 803
562 TTCCCTGAGATCAGGCTGGGCTCTTCCATGCGCTGAGCTCCCTCAAGAGCTCTGGGTC 621
804 ATGAACCTCAAGCTCAGGCTGAGTGAAGCGGAATGCTTTTGAAGGCTGGCTTCACTTGTG 863
622 ATGAACCTCAAGCTCAGGCTGAGTGAAGCGGAATGCTTTTGAAGGCTGGCTTCACTTGTG 681
864 GAACTCAAGCTGGGCGCAATTAACCTCTCTCTTTGGCCCATGACCTCTTTACCCCGCTG 923
682 GAACTCAAGCTGGGCGCAATTAACCTCTCTCTTTGGCCCATGACCTCTTTACCCCGCTG 741
924 AGGTACCTGGTGGAGTGTGATCTACACCAACACCCCTTGGAACTGTGATGTGACATTCG 983
742 AGGTACCTGGTGGAGTGTGATCTACACCAACACCCCTTGGAACTGTGATGTGACATTCG 801

984 TGGCTAGCTTGGTGGCTTCGAGAGTATATATACCAACCAATTCACCTGCTGTGCGCGCTGT 1043
802 TGGCTAGCTTGGTGGCTTCGAGAGTATATATACCAACCAATTCACCTGCTGTGCGCGCTGT 861
1044 CATGCTCCATGCAATGCAATGCAATGCAATGCAATGCAATGCAATGCAATGCAATGCAATG 1103
862 CATGCTCCATGCAATGCAATGCAATGCAATGCAATGCAATGCAATGCAATGCAATGCAATG 921
1104 TGCTCTGCGGCTTTCATCATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1163
922 TGCTCTGCGGCTTTCATCATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 981
1164 GAGAACTTAAGTGTGGAGTCTCCCTATGCTCTCGTGAAGTGTGCTGCGGCAATGGG 1223
982 GCAGAACTTAAGTGTGGAGTCTCCCTATGCTCTCGTGAAGTGTGCTGCGGCAATGGG 1041
1224 ACAGTGTCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1283
1042 ACAGTGTCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1101
1284 AACTTTTCCGAGCTGCTGCTTTTCAAGACTGGGGTGTACATGCTGCTGCTGCTGCTGCTGCT 1343
1102 AACTTTTCCGAGCTGCTGCTTTTCAAGACTGGGGTGTACATGCTGCTGCTGCTGCTGCTGCT 1161
1344 GCAGGAACTTCAAGCTGCTGCTTTTCAAGACTGGGGTGTACATGCTGCTGCTGCTGCTGCTGCT 1403
1162 GCAGGAACTTCAAGCTGCTGCTTTTCAAGACTGGGGTGTACATGCTGCTGCTGCTGCTGCTGCT 1221
1404 AACTTACAGCTTCTTCAAGACTGGGGTGTACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1463
1222 AACTTACAGCTTCTTCAAGACTGGGGTGTACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1281
1464 ACAGGAACTTCAAGCTGCTGCTTTTCAAGACTGGGGTGTACATGCTGCTGCTGCTGCTGCTGCT 1523
1282 ACAGGAACTTCAAGCTGCTGCTTTTCAAGACTGGGGTGTACATGCTGCTGCTGCTGCTGCTGCT 1341
1524 TCTACACGGT 1534
1342 TCTACACGGT 1352

RESULT 25
ABA06744
ID ABA06744 standard; cDNA; 1168 BP.
XX
AC ABA06744;
XX
DT 10-JAN-2002 (first entry)
XX
DE Human cDNA SEQ ID NO: 410.
XX
KW Human; gene therapy; neural disorder; immune system disorder;
KW muscular disorder; reproductive disorder; gastrointestinal disorder;
KW pulmonary disorder; cardiovascular disorder; renal disorder;
KW proliferative disorder; inflammation; ss.
OS Homo sapiens.
XX
PN WO200154474-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01349.
XX
PR 31-JAN-2000; 2000US-179065P.
PR 04-FEB-2000; 2000US-180628P.
PR 24-FEB-2000; 2000US-184664P.
PR 02-MAR-2000; 2000US-186350P.
PR 16-MAR-2000; 2000US-189874P.
PR 17-MAR-2000; 2000US-190076P.
PR 18-APR-2000; 2000US-198123P.
PR 19-MAY-2000; 2000US-205515P.
PR 07-JUN-2000; 2000US-209467P.

R 28-JUN-2000; 2000US-214986P.
R 30-JUN-2000; 2000US-215335P.
R 07-JUL-2000; 2000US-216647P.
R 07-JUL-2000; 2000US-216880P.
R 11-JUL-2000; 2000US-217487P.
R 11-JUL-2000; 2000US-217496P.
R 14-JUL-2000; 2000US-218290P.
R 26-JUL-2000; 2000US-220963P.
R 26-JUL-2000; 2000US-220964P.
R 14-AUG-2000; 2000US-224518P.
R 14-AUG-2000; 2000US-224519P.
R 14-AUG-2000; 2000US-225213P.
R 14-AUG-2000; 2000US-225214P.
R 14-AUG-2000; 2000US-225266P.
R 14-AUG-2000; 2000US-225267P.
R 14-AUG-2000; 2000US-225288P.
R 14-AUG-2000; 2000US-225270P.
R 14-AUG-2000; 2000US-225447P.
R 14-AUG-2000; 2000US-225757P.
R 14-AUG-2000; 2000US-225758P.
R 14-AUG-2000; 2000US-225759P.
R 18-AUG-2000; 2000US-226279P.
R 22-AUG-2000; 2000US-226681P.
R 22-AUG-2000; 2000US-226868P.
R 23-AUG-2000; 2000US-227182P.
R 30-AUG-2000; 2000US-228924P.
R 01-SEP-2000; 2000US-229287P.
R 01-SEP-2000; 2000US-229343P.
R 01-SEP-2000; 2000US-229344P.
R 01-SEP-2000; 2000US-229345P.
R 05-SEP-2000; 2000US-229509P.
R 05-SEP-2000; 2000US-229513P.
R 06-SEP-2000; 2000US-230437P.
R 06-SEP-2000; 2000US-230438P.
R 08-SEP-2000; 2000US-231242P.
R 08-SEP-2000; 2000US-231243P.
R 08-SEP-2000; 2000US-231244P.
R 08-SEP-2000; 2000US-231413P.
R 08-SEP-2000; 2000US-231414P.
R 08-SEP-2000; 2000US-232080P.
R 08-SEP-2000; 2000US-232081P.
R 12-SEP-2000; 2000US-231968P.
R 14-SEP-2000; 2000US-232397P.
R 14-SEP-2000; 2000US-232398P.
R 14-SEP-2000; 2000US-232399P.
R 14-SEP-2000; 2000US-232400P.
R 14-SEP-2000; 2000US-232401P.
R 14-SEP-2000; 2000US-233063P.
R 14-SEP-2000; 2000US-233064P.
R 21-SEP-2000; 2000US-233065P.
R 21-SEP-2000; 2000US-234223P.
R 21-SEP-2000; 2000US-234274P.
R 25-SEP-2000; 2000US-234997P.
R 25-SEP-2000; 2000US-234998P.
R 26-SEP-2000; 2000US-235484P.
R 27-SEP-2000; 2000US-235834P.
R 27-SEP-2000; 2000US-235836P.
R 29-SEP-2000; 2000US-236327P.
R 29-SEP-2000; 2000US-236328P.
R 29-SEP-2000; 2000US-236367P.
R 29-SEP-2000; 2000US-236368P.
R 29-SEP-2000; 2000US-236369P.
R 29-SEP-2000; 2000US-236370P.
R 02-OCT-2000; 2000US-236802P.
R 02-OCT-2000; 2000US-237037P.
R 02-OCT-2000; 2000US-237038P.
R 02-OCT-2000; 2000US-237039P.
R 02-OCT-2000; 2000US-237040P.
R 13-OCT-2000; 2000US-239933P.
R 13-OCT-2000; 2000US-239937P.
R 20-OCT-2000; 2000US-240860P.
R 20-OCT-2000; 2000US-241221P.
R 20-OCT-2000; 2000US-241785P.

PR 20-OCT-2000; 2000US-241786P.
PR 20-OCT-2000; 2000US-241787P.
PR 20-OCT-2000; 2000US-241808P.
PR 20-OCT-2000; 2000US-241809P.
PR 20-OCT-2000; 2000US-241826P.
PR 01-NOV-2000; 2000US-244617P.
PR 01-NOV-2000; 2000US-244674P.
PR 08-NOV-2000; 2000US-246475P.
PR 08-NOV-2000; 2000US-246476P.
PR 08-NOV-2000; 2000US-246477P.
PR 08-NOV-2000; 2000US-246478P.
PR 08-NOV-2000; 2000US-246523P.
PR 08-NOV-2000; 2000US-246524P.
PR 08-NOV-2000; 2000US-246525P.
PR 08-NOV-2000; 2000US-246526P.
PR 08-NOV-2000; 2000US-246527P.
PR 08-NOV-2000; 2000US-246528P.
PR 08-NOV-2000; 2000US-246532P.
PR 08-NOV-2000; 2000US-246609P.
PR 08-NOV-2000; 2000US-246610P.
PR 08-NOV-2000; 2000US-246611P.
PR 08-NOV-2000; 2000US-246613P.
PR 17-NOV-2000; 2000US-249207P.
PR 17-NOV-2000; 2000US-249208P.
PR 17-NOV-2000; 2000US-249209P.
PR 17-NOV-2000; 2000US-249210P.
PR 17-NOV-2000; 2000US-249211P.
PR 17-NOV-2000; 2000US-249212P.
PR 17-NOV-2000; 2000US-249213P.
PR 17-NOV-2000; 2000US-249214P.
PR 17-NOV-2000; 2000US-249215P.
PR 17-NOV-2000; 2000US-249216P.
PR 17-NOV-2000; 2000US-249217P.
PR 17-NOV-2000; 2000US-249218P.
PR 17-NOV-2000; 2000US-249244P.
PR 17-NOV-2000; 2000US-249245P.
PR 17-NOV-2000; 2000US-249264P.
PR 17-NOV-2000; 2000US-249265P.
PR 17-NOV-2000; 2000US-249297P.
PR 17-NOV-2000; 2000US-249299P.
PR 17-NOV-2000; 2000US-249300P.
PR 01-DEC-2000; 2000US-250160P.
PR 01-DEC-2000; 2000US-250391P.
PR 05-DEC-2000; 2000US-251030P.
PR 05-DEC-2000; 2000US-251988P.
PR 05-DEC-2000; 2000US-256719P.
PR 06-DEC-2000; 2000US-251479P.
PR 08-DEC-2000; 2000US-251856P.
PR 08-DEC-2000; 2000US-251868P.
PR 08-DEC-2000; 2000US-251869P.
PR 08-DEC-2000; 2000US-251989P.
PR 08-DEC-2000; 2000US-251990P.
PR 11-DEC-2000; 2000US-254097P.
PR 05-JAN-2001; 2001US-259678P.

(HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Barash SC, Ruben SM;

WPI; 2001-476161/51.
P-FSDS; ABB10522.

Isolated nucleic acid molecule encoding an inflammation-associated polypeptide is used in preventing, treating or ameliorating a medical condition.

Claim 1; SEQ ID NO: 410; 859pp + Sequence Listing; English.

The present invention provides human cDNAs, proteins and related genomic DNAs. These can be used in the treatment of neural, immune system, muscular, reproductive, gastrointestinal, pulmonary, cardiovascular, renal and proliferative disorders and inflammation. The present sequence is a cDNA of the invention.

XX SQ Sequence 1168 BP; 243 A; 364 C; 291 G; 264 T; 6 other;
 Query Match 34.7%; Score 758; DB 22; Length 1168;
 Best Local Similarity 99.9%; Pred. No. 0;
 Matches 808; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 718 AGGAGCTGGAGATGTCAGGGAACACCTCCCTGAGATCAGGCTGGCTCCCTCATGGCC 777
 359 AGGAGCTGGAGATGTCAGGGAACACCTCCCTGAGATCAGGCTGGCTCCCTCATGGCC 418
 778 TGAGCTCCCTCAAGAGCTCTGGGTGATGACTCAGAGTCAAGCTGATGAGCGGAATG 837
 419 TGAGCTCCCTCAAGAGCTCTGGGTGATGACTCAGAGTCAAGCTGATGAGCGGAATG 478
 838 CTTTGTGAGGCTGGCTTCACTTGTGGAACCTCACTTGGCCCAATAAATCTCTCTCTT 897
 479 CTTTGTGAGGCTGGCTTCACTTGTGGAACCTCACTTGGCCCAATAAATCTCTCTCTT 538
 898 TGGCCCATGACTCTTACCCCGCTGAGGTACCTGTTGGAGTTGCATCTACACCAAC 957
 539 TGGCCCATGACTCTTACCCCGCTGAGGTACCTGTTGGAGTTGCATCTACACCAAC 598
 958 CTTGGAATGTAATGTGACATCTTGTGGCTAGCTGTTGGCTTCGAGAGTATATACCCA 1017
 599 CTTGGAATGTAATGTGACATCTTGTGGCTAGCTGTTGGCTTCGAGAGTATATACCCA 658
 1018 CCAATTCACCTGCTGTGGCCGCTGTGATGCTCCATGCAATGCGAGGCGCTACTCG 1077
 659 CCAATTCACCTGCTGTGGCCGCTGTGATGCTCCATGCAATGCGAGGCGCTACTCG 718
 1078 TGGAGGTGAGCAGGCTCTCTTCAAGTGTCTGCTCCCTTCAATGAGGAGCTCTGAG 1137
 719 TGGAGGTGAGCAGGCTCTCTTCAAGTGTCTGCTCCCTTCAATGAGGAGCTCTGAG 778
 1138 ACCTCAACATTTCTGAGGCTGGATGAGGAGAACTTAAGTGTGAGCTCCCTCTATGTCCT 1197
 779 ACCTCAACATTTCTGAGGCTGGATGAGGAGAACTTAAGTGTGAGCTCCCTCTATGTCCT 838
 1198 CGGTGAAGTGTGCTGCTCCATGAGGAGGCTCAGCAGCTCCCGCCACCCAGGA 1257
 839 CGGTGAAGTGTGCTGCTCCATGAGGAGGCTCAGCAGCTCCCGCCACCCAGGA 898
 1258 TCTCTGTCTCAACAGCGGACCTTGAATTTTCCAGTGTCTGCTTTCAGACACTGGGG 1317
 899 TCTCTGTCTCAACAGCGGACCTTGAATTTTCCAGTGTCTGCTTTCAGACACTGGGG 958
 1318 TGTACACATGATGCTGACCAATGTTGAGGAGGCTCAGCAGCTCCCGCCACCCAGGA 1377
 959 TGTACACATGATGCTGACCAATGTTGAGGAGGCTCAGCAGCTCCCGCCACCCAGGA 1018
 1378 TGTACACATGATGCTGACCAATGTTGAGGAGGCTCAGCAGCTCCCGCCACCCAGGA 1437
 1019 TGTACACATGATGCTGACCAATGTTGAGGAGGCTCAGCAGCTCCCGCCACCCAGGA 1078
 1438 CCACGAGATCTGCTGAGGAGCAGCAGGAGGAGTACAGCTGTTCTTCAACAGCTCCA 1497
 1079 CCACGAGATCTGCTGAGGAGCAGCAGGAGGAGTACAGCTGTTCTTCAACAGCTCCA 1138
 1498 CTGGTTTACCGCGGCATATACCACTCT 1526
 1139 CTGGTTTACCGCGGCATATACCACTCT 1167

RESULT 26

AAS28872
 ID AAS28872 standard; cDNA; 1168 BP.

XX AC AAS28872;
 XX DT 07-NOV-2001 (first entry)

XX DE Human immunoglobulin encoding cDNA SEQ ID No 118.

XX KW

Immunoglobulin; primer; signal transduction pathway protein; cancer; ss;
 antisense therapy; gene therapy; neurological disorder; renal disorder;
 cardiovascular disorder; gastrointestinal disorder; pulmonary disorder;
 reproductive disorder; immune system disorder; proliferative disorder;
 muscular disorder.

OS Homo sapiens.

XX KW WO200155315-A2.

XX PD 02-AUG-2001.

XX PF 17-JAN-2001; 2001WO-US01326.

XX PR 31-JAN-2000; 2000US-0179065.

XX PR 04-FEB-2000; 2000US-0180628.

XX PR 24-FEB-2000; 2000US-0184664.

XX PR 02-MAR-2000; 2000US-0186350.

XX PR 16-MAR-2000; 2000US-0189874.

XX PR 17-MAR-2000; 2000US-0190076.

XX PR 18-APR-2000; 2000US-0198123.

XX PR 19-MAY-2000; 2000US-0205515.

XX PR 07-JUN-2000; 2000US-0209467.

XX PR 28-JUN-2000; 2000US-0214886.

XX PR 30-JUN-2000; 2000US-0215135.

XX PR 07-JUL-2000; 2000US-0216647.

XX PR 07-JUL-2000; 2000US-0216980.

XX PR 11-JUL-2000; 2000US-0217487.

XX PR 11-JUL-2000; 2000US-0217496.

XX PR 14-JUL-2000; 2000US-0218290.

XX PR 26-JUL-2000; 2000US-0220963.

XX PR 26-JUL-2000; 2000US-0220964.

XX PR 14-AUG-2000; 2000US-0224518.

XX PR 14-AUG-2000; 2000US-0224519.

XX PR 14-AUG-2000; 2000US-0225213.

XX PR 14-AUG-2000; 2000US-0225214.

XX PR 14-AUG-2000; 2000US-0225266.

XX PR 14-AUG-2000; 2000US-0225267.

XX PR 14-AUG-2000; 2000US-0225268.

XX PR 14-AUG-2000; 2000US-0225270.

XX PR 14-AUG-2000; 2000US-0225447.

XX PR 14-AUG-2000; 2000US-0225757.

XX PR 14-AUG-2000; 2000US-0225758.

XX PR 14-AUG-2000; 2000US-0225759.

XX PR 18-AUG-2000; 2000US-0226279.

XX PR 22-AUG-2000; 2000US-0226681.

XX PR 22-AUG-2000; 2000US-0226868.

XX PR 23-AUG-2000; 2000US-0227182.

XX PR 30-AUG-2000; 2000US-0227009.

XX PR 01-SEP-2000; 2000US-0228924.

XX PR 01-SEP-2000; 2000US-0229287.

XX PR 01-SEP-2000; 2000US-0229343.

XX PR 01-SEP-2000; 2000US-0229344.

XX PR 01-SEP-2000; 2000US-0229345.

XX PR 05-SEP-2000; 2000US-0229509.

XX PR 05-SEP-2000; 2000US-0229513.

XX PR 06-SEP-2000; 2000US-0230437.

XX PR 06-SEP-2000; 2000US-0230438.

XX PR 08-SEP-2000; 2000US-0231242.

XX PR 08-SEP-2000; 2000US-0231243.

XX PR 08-SEP-2000; 2000US-0231244.

XX PR 08-SEP-2000; 2000US-0231413.

XX PR 08-SEP-2000; 2000US-0231414.

XX PR 08-SEP-2000; 2000US-0232080.

XX PR 12-SEP-2000; 2000US-0232081.

XX PR 14-SEP-2000; 2000US-0231968.

XX PR 14-SEP-2000; 2000US-0232397.

XX PR 14-SEP-2000; 2000US-0232398.

XX PR 14-SEP-2000; 2000US-0232399.

XX PR 14-SEP-2000; 2000US-0232400.

XX PR 14-SEP-2000; 2000US-0232401.

XX PR 14-SEP-2000; 2000US-0233063.

14-SEP-2000; 2000US-0233064.
 14-SEP-2000; 2000US-0233065.
 21-SEP-2000; 2000US-0234223.
 21-SEP-2000; 2000US-0234274.
 25-SEP-2000; 2000US-0234997.
 25-SEP-2000; 2000US-0234998.
 26-SEP-2000; 2000US-0235484.
 27-SEP-2000; 2000US-0235834.
 27-SEP-2000; 2000US-0235836.
 29-SEP-2000; 2000US-0236327.
 29-SEP-2000; 2000US-0236367.
 29-SEP-2000; 2000US-0236368.
 29-SEP-2000; 2000US-0236369.
 29-SEP-2000; 2000US-0236370.
 02-OCT-2000; 2000US-0236802.
 02-OCT-2000; 2000US-0237037.
 02-OCT-2000; 2000US-0237038.
 02-OCT-2000; 2000US-0237039.
 02-OCT-2000; 2000US-0237040.
 13-OCT-2000; 2000US-0239935.
 13-OCT-2000; 2000US-0239937.
 20-OCT-2000; 2000US-0240960.
 20-OCT-2000; 2000US-0241221.
 20-OCT-2000; 2000US-0241785.
 20-OCT-2000; 2000US-0241786.
 20-OCT-2000; 2000US-0241787.
 20-OCT-2000; 2000US-0241808.
 20-OCT-2000; 2000US-0241809.
 20-OCT-2000; 2000US-0241826.
 01-NOV-2000; 2000US-0244617.
 08-NOV-2000; 2000US-0246474.
 08-NOV-2000; 2000US-0246475.
 08-NOV-2000; 2000US-0246476.
 08-NOV-2000; 2000US-0246477.
 08-NOV-2000; 2000US-0246478.
 08-NOV-2000; 2000US-0246523.
 08-NOV-2000; 2000US-0246524.
 08-NOV-2000; 2000US-0246525.
 08-NOV-2000; 2000US-0246526.
 08-NOV-2000; 2000US-0246527.
 08-NOV-2000; 2000US-0246528.
 08-NOV-2000; 2000US-0246532.
 08-NOV-2000; 2000US-0246609.
 08-NOV-2000; 2000US-0246610.
 08-NOV-2000; 2000US-0246611.
 08-NOV-2000; 2000US-0246613.
 17-NOV-2000; 2000US-0249207.
 17-NOV-2000; 2000US-0249208.
 17-NOV-2000; 2000US-0249209.
 17-NOV-2000; 2000US-0249210.
 17-NOV-2000; 2000US-0249211.
 17-NOV-2000; 2000US-0249212.
 17-NOV-2000; 2000US-0249213.
 17-NOV-2000; 2000US-0249214.
 17-NOV-2000; 2000US-0249215.
 17-NOV-2000; 2000US-0249216.
 17-NOV-2000; 2000US-0249217.
 17-NOV-2000; 2000US-0249218.
 17-NOV-2000; 2000US-0249244.
 17-NOV-2000; 2000US-0249245.
 17-NOV-2000; 2000US-0249264.
 17-NOV-2000; 2000US-0249265.
 17-NOV-2000; 2000US-0249267.
 17-NOV-2000; 2000US-0249297.
 17-NOV-2000; 2000US-0249299.
 17-NOV-2000; 2000US-0249300.
 01-DEC-2000; 2000US-0250160.
 01-DEC-2000; 2000US-0250391.
 05-DEC-2000; 2000US-0251030.
 05-DEC-2000; 2000US-0251988.
 05-DEC-2000; 2000US-0255719.
 06-DEC-2000; 2000US-0251479.
 08-DEC-2000; 2000US-0251856.
 08-DEC-2000; 2000US-0251868.

PR 08-DEC-2000; 2000US-0251869.
 PR 08-DEC-2000; 2000US-0251989.
 PR 08-DEC-2000; 2000US-0251990.
 PR 11-DEC-2000; 2000US-0254097.
 05-JAN-2001; 2001US-0259678.
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX
 XX Rosen CA, Barash SC, Ruben SM;
 PI WPI; 2001-457725/49.
 XX P-PSDB; AAU18084.
 DR
 XX Isolated novel immunoglobulin polypeptide for monitoring the presence
 PT and progression of diseases and for diagnosis -
 PT
 XX Claim 1; SEQ ID No 118; 551pp; English.
 PS
 XX Sequences AAS28765-AAS28877 represent cDNA molecules, which encode the
 CC immunoglobulin polypeptides of the invention, and primers for the
 CC polynucleotides. The polynucleotides and polypeptides can be used to
 CC diagnose a pathological condition or a susceptibility to a pathological
 CC condition in a subject by determining the presence or absence of a
 CC mutation in a DNA sequence or determining the presence or amount of
 CC expression of the protein. Alternatively the identification of a binding
 CC partner to a sequence allows determination of changes in protein
 CC activity. The sequences can be used as research tools for receptors or
 CC other signal transduction pathway proteins that interact with the
 CC polypeptides of the invention and can be used to treat, prevent or
 CC diagnose various types of disorders such as neurological disorders,
 CC cardiovascular disorders, gastrointestinal disorders, reproductive,
 CC disorders, immune system disorders, renal disorders, muscular disorders,
 CC pulmonary disorders, proliferative disorders and cancer.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at fp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 1168 BP; 243 A; 364 C; 291 G; 264 T; 6 other;
 Query Match 34.7%; Score 758; DB 22; Length 1168;
 Best Local Similarity 99.9%; Pred. No. 0;
 Matches 808; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 718 AGGAGCTGGAGTGTGAGGACACCTTCCCTGAGATCAGGCTGCTCTCCATGGCC 777
 DB 359 AGGAGCTGGAGTGTGAGGACACCTTCCCTGAGATCAGGCTGCTCTCCATGGCC 418
 QY 778 TGAGCTCCCTCAAGAGCTCTGGGTGATGAACTCAGCTCAGCTGATGAGCGGAATG 837
 DB 419 TGAGCTCCCTCAAGAGCTCTGGGTGATGAACTCAGCTCAGCTGATGAGCGGAATG 478
 QY 838 CTTTTCAGCGGCTGGCTTCACTTGTGGAATCAACTTGGCCCACTACCTCTCTTCTT 897
 DB 479 CTTTTCAGCGGCTGGCTTCACTTGTGGAATCAACTTGGCCCACTACCTCTCTTCTT 538
 QY 898 TGGCCCATGACCTCTTTTACCCCGCTGAGGTACTGCTGAGTGTGATCTACACCAACC 957
 DB 539 TGGCCCATGACCTCTTTTACCCCGCTGAGGTACTGCTGAGTGTGATCTACACCAACC 598
 QY 958 CTTTGGAACTGTGATGTGACATTTCTGTGCTAGCTGCTGGCTTGGAGATATACCCA 1017
 DB 599 CTTTGGAACTGTGATGTGACATTTCTGTGCTAGCTGCTGGCTTGGAGATATACCCA 658
 QY 1018 CCAATTCCACTGCTGTGGCGCTGTCATGCTCCCATGCAATGCGAGCGCGCTACCTCG 1077
 DB 659 CCAATTCCACTGCTGTGGCGCTGTCATGCTCCCATGCAATGCGAGCGCGCTACCTCG 718
 QY 1078 TGGAGTGGACCGAGCTCTCTCCAGTGTCTCCAGCTGTGCCCCCTTCATATGAGCGACCTCGAG 1137
 DB 719 TGGAGTGGACCGAGCTCTCTCCAGTGTCTCCAGTGTCTGCCCCCTTCATATGAGCGACCTCGAG 778
 QY 1138 ACCTACACTTCTGAGGCTGCGATGCGAGACTTAAGTGTGGACTCCCCCTATGCTCT 1197

1000US-228924P.
01-SEP-2000; 2000US-229287P.
01-SEP-2000; 2000US-229343P.
01-SEP-2000; 2000US-229344P.
01-SEP-2000; 2000US-229345P.
05-SEP-2000; 2000US-229509P.
05-SEP-2000; 2000US-229513P.
08-SEP-2000; 2000US-231413P.
21-SEP-2000; 2000US-234274P.
25-SEP-2000; 2000US-234977P.
27-SEP-2000; 2000US-235849P.
29-SEP-2000; 2000US-236327P.
29-SEP-2000; 2000US-236367P.
29-SEP-2000; 2000US-236368P.
29-SEP-2000; 2000US-236369P.
29-SEP-2000; 2000US-236370P.
02-OCT-2000; 2000US-236802P.
02-OCT-2000; 2000US-237037P.
02-OCT-2000; 2000US-237038P.
02-OCT-2000; 2000US-237039P.
13-OCT-2000; 2000US-237040P.
20-OCT-2000; 2000US-239935P.
20-OCT-2000; 2000US-240960P.
20-OCT-2000; 2000US-241785P.
20-OCT-2000; 2000US-241809P.
01-NOV-2000; 2000US-244617P.
17-NOV-2000; 2000US-249299P.
08-DEC-2000; 2000US-251856P.
08-DEC-2000; 2000US-251868P.
08-DEC-2000; 2000US-251869P.
(ROSE/) ROSEN C A.
(RUBE/) RUBEN S M.
(BARA/) BARASH S C.
Rosen CA, Ruben SM, Barash SC;
WPI, 2002-681727/73.
P-PSDB; ABP67109.
Novel polypeptide useful for diagnosis, prognosis, prevention, and
treatment of immune, hyperproliferative, renal, respiratory, and
cardiovascular, reproductive, endocrine, gastrointestinal and
neurological disorders -
Claim 1; SEQ ID NO 410; 369pp + Sequence Listing; English.
The invention relates to novel genes (ABV83682-ABV84101) and proteins
(ABP66710-ABP67129) useful for preventing, treating or ameliorating
medical conditions e.g. by protein or gene therapy. The genes are
isolated from a range of human tissues disclosed in the specification.
The nucleic acids, proteins, antibodies and (ant)agonists are useful
in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
and ovarian cancer and other cancers of the adrenal gland, bone, bone
marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
(b) immune disorders e.g. Addison's disease, diabetes mellitus, Crohn's
haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, ulcerative
colitis; (c) cardiovascular disorders such as myocardial ischaemias;
(d) wound healing; (e) neurological diseases e.g. cerebral anoxia and
epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
and parasitic infections.
Note: The sequence data for this patent did not form part of the
printed specification, but was obtained in electronic format directly
from WIPO at ftp.wipo.int/pub/published_pct_sequences.
Sequence 1168 BP; 243 A; 364 C; 291 G; 264 T; 6 other;
Query Match 34.7%; Score 758; DB 24; Length 1168;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 808; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

30-AUG-2000; 2000US-228924P.
01-SEP-2000; 2000US-229287P.
01-SEP-2000; 2000US-229343P.
01-SEP-2000; 2000US-229344P.
01-SEP-2000; 2000US-229345P.
05-SEP-2000; 2000US-229509P.
05-SEP-2000; 2000US-229513P.
08-SEP-2000; 2000US-231413P.
21-SEP-2000; 2000US-234274P.
25-SEP-2000; 2000US-234977P.
27-SEP-2000; 2000US-235849P.
29-SEP-2000; 2000US-236327P.
29-SEP-2000; 2000US-236367P.
29-SEP-2000; 2000US-236368P.
29-SEP-2000; 2000US-236369P.
29-SEP-2000; 2000US-236370P.
02-OCT-2000; 2000US-236802P.
02-OCT-2000; 2000US-237037P.
02-OCT-2000; 2000US-237038P.
02-OCT-2000; 2000US-237039P.
13-OCT-2000; 2000US-237040P.
20-OCT-2000; 2000US-239935P.
20-OCT-2000; 2000US-240960P.
20-OCT-2000; 2000US-241785P.
20-OCT-2000; 2000US-241809P.
01-NOV-2000; 2000US-244617P.
17-NOV-2000; 2000US-249299P.
08-DEC-2000; 2000US-251856P.
08-DEC-2000; 2000US-251868P.
08-DEC-2000; 2000US-251869P.
(ROSE/) ROSEN C A.
(RUBE/) RUBEN S M.
(BARA/) BARASH S C.
Rosen CA, Ruben SM, Barash SC;
WPI, 2002-681727/73.
P-PSDB; ABP67109.
Novel polypeptide useful for diagnosis, prognosis, prevention, and
treatment of immune, hyperproliferative, renal, respiratory, and
cardiovascular, reproductive, endocrine, gastrointestinal and
neurological disorders -
Claim 1; SEQ ID NO 410; 369pp + Sequence Listing; English.
The invention relates to novel genes (ABV83682-ABV84101) and proteins
(ABP66710-ABP67129) useful for preventing, treating or ameliorating
medical conditions e.g. by protein or gene therapy. The genes are
isolated from a range of human tissues disclosed in the specification.
The nucleic acids, proteins, antibodies and (ant)agonists are useful
in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
and ovarian cancer and other cancers of the adrenal gland, bone, bone
marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
(b) immune disorders e.g. Addison's disease, diabetes mellitus, Crohn's
haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, ulcerative
colitis; (c) cardiovascular disorders such as myocardial ischaemias;
(d) wound healing; (e) neurological diseases e.g. cerebral anoxia and
epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
and parasitic infections.
Note: The sequence data for this patent did not form part of the
printed specification, but was obtained in electronic format directly
from WIPO at ftp.wipo.int/pub/published_pct_sequences.
Sequence 1168 BP; 243 A; 364 C; 291 G; 264 T; 6 other;
Query Match 34.7%; Score 758; DB 24; Length 1168;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 808; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1000US-228924P.
01-SEP-2000; 2000US-229287P.
01-SEP-2000; 2000US-229343P.
01-SEP-2000; 2000US-229344P.
01-SEP-2000; 2000US-229345P.
05-SEP-2000; 2000US-229509P.
05-SEP-2000; 2000US-229513P.
08-SEP-2000; 2000US-231413P.
21-SEP-2000; 2000US-234274P.
25-SEP-2000; 2000US-234977P.
27-SEP-2000; 2000US-235849P.
29-SEP-2000; 2000US-236327P.
29-SEP-2000; 2000US-236367P.
29-SEP-2000; 2000US-236368P.
29-SEP-2000; 2000US-236369P.
29-SEP-2000; 2000US-236370P.
02-OCT-2000; 2000US-236802P.
02-OCT-2000; 2000US-237037P.
02-OCT-2000; 2000US-237038P.
02-OCT-2000; 2000US-237039P.
13-OCT-2000; 2000US-237040P.
20-OCT-2000; 2000US-239935P.
20-OCT-2000; 2000US-240960P.
20-OCT-2000; 2000US-241785P.
20-OCT-2000; 2000US-241809P.
01-NOV-2000; 2000US-244617P.
17-NOV-2000; 2000US-249299P.
08-DEC-2000; 2000US-251856P.
08-DEC-2000; 2000US-251868P.
08-DEC-2000; 2000US-251869P.
(ROSE/) ROSEN C A.
(RUBE/) RUBEN S M.
(BARA/) BARASH S C.
Rosen CA, Ruben SM, Barash SC;
WPI, 2002-681727/73.
P-PSDB; ABP67109.
Novel polypeptide useful for diagnosis, prognosis, prevention, and
treatment of immune, hyperproliferative, renal, respiratory, and
cardiovascular, reproductive, endocrine, gastrointestinal and
neurological disorders -
Claim 1; SEQ ID NO 410; 369pp + Sequence Listing; English.
The invention relates to novel genes (ABV83682-ABV84101) and proteins
(ABP66710-ABP67129) useful for preventing, treating or ameliorating
medical conditions e.g. by protein or gene therapy. The genes are
isolated from a range of human tissues disclosed in the specification.
The nucleic acids, proteins, antibodies and (ant)agonists are useful
in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
and ovarian cancer and other cancers of the adrenal gland, bone, bone
marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
(b) immune disorders e.g. Addison's disease, diabetes mellitus, Crohn's
haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, ulcerative
colitis; (c) cardiovascular disorders such as myocardial ischaemias;
(d) wound healing; (e) neurological diseases e.g. cerebral anoxia and
epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
and parasitic infections.
Note: The sequence data for this patent did not form part of the
printed specification, but was obtained in electronic format directly
from WIPO at ftp.wipo.int/pub/published_pct_sequences.
Sequence 1168 BP; 243 A; 364 C; 291 G; 264 T; 6 other;
Query Match 34.7%; Score 758; DB 24; Length 1168;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 808; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Y 718 AGAGCTGGAGATGTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTCCCTCCATGSCC 777
b 359 AGAGCTGGAGATGTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTCCCTCCATGSCC 418
Y 778 TGAGCTCCCTCAAGAGCTCTGGGTCAATCACTCAGAGTCAAGCTGATGAGCGGATG 837
b 419 TGAGCTCCCTCAAGAGCTCTGGGTCAATCACTCAGAGTCAAGCTGATGAGCGGATG 478
Y 838 CTTTGAAGGCTGGCTTCACTTGGAACTCACTTGGCCCAATTAACCTCTCTTT 897
b 479 CTTTGAAGGCTGGCTTCACTTGGAACTCACTTGGCCCAATTAACCTCTCTTT 538
Y 898 TGCCCATGAGCTCTTACCCGCTGAGTACTGCTGGAGTTCATCTACACACACACC 957
b 539 TGCCCATGAGCTCTTACCCGCTGAGTACTGCTGGAGTTCATCTACACACACACC 598
Y 958 CTTTGAAGCTGATGATGATCTGCTGAGTACTGCTGGAGTTCATCTACACACACACC 1017
b 599 CTTTGAAGCTGATGATGATCTGCTGAGTACTGCTGGAGTTCATCTACACACACACC 658
Y 1018 CCAATTCACCTGCTGGCGCTGTCATGCTCCATGCAATGCGAGCGCGCTACCTCG 1077
b 659 CCAATTCACCTGCTGGCGCTGTCATGCTCCATGCAATGCGAGCGCGCTACCTCG 718
Y 1078 TGAGGTGGAACAGGCTCTCTCCAGTGTCTGCCCCCTTCAATGAGAGCACTCGAG 1137
b 719 TGAGGTGGAACAGGCTCTCTCCAGTGTCTGCCCCCTTCAATGAGAGCACTCGAG 778
Y 1138 ACCTCAACATTTCTGAGGTCGATGCGAGTAACTTAACTGCGGCTCCCTATGCTCT 1197
b 779 ACCTCAACATTTCTGAGGTCGATGCGAGTAACTTAACTGCGGCTCCCTATGCTCT 838
Y 1198 CCGTGAAGTGGTGTGCTGCCAATGCGAGTGTCTCAGCAAGCTTCCCGCCCAACGGA 1257
b 839 CCGTGAAGTGGTGTGCTGCCAATGCGAGTGTCTCAGCAAGCTTCCCGCCCAACGGA 898
Y 1258 TCTCTGTCCTCAACGAGCGCACCTTGAACTTTTCCACAGTGTCTTTCAGACACTGGGG 1317
b 899 TCTCTGTCCTCAACGAGCGCACCTTGAACTTTTCCACAGTGTCTTTCAGACACTGGGG 958
Y 1318 TGATACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1377
b 959 TGATACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1018
Y 1378 TGAGCAGGCTGAGCTTAAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAAC 1437
b 1019 TGAGCAGGCTGAGCTTAAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAAC 1078
Y 1438 CCAGGAGATGCTGCTGAGGACACAGCGGAACTGAGGCTGCTTCCACAGTCA 1497
b 1079 CCAGGAGATGCTGCTGAGGACACAGCGGAACTGAGGCTGCTTCCACAGTCA 1138
Y 1498 CTGCTTACCGCGGCAATATACCACTCT 1526
b 1139 CTGCTTACCGCGGCAATATACCACTCT 1167

RESULT 28
AAV88338
ID AAV88338 standard; cDNA; 274 BP.
CX
CX AAV88338;
CX
CX 12-FEB-1999 (first entry)
CX EST clone FX353.
CX Expressed sequence tag; secreted protein; haematopoiesis regulator;
CX tissue growth; activin; inhibin; tumour invasion suppressor; EST; human;
CX chemotaxis; chemokinesis; haemostasis; gene therapy; thrombolysis;
CX receptor; ligand; anti-inflammatory; tumour inhibitor; ds.
CX Homo sapiens.

XX WO9845437-A2.
XX PN
XX PD 15-OCT-1998.
XX PF 10-APR-1998; 98WO-US06956.
XX PR 10-APR-1997; 97US-0837312.
XX PA (GENY) GENETICS INST INC.
XX PI Agostino MJ, Jacobs K, Lavallie ER, McCoy JM, Merberg D;
XX PT Racie LA, Spaulding V, Treacy M;
XX DR WPI; 1999-070078/06.
XX PT New polynucleotides encoding human secreted proteins - derived from
XX PT e.g. human blood, kidney, foetal lung, placenta, testes, brain,
XX PT ovary, pituitary, retina and colon cDNA libraries
XX PS Claim 1; Page 363; 641pp; English.
XX CC The present sequence represents an expressed sequence tag (EST), and is
XX CC a polynucleotide of the invention. The polynucleotides of the invention
XX CC are all secreted EST sequences isolated from a variety of human tissue
XX CC sources. The EST sequences and proteins encoded by them are predicted to
XX CC have useful biological activities which would make them suitable for
XX CC treating, preventing or ameliorating medical conditions in humans and
XX CC animals, although no supporting data is given. Suggested activities
XX CC include nutritional activity, immune stimulating or suppressing activity,
XX CC haematopoiesis regulating activity, tissue growth activity,
XX CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
XX CC and thrombolytic activity, receptor/ligand activity, anti-inflammatory
XX CC activity, cadherin/tumour invasion suppressor activity, tumour inhibition
XX CC activity. The EST sequences are also stated to be useful for gene
XX CC therapy.
XX SQ Sequence 274 BP; 70 A; 79 C; 71 G; 54 T; 0 other;
Query Match 11.9%; Score 259; DB 20; Length 274;
Best Local Similarity 100.0%; Pred. No. 1.5e-116;
Matches 259; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1528 CCACGGTGTCTTTCAGACTTACCCGTGTGCTCCCAAGCAGGTGGCAGTACCCGCGACAGACA 1587
Db 2 CCACGGTGTCTTTCAGACTTACCCGTGTGCTCCCAAGCAGGTGGCAGTACCCGCGACAGACA 61
QY 1588 CCACGTGACAGATGCGAGACAGCCGCTGGATGAGTCAATGAAGACCCACAGATCATCTG 1647
Db 62 CCACGTGACAGATGCGAGACAGCCGCTGGATGAGTCAATGAAGACCCACAGATCATCTG 121
QY 1648 GCTGCTTTGTGGCAGTGTCTGCTAGCTGCGCCCATGTTGATTGTTCTTATAAACTTC 1707
Db 122 GCTGCTTTGTGGCAGTGTCTGCTAGCTGCGCCCATGTTGATTGTTCTTATAAACTTC 181
QY 1708 GTAAAGCGCCACCGAGCGGAGTACAGTCAAGCCCGCGAGCTGTTGAGATTAATCAGG 1767
Db 182 GTAAAGCGCCACCGAGCGGAGTACAGTCAAGCCCGCGAGCTGTTGAGATTAATCAGG 241
QY 1768 TGGACGAGATCCCGAGC 1786
Db 242 TGGACGAGATCCCGAGC 260
RESULT 29
AAV89165
ID AAV89165 standard; cDNA; 257 BP.
CX
CX AAV89165;
CX
CX 15-FEB-1999 (first entry)
CX
CX EST clone CC359.

AAC58254;
29-JAN-2001 (first entry)
Human PRO1111 hybridisation probe SEQ ID NO:47.
Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth; proliferation; tumorigenesis; identification; cancer; PCR primer; hybridisation; probe; cytostatic; neurotropic; neuroprotective; anti-inflammatory; immunosuppressive; immunostimulant; antiangiogenic; leukaemia; lymphoid malignancy; neuronal disorder; glial disorder; astrocytal disorder; hypothalamic disorder; glandular disorder; mastophagal disorder; epithelial disorder; stromal disorder; blastocoele disorder; inflammatory disorder; angiogenic; immunologic disorder; ss.
Homo sapiens.
WO2000053755-A2.
14-SEP-2000.
06-JAN-2000; 2000WO-US00376.
08-MAR-1999; 99WO-US05028.
02-JUN-1999; 99WO-US12252.
23-JUN-1998; 99US-0141037.
07-JUL-1999; 99US-0143048.
26-JUL-1999; 99US-0145698.
30-NOV-1999; 99WO-US28313.
20-DEC-1999; 99WO-US30911.
05-JAN-2000; 2000WO-US00219.
(GETH) GENENTECH INC.
Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hillan KJ, Roy MA, Watanabe CK, Wood WI, WPI; 2000-572270/53.
Thirty PRO polynucleotides encoding PRO polypeptides, useful in the treatment, diagnosis and prevention of cancer -
Example 17; Page 125; 286pp; English.
The present invention describes an isolated antibody that binds to one of the human PRO proteins designated PRO212, PRO290, PRO341, PRO535, PRO619, PRO717, PRO809, PRO830, PRO848, PRO943, PRO1005, PRO1009, PRO1025, PRO1030, PRO1037, PRO1107, PRO1111, PRO1153, PRO1182, PRO1184, PRO1187, PRO1281, PRO23, PRO39, PRO834, PRO1317, PRO1710, PRO2094, PRO2145 OR PRO2198. PRO antagonists can be used to inhibit tumour cell growth. The PRO polypeptides and nucleotides are useful in the treatment, diagnosis and prevention of cancer. The antibodies and other anti-tumour compounds may be used to treat various conditions, including those characterised by overexpression and/or activation of the amplified PRO genes. Exemplary conditions or disorders to be treated with such antibodies and other compounds include benign or malignant tumours (e.g., renal, liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulva, thyroid, hepatic carcinomas, sarcomas, glioblastomas, and various head and neck tumours), leukaemias and lymphoid malignancies, other disorders such as neuronal, glial, astrocytal, hypothalamic and other glandular, mastophagal, epithelial, stromal and blastocoele disorders, and inflammatory, angiogenic and immunologic disorders. AAC58242 to AAC58366 represent PCR primers and hybridisation probes used in the isolation of the human PRO sequences. AAC58367 to AAC58396 and AAB24057 to AAB24089 represent human PRO polynucleotide and protein sequences given in the exemplification of the present invention.
Sequence 50 BP; 10 A; 16 C; 15 G; 9 T; 0 other;
Query Match 2.3%; Score 50; DB 21; Length 50;
Best Local Similarity 100.0%; Pred. No. 6.3e-14;

Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 350 CCACCACTGGAGTCTGACGTTGGGAGGAACTCCATCCGCGAGATTG 399
Db 1 CCACCACTGGAGTCTGACGTTGGGAGGAACTCCATCCGCGAGATTG 50
RESULT 32
AAZ65183
ID AAZ65183 standard; DNA; 50 BP.
XX
AC AAZ65183;
XX
DT 05-APR-2000 (first entry)
XX
DE Probe specific for human PRO1111.
XX
KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW pharmacological; receptor immunoadhesin; gene mapping; probe; ss.
XX
OS Homo sapiens.
XX
PN WO9963088-A2.
XX
PD 09-DEC-1999.
XX
PF 02-JUN-1999; 99WO-US12252.
XX
PR 02-JUN-1998; 98US-0087607.
PR 02-JUN-1998; 98US-0087609.
PR 02-JUN-1998; 98US-0087759.
PR 03-JUN-1998; 98US-0087827.
PR 04-JUN-1998; 98US-0088021.
PR 04-JUN-1998; 98US-0088025.
PR 04-JUN-1998; 98US-0088028.
PR 04-JUN-1998; 98US-0088029.
PR 04-JUN-1998; 98US-0088030.
PR 04-JUN-1998; 98US-0088033.
PR 04-JUN-1998; 98US-0088326.
PR 05-JUN-1998; 98US-0088167.
PR 05-JUN-1998; 98US-0088202.
PR 05-JUN-1998; 98US-0088212.
PR 05-JUN-1998; 98US-0088217.
PR 09-JUN-1998; 98US-0088655.
PR 10-JUN-1998; 98US-0088722.
PR 10-JUN-1998; 98US-0088730.
PR 10-JUN-1998; 98US-0088734.
PR 10-JUN-1998; 98US-0088738.
PR 10-JUN-1998; 98US-0088740.
PR 10-JUN-1998; 98US-0088741.
PR 10-JUN-1998; 98US-0088742.
PR 10-JUN-1998; 98US-0088810.
PR 10-JUN-1998; 98US-0088811.
PR 10-JUN-1998; 98US-0088824.
PR 10-JUN-1998; 98US-0088825.
PR 10-JUN-1998; 98US-0088826.
PR 11-JUN-1998; 98US-0088858.
PR 11-JUN-1998; 98US-0088861.
PR 11-JUN-1998; 98US-0088863.
PR 11-JUN-1998; 98US-0088876.
PR 12-JUN-1998; 98US-0089090.
PR 12-JUN-1998; 98US-0089105.
PR 16-JUN-1998; 98US-0089440.
PR 16-JUN-1998; 98US-0089512.
PR 16-JUN-1998; 98US-0089514.
PR 17-JUN-1998; 98US-0089532.
PR 17-JUN-1998; 98US-0089538.
PR 17-JUN-1998; 98US-0089598.
PR 17-JUN-1998; 98US-0089599.
PR 17-JUN-1998; 98US-0089600.
PR 17-JUN-1998; 98US-0089653.
PR 18-JUN-1998; 98US-0089801.
PR 18-JUN-1998; 98US-0089907.

PR 18-JUN-1998; 98US-0089903.
PR 19-JUN-1998; 98US-0089947.
PR 19-JUN-1998; 98US-0089948.
PR 19-JUN-1998; 98US-0089952.
PR 22-JUN-1998; 98US-0090246.
PR 22-JUN-1998; 98US-0090252.
PR 22-JUN-1998; 98US-0090254.
PR 23-JUN-1998; 98US-0090349.
PR 23-JUN-1998; 98US-0090355.
PR 24-JUN-1998; 98US-0090429.
PR 24-JUN-1998; 98US-0090431.
PR 24-JUN-1998; 98US-0090435.
PR 24-JUN-1998; 98US-0090444.
PR 24-JUN-1998; 98US-0090445.
PR 24-JUN-1998; 98US-0090461.
PR 24-JUN-1998; 98US-0090472.
PR 24-JUN-1998; 98US-0090535.
PR 24-JUN-1998; 98US-0090538.
PR 24-JUN-1998; 98US-0090540.
PR 24-JUN-1998; 98US-0090557.
PR 25-JUN-1998; 98US-0090676.
PR 25-JUN-1998; 98US-0090678.
PR 25-JUN-1998; 98US-0090688.
PR 25-JUN-1998; 98US-0090690.
PR 25-JUN-1998; 98US-0090691.
PR 25-JUN-1998; 98US-0090694.
PR 25-JUN-1998; 98US-0090695.
PR 25-JUN-1998; 98US-0090696.
PR 26-JUN-1998; 98US-0090862.
PR 26-JUN-1998; 98US-0090863.
PR 01-JUL-1998; 98US-0091358.
PR 01-JUL-1998; 98US-0091360.
PR 01-JUL-1998; 98US-0091544.
PR 02-JUL-1998; 98US-0091478.
PR 02-JUL-1998; 98US-0091486.
PR 02-JUL-1998; 98US-0091519.
PR 02-JUL-1998; 98US-0091628.
PR 02-JUL-1998; 98US-0091628.
PR 02-JUL-1998; 98US-0091633.
PR 02-JUL-1998; 98US-0091645.
PR 02-JUL-1998; 98US-0091673.
PR 07-JUL-1998; 98US-0091978.
PR 07-JUL-1998; 98US-0091983.
PR 09-JUL-1998; 98US-0092182.
PR 10-JUL-1998; 98US-0092472.
PR 20-JUL-1998; 98US-0093339.
PR 30-JUL-1998; 98US-0094651.
PR 04-AUG-1998; 98US-0095282.
PR 04-AUG-1998; 98US-0095285.
PR 04-AUG-1998; 98US-0095301.
PR 04-AUG-1998; 98US-0095302.
PR 04-AUG-1998; 98US-0095318.
PR 04-AUG-1998; 98US-0095321.
PR 04-AUG-1998; 98US-0095325.
PR 10-AUG-1998; 98US-0095916.
PR 10-AUG-1998; 98US-0095929.
PR 10-AUG-1998; 98US-0096012.
PR 11-AUG-1998; 98US-0096143.
PR 11-AUG-1998; 98US-0096146.
PR 12-AUG-1998; 98US-0096329.
PR 12-AUG-1998; 98US-0096757.
PR 17-AUG-1998; 98US-0096766.
PR 17-AUG-1998; 98US-0096768.
PR 17-AUG-1998; 98US-0096773.
PR 17-AUG-1998; 98US-0096791.
PR 17-AUG-1998; 98US-0096867.
PR 17-AUG-1998; 98US-0096891.
PR 17-AUG-1998; 98US-0096894.
PR 17-AUG-1998; 98US-0096895.
PR 17-AUG-1998; 98US-0096897.
PR 18-AUG-1998; 98US-0096899.
PR 18-AUG-1998; 98US-0096950.
PR 18-AUG-1998; 98US-0096959.
PR 18-AUG-1998; 98US-0096959.

PR 18-AUG-1998; 98US-0096960.
PR 18-AUG-1998; 98US-0097022.
PR 19-AUG-1998; 98US-0097141.
PR 20-AUG-1998; 98US-0097218.
PR 24-AUG-1998; 98US-0097661.
PR 26-AUG-1998; 98US-0097951.
PR 26-AUG-1998; 98US-0097952.
PR 26-AUG-1998; 98US-0097954.
PR 26-AUG-1998; 98US-0097955.
PR 26-AUG-1998; 98US-0097971.
PR 26-AUG-1998; 98US-0097974.
PR 26-AUG-1998; 98US-0097978.
PR 26-AUG-1998; 98US-0097979.
PR 26-AUG-1998; 98US-0097986.
PR 26-AUG-1998; 98US-0098014.
PR 31-AUG-1998; 98US-0098525.
PR 16-SEP-1998; 98US-0100634.
PR 12-JAN-1999; 99US-0115565.

XX (GETH) GENENTECH INC.

XX Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
PI Wood WI, Yuan J;

XX WPI; 2000-072883/06.

XX Membrane-bound proteins and related nucleotide sequences

XX Example 67; Page 431; 822pp; English.

XX The invention provides membrane-bound PRO polypeptides and polynucleotides encoding them. The PRO sequences of the invention were identified based on extracellular domain homology screening. The PRO sequences have homology with proteins including LDL receptors, TIE ligands and various enzymes. The membrane-bound proteins and receptor molecules are useful as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be used as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. The PRO encoding sequences are useful as hybridization probes, in chromosome and gene mapping and in the generation of antisense RNA and DNA. PRO nucleic acid sequences will also be useful for the preparation of PRO polypeptides, especially by recombinant techniques.

XX SQ Sequence 50 BP; 10 A; 16 C; 15 G; 9 T; 0 other;

Query Match 2.3%; Score 50; DB 21; Length 50;

Best Local Similarity 100.0%; Pred. NO. 6.3e-14;

Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 350 CCACCACCTGGAGGTCCTGCAGTTGGGCGAGCACTCCATCCGCGAGATTG 399

Db 1 CCACCACCTGGAGGTCCTGCAGTTGGGCGAGCACTCCATCCGCGAGATTG 50

RESULT 33

AAF44340

ID AAF44340 standard; DNA; 50 BP.

XX AAF44340;

XX 02-APR-2001 (first entry)

XX Human PRO1111 hybridisation probe SEQ ID NO:251.

XX Human; secreted and transmembrane protein; PRO; cytostatic;
KW cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
KW diagnostic assay; PCR primer; hybridisation; probe; ss.

XX Homo sapiens.

XX WO200073454-A1.

XX 07-DEC-2000.
XX 30-MAR-2000; 2000WO-US08439.
XX 02-JUN-1999; 99WO-US12252.
XX 23-JUN-1999; 99US-0141037.
XX 07-JUL-1999; 99US-0143048.
XX 20-JUL-1999; 99US-0144758.
XX 26-JUL-1999; 99US-0145698.
XX 28-JUL-1999; 99US-0146222.
XX 17-AUG-1999; 99US-0149396.
XX 15-SEP-1999; 99WO-US21090.
XX 13-SEP-1999; 99WO-US21547.
XX 08-OCT-1999; 99US-0158663.
XX 30-NOV-1999; 99WO-US28313.
XX 01-DEC-1999; 99WO-US28301.
XX 16-DEC-1999; 99WO-US30095.
XX 20-DEC-1999; 99WO-US30911.
XX 05-JAN-2000; 2000WO-US00219.
XX 06-JAN-2000; 2000WO-US00376.
XX 11-FEB-2000; 2000WO-US03565.
XX 18-FEB-2000; 2000WO-US04341.
XX 24-FEB-2000; 2000WO-US04914.
XX 02-MAR-2000; 2000WO-US05004.
XX 10-MAR-2000; 2000WO-US05841.
XX 15-MAR-2000; 2000WO-US06319.
XX 20-MAR-2000; 2000WO-US06884.
XX 30-MAR-2000; 2000WO-US07377.
XX 15-MAY-2000; 2000WO-US13358.
XX 17-MAY-2000; 2000WO-US13705.
XX 22-MAY-2000; 2000WO-US14042.
XX 30-MAY-2000; 2000WO-US14941.
XX 02-JUN-2000; 2000WO-US15264.
XX 28-JUL-2000; 2000WO-US20710.
XX 11-AUG-2000; 2000WO-US22031.
XX 23-AUG-2000; 2000WO-US23522.
XX 24-AUG-2000; 2000WO-US23328.
XX 08-NOV-2000; 2000WO-US30952.
XX 01-DEC-2000; 2000WO-US32678.
XX 28-FEB-2001; 2001WO-US06520.
XX 01-JUN-2001; 2001WO-US17800.
XX 20-JUN-2001; 2001WO-US19692.
XX 29-JUN-2001; 2001WO-US21066.
XX 09-JUL-2001; 2001WO-US21735.
XX 16-JUN-1997; 97US-049787P.
XX 17-OCT-1997; 97US-062250P.
(GETH) GENENTECH INC.
Ashkenazi AJ, Baker KP, Botstein D, Deanovsers L, Eaton DL;
Ferrara N, Fong S, Gerber H, Gertsen ME, Goddard A, Godowski PJ;
Grimaldi CJ, Gurney AL, KJavlin J, Napier MA, Pan J, Pechi NF;
Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams FM, Wood WI;
Zhang Z;
WPI; 2001-032160/04.
PRO polynucleotides used to produce polypeptides used to target
bioactive molecules such as toxins, radiolabels or antibodies, to
specific cells, to cause targeted cell death -
Example 67; Page 457; 935pp; English.
The present invention describes human secreted and transmembrane PRO
proteins. The PRO proteins have cytostatic activity. The PRO proteins
can be used for targeted delivery of bioactive molecules, such as
toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
sequences, and their fragments, can be used as hybridisation probes, in
chromosomal and gene mapping, and in the generation of anti-sense RNA
and DNA. They may also be used to produce transgenic animals which are
used to develop and screen therapeutically useful reagents. The PRO
nucleotide and protein sequence can be used for tissue typing and in
treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
AAAF4270 to AAFA4470 represent PCR primers and hybridisation probes used
in the isolation of human PRO sequences. AAFA4087 to AAFA4269 and
AAB65154 to AAB65300 represent human PRO polynucleotide and protein
sequences given in the exemplification of the present invention.
Sequence 50 BP; 10 A; 16 C; 15 G; 9 T; 0 other;
Query Match 2.3%; Score 50; DB 22; Length 50;
Best Local Similarity 100.0%; Pred. No. 6.3e-14;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Y 350 CCACCACTGGAGTCTCGAGTTGGCGGAGCACTCCATCCGCGCATG 399
b 1 CCACCACTGGAGTCTCGAGTTGGCGGAGCACTCCATCCGCGCATG 50
RESULT 34

ABX80286
ID ABX80286 standard; DNA; 50 BP.
XX AC ABX80286;
XX DT 28-APR-2003 (first entry)
XX DE Novel human secreted or transmembrane protein PRO1138 DNA.
XX KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; r-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; gene; ds.
XX OS Homo sapiens.
XX PN US2002132252-A1.
XX PD 19-SEP-2002.
XX PF 14-NOV-2001; 2001US-0990442.
XX PR 05-NOV-1997; 97WO-US20069.
XX PR 16-SEP-1998; 98WO-US19330.
XX PR 17-SEP-1998; 98WO-US19437.
XX PR 07-OCT-1998; 98WO-US21141.
XX PR 01-DEC-1998; 98WO-US25108.
XX PR 05-JAN-1999; 99WO-US00106.
XX PR 08-MAR-1999; 99WO-US05028.
XX PR 02-JUN-1999; 99WO-US12252.
XX PR 15-SEP-1999; 99WO-US21090.
XX PR 15-SEP-1999; 99WO-US21547.
XX PR 30-NOV-1999; 99WO-US28313.
XX PR 01-DEC-1999; 99WO-US28301.
XX PR 16-DEC-1999; 99WO-US28634.
XX PR 20-DEC-1999; 99WO-US30095.
XX PR 06-JAN-2000; 2000WO-US00219.
XX PR 11-FEB-2000; 2000WO-US03565.
XX PR 18-FEB-2000; 2000WO-US04341.
XX PR 22-FEB-2000; 2000WO-US04914.
XX PR 24-FEB-2000; 2000WO-US05004.
XX PR 02-MAR-2000; 2000WO-US05841.
XX PR 10-MAR-2000; 2000WO-US06319.
XX PR 15-MAR-2000; 2000WO-US06884.
XX PR 20-MAR-2000; 2000WO-US07377.
XX PR 30-MAR-2000; 2000WO-US08439.
XX PR 15-MAY-2000; 2000WO-US13358.
XX PR 17-MAY-2000; 2000WO-US13705.
XX PR 22-MAY-2000; 2000WO-US14042.
XX PR 30-MAY-2000; 2000WO-US14941.
XX PR 02-JUN-2000; 2000WO-US15264.
XX PR 28-JUL-2000; 2000WO-US20710.
XX PR 11-AUG-2000; 2000WO-US22031.
XX PR 23-AUG-2000; 2000WO-US23522.
XX PR 24-AUG-2000; 2000WO-US23328.
XX PR 08-NOV-2000; 2000WO-US30952.
XX PR 01-DEC-2000; 2000WO-US32678.
XX PR 28-FEB-2001; 2001WO-US06520.
XX PR 01-JUN-2001; 2001WO-US17800.
XX PR 20-JUN-2001; 2001WO-US19692.
XX PR 29-JUN-2001; 2001WO-US21066.
XX PR 09-JUL-2001; 2001WO-US21735.
XX PR 16-JUN-1997; 97US-049787P.
XX PR 17-OCT-1997; 97US-062250P.

PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-US9787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-085186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-065770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 05-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 09-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088866P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089606P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089947P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 23-JUN-1998; 98US-090349P.
PR 23-JUN-1998; 98US-090355P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090431P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090445P.
PR 24-JUN-1998; 98US-090472P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 24-JUN-1998; 98US-090542P.
PR 25-JUN-1998; 98US-090557P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091519P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091633P.
PR 02-JUL-1998; 98US-091646P.
PR 02-JUL-1998; 98US-091673P.
PR 07-JUL-1998; 98US-091978P.
PR 07-JUL-1998; 98US-091982P.
PR 09-JUL-1998; 98US-092182P.
PR 10-JUL-1998; 98US-092472P.
PR 20-JUL-1998; 98US-093339P.
PR 30-JUL-1998; 98US-094651P.
PR 04-AUG-1998; 98US-095282P.
PR 04-AUG-1998; 98US-095285P.
PR 04-AUG-1998; 98US-095301P.
PR 04-AUG-1998; 98US-095302P.
PR 04-AUG-1998; 98US-095318P.
PR 04-AUG-1998; 98US-095321P.
PR 04-AUG-1998; 98US-095325P.
PR 10-AUG-1998; 98US-095916P.
PR 10-AUG-1998; 98US-095929P.
PR 10-AUG-1998; 98US-096012P.
PR 11-AUG-1998; 98US-096143P.
PR 11-AUG-1998; 98US-096146P.
PR 12-AUG-1998; 98US-096329P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096773P.
PR 17-AUG-1998; 98US-096791P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096894P.
PR 17-AUG-1998; 98US-096895P.
PR 18-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096950P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-096960P.
PR 18-AUG-1998; 98US-097022P.

```

PR 19-AUG-1998; 98US-097141P.
PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 26-AUG-1998; 98US-098014P.
PR 31-AUG-1998; 98US-098525P.
PR 16-SEP-1998; 98US-100634P.
PR 17-SEP-1998; 98US-100858P.
PR 22-DEC-1998; 98US-113296P.
PR 12-MAR-1999; 98US-123957P.
PR 23-JUN-1999; 98US-141037P.

Query Match      2.3%; Score 50; DB 25; Length 50;
Best Local Similarity 100.0%; Pred. No. 6.3e-14;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QV 350 CCACCACTGAGGCTCTGACCTGGCAGGAACTCCATCCGCGAGATTG 399
Dd 1 CCACCACTGAGGCTCTGACCTGGCAGGAACTCCATCCGCGAGATTG 50

RESULT 36
ABX81173
ID ABX81173 standard; DNA; 50 BP.
XX AC ABX81173;
XX DT 22-APR-2003 (first entry)
XX DE Novel human secreted or transmembrane protein PRO1138 DNA.
XX KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumor; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disease;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; gene; ds.
XX OS Homo sapiens.
XX PN US2003027985-A1.
XX PD 06-FEB-2003.
XX PF 14-NOV-2001; 2001US-0990562.
XX PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 01-DEC-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 16-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30395.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.

```

```

PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.

```

R 18-JUN-1998; 98US-089801P.
R 18-JUN-1998; 98US-089907P.
R 18-JUN-1998; 98US-089908P.
R 19-JUN-1998; 98US-089947P.
R 19-JUN-1998; 98US-089948P.
R 19-JUN-1998; 98US-089952P.
R 22-JUN-1998; 98US-090246P.
R 22-JUN-1998; 98US-090252P.
R 22-JUN-1998; 98US-090254P.
R 23-JUN-1998; 98US-090349P.
R 23-JUN-1998; 98US-090355P.
R 24-JUN-1998; 98US-090429P.
R 24-JUN-1998; 98US-090431P.
R 24-JUN-1998; 98US-090435P.
R 24-JUN-1998; 98US-090444P.
R 24-JUN-1998; 98US-090445P.
R 24-JUN-1998; 98US-090472P.
R 24-JUN-1998; 98US-090535P.
R 24-JUN-1998; 98US-090540P.
R 24-JUN-1998; 98US-090542P.
R 24-JUN-1998; 98US-090557P.
R 25-JUN-1998; 98US-090676P.
R 25-JUN-1998; 98US-090678P.
R 25-JUN-1998; 98US-090690P.
R 25-JUN-1998; 98US-090694P.
R 25-JUN-1998; 98US-090695P.
R 25-JUN-1998; 98US-090696P.
R 26-JUN-1998; 98US-090862P.
R 26-JUN-1998; 98US-090863P.
R 01-JUL-1998; 98US-091360P.
R 01-JUL-1998; 98US-091544P.
R 02-JUL-1998; 98US-091478P.
R 02-JUL-1998; 98US-091519P.
R 02-JUL-1998; 98US-091626P.
R 02-JUL-1998; 98US-091628P.
R 02-JUL-1998; 98US-091633P.
R 02-JUL-1998; 98US-091646P.
R 02-JUL-1998; 98US-091673P.
R 07-JUL-1998; 98US-091978P.
R 07-JUL-1998; 98US-091982P.
R 09-JUL-1998; 98US-092182P.
R 10-JUL-1998; 98US-092472P.
R 20-JUL-1998; 98US-093133P.
R 30-JUL-1998; 98US-094531P.
R 04-AUG-1998; 98US-095282P.
R 04-AUG-1998; 98US-095285P.
R 04-AUG-1998; 98US-095301P.
R 04-AUG-1998; 98US-095302P.
R 04-AUG-1998; 98US-095318P.
R 04-AUG-1998; 98US-095321P.
R 04-AUG-1998; 98US-095325P.
R 10-AUG-1998; 98US-095946P.
R 10-AUG-1998; 98US-095959P.
R 10-AUG-1998; 98US-096012P.
R 11-AUG-1998; 98US-096143P.
R 11-AUG-1998; 98US-096146P.
R 12-AUG-1998; 98US-096329P.
R 17-AUG-1998; 98US-096757P.
R 17-AUG-1998; 98US-096766P.
R 17-AUG-1998; 98US-096773P.
R 17-AUG-1998; 98US-096791P.
R 17-AUG-1998; 98US-096867P.
R 17-AUG-1998; 98US-096891P.
R 17-AUG-1998; 98US-096894P.
R 17-AUG-1998; 98US-096895P.
R 17-AUG-1998; 98US-096897P.
R 18-AUG-1998; 98US-096949P.
R 18-AUG-1998; 98US-096950P.
R 18-AUG-1998; 98US-096959P.
R 18-AUG-1998; 98US-096960P.
R 18-AUG-1998; 98US-097022P.
R 19-AUG-1998; 98US-097141P.

PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 26-AUG-1998; 98US-097852P.
PR 26-AUG-1998; 98US-097854P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 26-AUG-1998; 98US-098014P.
PR 26-AUG-1998; 98US-098014P.

Query Match 2.3%; Score 50; DB 25; Length 50;
Best Local Similarity 100.0%; Pred. No. 6.3e-14;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 350 CCACCACTGGAGGCTCTCAGTTCGGCAGGAACTCCATCCGCGAGATTG 399
Db 1 CCACCACTGGAGGCTCTCAGTTCGGCAGGAACTCCATCCGCGAGATTG 50

RESULT 37
ABX90263
ID ABX90263 standard; DNA; 50 BP.
XX AC ABX90263;
XX DT 01-MAY-2003 (first entry)
XX DE Human secreted/transmembrane protein, #93, probe.
XX KW Human; probe; ss; PRO; secreted; transmembrane; signal peptide;
XX KW pharmaceutical; diagnostic; therapeutic; gene therapy.
XX OS Homo sapiens.
XX PN US2002160384-A1.
XX PD 31-OCT-2002.
XX PF 14-NOV-2001; 2001US-0992598.
XX PP 05-NOV-1997; 97MO-US200069.
PR 16-SEP-1998; 98MO-US19130.
PR 17-SEP-1998; 98MO-US19437.
PR 07-OCT-1998; 98MO-US21141.
PR 01-DEC-1998; 98MO-US25108.
PR 05-JAN-1999; 99MO-US00106.
PR 08-MAR-1999; 99MO-US05028.
PR 02-JUN-1999; 99MO-US12252.
PR 15-SEP-1999; 99MO-US21090.
PR 15-SEP-1999; 99MO-US21547.
PR 30-NOV-1999; 99MO-US28313.
PR 01-DEC-1999; 99MO-US28313.
PR 01-DEC-1999; 99MO-US28634.
PR 16-DEC-1999; 99MO-US30095.
PR 20-DEC-1999; 99MO-US30911.
PR 05-JAN-2000; 2000MO-US00219.
PR 06-JAN-2000; 2000MO-US00276.
PR 11-FEB-2000; 2000MO-US03565.
PR 11-FEB-2000; 2000MO-US04341.
PR 22-FEB-2000; 2000MO-US04414.
PR 24-FEB-2000; 2000MO-US04914.
PR 24-FEB-2000; 2000MO-US05004.
PR 02-MAR-2000; 2000MO-US05841.
PR 10-MAR-2000; 2000MO-US06319.
PR 15-MAR-2000; 2000MO-US06884.
PR 20-MAR-2000; 2000MO-US07377.
PR 30-MAR-2000; 2000MO-US08439.
PR 15-MAY-2000; 2000MO-US13358.
PR 17-MAY-2000; 2000MO-US13705.
PR 22-MAY-2000; 2000MO-US14042.
PR 30-MAY-2000; 2000MO-US14941.

02-JUN-2000; 2000WO-US15264.
 28-JUL-2000; 2000WO-US20710.
 11-AUG-2000; 2000WO-US22031.
 23-AUG-2000; 2000WO-US23522.
 24-AUG-2000; 2000WO-US23328.
 08-NOV-2000; 2000WO-US30952.
 01-DEC-2000; 2000WO-US32678.
 28-FEB-2001; 2001WO-US06520.
 01-JUN-2001; 2001WO-US17800.
 20-JUN-2001; 2001WO-US19632.
 29-JUN-2001; 2001WO-US21066.
 09-JUL-2001; 2001WO-US21735.
 16-JUN-1997; 97US-049787P.
 17-OCT-1997; 97US-062250P.
 12-NOV-1997; 97US-065118P.
 13-NOV-1997; 97US-065311P.
 24-NOV-1997; 97US-066770P.
 25-FEB-1998; 98US-075945P.
 20-MAR-1998; 98US-078910P.
 28-APR-1998; 98US-083322P.
 07-MAY-1998; 98US-084600P.
 28-MAY-1998; 98US-087106P.
 02-JUN-1998; 98US-087607P.
 02-JUN-1998; 98US-087609P.
 02-JUN-1998; 98US-087759P.
 03-JUN-1998; 98US-087827P.
 04-JUN-1998; 98US-088021P.
 04-JUN-1998; 98US-088025P.
 04-JUN-1998; 98US-088026P.
 04-JUN-1998; 98US-088028P.
 04-JUN-1998; 98US-088029P.
 04-JUN-1998; 98US-088030P.
 04-JUN-1998; 98US-088033P.
 04-JUN-1998; 98US-088326P.
 05-JUN-1998; 98US-088167P.
 05-JUN-1998; 98US-088202P.
 05-JUN-1998; 98US-088212P.
 05-JUN-1998; 98US-088217P.
 09-JUN-1998; 98US-088655P.
 10-JUN-1998; 98US-088734P.
 10-JUN-1998; 98US-088738P.
 10-JUN-1998; 98US-088742P.
 10-JUN-1998; 98US-088810P.
 10-JUN-1998; 98US-088824P.
 11-JUN-1998; 98US-088826P.
 11-JUN-1998; 98US-088858P.
 11-JUN-1998; 98US-088861P.
 12-JUN-1998; 98US-088876P.
 12-JUN-1998; 98US-089105P.
 16-JUN-1998; 98US-089440P.
 16-JUN-1998; 98US-089512P.
 16-JUN-1998; 98US-089514P.
 17-JUN-1998; 98US-089532P.
 17-JUN-1998; 98US-089538P.
 17-JUN-1998; 98US-089598P.
 17-JUN-1998; 98US-089599P.
 17-JUN-1998; 98US-089600P.
 17-JUN-1998; 98US-089653P.
 18-JUN-1998; 98US-089801P.
 18-JUN-1998; 98US-089807P.
 18-JUN-1998; 98US-089808P.
 28-AUG-2001; 2001US-0941992.
 (GSH) GENENTECH INC.
 Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 Ferrara N, Fong S, Gerber H, Gerritsen MB, Goddard A, Godowski PJ;
 Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
 Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI,
 Zhang Z;
 WPI; 2003-288106/28.

PT New transmembrane polypeptides and nucleic acids encoding the
 PT polypeptides, useful in gene therapy, in chromosome identification, as
 XX chromosome markers, or in generating probes -
 PS Example 67; Page 247; 650pp; English.
 XX
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC comprising a sequence without signal peptide and the nucleic acid
 CC encoding them. The polypeptides can be used to raise antibodies that
 CC specifically bind to the PRO polypeptide, for linking a bioactive
 CC molecule to a cell expressing a PRO protein and for modulating at least
 CC one biological activity of a cell. The PRO polypeptides or
 CC polynucleotides are also useful in gene therapy, in chromosome
 CC identification, as chromosome markers, or in generating probes. The PRO
 CC polypeptides are useful as molecular markers for protein
 CC electrophoresis, and the isolated nucleic acids may be used for
 CC recombinantly expressing those markers. The PRO polypeptides and nucleic
 CC acids may also be used in tissue typing. Anti-PRO antibodies are useful
 CC in diagnostic assays for PRO, and in affinity purification of PRO from
 CC recombinant cell culture or natural sources. The sequences presented in
 CC ABX90083-ABX90468 are the genes encoding, the primers amplifying and the
 CC probes detecting the PRO polynucleotides of the invention.
 CC Note: The sequence data for this patent is also available in electronic
 CC format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 50 BP; 10 A; 16 C; 15 G; 9 T; 0 other;
 Query Match 2.3%; Score 50; DB 25; Length 50;
 Best Local Similarity 100.0%; Pred. NO. 6.3e-14;
 Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 350 CCACCACCTGGAGTCTCTGCGAGTTGGGCGAGCACTCCATCGGCAGATTG 399
 DB 1 CCACCACCTGGAGTCTCTGCGAGTTGGGCGAGCACTCCATCGGCAGATTG 50
 RESULT 38
 ABX77874
 ID ABX77874 standard; DNA; 50 BP.
 AC ABX77874;
 XX
 XX 14-APR-2003 (first entry)
 DT
 XX Human PRO probe #26.
 DE
 XX Human; PRO; ss; cytostatic; tumour; cancer; breast; lung; stomach;
 KW liver; horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT; probe;
 KW antibody-dependent enzyme mediated produg therapy.
 XX Homo sapiens.
 OS
 XX US2003027153-A1.
 PN
 XX 06-FEB-2003.
 PD
 XX
 XX 15-NOV-2001; 2001US-0997666.
 PF
 XX 05-NOV-1997; 97WO-US20069.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.


```
PR 19-AUG-1998; 98US-097141P;
PR 20-AUG-1998; 98US-097219P;
PR 24-AUG-1998; 98US-097661P;
PR 26-AUG-1998; 98US-097952P;
PR 26-AUG-1998; 98US-097955P;
PR 26-AUG-1998; 98US-097971P;
PR 26-AUG-1998; 98US-097974P;
PR 26-AUG-1998; 98US-097978P;
PR 26-AUG-1998; 98US-097979P;
PR 26-AUG-1998; 98US-097986P;
PR 26-AUG-1998; 98US-098014P;
PR 31-AUG-1998; 98US-098525P;
PR 16-SEP-1998; 98US-100634P;
PR 17-SEP-1998; 98US-100858P;
PR 22-DEC-1998; 98US-113296P;
PR 12-MAR-1999; 98US-123957P;
PR 23-JUN-1999; 98US-141037P;
PR 07-JUL-1999; 98US-143048P;

Query Match 2.3%; Score 50; DB 25; Length 50;
Best Local Similarity 100.0%; Pred. No. 6.3e-14;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 350 CCACCCTGAGTCTCTGCGTGGCAGGAACTCCATCCGCGAGATTG 399
DB 1 CCACCCTGAGTCTCTGCGTGGCAGGAACTCCATCCGCGAGATTG 50

RESULT 39
ABX79470
ID ABX79470 standard; DNA; 50 BP.
XX
AC ABX79470;
XX
DT 17-APR-2003 (first entry)
XX
DE Human secreted/transmembrane protein, probe #2.
XX
KW Human; probe; ss; PRO; secreted; transmembrane; signal peptide;
KW pharmaceutical; diagnostic; biosensor; bioindicator; tumor; therapeutic;
KW colon cancer; lung cancer; breast cancer; cancer; gene therapy.
XX
OS Homo sapiens.
XX
XX US2002142961-A1.
XX
PD 03-OCT-2002.
XX
PE 19-NOV-2001; 2001US-0989721.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 12-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.

10-MAR-2000; 2000WO-US06319.
15-MAR-2000; 2000WO-US06884.
20-MAR-2000; 2000WO-US07377.
30-MAR-2000; 2000WO-US08439.
15-MAY-2000; 2000WO-US13358.
17-MAY-2000; 2000WO-US13705.
22-MAY-2000; 2000WO-US14042.
30-MAY-2000; 2000WO-US14941.
02-JUN-2000; 2000WO-US15264.
28-JUL-2000; 2000WO-US20710.
11-AUG-2000; 2000WO-US22031.
23-AUG-2000; 2000WO-US23522.
24-AUG-2000; 2000WO-US23328.
08-NOV-2000; 2000WO-US30952.
01-DEC-2000; 2000WO-US32678.
28-FEB-2001; 2001WO-US06520.
01-JUN-2001; 2001WO-US17800.
20-JUN-2001; 2001WO-US19692.
29-JUN-2001; 2001WO-US21066.
09-JUL-2001; 2001WO-US21735.
16-JUN-1997; 97US-049787P.
17-OCT-1997; 97US-062250P.
12-NOV-1997; 97US-065186P.
13-NOV-1997; 97US-065311P.
24-NOV-1997; 97US-066770P.
25-FEB-1998; 98US-075945P.
20-MAR-1998; 98US-073910P.
28-APR-1998; 98US-083322P.
07-MAY-1998; 98US-084600P.
28-MAY-1998; 98US-087106P.
02-JUN-1998; 98US-087607P.
02-JUN-1998; 98US-087609P.
02-JUN-1998; 98US-087759P.
03-JUN-1998; 98US-087827P.
04-JUN-1998; 98US-088021P.
04-JUN-1998; 98US-088025P.
04-JUN-1998; 98US-088026P.
04-JUN-1998; 98US-088028P.
04-JUN-1998; 98US-088029P.
04-JUN-1998; 98US-088030P.
04-JUN-1998; 98US-088033P.
04-JUN-1998; 98US-088326P.
05-JUN-1998; 98US-088167P.
05-JUN-1998; 98US-088202P.
05-JUN-1998; 98US-088212P.
09-JUN-1998; 98US-088655P.
10-JUN-1998; 98US-088734P.
10-JUN-1998; 98US-088738P.
10-JUN-1998; 98US-088742P.
10-JUN-1998; 98US-088810P.
10-JUN-1998; 98US-088824P.
11-JUN-1998; 98US-088826P.
11-JUN-1998; 98US-088858P.
11-JUN-1998; 98US-088861P.
11-JUN-1998; 98US-088876P.
12-JUN-1998; 98US-089105P.
16-JUN-1998; 98US-089440P.
16-JUN-1998; 98US-089512P.
16-JUN-1998; 98US-089514P.
17-JUN-1998; 98US-089532P.
17-JUN-1998; 98US-089536P.
17-JUN-1998; 98US-089598P.
17-JUN-1998; 98US-089599P.
17-JUN-1998; 98US-089600P.
17-JUN-1998; 98US-089653P.
18-JUN-1998; 98US-089801P.
18-JUN-1998; 98US-089907P.
18-JUN-1998; 98US-089908P.
28-AUG-2001; 2001US-0941992.

(GETH ) GENENTECH INC.
XX
PA
XX
```

Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ, Grisaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI, Zhang Z;

WPI; 2003-155950/15.

New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184, PRO361 or PRO846) useful as targets for therapeutic intervention in cancers (e.g. lung or breast cancers), or for diagnosing these cancers

Disclosure; SEQ ID NO 251; 647pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides comprising a sequence without signal peptide and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. The PRO polypeptides or polynucleotides are also useful as pharmaceuticals, diagnostics, biosensors or bioreactors, for detecting or treating e.g. tumours in mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or rabbits as targets for therapeutic intervention in certain cancers (e.g. colon, lung or breast cancers) and diagnostic determination of the presence of these cancers. The PRO polypeptides are also useful as molecular weight markers or for chromosome identification. The PRO genes are useful as hybridisation probes or for screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene therapy, particularly for replacing a defective gene. The sequences presented in ABX9290-ABX79675 are the genes encoding, the primers amplifying and the probes detecting the PRO polynucleotides of the invention.

Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 50 BP; 10 A; 15 C; 15 G; 9 T; 0 other;

Query Match 2.3%; Score 50; DB 25; Length 50;
Best Local Similarity 100.0%; Pred. No. 6.3e-14;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 350 CCACCACCTGGAGGTCCTGCACTGGGAGGAGCAATCCATCCGGCAGATTG 399
C 1 CCACCACCTGGAGGTCCTGCACTGGGAGGAGCAATCCATCCGGCAGATTG 50

RESULT 40

3X64109

C ABX64109 standard; DNA; 50 BP.

K ABX64109;

X I 26-FEB-2003 (first entry)

X Human PRO DNA probe #24.

X Human; PRO polypeptide; secreted protein; transmembrane protein;
X genetic disorder; antibacterial; immunosuppressive; probe; ss.

S Homo sapiens.

N US2002103125-A1.

N 01-AUG-2002.

D 20-NOV-2001; 2001US-0989731.

X 05-NOV-1997; 97WO-US20069.

X 16-SEP-1998; 98WO-US19330.

R 17-SEP-1998; 98WO-US19437.

R 07-OCT-1998; 98WO-US21141.

PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 06-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 28-JUL-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.

R 11-JUN-1998; 98US-088861P.
 R 11-JUN-1998; 98US-088876P.
 R 12-JUN-1998; 98US-089105P.
 R 16-JUN-1998; 98US-089440P.
 R 16-JUN-1998; 98US-089512P.
 R 16-JUN-1998; 98US-089514P.
 R 17-JUN-1998; 98US-089532P.
 R 17-JUN-1998; 98US-089538P.
 R 17-JUN-1998; 98US-089588P.
 R 17-JUN-1998; 98US-089599P.
 R 17-JUN-1998; 98US-089600P.
 R 17-JUN-1998; 98US-089653P.
 R 18-JUN-1998; 98US-089801P.
 R 18-JUN-1998; 98US-089907P.
 R 18-JUN-1998; 98US-089908P.
 R 28-AUG-2001; 2001US-094132Z.
 X X (GETH) GENENTECH LTD.
 X X Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
 X X Ferrara N, Fong S, Garber H, Gerritsen ME, Goddard A, Godowski PJ,
 X X Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF,
 X X Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI,
 X X Zhang Z;
 X X WPI; 2003-102117/09.
 X X Novel secreted and transmembrane polypeptide for modulating biological
 X X activity of cell expressing the polypeptide, identifying agonists or
 X X antagonists of polypeptide, and as molecular weight markers -
 X X Example 67; Page 246; 649pp; English.
 X X The present invention relates to the isolation of novel human PRO
 X X polypeptides, and the polynucleotide sequences encoding them. The
 X X PRO polypeptides are secreted and transmembrane proteins. The PRO
 X X polypeptides are useful for detecting other PRO polypeptides, for
 X X linking bioactive molecules to cells expressing PRO polypeptides,
 X X for modulating biological activities of cells expressing PRO
 X X polypeptides, and for identifying agonists or antagonists.
 X X The polynucleotide sequences encoding PRO polypeptides are useful as
 X X hybridisation probes, in chromosome and gene mapping, in the generation
 X X of antisense RNA and DNA, in the preparation of PRO polypeptides, for
 X X generating transgenic animals or knockout animals, to construct
 X X hybridisation probes for mapping the gene which encodes the PRO
 X X polypeptide, and for the genetic analysis of individuals with genetic
 X X disorders, in gene therapy, for chromosome identification, as
 X X chromosome markers, and for generating probes for PCR, Northern
 X X analysis, Southern analysis and Western analysis. The present sequence
 X X represents a probe used in the examples of the present invention.
 X X Note: The sequence data for this patent was obtained in electronic
 X X format directly from the USPTO web site at
 X X seqdata.uspto.gov/psipdbEntry.html.
 X X Sequence 50 BP; 10 A; 16 C; 15 G; 9 T; 0 other;
 X X
 X X Query Match 2.3%; Score 50; DB 25; Length 50;
 X X Best Local Similarity 100.0%; Pred. No. 6.3e-14;
 X X Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 X X
 QY 350 CCACCACCTGGAGGTCCTGCGAGTTGGCGAGGAATCCATCCGCGAGATTG 399
 Db 1 CCACCACCTGGAGGTCCTGCGAGTTGGCGAGGAATCCATCCGCGAGATTG 50
 X X
 RESULT 41
 ABX17073
 ID ABX17073 standard; DNA; 50 BP.
 XX
 AC ABX17073;
 XX
 DT 04-FEB-2003 (first entry)
 XX

DE Human PRO probe #25.
 XX Human; PRO; probe; ss; secreted polypeptide; transmembrane polypeptide;
 KW toxin; radiolabel; cell death; gene mapping; chromosome mapping;
 KW protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
 KW antibacterial.
 XX Homo sapiens.
 XX US2002123463-A1.
 PN 05-SEP-2002.
 XX 19-NOV-2001; 2001US-0989732.
 PR 05-NOV-1997; 97WO-US20069.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 06-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.

CC carcinomas, sarcomas, glioblastomas, and various head and neck tumours),
CC leukaemias and lymphoid malignancies, other disorders such as neuronal,
CC glial, astrocytal, hypothalamic and other glandular, macrophagal,
CC epithelial, stromal and blastocellic disorders, and inflammatory,
CC angiogenic and immunologic disorders. AAC58242 to AAC58366 represent PCR
CC primers and hybridisation probes used in the isolation of the human PRO
CC sequences. AAC58367 to AAC58396 and AAB24057 to AAB24089 represent human
CC PRO polynucleotide and protein sequences given in the exemplification of
CC the present invention.

XX
SQ Sequence 31 BP; 7 A; 15 C; 2 G; 7 T; 0 other;

Query Match 1.4%; Score 31; DB 21; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.00613;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1930 ACTCTCTGCACCCACAGTCACCACTATCTC 1960
Db 1 ACTCTCTGCACCCACAGTCACCACTATCTC 31

RESULT 43

AAP44427
ID AAP44427 standard; DNA; 31 BP.

XX
AC AAP44427;

XX
DT 02-APR-2001 (first entry)

DE Human PRO1111 hybridisation probe SEQ ID NO:466.

XX Human; secreted and transmembrane protein; PRO: cytostatic;
KW cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
KW diagnostic assay; PCR primer; hybridisation; probe; ss.

XX Homo sapiens.

XX WO2000073454-A1.

XX 07-DEC-2000.

XX 30-MAR-2000; 2000WO-US08439.

XX 02-JUN-1999; 99WO-US12252.

PR 23-JUN-1999; 99US-0141037.

PR 07-JUL-1999; 99US-0143048.

PR 20-JUL-1999; 99US-0144758.

PR 26-JUL-1999; 99US-0145698.

PR 28-JUL-1999; 99US-0146222.

PR 17-AUG-1999; 99US-0149396.

PR 15-SEP-1999; 99WO-US21090.

PR 15-SEP-1999; 99WO-US21547.

PR 08-OCT-1999; 99US-0158663.

PR 30-NOV-1999; 99WO-US28313.

PR 01-DEC-1999; 99WO-US28301.

PR 16-DEC-1999; 99WO-US30095.

PR 20-DEC-1999; 99WO-US30911.

PR 05-JAN-2000; 2000WO-US00219.

PR 06-JAN-2000; 2000WO-US00376.

PR 11-FEB-2000; 2000WO-US03565.

PR 18-FEB-2000; 2000WO-US04341.

PR 22-FEB-2000; 2000WO-US04414.

PR 24-FEB-2000; 2000WO-US04914.

PR 24-FEB-2000; 2000WO-US05004.

PR 02-MAR-2000; 2000WO-US05841.

PR 15-MAR-2000; 2000WO-US06884.

PR 20-MAR-2000; 2000WO-US07377.

XX (GETH) GENENTECH INC.

PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL;

PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PU;

PI Grimaldi CJ, Gurney AL, Kijavini IJ, Napier WA, Pan J, Paoni NF;

PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;

XX
DR WPI; 2001-032160/04.

XX PRO polynucleotides used to produce polypeptides used to target

PT bioactive molecules such as toxins, radiolabels or antibodies, to

PT specific cells, to cause targeted cell death -

XX
PS Example 170; Page 542; 935pp; English.

XX The present invention describes human secreted and transmembrane PRO
CC proteins. The PRO proteins have cytostatic activity. The PRO proteins
CC can be used for targeted delivery of bioactive molecules, such as
CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
CC sequences, and their fragments, can be used as hybridisation probes, in
CC chromosomal and gene mapping, and in the generation of anti-sense RNA
CC and DNA. They may also be used to produce transgenic animals which are
CC used to develop and screen therapeutically useful reagents. The PRO
CC nucleotide and protein sequence can be used for tissue typing and in
CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
CC AAP44270 to AAP44470 represent PCR primers and hybridisation probes used
CC in the isolation of human PRO sequences. AAP44087 to AAP44269 and
CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein
CC sequences given in the exemplification of the present invention.

XX
SQ Sequence 31 BP; 7 A; 15 C; 2 G; 7 T; 0 other;

Query Match 1.4%; Score 31; DB 22; Length 31;

Best Local Similarity 100.0%; Pred. No. 0.00613;

Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1930 ACTCTCTGCACCCACAGTCACCACTATCTC 1960

Db 1 ACTCTCTGCACCCACAGTCACCACTATCTC 31

RESULT 44

ABX80436

ID ABX80436 standard; DNA; 31 BP.

XX
AC ABX80436;

XX
DT 28-APR-2003 (first entry)

XX Human secreted or transmembrane protein related PCR primer #122.

XX Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; PCR;
KW primer; ss.

XX Homo sapiens.

XX US2002132252-A1.

XX 19-SEP-2002.

XX 14-NOV-2001; 2001US-0990442.

XX 05-NOV-1997; 97WO-US20069.

PR 16-SEP-1998; 98WO-US19330.

PR 17-SEP-1998; 98WO-US19437.

PR 07-OCT-1998; 98WO-US21141.

PR 01-DEC-1998; 98WO-US25108.

PR 05-JAN-1999; 99WO-US00106.

R 08-MAR-1999; 99WO-US05028.
R 02-JUN-1999; 99WO-US12252.
R 15-SEP-1999; 99WO-US21090.
R 15-SEP-1999; 99WO-US21547.
R 30-NOV-1999; 99WO-US28313.
R 01-DEC-1999; 99WO-US28301.
R 01-DEC-1999; 99WO-US28634.
R 16-DEC-1999; 99WO-US30095.
R 20-DEC-1999; 99WO-US30911.
R 06-JAN-2000; 2000WO-US00219.
R 06-JAN-2000; 2000WO-US00376.
R 11-FEB-2000; 2000WO-US03565.
R 18-FEB-2000; 2000WO-US04341.
R 22-FEB-2000; 2000WO-US04414.
R 24-FEB-2000; 2000WO-US04914.
R 02-MAR-2000; 2000WO-US05004.
R 02-MAR-2000; 2000WO-US05841.
R 15-MAR-2000; 2000WO-US06319.
R 20-MAR-2000; 2000WO-US06884.
R 30-MAR-2000; 2000WO-US07377.
R 15-MAY-2000; 2000WO-US08439.
R 17-MAY-2000; 2000WO-US13358.
R 22-MAY-2000; 2000WO-US13705.
R 30-MAY-2000; 2000WO-US14042.
R 02-JUN-2000; 2000WO-US14941.
R 28-JUL-2000; 2000WO-US20710.
R 11-AUG-2000; 2000WO-US22031.
R 23-AUG-2000; 2000WO-US23522.
R 24-AUG-2000; 2000WO-US23328.
R 08-NOV-2000; 2000WO-US30952.
R 01-DEC-2000; 2000WO-US32678.
R 28-FEB-2001; 2001WO-US06520.
R 01-JUN-2001; 2001WO-US17800.
R 29-JUN-2001; 2001WO-US19892.
R 09-JUL-2001; 2001WO-US21066.
R 16-JUN-1997; 97US-US21735.
R 17-OCT-1997; 97US-US06220P.
R 12-NOV-1997; 97US-US05186P.
R 13-NOV-1997; 97US-US05311P.
R 24-NOV-1997; 97US-US06770P.
R 25-FEB-1998; 98US-US05945P.
R 20-MAR-1998; 98US-US078910P.
R 28-APR-1998; 98US-US083322P.
R 07-MAY-1998; 98US-US084600P.
R 28-MAY-1998; 98US-US07106P.
R 02-JUN-1998; 98US-US07607P.
R 02-JUN-1998; 98US-US07609P.
R 02-JUN-1998; 98US-US07759P.
R 03-JUN-1998; 98US-US07827P.
R 04-JUN-1998; 98US-US08021P.
R 04-JUN-1998; 98US-US08025P.
R 04-JUN-1998; 98US-US08026P.
R 04-JUN-1998; 98US-US08028P.
R 04-JUN-1998; 98US-US08029P.
R 04-JUN-1998; 98US-US08030P.
R 04-JUN-1998; 98US-US08033P.
R 04-JUN-1998; 98US-US08336P.
R 05-JUN-1998; 98US-US08167P.
R 05-JUN-1998; 98US-US08202P.
R 05-JUN-1998; 98US-US08212P.
R 05-JUN-1998; 98US-US08217P.
R 09-JUN-1998; 98US-US08655P.
R 10-JUN-1998; 98US-US08734P.
R 10-JUN-1998; 98US-US08738P.
R 10-JUN-1998; 98US-US08742P.
R 10-JUN-1998; 98US-US08810P.
R 10-JUN-1998; 98US-US08824P.
R 10-JUN-1998; 98US-US08826P.
R 11-JUN-1998; 98US-US08858P.
R 11-JUN-1998; 98US-US08861P.
R 11-JUN-1998; 98US-US08876P.

PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
XX Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ,
XX Grimaldi JC, Gurney AL, Kujavlin IJ, Napier WA, Pan J, Paoni NF,
XX Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI,
XX Zhang Z;
XX WPI; 2003-247083/24.
XX
XX Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
XX and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
XX are therapeutically useful for enhancing immune response and in cancer
XX treatments -
XX
XX Example 170; Page 294; 648pp; English.
XX
XX The invention describes an isolated human PRO polypeptide. The PRO
XX polypeptides are useful in detecting PRO polypeptides in a sample, in
XX linking a bioactive molecule to a cell expressing a PRO polypeptide, and
XX in modulating at least one biological activity of a cell expressing a PRO
XX polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
XX useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
XX stimulate adrenal cortical capillary endothelial growth, and PRO536,
XX PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
XX PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
XX useful for treating conditions or disorders where angiogenesis would be
XX beneficial, e.g. wound healing and antagonist of this polypeptide are
XX useful for treating cancerous tumours. PRO812 inhibits vascular
XX endothelial growth factor (VEGF) stimulated proliferation of endothelial
XX cells and is thus useful for inhibiting endothelial cell growth in
XX mammals which would be beneficial in inhibiting tumour growth. PRO826,
XX PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
XX stimulated T-lymphocytes and are therapeutically useful for enhancing
XX immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
XX retinal neurons cells (PRO1132 is also enhances survival/proliferation of
XX rod photoreceptor cells) and therefore are useful for treating retinal
XX disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813
XX and PRO1066 induce proliferation of mammalian kidney mesangial cells,
XX and therefore are useful for treating kidney disorders associated with
XX decreased mesangial cell function such as Berger disease or other
XX nephropathies associated with dermatitis, herpiformis or Crohn's
XX disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
XX proliferation and/or redifferentiation of chondrocytes in culture and
XX are thus useful for treating sports injuries, and arthritis. This
XX sequence represents a primer used in the isolation of DNA encoding
XX novel human PRO polypeptides.
XX
XX Sequence 31 BP; 7 A; 15 C; 2 G; 7 T; 0 other;

Query Match 1.4%; Score 31; DB 25; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.00013;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1930 ACTCTGACCCCACTCAGTCACCACTATCTC 1960
Db 1 ACTCTGACCCCACTCAGTCACCACTATCTC 31

RESULT 45
 AX80940
 ID AX80940 standard; DNA; 31 BP.
 AC AX80940;
 DT 22-APR-2003 (first entry)
 CX Human secreted/transmembrane protein, TaqMan probe #13.
 DE Human; probe; ss; PRO; secreted; transmembrane; pharmaceutical;
 KW diagnostic; biosensor; bioreactor; tumour; therapeutic; TaqMan;
 KW gene therapy; tumour-associated antigenic target; TAT; ADAPT;
 KW antibody-dependent enzyme mediated prodrug therapy; cytostatic.
 CX Homo sapiens.
 JS
 CX
 CX US2003027162-A1.
 PN
 CX
 CX
 CX
 PD 06-FEB-2003.
 CX
 PF 15-NOV-2001; 2001US-0997428.
 CX
 CX 05-NOV-1997; 97WO-US20069.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00105.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28303.
 PR 01-DEC-1999; 99WO-US28634.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-065770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-075910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088128P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089588P.
 PR 17-JUN-1998; 98US-089593P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 19-JUN-1998; 98US-089947P.
 PR 19-JUN-1998; 98US-089948P.
 PR 19-JUN-1998; 98US-089952P.
 PR 22-JUN-1998; 98US-090246P.
 PR 22-JUN-1998; 98US-090252P.
 PR 22-JUN-1998; 98US-090254P.
 PR 23-JUN-1998; 98US-090349P.
 PR 23-JUN-1998; 98US-090355P.
 PR 24-JUN-1998; 98US-090423P.
 PR 24-JUN-1998; 98US-090431P.
 PR 24-JUN-1998; 98US-090435P.
 PR 24-JUN-1998; 98US-090444P.
 PR 24-JUN-1998; 98US-090445P.
 PR 24-JUN-1998; 98US-090472P.
 PR 24-JUN-1998; 98US-090535P.
 PR 24-JUN-1998; 98US-090540P.
 PR 24-JUN-1998; 98US-090542P.
 PR 24-JUN-1998; 98US-090557P.
 PR 25-JUN-1998; 98US-090676P.
 PR 25-JUN-1998; 98US-090678P.
 PR 25-JUN-1998; 98US-090690P.
 PR 25-JUN-1998; 98US-090694P.
 PR 25-JUN-1998; 98US-090695P.
 PR 25-JUN-1998; 98US-090696P.
 PR 26-JUN-1998; 98US-090862P.
 PR 26-JUN-1998; 98US-090863P.
 PR 01-JUL-1998; 98US-091360P.
 PR 01-JUL-1998; 98US-091544P.
 PR 02-JUL-1998; 98US-091478P.
 PR 02-JUL-1998; 98US-091519P.

R 02-JUL-1998; 98US-091626P.
R 02-JUL-1998; 98US-091628P.
R 02-JUL-1998; 98US-091633P.
R 02-JUL-1998; 98US-091646P.
R 02-JUL-1998; 98US-091673P.
R 07-JUL-1998; 98US-091978P.
R 07-JUL-1998; 98US-091982P.
R 07-JUL-1998; 98US-092182P.
R 10-JUL-1998; 98US-092472P.
R 20-JUL-1998; 98US-093339P.
R 30-JUL-1998; 98US-094651P.
R 04-AUG-1998; 98US-095282P.
R 04-AUG-1998; 98US-095285P.
R 04-AUG-1998; 98US-095301P.
R 04-AUG-1998; 98US-095302P.
R 04-AUG-1998; 98US-095318P.
R 04-AUG-1998; 98US-095321P.
R 04-AUG-1998; 98US-095325P.
R 10-AUG-1998; 98US-095916P.
R 10-AUG-1998; 98US-095929P.
R 11-AUG-1998; 98US-096012P.
R 11-AUG-1998; 98US-096143P.
R 11-AUG-1998; 98US-096146P.
R 12-AUG-1998; 98US-096329P.
R 17-AUG-1998; 98US-096757P.
R 17-AUG-1998; 98US-096766P.
R 17-AUG-1998; 98US-096768P.
R 17-AUG-1998; 98US-096773P.
R 17-AUG-1998; 98US-096791P.
R 17-AUG-1998; 98US-096867P.
R 17-AUG-1998; 98US-096891P.
R 17-AUG-1998; 98US-096894P.
R 17-AUG-1998; 98US-096895P.
R 17-AUG-1998; 98US-096897P.
R 18-AUG-1998; 98US-096949P.
R 18-AUG-1998; 98US-096950P.
R 18-AUG-1998; 98US-096959P.
R 18-AUG-1998; 98US-096960P.
R 18-AUG-1998; 98US-097022P.
R 19-AUG-1998; 98US-097141P.
R 20-AUG-1998; 98US-097218P.
R 24-AUG-1998; 98US-097661P.
R 24-AUG-1998; 98US-097952P.
R 26-AUG-1998; 98US-097954P.
R 26-AUG-1998; 98US-097955P.
R 26-AUG-1998; 98US-097971P.
R 26-AUG-1998; 98US-097974P.
R 26-AUG-1998; 98US-097978P.
R 26-AUG-1998; 98US-097979P.
R 26-AUG-1998; 98US-097986P.
R 26-AUG-1998; 98US-098014P.
R 31-AUG-1998; 98US-098525P.
R 16-SEP-1998; 98US-100634P.
R 17-SEP-1998; 98US-100858P.
R 22-DEC-1998; 98US-113296P.
R 12-MAR-1999; 98US-123957P.
R 23-JUN-1999; 98US-141037P.

Query Match 1.4%; Score 31; DB 25; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.00013;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 1930 ACTCTGTGACCCACAGTCACCACTATCTC 1960
|||||
b 1 ACTCTGTGACCCACAGTCACCACTATCTC 31

RESULT 46
BX81323
D AX81323 standard; DNA; 31 Bp.
X C AX81323;
X

DT 22-APR-2003 (first entry)
XX Human secreted or transmembrane protein related PCR primer #122.
DE Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
XX cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disease;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; PCR;
XX primer; ss.
XX Homo sapiens.
XX US2003027985-A1.
XX 06-FEB-2003.
XX 14-NOV-2001; 2001US-0990562.
XX 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 98WO-US00106.
PR 08-MAR-1999; 98WO-US05028.
PR 02-JUN-1999; 98WO-US12252.
PR 15-SEP-1999; 98WO-US21090.
PR 15-SEP-1999; 98WO-US21547.
PR 30-NOV-1999; 98WO-US28313.
PR 01-DEC-1999; 98WO-US28301.
PR 01-DEC-1999; 98WO-US28634.
PR 16-DEC-1999; 98WO-US30095.
PR 20-DEC-1999; 98WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 24-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23528.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.

PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 02-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089807P.
 PR 18-JUN-1998; 98US-089808P.
 PR 19-JUN-1998; 98US-089947P.
 PR 19-JUN-1998; 98US-089948P.
 PR 19-JUN-1998; 98US-089952P.
 PR 22-JUN-1998; 98US-090246P.
 PR 22-JUN-1998; 98US-090252P.
 PR 22-JUN-1998; 98US-090254P.
 PR 23-JUN-1998; 98US-090349P.
 PR 23-JUN-1998; 98US-090355P.
 PR 24-JUN-1998; 98US-090429P.
 PR 24-JUN-1998; 98US-090431P.
 PR 24-JUN-1998; 98US-090435P.
 PR 24-JUN-1998; 98US-090444P.
 PR 24-JUN-1998; 98US-090445P.
 PR 24-JUN-1998; 98US-090472P.
 PR 24-JUN-1998; 98US-090535P.
 PR 24-JUN-1998; 98US-090540P.
 PR 24-JUN-1998; 98US-090542P.
 PR 24-JUN-1998; 98US-090557P.
 PR 25-JUN-1998; 98US-090676P.
 PR 25-JUN-1998; 98US-090678P.
 PR 25-JUN-1998; 98US-090800P.
 PR 25-JUN-1998; 98US-090894P.
 PR 25-JUN-1998; 98US-090895P.
 PR 25-JUN-1998; 98US-090896P.
 PR 26-JUN-1998; 98US-090862P.
 PR 26-JUN-1998; 98US-090863P.
 PR 01-JUL-1998; 98US-091360P.
 PR 01-JUL-1998; 98US-091344P.
 PR 02-JUL-1998; 98US-091478P.
 PR 02-JUL-1998; 98US-091519P.

PR 02-JUL-1998; 98US-091626P.
 PR 02-JUL-1998; 98US-091628P.
 PR 02-JUL-1998; 98US-091633P.
 PR 02-JUL-1998; 98US-091646P.
 PR 02-JUL-1998; 98US-091673P.
 PR 07-JUL-1998; 98US-091978P.
 PR 07-JUL-1998; 98US-091982P.
 PR 09-JUL-1998; 98US-092182P.
 PR 10-JUL-1998; 98US-092477P.
 PR 10-JUL-1998; 98US-093339P.
 PR 30-JUL-1998; 98US-094651P.
 PR 04-AUG-1998; 98US-095282P.
 PR 04-AUG-1998; 98US-095285P.
 PR 04-AUG-1998; 98US-095301P.
 PR 04-AUG-1998; 98US-095302P.
 PR 04-AUG-1998; 98US-095318P.
 PR 04-AUG-1998; 98US-095321P.
 PR 04-AUG-1998; 98US-095325P.
 PR 10-AUG-1998; 98US-095916P.
 PR 10-AUG-1998; 98US-095929P.
 PR 10-AUG-1998; 98US-096013P.
 PR 11-AUG-1998; 98US-096143P.
 PR 11-AUG-1998; 98US-096148P.
 PR 12-AUG-1998; 98US-096323P.
 PR 17-AUG-1998; 98US-096757P.
 PR 17-AUG-1998; 98US-096766P.
 PR 17-AUG-1998; 98US-096768P.
 PR 17-AUG-1998; 98US-096773P.
 PR 17-AUG-1998; 98US-096791P.
 PR 17-AUG-1998; 98US-096867P.
 PR 17-AUG-1998; 98US-096891P.
 PR 17-AUG-1998; 98US-096894P.
 PR 17-AUG-1998; 98US-096895P.
 PR 17-AUG-1998; 98US-096897P.
 PR 18-AUG-1998; 98US-096949P.
 PR 18-AUG-1998; 98US-096950P.
 PR 18-AUG-1998; 98US-096959P.
 PR 18-AUG-1998; 98US-096960P.
 PR 18-AUG-1998; 98US-097022P.
 PR 19-AUG-1998; 98US-097141P.
 PR 20-AUG-1998; 98US-097218P.
 PR 24-AUG-1998; 98US-097661P.
 PR 26-AUG-1998; 98US-097952P.
 PR 26-AUG-1998; 98US-097954P.
 PR 26-AUG-1998; 98US-097955P.
 PR 26-AUG-1998; 98US-097971P.
 PR 26-AUG-1998; 98US-097974P.
 PR 26-AUG-1998; 98US-097978P.
 PR 26-AUG-1998; 98US-097979P.
 PR 26-AUG-1998; 98US-097986P.

Query Match 1.4%; Score 31; DB 25; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.00013;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1930 ACTCTCTGCACCCACACAGTCACCACTATCTC 1960
 |||||
 DB 1 ACTCTCTGCACCCACACAGTCACCACTATCTC 31

RESULT 47
 ABX90413
 ID ABX90413 standard; DNA; 31 BP.
 AC ABX90413;
 XX
 XX
 DT 01-MAY-2003 (first entry)
 XX Human secreted/transmembrane protein, TaqMan probe #13.
 DE
 XX Human; probe; ss; PRO; secreted; transmembrane; signal peptide;
 KW pharmaceutical; diagnostic; therapeutic; gene therapy; TaqMan.
 XX

S Homo sapiens.
X US2002160384-A1.
N
D
X 31-OCT-2002.
F
X 14-NOV-2001; 2001US-0992598.
R
R 05-NOV-1997; 97WO-US20069.
R 16-SEP-1998; 98WO-US19330.
R 17-SEP-1998; 98WO-US19437.
R 07-OCT-1998; 98WO-US21141.
R 01-DEC-1998; 98WO-US25108.
R 05-JAN-1999; 99WO-US00106.
R 08-MAR-1999; 99WO-US05028.
R 02-JUN-1999; 99WO-US12252.
R 13-SEP-1999; 99WO-US21090.
R 15-SEP-1999; 99WO-US21547.
R 30-NOV-1999; 99WO-US28313.
R 01-DEC-1999; 99WO-US28301.
R 16-DEC-1999; 99WO-US30095.
R 20-DEC-1999; 99WO-US30911.
R 03-JAN-2000; 2000WO-US00219.
R 06-JAN-2000; 2000WO-US00376.
R 11-FEB-2000; 2000WO-US03565.
R 18-FEB-2000; 2000WO-US04341.
R 22-FEB-2000; 2000WO-US04414.
R 24-FEB-2000; 2000WO-US04914.
R 24-FEB-2000; 2000WO-US05004.
R 02-MAR-2000; 2000WO-US05841.
R 10-MAR-2000; 2000WO-US06319.
R 15-MAR-2000; 2000WO-US06884.
R 20-MAR-2000; 2000WO-US07377.
R 30-MAR-2000; 2000WO-US08439.
R 17-MAY-2000; 2000WO-US13358.
R 22-MAY-2000; 2000WO-US13705.
R 30-MAY-2000; 2000WO-US14042.
R 02-JUN-2000; 2000WO-US14941.
R 28-JUL-2000; 2000WO-US15264.
R 11-AUG-2000; 2000WO-US20710.
R 23-AUG-2000; 2000WO-US22031.
R 08-NOV-2000; 2000WO-US23328.
R 01-DEC-2000; 2000WO-US30952.
R 28-FEB-2001; 2001WO-US32678.
R 01-JUN-2001; 2001WO-US06520.
R 20-JUN-2001; 2001WO-US17800.
R 29-JUN-2001; 2001WO-US19692.
R 09-JUL-2001; 2001WO-US21066.
R 16-JUN-1997; 97US-049787P.
R 17-OCT-1997; 97US-062250P.
R 12-NOV-1997; 97US-065186P.
R 13-NOV-1997; 97US-065311P.
R 24-NOV-1997; 97US-066770P.
R 25-FEB-1998; 98US-075945P.
R 20-MAR-1998; 98US-078910P.
R 28-APR-1998; 98US-083322P.
R 07-MAY-1998; 98US-084600P.
R 28-MAY-1998; 98US-087106P.
R 02-JUN-1998; 98US-087607P.
R 02-JUN-1998; 98US-087609P.
R 03-JUN-1998; 98US-087759P.
R 04-JUN-1998; 98US-087827P.
R 04-JUN-1998; 98US-088021P.
R 04-JUN-1998; 98US-088025P.
R 04-JUN-1998; 98US-088026P.
R 04-JUN-1998; 98US-088028P.
R 04-JUN-1998; 98US-088029P.
R 04-JUN-1998; 98US-088030P.
R 04-JUN-1998; 98US-088032P.
R 04-JUN-1998; 98US-088036P.

PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF,
PI Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WI,
PI Zhang Z;
XX WFI; 2003-288106/28.

New transmembrane polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, in chromosome identification, as chromosome markers, or in generating probes -
Example 170; Page 295; 650pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides comprising a sequence without signal peptide and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. The PRO polypeptides or polynucleotides are also useful in gene therapy, in chromosome identification, as chromosome markers, or in generating probes. The PRO polypeptides are useful as molecular markers for protein electrophoresis, and the isolated nucleic acids may be used for recombinantly expressing these markers. The PRO polypeptides and nucleic acids may also be used in tissue typing. Anti-PRO antibodies are useful in diagnostic assays for PRO, and in affinity purification of PRO from recombinant cell culture or natural sources. The sequences presented in AX90083-AX90468 are the genes encoding, the primers amplifying and the probes detecting the PRO polynucleotides of the invention.
Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 31 BP; 7 A; 15 C; 2 G; 7 T; 0 other;

Query Match 1.4%; Score 31; DB 25; Length 31;
Best Local Similarity 100.0%; Pred. NO. 0.00013;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1930 ACTCTGTGACCCACGACGTCACCATCTATCTC 1960
|||||
DB 1 ACTCTGTGACCCACGACGTCACCATCTATCTC 31

RESULT 48
 ABX78024
 ID ABX78024 standard; DNA; 31 BP.
 XX AC ABX78024;
 XX DT 14-APR-2003 (first entry)
 XX DE Human PRO probe #51.
 XX KW Human; PRO; ss; cytostatic; tumour; cancer; breast; lung; stomach;
 KW liver; horse; cow; dog; cat; sheep; pig; goat; rabbit; ADERT; probe;
 KW antibody-dependent enzyme mediated prodrug therapy.
 XX OS Homo sapiens.
 XX PN US2003027163-A1.
 XX PD 06-FEB-2003.
 XX PF 15-NOV-2001; 2001US-0997666.
 XX PR 05-NOV-1997; 97WO-US20069.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 98WO-US00106.
 PR 08-MAR-1999; 98WO-US05028.
 PR 02-JUN-1999; 98WO-US12252.
 PR 15-SEP-1999; 98WO-US21090.
 PR 15-SEP-1999; 98WO-US21547.
 PR 30-NOV-1999; 98WO-US28313.
 PR 01-DEC-1999; 98WO-US28301.
 PR 16-DEC-1999; 98WO-US28634.
 PR 20-DEC-1999; 98WO-US30911.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 02-MAR-2000; 2000WO-US05004.
 PR 10-MAR-2000; 2000WO-US05841.
 PR 15-MAR-2000; 2000WO-US06319.
 PR 20-MAR-2000; 2000WO-US06884.
 PR 30-MAR-2000; 2000WO-US07377.
 PR 15-MAY-2000; 2000WO-US08439.
 PR 17-MAY-2000; 2000WO-US13358.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30352.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.

PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 18-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 19-JUN-1998; 98US-089947P.
 PR 19-JUN-1998; 98US-089948P.
 PR 19-JUN-1998; 98US-089952P.
 PR 22-JUN-1998; 98US-090246P.
 PR 22-JUN-1998; 98US-090252P.
 PR 22-JUN-1998; 98US-090254P.
 PR 23-JUN-1998; 98US-090349P.
 PR 23-JUN-1998; 98US-090355P.
 PR 24-JUN-1998; 98US-090429P.
 PR 24-JUN-1998; 98US-090431P.
 PR 24-JUN-1998; 98US-090435P.
 PR 24-JUN-1998; 98US-090444P.
 PR 24-JUN-1998; 98US-090445P.
 PR 24-JUN-1998; 98US-090472P.
 PR 24-JUN-1998; 98US-090535P.
 PR 24-JUN-1998; 98US-090540P.
 PR 24-JUN-1998; 98US-090542P.
 PR 25-JUN-1998; 98US-090576P.
 PR 25-JUN-1998; 98US-090578P.
 PR 25-JUN-1998; 98US-090690P.
 PR 25-JUN-1998; 98US-090695P.
 PR 25-JUN-1998; 98US-090696P.
 PR 26-JUN-1998; 98US-090862P.
 PR 26-JUN-1998; 98US-090863P.
 PR 01-JUL-1998; 98US-091360P.
 PR 01-JUL-1998; 98US-091544P.
 PR 02-JUL-1998; 98US-091478P.
 PR 02-JUL-1998; 98US-091519P.

1	02-JUL-1998;	98US-091626P.	XX	17-APR-2003 (first entry)	Human secreted/transmembrane protein, TagMan probe #13.
2	02-JUL-1998;	98US-091628P.	DT		
3	02-JUL-1998;	98US-091633P.	XX		
4	02-JUL-1998;	98US-091646P.	DE		
5	02-JUL-1998;	98US-091673P.	XX		
6	07-JUL-1998;	98US-091978P.	KW		Human; probe; ss; PRO; secreted; transmembrane; signal peptide;
7	07-JUL-1998;	98US-091982P.	KW		pharmaceutical; diagnostic; biosensor; bioeffector; tumour; therapeutic;
8	09-JUL-1998;	98US-092182P.	KW		colon cancer; lung cancer; breast cancer; cancer; gene therapy; TagMan.
9	10-JUL-1998;	98US-092472P.	XX		
10	20-JUL-1998;	98US-093339P.	OS		Homo sapiens.
11	30-JUL-1998;	98US-094651P.	XX		
12	04-AUG-1998;	98US-095282P.	PN		US2002142961-A1.
13	04-AUG-1998;	98US-095285P.	XX		
14	04-AUG-1998;	98US-095301P.	PD		03-OCT-2002.
15	04-AUG-1998;	98US-095302P.	XX		
16	04-AUG-1998;	98US-095318P.	XX		
17	04-AUG-1998;	98US-095321P.	PF		19-NOV-2001; 2001US-0989721.
18	10-AUG-1998;	98US-095916P.	PR		05-NOV-1997; 97WO-US20069.
19	10-AUG-1998;	98US-095929P.	PR		17-SEP-1998; 98WO-US19437.
20	10-AUG-1998;	98US-096012P.	PR		07-OCT-1998; 98WO-US21141.
21	11-AUG-1998;	98US-096143P.	PR		01-DEC-1998; 98WO-US25108.
22	11-AUG-1998;	98US-096146P.	PR		05-JAN-1999; 99WO-US00106.
23	12-AUG-1998;	98US-096329P.	PR		08-MAR-1999; 99WO-US05028.
24	17-AUG-1998;	98US-096757P.	PR		02-JUN-1999; 99WO-US12252.
25	17-AUG-1998;	98US-096768P.	PR		15-SEP-1998; 99WO-US21090.
26	17-AUG-1998;	98US-096773P.	PR		15-SEP-1999; 99WO-US21547.
27	17-AUG-1998;	98US-096791P.	PR		30-NOV-1999; 99WO-US28313.
28	17-AUG-1998;	98US-096867P.	PR		01-DEC-1999; 99WO-US28301.
29	17-AUG-1998;	98US-096891P.	PR		16-DEC-1999; 99WO-US30095.
30	17-AUG-1998;	98US-096894P.	PR		20-DEC-1999; 99WO-US30911.
31	17-AUG-1998;	98US-096895P.	PR		05-JAN-2000; 2000WO-US00219.
32	17-AUG-1998;	98US-096897P.	PR		06-JAN-2000; 2000WO-US00376.
33	18-AUG-1998;	98US-096949P.	PR		11-FEB-2000; 2000WO-US03565.
34	18-AUG-1998;	98US-096950P.	PR		18-FEB-2000; 2000WO-US04341.
35	18-AUG-1998;	98US-096955P.	PR		22-FEB-2000; 2000WO-US04414.
36	18-AUG-1998;	98US-096960P.	PR		24-FEB-2000; 2000WO-US04914.
37	18-AUG-1998;	98US-097022P.	PR		24-FEB-2000; 2000WO-US05004.
38	20-AUG-1998;	98US-097218P.	PR		02-MAR-2000; 2000WO-US05841.
39	24-AUG-1998;	98US-097561P.	PR		10-MAR-2000; 2000WO-US06319.
40	26-AUG-1998;	98US-097552P.	PR		15-MAR-2000; 2000WO-US06884.
41	26-AUG-1998;	98US-097554P.	PR		20-MAR-2000; 2000WO-US07377.
42	26-AUG-1998;	98US-097555P.	PR		30-MAR-2000; 2000WO-US08439.
43	26-AUG-1998;	98US-097574P.	PR		15-MAY-2000; 2000WO-US13358.
44	26-AUG-1998;	98US-097578P.	PR		17-MAY-2000; 2000WO-US13705.
45	26-AUG-1998;	98US-097579P.	PR		22-MAY-2000; 2000WO-US14042.
46	26-AUG-1998;	98US-097586P.	PR		30-MAY-2000; 2000WO-US14941.
47	26-AUG-1998;	98US-098014P.	PR		02-JUN-2000; 2000WO-US15264.
48	31-AUG-1998;	98US-098525P.	PR		28-JUL-2000; 2000WO-US20710.
49	16-SEP-1998;	98US-100634P.	PR		11-AUG-2000; 2000WO-US22031.
50	17-SEP-1998;	98US-100858P.	PR		23-AUG-2000; 2000WO-US23522.
51	22-DEC-1998;	98US-113296P.	PR		24-AUG-2000; 2000WO-US23328.
52	12-MAR-1999;	98US-123957P.	PR		08-NOV-2000; 2000WO-US30952.
53	23-JUN-1999;	98US-141037P.	PR		01-DEC-2000; 2000WO-US32678.
54	07-JUL-1999;	98US-143048P.	PR		28-FEB-2001; 2001WO-US06520.
55			PR		01-JUN-2001; 2001WO-US17800.
56			PR		20-JUN-2001; 2001WO-US19692.
57			PR		29-JUN-2001; 2001WO-US21066.
58			PR		09-JUL-2001; 2001WO-US21735.
59			PR		16-JUN-1997; 97US-049787P.
60			PR		17-OCT-1997; 97US-062250P.
61			PR		12-NOV-1997; 97US-065186P.
62			PR		13-NOV-1997; 97US-065311P.
63			PR		24-NOV-1997; 97US-066770P.
64			PR		25-FEB-1998; 98US-075945P.
65			PR		20-MAR-1998; 98US-078910P.
66			PR		28-APR-1998; 98US-083322P.
67			PR		07-MAY-1998; 98US-084600P.
68			PR		28-MAY-1998; 98US-087106P.
69			PR		02-JUN-1998; 98US-087607P.
70			PR		02-JUN-1998; 98US-087609P.
71			PR		02-JUN-1998; 98US-087759P.
72			PR		03-JUN-1998; 98US-087827P.

Query Match 1.4%; Score 31; DB 25; Length 31;
Best Local Similarity 100.0%; Pred.No. 0.00013;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 1930 ACTCTCTGACCCACAGTCACACCTATCTC 1960
1 ACTCTCTGACCCACAGTCACACCTATCTC 31

RESULT 49
BX79620
ABX79620 standard; DNA; 31 BP.
ABX79620;

PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Kijavlin IJ, Napier MA, Pan J, Paoni NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 PI Zhang Z;

XX WPI; 2003-155950/15.

XX New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
 PT PRO361 or PRO366) useful as targets for therapeutic intervention in
 PT cancers (e.g. lung or breast cancers), or for diagnosing these cancers

XX Example 170; Page 294; 647pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC comprising a sequence without signal peptide and the nucleic acid
 CC encoding them. The polypeptides can be used to raise antibodies that
 CC specifically bind to the PRO polypeptide, for linking a bioactive
 CC molecule to a cell expressing a PRO protein and for modulating at least
 CC one biological activity of a cell. The PRO polypeptides or
 CC polynucleotides are also useful as pharmaceuticals, diagnostics,
 CC biosensors or bioreactors, for detecting or treating e.g. tumours in
 CC mammals, e.g. humans, dogs, cats, cattle, horses, sheep, goats or
 CC rabbits as targets for therapeutic intervention in certain cancers (e.g.
 CC colon, lung or breast cancers) and diagnostic determination of the
 CC presence of these cancers. The PRO polypeptides are also useful as
 CC molecular weight markers or for chromosome identification. The PRO genes
 CC are useful as hybridisation probes or for screening libraries of human
 CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
 CC therapy, particularly for replacing a defective gene. The sequences
 CC presented in ABX7290-ABX79675 are the genes encoding, the primers
 CC amplifying and the probes detecting the PRO polynucleotides of the
 CC invention.

CC Note: The sequence data for this patent is also available in electronic
 CC format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 31 BP; 7 A; 15 C; 2 G; 7 T; 0 other;

Query Match 1.4%; Score 31; DB 25; Length 31;

Best Local Similarity 100.0%; Pred. No. 0.00013;

Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1930 ACTCTCTGACCCACAGTACCACTATCTC 1960

DB 1 ACTCTCTGACCCACAGTACCACTATCTC 31

RESULT 50

ABX64259

ID ABX64259 standard; DNA; 31 BP.

AC ABX64259;

XX 26-FEB-2003 (first entry)

DT Human PRO DNA probe #49.

DE Human; PRO polypeptide; secreted protein; transmembrane protein;
 KW Genetic disorder; antibacterial; immunosuppressive; probe; ss.

XX Homo sapiens.

XX US2002103125-A1.

XX 01-AUG-2002.

XX 20-NOV-2001; 2001US-0989731.

PR 05-NOV-1997; 97WO-US20069.

PR 16-SEP-1998; 98WO-US19330.

PR 17-SEP-1998; 98WO-US19437.

PR 07-OCT-1998; 98WO-US21141.

PR 01-DEC-1998; 98WO-US25108.

PR 05-JAN-1999; 99WO-US00106.

PR 08-MAR-1999; 99WO-US05028.

PR 02-JUN-1999; 99WO-US12252.

PR 15-SEP-1999; 99WO-US21090.

PR 15-SEP-1999; 99WO-US21547.

PR 30-NOV-1999; 99WO-US28313.

PR 01-DEC-1999; 99WO-US28301.

PR 01-DEC-1999; 99WO-US28634.

PR 16-DEC-1999; 99WO-US30095.

PR 20-DEC-1999; 99WO-US30911.

PR 06-JAN-2000; 2000WO-US00219.

PR 06-JAN-2000; 2000WO-US00376.

PR 11-FEB-2000; 2000WO-US03565.

PR 18-FEB-2000; 2000WO-US04341.

PR 22-FEB-2000; 2000WO-US04414.

PR 24-FEB-2000; 2000WO-US04914.

PR 24-FEB-2000; 2000WO-US05004.

PR 02-MAR-2000; 2000WO-US05841.

PR 10-MAR-2000; 2000WO-US06319.

PR 15-MAR-2000; 2000WO-US06884.

PR 20-MAR-2000; 2000WO-US07377.

PR 30-MAR-2000; 2000WO-US08439.

PR 15-MAY-2000; 2000WO-US13358.

PR 17-MAY-2000; 2000WO-US13705.

PR 22-MAY-2000; 2000WO-US14042.

PR 30-MAY-2000; 2000WO-US14941.

PR 02-JUN-2000; 2000WO-US15264.

PR 28-JUL-2000; 2000WO-US20710.

PR 11-AUG-2000; 2000WO-US22031.

PR 23-AUG-2000; 2000WO-US23522.

PR 04-AUG-2000; 2000WO-US23328.

PR 08-NOV-2000; 2000WO-US30952.

PR 01-DEC-2000; 2000WO-US32678.

28-FEB-2001; 2001WO-US06520.
01-JUN-2001; 2001WO-US17800.
20-JUN-2001; 2001WO-US19692.
29-JUN-2001; 2001WO-US21066.
09-JUL-2001; 2001WO-US21735.
16-JUN-1997; 97US-049787P.
17-OCT-1997; 97US-062250P.
12-NOV-1997; 97US-065186P.
13-NOV-1997; 97US-065311P.
24-NOV-1997; 97US-066770P.
25-FEB-1998; 98US-075945P.
20-MAR-1998; 98US-078310P.
28-APR-1998; 98US-083322P.
07-MAY-1998; 98US-084600P.
28-MAY-1998; 98US-087106P.
02-JUN-1998; 98US-087607P.
02-JUN-1998; 98US-087609P.
02-JUN-1998; 98US-087759P.
03-JUN-1998; 98US-087827P.
04-JUN-1998; 98US-088021P.
04-JUN-1998; 98US-088025P.
04-JUN-1998; 98US-088026P.
04-JUN-1998; 98US-088028P.
04-JUN-1998; 98US-088029P.
04-JUN-1998; 98US-088030P.
04-JUN-1998; 98US-088033P.
04-JUN-1998; 98US-088326P.
05-JUN-1998; 98US-088167P.
05-JUN-1998; 98US-088202P.
05-JUN-1998; 98US-088212P.
05-JUN-1998; 98US-088217P.
09-JUN-1998; 98US-088655P.
10-JUN-1998; 98US-088734P.
10-JUN-1998; 98US-088738P.
10-JUN-1998; 98US-088742P.
10-JUN-1998; 98US-088810P.
10-JUN-1998; 98US-088824P.
10-JUN-1998; 98US-088826P.
11-JUN-1998; 98US-088858P.
11-JUN-1998; 98US-088861P.
11-JUN-1998; 98US-088876P.
12-JUN-1998; 98US-089105P.
16-JUN-1998; 98US-089440P.
16-JUN-1998; 98US-089512P.
16-JUN-1998; 98US-089514P.
17-JUN-1998; 98US-089532P.
17-JUN-1998; 98US-089538P.
17-JUN-1998; 98US-089598P.
17-JUN-1998; 98US-089599P.
17-JUN-1998; 98US-089600P.
17-JUN-1998; 98US-089653P.
18-JUN-1998; 98US-089801P.
18-JUN-1998; 98US-089907P.
18-JUN-1998; 98US-089908P.
28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH LTD.

Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurley AL, Kijavini LJ, Napier MA, Pan J, Paoni NF;
Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WI;
Zhang Z;

WPI; 2003-102117/09.

Novel secreted and transmembrane polypeptide for modulating biological
activity of cell expressing the polypeptide, identifying agonists or
antagonists of polypeptide, and as molecular weight markers

Example 170; Page 294; 649pp; English.

The present invention relates to the isolation of novel human PRO

CC polypeptides, and the polynucleotide sequences encoding them. The
CC PRO polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for
CC linking bioactive molecules to cells expressing PRO polypeptides,
CC for modulating biological activities of cells expressing PRO
CC polypeptides, and for identifying agonists or antagonists.
CC The polynucleotide sequences encoding PRO polypeptides are useful as
CC hybridisation probes, in chromosome and gene mapping, in the generation
CC of antisense RNA and DNA, in the preparation of PRO polypeptides, for
CC generating transgenic animals or knockout animals, to construct
CC hybridisation probes for mapping the gene which encodes the PRO
CC polypeptide, and for the genetic analysis of individuals with genetic
CC disorders, in gene therapy, for chromosome identification, as
CC chromosome markers, and for generating probes for PCR, Northern
CC analysis, Southern analysis and Western analysis. The present sequence
CC represents a probe used in the examples of the present invention.
CC Note: The sequence data for this patent was obtained in electronic
CC format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsideentry.html.

XX
SQ Sequence 31 BP; 7 A; 15 C; 2 G; 7 T; 0 other;

Query Match 1.4%; Score 31; DB 25; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.00019;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1930 ACTCTCTGACCCACAGTCACCACTATCTC 1960
Db 1 ACTCTCTGACCCACAGTCACCACTATCTC 31

Search completed: February 6, 2004, 02:47:46
Job time : 591 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

W nucleic - nucleic search, using sw model

on on: February 5, 2004, 22:30:48 ; Search time 4163 Seconds
(without alignments)
12756.493 Million cell updates/sec

itle: US-09-989-279-228
affect score: 2185
equence: 1 gttcccttcgagccaaa.....aaagacaaaagtcaaaaca 2185

oring table: OLIGO_NUC
Gapex 60.0 , Gapext 60.0

arched: 22781392 seqs, 12152238056 residues

ord size : 10

otal number of hits satisfying chosen parameters: 29496677

imum DB seq length: 0
aximum DB seq length: 2000000000

ost-processing: Listing first 150 summaries

atabase :

EST:*

- 1: em_estba:*
- 2: em_esthum:*
- 3: em_estin:*
- 4: em_estmu:*
- 5: em_estov:*
- 6: em_estpl:*
- 7: em_estro:*
- 8: em_htc:*
- 9: gb_est1:*
- 10: gb_est2:*
- 11: gb_htc:*
- 12: gb_est3:*
- 13: gb_est4:*
- 14: gb_est5:*
- 15: em_estfun:*
- 16: em_estom:*
- 17: em_gas_hum:*
- 18: em_gas_inv:*
- 19: em_gas_pln:*
- 20: em_gas_vrt:*
- 21: em_gas_fun:*
- 22: em_gas_mam:*
- 23: em_gas_mus:*
- 24: em_gas_pro:*
- 25: em_gas_rod:*
- 26: em_gas_pbg:*
- 27: em_gas_vri:*
- 28: gb_ges1:*
- 29: gb_ges2:*

pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

result No.	Score	Query Match	Length	ID	Description
C 1	621	28.4	564	13	BQ185392
C 2	569	26.0	590	13	BQ185165
C 3	563	25.8	711	12	BM975435
C 4	540	24.7	540	13	BQ187977
					BQ185392 UI-E-EJ1-
					BQ185165 UI-E-EJ1-
					BM975435 UI-CF-EN1
					BQ187977 UI-E-EJ1-

806	9	AV709803	806	9	AV709803
504	13	EX114395	488	13	EX114395
478	9	AI769814	478	9	AI769814
540	13	BQ189063	462	13	BQ189063
447	9	AI435407	441	20.1	20.1
514	13	BQ184873	431	19.7	19.7
609	13	BQ340625	412	18.9	18.9
780	14	CA310827	395	18.1	18.1
509	13	BJ783069	387	17.7	17.7
504	13	BI866663	385	17.6	17.6
393	9	AI470931	385	17.6	17.6
389	13	BQ340622	327	15.0	15.0
424	10	AW954538	298	13.6	13.6
362	13	BQ340572	283	13.0	13.0
528	14	H23116	278	12.7	12.7
632	12	EM724722	261	11.9	11.9
470	14	TI5752	252	11.5	11.5
452	9	AI332304	241	11.0	11.0
428	14	R43906	235	10.8	10.8
468	12	BM975594	224	10.3	10.3
325	14	T33015	223	10.2	10.2
483	14	H23117	213	9.7	9.7
626	13	BQ741381	193	9.1	9.1
254	9	AA077185	193	8.8	8.8
346	14	TI6288	186	8.5	8.5
359	14	R71701	177	8.1	8.1
544	9	AW524479	175	8.0	8.0
224	10	BE150550	170	7.8	7.8
273	10	BF850808	165	7.6	7.6
336	9	AI845568	165	7.6	7.6
356	10	BB805784	165	7.6	7.6
485	14	CA890728	165	7.6	7.6
2833	11	AK046781	155	7.1	7.1
283	13	BQ368354	155	7.1	7.1
505	9	AI769160	151	6.9	6.9
150	9	AA224351	150	6.9	6.9
377	10	BF457723	138	6.3	6.3
300	13	BQ340624	134	6.1	6.1
283	9	AW521479	124	5.7	5.7
437	9	AI568859	122	5.6	5.6
286	10	BB081954	115	5.3	5.3
401	9	AI412486	114	5.2	5.2
271	11	BC012209	114	5.2	5.2
288	9	AA223802	102	4.7	4.7
279	10	BB332777	101	4.6	4.6
256	10	BB700307	99	4.5	4.5
410	9	AA716223	99	4.5	4.5
410	10	BB711172	99	4.5	4.5
398	10	BB676413	94	4.3	4.3
289	10	BB081928	89	4.1	4.1
440	10	BB009844	88	4.0	4.0
565	12	BM087368	85	3.9	3.9
881	12	BI736237	83	3.8	3.8
177	9	AA349536	81	3.7	3.7
358	13	BY373892	79	3.6	3.6
883	10	BF165865	76	3.5	3.5
405	13	BY627183	74	3.4	3.4
258	10	BB256521	69	3.2	3.2
293	10	BB333179	68	3.1	3.1
337	14	T27055	68	3.1	3.1
271	10	BB331347	66	3.0	3.0
290	10	BB333380	66	3.0	3.0
442	14	R19556	66	3.0	3.0
245	10	BB675411	64	2.9	2.9
287	10	BB307316	64	2.9	2.9
267	10	BB339903	63	2.9	2.9
282	10	BB333065	62	2.8	2.8
288	10	BB334107	62	2.8	2.8
275	10	BB331644	73	6.0	2.7
290	10	BB335857	74	6.0	2.7
470	12	BM964085	75	5.9	2.7
611	10	BB559884	59	2.7	2.7
249	10	BB338748	58	2.7	2.7

AV709803	AV709803
EX114395	EX114395
AI769814	wj28h10.x
BQ189063	UI-E-EJ1-
AI435407	th94b04.x
BQ184873	UI-E-EJ1-
BQ340625	PMO-NN025
CA310827	UI-CF-PN0
BJ783069	io39d05.x
BI866663	UI-E-EJ1-
AI470931	ti91c05.x
BQ340622	PMO-NN025
AW954538	EST366608
BQ340572	PMO-NN025
H23116	ym51g12.x
EM724722	UI-E-EJ0-
TI5752	IBI846
AI332304	qp97e09.x
R43906	Y926h05.sl
BM975594	UI-CF-EN1
T33015	EST56321
H23117	ym51g12.sl
BQ741381	UI-E-EJ0-
AA077185	7805E10.C
TI6288	NIB1062
R71701	y785c08.r1
AW524479	UI-R-B00-
BE150550	RC1-HT026
BF850808	CM3-EN011
AI845568	UI-M-AQ1-
BB805784	BB805784
CA890728	B0161B05-
AK046781	Mus muscu
BQ368354	PM3-GN050
AI769160	wg34f03.x
AA224351	2r12f12.s
BF457723	UI-M-B21-
BQ340624	PMO-NN025
AW521479	UI-R-B00-
AI568859	to23b10.x
BB081954	BB081954
AI412486	EST340785
BC012209	Mus muscu
AA223802	2r12f12.r
BB332777	BB332777
BB700307	BB700307
AA716223	2g60e07.s
BB711172	BB711172
BB676413	BB676413
BB081928	BB081928
BB009844	PM3-BN017
BM087368	500121.MA
BI736237	603359928
AA349536	EST56322
BY373892	BY373892
BF165865	601774896
BY627183	BY627183
BB256521	BB256521
BB333179	BB333179
T27055	NIBT224D05R
BB331347	BB331347
BB333380	BB333380
R19556	Y926h05.r1
BB675411	BB675411
BB307316	BB307316
BB339903	BB339903
BB333065	BB333065
BB334107	BB334107
BB331644	BB331644
BB335857	BB335857
BM964085	UI-M-EQ0-
BB559884	UI-M-AQ1-
BB338748	BB338748

78	57	2.6	254	13	BQ327069	RC4-CN020	BQ327069	RC4-CN020
79	57	2.6	283	10	BQ330087	BQ330087	BQ330087	
80	56	2.6	177	10	BQ384608	BQ384608	BQ384608	
81	56	2.6	190	10	BQ170044	BQ170044	BQ170044	
82	56	2.6	190	10	BQ330516	BQ330516	BQ330516	
83	56	2.6	245	10	BQ332977	BQ332977	BQ332977	
84	56	2.6	251	10	BQ547634	BQ547634	BQ547634	
85	56	2.6	256	10	BQ546457	BQ546457	BQ546457	
86	56	2.6	258	10	BQ374788	BQ374788	BQ374788	
87	56	2.6	261	10	BQ332867	BQ332867	BQ332867	
88	56	2.6	266	10	BQ332941	BQ332941	BQ332941	
89	56	2.6	268	10	BQ524048	BQ524048	BQ524048	
90	56	2.6	272	10	BQ331672	BQ331672	BQ331672	
91	56	2.6	273	10	BQ329081	BQ329081	BQ329081	
92	56	2.6	273	10	BQ339961	BQ339961	BQ339961	
93	56	2.6	274	10	BQ129082	BQ129082	BQ129082	
94	56	2.6	276	10	BQ332920	BQ332920	BQ332920	
95	56	2.6	277	10	BQ330616	BQ330616	BQ330616	
96	56	2.6	277	10	BQ526444	BQ526444	BQ526444	
97	56	2.6	278	10	BQ440461	BQ440461	BQ440461	
98	56	2.6	279	10	BQ329980	BQ329980	BQ329980	
99	56	2.6	279	10	BQ334018	BQ334018	BQ334018	
100	56	2.6	279	10	BQ334334	BQ334334	BQ334334	
101	56	2.6	280	10	BQ335811	BQ335811	BQ335811	
102	56	2.6	282	10	BQ333175	BQ333175	BQ333175	
103	56	2.6	284	10	BQ334104	BQ334104	BQ334104	
104	56	2.6	285	10	BQ346200	BQ346200	BQ346200	
105	56	2.6	291	10	BQ268633	BQ268633	BQ268633	
106	56	2.6	304	10	BQ257516	BQ257516	BQ257516	
107	56	2.6	308	10	BQ342834	BQ342834	BQ342834	
108	56	2.6	309	10	BQ285129	BQ285129	BQ285129	
109	56	2.6	439	10	BQ807460	BQ807460	BQ807460	
110	56	2.6	607	28	AZ339722	IM0071M13	AZ339722	IM0071M13
111	55	2.5	250	10	BQ330286	BQ330286	BQ330286	
112	55	2.5	438	13	BY359783	BY359783	BY359783	
113	54	2.5	213	10	BQ332842	BQ332842	BQ332842	
114	54	2.5	222	10	BQ328890	BQ328890	BQ328890	
115	54	2.5	227	10	BQ328985	BQ328985	BQ328985	
116	54	2.5	228	10	BQ328728	BQ328728	BQ328728	
117	54	2.5	237	10	BQ168889	BQ168889	BQ168889	
118	54	2.5	246	10	BQ331485	BQ331485	BQ331485	
119	54	2.5	258	10	BQ335764	BQ335764	BQ335764	
120	54	2.5	259	10	BQ336204	BQ336204	BQ336204	
121	54	2.5	261	10	BQ330405	BQ330405	BQ330405	
122	54	2.5	267	10	BQ335306	BQ335306	BQ335306	
123	54	2.5	270	10	BQ331474	BQ331474	BQ331474	
124	54	2.5	274	10	BQ334203	BQ334203	BQ334203	
125	54	2.5	285	10	BQ329831	BQ329831	BQ329831	
126	54	2.5	298	10	BQ330061	BQ330061	BQ330061	
127	54	2.5	316	10	BQ332387	BQ332387	BQ332387	
128	53	2.4	250	10	BQ287841	BQ287841	BQ287841	
129	53	2.4	268	10	BQ528945	BQ528945	BQ528945	
130	52	2.4	241	10	BQ169976	BQ169976	BQ169976	
131	52	2.4	250	10	BQ333010	BQ333010	BQ333010	
132	52	2.4	295	10	BQ332927	BQ332927	BQ332927	
133	52	2.4	427	10	BQ647479	UI-M-BH1-	BQ647479	UI-M-BH1-
134	51	2.3	279	10	BQ333931	BQ333931	BQ333931	
135	51	2.3	287	10	BQ334056	BQ334056	BQ334056	
136	51	2.3	306	10	BQ333136	BQ333136	BQ333136	
137	51	2.3	317	10	BQ269855	BQ269855	BQ269855	
138	50	2.3	279	10	BQ331665	BQ331665	BQ331665	
139	50	2.3	286	10	BQ334084	BQ334084	BQ334084	
140	48	2.2	288	10	BQ336444	BQ336444	BQ336444	
141	48	2.2	487	29	BQ229666	CH230-272	BQ229666	CH230-272
142	47	2.2	287	10	BQ330035	BQ330035	BQ330035	
143	47	2.2	395	10	BQ286666	ST451257	BQ286666	ST451257
144	46	2.1	255	10	BQ355765	BQ355765	BQ355765	
145	46	2.1	257	10	BQ333688	BQ333688	BQ333688	
146	46	2.1	281	10	BQ330892	BQ330892	BQ330892	
147	45	2.1	266	10	BQ331119	BQ331119	BQ331119	
148	45	2.1	290	10	BQ330450	BQ330450	BQ330450	
149	45	2.1	290	10	BQ335154	BQ335154	BQ335154	
150	42	1.9	267	10	BQ336098	BQ336098	BQ336098	

ALIGNMENTS

RESULT 1

BQ185392 664 bp mRNA linear EST 30-APR-2002
 UI-E-EJ1-aju-f-24-0-UI.s1 UI-E-EJ1 Homo sapiens cDNA clone
 UI-E-EJ1-aju-f-24-0-UI 3', mRNA sequence.
 BQ185392.1 GI:20360943
 EST.
 BQ185392.1 GI:20360943
 EST.
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (Bases 1 to 664)
 Bonaldo,M.F., Lennon,G. and Soares,M.B.
 Normalization and subtraction: two approaches to facilitate gene
 discovery
 Genome Res. 6 (9), 791-806 (1996)
 97044477
 8889548
 Contact: Soares, MB
 Coordinated Laboratory for Computational Genomics
 University of Iowa
 375 Newton Road , 4156 MEBRF, Iowa City, IA 52242, USA
 Tel: 319 335 8250
 Fax: 319 335 9565
 Email: bento-soares@uiowa.edu
 Tissue Procurement: Dr. Gregg Hageman
 cDNA Library Preparation: Dr. M. Bento Soares, University of Iowa
 cDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
 DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
 Clone Distribution: Researchers may obtain clones from Research
 Genetics (www.resgen.com).
 The following repetitive elements were found in this cDNA
 sequence: 1-72, >POLY_A#Simple_repeat (matched complement) 399-429,
 >(CAG)n#Simple_repeat (matched complement)
 Seq primer: M13 FORWARD
 POLYA=Yes.

Location/Qualifiers
 1. 664
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clones="UI-E-EJ1-aju-f-24-0-UI"
 /tissue_type="fetal eyes, lens, eye anterior segment,
 optic nerve, retina, Retina Foveal and Macular, RPE and
 Choroid"
 /dev_stage="fetal and adult"
 /lab_host="DH10B (Life Technologies) (T1 phage resistant)"
 /clone_lib="UI-E-EJ1"
 /note="Organ: eye; Vector: pTT3-Pac (Pharmacia) with a
 modified polylinker; Site 1: EcoR I; Site 2: Not I;
 UI-E-EJ1 is a subtracted cDNA library constructed
 according to Bonaldo, Lennon and Soares, Genome Research,
 6:791-806, 1996. First strand cDNA synthesis was primed
 with an oligo-dT primer containing a Not I site. Double
 stranded cDNA was ligated to an EcoR I adaptor, digested
 with Not I, and cloned directionally into pTT3-Pac
 vector. The oligonucleotide used to prime the synthesis of
 first-strand cDNA contains a library tag sequence that is
 located between the Not I site and the (dT)18 tail. The
 sequence tags for this library are: fetal eyes, AGAATCCAGA
 ; lens, CGATACCGCA; eye anterior segment, AATGCCGAT;
 optic nerve, CCATTAGTG; retina, CCGCG; Retina Foveal and
 Macular, GTCC; RPE and Choroid, CCTCA. This library was
 created for the program, Gene Discovery in the Visual
 System, supported by National Eye Institute (NEI).
 TAG LIB=UI-E-EJ1
 TAG_TISSUE=Foveal and Macular Retina

FEATURES

source

```

BASE COUNT      134 a      136 c      162 g      232 t
ORIGIN
Query Match      28.4%; Score 621; DB 13; Length 664;
Best Local Similarity 100.0%; Pred. No. 1.9e-294; Mismatches 0; Indels 0; Gaps 0;
Matches 621; Conservative 0;

1565 GGTGGCAGTACCCGCGACAGACACCACTGACAGATGCGACAGCAGCTGATGAAGTCAT 1624
1647 GGTGGCAGTACCCGCGACAGACACCACTGACAGATGCGACAGCAGCTGATGAAGTCAT 588
1625 GAAGACACCAAGATCATCTGCTGCTTGTGGCAGTACTCTGCTAGCTCCGCCAT 1684
1687 GAAGACACCAAGATCATCTGCTGCTTGTGGCAGTACTCTGCTAGCTCCGCCAT 528
1685 GTTCATTTGTTCTTATATAAATTCCTAGAGCGGCGACAGCAGCGAGTACAGTCACAGCCG 1744
1627 GTTCATTTGTTCTTATATAAATTCCTAGAGCGGCGACAGCAGCGAGTACAGTCACAGCCG 468
1745 CCGGACTGTTGAGATTAATCCAGGTTGAGAGACATCCAGAGCGACCAATCCGCGACGAGC 1804
1667 CCGGACTGTTGAGATTAATCCAGGTTGAGAGACATCCAGAGCGACCAATCCGCGACGAGC 408
1805 AACGAGAGCTCCGTCGCTGATCAGCTGAGGCGGCGAGTACTGCTGCCACATTCATGA 1864
1607 AACGAGAGCTCCGTCGCTGATCAGCTGAGGCGGCGAGTACTGCTGCCACATTCATGA 348
1865 CCATATTAATACACCACTTACAAACAGACATGCGGCGGCGACATGCGACAGAAACAGCTT 1924
1647 CCATATTAATACACCACTTACAAACAGACATGCGGCGGCGACATGCGACAGAAACAGCTT 288
1825 GGGGAACTCTGCAACCCAGCAGTACACATCTCTGAACCTTATATATTCAGACGCCA 1984
1627 GGGGAACTCTGCAACCCAGCAGTACACATCTCTGAACCTTATATATTCAGACGCCA 228
1885 TACCAAGCAAGAGTACAGGAACTCAATATGACTCCCTCCGCCCAAAATTTATAA 2044
1627 TACCAAGCAAGAGTACAGGAACTCAATATGACTCCCTCCGCCCAAAATTTATAA 168
1645 ATGCAATAGATGACACAAAGACAGAACTTTGTACAGAGTGGGAGAGATTTTCT 2104
167 ATGCAATAGATGACACAAAGACAGAACTTTGTACAGAGTGGGAGAGATTTTCT 108
1605 TGTATATGCTTATATATTAAGTCTATGCTGCTTAAATTAATTAATTAATTAATTAAT 2164
1607 TGTATATGCTTATATATTAAGTCTATGCTGCTTAAATTAATTAATTAATTAATTAAT 48
1615 TAAAGACAAAAGTCAAAACA 2185
1617 TAAAGACAAAAGTCAAAACA 27

RESULT 2
90185165/c
JOCUS
DEFINITION
UI-E-EJ1-aju-e-03-0-UI.s1 UI-E-EJ1 Homo sapiens cDNA clone
UI-E-EJ1-aju-e-03-0-UI 3', mRNA sequence.
ACCESSION
B0185165
VERSION
B0185165.1 GI:20360716
KEYWORDS
EST.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 590)
Bonaldo, M.F., Lennon, G. and Soares, M.B.
Normalization and subtraction: two approaches to facilitate gene
discovery
JOURNAL
MEDLINE
PUBMED
8889548
Contact: Soares, MB

```

```

Coordinated Laboratory for Computational Genomics
University of Iowa
375 Newton Road, 4156 MEBRE, Iowa City, IA 52242, USA
Tel: 319 335 8250
Fax: 319 335 9565
Email: bentto-soares@uiowa.edu
Tissue Procurement: Dr. Gregg Hageman
cDNA Library preparation: Dr. M. Bento Soares, University of Iowa
cDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
Clone Distribution: Researchers may obtain clones from Research
Genetics (www.resgen.com).
The following repetitive elements were found in this cDNA
sequence: 385-415, >(CAG)n#Simple_repeat (matched complement)
Seq primer: M13 FORWARD
POLYA=Yes.
Location/Qualifiers
1. 590
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="UI-E-EJ1-aju-e-03-0-UI"
/tissue_type="fetal eyes, lens, eye anterior segment,
optic nerve, retina, Retina Foveal and Macular, RPE and
Choroid"
/dev_stage="fetal and adult"
/lab_hosts="DH10B (Life Technologies) (T1 phage resistant)"
/clone_lib="UI-E-EJ1"
/notes="Organ: eye; Vector: pF73-Pac (Pharmacia) with a
modified polylinker; Site 1: EcoR I; Site 2: Not I;
UI-E-EJ1 is a subtracted cDNA library constructed
according to Bonaldo, Lennon and Soares, Genome Research,
6:791-806, 1996. First strand cDNA synthesis was primed
with an oligo-dT primer containing a Not I site. Double
stranded cDNA was ligated to an EcoR I adaptor, digested
with Not I, and cloned directionally into pF73-Pac
vector. The oligonucleotide used to prime the synthesis of
first-strand cDNA contains a library tag sequence that is
located between the Not I site and the (dT)18 tail. The
sequence tags for this library are: fetal eyes, AGAATCAAGA
; lens, CGATTAGCGA; eye anterior segment, AATGCCGAT;
optic nerve, CCATTAGTG; retina, CCGG; Retina Foveal and
Macular, GTCC; RPE and Choroid, ACCTA. This library was
created for the program, Gene Discovery in the Visual
System, supported by National Eye Institute (NEI).
TAG LIB=UI-E-EJ1
TAG_TISSUE=human retina
TAG_SEQ=CCGCG"
BASE COUNT      123 a      121 c      144 g      202 t
ORIGIN
Query Match      26.0%; Score 569; DB 13; Length 590;
Best Local Similarity 100.0%; Pred. No. 8e-269;
Matches 569; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1617 GAATCTATGAGACCAACAGATCATCTTGGTCTTGTGGCAGTACTCTGCTAGCT 1676
DB      581 GAATCTATGAGACCAACAGATCATCTTGGTCTTGTGGCAGTACTCTGCTAGCT 522
QY      1677 GCCGCCATGTTGATTTGTTCTTATAAACTTCGTAAGCGGACCCAGCAGCGGAGTACAGTC 1736
DB      521 GCCGCCATGTTGATTTGTTCTTATAAACTTCGTAAGCGGACCCAGCAGCGGAGTACAGTC 462
QY      1737 ACAGCGCCCGGACTGTTGATGATTAATCAGGTGAGCAAGACATCCCGCAGCAACATCC 1796
DB      461 ACAGCGCCCGGACTGTTGATGATTAATCAGGTGAGCAAGACATCCCGCAGCAACATCC 402
QY      1797 GCAGCAGCAACAGCAGCTCCGTCGCTGCTGATTCAGGTGAGGGGCGAGTACTGCTGCCACA 1856
DB      401 GCAGCAGCAACAGCAGCTCCGTCGCTGCTGATTCAGGTGAGGGGCGAGTACTGCTGCCACA 342
QY      1857 ATTATGACCATATTAATTAACCAACCTTACAAACAGCATGCGGCCCTCTGACAGAA 1916

```

FEATURES
source


```

>SUT 4
>187977
>XUS
>FINITION
>CESSION
>RSION
>WORDS
>URCE
>ORGANISM
>REFERENCE
>AUTHORS
>TITLE
>JOURNAL
>MEDLINE
>PUBMED
>MENT

BQ187977 540 bp mRNA linear EST 30-APR-2002
UI-E-EJ1-aju-e-03-0-UI.r1 UI-E-EJ1 Homo sapiens cDNA clone
UI-E-EJ1-aju-e-03-0-UI 5', mRNA sequence.
BQ187977 1 GI:20363528
EST.
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 540)
Bonaldo, M.F., Lennon, G. and Soares, M.B.
Normalization and subtraction: two approaches to facilitate gene
discovery
Genome Res. 6 (9), 791-806 (1996)
97044477
889548
Contact: Soares, MB
Coordinated Laboratory for Computational Genomics
University of Iowa
375 Newton Road, 4156 MBRRF, Iowa City, IA 52242, USA
Tel: 319 335 8250
Fax: 319 335 9565
Email: bento-soares@uiowa.edu
Tissue Procurement: Dr. Gregg Hageman
cDNA Library preparation: Dr. M. Bento Soares, University of Iowa
cDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
Clone Distribution: Researchers may obtain clones from Research
Genetics (www.resgen.com).
The following repetitive elements were found in this cDNA
sequence: 167-197, (CAG)n#simple_repeat
Seq primer: M13 REVERSE.
Location/Qualifiers
1..540
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="UI-E-EJ1-aju-e-03-0-UI"
/tissue_type="fetal eyes, lens, eye anterior segment,
optic nerve, retina, Retina Foveal and Macular, RPE and
Choroid"
/dev_stage="fetal and adult"
/lab_host="DH10B (Life Technologies) (T1 phage resistant)"
/clone_lib="UI-E-EJ1"
/note="Organ: eye; Vector: pT7T3-Pac (Pharmacia) with a
modified polylinker; Site_1: EcoR I; Site_2: Not I;
UI-E-EJ1 is a subtracted cDNA library constructed
according to Bonaldo, Lennon and Soares, Genome Research,
6:791-806, 1996. First strand cDNA synthesis was primed
with an oligo-dT primer containing a Not I site. Double
stranded cDNA was ligated to an EcoR I adaptor, digested
with Not I, and cloned directionally into pT7T3-Pac
vector. The oligonucleotide used to prime the synthesis of
first-strand cDNA contains a library tag sequence that is
located between the Not I site and the (dT)18 tail. The
sequence tags for this library are: fetal eyes, AGAATCAAGA
; lens, CGATTAGCGA; eye anterior segment, AATGGCGCAT;
optic nerve, CCAATTAAGT; retina, CCGCG; Retina Foveal and
Macular, GTCC; RPE and Choroid, ACCTA. This library was
created for the program, Gene Discovery in the Visual
System, supported by National Eye Institute (NEI)."
```

Query Match 24.7%; Score 540; DB 13; Length 540;

Best Local Similarity 100.0%; Pred. No. 1.6e-254; Gaps 0;

Matches 540; Conservative 0; Mismatches 0; Indels 0;

1617 GAAGTCATGAAGACCAACCAAGATCATATGCTCTTTGGCGAGTCACTCTGCTAGCT 1676

```

Db 1 GAAGTCATGAAGACCAACCAAGATCATATGCTCTTTGGCGAGTCACTCTGCTAGCT 60
QY 1677 GCAGCCATGTTGATGTTCTTCTATTAACCTTCGTAAGCGGCACACGAGCGGAGTACAGTC 1736
Db 61 GCAGCCATGTTGATGTTCTTCTATTAACCTTCGTAAGCGGCACACGAGCGGAGTACAGTC 120
QY 1737 ACAGCCGCCCGGACTGTTGAGATTAATCCAGTGGACGAAGACATCCCGAGCAGCAATCC 1796
Db 121 ACAGCCGCCCGGACTGTTGAGATTAATCCAGTGGACGAAGACATCCCGAGCAGCAATCC 180
QY 1797 GCAGCAGCAACAGCAGCTCCCTCCGGTGTATCAGTGAAGGGGCGAGTAGTCTGCCACA 1856
Db 181 GCAGCAGCAACAGCAGCTCCCTCCGGTGTATCAGTGAAGGGGCGAGTAGTCTGCCACA 240
QY 1857 ATTCATGACCACTATTAACTCAACACCTTACAAACAGCAGCATGGGGCCCACTGGACGAA 1916
Db 241 ATTCATGACCACTATTAACTCAACACCTTACAAACAGCAGCATGGGGCCCACTGGACGAA 300
QY 1917 AACAGCCTGGGAACTCTTCGACCCCAACAGTCACCACTACTCTCTGAACCTTATATTA 1976
Db 301 AACAGCCTGGGAACTCTTCGACCCCAACAGTCACCACTACTCTCTGAACCTTATATTA 360
QY 1977 CAGACCCATACCAAGGACAGGTACAGGAACCTCAAAATATGACTCCCTCCCGCCAAAAA 2036
Db 361 CAGACCCATACCAAGGACAGGTACAGGAACCTCAAAATATGACTCCCTCCCGCCAAAAA 420
QY 2037 CTTATAAAATGCAATAGATGACACACAAAGACAGCAACTTTTGTACAGGTGGGAGAGA 2096
Db 421 CTTATAAAATGCAATAGATGACACACAAAGACAGCAACTTTTGTACAGGTGGGAGAGA 480
QY 2097 CTTTCTCTGTATATGCTTATATATTAACTGCTATGCTGTTTAAAAAACAAGATTATA 2156
Db 481 CTTTCTCTGTATATGCTTATATATTAACTGCTATGCTGTTTAAAAAACAAGATTATA 540
```

RESULT 5

AV709803 806 bp mRNA linear EST 09-OCT-2000
 AV709803 ADC Homo sapiens cDNA clone ADCAPC04 5', mRNA sequence.

AV709803
 AV709803.1 GI:10727827

EST.

KEYWORDS
 Homo sapiens (human)

SOURCE
 ORGANISM

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 806)

Peng, Y., Song, H., Huang, Q., Huang, C., Gu, Y., Yang, Y., Gao, G., Xiao

, H., Xu, X., Li, N., Qian, B., Liu, F., Qu, J., Gao, X., Cheng, Z., Xu, Z.,

Zeng, L., Xu, S., Gu, W., Tu, Y., Jia, J., Fu, G., Ren, S., Zhong, M., Lu

G., Hu, R., Chen, J. Chen, Z. and Han, Z.

Homo sapiens cDNA ADC clones

Unpublished

Contact: Zeguang Han

Chinese National Human Genome Center at Shanghai

351 Guo Shoujing Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai

201203, P. R. China

Tel: 86-21-50801919 (ex.45)

Fax: 86-21-50801922

Email: hanzg@chgc.sh.cn

This clone is available at CHGC in Shanghai.

Location/Qualifiers

1..806

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="ADCAPC04"

/tissue_type="Adrenal gland"

/dev_stage="Adult"

/lab_host="SOLR"

/clone_lib="ADC"

/note="Vector: pBluescript sk(-); Site_1: EcoRI; Site_2:

XhoI"

FEATURES

source

BASE COUNT 158 a 243 c 210 g 195 t
ORIGIN
Query Match 23.5%; Score 513; DB 9; Length 806;
Best Local Similarity 100.0%; Pred. No. 3.2e-241;
Matches 513; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Y 500 GCTCGGGAGCTCTGGCTTGGCAACACCCATCGAAAGCATCCCTCTTAGCCCTTCAA 559
X 1 GCTCGGGAGCTCTGGCTTGGCAACACCCATCGAAAGCATCCCTCTTAGCCCTTCAA 50
Y 560 CCGGCTGCTCCCTCATGTGGCTTGGAGCTCAAGATCTCAAGAGCTGAGATATCTC 619
X 61 CCGGCTGCTCCCTCATGTGGCTTGGAGCTCAAGATCTCAAGAGCTGAGATATCTC 120
Y 620 TGAGGAGCTTTTGAAGGCTTCAACCTCAAGTATCTGAATCTGGGCTATGGCAAT 679
X 121 TGAGGAGCTTTTGAAGGCTTCAACCTCAAGTATCTGAATCTGGGCTATGGCAAT 180
Y 680 TAAAGACATGCCCAATCTCAACCTTGGTGGGCTGGAGAGCTGAGATCTCAAGGAA 739
X 181 TAAAGACATGCCCAATCTCAACCTTGGTGGGCTGGAGAGCTGAGATCTCAAGGAA 240
Y 740 CCACCTCCCTGAGATCAGGCTGGCTTCCATGGCTGAGCTCCCTCAAGAGCTCTG 799
X 241 CCACCTCCCTGAGATCAGGCTGGCTTCCATGGCTGAGCTCCCTCAAGAGCTCTG 300
Y 800 GGTATGAACTCAGAGTCAAGCTGATTTGAGCGAATGCTTTTACGGGCTGGCTTCACT 859
X 301 GGTATGAACTCAGAGTCAAGCTGATTTGAGCGAATGCTTTTACGGGCTGGCTTCACT 360
Y 860 TGTGAACCTCAACTTGGCCCAATTAACCTCTCTTTTGGCCCATGACCTTTTACCCC 919
X 361 TGTGAACCTCAACTTGGCCCAATTAACCTCTCTTTTGGCCCATGACCTTTTACCCC 420
Y 920 GGTGAGTACCTGAGTGGCTTACACCAACCTTGGAGCTGATTTGAGCTGATTTGACAT 979
X 421 GGTGAGTACCTGAGTGGCTTACACCAACCTTGGAGCTGATTTGAGCTGATTTGACAT 480
Y 980 TCTGTGGCTAGCTGCTGGCTTGGAGTATAT 1012
X 481 TCTGTGGCTAGCTGCTGGCTTGGAGTATAT 513

RESULT 6
BX114395/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
BX114395 504 bp mRNA linear EST 07-FEB-2003
IMAGp998H10156; IMAGE:33723, mRNA sequence.
BX114395 GI:27838770
EST.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 504)
Ebert, L., Heil, O., Hennig, S., Neubert, P., Partsch, E., Peters, M.,
Radelof, U., Schneider, D. and Korn, B.
Human Unigeneset - RZPD3
Unpublished
Contact: Ina Rols
RZPD Deutsches Ressourcenzentrum fuer Genomforschung GmbH
Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany
RZPD; IMAGp998H10156
RZPDLib; I.M.A.G.E. cDNA Clone Collection;
Human Unigeneset - RZPD3 (RZPDLib No.972)
http://www.rzpd.de/CloneCards/cgi-bin/showLib.pl.cgi/response?libNo=972
RZPD Deutsches Ressourcenzentrum fuer Genomforschung GmbH
Heubnerweg 6, D-14059 Berlin, Germany
Tel: +49 30 32639 101
Fax: +49 30 32639 111

www.rzpd.de
This clone is available royalty-free from RZPD;
contact RZPD (clone@rzpd.de) for further information. Seq primer:
M13u, Primer sequence: CGTTGTAAACGACGCCAGT.
Location/Qualifiers
1. 504
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGp998H10156; IMAGE:33723"
/sex="female"
/dev_stage="73 days post natal"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares infant brain INIB"
/note="Organ: whole brain; Vector: Lfamid BA; Site 1: Not
I; Site 2: Hind III; 1st strand cDNA was primed with a Not
I - oligo(dT) primer 15'
R - oligo(dT) primer 3';
double-stranded cDNA was ligated to Hind III adaptors
(Pharmacia), digested with Not I and directionally cloned
into the Not I and Hind III sites of the Lfamid BA vector.
Library went through one round of normalization. Library
constructed by Bento Soares and M.Fatima Bonaide."
BASE COUNT 101 a 97 c 123 g 183 t
ORIGIN
Query Match 22.3%; Score 488; DB 13; Length 504;
Best Local Similarity 100.0%; Pred. No. 6.7e-229;
Matches 488; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Y 1695 TTCTATAAATTCGTAGCGGCACACGAGCGAGTACAGTCACAGCGCCCGGACTGTT 1754
X 504 TTCTATAAATTCGTAGCGGCACACGAGCGAGTACAGTCACAGCGCCCGGACTGTT 445
Y 1755 GAGTAAATCCAGGTGGAGCAAGACATCCAGCAGCAATCCGAGCAGCAGCAGCT 1814
X 444 GAGTAAATCCAGGTGGAGCAAGACATCCAGCAGCAATCCGAGCAGCAGCAGCT 385
Y 1815 CGTCCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCCAATTCATGACCATATTAAAC 1874
X 384 CGTCCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCCAATTCATGACCATATTAAAC 325
Y 1875 TACAACACTTACAACACGACATGGGGCCCATCTGGAGCAGAAACAGCCTGGGAACTCT 1934
X 324 TACAACACTTACAACACGACATGGGGCCCATCTGGAGCAGAAACAGCCTGGGAACTCT 265
Y 1935 CTGACCCCGCAGTCAACCATCTCTTGAACCTTATATATTTCAGACCCATACCAAGGAC 1994
X 264 CTGACCCCGCAGTCAACCATCTCTTGAACCTTATATATTTCAGACCCATACCAAGGAC 205
Y 1995 AAGGTACAGGAAACTCAAATATGACTCCCTCCCGCCCAAAACCTTATAAATGCAATAGA 2054
X 204 AAGGTACAGGAAACTCAAATATGACTCCCTCCCGCCCAAAACCTTATAAATGCAATAGA 145
Y 2055 ATGCACACAAAGACAGCAACTTTTGTACAGAGTGGGAGAGACTTTTCTGTATATGCT 2114
X 144 ATGCACACAAAGACAGCAACTTTTGTACAGAGTGGGAGAGACTTTTCTGTATATGCT 85
Y 2115 TATATATTAAAGTCTATGGCTGGTGTAAATAAAGACAGATTTATTTAAATTTAAAGACAAA 2174
X 84 TATATATTAAAGTCTATGGCTGGTGTAAATAAAGACAGATTTATTTAAATTTAAAGACAAA 25
Y 2175 AAGTCAAA 2182
X 24 AAGTCAAA 17

RESULT 7
AT769814/c
LOCUS
DEFINITION
ACCESSION
AT769814 478 bp mRNA linear EST 21-DEC-1999
WJ26H10.X1 NCI_CGAP_Kid12 Homo sapiens cDNA clone IMAGE:2404003 3',
mRNA sequence.
AT769814

```

VERSION
EYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

A1769814.1 GI:5236323
EST.
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 478)
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished
Contact: Robert Strausberg, Ph.D.
Email: cgaps@mail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: M. Bento Soares, Ph.D.
DNA Sequencing by: Greg Lennon, Ph.D.
Clone Distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bbrp/image/image.html
Insert length: 629 Std Error: 0.00
Seq primer: -400P from Gibco
High quality sequence stop: 462.
Location/Qualifiers
1..478
/organism="Homo sapiens"
/mol_type="cDNA"
/db_xref="taxon:9606"
/clone="IMAGE:2404003"
/tissue_type="2 pooled tumors (clear cell type)"
/lab_host="DH108"
/clone_lib="NCI CGAP Kid12"
/notes="Organ: kidney; Vector: p7773-Pac (Pharmacia) with
a modified polylinker; Site 1: Not 1; Site 2: Eco RI;
Plasmid DNA from the normalized library NCI-CGAP Kid5 was
prepared, and ss circles were made in vitro. Following HAP
purification, this DNA was used as tracer in a subtractive
hybridization reaction. The driver was PCR-amplified cDNAs
from a pool of 5,000 clones made from the same library
(cloneIDs 1323912-1325831, 1471368-1472903 and
1492104-1493255). Subtraction by Bento Soares and M.
Patima Bonaldo."
ASE COUNT 97 a 96 c 121 g 164 t
RIGIN

Query Match 21.9%; Score 478; DB 9; Length 478;
Best Local Similarity 100.0%; Pred. No. 5.7e-224;
Matches 478; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 1703 ACTTGTAAGCGGACAGCAGCGGAGTACAGTCACAGCGCGCCCGGACTGTTGAGATAAT 1762
|
|
|
b 478 ACTTGTAAGCGGACAGCAGCGGAGTACAGTCACAGCGCGCCCGGACTGTTGAGATAAT 419
|
|
|
Y 1763 CCAGGTGGAGAGACATCCAGCAGCAGCATCCGAGCAGCAACAGCAGCTCCGTCGG 1822
|
|
|
b 418 CCAGGTGGAGAGACATCCAGCAGCAGCATCCGAGCAGCAACAGCAGCTCCGTCGG 359
|
|
|
Y 1823 TGTATCAGGTGAGGGGCGAGTGTGCGCCACATTCATGACCATTAATTAACACAC 1882
|
|
|
b 358 TGTATCAGGTGAGGGGCGAGTGTGCGCCACATTCATGACCATTAATTAACACAC 299
|
|
|
Y 1883 CTACAAACAGCAGCAGTGGGCGCCACTGGACAGAAACAGCAGTGGGGAATCTCTGCAACC 1942
|
|
|
b 298 CTACAAACAGCAGCAGTGGGCGCCACTGGACAGAAACAGCAGTGGGGAATCTCTGCAACC 239
|
|
|
Y 1943 CACAGTCACCACTATCTCTGAACCTTATATTAATTCAGACCCATACCAAGCAGCAAGTACA 2002
|
|
|
b 238 CACAGTCACCACTATCTCTGAACCTTATATTAATTCAGACCCATACCAAGCAGCAAGTACA 179
|
|
|
Y 2003 GGAACTCAATATGATCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCT 2062
|
|
|
b 178 GGAACTCAATATGATCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCT 119
|
|
|

Cy 2063 AAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTTTCTTGATATGCTTATATTT 2122
|
|
|
Db 118 AAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTTTCTTGATATGCTTATATTT 59
|
|
|
Cy 2123 AAGCTCTATGGCTGGTTAAATAAAACAGATTTATTTAAATTTAAAGACAAAAGTCA 2180
|
|
|
Db 58 AAGCTCTATGGCTGGTTAAATAAAACAGATTTATTTAAATTTAAAGACAAAAGTCA 1
|
|
|

RESULT 8
BQ189063
LOCUS
DEFINITION
BQ189063 540 bp mRNA linear EST 30-APR-2002
UI-E-EJI-aju-f-24-0-UI.r1 UI-E-EJI Homo sapiens cDNA clone
UI-E-EJI-aju-f-24-0-UI.5', mRNA sequence.
BQ189063.1 GI:20364614
VERSION
BQ189063 Homo sapiens (human)
KEYWORDS
EST.
SOURCE
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 540)
Bonaldo,M.F., Lennon,G. and Soares,M.B.
Normalizaton and subtraction: two approaches to facilitate gene
discovery
Genome Res. 6 (9), 791-806 (1996)
97044477
8889548
Contact: Soares, MB
Coordinated Laboratory for Computational Genomics
University of Iowa
375 Newton Road, 4156 MEBRF, Iowa City, IA 52242, USA
Tel: 319 335 8250
Fax: 319 335 9565
Email: bento-soares@uiowa.edu
Tissue Procurement: Dr. Gregg Hageman
cDNA Library preparation: Dr. M. Bento Soares, University of Iowa
cDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
Clone Distribution: Researchers may obtain clones from Research
Genetics (www.resgen.com).
The following repetitive elements were found in this cDNA
sequence: 218-248, >(CAG)n#simple_repeat
Seq primer: M13 REVERSE.
Location/Qualifiers
1..540
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="UI-E-EJI-aju-f-24-0-UI"
/tissue_type="fetal eyes, lens, eye anterior segment,
optic nerve, retina, Retina Foveal and Macular, RPE and
Choroid"
/dev_stage="fetal and adult"
/lab_host="DH108 (Life Technologies) (T1 phage resistant)"
/clone_lib="UI-E-EJI"
/notes="Organ: eye; Vector: p7773-Pac (Pharmacia) with a
modified polylinker; Site 1: EcoR I; Site 2: Not I;
UI-E-EJI is a subtracted cDNA library constructed
according to Bonaldo, Lennon and Soares, Genome Research,
6:791-806, 1996. First strand cDNA synthesis was primed
with an oligo-dT primer containing a Not I site. Double
stranded cDNA was ligated to an EcoR I adaptor, digested
with Not I, and cloned directionally into p7773-Pac
vector. The oligonucleotide used to prime the synthesis of
first-strand cDNA contains a library tag sequence that is
located between the Not I site and the (dT)18 tail. The
sequence tags for this library are: fetal eyes, AGAATCAAGA
; lens, CGATTAGCGA; eye anterior segment, AATGCCCAT;
optic nerve, CCATTAGTGT; retina, CCGCG; Retina Foveal and
Macular, GTCC; RPE and Choroid, ACCTA. This library was
created for the program, Gene Discovery in the Visual

```


AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
COMMENT

Bonaldo,M.F., Lennon,G. and Soares,M.B.
 Normalization and subtraction: two approaches to facilitate gene
 discovery
 Genome Res. 6 (9), 791-806 (1996)
 97044477
 8889548
 Contact: Soares, MB
 Coordinated Laboratory for Computational Genomics
 University of Iowa
 375 Newton Road, 4156 MEBRF, Iowa City, IA 52242, USA
 Tel: 319 335 8250
 Fax: 319 335 9565
 Email: bento-soares@uiowa.edu
 Tissue Procurement: Dr. Gregg Hageman
 CDNA Library Preparation: Dr. M. Bento Soares, University of Iowa
 CDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
 DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
 Clone Distribution: Researchers may obtain clones from Research
 Genetics (www.resgen.com).
 The following repetitive elements were found in this cDNA
 sequence: 376-406 >(CAG)n#Simple_repeat (matched complement)
 Seq primer: M13 FORWARD
 POLYA=No.

FEATURES
 source

1..514
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="UI-E-EJ1-ajr-d-10-0-UI"
 /tissue_type="fetal eyes, lens, eye anterior segment,
 optic nerve, retina, Retina Foveal and Macular, RPE and
 Choroid"
 /dev_stage="fetal and adult"
 /lab_host="DH10B (Life Technologies) (T1 phage resistant)"
 /clone_lib="UI-E-EJ1"
 /notes="Organ: eye; Vector: p773-Pac (Pharmacia) with a
 modified polylinker; Site 1: EcoR I; Site 2: Not I;
 UI-E-EJ1 is a subtracted cDNA library constructed
 according to Bonaldo, Lennon and Soares, Genome Research,
 6:791-806, 1996. First strand cDNA synthesis was primed
 with an oligo-dT primer containing a Not I site. Double
 stranded cDNA was ligated to an EcoR I adaptor, digested
 with Not I, and cloned directionally into p773-Pac
 vector. The oligonucleotide used to prime the synthesis of
 first-strand cDNA contains a library tag sequence that is
 located between the Not I site and the (dT)18 tail. The
 sequence tags for this library are: fetal eyes, AGAATCAAGA
 ; lens, CGATTAGCGA; eye anterior segment, AATCGCGCAT;
 optic nerve, CCAATAGTG; retina, CCGCG; Retina Foveal and
 Macular, GTCC; RPE and Choroid, ACCTA. This library was
 created for the program, Gene Discovery in the Visual
 System, supported by National Eye Institute (NEI).
 TAG LIB=UI-E-EJ1
 TAG TISSUE=human fetal eyes
 TAG SEQ=AGAATCAAGA"
 BASE COUNT 110 a 104 c 125 g 175 t
 RIGIN

Query Match
 Best Local Similarity 99.8%; Pred. No. 8.4e-201;
 Matches 481; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1702 AACTTCGTAGCGGACACAGCGGAGTACATCCAGCGCCCGGAGTGTGAGTAA 1761
 487 AACTTCGTAGCGGACACAGCGGAGTACATCCAGCGCCCGGAGTGTGAGTAA 428
 1762 TCCAGGTGGAGAGACATCCAGCGACCAATCCGAGCAGCAACAGCAGCTCCGTCG 1821
 427 TCCAGGTGGAGAGACATCCAGCGACCAATCCGAGCAGCAACAGCAGCTCCGTCG 368
 1822 GTGTATCAGGTGAGGGGCGAGTGTGTCGCCACAAATTCATGACATTAATCACTACA 1881
 367 GTGTATCAGGTGAGGGGCGAGTGTGTCGCCACAAATTCATGACATTAATCACTACA 308

1882 CCTCAAAACACGACATGGGCCCTGACAGAGAAAACAGCCTGGGAACTCTCTGCACC 1941
 307 CTTCAAAACACGACATGGGCCCTGACAGAGAAAACAGCCTGGGAACTCTCTGCACC 248
 1942 CCACTGTCACCACTATCTCTGAACCTTATATATATATATATATATATATATATAT 2001
 247 CCACTGTCACCACTATCTCTGAACCTTATATATATATATATATATATATATATAT 188
 2002 AGGAATCTCAATATATGACTCCCTCCCAAAACCTTATATAAATGCAATAGATGACA 2061
 187 AGGAATCTCAATATATGACTCCCTCCCAAAACCTTATATAAATGCAATAGATGACA 128
 2062 CAAAGACAGCAACTTTGTACAGAGTGGGAGAGACTTTTCTGTATATATATATATAT 2121
 127 CAAAGACAGCAACTTTGTACAGAGTGGGAGAGACTTTTCTGTATATATATATATAT 68
 2122 TAAGTCTTGGTGGTGTAAATAAACAACATATATATAAATTTAAAGACAAAAGTCAA 2181
 67 TAAGTCTTGGTGGTGTAAATAAACAACATATATATAAATTTAAAGACAAAAGTCAA 8
 2182 AA 2183
 7 AA 6

RESULT 11
 BQ340625
 LOCUS
 DEFINITION
 BQ340625
 ACCSSION
 BQ340625.1 GI:21001706
 VERSION
 EST.
 KEYWORDS
 SOURCE
 ORGANISM

Homo sapiens
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutharia; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 609)
 Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
 Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.P.,
 Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
 Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
 ,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
 Simpson,A.J.
 Shotgun sequencing of the human transcriptome with ORF expressed
 sequence tags
 Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
 20202663
 10737800
 Contact: Simpson A.J.G.
 Laboratory of Cancer Genetics
 Ludwig Institute for Cancer Research
 Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
 Brazil
 Tel: +55-11-2704922
 Fax: +55-11-2707001
 Email: asimpson@ludwig.org.br
 This sequence was derived from the PAPESP/LICR Human Cancer Genome
 Project. This entry can be seen in the following URL
 (http://www.ludwig.org.br/scripts/gethtml2.pl?ti=PMO&t2=PMO-NN0258-
 220501-001-f07&t3=2001-05-22&t4=1)
 Seq primer: puc 18 forward
 High quality sequence start: 12
 High quality sequence stop: 601.

FEATURES
 source

1..609
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /dev_stage="Adult"
 /clone_lib="NN0258"
 /notes="Organ: nervous normal; Vector: puc18; Site 1: SmaI;
 Site 2: SmaI; A mini-library was made by cloning products

Choroid
 /dev stage="fetal and adult"
 /lab host="DH10B (Life Technologies) (T1 phage resistant)"
 /clone lib="UI-B-EJ1"
 /note="Organ: eye; Vector: pT73-Pac (Pharmacia) with a modified polylinker; Site: 1: EcoR 1; Site 2: Not I; UI-B-EJ1 is a subcloned cDNA library constructed according to Bonaldo, Lennon and Soares, Genome Research, 6:791-806, 1996. First strand cDNA synthesis was primed with an oligo-dT primer containing a Not I site. Double stranded cDNA was ligated to an EcoR I adaptor, digested with Not I, and cloned directionally into pT73-Pac vector. The oligonucleotide used to prime the synthesis of first-strand cDNA contains a library tag sequence that is located between the Not I site and the (dT)18 tail. The sequence tags for this library are: fetal eyes, AGAATCAAGA; lens, CCATTAGGCA; eye anterior segment, AATGCCGCAT; optic nerve, CCATTAGG; retina, CCGCG; Retina Foveal and Macular, GTCC; RPE and Choroid, ACCTA. This library was created for the program, Gene Discovery in the Visual System, supported by National Eye Institute (NEI)."
 BASE COUNT 175 a 123 c 99 g 105 t
 ORIGIN

Query Match 17.7%; Score 387; DB 13; Length 504;
 Best Local Similarity 99.8%; Pred. No. 4.1e-179;
 Matches 437; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1684 TGTGATTGCTCTTATTAACCTGTAAGCGGCACGAGCGGAGTACAGTCACGCGG 1743
 Db 1 TGTGATTGCTCTTATTAACCTGTAAGCGGCACGAGCGGAGTACAGTCACGCGG 60
 QY 1744 CCGGAGCTGTTGAGATTAATCCAGTGGACGAGACATCCAGCAGCAATCCGCGAGG 1803
 Db 61 CCGGAGCTGTTGAGATTAATCCAGTGGACGAGACATCCAGCAGCAATCCGCGAGG 120
 QY 1804 CAACAGAGCTCCGTCGCGGTATCAGTGGAGGGGAGTGTGCTGCCCAATTCATG 1863
 Db 121 CAACAGAGCTCCGTCGCGGTATCAGTGGAGGGGAGTGTGCTGCCCAATTCATG 180
 QY 1864 ACCATATTAACCAACACCTCAACACGACATCGGCGCCCACTGGACAGAAACAGCC 1923
 Db 181 ACCATATTAACCAACACCTCAACACGACATCGGCGCCCACTGGACAGAAACAGCC 240
 QY 1924 TGGGGAATCTCTGCAACCCACAGTACACATCTCTGACCTTATTAATTCAGACCC 1983
 Db 241 TGGGGAATCTCTGCAACCCACAGTACACATCTCTGACCTTATTAATTCAGACCC 300
 QY 1984 ATACAGAGCAGGTACAGAACTCAAAATATGACTCCCTCCCTCCCAAAACCTTATA 2043
 Db 301 ATACAGAGCAGGTACAGAACTCAAAATATGACTCCCTCCCTCCCAAAACCTTATA 360
 QY 2044 AATGCAATAGATGCACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGCTTTTC 2103
 Db 361 AATGCAATAGATGCACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGCTTTTC 420
 QY 2104 TTGTATATGCTTATATAT 2121
 Db 421 TTGTATATGCTTATATAT 438

RESULT 15
 LOCUS A1470931/c
 DEFINITION t19ic05.x1 NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE:2139368 3', mRNA sequence.
 ACCESSION A1470931
 VERSION A1470931.1 GI:4333021
 KEYWORDS EST.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 393)
 AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
 JOURNAL Unpublished
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgapbs@mail.nih.gov
 Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.
 cDNA library preparation: M. Bento Soares, Ph.D.
 cDNA library Arrayed by: Greg Lennon, Ph.D.
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www.bio.lnl.gov/bbrp/image/image.html
 Insert Length: 815 Std Error: 0.00
 Seq primer: -40UP from Gibco
 High quality sequence stop: 364.
 Location/Qualifiers
 1..393
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:2139368"
 /lab_host="DH10B"
 /clone_lib="NCI CGAP Kid11"
 /note="Organ: Kidney; Vector: pT73D-Pac (Pharmacia) with a modified polylinker; Site 1: Not I; Site 2: Eco RI; Plasmid DNA from the normalized library NCI_CGAP Kid1 was prepared, and ss circles were made in vitro. Following RAP hybridization, this DNA was used as tracer in a subtractive from a pool of 5,000 clones made from the same library (clones 1322376-1323911, 1456007-1456775, and 1500552-1502855). Subtraction by Bento Soares and M. Fatima Bonaldo."
 BASE COUNT 85 a 72 c 97 g 139 t
 ORIGIN

Query Match 17.6%; Score 385; DB 9; Length 393;
 Best Local Similarity 100.0%; Pred. No. 4e-178;
 Matches 385; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1795 CCGCAGCAGCAGCAGCAGCTCCGTCGCGGTATCAGTGGAGGGGAGTGTGCTGCCCA 1854
 Db 385 CCGCAGCAGCAGCAGCAGCTCCGTCGCGGTATCAGTGGAGGGGAGTGTGCTGCCCA 326
 QY 1855 CAATTTCATGACCATATTAATTAACCTAACAACCTTACAAACAGCAGCATGGGGCCCACTGGACAG 1914
 Db 325 CAATTTCATGACCATATTAATTAACCTAACAACCTTACAAACAGCAGCATGGGGCCCACTGGACAG 266
 QY 1915 AAAACAGCTGGGGAACCTCTCTGCACCCCAAGTCACCTATCTCTGAACCTTATATA 1974
 Db 265 AAAACAGCTGGGGAACCTCTCTGCACCCCAAGTCACCTATCTCTGAACCTTATATA 206
 QY 1975 TTTCAGACCCATACCAAGGAGGAGTACAGGAACCTCAATATGACTCCCTCCCTCCCAAAA 2034
 Db 205 TTTCAGACCCATACCAAGGAGGAGTACAGGAACCTCAATATGACTCCCTCCCTCCCAAAA 146
 QY 2035 AACTTATAAATGCAATAGATGACACAAAGCAGCACTTTGTACAGAGTGGGGAGA 2094
 Db 145 AACTTATAAATGCAATAGATGACACAAAGCAGCACTTTGTACAGAGTGGGGAGA 86
 QY 2095 GACTTTTCTTGTATATGCTTATATATTAAGTCTATGGCTGGTTAAAAAACAAGTTA 2154
 Db 85 GACTTTTCTTGTATATGCTTATATATTAAGTCTATGGCTGGTTAAAAAACAAGTTA 26
 QY 2155 TATTAAAAATTTAAAGACAAAAAGTC 2179
 Db 25 TATTAAAAATTTAAAGACAAAAAGTC 1

RESULT 16

Q0340622 B0340622 389 bp mRNA linear EST 20-MAY-2002
 LOCUS PM0-NN0258-220501-001-c05 NN0258 Homo sapiens cDNA, mRNA sequence.
 DEFINITION B0340622
 CCESSION B0340622
 ERSION B0340622.1 GI:21001702
 EYWORDS EST.
 ORUCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 389)
 AUTHORS Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
 Nagai,M.A., da Silva,W.Jr., Zago,M.A., Bordin,S., Costa,F.F.,
 Goldman,G.H., Carralho,A.P., Matsukuma,A., Baia,G.S., Simpson,D.H.,
 Brunstein,A., deOliveira,P.S., Sucher,P., Jongeneel,C.V., O'Hare
 W.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
 Simpson,A.J.
 TITLE Shotgun sequencing of the human transcriptome with ORF expressed
 sequence tags
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
 MEDLINE 20202663
 PUBMED 10737800
 COMMENT Contact: Simpson A.J.G.
 Laboratory of Cancer Genetics
 Ludwig Institute for Cancer Research
 Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
 Brazil
 Tel: +55-11-2704922
 Fax: +55-11-2707001
 Email: asimpson@ludwig.org.br
 This sequence was derived from the FAPESP/LICR Human Cancer Genome
 Project. This entry can be seen in the following URL
 (http://www.ludwig.org.br/scripts/gethtml2.pl?ti=PM0&t2=PM0-NN0258-
 220501-001-c05&t3=2001-05-22&t4=1)
 Seq primer: puc 18 forward
 High quality sequence start: 9
 High quality sequence stop: 389.
 FEATURES
 source
 Location/Qualifiers
 1..389
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /dev_stage="Adult"
 /clone_lib="NN0258"
 /note="Organ: nervous normal; Vector: puc18; Site:1: SmaI;
 Site 2: SmaI; A mini-library was made by cloning products
 derived from ORESTES PCR (U.S. Letters Patent application
 No. 196,716 - Ludwig Institute for Cancer Research)
 profiles into the pUC 18 vector. Reverse transcription of
 tissue mRNA and cDNA amplification were performed under
 low stringency conditions."
 76 a 120 c 102 t
 BASE COUNT 76 a 120 c
 ORIGIN
 Query Match 15.0%; Score 327; DB 13; Length 389;
 Best Local Similarity 100.0%; Pred. No. 1.5e+149; Indels 0; Gaps 0;
 Matches 32; Conservative 0; Mismatches 0;
 y 878 CCACATTAACCTCTCTTTTGGCCCATGACCTCTTTACCCCGCTGAGTACCTGTGGA 937
 b 63 CCACATTAACCTCTCTTTTGGCCCATGACCTCTTTACCCCGCTGAGTACCTGTGGA 122
 y 938 GTTGCATCTACACACACCTTGGAACTGTGATCTGACATCTGTGGCTAGCCTGGNG 997
 b 123 GTTGCATCTACACACACCTTGGAACTGTGATCTGACATCTGTGGCTAGCCTGGNG 182
 y 998 GTTTCGAGAGTATATACCCACCAATTCACCTGCTGTGGCGGTGTCATGCTCCCATGCA 1057
 b 183 GCTTCGAGAGTATATACCCACCAATTCACCTGCTGTGGCGGTGTCATGCTCCCATGCA 242
 y 1058 CATGCGAGGGCGGTACTCTGTGTGAGGTGGACGAGGCTCTCTCCAGTGTCTGCCCCCTT 1117
 b 243 CATGCGAGGGCGGTACTCTGTGTGAGGTGGACGAGGCTCTCTCCAGTGTCTGCCCCCTT 302

Qy 1118 CATCATGAGGACCTCGAGACCTCAACATTTCTGAGGCTCGATGGAGAACTTAAGTG 1177
 Db 303 CATCATGAGGACCTCGAGACCTCAACATTTCTGAGGCTCGATGGAGAACTTAAGTG 362
 Qy 1178 TCGGACTTCCCCCTATGCTCTCCGTGAA 1204
 Db 363 TCGGACTTCCCCCTATGCTCTCCGTGAA 389
 RESULT 17
 AW954538
 LOCUS EST366608 424 bp mRNA linear EST 01-JUN-2000
 DEFINITION EST366608 MAGE resequencings, MAGE Homo sapiens cDNA, mRNA sequence.
 ACCESSION AW954538
 VERSION AW954538.1 GI:8144221
 KEYWORDS EST.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 424)
 AUTHORS Hegde,P., Qi,R., Abernathy,K., Dharap,S., Gaspard,R., Gay,C., Holt
 J.E., Saeed,A.I., Sharov,V., Lee,N.H., Yeatman,T.J. and
 Quackenbush,J.
 TITLE Assessment of gene expression patterns in a model of colon tumor
 metastasis using a 19,200 element cDNA microarray
 JOURNAL Unpublished
 COMMENT Contact: John Quackenbush
 The Institute for Genomic Research
 9712 Medical Center Dr., Rockville, MD 20850, USA
 Tel: 301 838 3528
 Fax: 301 838 0208
 Email: johnq@tigr.org
 Plate: 65
 Seq primer: Reverse.
 Location/Qualifiers
 1..424
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone_lib="MAGE resequencings, MAGE"
 /note="Vector: pBluescript-SKm"
 BASE COUNT 85 a 135 c 101 g 103 t
 ORIGIN
 Query Match 13.6%; Score 298; DB 10; Length 424;
 Best Local Similarity 99.7%; Pred. No. 3e+135;
 Matches 348; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 894 TCCTTGGCCCATGACCTCTTTACCCCGCTGAGTACCTGGTGGAGTGCATCTACACCAC 953
 Db 28 TCCTTGGCCCATGACCTCTTTACCCCGCTGAGTACCTGGTGGAGTGCATCTACACCAC 87
 Qy 954 AACCCCTTGGAACTGTGATCTGTGACATTTCTGTGGCTAGCCTGTGGCTTCGAGAGTATATA 1013
 Db 88 AACCCCTTGGAACTGTGATCTGTGACATTTCTGTGGCTAGCCTGTGGCTTCGAGAGTATATA 147
 Qy 1014 CCACCAATTCACCTCTGTGGCGCTGTGATCTCCCATGCAATGAGGAGGCGCCCTAC 1073
 Db 148 CCACCAATTCACCTCTGTGGCGCTGTGATCTCCCATGCAATGAGGAGGCGCCCTAC 207
 Qy 1074 CTCTGTGAGGTGACACAGGCTCTCTTCCAGTGTCTGTGGCGCTTCATCATGAGCAGCCT 1133
 Db 208 CTCTGTGAGGTGACACAGGCTCTCTTCCAGTGTCTGTGGCGCTTCATCATGAGCAGCCT 267
 Qy 1134 CGAGACCTCAACATTTCTGAGGCTGAGTGGCAGAACTTAAGTGTGCGACTCCCCCTATG 1193
 Db 268 CGAGACCTCAACATTTCTGAGGCTGAGTGGCAGAACTTAAGTGTGCGACTCCCCCTATG 327
 Qy 1194 TCCTCCGTGAGGTGTGCTGCTGCCAATGGACAGTCTCAGCCACGCT 1242
 Db 328 TCCTCCGTGAGGTGTGCTGCTGCCAATGGACAGTCTCAGCCACGCT 376

NotI; The infant brain library, constructed by Bento Soares, Columbia University, was oligo-(dT) primed and directionally cloned into an M13-derived plasmid using total brain mRNA from a 72-day old human female afflicted with spinal muscular atrophy. "

Query Match	11.5%;	Score	252;	DB	14;	Length	470;
Best Local Similarity	99.7%;	Pred. No.	1.4e-112;				
Matches	302;	Conservative	0;	Mismatches	1;	Indels	0;
Gaps	0;						

y	1882	CCTACAAACCAGACACATGGGGCCCACTGCAGCAGAAAACAGCCTCGGGGAACCTCTCTGCACCC	1941
b	303	CCTACAAACCAGACACATGGGGCCCACTGCAGCAGAAAACAGCCTCGGGGAACCTCTCTGCACCC	244
y	1942	CCACAGTCACCACTATCTCTGAAACCTTATATATAATTGAGCCCATACCAAGGACAAGGTAC	2001
b	243	CCACAGTCACCACTATCTCTGAAACCTTATATATAATTGAGCCCATACCAAGGACAAGGTAC	184
y	2002	AGGAAATCAAAATATGACTCCCTCCCCCAAAAAAAGCTTATAAATGCAATGAATGCACA	2061
b	183	AGGAAATCAAAATATGACTCCCTCCCCCAAAAAAAGCTTATAAATGCAATGAATGCACA	124
y	2062	CAAGACAGCAAACTTTTGTACAGATGGGGAGAGACTTTTCTCTGATATGCTTATATAT	2121
b	123	CAAGACAGCAAACTTTTGTACAGATGGGGAGAGACTTTTCTCTGATATGCTTATATAT	64
y	2122	TAACTCTATGGCTGGTTAAAAAAGACAGATTATATAAAATTTAAAGCAAAAAAGTCAA	2181
b	63	TAACTCTATGGCTGGTTAAAAAAGACAGATTATATAAAATTTAAAGCAAAAAAGTCAA	4
y	2182	AAC	2184
b			
		3 AAC	1

```

RESULT 22
A1332304/c
LOCUS
DEFINITION
  qp37e09.x1 Soares fetal_lung NHLH19W Homo sapiens cDNA clone
  IMAGE:1930984 3', mRNA Sequence..
ACCESSION
  A1332304
VERSION
  A1332304.1 GI:4068863
KEYWORDS
  EST.
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 (bases 1 to 452)
  NCI-CCAP http://www.ncbi.nlm.nih.gov/ncicgap.
  National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
  Tumor Gene Index
JOURNAL
  Unpublished
COMMENT
  Contact: Robert Strausberg, Ph.D.
  Email: cgapbs-remail.nih.gov
  This clone is available royalty-free through LILN; contact the
  IMAGE Consortium (info@image.liln.gov) for further information.
  Insert Length: 940 Std Error: 0.00
  Seq primer: -40UP from Gibco
  High quality sequence stop: 450.

```

```

FEATURES
    source
    high quality
    Location/Qualifiers
        1..452
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
            /clone="IMAGE:1930984"
            /dev_stage="19 weeks"
            /lab_host="DH10B (ampicillin resistant)"
            /clone_lib="Soares fetal_lung_NHLL9W"
            /note="Organ: lung; Vector: pF73D (Pharmacia) with a
            modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st
            strand cDNA was primed with a Not I - oligo(dT) primer"

```

[5'-TGTTACCANTCGAGTCGGAGCGCGCCGCAATTTTTTTTTTTTTTTT-3'] double-stranded cDNA was size selected, ligated to Eco RI doublets (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified pMT3 vector (Pharmacia). Library went through one round of normalization to a Cot = 5. Library constructed by Soares and M. Fatima Bonaldo. This library was constructed from the same fetus as the fetal heart library, Soares fetal heart NBbH19W."

BASE COUNT	111 a	89 c	84 g	168 t
ORIGIN				
Query Match	11.0%;	Score 241;	DB 9;	Length 452;
Best Local Similarity	100.0%;	Pred. No. 3.8e-107;		
Matches 241; Conservative	0;	Mismatches	0;	Indels
			0;	Gaps
QY	1945	CAGTCACCACTATCTCTGACCTTATATATTAGACACCCATACCAAGGCAAGGTACAGG	2004	
DB	399	CAGTCACCACTATCTCTGACCTTATATATTAGACCCATACCAAGGCAAGGTACAGG	340	
QY	2005	AAACTCAAAATAGACTCCCTCCCTCCCAAAAAAATTATAAAATGCAATAGAAATGCACACAA	2064	
DB	339	AAACTCAATATAGCTCCCTCCCTCCCAAAAAAATTATAAAATGCAATAGAAATGCACACAA	280	
QY	2065	AGACAGCAACTTTTGTACAGAGTGGGAGAGACTTTTCTTGATATATGCTTATATATTA	2124	
DB	279	AGACAGCAACTTTTGTACAGAGTGGGAGAGACTTTTCTTGATATATGCTTATATATTA	220	
QY	2125	GTCTATGGGCTGGTATAAAAAAACAAGATTATATAAAAAATTTAAAGACAAAAGTCAAAAC	2184	
DB	219	GTCTATGGGCTGGTATAAAAAAACAAGATTATATAAAAAATTTAAAGACAAAAGTCAAAAC	160	
QY	2185	A	2185	
DB	159	A	159	

```

RESULT 23
R43906/c
LOCUS
DEFINITION
R43906.1 GI:821784
ACCESSION
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
REFERENCE
AUTHORS
Miller, E., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman
H., Hultman, M., Kucaba, T., Le, M., Lennon, G., Maier, M., Parsons, J.,
Rifkin, L., Rohlfing, T., Soares, M., Tan, F., Trevaskis, E., Waterston
R., Williamson, A., Wohlmann, P. and Wilson, R.
TITLE
The WashU-Merck EST Project
JOURNAL
Unpublished
COMMENT
On May 9, 1995 this sequence version replaced gi:802630.
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu

```

FEATURES
source
1..428
/organism="Homo sapiens"
High quality sequence stop: 328.
Location/Qualifiers
Seq primer: Promega -21m13
Insert Length: 1458 Std Error: 0.00
This clone is available royalty-free through LLNL ; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
High quality sequence stops: 328 Source: IMAGE Consortium, LLNL
Insert Size: 1458

/mol_type="mRNA"
/db_xref="GDB:406070"
/db_xref="taxon:9606"
/clone="IMAGE:33723"
/sex="female"

/dev_stage="73 days post natal"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares infant brain INB"
/notes="Organ: whole brain; Vector: Lfamid BA; Site:1: Not I; Site:2: Hind III; 1st strand cDNA was primed with a Not I - oligo(dT) primer 15'
AACTGAAGAAATTCGGCGCGAGAAATTTTTCCTTTT 3';
double-stranded cDNA was ligated to Hind III adaptors (Pharmacia), digested with Not I and directionally cloned into the Not I and Hind III sites of the Lfamid BA vector. Library went through one round of normalization. Library constructed by Bento Soares and M.Fatima Bonaldo."

87 a 72 c 112 g 154 t 3 others

ASE COUNT
RIGIN

Query Match 10.8%; Score 235; DB 14; Length 428;
Best Local Similarity 100.0%; Pred. No. 3.5e-104;
Matches 235; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1951 CCATCTCTCTGAACCTTATATATTCAGACCCTACCAAGGACAGGTACAGAACTC 2010
|||||
243 CCATCTCTCTGAACCTTATATATTCAGACCCTACCAAGGACAGGTACAGAACTC 184
|||||

2011 AATATGACCTCCCTCCCTCCCAAACTTATAAATGCAATGACACACAAAGACAG 2070
|||||

183 AATATGACCTCCCTCCCTCCCAAACTTATAAATGCAATGACACACAAAGACAG 124
|||||

2071 CAATTTTGTACAGAGTGGGAGAGACTTTTCTGTATATGCTTATATTAAGTCTAT 2130
|||||

123 CAATTTTGTACAGAGTGGGAGAGACTTTTCTGTATATGCTTATATTAAGTCTAT 64
|||||

2131 GGGCTGGTTAAATAAACAAGATTATATTAATAATTAAGACAAAAGTCAAAACA 2185
|||||

63 GGGCTGGTTAAATAAACAAGATTATATTAATAATTAAGACAAAAGTCAAAACA 9
|||||

BM975594 468 bp mRNA linear EST 21-FEB-2003
UI-CF-ENI-acu-d-14-0-UI.s1 UI-CF-ENI Homo sapiens cDNA clone
BM975594
BM975594.1 GI:19593185
EST.
Homo sapiens (human)
Homo sapiens

ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 468)
Bonaldo,M.F., Lennon,G. and Soares,M.B.
Normalization and subtraction: two approaches to facilitate gene
discovery
Genome Res. 6 (9), 791-806 (1996)

JOURNAL
MEDLINE
PUBMED
COMMENT

97044477
8889548
Contact: McCray, PB
McCray Lab
University of Iowa
2024 University of Iowa Med Labs, Iowa City, IA 52242, USA
Tel: 319 356 4866
Fax: 319 356 7171

Email: paul-mccray@uiowa.edu
Tissue Procurement: Dr. M. J. Welsh, University of Iowa
cDNA Library preparation: Dr. M. Bento Soares, University of Iowa
cDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
Clone Distribution: Researchers may obtain clones from Research
Genetics (www.resgen.com) or from Open Biosystems

(www.openbiosystems.com).
The following repetitive elements were found in this cDNA
sequence: 1-53, >AT-richLow_complexity (matched complement)
Seq primer: M13 FORWARD
POLYA=Yes.

FEATURES
source

Location/Qualifiers
1..468
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="UI-CF-ENI-acu-d-14-0-UI"
/tissue_type="Primary Lung Cystic Fibrosis Epithelial
Cells"

/dev_stage="Adult"
/lab_host="DH10B (Life Technologies) (T1 phage resistant)"
/clone_lib="UI-CF-ENI"
/note="Organ: Lung; Vector: pT7T3-Pac (Pharmacia) with a
modified polylinker; Site:1: EcoR I; Site:2: Not I;
UI-CF-ENI is a normalized cDNA library containing the
following tissue(s): Primary Lung Cystic Fibrosis
Epithelial Cells. The library was constructed according to
Bonaldo, Lennon and Soares, Genome Research, 6:791-806,
1996. First strand cDNA synthesis was primed with an
oligo-dT primer containing a Not I site. Double stranded
cDNA was ligated to an EcoR I adaptor, digested with Not
I, and cloned directionally into pT7T3-Pac vector. The
oligonucleotide used to prime the synthesis of
first-strand cDNA contains a library tag sequence that is
located between the Not I site and the (dT)18 tail. The
sequence tag for this library is CTGCTCAGGT.

TAG 118=UI-CF-ENI
TAG_TISSUE=Human Lung Epithelial Cell Lines untreated LPS
6hr to LPS 24h
TAG SEQ=CTGCTCAGGT"
BASE COUNT 128 a 103 c 104 g 133 t

ORIGIN

Query Match 10.3%; Score 224; DB 12; Length 468;
Best Local Similarity 100.0%; Pred. No. 9.1e-99;
Matches 224; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1208 GTTGCTGCCCAATGGGACAGTGTCTCAGCCACCGCTCCGCCACCCCAAGGATCTCTCT 1267

DB 434 GTTGCTGCCCAATGGGACAGTGTCTCAGCCACCGCTCCGCCACCCCAAGGATCTCTCTCT 375

QY 1268 CAACGACGGCACTTGACATTTTCCACAGCTGCTGCTTTCAGACACTGGGGTGTACACATG 1327

DB 374 CAACGACGGCACTTGACATTTTCCACAGCTGCTGCTTTCAGACACTGGGGTGTACACATG 315

QY 1328 CATGGTGACCAATGTTGCAGGCAACTCCAAACGCTCGGCTACCTCAATGTGACGACGGC 1387

DB 314 CATGGTGACCAATGTTGCAGGCAACTCCAAACGCTCGGCTACCTCAATGTGACGACGGC 255

QY 1388 TGAGCTTAAACACTCCCACTACAGCTTCTTCCACCAAGTAACAG 1431

DB 254 TGAGCTTAAACACTCCCACTACAGCTTCTTCCACCAAGTAACAG 211

RESULT 25

T33015/c

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

T33015 Human Brain Homo sapiens cDNA 3', end similar to None, mRNA
sequence.

T33015
T33015.1 GI:615113

EST.
Homo sapiens (human)

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 325)
Adams,M.D., Kerlavage,A.R., Fleischmann,R.D., Fuldner,R.A., Bult
,C.J., Lee,N., Kirkness,E.F., Weinstock,K.G., Gocayne,J.D., White


```

Y 2162 ATTAAAGACAAAGTCAAAACA 2185
      |||||
      34 ATTAAAGACAAAGTCAAAACA 11

RESULT 27
J741381/c
DEFINITION
  UI-E-EJ0-ais-1-18-0-UI si UI-E-EJ0 Homo sapiens cDNA clone
  UI-E-EJ0-ais-1-18-0-UI 3', mRNA sequence.
CESSION
  ESION
  EYWORDS
  URCE
  ORGANISM
    Homo sapiens (human)
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
    Bonaldo,M.F., Lennon,G. and Soares,M.B.
    Normalization and subtraction: two approaches to facilitate gene
    discovery
    Genome Res. 6 (9), 791-806 (1996)
    97044477
    8889548
    Contact: Soares, MB
    Coordinated Laboratory for Computational Genomics
    University of Iowa
    375 Newton Road , 4156 MEBRF, Iowa City, IA 52242, USA
    Tel: 319 335 8250
    Fax: 319 335 9565
    Email: bento-soares@uiowa.edu
    Tissue Procurement: Dr. Gregg Hageman
    cDNA Library preparation by: Dr. M. Bento Soares, University of Iowa
    cDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
    DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
    Clone Distribution: Researchers may obtain clones from Research
    Genetics (www.resgen.com).
    The following repetitive elements were found in this cDNA
    sequence: 1-30, >AT-rich#Low_complexity (matched complement)
    Seq primer: M13 FORWARD
    POLYA=Yes.

FEATURES
      source
      1..626
      /organism="Homo sapiens"
      /mol_type="mRNA"
      /db_xref="taxon:9606"
      /clone="UI-E-EJ0-ais-1-18-0-UI"
      /tissue_type="fetal eyes, lens, eye anterior segment,
      optic nerve, retina, Retina Foveal and Macular, RPE and
      Choroid"
      /dev_stage="fetal and adult"
      /lab_host="DH10B (Life Technologies) (T1 phage resistant)"
      /clone_lib="UI-E-EJ0"
      /notes="Organ: eye; Vector: p77T3-Pac (Pharmacia) with a
      modified polylinker; Site 1: EcoR I; Site 2: Not I;
      UI-E-EJ0 is a subtracted cDNA library constructed
      according to Bonaldo, Lennon and Soares, Genome Research,
      6:791-806, 1996. First strand cDNA synthesis was primed
      with an oligo-dT primer containing a Not I site. Double
      stranded cDNA was ligated to an EcoR I adaptor, digested
      with Not I, and cloned directionally into p77T3-Pac
      vector. The oligonucleotide used to prime the synthesis of
      first-strand cDNA contains a library tag sequence that is
      located between the Not I site and the (dT)18 tail. The
      sequence tags for this library are: fetal eyes, AGAATCAAGA
      ; lens, CCAATAGGGA; eye anterior segment, AATGCCGCAT;
      optic nerve, CCAATAGGAT; retina, CCGCG; Retina foveal and
      Macular, GTCC; RPE and Choroid, ACCTA. This library was
      created for the program, Gene Discovery in the Visual
      System, supported by National Eye Institute (NEI).
      TAG LIB=UI-E-EJ0
      TAG_TISSUE=human retina
  
```

```

BASE COUNT 159 a 131 c 110 g 226 t
ORIGIN
  Query Match 9.1%; Score 199; DB 13; Length 626;
  Best Local Similarity 100.0%; Pred. No. 1.9e-86;
  Matches 199; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1987 CCAAGGACAAAGTACAGGAACTCAATATGCTCCCTCCCAAAAAGCTATATAAT 2046
Db 528 CCAAGGACAAAGTACAGGAACTCAATATGCTCCCTCCCAAAAAGCTATATAAT 469
QY 2047 GCAATAGATGCACACAAAGCAGCACTTTTGTACAGTGGGGAGAGACTTTTCTTG 2106
Db 468 GCAATAGATGCACACAAAGCAGCACTTTTGTACAGTGGGGAGAGACTTTTCTTG 409
QY 2107 TATATGCTTATATATTAAGTCTATCGGTGTTAAAAAACAAGATTATATAATTTA 2166
Db 408 TATATGCTTATATATTAAGTCTATCGGTGTTAAAAAACAAGATTATATAATTTA 349
QY 2167 AAGACAAAAGTCAAAACA 2185
Db 348 AAGACAAAAGTCAAAACA 330

RESULT 28
AA077185 254 bp mRNA linear EST 24-SEP-1999
LOCUS 7B09E10 Chromosome 7 Fetal Brain cDNA Library Homo sapiens cDNA
DEFINITION
  clone 7B09E10, mRNA sequence.
ACCESSION
  AA077185
  AA077185.1 GI:1836673
KEYWORDS
  EST.
  Homo sapiens (human)
  ORGANISM
    Homo sapiens
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
    Touchman,J.W., Bouffard,G.G., Weintraub,L.A., Idol,J.R., Wang,L.,
    Robbins,C.M., Nussbaum,J.C., Lovett,M. and Green,E.D.
    2006 expressed-sequence tags derived from human chromosome
    7-enriched cDNA libraries
    Genome Res. 7 (3), 281-292 (1997)
    9728905
    9074931
    Contact: Eric D. Green
    Genome Technology Branch
    National Human Genome Research Institute/NIH
    49 Convent Dr., MSC4431, Building 49, Room 2A08, Bethesda, MD 20892
    Tel: 3014020201
    Fax: 3014024735
    Email: egreen@nhgri.nih.gov
    Plate: 09 row: E column: 10
    Seq primer: -21M13 (ABI).

FEATURES
      Location/Qualifiers
      1..254
      /organism="Homo sapiens"
      /mol_type="mRNA"
      /db_xref="taxon:9606"
      /clone="7B09E10"
      /sex="female and male mixture"
      /tissue_type="brain"
      /dev_stage="pool of 9 week and 12 week"
      /lab_host="E. coli strain DH5 alpha"
      /clone_lib="Chromosome 7 Fetal Brain cDNA Library"
      /notes="Organ: brain; Vector: pAMP10; cDNA was generated
      from cytoplasmic RNA using a mixture of random DNA
      hexamers and oligo(dT). From this pool of cDNA, human
      chromosome 7-enriched cDNA was isolated by direct cDNA
      selection using chromosome 7 genomic DNA (cosmids). The
      resulting direct-selected cDNA was cloned into a plasmid
      vector using a non-directional uracil DNA glycosylase (UDG
      )-mediated cloning strategy."
  
```

BASE COUNT	47 a	44 c	72 g	91 t
ORIGIN				
Query Match	8.8%	Score 193;	DB 9;	Length 254;
Best Local Similarity	100.0%;	Pred. No. 1.7e-83;		
Matches 193;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1837	GGCGAGTAGTCTGCCACCAATTCATGACCATATTAACCTACGACACCTACAAACCGAC	1896	
DB	254	GGCGAGTAGTCTGCCACCAATTCATGACCATATTAACCTACGACACCTACAAACCGAC	185	
QY	1897	ATGGGGGCCCACTGGACGAGAAAAAGAGCCTGGGGAATCTCTGCAACCCACAGCTCACCACTA	1956	
DB	194	ATGGGGGCCCACTGGACGAGAAAAAGAGCCTGGGGAATCTCTGCAACCCACAGCTCACCACTA	135	
QY	1957	TCTCTGACCTTATATTAATTCAGACCCATACGAGACAGCTACGAGAACTCAATAT	2016	
DB	134	TCTCTGACCTTATATTAATTCAGACCCATACGAGACAGCTACGAGAACTCAATAT	75	
QY	2017	GACTCCCCCTCCCC	2029	
DB	74	GACTCCCCCTCCCC	52	
RESULT 29				
T16288/c				
LOCUS				
DEFINITION	T16288	346 bp	mRNA	linear EST 25-JUL-1996
ACCESSION	NIB1062	Normalized infant brain, Bento Soares	Homo sapiens	CDNA
VERSION	3'end,	mRNA	sequence.	
KEYWORDS	T16288.1	GI:518450		
SOURCE	EST.			
ORGANISM	Homo sapiens	(human)		
REFERENCE				
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
JOURNAL	Berry,R., Stevens,T.J., Walter,N.A.R., Wilcox,A.S., Rubano,T.,			
MEDLINE	Hopkins,J.A., Weber,J., Good,R., Soares,M.B. and Sikela,J.M.			
PUBMED	Gene-based Sequence Tagged Sites (STS) as the basis for a human			
COMMENT	gene map			
	Nat. Genet. 10, 415-423 (1995)			
	670491			
	Contact: Sikela JM			
	Department of Pharmacology			
	University of Colorado Health Sciences Center			
	Box C236, 4200 E. 9th Ave, Denver CO 80262-0236			
	Tel: 3032708637			
	Fax: 3032707097			
	Email: nikkie@ally.uchsc.edu			
	Seq primer: -21M13 Universal.			
FEATURES	Location/Qualifiers			
source	1. .346			
	/organism="Homo sapiens"			
	/mol_type="mRNA"			
	/db_xref="taxon:9606"			
	/lab_host="E. coli DH5-alpha"			
	/clone_lib="Normalized infant brain, Bento Soares"			
	/note="Vector: BM, M13-derived; Site1: HindIII; Site 2:			
	NotI; The normalized infant brain library, constructed by			
	Bento Soares, Columbia University, was Oligo-(GT) primed			
	and directionally cloned into an M13-derived plasmid using			
	total brain mRNA from a 72-day old human female afflicted			
	with spinal muscular atrophy. The library was normalized			
	as described elsewhere."			
BASE COUNT	77 a	55 c	83 g	129 t
ORIGIN				
Query Match	8.8%	Score 193;	DB 14;	Length 346;
Best Local Similarity	99.1%;	Pred. No. 1.7e-83;		
Matches 343;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;

1839	QY	CGAGTAGTGTGCGCCCAATTCATGACCATATTTACTACAACCTTACAAACCGACACAT	1899
346	Db	CGAGTAGTGTGCGCCCAATTCATGACCATATTTACTACAACCTTACAAACCGACACAT	287
1899	QY	GGGGCCCACTGGACAGAAAAACAGCCTGGGAACTCTCTGCAACCCACAGTCACCACTATC	1958
286	Db	GGGGCCCACTGGACAGAAAAACAGCCTGGGAACTCTCTGCAACCCACAGTCACCACTATC	227
1959	QY	TCTGAACCTTATATAATTCAGACCCCATACCAAGGACAGAGTACAGGAACTCAAAATATGA	2018
236	Db	TCTGAACCTTATATAATTCAGACCCCATACCAAGGACAGAGTACAGGAACTCAAAATATGA	167
2019	QY	CTCCCTCTCCCCAAAAAATTTATAAATGCAATAGATGTCACCAAGACAGCACTTTT	2078
166	Db	CTCCCTCTCCCCAAAAAATTTATAAATGCAATAGATGTCACCAAGACAGCACTTTT	107
2079	QY	GTACAGAGTGGGAGAGACCTTTCTTGATATATGCTTATATATTAAGTCTATGGCTGGT	2138
106	Db	GTACAGAGTGGGAGAGACCTTTCTTGATATATGCTTATATATTAAGTCTATGGCTGGT	47
2139	QY	TAAAAAAAACAGATTATATATAAATTTAAAGACAAAAAGTCAAAAAC	2184
46	Db	TAAAAAAAACAGATTATATATAAATTTAAAGACAAAAAGTCAAAAAC	1
RESULT 30			
R71701	LOCUS	R71701	359 bp mRNA linear EST 02-JUN-1995
DEFINITION			
YJ8508.1 Soares breast 2NDHBT Homo sapiens cDNA clone			
IMAGE:155534 5' similar to SP:B36665 B36665 SLIT PROTEIN 2			
PRECURSOR - FRUIT FLY i, mRNA sequence.			
R71701	ACCESSION	R71701.1	GI:845733
R71701	VERSION	EST.	
R71701	KEYWORDS	Homo sapiens (human)	
R71701	SOURCE	Homo sapiens	
R71701	ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
R71701	REFERENCE	1 (bases 1 to 359)	
R71701	AUTHORS	Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M., Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F., Trevaskis, E., Waterston, R., Williamson, A., Wohlmann, P. and Wilson, R.	
R71701	TITLE	The WashU-Merck EST Project	
R71701	JOURNAL	Unpublished	
R71701	COMMENT	Contact: Willson RK Washington University School of Medicine 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108 Tel: 314 286 1800 Fax: 314 286 1810 Email: est@watson.wustl.edu Insert Size: 1447 High quality sequence steps: 149 Source: IMAGE Consortium, LLNL This clone is available royalty-free through LLNL / contact the IMAGE Consortium (info@image.llnl.gov) for further information. Insert Length: 1447 Std Error: 0.00 Seq primer: M13p1 High quality sequence step: 149. Location/Qualifiers 1. .359 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="GDB:573441" /db_xref="taxon:9606" /clone="IMAGE:155534" /sex="Female" /dev_stage="adult" /lab_host="DB10B (ampicillin resistant)" /clone_lib="Soares breast 2NDHBT"	
R71701	FEATURES		
R71701	SOURCE		

	ASE COUNT	68 a	107 c	87 g	91 t	6 others
RIGIN						
Query Match		8.5%;	Score 186;	DB 14;	Length 359;	
Best Local Similarity		99.6%;	Pred. No. 4.9e-80;			
Matches 236;	Conservative	0;	Mismatches	1;	Indels	0;
Gaps	0;					
y	894	TCATTGCCCCATGACACTCTTTACCCCGCTGAGGTACCTGGTGGAGTTGCCATCTACACACCAC	953			
b	18	TCATTTGCCCCCATGACACTCTTTACCCCGCTGAGGTACCTGGTGGAGTTGCCATCTACACACAC	77			
y	954	AACCCCTTGGAACTGTGATGTCACATTCCTGTGGCTAGCCTGTGGTGGCTTCGAGAGTATATA	1013			
b	78	AACCCCTTGGAACTGTGATGTCACATTCCTGTGGCTAGCCTGTGGTGGCTTCGAGAGTATATA	137			
y	1014	CCACACAAATTCACACCTGCTGTGGCCGCTGTCAATGCTCCCATGCACTGCCAGGCGCGCTAC	1073			
b	138	CCACACAAATTCACACCTGCTGTGGCCGCTGTCAATGCTCCCATGCACTGCCAGGCGCGCTAC	157			
y	1074	CTCGTGGAGGTGGACACAGCCCTCTTTCACAGNCTCTGCGCCCTTCATCATGAGCGCA	1130			
b	198	CTCGTGGAGGTGGACACAGCCCTCTTTCACAGTCTCTGCGCCCTTCATCATGAGCGCA	254			

[illegible]

CCRSION
ERSON
EYWORDS
SOURCE
ORGANISM

AW524479
AW524479.1
EST.
Rattus norvegicus (Norway rat)
Rattus norvegicus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.

REFERENCE
AUTHORS
TITLE
JOURNAL

1 (bases 1 to 544)
Bonaldo,M.F., Lennon,G. and Soares,M.B.
Normalization and subtraction: two approaches to facilitate gene
discovery
Genome Res. 6(9), 791-806 (1996)

MEDLINE
PUBMED
COMMENT

970444477
8889548
Contact: Soares, MB
Coordinated Laboratory for Computational Genomics
University of Iowa
375 Newton Road , 4156 MEBRF, Iowa City, IA 52242, USA
Tel: 319 335 8250
Fax: 319 335 9565

Email: bento-soares@uiowa.edu

The sequence contained an oligo-dT track that was present in the oligonucleotide that was used to prime the synthesis of first strand cDNA and therefore this may represent a bonafide PolyA tail. The sequence tag present in the cDNA between the NotI site and the oligo-dT track served to identify it as a clone from the normalized thalamus library cDNA library Preparation: M.S. Soares Lab Clone distribution: clones will be available through Research Genetics (www.resgen.com) The following repetitive elements were found in this cDNA sequence: 1-41, >AT_rich#Low_complexity 365-395, >(CAG)n#Simple repeat

Seq primer: M13 Forward

Poi:YA=Yes.

```

FEATURES      Location/Qualifiers
source        1..544
              /organism="Rattus norvegicus"

```

```

/mol_type="mRNA"
/strain="Sprague-Dawley"
/db_xref="taxon:10116"
/clone="UI-R-B00-ahx-h-11-0-UI"
/dev_stage="adult"
/lab_host="DH10B (Life Technologies)"
/clone_lib="UI-R-B00"
/notes="Vector: pTTT3D-Pac (Pharmacia) with a modified
polylinker; Site_1: Not I; Site_2: Eco RI: The library
(UI-R-B00) is a subtracted library derived from a mixture
of the following tissues: thalamus, cerebellum,
hypothalamus, medulla, pons, midbrain, cerebral cortex,
corpus striatum and hippocampus. For a detailed
description of the library from which this clone was
derived, please visit our web site at
xatext.eng.uiowa.edu. The subtraction has been previously
described in (Bonaldo, Lennon and Soares, Genome Research
6:791-806, 1996)
TAG_LIB=UI-R-B00
TAG_TISSUE=thalamus
TAG_SEQ=GATCG"
121 a _110 c 132 g 181 t

```

Query Match	8.1%	Score 177;	DB 9;	Length 544;
Best Local Similarity	99.6%;	Prod. No. 1.3e-75;		
Matches 227;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;
Qy	1797	GCAGCAGCAACAGCAGCTCCGTC	CGGTGTATCAGGTGAGGGGGCAGT	AGTGTGTCGCCACA 1856
Db	381	GCAGCAGCAACAGCAGCTCCGTC	CGGTGTATCAGGTGAGGGGGCAGT	AGTGTGTCGCCACA 322
Qy	1857	ATTCATGACCMATTAACACAACT	CAAAACGAGCAATGGG	GGCCACTGGACAGAA 1916
Db	321	ATCCATGACCMATTAACACAACT	CAAAACGAGCAATGGG	GGCCACTGGACAGAA 262
Qy	1917	TAACGCTGGGGAACTCTCTG	CACCCCAAGTCACCACTCTCT	GAACTTATATAATT 1976
Db	261	TAACGCTGGGGAACTCTCTG	CACCCCAAGTCACCACTCTCT	GAACTTATATAATT 202
Qy	1977	CAGACCCCATCAAGGCAAGGT	ACAGGAACTCAAAATATG	ATCTCCCC 2024
Db	201	CAGACCCCATCAAGGCAAGGT	ACAGGAACTCAAAATATG	ATCTCCCC 154

[illegible]

ESL.
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS

TITLE Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE 20020663
PUBMED 10737800
COMMENT Contact: Simpson A.J.G.

1073/800
PURNED
COMMENT
Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil

Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the PAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=st2=RC1-HT0268-200
400-016-g10&t3=2000-04-20&t4=1)
Seq primer: puc 18 forward
High quality sequence start: 18
High quality sequence stop: 224.
Location/Qualifiers
1. .224
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/dev_stage="Adult"
/clone_lib="HT0268"
/note="Organ: head neck; Vector: puc18; Site: i: SmaI;
Site 2: SmaI; A mini-library was made by cloning products
derived from ORSTES PCR (U.S. Letters Patent application
No. 196,716 - Ludwig Institute for Cancer Research)
profiles into the puc 18 vector. Reverse transcription of
tissue mRNA and cDNA amplification were performed under
low stringency conditions."
low stringency conditions."
45 a 53 c 69 g 57 c

BASE COUNT
ORIGIN

Query Match 8.0%; Score 175; DB 10; Length 224;
Best Local Similarity 100.0%; Pred. No. 1.3e-74;
Matches 175; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1283 GAACCTTTCCACGCTGCTTTCAGACACTGGGGTGACACATGCTGACCAATGT 1342
DB 212 GAACCTTTCCACGCTGCTTTCAGACACTGGGGTGACACATGCTGACCAATGT 153
QY 1343 TCAGGCAACTCCACGCTGCTTTCAGACACTGGGGTGACACATGCTGACCAATGT 1402
DB 152 TCAGGCAACTCCACGCTGCTTTCAGACACTGGGGTGACACATGCTGACCAATGT 93
QY 1403 CAACCTACAGCTTCTTCCACGCTGCTTTCAGACACTGGGGTGACACATGCTGACCAATGT 1457
DB 92 CAACCTACAGCTTCTTCCACGCTGCTTTCAGACACTGGGGTGACACATGCTGACCAATGT 38

RESULT 33
BF850808
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
COMMENT

BF850808 273 bp mRNA linear EST 16-JAN-2001
CM3-EN0111-231100-507-f07 EN0111 Homo sapiens CDNA, mRNA sequence.
BF850808
BF850808.1 GI:12237970
EST.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 273)
Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.P.,
Goldman,G.H., Cavallho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
Brunstein,A., deoliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
M.J., Soares,F., Brantani,R.R., Reis,L.F., de Souza,S.J. and
Simpson,A.J.
Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags
Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
20202663
10737800
Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922

Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the PAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=CM3&t2=CM3-EN0111-
231100-507-f07&t3=2000-11-23&t4=1)
Seq primer: puc 18 forward
High quality sequence start: 12
High quality sequence stop: 273.
Location/Qualifiers
1. .273
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/dev_stage="Adult"
/clone_lib="EN0111"
/note="Organ: lung normal; Vector: puc18; Site: i: SmaI;
Site 2: SmaI; A mini-library was made by cloning products
derived from ORSTES PCR (U.S. Letters Patent application
No. 196,716 - Ludwig Institute for Cancer Research)
profiles into the puc 18 vector. Reverse transcription of
tissue mRNA and cDNA amplification were performed under
low stringency conditions."
low stringency conditions."
52 a 86 c 71 g 64 t

BASE COUNT
ORIGIN

Query Match 7.8%; Score 170; DB 10; Length 273;
Best Local Similarity 100.0%; Pred. No. 3.8e-72;
Matches 170; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1062 CGAGGCCCTACCTCTGTCGAGGTGGACAGCCCTCTTCCAGTCTCTGCCCCCTCATC 1121
DB 87 CGAGGCCCTACCTCTGTCGAGGTGGACAGCCCTCTTCCAGTCTCTGCCCCCTCATC 146
QY 1122 ATGGACGACCTCGAGACCTCAACATTTTCAGAGTGGCGATGGCAGAACTTAAGTTCGG 1181
DB 147 ATGGACGACCTCGAGACCTCAACATTTTCAGAGTGGCGATGGCAGAACTTAAGTTCGG 206
QY 1182 ACTCCCTCTATGCTCTCCGTGAAGTGTGCTGCCCAATGGGACAGTCT 1231
DB 207 ACTCCCTCTATGCTCTCCGTGAAGTGTGCTGCCCAATGGGACAGTCT 256

RESULT 34
AI845568/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
PUBMED
COMMENT

AI845568 336 bp mRNA linear EST 15-JUL-1999
UI-M-A01-adx-a-11-0-UI-s1 NIH BMAP.MHI N Mus musculus CDNA clone
UI-M-A01-adx-a-11-0-UI 3', mRNA sequence.
AI845568
AI845568.1 GI:5489474
EST.
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 336)
Bonaldo,M.F., Lemmon,G. and Soares,M.B.
Normalization and subtraction: two approaches to facilitate gene
discovery
Genome Res. 6 (9), 791-806 (1996)
97044477
8899548
Contact: Chin, H
National Institute of Mental Health
6001 Executive Blvd. Room 7N-7190, MSC 9643, Bethesda, MD
20832-9643, USA
Tel: 301 443 1706
Fax: 301 443 9890
Email: mEST@mail.nih.gov
The sequence contained an oligo-dT track that was present in the
oligonucleotide that was used to prime the synthesis of first
strand cDNA and therefore this may represent a bonafide poly A
tail. The sequence tag present in the cDNA between the NotI site

and the oligo-dT track served to verify it as a clone from the normalized hippocampus library cDNA Library Preparation: M.B. Soares Lab Clone distribution: NIH BMAP cDNA clones will be made available by the means that is soon to be determined. When NIH determines the means for distribution of the BMAP cDNA clones, this record will be updated accordingly when that means is determined. The following repetitive elements were found in this cDNA sequence: 1-57, >AT rich#low complexity
Seq primer: M13 Forward
POLYA=Yes.

FEATURES
source
Location/Qualifiers
1. 336
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UI-M-AQ1-ada-a-11-0-UI"
/dev_stage="27-32 days"
/lab_host="DHI09 (Life Technologies)"
/note="Vector: pT7T3D-Pac (Pharmacia) with a modified polylinker; Site 1: Not 1; Site 2: Eco RI; The NIH BMAP.MHI n library is a normalized library constructed from mouse hippocampus. The tag is a string of 5 nucleotides present between the Not 1 site and the oligo-dT track. The library was constructed as described by Bonaldo, Lennon and Soares, Genome Research 6: 791-806, 1996. Tissue provided by Ms. Annie Novakovich, Zivic-Miller Laboratories.
TAG LIB=NIH BMAP MHI N
TAG TISSUE=hippocampus
TAG_SEQ=TTCTGA 72 g 140 t

BASE COUNT 76 a 48 c 72 g 140 t
ORIGIN
Query Match 7.6%; Score 165; DB 9; Length 336;
Best Local Similarity 100.0%; Pred. No. 1.1e-69;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1860 CATGACCATATTAACTACACACTACAAACAGCAGCATGGGCCCTGGACAGAAAC 1919
1860 CATGACCATATTAACTACACACTACAAACAGCAGCATGGGCCCTGGACAGAAAC 275
1920 AGCTGGGGAACTCTCTGACCCCAAGTCACCACTATCTCTGAACCTTATATATTCAG 1979
1920 AGCTGGGGAACTCTCTGACCCCAAGTCACCACTATCTCTGAACCTTATATATTCAG 215
1980 ACCATACCAAGGACAGGTACAGGAACCTCAATATGACTCCCC 2024
214 ACCATACCAAGGACAGGTACAGGAACCTCAATATGACTCCCC 170

RESULT 35
BB805784
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
Mus musculus (house mouse)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 356)
Akimura,T., Arakawa,T., Carninci,P., Furuno,M., Hanagaki,T., Hayatsu,N., Hiramoto,K., Hiraoka,T., Hirozane,T., Imocani,K., Ishii,Y., Ito,M., Kawai,J., Kojima,Y., Konno,H., Kouda,M., Matsuyama,T., Nakamura,M., Nishi,K., Nomura,K., Numasaki,R., Okazaki,Y., Okido,T., Saito,R., Sakai,C., Sakai,K., Sakazume,N., Sasaki,D., Sato,K., Shibata,K., Shinagawa,A., Shiraki,T., Sogabe,Y., Suzuki,H., Tagawa,A., Takahashi,F., Takaku-Akahira,S., Tanaka,T., Tomaru,A., Toya,T., Watahiki,A., Yasunishi,A., Muramatsu,M. and Hayashizaki,Y.

TITLE
JOURNAL
COMMENT
RIKEN Encyclopedia of Mouse Full-length cDNAs (Akimura,T., et al. 2001)
Unpublished
Contact: Yoshihide Hayashizaki
Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), Yokohama Institute
The Institute of Physical and Chemical Research (RIKEN)
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
Tel: 81-45-503-9222
Fax: 81-45-503-9216
Email: genome-res@gsc.riken.go.jp,
URL:http://genome.gsc.riken.go.jp/
Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K., Itoh,M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.
Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes. Genome Res. 10 (10), 1617-1630 (2000)
wagi,K., Fujiwaka,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E., Wataniki,M., Ioneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsuura,S., Kawai,J., Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and Hayashizaki,Y.
RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer. Genome Res. 10 (11), 1757-1771 (2000)
Konno,H., Fukunishi,Y., Shibata,K., Itoh,M., Carninci,P., Sugahara,Y. and Hayashizaki,Y.
Computer-based methods for the mouse full-length cDNA nonredundant cDNA library. Genome Res. 11 (2), 281-289 (2001)
Please visit our web site (http://genome.gsc.riken.go.jp) for further details.
e mouse tissues

FEATURES
Location/Qualifiers
1. 356
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="G63007F10"
/tissue_type="cerebellum"
/dev_stage="1 month neonate"
/clone_lib="RIKEN full-length enriched, 1 month neonate cerebellum"

BASE COUNT 123 a 85 c 65 g 83 t
ORIGIN
Query Match 7.6%; Score 165; DB 10; Length 356;
Best Local Similarity 100.0%; Pred. No. 1.1e-69;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1860 CATGACCATATTAACTACACACTACAAACAGCAGCATGGGCCCTGGACAGAAAC 1919
1860 CATGACCATATTAACTACACACTACAAACAGCAGCATGGGCCCTGGACAGAAAC 120
1920 AGCTGGGGAACTCTCTGACCCCAAGTCACCACTATCTCTGAACCTTATATATTCAG 1979
1920 AGCTGGGGAACTCTCTGACCCCAAGTCACCACTATCTCTGAACCTTATATATTCAG 180
1980 ACCATACCAAGGACAGGTACAGGAACCTCAATATGACTCCCC 2024
181 ACCATACCAAGGACAGGTACAGGAACCTCAATATGACTCCCC 225

RESULT 36
BB805784
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
Mus musculus (house mouse)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 356)
Akimura,T., Arakawa,T., Carninci,P., Furuno,M., Hanagaki,T., Hayatsu,N., Hiramoto,K., Hiraoka,T., Hirozane,T., Imocani,K., Ishii,Y., Ito,M., Kawai,J., Kojima,Y., Konno,H., Kouda,M., Matsuyama,T., Nakamura,M., Nishi,K., Nomura,K., Numasaki,R., Okazaki,Y., Okido,T., Saito,R., Sakai,C., Sakai,K., Sakazume,N., Sasaki,D., Sato,K., Shibata,K., Shinagawa,A., Shiraki,T., Sogabe,Y., Suzuki,H., Tagawa,A., Takahashi,F., Takaku-Akahira,S., Tanaka,T., Tomaru,A., Toya,T., Watahiki,A., Yasunishi,A., Muramatsu,M. and Hayashizaki,Y.

BASE COUNT 123 a 85 c 65 g 83 t
ORIGIN
Query Match 7.6%; Score 165; DB 10; Length 356;
Best Local Similarity 100.0%; Pred. No. 1.1e-69;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1860 CATGACCATATTAACTACACACTACAAACAGCAGCATGGGCCCTGGACAGAAAC 1919
1860 CATGACCATATTAACTACACACTACAAACAGCAGCATGGGCCCTGGACAGAAAC 120
1920 AGCTGGGGAACTCTCTGACCCCAAGTCACCACTATCTCTGAACCTTATATATTCAG 1979
1920 AGCTGGGGAACTCTCTGACCCCAAGTCACCACTATCTCTGAACCTTATATATTCAG 180
1980 ACCATACCAAGGACAGGTACAGGAACCTCAATATGACTCCCC 2024
181 ACCATACCAAGGACAGGTACAGGAACCTCAATATGACTCCCC 225

RESULT 36
BB805784
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
Mus musculus (house mouse)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 356)
Akimura,T., Arakawa,T., Carninci,P., Furuno,M., Hanagaki,T., Hayatsu,N., Hiramoto,K., Hiraoka,T., Hirozane,T., Imocani,K., Ishii,Y., Ito,M., Kawai,J., Kojima,Y., Konno,H., Kouda,M., Matsuyama,T., Nakamura,M., Nishi,K., Nomura,K., Numasaki,R., Okazaki,Y., Okido,T., Saito,R., Sakai,C., Sakai,K., Sakazume,N., Sasaki,D., Sato,K., Shibata,K., Shinagawa,A., Shiraki,T., Sogabe,Y., Suzuki,H., Tagawa,A., Takahashi,F., Takaku-Akahira,S., Tanaka,T., Tomaru,A., Toya,T., Watahiki,A., Yasunishi,A., Muramatsu,M. and Hayashizaki,Y.

RESULT 36
BB805784
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
Mus musculus (house mouse)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 356)
Akimura,T., Arakawa,T., Carninci,P., Furuno,M., Hanagaki,T., Hayatsu,N., Hiramoto,K., Hiraoka,T., Hirozane,T., Imocani,K., Ishii,Y., Ito,M., Kawai,J., Kojima,Y., Konno,H., Kouda,M., Matsuyama,T., Nakamura,M., Nishi,K., Nomura,K., Numasaki,R., Okazaki,Y., Okido,T., Saito,R., Sakai,C., Sakai,K., Sakazume,N., Sasaki,D., Sato,K., Shibata,K., Shinagawa,A., Shiraki,T., Sogabe,Y., Suzuki,H., Tagawa,A., Takahashi,F., Takaku-Akahira,S., Tanaka,T., Tomaru,A., Toya,T., Watahiki,A., Yasunishi,A., Muramatsu,M. and Hayashizaki,Y.

RESULT 36
BB805784
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
Mus musculus (house mouse)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 356)
Akimura,T., Arakawa,T., Carninci,P., Furuno,M., Hanagaki,T., Hayatsu,N., Hiramoto,K., Hiraoka,T., Hirozane,T., Imocani,K., Ishii,Y., Ito,M., Kawai,J., Kojima,Y., Konno,H., Kouda,M., Matsuyama,T., Nakamura,M., Nishi,K., Nomura,K., Numasaki,R., Okazaki,Y., Okido,T., Saito,R., Sakai,C., Sakai,K., Sakazume,N., Sasaki,D., Sato,K., Shibata,K., Shinagawa,A., Shiraki,T., Sogabe,Y., Suzuki,H., Tagawa,A., Takahashi,F., Takaku-Akahira,S., Tanaka,T., Tomaru,A., Toya,T., Watahiki,A., Yasunishi,A., Muramatsu,M. and Hayashizaki,Y.

RESULT 37

AK046781 2833 bp mRNA linear HTC 05-DEC-2002

AK046781

LOCUS

DEFINITION

Mus musculus 10 days neonate medulla oblongata cDNA, RIKEN full-length enriched library, clone:B83005D03 product:HBG-LIKS PROTEIN (FRAGMENT) homolog [Mus musculus], full insert sequence.

AK046781

ACCESSION

AK046781.1 GI:26338356

VERSION

HTC; CAP trapper.

KEYWORDS

Mus musculus (house mouse)

SOURCE

Mus musculus

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

1 Carninci,P. and Hayashizaki,Y.
High-efficiency full-length cDNA cloning
Meth. Enzymol. 303, 19-44 (1999)
99279253
10349636

2

3 Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K., Itoh,M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.
Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes
Genome Res. 10 (10), 1617-1630 (2000)
20499374
11042159

4

5 Shibata,K., Itoh,M., Aizawa,K., Nagaoka,S., Sasaki,N., Carninci,P., Konno,H., Akiyama,J., Nishi,K., Kitsunai,T., Tashiro,H., Itoh,M., Sumi,N., Ishii,Y., Nakamura,S., Hazama,M., Nishine,T., Harada,A., Yamamoto,R., Matsumoto,H., Sakaguchi,S., Ikegami,T., Kashiwagi,K., Fujiwara,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E., Watabiki,M., Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsura,S., Kawai,J., Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and Hayashizaki,Y.
RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer
Genome Res. 10 (11), 1757-1771 (2000)
20530913
11076861

6

7 Kawai,J., Shinagawa,A., Shibata,K., Yoshino,M., Itoh,M., Ishii,Y., Arakawa,T., Hara,A., Fukunishi,Y., Konno,H., Adachi,J., Fukuda,S., Aizawa,K., Izawa,M., Nishi,K., Kiyosawa,H., Kondo,S., Yamanaka,I., Saito,T., Okazaki,Y., Gojobori,T., Bono,H., Kasukawa,T., Saito,R., Kadota,K., Matsuda,H., Ashburner,M., Batalov,S., Casavant,T., Pleischmann,W., Gaasterland,T., Gissi,C., King,B., Kochiwa,H., Kuehl,P., Lewis,S., Matsuo,Y., Nikaido,I., Pesole,G., Quackenbush,J., Schriml,L.M., Staubli,P., Suzuki,R., Tomita,M., Wagner,L., Washio,T., Sakai,K., Okido,T., Furuno M., Aono,H., Baldarelli,R., Barsh,G., Blake,J., Boffelli,D., Bojunga,N., Carninci,P., de Bonaldo,M.F., Brownstein,M.J., Bult,C., Clench,A., Fujita,M., Gariboldi,M., Gustincich,S., Hill,D., Hofmann,M., Hume,D.A., Kamiya,M., Lee,N.H., Lyons,P., Marchionni,L., Mashima,J., Mazzarelli,J., Mombaerts,P., Nordone,P., Ring,B., Ringwald,M., Rodriguez,I., Sakamoto,N., Sasaki,H., Sato,K., Schonbach,C., Seye,T., Shibata,Y., Storch,K.F., Suzuki,H., Toyooka,K., Wang,K.H., Weitz,C., Whittaker,C., Wilming,L., Wyshah-Boris,A., Yoshida,K., Hasegawa,Y., Kawaji,H., Kohtsuki,S., Hayashizaki,Y.

8

9 Functional annotation of a full-length mouse cDNA collection
Nature 409 (6821), 685-690 (2001)
21085560
11217851

10

11 The PANTOX Consortium and the RIKEN Genome Exploration Research Group Phase I & II Team.
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs
Nature 420, 563-573 (2002)
6 (bases 1 to 2833)

12

13 Adachi,J., Aizawa,K., Akimura,T., Arakawa,T., Bono,H., Carninci,P., Fukuda,S., Furuno,M., Hanacek,T., Hara,A., Hashizume,W.,

Hayashida, K., Hayatsu, N., Hiramoto, K., Hiraoka, T., Hirozane, T., Hori, F., Imotani, K., Ishii, Y., Itoh, M., Kagawa, I., Kasukawa, T., Kato, H., Kawaji, S., Kojima, Y., Kondo, S., Konno, H., Kouda, M., Koya, S., Kurihara, C., Matsuyama, T., Miyazaki, A., Murata, M., Nakamura, M., Nishi, K., Nomura, K., Numazaki, R., Ohno, M., Ohsato, N., Okazaki, Y., Saito, R., Saitho, H., Sakai, C., Sakai, K., Sakazume, N., Sano, H., Sasaki, D., Shibata, K., Shingawa, A., Shiraki, T., Sojabe, Y., Tsgami, M., Tagawa, A., Takahashi, F., Takaku-Akahira, S., Takeda, Y., Tanaka, T., Tomaru, A., Toya, T., Yasunishi, A., Muramatsu, M. and Hayashizaki, Y.

Direct Submission

Submitted (16-JUL-2001) Yoshihide Hayashizaki, The Institute of Physiological and Chemical Research (RIKEN), Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan (E-mail: genome-resgsc@riken.go.jp, URL: <http://genome.gsc.riken.go.jp/>, Tel: 81-45-503-9222, Fax: 81-45-503-9216)

cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN Division of Experimental Animal Research in Riken contributed to prepare mouse tissues.

Please visit our web site for further details.

URL: <http://genome.gsc.riken.go.jp/>

URL: <http://fantom.gsc.riken.go.jp/>

[illegible]

```

1. .2833
  /organism="Mus musculus"
  /mol_type="mRNA"
  /strain="C57BL/6J"
  /db_xref="FANTOM DB:H830005D03"
  /db_xref="taxon:10090"
  /cclone="B830005D03"
  /tissue_type="medulla oblongata"
  /cclone_lib=R1KEN full-length enriched mouse cDNA library"
  /dev_stage="10 days neonate"
  10. .1299
  /note="unnamed protein product: L1BG-LIKE PROTEIN
  (FRAGMENT) homolog [Mus musculus] [STR|Q99PH1, evidence:
  FASTA, 100%ID, 97.9%length, match=1296]
  putative"

```

```

/codon_start=1
/protein_id="BAC32864.1"
/db_xref="GI:26338357"
/translation="MSGNHFFPIRGSTFGLSSLKLVNWSQVSLIERNADFGLAS
VELNLANNLSSHPDHFPIRYVELLHNLNPNCCDDILNLGAWMLREYIPNISTCC
LRCPAMVWGRHLYVEVQAPQSCAPIMDAPDLNDSIENWAEUKCRTPNWSVYK
GLEGCHPMVGRSHRPIISVANDTNGISRVLLIDTVGYCMVNVNAGNSNAYSLNVK
SKOLNPVNSFTFDTTVEIETSPEDIPKIPVPTSGPYATSTVLTQTPRS
PACLVNPFSTFDTTQWOTSLDEYKEDIIICFVAVTLAAAMLVFLKREHQORS
TVTAARTVEIIOVDESIIPAAAPAAATAAPSGVGEAGVLTPIHDHINVTNYTKPAAFGA
HVTANSLSNGHHPHTVTTTIVTITOTHKDKVORTQ."

```

BASE COUNT
ORIGIN

Match	7.6%	Score 165	DB 11	Length 2833	
Local Similarity 100.0%	Pred. No. 1.1e-69				
165; Conservative 0	Mismatches 0	Indels 0	Gaps 0		
1860	CATGACCATATTAACTACACACCTTACAAACAGCAGCATGGGGCCCACTGGACAGAAAC	1919			
1141	CATGACCATATTAACTACACACCTTACAAACAGCAGCATGGGGCCCACTGGACAGAAAC	1200			
1920	AGCCTGGGGAACTCTCTGCAACCCACAGTCACCACTATCTCTGAAACCTTATATATTCAG	1979			
1201	AGCCTGGGGAACTCTCTGCAACCCACAGTCACCACTATCTCTGAAACCTTATATATTCAG	1560			
1980	ACCCATACCAAGGACAGGTACAGGAAACTCAATATGACTCCCC	2024			
1261	ACCCATACCAAGGACAGGTACAGGAAACTCAATATGACTCCCC	1305			

12b

RESULT 38
BQ368354/0
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

REFERENCE AUTHORS

TITL8

JOURNAL	
MEDLINE	
PUBMED	
COMMENT	

FEATURES
SOURCE

[illegible]

Query Match
Best Local
Matches 15

1633 y

1693

159

99
p

RESULT 39

BQ368354 293 bp mRNA linear EST 21-MAY-2000
PM3-GNDS051-160501-003-f04 GN0501 Homo sapiens cDNA, mRNA sequence.
BQ368354 BQ368354
BQ368354.1 GI:21043868
EST.
Homo sapiens (human)
Homo sapiens
Homo sapiens
Sukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 283)
Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
Goldman,G.H., Carvalho,A.P., Satchukuma,A., Baia,G.S., Simpson,D.H.,
Brunstein,A., deoliveira,P.S., Bucker,P., Jongeneel,C.V., O'Hare
M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
Simpson,A.J.J.
Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags
Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
20202663
10737800
Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil

Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpcson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome project. This entry can be seen in the following URL
(<http://www.ludwig.org.br/scripts/gethtml2.pl?ti=PM3&t2=PM3-GND0501-160501-003-f04&t3=2001-05-16&t4=1>)
Seq primer: puc 18 forward
High quality sequence start: 17
High quality sequence stop: 264

```

Location/Qualifiers
1. 283
  /organism="Homo sapiens"
  /mol_type="mRNA"
  /db_xref="taxon:9606"
  /dev_stage="Adult"
  /clone_lib="GN0501"
  /note="organ: placenta normal; Vector: puc18; Site 1: SmaI
  ; Site 2: SmaI; A mini-library was made by cloning
  products derived from ORESTES PCR (U.S. Letters Patent
  application No. 195,716 - Ludwig Institute for Cancer
  Research) profiles into the pUC 18 vector. Reverse
  transcription of tissue mRNA and cDNA amplification were
  performed under low stringency conditions."

```

	performed	under low stringency conditions:
55 a	74 c	76 g
55 b	77 t	77 t
55 c	77 t	77 t
55 d	77 t	77 t
55 e	77 t	77 t
55 f	77 t	77 t
55 g	77 t	77 t
55 h	77 t	77 t
55 i	77 t	77 t
55 j	77 t	77 t
55 k	77 t	77 t
55 l	77 t	77 t
55 m	77 t	77 t
55 n	77 t	77 t
55 o	77 t	77 t
55 p	77 t	77 t
55 q	77 t	77 t
55 r	77 t	77 t
55 s	77 t	77 t
55 t	77 t	77 t
55 u	77 t	77 t
55 v	77 t	77 t
55 w	77 t	77 t
55 x	77 t	77 t
55 y	77 t	77 t
55 z	77 t	77 t
55 aa	77 t	77 t
55 ab	77 t	77 t
55 ac	77 t	77 t
55 ad	77 t	77 t
55 ae	77 t	77 t
55 af	77 t	77 t
55 ag	77 t	77 t
55 ah	77 t	77 t
55 ai	77 t	77 t
55 aj	77 t	77 t
55 ak	77 t	77 t
55 al	77 t	77 t
55 am	77 t	77 t
55 an	77 t	77 t
55 ao	77 t	77 t
55 ap	77 t	77 t
55 aq	77 t	77 t
55 ar	77 t	77 t
55 as	77 t	77 t
55 at	77 t	77 t
55 au	77 t	77 t
55 av	77 t	77 t
55 aw	77 t	77 t
55 ax	77 t	77 t
55 ay	77 t	77 t
55 az	77 t	77 t
55 ba	77 t	77 t
55 bb	77 t	77 t
55 bc	77 t	77 t
55 bd	77 t	77 t
55 be	77 t	77 t
55 bf	77 t	77 t
55 bg	77 t	77 t
55 bh	77 t	77 t
55 bi	77 t	77 t
55 bj	77 t	77 t
55 bk	77 t	77 t
55 bl	77 t	77 t
55 bm	77 t	77 t
55 bn	77 t	77 t
55 bo	77 t	77 t
55 bp	77 t	77 t
55 bq	77 t	77 t
55 br	77 t	77 t
55 bs	77 t	77 t
55 bt	77 t	77 t
55 bu	77 t	77 t
55 bv	77 t	77 t
55 bw	77 t	77 t
55 bx	77 t	77 t
55 by	77 t	77 t
55 bz	77 t	77 t
55 ca	77 t	77 t
55 cb	77 t	77 t
55 cc	77 t	77 t
55 cd	77 t	77 t
55 ce	77 t	77 t
55 cf	77 t	77 t
55 cg	77 t	77 t
55 ch	77 t	77 t
55 ci	77 t	77 t
55 cj	77 t	77 t
55 ck	77 t	77 t
55 cl	77 t	77 t
55 cm	77 t	77 t
55 cn	77 t	77 t
55 co	77 t	77 t
55 cp	77 t	77 t
55 cq	77 t	77 t
55 cr	77 t	77 t
55 cs	77 t	77 t
55 ct	77 t	77 t
55 cu	77 t	77 t
55 cv	77 t	77 t
55 cw	77 t	77 t
55 cx	77 t	77 t
55 cy	77 t	77 t
55 cz	77 t	77 t
55 da	77 t	77 t
55 db	77 t	77 t
55 dc	77 t	77 t
55 dd	77 t	77 t
55 de	77 t	77 t
55 df	77 t	77 t
55 dg	77 t	77 t
55 dh	77 t	77 t
55 di	77 t	77 t
55 dj	77 t	77 t
55 dk	77 t	77 t
55 dl	77 t	77 t
55 dm	77 t	77 t
55 dn	77 t	77 t
55 do	77 t	77 t

Ch 7.1%; Score 155; DB 13; Length 283;
 1 Similarity 100.0%; Pred. No. 9.4e-65;
 155; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

333 CCAAGATCATCATTTGGCTGCTTTGTGGCAGTGACTCTGCTAGCTGCCGCCATGTTGATTG 169222

93 TCCTCTATAAACTTCGTAAGCGGCCACCGACGCGGAGTACAGTCACAGCGCGCCGGACTG 1752

59 TCCTCTATAAACTTCGTAAGCGGCACAGCAGCGGAGTACAGTCACAGCGGCCCGACTG 100

TTGAGATAATCCAGGTGGACGAAGACATCCCAGCA 65

AA224351.1 GI:1844893
EST.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 150)
Hillier, L., Allen, M., Bowles, L., Dubuque, T., Geisel, G., Jost, S.,
Krizman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Marra, M., Martin
J., Moore, B., Schellenberg, K., Steptoe, M., Tan, F., Theising, B.,
White, Y., Wylie, T., Waterston, R. and Wilson, R.
WashU-NCI human EST Project
Unpublished
Contact: Willson RK
Washington University School of Medicine
444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
This clone is available royalty-free through LNL ; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
Insert Length: 1183 Std Error: 0.00
Seq primer: -41m13 fwd. ET from Amersham
High quality sequence stop: 140.

```

FEATURES
  source
    high quality, sequence, position, location/Qualifiers
      1. 150
        /organism="Homo sapiens"
        /mol_type="mRNA"
        /db_xref="GDB:5424652"
        /db_xref="taxon:9606"
        /clone="IMAGE:648623"
        /dev_stage="hmt neurons"
        /lab_host="SOLR (kanamycin resistant)"
        /clone_lib="stratagene hmt neuron (#937233)"
        /note="vector: pBluescript SK-; Site 1: EcoRI; Site 2:
        XhoI; Cloned unidirectionally. Primer: Oligo dt.
        Differentiated, post mitotic hmt neurons. Average insert
        size: 1.5 kb; Uni-AP XR vector: -5' adaptor sequence: 5'
        GATCGTCGACGAG 3' -3' adaptor sequence: 5'
        CTAATCGTTTTTTTTTTTTTTT 3'"
      43 a      25 c      18 g      64 t
      BASE COUNT
      ORIGIN
        Query Match      6.9%; Score: 150; DB 9; Length 150;
        Best Local Similarity 100.0%; Pred. NO. 2,7e-62;
        Matches 150; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

[illegible]

EST.
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 377)

AUTHORS Ronaldo M.F., Lennon G. and Soares M.B.
TITLE Normalization and subtraction: two approaches to facilitate gene discovery
JOURNAL Genome Res. 6 (9), 791-806 (1996)
MEDLINE 97044477
PUBMED 8889548
COMMENT Contact: Chin, H
National Institute of Mental Health
6001 Executive Blvd. Room 7N-7190, MSC 9643, Bethesda, MD 20892-9643, USA
Tel: 301 443 1706
Fax: 301 443 9890
Email: mEST@mail.nih.gov
The sequence contained an oligo-dT track that was present in the oligonucleotide that was used to prime the synthesis of first strand cDNA and therefore this may represent a bonafide poly A tail. The sequence tag present in the cDNA between the NciI site and the oligo-dT track served to verify it as a clone from the hippocampus tissue cDNA library Preparation: M.B. Soares Lab Clone distribution: Researchers may obtain BMAP cDNA clones from RESEARCH GENETICS. It should be noted that Bento Soares is generating a small number of additional specialized non-redundant arrays of BMAP cDNAs whose availability will be considered under appropriate and limited collaborative arrangements. The following repetitive elements were found in this cDNA sequence: 1-42,
>AT-rich#Low complexity 366-396, >(CAG)n#simple_repeat
Seq primer: M13 Forward
POLYA=Yes.

FEATURES
source
1..377
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UI-M-B21-bkx-c-06-0-UI"
/dev_stage="27-32 days"
/lab_host="DH10B (Life Technologies)"
/clone_lib="NIH BMAP MH12 S1"
/notes="Vector: pT73D-Pac (Pharmacia) with a modified polylinker; Site 1: Not I; Site 2: Eco RI; The NIH BMAP MH12 S1 library is a subtracted library derived from NIH BMAP MH12. NIH BMAP MH12 is a library derived from mouse hippocampus tissue. For a detailed description of the library from which this clone was derived, please visit our web site at brainest.eng.uiowa.edu.
TAG_LIB=NIH BMAP MH12 S1
TAG_TISSUE=hippocampus
TAG_SEQ=TAGTC"

BASE COUNT 80 a 74 c 98 g 125 t
ORIGIN
Query Match 6.3%; Score 138; DB 10; Length 377;
Best Local Similarity 100.0%; Pred. No. 2.3e-56;
Matches 138; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Y 1887 AACACGACATGGGGCCCACTGGACAGAAAACAGCCTGGGAATCTCTGCAACCCCA 1946
b 243 AACACGACATGGGGCCCACTGGACAGAAAACAGCCTGGGAATCTCTGCAACCCCA 184
Y 1947 GTACCACTATCTGAACTTATATATTCAGACCCATACAGACAGAGTACAGAA 2006
b 183 GTACCACTATCTGAACTTATATATTCAGACCCATACAGACAGAGTACAGAA 124
Y 2007 ACTCAATATGACTCCCC 2024
b 123 ACTCAATATGACTCCCC 106

RESULT 42
Q340624
LOCUS BQ340624 300 bp mRNA linear EST 20-MAY-2002
DEFINITION PMO-NN0258-220501-001-f05 NN0258 Homo sapiens cDNA, mRNA sequence.
ACCESSION BQ340624

VERSION BQ340624.1 GI:21001705
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 300)
AUTHORS Dias Neto, E., Garcia Correa, R., Verjovski-Almeida, S., Briones, M.R., Nagai, M.A., da Silva, W. Jr., Zago, M.A., Bordin, S., Costa, F.F., Goldman, G.H., Carvalho, A.P., Matsukuma, A., Baia, G.S., Simpson, D.H., Brunstein, A., deOliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare, M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.J. and Simpson, A.J.
TITLE Shotgun sequencing of the human transcriptome with ORF expressed sequence tags
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE 20202663
PUBMED 10737800
COMMENT Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP, Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=PMO&t2=PMO-NN0258-220501-001-f05&t3=2001-05-22&t4=1)
Seq primer: puc 18 forward
High quality sequence start: 19
High quality sequence stop: 254.
Location/Qualifiers
1..300
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/dev_stage="Adult"
/clone_lib="NN0258"

BASE COUNT 56 a 96 c 71 g 77 t
ORIGIN
Query Match 6.1%; Score 134; DB 13; Length 300;
Best Local Similarity 99.5%; Pred. No. 2.1e-54;
Matches 184; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 878 CCACATAAAGCTCTCTTTGGCCCATGACCTTTTACCCGCTGAGGTACTGGTGA 937
Db 55 CCACATAAAGCTCTCTTTGGCCCATGACCTTTTACCCGCTGAGGTACTGGTGA 114
QY 938 GTTGCACTACACACACACCCCTTGGAACTGTGATCTGACATTTCTGTGCTAGCCTGGTG 997
Db 115 GTTGCACTACACACACACCCCTTGGAACTGTGATCTGACATTTCTGTGCTAGCCTGGTG 174
QY 998 GCTTCGAGAGTATATACCCACCAATTCACCTGCTGCTGGCCGCTGTCTCCCATGCA 1057
Db 175 GCCTCGAGAGTATATACCCACCAATTCACCTGCTGCTGGCCGCTGTCTCCCATGCA 234
QY 1058 CATGC 1062
Db 235 CATGC 239

RESULT 43
AW521479/c

LOCUS AWS21479 283 bp mRNA linear EST 06-MAR-2000
DEFINITION UI-R-B00-agn-e-06-0-UI.s1 UI-R-B00 Rattus norvegicus cDNA clone
ACCESSION AWS21479
VERSION
KEYWORDS
SOURCE Rattus norvegicus (Norway rat)
ORGANISM
REFERENCE 1 (bases 1 to 283)
AUTHORS Ronaldo, M. P., Lennon, G. and Soares, M. B.
TITLE Normalization and subtraction: two approaches to facilitate gene
discovery
JOURNAL Genome Res. 6 (9), 791-806 (1996)
MEDLINE 97044477
PubMed 8889548
COMMENT Contact: Soares, MB
Coordinated Laboratory for Computational Genomics
University of Iowa
375 Newton Road, 4156 MEBRF, Iowa City, IA 52242, USA
Tel: 319 335 8250
Fax: 319 335 9565
Email: bento-soares@uiowa.edu
The sequence contained an oligo-dT track that was present in the
oligonucleotide that was used to prime the synthesis of first
strand cDNA and therefore this may represent a bonafide poly A
tail. The sequence tag present in the cDNA between the NotI site
and the oligo-dT track served to identify it as a clone from the
normalized corpus-striatum library cDNA library Preparation: M.B.
Soares Lab Clone distribution: clones will be available through
Research Genetics (www.resgen.com) The following repetitive
elements were found in this cDNA sequence: 1-47,
>AT rich#Low complexity
Seq primer: M13 Forward
POLYA=tes.
FEATURES
source
1..283
/organism="Rattus norvegicus"
/mol_type="mRNA"
/strain="Sprague-Dawley"
/db_xref="taxon:10116"
/clone="UI-R-B00-agn-e-06-0-UI"
/dev_stage="adult"
/lab_host="DH10B (Life Technologies)"
/clone_lib="UI-R-B00"
/note="Vector: pT730-Pac (Pharmacia) with a modified
polylinker. Site 1: Not I; Site 2: Eco RI. The library
(UI-R-B00) is a subtracted library derived from a mixture
of the following tissues: thalamus, cerebellum,
hypothalamus, medulla, pons, midbrain, cerebral
corpus striatum and hippocampus. For a detailed
description of the library from which this clone was
derived, please visit our web site at
raterst.eng.uiowa.edu. The subtraction has been previously
described in (Bonaldo, Lennon and Soares, Genome Research
6:791-806, 1996)
TAG_LIB=UI-R-B00
TAG_TISSUE=corpus-striatum
TAG_SEQ=CTAGG"
BASE COUNT 66 a 59 g 115 t
ORIGIN
5.7%; Score 124; DB 9; Length 283;
Query Match
Best Local Similarity 100.0%; Pred. No. 1.8e-49;
Matches 124; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1901 GGCCCACTGGACAGAAACAGCGCTGGGAACCTCTGCACCCCAAGTCAACCTATCTC 1960
Db 283 GGCCCACTGGACAGAAACAGCGCTGGGAACCTCTCTGCACCCCAAGTCAACCTATCTC 224
QY 1961 TGAACCTTATATATTCAGACCCCAACAGGACAGGAGTACAGGAACTCAATATGACT 2020

Db 223 TGAACCTTATATATTCAGACCCCAACAGGACAGGAGTACAGGAACTCAATATGACT 164
QY 2021 CCCC 2024
Db 163 CCCC 160
RESULT 44
AI568859/c
LOCUS
DEFINITION to23b10.x1 NCI_CGAP_Ut2 Homo sapiens cDNA clone IMAGE:2179867 3',
mRNA sequence.
ACCESSION AI568859
VERSION AI568859.1 GI:4532233
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 437)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgaubs-remail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bbrp/image/image.html
Insert Length: 511 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 407
POLYA=No.
FEATURES
Location/Qualifiers
1..437
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2179867"
/tissue_type="moderately-differentiated endometrial
adenocarcinoma, 3 pooled tumors"
/lab_host="DH10B"
/clone_lib="NCI CGAP Ut2"
/note="Organ: uterus; Vector: pCMV-SPORT6; Site 1: SalI;
Site 2: NotI; Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.85 kb. Life Technologies catalog #:
11539-012"
BASE COUNT 128 a 101 c 59 g 149 t
ORIGIN
5.6%; Score 122; DB 9; Length 437;
Query Match
Best Local Similarity 100.0%; Pred. No. 1.7e-48;
Matches 122; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2064 AAGACAGCAACTTTTGTACAGAGTGGGAGAGACTTTTCTTGATATGCTTATATTA 2123
Db 437 AAGACAGCAACTTTTGTACAGAGTGGGAGAGACTTTTCTTGATATGCTTATATTA 378
QY 2124 AGTCTATGGCTGTTTAAACAAAACAGATTATATTAAAGACAAAAGTCAAAA 2183
Db 377 AGTCTATGGCTGTTTAAACAAAACAGATTATATTAAAGACAAAAGTCAAAA 318
QY 2184 CA 2185
Db 317 CA 316

transcriptase and subsequently enriched for full-length by cap-trapper. cDNA went through one round of normalization to Rot = 10.0 and subtraction to Rot = 185.0. Second strand cDNA was prepared with the primer adapter of sequence [5' GAGAGAGATTCTCGAGTTAATAATTAATCCCTCCCCC 3']. cDNA was cloned into the XhoI and BamHI sites. Vector: a modified pBluescript KS(+) after bulk excision from Lambda FLC I. Cloning sites, 5' end: SalI; 3' end: BamHI"

BASE COUNT 102 a 74 c 41 g 69 t
ORIGIN

Query Match 5.3%; Score 115; DB 10; Length 286;
Best Local Similarity 100.0%; Pred. No. 4.9e-45;
Matches 115; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1910 GACAGAAACAGCTGGGAATCTCTGACCCACAGTCACACATATCTCTGAACCTTA 1969
DB 34 GACAGAAACAGCTGGGAATCTCTGACCCACAGTCACACATATCTCTGAACCTTA.93

QY 1970 TATATTCAGCCCATCAACGACAGTACAGAACTCAAAATATGACTCCCC 2024
DB 94 TATATTCAGCCCATCAACGACAGTACAGAACTCAAAATATGACTCCCC 148

RESULT 46
AL1412486/c 401 bp mRNA linear EST 09-FEB-1999

LOCUS EST240785 Normalized rat brain, Bento Soares Rattus sp. cDNA clone
DEFINITION RBRD21 3' end, mRNA sequence.
ACCESSION AL1412486
VERSION AL1412486.1 GI:4255990
KEYWORDS EST.
SOURCE Rattus sp.
ORGANISM Rattus sp.
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.

REFERENCE 1 (bases 1 to 401)
AUTHORS Lee, N.H., Glodok, A., Chandra, I., Mason, T.M., Quackenbush, J., Karlavage, A.R. and Adams, M.D.
Rat Genome Project: Generation of a Rat EST (RST) Catalog & Rat Gene Index
JOURNAL Unpublished
COMMENT Contact: Lee, NH
The Institute for Genomic Research
9712, Medical Center Drive, Rockville, MD 20850, USA
Tel: (301)-838-3529
Fax: (301)-838-0208
Email: nhlee@igr.org
Seq primer: M13-21.
Location/Qualifiers
1. .401
/organism="Rattus sp."
/mol_type="mRNA"
/db_xref="taxon:10118"
/clone="RBRD21"
/clone_lib="Normalized rat brain, Bento Soares"
/note="Organ: brain; Vector: pT73Pac; Site_1: EcoRI; Site_2: NotI"
BASE COUNT 86 a 103 g 143 t
ORIGIN

Query Match 5.2%; Score 114; DB 9; Length 401;
Best Local Similarity 99.4%; Pred. No. 1.5e-44;
Matches 164; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1860 CATGACCATTAATTAACAACCTACAAACAGCAGCATGGGCCCACTGGACAGAAAC 1919
DB 322 CATGACCATTAATTAACAACCTACAAACAGCAGCATGGGCCCACTGGACAGAAAC 263

QY 1920 AGCTGGGGAACTCTCTGACCCACAGTCACACTATCTCTGAACTTATATTCAG 1979

FEATURES
source
1. .286
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clones="9330171011"
/sex="male"
/tissue_type="diencephalon"
/dev_stage="adult"
/lab_host="DRI03"
/clone_lib="RIKEN full-length enriched, adult male diencephalon"
/note="Site 1: SalI; Site 2: BamHI; cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. 1st strand cDNA was primed with a primer [5' GAGAGAGAGATCCAGAGCTCTTTTTTTTTTTTNN 3'], cDNA was prepared by using trehalose thermo-activated reverse

EST 45
B081954
OCUS
EPINITION linear EST 28-JUN-2000
MUSCULUS cDNA clone 9330171011 3', mRNA sequence.
CESSION
ERSON
EYWORDS
ORCE
ORGANISM Mus musculus (house mouse)
Mus musculus
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 286)
Konno, H., Aizawa, K., Akhira, S., Akiyama, J., Arakawa, T., Carninci, P., Endo, T., Fukuda, S., Fukunishi, Y., Hara, A., Hayatsu, M., Hirozane, T., Hori, F., Ishii, Y., Ishikawa, J., Ishikawa, T., Itoh, M., Izawa, M., Kadota, K., Kagawa, I., Kai, C., Kawai, J., Kikuchi, N., Kiyosawa, H., Kojima, Y., Kondo, S., Koya, S., Kurihara, C., Kusakabe, M., Matsuyama, T., Miki, R., Mizuno, Y., Nakamura, M., Oda, H., Okazaki, Y., Ono, T., Owa, C., Saito, H., Sakai, C., Sato, K., Shibata, K., Shibata, Y., Shigemoto, Y., Shingawa, A., Shiraki, T., Sogabe, Y., Suganara, Y., Suzuki, H., Suzuki, H., Tagawa, A., Takahashi, F., Tomimaga, N., Toya, T., Tsunoda, Y., Watahiki, A., Watanabe, S., Yamamura, T., Yamanaka, I., Yano, R., Yasunishi, A., Yokota, T., Yoshida, K., Yoshiki, A., Yoshino, M., Muramatsu, M. and Hayashizaki, Y.
RIKEN Mouse ESTs (Konno, H., et al.)
Unpublished
Contact: Yoshihide Hayashizaki
Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), Yokohama Institute
The Institute of Physical and Chemical Research (RIKEN)
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
Tel: 81-45-503-9222
Fax: 81-45-503-9216
Email: genome-res@gs.riken.go.jp,
URL: http://genome.gsc.riken.go.jp/
Carninci, P., Nishiyama, Y., Westover, A., Itoh, M., Nagaoka, S., Sasaki, N., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
Thermotabilization and thermoactivation of thermolabile enzymes by trehalose and its application for the synthesis of full length cDNA. Proc. Natl. Acad. Sci. U.S.A. 95 (2), 520-524 (1998)
Itoh, M., Kitsuai, T., Akiyama, J., Shibata, K., Izawa, M., Kawai, J., Tomaru, Y., Carninci, P., Shibata, Y., Ozawa, Y., Muramatsu, M., Okazaki, Y. and Hayashizaki, Y.
Automated filtration-based high-throughput plasmid preparation system. Genome Res. 9 (5), 463-470 (1999)
Carninci, P. and Hayashizaki, Y.
High-efficiency full-length cDNA cloning. Methods Enzymol. 303, 19-44 (1999)
Please visit our web site (<http://genome.rtc.riken.go.jp>) for further details.
Location/Qualifiers
1. .286
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clones="9330171011"
/sex="male"
/tissue_type="diencephalon"
/dev_stage="adult"
/lab_host="DRI03"
/clone_lib="RIKEN full-length enriched, adult male diencephalon"
/note="Site 1: SalI; Site 2: BamHI; cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. 1st strand cDNA was primed with a primer [5' GAGAGAGAGATCCAGAGCTCTTTTTTTTTTTTNN 3'], cDNA was prepared by using trehalose thermo-activated reverse

Db 1995 AGCTGGGGAACTCTCTGCAACCCACAGTCACCACTATCTCTGAACCTTATATAATTTCAG 2055

QY 1980 ACCATACCAAGGACGAGGTACAGGAACTCAATATGACTCCCC 2024
|||||

Db 2055 ACCATACCAAGGACGAGGTACAGGAACTCAATATGACTCCCC 2099
|||||

RESULT 48
AA2233802 288 bp mRNA linear EST 11-MAR-1998
LOCUS zrl2f12.r1 Stratiogene hNT neuron (#9372233) Homo sapiens cDNA clone
DEFINITION IMAGE:648623 5', mRNA sequence.
AA2233802
AA2233802.1 GI:1844404
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 288)
AUTHORS Hillier,L., Allien,M., Bowles,L., Dubuque,T., Geisel,G., Jost,S.,
Krizman,D., Kucaba,T., Lacy,M., Le,N., Lennon,G., Maizra,M., Martin
,J., Moore,B., Schellenberg,K., Seftoe,M., Tan,P., Theising,B.,
White,Y., Wyllie,T., Waterston,R. and Wilson,R.
TITLE WashU-NCI human EST project
JOURNAL Unpublished
COMMENT Contact: Willson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
This clone is available royalty-free through LNL ; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
Insert Length: 1183 Std Error: 0.00
Seq primer: -28ml3 rev1 ET from Amersham
High quality sequence stop: 242.
Location/Qualifiers
1. 288
/organism="Homo sapiens"
/mol type="mRNA"
/db xref="GDB:5589142"
/db_xref="taxon:9606"
/clone="IMAGE:648623"
/dev stage="hNT neurons"
/lab host="SOLR (kanamycin resistant)"
/clone lib="Stratiogene hNT neuron (#9372233)"
/notes="Vector: pBluescript SK-; Site 1: EcoRI; Site_2:
XhoI; Cloned unidirectionally. Primer: Oligo dT.
Differentiated, post mitotic hNT neurons. Average insert
size: 1.5 Kb; Uni-ZAP XR Vector; -5' adaptor sequence: 5'
GAATTCGGCACGAG 3' -3' adaptor sequence: 5'
CTCAGATTTTTTTTTTTTTTTT 3'"

BASE COUNT 61 a 92 c 63 g 67 t 5 others
ORIGIN

Query Match 4.7%; Score 102; DB 9; Length 288;
Best Local Similarity 100.0%; Pred.No. 1.2e-38; Indels 0; Gaps 0;
Matches 102; Conservative 0; Mismatches 0;

QY 1287 TTTTCCCAACGCTGCTTTTCAGACACTGGGGGTGTACATGCAATGGTACCAATGTTGCA 1346
|||||

Db 134 TTTTCCCAACGCTGCTTTTCAGACACTGGGGGTGTACATGCAATGGTACCAATGTTGCA 213
|||||

QY 1347 GCGAAGCTTCAACGGCTCGGCTACCTCAATGTGACACGGCT 1388
|||||

Db 214 GCGAAGCTTCAACGGCTCGGCTACCTCAATGTGACACGGCT 255
|||||

RESULT 49
BB332277 279 bp mRNA linear EST 11-JUL-2000
LOCUS BB332277
DEFINITION BB332277 RIKEN full-length enriched, 10 days neonate medulla

oblongata Mus musculus cDNA clone B830002G05 3', mRNA sequence.

BB332777
BB332777.1 GI:9041540

EST.
Mus musculus (house mouse)

Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 279)

1918 ACAGCCTGGGGAACTCTCTGACCCACAGTCACAGTCCAGGAACTCAATATTC 1977
|||||
35 ACAGCCTGGGGAACTCTCTGACCCACAGTCACAGTCCAGGAACTCAATATTC 94
|||||

1978 AGACCCATCCAGGACACAGGTACAGGAACTCAATATTC 2018
|||||
95 AGACCCATCCAGGACACAGGTACAGGAACTCAATATTC 135
|||||

RESULT 50
BB700307 256 bp mRNA linear EST 11-OCT-2001

LOCUS
BB700307 RIKEN full-length enriched, in vitro fertilized eggs Mus
musculus cDNA clone 7420419L16 3', mRNA sequence.

ACCESSION
BB700307

VERSION
BB700307.1 GI:16049131

KEYWORDS
EST.

SOURCE
Mus musculus (house mouse)

ORGANISM
Mus musculus

REFERENCE
1 (bases 1 to 256)

AUTHORS
Akimura,T., Arakawa,T., Carninci,P., Furuno,M., Hanagaki,T.,
Hayatsu,N., Hiraoka,T., Hirozane,T., Imotani,K., Ishii,
Y., Ito,M., Kawai,J., Kojima,Y., Konno,H., Kouda,M., Matsuyama,T.,
Nakamura,M., Nishi,K., Nomura,K., Numasaki,R., Okazaki,Y., Okido,T.,
Saito,R., Sakai,C., Sakai,K., Sakazume,N., Sasaki,D., Sato,K.,
Shibata,K., Shingawa,A., Shiraki,T., Sogabe,Y., Suzuki,H., Tagawa,
A., Takahashi,F., Takaku-Akahira,S., Tanaka,T., Tomaru,A., Toya,T.,
Watahiki,A., Yasunishi,A., Muramatsu,M. and Hayashizaki,Y.
RIKEN Encyclopedia of Mouse Full-length cDNAs (Akimura,T., et al.
2001)

TITLE
Unpublished

JOURNAL
Contact: Yoshihide Hayashizaki
Laboratory for Genome Exploration Research Group, RIKEN Genomic
Sciences Center (GSC), Yokohama Institute
The Institute of Physical and Chemical Research (RIKEN)
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
Tel: 81-45-503-9222
Fax: 81-45-503-9216
Email: genome-resgsc.riken.go.jp,
URL: <http://genome.gsc.riken.go.jp/>
Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K., Itoh
M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.
Normalization and subtraction of cap-trapper-selected cDNAs to
prepare full-length cDNA libraries for rapid discovery of new
genes. Genome Res. 10 (10), 1617-1630 (2000)

COMMENT
wagi,K., Fujiwara,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E.,
Watahiki,M., Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsura
S., Kawai,J., Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and
Hayashizaki,Y.
RIKEN integrated sequence analysis (RISA) system--384-format
sequencing pipeline with 384 multicapillary sequencer. Genome Res.
10 (11), 1757-1771 (2000)

FEATURES
Computer-based methods for the mouse full-length cDNA
encyclopedia: real-time sequence clustering for construction of a
nonredundant cDNA library. Genome Res. 11 (2), 281-289 (2001)
Please visit our web site (<http://genome.gsc.riken.go.jp>) for
further details.
e mouse tissues.

LOCUS/Qualifiers
1. .256

```
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/ciOne="7420419L16"
/sex="female"
/tissue_type="in vitro fertilized eggs"
/dev_stage="egg"
/lab_host="DR10B"
/clone_lib="RIKEN full-length enriched, in vitro
fertilized eggs"
/note="Site 1: SalI; Site 2: BamHI; cDNA library was
prepared and sequenced in Mouse Genome Encyclopedia
Project of Genome Exploration Research Group in Riken
Genomic Sciences Center and Genome Science Laboratory in
RIKEN. Division of Experimental Animal Research in Riken
contributed to prepare mouse tissues. 1st strand cDNA was
primed with a primer [5'
GAGAGAGAGAGGATCCAGAGGCTTTTCTTTTITVN 3'], cDNA was
prepared by using trehalose thermo-activated reverse
transcriptase and subsequently enriched for full-length by
cap-trapper. Second strand cDNA was prepared with the
primer adapter of sequence [5'
GAGAGAGAGATCTCGAGTTAATTAATTAATGCCCCCCCC 3']. cDNA
was cloned into the XhoI and BamHI sites. Vector: a
modified phagescript KS(+) after bulk excision from Lambda
FLC 1. Cloning sites, 5' end: SalI; 3' end: BamHI"
```

```
BASE COUNT      96 a      53 C      40 G      67 T
ORIGIN
Query Match      4.5%; Score 99; DB 10; Length 256;
Best Local Similarity 100.0%; Pred.No. 3.9e-37;
Matches 99; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1926 GGGAACTCTGCAACCCACAGTCACCACTATCTGTGAACCTTATATATATTCAGACCCAT 1985
Db 20 GGGAACTCTGCAACCCACAGTCACCACTATCTGTGAACCTTATATATATTCAGACCCAT 79
QY 1986 ACCAAGGACAGGTACAGAACTCAATATGACTCCCC 2024
Db 80 ACCAAGGACAGGTACAGAACTCAATATGACTCCCC 118
```

Search completed: February 6, 2004, 03:57:25
Job time : 4180 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

CM nucleic - nucleic search, using sw model

Run on: February 6, 2004, 00:12:53 ; Search time 156 Seconds
(without alignments)
6182.193 Million cell updates/sec

Title: US-09-989-279-228

Perfect score: 2185

Sequence: 1 gttctcttccgagcaaa.....aaagacaaaagtcaaacaa 2185

Scoring table: OLIGO_NUC

Gapop 60.0 , Gapext 60.0

Searched: 569978 seqs, 220691566 residues

Word size : 10

Total number of hits satisfying chosen parameters: 249649

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 150 summaries

Database : Issued Patents, NA.*

1: /cgn2_6/ptodata/2/ina/5A COMB.seq.*

2: /cgn2_6/ptodata/2/ina/5B COMB.seq.*

3: /cgn2_6/ptodata/2/ina/6A COMB.seq.*

4: /cgn2_6/ptodata/2/ina/6B COMB.seq.*

5: /cgn2_6/ptodata/2/ina/PCFUS COMB.seq.*

6: /cgn2_6/ptodata/2/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2185	100.0	2185	4	US-09-996-243-228
2	50	2.3	50	4	US-09-996-243-251
3	31	1.4	31	4	US-09-996-243-466
4	29	1.3	973	4	US-09-482-273-13
5	29	1.3	984	4	US-09-482-273-82
6	26	1.2	26	4	US-09-996-243-465
7	20	0.9	20	4	US-09-996-243-464
8	20	0.9	1748	4	US-09-620-312D-712
9	19	0.9	997	4	US-09-690-454-33
10	19	0.9	1236	4	US-09-016-434-717
11	19	0.9	1243	1	US-08-702-344-27
12	19	0.9	6678	3	US-08-816-617A-1
13	19	0.9	9840	4	US-09-534-638-1
14	19	0.9	18853	4	US-09-820-005-3
15	19	0.9	42325	4	US-08-311-731A-131
16	19	0.9	43950	4	US-09-735-934A-3
17	19	0.9	43950	4	US-10-060-332-3
18	19	0.9	43716	4	US-08-965-048-5
19	19	0.9	45989	4	US-08-965-048-6
20	19	0.9	63588	4	US-09-873-404-3
21	19	0.9	112132	4	US-09-741-150-3
22	19	0.9	4403765	3	US-09-103-840A-2
23	19	0.9	4411529	3	US-09-103-840A-1
24	18	0.8	285	4	US-09-313-294A-3480
25	18	0.8	288	5	PCT-US94-04361-13
26	18	0.8	352	1	US-08-147-812-3
27	18	0.8	500	2	US-08-475-844-18

28	18	0.8	500	5	PCT-US95-08429-18	Sequence 18, Appl
29	18	0.8	531	4	US-09-328-352-2881	Sequence 2881, Ap
30	18	0.8	533	6	5482709-5	Patent No. 5482709
31	18	0.8	543	6	5273901-6	Patent No. 5273901
32	18	0.8	603	3	US-08-609-334-14	Sequence 25, Appl
33	18	0.8	687	5	PCT-US94-04361-25	Sequence 14, Appl
34	18	0.8	720	4	US-09-107-532A-3104	Sequence 3104, Ap
35	18	0.8	970	2	US-08-773-368-2	Sequence 2, Appl
36	18	0.8	970	3	US-09-199-887-2	Sequence 2, Appl
37	18	0.8	1119	4	US-09-252-991A-10559	Sequence 10559, A
38	18	0.8	1248	1	US-09-620-312D-936	Sequence 936, App
39	18	0.8	1275	4	US-08-588-113-1	Sequence 1, Appl
40	18	0.8	1425	4	US-09-252-991A-10301	Sequence 10301, A
41	18	0.8	1960	4	US-09-620-312D-764	Sequence 764, App
42	18	0.8	1986	4	US-09-252-991A-10499	Sequence 10499, A
43	18	0.8	2906	4	US-09-996-243-500	Sequence 500, App
44	18	0.8	3231	1	US-08-074-121-4	Sequence 4, Appl
45	18	0.8	3231	5	PCT-US94-06447-4	Sequence 4, Appl
46	18	0.8	4190	3	US-08-938-291A-2	Sequence 2, Appl
47	18	0.8	4307	4	US-09-589-619-2	Sequence 2, Appl
48	18	0.8	4307	4	US-09-552-950-2	Sequence 2, Appl
49	18	0.8	6156	4	US-09-392-812A-3	Sequence 3, Appl
50	18	0.8	9772	4	US-09-552-950-5	Sequence 5, Appl
51	18	0.8	9793	1	US-08-470-202-56	Sequence 56, Appl
52	18	0.8	9793	2	US-08-471-770-56	Sequence 56, Appl
53	18	0.8	9793	3	US-08-468-059-56	Sequence 56, Appl
54	18	0.8	9793	3	US-09-109-916-56	Sequence 56, Appl
55	18	0.8	9793	4	US-09-886-156-56	Sequence 56, Appl
56	18	0.8	9793	4	US-09-886-149-56	Sequence 56, Appl
57	18	0.8	9793	4	US-09-886-150-56	Sequence 56, Appl
58	18	0.8	9793	4	US-09-886-159-56	Sequence 56, Appl
59	18	0.8	21784	4	US-09-820-002-3	Sequence 3, Appl
60	18	0.8	24358	4	US-09-392-812A-1	Sequence 1, Appl
61	18	0.8	32654	4	US-09-801-191A-3	Sequence 3, Appl
62	18	0.8	174493	4	US-09-804-471A-3	Sequence 3, Appl
63	18	0.8	246240	2	US-08-724-394A-20	Sequence 20, Appl
64	18	0.8	246240	2	US-08-724-394A-21	Sequence 21, Appl
65	18	0.8	246240	2	US-08-724-394A-22	Sequence 22, Appl
66	17	0.8	42	3	US-09-162-484-7	Sequence 7, Appl
67	17	0.8	57	3	US-09-043-303-14	Sequence 14, Appl
68	17	0.8	65	3	US-09-043-303-13	Sequence 13, Appl
69	17	0.8	79	3	US-09-043-303-10	Sequence 10, Appl
70	17	0.8	78	3	US-09-043-303-11	Sequence 11, Appl
71	17	0.8	78	3	US-09-043-303-12	Sequence 12, Appl
72	17	0.8	107	4	US-09-205-995-75	Sequence 75, Appl
73	17	0.8	169	4	US-09-205-995-72	Sequence 72, Appl
74	17	0.8	190	4	US-09-205-995-77	Sequence 77, Appl
75	17	0.8	196	3	US-09-158-863C-63	Sequence 63, Appl
76	17	0.8	267	4	US-09-059-625-5	Sequence 5, Appl
77	17	0.8	267	4	US-09-059-625-8	Sequence 8, Appl
78	17	0.8	379	1	US-09-591-583-5	Sequence 5, Appl
79	17	0.8	403	3	US-08-145-617-5	Sequence 5, Appl
80	17	0.8	448	4	US-09-328-111-178	Sequence 178, App
81	17	0.8	448	4	US-09-669-751-88	Sequence 88, Appl
82	17	0.8	508	4	US-09-059-625-60	Sequence 60, Appl
83	17	0.8	539	2	US-08-709-924-1	Sequence 1, Appl
84	17	0.8	539	2	US-08-709-925-1	Sequence 1, Appl
85	17	0.8	539	4	US-08-709-948-1	Sequence 1, Appl
86	17	0.8	539	4	US-09-220-415-1	Sequence 1, Appl
87	17	0.8	549	3	US-08-918-288-37	Sequence 37, Appl
88	17	0.8	549	3	US-09-282-357-35	Sequence 35, Appl
89	17	0.8	562	4	US-09-669-751-15	Sequence 15, Appl
90	17	0.8	570	3	US-09-122-443-1	Sequence 1, Appl
91	17	0.8	570	4	US-09-558-089-1	Sequence 1, Appl
92	17	0.8	570	4	US-09-558-087-1	Sequence 1, Appl
93	17	0.8	575	3	US-08-918-288-35	Sequence 35, Appl
94	17	0.8	575	3	US-09-282-357-35	Sequence 35, Appl
95	17	0.8	587	4	US-09-059-625-2	Sequence 2, Appl
96	17	0.8	608	4	US-09-669-751-247	Sequence 247, App
97	17	0.8	623	3	US-09-043-303-5	Sequence 5, Appl
98	17	0.8	639	4	US-09-336-536-57	Sequence 57, Appl
99	17	0.8	672	4	US-09-328-352-629	Sequence 629, App
100	17	0.8	717	3	US-08-918-288-7	Sequence 7, Appl

Sequence 22, Appl
Sequence 25, Appl
Sequence 7, Appl
Sequence 25, Appl
Sequence 25, Appl
Sequence 10, Appl
Sequence 10, Appl
Sequence 36, Appl
Sequence 50, Appl
Sequence 55, Appl
Sequence 16, Appl
Sequence 19, Appl
Sequence 16, Appl
Sequence 19, Appl
Sequence 33, Appl
Sequence 44, Appl
Sequence 47, Appl
Sequence 5, Appl
Sequence 23, Appl
Sequence 23, Appl
Sequence 8, Appl
Sequence 14, Appl
Sequence 14, Appl
Sequence 17, Appl
Sequence 17, Appl
Sequence 7, Appl
Sequence 7, Appl
Sequence 7, Appl
Sequence 7, Appl
Sequence 7, Appl
Sequence 4, Appl
Sequence 40, Appl
Sequence 40, Appl
Sequence 2, Appl
Sequence 2, Appl
Sequence 38, Appl
Sequence 38, Appl
Sequence 23, Appl
Sequence 1, Appl
Sequence 1, Appl
Sequence 1, Appl
Sequence 3, Appl
Sequence 5, Appl
Sequence 6, Appl

101 17 0.8 717 3 US-08-918-288-22
102 17 0.8 717 3 US-08-918-288-25
103 17 0.8 717 3 US-09-282-357-7
104 17 0.8 717 3 US-09-282-357-22
105 17 0.8 717 3 US-09-282-357-25
106 17 0.8 718 3 US-08-918-288-10
107 17 0.8 718 3 US-08-918-288-16
108 17 0.8 725 4 US-09-059-625-36
109 17 0.8 725 4 US-09-059-625-50
110 17 0.8 725 4 US-09-059-625-55
111 17 0.8 726 3 US-08-918-288-16
112 17 0.8 726 3 US-08-918-288-19
113 17 0.8 726 3 US-09-282-357-16
114 17 0.8 726 3 US-09-282-357-19
115 17 0.8 729 4 US-09-059-625-33
116 17 0.8 729 4 US-09-059-625-44
117 17 0.8 729 4 US-09-059-625-47
118 17 0.8 743 3 US-08-918-288-5
119 17 0.8 743 3 US-08-918-288-20
120 17 0.8 743 3 US-08-918-288-23
121 17 0.8 743 3 US-09-282-357-5
122 17 0.8 743 3 US-09-282-357-20
123 17 0.8 743 3 US-09-282-357-23
124 17 0.8 744 3 US-08-918-288-8
125 17 0.8 744 3 US-09-282-357-8
126 17 0.8 752 3 US-08-918-288-14
127 17 0.8 752 3 US-08-918-288-17
128 17 0.8 752 3 US-09-282-357-14
129 17 0.8 752 3 US-09-282-357-17
130 17 0.8 800 1 US-08-468-853-7
131 17 0.8 800 1 US-08-468-853-7
132 17 0.8 800 1 US-08-310-357-7
133 17 0.8 800 1 US-08-468-853-7
134 17 0.8 800 2 US-08-468-857-7
135 17 0.8 834 3 US-08-918-288-4
136 17 0.8 834 3 US-09-282-357-4
137 17 0.8 835 3 US-08-918-288-40
138 17 0.8 835 3 US-09-282-357-40
139 17 0.8 836 3 US-08-918-288-2
140 17 0.8 836 3 US-09-282-357-2
141 17 0.8 837 3 US-08-918-288-38
142 17 0.8 837 3 US-09-282-357-38
143 17 0.8 837 4 US-08-339-214-23
144 17 0.8 879 1 US-08-243-545-1
145 17 0.8 879 2 US-08-933-963-1
146 17 0.8 879 3 US-09-160-841-1
147 17 0.8 879 5 PCT-US94-05365-1
148 17 0.8 893 3 US-09-142-320-3
149 17 0.8 893 3 US-09-142-320-5
150 17 0.8 893 3 US-09-142-320-6

ALIGNMENTS

RESULT 1
US-09-996-243-228
Sequence 228, Application US/09996243
Patent No. 8478825
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.

APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
Acids Encoding the Same
FILE REFERENCE: P2730P1C13
CURRENT APPLICATION NUMBER: US/09/996,243
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738

PRIOR FILING DATE:	1998-06-10
PRIOR APPLICATION NUMBER:	60/088742
PRIOR FILING DATE:	1998-06-10
PRIOR APPLICATION NUMBER:	60/088810
PRIOR FILING DATE:	1998-06-10
PRIOR APPLICATION NUMBER:	60/088824
PRIOR FILING DATE:	1998-06-10
PRIOR APPLICATION NUMBER:	60/088826
PRIOR FILING DATE:	1998-06-10
PRIOR APPLICATION NUMBER:	60/088858
PRIOR FILING DATE:	1998-06-11
PRIOR APPLICATION NUMBER:	60/088861
PRIOR FILING DATE:	1998-06-11
PRIOR APPLICATION NUMBER:	60/088876
PRIOR FILING DATE:	1998-06-11
PRIOR APPLICATION NUMBER:	60/089105
PRIOR FILING DATE:	1998-06-12
PRIOR APPLICATION NUMBER:	60/089440
PRIOR FILING DATE:	1998-06-16
PRIOR APPLICATION NUMBER:	60/089512
PRIOR FILING DATE:	1998-06-16
PRIOR APPLICATION NUMBER:	60/089514
PRIOR FILING DATE:	1998-06-16
PRIOR APPLICATION NUMBER:	60/089532
PRIOR FILING DATE:	1998-06-17
PRIOR APPLICATION NUMBER:	60/089538
PRIOR FILING DATE:	1998-06-17
PRIOR APPLICATION NUMBER:	60/089598
PRIOR FILING DATE:	1998-06-17
PRIOR APPLICATION NUMBER:	60/089599
PRIOR FILING DATE:	1998-06-17
PRIOR APPLICATION NUMBER:	60/089600
PRIOR FILING DATE:	1998-06-17
PRIOR APPLICATION NUMBER:	60/089653
PRIOR FILING DATE:	1998-06-17
PRIOR APPLICATION NUMBER:	60/089801
PRIOR FILING DATE:	1998-06-18
PRIOR APPLICATION NUMBER:	60/089907
PRIOR FILING DATE:	1998-06-18
PRIOR APPLICATION NUMBER:	60/089908
PRIOR FILING DATE:	1998-06-18
PRIOR APPLICATION NUMBER:	60/089947
PRIOR FILING DATE:	1998-06-19
PRIOR APPLICATION NUMBER:	60/089948
PRIOR FILING DATE:	1998-06-19
PRIOR APPLICATION NUMBER:	60/089952
PRIOR FILING DATE:	1998-06-19
PRIOR APPLICATION NUMBER:	60/090246
PRIOR FILING DATE:	1998-06-22
PRIOR APPLICATION NUMBER:	60/090252
PRIOR FILING DATE:	1998-06-22
PRIOR APPLICATION NUMBER:	60/090254
PRIOR FILING DATE:	1998-06-22
PRIOR APPLICATION NUMBER:	60/090349
PRIOR FILING DATE:	1998-06-23
PRIOR APPLICATION NUMBER:	60/090355
PRIOR FILING DATE:	1998-06-23
PRIOR APPLICATION NUMBER:	60/090429
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090431
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090445
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090472
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090535
PRIOR FILING DATE:	1998-06-24
PRIOR APPLICATION NUMBER:	60/090540
PRIOR FILING DATE:	1998-06-24

?	PRIOR APPLICATION NUMBER:	60/090542
?	PRIOR FILING DATE:	1998-06-24
?	PRIOR APPLICATION NUMBER:	60/090557
?	PRIOR FILING DATE:	1998-06-24
?	PRIOR APPLICATION NUMBER:	60/090676
?	PRIOR FILING DATE:	1998-06-25
?	PRIOR APPLICATION NUMBER:	60/090678
?	PRIOR FILING DATE:	1998-06-25
?	PRIOR APPLICATION NUMBER:	60/090690
?	PRIOR FILING DATE:	1998-06-25
?	PRIOR APPLICATION NUMBER:	60/090694
?	PRIOR FILING DATE:	1998-06-25
?	PRIOR APPLICATION NUMBER:	60/090695
?	PRIOR FILING DATE:	1998-06-25
?	PRIOR APPLICATION NUMBER:	60/090696
?	PRIOR FILING DATE:	1998-06-25
?	PRIOR APPLICATION NUMBER:	60/090862
?	PRIOR FILING DATE:	1998-06-26
?	PRIOR APPLICATION NUMBER:	60/090863
?	PRIOR FILING DATE:	1998-06-26
?	PRIOR APPLICATION NUMBER:	60/091360
?	PRIOR FILING DATE:	1998-07-01
?	PRIOR APPLICATION NUMBER:	60/091478
?	PRIOR FILING DATE:	1998-07-02
?	PRIOR APPLICATION NUMBER:	60/091544
?	PRIOR FILING DATE:	1998-07-01
?	PRIOR APPLICATION NUMBER:	60/091519
?	PRIOR FILING DATE:	1998-07-02
?	PRIOR APPLICATION NUMBER:	60/091626
?	PRIOR FILING DATE:	1998-07-02
?	PRIOR APPLICATION NUMBER:	60/091633
?	PRIOR FILING DATE:	1998-07-02
?	PRIOR APPLICATION NUMBER:	60/091978
?	PRIOR FILING DATE:	1998-07-07
?	PRIOR APPLICATION NUMBER:	60/091982
?	PRIOR FILING DATE:	1998-07-07
?	PRIOR APPLICATION NUMBER:	60/092182
?	PRIOR FILING DATE:	1998-07-09

Query Match 100.0%; Score 2185; DB 4; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185: Conservative 0; Mismatches 0; Indels 0;

Qy	1	GTTCCTCTTTCCGAGCCAAAATCCAGCGCATGGTGAATATGAAGTGCCACACCATGA	60
Db	1	GTTCCTCTTTCCGAGCCAAAATCCAGCGCATGGTGAATATGAAGTGCCACACCATGA	60
Qy	61	AGCTCTGTGGCAGGTAACTGTGCACCAACACCTGGGAATGCCATCTGTCTCCCGTTGC	120
Db	61	AGCTCTGTGGCAGGTAACTGTGCACCAACACCTGGGAATGCCATCTGTCTCCCGTTGC	120
Qy	121	TTCTACTCATCGCGCGCAAGTGTGGATTCGTGTGCAGCCATCGGTGCTGGCGGCTCAGCGC	180
Db	121	TTCTACTCATCGCGCGCAAGTGTGGATTCGTGTGCAGCCATCGGTGCTGGCGGCTCAGCGC	180
Qy	181	GGCCCCAGAACTGCCCCCTCCGTTTGCTGTCGTGACAGTAAACAGTTTCAGCAAGGTGGTGTGCA	240
Db	181	GGCCCCAGAACTGCCCCCTCCGTTTGCTGTCGTGACAGTAAACAGTTTCAGCAAGGTGGTGTGCA	240
Qy	241	CGCGCGGGGGCCTTCCGAGTCCCGCAGGGTATTCCTTCGAACAACCGGATACCTCAAC	300
Db	241	CGCGCGGGGGCCTTCCGAGTCCCGCAGGGTATTCCTTCGAACAACCGGATACCTCAAC	300
Qy	301	TCAATGAGAAACAATCCAGATGATCCAGCGCGCACCTTCGCGCACCTCCACCACTCGG	360
Db	301	TCAATGAGAAACAATCCAGATGATCCAGCGCGCACCTTCGCGCACCTCCACCACTCGG	360
Qy	361	AGGTCTGTGAGTTGGGCGAGGAATCCATCCGGCAGAGTTGAGGTGGGGGCTTCAACGGCC	420
Db	361	AGGTCTGTGAGTTGGGCGAGGAATCCATCCGGCAGAGTTGAGGTGGGGGCTTCAACGGCC	420
Qy	421	TGGCCAGGCTCAACCCCTGGAGCTGTTTCGACAACTTGGCTGACAGTCATCCCTTAGCGGG	480

421 TGCCAGCCTCAACACCCCTGAGCTGTTTCGACAACTGGCTGACAGTCAATCCCTAGCGGG 480
481 CCTTTGATATCTGTCAGAGCTGGGAGCTCTGGCTTCGCAACAACCCCTCAAGCA 540
481 CCTTTGATATCTGTCAGAGCTGGGAGCTCTGGCTTCGCAACAACCCCTCAAGCA 540
541 TCCCTCTTACGCCCTTCAACCGGCTGCTCCCTCATCGCGCTGGAATGGGGAGCTCA 600
541 TCCCTCTTACGCCCTTCAACCGGCTGCTCCCTCATCGCGCTGGAATGGGGAGCTCA 600
601 AGAGCTGAGTATCTCTCAGAGGAGCTTTGAGGGCTGTTCAACCTCAAGTACTGA 660
601 AGAGCTGAGTATCTCTCAGAGGAGCTTTGAGGGCTGTTCAACCTCAAGTACTGA 660
661 ACTTGGGCTATGCAACATTAAGAGCATGCCAATCTCACCCCTCTGGTGGGGCTGAGG 720
661 ACTTGGGCTATGCAACATTAAGAGCATGCCAATCTCACCCCTCTGGTGGGGCTGAGG 720
721 AGCTGAGATGTGAGGAGCACTTCCTCTGAGATCAGGCTGGCTCTTCCATGGGCTGA 780
721 AGCTGAGATGTGAGGAGCACTTCCTCTGAGATCAGGCTGGCTCTTCCATGGGCTGA 780
781 GCTCCCTCAAGAGCTCTGGGCTCATGAACCTCACAGCTCAGCTGATTCAGCGGAATCTT 840
781 GCTCCCTCAAGAGCTCTGGGCTCATGAACCTCACAGCTCAGCTGATTCAGCGGAATCTT 840
841 TTGACGGGCTGCTTCACTTGTGGAACCTCAACTTGGGCTGAGTGGCTCTTCTTTTCG 900
841 TTGACGGGCTGCTTCACTTGTGGAACCTCAACTTGGGCTGAGTGGCTCTTCTTTTCG 900
901 CCATGACCTCTTACCCGCTGAGTACCTGCTGGTGGCTGATCTACACCAACCCCTT 960
901 CCATGACCTCTTACCCGCTGAGTACCTGCTGGTGGCTGATCTACACCAACCCCTT 960
961 GGAATGTGATTTGACATCTCTGGCTAGCTGCTGGTGGCTGATCTACACCAACCCCTT 1020
961 GGAATGTGATTTGACATCTCTGGCTAGCTGCTGGTGGCTGATCTACACCAACCCCTT 1020
1021 ATTCCACCTGCTGGGCTGCTGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1080
1021 ATTCCACCTGCTGGGCTGCTGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1080
1081 AGGTGGACAGGCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140
1081 AGGTGGACAGGCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140
1141 TCACATTTCTGAGGTGGATGGAGACTTAAGTGTGAGCTTCCCTGCTGCTGCTGCTG 1200
1141 TCACATTTCTGAGGTGGATGGAGACTTAAGTGTGAGCTTCCCTGCTGCTGCTGCTG 1200
1201 TGAAGTGGTGTGCTGCCAATGGGACAGTGTGCTGAGCAAGCTTCCCTGCTGCTGCTG 1260
1201 TGAAGTGGTGTGCTGCCAATGGGACAGTGTGCTGAGCAAGCTTCCCTGCTGCTGCTG 1260
1261 CTGTCTGCTGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1320
1261 CTGTCTGCTGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1320
1321 ACACATGATGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1380
1321 ACACATGATGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1380
1381 GCAAGCTGATGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1440
1381 GCAAGCTGATGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1440
1441 CGAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1500
1441 CGAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1500
1501 GTTACAGCGGCTATACCACTTACCAAGTGTCTGCTGCTGCTGCTGCTGCTGCTG 1560
1501 GTTACAGCGGCTATACCACTTACCAAGTGTCTGCTGCTGCTGCTGCTGCTGCTG 1560

1561 AGCAGTGGCAGTACCGCGACAGACACCACTGCAAGATGCAAGACCGCCTGATGAAG 1620
1561 AGCAGTGGCAGTACCGCGACAGACACCACTGCAAGATGCAAGACCGCCTGATGAAG 1620
1621 TCATGAGAGCAACCAAGATCATCATGCTGCTTGTGGCAGTGAATCTGCTAGCTGCCG 1680
1621 TCATGAGAGCAACCAAGATCATCATGCTGCTTGTGGCAGTGAATCTGCTAGCTGCCG 1680
1681 CCATGTTGATTTGCTTCTTATAAACTTCGTAAGCGGCAACCGAGCGGAGTACAGTCAAG 1740
1681 CCATGTTGATTTGCTTCTTATAAACTTCGTAAGCGGCAACCGAGCGGAGTACAGTCAAG 1740
1741 CGCGCGGAGCTGTTGAGATATCCAGTGGAGCAAGATCCCGAGCGGAGTACAGTCAAG 1800
1741 CGCGCGGAGCTGTTGAGATATCCAGTGGAGCAAGATCCCGAGCGGAGTACAGTCAAG 1800
1801 CAGCAACAGCAGCTCCGCTCGCTGATCAGTGAAGCGGCAAGTGTGCTGCTGCTGCTGCTG 1860
1801 CAGCAACAGCAGCTCCGCTCGCTGATCAGTGAAGCGGCAAGTGTGCTGCTGCTGCTGCTG 1860
1861 ATGACCATATTAATCAACCACTTACAAACCGAGCAATGCGGCGGCTGAGTGTGCTGCTGCTG 1920
1861 ATGACCATATTAATCAACCACTTACAAACCGAGCAATGCGGCGGCTGAGTGTGCTGCTGCTG 1920
1921 GCTGCGGAGCTCTCTGCAACCGCAGTCACTATCTCTGAACTTATATATATATATATTA 1980
1921 GCTGCGGAGCTCTCTGCAACCGCAGTCACTATCTCTGAACTTATATATATATATATTA 1980
1981 CCATACCAAGCAAGGTACAGGAACTCAAAATATGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2040
1981 CCATACCAAGCAAGGTACAGGAACTCAAAATATGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2040
2041 TAAATGCAATAGATGACACCAAGCAAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
2041 TAAATGCAATAGATGACACCAAGCAAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
2101 TTCTGTTATATGCTTATATATTAAGTCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2160
2101 TTCTGTTATATGCTTATATATTAAGTCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2160
2161 AATTTAAAGCAAAAGTCAAAACA 2185
2161 AATTTAAAGCAAAAGTCAAAACA 2185

RESULT 2
US-09-996-243-251
Sequence 251, Application US/09996243
Patent No. 6478825
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey

APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730PIC13
CURRENT APPLICATION NUMBER: US/09/996,243
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088157
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088830
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690

Query Match 2.3%; Score 50; DB 4; Length 50;
Best Local Similarity 100.0%; Pred. No. 5.6e-14;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25

PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 1.4%; Score 31; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 5.7e-05;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1930 ACTCTGCGACCCACAGTCACCACTATCTC 1960
|||||
DB 1 ACTCTGCGACCCACAGTCACCACTATCTC 31
|||||

RESULT 4
US-09-482-273-13
; Sequence 13, Application US/09482273
; Patent No. 6534631
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 71 Human Secreted Proteins
; FILE REFERENCE: P2030P1
; CURRENT APPLICATION NUMBER: US/09/482,273
; CURRENT FILING DATE: 2000-01-13
; EARLIER APPLICATION NUMBER: PCT/US99/15849
; EARLIER FILING DATE: 1998-07-14
; EARLIER APPLICATION NUMBER: 60/092,921
; EARLIER FILING DATE: 1998-07-15
; EARLIER APPLICATION NUMBER: 60/092,922
; EARLIER FILING DATE: 1998-07-15
; EARLIER APPLICATION NUMBER: 60/092,956
; EARLIER FILING DATE: 1998-07-15
; NUMBER OF SEQ ID NOS: 267
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 13
; LENGTH: 973
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-482-273-13

Query Match 1.3%; Score 29; DB 4; Length 973;
Best Local Similarity 100.0%; Pred. No. 0.00045;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 489 TACCTGTCCAAGCTCGCGAGCTCTGGCT 517
|||||
DB 533 TACCTGTCCAAGCTCGCGAGCTCTGGCT 561
|||||

RESULT 5
US-09-482-273-82
; Sequence 82, Application US/09482273
; Patent No. 6534631
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.

```

; TITLE OF INVENTION: 71 Human Secreted Proteins
; FILE REFERENCE: P203051
; CURRENT APPLICATION NUMBER: US/09/482,273
; EARLIER FILING DATE: 2000-01-13
; EARLIER APPLICATION NUMBER: PCT/US99/15849
; EARLIER FILING DATE: 1999-07-14
; EARLIER APPLICATION NUMBER: 60/092,921
; EARLIER FILING DATE: 1998-07-15
; EARLIER APPLICATION NUMBER: 60/092,922
; EARLIER FILING DATE: 1998-07-15
; EARLIER APPLICATION NUMBER: 60/092,956
; EARLIER FILING DATE: 1998-07-15
; NUMBER OF SEQ ID NOS: 267
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 82
; LENGTH: 984
; TYPE: DNA
; ORGANISM: Homo sapiens
; JS-09-482-273-82

Query Match      1.3%   Score 29; DB 4; Length 984;
Best Local Similarity 100.0%; Pred. No. 0.00045;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

2y 489 TACCTGTCGAAGCTGCGGAGCTCTGGCT 517
   |||||
Db 539 TACCTGTCGAAGCTGCGGAGCTCTGGCT 567

RESULT 6
US-09-996-243-465/c
; Sequence 465, Application US/09996243
; Patent No. 6478825
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paolucci, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730PIC13
; TITLE OF INVENTION: Acids Encoding the Same
; CURRENT APPLICATION NUMBER: US/09/996,243
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
```

PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01

; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 1.2% Score 26; DB 4; Length 26;
Best Local Similarity 100.0%; Pred.No. 0.013; 0; Indels 0; Gaps 0;
Matches 26; Conservative 0; Mismatches 0

Qy 1969 ATATAATTCAGACCCATACCAAGGAC 1994
Db 26 ATATAATTCAGACCCATACCAAGGAC 1

RESULT 7

US-09-996-243-464
; Sequence 464, Application US/09996243
; Patent No. 6478825
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin I.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2730PIC13
; CURRENT APPLICATION NUMBER: US/09/996,243
; PRIOR FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600

PRIOR APPLICATION NUMBER: 60/089953	PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801	PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907	PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908	PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908	PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947	PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948	PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952	PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952	PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246	PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252	PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254	PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349	PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090355	PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862	PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863	PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360	PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478	PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544	PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519	PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626	PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633	PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978	PRIOR FILING DATE: 1998-07-02

PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 0.9%; Score 20; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1845 GTGCTGCCCAATTCATGA 1864
1 GTGCTGCCCAATTCATGA 20

RESULT 8
US-09-620-312D-712/c

Sequence 712, Application US/09620312D

Patent No. 6569662

GENERAL INFORMATION:

APPLICANT: Tang, Y. Tom

APPLICANT: Liu, Chenghua

APPLICANT: Asundi, Vinod

APPLICANT: Zhang, Jie

APPLICANT: Ren, Feiyang

APPLICANT: Chen, Rui-hong

APPLICANT: Zhao, Qing A.

APPLICANT: Wehrman, Tom

APPLICANT: Xue, Aidong J.

APPLICANT: Yang, Yonghong

APPLICANT: Wang, Jian-Rui

APPLICANT: Zhou, Ping

APPLICANT: Ma, Yunqing

APPLICANT: Wang, Dunrui

APPLICANT: Wang, Zhiwei

APPLICANT: John Tillinghast

APPLICANT: Drmanac, Radjic T.

TITLE OF INVENTION: No. 6569662el Nucleic Acids and

FILE REFERENCE: 784CIP2B

CURRENT APPLICATION NUMBER: US/09/620,312D

CURRENT FILING DATE: 2000-07-19

PRIOR APPLICATION NUMBER: 09/552,317

PRIOR FILING DATE: 2000-04-25

PRIOR APPLICATION NUMBER: 09/488,725

PRIOR FILING DATE: 2000-01-21

NUMBER OF SEQ ID NOS: 1105

SOFTWARE: pt FL_genes Version 1.0

SEQ ID NO 712

LENGTH: 1748

TYPE: DNA

ORGANISM: Homo sapiens

FEATURE:

NAME/KEY: CDS

LOCATION: (187)..(1467)

US-09-620-312D-712

Query Match 0.9%; Score 20; DB 4; Length 1748;

Best Local Similarity 100.0%; Pred. No. 8.2;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

163 CTGCTGCCCTCAGCGGG 182

59 CTGCTGCCCTCAGCGGG 40

RESULT 9

US-09-690-454-33/c

Sequence 33, Application US/09690454

Patent No. 6531447

GENERAL INFORMATION:

APPLICANT: Steven M. Ruben, et al.

TITLE OF INVENTION: 32 Human Secreted Proteins

FILE REFERENCES: P2006P1
CURRENT APPLICATION NUMBER: US/09/690,454
CURRENT FILING DATE: 2000-10-18
PRIOR APPLICATION NUMBER: 09/189,144
PRIOR FILING DATE: 1998-11-10
PRIOR APPLICATION NUMBER: 60/044,039
PRIOR FILING DATE: May 30, 1997
PRIOR APPLICATION NUMBER: 60/048,093
PRIOR FILING DATE: May 30, 1997
PRIOR APPLICATION NUMBER: 60/048,190
PRIOR FILING DATE: May 30, 1997
PRIOR APPLICATION NUMBER: 60/050,935
PRIOR FILING DATE: May 30, 1997
PRIOR APPLICATION NUMBER: 60/048,101
PRIOR FILING DATE: May 30, 1997
PRIOR APPLICATION NUMBER: 60/048,356
PRIOR FILING DATE: May 30, 1997
PRIOR APPLICATION NUMBER: 60/056,250
PRIOR FILING DATE: August 29, 1997
PRIOR APPLICATION NUMBER: 60/056,296
PRIOR FILING DATE: August 29, 1997
PRIOR APPLICATION NUMBER: 60/056,293
PRIOR FILING DATE: August 29, 1997
NUMBER OF SEQ ID NOS: 229
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 33
LENGTH: 997
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: SITE
LOCATION: (855)
OTHER INFORMATION: n equals a.t.g. or c
NAME/KEY: SITE
LOCATION: (881)
OTHER INFORMATION: n equals a.t.g. or c
NAME/KEY: SITE
LOCATION: (916)
OTHER INFORMATION: n equals a.t.g. or c
NAME/KEY: SITE
LOCATION: (957)
OTHER INFORMATION: n equals a.t.g. or c
US-09-690-454-33

Query Match 0.9%; Score 19; DB 4; Length 997;

Best Local Similarity 100.0%; Pred. No. 25;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 826 TTGAGCGGAATGCTTTGA 844

Db 796 TTGAGCGGAATGCTTTGA 778

RESULT 10

US-09-016-434-717/c

Sequence 717, Application US/09016434

Patent No. 6500938

GENERAL INFORMATION:

APPLICANT: Janice Au-Young

APPLICANT: Jeffrey J. Seihamer

TITLE OF INVENTION: COMPOSITION FOR THE DETECTION OF SIGNALING

TITLE OF INVENTION: PATHWAY GENE EXPRESSION

NUMBER OF SEQUENCES: 1490

CORRESPONDENCE ADDRESS:

ADDRESSEE: INCYTE PHARMACEUTICALS, INC.

STREET: 3174 PORTER DRIVE

CITY: PALO ALTO

STATE: CALIFORNIA

COUNTRY: USA

ZIP: 94304

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Word Perfect 6.1 for Windows/MS-DOS 6.2
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/016,434
FILING DATE: HERewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Zeller, Karen J.
REGISTRATION NUMBER: 37,071
REFERENCE/DOCKET NUMBER: PA-0002 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 855-0555
TELEFAX: (650) 345-4166
INFORMATION FOR SEQ ID NO: 717:
SEQUENCE CHARACTERISTICS:
LENGTH: 1236 base pairs
TYPE: nucleic acid
STRADEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: THYMOT02
CLONE: 346874
US-09-016-434-717

Query Match 0.9%; Score 19; DB 4; Length 1236;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 826 TTGAGCGGAATGCTTTTGA 844
DB 1088 TTGAGCGGAATGCTTTTGA 1070

RESULT 11
US-08-702-344-27/c
Sequence 27, Application US/08/702344
Patent No. 5723315
GENERAL INFORMATION:
APPLICANT: Jacobs, Kenneth
APPLICANT: McCoy, John
APPLICANT: Lavallie, Edward
APPLICANT: Racie, Lisa
APPLICANT: Merberg, David
APPLICANT: Treacy, Maurice
APPLICANT: Spaulding, Vikki
TITLE OF INVENTION: SECRETED PROTEINS AND POLYNUCLEOTIDES
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genetics Institute, Inc.
STREET: 87 Cambridgepark Drive
CITY: Cambridge
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02140
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/702,344
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Brown, Scott A.
REGISTRATION NUMBER: 32,724
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 498-8224

TELEFAX: (617) 876-5851
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 1243 base pairs
TYPE: nucleic acid
STRADEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-702-344-27

Query Match 0.9%; Score 19; DB 1; Length 1243;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 826 TTGAGCGGAATGCTTTTGA 844
DB 1081 TTGAGCGGAATGCTTTTGA 1063

RESULT 12
US-08-816-617A-1
Sequence 1, Application US/08816617A
Patent No. 6022741
GENERAL INFORMATION:
APPLICANT: Ting, Jenny P.-Y.
APPLICANT: Piskurich, Janet
TITLE OF INVENTION: No. 6022741el Regulatory Genetic DNA that
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Bell, Seltzer, Park & Gibson
STREET: 1211 East Morehead Street
CITY: Charlotte
STATE: No. 6022741th Carolina
COUNTRY: United States
ZIP: 28234
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/816,617A
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Sibley, Kenneth D.
REGISTRATION NUMBER: 31,665
REFERENCE/DOCKET NUMBER: 5470-143
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-420-2200
TELEFAX: 919-881-3175
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 6678 base pairs
TYPE: nucleic acid
STRADEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-816-617A-1

Query Match 0.9%; Score 19; DB 3; Length 6678;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 81 GTGCACCCACACCTTGA 99
DB 3191 GTGCACCCACACCTTGA 3209

RESULT 13
US-09-534-638-1/c
Sequence 1, Application US/09534638

Patent No. 6320038
GENERAL INFORMATION:
APPLICANT: Panula, Pertti A.J.
APPLICANT: Brandt, Annika
APPLICANT: Westerlund, Johanna
TITLE OF INVENTION: Promoter for Neuropeptide FF Promoter and use thereof
TITLE OF INVENTION: for therapy and diagnosis
FILE REFERENCE: 2530-104
CURRENT APPLICATION NUMBER: US/09/534,638
CURRENT FILING DATE: 2000-03-27
EARLIER APPLICATION NUMBER: 09/365755
EARLIER FILING DATE: 1999-08-03
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 1
LENGTH: 9840
TYPE: DNA
ORGANISM: Mouse
3-09-534-638-1

Query Match 0.9%; Score 19; DB 4; Length 9840;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 80 TGTGCACCAACACACCTGG 98
|||||
b 7923 TGTGCACCAACACACCTGG 7905

RESULT 14
3-09-820-005-3
Sequence 3, Application US/09820005
Patent No. 6489149
GENERAL INFORMATION:
APPLICANT: SHAO, Wei et al
TITLE OF INVENTION: ISOLATED HUMAN ENZYME PROTEINS, NUCLEIC
TITLE OF INVENTION: ACID MOLECULES ENCODING HUMAN ENZYME PROTEINS, AND USES
TITLE OF INVENTION: THEREOF
FILE REFERENCE: CL001198
CURRENT APPLICATION NUMBER: US/09/820,005
CURRENT FILING DATE: 2001-03-29
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 3
LENGTH: 18853
TYPE: DNA
ORGANISM: Human
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)...(18853)
OTHER INFORMATION: n = A,T,C or G
S-09-820-005-3

Query Match 0.9%; Score 19; DB 4; Length 18853;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 80 TGTGCACCAACACACCTGG 98
|||||
b 6311 TGTGCACCAACACACCTGG 6329

RESULT 15
S-08-311-731A-131/c
Sequence 131, Application US/08311731A
Patent No. 6583266
GENERAL INFORMATION:
APPLICANT: SMITH, DOUGLAS
APPLICANT: MAO, JEN-I
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES
TITLE OF INVENTION: RELATING TO MYCOBACTERIUM TUBERCULOSIS AND LAPRAE FOR
TITLE OF INVENTION: DIAGNOSTICS AND THERAPEUTICS
NUMBER OF SEQUENCES: 411

CORRESPONDENCE ADDRESS:
ADDRESSEE: WOLF, GREENFIELD & SACKS, P.C.
STREET: 600 ATLANTIC AVENUE
CITY: BOSTON
STATE: MASSACHUSETTS
COUNTRY: USA
ZIP: 02210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,731A
FILING DATE:
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: GATES, EDWARD R.
REGISTRATION NUMBER: 31,616
REFERENCE/DOCKET NUMBER: C0044/7125
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/720-3500
TELEFAX: 617/720-2441
INFORMATION FOR SEQ ID NO: 131:
SEQUENCE CHARACTERISTICS:
LENGTH: 42325 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: circular
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: MYCOBACTERIUM LEPRAE
US-08-311-731A-131

Query Match 0.9%; Score 19; DB 4; Length 42325;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1656 GTGGCAGTGCCTCTGCTAG 1674
|||||
Db 35665 GTGGCAGTGCCTCTGCTAG 35647

RESULT 16
US-09-735-934A-3/c
Sequence 3, Application US/09735934A
Patent No. 6372468
GENERAL INFORMATION:
APPLICANT: LI, Jiayin et al
TITLE OF INVENTION: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC
TITLE OF INVENTION: ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES
FILE REFERENCE: CL000851
CURRENT APPLICATION NUMBER: US/09/735,934A
CURRENT FILING DATE: 2000-12-14
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 3
LENGTH: 43950
TYPE: DNA
ORGANISM: Homo sapiens
US-09-735-934A-3

Query Match 0.9%; Score 19; DB 4; Length 43950;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 80 TGTGCACCAACACACCTGG 98
|||||
Db 23992 TGTGCACCAACACACCTGG 23974

; SEQ ID NO 6					
; LENGTH: 45989					
; TYPE: DNA					
; ORGANISM: Homo sapiens					
US-08-965-048-6					
Query Match 0.9%; Score 19; DB 4; Length 45989;					
Best Local Similarity 100.0%; Pred.No. 22;					
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	80	TGTGCACCAACCACCTGG	98		
DB	8049	TGTGCACCAACCACCTGG	8067		
RESULT 20					
US-09-873-404-3/c					
; Sequence 3, Application US/09873404					
; Patent No. 6500656					
; GENERAL INFORMATION:					
; APPLICANT: WEBSTER, Marion et al					
; TITLE OF INVENTION: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC					
; FILE REFERENCE: ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES					
; CURRENT FILING DATE: THEREOF					
; FILE REFERENCE: CL001212-CIP					
; CURRENT APPLICATION NUMBER: US/09/873,404					
; NUMBER OF SEQ ID NOS: 4					
; SOFTWARE: FastSeq for Windows Version 4.0					
; SEQ ID NO 3					
; LENGTH: 63588					
; TYPE: DNA					
; ORGANISM: Human					
; FEATURE:					
; NAME/KEY: misc_feature					
; LOCATION: (1)....(63588)					
; OTHER INFORMATION: n = A,T,C or G					
US-09-873-404-3					
Query Match 0.9%; Score 19; DB 4; Length 63588;					
Best Local Similarity 100.0%; Pred.No. 22;					
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	80	TGTGCACCAACCACCTGG	98		
DB	62145	TGTGCACCAACCACCTGG	62127		
RESULT 21					
US-09-741-150-3/c					
; Sequence 3, Application US/09741150					
; Patent No. 6436689					
; GENERAL INFORMATION:					
; APPLICANT: GUEGLER, Karl et al					
; TITLE OF INVENTION: ISOLATED HUMAN PROTEASE PROTEINS, AND					
; FILE REFERENCE: NUCLEIC ACID MOLECULES ENCODING HUMAN PROTEASE PROTEINS, AND					
; CURRENT FILING DATE: THEREOF					
; FILE REFERENCE: CL000968					
; CURRENT APPLICATION NUMBER: US/09/741,150					
; NUMBER OF SEQ ID NOS: 4					
; SOFTWARE: FastSeq for Windows Version 4.0					
; SEQ ID NO 3					
; LENGTH: 112132					
; TYPE: DNA					
; ORGANISM: Human					
; FEATURE:					
; NAME/KEY: misc_feature					
; LOCATION: (1)....(112132)					
; OTHER INFORMATION: n = A,T,C or G					
US-09-741-150-3					
Query Match 0.9%; Score 19; DB 4; Length 112132;					

Best Local Similarity 100.0%; Pred. No. 22;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

2y 80 TGTGACACACACCTGG 98
|||||
db 81836 TGTGACACACACCTGG 81818

RESULT 22

US-09-103-840A-2/c
Sequence 2, Application US/09103840A
Patent No. 6294328

GENERAL INFORMATION:

APPLICANT: FLEISCHMAN, Robert D.
APPLICANT: WHITE, Owen R.
APPLICANT: FRASER, Claire M.
APPLICANT: VENTER, John C.
TITLE OF INVENTION: DNA SEQUENCES FOR STRAIN ANALYSIS IN MYCOBACTERIUM
FILE REFERENCE: TUBERCULOSIS
FILE REFERENCE: 24366-20007.00
CURRENT APPLICATION NUMBER: US/09/103,840A
CURRENT FILING DATE: 1998-06-24
NUMBER OF SEQ ID NOS: 2
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 2 4403765
LENGTH: 4403765
TYPE: DNA

ORGANISM: Mycobacterium tuberculosis

FEATURE:

OTHER INFORMATION: CDC 1551
OTHER INFORMATION: "n" bases at various positions throughout the sequence
OTHER INFORMATION: represent a, t, c or g
US-09-103-840A-2

Query Match 0.9%; Score 19; DB 3; Length 4403765;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

2y 443 GCTGTTGACACCTGGCTG 461
|||||
db 318745 GCTGTTGACACCTGGCTG 318727

RESULT 23

US-09-103-840A-1/c
Sequence 1, Application US/09103840A
Patent No. 6294328

GENERAL INFORMATION:

APPLICANT: FLEISCHMAN, Robert D.
APPLICANT: WHITE, Owen R.
APPLICANT: FRASER, Claire M.
APPLICANT: VENTER, John C.
TITLE OF INVENTION: DNA SEQUENCES FOR STRAIN ANALYSIS IN MYCOBACTERIUM
FILE REFERENCE: TUBERCULOSIS
FILE REFERENCE: 24366-20007.00
CURRENT APPLICATION NUMBER: US/09/103,840A
CURRENT FILING DATE: 1998-06-24
NUMBER OF SEQ ID NOS: 2
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 1
LENGTH: 4411529

TYPE: DNA

ORGANISM: Mycobacterium tuberculosis

OTHER INFORMATION: H37Rv

US-09-103-840A-1

Query Match 0.9%; Score 19; DB 3; Length 4411529;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

2y 443 GCTGTTGACACCTGGCTG 461
|||||
db 318636 GCTGTTGACACCTGGCTG 318618

RESULT 24

US-09-313-294A-3480/c
Sequence 3480, Application US/09313294A
Patent No. 6476212

GENERAL INFORMATION:

APPLICANT: Lalgudi, Raghunath V.
APPLICANT: Ito, Laura Y.
APPLICANT: Sherman, Bradley K.
TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM CORN EAR
FILE REFERENCE: PL-0017 US
CURRENT APPLICATION NUMBER: US/09/313,294A
CURRENT FILING DATE: 1999-05-14
NUMBER OF SEQ ID NOS: 7600
SOFTWARE: PERL Program
SEQ ID NO 3480
LENGTH: 255
TYPE: DNA

ORGANISM: Zea mays

FEATURE:

NAME/KEY: misc feature
OTHER INFORMATION: Incyte ID No. 6476212 700611693H1
NAME/KEY: unsure
LOCATION: 69, 71, 130, 172, 206, 209-210, 234, 246, 248, 253
OTHER INFORMATION: a, t, c, g, or other
US-09-313-294A-3480

Query Match 0.8%; Score 18; DB 4; Length 255;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 609 GAGTATATCTCTGAGGGA 626
|||||

Db 194 GAGTATATCTCTGAGGGA 177
|||||

RESULT 25

PCT-US94-04361-13/c

Sequence 13, Application PC/TUS9404361

GENERAL INFORMATION:

APPLICANT: Brigham and Women's Hospital
APPLICANT: 75 Francis Street
APPLICANT: Boston, MA 02115
APPLICANT: Bunn, H. Franklin
APPLICANT: Wen, Danyi
APPLICANT: Showers, Mark O.
TITLE OF INVENTION: Erythropoietin Muteins With Enhanced
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sterne, Kessler, Goldstein & Fox
STREET: 1100 New York Avenue, Suite 600
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005-3934

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US94/04361

FILING DATE: Herewith

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/049,802

FILING DATE: 21-APR-1993

ATTORNEY/AGENT INFORMATION:

NAME: Cimbala, Michele A.

REGISTRATION NUMBER: 33,851

REFERENCE/DOCKET NUMBER: 0627.336PC01

TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 371-2600
TELEFAX: (202) 371-2540
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 288 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: both
PCT-US94-04361-13

Query Match 0.8%; Score 18; DB 5; Length 288;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1719 CAGCAGCGGAGTACGTC 1736
DB 210 CAGCAGCGGAGTACGTC 193

RESULT 26
US-08-147-812-3
Sequence 3, Application US/08147812
Patent No. 5766909
GENERAL INFORMATION:
APPLICANT: Xie, Qiao-wen
APPLICANT: Nathan, Carl F.
APPLICANT: Mumford, Richard A.
APPLICANT: Calaycay, Jimmy Ramos
TITLE OF INVENTION: DNA Encoding Inducible Nitric Oxide Synthase
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSER: Merck & Co., Inc.
STREET: 126 East Lincoln Avenue
CITY: Rahway
STATE: New Jersey
COUNTRY: USA
ZIP: 07065

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy Disk
COMPUTER: Macintosh Centris650
OPERATING SYSTEM: Macintosh 7.0.1
SOFTWARE: Microsoft Word 5.1a
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/147,812
FILING DATE: NO. 5766909 Available
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/841,641
FILING DATE: 02-FEB-1992
ATTORNEY/AGENT INFORMATION:
NAME: Wallen, John W III
REGISTRATION NUMBER: 35,403
REFERENCE/DOCKET NUMBER: 186581A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (908) 594-3905
TELEFAX: (908) 594-4720
TELEX: 138825
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 352 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-147-812-3

Query Match 0.8%; Score 18; DB 1; Length 352;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1429 CAGTGGAGACCGGAGA 1446
DB 95 CAGTGGAGACCGGAGA 112

RESULT 27
US-08-475-844-18
Sequence 18, Application US/08475844
Patent No. 5972643
GENERAL INFORMATION:
APPLICANT: Lobanenkov, Victor V.
APPLICANT: Reiman, Paul E.
APPLICANT: Klenova, Elena M.
APPLICANT: Goodwin, Graham H.
APPLICANT: Filippova, Galina N.
APPLICANT: Collins, Steven J.
TITLE OF INVENTION: CTCF
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Khourie and Crew
STREET: One Market Plaza
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,844
FILING DATE: 07-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/261,680
FILING DATE: 17-JUN-1994
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W.
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 14538A-11-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 500 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE: homo sapiens
IMMEDIATE SOURCE:
CLONE: E4-14
FEATURE:
NAME/KEY: -
LOCATION: 67..68
OTHER INFORMATION: /label= exon4/intron4
OTHER INFORMATION: /note= 'exon 4/intron 4 junction'
US-08-475-844-18

Query Match 0.8%; Score 18; DB 2; Length 500;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2024 CTCCTCCCAAAACTTAT 2041
DB 206 CTCCTCCCAAAACTTAT 223

RESULT 28
PCT-US95-08429-18
Sequence 18, Application PC/TUS9508429
GENERAL INFORMATION:

APPLICANT: CTCT
 TITLE OF INVENTION: CTCT
 NUMBER OF SEQUENCES: 21
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US95/08429
 FILING DATE: 15-JUN-1995
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/261,680
 FILING DATE: 17-JUN-1994
 CLASSIFICATION:
 ATTORNEY/AGENT INFORMATION:
 NAME: Parmelee, Steven W.
 REGISTRATION NUMBER: 31,990
 REFERENCE/DOCKET NUMBER: 14388A-11-1PC
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 206-467-9600
 TELEFAX: 415-543-5043
 INFORMATION FOR SEQ ID NO: 18:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 500 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 ORIGINAL SOURCE:
 ORGANISM: homo sapiens
 IMMEDIATE SOURCE:
 CLONE: B4-14
 FEATURE:
 NAME/KEY: -
 LOCATION: 67..68
 OTHER INFORMATION: /label= exon4/intron4
 OTHER INFORMATION: /note= "exon 4/intron 4 junction"
 CT-US95-08429-18

Query Match 0.8%; Score 18; DB 5; Length 500;
 Best Local Similarity 100.0%; Pred. No. 75;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Y 2024 CTCCTCCCAAACTTAT 2041
 |||||
 b 206 CTCCTCCCAAACTTAT 223
 |||||
 RESULT 29
 US-09-328-352-2881
 Sequence 2881, Application US/09328352
 Patent No. 6562958
 GENERAL INFORMATION:
 APPLICANT: Gary L. Breton et al.
 TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO ACINETOBACTER
 TITLE OF INVENTION: BAUMANNII FOR DIAGNOSTICS AND THERAPEUTICS
 FILE REFERENCE: GTC99-03PA
 CURRENT APPLICATION NUMBER: US/09/328,352
 CURRENT FILING DATE: 1999-06-04
 NUMBER OF SEQ ID NOS: 8252
 SEQ ID NO 2881
 LENGTH: 531
 TYPE: DNA
 ORGANISM: Acinetobacter baumannii
 US-09-328-352-2881
 Query Match 0.8%; Score 18; DB 4; Length 531;
 Best Local Similarity 100.0%; Pred. No. 75;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Y 1874 CTACAACACCTACAACC 1891

Db 407 CTACAACACCTACAACC 424
 |||||
 RESULT 30
 5482709-5
 Patent No. 5482709
 APPLICANT: JACOBSON, JAMES W.; STRAUSBERG, ROBERT L.; WILSON,
 SUSAN D.; POPE, SHARON H.; STRAUSBERG, SUSAN L.; RUFF, MICHAEL D.;
 AUGUSTINE, PATRICIA C.; DANFORTH, HARRY D.
 TITLE OF INVENTION: BIMERIC ANTIGENIC COMPOSITION WHICH
 ELICITS ANTIBODIES AGAINST AVIAN COCCIDIOSIS
 NUMBER OF SEQUENCES: 10
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/148,432
 FILING DATE: 08-NOV-1993
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 581,693
 FILING DATE: 12-SEP-1990
 APPLICATION NUMBER: 215,162
 FILING DATE: 05-JUL-1989
 APPLICATION NUMBER: 746,520
 FILING DATE: 19-JUN-1985
 APPLICATION NUMBER: 627,811
 FILING DATE: 05-JUL-1984
 SEQ ID NO: 5
 LENGTH: 533
 5482709-5
 Query Match 0.8%; Score 18; DB 6; Length 533;
 Best Local Similarity 100.0%; Pred. No. 75;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1797 GCAGCAGCAACAGCAGCT 1814
 |||||
 Db 145 GCAGCAGCAACAGCAGCT 162
 |||||
 RESULT 31
 5273901-6
 Patent No. 5273901
 APPLICANT: JACOBSON, JAMES W.; STRAUSBERG, ROBERT L.; WILSON,
 SUSAN D.; POPE, SHARON H.; STRAUSBERG, SUSAN L.; RUFF, MICHAEL D.;
 AUGUSTINE, PATRICIA C.; DANFORTH, HARRY D.
 TITLE OF INVENTION: GENETICALLY ENGINEERED COCCIDIOSIS
 SPOOROZITE 21.5 KB ANTIGEN, AC-6B
 NUMBER OF SEQUENCES: 11
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/07/581,693
 FILING DATE: 12-SEP-1990
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 215,162
 FILING DATE: 05-JUL-1988
 APPLICATION NUMBER: 746,520
 FILING DATE: 19-JUN-1985
 APPLICATION NUMBER: 627,811
 FILING DATE: 05-JUL-1984
 SEQ ID NO: 6
 LENGTH: 543
 5273901-6
 Query Match 0.8%; Score 18; DB 6; Length 543;
 Best Local Similarity 100.0%; Pred. No. 75;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1797 GCAGCAGCAACAGCAGCT 1814
 |||||
 Db 145 GCAGCAGCAACAGCAGCT 162
 |||||
 RESULT 32
 US-08-609-334-14
 Sequence 14, Application US/08609334

Patent No. 6015663
GENERAL INFORMATION:
APPLICANT: Wesley, Ronald D.
APPLICANT: Mengeling, William L.
APPLICANT: Clouser, Deborah F.
APPLICANT: Andrejev, Vladimir G.
APPLICANT: Vorwald, Ann C.
APPLICANT: Lager, Kelly M.
TITLE OF INVENTION: Restriction Enzyme Screen for
TITLE OF INVENTION: Differentiating Porcine Reproductive and Respiratory
TITLE OF INVENTION: Syndrome Virus Strains
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtis P. Ribando
STREET: 1815 N. University Street
CITY: Peoria
STATE: IL
COUNTRY: USA
ZIP: 61604
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/609,334
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Ribando, Curtis P.
REGISTRATION NUMBER: 27,976
TELECOMMUNICATION INFORMATION:
TELEPHONE: 309-681-6513
TELEFAX: 309-681-6688
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 603 base pairs
TYPE: nucleic acid
STRAINEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Porcine Reproductive and Respiratory Syndrome
ORGANISM: Virus
STRAIN: 41572-2 (NE)
US-08-609-334-14
Query Match 0.8%; Score 18; DB 3; Length 603;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1798 CAGCAGCAACAGCAGCTC 1815
DB 93 CAGCAGCAACAGCAGCTC 110
RESULT 33
PCT-US94-04361-25/c
Sequence 25, Application PC/TUS9404361
GENERAL INFORMATION:
APPLICANT: Brigham and Women's Hospital
APPLICANT: 75 Francis Street
APPLICANT: Boston, MA 02115
APPLICANT: Bunn, H. Franklin
APPLICANT: Wen, Danyl
APPLICANT: Showers, Mark O.
TITLE OF INVENTION: Erythropoietin Muteins With Enhanced
TITLE OF INVENTION: Activity
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sterne, Kessler, Goldstein & Fox

STREET: 1100 New York Avenue, Suite 600
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005-3934
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/04361
FILING DATE: Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/049,802
FILING DATE: 21-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Gimbala, Michele A.
REGISTRATION NUMBER: 33,851
REFERENCE/DOCKET NUMBER: 0627.336PC01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 371-2600
TELEFAX: (202) 371-2540
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 687 base pairs
TYPE: nucleic acid
STRAINEDNESS: single
TOPOLOGY: both
PCT-US94-04361-25
Query Match 0.8%; Score 18; DB 5; Length 687;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1719 CAGCAGCGGAGTACAGTC 1736
DB 20 CAGCAGCGGAGTACAGTC 3
RESULT 34
US-09-107-532A-3104/c
Sequence 3104, Application US/09107532A
Patent No. 6583275
GENERAL INFORMATION:
APPLICANT: Lynn A Doucette-Stamm and David Bush
TITLE OF INVENTION: ENTEROCOCCUS FAECIUM FOR DIAGNOSTICS AND THERAPEUTICS
NUMBER OF SEQUENCES: 7310
CORRESPONDENCE ADDRESS:
ADDRESSEE: GENOME THERAPEUTICS CORPORATION
STREET: 100 Beaver Street
CITY: Waltham
STATE: Massachusetts
COUNTRY: USA
ZIP: 02354
COMPUTER READABLE FORM:
MEDIUM TYPE: CD-ROM ISO9660
COMPUTER: PC
OPERATING SYSTEM: <Unknown>
SOFTWARE: ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/107,532A
FILING DATE: 30-Jun-1998
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/085,598
FILING DATE: 14 May 1998
APPLICATION NUMBER: 60/051571
FILING DATE: July 2, 1997
ATTORNEY/AGENT INFORMATION:
NAME: Ariniello, Pamela Deneke
REGISTRATION NUMBER: 40,489

REFERENCE/DOCKET NUMBER: GTC-012
TELECOMMUNICATION INFORMATION:
TELEPHONE: (781)893-5007
TELEFAX: (781)893-8277
INFORMATION FOR SEQ ID NO: 3104:
SEQUENCE CHARACTERISTICS:
LENGTH: 720 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: circular
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Enterococcus faecium
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8) LOCATION 1...720
SEQUENCE DESCRIPTION: SEQ ID NO: 3104:
S-09-107-532A-3104

Query Match 0.8%; Score 18; DB 4; Length 720;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 958 CTTGGAAGTGTGATTGG 975
|||||
b 256 CTTGGAAGTGTGATTGG 239

RESULT 35
US-08-773-368-2/c
Sequence 2, Application US/08773368
Patent No. 5856130
GENERAL INFORMATION:
APPLICANT: Bandman, Olga
APPLICANT: Goli, Surya K.
TITLE OF INVENTION: NOVEL HUMAN PATHOGENESIS-RELATED
TITLE OF INVENTION: PROTEIN
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/773,368
FILING DATE:
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy RJ
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PP-0186 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-845-4166
TELEX:
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 970 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

IMMEDIATE SOURCE:
CLONE: 1599164
US-08-773-368-2
Query Match 0.8%; Score 18; DB 2; Length 970;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 428 CCTCAACACCTGGAGCT 445
|||||
Db 474 CCTCAACACCTGGAGCT 457

RESULT 36
US-09-199-887-2/c
Sequence 2, Application US/09199887
Patent No. 6071874
GENERAL INFORMATION:
APPLICANT: Bandman, Olga
APPLICANT: Goli, Surya K.
TITLE OF INVENTION: NOVEL HUMAN PATHOGENESIS-RELATED
TITLE OF INVENTION: PROTEIN
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/199,887
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/773,368
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy RJ
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PP-0186 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-845-4166
TELEX:
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 970 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: 1599164
US-09-199-887-2

Query Match 0.8%; Score 18; DB 3; Length 970;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 428 CCTCAACACCTGGAGCT 445
|||||
Db 474 CCTCAACACCTGGAGCT 457

RESULT 37
US-09-252-991A-10559/c
Sequence 10559, Application US/09252991A
Patent No. 6551795

```

GENERAL INFORMATION:
APPLICANT: Marc J. Rubenfield et al.
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
FILE REFERENCE: 107196.136
CURRENT APPLICATION NUMBER: US/09/252,991A
PRIOR FILING DATE: 1999-02-18
PRIOR APPLICATION NUMBER: US 60/074,788
PRIOR FILING DATE: 1998-02-18
PRIOR APPLICATION NUMBER: US 60/094,190
PRIOR FILING DATE: 1998-07-27
NUMBER OF SEQ ID NOS: 33142
SEQ ID NO 10559
LENGTH: 1119
TYPE: DNA
ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-10559

Query Match 0.8%; Score 18; DB 4; Length 1119;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 GGCCTTCAAGCGCTGGC 424
DB 673 GGCCTTCAAGCGCTGGC 656

RESULT 38
US-09-620-312D-936/C
Sequence 936, Application US/09620312D
Patent No. 6569662
GENERAL INFORMATION:
APPLICANT: Tang, Y. Tom
APPLICANT: Liu, Chenghua
APPLICANT: Asundi, Vinod
APPLICANT: Zhang, Jie
APPLICANT: Ren, Feiyang
APPLICANT: Chen, Rui-hong
APPLICANT: Zhao, Qing A.
APPLICANT: Wehrman, Tom
APPLICANT: Xue, Aidong J.
APPLICANT: Yang, Yonghong
APPLICANT: Wang, Jian-Rui
APPLICANT: Zhou, Ping
APPLICANT: Ma, Yunging
APPLICANT: Wang, Dunrui
APPLICANT: Wang, Zhiwei
APPLICANT: John Tillinghast
APPLICANT: Drmanac, Radoje T.
TITLE OF INVENTION: No. 6569662el Nucleic Acids and
FILE REFERENCE: 784CIP28
CURRENT APPLICATION NUMBER: US/09/620,312D
CURRENT FILING DATE: 2000-07-19
PRIOR APPLICATION NUMBER: 09/552,317
PRIOR FILING DATE: 2000-04-25
PRIOR APPLICATION NUMBER: 09/488,725
PRIOR FILING DATE: 2000-01-21
NUMBER OF SEQ ID NOS: 1105
SOFTWARE: pt_FL_genes Version 1.0
SEQ ID NO 936
LENGTH: 1248
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: CDS
LOCATION: (279)...(932)
US-09-620-312D-936

Query Match 0.8%; Score 18; DB 4; Length 1248;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 341 CGCCACCTCCACCACT 358
DB 334 CGCCACCTCCACCACT 317

RESULT 39
US-08-588-113-1
Sequence 1, Application US/08588113
Patent No. 5710003
GENERAL INFORMATION:
APPLICANT: McHugh, Kirk M.
TITLE OF INVENTION: DIAGNOSTIC TEST FOR DETERMINING
TITLE OF INVENTION: MALIGNANCY OF SMOOTH MUSCLE TUMORS
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/588,113
FILING DATE:
CLASSIFICATION: 436
ATTORNEY/AGENT INFORMATION:
NAME: Ralph, Rebecca L.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: TUU-1652
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 1275 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 55..1186
US-08-588-113-1

Query Match 0.8%; Score 18; DB 1; Length 1275;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 574 TCATCGCTGGACTGG 591
DB 581 TCATCGCTGGACTGG 598

RESULT 40
US-09-252-991A-10301
Sequence 10301, Application US/09252991A
Patent No. 6551795
GENERAL INFORMATION:
APPLICANT: Marc J. Rubenfield et al.
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
FILE REFERENCE: 107196.136
CURRENT APPLICATION NUMBER: US/09/252,991A
CURRENT FILING DATE: 1999-02-18
PRIOR APPLICATION NUMBER: US 60/074,788
PRIOR FILING DATE: 1998-02-18
PRIOR APPLICATION NUMBER: US 60/094,190

```

PRIOR FILING DATE: 1998-07-27
NUMBER OF SEQ ID NOS: 33142
SEQ ID NO 10301
LENGTH: 1425
TYPE: DNA
ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-10301

Query Match 0.8%; Score 18; DB 4; Length 1425;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

y 407 GGCCTTCAACGGCTGGC 424
| | | | | | | | | | | | | | | | | | | | | |
b 858 GGCCTTCAACGGCTGGC 875
| | | | | | | | | | | | | | | | | | | | | |

RESULT 41
S-09-620-312D-764/c
Sequence 764, Application US/09620312D
Patent No. 6569662
GENERAL INFORMATION:
APPLICANT: Tang, Y. Tom
APPLICANT: Liu, Chenghua
APPLICANT: Asundi, Vinod
APPLICANT: Zhang, Jie
APPLICANT: Ren, Feiyan
APPLICANT: Chen, Rui-hong
APPLICANT: Zhao, Qing A.
APPLICANT: Wehrman, Tom
APPLICANT: Xue, Aigong J.
APPLICANT: Yang, Yonghong
APPLICANT: Wang, Jian-Rui
APPLICANT: Zhou, Ping
APPLICANT: Ma, Yungqing
APPLICANT: Wang, Dunrui
APPLICANT: Wang, Zhiwei
APPLICANT: John Tillinghast
APPLICANT: Drmanac, Radcoje T.
TITLE OF INVENTION: Polypeptides
FILE REFERENCE: 784CIP2B
CURRENT APPLICATION NUMBER: US/09/620,312D
CURRENT FILING DATE: 2000-07-19
PRIOR APPLICATION NUMBER: 09/552,317
PRIOR FILING DATE: 2000-04-25
PRIOR APPLICATION NUMBER: 09/488,725
PRIOR FILING DATE: 2000-01-21
NUMBER OF SEQ ID NOS: 1105
SOFTWARE: Pf_Fl_genes Version 1.0
SEQ ID NO 764
LENGTH: 1960
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: CDS
LOCATION: (511)...(1311)
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)...(1960)
OTHER INFORMATION: n = a,t,c or g
US-09-620-312D-764

Query Match 0.8%; Score 18; DB 4; Length 1960;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

y 428 CCTCAACCTGGAGCT 445
| | | | | | | | | | | | | | | | | | | | | |
b 973 CCTCAACCTGGAGCT 956
| | | | | | | | | | | | | | | | | | | | | |

RESULT 42

US-09-252-991A-10499
Sequence 10499, Application US/09252991A
Patent No. 6551795
GENERAL INFORMATION:
APPLICANT: Marc J. Rubenfield et al.
TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
FILE REFERENCE: 107196.136
CURRENT APPLICATION NUMBER: US/09/252,991A
CURRENT FILING DATE: 1999-02-18
PRIOR APPLICATION NUMBER: US 60/074,788
PRIOR FILING DATE: 1998-02-18
PRIOR APPLICATION NUMBER: US 60/094,190
PRIOR FILING DATE: 1998-07-27
NUMBER OF SEQ ID NOS: 33142
SEQ ID NO 10499
LENGTH: 1986
TYPE: DNA
ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-10499

Query Match 0.8%; Score 18; DB 4; Length 1986;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 407 GGCCTTCAACGGCTGGC 424
| | | | | | | | | | | | | | | | | | | | | |
Db 454 GGCCTTCAACGGCTGGC 471
| | | | | | | | | | | | | | | | | | | | | |

RESULT 43
US-09-996-243-500
Sequence 500, Application US/09996243
Patent No. 6478825
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary B.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas P.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730P1C13
CURRENT APPLICATION NUMBER: US/09/996,243
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770

PRIOR FILING DATE:	1997-11-24
PRIOR APPLICATION NUMBER:	60/075945
PRIOR FILING DATE:	1998-02-25
PRIOR APPLICATION NUMBER:	60/078910
PRIOR FILING DATE:	1998-03-20
PRIOR APPLICATION NUMBER:	60/083322
PRIOR FILING DATE:	1998-04-28
PRIOR APPLICATION NUMBER:	60/084600
PRIOR FILING DATE:	1998-05-07
PRIOR APPLICATION NUMBER:	60/087106
PRIOR FILING DATE:	1998-05-28
PRIOR APPLICATION NUMBER:	60/087607
PRIOR FILING DATE:	1998-06-02
PRIOR APPLICATION NUMBER:	60/087609
PRIOR FILING DATE:	1998-06-02
PRIOR APPLICATION NUMBER:	60/087759
PRIOR FILING DATE:	1998-06-02
PRIOR APPLICATION NUMBER:	60/087827
PRIOR FILING DATE:	1998-06-03
PRIOR APPLICATION NUMBER:	60/088021
PRIOR FILING DATE:	1998-06-04
PRIOR APPLICATION NUMBER:	60/088025
PRIOR FILING DATE:	1998-06-04
PRIOR APPLICATION NUMBER:	60/088026
PRIOR FILING DATE:	1998-06-04
PRIOR APPLICATION NUMBER:	60/088028
PRIOR FILING DATE:	1998-06-04
PRIOR APPLICATION NUMBER:	60/088029
PRIOR FILING DATE:	1998-06-04
PRIOR APPLICATION NUMBER:	60/088030
PRIOR FILING DATE:	1998-06-04
PRIOR APPLICATION NUMBER:	60/088033
PRIOR FILING DATE:	1998-06-04
PRIOR APPLICATION NUMBER:	60/088326
PRIOR FILING DATE:	1998-06-04
PRIOR APPLICATION NUMBER:	60/088167
PRIOR FILING DATE:	1998-06-05
PRIOR APPLICATION NUMBER:	60/088202
PRIOR FILING DATE:	1998-06-05
PRIOR APPLICATION NUMBER:	60/088212
PRIOR FILING DATE:	1998-06-05
PRIOR APPLICATION NUMBER:	60/088217
PRIOR FILING DATE:	1998-06-05
PRIOR APPLICATION NUMBER:	60/088655
PRIOR FILING DATE:	1998-06-09
PRIOR APPLICATION NUMBER:	60/088734
PRIOR FILING DATE:	1998-06-10
PRIOR APPLICATION NUMBER:	60/088738
PRIOR FILING DATE:	1998-06-10
PRIOR APPLICATION NUMBER:	60/088742
PRIOR FILING DATE:	1998-06-10
PRIOR APPLICATION NUMBER:	60/088810
PRIOR FILING DATE:	1998-06-10
PRIOR APPLICATION NUMBER:	60/088824
PRIOR FILING DATE:	1998-06-10
PRIOR APPLICATION NUMBER:	60/088826
PRIOR FILING DATE:	1998-06-10
PRIOR APPLICATION NUMBER:	60/088858
PRIOR FILING DATE:	1998-06-11
PRIOR APPLICATION NUMBER:	60/088861
PRIOR FILING DATE:	1998-06-11
PRIOR APPLICATION NUMBER:	60/088876
PRIOR FILING DATE:	1998-06-11
PRIOR APPLICATION NUMBER:	60/089105
PRIOR FILING DATE:	1998-06-12
PRIOR APPLICATION NUMBER:	60/089440
PRIOR FILING DATE:	1998-06-16
PRIOR APPLICATION NUMBER:	60/089512
PRIOR FILING DATE:	1998-06-16
PRIOR APPLICATION NUMBER:	60/089514
PRIOR FILING DATE:	1998-06-16
PRIOR APPLICATION NUMBER:	60/089532
PRIOR FILING DATE:	1998-06-17

Best Local Similarity 100.0%; Pred. No. 71;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 GGCTTCACGGCTGGC 424
DB 3108 GGCTTCACGGCTGGC 3125

RESULT 45
PCT-US94-06447-4
; Sequence 4, Application PC/TUS9406447
; GENERAL INFORMATION:
; APPLICANT: Calgene, Inc.
; TITLE OF INVENTION: Methods and Compositions for Modulating
; TITLE OF INVENTION: Lipid Content of Plant Tissues
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Weill, Gotshal & Manges
; STREET: 2882 Sand Hill Road, Suite 280
; CITY: Menlo Park
; STATE: California
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/06447
; FILING DATE: 06-JUN-1994
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Rae-Venter, Barbara
; REGISTRATION NUMBER: 32,750
; REFERENCE/DOCKET NUMBER: CGNE-097/NO
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 926-6200
; TELEFAX: (415) 854-3713
; TELEX:
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3231 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 861..1328
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1349..2695
PCT-US94-06447-4
Query Match 0.8%; Score 18; DB 5; Length 3231;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 GGCTTCACGGCTGGC 424
DB 3108 GGCTTCACGGCTGGC 3125

RESULT 46
US-08-938-291A-2
; Sequence 2, Application US/08938291A
; Patent No. 6117673
; GENERAL INFORMATION:
; APPLICANT: Lev, Sima
; APPLICANT: Plowman, Gregory D.
; APPLICANT: Schlensing, Joseph
; TITLE OF INVENTION: RDB PROTEINS AND RELATED

PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 0.8%; Score 18; DB 4; Length 2906;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 216 AACAGTTCAGCAAGTG 233
b 974 AACAGTTCAGCAAGTG 991

RESULT 44
US-08-074-121-4
; Sequence 4, Application US/08074121
; Patent No. 5767362
; GENERAL INFORMATION:
; APPLICANT: Best, Elaine
; APPLICANT: Knauf, Vic C.
; TITLE OF INVENTION: Methods and Compositions for Modulating
; TITLE OF INVENTION: Lipid Content of Plant Tissues
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: California
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/074,121
; FILING DATE: 08-JUN-1993
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Rae-Venter, Barbara
; REGISTRATION NUMBER: 32,750
; REFERENCE/DOCKET NUMBER: 05938/043001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 854-5277
; TELEFAX: (415) 854-0875
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3231 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 861..1328
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1349..2695
US-08-074-121-4
Query Match 0.8%; Score 18; DB 1; Length 3231;

TITLE OF INVENTION: PRODUCTS AND METHODS
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
SUITE: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/938,291A
FILING DATE: September 26, 1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/027,337
FILING DATE: October 11, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 228/172
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 4190 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-938-291A-2

Query Match 0.8%; Score 18; DB 3; Length 4190;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 714 CTGAGGAGCTGGAGATG 731
Db 2523 CTGAGGAGCTGGAGATG 2540

RESULT 47
US-09-589-619-2
Sequence 2, Application US/09589619
Patent No. 6576442
GENERAL INFORMATION:
APPLICANT: Lev, Sima
Plowman, Gregory D.
Schlessinger, Joseph
TITLE OF INVENTION: RGB PROTEINS AND RELATED
PRODUCTS AND METHODS
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
SUITE: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/589,619
FILING DATE: 07-Jun-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/938,291
FILING DATE: September 26, 1997
APPLICATION NUMBER: 60/027,337
FILING DATE: October 11, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 228/172
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 4190 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-589-619-2

Query Match 0.8%; Score 18; DB 4; Length 4190;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 714 CTGAGGAGCTGGAGATG 731
Db 2523 CTGAGGAGCTGGAGATG 2540

RESULT 48
US-09-552-950-2
Sequence 2, Application US/09552950
Patent No. 6541248
GENERAL INFORMATION:
APPLICANT: Oxford Biomedica (UK) Limited
TITLE OF INVENTION: Anti-Viral Vectors
FILE REFERENCE: 674524-2004
CURRENT APPLICATION NUMBER: US/09/552,950
CURRENT FILING DATE: 2000-04-20
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 2
LENGTH: 4307
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: gagpol-SYNGp - codon
US-09-552-950-2

Query Match 0.8%; Score 18; DB 4; Length 4307;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1830 GSTGAGGGGGCAGTAGTG 1847
Db 4173 GGTGAGGGGGCAGTAGTG 4190

RESULT 49
US-09-392-812A-3
Sequence 3, Application US/09392812A
Patent No. 6537778
GENERAL INFORMATION:
APPLICANT: Zuker, Charles S.
APPLICANT: Walker, Richard G.
APPLICANT: Wallingham, Aaron

APPLICANT: The Regents of the University of California
TITLE OF INVENTION: A Eukaryotic Mechanosensory Transduction Channel
FILE REFERENCE: 02307E-097600US
CURRENT APPLICATION NUMBER: US/09/392,812A
CURRENT FILING DATE: 1999-09-09
NUMBER OF SEQ ID NOS: 17
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 3
LENGTH: 6156
TYPE: DNA
ORGANISM: Drosophila melanogaster
FEATURE:
OTHER INFORMATION: nompC cDNA sequence
JS-09-392-812A-3

Query Match 0.8%; Score 18; DB 4; Length 6156;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

2Y 593 GGAGCTCAAGAGCTGGA 610
|||
3B 912 GGAGCTCAAGAGCTGGA 929

RESULT 50
JS-09-552-950-5
Sequence 5, Application US/39552950
Patent No. 6541248
GENERAL INFORMATION:
APPLICANT: Oxford Biomedica (UK) Limited
TITLE OF INVENTION: Anti-Viral Vectors
FILE REFERENCE: 674524-2004
CURRENT APPLICATION NUMBER: US/09/552,950
CURRENT FILING DATE: 2000-04-20
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 5
LENGTH: 9772
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: pSYNGP
JS-09-552-950-5

Query Match 0.8%; Score 18; DB 4; Length 9772;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

2Y 1830 GGTGAGGGGGCAGTAGTG 1847
|||
3B 5280 GGTGAGGGGGCAGTAGTG 5297

Search completed: February 6, 2004, 04:00:19
Job time : 177 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

M nucleic - nucleic search, using sw model

run on: February 6, 2004, 02:47:54 ; Search time 2687 Seconds
(without alignments)
2995.436 Million cell updates/sec

title: US-09-989-279-228

effect score: 2185

sequence: 1 gttcccttcgcagccaaa.....aaagacaaaagtcaaaaca 2185

scoring table: OLIGO_NUC

Gapop 60.0 , Gapext 60.0

searched: 2449703 seqs, 1841816367 residues

word size : 10

total number of hits satisfying chosen parameters: 2559074

minimum DB seq length: 0

maximum DB seq length: 2000000000

post-processing: Listing first 150 summaries

database :

Published Applications NA:**

- 1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq.*
- 2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq.*
- 3: /cgn2_6/ptodata/1/pubpna/US05_NEW_PUB.seq.*
- 4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq.*
- 5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq.*
- 6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq.*
- 7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq.*
- 8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq.*
- 9: /cgn2_6/ptodata/1/pubpna/US09A_PUBCOMB.seq.*
- 10: /cgn2_6/ptodata/1/pubpna/US09B_PUBCOMB.seq.*
- 11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq.*
- 12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq.*
- 13: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq.*
- 14: /cgn2_6/ptodata/1/pubpna/US10A_PUBCOMB.seq.*
- 15: /cgn2_6/ptodata/1/pubpna/US10B_PUBCOMB.seq.*
- 16: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq.*
- 17: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq.*
- 18: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2185	100.0	2185	9	US-09-989-722-228
2	2185	100.0	2185	9	US-09-989-723-228
3	2185	100.0	2185	9	US-09-989-729-228
4	2185	100.0	2185	9	US-09-989-727-228
5	2185	100.0	2185	10	US-09-989-731-228
6	2185	100.0	2185	10	US-09-989-732-228
7	2185	100.0	2185	10	US-09-991-073-228
8	2185	100.0	2185	10	US-09-990-442-228
9	2185	100.0	2185	10	US-09-991-163-228
10	2185	100.0	2185	10	US-09-993-604-228
11	2185	100.0	2185	10	US-09-990-456-228
12	2185	100.0	2185	10	US-09-992-721-228
13	2185	100.0	2185	10	US-09-992-598-228
14	2185	100.0	2185	10	US-09-989-293A-228
15	2185	100.0	2185	10	US-09-989-735-228

16	2185	100.0	2185	10	US-09-990-444-228	Sequence 228, App
17	2185	100.0	2185	10	US-09-991-181-228	Sequence 228, App
18	2185	100.0	2185	10	US-09-989-730-228	Sequence 228, App
19	2185	100.0	2185	10	US-09-990-436-228	Sequence 228, App
20	2185	100.0	2185	10	US-09-993-687-228	Sequence 228, App
21	2185	100.0	2185	11	US-09-989-734-228	Sequence 228, App
22	2185	100.0	2185	11	US-09-997-653-228	Sequence 228, App
23	2185	100.0	2185	11	US-09-993-667-228	Sequence 228, App
24	2185	100.0	2185	11	US-09-997-428-228	Sequence 228, App
25	2185	100.0	2185	11	US-09-997-666-228	Sequence 228, App
26	2185	100.0	2185	11	US-09-990-438-228	Sequence 228, App
27	2185	100.0	2185	11	US-09-990-562-228	Sequence 228, App
28	2185	100.0	2185	11	US-09-990-711-228	Sequence 228, App
29	2185	100.0	2185	11	US-09-989-726-228	Sequence 228, App
30	2185	100.0	2185	11	US-09-998-156-228	Sequence 228, App
31	2185	100.0	2185	11	US-09-990-437-228	Sequence 228, App
32	2185	100.0	2185	11	US-09-991-157-228	Sequence 228, App
33	2185	100.0	2185	11	US-09-997-514-228	Sequence 228, App
34	2185	100.0	2185	11	US-09-997-573-228	Sequence 228, App
35	2185	100.0	2185	11	US-09-991-172-228	Sequence 228, App
36	2185	100.0	2185	11	US-09-990-726-228	Sequence 228, App
37	2185	100.0	2185	11	US-09-997-559-228	Sequence 228, App
38	2185	100.0	2185	11	US-09-997-601-228	Sequence 228, App
39	2185	100.0	2185	11	US-09-990-443-228	Sequence 228, App
40	2185	100.0	2185	11	US-09-991-854-228	Sequence 228, App
41	2185	100.0	2185	11	US-09-997-628-228	Sequence 228, App
42	2185	100.0	2185	11	US-09-997-683-228	Sequence 228, App
43	2185	100.0	2185	11	US-09-989-729A-228	Sequence 228, App
44	2185	100.0	2185	11	US-09-997-349-228	Sequence 228, App
45	2185	100.0	2185	11	US-09-997-440-228	Sequence 228, App
46	2185	100.0	2185	11	US-09-990-440-228	Sequence 228, App
47	2185	100.0	2185	11	US-09-993-469-228	Sequence 228, App
48	2185	100.0	2185	11	US-09-997-542-228	Sequence 228, App
49	2185	100.0	2185	11	US-09-993-748-228	Sequence 228, App
50	2185	100.0	2185	11	US-09-990-439-228	Sequence 228, App
51	2185	100.0	2185	11	US-09-990-427-228	Sequence 228, App
52	2185	100.0	2185	11	US-09-989-328-228	Sequence 228, App
53	2185	100.0	2185	11	US-09-993-583-228	Sequence 228, App
54	2185	100.0	2185	11	US-09-941-392-228	Sequence 228, App
55	2185	100.0	2185	11	US-09-992-521-228	Sequence 228, App
56	2185	100.0	2185	11	US-09-997-333-228	Sequence 228, App
57	2185	100.0	2185	11	US-09-997-384-228	Sequence 228, App
58	2185	100.0	2185	11	US-09-998-041-228	Sequence 228, App
59	2185	100.0	2185	11	US-09-997-585-228	Sequence 228, App
60	2185	100.0	2185	11	US-09-997-614-228	Sequence 228, App
61	2185	100.0	2185	12	US-09-989-733-228	Sequence 228, App
62	2185	100.0	2185	12	US-09-992-643-228	Sequence 228, App
63	2185	100.0	2185	12	US-10-128-692A-437	Sequence 437, App
64	2185	100.0	2185	12	US-10-140-927-437	Sequence 437, App
65	2185	100.0	2185	13	US-09-989-862-228	Sequence 228, App
66	2185	100.0	2185	13	US-09-989-725-228	Sequence 228, App
67	2185	100.0	2185	13	US-09-997-529-228	Sequence 228, App
68	2185	100.0	2185	13	US-10-137-870-437	Sequence 437, App
69	2185	100.0	2185	13	US-10-140-018-437	Sequence 437, App
70	2185	100.0	2185	13	US-10-140-021-437	Sequence 437, App
71	2185	100.0	2185	13	US-10-140-274-437	Sequence 437, App
72	2185	100.0	2185	13	US-10-140-471-437	Sequence 437, App
73	2185	100.0	2185	13	US-10-140-807-437	Sequence 437, App
74	2185	100.0	2185	13	US-10-140-822-437	Sequence 437, App
75	2185	100.0	2185	13	US-10-140-926-437	Sequence 437, App
76	2185	100.0	2185	13	US-10-140-926-437	Sequence 437, App
77	2185	100.0	2185	13	US-10-141-698-437	Sequence 437, App
78	2185	100.0	2185	13	US-10-141-702-437	Sequence 437, App
79	2185	100.0	2185	13	US-10-141-704-437	Sequence 437, App
80	2185	100.0	2185	13	US-10-142-421-437	Sequence 437, App
81	2185	100.0	2185	13	US-10-142-432-437	Sequence 437, App
82	2185	100.0	2185	13	US-10-142-767-437	Sequence 437, App
83	2185	100.0	2185	13	US-10-143-033-437	Sequence 437, App
84	2185	100.0	2185	13	US-10-144-994-437	Sequence 437, App
85	2185	100.0	2185	13	US-10-145-628-437	Sequence 437, App
86	2185	100.0	2185	13	US-10-145-631-437	Sequence 437, App
87	2185	100.0	2185	13	US-10-145-633-437	Sequence 437, App
88	2185	100.0	2185	13	US-10-145-746-437	Sequence 437, App

89 2185 100.0 2185 13 US-10-145-748-437 Sequence 437, App
90 2185 100.0 2185 13 US-10-145-823-437 Sequence 437, App
91 2185 100.0 2185 13 US-10-145-826-437 Sequence 437, App
92 2185 100.0 2185 13 US-10-145-870-437 Sequence 437, App
93 2185 100.0 2185 13 US-10-145-876-437 Sequence 437, App
94 2185 100.0 2185 13 US-10-145-959-437 Sequence 437, App
95 2185 100.0 2185 13 US-10-146-724-437 Sequence 437, App
96 2185 100.0 2185 13 US-10-146-725-437 Sequence 437, App
97 2185 100.0 2185 13 US-10-146-795-437 Sequence 437, App
98 2185 100.0 2185 13 US-10-147-495-437 Sequence 437, App
99 2185 100.0 2185 13 US-10-147-501-437 Sequence 437, App
100 2185 100.0 2185 13 US-10-147-504-437 Sequence 437, App
101 2185 100.0 2185 13 US-10-147-506-437 Sequence 437, App
102 2185 100.0 2185 13 US-10-147-509-437 Sequence 437, App
103 2185 100.0 2185 13 US-10-147-510-437 Sequence 437, App
104 2185 100.0 2185 13 US-10-147-511-437 Sequence 437, App
105 2185 100.0 2185 13 US-10-147-529-437 Sequence 437, App
106 2185 100.0 2185 13 US-10-152-397-437 Sequence 437, App
107 2185 100.0 2185 13 US-10-153-586-437 Sequence 437, App
108 2185 100.0 2185 13 US-10-158-783-437 Sequence 437, App
109 2185 100.0 2185 13 US-10-158-786-437 Sequence 437, App
110 2185 100.0 2185 13 US-10-140-019-437 Sequence 437, App
111 2185 100.0 2185 13 US-10-140-022-437 Sequence 437, App
112 2185 100.0 2185 13 US-10-140-861-437 Sequence 437, App
113 2185 100.0 2185 13 US-10-140-862-437 Sequence 437, App
114 2185 100.0 2185 13 US-10-141-697-437 Sequence 437, App
115 2185 100.0 2185 13 US-10-141-700-437 Sequence 437, App
116 2185 100.0 2185 13 US-10-141-705-437 Sequence 437, App
117 2185 100.0 2185 13 US-10-141-753-437 Sequence 437, App
118 2185 100.0 2185 13 US-10-141-758-437 Sequence 437, App
119 2185 100.0 2185 13 US-10-142-418-437 Sequence 437, App
120 2185 100.0 2185 13 US-10-142-420-437 Sequence 437, App
121 2185 100.0 2185 13 US-10-142-422-437 Sequence 437, App
122 2185 100.0 2185 13 US-10-142-427-437 Sequence 437, App
123 2185 100.0 2185 13 US-10-142-760-437 Sequence 437, App
124 2185 100.0 2185 13 US-10-145-821-437 Sequence 437, App
125 2185 100.0 2185 13 US-10-152-531-437 Sequence 437, App
126 2185 100.0 2185 13 US-10-127-840A-437 Sequence 437, App
127 2185 100.0 2185 13 US-10-142-424-437 Sequence 437, App
128 2185 100.0 2185 13 US-10-142-761-437 Sequence 437, App
129 2185 100.0 2185 13 US-10-142-763-437 Sequence 437, App
130 2185 100.0 2185 13 US-10-142-765-437 Sequence 437, App
131 2185 100.0 2185 13 US-10-142-887-437 Sequence 437, App
132 2185 100.0 2185 13 US-10-142-888-437 Sequence 437, App
133 2185 100.0 2185 13 US-10-143-034-437 Sequence 437, App
134 2185 100.0 2185 13 US-10-143-116-437 Sequence 437, App
135 2185 100.0 2185 13 US-10-143-117-437 Sequence 437, App
136 2185 100.0 2185 13 US-10-144-957-437 Sequence 437, App
137 2185 100.0 2185 13 US-10-144-992-437 Sequence 437, App
138 2185 100.0 2185 13 US-10-145-015-437 Sequence 437, App
139 2185 100.0 2185 13 US-10-145-090-437 Sequence 437, App
140 2185 100.0 2185 13 US-10-145-091-437 Sequence 437, App
141 2185 100.0 2185 13 US-10-145-629-437 Sequence 437, App
142 2185 100.0 2185 13 US-10-145-630-437 Sequence 437, App
143 2185 100.0 2185 13 US-10-145-747-437 Sequence 437, App
144 2185 100.0 2185 13 US-10-145-752-437 Sequence 437, App
145 2185 100.0 2185 13 US-10-145-754-437 Sequence 437, App
146 2185 100.0 2185 13 US-10-145-755-437 Sequence 437, App
147 2185 100.0 2185 13 US-10-145-818-437 Sequence 437, App
148 2185 100.0 2185 13 US-10-145-820-437 Sequence 437, App
149 2185 100.0 2185 13 US-10-145-872-437 Sequence 437, App
150 2185 100.0 2185 13 US-10-145-873-437 Sequence 437, App

ALIGNMENTS

RESULT 1

US-09-989-722-228

; Sequence 228, Application US/09989722

; Patent No. US20020072067A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.

5

APPLICANT: Baker, Kevin P.
APPLICANT: Borstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730P1C63
CURRENT APPLICATION NUMBER: US/09/989,722
CURRENT FILING DATE: 2001-11-19
PRIOR APPLICATION NUMBER: 60/045787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167

PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24

PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 9; Length 2185;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTCTCTTTCCGAGCCAAATCCAGCGCATGGTAATATGAACTGACACACCATGA 60
Db 1 GTTCTCTTTCCGAGCCAAATCCAGCGCATGGTAATATGAACTGACACACCATGA 60
Qy 61 AGCTTTGTGTCAGGTAACTGTGCAACACCACTGGAATGCAATCTCTCTCCGTTCG 120
Db 61 AGCTTTGTGTCAGGTAACTGTGCAACACCACTGGAATGCAATCTCTCTCCGTTCG 120
Qy 121 TCTACCTCAGCGGCAAGTGTGATTTCTGTGTGTCAGCATGCTGTGCGCTCAGCGG 180
Db 121 TCTACCTCAGCGGCAAGTGTGATTTCTGTGTGTCAGCATGCTGTGCGCTCAGCGG 180
Qy 181 GGCCCCAGAACTGCCCTCCGTTTGTCTGTGTCAGTAAACAGTTTACAGAGTGTGTGCA 240
Db 181 GGCCCCAGAACTGCCCTCCGTTTGTCTGTGTCAGTAAACAGTTTACAGAGTGTGTGCA 240
Qy 241 CGCGCGGCGGCTCTCGAGTCCCGAGGTTTCCCTCGAACACCCGCTACTCAACC 300

Db 241 CGGGCGGGGCTCTCCGAGGTCCGCGAGGGATTCCTCGAACAACACCGGTAACCTCAACC 300
Qy 301 TCATGAGAAACAATCCAGATGATCCAGGCGGACACCTTCGGCCACCTCCACCACTGG 360
Db 301 TCATGAGAAACAATCCAGATGATCCAGGCGGACACCTTCGGCCACCTCCACCACTGG 360
Qy 361 AGGTCTGAGTTGGGACGAATCTCATTCGGCAGATTTGAGTGGGGCTTTCACGGCC 420
Db 361 AGGTCTGAGTTGGGACGAATCTCATTCGGCAGATTTGAGTGGGGCTTTCACGGCC 420
Qy 421 TGGCCAGCTCAACACCTCGAGCTGTTTCGACAACTGGCTGACAGTCAATCCCTAGCGGG 480
Db 421 TGGCCAGCTCAACACCTCGAGCTGTTTCGACAACTGGCTGACAGTCAATCCCTAGCGGG 480
Qy 481 CTTTGAATACCTGTCAGCTGCGGAGCTCTGGCTTCGCAACAACCCCATGAAAGCA 540
Db 481 CTTTGAATACCTGTCAGCTGCGGAGCTCTGGCTTCGCAACAACCCCATGAAAGCA 540
Qy 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATCGGCTGAGCTTGGGGAGCTCA 600
Db 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATCGGCTGAGCTTGGGGAGCTCA 600
Qy 601 AGAAGCTGAGTATATCTCTGAGGAGCTTTTGAGGGCTCTTCAACCTCAAGTATCTGA 660
Db 601 AGAAGCTGAGTATATCTCTGAGGAGCTTTTGAGGGCTCTTCAACCTCAAGTATCTGA 660
Qy 661 ACTTGGGATGTCACATTTAAAGACATGCCAACTCTCACCCCTCTGTTGGGGCTGGAG 720
Db 661 ACTTGGGATGTCACATTTAAAGACATGCCAACTCTCACCCCTCTGTTGGGGCTGGAG 720
Qy 721 AGCTGGAGTATGTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGAGCTGA 780
Db 721 AGCTGGAGTATGTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGAGCTGA 780
Qy 781 GCTCCTCAAGAGCTCTGGGTCAATCAAGTACAGGTCAGGCTGATTTGCGGAGTCTT 840
Db 781 GCTCCTCAAGAGCTCTGGGTCAATCAAGTACAGGTCAGGCTGATTTGCGGAGTCTT 840
Qy 841 TTGAGGGCTGGCTTCACTTTGAGAACTCAACTTTGGGCCCAATAAATCTCTCTTTTTC 900
Db 841 TTGAGGGCTGGCTTCACTTTGAGAACTCAACTTTGGGCCCAATAAATCTCTCTTTTTC 900
Qy 901 CCATGACCTCTTTACCGGCTGAGTACCTGGTGGAGTTGCATCTACACCAACACCTT 960
Db 901 CCATGACCTCTTTACCGGCTGAGTACCTGGTGGAGTTGCATCTACACCAACACCTT 960
Qy 961 GGAACTGTGATGTGACATCTGTGGCTAGCTGTGGCTTCGAGAGTATATACCAACA 1020
Db 961 GGAACTGTGATGTGACATCTGTGGCTAGCTGTGGCTTCGAGAGTATATACCAACA 1020
Qy 1021 ATTCCACTGTGTGGCGCTGTGATGCTCCATGCTCATGCGAGGCGCTTACTGTGG 1080
Db 1021 ATTCCACTGTGTGGCGCTGTGATGCTCCATGCTCATGCGAGGCGCTTACTGTGG 1080
Qy 1081 AGGTGGACGAGGCTCTCTTCAGTGTCTGCTCCCTTCATCATGAGGCGACCTGAGACC 1140
Db 1081 AGGTGGACGAGGCTCTCTTCAGTGTCTGCTCCCTTCATCATGAGGCGACCTGAGACC 1140
Qy 1141 TCACATTTCTGAGGCTCGATGCGAGAACTTAAGTGTGGACTCCCTCTATGTCTTCG 1200
Db 1141 TCACATTTCTGAGGCTCGATGCGAGAACTTAAGTGTGGACTCCCTCTATGTCTTCG 1200
Qy 1201 TGAAGTGTGTGCTGCCAATGGGACAGTGTCTGACGAGCTCCGCTCCGCGACCAAGGATCT 1260
Db 1201 TGAAGTGTGTGCTGCCAATGGGACAGTGTCTGACGAGCTCCGCTCCGCGACCAAGGATCT 1260
Qy 1261 CTGTCTCTCAAGCAGGCACTTTGAATTTTCCACGCTGCTTTTCAGACACTGGGGTGT 1320
Db 1261 CTGTCTCTCAAGCAGGCACTTTGAATTTTCCACGCTGCTTTTCAGACACTGGGGTGT 1320
Qy 1321 ACACATGATGTTGACCAATGTTGAGGCACTCAAGGCTCGGCTACTCAATGTGA 1380
Db 1321 ACACATGATGTTGACCAATGTTGAGGCACTCAAGGCTCGGCTACTCAATGTGA 1380

Qy 1381 GCACGGCTGAGCTTAACACCTCCAACTACAGCTTTCTTACCAACAGTAACAGTGAGACCA 1440
Db 1381 GCACGGCTGAGCTTAACACCTCCAACTACAGCTTTCTTACCAACAGTAACAGTGAGACCA 1440
Qy 1441 CGGAGATCTCGCTGAGGACACACCGCGAAGTACAGCTGTTTCTTACCAAGTCCACTG 1500
Db 1441 CGGAGATCTCGCTGAGGACACACCGCGAAGTACAGCTGTTTCTTACCAAGTCCACTG 1500
Qy 1501 GTTACAGCGGCAATATACCACTCTACCGTGTCTTATTCAGACTACCGTGTGCGCA 1560
Db 1501 GTTACAGCGGCAATATACCACTCTACCGTGTCTTATTCAGACTACCGTGTGCGCA 1560
Qy 1561 AGCAGTGGCAGTACCGCGGACAGACCACTGACAGTGCAGACGACGAGCTGATGAG 1620
Db 1561 AGCAGTGGCAGTACCGCGGACAGACCACTGACAGTGCAGACGAGCTGATGAG 1620
Qy 1621 TCATGAAGACCAACCAAGATCATTTGCTGCTTGTGGCAGTCACTTCTGCTAGCTGCG 1680
Db 1621 TCATGAAGACCAACCAAGATCATTTGCTGCTTGTGGCAGTCACTTCTGCTAGCTGCG 1680
Qy 1681 CATGTTGATGCTTCTTATAACTTGTAAAGCGGACAGGAGGAGTACAGTCAAG 1740
Db 1681 CATGTTGATGCTTCTTATAACTTGTAAAGCGGACAGGAGGAGTACAGTCAAG 1740
Qy 1741 CCGCCGCACTGTTGAGATAATCCAGGTGAGACGAGACATCCAGCAGCAACATCCGCG 1800
Db 1741 CCGCCGCACTGTTGAGATAATCCAGGTGAGACGAGACATCCAGCAGCAACATCCGCG 1800
Qy 1801 CAGCAACGAGCTCCGCTCGGTTGATCAGGTGAGGGGAGTGTGCTGCCCAATTC 1860
Db 1801 CAGCAACGAGCTCCGCTCGGTTGATCAGGTGAGGGGAGTGTGCTGCCCAATTC 1860
Qy 1861 ATGACCATATTAATACCAACCTCAAAACAGACATGCGGCGGCACTGGACAGAAACA 1920
Db 1861 ATGACCATATTAATACCAACCTCAAAACAGACATGCGGCGGCACTGGACAGAAACA 1920
Qy 1921 GCTGGGAACTCTTGCAACCTGCAACCTGCAACCTGCAACCTGCAACCTGCAACCTGCA 1980
Db 1921 GCTGGGAACTCTTGCAACCTGCAACCTGCAACCTGCAACCTGCAACCTGCAACCTGCA 1980
Qy 1981 CCATACCAAGGACAGGTACAGGAACTCAAAATGACTCCCTCCGCGGCACTTAAATTTA 2040
Db 1981 CCATACCAAGGACAGGTACAGGAACTCAAAATGACTCCCTCCGCGGCACTTAAATTTA 2040
Qy 2041 TAAATGCAATAGAAATGCAACAAAGACAGCAACTTTTGTACAGAGTGGGAGAGCTTT 2100
Db 2041 TAAATGCAATAGAAATGCAACAAAGACAGCAACTTTTGTACAGAGTGGGAGAGCTTT 2100
Qy 2101 TTCTTGTATATGCTTATATATTAAGTCTATGGCTGTTTAAAGAAACAGTATATTA 2160
Db 2101 TTCTTGTATATGCTTATATATTAAGTCTATGGCTGTTTAAAGAAACAGTATATTA 2160
Qy 2161 AATTTAAAGACAAAGTCAAAACA 2185
Db 2161 AATTTAAAGACAAAGTCAAAACA 2185

RESULT 2

US-09-989-723-228
; Sequence 228, Application US/09989723
; Patent No. US2002007202A1

GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730PIC62
CURRENT APPLICATION NUMBER: US/09/989,723
CURRENT FILING DATE: 2001-11-19
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09

PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089500
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535

1501 GTTACGAGCGGATATACCACTCTTACACGGTGTCTCATTCAGACTACCGGTGTGCCA 1560
 1501 GTTACGAGCGGATATACCACTCTTACACGGTGTCTCATTCAGACTACCGGTGTGCCA 1560
 1561 AGCAGTGGCAGTACCGGCGACAGACCACTCAAGATGAGACCGAGCTGGATGAAG 1620
 1561 AGCAGTGGCAGTACCGGCGACAGACCACTCAAGATGAGACCGAGCTGGATGAAG 1620
 1621 TCATGAAGACCAACCAAGATCATCATTTGGTGTCTTTGTGCGAGTCTGTAGCTGCCG 1680
 1621 TCATGAAGACCAACCAAGATCATCATTTGGTGTCTTTGTGCGAGTCTGTAGCTGCCG 1680
 1681 CCATGTGATTTGCTTCTTAATACTTGTAGCGGACCAAGAGCGGAGTACAGTCAAG 1740
 1681 CCATGTGATTTGCTTCTTAATACTTGTAGCGGACCAAGAGCGGAGTACAGTCAAG 1740
 1741 CCGCCGCGAGTGTGAGATATCCAGGTGAGACCAATCCAGCAGCAACATCCGAG 1800
 1741 CCGCCGCGAGTGTGAGATATCCAGGTGAGACCAATCCAGCAGCAACATCCGAG 1800
 1801 CAGCAACAGCAGCTCGTCCGGTGTATCAGGTGAGGCGGCGAGTGTGCGCCCAATTC 1860
 1801 CAGCAACAGCAGCTCGTCCGGTGTATCAGGTGAGGCGGCGAGTGTGCGCCCAATTC 1860
 1861 ATGACCATATTAATCAACCACTCAAAACCACTGAGGCGGCGAGTGTGCGCCCAATTC 1920
 1861 ATGACCATATTAATCAACCACTCAAAACCACTGAGGCGGCGAGTGTGCGCCCAATTC 1920
 1921 GCCTGGGGAATCTCTGCAACCCCAAGTCAACCACTATCTCTGAACTTATATAATTCAGA 1980
 1921 GCCTGGGGAATCTCTGCAACCCCAAGTCAACCACTATCTCTGAACTTATATAATTCAGA 1980
 1981 CCATACCAAGGACAGGTACAGGAACTCAATATGACTTCCCTCCCGGCAAAACTTA 2040
 1981 CCATACCAAGGACAGGTACAGGAACTCAATATGACTTCCCTCCCGGCAAAACTTA 2040
 2041 TAAATGCAATAGTACGACACCAAGGACGAGTCTTGTACAGAGTGGGAGAGACTTT 2100
 2041 TAAATGCAATAGTACGACACCAAGGACGAGTCTTGTACAGAGTGGGAGAGACTTT 2100
 2101 TTCTGTATATGCTTATATTAATTAAGTCTATGAGTGGTGGTGGTGGTGGTGGTGGT 2160
 2101 TTCTGTATATGCTTATATTAATTAAGTCTATGAGTGGTGGTGGTGGTGGTGGTGGT 2160
 2161 AATTTAAGCAAAAGTCAAAACA 2185
 2161 AATTTAAGCAAAAGTCAAAACA 2185

RESULT 3

S-09-989-279-228

Sequence 228 Application US/09989279

Patent No. US2002072496A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
 APPLICANT: Baker, Kevin P.
 APPLICANT: Botstein, David
 APPLICANT: Deenoyers, Luc
 APPLICANT: Eaton, Dan L.
 APPLICANT: Ferrara, Napoleone
 APPLICANT: Fong, Sherman
 APPLICANT: Gerber, Hanspeter
 APPLICANT: Gerritsen, Mary E.
 APPLICANT: Goddard, Audrey
 APPLICANT: Godowski, Paul J.
 APPLICANT: Grimaldi, J. Christopher
 APPLICANT: Gurney, Austin L.
 APPLICANT: Kljavin, Ivar J.
 APPLICANT: Napier, Mary A.
 APPLICANT: Pan, James
 APPLICANT: Paoni, Nicholas F.
 APPLICANT: Roy, Margaret Ann
 APPLICANT: Stewart, Timothy A.

APPLICANT: Tamas, Daniel
 APPLICANT: Watanabe, Colin K.
 APPLICANT: Williams, P. Mickey
 APPLICANT: Wood, William I.
 APPLICANT: Zhang, Xemin
 TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 TITLE OF INVENTION: Acids Encoding the Same
 FILE REFERENCE: P27301C56
 CURRENT APPLICATION NUMBER: US/09/989,279
 CURRENT FILING DATE: 2001-11-19
 PRIOR FILING DATE: 1997-06-16
 PRIOR APPLICATION NUMBER: 60/049787
 PRIOR FILING DATE: 1997-10-17
 PRIOR APPLICATION NUMBER: 60/062250
 PRIOR FILING DATE: 1997-11-12
 PRIOR APPLICATION NUMBER: 60/065186
 PRIOR FILING DATE: 1997-11-13
 PRIOR APPLICATION NUMBER: 60/065311
 PRIOR FILING DATE: 1997-11-24
 PRIOR APPLICATION NUMBER: 60/066770
 PRIOR FILING DATE: 1997-11-24
 PRIOR APPLICATION NUMBER: 60/075945
 PRIOR FILING DATE: 1998-02-25
 PRIOR APPLICATION NUMBER: 60/078910
 PRIOR FILING DATE: 1998-03-20
 PRIOR APPLICATION NUMBER: 60/083322
 PRIOR FILING DATE: 1998-04-28
 PRIOR APPLICATION NUMBER: 60/084600
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/087106
 PRIOR FILING DATE: 1998-05-28
 PRIOR APPLICATION NUMBER: 60/087607
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087609
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087759
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087827
 PRIOR FILING DATE: 1998-06-03
 PRIOR APPLICATION NUMBER: 60/088021
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088025
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088026
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088028
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088029
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088030
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088033
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088326
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088167
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088202
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088212
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088217
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088655
 PRIOR FILING DATE: 1998-06-09
 PRIOR APPLICATION NUMBER: 60/088734
 PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088738
 PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088742
 PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088810
 PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088824

PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088826
 PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088858
 PRIOR FILING DATE: 1998-06-11
 PRIOR APPLICATION NUMBER: 60/088861
 PRIOR FILING DATE: 1998-06-11
 PRIOR APPLICATION NUMBER: 60/088876
 PRIOR FILING DATE: 1998-06-11
 PRIOR APPLICATION NUMBER: 60/089105
 PRIOR FILING DATE: 1998-06-12
 PRIOR APPLICATION NUMBER: 60/089440
 PRIOR FILING DATE: 1998-06-16
 PRIOR APPLICATION NUMBER: 60/089512
 PRIOR FILING DATE: 1998-06-16
 PRIOR APPLICATION NUMBER: 60/089514
 PRIOR FILING DATE: 1998-06-16
 PRIOR APPLICATION NUMBER: 60/089532
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089538
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089598
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089599
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089600
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089653
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089801
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089907
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089908
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089947
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/089948
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/089952
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/090246
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090252
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090254
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090349
 PRIOR FILING DATE: 1998-06-23
 PRIOR APPLICATION NUMBER: 60/090355
 PRIOR FILING DATE: 1998-06-23
 PRIOR APPLICATION NUMBER: 60/090429
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090431
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090435
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090444
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090445
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090472
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090535
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090540
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090542
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090557
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090676
 PRIOR FILING DATE: 1998-06-25

PRIOR APPLICATION NUMBER: 60/090678
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090690
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090694
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090695
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090696
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090862
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/090863
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/091360
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091478
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091544
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091519
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091626
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091633
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091978
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/091982
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/092182
 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 9; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTCTCTTCCGAGCCAAATCCAGCGCATGGTGAATTATGACAGTGCACACCATGA 60
 DB 1 GTTCTCTTCCGAGCCAAATCCAGCGCATGGTGAATTATGACAGTGCACACCATGA 60
 QY 61 AGCTCTGTGCGAGTAACTGTGCACACACACACCTTCCATGCCATGCCATCTCTCCGCTCG 120
 DB 61 AGCTCTGTGCGAGTAACTGTGCACACACACACCTTCCATGCCATGCCATCTCTCCGCTCG 120
 QY 121 TCTACTCACGCGCAAGTGTGGATTCTGTGTGAGCCATCGCTGTGCGCCCTCAGCCG 180
 DB 121 TCTACTCACGCGCAAGTGTGGATTCTGTGTGAGCCATCGCTGTGCGCCCTCAGCCG 180
 QY 181 GCGCCCGAGACTGCCCTCCCTTTGCTGTCAGTAACTTCCAGTTCAGCAAGTGTGTGCA 240
 DB 181 GCGCCCGAGACTGCCCTCCCTTTGCTGTCAGTAACTTCCAGTTCAGCAAGTGTGTGCA 240
 QY 241 CCGCGCGGGGCTCTCCGAGGTCCCGCAGGTATTCCTCGAACACCCGCTACTCCTAAC 300
 DB 241 CCGCGCGGGGCTCTCCGAGGTCCCGCAGGTATTCCTCGAACACCCGCTACTCCTAAC 300
 QY 301 TCATGGAGAACACATCCAGATGATCCAGCGGACACTTCCGCGACCTCCACACCTGG 360
 DB 301 TCATGGAGAACACATCCAGATGATCCAGCGGACACTTCCGCGACCTCCACACCTGG 360
 QY 361 AGGTCTCTCAGTTGGGCGAGGAACCTCCATCCGCGCAGATTGAGTGGGGGCTTCAACCGCC 420
 DB 361 AGGTCTCTCAGTTGGGCGAGGAACCTCCATCCGCGCAGATTGAGTGGGGGCTTCAACCGCC 420
 QY 421 TGGCGAGCTCAACACCTCGAGCTGTTCGACACTGGTGCAGATCATCCCTAGCGGGG 480
 DB 421 TGGCGAGCTCAACACCTCGAGCTGTTCGACACTGGTGCAGATCATCCCTAGCGGGG 480
 QY 481 CTTTGAATACCTGTCCAAAGCTGCGGAGGTCTGCTTTCGCAACCAACCCCATCGAAAGCA 540
 DB 481 CTTTGAATACCTGTCCAAAGCTGCGGAGGTCTGCTTTCGCAACCAACCCCATCGAAAGCA 540

541 TCCGCTTTAGGCTTCAACCGGTCGCCCTCATGCGCTGAGCTTGGGGAGCTCA 600
541 TCCGCTTTAGGCTTCAACCGGTCGCCCTCATGCGCTGAGCTTGGGGAGCTCA 600
601 AGAAGCTGGAAGTATCTCTGAGGAGCTTTGAGGGCTGTTCAACCTCAAGTATCTGA 660
601 AGAAGCTGGAAGTATCTCTGAGGAGCTTTGAGGGCTGTTCAACCTCAAGTATCTGA 660
661 ACTTGGGCTGTCGAATTAAGAGATGCGGCTGTTGAGGGCTGTTGAGGGCTGAGG 720
661 ACTTGGGCTGTCGAATTAAGAGATGCGGCTGTTGAGGGCTGTTGAGGGCTGAGG 720
721 AGCTGAGAGTGCAGGGAACCACTTCCCTGAGATCAGGCTGCTCTTCCATGSCCTGA 780
721 AGCTGAGAGTGCAGGGAACCACTTCCCTGAGATCAGGCTGCTCTTCCATGSCCTGA 780
781 GCTCCCTCAAGAGCTCTGGGTCAAGAACTCAAGCTCAGCTGAGTGAAGGAATGCTT 840
781 GCTCCCTCAAGAGCTCTGGGTCAAGAACTCAAGCTCAGCTGAGTGAAGGAATGCTT 840
841 TTGACGGCTGCTTCACTGTTGGAATCACTGAGTCAAGCTCAGCTGAGTGAAGGAATGCTT 900
841 TTGACGGCTGCTTCACTGTTGGAATCACTGAGTCAAGCTCAGCTGAGTGAAGGAATGCTT 900
901 CCCATGACCTCTTTACCCCGCTGAGTACCTGGTGGAGTTGATCTACACCAACCCCTT 960
901 CCCATGACCTCTTTACCCCGCTGAGTACCTGGTGGAGTTGATCTACACCAACCCCTT 960
961 GGAAGTGTGATGAGATCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT 1020
961 GGAAGTGTGATGAGATCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCT 1020
1021 ATTCCACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1080
1021 ATTCCACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1080
1081 AGTGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140
1081 AGTGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140
1141 TCAACATTTCTGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1200
1141 TCAACATTTCTGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1200
1201 TGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1260
1201 TGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1260
1261 CTGCTCTCAAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1320
1261 CTGCTCTCAAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1320
1321 ACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1380
1321 ACATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1380
1381 GCAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1440
1381 GCAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1440
1441 CGGAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1500
1441 CGGAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1500
1501 GTTACAGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1560
1501 GTTACAGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1560
1561 AGCAGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1620
1561 AGCAGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1620
1621 TCATGAAGACCAACCAAGATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1680

Db 1621 TCATGAAGACCAACCAAGATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1680
Qy 1681 CCATGTTGATTTCTTCTATTAACCTTCTGTAAGCGGCACCGAGCGGAGTACAGTCAACAG 1740
Db 1681 CCATGTTGATTTCTTCTATTAACCTTCTGTAAGCGGCACCGAGCGGAGTACAGTCAACAG 1740
Qy 1741 CCGCCCGGAGCTGTTGAGATTAATCCAGGTGGAAGAGATCCAGAGCAACATCCGAG 1800
Db 1741 CCGCCCGGAGCTGTTGAGATTAATCCAGGTGGAAGAGATCCAGAGCAACATCCGAG 1800
Qy 1801 CAGCAACAGCAGCTCCGTCGCTGCTGATCAGGTGAGGGGCGAGTGTGCTGCCCAACAATTC 1860
Db 1801 CAGCAACAGCAGCTCCGTCGCTGCTGATCAGGTGAGGGGCGAGTGTGCTGCCCAACAATTC 1860
Qy 1861 ATGACCATTAATTAACCAACCACTACAAACCGAGCAGATGCGGCGCCTGCGAGAGAAACA 1920
Db 1861 ATGACCATTAATTAACCAACCACTACAAACCGAGCAGATGCGGCGCCTGCGAGAGAAACA 1920
Qy 1921 GCTTGGGGAACCTCTGCAACCCCACTGAGTCAACCTATCTCTGAACTTATATATATTAAT 1980
Db 1921 GCTTGGGGAACCTCTGCAACCCCACTGAGTCAACCTATCTCTGAACTTATATATTAAT 1980
Qy 1981 CCATACCAAGGACAGGTACAGGAACTCAATATGATCTCCCTCCCAAAAAACCTTA 2040
Db 1981 CCATACCAAGGACAGGTACAGGAACTCAATATGATCTCCCTCCCAAAAAACCTTA 2040
Qy 2041 TAAATGCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 2100
Db 2041 TAAATGCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 2100
Qy 2101 TTCTTGTATGCTTATATATTAATTAAGTCTATGAGTCTATGAGTCTATGAGTCTATGAG 2160
Db 2101 TTCTTGTATGCTTATATATTAATTAAGTCTATGAGTCTATGAGTCTATGAGTCTATGAG 2160
Qy 2161 AATTAAGACAAAGTCAABACA 2185
Db 2161 AATTAAGACAAAGTCAABACA 2185

RESULT 4

US-09-989-727-228

; Sequence 228 Application US/09989727

; Patent No. US20020072497A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Napier, Mary A.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K.

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same

; FILE REFERENCES: P2730P1C65

; CURRENT APPLICATION NUMBER: US/09/989,727

1 CURRENT FILING DATE: 2001-11-19
2 PRIOR APPLICATION NUMBER: 60/043787
3 PRIOR FILING DATE: 1997-06-16
4 PRIOR APPLICATION NUMBER: 60/062250
5 PRIOR FILING DATE: 1997-10-17
6 PRIOR APPLICATION NUMBER: 60/065186
7 PRIOR FILING DATE: 1997-11-12
8 PRIOR APPLICATION NUMBER: 60/065311
9 PRIOR FILING DATE: 1997-11-13
10 PRIOR APPLICATION NUMBER: 60/066770
11 PRIOR FILING DATE: 1997-11-24
12 PRIOR APPLICATION NUMBER: 60/075945
13 PRIOR FILING DATE: 1998-02-25
14 PRIOR APPLICATION NUMBER: 60/078910
15 PRIOR FILING DATE: 1998-03-20
16 PRIOR APPLICATION NUMBER: 60/083322
17 PRIOR FILING DATE: 1998-04-28
18 PRIOR APPLICATION NUMBER: 60/084600
19 PRIOR FILING DATE: 1998-05-07
20 PRIOR APPLICATION NUMBER: 60/087106
21 PRIOR FILING DATE: 1998-05-28
22 PRIOR APPLICATION NUMBER: 60/087607
23 PRIOR FILING DATE: 1998-06-02
24 PRIOR APPLICATION NUMBER: 60/087609
25 PRIOR FILING DATE: 1998-06-02
26 PRIOR APPLICATION NUMBER: 60/087759
27 PRIOR FILING DATE: 1998-06-02
28 PRIOR APPLICATION NUMBER: 60/087827
29 PRIOR FILING DATE: 1998-06-03
30 PRIOR APPLICATION NUMBER: 60/088021
31 PRIOR FILING DATE: 1998-06-04
32 PRIOR APPLICATION NUMBER: 60/088025
33 PRIOR FILING DATE: 1998-06-04
34 PRIOR APPLICATION NUMBER: 60/088026
35 PRIOR FILING DATE: 1998-06-04
36 PRIOR APPLICATION NUMBER: 60/088028
37 PRIOR FILING DATE: 1998-06-04
38 PRIOR APPLICATION NUMBER: 60/088029
39 PRIOR FILING DATE: 1998-06-04
40 PRIOR APPLICATION NUMBER: 60/088030
41 PRIOR FILING DATE: 1998-06-04
42 PRIOR APPLICATION NUMBER: 60/088033
43 PRIOR FILING DATE: 1998-06-04
44 PRIOR APPLICATION NUMBER: 60/088326
45 PRIOR FILING DATE: 1998-06-04
46 PRIOR APPLICATION NUMBER: 60/088167
47 PRIOR FILING DATE: 1998-06-05
48 PRIOR APPLICATION NUMBER: 60/088202
49 PRIOR FILING DATE: 1998-06-05
50 PRIOR APPLICATION NUMBER: 60/088212
51 PRIOR FILING DATE: 1998-06-05
52 PRIOR APPLICATION NUMBER: 60/088217
53 PRIOR FILING DATE: 1998-06-05
54 PRIOR APPLICATION NUMBER: 60/088655
55 PRIOR FILING DATE: 1998-06-09
56 PRIOR APPLICATION NUMBER: 60/088734
57 PRIOR FILING DATE: 1998-06-10
58 PRIOR APPLICATION NUMBER: 60/088738
59 PRIOR FILING DATE: 1998-06-10
60 PRIOR APPLICATION NUMBER: 60/088742
61 PRIOR FILING DATE: 1998-06-10
62 PRIOR APPLICATION NUMBER: 60/088810
63 PRIOR FILING DATE: 1998-06-10
64 PRIOR APPLICATION NUMBER: 60/088824
65 PRIOR FILING DATE: 1998-06-10
66 PRIOR APPLICATION NUMBER: 60/088826
67 PRIOR FILING DATE: 1998-06-10
68 PRIOR APPLICATION NUMBER: 60/088858
69 PRIOR FILING DATE: 1998-06-11
70 PRIOR APPLICATION NUMBER: 60/088861
71 PRIOR FILING DATE: 1998-06-11
72 PRIOR APPLICATION NUMBER: 60/088876
73 PRIOR FILING DATE: 1998-06-11
74 PRIOR APPLICATION NUMBER: 60/089105
75 PRIOR FILING DATE: 1998-06-12
76 PRIOR APPLICATION NUMBER: 60/089440
77 PRIOR FILING DATE: 1998-06-16
78 PRIOR APPLICATION NUMBER: 60/089512
79 PRIOR FILING DATE: 1998-06-16
80 PRIOR APPLICATION NUMBER: 60/089514
81 PRIOR FILING DATE: 1998-06-16
82 PRIOR APPLICATION NUMBER: 60/089532
83 PRIOR FILING DATE: 1998-06-17
84 PRIOR APPLICATION NUMBER: 60/089538
85 PRIOR FILING DATE: 1998-06-17
86 PRIOR APPLICATION NUMBER: 60/089598
87 PRIOR FILING DATE: 1998-06-17
88 PRIOR APPLICATION NUMBER: 60/089599
89 PRIOR FILING DATE: 1998-06-17
90 PRIOR APPLICATION NUMBER: 60/089600
91 PRIOR FILING DATE: 1998-06-17
92 PRIOR APPLICATION NUMBER: 60/089653
93 PRIOR FILING DATE: 1998-06-17
94 PRIOR APPLICATION NUMBER: 60/089801
95 PRIOR FILING DATE: 1998-06-18
96 PRIOR APPLICATION NUMBER: 60/089907
97 PRIOR FILING DATE: 1998-06-18
98 PRIOR APPLICATION NUMBER: 60/089908
99 PRIOR FILING DATE: 1998-06-18
100 PRIOR APPLICATION NUMBER: 60/089947
101 PRIOR FILING DATE: 1998-06-19
102 PRIOR APPLICATION NUMBER: 60/089948
103 PRIOR FILING DATE: 1998-06-19
104 PRIOR APPLICATION NUMBER: 60/089952
105 PRIOR FILING DATE: 1998-06-19
106 PRIOR APPLICATION NUMBER: 60/090246
107 PRIOR FILING DATE: 1998-06-22
108 PRIOR APPLICATION NUMBER: 60/090252
109 PRIOR FILING DATE: 1998-06-22
110 PRIOR APPLICATION NUMBER: 60/090254
111 PRIOR FILING DATE: 1998-06-22
112 PRIOR APPLICATION NUMBER: 60/090349
113 PRIOR FILING DATE: 1998-06-23
114 PRIOR APPLICATION NUMBER: 60/090355
115 PRIOR FILING DATE: 1998-06-23
116 PRIOR APPLICATION NUMBER: 60/090429
117 PRIOR FILING DATE: 1998-06-24
118 PRIOR APPLICATION NUMBER: 60/090431
119 PRIOR FILING DATE: 1998-06-24
120 PRIOR APPLICATION NUMBER: 60/090435
121 PRIOR FILING DATE: 1998-06-24
122 PRIOR APPLICATION NUMBER: 60/090444
123 PRIOR FILING DATE: 1998-06-24
124 PRIOR APPLICATION NUMBER: 60/090445
125 PRIOR FILING DATE: 1998-06-24
126 PRIOR APPLICATION NUMBER: 60/090472
127 PRIOR FILING DATE: 1998-06-24
128 PRIOR APPLICATION NUMBER: 60/090535
129 PRIOR FILING DATE: 1998-06-24
130 PRIOR APPLICATION NUMBER: 60/090540
131 PRIOR FILING DATE: 1998-06-24
132 PRIOR APPLICATION NUMBER: 60/090542
133 PRIOR FILING DATE: 1998-06-24
134 PRIOR APPLICATION NUMBER: 60/090557
135 PRIOR FILING DATE: 1998-06-24
136 PRIOR APPLICATION NUMBER: 60/090676
137 PRIOR FILING DATE: 1998-06-25
138 PRIOR APPLICATION NUMBER: 60/090678
139 PRIOR FILING DATE: 1998-06-25
140 PRIOR APPLICATION NUMBER: 60/090690
141 PRIOR FILING DATE: 1998-06-25
142 PRIOR APPLICATION NUMBER: 60/090694
143 PRIOR FILING DATE: 1998-06-25
144 PRIOR APPLICATION NUMBER: 60/090695
145 PRIOR FILING DATE: 1998-06-25
146 PRIOR APPLICATION NUMBER: 60/090696

```
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 9; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

/ 1 GTTCTCTTCGAGCCAAATCCAGCGGATGTAATTATGACGTGCGCACACCATGA 60
/ 1 GTTCTCTTCGAGCCAAATCCAGCGGATGTAATTATGACGTGCGCACACCATGA 60
/ 61 AGCTCTTGTGGCAGGTAACTGTGCACCAACCACTGGAATGCCATCTGCTCCGTTGC 120
/ 61 AGCTCTTGTGGCAGGTAACTGTGCACCAACCACTGGAATGCCATCTGCTCCGTTGC 120
/ 121 TCTACTCAGCGGCAAGTGTGATCTGTGTGAGCCATCGCTGCTGCGGCTCAGCG 180
/ 121 TCTACTCAGCGGCAAGTGTGATCTGTGTGAGCCATCGCTGCTGCGGCTCAGCG 180
/ 181 GSCGCCAGAACTGCCCTCCGTTGCTCGTGCAGTAACAGATTGACGAAGTGTGTGCA 240
/ 181 GSCGCCAGAACTGCCCTCCGTTGCTCGTGCAGTAACAGATTGACGAAGTGTGTGCA 240
/ 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGTATTCCTTCGAAACCCCGGTACCTCAACC 300
/ 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGTATTCCTTCGAAACCCCGGTACCTCAACC 300
/ 301 TCATGGAGAACCAATCCAGATGATCCAGGCCGACACCTTCGCGACCTCCACCACTGG 360
/ 301 TCATGGAGAACCAATCCAGATGATCCAGGCCGACACCTTCGCGACCTCCACCACTGG 360
/ 361 AGGTCTCGAGTTGGCAGGAATCCATCCGCGAGATTGAGTGGGGGCTTCACCGGCC 420
/ 361 AGGTCTCGAGTTGGCAGGAATCCATCCGCGAGATTGAGTGGGGGCTTCACCGGCC 420
/ 421 TGGCCAGCTCAACCTCGAGGTGTTGCACTGCTGACAGTATCCCTAGCGGGG 480
/ 421 TGGCCAGCTCAACCTCGAGGTGTTGCACTGCTGACAGTATCCCTAGCGGGG 480
/ 481 CTTTGAATACCTGTCCAGCTGCGGAGCTCTGGCTTCGAAACAAACCCCATCGAAGCA 540
/ 481 CTTTGAATACCTGTCCAGCTGCGGAGCTCTGGCTTCGAAACAAACCCCATCGAAGCA 540
/ 541 TCGCCTTTACGCTTCAACCGGCTCCCTCATGCGGCTGGACTTGGGGGAGCTCA 600
/ 541 TCGCCTTTACGCTTCAACCGGCTCCCTCATGCGGCTGGACTTGGGGGAGCTCA 600
/ 601 AGAAGCTGAGTATCTCTGAGGAGCTTTTGGGGGCTGTTCAACTCAAGTATCTGA 660
/ 601 AGAAGCTGAGTATCTCTGAGGAGCTTTTGGGGGCTGTTCAACTCAAGTATCTGA 660
/ 661 ACTTGGGCAATGCGAACATTAAAGACATGCCCAATCTCACCCCTGCTGGGCTGGAGG 720
```

1741 CGCCCGGAGCTGTTGAGATAATCCAGGTGGAGGAGACATCCGAGCAGCAACATCCGAG 1800
1801 CAGCAACAGCAGCTCCGTCGGTGTATCAGGTGAGGGGGCAGTAGTCTGCCACCAATTC 1860
1801 CAGCAACAGCAGCTCCGTCGGTGTATCAGGTGAGGGGGCAGTAGTCTGCCACCAATTC 1860
1861 ATGACCATATTAACATACAAACACCTTACAAACAGCAGATGGGGCCCACTGGACAGAAAAA 1920
1861 ATGACCATATTAACATACAAACACCTTACAAACAGCAGATGGGGCCCACTGGACAGAAAAA 1920
1921 GCCTGGGGAATCTCTGACGCCACAGTCCACCTATCTCTGACCTTATATTAATTCAGA 1980
1921 GCCTGGGGAATCTCTGACGCCACAGTCCACCTATCTCTGACCTTATATTAATTCAGA 1980
1981 CCCATACCAAGCAGCAGTACAGCAAACTCAAAATATGACTCCCTCCCAAAAACTTA 2040
1981 CCCATACCAAGCAGCAGTACAGCAAACTCAAAATATGACTCCCTCCCAAAAACTTA 2040
2041 TAAATGCAATAGATGACACCAAGCAGCAAACTTTTGTACAGTGGGGGAGAGACTTT 2100
2041 TAAATGCAATAGATGACACCAAGCAGCAAACTTTTGTACAGTGGGGGAGAGACTTT 2100
2101 TCTTGTATATGCTTATATATTAAGTCTATGGCTGTAAATAAAACAGATATATTA 2160
2101 TCTTGTATATGCTTATATATTAAGTCTATGGCTGTAAATAAAACAGATATATTA 2160
2161 AATTTAAAGCAAAAGTCAAAAACA 2185
2161 AATTTAAAGCAAAAGTCAAAAACA 2185

RESULT 5

US-09-989-731-228
Sequence 228, Application US/09989731
Patent No. US20020103125A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730PIC70
CURRENT APPLICATION NUMBER: US/09/989,731
CURRENT FILING DATE: 2001-11-20
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13

PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532

PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02

; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 10; Length 2185;

Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTCTCTTTCCGAGGCAAAATCCAGGCGATGSGAATTATGAACGTCCACACCATCA 60
Db 1 GTTCTCTTTCCGAGGCAAAATCCAGGCGATGSGAATTATGAACGTCCACACCATCA 60
Qy 61 AGCTCTTGCGAGGTAACCTGTCACCAACACCTGGAAATCCATCTCTGCTCCGGTTGG 120
Db 61 AGCTCTTGCGAGGTAACCTGTCACCAACACCTGGAAATCCATCTCTGCTCCGGTTGG 120
Qy 121 TCTACCTCAGCGGCAAGTGTGGATTCTGTGTCAGCCATCGCTGTGCGGCTCAGCGG 180
Db 121 TCTACCTCAGCGGCAAGTGTGGATTCTGTGTCAGCCATCGCTGTGCGGCTCAGCGG 180
Qy 181 GGGCCGAGAACTGCCCTCTCGTTTGTCTGTCAGTAACCAAGTTCAGCAAGGTGTGTGA 240
Db 181 GGGCCGAGAACTGCCCTCTCGTTTGTCTGTCAGTAACCAAGTTCAGCAAGGTGTGTGA 240
Qy 241 CGCGCGGGGCTCTCCGAGGTCCTCCGAGGTCCTCCGAGGTCCTCCGAGGTCCTCCGAGG 300
Db 241 CGCGCGGGGCTCTCCGAGGTCCTCCGAGGTCCTCCGAGGTCCTCCGAGGTCCTCCGAGG 300
Qy 301 TCATGAGAAACAAATCCAGATGATCCAGGCGGACACCTTCGCGCACCTCCACACCTGG 360
Db 301 TCATGAGAAACAAATCCAGATGATCCAGGCGGACACCTTCGCGCACCTCCACACCTGG 360
Qy 361 AGTCTCTGCAAGTTGGGCGAGAACTCCATCCGCGAGATTGAGGTGGGGGCTTCAACGGCC 420
Db 361 AGTCTCTGCAAGTTGGGCGAGAACTCCATCCGCGAGATTGAGGTGGGGGCTTCAACGGCC 420
Qy 421 TGGCCAGGCTCAACACCTGGAGCTGTTGCAACAACTGGCTGACAGTCACTCCCTAGCGGG 480
Db 421 TGGCCAGGCTCAACACCTGGAGCTGTTGCAACAACTGGCTGACAGTCACTCCCTAGCGGG 480
Qy 481 CCTTTGAATACCTGTCAGGAGCTCTGCTTCGCAACAACTGGCTGACAGTCACTCCCTAGCGGG 540
Db 481 CCTTTGAATACCTGTCAGGAGCTCTGCTTCGCAACAACTGGCTGACAGTCACTCCCTAGCGGG 540
Qy 541 TCCCTCTTACGGCTTCAACCGGGTCCCTCTCATGCGCTGAGCTTGGGGGAGCTCA 600
Db 541 TCCCTCTTACGGCTTCAACCGGGTCCCTCTCATGCGCTGAGCTTGGGGGAGCTCA 600
Qy 601 AGAAGCTGAGATATCTCTGAGGAGCTTTTGAGGGGCTGTTCAACCTCAAGTATCTGA 660
Db 601 AGAAGCTGAGATATCTCTGAGGAGCTTTTGAGGGGCTGTTCAACCTCAAGTATCTGA 660
Qy 661 ACTTGGGCTGTCACCAATTAAGAATGCCCCCAATCTCAACCTGCTGGGGCTGGAGG 720
Db 661 ACTTGGGCTGTCACCAATTAAGAATGCCCCCAATCTCAACCTGCTGGGGCTGGAGG 720
Qy 721 AGCTGAGATGTCAGGAAACCACTTCCCTGAGATCAGGCTGGCTCTCTTCCATGGCTGA 780
Db 721 AGCTGAGATGTCAGGAAACCACTTCCCTGAGATCAGGCTGGCTCTCTTCCATGGCTGA 780
Qy 781 GCTCCCTCAAGAGCTCTGGGTCATGAACCTCAGGTCAGGCTGATGAGCGGAATGCTT 840
Db 781 GCTCCCTCAAGAGCTCTGGGTCATGAACCTCAGGTCAGGCTGATGAGCGGAATGCTT 840

Db	781	GCTCCTCAAGAGCTCTGGTCAATGAACCTCAGGCTCAGCTGTATGTGAGCGGAATGCTT	840
QY	841	FTGAGGGCTGGCTTCACTTGTGAACTCAACTTGGCCACAAATACCTCTCTTCTTTGC	900
Db	841	FTGAGGGCTGGCTTCACTTGTGAACTCAACTTGGCCACAAATACCTCTCTTCTTTGC	900
QY	901	CCCATGAAGCTCTTTACCCCGCTGAGTACCTGTGTGAGTGTGATCTACACCAACACCTT	960
Db	901	CCCATGAAGCTCTTTACCCCGCTGAGTACCTGTGTGAGTGTGATCTACACCAACACCTT	960
QY	961	GGAACTGTGATGTGACATTCGTGGCTAGCTTGGTGGCTTCGAGAGTATATACCCACA	1020
Db	961	GGAACTGTGATGTGACATTCGTGGCTAGCTTGGTGGCTTCGAGAGTATATACCCACA	1020
QY	1021	ATTCAACTGTGTGGCGCGTGCATGCTCCCATGACATGGAGAGCCGCTACCTGTGTGG	1080
Db	1021	ATTCAACTGTGTGGCGCGTGCATGCTCCCATGACATGGAGAGCCGCTACCTGTGTGG	1080
QY	1081	AGGTGGAACAGGCTCTCTTCAGTGTCTGCCCCCTTCATCATGAGAGCACTGTGAGACC	1140
Db	1081	AGGTGGAACAGGCTCTCTTCAGTGTCTGCCCCCTTCATCATGAGAGCACTGTGAGACC	1140
QY	1141	TCAACTTCTGAGGTCGGATGGCAGAACTTAAGTGTGCGACTCCCCCTATGTCCTCG	1200
Db	1141	TCAACTTCTGAGGTCGGATGGCAGAACTTAAGTGTGCGACTCCCCCTATGTCCTCG	1200
QY	1201	TGAAGTGTGTCTGCCAATGGGACAGTGTCTAGCCACGCTCCGCCACGCAAGATCT	1260
Db	1201	TGAAGTGTGTCTGCCAATGGGACAGTGTCTAGCCACGCTCCGCCACGCAAGATCT	1260
QY	1261	CTGTCTCTCAAGAGCGGCACTTTGAACTTTTCCACGCTGTGCTTTTTCAGACACTGGGGTG	1320
Db	1261	CTGTCTCTCAAGAGCGGCACTTTGAACTTTTCCACGCTGTGCTTTTTCAGACACTGGGGTG	1320
QY	1321	ACACATGATGGTGACCAATGTTTCAGGGAACCTCCAAAGCGCTTCGCGCTTACCTCATGTGA	1380
Db	1321	ACACATGATGGTGACCAATGTTTCAGGGAACCTCCAAAGCGCTTCGCGCTTACCTCATGTGA	1380
QY	1381	GCACGGCTGAGCTTAAACACCTTCAAATCTACAGCTTCTTACCAAGTAAACAGTGGAGACCA	1440
Db	1381	GCACGGCTGAGCTTAAACACCTTCAAATCTACAGCTTCTTACCAAGTAAACAGTGGAGACCA	1440
QY	1441	CGGAGATCTCGCTGAGGACACAAACGCGAAAGTACAAAGCTCTTCTACCAAGTAAACAGTGGAGACCA	1500
Db	1441	CGGAGATCTCGCTGAGGACACAAACGCGAAAGTACAAAGCTCTTCTACCAAGTAAACAGTGGAGACCA	1500
QY	1501	GTTTACCGCGGACATATACACCTCTACACGCTGCTCATTCAGACTACCGGTGTGCCA	1560
Db	1501	GTTTACCGCGGACATATACACCTCTACACGCTGCTCATTCAGACTACCGGTGTGCCA	1560
QY	1561	AGCAGTGGCAGTACCGCGACAGACACCACTGACAAAGTGCAGACCAAGCTTGGATGAAG	1620
Db	1561	AGCAGTGGCAGTACCGCGACAGACACCACTGACAAAGTGCAGACCAAGCTTGGATGAAG	1620
QY	1621	TCATGAGAGACCAACCAAGTCAATATGGCTGCTTTGTGCACTGACTCTGCTAGCTGGC	1680
Db	1621	TCATGAGAGACCAACCAAGTCAATATGGCTGCTTTTGTGCACTGACTCTGCTAGCTGGC	1680
QY	1681	CCATGTGATGTCTTCTATAAATCTCGTAAAGCGCACAGACGCGGAGTACAGTCAAG	1740
Db	1681	CCATGTGATGTCTTCTATAAATCTCGTAAAGCGCACAGACGCGGAGTACAGTCAAG	1740
QY	1741	CGGCCCGGACCTGTTGAGTAAATCCAGTGTGACGAGACATCCAGCAGCACTCCGAG	1800
Db	1741	CGGCCCGGACCTGTTGAGTAAATCCAGTGTGACGAGACATCCAGCAGCACTCCGAG	1800
QY	1801	CAGCAACAGCAGCTCCGCTCGGTGTATCAGTGCAGGGGCGAGTGTGTGCCCAACAATTC	1860
Db	1801	CAGCAACAGCAGCTCCGCTCGGTGTATCAGTGCAGGGGCGAGTGTGTGCCCAACAATTC	1860
QY	1861	ATGACCATATTAACATAACAACCTTACAAACAGCACATGGGGCCCACTGGACAGAAAACA	1920
Db	1861	ATGACCATATTAACATAACAACCTTACAAACAGCACATGGGGCCCACTGGACAGAAAACA	1920

RESULT, T 6

```

US-09-989-732-228
? Sequence 228, Application US/09989732
? Patent No. US20020123463A1
? GENERAL INFORMATION:
? APPLICANT: Ashkenazi, Avi J.
? APPLICANT: Baker, Kevin P.
? APPLICANT: Botstein, David
? APPLICANT: Desnovers, Luc
? APPLICANT: Eaton, Dan L.
? APPLICANT: Ferrara, Napoleone
? APPLICANT: Fong, Sherman
? APPLICANT: Gerber, Hanspeter
? APPLICANT: Gerritsen, Mary E.
? APPLICANT: Goddard, Audrey
? APPLICANT: Godowski, Paul J.
? APPLICANT: Grimaldi, J. Christopher
? APPLICANT: Gurney, Austin L.
? APPLICANT: Kljavin, Ivar J.
? APPLICANT: Napier, Mary A.
? APPLICANT: Pan, James
? APPLICANT: Paoni, Nicholas F.
? APPLICANT: Roy, Margaret Ann
? APPLICANT: Stewart, Timothy A.
? APPLICANT: Tumas, Daniel
? APPLICANT: Watanabe, Colin K.
? APPLICANT: Williams, P. Mickey
? APPLICANT: Wood, William I.
? APPLICANT: Zhang, Zemin
? TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
? TITLE OF INVENTION: Acids Encoding the Same
? FILE REFERENCE: P2730PIC57
? CURRENT APPLICATION NUMBER: US/09/989,732
? CURRENT FILING DATE: 2001-11-19
? PRIOR APPLICATION NUMBER: 60/049787
? PRIOR FILING DATE: 1997-06-16
? PRIOR APPLICATION NUMBER: 60/062250
? PRIOR FILING DATE: 1997-10-17
? PRIOR APPLICATION NUMBER: 60/065186
? PRIOR FILING DATE: 1997-11-12
? PRIOR APPLICATION NUMBER: 60/065311
? PRIOR FILING DATE: 1997-11-13
? PRIOR APPLICATION NUMBER: 60/066770
? PRIOR FILING DATE: 1997-11-24
? PRIOR APPLICATION NUMBER: 60/075945
? PRIOR FILING DATE: 1998-02-25
? PRIOR APPLICATION NUMBER: 60/078910
? PRIOR FILING DATE: 1998-03-20
? PRIOR APPLICATION NUMBER: 60/093322
? PRIOR FILING DATE: 1998-04-28
? PRIOR APPLICATION NUMBER: 60/094600

```

1 PRIOR FILING DATE: 1998-05-07
2 PRIOR APPLICATION NUMBER: 60/087106
3 PRIOR FILING DATE: 1998-05-28
4 PRIOR APPLICATION NUMBER: 60/087607
5 PRIOR FILING DATE: 1998-06-02
6 PRIOR APPLICATION NUMBER: 60/087609
7 PRIOR FILING DATE: 1998-06-02
8 PRIOR APPLICATION NUMBER: 60/087759
9 PRIOR FILING DATE: 1998-06-02
10 PRIOR APPLICATION NUMBER: 60/087827
11 PRIOR FILING DATE: 1998-06-03
12 PRIOR APPLICATION NUMBER: 60/088021
13 PRIOR FILING DATE: 1998-06-04
14 PRIOR APPLICATION NUMBER: 60/088025
15 PRIOR FILING DATE: 1998-06-04
16 PRIOR APPLICATION NUMBER: 60/088026
17 PRIOR FILING DATE: 1998-06-04
18 PRIOR APPLICATION NUMBER: 60/088028
19 PRIOR FILING DATE: 1998-06-04
20 PRIOR APPLICATION NUMBER: 60/088029
21 PRIOR FILING DATE: 1998-06-04
22 PRIOR APPLICATION NUMBER: 60/088030
23 PRIOR FILING DATE: 1998-06-04
24 PRIOR APPLICATION NUMBER: 60/088033
25 PRIOR FILING DATE: 1998-06-04
26 PRIOR APPLICATION NUMBER: 60/088326
27 PRIOR FILING DATE: 1998-06-04
28 PRIOR APPLICATION NUMBER: 60/088167
29 PRIOR FILING DATE: 1998-06-05
30 PRIOR APPLICATION NUMBER: 60/088202
31 PRIOR FILING DATE: 1998-06-05
32 PRIOR APPLICATION NUMBER: 60/088212
33 PRIOR FILING DATE: 1998-06-05
34 PRIOR APPLICATION NUMBER: 60/088217
35 PRIOR FILING DATE: 1998-06-05
36 PRIOR APPLICATION NUMBER: 60/088655
37 PRIOR FILING DATE: 1998-06-09
38 PRIOR APPLICATION NUMBER: 60/088734
39 PRIOR FILING DATE: 1998-06-10
40 PRIOR APPLICATION NUMBER: 60/088738
41 PRIOR FILING DATE: 1998-06-10
42 PRIOR APPLICATION NUMBER: 60/088742
43 PRIOR FILING DATE: 1998-06-10
44 PRIOR APPLICATION NUMBER: 60/088810
45 PRIOR FILING DATE: 1998-06-10
46 PRIOR APPLICATION NUMBER: 60/088824
47 PRIOR FILING DATE: 1998-06-10
48 PRIOR APPLICATION NUMBER: 60/088826
49 PRIOR FILING DATE: 1998-06-10
50 PRIOR APPLICATION NUMBER: 60/088858
51 PRIOR FILING DATE: 1998-06-11
52 PRIOR APPLICATION NUMBER: 60/088861
53 PRIOR FILING DATE: 1998-06-11
54 PRIOR APPLICATION NUMBER: 60/088876
55 PRIOR FILING DATE: 1998-06-11
56 PRIOR APPLICATION NUMBER: 60/089105
57 PRIOR FILING DATE: 1998-06-12
58 PRIOR APPLICATION NUMBER: 60/089440
59 PRIOR FILING DATE: 1998-06-16
60 PRIOR APPLICATION NUMBER: 60/089512
61 PRIOR FILING DATE: 1998-06-16
62 PRIOR APPLICATION NUMBER: 60/089514
63 PRIOR FILING DATE: 1998-06-16
64 PRIOR APPLICATION NUMBER: 60/089532
65 PRIOR FILING DATE: 1998-06-17
66 PRIOR APPLICATION NUMBER: 60/089538
67 PRIOR FILING DATE: 1998-06-17
68 PRIOR APPLICATION NUMBER: 60/089598
69 PRIOR FILING DATE: 1998-06-17
70 PRIOR APPLICATION NUMBER: 60/089599
71 PRIOR FILING DATE: 1998-06-17
72 PRIOR APPLICATION NUMBER: 60/089600
73 PRIOR FILING DATE: 1998-06-17

74 PRIOR APPLICATION NUMBER: 60/089653
75 PRIOR FILING DATE: 1998-06-17
76 PRIOR APPLICATION NUMBER: 60/089801
77 PRIOR FILING DATE: 1998-06-18
78 PRIOR APPLICATION NUMBER: 60/089907
79 PRIOR FILING DATE: 1998-06-18
80 PRIOR APPLICATION NUMBER: 60/089908
81 PRIOR FILING DATE: 1998-06-18
82 PRIOR APPLICATION NUMBER: 60/089947
83 PRIOR FILING DATE: 1998-06-19
84 PRIOR APPLICATION NUMBER: 60/089948
85 PRIOR FILING DATE: 1998-06-19
86 PRIOR APPLICATION NUMBER: 60/089952
87 PRIOR FILING DATE: 1998-06-19
88 PRIOR APPLICATION NUMBER: 60/090246
89 PRIOR FILING DATE: 1998-06-22
90 PRIOR APPLICATION NUMBER: 60/090252
91 PRIOR FILING DATE: 1998-06-22
92 PRIOR APPLICATION NUMBER: 60/090254
93 PRIOR FILING DATE: 1998-06-22
94 PRIOR APPLICATION NUMBER: 60/090349
95 PRIOR FILING DATE: 1998-06-23
96 PRIOR APPLICATION NUMBER: 60/090355
97 PRIOR FILING DATE: 1998-06-23
98 PRIOR APPLICATION NUMBER: 60/090429
99 PRIOR FILING DATE: 1998-06-24
100 PRIOR APPLICATION NUMBER: 60/090431
101 PRIOR FILING DATE: 1998-06-24
102 PRIOR APPLICATION NUMBER: 60/090435
103 PRIOR FILING DATE: 1998-06-24
104 PRIOR APPLICATION NUMBER: 60/090444
105 PRIOR FILING DATE: 1998-06-24
106 PRIOR APPLICATION NUMBER: 60/090445
107 PRIOR FILING DATE: 1998-06-24
108 PRIOR APPLICATION NUMBER: 60/090472
109 PRIOR FILING DATE: 1998-06-24
110 PRIOR APPLICATION NUMBER: 60/090535
111 PRIOR FILING DATE: 1998-06-24
112 PRIOR APPLICATION NUMBER: 60/090540
113 PRIOR FILING DATE: 1998-06-24
114 PRIOR APPLICATION NUMBER: 60/090542
115 PRIOR FILING DATE: 1998-06-24
116 PRIOR APPLICATION NUMBER: 60/090557
117 PRIOR FILING DATE: 1998-06-24
118 PRIOR APPLICATION NUMBER: 60/090676
119 PRIOR FILING DATE: 1998-06-25
120 PRIOR APPLICATION NUMBER: 60/090678
121 PRIOR FILING DATE: 1998-06-25
122 PRIOR APPLICATION NUMBER: 60/090690
123 PRIOR FILING DATE: 1998-06-25
124 PRIOR APPLICATION NUMBER: 60/090694
125 PRIOR FILING DATE: 1998-06-25
126 PRIOR APPLICATION NUMBER: 60/090695
127 PRIOR FILING DATE: 1998-06-25
128 PRIOR APPLICATION NUMBER: 60/090696
129 PRIOR FILING DATE: 1998-06-25
130 PRIOR APPLICATION NUMBER: 60/090862
131 PRIOR FILING DATE: 1998-06-26
132 PRIOR APPLICATION NUMBER: 60/090863
133 PRIOR FILING DATE: 1998-06-26
134 PRIOR APPLICATION NUMBER: 60/091360
135 PRIOR FILING DATE: 1998-07-01
136 PRIOR APPLICATION NUMBER: 60/091478
137 PRIOR FILING DATE: 1998-07-02
138 PRIOR APPLICATION NUMBER: 60/091544
139 PRIOR FILING DATE: 1998-07-01
140 PRIOR APPLICATION NUMBER: 60/091519
141 PRIOR FILING DATE: 1998-07-02
142 PRIOR APPLICATION NUMBER: 60/091626
143 PRIOR FILING DATE: 1998-07-02
144 PRIOR APPLICATION NUMBER: 60/091633
145 PRIOR FILING DATE: 1998-07-02
146 PRIOR APPLICATION NUMBER: 60/091978

y 2041 TAAATGCAATAGATGCAACAAAGACAGCAACTTTTGTACAGAGTGGGAGAGACTTT 2100
b 2041 TAAATGCAATAGATGCAACAAAGACAGCAACTTTTGTACAGAGTGGGAGAGACTTT 2100
y 2101 TTCTGCTATGCTTATATATTAAGTCTATGGCTGTTAAABAAAACAGATTATATAA 2160
b 2101 TTCTGCTATGCTTATATATTAAGTCTATGGCTGTTAAABAAAACAGATTATATAA 2160
y 2161 AATTTAAAGACAAAAGTCAAAACA 2185
b 2161 AATTTAAAGACAAAAGTCAAAACA 2185

RESULT 7

S-09-991-073-228

Sequence 228, Application US/09991073

Patent No. US2002012756A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas P.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C15
CURRENT APPLICATION NUMBER: US/09/991,073
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947

1	QY	1	GTTCCTCTCCGAGCCAAATATCCAGCCGATGGTGAATATGAACTGTGCACACCATGA	60
1	Db	1	GTTCCTCTCCGAGCCAAATATCCAGCCGATGGTGAATATGAACTGTGCACACCATGA	60
61	QY	61	AGCTCTTGTGCGCAGTAACTGTGCACACACACACCTTGGAAATGCCATCTCTGCTCCGCTTCG	120
61	Db	61	AGCTCTTGTGCGCAGTAACTGTGCACACACACACCTTGGAAATGCCATCTCTGCTCCGCTTCG	120
121	QY	121	TCTACCTACAGGCGCAAGTGTGGATTCGTGTGAGCCATTCGCTGTGCGGCTCAGCGG	180
121	Db	121	TCTACCTACAGGCGCAAGTGTGGATTCGTGTGAGCCATTCGCTGTGCGGCTCAGCGG	180
181	QY	181	GGCCCCAGACTGCCCCCTCCGTTTGTCTGCTGCGAGTACACAGTTTCAGCAAGTGGTGTGCA	240
181	Db	181	GGCCCCAGACTGCCCCCTCCGTTTGTCTGCTGCGAGTACACAGTTTCAGCAAGTGGTGTGCA	240
241	QY	241	CGCGCCGCGGCTCTCCAGGTCGCGAGGTTCCCTTCGAACACCCGGTATCCTCAACC	300
241	Db	241	CGCGCCGCGGCTCTCCAGGTCGCGAGGTTCCCTTCGAACACCCGGTATCCTCAACC	300
301	QY	301	TCATGGAGAACACATCCAGATTCGCGAGGTTCCCTTCGAACACCCGGTATCCTCAACC	360
301	Db	301	TCATGGAGAACACATCCAGATTCGCGAGGTTCCCTTCGAACACCCGGTATCCTCAACC	360
361	QY	361	AGTCTCTGCACTTGGGCGAGAACTCCATCCGCGAGTTCGAGTGGGGGCTTCAACGGCC	420
361	Db	361	AGTCTCTGCACTTGGGCGAGAACTCCATCCGCGAGTTCGAGTGGGGGCTTCAACGGCC	420
421	QY	421	TGGCGAGCTCAACACACCTGGAGCTGTTCGACACTGGCTGACAGTCACTCCCTAGCGGG	480
421	Db	421	TGGCGAGCTCAACACACCTGGAGCTGTTCGACACTGGCTGACAGTCACTCCCTAGCGGG	480
481	QY	481	CCTTTGAATACCTGTCCAAAGCTCGGAGCTCTGGCTTCGCAACACCCCATCGAAAGCA	540
481	Db	481	CCTTTGAATACCTGTCCAAAGCTCGGAGCTCTGGCTTCGCAACACCCCATCGAAAGCA	540
541	QY	541	TCCCTCTTACGCTTCAACCGGGTGCCTCCCTCATCGGCTGAGCTCCCTAGCGGG	600
541	Db	541	TCCCTCTTACGCTTCAACCGGGTGCCTCCCTCATCGGCTGAGCTCCCTAGCGGG	600
601	QY	601	AGAGCTGGAGTATCTCTGAGGAGCTTTTGAAGGCTGTTCACCTCAAGTATCTGA	660
601	Db	601	AGAGCTGGAGTATCTCTGAGGAGCTTTTGAAGGCTGTTCACCTCAAGTATCTGA	660
661	QY	661	ACTTGGGCGATGTGCAACATTAAGACATGCGCCTATCTCACCCCTCTGGTGGGGCTGAGG	720
661	Db	661	ACTTGGGCGATGTGCAACATTAAGACATGCGCCTATCTCACCCCTCTGGTGGGGCTGAGG	720
721	QY	721	AGCTGGAGTGTGAGGGAACACCTTCCCTGAGATCAGGCTGCTCTCTCCATGGCTGA	780
721	Db	721	AGCTGGAGTGTGAGGGAACACCTTCCCTGAGATCAGGCTGCTCTCTCCATGGCTGA	780
781	QY	781	GCTCCCTCAAGAGCTCTGGGTCAATGAATCTCACAGGTCAGCTGATGAGCGGAATGCTT	840
781	Db	781	GCTCCCTCAAGAGCTCTGGGTCAATGAATCTCACAGGTCAGCTGATGAGCGGAATGCTT	840
841	QY	841	TTGACGGGCTGGCTTCACTTGTGGAACTCAACTTGGCGCCACATTAACCTCTCTTTTC	900
841	Db	841	TTGACGGGCTGGCTTCACTTGTGGAACTCAACTTGGCGCCACATTAACCTCTCTTTTC	900
901	QY	901	CCCATGACCTCTTTTACCCCGCTGAGGTACCTGGTGGAGTTGCACTTACACCAACCCCTT	960
901	Db	901	CCCATGACCTCTTTTACCCCGCTGAGGTACCTGGTGGAGTTGCACTTACACCAACCCCTT	960
961	QY	961	GGAACTGTGATGTGACATTTCTGGCTAGCTGCTGGCTTCCAGAGTATATACCCACCA	1020
961	Db	961	GGAACTGTGATGTGACATTTCTGGCTAGCTGCTGGCTTCCAGAGTATATACCCACCA	1020
1021	QY	1021	ATTCACCTGCTGTGGCGGCTGTCTCATGCTCCCATGCAATCGAGGCGCTTACCTCGTG	1080
1021	Db	1021	ATTCACCTGCTGTGGCGGCTGTCTCATGCTCCCATGCAATCGAGGCGCTTACCTCGTG	1080

Query Match 100.08; Score 2185; DB 10; Length 2185;
 Best Local Similarity 100.08; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1081	AGGTGGACCAAGGCTCTTTCCAGTGTCTGCGCCCTTCAATCATGAGACGACCTTCAGACCC	11140
1081	AGGTGGACCAAGGCTCTTTCCAGTGTCTGCGCCCTTCAATCATGAGACGACCTTCAGACCC	11140
1141	TCACATTTCTGAGGTCGATGGCAGAACTTAAAGTGTGGGACCTCCCTATGTCCTCCG	1200
1141	TCACATTTCTGAGGTCGATGGCAGAACTTAAAGTGTGGGACCTCCCTATGTCCTCCG	1200
1201	TCAAAGTGTTCTGCTGCCCAATGGGACAGTGTCTCAGCCACGCTCCCGCACCAAGATCT	1260
1201	TCAAAGTGTTCTGCTGCCCAATGGGACAGTGTCTCAGCCACGCTCCCGCACCAAGATCT	1260
1261	CTGTCTCTCAAGCGGACCTTGAATTTTTTCCACGCTGCTCTTCAGACACTGGGGTGT	1320
1261	CTGTCTCTCAAGCGGACCTTGAATTTTTTCCACGCTGCTCTTCAGACACTGGGGTGT	1320
1321	ACACATGTCATGTTGACCAATGTTTTCAGGCAACTTCCAAAGCTCTGGCCTTCAATGTGA	1380
1321	ACACATGTCATGTTGACCAATGTTTTCAGGCAACTTCCAAAGCTCTGGCCTTCAATGTGA	1380
1381	GCAAGGTGAGCTTAAACCTTCCAACTACAGCTTCTTCAACACAGTAAACAGTGGAGACCA	1440
1381	GCAAGGTGAGCTTAAACCTTCCAACTACAGCTTCTTCAACACAGTAAACAGTGGAGACCA	1440
1441	CGGAGATCTCGCTTGAGGACAAACGCGAAAGTACAAAGCTTGTCTTACCACAGCTCACTG	1500
1441	CGGAGATCTCGCTTGAGGACAAACGCGAAAGTACAAAGCTTGTCTTACCACAGCTCACTG	1500
1501	GTTACACGCGGATATACCACTCTTACCAAGCTGCTTTCAGACTACCGGTGCGCCA	1560
1501	GTTACACGCGGATATACCACTCTTACCAAGCTGCTTTCAGACTACCGGTGCGCCA	1560
1561	AGCAGGTGGAGTACCGCGACAGACACACCTACGACAAAGTACGACAGCAGCTGGATGAAG	1620
1561	AGCAGGTGGAGTACCGCGACAGACACACCTACGACAAAGTACGACAGCAGCTGGATGAAG	1620
1621	TCATGAAGACCAACCAAGATCATTTGGTGTCTTGTGGCAGTGACTTGTCTAGCTGCCG	1680
1621	TCATGAAGACCAACCAAGATCATTTGGTGTCTTGTGGCAGTGACTTGTCTAGCTGCCG	1680
1681	CCATGTTGATGTCTCTATAACTTCTGAAGCGCACCGACGCGGAGTACAGTGCACAG	1740
1681	CCATGTTGATGTCTCTATAACTTCTGAAGCGCACCGACGCGGAGTACAGTGCACAG	1740
1741	CCGCCGAGCTGTTGAGATAATCCAGGTGGACGAAGACATCCCAGCAGCAACATCCGAC	1800
1741	CCGCCGAGCTGTTGAGATAATCCAGGTGGACGAAGACATCCCAGCAGCAACATCCGAC	1800
1801	CAGCAACAGCAGCTCCGTCCGTGTATCAGGTGAGGGGCGAGTGTCTGCCCAATTC	1860
1801	CAGCAACAGCAGCTCCGTCCGTGTATCAGGTGAGGGGCGAGTGTCTGCCCAATTC	1860
1861	ATGACCATTTAACTACACACCTCAAAACCAGCACATGGGGGCCCTTGACAGAGAAACA	1920
1861	ATGACCATTTAACTACACACCTCAAAACCAGCACATGGGGGCCCTTGACAGAGAAACA	1920
1921	GCCTGGGGAACCTCTTGCAACCCACAGTCAACCACTCTCTGAACCTTATATATTCAGA	1980
1921	GCCTGGGGAACCTCTTGCAACCCACAGTCAACCACTCTCTGAACCTTATATATTCAGA	1980
1981	CCCATACCAAGGACAGGTACAGAAACTCAAAATATGACTCCCTCCCAAAAACTTA	2040
1981	CCCATACCAAGGACAGGTACAGAAACTCAAAATATGACTCCCTCCCAAAAACTTA	2040
2041	TAAATGCAATGAGATGCACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT	2100
2041	TAAATGCAATGAGATGCACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT	2100
2101	TTCTGTATATGCTTATATTTAACTATGGCTGTGTTAAAAAACAAGATATATTA	2160
2101	TTCTGTATATGCTTATATTTAACTATGGCTGTGTTAAAAAACAAGATATATTA	2160
2161	AAITTTAAAGACAAAAAGTCAAAACA	2185

Db 2161 AATTTAAGACAAAGATCAAAACA 2185

|||||

RESULT 8

US-09-990-442-228

; Sequence 228, Application US/09990442

; Patent No. US2020132252A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Girdlestein, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grumaidi, J. Christopher

; APPLICANT: Gruney, Austin L.

; APPLICANT: Kljavin, Ivar J.

; APPLICANT: Napier, Mary A.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas P.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K.

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: Secreted and Transmembrane Proteins

; TITLE OF INVENTION: Acids Encoding the Secreted and Transmembrane Proteins

; FILE REFERENCE: P2730P18

; CURRENT APPLICATION NUMBER: US/09/990,442

; CURRENT FILING DATE: 2001-11-14

; PRIOR APPLICATION NUMBER: 60/049787

; PRIOR FILING DATE: 1997-06-16

; PRIOR APPLICATION NUMBER: 60/062250

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/065186

; PRIOR FILING DATE: 1997-11-12

; PRIOR APPLICATION NUMBER: 60/065311

; PRIOR FILING DATE: 1997-11-13

; PRIOR APPLICATION NUMBER: 60/066770

; PRIOR FILING DATE: 1997-11-24

; PRIOR APPLICATION NUMBER: 60/075945

; PRIOR FILING DATE: 1998-02-25

; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/083322

; PRIOR FILING DATE: 1998-04-28

; PRIOR APPLICATION NUMBER: 60/084600

; PRIOR FILING DATE: 1998-05-07

; PRIOR APPLICATION NUMBER: 60/087106

; PRIOR FILING DATE: 1998-05-28

; PRIOR APPLICATION NUMBER: 60/087607

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087609

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087759

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087827

; PRIOR FILING DATE: 1998-06-03

; PRIOR APPLICATION NUMBER: 60/088021

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088025

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088026

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088028

PRIOR APPLICATION NUMBER: 60/090255	PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349	PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090355	PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429	PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090431	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557	PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090693	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862	PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090863	PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360	PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478	PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544	PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519	PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626	PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633	PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091787	PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982	PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182	PRIOR FILING DATE: 1998-07-09

```

Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185: Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy	1	GTTCCTCTTCCGAGCCAAATCCACAGCGAATGTGAATTATGAACTGTGCCACACCATGA	60
Db	1	GTTCCTCTTCCGAGCCAAATCCACAGCGAATGTGAATTATGAACTGTGCCACACCATGA	60
Qy	61	AGCTCTTTGTGGCAGGTPAACTGTGCACCAACCACTCGGAATGCCATCTGTCTCCCGTTGG	12
Db	61	AGCTCTTTGTGGCAGGTPAACTGTGCACCAACCACTCGGAATGCCATCTGTCTCCCGTTGG	12

121	TCTA	CCTC	ACGG	CGCA	AGTGTG	GAATCT	TGTGTG	CAGCCAT	CGCTGCT	GCAGCCT	CAGCG	180
y												
121	TCTA	CCTC	ACGG	CGCA	AGTGTG	GAATCT	TGTGTG	CAGCCAT	CGCTGCT	GCAGCCT	CAGCG	180
b												
181	GGCC	CGAG	AATC	CGCC	CTCG	TTTCTG	TGTCAG	TAAACC	AGTTT	CAGAAAG	GGTGTG	240
y												
181	GGCC	CGAG	AATC	CGCC	CTCG	TTTCTG	TGTCAG	TAAACC	AGTTT	CAGAAAG	GGTGTG	240
b												
241	CGCC	CGGG	CGCT	CTCC	GAGG	TCGCG	AGGTA	TTCCT	CGAA	CACCC	GTAACT	300
y												
241	CGCC	CGGG	CGCT	CTCC	GAGG	TCGCG	AGGTA	TTCCT	CGAA	CACCC	GTAACT	300
b												
301	TCAT	GAG	ACAC	ATC	CGATG	ATCC	AGGCG	ACAC	CTTC	CGGCCA	CCTCC	360
y												
301	TCAT	GAG	ACAC	ATC	CGATG	ATCC	AGGCG	ACAC	CTTC	CGGCCA	CCTCC	360
b												
361	AGGT	CTCT	GACG	TTGG	CAGCA	AACT	CCATC	CGSCA	GA	TAGG	TGGGG	420
y												
361	AGGT	CTCT	GACG	TTGG	CAGCA	AACT	CCATC	CGSCA	GA	TAGG	TGGGG	420
b												
421	TGGC	CGAC	CTCA	AC	CCCT	GAG	AGCT	GTTC	GAC	AACTGG	CTGAC	480
y												
421	TGGC	CGAC	CTCA	AC	CCCT	GAG	AGCT	GTTC	GAC	AACTGG	CTGAC	480
b												
481	CTTT	GAAT	ACCT	GTCT	CAAG	CTT	CGG	AGCT	CTTG	CTT	CGCAA	540
y												
481	CTTT	GAAT	ACCT	GTCT	CAAG	CTT	CGG	AGCT	CTTG	CTT	CGCAA	540
b												
541	TC	CCCT	TTAC	CG	CTTCA	AC	CGG	GTG	CCCT	CTCT	CA	600
y												
541	TC	CCCT	TTAC	CG	CTTCA	AC	CGG	GTG	CCCT	CTCT	CA	600
b												
601	AGA	AGCT	GAG	ATAT	ATCT	CTG	AGG	AGCT	TTT	TG	AGG	660
y												
601	AGA	AGCT	GAG	ATAT	ATCT	CTG	AGG	AGCT	TTT	TG	AGG	660
b												
661	ACT	TGG	CAAT	GTG	CA	ACAT	TTAA	AGA	CAT	CCCA	TCT	720
y												
661	ACT	TGG	CAAT	GTG	CA	ACAT	TTAA	AGA	CAT	CCCA	TCT	720
b												
721	AG	CTG	GAG	ATG	TCAG	AGAAC	CTT	CCCT	GAG	ATCAG	AGCT	780
y												
721	AG	CTG	GAG	ATG	TCAG	AGAAC	CTT	CCCT	GAG	ATCAG	AGCT	780
b												
781	GCT	CCCT	CAAG	AGCT	CTCG	GT	CAT	GAAT	CTCA	AGGT	CAG	840
y												
781	GCT	CCCT	CAAG	AGCT	CTCG	GT	CAT	GAAT	CTCA	AGGT	CAG	840
b												
841	TTGA	CGG	CTGG	CTT	CAT	TTG	TGG	AACT	CAACT	TGG	CCCA	900
y												
841	TTGA	CGG	CTGG	CTT	CAT	TTG	TGG	AACT	CAACT	TGG	CCCA	900
b												
901	CCAT	GAC	CTCT	TTT	TAC	CCG	CGT	GAG	TA	CTT	G	960

D	b	1201	TGAAGTGGTTGCTGCCCAATGGGACAGTGCTCAGCCACCGCTCCCCGCCACCCCAGGATCT	1260
Q	y	1261	CTGTCTCTAAACGACGGCACCTTGAACCTTTTCCCAACGCTGCTGCTTTTCAGACACACTGGSGGTGT	1320
D	b	1261	CTGTCTCTAACGACGGCACCTTGAACCTTTTCCCAACGCTGCTGCTTTTCAGACACACTGGSGGTGT	1320
Q	y	1321	ACAATGCATGGTGACCAATGTTGCAAGGCNACTCCAAACGCTCGGCTACTCTCAATGTGA	1380
D	b	1321	ACAATGCATGGTGACCAATGTTGCAAGGCNACTCCAAACGCTCGGCTACTCTCAATGTGA	1380
Q	y	1381	GCAAGCTGAGCTTAACACCTCCAACTACAGCTTCTTCAACCAGTAGAAGTAAAGTGGAGACCA	1440
D	b	1381	GCAAGCTGAGCTTAACACCTCCAACTACAGCTTCTTCAACCAGTAGAAGTAAAGTGGAGACCA	1440
Q	y	1441	CAGAGATCTCGCTGAGGACCAACCGCGAAAGTACAAGGCTGTTCCTACCACTCCCACTG	1500
D	b	1441	CAGAGATCTCGCTGAGGACCAACCGCGAAAGTACAAGGCTGTTCCTACCACTCCCACTG	1500
Q	y	1501	GTTACAGCGGGCATATACCACTCTTACCAACGGTGTCTATTAGATCTACCCGTGTGCCCA	1560
D	b	1501	GTTACAGCGGGCATATACCACTCTTACCAACGGTGTCTATTAGATCTACCCGTGTGCCCA	1560
Q	y	1561	AGCAGGTGGCAGTACCCGCGACAGACACCACTGACAAGATGCAAGACGAGCTCGATGAAG	1620
D	b	1561	AGCAGGTGGCAGTACCCGCGACAGACACCACTGACAAGATGCAAGACGAGCTCGATGAAG	1620
Q	y	1621	TCATGAAGACCAACAAGATCATATTGGCTGTCTTTGTGCAAGTGAATCTGCTAGCTGCCG	1680
D	b	1621	TCATGAAGACCAACAAGATCATATTGGCTGTCTTTGTGCAAGTGAATCTGCTAGCTGCCG	1680
Q	y	1681	CCATGTTGATGTCTTCTATAAAAACCTTCGTAAGCGGCAACAGACAGCGGAGTACAGTCAACAG	1740
D	b	1681	CCATGTTGATGTCTTCTATAAAAACCTTCGTAAGCGGCAACAGACAGCGGAGTACAGTCAACAG	1740
Q	y	1741	CGGCGCGGACGTGTGAGATTAATCCAGGTGGAAGAAGACATCCAGCAGAGCAAGTCCGCGAG	1800
D	b	1741	CGGCGCGGACGTGTGAGATTAATCCAGGTGGAAGAAGACATCCAGCAGAGCAAGTCCGCGAG	1800
Q	y	1801	CAGCAACAGCAGCTCCGTCCGGTGTTACAGTTCAGGGGGCAGTGTGCTGCCACAAATTC	1860
D	b	1801	CAGCAACAGCAGCTCCGTCCGGTGTTACAGTTCAGGGGGCAGTGTGCTGCCACAAATTC	1860
Q	y	1861	ATGACCATATTAACCTACCAACCTCAAAACCCAGCAGATGGGGGCCCATGGAAGAAAAACA	1920
D	b	1861	ATGACCATATTAACCTACCAACCTCAAAACCCAGCAGATGGGGGCCCATGGAAGAAAAACA	1920
Q	y	1921	GCCTGGGGAACCTCTGCAACCCACACAGTCAACCACTATCTCTGAACTTATATATATTCAGA	1980
D	b	1921	GCCTGGGGAACCTCTGCAACCCACACAGTCAACCACTATCTCTGAACTTATATATATTCAGA	1980
Q	y	1981	CCCATACCAAGGACAAGGTACAGGAAACTCAAATATGACTCCCTCCCCCAAAAACTTA	2040
D	b	1981	CCCATACCAAGGACAAGGTACAGGAAACTCAAATATGACTCCCTCCCCCAAAAACTTA	2040
Q	y	2041	TAAATGCANTAGANTGCACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTTT	2100
D	b	2041	TAAATGCANTAGANTGCACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTTT	2100
Q	y	2101	TTCTGTGTATGCTTATATATTAAGTCTATPGGCTCGTTTAAAAAAAACAGATTATATTA	2160
D	b	2101	TTCTGTGTATGCTTATATATTAAGTCTATPGGCTCGTTTAAAAAAAACAGATTATATTA	2160
Q	y	2161	AATTTAAAGCAAAAAGTCAAAAACA 2185	
D	b	2161	AATTTAAAGCAAAAAGTCAAAAACA 2185	

RESULT 9
US-09-991-163-228
; Sequence 228, Application US/09991163
; Patent No. US20020132253A1
; GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrata, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kijavir, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P273021C17
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: US/09/991,163
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431

PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 10; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
y 1 GTTCTCTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAACGTGCCACACCATGA 60
b 1 GTTCTCTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAACGTGCCACACCATGA 60
y 61 AGCTCTGTGGCAGTAACTGTGCACACACACACACACACACACACACACACACACAC 120
b 61 AGCTCTGTGGCAGTAACTGTGCACACACACACACACACACACACACACACACACAC 120
y 121 TCTACCTCAGCGCGCAGTGTGATTTCTGTGTGACACCATCTGTGTGCGGCTCAGCG 180
b 121 TCTACCTCAGCGCGCAGTGTGATTTCTGTGTGACACCATCTGTGTGCGGCTCAGCG 180
y 181 GGCCCGAGAACTCCCTCTGTTGTCTGTGTGAGTAAACAGTTACAGAGGTGTGTGCA 240
b 181 GGCCCGAGAACTCCCTCTGTTGTCTGTGTGAGTAAACAGTTACAGAGGTGTGTGCA 240
y 241 CGCGCGGCGCTCTCCGAGGTCCCGACGATTTCCCTCGAACACCCCGGTACCTCAACC 300

Db 241 CGCGCGGCGCTCTCCGAGGTCCCGACGAGGTATTCCTCGAACACCCCGGTACCTCAACC 300
Qy 301 TCATGGAGAACATCCAGATGATCCAGAGCGGACACCTTCGCGACACCTCCACACCTGG 360
Db 301 TCATGGAGAACATCCAGATGATCCAGAGCGGACACCTTCGCGACACCTCCACACCTGG 360
Qy 361 AGGTCTCTGACAGTTGGCGAGGAACTCCATCCGCGAGATTGAGGTGGGGGCTTCAACGGCC 420
Db 361 AGGTCTCTGACAGTTGGCGAGGAACTCCATCCGCGAGATTGAGGTGGGGGCTTCAACGGCC 420
Qy 421 TGCGCAGCTCAACACCTGGAGCTGTTCGACAACTGGCTGACAGTATCCCTAGCGGG 480
Db 421 TGCGCAGCTCAACACCTGGAGCTGTTCGACAACTGGCTGACAGTATCCCTAGCGGG 480
Qy 481 CTTTGAATACCTGTCTCAAGCTCGCGGAGCTCTGGCTTCGCAACACCCCACTCGAAAGCA 540
Db 481 CTTTGAATACCTGTCTCAAGCTCGCGGAGCTCTGGCTTCGCAACACCCCACTCGAAAGCA 540
Qy 541 TCCCTCTTACGCTTCAACCGGCTGCCCTCCCTCATGCGCTTGAACCTTGGGGGAGCTCA 600
Db 541 TCCCTCTTACGCTTCAACCGGCTGCCCTCCCTCATGCGCTTGAACCTTGGGGGAGCTCA 600
Qy 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGGGGGCTGTTCACCTCAAGTATCTGA 660
Db 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGGGGGCTGTTCACCTCAAGTATCTGA 660
Qy 661 ACTTGGCATGTGCAACATTAAGAGATGCCAAATCTCAACCCCTGGTGGGGCTGGAGG 720
Db 661 ACTTGGCATGTGCAACATTAAGAGATGCCAAATCTCAACCCCTGGTGGGGCTGGAGG 720
Qy 721 AGCTGGAGATGTGAGGAAACCACTTCCCTGAGATCAGGCTCGCTCTTCCATGCGCTGA 780
Db 721 AGCTGGAGATGTGAGGAAACCACTTCCCTGAGATCAGGCTCGCTCTTCCATGCGCTGA 780
Qy 781 GCTCCCTCAAGAGCTCTGGGTCTGATCACTCAGGTGAGCTGATTTGAGCGGATGCTT 840
Db 781 GCTCCCTCAAGAGCTCTGGGTCTGATCACTCAGGTGAGCTGATTTGAGCGGATGCTT 840
Qy 841 TTGACGGGCTGGCTTCACTTGTGGAATCAACTGGCCCAACATTAACCTCTCTTCTTTC 900
Db 841 TTGACGGGCTGGCTTCACTTGTGGAATCAACTGGCCCAACATTAACCTCTCTTCTTTC 900
Qy 901 CCATGACCTCTTTTACCCGCTGAGGTACTTGGTGGAGTTGCACTTACACCAACACCTTT 960
Db 901 CCATGACCTCTTTTACCCGCTGAGGTACTTGGTGGAGTTGCACTTACACCAACACCTTT 960
Qy 961 GGAATCTGATTTGACATTTCTGTGGCTAGCTTGGCTTGGCTTGGAGTATATACCCACA 1020
Db 961 GGAATCTGATTTGACATTTCTGTGGCTAGCTTGGCTTGGCTTGGAGTATATACCCACA 1020
Qy 1021 ATTCCACCTGTGTGGCGCTGTCATGCTCCCATGCACATGCGAGCGCTACCTCGTGG 1080
Db 1021 ATTCCACCTGTGTGGCGCTGTCATGCTCCCATGCACATGCGAGCGCTACCTCGTGG 1080
Qy 1081 AGGTGACACAGGCTCTTCCAGTGTCTGCGCCCTTTCATGTGAGCGCACCTCGAGAC 1140
Db 1081 AGGTGACACAGGCTCTTCCAGTGTCTGCGCCCTTTCATGTGAGCGCACCTCGAGAC 1140
Qy 1141 TCAACATTTCTGAGGCTCGGATGGGAGAACTTAAGTGTGGGACTCCCTTATGTCTCTCG 1200
Db 1141 TCAACATTTCTGAGGCTCGGATGGGAGAACTTAAGTGTGGGACTCCCTTATGTCTCTCG 1200
Qy 1201 TGAAGTGTGTGCTGCCAAATGGGACAGTGTCTCAGCCACGCTCCCGCCACCAAGATCT 1260
Db 1201 TGAAGTGTGTGCTGCCAAATGGGACAGTGTCTCAGCCACGCTCCCGCCACCAAGATCT 1260
Qy 1261 CTGTCTCAACAGCGGCACTTGAATTTTCCAGGTGTCTTTCAGACACTGGGGTGT 1320
Db 1261 CTGTCTCAACAGCGGCACTTGAATTTTCCAGGTGTCTTTCAGACACTGGGGTGT 1320
Qy 1321 ACACATGCTGATGTGAACAAATGTTGAGGCAACTCAAGCGCTCGGCGCTACCTCAATGTA 1380

Db 1321 ACACATGATGGTGACCAATGTTTCAGGCAACTCCAGCGCTCGGCTCACTCAATGTGA 1380
QY 1381 GCACGGCTGAGTTAAACCTCCCACTACAGCTTCTTCAACACAGTAACAGTGGAGACCA 1440
Db 1381 GCACGGCTGAGTTAAACCTCCCACTACAGCTTCTTCAACACAGTAACAGTGGAGACCA 1440
QY 1441 CGGAGATCTCGGCTGAGGACACACGCGAAGTAGTCAAGCGCTGTTCCCTACACAGTCCACTG 1500
Db 1441 CGGAGATCTCGGCTGAGGACACACGCGAAGTAGTCAAGCGCTGTTCCCTACACAGTCCACTG 1500
QY 1501 GTTACACGCGGCAATATACCACTCTTACCAAGGTGCTCAATTCAGACTACCCGTGTGCCCA 1560
Db 1501 GTTACACGCGGCAATATACCACTCTTACCAAGGTGCTCAATTCAGACTACCCGTGTGCCCA 1560
QY 1561 AGCAGTGGAGTCCCGGACAGACACCACTGACAGATGACAGACAGCAGCCTGAGTGAAG 1620
Db 1561 AGCAGTGGAGTCCCGGACAGACACCACTGACAGATGACAGACAGCAGCCTGAGTGAAG 1620
QY 1621 TCATGAAGACACCAAGATCATCATTTGGCTGCTTTTGGCAGTGACTCTGCTAGCTGCCG 1680
Db 1621 TCATGAAGACACCAAGATCATCATTTGGCTGCTTTTGGCAGTGACTCTGCTAGCTGCCG 1680
QY 1681 CCATGTTGATGTTCTTATATACTTGTAAAGCGGACACAGCAGCAGGAGTACAGTCAAG 1740
Db 1681 CCATGTTGATGTTCTTATATACTTGTAAAGCGGACACAGCAGCAGGAGTACAGTCAAG 1740
QY 1741 CGGCGGAGCTGTTGAGATAATCCAGGTGACGAAGACATCCAGCAGCAACATCCGCGAG 1800
Db 1741 CGGCGGAGCTGTTGAGATAATCCAGGTGACGAAGACATCCAGCAGCAACATCCGCGAG 1800
QY 1801 CAGCAACAGCAGCTCGGCTCGGCTGATCAGGTGAGGGGGGAGTGTCTGCCCAACATTC 1860
Db 1801 CAGCAACAGCAGCTCGGCTCGGCTGATCAGGTGAGGGGGGAGTGTCTGCCCAACATTC 1860
QY 1861 ATGACCATATTAATACAAACCTTACAAACAGCAGACATGGGGGCCCTGGACAGAAAAA 1920
Db 1861 ATGACCATATTAATACAAACCTTACAAACAGCAGACATGGGGGCCCTGGACAGAAAAA 1920
QY 1921 GCCTGGGAACTCTTGACCCCAAGTCACTATCTCTGAACTTATATTAATTCAGA 1980
Db 1921 GCCTGGGAACTCTTGACCCCAAGTCACTATCTCTGAACTTATATTAATTCAGA 1980
QY 1981 CCATACCAAGGACAGGTACAGGAACCTCAATATGACTCTCCCTCCCAAAAACTTA 2040
Db 1981 CCATACCAAGGACAGGTACAGGAACCTCAATATGACTCTCCCTCCCAAAAACTTA 2040
QY 2041 TAAATGCAATAGATGACACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
Db 2041 TAAATGCAATAGATGACACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
QY 2101 TTCTGTATATGCTTATATTAATTAAGTCTATGCTGCTTAAABAAACAGATTATATTA 2160
Db 2101 TTCTGTATATGCTTATATTAATTAAGTCTATGCTGCTTAAABAAACAGATTATATTA 2160
QY 2161 AATTTAAAGACAAAAAGTCAAAACA 2185
Db 2161 AATTTAAAGACAAAAAGTCAAAACA 2185

RESULT 10

JS-09-993-604-228

Sequence 228, Application US/09993604

Patent No. US20020137075A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.

APPLICANT: Baker, Kevin P.

APPLICANT: Botstein, David

APPLICANT: Desnoyers, Luc

APPLICANT: Eaton, Dan L.

APPLICANT: Ferrara, Napoleone

APPLICANT: Fong, Sherman

APPLICANT: Gerber, Hanspeter

APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730PIC25
CURRENT APPLICATION NUMBER: US/09/993,604
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655

PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24

PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 10; Length 2185;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTCTCTTTCCGAGCCAAATCCGAGCGATGGTGAATTATGAACGTGCCACACCATGA	60
Db	1	GTCTCTTTCCGAGCCAAATCCGAGCGATGGTGAATTATGAACGTGCCACACCATGA	60
Qy	61	AGCTCTTGTGGCAGGTAACTGTGCACACACACCTGGAATGCCATCCTGCTCCCGTTGG	120
Db	61	AGCTCTTGTGGCAGGTAACTGTGCACACACACCTGGAATGCCATCCTGCTCCCGTTGG	120
Qy	121	TCTACTCAGCGCGCAGTGTGGATTCTGTGTGAGCCATCGCTGCGCGCTCAGCG	180
Db	121	TCTACTCAGCGCGCAGTGTGGATTCTGTGTGAGCCATCGCTGCGCGCTCAGCG	180
Qy	181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTCAGTAACAGTTCAGCAAGGTGTGTGCA	240
Db	181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTCAGTAACAGTTCAGCAAGGTGTGTGCA	240
Qy	241	CGCGCGGGGCTCTCCGAGTCCGAGGTATTCCTCGAACACCGGTACTCTCAACC	300
Db	241	CGCGCGGGGCTCTCCGAGTCCGAGGTATTCCTCGAACACCGGTACTCTCAACC	300
Qy	301	TCATGGAGAAACAATCCAGATGATCAGGCGCGACACTTCCGCGCACTCCACCACTGG	360
Db	301	TCATGGAGAAACAATCCAGATGATCAGGCGCGACACTTCCGCGCACTCCACCACTGG	360
Qy	361	AGGTCCTCAGTTGGGCGAGGAATCCATCCGCGAGATGAGGTGGGGGCTTCAACGGCC	420
Db	361	AGGTCCTCAGTTGGGCGAGGAATCCATCCGCGAGATGAGGTGGGGGCTTCAACGGCC	420

361 AGGTCTGAGTGGGAGGAACTCATCGGAGATTGAGTGGGGGCTTCAACGGCC 420
421 TGGCCAGGCTCAACACCTTGAGGTGTTGCAACAACCTGGCTGACAGTCACTCCCTAGCGGG 480
421 TGGCCAGGCTCAACACCTTGAGGTGTTGCAACAACCTGGCTGACAGTCACTCCCTAGCGGG 480
481 CTTTGAATACCTGTCGAAGTGGGAGGCTGCTGGCTTGGCAACAACCCCAATGAAAGCA 540
481 CTTTGAATACCTGTCGAAGTGGGAGGCTGCTGGCTTGGCAACAACCCCAATGAAAGCA 540
541 TCCCTCTTACGCTTCAACCGGGTGGCTCCCTCATGCGGCTGGACTTGGGGAGTCA 600
541 TCCCTCTTACGCTTCAACCGGGTGGCTCCCTCATGCGGCTGGACTTGGGGAGTCA 600
601 AGAAGCTGGAGTATCTCTGAGGAGCTTTTGAGGGGCTTTCAACCTCAAGTATCTGA 660
601 AGAAGCTGGAGTATCTCTGAGGAGCTTTTGAGGGGCTTTCAACCTCAAGTATCTGA 660
661 ACTTGGGATGTGCAACATTAAGACATGCCCAATCTCACCCCTGGTGGGCTGGAG 720
661 ACTTGGGATGTGCAACATTAAGACATGCCCAATCTCACCCCTGGTGGGCTGGAG 720
721 AGCTGAGATGTGAGGAAACCACTTCCCTGAGATCAGGCTGGCTTCCATGGCCTGA 780
721 AGCTGAGATGTGAGGAAACCACTTCCCTGAGATCAGGCTGGCTTCCATGGCCTGA 780
781 GCTCCTCAAGAGCTCTGGGTGATGAATCTCACAGTCTGAGCTCAATTGAGGAGTCTT 840
781 GCTCCTCAAGAGCTCTGGGTGATGAATCTCACAGTCTGAGCTCAATTGAGGAGTCTT 840
841 TTGAGGGGCTGCTTCACTTTGGAACCTCAACTTGGCCCAATAAACCCTCTCTTTTC 900
841 TTGAGGGGCTGCTTCACTTTGGAACCTCAACTTGGCCCAATAAACCCTCTCTTTTC 900
901 CCATGACCTCTTTACCCGCTGAGGATCTGGTGGAGTTCATCTACACCAACCCCTT 960
901 CCATGACCTCTTTACCCGCTGAGGATCTGGTGGAGTTCATCTACACCAACCCCTT 960
961 GGAACTGTGATGTGACATTTCTGGGCTAGCTGCTGGCTTCGAGAGTATATACCAACA 1020
961 GGAACTGTGATGTGACATTTCTGGGCTAGCTGCTGGCTTCGAGAGTATATACCAACA 1020
1021 ATTCACTGTGTGGCGCTGTGATGCTCCATGCAATGCAAGGCGGCTGATCTGTGG 1080
1021 ATTCACTGTGTGGCGCTGTGATGCTCCATGCAATGCAAGGCGGCTGATCTGTGG 1080
1081 AGGTGACCGGCTCTTCCAGTGTCTGCTGCTCCCTTCACTGAGCGCACTCGAGACC 1140
1081 AGGTGACCGGCTCTTCCAGTGTCTGCTGCTCCCTTCACTGAGCGCACTCGAGACC 1140
1141 TCAACATTTCTGAGGCTCGGATGGAGAACTTAAGTGTGGGACTCCCTCTATGCTCTCG 1200
1141 TCAACATTTCTGAGGCTCGGATGGAGAACTTAAGTGTGGGACTCCCTCTATGCTCTCG 1200
1201 TGAAGTGTGTGCTGCCAATGGGACAGTGTCTGAGCGGCTCCCGGACCCAGGATCT 1260
1201 TGAAGTGTGTGCTGCCAATGGGACAGTGTCTGAGCGGCTCCCGGACCCAGGATCT 1260
1261 CTGTCTCAACGACGGCACTTTGAACTTTTCCACGCTGCTGCTTTTCAAGCACTGGGGTGT 1320
1261 CTGTCTCAACGACGGCACTTTGAACTTTTCCACGCTGCTGCTTTTCAAGCACTGGGGTGT 1320
1321 ACACATGATGTGACCAATGTGTGAGGCACTCTCAAGCGCTCGGCTTCTCATGTGA 1380
1321 ACACATGATGTGACCAATGTGTGAGGCACTCTCAAGCGCTCGGCTTCTCATGTGA 1380
1381 GCACGGCTGAGCTTAACCTCCCAACTACGCTTCTTCAACACAGTAACTGAGGACCA 1440
1381 GCACGGCTGAGCTTAACTCCCAACTACGCTTCTTCAACACAGTAACTGAGGACCA 1440
1441 CGGAGTCTGCTGAGGACCAACCGGAAAGTAAAGGCTGTTCTTCAACGCTTCACTG 1500
1441 CGGAGTCTGCTGAGGACCAACCGGAAAGTAAAGGCTGTTCTTCAACGCTTCACTG 1500

1501 GTTACCAGCGGCATATACCACTCTACACGGTGTCTCATTCAGACTACCGGTGTGCCA 1560
1501 GTTACCAGCGGCATATACCACTCTACACGGTGTCTCATTCAGACTACCGGTGTGCCA 1560
1561 AGCAGTGGAGTACCCGCGAGACACCACTGACAGATGACAGACCGAGCTGATGAG 1620
1561 AGCAGTGGAGTACCCGCGAGACACCACTGACAGATGACAGACCGAGCTGATGAG 1620
1621 TCATGAAGACCAACCAAGATCATCTGCTGCTTTGGGAGTGTCTGCTAGCTGCG 1680
1621 TCATGAAGACCAACCAAGATCATCTGCTGCTTTGGGAGTGTCTGCTAGCTGCG 1680
1681 CATGTTGATGCTTCTTATAAATCTGTAAGCGGACACAGCAGCGAGTACAGTCAAG 1740
1681 CATGTTGATGCTTCTTATAAATCTGTAAGCGGACACAGCAGCGAGTACAGTCAAG 1740
1741 CGCCCGGAGCTGTTGAGATTAATCCAGTGGAGCAAGACATCCAGCAGCAATCCCGAG 1800
1741 CGCCCGGAGCTGTTGAGATTAATCCAGTGGAGCAAGACATCCAGCAGCAATCCCGAG 1800
1801 CAGCAACGAGCTCCGTCGCTGTATCAGGTGAGGGGCGAGTAGTGTGCTGCCAATTC 1860
1801 CAGCAACGAGCTCCGTCGCTGTATCAGGTGAGGGGCGAGTAGTGTGCTGCCAATTC 1860
1861 ATGACCATATTAACCTACAAACACCTACAAACAGCAGCAATGGGGCCCACTGGACAGAAACA 1920
1861 ATGACCATATTAACCTACAAACACCTACAAACAGCAGCAATGGGGCCCACTGGACAGAAACA 1920
1921 GCTGGGAACTCTGTGACCCCACTGACCACTATCTCTGAACTTATATAATTCAGA 1980
1921 GCTGGGAACTCTGTGACCCCACTGACCACTATCTCTGAACTTATATAATTCAGA 1980
1981 CCCATCAAGAGCAAGGTACAGGAACTCAAAATGACTCCCTCCCAAAAACCTTA 2040
1981 CCCATCAAGAGCAAGGTACAGGAACTCAAAATGACTCCCTCCCAAAAACCTTA 2040
2041 TAAATGCAATAGATGACCAACAAAGCAGCAACTTTGTACAGAGTGGGAGAGCTTT 2100
2041 TAAATGCAATAGATGACCAACAAAGCAGCAACTTTGTACAGAGTGGGAGAGCTTT 2100
2101 TTCTGTATATGCTTATATATTAAGTCTATGGGCTGTAAATAAARACAGATATATA 2160
2101 TTCTGTATATGCTTATATATTAAGTCTATGGGCTGTAAATAAARACAGATATATA 2160
2161 AATTTAAAGCAAAAAGTCAAAACA 2185
2161 AATTTAAAGCAAAAAGTCAAAACA 2185

RESULT 11

US-09-990-456-228
; Sequence 228, Application US/09990456
; Patent No. US20020137890A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann

APPLICANT: Stewart, Timothy A.
 APPLICANT: Tumas, Daniel
 APPLICANT: Watanabe, Colin K.
 APPLICANT: Williams, P. Mickey
 APPLICANT: Wood, William I.
 APPLICANT: Zhang, Zemin
 TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 TITLE OF INVENTION: Acids Encoding the Same
 FILE REFERENCE: P2730PIC22
 CURRENT APPLICATION NUMBER: US/09/990,456
 CURRENT FILING DATE: 2001-11-14
 PRIOR APPLICATION NUMBER: 60/049787
 PRIOR FILING DATE: 1997-06-16
 PRIOR APPLICATION NUMBER: 60/062250
 PRIOR FILING DATE: 1997-10-17
 PRIOR APPLICATION NUMBER: 60/065186
 PRIOR FILING DATE: 1997-11-12
 PRIOR APPLICATION NUMBER: 60/065311
 PRIOR FILING DATE: 1997-11-13
 PRIOR APPLICATION NUMBER: 60/066770
 PRIOR FILING DATE: 1997-11-24
 PRIOR APPLICATION NUMBER: 60/075945
 PRIOR FILING DATE: 1998-02-25
 PRIOR APPLICATION NUMBER: 60/078910
 PRIOR FILING DATE: 1998-03-20
 PRIOR APPLICATION NUMBER: 60/083322
 PRIOR FILING DATE: 1998-04-28
 PRIOR APPLICATION NUMBER: 60/084600
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/087106
 PRIOR FILING DATE: 1998-05-28
 PRIOR APPLICATION NUMBER: 60/087607
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087609
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087759
 PRIOR FILING DATE: 1998-06-02
 PRIOR APPLICATION NUMBER: 60/087827
 PRIOR FILING DATE: 1998-06-03
 PRIOR APPLICATION NUMBER: 60/088021
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088025
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088026
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088028
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088029
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088030
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088033
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088326
 PRIOR FILING DATE: 1998-06-04
 PRIOR APPLICATION NUMBER: 60/088167
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088202
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088212
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088217
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/088655
 PRIOR FILING DATE: 1998-06-09
 PRIOR APPLICATION NUMBER: 60/088734
 PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088738
 PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088742
 PRIOR FILING DATE: 1998-06-10
 PRIOR APPLICATION NUMBER: 60/088810
 PRIOR FILING DATE: 1998-06-10

PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 10; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 GTTCTCTTCGGAGCCAAATCCAGCGCATGTTGAATTAAGCGTCCACCATGA 60
1 GTTCTCTTCGGAGCCAAATCCAGCGCATGTTGAATTAAGCGTCCACCATGA 60

61 AGCTCTTGTGCGAGTAACCTGTGCACACACACACCTGGAATGCCATCTGCTCCCGTTG 120
61 AGCTCTTGTGCGAGTAACCTGTGCACACACACACCTGGAATGCCATCTGCTCCCGTTG 120

121 TCTACCTCAOOGCGAGTGTGATTTCTGTGTGAGCCATCGCTGCTGCGCGCTGAGCG 180
121 TCTACCTCAOOGCGAGTGTGATTTCTGTGTGAGCCATCGCTGCTGCGCGCTGAGCG 180

181 GCGCCAGAACTGCCCTTCGGTTTGTCTGCTGAGTAACCTGAGTTCAGCAAGTGGTGTGA 240
181 GCGCCAGAACTGCCCTTCGGTTTGTCTGCTGAGTAACCTGAGTTCAGCAAGTGGTGTGA 240

241 CGCGCGGGGCTCTCCGAGTCCCGAGGATATTCCTCGAAACCGGTACTCAACC 300
241 CGCGCGGGGCTCTCCGAGTCCCGAGGATATTCCTCGAAACCGGTACTCAACC 300

301 TCATGGAACAACTCCAGATGATCCAGCGGACACTTCGCGCACTCCACCACTGG 360
301 TCATGGAACAACTCCAGATGATCCAGCGGACACTTCGCGCACTCCACCACTGG 360

361 AGGTCTCTGAGTGGCGAGGAATCCATCCGCGAGATGAGGTGGGGCTTCAACGGCC 420
361 AGGTCTCTGAGTGGCGAGGAATCCATCCGCGAGATGAGGTGGGGCTTCAACGGCC 420

421 TGGCCAGCTCAACCTTCGAGTGTGCACTGCTGAGTTCATCCCTAGCGGG 480
421 TGGCCAGCTCAACCTTCGAGTGTGCACTGCTGAGTTCATCCCTAGCGGG 480

481 CTTTGAATACCTGTCCAGCTGGGGAGCTCTGGCTTCGCAACACCCCAATCGAAGCA 540
481 CTTTGAATACCTGTCCAGCTGGGGAGCTCTGGCTTCGCAACACCCCAATCGAAGCA 540

QY 541 TCCCTCTTACGCTTCAACCGGTCCTCCCTCATGCGCTGGACTTGGGGAGCTCA 600
DB 541 TCCCTCTTACGCTTCAACCGGTCCTCCCTCATGCGCTGGACTTGGGGAGCTCA 600

QY 601 AGAGCTGGAGTATATCTCTGAGGAGCTTTTGAAGGGCTGTTCAACCTCAAGTATCTGA 660
DB 601 AGAGCTGGAGTATATCTCTGAGGAGCTTTTGAAGGGCTGTTTCAACCTCAAGTATCTGA 660

QY 661 ACTTGGGCTGTGCAACATTAAGACATGCCCAATCTCAACCCCTCTGGTGGGGCTGGAGG 720
DB 661 ACTTGGGCTGTGCAACATTAAGACATGCCCAATCTCAACCCCTCTGGTGGGGCTGGAGG 720

QY 721 AGCTGGAGTGTGAGGAAACCACTTCCCTGAGATGAGGCTGGCTTCTTCAATGGCTTGA 780
DB 721 AGCTGGAGTGTGAGGAAACCACTTCCCTGAGATGAGGCTGGCTTCTTCAATGGCTTGA 780

QY 781 GCTCCCTCAAGAAAGCTTCTGGGTCTGAACTCAAGCTCAGCTGATGAGCGGAATGCTT 840
DB 781 GCTCCCTCAAGAAAGCTTCTGGGTCTGAACTCAAGCTCAGCTGATGAGCGGAATGCTT 840

QY 841 TTGAOGGGCTGGCTTCACTTGTGAACTCAACTTTGGCCCAATAAACCTCTCTTCTTTGC 900
DB 841 TTGAOGGGCTGGCTTCACTTGTGAACTCAACTTTGGCCCAATAAACCTCTCTTCTTTGC 900

QY 901 CCCATGACCTCTTACCCCGCTGAGTACTCTGTGTGAGTTGCTATACACCAACCCCTT 960
DB 901 CCCATGACCTCTTACCCCGCTGAGTACTCTGTGTGAGTTGCTATACACCAACCCCTT 960

QY 961 GGAACCTGTGATTTGACATTTCTGTGCTAGCTTGTGCTTGTGAGTATATACCCACCA 1020
DB 961 GGAACCTGTGATTTGACATTTCTGTGCTAGCTTGTGCTTGTGAGTATATACCCACCA 1020

QY 1021 ATTCCACTGCTGTGGCGCTGTCTCCCTGAGTCTGCTGCTGCTGCTGCTGCTGCTGCTG 1080
DB 1021 ATTCCACTGCTGTGGCGCTGTCTCCCTGAGTCTGCTGCTGCTGCTGCTGCTGCTGCTG 1080

QY 1081 AGTGGACACAGGCTCTCTCCCTGAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140
DB 1081 AGTGGACACAGGCTCTCTCCCTGAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140

QY 1141 TCAACATTTCTGAGGCTGGAATGGCAGAACTTAAGTGTGCGACTTCCCTATGCTCTCG 1200
DB 1141 TCAACATTTCTGAGGCTGGAATGGCAGAACTTAAGTGTGCGACTTCCCTATGCTCTCG 1200

QY 1201 TGAAGTGGTGTGCTGCCCAATGGGACAGTGTCTGAGCCACGCTTCCCGCCACCAAGGATCT 1260
DB 1201 TGAAGTGGTGTGCTGCCCAATGGGACAGTGTCTGAGCCACGCTTCCCGCCACCAAGGATCT 1260

QY 1261 CTGTCTCTCAACGAGCGCACTTGTGAACTTTTCCACGCTGCTTTCAGACACTGGGGTGT 1320
DB 1261 CTGTCTCTCAACGAGCGCACTTGTGAACTTTTCCACGCTGCTTTCAGACACTGGGGTGT 1320

QY 1321 ACACATGCTGCTGAGCACTTGTGAGGCAACTTCCAGCGCTCGGCTTCAATGTGA 1380
DB 1321 ACACATGCTGCTGAGCACTTGTGAGGCAACTTCCAGCGCTCGGCTTCAATGTGA 1380

QY 1381 GCACGGCTGAGCTTAAACCTTCAACTAGCTTCTTCAACAGTAAAGTGGAGACCA 1440
DB 1381 GCACGGCTGAGCTTAAACCTTCAACTAGCTTCTTCAACAGTAAAGTGGAGACCA 1440

QY 1441 CGGAGTCTGCTGAGGACACAAOGGAAAGTACAGCTTCTTCAACAGCTTCAACTG 1500
DB 1441 CGGAGTCTGCTGAGGACACAAOGGAAAGTACAGCTTCTTCAACAGCTTCAACTG 1500

QY 1501 GTTACCAGCGCATATACCACTTCTACCACTGCTTCAATTCAGACTACCCGCTGCCCCA 1560
DB 1501 GTTACCAGCGCATATACCACTTCTACCACTGCTTCAATTCAGACTACCCGCTGCCCCA 1560

QY 1561 AGCAGTGGAGTACCCGCGAGCAGCCTGAGAGATGAGAGCAGCAGCTGAGTGAAG 1620
DB 1561 AGCAGTGGAGTACCCGCGAGCAGCCTGAGAGATGAGAGCAGCAGCTGAGTGAAG 1620

1621 TCATGAAGCCACCAAGATCATCATTTGGCTGCTTTGTGGCACTGACTCTGCTAGCTGCGG 1680
|||||
1621 TCATGAAGCCACCAAGATCATCATTTGGCTGCTTTGTGGCACTGACTCTGCTAGCTGCGG 1680
|||||
1681 CCATGTTGATGTTCTCTATAAACTTCGTAAGCGGCACACAGCAGCGGAGTACAGTCAAG 1740
|||||
1681 CCATGTTGATGTTCTCTATAAACTTCGTAAGCGGCACACAGCAGCGGAGTACAGTCAAG 1740
|||||
1741 CCGCCCGGACTGTTGAGATTAATCCAGGTGGAGAGAGATCCACAGCAGCAATCCGCGAG 1800
|||||
1741 CCGCCCGGACTGTTGAGATTAATCCAGGTGGAGAGAGATCCACAGCAGCAATCCGCGAG 1800
|||||
1801 CAGCAACAGCAGCTCCGTCGCGGTGATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC 1860
|||||
1801 CAGCAACAGCAGCTCCGTCGCGGTGATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC 1860
|||||
1861 ATGACCATTAATCAACACACTTACAAACCGACAGCATGGGGCCCACTGGGAGAGAAACA 1920
|||||
1861 ATGACCATTAATCAACACACTTACAAACCGACAGCATGGGGCCCACTGGGAGAGAAACA 1920
|||||
1921 GCGTGGGGAACCTCTCTGCAACCCACAGTCACCACTATCTCTGAACCTTATATAATTGAGA 1980
|||||
1921 GCGTGGGGAACCTCTCTGCAACCCACAGTCACCACTATCTCTGAACCTTATATAATTGAGA 1980
|||||
1981 CCATACCAAGGACCAAGGTACAGGAACTCAATATGACTCCCTCCCAAAAACCTTA 2040
|||||
1981 CCATACCAAGGACCAAGGTACAGGAACTCAATATGACTCCCTCCCAAAAACCTTA 2040
|||||
2041 TAAATGCAATAGATGACACACAAAGACAGCACTTTGTACAGAGTGGGAGAGACTTT 2100
|||||
2041 TAAATGCAATAGATGACACACAAAGACAGCACTTTGTACAGAGTGGGAGAGACTTT 2100
|||||
2101 TTCTTGATATGCTTATATATTAAAGTCTATGGGCTGGTTTAAAAAAACAGATTATATTAA 2160
|||||
2101 TTCTTGATATGCTTATATATTAAAGTCTATGGGCTGGTTTAAAAAAACAGATTATATTAA 2160
|||||
2161 AATTTAAACACAAAAGTCAAAACA 2185
|||||
2161 AATTTAAACACAAAAGTCAAAACA 2185
|||||

RESULT 12

S-09-989-721-228

Sequence 228, Application US/09989721

Patent No. US20020142961A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.

APPLICANT: Baker, Kevin P.

APPLICANT: Botstein, David

APPLICANT: Desnoyers, Luc

APPLICANT: Eaton, Dan L.

APPLICANT: Ferrara, Napoleone

APPLICANT: Fong, Sherman

APPLICANT: Gerber, Hanspeter

APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Grimaldi, J. Christopher

APPLICANT: Gurney, Austin L.

APPLICANT: Kljavin, Ivar J.

APPLICANT: Napier, Mary A.

APPLICANT: Pan, James

APPLICANT: Paoni, Nicholas F.

APPLICANT: Roy, Margaret Ann

APPLICANT: Stewart, Timothy A.

APPLICANT: Tumas, Daniel

APPLICANT: Watanabe, Colin K.

APPLICANT: Williams, P. Mickey

APPLICANT: Wood, William I.

APPLICANT: Zhang, Zemin

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

Acids Encoding the Same

FILE REFERENCE: P2730P1C55

CURRENT APPLICATION NUMBER: US/09/989, 721
CURRENT FILING DATE: 2001-11-19
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876

; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/089105
 ; PRIOR FILING DATE: 1998-06-12
 ; PRIOR APPLICATION NUMBER: 60/089440
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089512
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089514
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089532
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089538
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089598
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089599
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089600
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089653
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089598
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089907
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089908
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089947
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089948
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089952
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/090246
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090252
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090254
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090349
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090355
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090429
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090431
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090435
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090444
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090445
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090472
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090535
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090540
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090542
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090557
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090676
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090678
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090690
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090694
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090695
 ; PRIOR FILING DATE: 1998-06-25

; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 10; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GTCTCTCTTCGAGCCAAATCCAGGCGATGGTAATTAAGACGTCGACACCACTGA	60
DB	1	GTCTCTCTTCGAGCCAAATCCAGGCGATGGTAATTAAGACGTCGACACCACTGA	60
QY	61	AGCTCTTGTGGCAGGTAACTGTGCACCACTTGAATGCAATCTGTCTCCGCTCG	120
DB	61	AGCTCTTGTGGCAGGTAACTGTGCACCACTTGAATGCAATCTGTCTCCGCTCG	120
QY	121	TCTACTCTCAGCGCGCAAGTGTGGATTCTGTCTGAGCCATCGCTGCGCCCTCAGCG	180
DB	121	TCTACTCTCAGCGCGCAAGTGTGGATTCTGTCTGAGCCATCGCTGCGCCCTCAGCG	180
QY	181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTCAGTAACAGTTTCAGAAAGTGTGTGCA	240
DB	181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTCAGTAACAGTTTCAGAAAGTGTGTGCA	240
QY	241	CGCGCGCGGCGCTCTCCAGGTCCGCGAGGTATCCCTCGAACACCGGTACCTCAAC	300
DB	241	CGCGCGCGGCGCTCTCCAGGTCCGCGAGGTATCCCTCGAACACCGGTACCTCAAC	300
QY	301	TCATGGAGAACAACTCCAGATGATCCAGGCGCGACACTTCCGCGCACTCCACCCCTGG	360
DB	301	TCATGGAGAACAACTCCAGATGATCCAGGCGCGACACTTCCGCGCACTCCACCCCTGG	360
QY	361	AGGTCTCTGAGTTGGGAGGAACTCCATCCGCGAGATGAGTTGGGGGCTTCAACGGCC	420
DB	361	AGGTCTCTGAGTTGGGAGGAACTCCATCCGCGAGATGAGTTGGGGGCTTCAACGGCC	420
QY	421	TGGCCAGCTCAACACCTCGAGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG	480
DB	421	TGGCCAGCTCAACACCTCGAGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG	480
QY	481	CTTTGAATACCTGTTCAGCTCGGGAGCTCTGGCTTCGACAACTGGCTGAGTCACTCCCTAGCGGG	540
DB	481	CTTTGAATACCTGTTCAGCTCGGGAGCTCTGGCTTCGACAACTGGCTGAGTCACTCCCTAGCGGG	540
QY	541	TCGCCCTCTTACGCTTCAACCGGCTGCCCTCCCTCATGCGCTGAGCTTGGGGAGGTCA	600
DB	541	TCGCCCTCTTACGCTTCAACCGGCTGCCCTCCCTCATGCGCTGAGCTTGGGGAGGTCA	600
QY	601	AGAAGCTGGAGTATCTCTGAGGAGGCTTTTGGGGGCTTTCACCTCAAGTATCTGA	660
DB	601	AGAAGCTGGAGTATCTCTGAGGAGGCTTTTGGGGGCTTTCACCTCAAGTATCTGA	660

661 ACTTGGGCAATGTCACATTAAGACATGCCCCATCTCACCCCTCGTGGGCTGGAGG 720
661 ACTTGGGCAATGTCACATTAAGACATGCCCCATCTCACCCCTCGTGGGCTGGAGG 720
721 AGCTGGAGATGTCAGGGAACCACTTCCCTGAGATCAGGCTCGGCTCTTCCATGCGCTGA 780
721 AGCTGGAGATGTCAGGGAACCACTTCCCTGAGATCAGGCTCGGCTCTTCCATGCGCTGA 780
781 GCTCCCTCAAGAGCTCTGGGTCATGAACTACAGGTACAGGTACAGGTACAGGTACAGGT 840
781 GCTCCCTCAAGAGCTCTGGGTCATGAACTACAGGTACAGGTACAGGTACAGGTACAGGT 840
841 TTGAGGGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCAACAATAACCTCTCTTCTTTC 900
841 TTGAGGGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCAACAATAACCTCTCTTCTTTC 900
901 CCATGACCTCTTTACCCGCTGAGGTACTGTGGAGTTGAGTTGAGTTGAGTTGAGTTG 960
901 CCATGACCTCTTTACCCGCTGAGGTACTGTGGAGTTGAGTTGAGTTGAGTTGAGTTG 960
961 GCAACTGTGATGTGACATCTCTGCTGAGCTAGCTGCTGCTGCTGCTGCTGCTGCTGCT 1020
961 GCAACTGTGATGTGACATCTCTGCTGAGCTAGCTGCTGCTGCTGCTGCTGCTGCTGCT 1020
1021 ATTCCACTGCTGTGCGGCTGTCTATGCTGCCATGACATGCGAGGCGCTTACCTCGTG 1080
1021 ATTCCACTGCTGTGCGGCTGTCTATGCTGCCATGACATGCGAGGCGCTTACCTCGTG 1080
1081 AGTGGACAGAGCTCTTCCAGTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140
1081 AGTGGACAGAGCTCTTCCAGTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140
1141 TCAACATTTCTGAGGCTGAGGTCGAGAACTTAAGTGTGCGAGCTCCCTCTATGCTCTCG 1200
1141 TCAACATTTCTGAGGCTGAGGTCGAGAACTTAAGTGTGCGAGCTCCCTCTATGCTCTCG 1200
1201 TGAAGTGTGCTGCGCAATGAGGACAGTGTCTCAGCAGCGCTCCGCGCCACCGAGATCT 1260
1201 TGAAGTGTGCTGCGCAATGAGGACAGTGTCTCAGCAGCGCTCCGCGCCACCGAGATCT 1260
1261 CTGTCTCTCAACAGCGGCACTTGAACCTTTCACGCTGCTGCTTTCAGACACTGGGGTGT 1320
1261 CTGTCTCTCAACAGCGGCACTTGAACCTTTCACGCTGCTGCTTTCAGACACTGGGGTGT 1320
1321 ACATGATGCTGATGACCAATGTTGAGGGAATCCAGCTCTGCGCTTACCTCAATGTGA 1380
1321 ACATGATGCTGATGACCAATGTTGAGGGAATCCAGCTCTGCGCTTACCTCAATGTGA 1380
1381 GCACGCTGAGCTTAACACTCCAACTACAGCTTCTTCCACAGTACAGTACAGTACAGT 1440
1381 GCACGCTGAGCTTAACACTCCAACTACAGCTTCTTCCACAGTACAGTACAGTACAGT 1440
1441 CGGAGATCTCGCTGAGGACACAAACCGGAAAGTACAAGCTTCTTCTTACCACTGCTG 1500
1441 CGGAGATCTCGCTGAGGACACAAACCGGAAAGTACAAGCTTCTTCTTACCACTGCTG 1500
1501 GTTACAGCGGCAATATACCACTCTACAGGCTCTTACAGGCTCTTACAGACTACCGTGG 1560
1501 GTTACAGCGGCAATATACCACTCTACAGGCTCTTACAGGCTCTTACAGACTACCGTGG 1560
1561 AGCAGTGGCAGTACCGGACAGACACCACTGCAAGATGCAAGCTGCAAGCTGCAAGTGA 1620
1561 AGCAGTGGCAGTACCGGACAGACACCACTGCAAGATGCAAGCTGCAAGCTGCAAGTGA 1620
1621 TCATGAGACCAAGATATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1680
1621 TCATGAGACCAAGATATCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1680
1681 CCATGTTGATGCTCTTATTAACCTTCTGTAAGCGGACCAAGCTGAGTACAGTACAG 1740
1681 CCATGTTGATGCTCTTATTAACCTTCTGTAAGCGGACCAAGCTGAGTACAGTACAG 1740
1741 CCGCCCGGAGCTGTTGAGATTAATCCAGGTGGAGAGACATCCCGAGCGACATCCCGAG 1800

1741 CCGCCCGGAGCTGTTGAGATTAATCCAGGTGGAGAGACATCCCGAGCAACATCCCGAG 1800
1801 CAGCAACAGCACTCCGTCGCTGTATCAGGTGAGGGGCGAGTAGTCTGCCCAATTC 1860
1801 CAGCAACAGCACTCCGTCGCTGTATCAGGTGAGGGGCGAGTAGTCTGCCCAATTC 1860
1861 ATGACCATATTAACCTCAACACCTTCAAAACAGCAATGCGGGCCACCTGGACAGAAA 1920
1861 ATGACCATATTAACCTCAACACCTTCAAAACAGCAATGCGGGCCACCTGGACAGAAA 1920
1921 GCTGGGGAACCTCTCTGCAACCCACAGTCAACCTATCTCTGAACCTTATATTAATCAG 1980
1921 GCTGGGGAACCTCTCTGCAACCCACAGTCAACCTATCTCTGAACCTTATATTAATCAG 1980
1981 CCATACACAGGACAGGTACAGGAACTCAAAATATGATCTCCCTCCCGGCAAAACCTTA 2040
1981 CCATACACAGGACAGGTACAGGAACTCAAAATATGATCTCCCTCCCGGCAAAACCTTA 2040
2041 TAAATGCAATAGATGACACCAAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
2041 TAAATGCAATAGATGACACCAAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
2101 TTCTGTATATGCTTATATTAAGTCTATGGCTGTTAAAAAAGAGATTAATTA 2160
2101 TTCTGTATATGCTTATATTAAGTCTATGGCTGTTAAAAAAGAGATTAATTA 2160
2161 AATTTAAAGACAAAAGTCAAAACA 2185
2161 AATTTAAAGACAAAAGTCAAAACA 2185

RESULT 13

US-09-992-598-228
; Sequence 228, Application US/09992598
; Patent No. US20020160384A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumes, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730PIC20
; CURRENT APPLICATION NUMBER: US/09/992,598
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311

1 PRIOR FILING DATE: 1987-11-13
2 PRIOR APPLICATION NUMBER: 60/066770
3 PRIOR FILING DATE: 1987-11-24
4 PRIOR APPLICATION NUMBER: 60/075945
5 PRIOR FILING DATE: 1988-02-25
6 PRIOR APPLICATION NUMBER: 60/078910
7 PRIOR FILING DATE: 1988-03-20
8 PRIOR APPLICATION NUMBER: 60/083322
9 PRIOR FILING DATE: 1988-04-28
10 PRIOR APPLICATION NUMBER: 60/084600
11 PRIOR FILING DATE: 1988-05-07
12 PRIOR APPLICATION NUMBER: 60/087106
13 PRIOR FILING DATE: 1988-05-28
14 PRIOR APPLICATION NUMBER: 60/087607
15 PRIOR FILING DATE: 1988-06-02
16 PRIOR APPLICATION NUMBER: 60/087609
17 PRIOR FILING DATE: 1988-06-02
18 PRIOR APPLICATION NUMBER: 60/087759
19 PRIOR FILING DATE: 1988-06-02
20 PRIOR APPLICATION NUMBER: 60/087827
21 PRIOR FILING DATE: 1988-06-03
22 PRIOR APPLICATION NUMBER: 60/088021
23 PRIOR FILING DATE: 1988-06-04
24 PRIOR APPLICATION NUMBER: 60/088025
25 PRIOR FILING DATE: 1988-06-04
26 PRIOR APPLICATION NUMBER: 60/088026
27 PRIOR FILING DATE: 1988-06-04
28 PRIOR APPLICATION NUMBER: 60/088028
29 PRIOR FILING DATE: 1988-06-04
30 PRIOR APPLICATION NUMBER: 60/088029
31 PRIOR FILING DATE: 1988-06-04
32 PRIOR APPLICATION NUMBER: 60/088030
33 PRIOR FILING DATE: 1988-06-04
34 PRIOR APPLICATION NUMBER: 60/088033
35 PRIOR FILING DATE: 1988-06-04
36 PRIOR APPLICATION NUMBER: 60/088326
37 PRIOR FILING DATE: 1988-06-04
38 PRIOR APPLICATION NUMBER: 60/088167
39 PRIOR FILING DATE: 1988-06-05
40 PRIOR APPLICATION NUMBER: 60/088202
41 PRIOR FILING DATE: 1988-06-05
42 PRIOR APPLICATION NUMBER: 60/088212
43 PRIOR FILING DATE: 1988-06-05
44 PRIOR APPLICATION NUMBER: 60/088217
45 PRIOR FILING DATE: 1988-06-05
46 PRIOR APPLICATION NUMBER: 60/088655
47 PRIOR FILING DATE: 1988-06-09
48 PRIOR APPLICATION NUMBER: 60/088734
49 PRIOR FILING DATE: 1988-06-10
50 PRIOR APPLICATION NUMBER: 60/088738
51 PRIOR FILING DATE: 1988-06-10
52 PRIOR APPLICATION NUMBER: 60/088742
53 PRIOR FILING DATE: 1988-06-10
54 PRIOR APPLICATION NUMBER: 60/088810
55 PRIOR FILING DATE: 1988-06-10
56 PRIOR APPLICATION NUMBER: 60/088824
57 PRIOR FILING DATE: 1988-06-10
58 PRIOR APPLICATION NUMBER: 60/088826
59 PRIOR FILING DATE: 1988-06-10
60 PRIOR APPLICATION NUMBER: 60/088858
61 PRIOR FILING DATE: 1988-06-11
62 PRIOR APPLICATION NUMBER: 60/088861
63 PRIOR FILING DATE: 1988-06-11
64 PRIOR APPLICATION NUMBER: 60/088876
65 PRIOR FILING DATE: 1988-06-11
66 PRIOR APPLICATION NUMBER: 60/089105
67 PRIOR FILING DATE: 1988-06-12
68 PRIOR APPLICATION NUMBER: 60/089440
69 PRIOR FILING DATE: 1988-06-16
70 PRIOR APPLICATION NUMBER: 60/089512
71 PRIOR FILING DATE: 1988-06-16
72 PRIOR APPLICATION NUMBER: 60/089514
73 PRIOR FILING DATE: 1988-06-16

74 PRIOR APPLICATION NUMBER: 60/089532
75 PRIOR FILING DATE: 1988-06-17
76 PRIOR APPLICATION NUMBER: 60/089538
77 PRIOR FILING DATE: 1988-06-17
78 PRIOR APPLICATION NUMBER: 60/089598
79 PRIOR FILING DATE: 1988-06-17
80 PRIOR APPLICATION NUMBER: 60/089599
81 PRIOR FILING DATE: 1988-06-17
82 PRIOR APPLICATION NUMBER: 60/089600
83 PRIOR FILING DATE: 1988-06-17
84 PRIOR APPLICATION NUMBER: 60/089653
85 PRIOR FILING DATE: 1988-06-17
86 PRIOR APPLICATION NUMBER: 60/089801
87 PRIOR FILING DATE: 1988-06-18
88 PRIOR APPLICATION NUMBER: 60/089907
89 PRIOR FILING DATE: 1988-06-18
90 PRIOR APPLICATION NUMBER: 60/089908
91 PRIOR FILING DATE: 1988-06-18
92 PRIOR APPLICATION NUMBER: 60/089947
93 PRIOR FILING DATE: 1988-06-19
94 PRIOR APPLICATION NUMBER: 60/089948
95 PRIOR FILING DATE: 1988-06-19
96 PRIOR APPLICATION NUMBER: 60/089952
97 PRIOR FILING DATE: 1988-06-19
98 PRIOR APPLICATION NUMBER: 60/090246
99 PRIOR FILING DATE: 1988-06-22
100 PRIOR APPLICATION NUMBER: 60/090252
101 PRIOR FILING DATE: 1988-06-22
102 PRIOR APPLICATION NUMBER: 60/090254
103 PRIOR FILING DATE: 1988-06-22
104 PRIOR APPLICATION NUMBER: 60/090349
105 PRIOR FILING DATE: 1988-06-23
106 PRIOR APPLICATION NUMBER: 60/090355
107 PRIOR FILING DATE: 1988-06-23
108 PRIOR APPLICATION NUMBER: 60/090429
109 PRIOR FILING DATE: 1988-06-24
110 PRIOR APPLICATION NUMBER: 60/090431
111 PRIOR FILING DATE: 1988-06-24
112 PRIOR APPLICATION NUMBER: 60/090435
113 PRIOR FILING DATE: 1988-06-24
114 PRIOR APPLICATION NUMBER: 60/090444
115 PRIOR FILING DATE: 1988-06-24
116 PRIOR APPLICATION NUMBER: 60/090445
117 PRIOR FILING DATE: 1988-06-24
118 PRIOR APPLICATION NUMBER: 60/090542
119 PRIOR FILING DATE: 1988-06-24
120 PRIOR APPLICATION NUMBER: 60/090557
121 PRIOR FILING DATE: 1988-06-24
122 PRIOR APPLICATION NUMBER: 60/090676
123 PRIOR FILING DATE: 1988-06-25
124 PRIOR APPLICATION NUMBER: 60/090678
125 PRIOR FILING DATE: 1988-06-25
126 PRIOR APPLICATION NUMBER: 60/090690
127 PRIOR FILING DATE: 1988-06-25
128 PRIOR APPLICATION NUMBER: 60/090694
129 PRIOR FILING DATE: 1988-06-25
130 PRIOR APPLICATION NUMBER: 60/090695
131 PRIOR FILING DATE: 1988-06-25
132 PRIOR APPLICATION NUMBER: 60/090696
133 PRIOR FILING DATE: 1988-06-25
134 PRIOR APPLICATION NUMBER: 60/090862
135 PRIOR FILING DATE: 1988-06-26
136 PRIOR APPLICATION NUMBER: 60/090863
137 PRIOR FILING DATE: 1988-06-26
138 PRIOR APPLICATION NUMBER: 60/091360
139 PRIOR FILING DATE: 1988-07-01
140 PRIOR APPLICATION NUMBER: 60/091478

: PRIOR FILING DATE: 1998-07-02
 : PRIOR APPLICATION NUMBER: 60/091544
 : PRIOR FILING DATE: 1998-07-01
 : PRIOR APPLICATION NUMBER: 60/091519
 : PRIOR FILING DATE: 1998-07-02
 : PRIOR APPLICATION NUMBER: 60/091626
 : PRIOR FILING DATE: 1998-07-02
 : PRIOR APPLICATION NUMBER: 60/091633
 : PRIOR FILING DATE: 1998-07-02
 : PRIOR APPLICATION NUMBER: 60/091978
 : PRIOR FILING DATE: 1998-07-07
 : PRIOR APPLICATION NUMBER: 60/091982
 : PRIOR FILING DATE: 1998-07-07
 : PRIOR APPLICATION NUMBER: 60/092182
 : PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 10; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 GTTCTCTTTCCGAGCAAAATCCAGGCAATGGTGAATATGAACTGAGCTGCACACCAATGA 60
 1 GTTCTCTTTCCGAGCAAAATCCAGGCAATGGTGAATATGAACTGAGCTGCACACCAATGA 60
 61 AGCTCTTTGTGCGAGTAACGTGTGCACCAACACCTGGATGCACTCTGCTCCCGTTCG 120
 61 AGCTCTTTGTGCGAGTAACGTGTGCACCAACACCTGGATGCACTCTGCTCCCGTTCG 120
 121 TCTACCTCAAGGCGCAAGTGTGATTTCTGTGCGAGCAATCGTGTGCGGCTCAAGCGG 180
 121 TCTACCTCAAGGCGCAAGTGTGATTTCTGTGCGAGCAATCGTGTGCGGCTCAAGCGG 180
 181 GGCCCCAGAACTGCCCCCTCGGTTGCTGCGAGTAACCAATGTCAGCAAGTGTGTGCA 240
 181 GGCCCCAGAACTGCCCCCTCGGTTGCTGCGAGTAACCAATGTCAGCAAGTGTGTGCA 240
 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGATTCCTCGAAACCCCGGTACCTCAACC 300
 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGATTCCTCGAAACCCCGGTACCTCAACC 300
 301 TCATGGAGAACATCCAGATGATCCAGGCGAGCACTTCGCGCACTCCACCACTGG 360
 301 TCATGGAGAACATCCAGATGATCCAGGCGAGCACTTCGCGCACTCCACCACTGG 360
 361 AGGTCTCTGAGTTGGGAGGAATCCATCCGCGAGATTTGAGGTGGGGGCTTCAACGGCC 420
 361 AGGTCTCTGAGTTGGGAGGAATCCATCCGCGAGATTTGAGGTGGGGGCTTCAACGGCC 420
 421 TGGCGAGCTCAACACCTCGAGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480
 421 TGGCGAGCTCAACACCTCGAGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480
 481 CTTTGAATACCTCTCAAGCTGGGAGCTCTGGCTTCGAAACACCCCATCGAAGCA 540
 481 CTTTGAATACCTCTCAAGCTGGGAGCTCTGGCTTCGAAACACCCCATCGAAGCA 540
 541 TCCCTCTTAAGCTTCAACCGGAGCTCTCCCTCAATGCGCTGAGCTTGGGGAGCTCA 600
 541 TCCCTCTTAAGCTTCAACCGGAGCTCTCCCTCAATGCGCTGAGCTTGGGGAGCTCA 600
 601 AGAGCTGGAGTATCTCTGAGGAGCTTTGAGGGGCTTTCAACCTCAAGTATCTGA 660
 601 AGAGCTGGAGTATCTCTGAGGAGCTTTGAGGGGCTTTCAACCTCAAGTATCTGA 660
 661 ACTTGGGATGTGCAACATTAAGACATGCCAATCTCAACCCCTGGTGGGCTGGAGG 720
 661 ACTTGGGATGTGCAACATTAAGACATGCCAATCTCAACCCCTGGTGGGCTGGAGG 720
 721 AGCTGGAGTGTGAGGAAACCTTCCTGAGATCAGGCTGCTCTTCCATGGCCTGA 780
 721 AGCTGGAGTGTGAGGAAACCTTCCTGAGATCAGGCTGCTCTTCCATGGCCTGA 780
 781 GCTCCCTCAAGAGCTCTGGGCTCATGAATCAAGGTGAGCTGATTTGAGCGGAATGCTT 840

Db 781 GCTCCCTCAAGAGCTCTGGGTCATGAACCTCAAGGTGAGCTGATTTGAGCGGAATGCTT 840
 Qy 841 TTGACGGGCTGGCTTCACTTTGTGGAATCAACTTTGGCCCAATAAACCTCTCTTTTTC 900
 Db 841 TTGACGGGCTGGCTTCACTTTGTGGAATCAACTTTGGCCCAATAAACCTCTCTTTTTC 900
 Qy 901 CCCATGACCTCTTTTACCCCGCTGAGGTACCTGTGTGAGTTGCACTTACACCAACCTT 960
 Db 901 CCCATGACCTCTTTTACCCCGCTGAGGTACCTGTGTGAGTTGCACTTACACCAACCTT 960
 Qy 961 GGAACGTGTGATTTGACATTTCTGTGGCTAGCTTGTGGCTTTCGAGAGTATATACCA 1020
 Db 961 GGAACGTGTGATTTGACATTTCTGTGGCTAGCTTGTGGCTTTCGAGAGTATATACCA 1020
 Qy 1021 ATTCACCTCTGTGTGGCGCTGTCACTCTCCCAAGCAATGCGAGCGCTGCTGCTG 1080
 Db 1021 ATTCACCTCTGTGTGGCGCTGTCACTCTCCCAAGCAATGCGAGCGCTGCTGCTG 1080
 Qy 1081 AGGTGGACCAAGGCTCTCTTCCAGTGTCTGCCCCCTTCACTATGAGAGCACTTCA 1140
 Db 1081 AGGTGGACCAAGGCTCTCTTCCAGTGTCTGCCCCCTTCACTATGAGAGCACTTCA 1140
 Qy 1141 TCAACATTTCTGAGGGTCGGATGCGAGAACTTAAGTGTGCGACTCTCCCTTATGCTCC 1200
 Db 1141 TCAACATTTCTGAGGGTCGGATGCGAGAACTTAAGTGTGCGACTCTCCCTTATGCTCC 1200
 Qy 1201 TGAAGTGGTGTGCTGCCCAATGCGAGCACTGCTCAGCGCTCCCGCCACCAAGATCT 1260
 Db 1201 TGAAGTGGTGTGCTGCCCAATGCGAGCACTGCTCAGCGCTCCCGCCACCAAGATCT 1260
 Qy 1261 CTGTCTCTCAACGAGCGCACTTGAACCTTTTCCACGCTGTGCTTTTCAAGACACTT 1320
 Db 1261 CTGTCTCTCAACGAGCGCACTTGAACCTTTTCCACGCTGTGCTTTTCAAGACACTT 1320
 Qy 1321 ACATGCTATGCTGACCAATGTTGCGAGGCACTTCCAGCGCTCCCGCTTACCTCAAT 1380
 Db 1321 ACATGCTATGCTGACCAATGTTGCGAGGCACTTCCAGCGCTCCCGCTTACCTCAAT 1380
 Qy 1381 GCAGGCTGAGCTTAAACCTCCAACTTACAGCTTCTTCCACAGTAACAGTGGAGACCA 1440
 Db 1381 GCAGGCTGAGCTTAAACCTCCAACTTACAGCTTCTTCCACAGTAACAGTGGAGACCA 1440
 Qy 1441 CGGAGATCTCGCTGAGGACAAACCGGAAAGTACAGCTGTCTTCAACAGTCCACTG 1500
 Db 1441 CGGAGATCTCGCTGAGGACAAACCGGAAAGTACAGCTGTCTTCAACAGTCCACTG 1500
 Qy 1501 GTTACAGCGCGCATATACCACTTACCACTGCTGCTTCACTCAGACTACCCGTGCCCC 1560
 Db 1501 GTTACAGCGCGCATATACCACTTACCACTGCTGCTTCACTCAGACTACCCGTGCCCC 1560
 Qy 1561 AGCAGGTGGCAGTACCCGCGACAGACCACTCAAGATGACAGCCGCTGGATGAAG 1620
 Db 1561 AGCAGGTGGCAGTACCCGCGACAGACCACTCAAGATGACAGCCGCTGGATGAAG 1620
 Qy 1621 TCATGAAGACCAACAGATCATCTTGGCTGCTTGGCGAGTGACTCTGCTAGCTGCCG 1680
 Db 1621 TCATGAAGACCAACAGATCATCTTGGCTGCTTGGCGAGTGACTCTGCTAGCTGCCG 1680
 Qy 1681 CCATGTTGATTTCTTCTATAAACTTCTGTAAGCGGACCCAGCAGCGAGTACAGTCA 1740
 Db 1681 CCATGTTGATTTCTTCTATAAACTTCTGTAAGCGGACCCAGCAGCGAGTACAGTCA 1740
 Qy 1741 CCGCGCGGCTGTTGAGATTAATCCAGTGGACCAAGACATCCCGAGCAACATCCGAG 1800
 Db 1741 CCGCGCGGCTGTTGAGATTAATCCAGTGGACCAAGACATCCCGAGCAACATCCGAG 1800
 Qy 1801 CAGCAACAGCAGCTCCGTCCGCTGTATCAGGTGAGGGGCGAGTAGTGTGCCCAATTC 1860
 Db 1801 CAGCAACAGCAGCTCCGTCCGCTGTATCAGGTGAGGGGCGAGTAGTGTGCCCAATTC 1860
 Qy 1861 ATGACCAATATTAACCAACACTTCAACACAGCAATGCGGCGCTCTGAGCAAGAAACA 1920

1861	ATGACCHATTAACTACACACCTTACAAACAGCAGCATGGGGCCCACTGGACAGAAACA	1922
Db		
1921	GCCTGGGGAACCTCTGTGCACCCCAACAGTCACCACTATCTCTGAACCTTATATATTCAGA	1980
Qy		
1921	GCCTGGGGAACCTCTGTGCACCCCAACAGTCACCACTATCTCTGAACCTTATATATTCAGA	1980
Db		
1981	CCCATACCAAGGACAGGTACAGGAAACTCAATATAGTACCTCCCTCCCCCAAAAAACTTA	2040
Qy		
1981	CCCATACCAAGGACAGGTACAGGAAACTCAATATAGTACCTCCCTCCCCCAAAAAACTTA	2040
Db		
2041	TAAATGCAATAGAAATGCACACAAAGACAGCAACTTTTGTGTACAGATGGGGAGAGACTTT	2100
Qy		
2041	TAAATGCAATAGAAATGCACACAAAGACAGCAACTTTTGTGTACAGATGGGGAGAGACTTT	2100
Db		
2101	TCCTTTGTATATGCTTATATATTAAGTCTATGGCTGGTTTAAAAAAAACAGATATATTAA	2160
Qy		
2101	TCCTTTGTATATGCTTATATATTAAGTCTATGGCTGGTTTAAAAAAAACAGATATATTAA	2160
Db		
2161	AAITTTAAAGCAAAAAGTCAAAACA	2185
Qy		
2161	AAITTTAAAGCAAAAAGTCAAAACA	2185
Db		

RESULT 14

US-09-989-293A-228

Sequence 228, Application US/0989293A
Patent No. US20020177164A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kijavini, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
Acids Encoding the Same

FILE REFERENCE: P2730PIC66

CURRENT APPLICATION NUMBER: US/09/989,293A

CURRENT FILING DATE: 2001-11-20

PRIOR APPLICATION NUMBER: 60/049787

PRIOR FILING DATE: 1997-06-16

PRIOR APPLICATION NUMBER: 60/062250

PRIOR FILING DATE: 1997-10-17

PRIOR APPLICATION NUMBER: 60/065186

PRIOR FILING DATE: 1997-11-12

PRIOR APPLICATION NUMBER: 60/065311

PRIOR FILING DATE: 1997-11-13

PRIOR APPLICATION NUMBER: 60/066770

PRIOR FILING DATE: 1997-11-24

PRIOR APPLICATION NUMBER: 60/075945

PRIOR FILING DATE: 1998-02-25

PRIOR APPLICATION NUMBER: 60/078910

PRIOR FILING DATE: 1998-03-20

PRIOR APPLICATION NUMBER: 60/083322

PRIOR FILING DATE: 1998-04-28

PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02

PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 10; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTCTCTTTCCGAGGCAAAATCCAGGCGATGGTGAATTATGAACGTGCCACACCATGA 60
Db 1 GTTCTCTTTCCGAGGCAAAATCCAGGCGATGGTGAATTATGAACGTGCCACACCATGA 60

Qy 61 AGCTCTTGTGGCAGGTAACTGTGCACACCACTCGGAATGCCATCTCTGTCTCCCGTTGC 120
Db 61 AGCTCTTGTGGCAGGTAACTGTGCACACCACTCGGAATGCCATCTCTGTCTCCCGTTGC 120

Qy 121 TCTACCTCAGGCGGAGGTGTGATTTCTGTGTGACGACCATGCTGCTGCGGCTCAGCG 180
Db 121 TCTACCTCAGGCGGAGGTGTGATTTCTGTGTGACGACCATGCTGCTGCGGCTCAGCG 180

Qy 181 GGCCCCAGAACTGCCCTCCGTTTGTCTGTGAGTAAACAGTTTCAAGCAAGGTGGTGTGA 240
Db 181 GGCCCCAGAACTGCCCTCCGTTTGTCTGTGAGTAAACAGTTTCAAGCAAGGTGGTGTGA 240

Qy 241 CGGCGCGGGGCTCTCCGAGGTCCGCGAGGTATTCCTTCGAAACACCGGTAACCTCAACC 300
Db 241 CGGCGCGGGGCTCTCCGAGGTCCGCGAGGTATTCCTTCGAAACACCGGTAACCTCAACC 300

Qy 301 TCATGGAGAACCAATCCAGATGATCCAGGCGGACACCTTCGCGGACCTCCACACACCTGG 360
Db 301 TCATGGAGAACCAATCCAGATGATCCAGGCGGACACCTTCGCGGACCTCCACACACCTGG 360

Qy 361 AGTCTCTGCACTTGGCAGGAACTCCTCCGAGATTTGAGGTGGGGGCTTCAACGGCC 420
Db 361 AGTCTCTGCACTTGGCAGGAACTCCTCCGAGATTTGAGGTGGGGGCTTCAACGGCC 420

Qy 421 TGGCCAGCCTCAACACCTCGAGGTGTTCGAACTGGCTGACAGTCACTCCCTAGCGGG 480
Db 421 TGGCCAGCCTCAACACCTCGAGGTGTTCGAACTGGCTGACAGTCACTCCCTAGCGGG 480

Qy 481 CCTTTGAATACCTGTCCAAAGCTGCGGAGCTTGTGAGGGGCTTTCAACTCAAGTATCTGA 540
Db 481 CCTTTGAATACCTGTCCAAAGCTGCGGAGCTTGTGAGGGGCTTTCAACTCAAGTATCTGA 540

Qy 541 TCCCTCTTTACGCTTCAACCGGGTCCCTCCCTCATCGCGCTGGACTTGGGGGAGCTCA 600
Db 541 TCCCTCTTTACGCTTCAACCGGGTCCCTCCCTCATCGCGCTGGACTTGGGGGAGCTCA 600

Qy 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGGAGGGGCTTTCAACTCAAGTATCTGA 660
Db 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGGAGGGGCTTTCAACTCAAGTATCTGA 660

Qy 661 ACTTGGGCACTGTGCAACATTAAGACATGCCCAATCTCACCCCTCCCTGGTGGGGCTGAGG 720
Db 661 ACTTGGGCACTGTGCAACATTAAGACATGCCCAATCTCACCCCTCCCTGGTGGGGCTGAGG 720

Qy 721 AGCTGAGATGTGAGGAACTCACTTCCCTGAGATCAGGCTTGGCTCTTCCATGCGCTGA 780
Db 721 AGCTGAGATGTGAGGAACTCACTTCCCTGAGATCAGGCTTGGCTCTTCCATGCGCTGA 780

Qy 781 GCTCCCTCAAGAGCTCTGGGTCAATGAATCAGAGGTGAGGCTTGAAGAGGAAATGCTT 840
Db 781 GCTCCCTCAAGAGCTCTGGGTCAATGAATCAGAGGTGAGGCTTGAAGAGGAAATGCTT 840

Qy 841 TTGACGGGCTGGCTTCACTTGTGGAATCAACTTTGGGCCCAATAACTCTCTCTCTTTCG 900
Db 841 TTGACGGGCTGGCTTCACTTGTGGAATCAACTTTGGGCCCAATAACTCTCTCTCTTTCG 900

Qy 901 CCATGACCTCTTTTACCCCGCTGAGGTACCTGGTGGAGTTGCATCTACACCAACACCTT 960
Db 901 CCATGACCTCTTTTACCCCGCTGAGGTACCTGGTGGAGTTGCATCTACACCAACACCTT 960

PRIOR FILING DATE: 1998-06-02	PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03	PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04	PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04	PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04	PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04	PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04	PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04	PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04	PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04	PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05	PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05	PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05	PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05	PRIOR APPLICATION NUMBER: 60/088555
PRIOR FILING DATE: 1998-06-09	PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10	PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10	PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10	PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10	PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10	PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10	PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11	PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11	PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11	PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12	PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16	PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16	PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16	PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17	PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17	PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17	PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17	PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17	PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17	PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17	PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17	PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18	PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18	PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18	PRIOR APPLICATION NUMBER: 60/089908

1	PRIOR APPLICATION NUMBER: 60/089947	
2	PRIOR FILING DATE: 1998-06-19	
3	PRIOR APPLICATION NUMBER: 60/089948	
4	PRIOR FILING DATE: 1998-06-19	
5	PRIOR APPLICATION NUMBER: 60/089952	
6	PRIOR FILING DATE: 1998-06-19	
7	PRIOR APPLICATION NUMBER: 60/090246	
8	PRIOR FILING DATE: 1998-06-22	
9	PRIOR APPLICATION NUMBER: 60/090252	
10	PRIOR FILING DATE: 1998-06-22	
11	PRIOR APPLICATION NUMBER: 60/090254	
12	PRIOR FILING DATE: 1998-06-22	
13	PRIOR APPLICATION NUMBER: 60/090349	
14	PRIOR FILING DATE: 1998-06-23	
15	PRIOR APPLICATION NUMBER: 60/090355	
16	PRIOR FILING DATE: 1998-06-23	
17	PRIOR APPLICATION NUMBER: 60/090429	
18	PRIOR FILING DATE: 1998-06-24	
19	PRIOR APPLICATION NUMBER: 60/090431	
20	PRIOR FILING DATE: 1998-06-24	
21	PRIOR APPLICATION NUMBER: 60/090435	
22	PRIOR FILING DATE: 1998-06-24	
23	PRIOR APPLICATION NUMBER: 60/090444	
24	PRIOR FILING DATE: 1998-06-24	
25	PRIOR APPLICATION NUMBER: 60/090445	
26	PRIOR FILING DATE: 1998-06-24	
27	PRIOR APPLICATION NUMBER: 60/090472	
28	PRIOR FILING DATE: 1998-06-24	
29	PRIOR APPLICATION NUMBER: 60/090557	
30	PRIOR FILING DATE: 1998-06-24	
31	PRIOR APPLICATION NUMBER: 60/090535	
32	PRIOR FILING DATE: 1998-06-24	
33	PRIOR APPLICATION NUMBER: 60/090540	
34	PRIOR FILING DATE: 1998-06-24	
35	PRIOR APPLICATION NUMBER: 60/090542	
36	PRIOR FILING DATE: 1998-06-24	
37	PRIOR APPLICATION NUMBER: 60/090690	
38	PRIOR FILING DATE: 1998-06-25	
39	PRIOR APPLICATION NUMBER: 60/090694	
40	PRIOR FILING DATE: 1998-06-25	
41	PRIOR APPLICATION NUMBER: 60/090695	
42	PRIOR FILING DATE: 1998-06-25	
43	PRIOR APPLICATION NUMBER: 60/090696	
44	PRIOR FILING DATE: 1998-06-25	
45	PRIOR APPLICATION NUMBER: 60/090862	
46	PRIOR FILING DATE: 1998-06-26	
47	PRIOR APPLICATION NUMBER: 60/090863	
48	PRIOR FILING DATE: 1998-06-26	
49	PRIOR APPLICATION NUMBER: 60/091344	
50	PRIOR FILING DATE: 1998-07-01	
51	PRIOR APPLICATION NUMBER: 60/091359	
52	PRIOR FILING DATE: 1998-07-02	
53	PRIOR APPLICATION NUMBER: 60/091633	
54	PRIOR FILING DATE: 1998-07-02	
55	PRIOR APPLICATION NUMBER: 60/091778	
56	PRIOR FILING DATE: 1998-07-07	
57	PRIOR APPLICATION NUMBER: 60/091822	
58	PRIOR FILING DATE: 1998-07-07	
59	PRIOR APPLICATION NUMBER: 60/092182	
60	PRIOR FILING DATE: 1998-07-09	

Query Match	100.0%;	Score 2185;	DB 10;	Length 2185;
Best Local Similarity	100.0%;	Pred. No. 0;		

Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	GTCTCTCCGAGCCAAATCCAGCGAGAGGTGAATTATGAACGTGCCACCATGA	60
DB	1	GTCTCTCCGAGCCAAATCCAGCGAGAGGTGAATTATGAACGTGCCACCATGA	60
QY	61	AGCTCTGTGGCAGGTAACTGTGCACACACACACCTGGGAATGCATCTCCCGTTCG	120
DB	61	AGCTCTGTGGCAGGTAACTGTGCACACACACACCTGGGAATGCATCTCCCGTTCG	120
QY	121	TCTACCTCACGGCGCAAGTGTGATCTGTGTGCAGCCATCGTGTGCGGCTCAGCG	180
DB	121	TCTACCTCACGGCGCAAGTGTGATCTGTGTGCAGCCATCGTGTGCGGCTCAGCG	180
QY	181	GGCCCGAGAACTGCGCTCCCTTGTCTGTGCTGAGTAACTGAGTGTGCTGCA	240
DB	181	GGCCCGAGAACTGCGCTCCCTTGTCTGTGCTGAGTAACTGAGTGTGCTGCA	240
QY	241	CGCGCCGGGCTCTCCGAGGTCCCGAGGATATTCCTCGAAACACCGGTACTCAAC	300
DB	241	CGCGCCGGGCTCTCCGAGGTCCCGAGGATATTCCTCGAAACACCGGTACTCAAC	300
QY	301	TCATGGAGAACATCAGATGATCAGGCGGAGACCTTCGCGCACTCCACACTGG	360
DB	301	TCATGGAGAACATCAGATGATCAGGCGGAGACCTTCGCGCACTCCACACTGG	360
QY	361	AGTCTCTGAGTGGGAGGAACTCCATCCGCGAGATGAGGTGGGGCTTCAACGGCC	420
DB	361	AGTCTCTGAGTGGGAGGAACTCCATCCGCGAGATGAGGTGGGGCTTCAACGGCC	420
QY	421	TGGCCAGCTCAACACCTGAGCTGTGTGACAACTGAGTGAAGTCACTCCCTAGCGGG	480
DB	421	TGGCCAGCTCAACACCTGAGCTGTGTGACAACTGAGTGAAGTCACTCCCTAGCGGG	480
QY	481	CTTTGGAATACCTCCAGCTGGGAGCTCTGGCTTGCACAAACCCCATCGAAGCA	540
DB	481	CTTTGGAATACCTCCAGCTGGGAGCTCTGGCTTGCACAAACCCCATCGAAGCA	540
QY	541	TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTGGAGCTCA	600
DB	541	TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTGGAGCTCA	600
QY	601	AGAGCTGGAGTATCTGAGGGAGCTTTGAGGGGCTTTCAACCTCAAGTACTGA	660
DB	601	AGAGCTGGAGTATCTGAGGGAGCTTTGAGGGGCTTTCAACCTCAAGTACTGA	660
QY	661	ACTTGGGCTATGCAACATTAAGACATGCCAAATCTCACCCCTGGTGGGCTGAGG	720
DB	661	ACTTGGGCTATGCAACATTAAGACATGCCAAATCTCACCCCTGGTGGGCTGAGG	720
QY	721	AGCTGGAGATGTCAGGAAACATCTCCCTGAGATCAGGCTGGCTCTCCATGGCTGA	780
DB	721	AGCTGGAGATGTCAGGAAACATCTCCCTGAGATCAGGCTGGCTCTCCATGGCTGA	780
QY	781	GCTCCCTCAAGAGCTCTGGGTATGAATCAACAGGTGAGCTGATGAGCGGAATGCTT	840
DB	781	GCTCCCTCAAGAGCTCTGGGTATGAATCAACAGGTGAGCTGATGAGCGGAATGCTT	840
QY	841	TTGACGGGCTGGCTTCACTTGTGAACTCAACTTGGGCCCAATTAACCTCTCTTTTTC	900
DB	841	TTGACGGGCTGGCTTCACTTGTGAACTCAACTTGGGCCCAATTAACCTCTCTTTTTC	900
QY	901	CCCATGACCTTTTACCCCGCTGAGTACCTGGTGGAGTTGCATCTACACCAACCCCTT	960
DB	901	CCCATGACCTTTTACCCCGCTGAGTACCTGGTGGAGTTGCATCTACACCAACCCCTT	960
QY	961	GGAACTGTGATGTGACATCTGTGGCTAGCTGTGGCTTCGAGAGTATACCCACCA	1020
DB	961	GGAACTGTGATGTGACATCTGTGGCTAGCTGTGGCTTCGAGAGTATACCCACCA	1020
QY	1021	ATTCACCTGTGGGCTGTGATCTCCCATGACATGCGAGGCCCTACCTCGTGG	1080
DB	1021	ATTCACCTGTGGGCTGTGATCTCCCATGACATGCGAGGCCCTACCTCGTGG	1080

QY	1081	AGTGGACCGAGGCTCTTCCAGTGTCTGCCCCCTTCATCATGAGCGACCTTCGAGACC	1140
DB	1081	AGTGGACCGAGGCTCTTCCAGTGTCTGCCCCCTTCATCATGAGCGACCTTCGAGACC	1140
QY	1141	TCACATTTCTGAGGTCGATGCGAGAACTTAAGTGTGAGCTCCCTTATCTCTCCG	1200
DB	1141	TCACATTTCTGAGGTCGATGCGAGAACTTAAGTGTGAGCTCCCTTATCTCTCCG	1200
QY	1201	TGAAGTGTGTGCTGCCCAATGGGACAGTGTCTAGCGACGCTCCCGCACCCAGGATCT	1260
DB	1201	TGAAGTGTGTGCTGCCCAATGGGACAGTGTCTAGCGACGCTCCCGCACCCAGGATCT	1260
QY	1261	CTGTCTCTCAAGCGGACCTTGAATTTTCCAGCTGTCTTCAGACACTCTGGGTGT	1320
DB	1261	CTGTCTCTCAAGCGGACCTTGAATTTTCCAGCTGTCTTCAGACACTCTGGGTGT	1320
QY	1321	ACACATGATCTGCTGTGAGGACCAATGTTTCCAGGCAACTCCAAAGCTCCGCTACCTCAATGTGA	1380
DB	1321	ACACATGATCTGCTGTGAGGACCAATGTTTCCAGGCAACTCCAAAGCTCCGCTACCTCAATGTGA	1380
QY	1381	GCACGCTGTGCTTAAACACCTCCAACTACAGCTTCTTCCACAGTAAAGTGGAGACCA	1440
DB	1381	GCACGCTGTGCTTAAACACCTCCAACTACAGCTTCTTCCACAGTAAAGTGGAGACCA	1440
QY	1441	CGAGATCTGCTGTGAGGACCAACGCGAAAGTAAAGCTTCTTACCACTCCACTG	1500
DB	1441	CGAGATCTGCTGTGAGGACCAACGCGAAAGTAAAGCTTCTTACCACTCCACTG	1500
QY	1501	GTTACACCGGCTATATACACCTTACACGCTGCTTCTTACAGCTACCGTGGCCCA	1560
DB	1501	GTTACACCGGCTATATACACCTTACACGCTGCTTCTTACAGCTACCGTGGCCCA	1560
QY	1561	AGCAGTGGCAGTACCGCGACAGACCACTGACAAAGTAAAGCTTCTTACCACTCCACTG	1620
DB	1561	AGCAGTGGCAGTACCGCGACAGACCACTGACAAAGTAAAGCTTCTTACCACTCCACTG	1620
QY	1621	TCATGAAAGCAACCAAGATCATTTGGCTGCTTGTGGCGTGTGCTTGTAGCTGGCG	1680
DB	1621	TCATGAAAGCAACCAAGATCATTTGGCTGCTTGTGGCGTGTGCTTGTAGCTGGCG	1680
QY	1681	CCATGTTGATGCTTCTTATAAACTTCTGAAGCGGACCAAGCAGCGAGTACAGTCAACAG	1740
DB	1681	CCATGTTGATGCTTCTTATAAACTTCTGAAGCGGACCAAGCAGCGAGTACAGTCAACAG	1740
QY	1741	CCGCCCCGACTGTTGAGATAATCCAGTGGACGAGACATCCAGCAGCAACATCCGCGAG	1800
DB	1741	CCGCCCCGACTGTTGAGATAATCCAGTGGACGAGACATCCAGCAGCAACATCCGCGAG	1800
QY	1801	CAGCAACAGCAGCTCCGTCGGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCACAATTC	1860
DB	1801	CAGCAACAGCAGCTCCGTCGGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCACAATTC	1860
QY	1861	ATGACCATATTAACCTACCAACCTTCAAAACAGCACAATGGGGCCCTCGACAGAAAAACA	1920
DB	1861	ATGACCATATTAACCTACCAACCTTCAAAACAGCACAATGGGGCCCTCGACAGAAAAACA	1920
QY	1921	GCCTGGGAGTCTCTGACCCCGAGTACACTTCTTCTGAACTTATATTAATTCAG	1980
DB	1921	GCCTGGGAGTCTCTGACCCCGAGTACACTTCTTCTGAACTTATATTAATTCAG	1980
QY	1981	CCCATACCAAGGACAGGTACAGGAACTCAAAATATGACTCCCTCCCGCAAAAACTTA	2040
DB	1981	CCCATACCAAGGACAGGTACAGGAACTCAAAATATGACTCCCTCCCGCAAAAACTTA	2040
QY	2041	TAAATGCAATGAGATGCAACAAAGCAGCAACTTTTGTACAGAGTGGGAGACTTT	2100
DB	2041	TAAATGCAATGAGATGCAACAAAGCAGCAACTTTTGTACAGAGTGGGAGACTTT	2100
QY	2101	TTCTTGTATGCTTATATTAATTAAGTCTATGGCTGTTGTTAAAAAACAAGATTATTA	2160
DB	2101	TTCTTGTATGCTTATATTAATTAAGTCTATGGCTGTTGTTAAAAAACAAGATTATTA	2160

Y 2161 AATTAAAGACAAAAGTCAAAACA 2185
|||||
b 2161 AATTAAAGACAAAAGTCAAAACA 2185

RESULT 16

IS-09-990-444-228
Sequence 228, Application US/09990444
Publication No. US20020193300A1
GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary B.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730PIC19
CURRENT APPLICATION NUMBER: US/09/990,444
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04

APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary B.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin

PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252

1	PRIOR FILING DATE: 1998-06-22	QY	121	TCTACCTCAGCGGCGCAGTGTGGATTCTGTGTGAGCCATCGCTGTGCTGCGCCCTCAGCGC	180
1	PRIOR APPLICATION NUMBER: 60/090254	Db	121		180
1	PRIOR FILING DATE: 1998-06-22	QY	181	GSCTCCAGAACTGCCCCCTCGCTTTGCTGCTGCAAGTAAACAGTTTTCAGCAAGTGTGTGCA	240
1	PRIOR APPLICATION NUMBER: 60/090355	Db	181		240
1	PRIOR FILING DATE: 1998-06-23	QY	241	CGCGCGGGGCTCTCCGAGTCCCGAGGGTATTCCTCGAACACCGGGTACTCAACC	300
1	PRIOR APPLICATION NUMBER: 60/090431	Db	241		300
1	PRIOR FILING DATE: 1998-06-24	QY	301	TCATGGAGAACAACTCCAGATGATCCAGGCGGACACTTCCGCGACCTCCACACCTGG	360
1	PRIOR APPLICATION NUMBER: 60/090435	Db	301		360
1	PRIOR FILING DATE: 1998-06-24	QY	361	AGTCTCTGAGTGTGGGCGGAACTTCATTCGGCGAGATTGAGTGGGGGCTTCAACGGCC	420
1	PRIOR APPLICATION NUMBER: 60/090444	Db	361		420
1	PRIOR FILING DATE: 1998-06-24	QY	421	TGGCAGGCTCAACACCTCGAGCTGTTCCAGCAACTGGCTGACAGTCACTCCCTAGCGGG	480
1	PRIOR APPLICATION NUMBER: 60/090540	Db	421		480
1	PRIOR FILING DATE: 1998-06-24	QY	481	CCTTGAATACCTCTCAAGTGTGGGAGTCTGGCTTCCGCAACACCCCATCGAAAGCA	540
1	PRIOR APPLICATION NUMBER: 60/090557	Db	481		540
1	PRIOR FILING DATE: 1998-06-24	QY	541	TCCCTCTTACGCTTCAACCGGCTGCTCCCTCATGCGGCTTGGAGTGGGGGAGCTCA	600
1	PRIOR APPLICATION NUMBER: 60/090678	Db	541		600
1	PRIOR FILING DATE: 1998-06-25	QY	601	AGAGCTGGAGTATCTCTGAGGAGCTTTTGAAGGGCTGTTTCAACCTCAAGTATCTGA	660
1	PRIOR APPLICATION NUMBER: 60/090690	Db	601		660
1	PRIOR FILING DATE: 1998-06-25	QY	661	ACTTGGGATGTGCAACATTAAGACATGCCATCTCACCCCTGCTGGTGGGGCTGAGG	720
1	PRIOR APPLICATION NUMBER: 60/090694	Db	661		720
1	PRIOR FILING DATE: 1998-06-25	QY	721	AGCTGGAGATGTCAAGGAACTTCCCTGAGATCAGGCTGGCTCTTCCATGGGCTGA	780
1	PRIOR APPLICATION NUMBER: 60/090862	Db	721		780
1	PRIOR FILING DATE: 1998-06-26	QY	781	GCTCCCTCAGAGCTCTGGGTCACTGAACTCAGGTCAGGCTGATGAGCGGAATGCTT	840
1	PRIOR APPLICATION NUMBER: 60/091478	Db	781		840
1	PRIOR FILING DATE: 1998-07-02	QY	841	TTGACGGGCTGGCTTCACTTGTGAACTCAACTTGGCCCAATAAACCCTCTCTTTTC	900
1	PRIOR APPLICATION NUMBER: 60/091519	Db	841		900
1	PRIOR FILING DATE: 1998-07-02	QY	901	CCCATGACCTCTTACCCCGCTGAGGTACCTGGTGGAGTGGCATCTACACCAACCCCTT	960
1	PRIOR APPLICATION NUMBER: 60/091626	Db	901		960
1	PRIOR FILING DATE: 1998-07-02	QY	961	GAACTGTGATTTGACATTTCTGTGGCTAGCTGGTGGCTTCCGAGAGTATATACCAACA	1020
1	PRIOR APPLICATION NUMBER: 60/091633	Db	961		1020
1	PRIOR FILING DATE: 1998-07-07	QY	1021	ATTCACCTGCTGGGCGCTCTCCAGTGTCTGCCCCCTTTCATGAGGAGGCGGCTACTCTGG	1080
1	PRIOR APPLICATION NUMBER: 60/091978	Db	1021		1080
1	PRIOR FILING DATE: 1998-07-07	QY	1081	AGTGGACCAAGGCTCTCTCCAGTGTCTGCCCCCTTTCATGAGGAGGCGGCTACTCTGG	1140
1	PRIOR APPLICATION NUMBER: 60/091982	Db	1081		1140
1	PRIOR FILING DATE: 1998-07-07	QY	1141	TCAACATTTCTGAGGTCGATGCGAGAACTTAAGTGTGGAGTCTCCCCCTTATCTCTCG	1200
1	PRIOR APPLICATION NUMBER: 60/092182	Db	1141		1200

Query Match 100.0%; Score 2185; DB 10; Length 2185;
Sest Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

2y	1	GTTCTCTTCCGAGCCAAATCCAGCGATGGTGAATTAAGAGTGGCCACCATCA	60
Db	1	GTTCTCTTCCGAGCAAAATCCAGCGATGGTGAATTAAGAGTGGCCACCATCA	60
2y	61	AGCTCTGTGGCAGGTAACCTGTGACCAACACACCTGGAATGCCATCTCTCCCGTTGG	120
Db	61	AGCTCTGTGGCAGGTAACCTGTGACCAACACACCTGGAATGCCATCTCTCCCGTTGG	120

1201	TGAAGTGGTGTGTCGCCCAATGGGACAGTGTCTCAGCCACGGCTCCGGCACCCCAAGGATCT	1261
1201	TGAAGTGGTGTGTCGCCCAATGGGACAGTGTCTCAGCCACGGCTCCGGCACCCCAAGGATCT	1260
1261	CTGTCTCTCAACGACGGCACCTTGAACCTTTCCACAGTCTGCTTTTCCAGACACTGGGGTGT	1320
1261	CTGTCTCTCAACGACGGCACCTTGAACCTTTCCACAGTCTGCTTTTCCAGACACTGGGGTGT	1320
1321	ACACATGCAATGGTGACCAATGTTGACGGCAACTCCACGGCTTCGGGCTTACCTCAATGTGA	1380
1321	ACACATGCAATGGTGACCAATGTTGACGGCAACTCCACGGCTTCGGGCTTACCTCAATGTGA	1380
1381	GCACGGCTGAGCTTAAACACTCCAACTACAGCTTCTTCCACCACTAGTAACAGTGGAGACCA	1440
1381	GCACGGCTGAGCTTAAACACTCCAACTACAGCTTCTTCCACCACTAGTAACAGTGGAGACCA	1440
1441	CGGAGATCTCGCTGAGGACACAACGGGAAGTAGACGCTTTCCTTACCACTGCTCACTG	1500
1441	CGGAGATCTCGCTGAGGACACAACGGGAAGTAGACGCTTTCCTTACCACTGCTCACTG	1500
1501	GTATACAGCCGGCATATACCACTCTACCAAGTGTCTCAATTCAGACTACCGGTGTGCCCA	1560
1501	GTATACAGCCGGCATATACCACTCTACCAAGTGTCTCAATTCAGACTACCGGTGTGCCCA	1560
1561	AGCAGTGGCAGTACCCGGGACAGACACAATGACAGATCGACAGCCAGCCTGATGAAG	1620
1561	AGCAGTGGCAGTACCCGGGACAGACACAATGACAGATCGACAGCCAGCCTGATGAAG	1620
1621	TCATGAAGACCAACCAAGATCATCTATGGCTGCTTTGTGGCAGTGCATCTGCTAGCTCCCG	1680
1621	TCATGAAGACCAACCAAGATCATCTATGGCTGCTTTGTGGCAGTGCATCTGCTAGCTCCCG	1680
1681	CCATGTTGATGTCTTCTATAAAGTCTGTAAAGCGGCACAGCAGCGAGTACAGTCAACAG	1740
1681	CCATGTTGATGTCTTCTATAAAGTCTGTAAAGCGGCACAGCAGCGAGTACAGTCAACAG	1740
1741	CCGCCCGGACTGTTGAGATTAATCAGGTGGACGAAGACATCCACAGCAGCAACATCCGCGAG	1800
1741	CCGCCCGGACTGTTGAGATTAATCAGGTGGACGAAGACATCCACAGCAGCAACATCCGCGAG	1800
1801	CAGCAACACGACTCGCTCCGGTGATCAGGTGAGGGGCGAGTAGTGTCTGCCCAAAATTC	1860
1801	CAGCAACACGACTCGCTCCGGTGATCAGGTGAGGGGCGAGTAGTGTCTGCCCAAAATTC	1860
1861	ATGACCAATATTAACTACAAACACTCAAAACACAGCACATGGGGGCCACTGGACAGAAAACA	1920
1861	ATGACCAATATTAACTACAAACACTCAAAACACAGCACATGGGGGCCACTGGACAGAAAACA	1920
1921	GCCTGGGAACTCTCTGCAACCCCAAGTCAACATCTCTGGAACCTTATATATTAATTCAGA	1980
1921	GCCTGGGAACTCTCTGCAACCCCAAGTCAACATCTCTGGAACCTTATATATTAATTCAGA	1980
1981	CCCATACCAAGACAGGTACAGGAAAATCAAAATATGACTCCCTCCCTCCCCCAAAAACCTTA	2040
1981	CCCATACCAAGACAGGTACAGGAAAATCAAAATATGACTCCCTCCCTCCCCCAAAAACCTTA	2040
2041	TAAAAATGCAATGAATGCAACAAAGACAGCAACTTTTGTACAGAGTGGGGAGAGACTTTT	2100
2041	TAAAAATGCAATGAATGCAACAAAGACAGCAACTTTTGTACAGAGTGGGGAGAGACTTTT	2100
2101	TTCTTCTATATCTTATATATTAATTAAGTCTATGGCTGGTTAAATAAAACAGATATTATTA	2160
2101	TTCTTCTATATCTTATATATTAATTAAGTCTATGGCTGGTTAAATAAAACAGATATTATTA	2160
2161	AAATTTAAAGACAAAAGTCAAAACA	2185
2161	AAATTTAAAGACAAAAGTCAAAACA	2185

ESULT 17

3-09-993-181-228

3-09-991-181-228
Sequence 228, Application US/09991181

Sequence 228, Application US/US
Publication No. US20020197615A1

; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088167
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088202
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088212
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088217
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088655
 ; PRIOR FILING DATE: 1998-06-09
 ; PRIOR APPLICATION NUMBER: 60/088734
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088738
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088742
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088810
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088824
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088826
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088858
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/088861
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/088876
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/089105
 ; PRIOR FILING DATE: 1998-06-12
 ; PRIOR APPLICATION NUMBER: 60/089440
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089512
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089514
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089532
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089538
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089598
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089599
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089600
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089653
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089801
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089907
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089908
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089947
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089948
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089952
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/090246
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090252
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090254
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090349
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090355
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090429
 ; PRIOR FILING DATE: 1998-06-24

; PRIOR APPLICATION NUMBER: 60/090431
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090435
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090444
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090445
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090472
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090535
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090540
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090542
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090557
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090676
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090678
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090690
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090694
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090695
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 10; Length 2185;

Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTCTCTTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAACGTGCCACCAATGA 60
 |||||
 Db 1 GTTCTCTTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAACGTGCCACCAATGA 60
 |||||
 QY 61 AGCTTTGTGCGAGGTAACTGTGCACACACACCTGGAATGCCATCTGCTCCGTTGG 120
 |||||
 Db 61 AGCTTTGTGCGAGGTAACTGTGCACACACACCTGGAATGCCATCTGCTCCGTTGG 120
 |||||
 QY 121 TCTACTCTACGCGCAAGTGTGGATTCTGTGTGAGCCATCGCTGCTCCGCTTCAGCCG 180
 |||||
 Db 121 TCTACTCTACGCGCAAGTGTGGATTCTGTGTGAGCCATCGCTGCTCCGCTTCAGCCG 180
 |||||
 QY 181 GCGCCCGAAGTGCCTCCCTCCCTTTGCTGCTGCAATACCACTTACAGAGTGTGTGCA 240
 |||||
 Db 181 GCGCCCGAAGTGCCTCCCTCCCTTTGCTGCTGCAATACCACTTACAGAGTGTGTGCA 240
 |||||

241 CGCGCGGGGCTCTCGAGGTCCCGAGGTTATCCCTCGAACCACCGGTACCTCAACC 300
b CGCGCGGGGCTCTCGAGGTCCCGAGGTTATCCCTCGAACCACCGGTACCTCAACC 300
301 TCATGAGAACAAATCCAGATGATCCAGGCGAGCACTTCGCGCACTCCACACCTGG 360
b TCATGAGAACAAATCCAGATGATCCAGGCGAGCACTTCGCGCACTCCACACCTGG 360
361 AGGTCTCGAGTTGGGCGAGCACTCCAGGCGAGCACTTCGAGGTGGGGGCTTCACAGGCC 420
b AGGTCTCGAGTTGGGCGAGCACTCCAGGCGAGCACTTCGAGGTGGGGGCTTCACAGGCC 420
421 TGSCCAGGCTCAACACCTTCGAGGTGTTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480
b TGSCCAGGCTCAACACCTTCGAGGTGTTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480
481 CCTTTGAATACCTGTTCCAGGCTGGGAGCTCTGGCTTCGCAACAACTCCATCGAAGCA 540
b CCTTTGAATACCTGTTCCAGGCTGGGAGCTCTGGCTTCGCAACAACTCCATCGAAGCA 540
541 TCCCTCTTACGCTTCAACCGGCTGCGCTCCCTCATGCGCTGGACTTGGGGGAGCTCA 600
b TCCCTCTTACGCTTCAACCGGCTGCGCTCCCTCATGCGCTGGACTTGGGGGAGCTCA 600
601 AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGGGGGCTTTTGAAGCTCAAGTATCTGA 660
b AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGGGGGCTTTTGAAGCTCAAGTATCTGA 660
661 ACTTGGGCTGTCAGCACTTAAAGACATCCCAATCTCAACCGCTGGTGGGCTGGAGG 720
b ACTTGGGCTGTCAGCACTTAAAGACATCCCAATCTCAACCGCTGGTGGGCTGGAGG 720
721 AGCTGAGATGTCAGGAAACCACTTCCCTGAGATCAGGCTGGCTTCCCTCAATGGCCTGA 780
b AGCTGAGATGTCAGGAAACCACTTCCCTGAGATCAGGCTGGCTTCCCTCAATGGCCTGA 780
781 GCTCCCTCAAGAGCTCTGGGCTCACTGATCAGCTCAGCTGAGCTGATTCAGCGGAGTCT 840
b GCTCCCTCAAGAGCTCTGGGCTCACTGATCAGCTCAGCTGAGCTGATTCAGCGGAGTCT 840
841 TTGACGGGCTGGCTTCACTTGTGAACTCAAATGGGCTCCCAATTAACCTCTCTCTTTCG 900
b TTGACGGGCTGGCTTCACTTGTGAACTCAAATGGGCTCCCAATTAACCTCTCTCTTTCG 900
901 CCATGACCTCTTACCGCTGAGTACCTGGTGGGCTGGCTGATCTACACACACACCTTT 960
b CCATGACCTCTTACCGCTGAGTACCTGGTGGGCTGGCTGATCTACACACACACCTTT 960
961 GGAACCTGATGTCGATCTCTGCTAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1020
b GGAACCTGATGTCGATCTCTGCTAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1020
1021 ATTCCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1080
b ATTCCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1080
1081 AGGTGACACAGGCTCTCTTCCAGTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140
b AGGTGACACAGGCTCTCTTCCAGTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1140
1141 TCACATTTCTGAGGTGCTGAGTGAAGCTTAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1200
b TCACATTTCTGAGGTGCTGAGTGAAGCTTAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1200
1201 TGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1260
b TGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1260
1261 CTGTCTCAACGAGCACTTTGAAGCTTTTCCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1320
b CTGTCTCAACGAGCACTTTGAAGCTTTTCCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1320
1321 ACATGTCATGCTGACCAATGTTGAGGCACTTCCCAACCGCTGCGGCTACCTCAATGTA 1380

Db ACATGTCATGCTGACCAATGTTGAGGCAACTCCAAACCGCTGCGCTACCTCAATGTA 1380
Qy GCAAGCTGAGCTTAACTACCTCAACTAGCTTCTTCAACAGCTGAGTGAAGCA 1440
Db GCAAGCTGAGCTTAACTACCTCAACTAGCTTCTTCAACAGCTGAGTGAAGCA 1440
Qy CGAGATCTCGCTGAGGACACAAACCGGAAAGTCAAGCTTCTTCAACAGCTGAGTGA 1500
Db CGAGATCTCGCTGAGGACACAAACCGGAAAGTCAAGCTTCTTCAACAGCTGAGTGA 1500
Qy GTTACAGCGGCTATATACCACTCTTCAACAGCTGAGTGAAGTCAAGCTGAGTGA 1560
Db GTTACAGCGGCTATATACCACTCTTCAACAGCTGAGTGAAGTCAAGCTGAGTGA 1560
Qy AGCAGTGGAGTACCCGCGGACAGCACTTCAAGTGAAGTCAAGCTGAGTGAAGTGA 1620
Db AGCAGTGGAGTACCCGCGGACAGCACTTCAAGTGAAGTCAAGCTGAGTGAAGTGA 1620
Qy TCATGAGAACCAACAGATCATCTTGGCTGCTTGGTGGAGTGAAGTCAAGCTGAGTGA 1680
Db TCATGAGAACCAACAGATCATCTTGGCTGCTTGGTGGAGTGAAGTCAAGCTGAGTGA 1680
Qy CCATGTTGATGTTCTTCTATAAACTTCAAGCTGAGTGAAGTCAAGCTGAGTGA 1740
Db CCATGTTGATGTTCTTCTATAAACTTCAAGCTGAGTGAAGTCAAGCTGAGTGA 1740
Qy CGCCCGGCTGTTGAGTAAATCCAGGCTGAGTGAAGTCAAGCTGAGTGAAGTGA 1800
Db CGCCCGGCTGTTGAGTAAATCCAGGCTGAGTGAAGTCAAGCTGAGTGAAGTGA 1800
Qy CAGCAACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1860
Db CAGCAACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1860
Qy ATGACCATATTAATCAACACCTTCAACAGCTGAGTGAAGTCAAGCTGAGTGAAGTGA 1920
Db ATGACCATATTAATCAACACCTTCAACAGCTGAGTGAAGTCAAGCTGAGTGAAGTGA 1920
Qy GCTGCGGAGCTCTGCGACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1980
Db GCTGCGGAGCTCTGCGACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1980
Qy CCATACCAAGGACAGTACAGGAACTCAAAATGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2040
Db CCATACCAAGGACAGTACAGGAACTCAAAATGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2040
Qy TAAATGCAATGAGTGAAGTCAACAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGA 2100
Db TAAATGCAATGAGTGAAGTCAACAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGA 2100
Qy TTCTGCTATATGCTTAT 2160
Db TTCTGCTATATGCTTAT 2160
Qy AATTTAAAGCAAAAGTCAAAACA 2185
Db AATTTAAAGCAAAAGTCAAAACA 2185

RESULT 18

US-09-989-730-228
; Sequence 228, Application US/09989730
; Publication No. US20020197674A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Deonoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter

APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas P.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C69
CURRENT APPLICATION NUMBER: US/09/989,730
CURRENT FILING DATE: 2001-11-20
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-15
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-25

Prior Filing Date: 1998-06-24
 Prior Application Number: 60/090535
 Prior Filing Date: 1998-06-24
 Prior Application Number: 60/090540
 Prior Filing Date: 1998-06-24
 Prior Application Number: 60/090542
 Prior Filing Date: 1998-06-24
 Prior Application Number: 60/090557
 Prior Filing Date: 1998-06-24
 Prior Application Number: 60/090576
 Prior Filing Date: 1998-06-25
 Prior Application Number: 60/090678
 Prior Filing Date: 1998-06-25
 Prior Application Number: 60/090690
 Prior Filing Date: 1998-06-25
 Prior Application Number: 60/090694
 Prior Filing Date: 1998-06-25
 Prior Application Number: 60/090695
 Prior Filing Date: 1998-06-25
 Prior Application Number: 60/090696
 Prior Filing Date: 1998-06-25
 Prior Application Number: 60/090862
 Prior Filing Date: 1998-06-26
 Prior Application Number: 60/090863
 Prior Filing Date: 1998-06-26
 Prior Application Number: 60/091360
 Prior Filing Date: 1998-07-01
 Prior Application Number: 60/091478
 Prior Filing Date: 1998-07-02
 Prior Application Number: 60/091544
 Prior Filing Date: 1998-07-01
 Prior Application Number: 60/091519
 Prior Filing Date: 1998-07-02
 Prior Application Number: 60/091626
 Prior Filing Date: 1998-07-02
 Prior Application Number: 60/091633
 Prior Filing Date: 1998-07-02
 Prior Application Number: 60/091978
 Prior Filing Date: 1998-07-07
 Prior Application Number: 60/091982
 Prior Filing Date: 1998-07-07
 Prior Application Number: 60/092182
 Prior Filing Date: 1998-07-09

Query Match 100.0%; Score 2185; DB 10; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 GTTCTCCTTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAACGTGGCCACCATGA 60
 1 GTTCTCCTTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAACGTGGCCACCATGA 60

61 AGCTCTTGTGGCAGGTAACTGTGCACACACACCTGGAAATGCCATCTGCTCCCGTTTCG 120
 61 AGCTCTTGTGGCAGGTAACTGTGCACACACACCTGGAAATGCCATCTGCTCCCGTTTCG 120

121 TCTACCTCAAGCGCAAGTGTGATTTCTGTGCGAGCAATCTGCTGCTGCTGCTGCTGCTG 180
 121 TCTACCTCAAGCGCAAGTGTGATTTCTGTGCGAGCAATCTGCTGCTGCTGCTGCTGCTG 180

181 GGGCCAGAACTGCCCTCGCTTGTGCTGCAAGTAAACAGTTTCAAGAGTGGTGTGCA 240
 181 GGGCCAGAACTGCCCTCGCTTGTGCTGCAAGTAAACAGTTTCAAGAGTGGTGTGCA 240

241 CGCGCGGGGCTCTCTCCGAGGTCCCGAGGGTATTCCTTCGAACACCCGGTACCTCAACC 300
 241 CGCGCGGGGCTCTCTCCGAGGTCCCGAGGGTATTCCTTCGAACACCCGGTACCTCAACC 300

301 TATGAGAAACAATCCAGATATCCAGGCCGACACTTCCGCCACCTCCGACCACTGG 360
 301 TATGAGAAACAATCCAGATATCCAGGCCGACACTTCCGCCACCTCCGACCACTGG 360

361 AGTCTCTCAGTTGGGCGAGAACTCCATCCGCGAGATTGAGGTGGGGGCTTCCACCGGCC 420

361 AGTCTCTCAGTTGGGCGAGAACTCCATCCGCGAGATTGAGGTGGGGGCTTCCACCGGCC 420
 421 TGGCCAGCCTCAACACCTCTGGAGCTGTTTCGAACAATGGCTGACAGTCACTCTAGCGGG 480
 421 TGGCCAGCCTCAACACCTCTGGAGCTGTTTCGAACAATGGCTGACAGTCACTCTAGCGGG 480
 481 CTTTGAATACCTGTCCAAAGCTGGGAGCTTGGCTTCGCAACAAACCCCATCCAAAGCA 540
 481 CTTTGAATACCTGTCCAAAGCTGGGAGCTTGGCTTCGCAACAAACCCCATCCAAAGCA 540
 541 TCCCTCTTTACGCTTCAACCGGGTGGCTTCCCTCATGCGCTGGACTTGGGGAGCTCA 600
 541 TCCCTCTTTACGCTTCAACCGGGTGGCTTCCCTCATGCGCTGGACTTGGGGAGCTCA 600
 601 AGAGCTGAGTATATCTCTGAGGAGCTTTTGAAGGCTGTTTCAACCTCAAGTATCTGA 660
 601 AGAGCTGAGTATATCTCTGAGGAGCTTTTGAAGGCTGTTTCAACCTCAAGTATCTGA 660
 661 ACTTGGGCAATGCAACATTTAAAGACATGCCCCTCATGCGCTGGCTGGGGTGGAGG 720
 661 ACTTGGGCAATGCAACATTTAAAGACATGCCCCTCATGCGCTGGCTGGGGTGGAGG 720
 721 AGCTGAGATGTCAAGGAACCACTTCCCTGAGATCAGGCTTGGCTTCCATGAGCTCTGA 780
 721 AGCTGAGATGTCAAGGAACCACTTCCCTGAGATCAGGCTTGGCTTCCATGAGCTCTGA 780
 781 GCTCCCTCAAGAGCTCTGGGTCATGAATCAGCTCAGCTGATGAGCGGAATGCTT 840
 781 GCTCCCTCAAGAGCTCTGGGTCATGAATCAGCTCAGCTGATGAGCGGAATGCTT 840
 841 TTGACGGGCTGGCTTCACTTGTGGAACTCAACTGGGCGCAAACTCTCTTCTTTTC 900
 841 TTGACGGGCTGGCTTCACTTGTGGAACTCAACTGGGCGCAAACTCTCTTCTTTTC 900
 901 CCATGACCTTTTACCGCTGAGTACCTGGTGGAGTGGCTTACACCAACCTT 960
 901 CCATGACCTTTTACCGCTGAGTACCTGGTGGAGTGGCTTACACCAACCTT 960
 961 GGAACCTGTGATTTGACATTTCTGTGCTAGCTTGGCTTGGAGTATATACCCACA 1020
 961 GGAACCTGTGATTTGACATTTCTGTGCTAGCTTGGCTTGGAGTATATACCCACA 1020
 1021 ATTCCACCTGCTGTGGCGCTGTCAATGCTCCATGCTGAGCTTACACCAACCTT 1080
 1021 ATTCCACCTGCTGTGGCGCTGTCAATGCTCCATGCTGAGCTTACACCAACCTT 1080
 1081 AGTGGACAGGCTTCTTCCAGTGTCTGCTGCGCTTCACTCATGACGACCTCGAGACC 1140
 1081 AGTGGACAGGCTTCTTCCAGTGTCTGCTGCGCTTCACTCATGACGACCTCGAGACC 1140
 1141 TCAACATTTCTGAGGCTGGATGGAGAACTTAAAGTGTGGACTCCCTCATGCTCTCG 1200
 1141 TCAACATTTCTGAGGCTGGATGGAGAACTTAAAGTGTGGACTCCCTCATGCTCTCG 1200
 1201 TGAAGTGTGCTGCTCCATGAGGAGCTGCTCAGCCAGCTTCCCGCCAGCAAGATCT 1260
 1201 TGAAGTGTGCTGCTCCATGAGGAGCTGCTCAGCCAGCTTCCCGCCAGCAAGATCT 1260
 1261 CTGCTCTCAACAGCGCACTTGAACCTTTTCCAGCTGCTGCTTTTCAAGCACTGGGGT 1320
 1261 CTGCTCTCAACAGCGCACTTGAACCTTTTCCAGCTGCTGCTTTTCAAGCACTGGGGT 1320
 1321 ACATGCTATGAGTGAACATGTTGAGGCACTTCCAAAGCTTGGGCTTACCTCAATGTA 1380
 1321 ACATGCTATGAGTGAACATGTTGAGGCACTTCCAAAGCTTGGGCTTACCTCAATGTA 1380
 1381 GCAGGCTGAGTGAACCTTCAACCTTCAAGCTTCTTCAACAGTAACTGGAGACCA 1440
 1381 GCAGGCTGAGTGAACCTTCAACCTTCAAGCTTCTTCAACAGTAACTGGAGACCA 1440
 1441 CGAGATCTGCTGAGGACCAACAGCGAAAGTACAAGCTGTTCTTCAACAGTCCACTG 1500

Db 1441 CGAGATCTGCTGAGGACACAAACGCGAAAGTACAAAGCTGTCTTACCAAGTCCACTG 1500
Qy 1501 GTTACAGCGGATATACCACTCTTACACGGTGTCTATTACAGATACCGGTGTGCCA 1560
Db 1501 GTTACAGCGGATATACCACTCTTACACGGTGTCTATTACAGATACCGGTGTGCCA 1560
Qy 1561 AGCAGGTGGAGTACCGCGACAGACCACTGTCAAGATGACAGCAGCGCTGTGATGAAG 1620
Db 1561 AGCAGGTGGAGTACCGCGACAGACCACTGTCAAGATGACAGCAGCGCTGTGATGAAG 1620
Qy 1621 TCATGAAGACACCAAGATCATCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1680
Db 1621 TCATGAAGACACCAAGATCATCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1680
Qy 1681 CCATGTTGATGCTCTTATATAAATCTTGTAAAGCGGACCGAGCGGAGTACAGTCAAG 1740
Db 1681 CCATGTTGATGCTCTTATATAAATCTTGTAAAGCGGACCGAGCGGAGTACAGTCAAG 1740
Qy 1741 CGCGCGGAGCTGTGAGATATCCAGGTGGAGAGACATCCCGAGCAGCAATCCGCGAG 1800
Db 1741 CGCGCGGAGCTGTGAGATATCCAGGTGGAGAGACATCCCGAGCAGCAATCCGCGAG 1800
Qy 1801 CAGCAACAGCAGCTCCGCTCGGCTGTATCAGGTGAGGGGGGAGTGTCTGCTCCCAATTC 1860
Db 1801 CAGCAACAGCAGCTCCGCTCGGCTGTATCAGGTGAGGGGGGAGTGTCTGCTCCCAATTC 1860
Qy 1861 ATGACATATTAATACAACTTACAACTTACAACTTACAACTTACAACTTACAACTTAC 1920
Db 1861 ATGACATATTAATACAACTTACAACTTACAACTTACAACTTACAACTTACAACTTAC 1920
Qy 1921 GCCTGGGAACTCTCTGACCCCACTGACCTTCTCTGAACTTATATATTAATTCAGA 1980
Db 1921 GCCTGGGAACTCTCTGACCCCACTGACCTTCTCTGAACTTATATATTAATTCAGA 1980
Qy 1981 CCCATACCAAGACAGGTACAGGAACCTAAATGATGCTCCCTCCCTCCCAAAACTTAA 2040
Db 1981 CCCATACCAAGACAGGTACAGGAACCTAAATGATGCTCCCTCCCTCCCAAAACTTAA 2040
Qy 2041 TAAATGCAATAGATGACACAAAGACAGCACTTTTGTACAGGTGGGGAGAGACTTT 2100
Db 2041 TAAATGCAATAGATGACACAAAGACAGCACTTTTGTACAGGTGGGGAGAGACTTT 2100
Qy 2101 TCTTGTATATGCTTATATATTAAGTCTATAGTGTGCTGCTGCTGCTGCTGCTGCTGCT 2160
Db 2101 TCTTGTATATGCTTATATATTAAGTCTATAGTGTGCTGCTGCTGCTGCTGCTGCTGCT 2160
Qy 2161 AATTAAAGACAAAAGTCAAAACA 2185
Db 2161 AATTAAAGACAAAAGTCAAAACA 2185

RESULT 19
US-09-990-436-228

Sequence 228 Application US/09990436
Publication No. US20020198148A1

GENERAL INFORMATION:

- APPLICANT: Ashkenazi, Avi J.
- APPLICANT: Baker, Kevin P.
- APPLICANT: Botstein, David
- APPLICANT: Desnovers, Luc
- APPLICANT: Eaton, Dan L.
- APPLICANT: Ferrara, Napoleone
- APPLICANT: Fong, Sherman
- APPLICANT: Gerber, Hanspeter
- APPLICANT: Gerritsen, Mary E.
- APPLICANT: Goddard, Audrey
- APPLICANT: Godowski, Paul J.
- APPLICANT: Grimaldi, J. Christopher
- APPLICANT: Gurney, Austin L.
- APPLICANT: Kijavini, Iwar J.
- APPLICANT: Napier, Mary A.
- APPLICANT: Pan, James
- APPLICANT: Paoni, Nicholas P.

- APPLICANT: Roy, Margaret Ann
- APPLICANT: Stewart, Timothy A.
- APPLICANT: Tamas, Daniel
- APPLICANT: Watanabe, Colin K.
- APPLICANT: Williams, P. Mickey
- APPLICANT: Wood, William I.
- APPLICANT: Zhang, Zemin
- TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
- FILE REFERENCE: P2730P1C14
- CURRENT APPLICATION NUMBER: US/09/990,436
- PRIOR FILING DATE: 2001-11-14
- PRIOR APPLICATION NUMBER: 60/049787
- PRIOR FILING DATE: 1997-06-16
- PRIOR APPLICATION NUMBER: 60/062250
- PRIOR FILING DATE: 1997-10-17
- PRIOR APPLICATION NUMBER: 60/065186
- PRIOR FILING DATE: 1997-11-12
- PRIOR APPLICATION NUMBER: 60/065311
- PRIOR FILING DATE: 1997-11-13
- PRIOR APPLICATION NUMBER: 60/066770
- PRIOR FILING DATE: 1997-11-24
- PRIOR APPLICATION NUMBER: 60/075945
- PRIOR FILING DATE: 1998-02-25
- PRIOR APPLICATION NUMBER: 60/078910
- PRIOR FILING DATE: 1998-03-20
- PRIOR APPLICATION NUMBER: 60/083322
- PRIOR FILING DATE: 1998-04-28
- PRIOR APPLICATION NUMBER: 60/084600
- PRIOR FILING DATE: 1998-05-07
- PRIOR APPLICATION NUMBER: 60/087106
- PRIOR FILING DATE: 1998-05-28
- PRIOR APPLICATION NUMBER: 60/087607
- PRIOR FILING DATE: 1998-06-02
- PRIOR APPLICATION NUMBER: 60/087609
- PRIOR FILING DATE: 1998-06-02
- PRIOR APPLICATION NUMBER: 60/087759
- PRIOR FILING DATE: 1998-06-02
- PRIOR APPLICATION NUMBER: 60/087827
- PRIOR FILING DATE: 1998-06-03
- PRIOR APPLICATION NUMBER: 60/088021
- PRIOR FILING DATE: 1998-06-04
- PRIOR APPLICATION NUMBER: 60/088025
- PRIOR FILING DATE: 1998-06-04
- PRIOR APPLICATION NUMBER: 60/088026
- PRIOR FILING DATE: 1998-06-04
- PRIOR APPLICATION NUMBER: 60/088028
- PRIOR FILING DATE: 1998-06-04
- PRIOR APPLICATION NUMBER: 60/088029
- PRIOR FILING DATE: 1998-06-04
- PRIOR APPLICATION NUMBER: 60/088030
- PRIOR FILING DATE: 1998-06-04
- PRIOR APPLICATION NUMBER: 60/088033
- PRIOR FILING DATE: 1998-06-04
- PRIOR APPLICATION NUMBER: 60/088326
- PRIOR FILING DATE: 1998-06-04
- PRIOR APPLICATION NUMBER: 60/088167
- PRIOR FILING DATE: 1998-06-05
- PRIOR APPLICATION NUMBER: 60/088202
- PRIOR FILING DATE: 1998-06-05
- PRIOR APPLICATION NUMBER: 60/088212
- PRIOR FILING DATE: 1998-06-05
- PRIOR APPLICATION NUMBER: 60/088217
- PRIOR FILING DATE: 1998-06-05
- PRIOR APPLICATION NUMBER: 60/088655
- PRIOR FILING DATE: 1998-06-09
- PRIOR APPLICATION NUMBER: 60/088734
- PRIOR FILING DATE: 1998-06-10
- PRIOR APPLICATION NUMBER: 60/088738
- PRIOR FILING DATE: 1998-06-10
- PRIOR APPLICATION NUMBER: 60/088742
- PRIOR FILING DATE: 1998-06-10
- PRIOR APPLICATION NUMBER: 60/088810

PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24

PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 10; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTCTCTTTCCGAGCCAAATCCGAGCGATGTGCAATTATGAACGTGCCACACCATGA 60
Db 1 GTTCTCTTTCCGAGCCAAATCCGAGCGATGTGCAATTATGAACGTGCCACACCATGA 60

Qy 61 AGCTTTGTGGCAGGTAATGTGCAACCACTGGAATGCCATCTCTCTCCGCTTCCGTTGG 120
Db 61 AGCTTTGTGGCAGGTAATGTGCAACCACTGGAATGCCATCTCTCTCCGCTTCCGTTGG 120

Qy 121 TCTACTCTACGGCGCAAGTGTGATTTCTGTGTGAGCCATCGCTCTCGCGCTCAGCGG 180
Db 121 TCTACTCTACGGCGCAAGTGTGATTTCTGTGTGAGCCATCGCTCTCGCGCTCAGCGG 180

Qy 181 GGCCCCAGAACTGCCCTTCCGTTTGTGCTGTGAGTAACAGTTGAGCAAGTGTGTGCA 240
Db 181 GGCCCCAGAACTGCCCTTCCGTTTGTGCTGTGAGTAACAGTTGAGCAAGTGTGTGCA 240

Qy 241 CGCGCGGGGCTCTCCGAGGTCCGCGAGGTATTCCTCGAAGCAGCGGTACCTCAACC 300
Db 241 CGCGCGGGGCTCTCTCCGAGGTCCGCGAGGTATTCCTCGAAGCAGCGGTACCTCAACC 300

Qy 301 TCATGAGAACCAATCCAGATGATCCAGGGCGGACACTTTCGGCCACTCCACCACTGG 360
Db 301 TCATGAGAACCAATCCAGATGATCCAGGGCGGACACTTTCGGCCACTCCACCACTGG 360

Qy 361 AGGTCTGTGAGTTGGGCAAGGACTCCATCCGCGAGATTGAGTGGGGGCTTCAACGGCC 420
Db 361 AGGTCTGTGAGTTGGGCAAGGACTCCATCCGCGAGATTGAGTGGGGGCTTCAACGGCC 420

Qy 421 TGGCCAGGCTCAACACCTCTGGAGCTGTTCGCAACTGGCTGACAGTTCATCTCAGGGG 480
Db 421 TGGCCAGGCTCAACACCTCTGGAGCTGTTCGCAACTGGCTGACAGTTCATCTCAGGGG 480

Qy 481 CTTTGAATACCTGTCCAGAGCTGGGGAGCTCTGGCTTCGCAACACCCCATCGAAGCA 540
Db 481 CTTTGAATACCTGTCCAGAGCTGGGGAGCTCTGGCTTCGCAACACCCCATCGAAGCA 540

Db	481	CTTTGTAATACCTGTTCAGCTGCGGGAGCTCTGGCTTCGCAACAAACCCCATCGAAAGCA	540
Qy	541	TCCCTCTTTAGCCTTCAACCGGGTGCCTCCCTCCCTCATGCGCCTGGACATTGGGGGAGCTCA	600
Db	541	TCCCTCTTTAGCCTTCAACCGGGTGCCTCCCTCCCTCATGCGCCTGGACATTGGGGGAGCTCA	600
Qy	601	AGAACTCGGATATATCTCTCAGAGGGAGCTTTGAGGGGCTGTTCAACTCAAGTATCTGA	660
Db	601	AGAACTCGGATATATCTCTCAGAGGGAGCTTTGAGGGGCTGTTCAACTCAAGTATCTGA	660
Qy	661	ACTTGGGCATGTGCAACATTAAAGACATGCCCAATCTCACCCCCCTGGTGGGGCTGGAGG	720
Db	661	ACTTGGGCATGTGCAACATTAAAGACATGCCCAATCTCACCCCCCTGGTGGGGCTGGAGG	720
Qy	721	AGCTGGAGATGTACGGGACCACTTCCCTGAGATCAGGCTGGCTCCTTCATGGCCTGA	780
Db	721	AGCTGGAGATGTACGGGACCACTTCCCTGAGATCAGGCTGGCTCCTTCATGGCCTGA	780
Qy	781	GCTCCTCTCAAGAAGCTCTGGGTCAATGAACCTCACAGGTCAAGCTGATTCAGCGGAATGCTT	840
Db	781	GCTCCTCTCAAGAAGCTCTGGGTCAATGAACCTCACAGGTCAAGCTGATTCAGCGGAATGCTT	840
Qy	841	TTGACGGGCTGGCTTCACTTGTGTGGAATCAACTTTGGGCCACAATAAACCCTCTCTCTTTGC	900
Db	841	TTGACGGGCTGGCTTCACTTGTGTGGAATCAACTTTGGGCCACAATAAACCCTCTCTCTTTGC	900
Qy	901	CCCATTGACCTCTTTACCCCGCTGAGGTACCTGTGTGAGTTGCATCTACACCAACACCCCTT	960
Db	901	CCCATTGACCTCTTTACCCCGCTGAGGTACCTGTGTGAGTTGCATCTACACCAACACCCCTT	960
Qy	961	GGAACTGTGATGTGACATTCCTGTGTGGCTAGCCTGTGGCTTCGAGAGTATATACCCACCA	1020
Db	961	GGAACTGTGATGTGACATTCCTGTGTGGCTAGCCTGTGGCTTCGAGAGTATATACCCACCA	1020
Qy	1021	ATTCCACCTGTGTGGCGCGTGATCCTCCATGTGACATGCGAGGCGCTACCTCGTGG	1080
Db	1021	ATTCCACCTGTGTGGCGCGTGATCCTCCATGTGACATGCGAGGCGCTACCTCGTGG	1080
Qy	1081	AGGTGGACCAAGGCTCTCTTCCAGTGTCTTCCGCCCTTCATCATGGACGCACTCGAGACC	1140
Db	1081	AGGTGGACCAAGGCTCTCTTCCAGTGTCTTCCGCCCTTCATCATGGACGCACTCGAGACC	1140
Qy	1141	TCACAATTTCTGAGGCTCGAATGGCAGAACTTAAGTGTGGAACTCCCTCATATGTCCTCG	1200
Db	1141	TCACAATTTCTGAGGCTCGAATGGCAGAACTTAAGTGTGGAACTCCCTCATATGTCCTCG	1200
Qy	1201	TGAAGTGTGTCTGCCCAATGGGACAGTGTCTAGCACAAGCCTCCCGCCACCAAGGATCT	1260
Db	1201	TGAAGTGTGTCTGCCCAATGGGACAGTGTCTAGCACAAGCCTCCCGCCACCAAGGATCT	1260
Qy	1261	TGTGTCTCAAAGCAGCACTTTGAACCTTTTCCAGTGTCTGTCTTTACAGACACTGGGATGT	1320
Db	1261	TGTGTCTCAAAGCAGCACTTTGAACCTTTTCCAGTGTCTGTCTTTACAGACACTGGGATGT	1320
Qy	1321	ACACATGCACTGGTGCACCAATGTTGTCAGGGAACCTCCAAAGCCTCGGCTACCTCAATCTGA	1380
Db	1321	ACACATGCACTGGTGCACCAATGTTGTCAGGGAACCTCCAAAGCCTCGGCTACCTCAATCTGA	1380
Qy	1381	GCAAGGCTGAGCTTAAACACCTTCAAGCTTCTTACACAGTAAACAGTGGAGACCA	1440
Db	1381	GCAAGGCTGAGCTTAAACACCTTCAAGCTTCTTACACAGTAAACAGTGGAGACCA	1440
Qy	1441	CGGAGATCTCGCTTGAGGACACAAACGGGAAGTAAAGCCTGTTCTTACAGCTTCACTG	1500
Db	1441	CGGAGATCTCGCTTGAGGACACAAACGGGAAGTAAAGCCTGTTCTTACAGCTTCACTG	1500
Qy	1501	GTTTACAGCGGCTATATACACTCTTACACAGGCTGTCAATTACAGACTACCGCTTGCCCA	1560
Db	1501	GTTTACAGCGGCTATATACACTCTTACACAGGCTGTCAATTACAGACTACCGCTTGCCCA	1560
Qy	1561	AGCAGGTGGCAGTACCCGCGACACACCACTGACAAAGATGACAGCCAGCTGGAATGAAG	1620
Db	1561	AGCAGGTGGCAGTACCCGCGACACACCACTGACAAAGATGACAGCCAGCTGGAATGAAG	1620

Qy	1621	TCATGAAGACCAACAGATCATCACTGGCTGCTTTGGCAGAGTACCTCTGCTAGCTCCG	1681
Db	1621	TCATGAAGACCAACAGATCATCATTTGGCTGCTTTGGCAGAGTACTCTCTAGCTCCG	1680
Qy	1681	CCATGTTGATTGCTTCTCTATAAACTTCGTAAGCGGCACCGACAGCGAGTACAGTCACAG	1740
Db	1681	CCATGTTGATTGCTTCTCTATAAACTTCGTAAGCGGCACCGACAGCGAGTACAGTCACAG	1740
Qy	1741	CCGCCCCGAGACTGTTTGACATTAATCCAGGTGACGAAGAATCCCGACAGCAACATCCCGCAG	1800
Db	1741	CCGCCCCGAGACTGTTTGAGTATATCCAGGTGACGAAGAATCCCGACAGCAATCCCGCAG	1800
Qy	1801	CAGCAACAGCAGCTCCGTCGGGTATATCAGGTGAGGGGGCAGTAGTGCTCTCCCAAAATTC	1860
Db	1801	CAGCAACAGCAGCTCCGTCGGGTATATCAGGTGAGGGGGCAGTAGTGCTCTCCCAAAATTC	1860
Qy	1861	ATGACCATATTTAATCAACACACCTTACAAACCCAGCACATGGGGCCCACTGGACAGAAACA	1920
Db	1861	ATGACCATATTTAATCAACACACCTTACAAACCCAGCACATGGGGCCCACTGGACAGAAACA	1920
Qy	1921	GCCTGGGGAACTCTCTGCAACCCACAGTCAACCACTATCTCTGAACCTTATATTAATTCAGA	1980
Db	1921	GCCTGGGGAACTCTCTGCAACCCACAGTCAACCACTATCTCTGAACCTTATATTAATTCAGA	1980
Qy	1981	CCCATACCAAGGACAGGTACAGGAACCTCAATATGACTCTCCCTCCCAAAAACTTA	2040
Db	1981	CCCATACCAAGGACAGGTACAGGAACCTCAATATGACTCTCCCTCCCAAAAACTTA	2040
Qy	2041	TAAATTCGAATAGATGCAACACAAAGCAGCAACTTTTGTACAGAGTGGGAGAGACTTT	2100
Db	2041	TAAATTCGAATAGATGCAACACAAAGCAGCAACTTTTGTACAGAGTGGGAGAGACTTT	2100
Qy	2101	TTCTGTGATATGCTTTATATATTAAAGTCTATGGGCTGGTTAAABAAACAGATTATATTAA	2160
Db	2101	TTCTGTGATATGCTTTATATATTAAAGTCTATGGGCTGGTTAAABAAACAGATTATATTAA	2160
Qy	2161	AAATTTAAGACAAAAAGTCAAAAACA	2185
Db	2161	AAATTTAAGACAAAAAGTCAAAAACA	2185

RESULT 20

```

RES001 20
US-99-993-687-228
; Sequence 228, Application US/09993687
; Publication No. US20020198149A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Garber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Pao, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transcribed
; TITLE OF INVENTION: Acids Encoding

```

1	PRIOR APPLICATION NUMBER: 60/088871
2	PRIOR FILING DATE: 1998-06-11
3	PRIOR APPLICATION NUMBER: 60/089105
4	PRIOR FILING DATE: 1998-06-12
5	PRIOR APPLICATION NUMBER: 60/089440
6	PRIOR FILING DATE: 1998-06-16
7	PRIOR APPLICATION NUMBER: 60/089512
8	PRIOR FILING DATE: 1998-06-16
9	PRIOR APPLICATION NUMBER: 60/089514
10	PRIOR FILING DATE: 1998-06-16
11	PRIOR APPLICATION NUMBER: 60/089532
12	PRIOR FILING DATE: 1998-06-17
13	PRIOR APPLICATION NUMBER: 60/089538
14	PRIOR FILING DATE: 1998-06-17
15	PRIOR APPLICATION NUMBER: 60/089598
16	PRIOR FILING DATE: 1998-06-17
17	PRIOR APPLICATION NUMBER: 60/089599
18	PRIOR FILING DATE: 1998-06-17
19	PRIOR APPLICATION NUMBER: 60/089600
20	PRIOR FILING DATE: 1998-06-17
21	PRIOR APPLICATION NUMBER: 60/089553
22	PRIOR FILING DATE: 1998-06-17
23	PRIOR APPLICATION NUMBER: 60/089801
24	PRIOR FILING DATE: 1998-06-18
25	PRIOR APPLICATION NUMBER: 60/089907
26	PRIOR FILING DATE: 1998-06-18
27	PRIOR APPLICATION NUMBER: 60/089908
28	PRIOR FILING DATE: 1998-06-18
29	PRIOR APPLICATION NUMBER: 60/089947
30	PRIOR FILING DATE: 1998-06-19
31	PRIOR APPLICATION NUMBER: 60/089948
32	PRIOR FILING DATE: 1998-06-19
33	PRIOR APPLICATION NUMBER: 60/089952
34	PRIOR FILING DATE: 1998-06-22
35	PRIOR APPLICATION NUMBER: 60/090246
36	PRIOR FILING DATE: 1998-06-22
37	PRIOR APPLICATION NUMBER: 60/090252
38	PRIOR FILING DATE: 1998-06-22
39	PRIOR APPLICATION NUMBER: 60/090254
40	PRIOR FILING DATE: 1998-06-22
41	PRIOR APPLICATION NUMBER: 60/090349
42	PRIOR FILING DATE: 1998-06-23
43	PRIOR APPLICATION NUMBER: 60/090355
44	PRIOR FILING DATE: 1998-06-23
45	PRIOR APPLICATION NUMBER: 60/090429
46	PRIOR FILING DATE: 1998-06-24
47	PRIOR APPLICATION NUMBER: 60/090431
48	PRIOR FILING DATE: 1998-06-24
49	PRIOR APPLICATION NUMBER: 60/090435
50	PRIOR FILING DATE: 1998-06-24
51	PRIOR APPLICATION NUMBER: 60/090444
52	PRIOR FILING DATE: 1998-06-24
53	PRIOR APPLICATION NUMBER: 60/090445
54	PRIOR FILING DATE: 1998-06-24
55	PRIOR APPLICATION NUMBER: 60/090472
56	PRIOR FILING DATE: 1998-06-24
57	PRIOR APPLICATION NUMBER: 60/090535
58	PRIOR FILING DATE: 1998-06-24
59	PRIOR APPLICATION NUMBER: 60/090540
60	PRIOR FILING DATE: 1998-06-24
61	PRIOR APPLICATION NUMBER: 60/090542
62	PRIOR FILING DATE: 1998-06-24
63	PRIOR APPLICATION NUMBER: 60/090557
64	PRIOR FILING DATE: 1998-06-24
65	PRIOR APPLICATION NUMBER: 60/090676
66	PRIOR FILING DATE: 1998-06-25
67	PRIOR APPLICATION NUMBER: 60/090678
68	PRIOR FILING DATE: 1998-06-25
69	PRIOR APPLICATION NUMBER: 60/090690
70	PRIOR FILING DATE: 1998-06-25
71	PRIOR APPLICATION NUMBER: 60/090694
72	PRIOR FILING DATE: 1998-06-25
73	PRIOR APPLICATION NUMBER: 60/090695

; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 10; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GTCTCTCTTCCGAGCCAAATCCAGCGATGCTGATTAATGAACTGACACCATGA	60
DB	1	GTCTCTCTTCCGAGCCAAATCCAGCGATGCTGATTAATGAACTGACACCATGA	60
QY	61	AGCTCTTGTGGCAGTAATCTGTGACACCAACACTGGAATGCCATCTCTCCCGTTG	120
DB	61	AGCTCTTGTGGCAGTAATCTGTGACACCAACACTGGAATGCCATCTCTCCCGTTG	120
QY	121	TCTACTCAGCGCGCAATGTGGATCTGTGTGAGCGATCGCTGTGCGCCTCAGCG	180
DB	121	TCTACTCAGCGCGCAATGTGGATCTGTGTGAGCGATCGCTGTGCGCCTCAGCG	180
QY	181	GGCCCCAGAACTGCCCTTCCCTGCTGCTGAGTAACCAAGTTCAGCAAGTGTGTGCA	240
DB	181	GGCCCCAGAACTGCCCTTCCCTGCTGCTGAGTAACCAAGTTCAGCAAGTGTGTGCA	240
QY	241	CGCGCGGGGCTCTCCGAGTCCGCGAGGTATTCCTTGAGCAACCCGGTACTCAAC	300
DB	241	CGCGCGGGGCTCTCCGAGTCCGCGAGGTATTCCTTGAGCAACCCGGTACTCAAC	300
QY	301	TCATGGAGAAACAATCCAGATGATCCAGCGCGACACTTCCGCGCACTCCACACCTGG	360
DB	301	TCATGGAGAAACAATCCAGATGATCCAGCGCGACACTTCCGCGCACTCCACACCTGG	360
QY	361	AGGTCTCTGAGTTGGCGAGAACTCCATCCGCGAGTTGAGTGGGGGCTTCAACGGCC	420
DB	361	AGGTCTCTGAGTTGGCGAGAACTCCATCCGCGAGTTGAGTGGGGGCTTCAACGGCC	420
QY	421	TGGCCAGGCTCAACACCTTGAGCTGTTCGACAACTGGCTGACAGTCAATCCCTAGCGGG	480
DB	421	TGGCCAGGCTCAACACCTTGAGCTGTTCGACAACTGGCTGACAGTCAATCCCTAGCGGG	480
QY	481	CTTTTGAATACCTGTCCAGCTGCGGAGCTCTGGCTTCGCAACAAACCCCATCGAAAGCA	540
DB	481	CTTTTGAATACCTGTCCAGCTGCGGAGCTCTGGCTTCGCAACAAACCCCATCGAAAGCA	540
QY	541	TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATCGCGCTGAGCTTGGGGGAGCTCA	600
DB	541	TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATCGCGCTGAGCTTGGGGGAGCTCA	600
QY	601	AGAAGCTGAGTATATCTCTGAGGAGCTTTTGGGGGCTCTTCAACCTCAAGTATCTGA	660
DB	601	AGAAGCTGAGTATATCTCTGAGGAGCTTTTGGGGGCTCTTCAACCTCAAGTATCTGA	660

QY	661	ACTTGGGCAATGTGCAACATTAAGACATGCGCCATCTCACGCCCCCTGGTGGGCTGAGG	720
DB	661	ACTTGGGCAATGTGCAACATTAAGACATGCGCCATCTCACGCCCCCTGGTGGGCTGAGG	720
QY	721	AGCTGGAGATCTCAGGGAAACCACTTCCCTGAGATCAGGCTCTCTTCCATCGGCTGA	780
DB	721	AGCTGGAGATCTCAGGGAAACCACTTCCCTGAGATCAGGCTCTCTTCCATCGGCTGA	780
QY	781	GCTCCCTCAAGAACTCTGGGTCAATGAATCTCACAGGTCAGGCTGATTTAGCGGAATGCTT	840
DB	781	GCTCCCTCAAGAACTCTGGGTCAATGAATCTCACAGGTCAGGCTGATTTAGCGGAATGCTT	840
QY	841	TTGACGGGCTGGCTTCACTTGTGAACTCAACTTGGGCCCAATAAACCCTCTCTTTTC	900
DB	841	TTGACGGGCTGGCTTCACTTGTGAACTCAACTTGGGCCCAATAAACCCTCTCTTTTC	900
QY	901	CCCATGACCTCTTTACCCCGCTGAGGTACCTGGTGGAGTTGCATCTACACCAACCCCTT	960
DB	901	CCCATGACCTCTTTACCCCGCTGAGGTACCTGGTGGAGTTGCATCTACACCAACCCCTT	960
QY	961	GGAAGTGTGATTGTGACATCTCTGTGGCTAGCTGTGGCTTCGAGAGTATATATACCA	1020
DB	961	GGAAGTGTGATTGTGACATCTCTGTGGCTAGCTGTGGCTTCGAGAGTATATATACCA	1020
QY	1021	ATTCCACCTGTGTGGCGCTGTCTATGCTCCATGACATGCGAGGCGCTACTCTGTGG	1080
DB	1021	ATTCCACCTGTGTGGCGCTGTCTATGCTCCATGACATGCGAGGCGCTACTCTGTGG	1080
QY	1081	AGGTGGACAGGCTCTCTTCCAGTGCTCTGCCCTTTCATCTGACGACGACCTCGAGACC	1140
DB	1081	AGGTGGACAGGCTCTCTTCCAGTGCTCTGCCCTTTCATCTGACGACGACCTCGAGACC	1140
QY	1141	TCACATTTCTGAGGTCGAGTGGCAGAACTTAAGTGTGGAGCTTCCCTCTATGCTCTCG	1200
DB	1141	TCACATTTCTGAGGTCGAGTGGCAGAACTTAAGTGTGGAGCTTCCCTCTATGCTCTCG	1200
QY	1201	TGAGTGTGTCTGCCCAATGGGACAGTGTCTCAGCAGCGCTCCCGCCACCCAGGATCT	1260
DB	1201	TGAGTGTGTCTGCCCAATGGGACAGTGTCTCAGCAGCGCTCCCGCCACCCAGGATCT	1260
QY	1261	CTGTCTCTCAACGAGCGACCTTGAACCTTTCCACGCTGCTTTCAGACACTGGGGTGT	1320
DB	1261	CTGTCTCTCAACGAGCGACCTTGAACCTTTCCACGCTGCTTTCAGACACTGGGGTGT	1320
QY	1321	ACACATGCTGCTGAGGACCAATGCTTCAGGCACTCCACGCTCGGCTTACTCTCAATGTA	1380
DB	1321	ACACATGCTGCTGAGGACCAATGCTTCAGGCACTCCACGCTCGGCTTACTCTCAATGTA	1380
QY	1381	GCAAGGCTGAGCTTAAACACCTTCAACTACAGCTTCTTCAACACAGTAAACAGTGA	1440
DB	1381	GCAAGGCTGAGCTTAAACACCTTCAACTACAGCTTCTTCAACACAGTAAACAGTGA	1440
QY	1441	CGGAGATCTCGCTGAGGACCAACGCGGAAAGTACAGGCTTCTTCCACCGTCCACTG	1500
DB	1441	CGGAGATCTCGCTGAGGACCAACGCGGAAAGTACAGGCTTCTTCCACCGTCCACTG	1500
QY	1501	GTATACAGCGCGCATATACCACTCTACCGGTGCTCATTCAGACTACCGGTGCGCCA	1560
DB	1501	GTATACAGCGCGCATATACCACTCTACCGGTGCTCATTCAGACTACCGGTGCGCCA	1560
QY	1561	AGCAGGTGCGAGTACCGCGACAGACCACTGACAGAGTGCAGACCGCTGAGTGAAG	1620
DB	1561	AGCAGGTGCGAGTACCGCGACAGACCACTGACAGAGTGCAGACCGCTGAGTGAAG	1620
QY	1621	TCATGAAGACCAACCAAGATCATCTGCTTGTGGGAGTGACTCTGCTAGCTGCGG	1680
DB	1621	TCATGAAGACCAACCAAGATCATCTGCTTGTGGGAGTGACTCTGCTAGCTGCGG	1680
QY	1681	CCATCTTGAATGCTTCTATATAAATCTGTAAGCGGACCCAGCGGAGTACAGTCAAG	1740
DB	1681	CCATCTTGAATGCTTCTATATAAATCTGTAAGCGGACCCAGCGGAGTACAGTCAAG	1740

1741 CGCCCGGAGCTGTGAGATAATCCAGGTGGACGAGAGACATCCCGACGACACATCCCGAG 1800
1741 CGCCCGGAGCTGTGAGATAATCCAGGTGGACGAGAGACATCCCGACGACACATCCCGAG 1800
1801 CAGCAACAGCAGCTCCGTCGGGTGTATCAGGTGAGGGGGCAGTAGTGTGCCCCCAATTC 1860
1801 CAGCAACAGCAGCTCCGTCGGGTGTATCAGGTGAGGGGGCAGTAGTGTGCCCCCAATTC 1860
1861 ATGACATATTAATCAACACCTACAAACGACGACATGGGGGCCCACTGGACAGAAACA 1920
1861 ATGACATATTAATCAACACCTACAAACGACGACATGGGGGCCCACTGGACAGAAACA 1920
1921 GCTGGGGAACTCTCTGCAACCCACAGTCACCACTATCTCTGAACCTTATATATTCAGA 1980
1921 GCTGGGGAACTCTCTGCAACCCACAGTCACCACTATCTCTGAACCTTATATATTCAGA 1980
1981 CCGTACCAAGCAGACAGGTACAGGAACTCAATATGATCTCCCTCCCGGAAAAAAGCTTA 2040
1981 CCGTACCAAGCAGACAGGTACAGGAACTCAATATGATCTCCCTCCCGGAAAAAAGCTTA 2040
2041 TAAATGCAATAGATGACACACAAAGACAGCAACTTTGTACAGAGTGGGAGAGACTTT 2100
2041 TAAATGCAATAGATGACACACAAAGACAGCAACTTTGTACAGAGTGGGAGAGACTTT 2100
2101 TTCTGTATATCTTATATATTAAGTCTATGAGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 2160
2101 TTCTGTATATCTTATATATTAAGTCTATGAGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 2160
2161 ATTTAAAGCAAAAAGTCAAAACA 2185
2161 ATTTAAAGCAAAAAGTCAAAACA 2185

RESULT 21

S-09-989-734-228

Sequence 228, Application US/09989734

Publication No. US20030003531A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730PIC64
CURRENT APPLICATION NUMBER: US/09/989,734
CURRENT FILING DATE: 2001-11-19
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12

PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084500
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514

PRIOR FILING DATE: 1998-06-16
 PRIOR APPLICATION NUMBER: 60/089532
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089538
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089598
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089599
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089600
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089653
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089801
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089907
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089908
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089947
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/089948
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/089952
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/090246
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090252
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090254
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090349
 PRIOR FILING DATE: 1998-06-23
 PRIOR APPLICATION NUMBER: 60/090355
 PRIOR FILING DATE: 1998-06-23
 PRIOR APPLICATION NUMBER: 60/090429
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090431
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090435
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090444
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090445
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090472
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090535
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090540
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090542
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090557
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090676
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090678
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090690
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090694
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090695
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090696
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090862
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/090863
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/091360
 PRIOR FILING DATE: 1998-07-01

; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GTTCCTCTTCGAGCCAAATCCAGGCGATGTTGAATATTAACAGTGCACACCATGA	60
DB	1	GTTCCTCTTCGAGCCAAATCCAGGCGATGTTGAATATTAACAGTGCACACCATGA	60
QY	61	AGCTCTTTGTGGCAGTAATCTGTGCACCAACACCACTGGAAATGCATCTCTCCGTTGG	120
DB	61	AGCTCTTTGTGGCAGTAATCTGTGCACCAACACCACTGGAAATGCATCTCTCCGTTGG	120
QY	121	TCTACCTCAGGGCGCAAGTGTGGATCTGTGCAGCCATCGCTGCGGCTCAGCCG	180
DB	121	TCTACCTCAGGGCGCAAGTGTGGATCTGTGCAGCCATCGCTGCGGCTCAGCCG	180
QY	181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTGCAGTAACACAGTTTCAGCAAGTGTGTGA	240
DB	181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTGCAGTAACACAGTTTCAGCAAGTGTGTGA	240
QY	241	CGCGCGGGGCTCTCGAGSTCCGAGGGTATTCCTCGACACCCGCTACTCAACC	300
DB	241	CGCGCGGGGCTCTCGAGSTCCGAGGGTATTCCTCGACACCCGCTACTCAACC	300
QY	301	TCATGGAGAACAAATCCAGATGATCCAGGCGGACACTTCCGCGCACCTCCACCACTGG	360
DB	301	TCATGGAGAACAAATCCAGATGATCCAGGCGGACACTTCCGCGCACCTCCACCACTGG	360
QY	361	AGGTCCTGAGTTGGGCGAGAACTCCATCCGCGCAGATTGAGGTGGGGGCTTCAAGGCC	420
DB	361	AGGTCCTGAGTTGGGCGAGAACTCCATCCGCGCAGATTGAGGTGGGGGCTTCAAGGCC	420
QY	421	TGGCCAGCTCAACACCTCGAGCTGTTTCGACAACTGCTGACAGTCAATCCCTAGCGGG	480
DB	421	TGGCCAGCTCAACACCTCGAGCTGTTTCGACAACTGCTGACAGTCAATCCCTAGCGGG	480
QY	481	CCTTTGAATACCTGTCCAAAGCTGGGAGCTCTGGCTTCGCAACCAACCCCATCGAAGCA	540
DB	481	CCTTTGAATACCTGTCCAAAGCTGGGAGCTCTGGCTTCGCAACCAACCCCATCGAAGCA	540
QY	541	TCCCTCTTACGCTTCAACCGGGTGCCTCCCTCATGCGCTTGGACTTGGGGGAGCTCA	600
DB	541	TCCCTCTTACGCTTCAACCGGGTGCCTCCCTCATGCGCTTGGACTTGGGGGAGCTCA	600
QY	601	AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGGGGCTTTTCAACCTCAAGTATCTGA	660
DB	601	AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGGGGCTTTTCAACCTCAAGTATCTGA	660
QY	661	ACTTGGGCTATGCAACATTAAGACATGCCAATCTCACCCCTGCTGGGGCTGAGG	720
DB	661	ACTTGGGCTATGCAACATTAAGACATGCCAATCTCACCCCTGCTGGGGCTGAGG	720
QY	721	AGCTGGAGATGTCAAGGGAACCACTTCCCTGAGATCAAGGCTTCCCTTCAATGGCTGA	780
DB	721	AGCTGGAGATGTCAAGGGAACCACTTCCCTGAGATCAAGGCTTCCCTTCAATGGCTGA	780

[illegible]

PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091978
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/091982
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/092182
 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 1 GTTCTCTTCGAGCAAAATCCAGGCGATGGTGAATTAATGAACGTGCCACCATGA 60
 b 1 GTTCTCTTCGAGCAAAATCCAGGCGATGGTGAATTAATGAACGTGCCACCATGA 60

Y 61 AGCTCTGTGGGAGTAACCTGTGCACACACACCTGGAAATGCCATCTGTCCCGTTGG 120
 b 61 AGCTCTGTGGGAGTAACCTGTGCACACACACCTGGAAATGCCATCTGTCCCGTTGG 120

Y 121 TCTACTCTACGGCGCAAGTGTGATTTCTGTGTGCAGCCATCTGTCTGCGGCTCAGCG 180
 b 121 TCTACTCTACGGCGCAAGTGTGATTTCTGTGTGCAGCCATCTGTCTGCGGCTCAGCG 180

Y 181 GSCCCAGAACTGCCCTCGTGTGCTGTGCTGAGTAACCGATTGAGCAAGTGTGCA 240
 b 181 GSCCCAGAACTGCCCTCGTGTGCTGTGCTGAGTAACCGATTGAGCAAGTGTGCA 240

Y 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGGTATTCCTCGAAACCCGGTACCTCAACC 300
 b 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGGTATTCCTCGAAACCCGGTACCTCAACC 300

Y 301 TATGAGAAACAACTCCAGATGATTCAGGCGGAGCACTTCGCGCACCTCAACGCTGG 360
 b 301 TATGAGAAACAACTCCAGATGATTCAGGCGGAGCACTTCGCGCACCTCAACGCTGG 360

Y 361 AGTCTCTGAGTGGGCAAGTTCATCCGGCAGATTGAGTGGGGGCTTCAACGSCC 420
 b 361 AGTCTCTGAGTGGGCAAGTTCATCCGGCAGATTGAGTGGGGGCTTCAACGSCC 420

Y 421 TGGCCAGCTCAACACCTTGGAGCTGTTCGACAACTGGCTGACATCTCCTAGCGGG 480
 b 421 TGGCCAGCTCAACACCTTGGAGCTGTTCGACAACTGGCTGACATCTCCTAGCGGG 480

Y 481 CTTTGAATACCTGTCAGAGCTGCGGAGCTCTGCTTGGCAACCCCAATCCGAAAGCA 540
 b 481 CTTTGAATACCTGTCAGAGCTGCGGAGCTCTGCTTGGCAACCCCAATCCGAAAGCA 540

Y 541 TCCCTCTTACGCTTCAACCGGGTGCCCTCCTCATGCGCTGGACTTGGGGGAGCTCA 600
 b 541 TCCCTCTTACGCTTCAACCGGGTGCCCTCCTCATGCGCTGGACTTGGGGGAGCTCA 600

Y 601 AGAAGCTGAGTATATCTCTGAGGAGCTTTGAGGGGCTGTTCAACTCAAGTATCTGA 660
 b 601 AGAAGCTGAGTATATCTCTGAGGAGCTTTGAGGGGCTGTTCAACTCAAGTATCTGA 660

Y 661 ACTTGGGCAATGTGCAACATTAAGACATGCCCAATCTCAACCCCTGSGTGGGCTGGAG 720
 b 661 ACTTGGGCAATGTGCAACATTAAGACATGCCCAATCTCAACCCCTGSGTGGGCTGGAG 720

Y 721 AGCTGAGATGTGAGGAAACCACTTCCTCTGAGATCAGGCTGGCTCTTCACTGCGCTGA 780
 b 721 AGCTGAGATGTGAGGAAACCACTTCCTCTGAGATCAGGCTGGCTCTTCACTGCGCTGA 780

Y 781 GCTCCCTCAAGAGCTCTGGGTCTAGTAATCAAGTTCAGCTCAGCTGATGAGCGGAATGCTT 840
 b 781 GCTCCCTCAAGAGCTCTGGGTCTAGTAATCAAGTTCAGCTCAGCTGATGAGCGGAATGCTT 840

Y 841 TTGAGGGCTGCTCTCACTTGTGGAACTCAACTTGGGCCCAAAATAAAGCTCTCTTTTTC 900
 b 841 TTGAGGGCTGCTCTCACTTGTGGAACTCAACTTGGGCCCAAAATAAAGCTCTCTTTTTC 900

Y 901 CCCATACCAAGGAGGTACAGGAACTCAAAATATGACTCCCTCCGCCCAAAACCTTA 960

Db 901 CCCATGACCTCTTTA CCGGCTGAGTACTGTGGAGTTGCATCTACACCAACCCCTT 960
 Qy 961 GGAACGTGTGATTGTGACATTTCTGTGGCTAGCTAGCTGTGGCTTCGAGAGTATATACCAACA 1020
 Db 961 GGAACGTGTGATTGTGACATTTCTGTGGCTAGCTAGCTGTGGCTTCGAGAGTATATACCAACA 1020
 Qy 1021 ATTCCACCTGTCTGTGGCGCTGTCATGCTCCCATGCACATGCAGGCGCTACCTCGTGG 1080
 Db 1021 ATTCCACCTGTCTGTGGCGCTGTCATGCTCCCATGCACATGCAGGCGCTACCTCGTGG 1080
 Qy 1081 AGTGGACCAAGGCTCTCTTCCAGTGTCTGCCCCCTTCAATFATGAGCGCACTCGAGACC 1140
 Db 1081 AGTGGACCAAGGCTCTCTTCCAGTGTCTGCCCCCTTCAATFATGAGCGCACTCGAGACC 1140
 Qy 1141 TCAACATTTCTAGGGTTCGATGGCAGAACTTAAGTGTGGAGTCCCTTATGTCTCTCG 1200
 Db 1141 TCAACATTTCTAGGGTTCGATGGCAGAACTTAAGTGTGGAGTCCCTTATGTCTCTCG 1200
 Qy 1201 TGAAGTGTGTCTGCCAATGGGACAGTGTCTCAGCCAAGCTTCCGCGCAACCAAGATCT 1260
 Db 1201 TGAAGTGTGTCTGCCAATGGGACAGTGTCTCAGCCAAGCTTCCGCGCAACCAAGATCT 1260
 Qy 1261 CTGTCTCTCAAGAGCGCACTTGAACCTTTTCCACGCTGTCTTTTACAGACATGGGGTGT 1320
 Db 1261 CTGTCTCTCAAGAGCGCACTTGAACCTTTTCCACGCTGTCTTTTACAGACATGGGGTGT 1320
 Qy 1321 ACATGCTATGTGTGACCAATGTTCAGGCAACTCAAAAGCTTCCGCTCGGCTACCTCAATGTGA 1380
 Db 1321 ACATGCTATGTGTGACCAATGTTCAGGCAACTCAAAAGCTTCCGCTCGGCTACCTCAATGTGA 1380
 Qy 1381 GCAAGCTGAGCTTAACACTTCAACTAGCTTCTTCCACAGTACAGTACAGTGGAGACA 1440
 Db 1381 GCAAGCTGAGCTTAACACTTCAACTAGCTTCTTCCACAGTACAGTACAGTGGAGACA 1440
 Qy 1441 CGAGATCTCGCTGAGGACACAAAGCTTCAAGCTTCTTCCACAGTACAGTGGAGACA 1500
 Db 1441 CGAGATCTCGCTGAGGACACAAAGCTTCAAGCTTCTTCCACAGTACAGTGGAGACA 1500
 Qy 1501 GTTACAGCGCGCATATACCACTTACCAAGTGTCTTATTCAGACTACCTGCTGAGTGGCCA 1560
 Db 1501 GTTACAGCGCGCATATACCACTTACCAAGTGTCTTATTCAGACTACCTGCTGAGTGGCCA 1560
 Qy 1561 AGCAGTGGCAGTACCGGACAGACACACTGACAAGTGCAGACAGCTTGGATGAAG 1620
 Db 1561 AGCAGTGGCAGTACCGGACAGACACACTGACAAGTGCAGACAGCTTGGATGAAG 1620
 Qy 1621 TCAATGAAGCACCAAGATCATATTTGGCTGCTTTTGGCAGTGACTCTGCTAGTGGCG 1680
 Db 1621 TCAATGAAGCACCAAGATCATATTTGGCTGCTTTTGGCAGTGACTCTGCTAGTGGCG 1680
 Qy 1681 CCATGTTGATTTCTTCTATTAACCTTCTTAAGCGCACCGACGCGGAGTACAGTCAAG 1740
 Db 1681 CCATGTTGATTTCTTCTTATAAATCTTGAAGCGCACCGACGCGGAGTACAGTCAAG 1740
 Qy 1741 CCGCCCGACTGTTGAGATAATCCAGTGGAGAGACATCCAGCAGCAACATCCCGAG 1800
 Db 1741 CCGCCCGACTGTTGAGATAATCCAGTGGAGAGACATCCAGCAGCAACATCCCGAG 1800
 Qy 1801 CAGCAACAGCAGCTCGTCCGCTGTATCAGTGGAGGGGAGTAGTGTGCGCCCAATTC 1860
 Db 1801 CAGCAACAGCAGCTCGTCCGCTGTATCAGTGGAGGGGAGTAGTGTGCGCCCAATTC 1860
 Qy 1861 ATGACCATTAATTAACATCAACACCTTCAAAACAGACATATGGGGCCACCTGGACAGAAAACA 1920
 Db 1861 ATGACCATTAATTAACATCAACACCTTCAAAACAGACATATGGGGCCACCTGGACAGAAAACA 1920
 Qy 1921 GCGTGGGAACTCTCTGACCCCAAGTCAACATATCTCTGAACCTTATATATTAATTGAGA 1980
 Db 1921 GCGTGGGAACTCTCTGACCCCAAGTCAACATATCTCTGAACCTTATATATTAATTGAGA 1980
 Qy 1981 CCCATACCAAGGAGGTACAGGAACTCAAAATATGACTCCCTCCGCCCAAAACCTTA 2040

Db 1981 CCCATACCAAGACAGGTACAGGAACTCAATATFACCTCCCTCCCAAAAACTTA 2040
QY 2041 TAAATGCAATAGATGACACAAAGACAGCAACTTTTGTACAGATGGGGAGAGACTTT 2100
Db 2041 TAAATGCAATAGATGACACAAAGACAGCAACTTTTGTACAGATGGGGAGAGACTTT 2100
QY 2101 TCTTGTATATGCTTATATATTAAGTCTATGCGTGGTTAAAAAACAACATATATATA 2160
Db 2101 TCTTGTATATGCTTATATATTAAGTCTATGCGTGGTTAAAAAACAACATATATATA 2160
QY 2161 AATTTAAAGACAAAAGTCAAAACA 2185
Db 2161 AATTTAAAGACAAAAGTCAAAACA 2185

RESULT 23

JS-09-993-667-228
Sequence 228, Application US/09993667
Publication No. US20030022187A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C4
CURRENT APPLICATION NUMBER: US/09/993,667
PRIOR FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/048787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02

PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908

PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;

Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTCTCTTTCCGAGCCAAATCCCGAGGCGATGGTGAATATGAAAGCTGCCACCATGA 60
Db |||||
Qy 1 GTTCTCTTTCCGAGCCAAATCCCGAGGCGATGGTGAATATGAAAGCTGCCACCATGA 60
Db |||||

Qy 61 AGCTCTTGTGGCAGGTAACTGTGTCACACACCTGGAAATCCATCTCTGCTCCCGTTGG 120
Db |||||

Qy 61 AGCTCTTGTGGCAGGTAACTGTGTCACACACCTGGAAATCCATCTCTGCTCCCGTTGG 120
Db |||||

Qy 121 TCTACCTCACGGCGCAAGTGTGAATCTGTGTGACGCCATGCTGTGCTCGCGCTCAGCGG 180
Db |||||

Qy 121 TCTACCTCACGGCGCAAGTGTGAATCTGTGTGACGCCATGCTGTGCTCGCGCTCAGCGG 180
Db |||||

Qy 181 GGGCCAGAACTGCGCTCCGTTTGTGTCGAGTAACCACTTACGAAAGGTGGTGTGA 240
Db |||||

Qy 181 GGGCCAGAACTGCGCTCCGTTTGTGTCGAGTAACCACTTACGAAAGGTGGTGTGA 240
Db |||||

Qy 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGGTATTCCTCGAACACCCGGTACCTCAACC 300
Db |||||

Qy 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGGTATTCCTCGAACACCCGGTACCTCAACC 300
Db |||||

Qy 301 TCATGGAGAACACATCCAGATGATCCAGGCGACACCTTCGCGCACCTCCACCTGG 360
Db |||||

Qy 301 TCATGGAGAACACATCCAGATGATCCAGGCGACACCTTCGCGCACCTCCACCTGG 360
Db |||||

Qy 361 AGTCTCTGCAAGTTGGCAGGAACTCCATCCGCGCAGATTGAGTGGGGGCTTCAACGGCC 420
Db |||||

Qy 361 AGTCTCTGCAAGTTGGCAGGAACTCCATCCGCGCAGATTGAGTGGGGGCTTCAACGGCC 420
Db |||||

Qy 421 TGGCCAGCTCAACACGCTGGAGCTGTTTCGAACAATGGGCTGACAGTCATCCCTAGCGGG 480
Db |||||

Qy 421 TGGCCAGCTCAACACGCTGGAGCTGTTTCGAACAATGGGCTGACAGTCATCCCTAGCGGG 480
Db |||||

Qy 481 CCTTTGAATACCTGTCCAAAGCTCGGGAGCTCTGGCTTCGCAACACCCCATCGAAAGCA 540
Db |||||

Qy 481 CCTTTGAATACCTGTCCAAAGCTCGGGAGCTCTGGCTTCGCAACACCCCATCGAAAGCA 540
Db |||||

Qy 541 TCCCTCTTACGCTTCAACCGGGTGGCTTCCCTCATGCGCTGAGCTTGGGGGAGCTCA 600
Db |||||

Qy 541 TCCCTCTTACGCTTCAACCGGGTGGCTTCCCTCATGCGCTGAGCTTGGGGGAGCTCA 600
Db |||||

Qy 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGGGGGCTGTTCAACCTCAAGTATCTGA 660
Db |||||

Qy 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGGGGGCTGTTCAACCTCAAGTATCTGA 660
Db |||||

Qy 661 ACTTGGGCAATGTCAGAAATTAAGACATGCCCAATCTCACCCCTGCTGGGGCTGGAGG 720
Db |||||

Qy 661 ACTTGGGCAATGTCAGAAATTAAGACATGCCCAATCTCACCCCTGCTGGGGCTGGAGG 720
Db |||||

Qy 721 AGCTGGAGATGTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGCGCTGA 780
Db |||||

Qy 721 AGCTGGAGATGTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGCGCTGA 780
Db |||||

Qy 781 GCTCCCTCAAGAGCTCTGGGTCAAGAACTCAAGCTCAGCTGATTTGAGCGGAATGTT 840
Db |||||

Qy 781 GCTCCCTCAAGAGCTCTGGGTCAAGAACTCAAGCTCAGCTGATTTGAGCGGAATGTT 840
Db |||||

Qy 841 TTGACCGGCTGGCTTCACTTGTGGAACTCACTGAGCTGGCGCAATTAACCTCTCTTTTTC 900
Db |||||

Qy 841 TTGACCGGCTGGCTTCACTTGTGGAACTCACTGAGCTGGCGCAATTAACCTCTCTTTTTC 900
Db |||||

Qy 901 CCATGACCTCTTTTACCCCGCTGAGGTACCTGGTGGAGTTGATCTACACCAACACCTT 960
Db |||||

Qy 901 CCATGACCTCTTTTACCCCGCTGAGGTACCTGGTGGAGTTGATCTACACCAACACCTT 960
Db |||||

Qy 961 GGAAGTGTGATGAGCAATCTGTGGTGGCTGCTGGCTGGAGAGTATATACCAACA 1020
Db |||||

Qy 961 GGAAGTGTGATGAGCAATCTGTGGTGGCTGCTGGCTGGAGAGTATATACCAACA 1020
Db |||||

Qy 1021 ATTCCACCTGCTGTGGCGCTGTCATGCTCCCATGCAATGCGAGGCGCTACCTCGTGG 1080
Db |||||

1021 ATTCCACCTGCTGTGGCGCTCATGCTCCCATGACATGCGAGGCGGCTACCTCGTGG 1080
 1081 AGGTGGACGAGCTCTCTTCAAGTGTCTGCGCCCTTCATCATGCGAGGCGGCTCGAGACC 1140
 1081 AGGTGGACGAGCTCTCTTCAAGTGTCTGCGCCCTTCATCATGCGAGGCGGCTCGAGACC 1140
 1141 TCAACATTTCTGAGGGTGGATGCGAGCACTTAAAGTGTGAGCTCCCGCTATGTCCTCG 1200
 1141 TCAACATTTCTGAGGGTGGATGCGAGCACTTAAAGTGTGAGCTCCCGCTATGTCCTCG 1200
 1201 TGAAGTGTGCTGCTCCCAATGGGACAGTGTCTGAGCGAGGCTCCGCGACCCCAAGATCT 1260
 1201 TGAAGTGTGCTGCTCCCAATGGGACAGTGTCTGAGCGAGGCTCCGCGACCCCAAGATCT 1260
 1261 CTGTCTCTCAACGAGCGGACCTTGAACCTTTTCCACAGTGTCTTTCAGACACTGCGGCTG 1320
 1261 CTGTCTCTCAACGAGCGGACCTTGAACCTTTTCCACAGTGTCTTTCAGACACTGCGGCTG 1320
 1321 ACATGATGCTGAGCACTTGAACCTTTTCCACAGTGTCTTTCAGACACTGCGGCTG 1380
 1321 ACATGATGCTGAGCACTTGAACCTTTTCCACAGTGTCTTTCAGACACTGCGGCTG 1380
 1381 GCAGGCTGAGCTTGAACCTTTTCCACAGTGTCTTTCAGACACTGCGGCTG 1440
 1381 GCAGGCTGAGCTTGAACCTTTTCCACAGTGTCTTTCAGACACTGCGGCTG 1440
 1441 CGGAGATCTGCTGAGCACTTGAACCTTTTCCACAGTGTCTTTCAGACACTGCGGCTG 1500
 1441 CGGAGATCTGCTGAGCACTTGAACCTTTTCCACAGTGTCTTTCAGACACTGCGGCTG 1500
 1501 GTTACCGCGGCTATACCACTTCTTACAGGCTCTTTCAGACACTGCGGCTG 1560
 1501 GTTACCGCGGCTATACCACTTCTTACAGGCTCTTTCAGACACTGCGGCTG 1560
 1561 AGCAGTGTGAGTATACCACTTCTTACAGGCTCTTTCAGACACTGCGGCTG 1620
 1561 AGCAGTGTGAGTATACCACTTCTTACAGGCTCTTTCAGACACTGCGGCTG 1620
 1621 TCATGAGCACTGAGTATACCACTTCTTACAGGCTCTTTCAGACACTGCGGCTG 1680
 1621 TCATGAGCACTGAGTATACCACTTCTTACAGGCTCTTTCAGACACTGCGGCTG 1680
 1681 CCATGTTGATGCTCTTATTAACCTTCTTACAGGCTCTTTCAGACACTGCGGCTG 1740
 1681 CCATGTTGATGCTCTTATTAACCTTCTTACAGGCTCTTTCAGACACTGCGGCTG 1740
 1741 CGCGCGGCTGAGTATACCACTTCTTACAGGCTCTTTCAGACACTGCGGCTG 1800
 1741 CGCGCGGCTGAGTATACCACTTCTTACAGGCTCTTTCAGACACTGCGGCTG 1800
 1801 CAGCAACAGCAGCTCCGCTGCTGATCAGGTGAGGCGGCTGAGTGTCTGCCCAATTC 1860
 1801 CAGCAACAGCAGCTCCGCTGCTGATCAGGTGAGGCGGCTGAGTGTCTGCCCAATTC 1860
 1861 ATGACCATATTAATACCACTTACCAACAGCAGTGTGAGGCGGCTGAGTGTCTGCCCAATTC 1920
 1861 ATGACCATATTAATACCACTTACCAACAGCAGTGTGAGGCGGCTGAGTGTCTGCCCAATTC 1920
 1921 GCTGCGGAGCTCTCTGACCGGCTGATCAGGTGAGGCGGCTGAGTGTCTGCCCAATTC 1980
 1921 GCTGCGGAGCTCTCTGACCGGCTGATCAGGTGAGGCGGCTGAGTGTCTGCCCAATTC 1980
 1981 CCATACCAAGGAGGAGTACAGGAGGAGTGTGAGGCGGCTGAGTGTCTGCCCAATTC 2040
 1981 CCATACCAAGGAGGAGTACAGGAGGAGTGTGAGGCGGCTGAGTGTCTGCCCAATTC 2040
 2041 TAAATGCAATGAGTACCAAGGAGGAGTGTGAGGCGGCTGAGTGTCTGCCCAATTC 2100
 2041 TAAATGCAATGAGTACCAAGGAGGAGTGTGAGGCGGCTGAGTGTCTGCCCAATTC 2100
 2101 TTCTGTATATGCTTATATATTAATGCTGTATGCTGTATGCTGTATGCTGTATGCTGTAT 2160
 2101 TTCTGTATATGCTTATATATTAATGCTGTATGCTGTATGCTGTATGCTGTATGCTGTAT

QY 2161 AATTAAAGACAAAGTCAAAACA 2185
 DB 2161 AATTAAAGACAAAGTCAAAACA 2185
 RESULT 24
 US-09-997-428-228
 ; Sequence 228, Application US/09997428
 ; Publication No. US20030027162A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaudo, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Napier, Mary A.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas F.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tamas, Daniel
 ; APPLICANT: Matanabe, Colin K.
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William I.
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; FILE OF INVENTION: Acids Encoding the Same
 ; FILE REFERENCE: P273091C44
 ; CURRENT APPLICATION NUMBER: US/09/997,428
 ; CURRENT FILING DATE: 2001-11-15
 ; PRIOR APPLICATION NUMBER: 60/049787
 ; PRIOR FILING DATE: 1997-06-16
 ; PRIOR APPLICATION NUMBER: 60/062250
 ; PRIOR FILING DATE: 1997-10-17
 ; PRIOR APPLICATION NUMBER: 60/065186
 ; PRIOR FILING DATE: 1997-11-12
 ; PRIOR APPLICATION NUMBER: 60/065311
 ; PRIOR FILING DATE: 1997-11-13
 ; PRIOR APPLICATION NUMBER: 60/066770
 ; PRIOR FILING DATE: 1997-11-24
 ; PRIOR APPLICATION NUMBER: 60/075945
 ; PRIOR FILING DATE: 1998-02-25
 ; PRIOR APPLICATION NUMBER: 60/078910
 ; PRIOR FILING DATE: 1998-03-20
 ; PRIOR APPLICATION NUMBER: 60/083322
 ; PRIOR FILING DATE: 1998-04-28
 ; PRIOR APPLICATION NUMBER: 60/084600
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/087106
 ; PRIOR FILING DATE: 1998-05-28
 ; PRIOR APPLICATION NUMBER: 60/087607
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087609
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087759
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087827
 ; PRIOR FILING DATE: 1998-06-03
 ; PRIOR APPLICATION NUMBER: 60/088021
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088025
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088026

PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088555
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22

PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090578
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
Best Local Similarity 100.0%; Pred.No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTCTCTTTCGAGCCAAATCCAGCGATGTGAATTATGACCTGCCACACCAATGA 60
Db 1 GTTCTCTTTCGAGCCAAATCCAGCGATGTGAATTATGACCTGCCACACCAATGA 60
Qy 61 AGCTCTTGTGCAGTAACTGTGCACCAACCACTCGAATGCCTCTGCTCCGTTGG 120

Db 61 AGCTCTGTGGCAGGTAACTGTGCACCAACAACCTGGAAATGCATCTCTGCTCCCGTTGG 120
Qy 121 TCTACTCTCACGGCGCAAGTGTGGATTCTGTGTGCAGCCATCGTGTGCGCGCTCAGCGG 180
Db 121 TCTACTCTCACGGCGCAAGTGTGGATTCTGTGTGCAGCCATCGTGTGCGCGCTCAGCGG 180
Qy 181 GCGCCCGAGAACTGCCCTCCGTTTGTGTGTGTCAGTAACTGTTTCAAGAAAGTGTGTGCA 240
Db 181 GCGCCCGAGAACTGCCCTCCGTTTGTGTGTGTCAGTAACTGTTTCAAGAAAGTGTGTGCA 240
Qy 241 GCGCGCGGGGCTCTCCAGAGTCCGCGAGGCTATTCCTCTCGAAACACCCGGTACTCAACC 300
Db 241 GCGCGCGGGGCTCTCCAGAGTCCGCGAGGCTATTCCTCTCGAAACACCCGGTACTCAACC 300
Qy 301 TCATGGAGAAACAATCCAGATGATCCAGGCGGAGACCTTCGCGCACTCTCAACCTG 360
Db 301 TCATGGAGAAACAATCCAGATGATCCAGGCGGAGACCTTCGCGCACTCTCAACCTG 360
Qy 361 AGGTCTCTCAGTTGGGCGAGGAATCCATCCGCGAGATGTAGGTGGGGGCTTCAACGGCC 420
Db 361 AGGTCTCTCAGTTGGGCGAGGAATCCATCCGCGAGATGTAGGTGGGGGCTTCAACGGCC 420
Qy 421 TGGCCAGGCTCAACACCTGGAGTGTTCGACAACTGGCTGACAGTCAATCCCTAGCGGG 480
Db 421 TGGCCAGGCTCAACACCTGGAGTGTTCGACAACTGGCTGACAGTCAATCCCTAGCGGG 480
Qy 481 CCTTTGAATACCTGTCCAGCTCGGGAGCTCTGGCTTCGCAACAATGGCTGACAGTCAAT 540
Db 481 CCTTTGAATACCTGTCCAGCTCGGGAGCTCTGGCTTCGCAACAATGGCTGACAGTCAAT 540
Qy 541 TCCCTCTTACGCTTCAACCGGCTGCTCTCTCATGCGGCTGGAATGGGGGAGCTCA 600
Db 541 TCCCTCTTACGCTTCAACCGGCTGCTCTCTCATGCGGCTGGAATGGGGGAGCTCA 600
Qy 601 AGAAGCTGGATATATCTCTGAGGAGCTTTTGGGGGCTCTTCAACCTCAAGTATCTGA 660
Db 601 AGAAGCTGGATATATCTCTGAGGAGCTTTTGGGGGCTCTTCAACCTCAAGTATCTGA 660
Qy 661 ACTTGGGATGTGCAACATTAAGACATGCCAATCTCACCCCTCTGGTGGGGCTGAGG 720
Db 661 ACTTGGGATGTGCAACATTAAGACATGCCAATCTCACCCCTCTGGTGGGGCTGAGG 720
Qy 721 AGCTGGAGTGTGAGGAACTCTCTCTGAGATCAGGCTGCTCTCTCCATGGGCTGA 780
Db 721 AGCTGGAGTGTGAGGAACTCTCTCTGAGATCAGGCTGCTCTCTCCATGGGCTGA 780
Qy 781 GTCTCCTCAAGAGCTCTGGGTCATGAATCACTCAGGTCAGCTGAGTGGGGAATGCTT 840
Db 781 GTCTCCTCAAGAGCTCTGGGTCATGAATCACTCAGGTCAGCTGAGTGGGGAATGCTT 840
Qy 841 TTGAGGGGCTGGCTTCACTGTGTGGAATCACTTGGGCGCAATTAACCTCTCTCTTTC 900
Db 841 TTGAGGGGCTGGCTTCACTGTGTGGAATCACTTGGGCGCAATTAACCTCTCTCTTTC 900
Qy 901 CCATGACCTCTTTACCCGCTGAGTACCTGGTGGAGTGCATCTACACCAACACCTT 960
Db 901 CCATGACCTCTTTACCCGCTGAGTACCTGGTGGAGTGCATCTACACCAACACCTT 960
Qy 961 GGAATGTGATGTGACATCTGTGGCTAGCTGTGGCTTCGAGAGTATATACCCACCA 1020
Db 961 GGAATGTGATGTGACATCTGTGGCTAGCTGTGGCTTCGAGAGTATATACCCACCA 1020
Qy 1021 ATTCCACCTGTGTGGCGCTGATGTCGCCATGCATCGAGGCGCTACCTGTGG 1080
Db 1021 ATTCCACCTGTGTGGCGCTGATGTCGCCATGCATCGAGGCGCTACCTGTGG 1080
Qy 1081 AGGTGACCCAGGCTCTCTTCCAGTGTCTTGGCCCTTTCATCATGAGCGACCTCGAGAC 1140
Db 1081 AGGTGACCCAGGCTCTCTTCCAGTGTCTTGGCCCTTTCATCATGAGCGACCTCGAGAC 1140
Qy 1141 TCAACATTTCTGAGGCTGGATGGAGAACTTAAGTGTGGAGCTCTCCCTATGTCTCCG 1200
Db 1141 TCAACATTTCTGAGGCTGGATGGAGAACTTAAGTGTGGAGCTCTCCCTATGTCTCCG 1200

RESULT 25
US-09-997-666-228
; Sequence 228, Application US/09997666

Qy 1201 TGAAGTGTGCTCTCCCAATGGGACAGTGTCTCAGCAGCGCTCCGCGCACCCAGGATCT 1260
Db 1201 TGAAGTGTGCTCTCCCAATGGGACAGTGTCTCAGCAGCGCTCCGCGCACCCAGGATCT 1260
Qy 1261 CTGTCTCTCAACGACGCACTTGTGAATTTTCCACGCTGCTGCTTTTCCAGACACTGGGCTGT 1320
Db 1261 CTGTCTCTCAACGACGCACTTGTGAATTTTCCACGCTGCTGCTTTTCCAGACACTGGGCTGT 1320
Qy 1321 ACACATGTGTGTGACCAATGTGTGAGGCACTTCCAGGCTCGGCTTACCTCAATGTGA 1380
Db 1321 ACACATGTGTGTGACCAATGTGTGAGGCACTTCCAGGCTCGGCTTACCTCAATGTGA 1380
Qy 1381 GCAGGCTGAGCTTAAACACCTTCAACCTTCTTCAACAGTAACTGAGGAGACCA 1440
Db 1381 GCAGGCTGAGCTTAAACACCTTCAACCTTCTTCAACAGTAACTGAGGAGACCA 1440
Qy 1441 CGGAGATCTGCTGTGAGGACCAACGCGGAAAGTAAAGGCTTCTTCAACGCTTCACTG 1500
Db 1441 CGGAGATCTGCTGTGAGGACCAACGCGGAAAGTAAAGGCTTCTTCAACGCTTCACTG 1500
Qy 1501 GTTACGAGCGGCAATATACCACTTACCAAGGCTTCACTTCAAGTACCGCTGTGCGCA 1560
Db 1501 GTTACGAGCGGCAATATACCACTTACCAAGGCTTCACTTCAAGTACCGCTGTGCGCA 1560
Qy 1561 AGCAGTGGCAGTACCCGCGACAGACCACTGCAAGATGACAGACCGCTGATGAAG 1620
Db 1561 AGCAGTGGCAGTACCCGCGACAGACCACTGCAAGATGACAGACCGCTGATGAAG 1620
Qy 1621 TCATGAGACCAACAGATCATGCTTGGCTTGTGGCAGTACCTGCTAGCTGCCG 1680
Db 1621 TCATGAGACCAACAGATCATGCTTGGCTTGTGGCAGTACCTGCTAGCTGCCG 1680
Qy 1681 CCATGTGATGTCTTCTTATAAATCTTGTAAAGCGGCAACAGCAGCGGAGTACAGTCAAG 1740
Db 1681 CCATGTGATGTCTTCTTATAAATCTTGTAAAGCGGCAACAGCAGCGGAGTACAGTCAAG 1740
Qy 1741 CCGCCGAGCTTGTGAGATATCCAGTGGGAGGACATCCAGCAGCAGACATCCCGAG 1800
Db 1741 CCGCCGAGCTTGTGAGATATCCAGTGGGAGGACATCCAGCAGCAGACATCCCGAG 1800
Qy 1801 CAGCAACAGCAGCTCCGCTCCGCTGATCAGGTGAGGGGCGAGTAGTGTGCCCAATTC 1860
Db 1801 CAGCAACAGCAGCTCCGCTCCGCTGATCAGGTGAGGGGCGAGTAGTGTGCCCAATTC 1860
Qy 1861 ATGACATATTAATTAACCACTTCAAAACAGCAGCAGCATGGGGCCCACTGGNACAGAAACA 1920
Db 1861 ATGACATATTAATTAACCACTTCAAAACAGCAGCAGCATGGGGCCCACTGGNACAGAAACA 1920
Qy 1921 GCTTGGGAACTCTCTGCAACCCCACTGATCTCTGAACTTATATAATTGAGA 1980
Db 1921 GCTTGGGAACTCTCTGCAACCCCACTGATCTCTGAACTTATATAATTGAGA 1980
Qy 1981 CCCATACCAAGGACAGGTACAGGAACTCAATATGACTCCCTCCCGGAAAAACTTA 2040
Db 1981 CCCATACCAAGGACAGGTACAGGAACTCAATATGACTCCCTCCCGGAAAAACTTA 2040
Qy 2041 TAAATGCAATAGATGACACAAAGCAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
Db 2041 TAAATGCAATAGATGACACAAAGCAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
Qy 2101 TTCTTGTATGCTTATATATTAAGTCTATGGCTGTGTTAAAAAAGACAGATTATATAA 2160
Db 2101 TTCTTGTATGCTTATATATTAAGTCTATGGCTGTGTTAAAAAAGACAGATTATATAA 2160
Qy 2161 AATTTAAAGACAAAAGTCAAAACA 2185
Db 2161 AATTTAAAGACAAAAGTCAAAACA 2185

Publication No. US20030027163A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kijavio, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

ACIDS Encoding the Same

FILE REFERENCE: P2730Pic42

CURRENT APPLICATION NUMBER: US/09/997,666

CURRENT FILING DATE: 2001-11-15

PRIOR APPLICATION NUMBER: 60/049787

PRIOR FILING DATE: 1997-06-16

PRIOR APPLICATION NUMBER: 60/062250

PRIOR FILING DATE: 1997-10-17

PRIOR APPLICATION NUMBER: 60/065186

PRIOR FILING DATE: 1997-11-12

PRIOR APPLICATION NUMBER: 60/065311

PRIOR FILING DATE: 1997-11-13

PRIOR APPLICATION NUMBER: 60/066770

PRIOR FILING DATE: 1997-11-24

PRIOR APPLICATION NUMBER: 60/075945

PRIOR FILING DATE: 1998-02-25

PRIOR APPLICATION NUMBER: 60/078910

PRIOR FILING DATE: 1998-03-20

PRIOR APPLICATION NUMBER: 60/083322

PRIOR FILING DATE: 1998-04-28

PRIOR APPLICATION NUMBER: 60/084600

PRIOR FILING DATE: 1998-05-07

PRIOR APPLICATION NUMBER: 60/087106

PRIOR FILING DATE: 1998-05-28

PRIOR APPLICATION NUMBER: 60/087607

PRIOR FILING DATE: 1998-06-02

PRIOR APPLICATION NUMBER: 60/087609

PRIOR FILING DATE: 1998-06-02

PRIOR APPLICATION NUMBER: 60/087759

PRIOR FILING DATE: 1998-06-02

PRIOR APPLICATION NUMBER: 60/087827

PRIOR FILING DATE: 1998-06-03

PRIOR APPLICATION NUMBER: 60/088021

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088025

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088026

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088028

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088029

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088030

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088033

PRIOR FILING DATE: 1998-06-04

?, PRIOR APPLICATION NUMBER: 60/088326
?, PRIOR FILING DATE: 1998-06-04
?, PRIOR APPLICATION NUMBER: 60/088167
?, PRIOR FILING DATE: 1998-06-05
?, PRIOR APPLICATION NUMBER: 60/088202
?, PRIOR FILING DATE: 1998-06-05
?, PRIOR APPLICATION NUMBER: 60/088212
?, PRIOR FILING DATE: 1998-06-05
?, PRIOR APPLICATION NUMBER: 60/088217
?, PRIOR FILING DATE: 1998-06-05
?, PRIOR APPLICATION NUMBER: 60/088655
?, PRIOR FILING DATE: 1998-06-09
?, PRIOR APPLICATION NUMBER: 60/088734
?, PRIOR FILING DATE: 1998-06-10
?, PRIOR APPLICATION NUMBER: 60/088738
?, PRIOR FILING DATE: 1998-06-10
?, PRIOR APPLICATION NUMBER: 60/088742
?, PRIOR FILING DATE: 1998-06-10
?, PRIOR APPLICATION NUMBER: 60/088810
?, PRIOR FILING DATE: 1998-06-10
?, PRIOR APPLICATION NUMBER: 60/088824
?, PRIOR FILING DATE: 1998-06-10
?, PRIOR APPLICATION NUMBER: 60/088826
?, PRIOR FILING DATE: 1998-06-10
?, PRIOR APPLICATION NUMBER: 60/088858
?, PRIOR FILING DATE: 1998-06-11
?, PRIOR APPLICATION NUMBER: 60/088861
?, PRIOR FILING DATE: 1998-06-11
?, PRIOR APPLICATION NUMBER: 60/088876
?, PRIOR FILING DATE: 1998-06-11
?, PRIOR APPLICATION NUMBER: 60/089105
?, PRIOR FILING DATE: 1998-06-12
?, PRIOR APPLICATION NUMBER: 60/089440
?, PRIOR FILING DATE: 1998-06-16
?, PRIOR APPLICATION NUMBER: 60/089512
?, PRIOR FILING DATE: 1998-06-16
?, PRIOR APPLICATION NUMBER: 60/089514
?, PRIOR FILING DATE: 1998-06-16
?, PRIOR APPLICATION NUMBER: 60/089532
?, PRIOR FILING DATE: 1998-06-17
?, PRIOR APPLICATION NUMBER: 60/089538
?, PRIOR FILING DATE: 1998-06-17
?, PRIOR APPLICATION NUMBER: 60/089598
?, PRIOR FILING DATE: 1998-06-17
?, PRIOR APPLICATION NUMBER: 60/089599
?, PRIOR FILING DATE: 1998-06-17
?, PRIOR APPLICATION NUMBER: 60/089600
?, PRIOR FILING DATE: 1998-06-17
?, PRIOR APPLICATION NUMBER: 60/089653
?, PRIOR FILING DATE: 1998-06-17
?, PRIOR APPLICATION NUMBER: 60/089801
?, PRIOR FILING DATE: 1998-06-18
?, PRIOR APPLICATION NUMBER: 60/089907
?, PRIOR FILING DATE: 1998-06-18
?, PRIOR APPLICATION NUMBER: 60/089908
?, PRIOR FILING DATE: 1998-06-18
?, PRIOR APPLICATION NUMBER: 60/089947
?, PRIOR FILING DATE: 1998-06-19
?, PRIOR APPLICATION NUMBER: 60/089948
?, PRIOR FILING DATE: 1998-06-19
?, PRIOR APPLICATION NUMBER: 60/089952
?, PRIOR FILING DATE: 1998-06-19
?, PRIOR APPLICATION NUMBER: 60/090246
?, PRIOR FILING DATE: 1998-06-22
?, PRIOR APPLICATION NUMBER: 60/090252
?, PRIOR FILING DATE: 1998-06-22
?, PRIOR APPLICATION NUMBER: 60/090254
?, PRIOR FILING DATE: 1998-06-22
?, PRIOR APPLICATION NUMBER: 60/090349
?, PRIOR FILING DATE: 1998-06-23
?, PRIOR APPLICATION NUMBER: 60/090355
?, PRIOR FILING DATE: 1998-06-23
?, PRIOR APPLICATION NUMBER: 60/090429

1	PRIOR FILING DATE: 1998-06-24	
2	PRIOR APPLICATION NUMBER: 60/090431	
3	PRIOR FILING DATE: 1998-06-24	
4	PRIOR APPLICATION NUMBER: 60/090435	
5	PRIOR FILING DATE: 1998-06-24	
6	PRIOR APPLICATION NUMBER: 60/090444	
7	PRIOR FILING DATE: 1998-06-24	
8	PRIOR APPLICATION NUMBER: 60/090445	
9	PRIOR FILING DATE: 1998-06-24	
10	PRIOR APPLICATION NUMBER: 60/090472	
11	PRIOR FILING DATE: 1998-06-24	
12	PRIOR APPLICATION NUMBER: 60/090535	
13	PRIOR FILING DATE: 1998-06-24	
14	PRIOR APPLICATION NUMBER: 60/090540	
15	PRIOR FILING DATE: 1998-06-24	
16	PRIOR APPLICATION NUMBER: 60/090542	
17	PRIOR FILING DATE: 1998-06-24	
18	PRIOR APPLICATION NUMBER: 60/090557	
19	PRIOR FILING DATE: 1998-06-24	
20	PRIOR APPLICATION NUMBER: 60/090676	
21	PRIOR FILING DATE: 1998-06-25	
22	PRIOR APPLICATION NUMBER: 60/090678	
23	PRIOR FILING DATE: 1998-06-25	
24	PRIOR APPLICATION NUMBER: 60/090690	
25	PRIOR FILING DATE: 1998-06-25	
26	PRIOR APPLICATION NUMBER: 60/090694	
27	PRIOR FILING DATE: 1998-06-25	
28	PRIOR APPLICATION NUMBER: 60/090695	
29	PRIOR FILING DATE: 1998-06-25	
30	PRIOR APPLICATION NUMBER: 60/090696	
31	PRIOR FILING DATE: 1998-06-25	
32	PRIOR APPLICATION NUMBER: 60/090822	
33	PRIOR FILING DATE: 1998-06-26	
34	PRIOR APPLICATION NUMBER: 60/090863	
35	PRIOR FILING DATE: 1998-06-26	
36	PRIOR APPLICATION NUMBER: 60/091360	
37	PRIOR FILING DATE: 1998-07-01	
38	PRIOR APPLICATION NUMBER: 60/091478	
39	PRIOR FILING DATE: 1998-07-02	
40	PRIOR APPLICATION NUMBER: 60/091544	
41	PRIOR FILING DATE: 1998-07-01	
42	PRIOR APPLICATION NUMBER: 60/091519	
43	PRIOR FILING DATE: 1998-07-02	
44	PRIOR APPLICATION NUMBER: 60/091626	
45	PRIOR FILING DATE: 1998-07-02	
46	PRIOR APPLICATION NUMBER: 60/091633	
47	PRIOR FILING DATE: 1998-07-02	
48	PRIOR APPLICATION NUMBER: 60/091978	
49	PRIOR FILING DATE: 1998-07-07	
50	PRIOR APPLICATION NUMBER: 60/091982	
51	PRIOR FILING DATE: 1998-07-07	
52	PRIOR APPLICATION NUMBER: 60/092182	
53	PRIOR FILING DATE: 1998-07-09	

Query Match	100.0%	Score 2185;	DB 11;	Length 2185;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 2185;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
2y	1	GTCTCCTTTTCGAGCCAAATCCACGGCATGTGAAATTATGAACGTGCCACACATGA	60	
2b	1	GTCTCCTTTTCGAGCCAAATCCACGGCATGTGAAATTATGAACGTGCCACACATGA	60	
2y	61	AGCTCTTTTGGCAGGTAACTGTGCACCAACACCTTGGAAATGCCATCTGCTCCCGTTGC	120	
2b	61	AGCTCTTTTGGCAGGTAACTGTGCACCAACACCTTGGAAATGCCATCTGCTCCCGTTGC	120	
2y	121	TCTACTCTACGGCCAGTGTGGATCTGTGTGCAGCCATCGCTGTGGCGCTCAGCG	180	
2b	121	TCTACTCTACGGCCAGTGTGGATCTGTGTGCAGCCATCGCTGTGGCGCTCAGCG	180	
2y	181	GGCCCCAGAACTGCCCTTCCTCGTCTGTCAGTAAACAGTTTCACAGAGTGGTGTGCA	240	
2b	181	GGCCCCAGAACTGCCCTTCCTCGTCTGTCAGTAAACAGTTTCACAGAGTGGTGTGCA	240	

Qy	241	CGCGCGGGGCTCTCTCCGAGGTTCCCGACGGGTATTCCCTTCGAACACCCGGTACTCCACC	300
Db	241	CGCGCGGGGGCTCTCTCCGAGGTTCCCGACGGGTATTCCCTTCGAACACCCGGTACTCCACC	300
Qy	301	TCATGAGAGAACAACTCCAGATGATCAGGCGGACACCTTCGCGCCACTCCACCACTCG	360
Db	301	TCATGAGAACAACTCCAGATGATCAGGCGGACACCTTCGCGCCACTCCACCACTCG	360
Qy	361	AGGTCTGCAGTTGGGACGAACTCCATCGGCGAGATTCAGGTGGGGGCTTCAACGGCC	420
Db	361	AGGTCTGCAGTTGGGACGAACTCCATCGGCGAGATTCAGGTGGGGGCTTCAACGGCC	420
Qy	421	TGGCCAGCCTCAACACCCCTGGAGCTGTTCGAACAACTGGCTGACAGTCATCCCTAGCGGG	480
Db	421	TGGCCAGCCTCAACACCCCTGGAGCTGTTCGAACAACTGGCTGACAGTCATCCCTAGCGGG	480
Qy	481	CCTTTGAATACTGTTCCAGCTCGGGAGCTCTGGGCTTCGCAACAACCCCATCGAAGCA	540
Db	481	CCTTTGAATACTGTTCCAGCTCGGGAGCTCTGGGCTTCGCAACAACCCCATCGAAGCA	540
Qy	541	TCCCTCTTTACGCTTTCAACCGGGTCCCTCCCTCATGCGCTGGACTTGGGGGAGCTCA	600
Db	541	TCCCTCTTTACGCTTTCAACCGGGTCCCTCCCTCATGCGCTGGACTTGGGGGAGCTCA	600
Qy	601	AGAGCTGGAGTATATCTCTGAGGGAGCTTTTGAGGGGCTGTTCACTTCAAGTATCTGA	660
Db	601	AGAGCTGGAGTATATCTCTGAGGGAGCTTTTGAGGGGCTGTTCAACTCAAGTATCTGA	660
Qy	661	ACTTGGCATGTGCCAACTTAAGAATGCCAACTCAACCCCTCGTGGGCTGGAGG	720
Db	661	ACTTGGCATGTGCCAACTTAAGAATGCCAACTCAACCCCTCGTGGGCTGGAGG	720
Qy	721	AGCTGGAGATGTCAGGGAACCACTCCCTCGAGATCAGGCTGGCTCCTTCCATGGGCTGA	780
Db	721	AGCTGGAGATGTCAGGGAACCACTTCCCTCGAGATCAGGCTGGCTCCTTCCATGGGCTGA	780
Qy	781	GCTCCCTCAAGAAGCTCTGGGTCAAGACTCAGAGTCAAGCTCAAGCTGATGACGCGAATGCTT	840
Db	781	GCTCCCTCAAGAAGCTCTGGGTCAAGACTCAGAGTCAAGCTGATGACGCGAATGCTT	840
Qy	841	TTGACGGCTGGCTTCACTTGTGGAATCAACTTGGCCACAAATAACCTCTCTTCTTTGC	900
Db	841	TTGACGGCTGGCTTCACTTGTGGAATCAACTTGGCCCCAAATAACCTCTCTTCTTTGC	900
Qy	901	CCCATGACTCTTTTACCCTGCTGAGTACCTGCTGGAGTTGCATCTACACCAACACCTT	960
Db	901	CCCATGACTCTTTTACCCTGCTGAGTACCTGCTGGAGTTGCATCTACACCAACACCTT	960
Qy	961	GGAACTGAGTGTGATCTCTGTGCTAGCTAGCTGGCTTCGAGAGTATATACCCACCA	1020
Db	961	GGAACTGAGTGTGATCTCTGTGCTAGCTAGCTGGCTTCGAGAGTATATACCCACCA	1020
Qy	1021	ATTCCACTGCTGTGCGCTGTCACTGCTCCCATGCACATGCGAGCGCGTACTCGTGG	1080
Db	1021	ATTCCACTGCTGTGCGCTGTCACTGCTCCCATGTCTCCCATGCACATGCGAGCGCGTACTCGTGG	1080
Qy	1081	AGGTGACAGGCTCTTTCAGTGTCTGCCCCCTTCATCATGAGACGCACTCCGAGACC	1140
Db	1081	AGGTGACAGGCTCTTTCAGTGTCTGCCCCCTTCATCATGAGACGCACTCCGAGACC	1140
Qy	1141	TCAACTTCTGAGGTTGGATGGCAGAACTTAAGTGTGGAATCCCTCCCTATGTCCTTCG	1200
Db	1141	TCAACTTCTGAGGTTGGATGGCAGAACTTAAGTGTGGAATCCCTCCCTATGTCCTTCG	1200
Qy	1201	TGAAGTGGTGTGCCCCAATGGGACAGTGTCTCAGGCCACGCTCCCGCCACCCCAAGATCT	1260
Db	1201	TGAAGTGGTGTGCCCCAATGGGACAGTGTCTCAGGCCACGCTCCCGCCACCCCAAGATCT	1260
Qy	1261	CTGTCTCAAACGACCGCACTTGAACTTTTCCACGCTGTGCTTTTGACACACTGGGGTGT	1320
Db	1261	CTGTCTCAAACGACCGCACTTGAACTTTTCCACGCTGTGCTTTTGACACACTGGGGTGT	1320

1321 ACACATGATGTTGACCAATGTTGACGGCAACTCCAAAGCTGGCTACCTCAATGTGA 1380
1321 ACACATGATGTTGACCAATGTTGACGGCAACTCCAAAGCTGGCTACCTCAATGTGA 1380
1381 GCACGGCTGAGCTTACACCTCCAACTACAGCTCTTCCACCAAGTAAACAGTGGAGACA 1440
1381 GCACGGCTGAGCTTACACCTCCAACTACAGCTCTTCCACCAAGTAAACAGTGGAGACA 1440
1441 CGGAGATCTCGCTGAGGACACCAACCGAAAGTACAAAGCTGTTCTTACCAAGTCCACTG 1500
1441 CGGAGATCTCGCTGAGGACACCAACCGAAAGTACAAAGCTGTTCTTACCAAGTCCACTG 1500
1501 GTTACACAGCGGATATACCACTCTTACCAAGTCTCTTACAGACTCCCTGTGGCCA 1560
1501 GTTACACAGCGGATATACCACTCTTACCAAGTCTCTTACAGACTCCCTGTGGCCA 1560
1561 AGCAGTGGCAGTACCGGACACAGACACCACTGACAAAGATGACAGACCGCTGGATGAAG 1620
1561 AGCAGTGGCAGTACCGGACACAGACACCACTGACAAAGATGACAGACCGCTGGATGAAG 1620
1621 TCATGAAGACCAAGATATCACTGCTGCTTGTGCGAGTACTCTGTAGCTGCGG 1680
1621 TCATGAAGACCAAGATATCACTGCTGCTTGTGCGAGTACTCTGTAGCTGCGG 1680
1681 CCATGTTGATGCTTCTATATAAATTCGTAAGCGGACACAGAGCGAGTACAGTCAAG 1740
1681 CCATGTTGATGCTTCTATATAAATTCGTAAGCGGACACAGAGCGAGTACAGTCAAG 1740
1741 CCGCCCGGACTGTTGAGATAATCCAGGTGGAAGAGACATCCAGAGCAACATCCGAG 1800
1741 CCGCCCGGACTGTTGAGATAATCCAGGTGGAAGAGACATCCAGAGCAACATCCGAG 1800
1801 CAGCACAGCAGCTCCGCTCGGTGATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC 1860
1801 CAGCACAGCAGCTCCGCTCGGTGATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC 1860
1861 ATGACCATATTAATCTACCAACCTTACAAACCCAGACATATGGGGCCCACTGGACAGAAAAA 1920
1861 ATGACCATATTAATCTACCAACCTTACAAACCCAGACATATGGGGCCCACTGGACAGAAAAA 1920
1921 GCCTGGGAACTCTTGCACCCACAGTACCACTATCTTGAACCTTATATAATTCAGA 1980
1921 GCCTGGGAACTCTTGCACCCACAGTACCACTATCTTGAACCTTATATAATTCAGA 1980
1981 CCCATACCAAGGACAGGTACAGAAACTCAATATGACTCCCTCCCTCCCAAAAACTTA 2040
1981 CCCATACCAAGGACAGGTACAGAAACTCAATATGACTCCCTCCCTCCCAAAAACTTA 2040
2041 TAAATGCAATAGATGCAACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
2041 TAAATGCAATAGATGCAACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
2101 TTCTTGTATGCTTATATATTAAGTCTATGGCTGTTAAAAAAGACAGATTATATTA 2160
2101 TTCTTGTATGCTTATATATTAAGTCTATGGCTGTTAAAAAAGACAGATTATATTA 2160
2161 AATTTAAAGACAAAAGTCAAAACA 2185
2161 AATTTAAAGACAAAAGTCAAAACA 2185

RESULT 26

S-09-990-438-228
Sequence 228, Application US/09990438
Publication No. US2003002754A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman

APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730P1C3
CURRENT APPLICATION NUMBER: US/09/990,438
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217

; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088655
 ; PRIOR FILING DATE: 1998-06-09
 ; PRIOR APPLICATION NUMBER: 60/088734
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088738
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088742
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088810
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088824
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088826
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088858
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/088861
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/088876
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/089105
 ; PRIOR FILING DATE: 1998-06-12
 ; PRIOR APPLICATION NUMBER: 60/089440
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089512
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089514
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089532
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089538
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089598
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089599
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089600
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089653
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089801
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089907
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089908
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089947
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089948
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089952
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/090246
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090252
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090254
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090349
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090355
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090429
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090431
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090435
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090444
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090445
 ; PRIOR FILING DATE: 1998-06-24

; PRIOR APPLICATION NUMBER: 60/090472
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090535
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090540
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090542
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090557
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090676
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090678
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090690
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090694
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090695
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTCTCTTCCGAGCCAAATCCAGCGCATGCTGAATTATGAACGTGCCACACCATGA 60
 DB 1 GTTCTCTTCCGAGCCAAATCCAGCGCATGCTGAATTATGAACGTGCCACACCATGA 60
 QY 61 AGCTCTTGTCGAGGTAACTGTGCACACCACTCGGAAATGCCATCTCTGCTCCCGTTGG 120
 DB 61 AGCTCTTGTCGAGGTAACTGTGCACACCACTCGGAAATGCCATCTCTGCTCCCGTTGG 120
 QY 121 TCTACCTCAGCGCCCAAGTGTGGATCTGTGTGCAGCATCGCTGTGCGCGCTCAGCCG 180
 DB 121 TCTACCTCAGCGCCCAAGTGTGGATCTGTGTGCAGCATCGCTGTGCGCGCTCAGCCG 180
 QY 181 GCGCCGAGAACTGCCCTCCGTTTCTGTGTCAGTAACACAGTTTCAGCAAGTGTGTGCA 240
 DB 181 GCGCCGAGAACTGCCCTCCGTTTCTGTGTCAGTAACACAGTTTCAGCAAGTGTGTGCA 240
 QY 241 GCGCGCGGGGCTCTCCGAGGTCCCGCAGAGGTATCCCTCGAACACCCGCTACTCAAC 300
 DB 241 GCGCGCGGGGCTCTCCGAGGTCCCGCAGAGGTATCCCTCGAACACCCGCTACTCAAC 300
 QY 301 TCATGGAGAACAACTCCAGATCCAGGCCGACACCTTCCGCCACCTCCACCACTGG 360
 DB 301 TCATGGAGAACAACTCCAGATCCAGGCCGACACCTTCCGCCACCTCCACCACTGG 360

APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C18
CURRENT APPLICATION NUMBER: US/09/990,562
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557

PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090676
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090678
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090690
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090694
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090695
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090696
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090862
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/090863
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/091360
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091478
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091544
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091519
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091626
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091633
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091978
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/091982
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/092182
 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 GTTCTCCTTCCGAGCCAAATCCAGGCGATGGTGAATATGAAGTGGCCACCATGA 60
 1 GTTCTCCTTCCGAGCCAAATCCAGGCGATGGTGAATATGAAGTGGCCACCATGA 60

61 AGCTCTTGTGGCAGGTAACTGTGCACACCACTGGGAATGCATCTCGTCCCGTTGG 120
 61 AGCTCTTGTGGCAGGTAACTGTGCACACCACTGGGAATGCATCTCGTCCCGTTGG 120

121 TCTACCTCAGCGGCAAGTGTGATTTCTGTGTCAGCCATGCTGTGCTGCGCTCAGCG 180
 121 TCTACCTCAGCGGCAAGTGTGATTTCTGTGTCAGCCATGCTGTGCTGCGCTCAGCG 180

181 GGGCCGAGAACTGGCCCTCCGTTGCTGTCGTCAGTAACTGTCAGAGGTGGTGCA 240
 181 GGGCCGAGAACTGGCCCTCCGTTGCTGTCGTCAGTAACTGTCAGAGGTGGTGCA 240

241 CGCGCCGGGGCCCTCCGAGGTCGCGAGGTATTCCTCGAACCACCGGTACCTCAACC 300
 241 CGCGCCGGGGCCCTCCGAGGTCGCGAGGTATTCCTCGAACCACCGGTACCTCAACC 300

301 TCATGGAGAACACATCCAGATGTCAGGCGGACACCTTCGCGGACCTGACACCTGG 360
 301 TCATGGAGAACACATCCAGATGTCAGGCGGACACCTTCGCGGACCTGACACCTGG 360

361 AGGTCTTCAGTGGGAGCAACTCCATCCGAGATTTAGGTGGGGGCTTCACACGGCC 420
 361 AGGTCTTCAGTGGGAGCAACTCCATCCGAGATTTAGGTGGGGGCTTCACACGGCC 420

421 TGGCCAGCTCAACACCTCGAGGTGTGCAACTGGGTGACAGTATCTCTAGCGGG 480
 421 TGGCCAGCTCAACACCTCGAGGTGTGCAACTGGGTGACAGTATCTCTAGCGGG 480

481 CCTTTGATACCTGTCCAGCTGGGGAGCTCTGGCTTCGCAACACCCCATCGAAGCA 540

Db 481 CCTTTGAATACCTGTCCAAAGCTCGGGAGCTCTGGCTTCGCAACCAACCCATCGAAGCA 540
 QY 541 TCCCTCTTTAGCGCTTCAACCCGGTGGCTCCTCATGCGCTGAGCTTTGGGGAGCTCA 600
 Db 541 TCCCTCTTTAGCGCTTCAACCCGGTGGCTCCTCATGCGCTGAGCTTTGGGGAGCTCA 600
 QY 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGAGGGGCTGTTCACCTCAAGTATCTGA 660
 Db 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGAGGGGCTGTTCACCTCAAGTATCTGA 660
 QY 661 ACTTGGGCAATGTCBAACATTAAGACATGCCCAATCTCACCCCTCGTGGTGGGGTGG 720
 Db 661 ACTTGGGCAATGTCBAACATTAAGACATGCCCAATCTCACCCCTCGTGGTGGGGTGG 720
 QY 721 AGCTGGAGATGTCAAGGAAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGCCTGA 780
 Db 721 AGCTGGAGATGTCAAGGAAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGCCTGA 780
 QY 781 GCTCCCTCAAGAGCTCTGGTTCATGAATCAGGTGAGCTGAGCTGAGTGGCGAATGCTT 840
 Db 781 GCTCCCTCAAGAGCTCTGGTTCATGAATCAGGTGAGCTGAGCTGAGTGGCGAATGCTT 840
 QY 841 TTGACGGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCAACAATACCTCTCTTCTTTCG 900
 Db 841 TTGACGGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCAACAATACCTCTCTTCTTTCG 900
 QY 901 CCATGACCTCTTTACCCCGCTGAGGTACCTGGTGGAGTTCATCTACACCAACACCTT 960
 Db 901 CCATGACCTCTTTACCCCGCTGAGGTACCTGGTGGAGTTCATCTACACCAACACCTT 960
 QY 961 GGAAGTGTGATTCGACATTTCTGTGCTAGCTGGTGGTTCGAGAGTATATACCCACCA 1020
 Db 961 GGAAGTGTGATTCGACATTTCTGTGCTAGCTGGTGGTTCGAGAGTATATACCCACCA 1020
 QY 1021 ATTCCACTCTGTGGCGCTGTCTATCTCCATGATGAGGAGCGCTACCTCGTGG 1080
 Db 1021 ATTCCACTCTGTGGCGCTGTCTATCTCCATGATGAGGAGCGCTACCTCGTGG 1080
 QY 1081 AGGTGGACCGAGGCTCTTCCAGTGTCTGCCCCCTTCATCTGAGAGCGACCTCGAGAC 1140
 Db 1081 AGGTGGACCGAGGCTCTTCCAGTGTCTGCCCCCTTCATCTGAGAGCGACCTCGAGAC 1140
 QY 1141 TCAACATTTCTGAGGGTGGATGGCAGAACTTAAGTGTGCGACTCCCCCTATGTCTCCG 1200
 Db 1141 TCAACATTTCTGAGGGTGGATGGCAGAACTTAAGTGTGCGACTCCCCCTATGTCTCCG 1200
 QY 1201 TGAAGTGTGCTGCTCCCAATGGGACAGTGTGAGCCAGCGCTCCCGCCACCGAAGATCT 1260
 Db 1201 TGAAGTGTGCTGCTCCCAATGGGACAGTGTGAGCCAGCGCTCCCGCCACCGAAGATCT 1260
 QY 1261 CTGTCTCAACGACGGCACCCTTGAACTTTTCCCACTGTCTGCTTTTCAGACACTGGGGTGT 1320
 Db 1261 CTGTCTCAACGACGGCACCCTTGAACTTTTCCCACTGTCTGCTTTTCAGACACTGGGGTGT 1320
 QY 1321 ACACATGATGCTGAGCCATGTTGCGAGGAACTTCCAAAGCTCGGCTACCTCAATGTGA 1380
 Db 1321 ACACATGATGCTGAGCCATGTTGCGAGGAACTTCCAAAGCTCGGCTACCTCAATGTGA 1380
 QY 1381 GCAGGCTGAGCTTAAACACCTCCAACTAGAGCTTTCTTCCACAGTAACAGTGGAGCCA 1440
 Db 1381 GCAGGCTGAGCTTAAACACCTCCAACTAGAGCTTTCTTCCACAGTAACAGTGGAGCCA 1440
 QY 1441 CGGAGATCTCGCTGAGGACCAACCGGAAAGTACAAAGCTGTTCCTACCACTGCTG 1500
 Db 1441 CGGAGATCTCGCTGAGGACCAACCGGAAAGTACAAAGCTGTTCCTACCACTGCTG 1500
 QY 1501 GTTACAGCGCGCATATACCACTCTTACCACTGCTGCTTTCAGACTACCGTGGCCCA 1560
 Db 1501 GTTACAGCGCGCATATACCACTCTTACCACTGCTGCTTTCAGACTACCGTGGCCCA 1560
 QY 1561 AGCAGGTGGAGTACCGCGGACAGACCACTGCAAGATGACAGCAGCTGGATGAAG 1620

1561 AGCAGGTGGCAGTACCCGCGCAGCAGACACCACTGACAGATGCGACAGCGCTGGATGAAG 1620
 1621 TCATGAAGACACCAAGATCATCTTGGCTGCTTTTGTGGCAGTGAATCTCTAGCTGCGC 1680
 1621 TCATGAAGACACCAAGATCATCTTGGCTGCTTTTGTGGCAGTGAATCTCTAGCTGCGC 1680
 1681 CCATGTTGATGTTCTTCTATTAATCTTCTAAGCGGCGCAGCAGCGGAGTACAGTCAAG 1740
 1681 CCATGTTGATGTTCTTCTATTAATCTTCTAAGCGGCGCAGCAGCGGAGTACAGTCAAG 1740
 1741 CCGCCCGGAGCTGTTGAGATTAATCCAGGTGAGCAGCAATCCAGCAGCAATCCAGCAG 1800
 1741 CCGCCCGGAGCTGTTGAGATTAATCCAGGTGAGCAGCAATCCAGCAGCAATCCAGCAG 1800
 1801 CAGCAACAGCAGCTCCGTCGGGTGATCAGGTGAGGCGGCGAGTGTGCTGCCCAATTC 1860
 1801 CAGCAACAGCAGCTCCGTCGGGTGATCAGGTGAGGCGGCGAGTGTGCTGCCCAATTC 1860
 1861 ATGACCATATTAATCTACCAACCTTACAAACAGCAGCAATGGGCGGCGAGTGTGCTGCCCAATTC 1920
 1861 ATGACCATATTAATCTACCAACCTTACAAACAGCAGCAATGGGCGGCGAGTGTGCTGCCCAATTC 1920
 1921 GCCTGGGGAATCTCTGACACCCCACTGACCTATCTCTGAACTTATATTAATTCAGA 1980
 1921 GCCTGGGGAATCTCTGACACCCCACTGACCTATCTCTGAACTTATATTAATTCAGA 1980
 1981 CCCATACCAAGCAGCAAGGTACAGGAACTCAATATGACTCCCTCCCTCCCAAAACTTA 2040
 1981 CCCATACCAAGCAGCAAGGTACAGGAACTCAATATGACTCCCTCCCTCCCAAAACTTA 2040
 2041 TAAATGCAATAGATGACACCAAGCAGCAATCTTTGTACAGAGTGGGAGAGACTTT 2100
 2041 TAAATGCAATAGATGACACCAAGCAGCAATCTTTGTACAGAGTGGGAGAGACTTT 2100
 2101 TCTTGTATATGCTTATATTAATTAATGCTGCTGCTTAAATTAATTAATTAATTA 2160
 2101 TCTTGTATATGCTTATATTAATTAATGCTGCTGCTTAAATTAATTAATTAATTA 2160
 2161 AATTTAAAGACAAAAGTCAAAACA 2185
 2161 AATTTAAAGACAAAAGTCAAAACA 2185

RESULT 28

JS-09-990-711-228
 ; Sequence 228, Application US/09990711
 ; Publication No. US20030032023A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnovers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Klijavin, Ivar J.
 ; APPLICANT: Napier, Mary A.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas P.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K.
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William I.
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same
 ; FILE REFERENCE: P2730P1C2
 ; CURRENT APPLICATION NUMBER: US/09/990,711
 ; CURRENT FILING DATE: 2001-11-14
 ; PRIOR APPLICATION NUMBER: 60/049787
 ; PRIOR FILING DATE: 1997-06-16
 ; PRIOR APPLICATION NUMBER: 60/062250
 ; PRIOR FILING DATE: 1997-10-17
 ; PRIOR APPLICATION NUMBER: 60/065186
 ; PRIOR FILING DATE: 1997-11-12
 ; PRIOR APPLICATION NUMBER: 60/065311
 ; PRIOR FILING DATE: 1997-11-13
 ; PRIOR APPLICATION NUMBER: 60/066770
 ; PRIOR FILING DATE: 1997-11-24
 ; PRIOR APPLICATION NUMBER: 60/075945
 ; PRIOR FILING DATE: 1998-02-25
 ; PRIOR APPLICATION NUMBER: 60/078910
 ; PRIOR FILING DATE: 1998-03-20
 ; PRIOR APPLICATION NUMBER: 60/083322
 ; PRIOR FILING DATE: 1998-04-28
 ; PRIOR APPLICATION NUMBER: 60/084600
 ; PRIOR FILING DATE: 1998-05-07
 ; PRIOR APPLICATION NUMBER: 60/087106
 ; PRIOR FILING DATE: 1998-05-28
 ; PRIOR APPLICATION NUMBER: 60/087607
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087609
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087759
 ; PRIOR FILING DATE: 1998-06-02
 ; PRIOR APPLICATION NUMBER: 60/087827
 ; PRIOR FILING DATE: 1998-06-03
 ; PRIOR APPLICATION NUMBER: 60/088021
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088025
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088026
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088028
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088029
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088030
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088033
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088326
 ; PRIOR FILING DATE: 1998-06-04
 ; PRIOR APPLICATION NUMBER: 60/088167
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088202
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088212
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088217
 ; PRIOR FILING DATE: 1998-06-05
 ; PRIOR APPLICATION NUMBER: 60/088655
 ; PRIOR FILING DATE: 1998-06-09
 ; PRIOR APPLICATION NUMBER: 60/088734
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088738
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088742
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088810
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088824
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088826
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088858
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/088861

PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25

Query Match 100.0%; Score 2185; DB 11; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GTTCTCTTTTCGAGCCAAATCCGAGGCGATGGTGAATTATGAACGTGCCACCATGA 60
Db 1 GTTCTCTTTTCGAGCCAAATCCGAGGCGATGGTGAATTATGAACGTGCCACCATGA 60
Qy 61 AGCTCTGTGGCAGGTAACTGTGTCACACACACCTGGATGCCATCTCTGCTCCCGTTG 120
Db 61 AGCTCTGTGGCAGGTAACTGTGTCACACACCTGGATGCCATCTCTGCTCCCGTTG 120
Qy 121 TCTACTCTACGGCGCAAGTGTGATTTCTGTGTGACCCATGCTGTGCGGCTCAGCG 180
Db 121 TCTACTCTACGGCGCAAGTGTGATTTCTGTGTGACCCATGCTGTGCGGCTCAGCG 180
Qy 181 GGCCCGAGAACTGCCCCCTCGTTTGTCTGTGAGTAACAGTTTCAGACAGGTGGTGTGA 240
Db 181 GGCCCGAGAACTGCCCCCTCGTTTGTCTGTGAGTAACAGTTTCAGACAGGTGGTGTGA 240
Qy 241 CGGCGCGGGGCTCTCGAGGTCCCGAGGCTCCCGAGGATTCCTCTCGAACACCCGCTACCTCAAC 300
Db 241 CGGCGCGGGGCTCTCGAGGTCCCGAGGATTCCTCTCGAACACCCGCTACCTCAAC 300
Qy 301 TCATGGAGAACAAATCCAGATGATCCAGGCGGACGACCTTCGCGGCTCCGACCACTGG 360
Db 301 TCATGGAGAACAAATCCAGATGATCCAGGCGGACGACCTTCGCGGCTCCGACCACTGG 360
Qy 361 AGTCTCTGCAAGTTGGGCGAGAACTCCATCCGCGAGATTCAGGTGGGGGCTTCAACGGCC 420
Db 361 AGTCTCTGCAAGTTGGGCGAGAACTCCATCCGCGAGATTCAGGTGGGGGCTTCAACGGCC 420
Qy 421 TGCCGAGCTTCAACACCTTGGAGCTTTTGAACAACTGGCTGACAGTTCATCTCCAGCGGG 480
Db 421 TGCCGAGCTTCAACACCTTGGAGCTTTTGAACAACTGGCTGACAGTTCATCTCCAGCGGG 480
Qy 481 CCTTGTGATACCTGTCCAAAGCTGCGGGAGCTCTGGCTTCGCAACACCCCTCAGAAAGCA 540
Db 481 CCTTGTGATACCTGTCCAAAGCTGCGGGAGCTCTGGCTTCGCAACACCCCTCAGAAAGCA 540
Qy 541 TCCCTCTTTAGCGCTTCAACACCGGGTSCCTCCCTCATGCGCTGAGCTTTGGGGAGCTCA 600
Db 541 TCCCTCTTTAGCGCTTCAACACCGGGTSCCTCCCTCATGCGCTGAGCTTTGGGGAGCTCA 600
Qy 601 AGAGCTGGAGTATATCTCTGAGGGGCTTTTGGGGGCTTTTCAACCTCAAGTATCTCA 660
Db 601 AGAGCTGGAGTATATCTCTGAGGGGCTTTTGGGGGCTTTTCAACCTCAAGTATCTCA 660

601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGAGGGGCTGTTCAACCTCAAGTATCTGA 560
661 ACTTGGGCACTGTGAACATTAAGAGACATGCCAAATCTCACCCCTCTGGTGGGCTGGAGG 720
661 ACTTGGGCACTGTGAACATTAAGAGACATGCCAAATCTCACCCCTCTGGTGGGCTGGAGG 720
721 AGCTGGGAGTGTGAGGAGACATCTTCCCTGAGATCAGGCGCTGCTCTTCCATGGGCTGA 780
721 AGCTGGGAGTGTGAGGAGACATCTTCCCTGAGATCAGGCGCTGCTCTTCCATGGGCTGA 780
781 GCTTCCCTCAAGAGCTCTGAGGAGACATCTTCCCTGAGATCAGGCGCTGCTCTTCCATGGGCTGA 840
781 GCTTCCCTCAAGAGCTCTGAGGAGACATCTTCCCTGAGATCAGGCGCTGCTCTTCCATGGGCTGA 840
841 TTGAGGGGCTGGCTTCACTTGTGGAACCTCAACTTGGGCGCAATTAACCTCTCTTCTTTTCG 900
841 TTGAGGGGCTGGCTTCACTTGTGGAACCTCAACTTGGGCGCAATTAACCTCTCTTCTTTTCG 900
901 CCCATGACCTCTTTTACCCCGCTGAGGTACCTGGTGGAGTGTGATCTACACCAACACCTTT 960
901 CCCATGACCTCTTTTACCCCGCTGAGGTACCTGGTGGAGTGTGATCTACACCAACACCTTT 960
961 GGAATGTGATGTGAATCTGTGGGCTAGCTGTGGGCTTTCAGAGATATATACCCACCA 1020
961 GGAATGTGATGTGAATCTGTGGGCTAGCTGTGGGCTTTCAGAGATATATACCCACCA 1020
1021 ATTCCACCTGTGTGGGCTGTGATCTGTGAGTGTGATCTGTGAGTGTGATCTGTGAGTGTG 1080
1021 ATTCCACCTGTGTGGGCTGTGATCTGTGAGTGTGATCTGTGAGTGTGATCTGTGAGTGTG 1080
1081 AGGTGGACCAAGGCTCTCTTCAAGTGTCTTCCGCTCTTCAAGTGTCTTCCGCTCTTCAAGTGTCT 1140
1081 AGGTGGACCAAGGCTCTCTTCAAGTGTCTTCCGCTCTTCAAGTGTCTTCCGCTCTTCAAGTGTCT 1140
1141 TCACATTTCTGAGGCTGGATGCGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1200
1141 TCACATTTCTGAGGCTGGATGCGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1200
1201 TGAAGTGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
1201 TGAAGTGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
1261 CTGTCTCTCAAGGAGGAGCTTGAATCTTCCAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
1261 CTGTCTCTCAAGGAGGAGCTTGAATCTTCCAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
1321 ACACATGATGCT 1380
1321 ACACATGATGCT 1380
1381 GCACGCTGAGCTTAAACCTTCAAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1440
1381 GCACGCTGAGCTTAAACCTTCAAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1440
1441 CGGAGATCTGCT 1500
1441 CGGAGATCTGCT 1500
1501 GTTACACGCGGATATACCACTTCAAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1560
1501 GTTACACGCGGATATACCACTTCAAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1560
1561 AGCAGGTGGAGTACCGGAGAGACACCACTGACAGATGACAGACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1620
1561 AGCAGGTGGAGTACCGGAGAGACACCACTGACAGATGACAGACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1620
1621 TCATGAGAGACCAAGATCATCTTGGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1680
1621 TCATGAGAGACCAAGATCATCTTGGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1680
1681 CCATCTTGAATGTCTTCTATTAATCTTCTGTAAGCGGACACAGAGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1740
1681 CCATCTTGAATGTCTTCTATTAATCTTCTGTAAGCGGACACAGAGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTGAGTGTG 1740

RESULT 29

US-09-989-726-228
; Sequence 228, Application US/09989726
; Publication No. US2003004073A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gezber, Hanspeter
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Nepier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas P.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730P1660
; CURRENT APPLICATION NUMBER: US/09/989, 726
; CURRENT FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186

QY 1741 CCGCCCCGAGCTGTGTGAGATTAATTCAGGTGGA CGAAGACATCCGAGCAGCAACATTCGGCAG 1800
Db 1741 CCGCCCCGAGCTGTGTGAGATTAATTCAGGTGGA CGAAGACATCCGAGCAGCAACATTCGGCAG 1800
QY 1801 CAGCAACAGCAGCTCCCTCCGGTGTATCAGGTGAGGGGCGAGTAGTGTCTGCCCAATTC 1860
Db 1801 CAGCAACAGCAGCTCCCTCCGGTGTATCAGGTGAGGGGCGAGTAGTGTCTGCCCAATTC 1860
QY 1861 ATGACCAATATTAACCTCAACACCTTAACACCTTAACACCTTAACACCTTAACACCTTAACACCTTA 1920
Db 1861 ATGACCAATATTAACCTCAACACCTTAACACCTTAACACCTTAACACCTTAACACCTTAACACCTTA 1920
QY 1921 GCCTGGGGAATCTCTGCAACCCACACCTTAACACCTTAACACCTTAACACCTTAACACCTTAACACCTTA 1980
Db 1921 GCCTGGGGAATCTCTGCAACCCACACCTTAACACCTTAACACCTTAACACCTTAACACCTTAACACCTTA 1980
QY 1981 CCCATACCAAGGACAGGTACAGGAACTCAAAATATGACTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTTA 2040
Db 1981 CCCATACCAAGGACAGGTACAGGAACTCAAAATATGACTCCCTCCCTCCCTCCCTCCCTCCCTCCCTTA 2040
QY 2041 TAAATGCAATGAGTGTGCAACACCTTAACACCTTAACACCTTAACACCTTAACACCTTAACACCTTA 2100
Db 2041 TAAATGCAATGAGTGTGCAACACCTTAACACCTTAACACCTTAACACCTTAACACCTTAACACCTTA 2100
QY 2101 TTCTGTATATGCTTATATATTAAGTCTATGGCTGTGTTTAAATAAAGAGATTATATTA 2160
Db 2101 TTCTGTATATGCTTATATATTAAGTCTATGGCTGTGTTTAAATAAAGAGATTATATTA 2160
QY 2161 AATTTAAGACAAAGAGTCAAAACA 2185
Db 2161 AATTTAAGACAAAGAGTCAAAACA 2185

1	PRIOR APPLICATION NUMBER: 60/089515	
2	PRIOR FILING DATE: 1998-06-16	
3	PRIOR APPLICATION NUMBER: 60/089532	
4	PRIOR FILING DATE: 1998-06-17	
5	PRIOR APPLICATION NUMBER: 60/089538	
6	PRIOR FILING DATE: 1998-06-17	
7	PRIOR APPLICATION NUMBER: 60/089598	
8	PRIOR FILING DATE: 1998-06-17	
9	PRIOR APPLICATION NUMBER: 60/089599	
10	PRIOR FILING DATE: 1998-06-17	
11	PRIOR APPLICATION NUMBER: 60/089600	
12	PRIOR FILING DATE: 1998-06-17	
13	PRIOR APPLICATION NUMBER: 60/089653	
14	PRIOR FILING DATE: 1998-06-17	
15	PRIOR APPLICATION NUMBER: 60/089801	
16	PRIOR FILING DATE: 1998-06-18	
17	PRIOR APPLICATION NUMBER: 60/089907	
18	PRIOR FILING DATE: 1998-06-18	
19	PRIOR APPLICATION NUMBER: 60/089908	
20	PRIOR FILING DATE: 1998-06-18	
21	PRIOR APPLICATION NUMBER: 60/089947	
22	PRIOR FILING DATE: 1998-06-19	
23	PRIOR APPLICATION NUMBER: 60/089948	
24	PRIOR FILING DATE: 1998-06-19	
25	PRIOR APPLICATION NUMBER: 60/089952	
26	PRIOR FILING DATE: 1998-06-19	
27	PRIOR APPLICATION NUMBER: 60/090246	
28	PRIOR FILING DATE: 1998-06-22	
29	PRIOR APPLICATION NUMBER: 60/090252	
30	PRIOR FILING DATE: 1998-06-22	
31	PRIOR APPLICATION NUMBER: 60/090254	
32	PRIOR FILING DATE: 1998-06-22	
33	PRIOR APPLICATION NUMBER: 60/090349	
34	PRIOR FILING DATE: 1998-06-23	
35	PRIOR APPLICATION NUMBER: 60/090355	
36	PRIOR FILING DATE: 1998-06-23	
37	PRIOR APPLICATION NUMBER: 60/090429	
38	PRIOR FILING DATE: 1998-06-24	
39	PRIOR APPLICATION NUMBER: 60/090431	
40	PRIOR FILING DATE: 1998-06-24	
41	PRIOR APPLICATION NUMBER: 60/090435	
42	PRIOR FILING DATE: 1998-06-24	
43	PRIOR APPLICATION NUMBER: 60/090444	
44	PRIOR FILING DATE: 1998-06-24	
45	PRIOR APPLICATION NUMBER: 60/090454	
46	PRIOR FILING DATE: 1998-06-24	
47	PRIOR APPLICATION NUMBER: 60/090472	
48	PRIOR FILING DATE: 1998-06-24	
49	PRIOR APPLICATION NUMBER: 60/090535	
50	PRIOR FILING DATE: 1998-06-24	
51	PRIOR APPLICATION NUMBER: 60/090540	
52	PRIOR FILING DATE: 1998-06-24	
53	PRIOR APPLICATION NUMBER: 60/090542	
54	PRIOR FILING DATE: 1998-06-24	
55	PRIOR APPLICATION NUMBER: 60/090555	
56	PRIOR FILING DATE: 1998-06-24	
57	PRIOR APPLICATION NUMBER: 60/090676	
58	PRIOR FILING DATE: 1998-06-25	
59	PRIOR APPLICATION NUMBER: 60/090678	
60	PRIOR FILING DATE: 1998-06-25	
61	PRIOR APPLICATION NUMBER: 60/090696	
62	PRIOR FILING DATE: 1998-06-25	
63	PRIOR APPLICATION NUMBER: 60/090690	
64	PRIOR FILING DATE: 1998-06-25	
65	PRIOR APPLICATION NUMBER: 60/090842	
66	PRIOR FILING DATE: 1998-06-26	
67	PRIOR APPLICATION NUMBER: 60/090863	
68	PRIOR FILING DATE: 1998-06-26	
69	PRIOR APPLICATION NUMBER: 60/091360	
70	PRIOR FILING DATE: 1998-06-26	

PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091478
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091544
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091519
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091626
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091633
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091978
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/091982
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/092182
 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1	GTCTCTCTTCCGAGCCAAATCCAGGCGATGGTGAATATGAAGTGCACACCATGA	60
1	GTCTCTCTTCCGAGCCAAATCCAGGCGATGGTGAATATGAAGTGCACACCATGA	60
61	AGCTCTTTGGCAGGTAAGTGTGCACACACACACACACACACACACACACACAC	120
61	AGCTCTTTGGCAGGTAAGTGTGCACACACACACACACACACACACACACACAC	120
121	TCTACCTCAGCGGCAAGTGTGATCTGTGCAGCATCTGTGCGGCTCAGCGC	180
121	TCTACCTCAGCGGCAAGTGTGATCTGTGCAGCATCTGTGCGGCTCAGCGC	180
181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTCAGTAACCAAGTTGACAAAGTGGTGA	240
181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTCAGTAACCAAGTTGACAAAGTGGTGA	240
241	CGCGCGGGGCTCTCCAGGTCCGCGAGGATATCCCTCGAACACCGGTACTCAAC	300
241	CGCGCGGGGCTCTCCAGGTCCGCGAGGATATCCCTCGAACACCGGTACTCAAC	300
301	TCATGGAGAACACATCAGATGATCCAGGCGGACACCTTCCGCGACCTCCACACTG	360
301	TCATGGAGAACACATCAGATGATCCAGGCGGACACCTTCCGCGACCTCCACACTG	360
361	AGGTCTCGAGTTGGGCGAGAACTCCATCCGCGGAGATGAGGTGGGGGCTTCAACGG	420
361	AGGTCTCGAGTTGGGCGAGAACTCCATCCGCGGAGATGAGGTGGGGGCTTCAACGG	420
421	TGGCCAGCTCAACACCTGAGGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG	480
421	TGGCCAGCTCAACACCTGAGGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG	480
481	CTTTTGAATACCTGTCAGGAGCTGGGAGCTGTGGTTCGCAACACCCCATCGAAGCA	540
481	CTTTTGAATACCTGTCAGGAGCTGGGAGCTGTGGTTCGCAACACCCCATCGAAGCA	540
541	TCGCTCTTACGCTTCAACCGGGTCCCTCCCTCATCGGCTGGACTTGGGGAGCTCA	600
541	TCGCTCTTACGCTTCAACCGGGTCCCTCCCTCATCGGCTGGACTTGGGGAGCTCA	600
601	AGAAGCTGAGTATATCTCTGAGGAGCTTTTGAAGGGGCTGTTCAACTCAAGTATCTGA	660
601	AGAAGCTGAGTATATCTCTGAGGAGCTTTTGAAGGGGCTGTTCAACTCAAGTATCTGA	660
661	ACTTGGGATGTGAACATTAAGCATGCCCATCTCACCCCTCGTGGGCTGGAGG	720
661	ACTTGGGATGTGAACATTAAGCATGCCCATCTCACCCCTCGTGGGCTGGAGG	720
721	AGCTGAGATGTCAAGGAAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGGCTGA	780
721	AGCTGAGATGTCAAGGAAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGGCTGA	780

QY	781	GCTCCCTCAAGAAAGCTCTGGGTCAATGAACCTCAGGCTCAGCTGATTCAGCGGAATGCTT	840
DB	781	GCTCCCTCAAGAAAGCTCTGGGTCAATGAACCTCAGGCTCAGCTGATTCAGCGGAATGCTT	840
QY	841	TTGACGGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCAACAATTAACCTCTCTTTTTC	900
DB	841	TTGACGGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCAACAATTAACCTCTCTTTTTC	900
QY	901	CCATGACCTCTTTTACCCGCTGAGGTACTGTGTGAGTTGCACTCTACACCAACACCTT	960
DB	901	CCATGACCTCTTTTACCCGCTGAGGTACTGTGTGAGTTGCACTCTACACCAACACCTT	960
QY	961	GGAACTGTGATTTGCACTTGTGTGAGCTGTGGCTTGGAGAGTATATACCCACCA	1020
DB	961	GGAACTGTGATTTGCACTTGTGTGAGCTGTGGCTTGGAGAGTATATACCCACCA	1020
QY	1021	ATTCCACCTCTGTGGCGCTGTCATGCTCCCATGACATGCGAGCGCTACCTCGTGG	1080
DB	1021	ATTCCACCTCTGTGGCGCTGTCATGCTCCCATGACATGCGAGCGCTACCTCGTGG	1080
QY	1081	AGGTGGACCAAGGCTCTCTCCAGTGTCTGCCCCCTTCATGATGAGCGACCTCGAGAC	1140
DB	1081	AGGTGGACCAAGGCTCTCTCCAGTGTCTGCCCCCTTCATGATGAGCGACCTCGAGAC	1140
QY	1141	TCACATTTCTGAGGGTCCGATGCGAGACTTAAGTGTGGACTCCCCCTATGCTCTCG	1200
DB	1141	TCACATTTCTGAGGGTCCGATGCGAGACTTAAGTGTGGACTCCCCCTATGCTCTCG	1200
QY	1201	TGAAGTGTGTCTGCCCAATGGGACAGTGTCTGACCAAGCTCTCCGCGACCCCAAGATCT	1260
DB	1201	TGAAGTGTGTCTGCCCAATGGGACAGTGTCTGACCAAGCTCTCCGCGACCCCAAGATCT	1260
QY	1261	CTGTCTTCAAGAGCGGACCTTGAATTTTCCACGCTGCTTTCAGACACTGGGGTGT	1320
DB	1261	CTGTCTTCAAGAGCGGACCTTGAATTTTCCACGCTGCTTTCAGACACTGGGGTGT	1320
QY	1321	ACACATGATGTGACCAATGTTGCGAGCAACTCCAAAGCTCTCGGCTTACCTCAATGTA	1380
DB	1321	ACACATGATGTGACCAATGTTGCGAGCAACTCCAAAGCTCTCGGCTTACCTCAATGTA	1380
QY	1381	GCAGGCTGAGCTTAAACCTTCAAGCTTCTTCCACAGTAAAGTAAAGTAAAGTAAAG	1440
DB	1381	GCAGGCTGAGCTTAAACCTTCAAGCTTCTTCCACAGTAAAGTAAAGTAAAGTAAAG	1440
QY	1441	CGGAGATCTGCTCGGACGACACAAAGCTTCTTCCACAGTAAAGTAAAGTAAAGTAAAG	1500
DB	1441	CGGAGATCTGCTCGGACGACACAAAGCTTCTTCCACAGTAAAGTAAAGTAAAGTAAAG	1500
QY	1501	GTACACCGCGGACATATACCACTTACCAAGCTTCTTCCACAGTAAAGTAAAGTAAAG	1560
DB	1501	GTACACCGCGGACATATACCACTTACCAAGCTTCTTCCACAGTAAAGTAAAGTAAAG	1560
QY	1561	AGCAGGTGGAGTACCGCGGACGACACCACTGACAAAGTAAAGTAAAGTAAAGTAAAG	1620
DB	1561	AGCAGGTGGAGTACCGCGGACGACACCACTGACAAAGTAAAGTAAAGTAAAGTAAAG	1620
QY	1621	TCATGAGAACCAACCAAGTATCATTTGGCTTGTGGTGGAGTGAAGTCTGTAGTCTCG	1680
DB	1621	TCATGAGAACCAACCAAGTATCATTTGGCTTGTGGTGGAGTGAAGTCTGTAGTCTCG	1680
QY	1681	CCATGTTCAATGTCTTCTATAAATCTGTAAGCGGACACGAGCGAGTACAGTACAG	1740
DB	1681	CCATGTTCAATGTCTTCTATAAATCTGTAAGCGGACACGAGCGAGTACAGTACAG	1740
QY	1741	CCGCCCCGAGCTGTTGAGATAATCCAGGTGACGAGACATCCACAGCAACATCCCGAG	1800
DB	1741	CCGCCCCGAGCTGTTGAGATAATCCAGGTGACGAGACATCCACAGCAACATCCCGAG	1800
QY	1801	CAGCAACAGAGCTCTCGTCCGTTATCAGGTGAGGGGCGAGTAGTCTGCCCAATTC	1860
DB	1801	CAGCAACAGAGCTCTCGTCCGTTATCAGGTGAGGGGCGAGTAGTCTGCCCAATTC	1860

1861 ATGACCATATTAACATCAACACCTACAAACCCAGCAGCATGGGCGCCACTGGACAGAAAAACA 1920
1861 ATGACCATATTAACATCAACACCTACAAACCCAGCAGCATGGGCGCCACTGGACAGAAAAACA 1920
1921 GCCTGGGGAACCTCTGACCCCAAGGTACAGAAACTCAATATGACTCCCTCCCAAAAAAAGTTA 2040
1921 GCCTGGGGAACCTCTGACCCCAAGGTACAGAAACTCAATATGACTCCCTCCCAAAAAAAGTTA 2040
1981 CCATACCAAGGACCAAGGTACAGAAACTCAATATGACTCCCTCCCAAAAAAAGTTA 2040
1981 CCATACCAAGGACCAAGGTACAGAAACTCAATATGACTCCCTCCCAAAAAAAGTTA 2040
2041 TAAATGCAATAGATGACCAACAGCAGCAACTTTGTACAGAGTGGGAGAGACTTT 2100
2041 TAAATGCAATAGATGACCAACAGCAGCAACTTTGTACAGAGTGGGAGAGACTTT 2100
2101 TTCTTGATATGCTTATATATTAAAGTCTATGGCTGGTTAAAAAAAACAGATTATATTAA 2160
2101 TTCTTGATATGCTTATATATTAAAGTCTATGGCTGGTTAAAAAAAACAGATTATATTAA 2160
2161 AATTTAAAGCAAAAAAGTCAAAACA 2185
2161 AATTTAAAGCAAAAAAGTCAAAACA 2185

RESULT 30

S-09-988-156-228

Sequence 228, Application US/09998156

Publication No. US20030044806A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.

APPLICANT: Baker, Kevin P.

APPLICANT: Botstein, David

APPLICANT: Desnoyers, Luc

APPLICANT: Baton, Dan L.

APPLICANT: Ferrara, Napoleone

APPLICANT: Fong, Sherman

APPLICANT: Gerber, Hanspeter

APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Grimaldi, J. Christopher

APPLICANT: Gurney, Austin L.

APPLICANT: Kljavin, Ivar J.

APPLICANT: Napier, Mary A.

APPLICANT: Pan, James

APPLICANT: Paoni, Nicholas F.

APPLICANT: Roy, Margaret Ann

APPLICANT: Stewart, Timothy A.

APPLICANT: Tumas, Daniel

APPLICANT: Watanabe, Colin K.

APPLICANT: Williams, P. Mickey

APPLICANT: Wood, William I.

APPLICANT: Zhang, Zemin

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

FILE OF INVENTION: Acids Encoding the Same

FILE REFERENCE: P2730P1C28

CURRENT APPLICATION NUMBER: US/09/998,156

CURRENT FILING DATE: 2001-11-15

PRIOR APPLICATION NUMBER: 60/049787

PRIOR FILING DATE: 1997-06-16

PRIOR APPLICATION NUMBER: 60/062250

PRIOR FILING DATE: 1997-10-17

PRIOR APPLICATION NUMBER: 60/065186

PRIOR FILING DATE: 1997-11-12

PRIOR APPLICATION NUMBER: 60/065311

PRIOR FILING DATE: 1997-11-13

PRIOR APPLICATION NUMBER: 60/066770

PRIOR FILING DATE: 1997-11-24

PRIOR APPLICATION NUMBER: 60/075945

PRIOR FILING DATE: 1998-02-25

PRIOR APPLICATION NUMBER: 60/078910

PRIOR FILING DATE: 1998-03-20

PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599

1 PRIOR FILING DATE: 1998-06-02
2 PRIOR APPLICATION NUMBER: 60/087759
3 PRIOR FILING DATE: 1998-06-02
4 PRIOR APPLICATION NUMBER: 60/087827
5 PRIOR FILING DATE: 1998-06-03
6 PRIOR APPLICATION NUMBER: 60/088021
7 PRIOR FILING DATE: 1998-06-04
8 PRIOR APPLICATION NUMBER: 60/088025
9 PRIOR FILING DATE: 1998-06-04
10 PRIOR APPLICATION NUMBER: 60/088026
11 PRIOR FILING DATE: 1998-06-04
12 PRIOR APPLICATION NUMBER: 60/088028
13 PRIOR FILING DATE: 1998-06-04
14 PRIOR APPLICATION NUMBER: 60/088029
15 PRIOR FILING DATE: 1998-06-04
16 PRIOR APPLICATION NUMBER: 60/088030
17 PRIOR FILING DATE: 1998-06-04
18 PRIOR APPLICATION NUMBER: 60/088033
19 PRIOR FILING DATE: 1998-06-04
20 PRIOR APPLICATION NUMBER: 60/088326
21 PRIOR FILING DATE: 1998-06-04
22 PRIOR APPLICATION NUMBER: 60/088167
23 PRIOR FILING DATE: 1998-06-05
24 PRIOR APPLICATION NUMBER: 60/088202
25 PRIOR FILING DATE: 1998-06-05
26 PRIOR APPLICATION NUMBER: 60/088212
27 PRIOR FILING DATE: 1998-06-05
28 PRIOR APPLICATION NUMBER: 60/088217
29 PRIOR FILING DATE: 1998-06-05
30 PRIOR APPLICATION NUMBER: 60/088655
31 PRIOR FILING DATE: 1998-06-09
32 PRIOR APPLICATION NUMBER: 60/088734
33 PRIOR FILING DATE: 1998-06-10
34 PRIOR APPLICATION NUMBER: 60/088738
35 PRIOR FILING DATE: 1998-06-10
36 PRIOR APPLICATION NUMBER: 60/088742
37 PRIOR FILING DATE: 1998-06-10
38 PRIOR APPLICATION NUMBER: 60/088810
39 PRIOR FILING DATE: 1998-06-10
40 PRIOR APPLICATION NUMBER: 60/088824
41 PRIOR FILING DATE: 1998-06-10
42 PRIOR APPLICATION NUMBER: 60/088826
43 PRIOR FILING DATE: 1998-06-10
44 PRIOR APPLICATION NUMBER: 60/088858
45 PRIOR FILING DATE: 1998-06-11
46 PRIOR APPLICATION NUMBER: 60/088861
47 PRIOR FILING DATE: 1998-06-11
48 PRIOR APPLICATION NUMBER: 60/088876
49 PRIOR FILING DATE: 1998-06-11
50 PRIOR APPLICATION NUMBER: 60/089105
51 PRIOR FILING DATE: 1998-06-12
52 PRIOR APPLICATION NUMBER: 60/089440
53 PRIOR FILING DATE: 1998-06-16
54 PRIOR APPLICATION NUMBER: 60/089512
55 PRIOR FILING DATE: 1998-06-16
56 PRIOR APPLICATION NUMBER: 60/089514
57 PRIOR FILING DATE: 1998-06-16
58 PRIOR APPLICATION NUMBER: 60/089532
59 PRIOR FILING DATE: 1998-06-17
60 PRIOR APPLICATION NUMBER: 60/089538
61 PRIOR FILING DATE: 1998-06-17
62 PRIOR APPLICATION NUMBER: 60/089598
63 PRIOR FILING DATE: 1998-06-17
64 PRIOR APPLICATION NUMBER: 60/089599
65 PRIOR FILING DATE: 1998-06-17
66 PRIOR APPLICATION NUMBER: 60/089600
67 PRIOR FILING DATE: 1998-06-17
68 PRIOR APPLICATION NUMBER: 60/089653
69 PRIOR FILING DATE: 1998-06-17
70 PRIOR APPLICATION NUMBER: 60/089801
71 PRIOR FILING DATE: 1998-06-18
72 PRIOR APPLICATION NUMBER: 60/089907
73 PRIOR FILING DATE: 1998-06-18

1 PRIOR APPLICATION NUMBER: 60/089908
2 PRIOR FILING DATE: 1998-06-18
3 PRIOR APPLICATION NUMBER: 60/089947
4 PRIOR FILING DATE: 1998-06-19
5 PRIOR APPLICATION NUMBER: 60/089948
6 PRIOR FILING DATE: 1998-06-19
7 PRIOR APPLICATION NUMBER: 60/089952
8 PRIOR FILING DATE: 1998-06-19
9 PRIOR APPLICATION NUMBER: 60/090246
10 PRIOR FILING DATE: 1998-06-22
11 PRIOR APPLICATION NUMBER: 60/090252
12 PRIOR FILING DATE: 1998-06-22
13 PRIOR APPLICATION NUMBER: 60/090254
14 PRIOR FILING DATE: 1998-06-22
15 PRIOR APPLICATION NUMBER: 60/090349
16 PRIOR FILING DATE: 1998-06-23
17 PRIOR APPLICATION NUMBER: 60/090355
18 PRIOR FILING DATE: 1998-06-23
19 PRIOR APPLICATION NUMBER: 60/090429
20 PRIOR FILING DATE: 1998-06-24
21 PRIOR APPLICATION NUMBER: 60/090431
22 PRIOR FILING DATE: 1998-06-24
23 PRIOR APPLICATION NUMBER: 60/090435
24 PRIOR FILING DATE: 1998-06-24
25 PRIOR APPLICATION NUMBER: 60/090444
26 PRIOR FILING DATE: 1998-06-24
27 PRIOR APPLICATION NUMBER: 60/090445
28 PRIOR FILING DATE: 1998-06-24
29 PRIOR APPLICATION NUMBER: 60/090472
30 PRIOR FILING DATE: 1998-06-24
31 PRIOR APPLICATION NUMBER: 60/090535
32 PRIOR FILING DATE: 1998-06-24
33 PRIOR APPLICATION NUMBER: 60/090540
34 PRIOR FILING DATE: 1998-06-24
35 PRIOR APPLICATION NUMBER: 60/090542
36 PRIOR FILING DATE: 1998-06-24
37 PRIOR APPLICATION NUMBER: 60/090557
38 PRIOR FILING DATE: 1998-06-24
39 PRIOR APPLICATION NUMBER: 60/090676
40 PRIOR FILING DATE: 1998-06-25
41 PRIOR APPLICATION NUMBER: 60/090678
42 PRIOR FILING DATE: 1998-06-25
43 PRIOR APPLICATION NUMBER: 60/090690
44 PRIOR FILING DATE: 1998-06-25
45 PRIOR APPLICATION NUMBER: 60/090694
46 PRIOR FILING DATE: 1998-06-25
47 PRIOR APPLICATION NUMBER: 60/090695
48 PRIOR FILING DATE: 1998-06-25
49 PRIOR APPLICATION NUMBER: 60/090696
50 PRIOR FILING DATE: 1998-06-25
51 PRIOR APPLICATION NUMBER: 60/090862
52 PRIOR FILING DATE: 1998-06-26
53 PRIOR APPLICATION NUMBER: 60/090863
54 PRIOR FILING DATE: 1998-06-26
55 PRIOR APPLICATION NUMBER: 60/091360
56 PRIOR FILING DATE: 1998-07-01
57 PRIOR APPLICATION NUMBER: 60/091478
58 PRIOR FILING DATE: 1998-07-02
59 PRIOR APPLICATION NUMBER: 60/091544
60 PRIOR FILING DATE: 1998-07-01
61 PRIOR APPLICATION NUMBER: 60/091519
62 PRIOR FILING DATE: 1998-07-02
63 PRIOR APPLICATION NUMBER: 60/091626
64 PRIOR FILING DATE: 1998-07-02
65 PRIOR APPLICATION NUMBER: 60/091633
66 PRIOR FILING DATE: 1998-07-02
67 PRIOR APPLICATION NUMBER: 60/091978
68 PRIOR FILING DATE: 1998-07-07
69 PRIOR APPLICATION NUMBER: 60/091982
70 PRIOR FILING DATE: 1998-07-07
71 PRIOR APPLICATION NUMBER: 60/092182
72 PRIOR FILING DATE: 1998-07-09

Query Match		100.0%;	Score 2185;	DB 11;	Length 2185;		
Best Local Similarity		100.0%;	Pred. No. 0;				
Matches 2185;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps
1	GTCTCTCTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAAAGTGCCACACATCA	60					
1	GTCTCTCTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAAAGTGCCACACATCA	60					
61	AGCTCTTGTGCGAGGTAACCTGTGCACCAACACACCTGGGAATGCATCTGCTCCCGTTCG	120					
61	AGCTCTTGTGCGAGGTAACCTGTGCACCAACACACCTGGGAATGCATCTGCTCCCGTTCG	120					
121	TCTACCTCAACGCGGCAAGTGTGGAATCTGTGTGCAGCCATCGCTGTGCGGCTCAGCG	180					
121	TCTACCTCAACGCGGCAAGTGTGGAATCTGTGTGCAGCCATCGCTGTGCGGCTCAGCG	180					
181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTGAGTAAACAGTTCACAGAGTGTGTGCA	240					
181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTGAGTAAACAGTTCACAGAGTGTGTGCA	240					
241	CGCGCCGGGCGCTCTCCGAGGTCGCGAGGGTATTCCTCGAAACCCCGGTACCTCAACC	300					
241	CGCGCCGGGCGCTCTCCGAGGTCGCGAGGGTATTCCTCGAAACCCCGGTACCTCAACC	300					
301	TCATGGAGAACATCCAGATGATTCAGGCCGACACCTTTCGCGCACTCCACACCTGG	360					
301	TCATGGAGAACATCCAGATGATTCAGGCCGACACCTTTCGCGCACTCCACACCTGG	360					
361	AGTTCCTGCAAGTGGGAGGAACTCCATCCGCGAGATTGAGGTGGGGGCTTCAACGGCC	420					
361	AGTTCCTGCAAGTGGGAGGAACTCCATCCGCGAGATTGAGGTGGGGGCTTCAACGGCC	420					
421	TGGCGAGCTCAACACCTGGAAGTGTGTGACAACTGGGTGACAGTATCTCTAGCGGG	480					
421	TGGCGAGCTCAACACCTGGAAGTGTGTGACAACTGGGTGACAGTATCTCTAGCGGG	480					
481	CTTTGAACTACCTGTCCAACTCGGGAGCTCTGGCTTCGCAACCTCCCAACGCA	540					
481	CTTTGAACTACCTGTCCAACTCGGGAGCTCTGGCTTCGCAACCTCCCAACGCA	540					
541	TCCCTCTTACGCTTTCAACCGGCTCCCTCCCTCATGCGCTGGAGCTTGGGGAGCTCA	600					
541	TCCCTCTTACGCTTTCAACCGGCTCCCTCCCTCATGCGCTGGAGCTTGGGGAGCTCA	600					
601	AGAGCTGGAGTATCTCTGAGGAGCTTTGAGGGGCTTTGAGGGGCTTTGAGGGGCTTGA	660					
601	AGAGCTGGAGTATCTCTGAGGAGCTTTGAGGGGCTTTGAGGGGCTTTGAGGGGCTTGA	660					
661	ACTTGGGCATGTGCAACATTAAGACATGCCAACTCTCACCCCTCTGGTGGGCTGGAGG	720					
661	ACTTGGGCATGTGCAACATTAAGACATGCCAACTCTCACCCCTCTGGTGGGCTGGAGG	720					
721	AGCTGGAGATGTGAGGAAACCACTTCCCTGAGATCAGGCTCGCTTTCATGCGCTTGA	780					
721	AGCTGGAGATGTGAGGAAACCACTTCCCTGAGATCAGGCTCGCTTTCATGCGCTTGA	780					
781	GCTCCCTCAAGAGCTCTGGGTATCAACTCAACAGTCAAGCTGAGCTGATGAGGGAGTGT	840					
781	GCTCCCTCAAGAGCTCTGGGTATCAACTCAACAGTCAAGCTGAGCTGATGAGGGAGTGT	840					
841	TTGACGGGCTGGCTTCACTTGTGAACTCAACTTGGCCCAATTAACCTCTCTTCTTTC	900					
841	TTGACGGGCTGGCTTCACTTGTGAACTCAACTTGGCCCAATTAACCTCTCTTCTTTC	900					
901	CCCATGACCTTTTACCCCGCTGAGTACTCTGGTGGAGTTGATCTACACACACCTTT	960					
901	CCCATGACCTTTTACCCCGCTGAGTACTCTGGTGGAGTTGATCTACACACACCTTT	960					
961	GGAACTGTGATGTGACATTTCTGTGGCTAGCTGGTGGCTTCGAGAGTATATACCACA	1020					
961	GGAACTGTGATGTGACATTTCTGTGGCTAGCTGGTGGCTTCGAGAGTATATACCACA	1020					
1021	ATTCCACCTGCTGTGCGCGCTGTCTGCTCCCATGCAATGCGAGCGCGCTACCTGTGG	1080					

1021	ATTCCACCTGCTGTGCGCGCTGTCTGCTCCCATGCAATGCGAGCGCGCTACCTGTGG	1080					
1081	AGTGGACCAAGGCTCTCTCCAGTGTCTTCCAGTGTCTTCCCGCTTCAATCATGGAACCTCGAGACC	1140					
1081	AGTGGACCAAGGCTCTCTCCAGTGTCTTCCAGTGTCTTCCCGCTTCAATCATGGAACCTCGAGACC	1140					
1141	TCACATTTCTGAGGCTCGGATGCGAGAACTTAAGTGTGGACTCCCGCTATGCTCTCG	1200					
1141	TCACATTTCTGAGGCTCGGATGCGAGAACTTAAGTGTGGACTCCCGCTATGCTCTCG	1200					
1201	TGAAGTGTGCTGCTCCCAATGGAATGGAAGTGTCTCAGCAACCTCCCGCTCCCGCTACCAAGATCT	1260					
1201	TGAAGTGTGCTGCTCCCAATGGAATGGAAGTGTCTCAGCAACCTCCCGCTCCCGCTACCAAGATCT	1260					
1261	CTGTCTCAACGACGCGCACTTGAACCTTTTCCACGCTGTCTTTCAGACACTCTGGGGTGT	1320					
1261	CTGTCTCAACGACGCGCACTTGAACCTTTTCCACGCTGTCTTTCAGACACTCTGGGGTGT	1320					
1321	ACACATGATGTGACCAATGTTGCAAGGCAACTCCAAACCTCCCGCTACCTCAATGTGA	1380					
1321	ACACATGATGTGACCAATGTTGCAAGGCAACTCCAAACCTCCCGCTACCTCAATGTGA	1380					
1381	GCACGCTGAGCTTAAACCTCCAACTAAGCTTCTTCAACAGTAACAGTGAACCA	1440					
1381	GCACGCTGAGCTTAAACCTCCAACTAAGCTTCTTCAACAGTAACAGTGAACCA	1440					
1441	CGGAGATCTCGCTGAGGACCAACCGGAAAGTACAAAGCTGTTCCTACACCTCCACTG	1500					
1441	CGGAGATCTCGCTGAGGACCAACCGGAAAGTACAAAGCTGTTCCTACACCTCCACTG	1500					
1501	GTACACAGCGGCTATPACCACTCTACCAACCTGCTCAATTCAGACTACCCGCTGCCCA	1560					
1501	GTACACAGCGGCTATPACCACTCTACCAACCTGCTCAATTCAGACTACCCGCTGCCCA	1560					
1561	AGCAGGTGGAGTACCGCGGACGACCACTCAACAGTACGACCAACGCTCGGATGAAG	1620					
1561	AGCAGGTGGAGTACCGCGGACGACCACTCAACAGTACGACCAACGCTCGGATGAAG	1620					
1621	TCATGAGACCAACAGATCATCATTTGGCTGCTTTGTCAGTGTCTCTGTAGCTGCG	1680					
1621	TCATGAGACCAACAGATCATCATTTGGCTGCTTTGTCAGTGTCTCTGTAGCTGCG	1680					
1681	CGATGTGATGTCTTATTAACCTTCTAAGCGGCAACGAGCGGAGTACAGTCAAG	1740					
1681	CGATGTGATGTCTTATTAACCTTCTAAGCGGCAACGAGCGGAGTACAGTCAAG	1740					
1741	CCGCCCGGACTGTGAGATAATCCAGTGGACGACATCCAGCAGCAACATCCGAG	1800					
1741	CCGCCCGGACTGTGAGATAATCCAGTGGACGACATCCAGCAGCAACATCCGAG	1800					
1801	CAGCAACAGAGCTCTGCTCGGCTGATCAGGTGAGGGGAGTGTGCTGCCCAATTC	1860					
1801	CAGCAACAGAGCTCTGCTCGGCTGATCAGGTGAGGGGAGTGTGCTGCCCAATTC	1860					
1861	ATGACCATTAATTAACATCAACCTCAACACGAGCATGCGGCGCCACTGGACAGAAACA	1920					
1861	ATGACCATTAATTAACATCAACCTCAACACGAGCATGCGGCGCCACTGGACAGAAACA	1920					
1921	GCTGGGGAACCTCTGACACCCCAAGTCACTATCTCTGAACTTATATAATTCAGA	1980					
1921	GCTGGGGAACCTCTGACACCCCAAGTCACTATCTCTGAACTTATATAATTCAGA	1980					
1981	CCCATACCAAGGACAGGTACAGGAACCTCAATATGATCTCCCTCCCGCTCCCGCTTAA	2040					
1981	CCCATACCAAGGACAGGTACAGGAACCTCAATATGATCTCCCTCCCGCTCCCGCTTAA	2040					
2041	TAAATGCAATAGATGACACAAAGACAGCAACTTTTGTACAGAGTGGGGAGACTTT	2100					
2041	TAAATGCAATAGATGACACAAAGACAGCAACTTTTGTACAGAGTGGGGAGACTTT	2100					
2101	TTCCTGTATATGCTTATATATTAAGTCTATGGCTGTGTAAAAAACAAGATATATTA	2160					

Db 2101 TTCTTGATATGCTTATATATATTAATTAAGTCTATGCGTGGTTAAAAAAGAGATTATATTAA 2160

QY 2161 AATTTAAAGACAAAAGTCAAAACA 2185

Db 2161 AATTTAAAGACAAAAGTCAAAACA 2185

RESULT 32

US-09-991-157-228

Sequence 228, Application US/09991157

Publication No. US20030049638A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.

APPLICANT: Baker, Kevin P.

APPLICANT: Botstein, David

APPLICANT: Desnoyers, Luc

APPLICANT: Eaton, Dan L.

APPLICANT: Ferrara, Napoleone

APPLICANT: Fong, Sherman

APPLICANT: Gerber, Hanspeter

APPLICANT: Gerritsen, Mary E.

APPLICANT: Goddard, Audrey

APPLICANT: Godowski, Paul J.

APPLICANT: Grimaldi, J. Christopher

APPLICANT: Gurney, Austin L.

APPLICANT: Kljavin, Ivar J.

APPLICANT: Napier, Mary A.

APPLICANT: Pan, James

APPLICANT: Paoni, Nicholas F.

APPLICANT: Roy, Margaret Ann

APPLICANT: Stewart, Timothy A.

APPLICANT: Tamas, Daniel

APPLICANT: Watanabe, Colin K.

APPLICANT: Williams, P. Mickey

APPLICANT: Wood, William I.

APPLICANT: Zhang, Zemin

TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

FILE REFERENCE: P2730P1C51

CURRENT APPLICATION NUMBER: US/09/991,157

CURRENT FILING DATE: 2001-11-15

PRIOR APPLICATION NUMBER: 60/049787

PRIOR FILING DATE: 1997-06-16

PRIOR APPLICATION NUMBER: 60/062250

PRIOR FILING DATE: 1997-10-17

PRIOR APPLICATION NUMBER: 60/065186

PRIOR FILING DATE: 1997-11-12

PRIOR APPLICATION NUMBER: 60/065311

PRIOR FILING DATE: 1997-11-13

PRIOR APPLICATION NUMBER: 60/066770

PRIOR FILING DATE: 1997-11-24

PRIOR APPLICATION NUMBER: 60/075945

PRIOR FILING DATE: 1998-02-25

PRIOR APPLICATION NUMBER: 60/078910

PRIOR FILING DATE: 1998-03-20

PRIOR APPLICATION NUMBER: 60/083322

PRIOR FILING DATE: 1998-04-28

PRIOR APPLICATION NUMBER: 60/084600

PRIOR FILING DATE: 1998-05-07

PRIOR APPLICATION NUMBER: 60/087106

PRIOR FILING DATE: 1998-05-28

PRIOR APPLICATION NUMBER: 60/087607

PRIOR FILING DATE: 1998-06-02

PRIOR APPLICATION NUMBER: 60/087609

PRIOR FILING DATE: 1998-06-02

PRIOR APPLICATION NUMBER: 60/087759

PRIOR FILING DATE: 1998-06-02

PRIOR APPLICATION NUMBER: 60/087827

PRIOR FILING DATE: 1998-06-03

PRIOR APPLICATION NUMBER: 60/088021

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088025

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088026

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088028

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088029

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088030

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088033

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088326

PRIOR FILING DATE: 1998-06-04

PRIOR APPLICATION NUMBER: 60/088167

PRIOR FILING DATE: 1998-06-05

PRIOR APPLICATION NUMBER: 60/088202

PRIOR FILING DATE: 1998-06-05

PRIOR APPLICATION NUMBER: 60/088212

PRIOR FILING DATE: 1998-06-05

PRIOR APPLICATION NUMBER: 60/088217

PRIOR FILING DATE: 1998-06-05

PRIOR APPLICATION NUMBER: 60/088655

PRIOR FILING DATE: 1998-06-09

PRIOR APPLICATION NUMBER: 60/088734

PRIOR FILING DATE: 1998-06-10

PRIOR APPLICATION NUMBER: 60/088738

PRIOR FILING DATE: 1998-06-10

PRIOR APPLICATION NUMBER: 60/088742

PRIOR FILING DATE: 1998-06-10

PRIOR APPLICATION NUMBER: 60/088810

PRIOR FILING DATE: 1998-06-10

PRIOR APPLICATION NUMBER: 60/088824

PRIOR FILING DATE: 1998-06-10

PRIOR APPLICATION NUMBER: 60/088826

PRIOR FILING DATE: 1998-06-10

PRIOR APPLICATION NUMBER: 60/088858

PRIOR FILING DATE: 1998-06-11

PRIOR APPLICATION NUMBER: 60/088861

PRIOR FILING DATE: 1998-06-11

PRIOR APPLICATION NUMBER: 60/088876

PRIOR FILING DATE: 1998-06-11

PRIOR APPLICATION NUMBER: 60/089105

PRIOR FILING DATE: 1998-06-12

PRIOR APPLICATION NUMBER: 60/089440

PRIOR FILING DATE: 1998-06-16

PRIOR APPLICATION NUMBER: 60/089512

PRIOR FILING DATE: 1998-06-16

PRIOR APPLICATION NUMBER: 60/089514

PRIOR FILING DATE: 1998-06-16

PRIOR APPLICATION NUMBER: 60/089532

PRIOR FILING DATE: 1998-06-17

PRIOR APPLICATION NUMBER: 60/089538

PRIOR FILING DATE: 1998-06-17

PRIOR APPLICATION NUMBER: 60/089598

PRIOR FILING DATE: 1998-06-17

PRIOR APPLICATION NUMBER: 60/089599

PRIOR FILING DATE: 1998-06-17

PRIOR APPLICATION NUMBER: 60/089600

PRIOR FILING DATE: 1998-06-17

PRIOR APPLICATION NUMBER: 60/089653

PRIOR FILING DATE: 1998-06-17

PRIOR APPLICATION NUMBER: 60/089801

PRIOR FILING DATE: 1998-06-18

PRIOR APPLICATION NUMBER: 60/089907

PRIOR FILING DATE: 1998-06-18

PRIOR APPLICATION NUMBER: 60/089908

PRIOR FILING DATE: 1998-06-18

PRIOR APPLICATION NUMBER: 60/089947

PRIOR FILING DATE: 1998-06-19

PRIOR APPLICATION NUMBER: 60/089948

PRIOR FILING DATE: 1998-06-19

PRIOR APPLICATION NUMBER: 60/089952

PRIOR FILING DATE: 1998-06-19

PRIOR APPLICATION NUMBER: 60/090246

; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090252
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090254
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090349
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090355
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090429
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090431
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090435
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090444
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090445
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090472
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090535
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090540
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090542
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090557
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090676
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090678
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090690
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090694
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090695
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 y 1 GTTCTCTTCGAGCCAAATCCCGGCGATGGTGAATTATGAACGTGCACACCATGA 60
 b 1 GTTCTCTTCGAGCCAAATCCCGGCGATGGTGAATTATGAACGTGCACACCATGA 60
 y 61 AGCTCTTGTGGCAGGTAACCTGTGACCAACCACTGGAAATGCCATCTCGCTCCGCTTCG 120

Db 61 AGCTCTTGTGGCAGGTAACCTGTGACCAACCACTGGAAATGCCATCTCGCTCCGCTTCG 120
 Qy 121 TCTACCTCACGGCGCAAGTGTGATTTCTGTGTCAGCCATCGCTGTGCGGCTTCAGCG 180
 Db 121 TCTACCTCACGGCGCAAGTGTGATTTCTGTGTCAGCCATCGCTGTGCGGCTTCAGCG 180
 Qy 181 GGCCCGCAAACTGCCCCCTCCGTTTGTGTCAGTAACCAAGTTTCAGCAAGTGGTGTGA 240
 Db 181 GGCCCGCAAACTGCCCCCTCCGTTTGTGTCAGTAACCAAGTTTCAGCAAGTGGTGTGA 240
 Qy 241 CGCGCGGGGCTCTCGAGGTCGCCGAGGTATTCCTCGAACACCCGCTACCTCAACC 300
 Db 241 CGCGCGGGGCTCTCGAGGTCGCCGAGGTATTCCTCGAACACCCGCTACCTCAACC 300
 Qy 301 TCATGAGAAACAACATCCAGATGATCCAGGCCGACACCTTCCGCCACCTCCACCACTGG 360
 Db 301 TCATGAGAAACAACATCCAGATGATCCAGGCCGACACCTTCCGCCACCTCCACCACTGG 360
 Qy 361 AGTCTCTGCAAGTGGGCGAGAACTCCATCCGCGAGATTGAGTGGGGGCTTCAACGGCC 420
 Db 361 AGTCTCTGCAAGTGGGCGAGAACTCCATCCGCGAGATTGAGTGGGGGCTTCAACGGCC 420
 Qy 421 TGGCCAGCTCAACACCCCTGGAGCTGTTGCAACAACCTGGCTGACAGTCACTCCCTAGCGGG 480
 Db 421 TGGCCAGCTCAACACCCCTGGAGCTGTTGCAACAACCTGGCTGACAGTCACTCCCTAGCGGG 480
 Qy 481 CTTTGAATACCTGTCCAAGCTGCGGAGCTCTGGCTTGGCAACACCCCATCGAAAGCA 540
 Db 481 CTTTGAATACCTGTCCAAGCTGCGGAGCTCTGGCTTGGCAACACCCCATCGAAAGCA 540
 Qy 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTTGGAGCTTGGGGAGCTCA 600
 Db 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTTGGAGCTTGGGGAGCTCA 600
 Qy 601 AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGAAGGGCTGTTTCAACCTCAAGATCTGA 660
 Db 601 AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGAAGGGCTGTTTCAACCTCAAGATCTGA 660
 Qy 661 ACTTGGGCATGTGCAACATTAAGACATGCCCAATCTCAACCCCTGCTGGGGCTGGAGG 720
 Db 661 ACTTGGGCATGTGCAACATTAAGACATGCCCAATCTCAACCCCTGCTGGGGCTGGAGG 720
 Qy 721 AGCTGAGAGTGTCAAGGAAACACTTCCCTGAGATCAGGCTCGGCTCTTCCATGGCTGA 780
 Db 721 AGCTGAGAGTGTCAAGGAAACACTTCCCTGAGATCAGGCTCGGCTCTTCCATGGCTGA 780
 Qy 781 GCTCCCTCAAGAGCTCTGGCTCATGAACCTCAGCTCAGCTGATGAGCGGATGCTT 840
 Db 781 GCTCCCTCAAGAGCTCTGGCTCATGAACCTCAGCTCAGCTGATGAGCGGATGCTT 840
 Qy 841 TTGACGGGCTGGCTTCACTTGTGGAACCTCAACTTGGCCCACTAATACCTCTCTTCTTGC 900
 Db 841 TTGACGGGCTGGCTTCACTTGTGGAACCTCAACTTGGCCCACTAATACCTCTCTTCTTGC 900
 Qy 901 CCATGACCTTTTACCCGCTGAGTACCTGGTGGAGTGTGATCTACACCAACACCTT 960
 Db 901 CCATGACCTTTTACCCGCTGAGTACCTGGTGGAGTGTGATCTACACCAACACCTT 960
 Qy 961 GGAACGTGATTTGACATTTCTGTGCTAGCTGTGGCTTCGAGAGTATATACCCACA 1020
 Db 961 GGAACGTGATTTGACATTTCTGTGCTAGCTGTGGCTTCGAGAGTATATACCCACA 1020
 Qy 1021 ATTCCACCTGCTGTGCGCTGTCTATGCTCCCATGACATGCGAGCGGCTACCTCGTGG 1080
 Db 1021 ATTCCACCTGCTGTGCGCTGTCTATGCTCCCATGACATGCGAGCGGCTACCTCGTGG 1080
 Qy 1081 AGGTGACACGAGCTCTTCCAGTGTCTGCCCCCTTCATCATGCAACGCACTCGAGACC 1140
 Db 1081 AGGTGACACGAGCTCTTCCAGTGTCTGCCCCCTTCATCATGCAACGCACTCGAGACC 1140
 Qy 1141 TCAACATTTCTGAGGGTGGATGGGAGAACTTAAGTGTGCGGACTCCCTCTATGCTCTCG 1200

PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23

PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTCTCTTTCCGAGCGCAAAATCCGAGGCGATGGTGAATTATGAACGTGCCACACCATGA 60

Db 1 GTTCTCTTTCCGAGCGCAAAATCCGAGGCGATGGTGAATTATGAACGTGCCACACCATGA 60

Qy 61 AGCTCTTGTGGCAGGTAACTGTGACACCAACCTGGAATGCCATCTGCTCCCGTTCCG 120

Db 61 AGCTCTTGTGGCAGGTAACTGTGACACCAACCTGGAATGCCATCTGCTCCCGTTCCG 120

Qy 121 TCTACCTCAGCGCGCAAGTGTGGAATTCGTGTGACGCAATGCTGTCTCCGCTCAGCG 180

Db 121 TCTACCTCAGCGCGCAAGTGTGGAATTCGTGTGACGCAATGCTGTCTCCGCTCAGCG 180

Qy 181 GSCCCAGAACTGCCCTCCGTTTCTGTCAGTAAACAGTTCAGGCAAGTGTGTGCA 240

|||||

Db 181 GGCCCGAGAACTGCGCCCTCCGTTCTGCTGTCAGTAACCAAGTTGAGCAAGTGCTGTGCA 240
Qy 241 CGCGCGGGGCTCTCCGAGGTCGCGAGGTAATCCCTCGAACAACCGGTAACCTCAACC 300
Db 241 CGCGCGGGGCTCTCCGAGGTCGCGAGGTAATCCCTCGAACAACCGGTAACCTCAACC 300
Qy 301 TCATGGAGAACACATCCAGATGATCCAGGCGACACCTCCGCCACCTCCACCACTGG 360
Db 301 TCATGGAGAACACATCCAGATGATCCAGGCGACACCTCCGCCACCTCCACCACTGG 360
Qy 361 AGGTCTCGAGTTGGGACAGAACTCCATCCGCGAGATTGAGGTGGGGCTTTCAACGGCC 420
Db 361 AGGTCTCGAGTTGGGACAGAACTCCATCCGCGAGATTGAGGTGGGGCTTTCAACGGCC 420
Qy 421 TGGCCAGCCTCAGACCCCTGGAGCTGTCGACAACTGCTGACAGTCACTCCCTAGCGGG 480
Db 421 TGGCCAGCCTCAGACCCCTGGAGCTGTCGACAACTGCTGACAGTCACTCCCTAGCGGG 480
Qy 481 CTTTGAATACCTGTCCAGCTGCGGGAGCTGTGGCTTCGCAACAACCCCATCGAAAGCA 540
Db 481 CTTTGAATACCTGTCCAGCTGCGGGAGCTGTGGCTTCGCAACAACCCCATCGAAAGCA 540
Qy 541 TCCCTCTTACGCTTCAACCGGTCCTCTCCCTCATGCGCTGAGACTTGGGGAGCTCA 600
Db 541 TCCCTCTTACGCTTCAACCGGTCCTCTCCCTCATGCGCTGAGACTTGGGGAGCTCA 600
Qy 601 AGAAGCTGAGTATATCTCTGAGGAGCTTTTGAGGGCTGTTCAGCTCAAGTATCTGA 660
Db 601 AGAAGCTGAGTATATCTCTGAGGAGCTTTTGAGGGCTGTTCAGCTCAAGTATCTGA 660
Qy 661 ACTTGGGATGTGAACATTAAGACATGCCAATCTCAACCCCTGCTGGGGTGGAGG 720
Db 661 ACTTGGGATGTGAACATTAAGACATGCCAATCTCAACCCCTGCTGGGGTGGAGG 720
Qy 721 AGCTGAGATGTCAGGGAACCATCTCCCTGAGTACAGGCTGGCTCTTCCATGCGCTGA 780
Db 721 AGCTGAGATGTCAGGGAACCATCTCCCTGAGTACAGGCTGGCTCTTCCATGCGCTGA 780
Qy 781 GTCCTCCTCAAGAGCTCTGGGTGATGAACCTCAAGTCAAGTCAAGTCAAGTCAAGTCA 840
Db 781 GTCCTCCTCAAGAGCTCTGGGTGATGAACCTCAAGTCAAGTCAAGTCAAGTCAAGTCA 840
Qy 841 TTGAGGGGTGCTTCACTTGTGGAACTCAACTTGGGCCCACTAATCTCTCTCTTTTTC 900
Db 841 TTGAGGGGTGCTTCACTTGTGGAACTCAACTTGGGCCCACTAATCTCTCTCTTTTTC 900
Qy 901 CCATGACCTCTTTTACCCCGCTGAGGTACTGCTGGTGAAGTGCATCTACACCAACCCCT 960
Db 901 CCATGACCTCTTTTACCCCGCTGAGGTACTGCTGGTGAAGTGCATCTACACCAACCCCT 960
Qy 961 GGAATGTGATGTGACATCTGTGGCTAGCTGCTGGCTGAGAGTATATACCAACCA 1020
Db 961 GGAATGTGATGTGACATCTGTGGCTAGCTGCTGGCTGAGAGTATATACCAACCA 1020
Qy 1021 ATTCCACCTGCTGTGGCGCTGCTCATGCTGCCATGACATCGAGGCGCTTACCTCTGG 1080
Db 1021 ATTCCACCTGCTGTGGCGCTGCTCATGCTGCCATGACATCGAGGCGCTTACCTCTGG 1080
Qy 1081 AGGTGGAACGAGGCTCTTTCAGTGTCTGTGCCCCCTTCATCATGAGCGACTCGAGACC 1140
Db 1081 AGGTGGAACGAGGCTCTTTCAGTGTCTGTGCCCCCTTCATCATGAGCGACTCGAGACC 1140
Qy 1141 TCAACATTTCTGAGGTCGGATGGCAGAACTTAAGTTCGGACTCCCTCATGCTCTCG 1200
Db 1141 TCAACATTTCTGAGGTCGGATGGCAGAACTTAAGTTCGGACTCCCTCATGCTCTCG 1200
Qy 1201 TGAAGTGTGTGCTGCCCAATGGGACAGTCTCAGCCAGCCTCCCGCCACCCAGAGTCT 1260
Db 1201 TGAAGTGTGTGCTGCCCAATGGGACAGTCTCAGCCAGCCTCCCGCCACCCAGAGTCT 1260
Qy 1261 CTGTCTCTCAACGAGGCTTGAACCTTTCCAGCTGCTCTTTCAGACACTGGGGTGT 1320
Db 1261 CTGTCTCTCAACGAGGCTTGAACCTTTTCAGCTGCTCTTTCAGACACTGGGGTGT 1320

Qy 1321 ACATATGATGTGTGACCAATGTTGAGGCAACTCCAGCGCTCGGCTTACCTCAATGTGA 1380
Db 1321 ACATATGATGTGTGACCAATGTTGAGGCAACTCCAGCGCTCGGCTTACCTCAATGTGA 1380
Qy 1381 GCACGGCTGAGCTTAAACCTCCCACTACAGCTTCTTCCACACAGTAACTGAGAGCA 1440
Db 1381 GCACGGCTGAGCTTAAACCTCCCACTACAGCTTCTTCCACACAGTAACTGAGAGCA 1440
Qy 1441 CGAGATCTCGCTTGAAGACACACCGGAAAGTACAAGCTTCTTCTTACCACTGCTCACTG 1500
Db 1441 CGAGATCTCGCTTGAAGACACACCGGAAAGTACAAGCTTCTTCTTACCACTGCTCACTG 1500
Qy 1501 GTTACACCGCGCATATACCACTTACCAAGTCTCATTCAGACTTACCGTGTGCCCA 1560
Db 1501 GTTACACCGCGCATATACCACTTACCAAGTCTCATTCAGACTTACCGTGTGCCCA 1560
Qy 1561 AGCAGTGGCAGTACCCCGCAGACACCACTGACAGATGACAGCCAGCTGGATGAAG 1620
Db 1561 AGCAGTGGCAGTACCCCGCAGACACCACTGACAGATGACAGCCAGCTGGATGAAG 1620
Qy 1621 TCATGAGGACCAACCAAGATCATTTGGCTGCTTGTGGAGTGACTGCTGTAGTGGCG 1680
Db 1621 TCATGAGGACCAACCAAGATCATTTGGCTGCTTGTGGAGTGACTGCTGTAGTGGCG 1680
Qy 1681 CCATGTTGATGCTTCTTATATAAATCTTCTGTAAGCGCACACAGCGAGTACAGTCAAG 1740
Db 1681 CCATGTTGATGCTTCTTATATAAATCTTCTGTAAGCGCACACAGCGAGTACAGTCAAG 1740
Qy 1741 CGCGCGGAGCTTGTGAGATTAATCCAGTGGAGAGACATCCAGCAGCAATCCCGGAG 1800
Db 1741 CGCGCGGAGCTTGTGAGATTAATCCAGTGGAGAGACATCCAGCAGCAATCCCGGAG 1800
Qy 1801 CAGCAACAGCAGCTCCGCTCCGTGATCAGGTGAGGGGAGTGTGCTGCCCAATTC 1860
Db 1801 CAGCAACAGCAGCTCCGCTCCGTGATCAGGTGAGGGGAGTGTGCTGCCCAATTC 1860
Qy 1861 ATGACCATTAATTAACCAACCTTCAAAACCTGAGGAGTCAATGAGTGGGAGAGCA 1920
Db 1861 ATGACCATTAATTAACCAACCTTCAAAACCTGAGGAGTCAATGAGTGGGAGAGCA 1920
Qy 1921 GCTCGGGAGCTCTTGCACCCCAAGTCAACCACTGAGTGGGAGTGTGAGTGTGAGT 1980
Db 1921 GCTCGGGAGCTCTTGCACCCCAAGTCAACCACTGAGTGGGAGTGTGAGTGTGAGT 1980
Qy 1981 CCATACCAAGGACAGGTACAGGAACTCAAAATGATGACTCCCTCCCAAAACTTA 2040
Db 1981 CCATACCAAGGACAGGTACAGGAACTCAAAATGATGACTCCCTCCCAAAACTTA 2040
Qy 2041 TAAATGCAATAGATGACACAAAGACAGCACTTTGTACAGAGTGGGAGAGCTTT 2100
Db 2041 TAAATGCAATAGATGACACAAAGACAGCACTTTGTACAGAGTGGGAGAGCTTT 2100
Qy 2101 TTTCTGTATGCTTATATATTAAGTCTATGGGCTGTTAAAGGAGTCAATATTA 2160
Db 2101 TTTCTGTATGCTTATATATTAAGTCTATGGGCTGTTAAAGGAGTCAATATTA 2160
Qy 2161 AATTTAAAGCAAAAAGTCAAAACA 2185
Db 2161 AATTTAAAGCAAAAAGTCAAAACA 2185

RESULT 34

US-09-997-573-228

; Sequence 228, Application US/09997573

; Publication NO. US20030049682A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Nabier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C45
CURRENT APPLICATION NUMBER: US/09/997,573
CURRENT FILING DATE: 2001-11-15
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/085311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05

PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445

/ PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090472
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090535
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090540
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090542
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090557
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090676
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090678
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090690
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090694
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090695
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090696
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090862
 / PRIOR FILING DATE: 1998-06-26
 / PRIOR APPLICATION NUMBER: 60/090863
 / PRIOR FILING DATE: 1998-06-26
 / PRIOR APPLICATION NUMBER: 60/091360
 / PRIOR FILING DATE: 1998-07-01
 / PRIOR APPLICATION NUMBER: 60/091478
 / PRIOR FILING DATE: 1998-07-02
 / PRIOR APPLICATION NUMBER: 60/091544
 / PRIOR FILING DATE: 1998-07-01
 / PRIOR APPLICATION NUMBER: 60/091519
 / PRIOR FILING DATE: 1998-07-02
 / PRIOR APPLICATION NUMBER: 60/091626
 / PRIOR FILING DATE: 1998-07-02
 / PRIOR APPLICATION NUMBER: 60/091633
 / PRIOR FILING DATE: 1998-07-02
 / PRIOR APPLICATION NUMBER: 60/091978
 / PRIOR FILING DATE: 1998-07-07
 / PRIOR APPLICATION NUMBER: 60/091982
 / PRIOR FILING DATE: 1998-07-07
 / PRIOR APPLICATION NUMBER: 60/092182
 / PRIOR FILING DATE: 1998-07-09

Query Match 100.08; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.08; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 GTTCTCTTTCCGAGCCAAAATCCAGCGCATGGTGAATTATGAACGTGCCACCATGA 60
 1 GTTCTCTTTCCGAGCCAAAATCCAGCGCATGGTGAATTATGAACGTGCCACCATGA 60
 61 AGCTCTTGCCGAGTCACTGTCGACCAACACACCTGGAATGCCATCTGCTCCCGTTG 120
 61 AGCTCTTGCCGAGTCACTGTCGACCAACACACCTGGAATGCCATCTGCTCCCGTTG 120
 121 TCTACCTCAOCCGCGCAAGTGTGGATTCGTGTGCGAGCCATCGCTGCTCGCGCTCAGCG 180
 121 TCTACCTCAOCCGCGCAAGTGTGGATTCGTGTGCGAGCCATCGCTGCTCGCGCTCAGCG 180
 191 GGCCTCAGAACTGCGCTCCGTTGCTGTCAGTACCAAGTTCAGCAAGGTGGTGTGA 240
 191 GGCCTCAGAACTGCGCTCCGTTGCTGTCAGTACCAAGTTCAGCAAGGTGGTGTGA 240
 241 CGCGCCGCGGCTCTCCGAGTCCGCGAGGATTCCTCGAACACCCGCTACTCAACC 300
 241 CGCGCCGCGGCTCTCCGAGTCCGCGAGGATTCCTCGAACACCCGCTACTCAACC 300
 301 TCATGGAGAACAAATCAGATGATCCAGCCGACACCTTCGCGGACCTCCACCACTGG 360
 301 TCATGGAGAACAAATCAGATGATCCAGCCGACACCTTCGCGGACCTCCACCACTGG 360

QY 361 AGGTCTCTGAGTTGGGCAAGAACTCCATCCGCGAGATTGAGGTGGGGGCTTCAACCGGCC 420
 DB 361 AGGTCTCTGAGTTGGGCAAGAACTCCATCCGCGAGATTGAGGTGGGGGCTTCAACCGGCC 420
 QY 421 TGGCCAGGCTCAACACCCCTGGAGCTGTTCGACATCGCTGAGTCACTATCCCTAGCGGG 480
 DB 421 TGGCCAGGCTCAACACCCCTGGAGCTGTTCGACATCGCTGAGTCACTATCCCTAGCGGG 480
 QY 481 CTTTGAATACCTGTCCAAAGCTGCGGAGCTCTGGCTTCGCAACAAACCCCATCGAAGCA 540
 DB 481 CTTTGAATACCTGTCCAAAGCTGCGGAGCTCTGGCTTCGCAACAAACCCCATCGAAGCA 540
 QY 541 TCCCTCTTAAGCTTCAACCCGCTGCTCCCTCATGCGCTGAGCTTGGGGAGTCA 600
 DB 541 TCCCTCTTAAGCTTCAACCCGCTGCTCCCTCATGCGCTGAGCTTGGGGAGTCA 600
 QY 601 AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGAAGGCTGTTCAAGCTCAAGTATCTGA 660
 DB 601 AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGAAGGCTGTTCAAGCTCAAGTATCTGA 660
 QY 661 ACTTGGGCTATGTGCAACATTAAGACATGCCCCTTCAACCCCTTGGGGGCTGGAGG 720
 DB 661 ACTTGGGCTATGTGCAACATTAAGACATGCCCCTTCAACCCCTTGGGGGCTGGAGG 720
 QY 721 AGCTGGAGATCTCAGGGAACCACTTCCCTGAGATCAGGCTGCGCTTCCATGGCCGTA 780
 DB 721 AGCTGGAGATCTCAGGGAACCACTTCCCTGAGATCAGGCTGCGCTTCCATGGCCGTA 780
 QY 781 GCTCCCTCAAGAACTCTGGGTATGAACCTCAGAGTCAAGCTGATGAGCGGAATGCTT 840
 DB 781 GCTCCCTCAAGAACTCTGGGTATGAACCTCAGAGTCAAGCTGATGAGCGGAATGCTT 840
 QY 841 TTGAGGGCTGCTTCACTTGTGGAACCTCAACTTGGCCCAACAATACCTCTCTTCTTTC 900
 DB 841 TTGAGGGCTGCTTCACTTGTGGAACCTCAACTTGGCCCAACAATACCTCTCTTCTTTC 900
 QY 901 CCCATGACCTCTTTACCCCGCTGAGGTACCTGGTGGAGTTGCACTACACCAACCCCTT 960
 DB 901 CCCATGACCTCTTTACCCCGCTGAGGTACCTGGTGGAGTTGCACTACACCAACCCCTT 960
 QY 961 GGAACCTGTGATGTGACATTTCTGTGGCTAGCTGCTGGTGGAGTATATACCAACCA 1020
 DB 961 GGAACCTGTGATGTGACATTTCTGTGGCTAGCTGCTGGTGGAGTATATACCAACCA 1020
 QY 1021 ATTCCACCTGCTGTGGCGCTGTCTCATGCTCCCATGCAATCGAGGCGCTTACTCTGTG 1080
 DB 1021 ATTCCACCTGCTGTGGCGCTGTCTCATGCTCCCATGCAATCGAGGCGCTTACTCTGTG 1080
 QY 1081 AGGTGGACGAGGCTCTCTTCAAGTCTCTGCGCTTTCATCTGAGGACCTCGAGACC 1140
 DB 1081 AGGTGGACGAGGCTCTCTTCAAGTCTCTGCGCTTTCATCTGAGGACCTCGAGACC 1140
 QY 1141 TCAACATTTCTGAGGCTCGGATGCGAATTTAAGTGTGCGAATCTCCCTTATGCTCTCCG 1200
 DB 1141 TCAACATTTCTGAGGCTCGGATGCGAATTTAAGTGTGCGAATCTCCCTTATGCTCTCCG 1200
 QY 1201 TGAAGTGTGCTGCTCCCAATGGGACAGTGTCTGAGCAAGCTTCCCGCCACCAAGATCT 1260
 DB 1201 TGAAGTGTGCTGCTCCCAATGGGACAGTGTCTGAGCAAGCTTCCCGCCACCAAGATCT 1260
 QY 1261 CTGTCTTCAAGCGGACCTTGAACCTTTTCCACGCTGCTGCTTTCAGACACTGGGGTGT 1320
 DB 1261 CTGTCTTCAAGCGGACCTTGAACCTTTTCCACGCTGCTGCTTTCAGACACTGGGGTGT 1320
 QY 1321 ACACATGATGTTGACCAATGTTGAGGCAACTCCAAAGCTCGGCTTACTCAATGTGA 1380
 DB 1321 ACACATGATGTTGACCAATGTTGAGGCAACTCCAAAGCTCGGCTTACTCAATGTGA 1380
 QY 1381 GCAGGGCTGAGCTTAAACCTTCAAGCTTCTTCCACAGTAAACAGTGGAGACCA 1440
 DB 1381 GCAGGGCTGAGCTTAAACCTTCAAGCTTCTTCCACAGTAAACAGTGGAGACCA 1440

1441 CGGAGATCTCGCTGAGGACACACCGGAAAGTACAAAGCCTGTTCTTACCAAGTCCACTG 1500
1441 CGGAGATCTCGCTGAGGACACACCGGAAAGTACAAAGCCTGTTCTTACCAAGTCCACTG 1500
1501 GTTACCAAGCGGCGATATACCACTCTTACCAAGCGTGTCTATTAGAGTACCTGCTGCGCA 1560
1501 GTTACCAAGCGGCGATATACCACTCTTACCAAGCGTGTCTATTAGAGTACCTGCTGCGCA 1560
1561 AGCAGTGGCAGTACCGGCGAGACACCACTGACAAAGTACGAGACCGGCGGATGAAG 1620
1561 AGCAGTGGCAGTACCGGCGAGACACCACTGACAAAGTACGAGACCGGCGGATGAAG 1620
1621 TCATGAAGACCAACCAAGATCATCATTTGGCTGCTTTGTGCGAGTACTTGTAGCTGCGG 1680
1621 TCATGAAGACCAACCAAGATCATCATTTGGCTGCTTTGTGCGAGTACTTGTAGCTGCGG 1680
1681 CCATGTTGATGTTCTTCTATAAATTCGTAAGCGGACACAGCGGAGTACAGTACAG 1740
1681 CCATGTTGATGTTCTTCTATAAATTCGTAAGCGGACACAGCGGAGTACAGTACAG 1740
1741 CCGCCCGGACTGTGAGATAATCCAGGTGGAACGAGACATCCAGCAGCAACATCCGCGAG 1800
1741 CCGCCCGGACTGTGAGATAATCCAGGTGGAACGAGACATCCAGCAGCAACATCCGCGAG 1800
1801 CAGCAACAGAGCTCGCTCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC 1860
1801 CAGCAACAGAGCTCGCTCGGTGTATCAGGTGAGGGGCGAGTGTGCTGCCCAATTC 1860
1861 ATGACCATATTAATCAACACCTTACAAACAGCAGCATGGGCGCCACTGGGAGAGAAACA 1920
1861 ATGACCATATTAATCAACACCTTACAAACAGCAGCATGGGCGCCACTGGGAGAGAAACA 1920
1921 GCTTGGGGAATCTCTGCAACCCAGTCACCACTATCTTGAACCTTATATATATTA 1980
1921 GCTTGGGGAATCTCTGCAACCCAGTCACCACTATCTTGAACCTTATATATATTA 1980
1981 CCATACCAAGCAGCAGGTACAGGAACTCAATATGATCCCTCCCGGAGAAACCTTA 2040
1981 CCATACCAAGCAGCAGGTACAGGAACTCAATATGATCCCTCCCGGAGAAACCTTA 2040
2041 TAAATGCAANTAGATGACACAAAGACAGCAACTTTTGTACAGAGTGGGAGAGACTTT 2100
2041 TAAATGCAANTAGATGACACAAAGACAGCAACTTTTGTACAGAGTGGGAGAGACTTT 2100
2101 TTCTGTATATGCTTATATATTAATGCTTATGCTGCTGTTTAAAAAAGAGATTATTA 2160
2101 TTCTGTATATGCTTATATATTAATGCTTATGCTGCTGTTTAAAAAAGAGATTATTA 2160
2161 AATTTAAAGACAAAAGTCAAAACA 2185
2161 AATTTAAAGACAAAAGTCAAAACA 2185

RESULT 35
S-09-991-172-228
Sequence 228, Application US/09991172
Publication No. US20030050457A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.

APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730PIC50
CURRENT APPLICATION NUMBER: US/09/991,172
CURRENT FILING DATE: 2001-11-16
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084500
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742

; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088810
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088824
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088826
 ; PRIOR FILING DATE: 1998-06-10
 ; PRIOR APPLICATION NUMBER: 60/088858
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/088861
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/088876
 ; PRIOR FILING DATE: 1998-06-11
 ; PRIOR APPLICATION NUMBER: 60/089105
 ; PRIOR FILING DATE: 1998-06-12
 ; PRIOR APPLICATION NUMBER: 60/089440
 ; PRIOR FILING DATE: 1998-06-15
 ; PRIOR APPLICATION NUMBER: 60/089512
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089514
 ; PRIOR FILING DATE: 1998-06-16
 ; PRIOR APPLICATION NUMBER: 60/089532
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089538
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089598
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089599
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089600
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089653
 ; PRIOR FILING DATE: 1998-06-17
 ; PRIOR APPLICATION NUMBER: 60/089801
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089907
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089908
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: 60/089947
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089948
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/089952
 ; PRIOR FILING DATE: 1998-06-19
 ; PRIOR APPLICATION NUMBER: 60/090246
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090252
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090254
 ; PRIOR FILING DATE: 1998-06-22
 ; PRIOR APPLICATION NUMBER: 60/090349
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090355
 ; PRIOR FILING DATE: 1998-06-23
 ; PRIOR APPLICATION NUMBER: 60/090429
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090431
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090435
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090444
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090445
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090472
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090535
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090540
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090542
 ; PRIOR FILING DATE: 1998-06-24

; PRIOR APPLICATION NUMBER: 60/090557
 ; PRIOR FILING DATE: 1998-06-24
 ; PRIOR APPLICATION NUMBER: 60/090676
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090678
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090690
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090694
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090695
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090696
 ; PRIOR FILING DATE: 1998-06-25
 ; PRIOR APPLICATION NUMBER: 60/090862
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/090863
 ; PRIOR FILING DATE: 1998-06-26
 ; PRIOR APPLICATION NUMBER: 60/091360
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091478
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091544
 ; PRIOR FILING DATE: 1998-07-01
 ; PRIOR APPLICATION NUMBER: 60/091519
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091626
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091633
 ; PRIOR FILING DATE: 1998-07-02
 ; PRIOR APPLICATION NUMBER: 60/091978
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/091982
 ; PRIOR FILING DATE: 1998-07-07
 ; PRIOR APPLICATION NUMBER: 60/092182
 ; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTCTCTTTCCGAGCCAAATCCGAGCGATGGTGAATTATGAACTGCGCCACCATGA 60
 DB 1 GTTCTCTTTCCGAGCCAAATCCGAGCGATGGTGAATTATGAACTGCGCCACCATGA 60
 QY 61 AGCTCTTGTGGCAGGTAACTGTGCACACCACTGGAATGCCATCTGCTCCCGTTCG 120
 DB 61 AGCTCTTGTGGCAGGTAACTGTGCACACCACTGGAATGCCATCTGCTCCCGTTCG 120
 QY 121 TCTACTCTACGCGCAAGTGTGGATTCTGTGTGCAGCCATCGCTGCTCCGCTCAGCG 180
 DB 121 TCTACTCTACGCGCAAGTGTGGATTCTGTGTGCAGCCATCGCTGCTCCGCTCAGCG 180
 QY 181 GGGCCGAGAACTGCCCTCCGTTTGTCTGTGAGTAACAGTTGAGCAGGTGTGTGCA 240
 DB 181 GGGCCGAGAACTGCCCTCCGTTTGTCTGTGAGTAACAGTTGAGCAGGTGTGTGCA 240
 QY 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGGTATTCCTCGAAACCCGGTACCTCAACC 300
 DB 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGGTATTCCTCGAAACCCGGTACCTCAACC 300
 QY 301 TCATGGAGAACAACTCCAGATGATTCAGGGCGGACCTTCCGGCACCTTCCACCTGG 360
 DB 301 TCATGGAGAACAACTCCAGATGATTCAGGGCGGACCTTCCGGCACCTTCCACCTGG 360
 QY 361 AGGTCTCTCAGTTGGGAGGAACCTCATCCGGCAGATTGAGGTGGGGCCCTTCAACGGCC 420
 DB 361 AGGTCTCTCAGTTGGGAGGAACCTCATCCGGCAGATTGAGGTGGGGCCCTTCAACGGCC 420
 QY 421 TGGCCAGCTCAACACCTCGAGCTGTTCGACAACTGCTGACAGTATCATCTAGCGGG 480
 DB 421 TGGCCAGCTCAACACCTCGAGCTGTTCGACAACTGCTGACAGTATCATCTAGCGGG 480

2y	481	CTTTTGAATACCTGTCTCAGCTGCGGAGCTCTGGCTTTCGCAACACCCATCGAAAGCA	540
2b	481	CTTTTGAATACCTGTCCAAGCTGCGGAGCTCTGGCTTTCGCAACACCCATCGAAAGCA	540
2y	541	TCCCTCTTTAGCCCTTCAACCGGCTGCCCTCCCTCATGCGCTGGACTTTGGGGGAGCTCA	600
2b	541	TCCCTCTTTAGCCCTTCAACCGGCTGCCCTCCCTCATGCGCTGGACTTTGGGGGAGCTCA	600
2y	601	AGAAGCTGGAGTATATCTCTGAGGAGAGCTTTTGAGGGGCTGTTCACCTCAAGTATCTGA	660
2b	601	AGAAGCTGGAGTATATCTCTGAGGAGAGCTTTTGAGGGGCTGTTCACCTCAAGTATCTGA	660
2y	661	ACTTGGGCAATGTGCACCAATTAAGACATGCCCAATCTCACCCCTCTGGGGGGCTGGAGG	720
2b	661	ACTTGGGCAATGTGCACCAATTAAGACATGCCCAATCTCACCCCTCTGGGGGGCTGGAGG	720
2y	721	AGCTGGAGATGTCAAGGGAACCACTTCCCTGAGATCAGGCTTGGCTTCTCTTTGCG	780
2b	721	AGCTGGAGATGTCAAGGGAACCACTTCCCTGAGATCAGGCTTGGCTTCTCTTTGCG	780
2y	781	GCTCCCTCAGAAGCTCTGGGTCAATGACATCAAGGTGAGCTGATTTGAGGCGAATGCTT	840
2b	781	GCTCCCTCAGAAGCTCTGGGTCAATGACATCAAGGTGAGCTGATTTGAGGCGAATGCTT	840
2y	841	TTGAGGGCTGGCTTCACTTGTGGAATCAACTTGGCCCAATAAACCTCTCTCTTTGCG	900
2b	841	TTGAGGGCTGGCTTCACTTGTGGAATCAACTTGGCCCAATAAACCTCTCTCTTTGCG	900
2y	901	CCCATGACCTCTTTACCCCGCTGAGGTACCTGTGTGAGTTGCAATCTACCAACACCCCTT	960
2b	901	CCCATGACCTCTTTACCCCGCTGAGGTACCTGTGTGAGTTGCAATCTACCAACACCCCTT	960
2y	961	GGAACTGTGATTTGCAATCTCTGGCTAGCTTGGCTTCGACGAGTATATACCAACCA	1020
2b	961	GGAACTGTGATTTGCAATCTCTGGCTAGCTTGGCTTCGACGAGTATATACCAACCA	1020
2y	1021	ATTCCACTGCTGTGGCGCTGTGATCTTCCCATGACATGCGAGGCGCTTACCTCTGTG	1080
2b	1021	ATTCCACTGCTGTGGCGCTGTGATCTTCCCATGACATGCGAGGCGCTTACCTCTGTG	1080
2y	1081	AGGTGGACAGGCTTCCCTCCAGTGTCTGCCCCCTTTCATCATGAGAGCGACCTCGAGAC	1140
2b	1081	AGGTGGACAGGCTTCCCTCCAGTGTCTGCCCCCTTTCATCATGAGAGCGACCTCGAGAC	1140
2y	1141	TCAACATTTTCGAGGTCGGATGCGCAGAACTTAAAGTGTGCGACTCCGCCCTATGTCTCG	1200
2b	1141	TCAACATTTTCGAGGTCGGATGCGCAGAACTTAAAGTGTGCGACTCCGCCCTATGTCTCG	1200
2y	1201	TGAAGTGGTTGCTGCCCAATGGACACAGTGTCTCAGCCAGCTTCCGCCACCCAGAGTCT	1260
2b	1201	TGAAGTGGTTGCTGCCCAATGGACACAGTGTCTCAGCCAGCTTCCGCCACCCAGAGTCT	1260
2y	1261	GTGTCTTCAACGAGCGCACCTTGAACTTTTCCACGTGTCTTTCAGACACACTGGGGTGT	1320
2b	1261	GTGTCTTCAACGAGCGCACCTTGAACTTTTCCACGTGTCTTTCAGACACACTGGGGTGT	1320
2y	1321	ACACATGCAATGTGTGACCAATTTTCAGGCAACTCCAAAGCTCTGGGCTTACTCAATGTGA	1380
2b	1321	ACACATGCAATGTGTGACCAATTTTCAGGCAACTCCAAAGCTCTGGGCTTACTCAATGTGA	1380
2y	1381	GCAOGGTGAGCTTAAACACTTCCAACTACAGTCTTCTCACACACAGTAACTGAGACCA	1440
2b	1381	GCAOGGTGAGCTTAAACACTTCCAACTACAGTCTTCTCACACACAGTAACTGAGACCA	1440
2y	1441	CGGAGATCTCGCTGAGGACACAAACCGGAAGTACAAGCTTGTCTCTACCAAGCTGCACTG	1500
2b	1441	CGGAGATCTCGCTGAGGACACAAACCGGAAGTACAAGCTTGTCTCTACCAAGCTGCACTG	1500
2y	1501	GTTACCAAGCGGATATACCACTTCTTACCAAGGTGCTCAATTCAGACTTACCGGTGTGCCA	1560
2b	1501	GTTACCAAGCGGATATACCACTTCTTACCAAGGTGCTCAATTCAGACTTACCGGTGTGCCA	1560
2y	1561	AGCAGGTGGCAGTATCCCGGACAGACACACTGACAGATGCAGACAGGCTCGATGAAG	1620

DB	1561	AGCAGGTGGCAGTACCCGCGACACAGACACCACTGACAAGATGTCAGACCGCTGGATGAAG	1620
QY	1621	TCATGAAGACCCACAGATCATCATTTGGCTGCTTTGTGGCAGTGACTCTGCTAGCTGCCG	1680
DB	1621	TCATGAAGACCCACAGATCATCATTTGGCTGCTTTGTGGCAGTGACTCTGCTAGCTGCCG	1680
QY	1681	CCATGTTGATGTCCTCTATAAACTTCGTAAGCGGCAACAGACGCGAGGTACAGTCAACAG	1740
DB	1681	CCATGTTGATGTCCTCTATAAACTTCGTAAGCGGCAACAGACGCGAGGTACAGTCAACAG	1740
QY	1741	CCGCCCGGACTGTTGAGATAATCCAGGTGGAACGACATCCAGCAGCAACAATCCGCGAG	1800
DB	1741	CCGCCCGGACTGTTGAGATAATCCAGGTGGAACGACATCCAGCAGCAACAATCCGCGAG	1800
QY	1801	CAGCAACAGCAGCTCCGTCCGGTGTATCAGGTGAGGGCGCAGTGTGCTGCCACAAATTC	1860
DB	1801	CAGCAACAGCAGCTCCGTCCGGTGTATCAGGTGAGGGCGCAGTGTGCTGCCACAAATTC	1860
QY	1861	ATGACCATATTAACCTACAACACCTTACAAACCCAGCATCGGGCCCACTGGACAGAAAACA	1920
DB	1861	ATGACCATATTAACCTACAACACCTTACAAACCCAGCATCGGGCCCACTGGACAGAAAACA	1920
QY	1921	GCCTGGGGAACCTCTGTGCACCCCACAGTCAACACTATCTCTGAACTTATATAATTCAGA	1980
DB	1921	GCCTGGGGAACCTCTGTGCACCCCACAGTCAACACTATCTCTGAACTTATATAATTCAGA	1980
QY	1981	CCCATACCAAGGACAAGGTACAGGAACTCAAAATATGACTCCCTCCGCCCAAAAACCTTA	2040
DB	1981	CCCATACCAAGGACAAGGTACAGGAACTCAAAATATGACTCCCTCCGCCCAAAAACCTTA	2040
QY	2041	TAAATATGAATGAATGCAACAAAGACAGCAACTTTTGTACAGAGTGGGGAGAGACTTT	2100
DB	2041	TAAATATGAATGAATGCAACAAAGACAGCAACTTTTGTACAGAGTGGGGAGAGACTTT	2100
QY	2101	TTCTTGTATATGCTTATATATTAAGTCTATGGCTGGTTAABAAAACAGATTATATTAA	2160
DB	2101	TTCTTGTATATGCTTATATATTAAGTCTATGGCTGGTTAABAAAACAGATTATATTAA	2160
QY	2161	AATTTAAAGACAAAAAGTCAAAACA	2185
DB	2161	AATTTAAAGACAAAAAGTCAAAACA	2185

```

RESULT 36
US-09-990-726-228
; Sequence 228, Application US/09990726
; Publication No. US20030054359A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar A.
; APPLICANT: Napier, Gary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin

```

;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; FILE REFERENCE: P2730PIC16

;; CURRENT APPLICATION NUMBER: US/09/990.726
;; CURRENT FILING DATE: 2001-11-14

;; PRIOR APPLICATION NUMBER: 60/049787
;; PRIOR FILING DATE: 1997-06-16
;; PRIOR APPLICATION NUMBER: 60/062250
;; PRIOR FILING DATE: 1997-10-17
;; PRIOR APPLICATION NUMBER: 60/065186
;; PRIOR FILING DATE: 1997-11-12
;; PRIOR APPLICATION NUMBER: 60/065311
;; PRIOR FILING DATE: 1997-11-13
;; PRIOR APPLICATION NUMBER: 60/066770
;; PRIOR FILING DATE: 1997-11-24
;; PRIOR APPLICATION NUMBER: 60/075945
;; PRIOR FILING DATE: 1998-02-25
;; PRIOR APPLICATION NUMBER: 60/078910
;; PRIOR FILING DATE: 1998-03-20
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/087106
;; PRIOR FILING DATE: 1998-05-28
;; PRIOR APPLICATION NUMBER: 60/087607
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087609
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087759
;; PRIOR FILING DATE: 1998-06-02
;; PRIOR APPLICATION NUMBER: 60/087827
;; PRIOR FILING DATE: 1998-06-03
;; PRIOR APPLICATION NUMBER: 60/088021
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088025
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088026
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088028
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088029
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088030
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088033
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088326
;; PRIOR FILING DATE: 1998-06-04
;; PRIOR APPLICATION NUMBER: 60/088167
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088202
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088212
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088217
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/088655
;; PRIOR FILING DATE: 1998-06-09
;; PRIOR APPLICATION NUMBER: 60/088734
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088738
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088742
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088810
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088824
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088826
;; PRIOR FILING DATE: 1998-06-10
;; PRIOR APPLICATION NUMBER: 60/088858
;; PRIOR FILING DATE: 1998-06-11

;; PRIOR APPLICATION NUMBER: 60/088861
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/088876
;; PRIOR FILING DATE: 1998-06-11
;; PRIOR APPLICATION NUMBER: 60/089105
;; PRIOR FILING DATE: 1998-06-12
;; PRIOR APPLICATION NUMBER: 60/089440
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089512
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089514
;; PRIOR FILING DATE: 1998-06-16
;; PRIOR APPLICATION NUMBER: 60/089532
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089538
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089598
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089599
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089600
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089653
;; PRIOR FILING DATE: 1998-06-17
;; PRIOR APPLICATION NUMBER: 60/089801
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089907
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089908
;; PRIOR FILING DATE: 1998-06-18
;; PRIOR APPLICATION NUMBER: 60/089947
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089948
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/089952
;; PRIOR FILING DATE: 1998-06-19
;; PRIOR APPLICATION NUMBER: 60/090246
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090252
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090254
;; PRIOR FILING DATE: 1998-06-22
;; PRIOR APPLICATION NUMBER: 60/090349
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090355
;; PRIOR FILING DATE: 1998-06-23
;; PRIOR APPLICATION NUMBER: 60/090429
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090431
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090435
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090444
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090445
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090472
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090535
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090540
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090542
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090557
;; PRIOR FILING DATE: 1998-06-24
;; PRIOR APPLICATION NUMBER: 60/090676
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090678
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090690
;; PRIOR FILING DATE: 1998-06-25
;; PRIOR APPLICATION NUMBER: 60/090694

PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090695
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090696
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090862
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090863
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/091360
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091478
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091544
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091519
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091626
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091633
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091978
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/091982
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/092182
 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 GTTCTCTTTCCGAGCAAAATCCAGGCGATGGTGAATTATGAACCTGGCCACCATGA 60
 1 GTTCTCTTTCCGAGCAAAATCCAGGCGATGGTGAATTATGAACCTGGCCACCATGA 60
 61 AGCTCTTGTGGAGGTAATCTGTGACCAACAACCTGGAAATGCCATCTGTCCGTTTCG 120
 61 AGCTCTTGTGGAGGTAATCTGTGACCAACAACCTGGAAATGCCATCTGTCCGTTTCG 120
 121 TCTACTCTACGGGCAAGTGTGATTTCTGTGACGCAATCTCTCGCGCTCAGCG 180
 121 TCTACTCTACGGGCAAGTGTGATTTCTGTGACGCAATCTCTCGCGCTCAGCG 180
 181 GGCCCCAGAACTCCGCTTCTGTGAGTAAACAGTTTCAAGAGTGTGTGCA 240
 181 GGCCCCAGAACTCCGCTTCTGTGAGTAAACAGTTTCAAGAGTGTGTGCA 240
 241 CGCGCGGGGCTCTCCGAGGTCCCGGAGGTATTCCTGCGACACACCTTCAACC 300
 241 CGCGCGGGGCTCTCCGAGGTCCCGGAGGTATTCCTGCGACACACCTTCAACC 300
 301 TCATGAGAAACATCCAGATGATCCAGGCGGACACCTTCCGCACTCCACCACTGG 360
 301 TCATGAGAAACATCCAGATGATCCAGGCGGACACCTTCCGCACTCCACCACTGG 360
 361 AGTCTCTGAGTTGGGAGCAATCCATCCGCAATGATGAGTGGGGGCTTCAACGGCC 420
 361 AGTCTCTGAGTTGGGAGCAATCCATCCGCAATGATGAGTGGGGGCTTCAACGGCC 420
 421 TGGCAGAGCTCAACACCTTGGAGCTGTTGCAAACTGGCTGACAGTCACTCCAGCGGG 480
 421 TGGCAGAGCTCAACACCTTGGAGCTGTTGCAAACTGGCTGACAGTCACTCCAGCGGG 480
 481 CTTTGAATACCTGTCAGAGTGGGAGCTCTGGCTTGGCAAAACCCCATCGAAAGCA 540
 481 CTTTGAATACCTGTCAGAGTGGGAGCTCTGGCTTGGCAAAACCCCATCGAAAGCA 540
 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTGAGCTTGGGGAGCTCA 600
 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTGAGCTTGGGGAGCTCA 600
 601 AGAAGCTGGAGTATATCTCTGAGGAGGCTTTTGGGGGCTGTTCAACCTCAAGTATCTGA 660

601 AGAAGCTGGAGTATATCTCTGAGGAGGCTTTTGGGGGCTGTTCAACCTCAAGTATCTGA 660
 661 ACTTGGGCAATGTGCAACATTAAGACATGATCCCAATCTCAACCTTGGGGGCTGGAG 720
 661 ACTTGGGCAATGTGCAACATTAAGACATGATCCCAATCTCAACCTTGGGGGCTGGAG 720
 721 AGCTGGAGATGTGAGGAAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGGCTGA 780
 721 AGCTGGAGATGTGAGGAAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGGCTGA 780
 781 GCTCCCTCAAGAGCTCTGGGTCAATGAATCTCAAGCTCAGCTGATGAGCGGAATGCTT 840
 781 GCTCCCTCAAGAGCTCTGGGTCAATGAATCTCAAGCTCAGCTGATGAGCGGAATGCTT 840
 841 TTGACGGGCTGGCTTCACTTGTGGAATCAACTTGGCCCAATAAATCTCTCTTCTTTCG 900
 841 TTGACGGGCTGGCTTCACTTGTGGAATCAACTTGGCCCAATAAATCTCTCTTCTTTCG 900
 901 CCATGACCTCTTTACCCGCTGAGGTAATCTGTGTGAGTGTGATCTACACCAACCTT 960
 901 CCATGACCTCTTTACCCGCTGAGGTAATCTGTGTGAGTGTGATCTACACCAACCTT 960
 961 GGAATCTGATTTGTGACATTTCTGTGCTAGCTGTGGCTTGGAGATATATACCCACCA 1020
 961 GGAATCTGATTTGTGACATTTCTGTGCTAGCTGTGGCTTGGAGATATATACCCACCA 1020
 1021 ATTCCACCTGCTGTGGGCTGTCTGCTCCATGACATGAGGCGCTACCTCTGCTGG 1080
 1021 ATTCCACCTGCTGTGGGCTGTCTGCTCCATGACATGAGGCGCTACCTCTGCTGG 1080
 1081 AGTGGACCAAGGCTCTCTTCCAGTGTCTGCGCCCTTCAATGAGGAGGCTCTCGAGAC 1140
 1081 AGTGGACCAAGGCTCTCTTCCAGTGTCTGCGCCCTTCAATGAGGAGGCTCTCGAGAC 1140
 1141 TCAACATTTCTGAGGCTGGATGGAGAACTTAAAGTGTGGACTCTCCCTATATGTCTCG 1200
 1141 TCAACATTTCTGAGGCTGGATGGAGAACTTAAAGTGTGGACTCTCCCTATATGTCTCG 1200
 1201 TGAAGTGTGTGCTGCCAATGGGACAGTCTCAGGACGCTCCGCGCCACCAAGATCT 1260
 1201 TGAAGTGTGTGCTGCCAATGGGACAGTCTCAGGACGCTCCGCGCCACCAAGATCT 1260
 1261 CTCTCTCAACGAGCACTTTTCCAACTTCCCAAGTGTGCTTTTCCAGACACTGGGCTG 1320
 1261 CTCTCTCAACGAGCACTTTTCCAACTTCCCAAGTGTGCTTTTCCAGACACTGGGCTG 1320
 1321 ACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1380
 1321 ACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1380
 1381 GCAAGGCTGAGCTTAACTCACTCAAGTGTGCTTTTCCCAAGTGTGCTTTTCCCAAGTGTG 1440
 1381 GCAAGGCTGAGCTTAACTCACTCAAGTGTGCTTTTCCCAAGTGTGCTTTTCCCAAGTGTG 1440
 1441 CGGAGATCTGCTGAGGACCAACGCGAAGTCAAGCTGCTTCCCTTCCAGCTGCTGCTG 1500
 1441 CGGAGATCTGCTGAGGACCAACGCGAAGTCAAGCTGCTTCCCTTCCAGCTGCTGCTG 1500
 1501 GTTACCAAGCGGATATACCACTTCACTCAAGGCTGCTTCACTCAAGCTGCTGCTGCTG 1560
 1501 GTTACCAAGCGGATATACCACTTCACTCAAGGCTGCTTCACTCAAGCTGCTGCTGCTG 1560
 1561 AGAGGTGGAGTACCGGAGACAGACCACTGCAAGATGAGACCAAGCTGAGTGAAG 1620
 1561 AGAGGTGGAGTACCGGAGACAGACCACTGCAAGATGAGACCAAGCTGAGTGAAG 1620
 1621 TCATGAGACCAAGATCACTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1680
 1621 TCATGAGACCAAGATCACTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1680
 1681 CCATGTTGATTTCTTCTTATAAATCTTCAAGCGGACACAGGAGGAGTACAGTCAAG 1740

1681 CCATGTTGATTGCTCTTCTATAAACTTCGTAAGCGGCACCCAGCAGCGGAGTACAGTCACAG 1740
1741 CGGCCGAGCTGTTGAGATATCCAGGTGACGAGCAATCCCGAGCAGCAATCCGCGAG 1800
1741 CGGCCGAGCTGTTGAGATATCCAGGTGACGAGCAATCCCGAGCAGCAATCCGCGAG 1800
1801 CAGCAACAGCAGCTCCGTCGGTGTATCAGGTGAGGGGGCAGTAGTGTGCCCAATTC 1860
1801 CAGCAACAGCAGCTCCGTCGGTGTATCAGGTGAGGGGGCAGTAGTGTGCCCAATTC 1860
1861 ATGACCATATTAATACCAACACCTTACAAACCCAGCAGATGGGGCCCACTGCGACAGAAAAA 1920
1861 ATGACCATATTAATACCAACACCTTACAAACCCAGCAGATGGGGCCCACTGCGACAGAAAAA 1920
1921 GCCTGGGGAATCTCTGCAACCCCAAGTCACCACTATCTCTGAACTTATATTAATTCAGA 1980
1921 GCCTGGGGAATCTCTGCAACCCCAAGTCACCACTATCTCTGAACTTATATTAATTCAGA 1980
1981 CCCATACCAAGCAGGTACAGGAACTCAAAATATGACTCCCTCCCTCCCAAAAACTTA 2040
1981 CCCATACCAAGCAGGTACAGGAACTCAAAATATGACTCCCTCCCTCCCAAAAACTTA 2040
2041 TAAATGCAATAGATGACACCAAAAGACAGCACTTTTGTACAGAGTGGGGGAGACTTT 2100
2041 TAAATGCAATAGATGACACCAAAAGACAGCACTTTTGTACAGAGTGGGGGAGACTTT 2100
2101 TTCTGTATATGCTTATATATTAAGTCTATGCGCTGTTAAAAAAGACATATATTAA 2160
2101 TTCTGTATATGCTTATATATTAAGTCTATGCGCTGTTAAAAAAGACATATATTAA 2160
2161 AATTTAAAGACAAAAAGTCAAAACA 2185
2161 AATTTAAAGACAAAAAGTCAAAACA 2185

RESULT 37

JS-09-997-559-228
; Sequence 228, Application US/09997559
; Publication No. US20030054403A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gutney, Austin L.
; APPLICANT: Kliaavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730P1C40
; CURRENT APPLICATION NUMBER: US/09/997,559
; CURRENT FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/081322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512

PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26

PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTCTCTTTCCGAGCCAAAATCCAGGCGATGGTGAATATGAACCTGCCACACCATGA 60
DB 1 GTTCTCTTTCCGAGCCAAAATCCAGGCGATGGTGAATATGAACCTGCCACACCATGA 60

QY 61 AGCTTTGTGGAGGTAACTGTGTGCAACACACCTGTGGAATGCCATCTGTCTCCGTTGG 120
DB 61 AGCTTTGTGGAGGTAACTGTGTGCAACACACCTGTGGAATGCCATCTGTCTCCGTTGG 120

QY 121 TCTACCTCAGCGCGAGTGTGATTTCTGTGTGCAACCTGTGTGCAACCTGTGTGCAACCTGTGTGCA 180
DB 121 TCTACCTCAGCGCGAGTGTGATTTCTGTGTGCAACCTGTGTGCAACCTGTGTGCAACCTGTGTGCA 180

QY 181 GGCCCCAGAACTGCCCTCCGTTGTGTGTGCAAGTAAACAGTTTCAGCAAGGTGTGTGA 240
DB 181 GGCCCCAGAACTGCCCTCCGTTGTGTGTGCAAGTAAACAGTTTCAGCAAGGTGTGTGA 240

QY 241 CGGCGCGGGGCTCTCGAGGTCCCGAGGTATTCCTCTCGAACACCCGCTCAAC 300
DB 241 CGGCGCGGGGCTCTCGAGGTCCCGAGGTATTCCTCTCGAACACCCGCTCAAC 300

QY 301 TCATGGAGAAACAATCCAGATGATCCAGGCGGACACCTTTCCGCGCACCTCCACCACTGG 360
DB 301 TCATGGAGAAACAATCCAGATGATCCAGGCGGACACCTTTCCGCGCACCTCCACCACTGG 360

QY 361 AGTCTGTGAGTTGGGAGGAACTCCATCCGAGATTCAGTGGGGGGCTTCAAGGGCC 420
DB 361 AGTCTGTGAGTTGGGAGGAACTCCATCCGAGATTCAGTGGGGGGCTTCAAGGGCC 420

QY 421 TGGCCAGCTCAACACCCCTGGAGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480
DB 421 TGGCCAGCTCAACACCCCTGGAGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480

QY 481 CTTTGAATACCTGTCCAGCTCGGGAGCTCTGGCTTCGCAACAAACCCCACTCGAAAGCA 540
DB 481 CTTTGAATACCTGTCCAGCTCGGGAGCTCTGGCTTCGCAACAAACCCCACTCGAAAGCA 540

QY 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGGCTTGGAGTCTGGGGGAGCTCA 600
DB 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGGCTTGGAGTCTGGGGGAGCTCA 600

QY 601 AGAGCTGGAGTATCTCTGAGGGAGCTTTTGAGGGGCTGTGTCAACCTCAAGATCTGA 660
DB 601 AGAGCTGGAGTATCTCTGAGGGAGCTTTTGAGGGGCTGTGTCAACCTCAAGATCTGA 660

QY 661 ACTTGGCATGTGCAACATTAAGACATGCCCAATCTCAACCCCTCTGGTGGGGTGGAGG 720
DB 661 ACTTGGCATGTGCAACATTAAGACATGCCCAATCTCAACCCCTCTGGTGGGGTGGAGG 720

QY 721 AGCTGGAGATGTGAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGCCTGA 780
DB 721 AGCTGGAGATGTGAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTTCCATGGCCTGA 780

DB 721 AGCTGGAGATGTCAGGGAACCACTTCCCTGAGATCAGGCTGGCTCTCCATGGCCCTGA 780
 QY 781 GGTCCCTCAAGAAGCTCTGGGTGATGAATCACTCAGGTCAGGCTGATTCAGCGGAATGCTT 840
 DB 781 GGTCCCTCAAGAAGCTCTGGGTGATGAATCACTCAGGTCAGGCTGATTCAGCGGAATGCTT 840
 QY 841 TTGAGGGGCTGCTTCACTTGTGGAACTCAACTTGGGCCCAATAAATCTCTCTCTTTTTC 900
 DB 841 TTGAGGGGCTGCTTCACTTGTGGAACTCAACTTGGGCCCAATAAATCTCTCTCTTTTTC 900
 QY 901 CCATGACCTCTTTACCCCGCTGAGGTGAGTACCTTGGTGGAGTGCATCTACACCAACCCCTT 960
 DB 901 CCATGACCTCTTTACCCCGCTGAGGTGAGTACCTTGGTGGAGTGCATCTACACCAACCCCTT 960
 QY 961 GGAATGTGATGTGACATCTCTGGCTGAGCTGTGGTGTCTCGAGAGTATATACCCACCA 1020
 DB 961 GGAATGTGATGTGACATCTCTGGCTGAGCTGTGGTGTCTCGAGAGTATATACCCACCA 1020
 QY 1021 ATTCCACCTGCTGTGGCGCTGTGATGCTCCCATGACATCGGAGGCGCTACCTCGTGG 1080
 DB 1021 ATTCCACCTGCTGTGGCGCTGTGATGCTCCCATGACATCGGAGGCGCTACCTCGTGG 1080
 QY 1081 AGGTGGAACAGGCTCTCTTCCAGTCTCTGCCCCCTTCATCATGAGGCGACCTCGAGACC 1140
 DB 1081 AGGTGGAACAGGCTCTCTTCCAGTCTCTGCCCCCTTCATCATGAGGCGACCTCGAGACC 1140
 QY 1141 TCAACATTTCTGAGGTCGGATGCGAGAACCTTAGTGTGGACTCCCTCTATGTCCTCG 1200
 DB 1141 TCAACATTTCTGAGGTCGGATGCGAGAACCTTAGTGTGGACTCCCTCTATGTCCTCG 1200
 QY 1201 TGAAGTGTGTGCTGCCCAATGGGACAGTCTCAGCCAGCTCCCGCCACCCCAAGATCT 1260
 DB 1201 TGAAGTGTGTGCTGCCCAATGGGACAGTCTCAGCCAGCTCCCGCCACCCCAAGATCT 1260
 QY 1261 CTGTCTCAAGACGGGACCTTGAATTTTCCAGTGTCTTTCAGACACTGGGGTGT 1320
 DB 1261 CTGTCTCAAGACGGGACCTTGAATTTTCCAGTGTCTTTCAGACACTGGGGTGT 1320
 QY 1321 ACACATGATGTGACCAATGTTGAGGCAACTCCAGCGCTCGGCTTCACTCAATGTGA 1380
 DB 1321 ACACATGATGTGACCAATGTTGAGGCAACTCCAGCGCTCGGCTTCACTCAATGTGA 1380
 QY 1381 GCAGGCTGAGCTTAACTTCACTCACTAGCTTCTTCCACAGTACAGTGGAGACCA 1440
 DB 1381 GCAGGCTGAGCTTAACTTCACTCACTAGCTTCTTCCACAGTACAGTGGAGACCA 1440
 QY 1441 CGAGATCTGCTGAGGACACAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAAAG 1500
 DB 1441 CGAGATCTGCTGAGGACACAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAAAGTAAAG 1500
 QY 1501 GTTACAGCCGCTATACCACTCTTACAGGCTGCTCAATTCAGACTACCGGTGCGCCA 1560
 DB 1501 GTTACAGCCGCTATACCACTCTTACAGGCTGCTCAATTCAGACTACCGGTGCGCCA 1560
 QY 1561 ASCAGTGTGCTGCTGAGGACACCACTTCAAGTACAGTACAGTACAGTACAGTACAG 1620
 DB 1561 ASCAGTGTGCTGCTGAGGACACCACTTCAAGTACAGTACAGTACAGTACAGTACAG 1620
 QY 1621 TCATGAAGACCAACAGATATCACTTGTGGAGTGTGCTGCTGCTGCTGCTGCTGCTGCT 1680
 DB 1621 TCATGAAGACCAACAGATATCACTTGTGGAGTGTGCTGCTGCTGCTGCTGCTGCTGCT 1680
 QY 1681 CCATGTTGATGCTCTTCTATAAATCTTCTGAGGACCAAGTACAGTACAGTACAGTACAG 1740
 DB 1681 CCATGTTGATGCTCTTCTATAAATCTTCTGAGGACCAAGTACAGTACAGTACAGTACAG 1740
 QY 1741 CCGCCCGGACTTGTGAGATAATCCAGGTGAGAGATCCAGGAGGAGGAGGAGGAGGAGGAG 1800
 DB 1741 CCGCCCGGACTTGTGAGATAATCCAGGTGAGAGATCCAGGAGGAGGAGGAGGAGGAGGAG 1800
 QY 1801 CAGCAACAGCAGCTCCGCTGCTGATCAGGTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1860
 DB 1801 CAGCAACAGCAGCTCCGCTGCTGATCAGGTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1860

RESULT 38

US-09-997-601-228
 ; Sequence 228, Application US/09997601
 ; Publication No. US20030054404A1

GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Botstein, David
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Eaton, Dan L.
 ; APPLICANT: Ferrara, Napoleone
 ; APPLICANT: Fong, Sherman
 ; APPLICANT: Gerber, Hanspeter
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Grimaldi, J. Christopher
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Kljavin, Ivar J.
 ; APPLICANT: Napier, Mary A.
 ; APPLICANT: Pan, James
 ; APPLICANT: Paoni, Nicholas P.
 ; APPLICANT: Roy, Margaret Ann
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K.
 ; APPLICANT: Williams, P. Mickey
 ; APPLICANT: Wood, William I.
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 ; TITLE OF INVENTION: Acids Encoding the Same
 ; FILE REFERENCE: P2730PLC36
 ; CURRENT APPLICATION NUMBER: US/09/997,601
 ; CURRENT FILING DATE: 2001-11-15
 ; PRIOR APPLICATION NUMBER: 60/049787
 ; PRIOR FILING DATE: 1997-06-16
 ; PRIOR APPLICATION NUMBER: 60/062250
 ; PRIOR FILING DATE: 1997-10-17
 ; PRIOR APPLICATION NUMBER: 60/065186
 ; PRIOR FILING DATE: 1997-11-12
 ; PRIOR APPLICATION NUMBER: 60/065311
 ; PRIOR FILING DATE: 1997-11-13
 ; PRIOR APPLICATION NUMBER: 60/065770
 ; PRIOR FILING DATE: 1997-11-24
 ; PRIOR APPLICATION NUMBER: 60/075945
 ; PRIOR FILING DATE: 1998-02-25
 ; PRIOR APPLICATION NUMBER: 60/078910

1	PRIOR APPLICATION NUMBER: 60/089599	
2	PRIOR FILING DATE: 1998-06-17	
3	PRIOR APPLICATION NUMBER: 60/089600	
4	PRIOR FILING DATE: 1998-06-17	
5	PRIOR APPLICATION NUMBER: 60/089653	
6	PRIOR FILING DATE: 1998-06-17	
7	PRIOR APPLICATION NUMBER: 60/089801	
8	PRIOR FILING DATE: 1998-06-18	
9	PRIOR APPLICATION NUMBER: 60/089907	
10	PRIOR FILING DATE: 1998-06-18	
11	PRIOR APPLICATION NUMBER: 60/089908	
12	PRIOR FILING DATE: 1998-06-18	
13	PRIOR APPLICATION NUMBER: 60/089947	
14	PRIOR FILING DATE: 1998-06-19	
15	PRIOR APPLICATION NUMBER: 60/089948	
16	PRIOR FILING DATE: 1998-06-19	
17	PRIOR APPLICATION NUMBER: 60/089952	
18	PRIOR FILING DATE: 1998-06-19	
19	PRIOR APPLICATION NUMBER: 60/090246	
20	PRIOR FILING DATE: 1998-06-22	
21	PRIOR APPLICATION NUMBER: 60/090252	
22	PRIOR FILING DATE: 1998-06-22	
23	PRIOR APPLICATION NUMBER: 60/090254	
24	PRIOR FILING DATE: 1998-06-22	
25	PRIOR APPLICATION NUMBER: 60/090349	
26	PRIOR FILING DATE: 1998-06-23	
27	PRIOR APPLICATION NUMBER: 60/090355	
28	PRIOR FILING DATE: 1998-06-23	
29	PRIOR APPLICATION NUMBER: 60/090429	
30	PRIOR FILING DATE: 1998-06-24	
31	PRIOR APPLICATION NUMBER: 60/090431	
32	PRIOR FILING DATE: 1998-06-24	
33	PRIOR APPLICATION NUMBER: 60/090435	
34	PRIOR FILING DATE: 1998-06-24	
35	PRIOR APPLICATION NUMBER: 60/090444	
36	PRIOR FILING DATE: 1998-06-24	
37	PRIOR APPLICATION NUMBER: 60/090445	
38	PRIOR FILING DATE: 1998-06-24	
39	PRIOR APPLICATION NUMBER: 60/090472	
40	PRIOR FILING DATE: 1998-06-24	
41	PRIOR APPLICATION NUMBER: 60/090535	
42	PRIOR FILING DATE: 1998-06-24	
43	PRIOR APPLICATION NUMBER: 60/090540	
44	PRIOR FILING DATE: 1998-06-24	
45	PRIOR APPLICATION NUMBER: 60/090542	
46	PRIOR FILING DATE: 1998-06-24	
47	PRIOR APPLICATION NUMBER: 60/090557	
48	PRIOR FILING DATE: 1998-06-24	
49	PRIOR APPLICATION NUMBER: 60/090676	
50	PRIOR FILING DATE: 1998-06-25	
51	PRIOR APPLICATION NUMBER: 60/090678	
52	PRIOR FILING DATE: 1998-06-25	
53	PRIOR APPLICATION NUMBER: 60/090690	
54	PRIOR FILING DATE: 1998-06-25	
55	PRIOR APPLICATION NUMBER: 60/090694	
56	PRIOR FILING DATE: 1998-06-25	
57	PRIOR APPLICATION NUMBER: 60/090695	
58	PRIOR FILING DATE: 1998-06-25	
59	PRIOR APPLICATION NUMBER: 60/090696	
60	PRIOR FILING DATE: 1998-06-25	
61	PRIOR APPLICATION NUMBER: 60/090862	
62	PRIOR FILING DATE: 1998-06-26	
63	PRIOR APPLICATION NUMBER: 60/090863	
64	PRIOR FILING DATE: 1998-06-26	
65	PRIOR APPLICATION NUMBER: 60/091360	
66	PRIOR FILING DATE: 1998-07-01	
67	PRIOR APPLICATION NUMBER: 60/091478	
68	PRIOR FILING DATE: 1998-07-02	
69	PRIOR APPLICATION NUMBER: 60/091544	
70	PRIOR FILING DATE: 1998-07-01	
71	PRIOR APPLICATION NUMBER: 60/091519	
72	PRIOR FILING DATE: 1998-07-02	
73	PRIOR APPLICATION NUMBER: 60/091626	

```

; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match      100.0%; Score 2185; DB 11; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

2y 1 GTTCTCTTTCCGAGCCAAAATCCAGCGCATGTGTAATTAGAACGTGCCACACATGA 60
db 1 GTTCTCTTTCCGAGCCAAAATCCAGCGCATGTGTAATTAGAACGTGCCACACATGA 60

2y 61 AGCTCTTGTGCGAGTAATCTGTCACCAACACCTGGAATGCCATCCTGCTCCCGTTGC 120
db 61 AGCTCTTGTGCGAGTAATCTGTCACCAACACACCTGGAATGCCATCCTGCTCCCGTTGC 120

2y 121 TCTACCTCAGCGCCAAAGTGTGATTTCTGTGTGAGCCATCGTGTGCGCGCTCAGCGG 180
db 121 TCTACCTCAGCGCCAAAGTGTGATTTCTGTGTGAGCCATCGTGTGCGCGCTCAGCGG 180

2y 181 GCGCCAGAACTGCCCTTCCGTTGCTGTGTCAGTACCAAGTTCAGCAAGTGTGTGCA 240
db 181 GCGCCAGAACTGCCCTTCCGTTGCTGTGTCAGTACCAAGTTCAGCAAGTGTGTGCA 240

2y 241 GCGCGCGGGGCTCTCCAGAGTCCCGAGGATTTCCCTCGAACCCCGGTACTCAACC 300
db 241 GCGCGCGGGGCTCTCCAGAGTCCCGAGGATTTCCCTCGAACCCCGGTACTCAACC 300

2y 301 TCATGAGAAACAACTCCAGATGATTCAGGCGGACACTTCCTCGGCGACTCCACCACTGG 360
db 301 TCATGAGAAACAACTCCAGATGATTCAGGCGGACACTTCCTCGGCGACTCCACCACTGG 360

2y 361 AGTCTCAGTGTGGGAGGAATCCATCCGCGAGATTTAGGTTGGGGGCTTCAACGGCC 420
db 361 AGTCTCAGTGTGGGAGGAATCCATCCGCGAGATTTAGGTTGGGGGCTTCAACGGCC 420

2y 421 TGGCAGGCTCAACACCTGAGCTGTTCGAACTGGCTGACAGTCAATCCCTAGCGGGG 480
db 421 TGGCAGGCTCAACACCTGAGCTGTTCGAACTGGCTGACAGTCAATCCCTAGCGGGG 480

2y 481 CTTTGAATCTGTCAGCTGCGGAGCTTGGCTTCGCAACACACCCCATCGAAGCA 540
db 481 CTTTGAATCTGTCAGCTGCGGAGCTTGGCTTCGCAACACACCCCATCGAAGCA 540

2y 541 TCCCTCTTACGCTTCAACCGGGTGGCTCCCTCATCGCGCTGGACTTGGGGGAGCTCA 600
db 541 TCCCTCTTACGCTTCAACCGGGTGGCTCCCTCATCGCGCTGGACTTGGGGGAGCTCA 600

2y 601 AGAAGCTGAGATATCTCTGAGGAGCTTTTGGGGGCTGTTCAACTCAAGTATCTGA 660
db 601 AGAAGCTGAGATATCTCTGAGGAGCTTTTGGGGGCTGTTCAACTCAAGTATCTGA 660

2y 661 ACTTGGGATGTGCAACATTAAGACATGCCCAATCTCACCCCTGGTGGGGCTGGAG 720
db 661 ACTTGGGATGTGCAACATTAAGACATGCCCAATCTCACCCCTGGTGGGGCTGGAG 720

2y 721 AGCTGGAATGTGAGGAAACCACTTCCCTGAGATGAGGCTTGGCTTCCATGGGCTGA 780
db 721 AGCTGGAATGTGAGGAAACCACTTCCCTGAGATGAGGCTTGGCTTCCATGGGCTGA 780

2y 781 GCTCCCTCAGAGCTCTGGGTCTGATGATTCAGAGTTCAGCTGAGTGGGAAATGCTT 840
db 781 GCTCCCTCAGAGCTCTGGGTCTGATGATTCAGAGTTCAGCTGAGTGGGAAATGCTT 840

2y 841 TTGACGGGCTGGCTTCACTTGTGGAATCAACTTGGGCCCAATAAATCTCTCTTTTC 900
db 841 TTGACGGGCTGGCTTCACTTGTGGAATCAACTTGGGCCCAATAAATCTCTCTTTTC 900

```

```

901 CCATGACCTCTTTACCCCGCTGAGGTACCTGGTGGAGTTGCATCTACACCAACCCCTT 960
901 CCATGACCTCTTTACCCCGCTGAGGTACCTGGTGGAGTTGCATCTACACCAACCCCTT 960
961 GGAAGTGTGATGTGACATTTCTGTGGCTAGCTGGTGGCTTCGAGAGTATATACCAACCA 1020
961 GGAAGTGTGATGTGACATTTCTGTGGCTAGCTGGTGGCTTCGAGAGTATATACCAACCA 1020
1021 ATTCCACCTGCTGTGGCGCTGCTCATCTCCCATGCAATCGCGAGCGCTACTCTGTGG 1080
1021 ATTCCACCTGCTGTGGCGCTGCTCATCTCCCATGCAATCGCGAGCGCTACTCTGTGG 1080
1081 AGGTGAGACAGGCTCTTCCAGTGTCTGCGCCCTTCATCATGAGGACCTCGAGACC 1140
1081 AGGTGAGACAGGCTCTTCCAGTGTCTGCGCCCTTCATCATGAGGACCTCGAGACC 1140
1141 TCAACATTTCTGAGGGTGGATGGCAGAACTTAAGTGTGGAGTCCCCCTATGTCTCTCG 1200
1141 TCAACATTTCTGAGGGTGGATGGCAGAACTTAAGTGTGGAGTCCCCCTATGTCTCTCG 1200
1201 TGAAGTGTGCTGCTGCCAATGGGACAGTGTCTGAGCAGCGCTCCCGCACCAAGATCT 1260
1201 TGAAGTGTGCTGCTGCCAATGGGACAGTGTCTGAGCAGCGCTCCCGCACCAAGATCT 1260
1261 CTGTCTTCAAGCGGCGACCTTTGAACCTTTTCCACGCTGCTCTTTCAGACACTGGGGTGT 1320
1261 CTGTCTTCAAGCGGCGACCTTTGAACCTTTTCCACGCTGCTCTTTCAGACACTGGGGTGT 1320
1321 ACACATGATGGTGAACCAATGTTGTCAGGCAACTTCCAAAGCTCTGGGCTACTCTCAATGTGA 1380
1321 ACACATGATGGTGAACCAATGTTGTCAGGCAACTTCCAAAGCTCTGGGCTACTCTCAATGTGA 1380
1381 GCAGGCTGAGCTTAAACACCTCCCACTACAGCTTCTTCCACAGTAACAGTGGAGACCA 1440
1381 GCAGGCTGAGCTTAAACACCTCCCACTACAGCTTCTTCCACAGTAACAGTGGAGACCA 1440
1441 CGGAGATCTGCTGTCGAGGACAAACCGGAAAGTACAAAGCTTCTTACCAAGTGGAG 1500
1441 CGGAGATCTGCTGTCGAGGACAAACCGGAAAGTACAAAGCTTCTTACCAAGTGGAG 1500
1501 GTTACAGCGCGGATATACACCTTACCGAGTGTCTCTTTCAGACTACCGCTGGGCCA 1560
1501 GTTACAGCGCGGATATACACCTTACCGAGTGTCTCTTTCAGACTACCGCTGGGCCA 1560
1561 AGCAGGTGGCAGTATACCGGACAGACACCACTGACAGATGACAGCCAGGCTGGATGAAG 1620
1561 AGCAGGTGGCAGTATACCGGACAGACACCACTGACAGATGACAGCCAGGCTGGATGAAG 1620
1621 TCATGAGACCAACAGATCATCTGCTGCTGTTGGCAGTGAATCTGCTAGTGTGG 1680
1621 TCATGAGACCAACAGATCATCTGCTGCTGTTGGCAGTGAATCTGCTAGTGTGG 1680
1681 CCATGTTGATTTGCTTCTATAAACTTCGTAAAGCGGACACAGCAGCGGAGTACAGTCAAG 1740
1681 CCATGTTGATTTGCTTCTATAAACTTCGTAAAGCGGACACAGCAGCGGAGTACAGTCAAG 1740
1741 CCGCCCGGACTGTTGAGATATCCAGTGGACGAGACATCCCGAGCGAGCAATCCCGCAG 1800
1741 CCGCCCGGACTGTTGAGATATCCAGTGGACGAGACATCCCGAGCGAGCAATCCCGCAG 1800
1801 CAGCAACAGAGCTCCGTCGGTGTATCAGGTGAGGGGCGAGTAGTCTGCCCAATTC 1860
1801 CAGCAACAGAGCTCCGTCGGTGTATCAGGTGAGGGGCGAGTAGTCTGCCCAATTC 1860
1861 ATGACCATATTAATCAACACCTTACAAACAGCAGCAATGGGGCCACTGGACAGAAACA 1920
1861 ATGACCATATTAATCAACACCTTACAAACAGCAGCAATGGGGCCACTGGACAGAAACA 1920
1921 GCTTGGGAGACTCTCTGCAACCCGACAGTCACTATCTCTGAGCTTATATATTTCAGA 1980
1921 GCTTGGGAGACTCTCTGCAACCCGACAGTCACTATCTCTGAGCTTATATATTTCAGA 1980

```


/ PRIOR FILING DATE: 1998-06-18
 / PRIOR APPLICATION NUMBER: 60/089908
 / PRIOR FILING DATE: 1998-06-18
 / PRIOR APPLICATION NUMBER: 60/089947
 / PRIOR FILING DATE: 1998-06-19
 / PRIOR APPLICATION NUMBER: 60/089948
 / PRIOR FILING DATE: 1998-06-19
 / PRIOR APPLICATION NUMBER: 60/089952
 / PRIOR FILING DATE: 1998-06-19
 / PRIOR APPLICATION NUMBER: 60/090246
 / PRIOR FILING DATE: 1998-06-22
 / PRIOR APPLICATION NUMBER: 60/090252
 / PRIOR FILING DATE: 1998-06-22
 / PRIOR APPLICATION NUMBER: 60/090254
 / PRIOR FILING DATE: 1998-06-22
 / PRIOR APPLICATION NUMBER: 60/090349
 / PRIOR FILING DATE: 1998-06-23
 / PRIOR APPLICATION NUMBER: 60/090355
 / PRIOR FILING DATE: 1998-06-23
 / PRIOR APPLICATION NUMBER: 60/090429
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090431
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090435
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090444
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090445
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090472
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090535
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090540
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090542
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090557
 / PRIOR FILING DATE: 1998-06-24
 / PRIOR APPLICATION NUMBER: 60/090676
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090678
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090690
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090694
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090695
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090696
 / PRIOR FILING DATE: 1998-06-25
 / PRIOR APPLICATION NUMBER: 60/090862
 / PRIOR FILING DATE: 1998-06-26
 / PRIOR APPLICATION NUMBER: 60/090863
 / PRIOR FILING DATE: 1998-06-26
 / PRIOR APPLICATION NUMBER: 60/091360
 / PRIOR FILING DATE: 1998-07-01
 / PRIOR APPLICATION NUMBER: 60/091478
 / PRIOR FILING DATE: 1998-07-02
 / PRIOR APPLICATION NUMBER: 60/091544
 / PRIOR FILING DATE: 1998-07-01
 / PRIOR APPLICATION NUMBER: 60/091519
 / PRIOR FILING DATE: 1998-07-02
 / PRIOR APPLICATION NUMBER: 60/091626
 / PRIOR FILING DATE: 1998-07-02
 / PRIOR APPLICATION NUMBER: 60/091633
 / PRIOR FILING DATE: 1998-07-02
 / PRIOR APPLICATION NUMBER: 60/091978
 / PRIOR FILING DATE: 1998-07-07
 / PRIOR APPLICATION NUMBER: 60/091982
 / PRIOR FILING DATE: 1998-07-07
 / PRIOR APPLICATION NUMBER: 60/092182
 / PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.0%; Pred. Nc. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTCTCTTTTCGAGCCAAATCCAGCGGATGTGAATATTAAGACGTGCGCACCACTGA 60
 DB 1 GTTCTCTTTTCGAGCCAAATCCAGCGGATGTGAATATTAAGACGTGCGCACCACTGA 60
 QY 61 AGCTTTTGTGCGAGTAATCTGTGACACCACTGGAATGCGCATCTGTCTCCGCTGG 120
 DB 61 AGCTTTTGTGCGAGTAATCTGTGACACCACTGGAATGCGCATCTGTCTCCGCTGG 120
 QY 121 TCTACTCTACGCGCAAGTGTGATTCGTGTGAGCCATGCTGTGCGCCCTCAGCCG 180
 DB 121 TCTACTCTACGCGCAAGTGTGATTCGTGTGAGCCATGCTGTGCGCCCTCAGCCG 180
 QY 181 GGCCCCAGAACTGCCCTCCGTTTCTGTGCAAGTAACAGTTGAGCAAGTGTGTGCA 240
 DB 181 GGCCCCAGAACTGCCCTCCGTTTCTGTGCAAGTAACAGTTGAGCAAGTGTGTGCA 240
 QY 241 CGCGCGGGGCTCTCCGAGGTCCGCGAGGCTATTCCTCGAACACCGGTTACCTCAAC 300
 DB 241 CGCGCGGGGCTCTCCGAGGTCCGCGAGGCTATTCCTCGAACACCGGTTACCTCAAC 300
 QY 301 TCATGGAGAACTCAACACCTTGGAGCTGTTTCGACAACTGGCTGACAGTCACTCCTAGCGGG 360
 DB 301 TCATGGAGAACTCAACACCTTGGAGCTGTTTCGACAACTGGCTGACAGTCACTCCTAGCGGG 360
 QY 361 AGTCTCTGCAAGTTGGGCGAGAACTTCATCCGGCAGATTGAGTTGGGGGCTTCAACGCC 420
 DB 361 AGTCTCTGCAAGTTGGGCGAGAACTTCATCCGGCAGATTGAGTTGGGGGCTTCAACGCC 420
 QY 421 TGGCCAGCTCAACACCTTGGAGCTGTTTCGACAACTGGCTGACAGTCACTCCTAGCGGG 480
 DB 421 TGGCCAGCTCAACACCTTGGAGCTGTTTCGACAACTGGCTGACAGTCACTCCTAGCGGG 480
 QY 481 CTTTGAATACCTGTCCAGCTGCGGGAGCTCTGGCTTCGACAACTGGCTGACAGTCACTCCTAGCGGG 540
 DB 481 CTTTGAATACCTGTCCAGCTGCGGGAGCTCTGGCTTCGACAACTGGCTGACAGTCACTCCTAGCGGG 540
 QY 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTGAGCTTGGGGAGCTCA 600
 DB 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTGAGCTTGGGGAGCTCA 600
 QY 601 AGAAGCTGAGTATCTCTGAGGAGCTTTTGGGGGCTGTTCAACCTCAAGTAICTGA 660
 DB 601 AGAAGCTGAGTATCTCTGAGGAGCTTTTGGGGGCTGTTCAACCTCAAGTAICTGA 660
 QY 661 ACTTGGGCGATGTGCAACATTAAGACATGCCCAATCTCACCCCTGCTGGGGTGGAGG 720
 DB 661 ACTTGGGCGATGTGCAACATTAAGACATGCCCAATCTCACCCCTGCTGGGGTGGAGG 720
 QY 721 AGCTGAGATGTGAGGAACTTCCCTGAGATCAGGCTGGCTCTTCCATGGCCCTGA 780
 DB 721 AGCTGAGATGTGAGGAACTTCCCTGAGATCAGGCTGGCTCTTCCATGGCCCTGA 780
 QY 781 GCTCCCTCAAGAAGCTCTGGGTCATGAATCAGCTCAGCTGATTCAGCGGATGCTT 840
 DB 781 GCTCCCTCAAGAAGCTCTGGGTCATGAATCAGCTCAGCTGATTCAGCGGATGCTT 840
 QY 841 TTGACGGGCTGGCTTCACTTTGTGGAATCAACTTGGGCCCAATAAATCTCTCTTTTGC 900
 DB 841 TTGACGGGCTGGCTTCACTTTGTGGAATCAACTTGGGCCCAATAAATCTCTCTTTTGC 900
 QY 901 CCCATGACCTCTTTACCCCGCTGAGGTTACCTGGTGGAGTTGATCTACACCAACCTT 960
 DB 901 CCCATGACCTCTTTACCCCGCTGAGGTTACCTGGTGGAGTTGATCTACACCAACCTT 960
 QY 961 GGAACGTGATTTGTGACATTCGTGGCTAGCTGCTGAGGCTTTCGAGAGTATATACCCACA 1020
 DB 961 GGAACGTGATTTGTGACATTCGTGGCTAGCTGCTGAGGCTTTCGAGAGTATATACCCACA 1020

1021 ATTCCACCTGCTGTGGCCGCTGTATGCTCCCATGCAATGCGAGGCGCTACCTCGTGG 1080
1021 ATTCCACCTGCTGTGGCCGCTGTATGCTCCCATGCAATGCGAGGCGCTACCTCGTGG 1080
1081 AGGTGACACAGGCGCTCTTCCAGTGTCTGCCCCCTTCATCATGACCGCCTCGAGACC 1140
1081 AGGTGACACAGGCGCTCTTCCAGTGTCTGCCCCCTTCATCATGACCGCCTCGAGACC 1140
1141 TCACATATTTCTAGGGTTCGGATGGCGAGAACTTAAGTGTGCGACTCCCTCTATGCTCTCG 1200
1141 TCACATATTTCTAGGGTTCGGATGGCGAGAACTTAAGTGTGCGACTCCCTCTATGCTCTCG 1200
1201 TGAAGTGTGTGCTGCCCCCAATGGAGAGTGTCTCAGCCAGCCCTCCCGCCACCCAGGATCT 1260
1201 TGAAGTGTGTGCTGCCCCCAATGGAGAGTGTCTCAGCCAGCCCTCCCGCCACCCAGGATCT 1260
1261 CTGTCTCTCAACGACGCGCACTTGAACCTTTTCCACAGTGTCTGCTTTTCAGACACTGGGGTGT 1320
1261 CTGTCTCTCAACGACGCGCACTTGAACCTTTTCCACAGTGTCTGCTTTTCAGACACTGGGGTGT 1320
1321 ACACATGCTGTTGATGCAATGTTGCGAGGCAATCCCAAGCTCTGCGCTACCTCAATGTGA 1380
1321 ACACATGCTGTTGATGCAATGTTGCGAGGCAATCCCAAGCTCTGCGCTACCTCAATGTGA 1380
1381 GCACGCTGAGCTTAAACACTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTT 1440
1381 GCACGCTGAGCTTAAACACTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTT 1440
1441 CGGAGATCTGCTGCTGAGGAGCAACACCGGAAATGACAAAGCTCTTCTAGCAGCTCCACTG 1500
1441 CGGAGATCTGCTGCTGAGGAGCAACACCGGAAATGACAAAGCTCTTCTAGCAGCTCCACTG 1500
1501 GTTACAGCGCGGATATACCACTCTTACCAAGCTGTCTTACCTGAGTCTGCTGAGTGGCCA 1560
1501 GTTACAGCGCGGATATACCACTCTTACCAAGCTGTCTTACCTGAGTCTGCTGAGTGGCCA 1560
1561 AGCAGTGGCAGTACCGCGGAGACACCACTGACAAAGATGACAGCCAGCTCTGAGTGAAG 1620
1561 AGCAGTGGCAGTACCGCGGAGACACCACTGACAAAGATGACAGCCAGCTCTGAGTGAAG 1620
1621 TCATGAGACCAACAGATCATCATTTGGCTGTCTTGTGCGAGTCTGCTGAGTGGCG 1680
1621 TCATGAGACCAACAGATCATCATTTGGCTGTCTTGTGCGAGTCTGCTGAGTGGCG 1680
1681 CCATGTTGATGTTCTTCTATAAATCTTGAAGCGGACCGAGCGGAGTACAGTCAAG 1740
1681 CCATGTTGATGTTCTTCTATAAATCTTGAAGCGGACCGAGCGGAGTACAGTCAAG 1740
1741 CCGCGCGGACTGTTGAGATATCCAGTGGAGAGACATCCAGCGGACAGATCCGAG 1800
1741 CCGCGCGGACTGTTGAGATATCCAGTGGAGAGACATCCAGCGGACAGATCCGAG 1800
1801 CAGCAACAGCAGCTCGGTCCGGTGTATCAGTGGAGGCGGAGTGTGCTGCCCAATTC 1860
1801 CAGCAACAGCAGCTCGGTCCGGTGTATCAGTGGAGGCGGAGTGTGCTGCCCAATTC 1860
1861 ATGACCATATTAATACCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCA 1920
1861 ATGACCATATTAATACCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTTCA 1920
1921 GCCTGGGGAATCTCTGACCCCAAGTGTACCACTATCTGCAACCTTATATAATTCAGA 1980
1921 GCCTGGGGAATCTCTGACCCCAAGTGTACCACTATCTGCAACCTTATATAATTCAGA 1980
1981 CCCATACCAAGGACAAGGTACAGAACTCAATATGACTCCCTCCCTCCCAAAACCTTA 2040
1981 CCCATACCAAGGACAAGGTACAGAACTCAATATGACTCCCTCCCTCCCAAAACCTTA 2040
2041 TAAATGCAATAGATGCAACAAAGCAGCACTTTTGTACAGTGGGGGAGACTTT 2100
2041 TAAATGCAATAGATGCAACAAAGCAGCACTTTTGTACAGTGGGGGAGACTTT 2100
2101 TTCTTGTATATGCTTATATTAAGTCTATGCGCTGTTTAAAAAACAAGATTATATAA 2160

Db 2101 TTCTTGTATATGCTTATATTAAGTCTATGCGCTGTTAAAAAACAAGATTATATAA 2160
Qy 2161 AATTTAAAGACAAAAGTCAAAACA 2185
Db 2161 AATTTAAAGACAAAAGTCAAAACA 2185

RESULT 40

US-09-991-854-228
; Sequence 228, Application US/09991854
; Publication No. US20030059780A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Saton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Pong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730P1C24
; CURRENT APPLICATION NUMBER: US/09/991,854
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025

7	PRIOR FILING DATE: 1998-06-04	
7	PRIOR APPLICATION NUMBER: 60/088026	
7	PRIOR FILING DATE: 1998-06-04	
7	PRIOR APPLICATION NUMBER: 60/088028	
7	PRIOR FILING DATE: 1998-06-04	
7	PRIOR APPLICATION NUMBER: 60/088029	
7	PRIOR FILING DATE: 1998-06-04	
7	PRIOR APPLICATION NUMBER: 60/088030	
7	PRIOR FILING DATE: 1998-06-04	
7	PRIOR APPLICATION NUMBER: 60/088033	
7	PRIOR FILING DATE: 1998-06-04	
7	PRIOR APPLICATION NUMBER: 60/088326	
7	PRIOR FILING DATE: 1998-06-04	
7	PRIOR APPLICATION NUMBER: 60/088167	
7	PRIOR FILING DATE: 1998-06-05	
7	PRIOR APPLICATION NUMBER: 60/088202	
7	PRIOR FILING DATE: 1998-06-05	
7	PRIOR APPLICATION NUMBER: 60/088212	
7	PRIOR FILING DATE: 1998-06-05	
7	PRIOR APPLICATION NUMBER: 60/088217	
7	PRIOR FILING DATE: 1998-06-10	
7	PRIOR APPLICATION NUMBER: 60/088738	
7	PRIOR FILING DATE: 1998-06-10	
7	PRIOR APPLICATION NUMBER: 60/088742	
7	PRIOR FILING DATE: 1998-06-10	
7	PRIOR APPLICATION NUMBER: 60/088810	
7	PRIOR FILING DATE: 1998-06-10	
7	PRIOR APPLICATION NUMBER: 60/088824	
7	PRIOR FILING DATE: 1998-06-10	
7	PRIOR APPLICATION NUMBER: 60/088826	
7	PRIOR FILING DATE: 1998-06-10	
7	PRIOR APPLICATION NUMBER: 60/088858	
7	PRIOR FILING DATE: 1998-06-11	
7	PRIOR APPLICATION NUMBER: 60/088861	
7	PRIOR FILING DATE: 1998-06-11	
7	PRIOR APPLICATION NUMBER: 60/088876	
7	PRIOR FILING DATE: 1998-06-11	
7	PRIOR APPLICATION NUMBER: 60/089105	
7	PRIOR FILING DATE: 1998-06-12	
7	PRIOR APPLICATION NUMBER: 60/089440	
7	PRIOR FILING DATE: 1998-06-16	
7	PRIOR APPLICATION NUMBER: 60/089512	
7	PRIOR FILING DATE: 1998-06-16	
7	PRIOR APPLICATION NUMBER: 60/089514	
7	PRIOR FILING DATE: 1998-06-16	
7	PRIOR APPLICATION NUMBER: 60/089532	
7	PRIOR FILING DATE: 1998-06-17	
7	PRIOR APPLICATION NUMBER: 60/089538	
7	PRIOR FILING DATE: 1998-06-17	
7	PRIOR APPLICATION NUMBER: 60/089538	
7	PRIOR FILING DATE: 1998-06-17	
7	PRIOR APPLICATION NUMBER: 60/089593	
7	PRIOR FILING DATE: 1998-06-17	
7	PRIOR APPLICATION NUMBER: 60/089599	
7	PRIOR FILING DATE: 1998-06-17	
7	PRIOR APPLICATION NUMBER: 60/089600	
7	PRIOR FILING DATE: 1998-06-17	
7	PRIOR APPLICATION NUMBER: 60/089653	
7	PRIOR FILING DATE: 1998-06-17	
7	PRIOR APPLICATION NUMBER: 60/089801	
7	PRIOR FILING DATE: 1998-06-18	
7	PRIOR APPLICATION NUMBER: 60/089907	
7	PRIOR FILING DATE: 1998-06-18	
7	PRIOR APPLICATION NUMBER: 60/089908	
7	PRIOR FILING DATE: 1998-06-18	
7	PRIOR APPLICATION NUMBER: 60/089947	
7	PRIOR FILING DATE: 1998-06-13	
7	PRIOR APPLICATION NUMBER: 60/089948	
7	PRIOR FILING DATE: 1998-06-19	
7	PRIOR APPLICATION NUMBER: 60/089952	
7	PRIOR FILING DATE: 1998-06-19	

1	PRIOR APPLICATION NUMBER: 60/090246
2	PRIOR FILING DATE: 1998-06-22
3	PRIOR APPLICATION NUMBER: 60/090252
4	PRIOR FILING DATE: 1998-06-22
5	PRIOR APPLICATION NUMBER: 60/090254
6	PRIOR FILING DATE: 1998-06-22
7	PRIOR APPLICATION NUMBER: 60/090349
8	PRIOR FILING DATE: 1998-06-23
9	PRIOR APPLICATION NUMBER: 60/090355
10	PRIOR FILING DATE: 1998-06-23
11	PRIOR APPLICATION NUMBER: 60/090429
12	PRIOR FILING DATE: 1998-06-24
13	PRIOR APPLICATION NUMBER: 60/090431
14	PRIOR FILING DATE: 1998-06-24
15	PRIOR APPLICATION NUMBER: 60/090435
16	PRIOR FILING DATE: 1998-06-24
17	PRIOR APPLICATION NUMBER: 60/090444
18	PRIOR FILING DATE: 1998-06-24
19	PRIOR APPLICATION NUMBER: 60/090445
20	PRIOR FILING DATE: 1998-06-24
21	PRIOR APPLICATION NUMBER: 60/090472
22	PRIOR FILING DATE: 1998-06-24
23	PRIOR APPLICATION NUMBER: 60/090535
24	PRIOR FILING DATE: 1998-06-24
25	PRIOR APPLICATION NUMBER: 60/090540
26	PRIOR FILING DATE: 1998-06-24
27	PRIOR APPLICATION NUMBER: 60/090542
28	PRIOR FILING DATE: 1998-06-24
29	PRIOR APPLICATION NUMBER: 60/090557
30	PRIOR FILING DATE: 1998-06-24
31	PRIOR APPLICATION NUMBER: 60/090676
32	PRIOR FILING DATE: 1998-06-25
33	PRIOR APPLICATION NUMBER: 60/090678
34	PRIOR FILING DATE: 1998-06-25
35	PRIOR APPLICATION NUMBER: 60/090690
36	PRIOR FILING DATE: 1998-06-25
37	PRIOR APPLICATION NUMBER: 60/090694
38	PRIOR FILING DATE: 1998-06-25
39	PRIOR APPLICATION NUMBER: 60/090695
40	PRIOR FILING DATE: 1998-06-25
41	PRIOR APPLICATION NUMBER: 60/090696
42	PRIOR FILING DATE: 1998-06-25
43	PRIOR APPLICATION NUMBER: 60/090862
44	PRIOR FILING DATE: 1998-06-26
45	PRIOR APPLICATION NUMBER: 60/090863
46	PRIOR FILING DATE: 1998-06-26
47	PRIOR APPLICATION NUMBER: 60/091544
48	PRIOR FILING DATE: 1998-07-01
49	PRIOR APPLICATION NUMBER: 60/091519
50	PRIOR FILING DATE: 1998-07-02
51	PRIOR APPLICATION NUMBER: 60/091626
52	PRIOR FILING DATE: 1998-07-02
53	PRIOR APPLICATION NUMBER: 60/091633
54	PRIOR FILING DATE: 1998-07-02
55	PRIOR APPLICATION NUMBER: 60/091787
56	PRIOR FILING DATE: 1998-07-07
57	PRIOR APPLICATION NUMBER: 60/091982
58	PRIOR FILING DATE: 1998-07-07
59	PRIOR APPLICATION NUMBER: 60/092182
60	PRIOR FILING DATE: 1998-07-09

```
Query Match
100.0%: Score 2185: DB 11: Length 2185;
```

[illegible]

Qy 1 GTTCTCTTTCCGAGCCAAATCCCAGGCGATGTTGAATTATGAACTGTGCACACCATGA 60

Dh 1 GTTCTCTTTCCGAGCCAAATCCCAGGCGATGTTGAATTATGAACTGTGCACACCATGA 60

61	AGCTCTTTGGCAGGTAACCTGTGCACCAACCACTCGGAATGCCATCTCTGCTCCCGTTGC	120
61	AGCTCTTTGGCAGGTAACCTGTGCACCAACCACTCGGAATGCCATCTCTGCTCCCGTTGC	120
121	TCTACCTCAAGGCGCAAGTGTGATCTGTGTGCAGCCATCGCTGTCTCGCGCTCAGCG	180
121	TCTACCTCAAGGCGCAAGTGTGATCTGTGTGCAGCCATCGCTGTCTCGCGCTCAGCG	180
181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTGTGCAAGTTCAGCAAGAGTGGTGTCA	240
181	GGCCCCAGAACTGCCCTCCGTTTGTCTGTGTGCAAGTTCAGCAAGAGTGGTGTCA	240
241	CGCGCGGGGCTCTCGAGGTCCCGCAGGGTATTCCTCTGGAACAACCGGTACTCAAC	300
241	CGCGCGGGGCTCTCGAGGTCCCGCAGGGTATTCCTCTGGAACAACCGGTACTCAAC	300
301	TCATGAGAAACAATCCAGATGATCAGAGCCAGACCTTCGCGCATCTCCACCACTGG	360
301	TCATGAGAAACAATCCAGATGATCAGAGCCAGACCTTCGCGCATCTCCACCACTGG	360
361	AGGTCCTGACGTTGGCAGGAATCCATTCGCGCAGATTGAGGTGGGGGCTTCAACGGGC	420
361	AGGTCCTGACGTTGGCAGGAATCCATTCGCGCAGATTGAGGTGGGGGCTTCAACGGGC	420
421	TGGCGAGCCTCAACACCTCGAGCTGTGCAACTCGGCTGACAGTCATCCCTAGCGGG	480
421	TGGCGAGCCTCAACACCTCGAGCTGTGCAACTCGGCTGACAGTCATCCCTAGCGGG	480
481	CTTTTGAATACCTGTCCAAGCTGGGAGGCTCTGGCTTCGCAACAACCCCATCGAAAGCA	540
481	CTTTTGAATACCTGTCCAAGCTGGGAGGCTCTGGCTTCGCAACAACCCCATCGAAAGCA	540
541	TCCCTCTTAAGCTTCAACCGGGTCCCTCCCTCATGCGGCTGGACTTGGGGGAGCTCA	600
541	TCCCTCTTAAGCTTCAACCGGGTCCCTCCCTCATGCGGCTGGACTTGGGGGAGCTCA	600
601	AGAGCTGAGATATATCTCTCAGGGAGCTTTTGAGGGGCTGTTCAACCTCAAGTATCTGA	660
601	AGAGCTGAGATATATCTCTCAGGGAGCTTTTGAGGGGCTGTTCAACCTCAAGTATCTGA	660
661	ACTTGGGATGTGCACCAATTAAGACATGCCAATCTCAACCCCTGGTGGGGCTGGAG	720
661	ACTTGGGATGTGCACCAATTAAGACATGCCAATCTCAACCCCTGGTGGGGCTGGAG	720
721	AGCTGAGATGTCAAGGAACACTTCCTCGAGATCAGGCTGGCTCTCCATGGGCTGA	780
721	AGCTGAGATGTCAAGGAACACTTCCTCGAGATCAGGCTGGCTCTCCATGGGCTGA	780
781	GCTCCTCAAGAGCTCTGGGTATGAATCTCAGAGTCAGGCTGATTTGAGCGGAATGCTT	840
781	GCTCCTCAAGAGCTCTGGGTATGAATCTCAGAGTCAGGCTGATTTGAGCGGAATGCTT	840
841	TTGACGGGCTGCTTCACTTTGTGGAACCTCAACTTTGGGCCCAATAAAGCTCTCTCTTTTC	900
841	TTGACGGGCTGCTTCACTTTGTGGAACCTCAACTTTGGGCCCAATAAAGCTCTCTCTTTTC	900
901	CCCATGACCTTTTAACCGGCTGAGGTACCTGGTGGAGTTGCATCTACACCAACCCCTT	960
901	CCCATGACCTTTTAACCGGCTGAGGTACCTGGTGGAGTTGCATCTACACCAACCCCTT	960
961	GGAGCTGTGATGTGACCAATCTGTGCGTAGCCTGGTGGCTTCGAGAGTATATACCAACA	1020
961	GGAGCTGTGATGTGACCAATCTGTGCGTAGCCTGGTGGCTTCGAGAGTATATACCAACA	1020
1021	ATTTCACCTGTGTGGCGGCTGTCAATGCTCCCATGCAATCGGAGGCGCTACTCGTGG	1080
1021	ATTTCACCTGTGTGGCGGCTGTCAATGCTCCCATGCAATCGGAGGCGCTACTCGTGG	1080
1081	AGGTGACAGAGCCTCTTCCAGTGCTCTGCCCCCTTCATCATGAGCGCACTCTCGAGAC	1140
1081	AGGTGACAGAGCCTCTTCCAGTGCTCTGCCCCCTTCATCATGAGCGCACTCTCGAGAC	1140
1141	TCAACATTTCTGAGGGTGGAGTGGCAGAACTTAAGTGTGAGACTCCCGCTATGCTCCG	1200

RESULT 41

JS-09-997-628-228
; Sequence 228, Application US/09997628
; Publication No. US20030059782A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Deenoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730PIC30
; CURRENT APPLICATION NUMBER: US/09/997,628
; CURRENT FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084500
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355

PRIOR FILING DATE: 1998-06-23
 PRIOR APPLICATION NUMBER: 60/090429
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090431
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090435
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090444
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090445
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090472
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090535
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090540
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090542
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090557
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090676
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090678
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090690
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090694
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090695
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090696
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090862
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/090863
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/091360
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091478
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091544
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091519
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091626
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091633
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091978
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/091982
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/092182
 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 GTTCTCTTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAACTGACGTCGCCACCATGA 60
 1 GTTCTCTTTCCGAGCCAAATCCAGGCGATGGTGAATTATGAACTGACGTCGCCACCATGA 60
 61 AGCTCTTTGGCAGGTAACCTGTCACACACACCTGGATGCCATCTCTCCGTTCCG 120
 61 AGCTCTTTGGCAGGTAACCTGTCACACACACCTGGATGCCATCTCTCCGTTCCG 120
 121 TCTACCTCAGCGGCAAGTGGATTCTGTGTCAGCCATCGCTGTCGCGCTCAGCGG 180
 121 TCTACCTCAGCGGCAAGTGGATTCTGTGTCAGCCATCGCTGTCGCGCTCAGCGG 180
 181 GGCCCCAGAACTGCCCTCCGTTTCTGTCGTCGATTAACGTTTCAGCAAGGTGGTGTGCA 240

Db 181 GGCCCCAGAACTGCCCTCCGTTTCTGTCGTCGATTAACGTTTCAGCAAGGTGGTGTGCA 240
 Qy 241 CGGCGCGGGGCTCTCCGAGGTCGCGAGGGTATTCCTCGAACAACCCGCTACCTCAACC 300
 Db 241 CGGCGCGGGGCTCTCCGAGGTCGCGAGGGTATTCCTCGAACAACCCGCTACCTCAACC 300
 Qy 301 TCATGGAGAACCAATCCAGATGATCCAGGGCGACAACCTTCGGCCACCTCCACCACTGG 360
 Db 301 TCATGGAGAACCAATCCAGATGATCCAGGGCGACAACCTTCGGCCACCTCCACCACTGG 360
 Qy 361 AGGTCTGTCAGTTGGGCGGAACTCCATCCGACATGAGTGGGGGCTTCACACGGCC 420
 Db 361 AGGTCTGTCAGTTGGGCGGAACTCCATCCGACATGAGTGGGGGCTTCACACGGCC 420
 Qy 421 TGGCCAGCCTCAACACACCTGGAGCTGTTTCGACAACTGGCTGACATGCTTCTACGGGG 480
 Db 421 TGGCCAGCCTCAACACACCTGGAGCTGTTTCGACAACTGGCTGACATGCTTCTACGGGG 480
 Qy 481 CTTTGAATACCTGTCAGCTCGGGAGCTCTGGCTCGCAACCTGGCTGACATGCTTCTACGGGG 540
 Db 481 CTTTGAATACCTGTCAGCTCGGGAGCTCTGGCTCGCAACCTGGCTGACATGCTTCTACGGGG 540
 Qy 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTCGCAACTGGGGGAGCTCA 600
 Db 541 TCCCTCTTACGCTTCAACCGGGTCCCTCCCTCATGCGCTCGCAACTGGGGGAGCTCA 600
 Qy 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGAAGGCTGTTTCAAGTATCTGA 660
 Db 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGAAGGCTGTTTCAAGTATCTGA 660
 Qy 661 ACTTGGGCACTGCAACATTAAGACATGCGCAATGCCCCCTGCTGGTGGGGTGGAGG 720
 Db 661 ACTTGGGCACTGCAACATTAAGACATGCGCAATGCCCCCTGCTGGTGGGGTGGAGG 720
 Qy 721 AGCTGAGATGTCAGGAACTCACTTCCCTGAGATGAGGCTGGCTCTCTTCTTCTGCTGA 780
 Db 721 AGCTGAGATGTCAGGAACTCACTTCCCTGAGATGAGGCTGGCTCTCTTCTTCTGCTGA 780
 Qy 781 GCTCCCTCAGAGAGCTCTGGCTCATGAATCAGCTCAGCTCAGCTGATGAGCGGAATGCTT 840
 Db 781 GCTCCCTCAGAGAGCTCTGGCTCATGAATCAGCTCAGCTCAGCTGATGAGCGGAATGCTT 840
 Qy 841 TTGACGGGCTGGCTTCACTTGTGGAACTCACTTGGCCCAACAATACCTCTCTTCTTTCG 900
 Db 841 TTGACGGGCTGGCTTCACTTGTGGAACTCACTTGGCCCAACAATACCTCTCTTCTTTCG 900
 Qy 901 CCATGACCTCTTTACCCCGCTGAGGTAACCTGGTGGAGTTCATCTACACCAACACCTT 960
 Db 901 CCATGACCTCTTTACCCCGCTGAGGTAACCTGGTGGAGTTCATCTACACCAACACCTT 960
 Qy 961 GGAACCTGTGATGTCGACATTTCTGCTGCTAGCTGCTGCTTCCAGAGTATATACCCACCA 1020
 Db 961 GGAACCTGTGATGTCGACATTTCTGCTGCTAGCTGCTGCTTCCAGAGTATATACCCACCA 1020
 Qy 1021 ATTCCACCTGCTGTGGCGCTGTCTCCCATGCTCCCATGCACTGGAGGCGCTACCTGCTGG 1080
 Db 1021 ATTCCACCTGCTGTGGCGCTGTCTCCCATGCTCCCATGCACTGGAGGCGCTACCTGCTGG 1080
 Qy 1081 AGGTGACACAGGCTCTCTCCAGTCTCTGCGCCCTTCACTCATGAGCGCAGCTCTCGAGAC 1140
 Db 1081 AGGTGACACAGGCTCTCTCCAGTCTCTGCGCCCTTCACTCATGAGCGCAGCTCTCGAGAC 1140
 Qy 1141 TCACATTTCTGAGGTCGGATGCGAGAACTTAAGTGTGGACTCCCTTATGTCCTCG 1200
 Db 1141 TCACATTTCTGAGGTCGGATGCGAGAACTTAAGTGTGGACTCCCTTATGTCCTCG 1200
 Qy 1201 TGAAGTGGTCTGCCCAATGGGACAGTGTCTGACCCAGCTCCCGCCACCCAGGATCT 1260
 Db 1201 TGAAGTGGTCTGCCCAATGGGACAGTGTCTGACCCAGCTCCCGCCACCCAGGATCT 1260
 Qy 1261 CTGTCTCAACGACGCGCACTTGAACCTTTTCCACGCTGCTGCTTTCAGACATGCGGGGTGT 1320

b 1261 CTGCTCTCAACGAGCGCACCTTGAACCTTTCCACGCTGCTGCTTTCCAGACACTGGGGTGT 1320
y 1321 ACACATGCTATGCTGACATGCTGACGCACTCCACGCTCGGCTACTCTCAATGTGA 1380
b 1321 ACACATGCTATGCTGACATGCTGACGCACTCCACGCTCGGCTACTCTCAATGTGA 1380
y 1381 GCACGCTGAGCTTAACACCTCCACTCAGCTTTTCCACACAGTAACTAGTGAGACCA 1440
b 1381 GCACGCTGAGCTTAACACCTCCACTCAGCTTTTCCACACAGTAACTAGTGAGACCA 1440
y 1441 CGGAGATCTCGCTGAGGACACACGCGAAAGTACAGGCTGTTCTTACCACGCTCCACTG 1500
b 1441 CGGAGATCTCGCTGAGGACACACGCGAAAGTACAGGCTGTTCTTACCACGCTCCACTG 1500
y 1501 GTTACACGCGGATATACCACTTACACGCTGCTCAATTCAGACTACCCGCTGTGCCA 1560
b 1501 GTTACACGCGGATATACCACTTACACGCTGCTCAATTCAGACTACCCGCTGTGCCA 1560
y 1561 AGCAGTGGCAGTACCGCGACACACACCTGACAGGCTGACACGAGCTCGATGAAG 1620
b 1561 AGCAGTGGCAGTACCGCGACACACACCTGACAGGCTGACACGAGCTCGATGAAG 1620
y 1621 TCATGAAGACCCCAAGATCATCATCTTGTGAGGAGTCTCTCTAGCTGCGG 1680
b 1621 TCATGAAGACCCCAAGATCATCATCTTGTGAGGAGTCTCTCTAGCTGCGG 1680
y 1681 CCATGTTGATTTCTTCTATAACTTCGTAAGCGGACCCAGCGGAGTACAGTCCAG 1740
b 1681 CCATGTTGATTTCTTCTATAACTTCGTAAGCGGACCCAGCGGAGTACAGTCCAG 1740
y 1741 CGCCCGGACTGTTGAGTATTCAGAGTGCAGAGATCCAGAGCAATCCAGCAAGCAATCC 1800
b 1741 CGCCCGGACTGTTGAGTATTCAGAGTGCAGAGATCCAGAGCAATCCAGCAAGCAATCC 1800
y 1801 CAGCAACACAGCTCGCTCGGCTGATCAGTGCAGGCGGAGTAGTCTCCACCAATTC 1860
b 1801 CAGCAACACAGCTCGCTCGGCTGATCAGTGCAGGCGGAGTAGTCTCCACCAATTC 1860
y 1861 ATGACCATATTAATACAACTTACAAACCCAGCAATCCAGGAGGAGTCTGACAGAGAAACA 1920
b 1861 ATGACCATATTAATACAACTTACAAACCCAGCAATCCAGGAGGAGTCTGACAGAGAAACA 1920
y 1921 GCTGGGGAACCTCTGCAACCCCAAGTACCACTTCTCTGAACTTATATATTTTCA 1980
b 1921 GCTGGGGAACCTCTGCAACCCCAAGTACCACTTCTCTGAACTTATATATTTTCA 1980
y 1981 CCATACCAAGGACAGGTACAGGAACTCAATATGACTCCCTCCCAAAAACTTA 2040
b 1981 CCATACCAAGGACAGGTACAGGAACTCAATATGACTCCCTCCCAAAAACTTA 2040
y 2041 TAAATGCAATAGATGACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
b 2041 TAAATGCAATAGATGACACAAAGACAGCACTTTTGTACAGAGTGGGAGAGACTTT 2100
y 2101 TTCTGTATATGCTTATATATTAAGTCTATGGCTGTTAAAAAAGACAGATATATTA 2160
b 2101 TTCTGTATATGCTTATATATTAAGTCTATGGCTGTTAAAAAAGACAGATATATTA 2160
y 2161 AATTTTAAAGCAAAAAAGTCAAAACA 2185
b 2161 AATTTTAAAGCAAAAAAGTCAAAACA 2185

RESULT 42

US-09-997-683-228
; Sequence 228, Application US/09997683
; Publication No. US20030059783A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.

APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary B.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas P.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C32
CURRENT APPLICATION NUMBER: US/09/997,683
CURRENT FILING DATE: 2001-11-15
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212

1	PRIOR APPLICATION NUMBER: 60/090445
2	PRIOR FILING DATE: 1998-06-24
3	PRIOR APPLICATION NUMBER: 60/090472
4	PRIOR FILING DATE: 1998-06-24
5	PRIOR APPLICATION NUMBER: 60/090535
6	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090540
8	PRIOR FILING DATE: 1998-06-24
9	PRIOR APPLICATION NUMBER: 60/090542
10	PRIOR FILING DATE: 1998-06-24
11	PRIOR APPLICATION NUMBER: 60/090557
12	PRIOR FILING DATE: 1998-06-24
13	PRIOR APPLICATION NUMBER: 60/090676
14	PRIOR FILING DATE: 1998-06-25
15	PRIOR APPLICATION NUMBER: 60/090678
16	PRIOR FILING DATE: 1998-06-25
17	PRIOR APPLICATION NUMBER: 60/090690
18	PRIOR FILING DATE: 1998-06-25
19	PRIOR APPLICATION NUMBER: 60/090694
20	PRIOR FILING DATE: 1998-06-25
21	PRIOR APPLICATION NUMBER: 60/090695
22	PRIOR FILING DATE: 1998-06-25
23	PRIOR APPLICATION NUMBER: 60/090696
24	PRIOR FILING DATE: 1998-06-25
25	PRIOR APPLICATION NUMBER: 60/090862
26	PRIOR FILING DATE: 1998-06-26
27	PRIOR APPLICATION NUMBER: 60/090863
28	PRIOR FILING DATE: 1998-06-26
29	PRIOR APPLICATION NUMBER: 60/091360
30	PRIOR FILING DATE: 1998-07-01
31	PRIOR APPLICATION NUMBER: 60/091478
32	PRIOR FILING DATE: 1998-07-02
33	PRIOR APPLICATION NUMBER: 60/091544
34	PRIOR FILING DATE: 1998-07-01
35	PRIOR APPLICATION NUMBER: 60/091519
36	PRIOR FILING DATE: 1998-07-02
37	PRIOR APPLICATION NUMBER: 60/091626
38	PRIOR FILING DATE: 1998-07-02
39	PRIOR APPLICATION NUMBER: 60/091633
40	PRIOR FILING DATE: 1998-07-02
41	PRIOR APPLICATION NUMBER: 60/091978
42	PRIOR FILING DATE: 1998-07-07
43	PRIOR APPLICATION NUMBER: 60/091982
44	PRIOR FILING DATE: 1998-07-07
45	PRIOR APPLICATION NUMBER: 60/092182
46	PRIOR FILING DATE: 1998-07-09

301 TCATGGAGAAACATCCAGATGATCCAGGCGAGACACTTCCGCCACTCCACCACTGG 360
361 AGTCTCTGAGTTGGGAGAGAACTCCATCGGCGAGATTGAGGTGGGGCTTCAAGGCC 420
361 AGTCTCTGAGTTGGGAGAGAACTCCATCGGCGAGATTGAGGTGGGGCTTCAAGGCC 420
421 TGGCCAGCCTCAACACCTCTGAGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480
421 TGGCCAGCCTCAACACCTCTGAGCTGTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480
481 CTTTGAATACCTGTCCAACTGCGGAGCTCTGGCTTGCACAAACCCCATGGAAGCA 540
481 CTTTGAATACCTGTCCAACTGCGGAGCTCTGGCTTGCACAAACCCCATGGAAGCA 540
541 TCCCTCTTACGCTTCAACCGGCTGCTCCCTCATGCGCTGGACTTGGGGAGCTCA 600
541 TCCCTCTTACGCTTCAACCGGCTGCTCCCTCATGCGCTGGACTTGGGGAGCTCA 600
601 AGAAGCTGGAGTATCTCTGAGGAGCTTTCAGGGGCTTTCACACTCAAGTATCTGA 660
601 AGAAGCTGGAGTATCTCTGAGGAGCTTTCAGGGGCTTTCACACTCAAGTATCTGA 660
661 ACTTGGGAGTGTCAACATTAAGACATGCCAATCTCACCCCTGCTGGGGCTGGAGG 720
661 ACTTGGGAGTGTCAACATTAAGACATGCCAATCTCACCCCTGCTGGGGCTGGAGG 720
721 AGCTGGAGATGTCAAGGAACCACTTCCCTGAGATCAGGCTGCTGCTCCATGCGCTGA 780
721 AGCTGGAGATGTCAAGGAACCACTTCCCTGAGATCAGGCTGCTGCTCCATGCGCTGA 780
781 GCTCCCTCAAGAGCTCTGGGTGATGACTCAGAGTCAAGCTGAGTGGGGAATGCTT 840
781 GCTCCCTCAAGAGCTCTGGGTGATGACTCAGAGTCAAGCTGAGTGGGGAATGCTT 840
841 TTGACGGCTGGCTTCACTTGTGAACTCACTTGGGCCCAATAACTCTCTTCTTTTC 900
841 TTGACGGCTGGCTTCACTTGTGAACTCACTTGGGCCCAATAACTCTCTTCTTTTC 900
901 CCCATGACCTTTTACCCCGTGAAGTACCTGGTGGAGTTCATCTACACCAACCTT 960
901 CCCATGACCTTTTACCCCGTGAAGTACCTGGTGGAGTTCATCTACACCAACCTT 960
961 GGAATGTGATTTGACATTTCTGGCTGAGCTGCTGGTTCGAGAGTATATACCAACA 1020
961 GGAATGTGATTTGACATTTCTGGCTGAGCTGCTGGTTCGAGAGTATATACCAACA 1020
1021 APTCCACTGTGTGGCGCTGTGATGCTCCATGCACTGCGAGGCGCTACTGTGG 1080
1021 APTCCACTGTGTGGCGCTGTGATGCTCCATGCACTGCGAGGCGCTACTGTGG 1080
1081 AGTGGGCGAGGCTCTTCCAGTGTCTGCTCCCTTTCATGAGGAGGCTGAGAGC 1140
1081 AGTGGGCGAGGCTCTTCCAGTGTCTGCTCCCTTTCATGAGGAGGCTGAGAGC 1140
1141 TCAACATTTCTGAGGCTGAGTGGAGAACTTAAGTGTGAGCTTCCCTCTATGTCCTCG 1200
1141 TCAACATTTCTGAGGCTGAGTGGAGAACTTAAGTGTGAGCTTCCCTCTATGTCCTCG 1200
1201 TGAAGTGTGTGCTGCCAATGGAAGTGTGAGCTTCCCGCTCCCGCAACAGGATCT 1260
1201 TGAAGTGTGTGCTGCCAATGGAAGTGTGAGCTTCCCGCTCCCGCAACAGGATCT 1260
1261 CTGTCTCTCAACGAGGCTTGAACCTTTCCAGTGTCTGCTTTCAGACACTGGGTGT 1320
1261 CTGTCTCTCAACGAGGCTTGAACCTTTCCAGTGTCTGCTTTCAGACACTGGGTGT 1320
1321 ACATGATGTGTGAGCAATGTGAGGCACTTCCAGGCTTCCCGCTCCCGCAACAGGATCT 1380
1321 ACATGATGTGTGAGCAATGTGAGGCACTTCCAGGCTTCCCGCTCCCGCAACAGGATCT 1380
1381 GCAAGCTGAGTGTAACTCACTGAGTGTCTTCCAGGCTTCCCGCTCCCGCAACAGGATCT 1440
1381 GCAAGCTGAGTGTAACTCACTGAGTGTCTTCCAGGCTTCCCGCTCCCGCAACAGGATCT 1440

1441 CGGAGATCTCGCTGAGGACACAAACGCGAAAGTACAGCTTCTTCTACCAAGTCCACTG 1500
1441 CGGAGATCTCGCTGAGGACACAAACGCGAAAGTACAGCTTCTTCTACCAAGTCCACTG 1500
1501 GTTACAGCGCGGATATACCACTTACCAAGTGTCTCAATTCAGACTACCGCTGCGCA 1560
1501 GTTACAGCGCGGATATACCACTTACCAAGTGTCTCAATTCAGACTACCGCTGCGCA 1560
1561 AGCAGTGGGAGTACCGCGGACAGACACCACTGACAAAGTACAGACCACTGGATGAAG 1620
1561 AGCAGTGGGAGTACCGCGGACAGACACCACTGACAAAGTACAGACCACTGGATGAAG 1620
1621 TCATGAAGACACCAAGATCATCATTTGGCTGCTTTCGAGCTGACTTCTGCTAGCTGCG 1680
1621 TCATGAAGACACCAAGATCATCATTTGGCTGCTTTCGAGCTGACTTCTGCTAGCTGCG 1680
1681 CCATGTTGATGCTTCTTATAAACTTCTGTAAGCGGACCAAGGAGTACAGTCAAGTTC 1740
1681 CCATGTTGATGCTTCTTATAAACTTCTGTAAGCGGACCAAGGAGTACAGTCAAGTTC 1740
1741 CCGCCCGGACTGTTGAGATTAATCCAGTGGACCAAGACATCCAGGAGCAATCCGCGAG 1800
1741 CCGCCCGGACTGTTGAGATTAATCCAGTGGACCAAGACATCCAGGAGCAATCCGCGAG 1800
1801 CAGCAACAGAGCTCGCTCGCTGATATCAGTGGGCGGAGTGTCTGCTGCGCAACTTC 1860
1801 CAGCAACAGAGCTCGCTCGCTGATATCAGTGGGCGGAGTGTCTGCTGCGCAACTTC 1860
1861 ATGACCTATTTAATCAACACCTTACAAACAGCAATGCGGCGGCTGAGCAAGAAACA 1920
1861 ATGACCTATTTAATCAACACCTTACAAACAGCAATGCGGCGGCTGAGCAAGAAACA 1920
1921 GCCTGGGAGTCTCTGCGCCCAAGTCACTTCTCTGAACTTATATATTAATTCA 1980
1921 GCCTGGGAGTCTCTGCGCCCAAGTCACTTCTCTGAACTTATATATTAATTCA 1980
1981 CCCATACCAAGCAAGGTACAGGAACTCAAAATATGACTCCCTCCCTCCCAAAACTTA 2040
1981 CCCATACCAAGCAAGGTACAGGAACTCAAAATATGACTCCCTCCCTCCCAAAACTTA 2040
2041 TAAATGCAATAGTATGACACCAAGGACGCACTTTTGTACAGAGTGGGAGAGCTTT 2100
2041 TAAATGCAATAGTATGACACCAAGGACGCACTTTTGTACAGAGTGGGAGAGCTTT 2100
2101 TTCTTGTATGCTTATATATTAAGTCTATGGCTGCTTAAATAAAACAGATTATATA 2160
2101 TTCTTGTATGCTTATATATTAAGTCTATGGCTGCTTAAATAAAACAGATTATATA 2160
2161 AATTTAAAGACAAAGTCAAAACA 2185
2161 AATTTAAAGACAAAGTCAAAACA 2185

RESULT 43
US-09-989-729A-228
; Sequence 228, Application US/09989729A
; Publication NO. US2003005983A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gertsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.

APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730PIC59
CURRENT APPLICATION NUMBER: US/09/989,729A
CURRENT FILING DATE: 2001-11-19
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542

7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090557
7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090676
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/090678
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/090690
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/090694
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/090695
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/090696
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/090862
7 PRIOR FILING DATE: 1998-06-26
7 PRIOR APPLICATION NUMBER: 60/090863
7 PRIOR FILING DATE: 1998-06-26
7 PRIOR APPLICATION NUMBER: 60/091360
7 PRIOR FILING DATE: 1998-07-01
7 PRIOR APPLICATION NUMBER: 60/091478
7 PRIOR FILING DATE: 1998-07-02
7 PRIOR APPLICATION NUMBER: 60/091544
7 PRIOR FILING DATE: 1998-07-01
7 PRIOR APPLICATION NUMBER: 60/091519
7 PRIOR FILING DATE: 1998-07-02
7 PRIOR APPLICATION NUMBER: 60/091626
7 PRIOR FILING DATE: 1998-07-02
7 PRIOR APPLICATION NUMBER: 60/091633
7 PRIOR FILING DATE: 1998-07-02
7 PRIOR APPLICATION NUMBER: 60/091978
7 PRIOR FILING DATE: 1998-07-07
7 PRIOR APPLICATION NUMBER: 60/091982
7 PRIOR FILING DATE: 1998-07-07
7 PRIOR APPLICATION NUMBER: 60/092182
7 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTCTCTTTCCGAGCAAAATCCAGCGATGTGTAATTATGAACGTGCCACACATGA 60
DB 1 GTTCTCTTTCCGAGCCAAATCCAGCGATGTGTAATTATGAACGTGCCACACATGA 60
QY 61 AGCTCTTGTCAGGTAATGTGACACCAACACACTGGAATGCCATCCTGCTCCCGTTG 120
DB 61 AGCTCTTGTCAGGTAATGTGACACCAACACACTGGAATGCCATCCTGCTCCCGTTG 120
QY 121 TCTACTCACGCGCAAGTGTGATTTCTGTGAGCCATCGCTGCGCCCTCAGCG 180
DB 121 TCTACTCACGCGCAAGTGTGATTTCTGTGAGCCATCGCTGCGCCCTCAGCG 180
QY 181 GSCCCAGAACTGCCCTCCGTTTCTGTCAGTAACCACTTCCAGCAAGTGTGTGCA 240
DB 181 GSCCCAGAACTGCCCTCCGTTTCTGTCAGTAACCACTTCCAGCAAGTGTGTGCA 240
QY 241 CGCGCGGGGCTCTCCAGGTCCGGAGGTATTCCTCGAACACCGGTACTCAACC 300
DB 241 CGCGCGGGGCTCTCCAGGTCCGGAGGTATTCCTCGAACACCGGTACTCAACC 300
QY 301 TCATGGAGAAACAATCCAGATGATCCAGGCGGACACCTTCCGCGCACTCCACACCTGG 360
DB 301 TCATGGAGAAACAATCCAGATGATCCAGGCGGACACCTTCCGCGCACTCCACACCTGG 360
QY 361 AGGTCTCGAGTTGGGAGGAATCTCCATCCGCGAGATFGAGGTGGGGGCTTCAACGGCC 420
DB 361 AGGTCTCGAGTTGGGAGGAATCTCCATCCGCGAGATFGAGGTGGGGGCTTCAACGGCC 420
QY 421 TGGCCAGCTCAACACCTCGAGGTGTTCGACAACTGCTGACAGTCACTCCCTAGCGGG 480
DB 421 TGGCCAGCTCAACACCTCGAGGTGTTCGACAACTGCTGACAGTCACTCCCTAGCGGG 480

QY 481 CCTTTGAATACCTGTCCAAAGCTGGGAGCTCTGGCTTCGCAACCAACCCCATCAAGCA 540
DB 481 CCTTTGAATACCTGTCCAAAGCTGGGAGCTCTGGCTTCGCAACCAACCCCATCAAGCA 540
QY 541 TCCCTCTTACGCTTCAACCGGCTGCTCCCTCATGCGCTGAGACTTGGGGAGGTCA 600
DB 541 TCCCTCTTACGCTTCAACCGGCTGCTCCCTCATGCGCTGAGACTTGGGGAGGTCA 600
QY 601 AGNAGCTGGAGTATATCTCTGAGGGAGCTTTTGAAGGGCTGTTCAACCTCAAGTATCTGA 660
DB 601 AGNAGCTGGAGTATATCTCTGAGGGAGCTTTTGAAGGGCTGTTTCAACCTCAAGTATCTGA 660
QY 661 ACTTGGGCAATGTGCAACATTAAGACATGCCCCAATCTCAACCCCTGGTGGGCTGAGG 720
DB 661 ACTTGGGCAATGTGCAACATTAAGACATGCCCCAATCTCAACCCCTGGTGGGCTGAGG 720
QY 721 AGCTGGAGATGTGAGGAAACCACTTCCCTGAGATCAGGCTGCTCTTCCATGGCCCTGA 780
DB 721 AGCTGGAGATGTGAGGAAACCACTTCCCTGAGATCAGGCTGCTCTTCCATGGCCCTGA 780
QY 781 GCTCCCTCAAGAAAGCTCTGGGTCAATGAACCTCAGAGTCAAGCTGATGAGCGGAATCTT 840
DB 781 GCTCCCTCAAGAAAGCTCTGGGTCAATGAACCTCAGAGTCAAGCTGATGAGCGGAATCTT 840
QY 841 TTGACGGCTGCTCTTCACTTGTGGAATCACTTGGGCGGCAATTAACCTCTCTCTTTTC 900
DB 841 TTGACGGCTGCTCTTCACTTGTGGAATCACTTGGGCGGCAATTAACCTCTCTCTTTTC 900
QY 901 CCATGACCTCTTTACCCCGCTGAGGTACCTGGTGGAGTTGCACTTACACCAACACCTT 960
DB 901 CCATGACCTCTTTACCCCGCTGAGGTACCTGGTGGAGTTGCACTTACACCAACACCTT 960
QY 961 GGAAGTGTGATGTGACATTTCTGGGTAGCTTGGTGGCTTGGAGTATATATACCA 1020
DB 961 GGAAGTGTGATGTGACATTTCTGGGTAGCTTGGTGGCTTGGAGTATATATACCA 1020
QY 1021 ATTCCACCTGCTGGGCGCTCATCTCCATGACATGCGAGGCGGCTACCTCTG 1080
DB 1021 ATTCCACCTGCTGGGCGCTCATCTCCATGACATGCGAGGCGGCTACCTCTG 1080
QY 1081 AGGTGGACAGGCTCTTCCAGTGTCTGCGGCTTCACTGAGCGACCTCGAGAC 1140
DB 1081 AGGTGGACAGGCTCTTCCAGTGTCTGCGGCTTCACTGAGCGACCTCGAGAC 1140
QY 1141 TCACATTTCTGAGGTGCGATGCGAGACTTAAGTGTGCGGCTCCCCCTATGCTCTCG 1200
DB 1141 TCACATTTCTGAGGTGCGATGCGAGACTTAAGTGTGCGGCTCCCCCTATGCTCTCG 1200
QY 1201 TGAAGTGTGCTGCTGCCAAATGCGGACAGTGTCTCAGCAGCGCTCCCGCACCAAGATCT 1260
DB 1201 TGAAGTGTGCTGCTGCCAAATGCGGACAGTGTCTCAGCAGCGCTCCCGCACCAAGATCT 1260
QY 1261 CTGCTCTCAACGAGCGCACCTTGAACCTTTTCCACGCTGCTTTCAGACACTGGGGTGT 1320
DB 1261 CTGCTCTCAACGAGCGCACCTTGAACCTTTTCCACGCTGCTTTCAGACACTGGGGTGT 1320
QY 1321 ACACATGATGCTGAGCAATGCTTGCAGCAACTCCAAAGCTCTCGGCTTACTCAATGTA 1380
DB 1321 ACACATGATGCTGAGCAATGCTTGCAGCAACTCCAAAGCTCTCGGCTTACTCAATGTA 1380
QY 1381 GCAOGCTGAGCTTAAACCTTCAACCTTCTTCAACAGTCTTCTTCAACAGTAACTGAGACCA 1440
DB 1381 GCAOGCTGAGCTTAAACCTTCAACCTTCTTCAACAGTAACTGAGACCA 1440
QY 1441 CGGAGATCTCCCTGAGGACACAAACGGAAGTACAAAGCTGTTCTTACCACTG 1500
DB 1441 CGGAGATCTCCCTGAGGACACAAACGGAAGTACAAAGCTGTTCTTACCACTG 1500
QY 1501 GTTACCAGCGGCAATATACCACTTACCGGTGCTCAATTCAGACTACCGGTGCGCCA 1560
DB 1501 GTTACCAGCGGCAATATACCACTTACCGGTGCTCAATTCAGACTACCGGTGCGCCA 1560

PRIOR FILING DATE: 1998-06-11
 PRIOR APPLICATION NUMBER: 60/088861
 PRIOR FILING DATE: 1998-06-11
 PRIOR APPLICATION NUMBER: 60/088876
 PRIOR FILING DATE: 1998-06-11
 PRIOR APPLICATION NUMBER: 60/089105
 PRIOR FILING DATE: 1998-06-12
 PRIOR APPLICATION NUMBER: 60/089440
 PRIOR FILING DATE: 1998-06-16
 PRIOR APPLICATION NUMBER: 60/089512
 PRIOR FILING DATE: 1998-06-16
 PRIOR APPLICATION NUMBER: 60/089514
 PRIOR FILING DATE: 1998-06-16
 PRIOR APPLICATION NUMBER: 60/089532
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089538
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089598
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089599
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089600
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089653
 PRIOR FILING DATE: 1998-06-17
 PRIOR APPLICATION NUMBER: 60/089801
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089907
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089908
 PRIOR FILING DATE: 1998-06-18
 PRIOR APPLICATION NUMBER: 60/089947
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/089948
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/089952
 PRIOR FILING DATE: 1998-06-19
 PRIOR APPLICATION NUMBER: 60/090246
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090252
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090254
 PRIOR FILING DATE: 1998-06-22
 PRIOR APPLICATION NUMBER: 60/090349
 PRIOR FILING DATE: 1998-06-23
 PRIOR APPLICATION NUMBER: 60/090355
 PRIOR FILING DATE: 1998-06-23
 PRIOR APPLICATION NUMBER: 60/090429
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090431
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090435
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090444
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090445
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090472
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090535
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090540
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090542
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090557
 PRIOR FILING DATE: 1998-06-24
 PRIOR APPLICATION NUMBER: 60/090676
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090678
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090690
 PRIOR FILING DATE: 1998-06-25

PRIOR APPLICATION NUMBER: 60/090694
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090695
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090696
 PRIOR FILING DATE: 1998-06-25
 PRIOR APPLICATION NUMBER: 60/090862
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/090863
 PRIOR FILING DATE: 1998-06-26
 PRIOR APPLICATION NUMBER: 60/091360
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091478
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091544
 PRIOR FILING DATE: 1998-07-01
 PRIOR APPLICATION NUMBER: 60/091519
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091626
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091633
 PRIOR FILING DATE: 1998-07-02
 PRIOR APPLICATION NUMBER: 60/091978
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/091982
 PRIOR FILING DATE: 1998-07-07
 PRIOR APPLICATION NUMBER: 60/092182
 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DY 1 GTTCTCTTTCCGAGCCAAATCCAGGCGATGTGTAATTATGAACGTGCCACACCATGA 60
 DB 1 GTTCTCTTTCCGAGCCAAATCCAGGCGATGTGTAATTATGAACGTGCCACACCATGA 60
 QY 61 AGCTTTGTGGAGGTAACGTGTGCACACACACACCTGGAATGCATCTCTCCCTTCG 120
 DB 61 AGCTTTGTGGAGGTAACGTGTGCACACACACACCTGGAATGCATCTCTCCCTTCG 120
 QY 121 TCTACCTCAGCGCGCAAGTGTGGATTCTGTGTGACGCCATGCTGTGCTGCGCTCAGCG 180
 DB 121 TCTACCTCAGCGCGCAAGTGTGGATTCTGTGTGACGCCATGCTGTGCTGCGCTCAGCG 180
 QY 181 GGCCCCAGAACTGCCCCCTCCGTTTGTGTGCAAGTAAACAGTTTCAAGAGGTGTGTGA 240
 DB 181 GGCCCCAGAACTGCCCCCTCCGTTTGTGTGCAAGTAAACAGTTTCAAGAGGTGTGTGA 240
 QY 241 CGCGCGCGGCGCTCTCCGAGGTCCCGCAGGGTATTCCTTCGAACACCCCGGTACTCAACC 300
 DB 241 CGCGCGCGGCGCTCTCCGAGGTCCCGCAGGGTATTCCTTCGAACACCCCGGTACTCAACC 300
 QY 301 TCATGGAGAAACAATCCAGATGATCCAGCCCGACACTTCCGCCACCTCCACCACCTGG 360
 DB 301 TCATGGAGAAACAATCCAGATGATCCAGCCCGACACTTCCGCCACCTCCACCACCTGG 360
 QY 361 AGGTCTTCGAGTTGGGCGAGAACTCCATCCGCGCAGATTGAGGTGGGGGCTTCAACGGCC 420
 DB 361 AGGTCTTCGAGTTGGGCGAGAACTCCATCCGCGCAGATTGAGGTGGGGGCTTCAACGGCC 420
 QY 421 TGGCCAGCCTCAACACACCTCGAGCTGTTGCAACTGCTGCTGCAAGTCACTCTTAGGGGG 480
 DB 421 TGGCCAGCCTCAACACACCTCGAGCTGTTGCAACTGCTGCTGCAAGTCACTCTTAGGGGG 480
 QY 481 CTTTGAATACCTGTCCAGCTGGGGAGCTCTGGGTTCGCAACCAACCCCATCGAAAGCA 540
 DB 481 CTTTGAATACCTGTCCAGCTGGGGAGCTCTGGGTTCGCAACCAACCCCATCGAAAGCA 540
 QY 541 TCCCTCTTACGCTTCAACCGGGTGCCTCCCTCCATGCGCCTTGGACTTTGGGGAGCTCA 600
 DB 541 TCCCTCTTACGCTTCAACCGGGTGCCTCCCTCCATGCGCCTTGGACTTTGGGGAGCTCA 600

601 AGAAGCTGGAGTATATCTCTGAGGGAGAGCTTTTGGAGGGCTGTTCAACCTCAAGTATCTGA 660
601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGGAGGGCTGTTCAACCTCAAGTATCTGA 660
661 ACTTGGGCATGTGCAACATTAAAGACATGCCCAATCTCAACCCCTGTTGGGGCTGGAGG 720
661 ACTTGGGCATGTGCAACATTAAAGACATGCCCAATCTCAACCCCTGTTGGGGCTGGAGG 720
721 AGCTGAGAGTGCAGGAAACCACTTCCCTGAGATCAGGCTTGGCTCTCTTCAAGGCTCTGA 780
721 AGCTGAGAGTGCAGGAAACCACTTCCCTGAGATCAGGCTTGGCTCTCTTCAAGGCTCTGA 780
781 GCTCCCTCAAGAGCTCTGGGTCATGAGTCAAGCTCAGGCTCAGGCTCTCTTCAAGGCTCTGA 840
781 GCTCCCTCAAGAGCTCTGGGTCATGAGTCAAGCTCAGGCTCAGGCTCTCTTCAAGGCTCTGA 840
841 TTGACGGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCAACAATAACCTCTCTTCTTTCG 900
841 TTGACGGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCAACAATAACCTCTCTTCTTTCG 900
901 CCCATGACCTCTTTACCCCGCTGAGTACCTGCTGAGTACCTGCTGAGTATATACCAACCTT 960
901 CCCATGACCTCTTTACCCCGCTGAGTACCTGCTGAGTACCTGCTGAGTATATACCAACCTT 960
961 GGAACCTGATGTGACATCTCTGCTGAGTACCTGCTGAGTATATACCAACCTT 1020
961 GGAACCTGATGTGACATCTCTGCTGAGTACCTGCTGAGTATATACCAACCTT 1020
1021 ATTCCACCTGCTGAGGCTGCTGAGTACCTGCTGAGTATATACCAACCTT 1080
1021 ATTCCACCTGCTGAGGCTGCTGAGTACCTGCTGAGTATATACCAACCTT 1080
1081 AGGTGACACAGGCTCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
1081 AGGTGACACAGGCTCTCTTCCAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
1141 TCAACATTTCTGAGGCTGGAGTGGAGAACTTAAAGTGTGAGTCTGCTGCTGCTGCTGCTGCTGCT 1200
1141 TCAACATTTCTGAGGCTGGAGTGGAGAACTTAAAGTGTGAGTCTGCTGCTGCTGCTGCTGCTGCT 1200
1201 TGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
1201 TGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
1261 CTGCTCTCAACGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
1261 CTGCTCTCAACGACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
1321 ACATGCT 1380
1321 ACATGCT 1380
1381 GCACGCT 1440
1381 GCACGCT 1440
1441 CGAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1500
1441 CGAGATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1500
1501 GTTACACGCT 1560
1501 GTTACACGCT 1560
1561 AGCAGTGGCAGTACCCGCGACAGACCACTGCAAGATGCAAGATGCAAGATGCAAGATGCAAGATGCAAG 1620
1561 AGCAGTGGCAGTACCCGCGACAGACCACTGCAAGATGCAAGATGCAAGATGCAAGATGCAAGATGCAAG 1620
1621 TCATGAGACCACTGAGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1680
1621 TCATGAGACCACTGAGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1680
1681 CCAATGTTGATGTTCTTCTATAAACTTCTGTAAGCGGCAACGAGCGGAGTACAGTACAG 1740

1681 CCAATGTTGATGTTCTTCTATAAACTTCTGTAAGCGGCAACGAGCGGAGTACAGTACAG 1740
1741 CCSCCCGGGACTGTTGAGATAATCCAGGTGGACGAAGACATCCAGCAGCAACATCCCGCAG 1800
1741 CCSCCCGGGACTGTTGAGATAATCCAGGTGGACGAAGACATCCAGCAGCAACATCCCGCAG 1800
1801 CAGCAGACAGCT 1860
1801 CAGCAGACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1860
1861 ATGACCATATTAATACAAACACCTCAAAACAGCAGCAGTGGGGCCCACTGGACAGAAAACA 1920
1861 ATGACCATATTAATACAAACACCTCAAAACAGCAGCAGTGGGGCCCACTGGACAGAAAACA 1920
1921 GCTGGGGAACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1980
1921 GCTGGGGAACCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1980
1981 CCATATACCAAGGACAGGTAAGGAACTCAAAATGACTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCT 2040
1981 CCATATACCAAGGACAGGTAAGGAACTCAAAATGACTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCT 2040
2041 TAAATGCAATGAAATGACACACAAAGACAGCAACTTTTGTGACAGAGTGGGGAGAGACTTT 2100
2041 TAAATGCAATGAAATGACACACAAAGACAGCAACTTTTGTGACAGAGTGGGGAGAGACTTT 2100
2101 TTCTTCTATATGCTTATATATTAAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2160
2101 TTCTTCTATATGCTTATATATTAAGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2160
2161 AATTTAAAGACAAAAGTCAAAAACA 2185
2161 AATTTAAAGACAAAAGTCAAAAACA 2185

RESULT 45

US-09-997-440-228
; Sequence 228, Application US/09997440
; Publication No. US20030059833A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Pong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Pao, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tamas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730PIC31
CURRENT APPLICATION NUMBER: US/09/997,440
CURRENT FILING DATE: 2001-11-15
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250

41

1801 CAGCAACAGCAGCTCCGTCGGTGTATCAGGTGAGGGGSCAGTAGTGTGCCCAAAATTC 1860
1861 ATGACCATATTAATCAACACCTTACAAACCCAGCAGATGGGGCCCACTGGAGAGAAACA 1920
1861 ATGACCATATTAATCAACACCTTACAAACCCAGCAGATGGGGCCCACTGGAGAGAAACA 1920
1921 GCCTGGGGAATCTCTGCACCCCAAGTCACCACTATCTCTGAACTTATATAATTCAGA 1980
1921 GCCTGGGGAATCTCTGCACCCCAAGTCACCACTATCTCTGAACTTATATAATTCAGA 1980
1981 CCCATACAGGACAAAGTACAGGAAGTCAATATGATCTCCCTCCCAAAACTTA 2040
1981 CCCATACAGGACAAAGTACAGGAAGTCAATATGATCTCCCTCCCAAAACTTA 2040
2041 TAAATGCAATAGATGACACAAAGACAGCAACTTTTGTACAGAGTGGGGAGAGACTTT 2100
2041 TAAATGCAATAGATGACACAAAGACAGCAACTTTTGTACAGAGTGGGGAGAGACTTT 2100
2101 TTCTGTATATGCTTATATATTAATTAAGTCTGAGTGGTGGTAAACAAACATATATTAA 2160
2101 TTCTGTATATGCTTATATATTAATTAAGTCTGAGTGGTGGTAAACAAACATATATTAA 2160
2161 AATTTAAAGACAAAGTCAAAACA 2185
2161 AATTTAAAGACAAAGTCAAAACA 2185

RESULT 46
JS-09-990-440-228
Sequence 228, Application US/09990440
Publication No. US20030060407A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi J.
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2730P1C21
CURRENT APPLICATION NUMBER: US/09/990,440
CURRENT FILING DATE: 2001-11-14
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25

PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598

PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02

;
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
;
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
;
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
;
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
;
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
;
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;

Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTCTCTTTCCGAGCCAAAATCCGAGGCGATGTGAATTAATGAACGTGCCACACATGA 60
Db 1 GTTCTCTTTCCGAGCCAAAATCCGAGGCGATGTGAATTAATGAACGTGCCACACATGA 60
Qy 61 AGCTCTTGTGGCAGGTAACTGTGCACCAACACCTGGAATCCATCTCCCTCCGTTGCG 120
Db 61 AGCTCTTGTGGCAGGTAACTGTGCACCAACACCTGGAATCCATCTCCCTCCGTTGCG 120
Qy 121 TCTACCTCAGCGGCGAAAGTGTGGAATCTGTGTGCAGCATCTGCTGCGCGCTCAGCGG 180
Db 121 TCTACCTCAGCGGCGAAAGTGTGGAATCTGTGTGCAGCATCTGCTGCGCGCTCAGCGG 180
Qy 181 GGGCCAGAACTGCCCCCTCCGTTTGTGTGCAGTAACAGATTTCAGAGGTGTGTGCA 240
Db 181 GGGCCAGAACTGCCCCCTCCGTTTGTGTGCAGTAACAGATTTCAGAGGTGTGTGCA 240
Qy 241 CGCGCGGGGCTCTCCGAGGTCGCGAGGTATTCCTCGAACACCGCGTACCTCAACC 300
Db 241 CGCGCGGGGCTCTCCGAGGTCGCGAGGTATTCCTCGAACACCGCGTACCTCAACC 300
Qy 301 TCATGGAGAAACATCCAGATGATCCAGGCGGACACCTTCGCGCACTCTCCACCTCGG 360
Db 301 TCATGGAGAAACATCCAGATGATCCAGGCGGACACCTTCGCGCACTCTCCACCTCGG 360
Qy 361 AGCTCTGCAAGTTGGGCGAGGACTCCATCCGCGAGATGAGGTGGGGGCTTCAAGGCC 420
Db 361 AGCTCTGCAAGTTGGGCGAGGACTCCATCCGCGAGATGAGGTGGGGGCTTCAAGGCC 420
Qy 421 TGCCAGGCTCAACACCTCGAGGCTGTTTCGACAACTGGCTGACAGTATCCCTAGCGGG 480
Db 421 TGCCAGGCTCAACACCTCGAGGCTGTTTCGACAACTGGCTGACAGTATCCCTAGCGGG 480
Qy 481 CTTTGAATACCTGTCCAAAGCTCGGGGAGCTGTGGCTTCGCAACACCCCATCGAAGCA 540
Db 481 CTTTGAATACCTGTCCAAAGCTCGGGGAGCTGTGGCTTCGCAACACCCCATCGAAGCA 540
Qy 541 TCCCTCTTACGCGCTTCAACCGGGTCCCTCCTCATGGGCTGCACTTGGGGGAGCTCA 600
Db 541 TCCCTCTTACGCGCTTCAACCGGGTCCCTCCTCATGGGCTGCACTTGGGGGAGCTCA 600
Qy 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGAAGGGCTGTTCACCTCAAGTATCTGA 660
Db 601 AGAAGCTGGAGTATATCTCTGAGGGAGCTTTTGAAGGGCTGTTCACCTCAAGTATCTGA 660
Qy 661 ACTTGGGCAATGTGCAACATTAAGCATGCCCAATCTCAACCCCTGGTGGGGCTGGAGG 720
Db 661 ACTTGGGCAATGTGCAACATTAAGCATGCCCAATCTCAACCCCTGGTGGGGCTGGAGG 720
Qy 721 AGCTGGAGATGTGAGGGAACCACTTCCCTGAGATCAGGCTGGCTCCTTCCATGGCTGA 780
Db 721 AGCTGGAGATGTGAGGGAACCACTTCCCTGAGATCAGGCTGGCTCCTTCCATGGCTGA 780
Qy 781 GCTCCCTCAAGAGCTCTGGGTGATGAATCTCAGCTCAGCTGATTCAGCGGGAATGCTT 840
Db 781 GCTCCCTCAAGAGCTCTGGGTGATGAATCTCAGCTCAGCTGATTCAGCGGGAATGCTT 840
Qy 841 TTGACGGGCTGGCTTCACTTGTGGAATCAACTTGGCCCAACAATAACCTCTCTTCTTTCG 900

841 TTGACGGCTGGCTTCACTTGTGAATCAACTTGGCCCAATAAATACCTCTCTTCTTTGGC 900
 901 CCCATGACCTCTTTTACCCCGCTGAGTACCTGGTGGAGTTGCACTTACACCAACCACTTT 960
 901 CCCATGACCTCTTTTACCCCGCTGAGTACCTGGTGGAGTTGCACTTACACCAACCACTTT 960
 961 GGAATGTTGATGTGACATTTCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 1020
 961 GGAATGTTGATGTGACATTTCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 1020
 1021 APTTCACTGCTGTTGGCGGCTGTGATGCTCCATGACATGCGAGGCGGCTACCTGCTGG 1080
 1021 APTTCACTGCTGTTGGCGGCTGTGATGCTCCATGACATGCGAGGCGGCTACCTGCTGG 1080
 1081 AGGTGGACGAGGCTCTTTCAGTGGTCTGCGGCTTCAATGAGAGGAGGAGGAGGAGGAGG 1140
 1081 AGGTGGACGAGGCTCTTTCAGTGGTCTGCGGCTTCAATGAGAGGAGGAGGAGGAGGAGG 1140
 1141 TCAACATTTCTGAGGCTCGGATGGCAGAACTTAAGTGTGGAGCTCCCTTATGCTCTCGG 1200
 1141 TCAACATTTCTGAGGCTCGGATGGCAGAACTTAAGTGTGGAGCTCCCTTATGCTCTCGG 1200
 1201 TGAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 1260
 1201 TGAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 1260
 1261 CTGTCTCTCAACGAGCGACCTTGAACCTTTTCCACGCTGCTTTTCCAGACACTGGGGTGT 1320
 1261 CTGTCTCTCAACGAGCGACCTTGAACCTTTTCCACGCTGCTTTTCCAGACACTGGGGTGT 1320
 1321 ACACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1380
 1321 ACACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1380
 1381 GCACGGCTGAGCTTAACACCTCCAACTTACAGCTTTTCCACGAGTAAACAGTGGAGACCA 1440
 1381 GCACGGCTGAGCTTAACACCTCCAACTTACAGCTTTTCCACGAGTAAACAGTGGAGACCA 1440
 1441 CGGAGTCTGGCTGAGGACGACGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1500
 1441 CGGAGTCTGGCTGAGGACGACGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1500
 1501 GTTACAGCGCGCATATACCACTTCTACACGCTGCTTACAGCTGCTTACAGCTGCTTACAG 1560
 1501 GTTACAGCGCGCATATACCACTTCTACACGCTGCTTACAGCTGCTTACAGCTGCTTACAG 1560
 1561 AGCAGTGGCTGAGTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1620
 1561 AGCAGTGGCTGAGTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1620
 1621 TCATGAAGACCAACCAAGATCATTTGGCTGCTTTTGGGAGTGAATCTGCTAGCTGGCG 1680
 1621 TCATGAAGACCAACCAAGATCATTTGGCTGCTTTTGGGAGTGAATCTGCTAGCTGGCG 1680
 1681 CCATGTTGATGCTCTTCTATTAATCTTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1740
 1681 CCATGTTGATGCTCTTCTATTAATCTTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1740
 1741 CCGCCCGGCTGTTGAGATTAATCCAGTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1800
 1741 CCGCCCGGCTGTTGAGATTAATCCAGTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1800
 1801 CAGCAACGAGCTGCTGCTGGTGTATCAGTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1860
 1801 CAGCAACGAGCTGCTGCTGGTGTATCAGTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1860
 1861 ATGACCATTAATACCAACCTTCAAAACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1920
 1861 ATGACCATTAATACCAACCTTCAAAACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1920
 1921 GCTGGGAGGAGCTCTGCAACCCCAAGTCAACACTTCTGTAACCTTATATATATATATATAT 1980
 1921 GCTGGGAGGAGCTCTGCAACCCCAAGTCAACACTTCTGTAACCTTATATATATATATATAT 1980

RESULT 47

US-09-993-469-228
 ; Sequence 228, Application US/09993469
 ; Publication No. US20030068623A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi J.
 APPLICANT: Baker, Kevin P.
 APPLICANT: Botstein, David
 APPLICANT: Desnoyers, Luc
 APPLICANT: Eaton, Dan L.
 APPLICANT: Ferrara, Napoleone
 APPLICANT: Fong, Sherman
 APPLICANT: Gerber, Hanspeter
 APPLICANT: Gerritsen, Mary E.
 APPLICANT: Goddard, Audrey
 APPLICANT: Godowski, Paul J.
 APPLICANT: Grimaldi, J. Christopher
 APPLICANT: Gurney, Austin L.
 APPLICANT: Kljavin, Ivar J.
 APPLICANT: Napier, Mary A.
 APPLICANT: Pan, James
 APPLICANT: Paoni, Nicholas F.
 APPLICANT: Roy, Margaret Ann
 APPLICANT: Stewart, Timothy A.
 APPLICANT: Tumas, Daniel
 APPLICANT: Watanabe, Colin K.
 APPLICANT: Williams, P. Mickey
 APPLICANT: Wood, William I.
 APPLICANT: Zhang, Zemin
 TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 TITLE OF INVENTION: Acids Encoding the Same
 FILE REFERENCE: P2730PIC5
 CURRENT APPLICATION NUMBER: US/09/993,469
 CURRENT FILING DATE: 2001-11-14
 PRIOR APPLICATION NUMBER: 60/049787
 PRIOR FILING DATE: 1997-06-16
 PRIOR APPLICATION NUMBER: 60/062250
 PRIOR FILING DATE: 1997-10-17
 PRIOR APPLICATION NUMBER: 60/065186
 PRIOR FILING DATE: 1997-11-12
 PRIOR APPLICATION NUMBER: 60/065311
 PRIOR FILING DATE: 1997-11-13
 PRIOR APPLICATION NUMBER: 60/066770
 PRIOR FILING DATE: 1997-11-24
 PRIOR APPLICATION NUMBER: 60/075945
 PRIOR FILING DATE: 1998-02-25
 PRIOR APPLICATION NUMBER: 60/078910
 PRIOR FILING DATE: 1998-03-20
 PRIOR APPLICATION NUMBER: 60/083322
 PRIOR FILING DATE: 1998-04-28
 PRIOR APPLICATION NUMBER: 60/084600
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/087106
 PRIOR FILING DATE: 1998-05-28
 PRIOR APPLICATION NUMBER: 60/087607

QY 1981 CCATACCAAGGACAAAGGTACAGGAAACTCAAAATATGACTCCCTCCCTCCCAAAAACCTTA 2040
 DB 1981 CCATACCAAGGACAAAGGTACAGGAAACTCAAAATATGACTCCCTCCCTCCCAAAAACCTTA 2040
 QY 2041 TAAATGCAATAGATGACACAAAGACAGCAACTTTTGTACAGAGTGGGGAGAGACTTT 2100
 DB 2041 TAAATGCAATAGATGACACAAAGACAGCAACTTTTGTACAGAGTGGGGAGAGACTTT 2100
 QY 2101 TTCTTGTATATCTTATATATATTAAGTCTTATGGCTGGTTAAAAAAAACAGTATATATTA 2160
 DB 2101 TTCTTGTATATCTTATATATATTAAGTCTTATGGCTGGTTAAAAAAAACAGTATATATTA 2160
 QY 2161 AATTTAAAGACAAAAGTCAAAACA 2185
 DB 2161 AATTTAAAGACAAAAGTCAAAACA 2185

7	PRIOR APPLICATION NUMBER: 60/089907
7	PRIOR FILING DATE: 1998-06-18
7	PRIOR APPLICATION NUMBER: 60/089908
7	PRIOR FILING DATE: 1998-06-18
7	PRIOR APPLICATION NUMBER: 60/089947
7	PRIOR FILING DATE: 1998-06-18
7	PRIOR APPLICATION NUMBER: 60/089948
7	PRIOR FILING DATE: 1998-06-19
7	PRIOR APPLICATION NUMBER: 60/089952
7	PRIOR FILING DATE: 1998-06-19
7	PRIOR APPLICATION NUMBER: 60/090246
7	PRIOR FILING DATE: 1998-06-22
7	PRIOR APPLICATION NUMBER: 60/090252
7	PRIOR FILING DATE: 1998-06-22
7	PRIOR APPLICATION NUMBER: 60/090254
7	PRIOR FILING DATE: 1998-06-22
7	PRIOR APPLICATION NUMBER: 60/090349
7	PRIOR FILING DATE: 1998-06-23
7	PRIOR APPLICATION NUMBER: 60/090355
7	PRIOR FILING DATE: 1998-06-23
7	PRIOR APPLICATION NUMBER: 60/090429
7	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090431
7	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090435
7	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090444
7	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090445
7	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090472
7	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090535
7	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090540
7	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090542
7	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090557
7	PRIOR FILING DATE: 1998-06-24
7	PRIOR APPLICATION NUMBER: 60/090676
7	PRIOR FILING DATE: 1998-06-25
7	PRIOR APPLICATION NUMBER: 60/090678
7	PRIOR FILING DATE: 1998-06-25
7	PRIOR APPLICATION NUMBER: 60/090690
7	PRIOR FILING DATE: 1998-06-25
7	PRIOR APPLICATION NUMBER: 60/090694
7	PRIOR FILING DATE: 1998-06-25
7	PRIOR APPLICATION NUMBER: 60/090695
7	PRIOR FILING DATE: 1998-06-25
7	PRIOR APPLICATION NUMBER: 60/090696
7	PRIOR FILING DATE: 1998-06-25
7	PRIOR APPLICATION NUMBER: 60/090862
7	PRIOR FILING DATE: 1998-06-26
7	PRIOR APPLICATION NUMBER: 60/090863
7	PRIOR FILING DATE: 1998-06-26
7	PRIOR APPLICATION NUMBER: 60/091360
7	PRIOR FILING DATE: 1998-07-01
7	PRIOR APPLICATION NUMBER: 60/091478
7	PRIOR FILING DATE: 1998-07-02
7	PRIOR APPLICATION NUMBER: 60/091544
7	PRIOR FILING DATE: 1998-07-01
7	PRIOR APPLICATION NUMBER: 60/091519
7	PRIOR FILING DATE: 1998-07-02
7	PRIOR APPLICATION NUMBER: 60/091626
7	PRIOR FILING DATE: 1998-07-02
7	PRIOR APPLICATION NUMBER: 60/091633
7	PRIOR FILING DATE: 1998-07-02
7	PRIOR APPLICATION NUMBER: 60/091378
7	PRIOR FILING DATE: 1998-07-07
7	PRIOR APPLICATION NUMBER: 60/091982
7	PRIOR FILING DATE: 1998-07-07
7	PRIOR APPLICATION NUMBER: 60/092182

PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
 Best local Similarity 100.0%; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTCTCTCTTCGAGCCAAATCCAGGCGATGTGAATATGAAGTGCACACCATGA 60
 DB 1 GTCTCTCTTCGAGCCAAATCCAGGCGATGTGAATATGAAGTGCACACCATGA 60
 QY 61 AGCTCTTGTGGCAGTAACTGTGCACCAACACACCTCGGAATGCATCTCTCTCGCTTGG 120
 DB 61 AGCTCTTGTGGCAGTAACTGTGCACCAACACACCTCGGAATGCATCTCTCTCGCTTGG 120
 QY 121 TCTACTCTCAAGCGAAGTGTGAATCTGTGTGAGCCATCGCTGTGCGGCTCAGCGG 180
 DB 121 TCTACTCTCAAGCGAAGTGTGAATCTGTGTGAGCCATCGCTGTGCGGCTCAGCGG 180
 QY 181 GSCCCAGAACTGCCCTCCGCTTGTCTGTGTCAGTAAACCAAGTTCAGCAAGTGTGTGCA 240
 DB 181 GSCCCAGAACTGCCCTCCGCTTGTCTGTGTCAGTAAACCAAGTTCAGCAAGTGTGTGCA 240
 QY 241 CGCGCGGGGCTCTCGAGGTCGCGGAGGATTCCTCGGACACCGGTAACCTCAAC 300
 DB 241 CGCGCGGGGCTCTCGAGGTCGCGGAGGATTCCTCGGACACCGGTAACCTCAAC 300
 QY 301 TCATGGAGAAACAACTCCAGATGATCCAGGCGGACACCTTCCGCGACCTCCACACCTGG 360
 DB 301 TCATGGAGAAACAACTCCAGATGATCCAGGCGGACACCTTCCGCGACCTCCACACCTGG 360
 QY 361 AGCTCTCTGAGTGGGCGAGGAACTCCATCCGCGGAGATGAGGTCGAGGCTTCAAGCGGC 420
 DB 361 AGCTCTCTGAGTGGGCGAGGAACTCCATCCGCGGAGATGAGGTCGAGGCTTCAAGCGGC 420
 QY 421 TGGCGAGGCTCAACACCTCGAGCTGTTCGACAACTGCTGACAGTCACTCCCTAGCGGGG 480
 DB 421 TGGCGAGGCTCAACACCTCGAGCTGTTCGACAACTGCTGACAGTCACTCCCTAGCGGGG 480
 QY 481 CCTTTGAATACCTGTCAGGAGCTTGGAGTCTGGCTTCGACAACTCCCTAGCGGGG 540
 DB 481 CCTTTGAATACCTGTCAGGAGCTTGGAGTCTGGCTTCGACAACTCCCTAGCGGGG 540
 QY 541 TCCCTCTTACGCTTCAACCGGCTGCCCTCCCTCATGCGCTGAGCTTGGGCGAGCTCA 600
 DB 541 TCCCTCTTACGCTTCAACCGGCTGCCCTCCCTCATGCGCTGAGCTTGGGCGAGCTCA 600
 QY 601 AGAAGCTGGAGTATCTCTGAGGAGCTTGGAGGCTTGGAGGCTTGGAGTATCTGA 660
 DB 601 AGAAGCTGGAGTATCTCTGAGGAGCTTGGAGGCTTGGAGGCTTGGAGTATCTGA 660
 QY 661 ACTTGGGCACTGCAACATTAAGACATGCCCCATCTCACCCCCCTGCTGGGCTGGAGG 720
 DB 661 ACTTGGGCACTGCAACATTAAGACATGCCCCATCTCACCCCCCTGCTGGGCTGGAGG 720
 QY 721 AGCTGGAGATGTCAGGAGCACTTCCCTGAGATCAGGCTGCTCTTCCATGGCTGA 780
 DB 721 AGCTGGAGATGTCAGGAGCACTTCCCTGAGATCAGGCTGCTCTTCCATGGCTGA 780
 QY 781 GCTCCTCTCAAGAGCTCTGGGTCATGAACCTCAAGGTCAGGCTGATGAGCGGAATGCTT 840
 DB 781 GCTCCTCTCAAGAGCTCTGGGTCATGAACCTCAAGGTCAGGCTGATGAGCGGAATGCTT 840
 QY 841 TTGAGGCTGGCTCTCACTTGGGAATCTCAACTTGGGCGGACATACCTCTCTCTTTCG 900
 DB 841 TTGAGGCTGGCTCTCACTTGGGAATCTCAACTTGGGCGGACATACCTCTCTCTTTCG 900
 QY 901 CCCATGACCTCTTACCCCGCTGAGGTACCTGTGGAGTTGCACTACACCAACACCTTT 960
 DB 901 CCCATGACCTCTTACCCCGCTGAGGTACCTGTGGAGTTGCACTACACCAACACCTTT 960
 QY 961 GGAAGTGTGATGCACTCTGTGGCTAGCTGCTGCTTGGAGTATATACCCCA 1020
 DB 961 GGAAGTGTGATGCACTCTGTGGCTAGCTGCTGCTTGGAGTATATACCCCA 1020

QY 1021 ATTCCACTCTGTGTGCGGCTGTCTCATGTCTCCATGACATCGAGGCGCTTACCTCGTGG 1080
 DB 1021 ATTCCACTCTGTGTGCGGCTGTCTCATGTCTCCATGACATCGAGGCGCTTACCTCGTGG 1080
 QY 1081 AGTGGACACAGGCTCTCTTCCAGTGTCTGCGCCCTTTCATCATGAGCAGCCTCGAGCC 1140
 DB 1081 AGTGGACACAGGCTCTCTTCCAGTGTCTGCGCCCTTTCATCATGAGCAGCCTCGAGCC 1140
 QY 1141 TCAACATTTTCTGAGGCTCGGATGCGAGAACTTAAAGTGTGCGACTTCCCTATGCTCTCG 1200
 DB 1141 TCAACATTTTCTGAGGCTCGGATGCGAGAACTTAAAGTGTGCGACTTCCCTATGCTCTCG 1200
 QY 1201 TGAAGTGTGTCTGCGCAATGCGAGCAGTGTCTCAGCAGCAGCCTCCGCGCACCAAGGATCT 1260
 DB 1201 TGAAGTGTGTCTGCGCAATGCGAGCAGTGTCTCAGCAGCAGCCTCCGCGCACCAAGGATCT 1260
 QY 1261 CTCTCTCAACAGCAGCAGCTTGAACCTTTTCCAGCTGTCTCTTTCAGACACTGGGGTGT 1320
 DB 1261 CTCTCTCAACAGCAGCAGCTTGAACCTTTTCCAGCTGTCTCTTTCAGACACTGGGGTGT 1320
 QY 1321 ACATGTCATGTGTGACCAATGTCAGGCACTTCCAAAGCTTCCAGCCTCGGCTTACCTCAATGTGA 1380
 DB 1321 ACATGTCATGTGTGACCAATGTCAGGCACTTCCAAAGCTTCCAGCCTCGGCTTACCTCAATGTGA 1380
 QY 1381 GCAGGCTGAGCTTAACTTCCAACTAAGCTTCTTCCAAAGCTTCCAAAGCTTCCAAAGCTT 1440
 DB 1381 GCAGGCTGAGCTTAACTTCCAACTAAGCTTCTTCCAAAGCTTCCAAAGCTTCCAAAGCTT 1440
 QY 1441 CGGAGATCTCGCTGAGGACACACGCGGAAAGTACAAAGCTTCTTCCAAAGCTTCCAAAGCTT 1500
 DB 1441 CGGAGATCTCGCTGAGGACACACGCGGAAAGTACAAAGCTTCTTCCAAAGCTTCCAAAGCTT 1500
 QY 1501 GTTACCAGCGGCAATATACCACTCTTCCAGCTGTCTCAATCAGACTACCTGTGCGCA 1560
 DB 1501 GTTACCAGCGGCAATATACCACTCTTCCAGCTGTCTCAATCAGACTACCTGTGCGCA 1560
 QY 1561 AGCAGTGTGAGTACCGCGCAGACACCACTTGAAGAGTACAGCAGCTTCCAGCTTCCAGCT 1620
 DB 1561 AGCAGTGTGAGTACCGCGCAGACACCACTTGAAGAGTACAGCAGCTTCCAGCTTCCAGCT 1620
 QY 1621 TCATGAAGACCAACAGATCATCTTGTGCTTGTGCGAGTGTCTGTCTGTCTGTCTGTCTGT 1680
 DB 1621 TCATGAAGACCAACAGATCATCTTGTGCTTGTGCGAGTGTCTGTCTGTCTGTCTGTCTGT 1680
 QY 1681 CCATGTTGATCTCTTCTTATAAATCTTGTGAGGCGCACAGCAGGAGTACAGTCAAG 1740
 DB 1681 CCATGTTGATCTCTTCTTATAAATCTTGTGAGGCGCACAGCAGGAGTACAGTCAAG 1740
 QY 1741 CGCCCGGACTGTGTGAGATATCCAGGTGGAAGAGCATCCAGAGCAGCAATCCAGCAATCC 1800
 DB 1741 CGCCCGGACTGTGTGAGATATATCCAGGTGGAAGAGCATCCAGAGCAGCAATCCAGCAATCC 1800
 QY 1801 CAGCAGCAGCTCGCTCGGCTGTATCAGGTGAGGCGGAGTGTGTGTGTGTGTGTGTGTGTGT 1860
 DB 1801 CAGCAGCAGCTCGCTCGGCTGTATCAGGTGAGGCGGAGTGTGTGTGTGTGTGTGTGTGTGT 1860
 QY 1861 ATGACCATTAATTAACCAACCTTCAAAACAGCAGCAATGAGGCGGCTTGGAGCAAGAAACA 1920
 DB 1861 ATGACCATTAATTAACCAACCTTCAAAACAGCAGCAATGAGGCGGCTTGGAGCAAGAAACA 1920
 QY 1921 GCTTGGGGAATCTCTGCAACCCCAAGTCAACCTTCTGAAACCTTATATATTTTGA 1980
 DB 1921 GCTTGGGGAATCTCTGCAACCCCAAGTCAACCTTCTGAAACCTTATATATTTTGA 1980
 QY 1981 CCATACCAAGGAGCAAGGTACAGGAACTCAAAATATGACTTCCCTTCCCTTCCCTTCCCTT 2040
 DB 1981 CCATACCAAGGAGCAAGGTACAGGAACTCAAAATATGACTTCCCTTCCCTTCCCTTCCCTT 2040
 QY 2041 TAAATGCAATGAGTACACCAAGAGCAGCACTTTTGTACAGTGGGAGAGACTTT 2100
 DB 2041 TAAATGCAATGAGTACACCAAGAGCAGCACTTTTGTACAGTGGGAGAGACTTT 2100

1 PRIOR FILING DATE: 1998-06-19
 2 PRIOR APPLICATION NUMBER: 60/090246
 3 PRIOR FILING DATE: 1998-06-22
 4 PRIOR APPLICATION NUMBER: 60/090252
 5 PRIOR FILING DATE: 1998-06-22
 6 PRIOR APPLICATION NUMBER: 60/090254
 7 PRIOR FILING DATE: 1998-06-22
 8 PRIOR APPLICATION NUMBER: 60/090349
 9 PRIOR FILING DATE: 1998-06-23
 10 PRIOR APPLICATION NUMBER: 60/090355
 11 PRIOR FILING DATE: 1998-06-23
 12 PRIOR APPLICATION NUMBER: 60/090429
 13 PRIOR FILING DATE: 1998-06-24
 14 PRIOR APPLICATION NUMBER: 60/090431
 15 PRIOR FILING DATE: 1998-06-24
 16 PRIOR APPLICATION NUMBER: 60/090435
 17 PRIOR FILING DATE: 1998-06-24
 18 PRIOR APPLICATION NUMBER: 60/090444
 19 PRIOR FILING DATE: 1998-06-24
 20 PRIOR APPLICATION NUMBER: 60/090445
 21 PRIOR FILING DATE: 1998-06-24
 22 PRIOR APPLICATION NUMBER: 60/090472
 23 PRIOR FILING DATE: 1998-06-24
 24 PRIOR APPLICATION NUMBER: 60/090535
 25 PRIOR FILING DATE: 1998-06-24
 26 PRIOR APPLICATION NUMBER: 60/090540
 27 PRIOR FILING DATE: 1998-06-24
 28 PRIOR APPLICATION NUMBER: 60/090542
 29 PRIOR FILING DATE: 1998-06-24
 30 PRIOR APPLICATION NUMBER: 60/090557
 31 PRIOR FILING DATE: 1998-06-24
 32 PRIOR APPLICATION NUMBER: 60/090676
 33 PRIOR FILING DATE: 1998-06-25
 34 PRIOR APPLICATION NUMBER: 60/090678
 35 PRIOR FILING DATE: 1998-06-25
 36 PRIOR APPLICATION NUMBER: 60/090690
 37 PRIOR FILING DATE: 1998-06-25
 38 PRIOR APPLICATION NUMBER: 60/090694
 39 PRIOR FILING DATE: 1998-06-25
 40 PRIOR APPLICATION NUMBER: 60/090695
 41 PRIOR FILING DATE: 1998-06-25
 42 PRIOR APPLICATION NUMBER: 60/090696
 43 PRIOR FILING DATE: 1998-06-25
 44 PRIOR APPLICATION NUMBER: 60/090862
 45 PRIOR FILING DATE: 1998-06-26
 46 PRIOR APPLICATION NUMBER: 60/090863
 47 PRIOR FILING DATE: 1998-06-26
 48 PRIOR APPLICATION NUMBER: 60/091360
 49 PRIOR FILING DATE: 1998-07-01
 50 PRIOR APPLICATION NUMBER: 60/091478
 51 PRIOR FILING DATE: 1998-07-02
 52 PRIOR APPLICATION NUMBER: 60/091544
 53 PRIOR FILING DATE: 1998-07-01
 54 PRIOR APPLICATION NUMBER: 60/091519
 55 PRIOR FILING DATE: 1998-07-02
 56 PRIOR APPLICATION NUMBER: 60/091626
 57 PRIOR FILING DATE: 1998-07-02
 58 PRIOR APPLICATION NUMBER: 60/091633
 59 PRIOR FILING DATE: 1998-07-02
 60 PRIOR APPLICATION NUMBER: 60/091978
 61 PRIOR FILING DATE: 1998-07-07
 62 PRIOR APPLICATION NUMBER: 60/091982
 63 PRIOR FILING DATE: 1998-07-07
 64 PRIOR APPLICATION NUMBER: 60/092182
 65 PRIOR FILING DATE: 1998-07-09

Query Match 100.08; Score 2185; DB 11; Length 2185;
 Best Local Similarity 100.08; Pred. No. 0;
 Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTCTCCTTCGAGCCAAAATCCAGCGGATGTGAATTATGAACGTGCGCACCACTGA 60
 DB 1 GTTCTCCTTCGAGCCAAAATCCAGCGGATGTGAATTATGAACGTGCGCACCACTGA 60

61 AGCTCTTGTGGCAGTAACTGTGCACCAACACCTTGGAAATGCCATCTCTGCTCCCGTTGC 120
 DB 61 AGCTCTTGTGGCAGTAACTGTGCACCAACACCTTGGAAATGCCATCTCTGCTCCCGTTGC 120
 121 TCTACTCAGCGGCGAAGTGTGGATTCTGTGTGAGCATCGCTGCTGCGCGCTCAGCGG 180
 DB 121 TCTACTCAGCGGCGAAGTGTGGATTCTGTGTGAGCATCGCTGCTGCGCGCTCAGCGG 180
 181 GGCCCCAGAACTGCCCCCTCCGTTTGTCTGTGCAAGTAACTGAGTTGAGCAAGTGTGTGCA 240
 DB 181 GGCCCCAGAACTGCCCCCTCCGTTTGTCTGTGCAAGTAACTGAGTTGAGCAAGTGTGTGCA 240
 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGGTATTCCTCGAAGTATTCCTCGAAGTATTCCTCAACC 300
 DB 241 CGCGCGGGGCTCTCCGAGGTCCCGAGGGTATTCCTCGAAGTATTCCTCGAAGTATTCCTCAACC 300
 301 TCATGGAGAACAAATCCAGATGATCCAGGCGGACACTTCCGCGACCTCCACCACTGG 360
 DB 301 TCATGGAGAACAAATCCAGATGATCCAGGCGGACACTTCCGCGACCTCCACCACTGG 360
 361 AGGTCCTTCAGTTGGGCGAGGAACTCCATCCGCGCAGATTGAGGTGGGGGCTTCAACGGCC 420
 DB 361 AGGTCCTTCAGTTGGGCGAGGAACTCCATCCGCGCAGATTGAGGTGGGGGCTTCAACGGCC 420
 421 TGGCCAGGCTCAACCACTGAGCTGTTGCAACACTGGCTGACAGTCACTCCCTAGCGGGG 480
 DB 421 TGGCCAGGCTCAACCACTGAGCTGTTGCAACACTGGCTGACAGTCACTCCCTAGCGGGG 480
 481 CCTTTGAATACCTGTCCAAAGCTGCGGAGGCTCTGGCTTCGCAACCAACCCCATCGAAAGCA 540
 DB 481 CCTTTGAATACCTGTCCAAAGCTGCGGAGGCTCTGGCTTCGCAACCAACCCCATCGAAAGCA 540
 541 TCCCTCTTACGCTTCAACCGGGTGCCTCCCTCATGCGGCTGAGTGGGGGAGCTCA 600
 DB 541 TCCCTCTTACGCTTCAACCGGGTGCCTCCCTCATGCGGCTGAGTGGGGGAGCTCA 600
 601 AGAAGCTGGAGTATCTCTGAGGAGGCTTTGAGGGGCTGTTCAACCTCAAGTATCTGA 660
 DB 601 AGAAGCTGGAGTATCTCTGAGGAGGCTTTGAGGGGCTGTTCAACCTCAAGTATCTGA 660
 661 ACTTGGGATGTGCAACATTAAGACATGCCCCTCATGCGGCTGAGTGGGGGAGCTCA 720
 DB 661 ACTTGGGATGTGCAACATTAAGACATGCCCCTCATGCGGCTGAGTGGGGGAGCTCA 720
 721 AGCTGGAGTGTGAGGAAACCACTTCCCTGAGATCAGGCTGGCTTCCATGGGCTGA 780
 DB 721 AGCTGGAGTGTGAGGAAACCACTTCCCTGAGATCAGGCTGGCTTCCATGGGCTGA 780
 781 GCTCCCTCAAGAAAGCTCTGGGTCAATGAACCTCACAGGTGAGCTGATGAGCGGAATGCTT 840
 DB 781 GCTCCCTCAAGAAAGCTCTGGGTCAATGAACCTCACAGGTGAGCTGATGAGCGGAATGCTT 840
 841 TTGAGGGGCTGGCTTCACTTGTGGAACCTCAACTGGGCGCCCAATAACTCTCTCTTTTC 900
 DB 841 TTGAGGGGCTGGCTTCACTTGTGGAACCTCAACTGGGCGCCCAATAACTCTCTCTTTTC 900
 901 CCCATGACCTCTTTTACCCCGCTGAGGTACCTGCTGGAGTTGCACTTACCAACCAACCTT 960
 DB 901 CCCATGACCTCTTTTACCCCGCTGAGGTACCTGCTGGAGTTGCACTTACCAACCAACCTT 960
 961 GGAAGTGTGATGTGACATTTCTGTGGCTAGCTGCTGGCTTGGAGTATATACCAACCA 1020
 DB 961 GGAAGTGTGATGTGACATTTCTGTGGCTAGCTGCTGGCTTGGAGTATATACCAACCA 1020
 1021 ATTCCACCTGTGTGGGCGCTGCTCATGCTCCCATGACATGCGAGGCGGCTTACCTGTGG 1080
 DB 1021 ATTCCACCTGTGTGGGCGCTGCTCATGCTCCCATGACATGCGAGGCGGCTTACCTGTGG 1080
 1081 AGGTGGACAGGCTCTCTTCCAGTGTCTGCGGCTTCCATGAGGAGCTTCCGAGCTCGAGAC 1140
 DB 1081 AGGTGGACAGGCTCTCTTCCAGTGTCTGCGGCTTCCATGAGGAGCTTCCGAGCTCGAGAC 1140

1141 TCACATTTCTGAGGGTCGGATGGCAGAACTTAAGTGTCCGACTCCCTCTATGTCCTCG 1200
1141 TCACATTTCTGAGGGTCGGATGGCAGAACTTAAGTGTCCGACTCCCTCTATGTCCTCG 1200
1201 TGAAGTGGTCTGCTCCCAATGGAGCAGTGTGACCAAGCTCTCCGACCCAGGATCT 1260
1201 TGAAGTGGTGTGCTGCCCAATGGAGCAGTGTGACCAAGCTCTCCGACCCAGGATCT 1260
1261 CTGTCTCTCAACGAGCGACCTTGAACCTTTTCCACGCTGCTGCTTTTTCAGACATGCGGTG 1320
1261 CTGTCTCTCAACGAGCGACCTTGAACCTTTTCCACGCTGCTGCTTTTTCAGACATGCGGTG 1320
1321 ACACATGATGGTGACCAATGTTTCAGAGGAACTTCAACGCTCGGCTACCTCAATGTGA 1380
1321 ACACATGATGGTGACCAATGTTTCAGAGGAACTTCAACGCTCGGCTACCTCAATGTGA 1380
1381 GCAGGGTGTGAGCTTAACACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTT 1440
1381 GCAGGGTGTGAGCTTAACACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTT 1440
1441 CGGAGATCTCGCTTCAACGAGCAACCAAGGAACTTAACGCTTGTCTTCAACCTTCACTG 1500
1441 CGGAGATCTCGCTTCAACGAGCAACCAAGGAACTTAACGCTTGTCTTCAACCTTCACTG 1500
1501 GTTACGAGCGGATATACCACTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTT 1560
1501 GTTACGAGCGGATATACCACTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTT 1560
1561 AGCAGGTGGAGTATCCCGGACAGACCACTTCAACCTTCAACCTTCAACCTTCAACCTT 1620
1561 AGCAGGTGGAGTATCCCGGACAGACCACTTCAACCTTCAACCTTCAACCTTCAACCTT 1620
1621 TCATGAAGACCAACCAAGTATCACTTGGCTGCTTTTGGGAGTCACTCTGCTAGCTGCG 1680
1621 TCATGAAGACCAACCAAGTATCACTTGGCTGCTTTTGGGAGTCACTCTGCTAGCTGCG 1680
1681 CCATGTTGATGCTTCTTATATACTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTT 1740
1681 CCATGTTGATGCTTCTTATATACTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTT 1740
1741 CGGCGCGGACTGTTGAGTATATCCAGTGGAGCAAGATCCAGAGCAACATCCAGAGCAATCC 1800
1741 CGGCGCGGACTGTTGAGTATATCCAGTGGAGCAAGATCCAGAGCAACATCCAGAGCAATCC 1800
1801 CAGCAACAGAGCTCCGTCGGGTGTATCAGTGGAGGGGCAAGTGTGCTGCCCAATTC 1860
1801 CAGCAACAGAGCTCCGTCGGGTGTATCAGTGGAGGGGCAAGTGTGCTGCCCAATTC 1860
1861 ATGACCATATTAATCAACACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTT 1920
1861 ATGACCATATTAATCAACACCTTCAACCTTCAACCTTCAACCTTCAACCTTCAACCTT 1920
1921 GCTGGGGAATCTCTGACCCCAAGTCAACCTTCTGAACTTATATATTTTCA 1980
1921 GCTGGGGAATCTCTGACCCCAAGTCAACCTTCTGAACTTATATATTTTCA 1980
1921 GCTGGGGAATCTCTGACCCCAAGTCAACCTTCTGAACTTATATATTTTCA 1980
1981 CCATACCAAGGACAGGATGACGAACTTCAAAATGATCTCCCTCCCTCCCAAAATTTA 2040
1981 CCATACCAAGGACAGGATGACGAACTTCAAAATGATCTCCCTCCCTCCCAAAATTTA 2040
2041 TAAATGCAATGATGACACAAAGACAGCACTTTTGTACAGTGGGAGAGACTTT 2100
2041 TAAATGCAATGATGACACAAAGACAGCACTTTTGTACAGTGGGAGAGACTTT 2100
2101 TTCTGTATATGCTTATATATTTAAGTCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2160
2101 TTCTGTATATGCTTATATATTTAAGTCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2160
2161 AATTTAAAGCAAAAGTCAAAACA 2185
2161 AATTTAAAGCAAAAGTCAAAACA 2185

RESULT 49
US-09-989-748-228
; Sequence 228, Application US/09993748
; Publication No. US20030069403A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Grimes, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730PIC23
; CURRENT APPLICATION NUMBER: US/09/993,748
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065185
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030

7 PRIOR FILING DATE: 1998-06-04
7 PRIOR APPLICATION NUMBER: 60/088033
7 PRIOR FILING DATE: 1998-06-04
7 PRIOR APPLICATION NUMBER: 60/088326
7 PRIOR FILING DATE: 1998-06-04
7 PRIOR APPLICATION NUMBER: 60/088167
7 PRIOR FILING DATE: 1998-06-05
7 PRIOR APPLICATION NUMBER: 60/088202
7 PRIOR FILING DATE: 1998-06-05
7 PRIOR APPLICATION NUMBER: 60/088212
7 PRIOR FILING DATE: 1998-06-05
7 PRIOR APPLICATION NUMBER: 60/088217
7 PRIOR FILING DATE: 1998-06-05
7 PRIOR APPLICATION NUMBER: 60/088655
7 PRIOR FILING DATE: 1998-06-09
7 PRIOR APPLICATION NUMBER: 60/088734
7 PRIOR FILING DATE: 1998-06-10
7 PRIOR APPLICATION NUMBER: 60/088738
7 PRIOR FILING DATE: 1998-06-10
7 PRIOR APPLICATION NUMBER: 60/088742
7 PRIOR FILING DATE: 1998-06-10
7 PRIOR APPLICATION NUMBER: 60/088810
7 PRIOR FILING DATE: 1998-06-10
7 PRIOR APPLICATION NUMBER: 60/088824
7 PRIOR FILING DATE: 1998-06-10
7 PRIOR APPLICATION NUMBER: 60/088826
7 PRIOR FILING DATE: 1998-06-10
7 PRIOR APPLICATION NUMBER: 60/088858
7 PRIOR FILING DATE: 1998-06-11
7 PRIOR APPLICATION NUMBER: 60/088861
7 PRIOR FILING DATE: 1998-06-11
7 PRIOR APPLICATION NUMBER: 60/088876
7 PRIOR FILING DATE: 1998-06-11
7 PRIOR APPLICATION NUMBER: 60/089105
7 PRIOR FILING DATE: 1998-06-12
7 PRIOR APPLICATION NUMBER: 60/089440
7 PRIOR FILING DATE: 1998-06-16
7 PRIOR APPLICATION NUMBER: 60/089512
7 PRIOR FILING DATE: 1998-06-16
7 PRIOR APPLICATION NUMBER: 60/089514
7 PRIOR FILING DATE: 1998-06-16
7 PRIOR APPLICATION NUMBER: 60/089532
7 PRIOR FILING DATE: 1998-06-17
7 PRIOR APPLICATION NUMBER: 60/089538
7 PRIOR FILING DATE: 1998-06-17
7 PRIOR APPLICATION NUMBER: 60/089598
7 PRIOR FILING DATE: 1998-06-17
7 PRIOR APPLICATION NUMBER: 60/089599
7 PRIOR FILING DATE: 1998-06-17
7 PRIOR APPLICATION NUMBER: 60/089600
7 PRIOR FILING DATE: 1998-06-17
7 PRIOR APPLICATION NUMBER: 60/089653
7 PRIOR FILING DATE: 1998-06-17
7 PRIOR APPLICATION NUMBER: 60/089801
7 PRIOR FILING DATE: 1998-06-18
7 PRIOR APPLICATION NUMBER: 60/089907
7 PRIOR FILING DATE: 1998-06-18
7 PRIOR APPLICATION NUMBER: 60/089908
7 PRIOR FILING DATE: 1998-06-18
7 PRIOR APPLICATION NUMBER: 60/089947
7 PRIOR FILING DATE: 1998-06-19
7 PRIOR APPLICATION NUMBER: 60/089948
7 PRIOR FILING DATE: 1998-06-19
7 PRIOR APPLICATION NUMBER: 60/089952
7 PRIOR FILING DATE: 1998-06-19
7 PRIOR APPLICATION NUMBER: 60/090246
7 PRIOR FILING DATE: 1998-06-22
7 PRIOR APPLICATION NUMBER: 60/090252
7 PRIOR FILING DATE: 1998-06-22
7 PRIOR APPLICATION NUMBER: 60/090254
7 PRIOR FILING DATE: 1998-06-22
7 PRIOR APPLICATION NUMBER: 60/090349
7 PRIOR FILING DATE: 1998-06-23

7 PRIOR APPLICATION NUMBER: 60/090355
7 PRIOR FILING DATE: 1998-06-23
7 PRIOR APPLICATION NUMBER: 60/090429
7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090431
7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090435
7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090444
7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090445
7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090472
7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090535
7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090540
7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090542
7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090557
7 PRIOR FILING DATE: 1998-06-24
7 PRIOR APPLICATION NUMBER: 60/090676
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/090695
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/090696
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/090690
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/090694
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/090695
7 PRIOR FILING DATE: 1998-06-25
7 PRIOR APPLICATION NUMBER: 60/091360
7 PRIOR FILING DATE: 1998-07-01
7 PRIOR APPLICATION NUMBER: 60/091478
7 PRIOR FILING DATE: 1998-07-02
7 PRIOR APPLICATION NUMBER: 60/091544
7 PRIOR FILING DATE: 1998-07-01
7 PRIOR APPLICATION NUMBER: 60/091519
7 PRIOR FILING DATE: 1998-07-02
7 PRIOR APPLICATION NUMBER: 60/091626
7 PRIOR FILING DATE: 1998-07-02
7 PRIOR APPLICATION NUMBER: 60/091633
7 PRIOR FILING DATE: 1998-07-02
7 PRIOR APPLICATION NUMBER: 60/091978
7 PRIOR FILING DATE: 1998-07-07
7 PRIOR APPLICATION NUMBER: 60/091982
7 PRIOR FILING DATE: 1998-07-07
7 PRIOR APPLICATION NUMBER: 60/092182
7 PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GTCTCTTTCCGAGCCAAATCCAGCGATGCTGAATTATGAACCTGCACACCATGA	60
Db	1	GTCTCTTTCCGAGCCAAATCCAGCGATGCTGAATTATGAACCTGCACACCATGA	60
Qy	61	AGCTCTTGGCAGTAACTGTGCACCAACCACTTGGAAATGCCATCTGTCCCGTTG	120
Db	61	AGCTCTTGGCAGTAACTGTGCACCAACCACTTGGAAATGCCATCTGTCCCGTTG	120
Qy	121	TCTACTCTACCGCCAGTGGATTCTGTGTGAGCATGCTGTGCGGCTCAGCCG	180
Db	121	TCTACTCTACCGCCAGTGGATTCTGTGTGAGCATGCTGTGCGGCTCAGCCG	180

181 GGCCCCAGAACTGCCCTCCGTTGCTGTCAGTAACCAAGTTACAGAAAGTGGTGTGCA 240
181 GGCCCCAGAACTGCCCTCCGTTGCTGTCAGTAACCAAGTTACAGAAAGTGGTGTGCA 240
241 CCGCCCGGGGCTCTCCGAGTCCCGAGGTATTCCTTCGACACCCCGGTACTCTCAACC 300
241 CCGCCCGGGGCTCTCCGAGTCCCGAGGTATTCCTTCGACACCCCGGTACTCTCAACC 300
301 TCATGAGAAACAATCCAGATATCCAGGCCGACACCTTCGCGCACTCTCCACCACTGG 360
301 TCATGAGAAACAATCCAGATATCCAGGCCGACACCTTCGCGCACTCTCCACCACTGG 360
361 AGTCTGCAAGTTGGGAGGAACTCCATCCGGGAGATTGAGGTGGGGGCTTCACAGGCC 420
361 AGTCTGCAAGTTGGGAGGAACTCCATCCGGGAGATTGAGGTGGGGGCTTCACAGGCC 420
421 TGCCAGGCTCAACACCTCGAGCTGTTCAGAACTGGCTGACAGTCACTCCCTAGCGGG 480
421 TGCCAGGCTCAACACCTCGAGCTGTTCAGAACTGGCTGACAGTCACTCCCTAGCGGG 480
481 CTTTGAATACCTGTCCAGCTCGGGAGCTCTGGCTTCGCAACACCCCATCGAAAGCA 540
481 CTTTGAATACCTGTCCAGCTCGGGAGCTCTGGCTTCGCAACACCCCATCGAAAGCA 540
541 TCCCTCTTACGCTTCAACCGGCTGCCCTCCCTCATGCGCTGAGCTTGGGGGAGCTCA 600
541 TCCCTCTTACGCTTCAACCGGCTGCCCTCCCTCATGCGCTGAGCTTGGGGGAGCTCA 600
601 AGAAGCTGAGTATATCTCTGAGGAGCTTTGAGGGGCTGTTCAACTCAAGTATCTGA 660
601 AGAAGCTGAGTATATCTCTGAGGAGCTTTGAGGGGCTGTTCAACTCAAGTATCTGA 660
661 ACTTGGGCTGTGCAATTAAGATGATCCCAATCTCAACCCCTGGTGGGGCTGGAGG 720
661 ACTTGGGCTGTGCAATTAAGATGATCCCAATCTCAACCCCTGGTGGGGCTGGAGG 720
721 AGTGGAGAGTTCAGGGAACCACTTCCCTGAGATCAGGCTTGGCTCTCTTCATGAGCTGA 780
721 AGTGGAGAGTTCAGGGAACCACTTCCCTGAGATCAGGCTTGGCTCTCTTCATGAGCTGA 780
781 GTCCTCTCAAGAGCTCTGGGTCAAGATCAAGTCAAGTCAAGTCAAGTCAAGTCAAGT 840
781 GTCCTCTCAAGAGCTCTGGGTCAAGATCAAGTCAAGTCAAGTCAAGTCAAGTCAAGT 840
841 TTGAGGGCTGGCTTCACTTGTGMACTCAACTTGGCCCAATTAACCTCTCTTCTTTCG 900
841 TTGAGGGCTGGCTTCACTTGTGMACTCAACTTGGCCCAATTAACCTCTCTTCTTTCG 900
901 CCCATGACCTTTTACCCGCTGAGTACCTGCTGAGTTCATCTACACCAACCCCTT 960
901 CCCATGACCTTTTACCCGCTGAGTACCTGCTGAGTTCATCTACACCAACCCCTT 960
961 GGAATCTGATGTGACATCTGCTGAGTACCTGCTGAGTTCATCTACACCAACCCCTT 1020
961 GGAATCTGATGTGACATCTGCTGAGTACCTGCTGAGTTCATCTACACCAACCCCTT 1020
1021 ATTCCAGCTGTGTGGCGCTGTGATGCTCCCAATGACATGCGAGGCCGCTACCTCGTGG 1080
1021 ATTCCAGCTGTGTGGCGCTGTGATGCTCCCAATGACATGCGAGGCCGCTACCTCGTGG 1080
1081 AGTGGAGCAGGCTCTTCAAGTCTGCTGAGTACCTGCTGAGTTCATCTACACCAACCCCTT 1140
1081 AGTGGAGCAGGCTCTTCAAGTCTGCTGAGTACCTGCTGAGTTCATCTACACCAACCCCTT 1140
1141 TCAACATTTCTGAGGCTCGATGGCAGAACTTAAGTGTGAGTTCGAGTCCCTCTATGCTCCG 1200
1141 TCAACATTTCTGAGGCTCGATGGCAGAACTTAAGTGTGAGTTCGAGTCCCTCTATGCTCCG 1200
1201 TGAAGTGTGTGCTGCCCAATGGGACGTGCTCAGCAGGCTCCGCGCAACCCAGGATCT 1260
1201 TGAAGTGTGTGCTGCCCAATGGGACGTGCTCAGCAGGCTCCGCGCAACCCAGGATCT 1260
1261 CTGTCTCAACGAGCGGACCTTGAACCTTTTCCCAAGTGTGCTTTTCAGACACTGGGGTGT 1320

Db 1261 CTGTCTCAACGAGCGGACCTTGAACCTTTTCCAGTGTGCTTTTCAGACACTGGGGTGT 1320
Qy 1321 ACATGTCATGTGAGCAAACTGTTGTCAGGCAACTCCAAAGCTCTGGGCTTACCTCAATGGA 1380
Db 1321 ACATGTCATGTGAGCAAACTGTTGTCAGGCAACTCCAAAGCTCTGGGCTTACCTCAATGGA 1380
Qy 1381 GCAAGCTGAGCTTAAACACTCTCAACTACAGCTTCTTCAACCAAGTAAAGTGGAGACCA 1440
Db 1381 GCAAGCTGAGCTTAAACACTCTCAACTACAGCTTCTTCAACCAAGTAAAGTGGAGACCA 1440
Qy 1441 CGAGATCTCGCTGAGGACCAAAACCGGAAAGTACAAAGCTGTTCCTACCAAGTCCACTG 1500
Db 1441 CGAGATCTCGCTGAGGACCAAAACCGGAAAGTACAAAGCTGTTCCTACCAAGTCCACTG 1500
Qy 1501 GTTACAGAGCCGCAATTAACACTCTTACCAAGTAAAGTGGAGACCA 1560
Db 1501 GTTACAGAGCCGCAATTAACACTCTTACCAAGTAAAGTGGAGACCA 1560
Qy 1561 AGCAGGTGGCAGTACCGGACAGACCACTGACAAAGTAAAGTGGAGACCA 1620
Db 1561 AGCAGGTGGCAGTACCGGACAGACCACTGACAAAGTAAAGTGGAGACCA 1620
Qy 1621 TCATGAAGACCAAAAGTATCATTTGGGCTGTTCGAGTAAAGTGGAGACCA 1680
Db 1621 TCATGAAGACCAAAAGTATCATTTGGGCTGTTCGAGTAAAGTGGAGACCA 1680
Qy 1681 CCATGTTGATGTCTTCTATAAATCTTCTAAAGTAAAGTGGAGACCA 1740
Db 1681 CCATGTTGATGTCTTCTATAAATCTTCTAAAGTAAAGTGGAGACCA 1740
Qy 1741 CCGCCGAGCTGTGAGATAATCCAGGTGACAAAGTAAAGTGGAGACCA 1800
Db 1741 CCGCCGAGCTGTGAGATAATCCAGGTGACAAAGTAAAGTGGAGACCA 1800
Qy 1801 CAGCAAGCAGCTCCGTCGGGTATCAGGTGAGGGGCTAGTGTGCTGCCCAACTTC 1860
Db 1801 CAGCAAGCAGCTCCGTCGGGTATCAGGTGAGGGGCTAGTGTGCTGCCCAACTTC 1860
Qy 1861 ATGACCAATATACTCAACACCTCAAAACCTCAAAACCTCAAAACCTCAAAACCTCA 1920
Db 1861 ATGACCAATATACTCAACACCTCAAAACCTCAAAACCTCAAAACCTCAAAACCTCA 1920
Qy 1921 GCCTGGGAACTCTCTGACCCCAAGTACCACTATCTCTGACCTTATATATTTTCA 1980
Db 1921 GCCTGGGAACTCTCTGACCCCAAGTACCACTATCTCTGACCTTATATATTTTCA 1980
Qy 1981 CCCATCAAGGACAGGTACAGGAACTCAAAATATGACTCCCTCCCTCCCAAAACTTA 2040
Db 1981 CCCATCAAGGACAGGTACAGGAACTCAAAATATGACTCCCTCCCTCCCAAAACTTA 2040
Qy 2041 TAAATGCAATGAGATGCAACAAAGCAGCAACTTTTGTACAGGTGGGGAGAGACTTT 2100
Db 2041 TAAATGCAATGAGATGCAACAAAGCAGCAACTTTTGTACAGGTGGGGAGAGACTTT 2100
Qy 2101 TCTGTGATGCTTATATATTAAGTCTATGGCTGTTAAAGGATATATTTAA 2160
Db 2101 TCTGTGATGCTTATATATTAAGTCTATGGCTGTTAAAGGATATATTTAA 2160
Qy 2161 AATTTAAAGCAAAAGTCAAAACA 2185
Db 2161 AATTTAAAGCAAAAGTCAAAACA 2185

RESULT 50
US-09-980-439-228
; Sequence 228, Application US/09990439
; Publication No. US2003007309A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi J.
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc

APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Kijavicius, Ivar J.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2730P1C52
CURRENT APPLICATION NUMBER: US/09/990,439
CURRENT FILING DATE: 2001-11-15
PRIOR APPLICATION NUMBER: 60/049787
PRIOR FILING DATE: 1997-06-16
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/075945
PRIOR FILING DATE: 1998-02-25
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/087106
PRIOR FILING DATE: 1998-05-28
PRIOR APPLICATION NUMBER: 60/087607
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087609
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087759
PRIOR FILING DATE: 1998-06-02
PRIOR APPLICATION NUMBER: 60/087827
PRIOR FILING DATE: 1998-06-03
PRIOR APPLICATION NUMBER: 60/088021
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088025
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088026
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088028
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088029
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088030
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088033
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088326
PRIOR FILING DATE: 1998-06-04
PRIOR APPLICATION NUMBER: 60/088167
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088202
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088212
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088217
PRIOR FILING DATE: 1998-06-05
PRIOR APPLICATION NUMBER: 60/088655
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/088734
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088738
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088742
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088810
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088824
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088826
PRIOR FILING DATE: 1998-06-10
PRIOR APPLICATION NUMBER: 60/088858
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088861
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/088876
PRIOR FILING DATE: 1998-06-11
PRIOR APPLICATION NUMBER: 60/089105
PRIOR FILING DATE: 1998-06-12
PRIOR APPLICATION NUMBER: 60/089440
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089512
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089514
PRIOR FILING DATE: 1998-06-16
PRIOR APPLICATION NUMBER: 60/089532
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089538
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089598
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089599
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089600
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089653
PRIOR FILING DATE: 1998-06-17
PRIOR APPLICATION NUMBER: 60/089801
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089907
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089908
PRIOR FILING DATE: 1998-06-18
PRIOR APPLICATION NUMBER: 60/089947
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089948
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/089952
PRIOR FILING DATE: 1998-06-19
PRIOR APPLICATION NUMBER: 60/090246
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090252
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090254
PRIOR FILING DATE: 1998-06-22
PRIOR APPLICATION NUMBER: 60/090349
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090355
PRIOR FILING DATE: 1998-06-23
PRIOR APPLICATION NUMBER: 60/090429
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090431
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090435
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090444

PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090445
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090472
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090535
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090540
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090542
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090557
PRIOR FILING DATE: 1998-06-24
PRIOR APPLICATION NUMBER: 60/090676
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090678
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090690
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090694
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090695
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090696
PRIOR FILING DATE: 1998-06-25
PRIOR APPLICATION NUMBER: 60/090862
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/090863
PRIOR FILING DATE: 1998-06-26
PRIOR APPLICATION NUMBER: 60/091360
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091478
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091544
PRIOR FILING DATE: 1998-07-01
PRIOR APPLICATION NUMBER: 60/091519
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091626
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091633
PRIOR FILING DATE: 1998-07-02
PRIOR APPLICATION NUMBER: 60/091978
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/091982
PRIOR FILING DATE: 1998-07-07
PRIOR APPLICATION NUMBER: 60/092182
PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 2185; DB 11; Length 2185;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2185; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
y 1 GTTCTCTTCCAGCCCAATCCAGGCGATGGTGAATTATGACGTGCCACCATGA 60
b 1 GTTCTCTTCCAGCCCAATCCAGGCGATGGTGAATTATGACGTGCCACCATGA 60
y 61 AGCTCTGTGCGAGTAATGTGCACACACACCTGGAATGCCATCTGCTCCGCTTCG 120
b 61 AGCTCTGTGCGAGTAATGTGCACACACACCTGGAATGCCATCTGCTCCGCTTCG 120
y 121 TCTACTCAGGCGCAAGTGTGATTTCTGTGTGACGCAATCGTGTGCGCTCAGCG 180
b 121 TCTACTCAGGCGCAAGTGTGATTTCTGTGTGACGCAATCGTGTGCGCTCAGCG 180
y 181 GGCCTCAGAACTGCCCTCCGTTGTCTGTGCAATTAACAGTTTACAGAGTGTGTGA 240
b 181 GGCCTCAGAACTGCCCTCCGTTGTCTGTGCAATTAACAGTTTACAGAGTGTGTGA 240
y 241 CGGCGCGGCGCTTCTCGAGTCCGAGGATTTCCCTCGAACACCCGATACCTCAACC 300
b 241 CGGCGCGGCGCTTCTCGAGTCCGAGGATTTCCCTCGAACACCCGATACCTCAACC 300
y 301 TCATGGAGAACATCCAGATGATCCAGGCGGACACTTCCGCGACCTTCCACCACTGG 360

Db 301 TCATGGAGAACATCCAGATGATCCAGGCGGACACCTTCCGCGACCTTCCACCACTGG 360
Qy 361 AGCTCTGTGCGAGTAATGTGCACACACCTGGAATGCCATCTGCTCCGCTTCAGCG 420
Db 361 AGCTCTGTGCGAGTAATGTGCACACACCTGGAATGCCATCTGCTCCGCTTCAGCG 420
Qy 421 TGCCGAGCTTCAACACCTTGGAGTCTTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480
Db 421 TGCCGAGCTTCAACACCTTGGAGTCTTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 480
Qy 481 CCTTTGATTAACCTGTCGAAGCTTGGGAGCTCTGGCTTGGCAACACCCCATCGAAAGCA 540
Db 481 CCTTTGATTAACCTGTCGAAGCTTGGGAGCTCTGGCTTGGCAACACCCCATCGAAAGCA 540
Qy 541 TCCCTCTTACGCTTCAACACCTTGGAGTCTTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 600
Db 541 TCCCTCTTACGCTTCAACACCTTGGAGTCTTTCGACAACTGGCTGACAGTCACTCCCTAGCGGG 600
Qy 601 AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGAAGGCTGTTCACCTCAAGTATCTGA 660
Db 601 AGAAGCTGGAGTATATCTCTGAGGAGCTTTTGAAGGCTGTTCACCTCAAGTATCTGA 660
Qy 661 ACTTGGGCGATGTGCAACATTAAGACATGCCCAATCTCACCCCTCTGGTGGGCTGGAGG 720
Db 661 ACTTGGGCGATGTGCAACATTAAGACATGCCCAATCTCACCCCTCTGGTGGGCTGGAGG 720
Qy 721 AGCTGGAGTGTGAGGAAACCACTTCCCTGAGATCAGGCTGGCTCTTTCACCTCAAGTATCTGA 780
Db 721 AGCTGGAGTGTGAGGAAACCACTTCCCTGAGATCAGGCTGGCTCTTTCACCTCAAGTATCTGA 780
Qy 781 GCTCCCTCAGAGACTCTGGGTCATGAACCTCACAGTGTGAGCTGTGAGCGGATGCTT 840
Db 781 GCTCCCTCAGAGACTCTGGGTCATGAACCTCACAGTGTGAGCTGTGAGCGGATGCTT 840
Qy 841 TTGACGGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCAACAATACCTCTCTTCTTTCG 900
Db 841 TTGACGGGCTGGCTTCACTTGTGGAACTCAACTTGGCCCAACAATACCTCTCTTCTTTCG 900
Qy 901 CCATGACCTCTTTACCCGCTGAGGTACTCTGGTGTGAGTGTGATCTACACCAACCTT 960
Db 901 CCATGACCTCTTTACCCGCTGAGGTACTCTGGTGTGAGTGTGATCTACACCAACCTT 960
Qy 961 GGAACCTGTGATGTGACATCTGTGGCTAGCTGTGGCTTGGAGTGTGATCTACACCAACCTT 1020
Db 961 GGAACCTGTGATGTGACATCTGTGGCTAGCTGTGGCTTGGAGTGTGATCTACACCAACCTT 1020
Qy 1021 ATTCCACCTGTGTGGCGCTGTGATGTGCTTCCCAATGCAATGAGGCGGCTACCTCGTGG 1080
Db 1021 ATTCCACCTGTGTGGCGCTGTGATGTGCTTCCCAATGCAATGAGGCGGCTACCTCGTGG 1080
Qy 1081 AGTGGACCAAGGCTCTCTTCCAGTGTCTGCGCCCTTCAATGAGGCGGCTACCTCGAGAC 1140
Db 1081 AGTGGACCAAGGCTCTCTTCCAGTGTCTGCGCCCTTCAATGAGGCGGCTACCTCGAGAC 1140
Qy 1141 TCAACATTTCTGAGGCTCGGATGGCAGAACTTAAAGTGTGCGACTCCCTATGTCTCTCG 1200
Db 1141 TCAACATTTCTGAGGCTCGGATGGCAGAACTTAAAGTGTGCGACTCCCTATGTCTCTCG 1200
Qy 1201 TGAAGTGTGTGCTGCGCAATGGAGAGTCTCAGCCAGCTCCGCGCAACCAAGATCT 1260
Db 1201 TGAAGTGTGTGCTGCGCAATGGAGAGTCTCAGCCAGCTCCGCGCAACCAAGATCT 1260
Qy 1261 CTGTCTCTCAACGAGCGGCTTGAACCTTTTCCAGTGTGCTTTTTCAGACACTGGGGTGT 1320
Db 1261 CTGTCTCTCAACGAGCGGCTTGAACCTTTTCCAGTGTGCTTTTTCAGACACTGGGGTGT 1320
Qy 1321 ACACATGCTGTGACCAATGTGAGGCAACTCCAAAGCTTCCGCTCGGCTACCTCAATGTA 1380
Db 1321 ACACATGCTGTGACCAATGTGAGGCAACTCCAAAGCTTCCGCTCGGCTACCTCAATGTA 1380
Qy 1381 GCACGCTGTGCTTAAACCTCTCAACCTACAGCTTCTTCAACAGTAAACAGTGGAGACCA 1440

Db 1381 GCACGGCTGAGCTTAACACCTCCAACTACAGCTTCTTCCACACAGTAACAGTGGAGACCA 1440
Qy 1441 CGGAGATCTCGCTTGAGGACACCAACGCAAGAGTACAGCTTGTCTTACACAGTCCCACTG 1500
Db 1441 CGGAGATCTCGCTTGAGGACACCAACGCAAGAGTACAGCTTGTCTTACACAGTCCCACTG 1500
Qy 1501 GTTACAGCCGGCATATACCACTCTACACAGGTGCTCATTCAGACTACCGTGTGCCCA 1560
Db 1501 GTTACAGCCGGCATATACCACTCTACACAGGTGCTCATTCAGACTACCGTGTGCCCA 1560
Qy 1561 AGCAGTGGCAGTACCCGCGACAGACACCACTGACAGATGACAGACAGGCTTGGATGAAG 1620
Db 1561 AGCAGTGGCAGTACCCGCGACAGACACCACTGACAGATGACAGACAGGCTTGGATGAAG 1620
Qy 1621 TCATGAAGACCAACCAAGATCATATGCTGCTTGTGGAGTGAATCTCTAGTCTCCG 1680
Db 1621 TCATGAAGACCAACCAAGATCATATGCTGCTTGTGGAGTGAATCTCTAGTCTCCG 1680
Qy 1681 CCATGTTGATGCTTCTTATATAAATCTTCTAAGCGGCACACAGCGGAGTACAGTCAAG 1740
Db 1681 CCATGTTGATGCTTCTTATATAAATCTTCTAAGCGGCACACAGCGGAGTACAGTCAAG 1740
Qy 1741 CCGCCCGGACTGTTGAGATATCCAGGTGAGACAGATCCACAGAGCAACATCCGCGAG 1800
Db 1741 CCGCCCGGACTGTTGAGATATCCAGGTGAGACAGATCCACAGAGCAACATCCGCGAG 1800
Qy 1801 CAGCAACAGCAGCTCCGCTGCTATCAGGTGAGGGGCGAGTGTCTGCCACATTC 1860
Db 1801 CAGCAACAGCAGCTCCGCTGCTATCAGGTGAGGGGCGAGTGTCTGCCACATTC 1860
Qy 1861 ATGACCATATTAATACAAACACCTACAAACAGCAGCATGGGGCCCACTGGACAGAAAAA 1920
Db 1861 ATGACCATATTAATACAAACACCTACAAACAGCAGCATGGGGCCCACTGGACAGAAAAA 1920
Qy 1921 GCTGGGGNACTCTCTGCACCCACNGTCACGACTATCTGACCTTATATATTCAGA 1980
Db 1921 GCTGGGGNACTCTCTGCACCCACNGTCACGACTATCTGACCTTATATATTCAGA 1980
Qy 1981 CCCATACCAAGGACAGGTACAGGAACTCAATATGACTCCCTCCCAAAAAA 2040
Db 1981 CCCATACCAAGGACAGGTACAGGAACTCAATATGACTCCCTCCCAAAAAA 2040
Qy 2041 TAAATGCAATAGATGACACCAAGAGCAGCACTTTGTACAGAGTGGGAGAGCTTT 2100
Db 2041 TAAATGCAATAGATGACACCAAGAGCAGCACTTTGTACAGAGTGGGAGAGCTTT 2100
Qy 2101 TCTTTGTATATGCTTATATATTAAGTCTATGGGCTGGTTAAAAAACAAGATTATATA 2160
Db 2101 TCTTTGTATATGCTTATATATTAAGTCTATGGGCTGGTTAAAAAACAAGATTATATA 2160
Qy 2161 AATTTAAAGACAAAAAGTCAAAAAA 2185
Db 2161 AATTTAAAGACAAAAAGTCAAAAAA 2185

Search completed: February 6, 2004, 07:14:12
Job time : 2721 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

DM protein - protein search, using sw model

Run on: February 5, 2004, 15:45:19 ; Search time 47 Seconds
(without alignments)
2205.286 Million cell updates/sec

Title: US-09-989-279-229

Perfect score: 3440
Sequence: 1 MKLLQVTHVHTWNAILLP.....ISEPYIQHTKDKVQETQI 653

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 150 summaries

- Database : A Geneseq 19Jun03:*
- 1: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
 - 2: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
 - 3: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
 - 4: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
 - 5: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
 - 6: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
 - 7: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
 - 8: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
 - 9: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
 - 10: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
 - 11: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
 - 12: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
 - 13: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
 - 14: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
 - 15: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
 - 16: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
 - 17: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
 - 18: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
 - 19: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
 - 20: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
 - 21: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
 - 22: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
 - 23: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*
 - 24: /SIDSI1/gcgdata/geneseq/geneseq-emb1/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

result No.	Score	Match	Length	ID	Description
1	3440	100.0	653	21	Human PRO1111 prot
2	3440	100.0	653	21	Membrane-bound pro
3	3440	100.0	653	22	Human SSGPRO331a p
4	3440	100.0	653	22	Human PRO1111 poly
5	3440	100.0	653	22	Human PRO1111 (UNQ
6	3440	100.0	653	24	Human PRO polypept
7	3440	100.0	653	24	Human secreted/tra
8	3440	100.0	653	24	Human secreted and
9	3440	100.0	653	24	Novel human secret

653	24	ABU59257	Human secreted/tra
653	24	ABU59406	Novel human secret
653	24	ABU60541	Human secreted/tra
653	24	ABU58032	Human PRO polypept
653	24	ABU58963	Human secreted/tr
653	24	ABU13923	Human PRO1111 poly
653	24	ABU10878	Human PRO polypept
653	20	AA128806	cc359_4 secreted p
649	23	ABG98014	Human leucine rich
694	21	AA323033	Human SLIT protein
606	22	AAU18035	Human immunoglobul
590	21	AA323034	Human SLIT protein
553	22	AB310349	Human cDNA SEQ ID
553	23	AB266936	Human polypeptide
448	21	AA323044	Human SLIT protein
441	21	AA343091	Human ORFX ORF2855
713	22	AA313006	Human leucine-rich
713	23	ABG97991	Human nervous syst
713	23	AAU91335	Human novel secret
713	24	ABU52381	Human GPCR related
640	20	AAU08100	Human PRO331 prote
640	20	AAW85722	Novel protein (Cio
640	20	AAU13394	Amino acid sequenc
640	21	AA324407	Human PRO331 prote
640	21	AAU70673	Human PRO331 prote
640	22	AAU12355	Human PRO331 polyp
640	22	AAU00826	Human immune respo
640	22	AA380262	Human PRO331 prote
640	22	AA365292	Human PRO331 prote
640	22	AA353089	Human angiogenesis
640	24	ABU069672	Novel human secret
640	24	ABU71495	Human PRO polypept
640	24	ABU71941	Human secreted/tra
640	24	ABU656753	Human PRO polypept
640	24	ABU67029	Human secreted/tra
640	24	ABU67395	Human secreted pro
640	24	ABU59834	Novel secreted and
640	24	ABU64549	Human secreted/tra
640	24	ABU59185	Novel human secret
640	24	ABU59332	Human secreted/tra
640	24	ABU59481	Novel human secret
640	24	ABU60461	Human secreted/tra
640	24	ABU58107	Human PRO polypept
640	24	ABU59038	Human secreted/tr
640	24	ABU54397	Human secreted/tra
640	24	ABU13998	Human PRO331 polyp
640	24	ABU10953	Human PRO polypept
656	23	AAU91341	Human novel secret
656	23	ABG97967	Human nervous syst
281	22	AB310522	Human cDNA SEQ ID
281	23	AAU18084	Human immunoglobul
281	23	ABP67109	Human polypeptide
295	24	AA347760	Human secreted pro
302	21	AA387066	Human secreted pro
302	22	AA360604	Human gene 3 encod
302	23	ABG33865	Human secreted pro
302	24	AB348030	Human secreted pro
224	21	AA387135	Human secreted pro
224	22	AA306112	Human gene 3 encod
224	23	ABG33934	Human secreted pro
224	24	AB348031	Human secreted pro
606	23	AAU96850	Human NOV4b protei
606	23	ABG60230	Human Slit-3-like
606	23	AAU85411	Human protein NOV9
614	20	AA3484596	Amino acid sequenc
620	22	AA3474705	Human membrane ass
606	22	AA3060799	Human neuronal gui
606	23	ABP60969	Novel human protei
606	23	ABP60970	Human human protei
579	22	AA306804	Mature human neuro
606	23	AAU96849	Human NOV4a protei
606	23	ABG60229	Human Slit-3-like
606	23	AAU95410	Human protein NOV8

83	518	15.1	606	23	AAU85418	NOV8 allelic varia
84	516.5	15.0	620	20	AAU13357	Amino acid sequenc
85	516.5	15.0	620	22	AAU12333	Human PRO227 poly
86	516.5	15.0	620	22	AA802225	Human PRO227 prote
87	516.5	15.0	620	24	ABU69635	Novel human secret
88	516.5	15.0	620	24	ABU71458	Human PRO polypept
89	516.5	15.0	620	24	ABU71458	Human secreted/t
90	516.5	15.0	620	24	ABU71904	Human secreted/t
91	516.5	15.0	620	24	ABU67311	Human secreted/t
92	516.5	15.0	620	24	ABU67007	Human secreted/t
93	516.5	15.0	620	24	ABU67358	Human secreted pro
94	516.5	15.0	620	24	ABU59812	Novel secreted and
95	516.5	15.0	620	24	ABU64512	Human secreted/t
96	513	14.9	578	23	ABU54360	Human secreted/t
97	506.5	14.7	592	23	AAE14783	Human immunoglobul
98	494	14.4	592	22	AB880578	Human sbg190C69LRR
99	494	14.4	592	22	ABE09437	Human sbgTango79a
100	494	14.4	592	23	AAE25351	Human LP polypepti
101	494	14.4	592	23	ABE260396	Novel human protei
102	494	14.4	592	23	AAU79167	Human leucine-rich
103	494	14.4	592	23	AAU91329	Human novel secret
104	494	14.4	608	23	ABU911770	Novel leucine-rich
105	490	14.2	592	24	ABG74693	Human CGD protein
106	451.5	13.1	1077	23	ABG69674	Human secreted pro
107	451.5	13.1	1093	23	ABP70116	Human NOV30a. Hom
108	443	12.9	548	22	AA831161	Human secreted pro
109	438	12.7	1091	18	AAW41841	Amino acid sequenc
110	438	12.7	1091	20	AAU40899	Sequence used in d
111	438	12.7	1091	20	AAU08010	Murine glial cell
112	438	12.7	1091	21	AAU97833	Mouse Lig-1 protei
113	437	12.7	981	22	ABG22633	Murine Lig-1 protei
114	433	12.6	1021	22	ABG80162	Novel human diagn
115	427.5	12.4	716	20	AAU08008	Drosophila melanog
116	425.5	12.4	716	21	AAU33472	Human HLIG-1 prote
117	425.5	12.4	716	22	AAU12427	Human PRO1338 prot
118	425.5	12.4	716	22	AAU27234	Human PRO1338 poly
119	425.5	12.4	716	22	ABU50965	Human EXMAD-12 SEQ
120	425.5	12.4	716	22	ABG57530	Human PRO1338 prot
121	425.5	12.4	716	23	ABG95533	Amino acid sequenc
122	425.5	12.4	716	23	ABU84937	Human angiogenesis
123	425.5	12.4	716	23	AAU83686	Human PRO1338 prot
124	425.5	12.4	716	24	ABU71431	Human neoplasia in
125	425.5	12.4	716	24	ABU56825	Human PRO polypept
126	425.5	12.4	716	24	ABU57101	Human secreted/t
127	425.5	12.4	716	24	ABU59906	Human secreted and
128	423.5	12.3	791	20	AAU08036	Murine Glial cell
129	423.5	12.3	825	20	AAU08115	Murine Glial cell
130	420	12.2	1119	20	AAU08114	Human PRO326 prote
131	420	12.2	1119	21	AAU70674	Human PRO326 prote
132	420	12.2	1119	22	AAU12347	Human PRO326 poly
133	420	12.2	1119	22	AAU00827	Human immune respo
134	420	12.2	1119	22	AAU00827	Human PRO326 prote
135	420	12.2	1119	22	ABU48163	Human PRO326 poly
136	420	12.2	1119	24	ABU59673	Novel human secret
137	420	12.2	1119	24	ABU71496	Human PRO polypept
138	420	12.2	1119	24	ABU71942	Human secreted/t
139	420	12.2	1119	24	ABU56745	Human secreted/t
140	420	12.2	1119	24	ABU67031	Human secreted pro
141	420	12.2	1119	24	ABU57396	Novel secreted and
142	420	12.2	1119	24	ABU59826	Human secreted/t
143	420	12.2	1119	24	ABU54550	Human secreted/t
144	420	12.2	1119	24	ABU54398	Human secreted/t
145	419.5	12.1	533	22	AAU713395	Amino acid sequenc
146	415.5	12.1	533	22	ABG67511	Amino acid sequenc
147	415	12.1	719	23	ABP43533	Human secreted pro
148	415	12.1	766	22	ABG67505	Amino acid sequenc
149	415	12.1	766	24	ABU19357	NOVX related prote
150	413.5	12.0	611	21	AAU56643	Membrane-bound pro

ALIGNMENTS

RESULT 1
AAB24073
ID AAB24073 standard; Protein; 553 AA.
XX
XX AAB24073;
XX
XX 29-JAN-2001 (first entry)
XX
XX Human PRO1111 protein sequence SEQ ID NO:46.
DE
XX Human; tumor; diagnosis; neoplastic disease; neoplastic cell growth;
XX proliferation; tumorigenesis; identification; cancer; cytostatic;
XX neotropic; neuroprotective; antiinflammatory; immunosuppressive;
XX immunostimulant; antiangiogenic; leukaemia; lymphoid malignancy;
XX neuronal disorder; glial disorder; astrocytal disorder; angiogenic;
XX hypothalamic disorder; glandular disorder; macrophagal disorder;
XX epithelial disorder; stromal disorder; blastocoelic disorder;
XX inflammatory disorder; immunologic disorder.
XX
XX Homo sapiens.
OS
XX WO200053755-A2.
XX
XX 14-SEP-2000.
PD
XX 06-JAN-2000; 2000WO-US00376.
PP
XX 08-MAR-1999; 99WO-US05028.
XX
XX 02-JUN-1999; 99WO-US21252.
PP
XX 23-JUN-1999; 99US-0141037.
PP
XX 07-JUL-1999; 99US-0143048.
PP
XX 26-JUL-1999; 99US-0145698.
PP
XX 30-NOV-1999; 99WO-US28313.
PP
XX 20-DEC-1999; 99WO-US30911.
PP
XX 05-JAN-2000; 2000WO-US00219.
PP
XX (GETH) GENENTECH INC.
PA
XX Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hillan KJ, Roy MA;
XX Watanabe CK, Wood WJ;
PI
XX WPI; 2000-572270/53.
PI
XX N-PSDB; AAC58363.
DR
XX
XX Thirty PRO polynucleotides encoding PRO polypeptides, useful in the
PT treatment, diagnosis and prevention of cancer -
FT
XX
XX Claim 61; Fig 34; 286pp; English.
XX
XX The present invention describes an isolated antibody that binds to
XX one of the human PRO proteins designated PRO212, PRO290, PRO341, PRO535,
XX PRO639, PRO717, PRO809, PRO930, PRO848, PRO943, PRO1005, PRO1009,
XX PRO1025, PRO1030, PRO1097, PRO1107, PRO1111, PRO1153, PRO1182, PRO1184,
XX PRO1245 OR PRO2198. PRO antagonists can be used to inhibit tumour cell
XX growth. The PRO polypeptides and nucleotides are useful in the
XX treatment, diagnosis and prevention of cancer. The antibodies and other
XX anti-tumour compounds may be used to treat various conditions, including
XX those characterised by overexpression and/or activation of the amplified
XX PRO genes. Exemplary conditions or disorders to be treated with such
XX antibodies and other compounds include benign or malignant tumours
XX (e.g., renal, liver, kidney, bladder, breast, gastric, ovarian,
XX colorectal, prostate, pancreatic, lung, vulva, thyroid, hepatic
XX carcinomas, sarcomas, glioblastomas, and various head and neck tumours),
XX leukaemias and lymphoid malignancies, other disorders such as neuronal,
XX glial, astrocytal, hypothalamic and other glandular, macrophagal,
XX epithelial, stromal and blastocoelic disorders, and inflammatory,
XX angiogenic and immunologic disorders. AAC58242 to AAC58366 represent PCR
XX primers and hybridisation probes used in the isolation of the human PRO
XX sequences. AAC58367 to AAC58396 and AAB24057 to AAB24089 represent human
XX PRO polynucleotide and protein sequences given in the exemplification of
XX the present invention.
XX

[illegible]

26-JUN-1998; 98US-0090863.
 01-JUL-1998; 98US-0091358.
 01-JUL-1998; 98US-0091360.
 01-JUL-1998; 98US-0091364.
 01-JUL-1998; 98US-0091444.
 02-JUL-1998; 98US-0091478.
 02-JUL-1998; 98US-0091486.
 02-JUL-1998; 98US-0091519.
 02-JUL-1998; 98US-0091626.
 02-JUL-1998; 98US-0091628.
 02-JUL-1998; 98US-0091633.
 02-JUL-1998; 98US-0091646.
 02-JUL-1998; 98US-0091673.
 02-JUL-1998; 98US-0091978.
 07-JUL-1998; 98US-0091982.
 08-JUL-1998; 98US-0092184.
 10-JUL-1998; 98US-0092472.
 20-JUL-1998; 98US-0093339.
 30-JUL-1998; 98US-0094651.
 04-AUG-1998; 98US-0095282.
 04-AUG-1998; 98US-0095285.
 04-AUG-1998; 98US-0095301.
 04-AUG-1998; 98US-0095302.
 04-AUG-1998; 98US-0095315.
 04-AUG-1998; 98US-0095321.
 04-AUG-1998; 98US-0095325.
 10-AUG-1998; 98US-0095916.
 10-AUG-1998; 98US-0095929.
 11-AUG-1998; 98US-0096012.
 11-AUG-1998; 98US-0096143.
 11-AUG-1998; 98US-0096145.
 12-AUG-1998; 98US-0096323.
 17-AUG-1998; 98US-0096757.
 17-AUG-1998; 98US-0096766.
 17-AUG-1998; 98US-0096768.
 17-AUG-1998; 98US-0096773.
 17-AUG-1998; 98US-0096791.
 17-AUG-1998; 98US-0096867.
 17-AUG-1998; 98US-0096891.
 17-AUG-1998; 98US-0096894.
 17-AUG-1998; 98US-0096895.
 17-AUG-1998; 98US-0096897.
 18-AUG-1998; 98US-0096949.
 18-AUG-1998; 98US-0096950.
 18-AUG-1998; 98US-0096959.
 18-AUG-1998; 98US-0096960.
 18-AUG-1998; 98US-0097022.
 19-AUG-1998; 98US-0097141.
 20-AUG-1998; 98US-0097218.
 24-AUG-1998; 98US-0097661.
 26-AUG-1998; 98US-0097951.
 26-AUG-1998; 98US-0097952.
 26-AUG-1998; 98US-0097954.
 26-AUG-1998; 98US-0097955.
 26-AUG-1998; 98US-0097971.
 26-AUG-1998; 98US-0097974.
 26-AUG-1998; 98US-0097978.
 26-AUG-1998; 98US-0097979.
 26-AUG-1998; 98US-0097986.
 26-AUG-1998; 98US-0098014.
 31-AUG-1998; 98US-0098052.
 16-SEP-1998; 98US-0100634.
 12-JAN-1999; 98US-0115565.

(GETH) GENENTECH INC.

Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
 PI Wood WI, Yuan J;

WPI: 2000-072883/06.
 N-PSDB; AA065033.

Membrane-bound proteins and related nucleotide sequences

PS claim 12; Fig 157; 822pp; English.
 XX The invention provides membrane-bound PRO polypeptides and
 CC polynucleotides encoding them. The PRO sequences of the invention were
 CC identified based on extracellular domain homology screening. The PRO
 CC sequences have homology with proteins including LBL receptors, TIS
 CC ligands and various enzymes. The membrane-bound proteins and receptor
 CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
 CC immunoadhesins, for instance, can be used as therapeutic agents to block
 CC receptor-ligand interactions. The membrane-bound proteins can also be
 CC employed for screening of potential peptide or small molecule inhibitors
 CC of the relevant receptor/ligand interaction. The PRO encoding sequences
 CC are useful as hybridization probes in chromosome and gene mapping and in
 CC the generation of antisense RNA and DNA. PRO nucleic acid sequences
 CC will also be useful for the preparation of PRO polypeptides, especially
 CC by recombinant techniques.

XX Sequence 653 AA;

Query Match 100.0%; Score 3440; DB 21; Length 653;
 Best Local Similarity 100.0%; Pred. No. 6.4e-278;
 Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MKLLAQVTVHHTWNAILLPFVYLTAQWVILCAIAAASAGPQNCPSVCSNQPFSKV 60
 Db 1 MKLLAQVTVHHTWNAILLPFVYLTAQWVILCAIAAASAGPQNCPSVCSNQPFSKV 60
 Qy 61 CTRERGLSEVPQGPISNTRYLNLMENNIQMIQADTFPHLHLEVLQLGNSIRQIEVGFN 120
 Db 61 CTRERGLSEVPQGPISNTRYLNLMENNIQMIQADTFPHLHLEVLQLGNSIRQIEVGFN 120
 Qy 121 GLASLNTLELFDNWLTVTPSGAFEYLSKRLRLMNNPDIPIPSYAFNRVPSLMRLDGE 180
 Db 121 GLASLNTLELFDNWLTVTPSGAFEYLSKRLRLMNNPDIPIPSYAFNRVPSLMRLDGE 180
 Qy 181 LKLEVISSEGAPEGLFNKLVNLGNKNIKMPNLTPLVGLSELEMSGNHPEIRPSFGH 240
 Db 181 LKLEVISSEGAPEGLFNKLVNLGNKNIKMPNLTPLVGLSELEMSGNHPEIRPSFGH 240
 Qy 241 LSSLKLVNNSQVSLIBERNAPDGLASIVELNLAHNNLSLPHDLFTPLRYLVHLHNN 300
 Db 241 LSSLKLVNNSQVSLIBERNAPDGLASIVELNLAHNNLSLPHDLFTPLRYLVHLHNN 300
 Qy 301 PWNCDLILWLAWLREYIPTNSTCCGCHAPMWRGRLVVEVDQASFOCSAPFMDAPR 360
 Db 301 PWNCDLILWLAWLREYIPTNSTCCGCHAPMWRGRLVVEVDQASFOCSAPFMDAPR 360
 Qy 361 DLNISEGRMAELKCTPPMSSVKVLLPMTGTVLSHSHRPRISVINDGTLPFSVLLSDTG 420
 Db 361 DLNISEGRMAELKCTPPMSSVKVLLPMTGTVLSHSHRPRISVINDGTLPFSVLLSDTG 420
 Qy 421 VYTCMVTVNAGNSASVILNVSTAEINTSNYSFFTVTVETETSPEDTTRKYKVPPTTS 480
 Db 421 VYTCMVTVNAGNSASVILNVSTAEINTSNYSFFTVTVETETSPEDTTRKYKVPPTTS 480
 Qy 481 TGYQPAYTTSITVLITQTRVPKQAVPATDTDDKQVSLDEWMTTKIIIGCFVAVTLLA 540
 Db 481 TGYQPAYTTSITVLITQTRVPKQAVPATDTDDKQVSLDEWMTTKIIIGCFVAVTLLA 540
 Qy 541 AAMLIVFYKLRERHQORSTVTAARTVEIIQVDEDI PAATSAATAAPSGVSGEAVLPT 600
 Db 541 AAMLIVFYKLRERHQORSTVTAARTVEIIQVDEDI PAATSAATAAPSGVSGEAVLPT 600
 Qy 601 IHDHINYNITKPAHGAHWNTENSLGSLHPTVTITISEPYIIQTHTKDKVQETQI 653
 Db 601 IHDHINYNITKPAHGAHWNTENSLGSLHPTVTITISEPYIIQTHTKDKVQETQI 653

RESULT 3

AAE09438

ID AAE09438 standard; Protein; 653 AA.

XX AAE09438;

XX DT 19-NOV-2001 (first entry)
 XX DE Human sbgPRO331a protein.
 XX DE Human sbgPRO331a protein.
 XX KW Human; Alzheimer's disease; amyotrophic lateral sclerosis;
 KW ALS; Zöllinger-Ellison syndrome; immune system disease; schizophrenia;
 KW inflammation; haematopoietic disease; anxiety; feeding disorder; aging;
 KW anorexia; depression; cardiovascular disease; sleep disorder; seizure;
 KW memory alteration; migraine; stroke; asthma; neuropathy; hypoglycaemia;
 KW sexual disorder; growth abnormality; infection; autoimmune disease;
 KW rheumatoid arthritis; cataractogenesis; angiogenesis; atherosclerosis;
 KW cerebral ischaemia; cirrhosis; Huntington's disease; Hodgson's disease;
 KW hypercholesterolaemia; headache; amnesia; cardiac arrhythmia; obesity;
 KW diabetes mellitus; glomerulonephritis; renovascular hypertension;
 KW cancer; vaccine; gene therapy; sbgPRO331a gene.
 XX KW Homo sapiens.
 XX KW WO200150850-A1.
 XX PN 23-AUG-2001.
 XX PD 14-FEB-2001; 2001WO-US04703.
 XX PF 14-FEB-2000; 2000US-0182172.
 XX PR 29-FEB-2000; 2000US-0186084.
 XX PR 18-APR-2000; 2000US-0198583.
 XX PR 04-OCT-2000; 2000US-0237963.
 XX PR (SMIK) SMITHKLINE BEECHAM CORP.
 XX PA (SMIK) SMITHKLINE BEECHAM PLC.
 XX AG Agarwal P, Kabnick KS, Murdoch PR, Rizvi SK, Smith RF, Xiang Z;
 XX WPI; 2001-536566/59.
 XX N-PSDB; RAD16345.
 XX NT New secreted and membrane associated polypeptides for treating
 XX Alzheimer's disease, psoriasis, cancer, enterocolitis, sleep and sexual
 XX disorders, stroke, and asthma
 XX Claim 1; Page 56-58; 94pp; English.
 XX The present sequence is a human sbgPRO331a protein,
 XX a membrane bound protein of the invention.
 XX The invention relates to secreted and membrane associated polypeptides
 XX and nucleic acid molecules encoding such polypeptides. Sequences of the
 XX invention are useful for treating diseases such as Alzheimer's disease,
 XX amyotrophic lateral sclerosis (ALS), Zöllinger-Ellison syndrome, diseases
 XX of the immune system, haematopoietic disease, inflammation, anxiety,
 XX schizophrenia, feeding disorders, anorexia, depression, social, sexual
 XX and memory alteration and altered immune response, sleep disorder, learning
 XX cancer, stroke, asthma, neuropathy, aging, sexual disorders, treatment
 XX of transsexuals, growth abnormalities, obesity, infections, autoimmune
 XX diseases (e.g. rheumatoid arthritis), cataractogenesis, angiogenesis,
 XX disorders associated with healthy maintenance of gastric mucosa and
 XX repair of acute and chronic mucosal lesion, lung carcinoma, cerebral
 XX ischaemia, atherosclerosis, cirrhosis, Huntington's disease, headache,
 XX amnesia, multiple sclerosis, Hodgson's disease, dilated cardiomyopathy,
 XX congestive heart failure, cardiac arrhythmias, hypercholesterolaemia,
 XX viral and non-viral hepatitis, type I and type II diabetes mellitus,
 XX glomerulonephritis, renovascular hypertension, hypoglycaemia, periodic
 XX paralyses, tendinitis and malignant hyperthermia. Polypeptides of the
 XX invention are used to identify membrane bound and soluble receptors.
 XX They are also useful as vaccines for inducing an immunological response
 XX in a mammal. Polynucleotides of the invention are used in gene therapy.
 XX They are also valuable for chromosome localisation studies and tissue
 XX expression studies.
 XX Sequence 653 AA;

Query Match 100.0%; Score 3440; DB 22; Length 653;
 Best Local Similarity 100.0%; Pred. No. 6.4e-278;
 Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MKLLMQVTVHHTWNAILLPFVYLTQAQVHILCAALAAASAGPQNCPSVCSNQPSKV 60
 DB 1 MKLLMQVTVHHTWNAILLPFVYLTQAQVHILCAALAAASAGPQNCPSVCSNQPSKV 60
 QY 61 CTRGLSVPOGIPSNTRYLNMENNIOIQADTFRLHLEVLQGLGNSIRQIEVGA 120
 DB 61 CTRGLSVPOGIPSNTRYLNMENNIOIQADTFRLHLEVLQGLGNSIRQIEVGA 120
 QY 121 GLASNTLLEFDNMLTVIPSGAFYLSKRLMELRNPIESIPSYANRPVSLMLDLGE 180
 DB 121 GLASNTLLEFDNMLTVIPSGAFYLSKRLMELRNPIESIPSYANRPVSLMLDLGE 180
 QY 181 LKCLEYISSEGAPEGLFNLKYLNLGMCNIKOMPNTPLVGLLEEMSGNHPEIRPSFG 240
 DB 181 LKCLEYISSEGAPEGLFNLKYLNLGMCNIKOMPNTPLVGLLEEMSGNHPEIRPSFG 240
 QY 241 LSSLEKLVWNSOVSLIERNAFDGLASIVELNLAHNLSSLPHDLFTPLRYLVELHLHN 300
 DB 241 LSSLEKLVWNSOVSLIERNAFDGLASIVELNLAHNLSSLPHDLFTPLRYLVELHLHN 300
 QY 301 FWCDCDILAWMLRBYIPTNSTCCGRCCHAPMGRGYLVVDQASFOCSAPFMDAPR 360
 DB 301 FWCDCDILAWMLRBYIPTNSTCCGRCCHAPMGRGYLVVDQASFOCSAPFMDAPR 360
 QY 361 DLNISEGRMAELKCTPPMSGVKWLPLNGTVLHSHRPRISVLNDGTLNFSHYLSDTG 420
 DB 361 DLNISEGRMAELKCTPPMSGVKWLPLNGTVLHSHRPRISVLNDGTLNFSHYLSDTG 420
 QY 421 VYTCWNTNVAAGNSAYLVNSTAEINTSNYSPTFTVTVEITTEISPEDTRKYPVPTTS 480
 DB 421 VYTCWNTNVAAGNSAYLVNSTAEINTSNYSPTFTVTVEITTEISPEDTRKYPVPTTS 480
 QY 481 TGYOPAVTSTTVLIQTRVPKQVAVPATDTDKMOTSLDEVNMTTKIIGCFVAVTLA 540
 DB 481 TGYOPAVTSTTVLIQTRVPKQVAVPATDTDKMOTSLDEVNMTTKIIGCFVAVTLA 540
 QY 541 AAMLIVFYKLRKHQQRSTVTAARTVEIIQVDEDIQAATSAATAAPSUGSGAVLPT 600
 DB 541 AAMLIVFYKLRKHQQRSTVTAARTVEIIQVDEDIQAATSAATAAPSUGSGAVLPT 600
 QY 601 IHDHINYNTYKPAAGAHWTENSLGNSLHPTVTVTTSISEPYIIQTHKDKVQETQI 653
 DB 601 IHDHINYNTYKPAAGAHWTENSLGNSLHPTVTVTTSISEPYIIQTHKDKVQETQI 653

RESULT 4
 AAU12390
 ID AAU12390 standard; Protein; 653 AA.
 XX AC AAU12390;
 XX AC AAU12390;
 XX DT 24-OCT-2001 (first entry)
 XX DE Human PRO1111 polypeptide sequence.
 XX KW Human secretory and transmembrane; PRO; mammalian; cancer; lung;
 KW breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
 KW cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
 KW adipocyte; A-peptide; factor VIIa; gene therapy.
 XX OS Homo sapiens.
 XX PN WO200140466-A2.
 XX XX
 XX PD 07-JUN-2001.
 XX PF 01-DEC-2000; 2000WO-US32678.
 XX PR 01-DEC-1999; 99WO-US28301.

PR 01-DEC-1999; 99MO-US28634.
PR 02-DEC-1999; 99MO-US28551.
PR 02-DEC-1999; 99MO-US28564.
PR 02-DEC-1999; 99MO-US28565.
PR 09-DEC-1999; 99US-0170262.
PR 16-DEC-1999; 99MO-US30095.
PR 20-DEC-1999; 99MO-US30911.
PR 20-DEC-1999; 99MO-US30999.
PR 30-DEC-1999; 99MO-US32243.
PR 06-JAN-2000; 2000MO-US00277.
PR 06-JAN-2000; 2000MO-US00376.
PR 11-FEB-2000; 2000MO-US03565.
PR 18-FEB-2000; 2000MO-US04341.
PR 22-FEB-2000; 2000MO-US04342.
PR 24-FEB-2000; 2000MO-US04914.
PR 24-FEB-2000; 2000MO-US05004.
PR 01-MAR-2000; 2000MO-US05601.
PR 20-MAR-2000; 2000MO-US07377.
PR 21-MAR-2000; 2000MO-US07532.
PR 30-MAR-2000; 2000MO-US08439.
PR 17-MAY-2000; 2000MO-US13705.
PR 22-MAY-2000; 2000MO-US14042.
PR 02-JUN-2000; 2000MO-US14941.
PR 10-NOV-2000; 2000MO-US15264.
PR 10-NOV-2000; 2000MO-US30873.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen WB, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX MPI; 2001-408281/43.
XX N-PSDB; AAS21462.
XX Isolated, secretory and transmembrane PRO polypeptide used to detect
XX other PRO polypeptides, link bioactive molecules to cells expressing
XX PRO polypeptides, and detect the presence of mammalian tumours e.g.
XX lung, breast, prostate, cervical -
XX Claim 12; Fig 438; 813pp; English.
XX AAU12172-AAU12446 represent novel human secretory and transmembrane
XX PRO polypeptides. The PRO polypeptides are useful to detect other
XX PRO polypeptides, to link bioactive molecules to cells expressing
XX PRO polypeptides, to modulate biological activities of cells expressing
XX PRO polypeptides, and to detect the presence of mammalian lung, colon,
XX breast, prostate, rectal, cervical or liver tumours by comparing PRO
XX polypeptide expression in a cell sample to that in a control sample.
XX Some of the 275 sequences are also useful to stimulate the release of
XX tumour necrosis factor-alpha (TNF-alpha) from human blood, the
XX proliferation or differentiation of chondrocytes, the proliferation or
XX gene expression in pericyte cells, the release of proteoglycans from
XX cartilage, the proliferation of inner ear utricular supporting cells or
XX of T-lymphocytes, the release of a cytokine from peripheral blood
XX monocytes (PBMCs), or the proliferation of endothelial cells. Some of
XX the PRO polypeptides may modulate glucose or free fatty acid uptake by
XX skeletal muscle cells or by adipocytes, or inhibit binding of A-peptide
XX to factor VIIA. The PRO polypeptides can be used in assays to identify
XX molecules involved in binding interactions. The polynucleotides encoding
XX PRO polypeptides can be used to generate probes, antisense RNA/DNA,
XX transgenic or knock out animals and can be used in gene therapy.
XX Sequence 653 AA;
XX Query Match 100.0%; Score 3440; DB 22; Length 653;
XX Best Local Similarity 100.0%; Pred. No. 6.4e-278;
XX Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 MKLLQVTVHHHTNAILLPVYLTAAQWILCAIAAASAGPQNCPSVCSNQSFKV 60
XX 1 MKLLQVTVHHHTNAILLPVYLTAAQWILCAIAAASAGPQNCPSVCSNQSFKV 60

QY 61 CTRRGLSEVPGQIPENTRYLNLMMENNIQMIQADTFRLHLHLLEVQLGRNSIRQIEVGAFN 120
DB 61 CTRRGLSEVPGQIPENTRYLNLMMENNIQMIQADTFRLHLHLLEVQLGRNSIRQIEVGAFN 120
QY 121 GLASLNTLELFDNWLTVIPSGAFYVSKLRELALRNPIESIPSYAFNRVPSLWRLDGE 180
DB 121 GLASLNTLELFDNWLTVIPSGAFYVSKLRELALRNPIESIPSYAFNRVPSLWRLDGE 180
QY 181 LKKLEYISGEGEGLFNLKYLNLGMNCNIKMPNLTPLVGLLEEMSGNHFFPIRPGSPHG 240
DB 181 LKKLEYISGEGEGLFNLKYLNLGMNCNIKMPNLTPLVGLLEEMSGNHFFPIRPGSPHG 240
QY 241 LSSLKXLWYMNQSVLSIERNAPDGLASLVELNLAHNLSLIPDELFTPLRYLVLHLHN 300
DB 241 LSSLKXLWYMNQSVLSIERNAPDGLASLVELNLAHNLSLIPDELFTPLRYLVLHLHN 300
QY 301 PNKDCDILNLAWLREYIPTNSTCCGCHAPMMRMGRYLVEVDQASQCSAPPTMDAPR 360
DB 301 PNKDCDILNLAWLREYIPTNSTCCGCHAPMMRMGRYLVEVDQASQCSAPPTMDAPR 360
QY 361 DLNISGRMAELKCRTPPMSSVKWLLPMTGTVLSHASRHPRI SVINDGTLNFSHLLSDTG 420
DB 361 DLNISGRMAELKCRTPPMSSVKWLLPMTGTVLSHASRHPRI SVINDGTLNFSHLLSDTG 420
QY 421 VYTCWTVNAGNSASAYLNVSABLNTSNYSFFTTVTVEITEISPEDTTRKYKVPPTIS 480
DB 421 VYTCWTVNAGNSASAYLNVSABLNTSNYSFFTTVTVEITEISPEDTTRKYKVPPTIS 480
QY 481 TGYQPAYTSTTVLIQTTRVPKQVAVPATDTDKMOTSLDVEVMKTKIIIGCFVAVTILA 540
DB 481 TGYQPAYTSTTVLIQTTRVPKQVAVPATDTDKMOTSLDVEVMKTKIIIGCFVAVTILA 540
QY 541 AAMLIVFYKLRKHQORSTVTAARTVEIIQVDEDIPAAATSAATAAPSGVSGEGAVVLPT 600
DB 541 AAMLIVFYKLRKHQORSTVTAARTVEIIQVDEDIPAAATSAATAAPSGVSGEGAVVLPT 600
QY 601 IHHDHINYTKPAHGAHWTEISGLNSLHPTVTITISEPVIIQHTKDKVQETQI 653
DB 601 IHHDHINYTKPAHGAHWTEISGLNSLHPTVTITISEPVIIQHTKDKVQETQI 653
RESULT 5
AAB65217
ID AAB65217 standard; Protein; 653 AA.
XX AC AAB65217;
XX AC AAB65217;
XX DT 02-APR-2001 (first entry)
XX DE Human PRO1111 (UNQ554) protein sequence SEQ ID NO:229.
XX KW Human; secreted and transmembrane protein; PRO; cytostatic;
XX KW cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
XX KW diagnostic assay.
XX OS Homo sapiens.
XX FN WO200073454-A1.
XX PD 07-DEC-2000.
XX EF 30-MAR-2000; 2000MO-US08439.
XX PR 02-JUN-1999; 99MO-US12252.
XX PR 23-JUN-1999; 99US-0141037.
XX PR 07-JUL-1999; 99US-0143048.
XX PR 20-JUL-1999; 99US-0144758.
XX PR 26-JUL-1999; 99US-0145698.
XX PR 28-JUL-1999; 99US-0146222.
XX PR 17-AUG-1999; 99US-0149396.
XX PR 15-SEP-1999; 99MO-US21090.
XX PR 15-SEP-1999; 99MO-US21547.

R 08-OCT-1999; 99US-0158663.
R 30-NOV-1999; 99WO-US28313.
R 01-DEC-1999; 99WO-US28301.
R 16-DEC-1999; 99WO-US30095.
R 20-DEC-1999; 99WO-US30911.
R 05-JAN-2000; 2000WO-US00219.
R 06-JAN-2000; 2000WO-US00376.
R 11-FEB-2000; 2000WO-US03565.
R 18-FEB-2000; 2000WO-US04341.
R 22-FEB-2000; 2000WO-US04414.
R 24-FEB-2000; 2000WO-US04914.
R 24-FEB-2000; 2000WO-US05004.
R 02-MAR-2000; 2000WO-US05841.
R 15-MAR-2000; 2000WO-US06884.
R 20-MAR-2000; 2000WO-US07377.
R X A (GETH) GENENTECH INC.
R X A Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
R X I Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
R X I Grimaldi CJ, Gurney AU, Kljavin IO, Napier MA, Pan J, Paoni NF;
R X I Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
R X I Zhang Z;
R X X WPI; 2001-032160/04.
R X R N-PSDB; AAF44179.
R X X
R X T PRO polynucleotides used to produce polypeptides used to target
R X T bioactive molecules such as toxins, radiolabels or antibodies, to
R X T specific cells, to cause targeted cell death -
R X X
R X X Claim 12; Fig 157; 935pp; English.
R X X
R X X The present invention describes human secreted and transmembrane PRO
R X X proteins. The PRO proteins have cytostatic activity. The PRO proteins
R X X can be used for targeted delivery of bioactive molecules, such as
R X X toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
R X X sequences, and their fragments, can be used as hybridisation probes, in
R X X chromosomal and gene mapping, and in the generation of anti-sense RNA
R X X and DNA. They may also be used to produce transgenic animals which are
R X X used to develop and screen therapeutically useful reagents. The PRO
R X X nucleotide and protein sequence can be used for tissue typing and in
R X X treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
R X X AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
R X X in the isolation of human PRO sequences. AAF44087 to AAF44269 and
R X X AAB65154 to AAB65300 represent human PRO polynucleotide and protein
R X X sequences given in the exemplification of the present invention.
R X X
R X X Sequence 653 AA;
R X X
R X X Query Match 100.0%; Score 3440; DB 22; Length 653;
R X X Best Local Similarity 100.0%; Pred. No. 6.4e-278;
R X X Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
R X X
R X X 1 MKLLWQVTHHTWNAILLFVYLTQVWILCAALAAASAGPQNCPSVCSNPFKVV 50
R X X 1 MKLLWQVTHHTWNAILLFVYLTQVWILCAALAAASAGPQNCPSVCSNPFKVV 60
R X X
R X X 61 CTRRGLSEVPQGPSNRYLNLMNENIQADTFRLHLHLVLQLGRNSIRQIEVGAFN 120
R X X 61 CTRRGLSEVPQGPSNRYLNLMNENIQADTFRLHLHLVLQLGRNSIRQIEVGAFN 120
R X X
R X X 121 GLASLNTLEIFDNWLTVPISGAFYLSKLRELWLRNNPIESIPSYAFNRPVSLMLDLGE 180
R X X 121 GLASLNTLEIFDNWLTVPISGAFYLSKLRELWLRNNPIESIPSYAFNRPVSLMLDLGE 180
R X X
R X X 181 LKLEYISEGAFGLFLVKYLNLMGNCKDKMPLNLTPLVGLLELMGSGNHPFPIRPGSFH 240
R X X 181 LKLEYISEGAFGLFLVKYLNLMGNCKDKMPLNLTPLVGLLELMGSGNHPFPIRPGSFH 240
R X X
R X X 241 LSSLKLLWVANSQVSLIERNAFGLASLVELNLAAHNLSSLPHDLFTPLRYLVELHLHN 300
R X X 241 LSSLKLLWVANSQVSLIERNAFGLASLVELNLAAHNLSSLPHDLFTPLRYLVELHLHN 300

QY 301 PWNCDILMAWLREYIPTNSTCCGRCHAPMHMGRYLVEVDQASFOCSAPFINDAPR 360
DB 301 PWNCDILMAWLREYIPTNSTCCGRCHAPMHMGRYLVEVDQASFOCSAPFINDAPR 360
QY 361 DLNISEGRMAELKCRTPPMSSVKWLLPNGTIVLSHSHRPRISVLNDGTILNFSHVLSDTG 420
DB 361 DLNISEGRMAELKCRTPPMSSVKWLLPNGTIVLSHSHRPRISVLNDGTILNFSHVLSDTG 420
QY 421 VYTCMVTNAGNSNAGLAYLNVTAEALNTSNYSPTTIVTVEITISPEDTRKYPVPTTS 480
DB 421 VYTCMVTNAGNSNAGLAYLNVTAEALNTSNYSPTTIVTVEITISPEDTRKYPVPTTS 480
QY 481 TGYOPAYTSTTVLIQTTRVPKQVAVPATDTTDMKQTSIDEVWMTTKIILGCPVAVTLA 540
DB 481 TGYOPAYTSTTVLIQTTRVPKQVAVPATDTTDMKQTSIDEVWMTTKIILGCPVAVTLA 540
QY 541 AAMLIVFYKLRKRHQQRSTVTAARTVEIIQVDESDI PAATSAATAAPSGVSGEAVVLP 600
DB 541 AAMLIVFYKLRKRHQQRSTVTAARTVEIIQVDESDI PAATSAATAAPSGVSGEAVVLP 600
QY 601 IHDHINFTYKPAHGAHWIENSLGNSLHPTVTIISSEPIIOTHTKDKVQETQI 653
DB 601 IHDHINFTYKPAHGAHWIENSLGNSLHPTVTIISSEPIIOTHTKDKVQETQI 653
R X X
R X X RESULT 6
R X X ABU66788
R X X ID ABU66788 standard; Protein; 653 AA.
R X X AC ABU66788;
R X X XX 23-MAY-2003 (first entry)
R X X DT Human PRO polypeptide #219.
R X X DE Human; PRO polypeptide; secreted and transmembrane protein;
R X X KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
R X X KW differentiation; chondrocyte; tumour; genetic disorder;
R X X KW cytostatic.
R X X OS Homo sapiens.
R X X XX US2003036180-A1.
R X X PN 20-FEB-2003.
R X X PD 09-MAY-2002; 2002US-0143114.
R X X PF 31-MAR-1997; 97WO-US05230.
R X X PR 12-JUN-1998; 98WO-US12456.
R X X PR 14-JUL-1998; 98WO-US14552.
R X X PR 28-AUG-1998; 98WO-US17888.
R X X PR 10-SEP-1998; 98WO-US18824.
R X X PR 14-SEP-1998; 98WO-US19093.
R X X PR 14-SEP-1998; 98WO-US19094.
R X X PR 14-SEP-1998; 98WO-US19177.
R X X PR 16-SEP-1998; 98WO-US19330.
R X X PR 17-SEP-1998; 98WO-US19437.
R X X PR 07-OCT-1998; 98WO-US21141.
R X X PR 29-OCT-1998; 98WO-US22991.
R X X PR 29-OCT-1998; 98WO-US22992.
R X X PR 20-NOV-1998; 98WO-US24855.
R X X PR 01-DEC-1998; 98WO-US25108.
R X X PR 05-JAN-1999; 99WO-US00106.
R X X PR 08-MAR-1999; 99WO-US05028.
R X X PR 20-MAR-1999; 99WO-US05190.
R X X PR 20-APR-1999; 99WO-US08615.
R X X PR 14-MAY-1999; 99WO-US10733.
R X X PR 02-JUN-1999; 99WO-US12252.
R X X PR 01-SEP-1999; 99WO-US20111.
R X X PR 08-SEP-1999; 99WO-US20594.
R X X PR 13-SEP-1999; 99WO-US20944.

```
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 30-NOV-1999; 99WO-US28401.
PR 01-DEC-1999; 99WO-US28309.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03569.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04343.
PR 22-FEB-2000; 2000WO-US04144.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13709.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06665.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887875.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.

PR 16-AUG-2001; 2001US-0931836.
PR 19-DEC-2001; 2001US-0028072.
PA (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-332040/31.
DR N-PSDB; ACA03821.
XX
XX New secreted and transmembrane PRO nucleic acids, useful for gene
PT therapy, in chromosome and gene mapping, as chromosome markers, in
PT tissue typing, and in chromosome identification
XX
PS Claim 12; Fig 438; 660pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The
CC PRO polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for
CC linking bioactive molecules to cells expressing PRO polypeptides,
CC for modulating biological activities of cells expressing PRO
CC polypeptides, and for identifying agonists or antagonists.
CC The PRO polypeptides are useful for stimulating the release of
CC tumour necrosis factor (TNF)-alpha from human blood, for stimulating
CC the proliferation or differentiation of chondrocytes, and detecting the
CC presence of tumours. The polynucleotide sequences encoding PRO
CC polypeptides are useful as hybridisation probes, in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptides, for generating transgenic animals or
CC knockout animals, for the genetic analysis of individuals with genetic
CC disorders, and in gene therapy. ABU66570-ABU66844 represent the human
CC PRO polypeptides of the invention.
CC Note: The sequence data for this patent was obtained in electronic
CC format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsdIDEntry.html.
XX
SQ Sequence 653 AA;

Query Match 100.0%; Score 3440; DB 24; Length 653;
Best Local Similarity 100.0%; Pred. NO. 6.4e-278;
Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKLLWQVTVHHHTWNAILLPFVYLTQVWILCAIAAASAGPQNCPSVCSNQSFKV 60
DB 1 MKLLWQVTVHHHTWNAILLPFVYLTQVWILCAIAAASAGPQNCPSVCSNQSFKV 60

QY 61 CTRGLSEVPQGPSNTRYLNLMENNIQMTQDTFRHLHLEVLQGRNSIRQIEVGFN 120
DB 61 CTRGLSEVPQGPSNTRYLNLMENNIQMTQDTFRHLHLEVLQGRNSIRQIEVGFN 120

QY 121 GLASINTLELFDNMLTVIPGAPYLSKLRELWRNNPIESIPSYAFNRVPSLMRLDLGE 180
DB 121 GLASINTLELFDNMLTVIPGAPYLSKLRELWRNNPIESIPSYAFNRVPSLMRLDLGE 180

QY 181 LKLEYISEGAFGLFNKLYNLGMCKNDMPMLTPLVGLLEEMSGNHNHPPRPSFGH 240
DB 181 LKLEYISEGAFGLFNKLYNLGMCKNDMPMLTPLVGLLEEMSGNHNHPPRPSFGH 240

QY 241 LSSLLKLVWMSQVSLIERNAPDGLASLVELNLAHNNLSLPHDLFTPLLYLVELLHN 300
DB 241 LSSLLKLVWMSQVSLIERNAPDGLASLVELNLAHNNLSLPHDLFTPLLYLVELLHN 300

QY 301 PWCDCDILANWLREYIPTNSTCCGRCHAPNMRGRYLVEVDQASFCQSAPFINDAPR 360
DB 301 PWCDCDILANWLREYIPTNSTCCGRCHAPNMRGRYLVEVDQASFCQSAPFINDAPR 360

QY 361 DLNTSEGMRELKCRTPMSSVKLLPNGTVLSHSHRPRISVLNDGTLANFSHVLLSDTG 420
DB 361 DLNTSEGMRELKCRTPMSSVKLLPNGTVLSHSHRPRISVLNDGTLANFSHVLLSDTG 420
```


Y 421 VYTCMTNAGNSASAYLNVSALNTSNYSFFTVTVVETTESPEDTRKYKVPPTTS 480
b 421 VYTCMTNAGNSASAYLNVSALNTSNYSFFTVTVVETTESPEDTRKYKVPPTTS 480
Y 481 TGYQPAYTSTTVLIQTTTRVPKQVAPATDDTKQKQTSLSDEVMTKIIIGCFVAVTLLA 540
b 481 TGYQPAYTSTTVLIQTTTRVPKQVAPATDDTKQKQTSLSDEVMTKIIIGCFVAVTLLA 540
Y 541 AAMLIYVYKLRKHQRSTVTAARTVEIIQVDEDPATSAATAAPSGVSGEGAVLPT 600
b 541 AAMLIYVYKLRKHQRSTVTAARTVEIIQVDEDPATSAATAAPSGVSGEGAVLPT 600
Y 601 IHDHINNTYKPAHGAHNTENSLSLHPTVTTISBPYIIQTHTKDKVQETQI 653
b 601 IHDHINNTYKPAHGAHNTENSLSLHPTVTTISBPYIIQTHTKDKVQETQI 653
RESULT 7
BU67064
D ABU67064 standard; Protein; 653 AA.
C ABU67064;
X T 27-MAY-2003 (first entry)
X Human secreted/transmembrane, PRO, protein SEQ ID 438.
E Human; secreted protein; transmembrane protein; PRO;
X inflammatory disease; organ failure; atherosclerosis; cardiac injury;
W infertility; birth defects; premature aging; AIDS; biosensor;
W acquired immunodeficiency syndrome; cancer; diabetic complication;
W bioreactor; tumour.
X Homo sapiens.
S US2003032155-A1.
X 13-FEB-2003.
D 03-MAY-2002; 2002US-0137865.
F 31-MAR-1997; 97WO-US050230.
X 12-JUN-1998; 98WO-US12456.
R 14-JUL-1998; 98WO-US14552.
R 28-AUG-1998; 98WO-US17888.
R 10-SEP-1998; 98WO-US18824.
R 14-SEP-1998; 98WO-US19093.
R 14-SEP-1998; 98WO-US19094.
R 14-SEP-1998; 98WO-US19177.
R 16-SEP-1998; 98WO-US19330.
R 17-SEP-1998; 98WO-US19437.
R 07-OCT-1998; 98WO-US21141.
R 29-OCT-1998; 98WO-US22991.
R 29-OCT-1998; 98WO-US22992.
R 20-NOV-1998; 98WO-US24955.
R 01-DEC-1998; 98WO-US25108.
R 05-JAN-1999; 98WO-US00106.
R 08-MAR-1999; 98WO-US05028.
R 10-MAR-1999; 98WO-US05190.
R 20-APR-1999; 98WO-US08615.
R 14-MAY-1999; 98WO-US10733.
R 02-JUN-1999; 98WO-US12252.
R 01-SEP-1999; 98WO-US20111.
R 08-SEP-1999; 98WO-US20594.
R 13-SEP-1999; 98WO-US20944.
R 13-SEP-1999; 98WO-US21090.
R 15-SEP-1999; 98WO-US21547.
R 05-OCT-1999; 98WO-US23089.
R 29-NOV-1999; 98WO-US28214.
R 30-NOV-1999; 98WO-US28313.
R 30-NOV-1999; 98WO-US28409.
R 01-DEC-1999; 98WO-US28301.
R 01-DEC-1999; 98WO-US28634.

PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04344.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07177.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-DEC-2000; 2000WO-US21759.
PR 28-FEB-2001; 2001WO-US27498.
PR 09-MAR-2001; 2001WO-US02706.
PR 14-MAR-2001; 2001WO-US08689.
PR 22-MAR-2001; 2001WO-US16744.
PR 05-APR-2001; 2001WO-US28366.
PR 10-MAY-2001; 2001WO-US54208.
PR 10-MAY-2001; 2001WO-US54280.
PR 18-MAY-2001; 2001WO-US60216.
PR 25-MAY-2001; 2001WO-US66028.
PR 25-MAY-2001; 2001WO-US66034.
PR 01-JUN-2001; 2001WO-US72035.
PR 05-JUN-2001; 2001WO-US74503.
PR 14-JUN-2001; 2001WO-US82536.
PR 19-JUN-2001; 2001WO-US86342.
PR 21-JUN-2001; 2001WO-US88789.
PR 18-JUL-2001; 2001WO-US90827.
PR 06-AUG-2001; 2001WO-US92419.
PR 09-AUG-2001; 2001WO-US92796.
PR 16-AUG-2001; 2001WO-US931836.
PR 19-DEC-2001; 2001WO-US028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Garritsen ME, Godowski RJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
PI

QY 1 MKLLQVTVHHTWVAILLPVYLTQVWTLCAIAAASAGPQPCPSVCSNCFSKV 60
 Db 1 MKLLQVTVHHTWVAILLPVYLTQVWTLCAIAAASAGPQPCPSVCSNCFSKV 60
 QY 61 CTRGLSEVPQGPISNTRYLNLMENNIOQTQADTFRLHLEHLVQLGRNSIRQIEVGAFN 120
 Db 61 CTRGLSEVPQGPISNTRYLNLMENNIOQTQADTFRLHLEHLVQLGRNSIRQIEVGAFN 120
 QY 121 GLASLNTLELFDNMLTVIPSGAPFVLSKRLRNPTIESPSVAFNRVPSLMRLDGE 180
 Db 121 GLASLNTLELFDNMLTVIPSGAPFVLSKRLRNPTIESPSVAFNRVPSLMRLDGE 180
 QY 181 LKLEYISEGAFEGLEFNLKYNLNCMKNDKMPMLTFLVGLLEEMSGNHFPIRPGSFHG 240
 Db 181 LKLEYISEGAFEGLEFNLKYNLNCMKNDKMPMLTFLVGLLEEMSGNHFPIRPGSFHG 240
 QY 241 LSSLKLWVNSQVSLTERNAFGLASVLELNALHNNLSLPHDLFTPLRYLVELHLHN 300
 Db 241 LSSLKLWVNSQVSLTERNAFGLASVLELNALHNNLSLPHDLFTPLRYLVELHLHN 300
 QY 301 PNCDCDILMLAWLRYIPTNSTCCGRCHAPMHMERGRVLYVEVDQASFOCSAPFIMDAPR 360
 Db 301 PNCDCDILMLAWLRYIPTNSTCCGRCHAPMHMERGRVLYVEVDQASFOCSAPFIMDAPR 360
 QY 361 DLNISEGRMAELKCRTPPMSSVKVLLPENGTVLASHRHPRIISVINDGTINFSHVLSDTG 420

The invention relates to an isolated nucleic acid comprising, or which is at least 80% identical to, or the full-length coding sequence of, any of the 275 nucleotide sequences, encoding the corresponding PRO polypeptide (one of 275 secreted or transmembrane proteins). The nucleic acid further comprises the full-length coding sequence of the DNA deposited under American Type Culture Collection (ATCC) accession number in a list given in the specification. Also included are vectors and host cells for producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO extracellular domains and mature sequences, methods of detecting PRO proteins, methods for stimulating the release of TNF-alpha (tumour necrosis factor alpha) from human blood, (and the proliferation of differentiation of chondrocyte cells, the proliferation of, or gene expression in pericyte cells, the release or proteoglycans from cartilage, proliferation of inner ear utricular supporting cells, the proliferation of T-lymphocyte cells, the release of a cytokine from peripheral blood mononuclear cells (PBMC), or the proliferation of endothelial cells), a method for modulating the uptake of glucose or free fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the binding of A-peptide to factor VIIA, or the differentiation of adipocyte cells, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the nucleotide sequences cited above. The nucleic acids and polypeptides are useful for treating inflammatory diseases, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS (acquired immunodeficiency syndrome), cancer, or diabetic complications. The nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, and in generating antisense RNA or DNA. The polypeptides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. Both are useful in tissue typing. The present sequence represents a PRO protein of the invention.

QY Sequence 653 AA;
 XX

Query Match 100.0%; Score 3440; DB 24; Length 653;
 Best Local Similarity 100.0%; Pred. No. 6.4e-278;
 Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKLLQVTVHHTWVAILLPVYLTQVWTLCAIAAASAGPQPCPSVCSNCFSKV 60
 Db 1 MKLLQVTVHHTWVAILLPVYLTQVWTLCAIAAASAGPQPCPSVCSNCFSKV 60
 QY 61 CTRGLSEVPQGPISNTRYLNLMENNIOQTQADTFRLHLEHLVQLGRNSIRQIEVGAFN 120
 Db 61 CTRGLSEVPQGPISNTRYLNLMENNIOQTQADTFRLHLEHLVQLGRNSIRQIEVGAFN 120
 QY 121 GLASLNTLELFDNMLTVIPSGAPFVLSKRLRNPTIESPSVAFNRVPSLMRLDGE 180
 Db 121 GLASLNTLELFDNMLTVIPSGAPFVLSKRLRNPTIESPSVAFNRVPSLMRLDGE 180
 QY 181 LKLEYISEGAFEGLEFNLKYNLNCMKNDKMPMLTFLVGLLEEMSGNHFPIRPGSFHG 240
 Db 181 LKLEYISEGAFEGLEFNLKYNLNCMKNDKMPMLTFLVGLLEEMSGNHFPIRPGSFHG 240
 QY 241 LSSLKLWVNSQVSLTERNAFGLASVLELNALHNNLSLPHDLFTPLRYLVELHLHN 300
 Db 241 LSSLKLWVNSQVSLTERNAFGLASVLELNALHNNLSLPHDLFTPLRYLVELHLHN 300
 QY 301 PNCDCDILMLAWLRYIPTNSTCCGRCHAPMHMERGRVLYVEVDQASFOCSAPFIMDAPR 360
 Db 301 PNCDCDILMLAWLRYIPTNSTCCGRCHAPMHMERGRVLYVEVDQASFOCSAPFIMDAPR 360
 QY 361 DLNISEGRMAELKCRTPPMSSVKVLLPENGTVLASHRHPRIISVINDGTINFSHVLSDTG 420

Db 361 DLNISEGRMAELKCRTPPMSSVKVLLPENGTVLASHRHPRIISVINDGTINFSHVLSDTG 420
 QY 421 VYTCWTVNAGNSASAYLNSTAEALNTSNYSFFTTVTETTEISPEDTRKYPVPTTS 480
 Db 421 VYTCWTVNAGNSASAYLNSTAEALNTSNYSFFTTVTETTEISPEDTRKYPVPTTS 480
 QY 481 TGYQPAYTSTVLIQITRVKQVAVPATOTDKMOTSLDEVMKTKIILGCFVAVTLLA 540
 Db 481 TGYQPAYTSTVLIQITRVKQVAVPATOTDKMOTSLDEVMKTKIILGCFVAVTLLA 540
 QY 541 AAMLIVPVYKLRKRQORSTVTAARTVEIIQVDEIDIPAATSAATAAPSGVSGEAVVLEPT 600
 Db 541 AAMLIVPVYKLRKRQORSTVTAARTVEIIQVDEIDIPAATSAATAAPSGVSGEAVVLEPT 600
 QY 601 IHDLINVTYKPAHGHWTENSLGNSLHPTVTIISSEPIIIQTHTKDKVQETOI 653
 Db 601 IHDLINVTYKPAHGHWTENSLGNSLHPTVTIISSEPIIIQTHTKDKVQETOI 653

RESULT 8
 ABUS9869
 ID ABUS9869 standard, Protein; 653 AA.
 AC ABUS9869;
 XX
 DT 13-MAY-2003 (first entry)
 XX
 DE Novel secreted and transmembrane protein PRO111.
 XX
 KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
 KW cardiac insufficiency disorder; cancer; tumour; immune response;
 KW adrenal cortical capillary endothelial growth; c-fos induction;
 KW vascular endothelial growth factor inhibition; VEGF inhibition;
 KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
 KW retinal neurons cell survival; rod photoreceptor cell survival;
 KW retinal disorder; retinitis pigmentosum; kidney disorder;
 KW mammalian kidney mesangial cell proliferation; Berger disease;
 KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
 KW chondrocyte redifferentiation; sports injury; arthritis.
 XX
 OS Homo sapiens.
 XX
 XX US2003017563-A1.
 XX
 PD 23-JAN-2003.
 XX
 PF 07-MAY-2002; 2002US-0140808.
 XX
 PR 31-MAR-1997; 97WO-US05230.
 PR 12-JUN-1996; 96WO-US12456.
 PR 14-JUL-1998; 98WO-US14552.
 PR 28-AUG-1998; 98WO-US17888.
 PR 10-SEP-1998; 98WO-US18824.
 PR 14-SEP-1998; 98WO-US19093.
 PR 14-SEP-1998; 98WO-US19094.
 PR 14-SEP-1998; 98WO-US19177.
 PR 15-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 29-OCT-1998; 98WO-US22991.
 PR 29-OCT-1998; 98WO-US22992.
 PR 20-NOV-1998; 98WO-US24855.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 10-MAR-1999; 99WO-US05190.
 PR 20-APR-1999; 99WO-US08615.
 PR 14-MAY-1999; 99WO-US10733.
 PR 02-JUN-1999; 99WO-US12252.
 PR 01-SEP-1999; 99WO-US20111.
 PR 08-SEP-1999; 99WO-US20594.
 PR 13-SEP-1999; 99WO-US20944.

15-SEP-1999; 99WO-US21090.
 15-SEP-1999; 99WO-US21547.
 05-OCT-1999; 99WO-US23089.
 29-NOV-1999; 99WO-US28214.
 30-NOV-1999; 99WO-US28313.
 30-NOV-1999; 99WO-US28409.
 01-DEC-1999; 99WO-US28301.
 01-DEC-1999; 99WO-US28634.
 02-DEC-1999; 99WO-US28551.
 02-DEC-1999; 99WO-US28564.
 02-DEC-1999; 99WO-US28565.
 16-DEC-1999; 99WO-US30095.
 20-DEC-1999; 99WO-US30911.
 20-DEC-1999; 99WO-US30999.
 22-DEC-1999; 99WO-US30720.
 30-DEC-1999; 99WO-US31243.
 30-DEC-1999; 99WO-US31274.
 05-JAN-2000; 2000WO-US00219.
 06-JAN-2000; 2000WO-US00277.
 06-JAN-2000; 2000WO-US00376.
 11-FEB-2000; 2000WO-US03565.
 18-FEB-2000; 2000WO-US04341.
 22-FEB-2000; 2000WO-US04342.
 24-FEB-2000; 2000WO-US04414.
 24-FEB-2000; 2000WO-US04914.
 01-MAR-2000; 2000WO-US05004.
 01-MAR-2000; 2000WO-US05601.
 02-MAR-2000; 2000WO-US05745.
 02-MAR-2000; 2000WO-US05841.
 10-MAR-2000; 2000WO-US06319.
 15-MAR-2000; 2000WO-US06884.
 20-MAR-2000; 2000WO-US07377.
 21-MAR-2000; 2000WO-US07532.
 30-MAR-2000; 2000WO-US08439.
 17-MAY-2000; 2000WO-US13705.
 20-MAY-2000; 2000WO-US14042.
 30-MAY-2000; 2000WO-US14941.
 02-JUN-2000; 2000WO-US15264.
 28-JUL-2000; 2000WO-US20710.
 11-AUG-2000; 2000WO-US22031.
 23-AUG-2000; 2000WO-US21522.
 24-AUG-2000; 2000WO-US21328.
 08-NOV-2000; 2000WO-US30952.
 10-NOV-2000; 2000WO-US30873.
 01-DEC-2000; 2000WO-US32678.
 20-DEC-2000; 2000WO-US34956.
 28-FEB-2001; 2001WO-US06520.
 01-MAR-2001; 2001WO-US06666.
 25-MAY-2001; 2001WO-US17092.
 01-JUN-2001; 2001WO-US17800.
 20-JUN-2001; 2001WO-US19692.
 22-JUN-2001; 2001WO-US20116.
 29-JUN-2001; 2001WO-US21066.
 09-JUL-2001; 2001WO-US21735.
 20-DEC-2000; 2000US-0747259.
 28-FEB-2001; 2001US-0796498.
 09-MAR-2001; 2001US-0802706.
 14-MAR-2001; 2001US-0806589.
 22-MAR-2001; 2001US-0816744.
 05-APR-2001; 2001US-0828366.
 10-MAY-2001; 2001US-0854208.
 10-MAY-2001; 2001US-0854280.
 18-MAY-2001; 2001US-0860216.
 25-MAY-2001; 2001US-0866028.
 31-MAY-2001; 2001US-0866034.
 01-JUN-2001; 2001US-0872035.
 05-JUN-2001; 2001US-0874503.
 14-JUN-2001; 2001US-0882636.
 19-JUN-2001; 2001US-0886342.
 21-JUN-2001; 2001US-0887879.
 18-JUL-2001; 2001US-0908827.
 06-AUG-2001; 2001US-0924419.
 09-AUG-2001; 2001US-0927796.

16-AUG-2001; 2001US-0931836.
 19-DEC-2001; 2001US-0028072.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W, Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S, Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z, WPI; 2003-148238/14.
 N-PSDB; ABX89359.
 Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346 and PRO1375, which stimulate proliferation of stimulated T-lymphocytes are therapeutically useful for enhancing immune response and in cancer treatments.
 Claim 12; Fig 438; 659pp; English.
 The invention describes an isolated human PRO polypeptide. The PRO polypeptides are useful in detecting PRO polypeptides in a sample, in linking a bioactive molecule to a cell expressing a PRO polypeptide, and in modulating at least one biological activity of a cell expressing a PRO polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186 stimulate adrenal cortical capillary endothelial growth and PRO536, PRO943, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126, PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus useful for treating conditions or disorders where angiogenesis would be beneficial, e.g. wound healing and antagonist of this polypeptide are useful for treating cancerous tumours. PRO812 inhibits vascular endothelial growth factor (VEGF) stimulated proliferation of endothelial cells and is thus useful for inhibiting endothelial cell growth in mammals which would be beneficial in inhibiting tumour growth. PRO826, PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of stimulated T-lymphocytes and are therapeutically useful for enhancing immune response. PRO828, PRO1068 or PRO1132 enhance survival of retinal neurons cells (PRO1132 is also enhances survival/proliferation of rod photoreceptor cells) and therefore are useful for treating retinal disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813 and PRO1066 induce proliferation of mammalian kidney mesangial cells, and therefore are useful for treating kidney disorders associated with decreased mesangial cell function such as Berger disease or other nephropathies associated with dermatitis, herpeticiformis or Crohn's disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the proliferation and/or redifferentiation of chondrocytes in culture and are thus useful for treating sports injuries, and arthritis. This CC is the amino acid sequence of a novel human PRO protein.

XX SQ Sequence 653 AA;

Query Match 100.0%; Score 3440; DB 24; Length 653;
 Best local similarity 100.0%; Pred. No. 6.4e-278;
 Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MKLLQVTVHHHTNAILLPFVLTQAQWILCAIAAASAGPQCPCSCNQFSKV 60
 DB 1 MKLLQVTVHHHTNAILLPFVLTQAQWILCAIAAASAGPQCPCSCNQFSKV 60
 QY 61 CTRGLSEVPQIPSNTRYLNMENNIIQIADTFRHLHLEVLQLGNSIRQIEVGF 120
 DB 61 CTRGLSEVPQIPSNTRYLNMENNIIQIADTFRHLHLEVLQLGNSIRQIEVGF 120
 QY 121 GLASLNTLELFDNMLTVIPSGAFYLSKRLRLNPNPIESIPSYAFNRVPSLMRLDGE 180
 DB 121 GLASLNTLELFDNMLTVIPSGAFYLSKRLRLNPNPIESIPSYAFNRVPSLMRLDGE 180
 QY 181 LKLEYISEGAFEGFLNKLKYNLGNCKNPKMNPITPLVGLSELEMSGNHPEIRPSFG 240
 DB 181 LKLEYISEGAFEGFLNKLKYNLGNCKNPKMNPITPLVGLSELEMSGNHPEIRPSFG 240
 QY 241 LSSLKLVWMSQVSLIERNAPDGLASLVELNLAHNNLSLPHDLFTPLRYLVELHLH 300

Db 241 LSSLKLVWMSQVSLIERNAPDGLASIVELNLAHNNLSLPHDLFTPLRYLVELHLEN 300

QY 301 PWCDCDILNLAWLREVIPTNSICCGCHAPMGRGYLVEVDOAFQCSAPFIMDAPR 360

Db 301 PWCDCDILNLAWLREVIPTNSICCGCHAPMGRGYLVEVDOAFQCSAPFIMDAPR 360

QY 361 DLNISGRMAELKCRTPPMSSVKWLLPNGTIVLSHASRPRISVLNDGTLNFSHVLLSDTG 420

Db 361 DLNISGRMAELKCRTPPMSSVKWLLPNGTIVLSHASRPRISVLNDGTLNFSHVLLSDTG 420

QY 421 VYTCMTNVAGNSASAVLNSTAEALNTSNYSFFTTVTVEITEISPEDTTRKYPVPTTS 480

Db 421 VYTCMTNVAGNSASAVLNSTAEALNTSNYSFFTTVTVEITEISPEDTTRKYPVPTTS 480

QY 481 TGYQPAYTSTTVLQITRVPKQVAVPATDITDKMOTSLDEVMTKTIILIIICFPVAVLLA 540

Db 481 TGYQPAYTSTTVLQITRVPKQVAVPATDITDKMOTSLDEVMTKTIILIIICFPVAVLLA 540

QY 541 AAMLIVFYKLRKHOOORSTVTAARTVEIIQVDEDIPAATSAATAAPSGVSGEGAVVLPT 600

Db 541 AAMLIVFYKLRKHOOORSTVTAARTVEIIQVDEDIPAATSAATAAPSGVSGEGAVVLPT 600

QY 601 IHDHINNTYKPAHGAHTWENSLGNSLHPTVTIIEPVIIOTHKDKVQETQI 653

Db 601 IHDHINNTYKPAHGAHTWENSLGNSLHPTVTIIEPVIIOTHKDKVQETQI 653

RESULT 9

ID ABUS9110 standard; Protein; 653 AA.

XX ABUS9110;

AC ABUS9110;

XX XX

DT 28-APR-2003 (first entry)

XX XX

DE Novel human secreted or transmembrane protein PRO1111.

XX XX

KN Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;

KN cardiac insufficiency disorder; cancer; tumour; immune response;

KN adrenal cortical capillary endothelial growth; c-fos induction;

KN vascular endothelial growth factor inhibition; VEGF inhibition;

KN endothelial cell growth inhibitor; T-lymphocytes stimulation;

KN retinal neurons cell survival; rod photoreceptor cell survival;

KN retinal disorder; retinitis pigmentosa; kidney disorder;

KN mammalian kidney mesangial cell proliferation; Berger disease;

KN dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;

KN chondrocyte redifferentiation; sports injury; arthritis.

XX Homo sapiens.

XX XX

PN US2002132252-A1.

XX XX

PD 19-SEP-2002.

XX XX

PF 14-NOV-2001; 2001US-0990442.

XX XX

PR 05-NOV-1997; 97WO-US200069.

PR 16-SEP-1998; 98WO-US19330.

PR 17-SEP-1998; 98WO-US19437.

PR 07-OCT-1998; 98WO-US21141.

PR 01-DEC-1998; 98WO-US25108.

PR 05-JAN-1999; 99WO-US00106.

PR 08-MAR-1999; 99WO-US05028.

PR 02-JUN-1999; 99WO-US12252.

PR 15-SEP-1999; 99WO-US21090.

PR 30-NOV-1999; 99WO-US28313.

PR 01-DEC-1999; 99WO-US28301.

PR 01-DEC-1999; 99WO-US28634.

PR 16-DEC-1999; 99WO-US30095.

PR 20-DEC-1999; 99WO-US30911.

PR 06-JAN-2000; 2000WO-US00219.

PR 06-JAN-2000; 2000WO-US00376.

PR 11-FEB-2000; 2000WO-US03565.

PR 18-FEB-2000; 2000WO-US04341.

PR 22-FEB-2000; 2000WO-US04414.

PR 24-FEB-2000; 2000WO-US04914.

PR 24-FEB-2000; 2000WO-US05004.

PR 02-MAR-2000; 2000WO-US05841.

PR 10-MAR-2000; 2000WO-US06319.

PR 15-MAR-2000; 2000WO-US06884.

PR 20-MAR-2000; 2000WO-US07377.

PR 30-MAR-2000; 2000WO-US08439.

PR 15-MAY-2000; 2000WO-US13358.

PR 17-MAY-2000; 2000WO-US13705.

PR 22-MAY-2000; 2000WO-US14042.

PR 30-MAY-2000; 2000WO-US14941.

PR 02-JUN-2000; 2000WO-US15264.

PR 28-JUN-2000; 2000WO-US20710.

PR 11-AUG-2000; 2000WO-US22031.

PR 23-AUG-2000; 2000WO-US23522.

PR 24-AUG-2000; 2000WO-US23328.

PR 08-NOV-2000; 2000WO-US30952.

PR 01-DEC-2000; 2000WO-US32678.

PR 28-FEB-2001; 2001WO-US08520.

PR 01-JUN-2001; 2001WO-US17800.

PR 20-JUN-2001; 2001WO-US19692.

PR 29-JUN-2001; 2001WO-US21066.

PR 09-JUL-2001; 2001WO-US21735.

PR 16-JUN-1997; 97US-049787P.

PR 17-OCT-1997; 97US-062250P.

PR 12-NOV-1997; 97US-065186P.

PR 13-NOV-1997; 97US-065311P.

PR 24-NOV-1997; 97US-066770P.

PR 25-FEB-1998; 98US-075945P.

PR 20-MAR-1998; 98US-078910P.

PR 28-APR-1998; 98US-083322P.

PR 07-MAY-1998; 98US-084500P.

PR 28-MAY-1998; 98US-087106P.

PR 02-JUN-1998; 98US-087607P.

PR 02-JUN-1998; 98US-087609P.

PR 03-JUN-1998; 98US-087759P.

PR 04-JUN-1998; 98US-088021P.

PR 04-JUN-1998; 98US-088025P.

PR 04-JUN-1998; 98US-088026P.

PR 04-JUN-1998; 98US-088028P.

PR 04-JUN-1998; 98US-088029P.

PR 04-JUN-1998; 98US-088030P.

PR 04-JUN-1998; 98US-088033P.

PR 04-JUN-1998; 98US-088326P.

PR 05-JUN-1998; 98US-088167P.

PR 05-JUN-1998; 98US-088202P.

PR 05-JUN-1998; 98US-088212P.

PR 05-JUN-1998; 98US-088217P.

PR 09-JUN-1998; 98US-088555P.

PR 10-JUN-1998; 98US-088734P.

PR 10-JUN-1998; 98US-088738P.

PR 10-JUN-1998; 98US-088742P.

PR 10-JUN-1998; 98US-088810P.

PR 10-JUN-1998; 98US-088824P.

PR 10-JUN-1998; 98US-088826P.

PR 11-JUN-1998; 98US-088858P.

PR 11-JUN-1998; 98US-088861P.

PR 11-JUN-1998; 98US-088876P.

PR 12-JUN-1998; 98US-089105P.

PR 16-JUN-1998; 98US-089440P.

PR 16-JUN-1998; 98US-089512P.

PR 16-JUN-1998; 98US-089514P.

PR 17-JUN-1998; 98US-089532P.

PR 17-JUN-1998; 98US-089538P.

PR 17-JUN-1998; 98US-089598P.

PR 17-JUN-1998; 98US-089599P.

PR 17-JUN-1998; 98US-089600P.

PR 17-JUN-1998; 98US-089653P.

PR 18-JUN-1998; 98US-089801P.

PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX PA (GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Raton DL;
PI Perrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NP;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;

XX WPI; 2003-247083/24.
XX N-PSDB; ABX80269.

XX Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
XX and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
XX are therapeutically useful for enhancing immune response and in cancer
XX treatments

XX Claim 12; Fig 157; 548pp; English.

XX The invention describes an isolated human PRO polypeptide. The PRO
XX polypeptides are useful in detecting PRO polypeptides in a sample, in
XX linking a bioactive molecule to a cell expressing a PRO polypeptide, and
XX in modulating at least one biological activity of a cell expressing a PRO
XX polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
XX useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
XX stimulate adrenal cortical capillary endothelial growth, and PRO536,
XX PRO943, PRO828, PRO826, PRO1068 or PRO335, PRO826, PRO819, PRO1126,
XX PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
XX useful for treating conditions or disorders where angiogenesis would be
XX beneficial, e.g. wound healing and antagonist of this polypeptide are
XX useful for treating cancerous tumours. PRO812 inhibits vascular
XX endothelial growth factor (VEGF) stimulated proliferation of endothelial
XX cells and is thus useful for inhibiting endothelial cell growth in
XX mammals which would be beneficial in inhibiting tumour growth. PRO826,
XX PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
XX stimulated T-lymphocytes and are therapeutically useful for enhancing
XX immune response. PRO826, PRO826, PRO1068 or PRO1132 enhance survival of
XX retinal neurons cells (PRO1132 is also enhances survival/proliferation of
XX rod photoreceptor cells) and therefore are useful for treating retinal
XX disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813
XX and PRO1066 induce proliferation of mammalian kidney mesangial cells,
XX and therefore are useful for treating kidney disorders associated with
XX decreased mesangial cell function such as Berger disease or other
XX nephropathies associated with dermatitis, herpeticiformis or Crohn's
XX disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
XX proliferation and/or redifferentiation of chondrocytes in culture and
XX are thus useful for treating sports injuries, and arthritis. This
XX is the amino acid sequence of a novel human PRO protein.

XX Sequence 653 AA;

XX Query Match 100.0%; Score 3440; DB 24; Length 653;
XX Best Local Similarity 100.0%; Pred. No. 6.4e-278;
XX Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 1 MKLLWQVTHHTWNAILLPFVYLTQVILCAATAAASAGPQNCPCSCNPFQSKV 60
b 1 MKLLWQVTHHTWNAILLPFVYLTQVILCAATAAASAGPQNCPCSCNPFQSKV 60
Y 61 CTRGLSEVFGQIPSNTRYLNLMENNMIQADTFRHLHLHLVQLGRNSIRQIEVGAFN 120
b 61 CTRGLSEVFGQIPSNTRYLNLMENNMIQADTFRHLHLHLVQLGRNSIRQIEVGAFN 120
Y 121 GLASLNTLSELPDNLTVIPSGAFYLSKRLWLNRPSTPSYAFNRVPSLRLDLGE 180
b 121 GLASLNTLSELPDNLTVIPSGAFYLSKRLWLNRPSTPSYAFNRVPSLRLDLGE 180
Y 181 LKKLEYISGAFEGFLNLYLNGLMCNTKMPNLTPVLGLEBLEMSGNHPEIRPGSFHG 240
C 181 LKKLEYISGAFEGFLNLYLNGLMCNTKMPNLTPVLGLEBLEMSGNHPEIRPGSFHG 240

QY 241 LSSLEKKLWMNSQVSLIERNAFDGLASLVELNLAHNNLSLPHDLFTPLRYLYVELHLHN 300
DB 241 LSSLEKKLWMNSQVSLIERNAFDGLASLVELNLAHNNLSLPHDLFTPLRYLYVELHLHN 300
QY 301 PWNCDLILAWMLREYIPNNTCCGRCCHAPMHRGRYLVEDVQASFOCSAPPIMDAPR 360
DB 301 PWNCDLILAWMLREYIPNNTCCGRCCHAPMHRGRYLVEDVQASFOCSAPPIMDAPR 360
QY 361 DLNISEGRMAELKCRTPPMSSVKWLLPNTGVLSHSHRPRISVLNDGTLPFSHYLLSDTG 420
DB 361 DLNISEGRMAELKCRTPPMSSVKWLLPNTGVLSHSHRPRISVLNDGTLPFSHYLLSDTG 420
QY 421 VYTCVNTVAGNSASAYLVNSTAELNTSNYSPTTIVTTELSPEDTTRKKYKVPPTS 480
DB 421 VYTCVNTVAGNSASAYLVNSTAELNTSNYSPTTIVTTELSPEDTTRKKYKVPPTS 480
QY 481 TGYOPAYTSTTVLIQTRVPEKQVAVPATDTTDMQTSLELVKTKTIIIGCFVAVTLLA 540
DB 481 TGYOPAYTSTTVLIQTRVPEKQVAVPATDTTDMQTSLELVKTKTIIIGCFVAVTLLA 540
QY 541 AAMLIVFYKLRKHQRSTVTAARTVEIIQVDEDI PAATSAATAAPSGVSGEAVVLP 600
DB 541 AAMLIVFYKLRKHQRSTVTAARTVEIIQVDEDI PAATSAATAAPSGVSGEAVVLP 600
QY 601 IHDHINTYKPAHGAHWNTENSLNSLHPTVTIISBPYIIQTHTKDKVQETQI 653
DB 601 IHDHINTYKPAHGAHWNTENSLNSLHPTVTIISBPYIIQTHTKDKVQETQI 653
RESULT 10
ABU59257
ID ABU59257 standard; Protein; 653 AA.
XX AC ABU59257;
XX AC
XX 22-APR-2003 (first entry)
XX Human secreted/transmembrane protein, #93.
XX Human; PRO; secreted; transmembrane; pharmaceutical;
XX diagnostic; biosensor; bioreactor; tumour; therapeutic;
XX gene therapy; tumour-associated antigenic target; TAT; ADEPT;
XX antibody-dependent enzyme mediated prodrug therapy; cytostatic.
XX Homo sapiens.
XX US2003027162-A1.
XX 06-FEB-2003.
XX 15-NOV-2001; 2001US-0997428.
XX 05-NOV-1997; 97WO-US200069.
XX 16-SEP-1998; 98WO-US19330.
XX 17-SEP-1998; 98WO-US19437.
XX 07-OCT-1998; 98WO-US21141.
XX 01-DEC-1998; 98WO-US25108.
XX 05-JAN-1999; 99WO-US00106.
XX 08-MAR-1999; 99WO-US05028.
XX 02-JUN-1999; 99WO-US12252.
XX 15-SEP-1999; 99WO-US21090.
XX 15-SEP-1999; 99WO-US21547.
XX 30-NOV-1999; 99WO-US28313.
XX 01-DEC-1999; 99WO-US28301.
XX 01-DEC-1999; 99WO-US28634.
XX 16-DEC-1999; 99WO-US30095.
XX 20-DEC-1999; 99WO-US30911.
XX 05-JAN-2000; 2000WO-US00219.
XX 06-JAN-2000; 2000WO-US00376.
XX 11-FEB-2000; 2000WO-US03565.
XX 15-FEB-2000; 2000WO-US04341.
XX 22-FEB-2000; 2000WO-US04414.

PR	24-FEB-2000;	2000WO-US04914.	PR	19-JUN-1998;	98US-0899481.
PR	24-FEB-2000;	2000WO-US05004.	PR	19-JUN-1998;	98US-089952P.
PR	02-MAR-2000;	2000WO-US05841.	PR	22-JUN-1998;	98US-090246P.
PR	10-MAR-2000;	2000WO-US06319.	PR	22-JUN-1998;	98US-090252P.
PR	15-MAR-2000;	2000WO-US06884.	PR	22-JUN-1998;	98US-090254P.
PR	20-MAR-2000;	2000WO-US07377.	PR	23-JUN-1998;	98US-090349P.
PR	30-MAR-2000;	2000WO-US08439.	PR	23-JUN-1998;	98US-090355P.
PR	15-MAY-2000;	2000WO-US13358.	PR	24-JUN-1998;	98US-090429P.
PR	17-MAY-2000;	2000WO-US13705.	PR	24-JUN-1998;	98US-090431P.
PR	22-MAY-2000;	2000WO-US14042.	PR	24-JUN-1998;	98US-090435P.
PR	30-MAY-2000;	2000WO-US14941.	PR	24-JUN-1998;	98US-090444P.
PR	02-JUN-2000;	2000WO-US15264.	PR	24-JUN-1998;	98US-090445P.
PR	28-JUL-2000;	2000WO-US20710.	PR	24-JUN-1998;	98US-090472P.
PR	11-AUG-2000;	2000WO-US22031.	PR	24-JUN-1998;	98US-090535P.
PR	23-AUG-2000;	2000WO-US23522.	PR	24-JUN-1998;	98US-090540P.
PR	24-AUG-2000;	2000WO-US23328.	PR	24-JUN-1998;	98US-090542P.
PR	08-NOV-2000;	2000WO-US30952.	PR	24-JUN-1998;	98US-090557P.
PR	01-DEC-2000;	2000WO-US32678.	PR	25-JUN-1998;	98US-090676P.
PR	28-FEB-2001;	2001WO-US06520.	PR	25-JUN-1998;	98US-090678P.
PR	01-JUN-2001;	2001WO-US17800.	PR	25-JUN-1998;	98US-090690P.
PR	20-JUN-2001;	2001WO-US19692.	PR	25-JUN-1998;	98US-090694P.
PR	29-JUN-2001;	2001WO-US21066.	PR	25-JUN-1998;	98US-090695P.
PR	09-JUL-2001;	2001WO-US21735.	PR	25-JUN-1998;	98US-090696P.
PR	16-JUN-1997;	97US-049787P.	PR	26-JUN-1998;	98US-090862P.
PR	17-OCT-1997;	97US-062250P.	PR	26-JUN-1998;	98US-090863P.
PR	12-NOV-1997;	97US-065186P.	PR	01-JUL-1998;	98US-091360P.
PR	13-NOV-1997;	97US-065311P.	PR	01-JUL-1998;	98US-091360P.
PR	24-NOV-1997;	97US-066770P.	PR	02-JUL-1998;	98US-091478P.
PR	25-FEB-1998;	98US-075945P.	PR	02-JUL-1998;	98US-091519P.
PR	20-MAR-1998;	98US-078910P.	PR	02-JUL-1998;	98US-091626P.
PR	28-APR-1998;	98US-083322P.	PR	02-JUL-1998;	98US-091628P.
PR	07-MAY-1998;	98US-084600P.	PR	02-JUL-1998;	98US-091633P.
PR	28-MAY-1998;	98US-087106P.	PR	02-JUL-1998;	98US-091646P.
PR	02-JUN-1998;	98US-087507P.	PR	02-JUL-1998;	98US-091673P.
PR	02-JUN-1998;	98US-087509P.	PR	07-JUL-1998;	98US-091978P.
PR	02-JUN-1998;	98US-087559P.	PR	07-JUL-1998;	98US-091982P.
PR	03-JUN-1998;	98US-087527P.	PR	09-JUL-1998;	98US-092182P.
PR	04-JUN-1998;	98US-088021P.	PR	10-JUL-1998;	98US-092472P.
PR	04-JUN-1998;	98US-088025P.	PR	10-JUL-1998;	98US-092472P.
PR	04-JUN-1998;	98US-088026P.	PR	30-JUL-1998;	98US-094651P.
PR	04-JUN-1998;	98US-088026P.	PR	04-AUG-1998;	98US-095282P.
PR	04-JUN-1998;	98US-088029P.	PR	04-AUG-1998;	98US-095285P.
PR	04-JUN-1998;	98US-088030P.	PR	04-AUG-1998;	98US-095301P.
PR	04-JUN-1998;	98US-088033P.	PR	04-AUG-1998;	98US-095302P.
PR	04-JUN-1998;	98US-088326P.	PR	04-AUG-1998;	98US-095318P.
PR	05-JUN-1998;	98US-088167P.	PR	04-AUG-1998;	98US-095321P.
PR	05-JUN-1998;	98US-088202P.	PR	04-AUG-1998;	98US-095325P.
PR	05-JUN-1998;	98US-088212P.	PR	10-AUG-1998;	98US-095351P.
PR	05-JUN-1998;	98US-088217P.	PR	10-AUG-1998;	98US-095352P.
PR	09-JUN-1998;	98US-088555P.	PR	10-AUG-1998;	98US-095929P.
PR	10-JUN-1998;	98US-088734P.	PR	11-AUG-1998;	98US-096012P.
PR	10-JUN-1998;	98US-088738P.	PR	11-AUG-1998;	98US-096143P.
PR	10-JUN-1998;	98US-088742P.	PR	12-AUG-1998;	98US-096146P.
PR	10-JUN-1998;	98US-088742P.	PR	12-AUG-1998;	9

PR	02-JUN-1998;	98US-087609P.	PR	07-JUL-1998;	98US-091978P.
PR	02-JUN-1998;	98US-087759P.	PR	07-JUL-1998;	98US-091982P.
PR	03-JUN-1998;	98US-087827P.	PR	09-JUL-1998;	98US-092182P.
PR	04-JUN-1998;	98US-088021P.	PR	10-JUL-1998;	98US-092472P.
PR	04-JUN-1998;	98US-088025P.	PR	20-JUL-1998;	98US-093339P.
PR	04-JUN-1998;	98US-088026P.	PR	30-JUL-1998;	98US-094651P.
PR	04-JUN-1998;	98US-088028P.	PR	04-AUG-1998;	98US-095282P.
PR	04-JUN-1998;	98US-088029P.	PR	04-AUG-1998;	98US-095285P.
PR	04-JUN-1998;	98US-088030P.	PR	04-AUG-1998;	98US-095301P.
PR	04-JUN-1998;	98US-088033P.	PR	04-AUG-1998;	98US-095302P.
PR	04-JUN-1998;	98US-088326P.	PR	04-AUG-1998;	98US-095318P.
PR	05-JUN-1998;	98US-088167P.	PR	04-AUG-1998;	98US-095321P.
PR	05-JUN-1998;	98US-088202P.	PR	04-AUG-1998;	98US-095325P.
PR	05-JUN-1998;	98US-088212P.	PR	10-AUG-1998;	98US-095916P.
PR	05-JUN-1998;	98US-088217P.	PR	10-AUG-1998;	98US-095929P.
PR	05-JUN-1998;	98US-088553P.	PR	10-AUG-1998;	98US-096012P.
PR	10-JUN-1998;	98US-088734P.	PR	11-AUG-1998;	98US-096143P.
PR	10-JUN-1998;	98US-088738P.	PR	11-AUG-1998;	98US-096146P.
PR	10-JUN-1998;	98US-088742P.	PR	12-AUG-1998;	98US-096329P.
PR	10-JUN-1998;	98US-088810P.	PR	17-AUG-1998;	98US-096757P.
PR	10-JUN-1998;	98US-088824P.	PR	17-AUG-1998;	98US-096766P.
PR	10-JUN-1998;	98US-088826P.	PR	17-AUG-1998;	98US-096768P.
PR	11-JUN-1998;	98US-088858P.	PR	17-AUG-1998;	98US-096773P.
PR	11-JUN-1998;	98US-088861P.	PR	17-AUG-1998;	98US-096791P.
PR	11-JUN-1998;	98US-088876P.	PR	17-AUG-1998;	98US-096867P.
PR	12-JUN-1998;	98US-089105P.	PR	17-AUG-1998;	98US-096891P.
PR	16-JUN-1998;	98US-089440P.	PR	17-AUG-1998;	98US-096894P.
PR	16-JUN-1998;	98US-089512P.	PR	17-AUG-1998;	98US-096895P.
PR	16-JUN-1998;	98US-089514P.	PR	17-AUG-1998;	98US-096897P.
PR	17-JUN-1998;	98US-089532P.	PR	18-AUG-1998;	98US-096949P.
PR	17-JUN-1998;	98US-089538P.	PR	18-AUG-1998;	98US-096950P.
PR	17-JUN-1998;	98US-089598P.	PR	18-AUG-1998;	98US-096959P.
PR	17-JUN-1998;	98US-089599P.	PR	18-AUG-1998;	98US-096960P.
PR	17-JUN-1998;	98US-089600P.	PR	19-AUG-1998;	98US-097022P.
PR	17-JUN-1998;	98US-089653P.	PR	19-AUG-1998;	98US-097141P.
PR	18-JUN-1998;	98US-089801P.	PR	20-AUG-1998;	98US-097218P.
PR	18-JUN-1998;	98US-089807P.	PR	24-AUG-1998;	98US-097661P.
PR	18-JUN-1998;	98US-089808P.	PR	26-AUG-1998;	98US-097952P.
PR	19-JUN-1998;	98US-089947P.	PR	26-AUG-1998;	98US-097954P.
PR	19-JUN-1998;	98US-089948P.	PR	26-AUG-1998;	98US-097955P.
PR	19-JUN-1998;	98US-089952P.	PR	26-AUG-1998;	98US-097971P.
PR	22-JUN-1998;	98US-090246P.	PR	26-AUG-1998;	98US-097974P.
PR	22-JUN-1998;	98US-090252P.	PR	26-AUG-1998;	98US-097978P.
PR	22-JUN-1998;	98US-090254P.	PR	26-AUG-1998;	98US-097979P.
PR	23-JUN-1998;	98US-090349P.	PR	26-AUG-1998;	98US-097986P.
PR	23-JUN-1998;	98US-090355P.	PR	26-AUG-1998;	98US-098014P.
PR	24-JUN-1998;	98US-090429P.			
PR	24-JUN-1998;	98US-090431P.			
PR	24-JUN-1998;	98US-090435P.			
PR	24-JUN-1998;	98US-090444P.			
PR	24-JUN-1998;	98US-090445P.			
PR	24-JUN-1998;	98US-090472P.			
PR	24-JUN-1998;	98US-090535P.			
PR	24-JUN-1998;	98US-090540P.			
PR	24-JUN-1998;	98US-090542P.			
PR	24-JUN-1998;	98US-090557P.			
PR	25-JUN-1998;	98US-090576P.			
PR	25-JUN-1998;	98US-090578P.			
PR	25-JUN-1998;	98US-090609P.			
PR	25-JUN-1998;	98US-090694P.			
PR	25-JUN-1998;	98US-090695P.			
PR	25-JUN-1998;	98US-090696P.			
PR	25-JUN-1998;	98US-090862P.			
PR	26-JUN-1998;	98US-090863P.			
PR	01-JUL-1998;	98US-091326P.			
PR	01-JUL-1998;	98US-091344P.			
PR	02-JUL-1998;	98US-091478P.			
PR	02-JUL-1998;	98US-091519P.			
PR	02-JUL-1998;	98US-091622P.			
PR	02-JUL-1998;	98US-091628P.			
PR	02-JUL-1998;	98US-091633P.			
PR	02-JUL-1998;	98US-091646P.			
PR	02-JUL-1998;	98US-091673P.			
			Query Match 100.0%; Score 3440; DB 24; length 653; Best Local Similarity 100.0%; Pred. No. 6.4e-278; Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	1	MKLLWQVTHHTWNAILLPFVYLTAQVWILCAIAAASAGPQNCPSVCSCNQSKV 60	Qy	1	MKLLWQVTHHTWNAILLPFVYLTAQVWILCAIAAASAGPQNCPSVCSCNQSKV 60
Db	1	MKLLWQVTHHTWNAILLPFVYLTAQVWILCAIAAASAGPQNCPSVCSCNQSKV 60	Db	1	MKLLWQVTHHTWNAILLPFVYLTAQVWILCAIAAASAGPQNCPSVCSCNQSKV 60
Qy	61	CTRGISEVPOGIPSNTRYLNMENNIOQADTFRLHLEVLQLRNSIROIEVGAFN 120	Qy	61	CTRGISEVPOGIPSNTRYLNMENNIOQADTFRLHLEVLQLRNSIROIEVGAFN 120
Db	61	CTRGISEVPOGIPSNTRYLNMENNIOQADTFRLHLEVLQLRNSIROIEVGAFN 120	Db	61	CTRGISEVPOGIPSNTRYLNMENNIOQADTFRLHLEVLQLRNSIROIEVGAFN 120
Qy	121	GLASINTLELFDNNLTVIPSGAFYLSKLRELMRNPNIESISYAFNRVPSLMRLDGE 180	Qy	121	GLASINTLELFDNNLTVIPSGAFYLSKLRELMRNPNIESISYAFNRVPSLMRLDGE 180
Db	121	GLASINTLELFDNNLTVIPSGAFYLSKLRELMRNPNIESISYAFNRVPSLMRLDGE 180	Db	121	GLASINTLELFDNNLTVIPSGAFYLSKLRELMRNPNIESISYAFNRVPSLMRLDGE 180
Qy	181	LKKLEYISEGAFEGFLNLYLNLGMCNIKMPNLTPLVGLELEMSGNHPEIRPGSFHG 240	Qy	181	LKKLEYISEGAFEGFLNLYLNLGMCNIKMPNLTPLVGLELEMSGNHPEIRPGSFHG 240
Db	181	LKKLEYISEGAFEGFLNLYLNLGMCNIKMPNLTPLVGLELEMSGNHPEIRPGSFHG 240	Db	181	LKKLEYISEGAFEGFLNLYLNLGMCNIKMPNLTPLVGLELEMSGNHPEIRPGSFHG 240
Qy	241	LSSKKLWVWNSQVSLIERNAPDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHN 300	Qy	241	LSSKKLWVWNSQVSLIERNAPDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHN 300
Db	241	LSSKKLWVWNSQVSLIERNAPDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHN 300	Db	241	LSSKKLWVWNSQVSLIERNAPDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHN 300
Qy	301	PWNCDDILMLAWLREYIPTNSTCCORCHAPWHRGCRYLVEVDQASFQCSAPPIMDAPR 360	Qy	301	PWNCDDILMLAWLREYIPTNSTCCORCHAPWHRGCRYLVEVDQASFQCSAPPIMDAPR 360
PR	02-JUL-1998;		PR	02-JUL-1998;	

DR WPI: 2003-288106/28.
 DR N-PSDB; AEX90247.
 XX
 PT New transmembrane polypeptides and nucleic acids encoding the
 PT polypeptides, useful in gene therapy, in chromosome identification, as
 PT chromosome markers, or in generating probes -
 XX
 PS Claim 12; Fig 157; 650pp; English.
 PS
 XX The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC comprising a sequence without signal peptide and the nucleic acid
 CC encoding them. The polypeptides can be used to raise antibodies that
 CC specifically bind to the PRO polypeptide, for linking a bioactive
 CC molecule to a cell expressing a PRO protein and for modulating at least
 CC one biological activity of a cell. The PRO polypeptides or
 CC polynucleotides are also useful in gene therapy, in chromosome
 CC identification, as chromosome markers, or in generating probes. The PRO
 CC polypeptides are useful as molecular markers for protein
 CC electrophoresis, and the isolated nucleic acids may be used for
 CC recombinantly expressing those markers. The PRO polypeptides and nucleic
 CC acids may also be used in tissue typing. Anti-PRO antibodies are useful
 CC in diagnostic assays for PRO, and in affinity purification of PRO from
 CC recombinant cell culture or natural sources. The sequences presented in
 CC ABU60478-ABU60624 are the PRO polynucleotides of the invention.
 CC Note: The sequence data for this patent is also available in electronic
 CC format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 653 AA;

Query Match 100.0%; Score 3440; DB 24; Length 653;
 Best Local Similarity 100.0%; Pred. No. 6.4e-278; Indels 0; Gaps 0;
 Matches 653; Conservative 0; Mismatches 0;

QY 1 MKLLMQVTYVHHHTNAILLFPVYLAQWILCAIAAASAGPQNCPSVCSCSNQPSKV 60
 DB 1 MKLLMQVTYVHHHTNAILLFPVYLAQWILCAIAAASAGPQNCPSVCSCSNQPSKV 60

QY 61 CTRGLSEVPOGIPENTRYLNLMENNIOMIQADTFHLLHLEVLQLGNSRQIEVGA 120
 DB 61 CTRGLSEVPOGIPENTRYLNLMENNIOMIQADTFHLLHLEVLQLGNSRQIEVGA 120

QY 121 GLASINTLELFPNLTVPISGAFYLSKRLRLANNPIESIPSVAFNRVPSLRLDLGE 180
 DB 121 GLASINTLELFPNLTVPISGAFYLSKRLRLANNPIESIPSVAFNRVPSLRLDLGE 180

QY 181 LKXLEVISGAFEGFLNLYLMLGNCKNDMPNLTPLVGLSELENSGNHPEIEPGSPHG 240
 DB 181 LKXLEVISGAFEGFLNLYLMLGNCKNDMPNLTPLVGLSELENSGNHPEIEPGSPHG 240

QY 241 LSSLKXLYWNSQVSLIERNADGLASLVEMLAHNNLSLPHDLFTPLRYLVELHLHN 300
 DB 241 LSSLKXLYWNSQVSLIERNADGLASLVEMLAHNNLSLPHDLFTPLRYLVELHLHN 300

QY 301 PNWCDCDILALAWLREYIPTNSTCCGRCHAPMHRGRYLVEVDQASPCQAPFIMDAPR 360
 DB 301 PNWCDCDILALAWLREYIPTNSTCCGRCHAPMHRGRYLVEVDQASPCQAPFIMDAPR 360

QY 361 DLNISSEGRAELKCRTPPMSVYKMLLPNGTVLSHARPRISVLNDGTLNLSHVLSDTG 420
 DB 361 DLNISSEGRAELKCRTPPMSVYKMLLPNGTVLSHARPRISVLNDGTLNLSHVLSDTG 420

QY 421 VYTCMTVNVAGNSNAYLNVSATLNTSNYSFFTTVTTEISPEDTTRKYKVPPTTS 480
 DB 421 VYTCMTVNVAGNSNAYLNVSATLNTSNYSFFTTVTTEISPEDTTRKYKVPPTTS 480

QY 481 TGYPATYTTTTLVLOTTRVPQVAPATDTDDKMGCSLDEYKTKTLIIGCFVAVTLLA 540
 DB 481 TGYPATYTTTTLVLOTTRVPQVAPATDTDDKMGCSLDEYKTKTLIIGCFVAVTLLA 540

QY 541 AAMLIVFYKLRKHQRSTVTAARTVEIIQVDEIDIPATSAATAAPSGVSGEAVLPT 600
 DB 541 AAMLIVFYKLRKHQRSTVTAARTVEIIQVDEIDIPATSAATAAPSGVSGEAVLPT 600

QY 601 IHDHINVTYKPAHGAHWIENSLGNSLHPTVTVTIISFPYIIQTHTKDKVQETQI 653
 DB 601 IHDHINVTYKPAHGAHWIENSLGNSLHPTVTVTIISFPYIIQTHTKDKVQETQI 653

RESULT 13
 ABUS8032
 ID ABUS8032 standard; Protein; 653 AA.
 XX
 AC ABUS8032;
 XX
 DT 14-APR-2003 (first entry)
 XX
 DE Human PRO polypeptide #64.
 XX
 KW Human; PRO; cytostatic; tumour; cancer; lung; stomach; liver;
 KW horse; dog; cat; sheep; pig; goat; rabbit; ADEPT;
 KW antibody-dependent enzyme mediated prodrug therapy.
 XX
 OS Homo sapiens.
 XX
 PN US2003027163-A1.
 XX
 PD 06-FEB-2003.
 XX
 PF 15-NOV-2001; 2001US-0997666.
 XX
 PR 05-NOV-1997; 97WO-US20069.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 98WO-US00106.
 PR 08-MAR-1999; 98WO-US05028.
 PR 02-JUN-1999; 98WO-US12252.
 PR 15-SEP-1999; 98WO-US21090.
 PR 15-SEP-1999; 98WO-US21547.
 PR 30-NOV-1999; 98WO-US28313.
 PR 01-DEC-1999; 98WO-US28301.
 PR 01-DEC-1999; 98WO-US28634.
 PR 16-DEC-1999; 98WO-US30095.
 PR 20-DEC-1999; 98WO-US30911.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 02-MAR-2000; 2000WO-US05004.
 PR 10-MAR-2000; 2000WO-US05841.
 PR 15-MAR-2000; 2000WO-US06319.
 PR 20-MAR-2000; 2000WO-US06884.
 PR 30-MAR-2000; 2000WO-US07377.
 PR 15-MAY-2000; 2000WO-US08439.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23528.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.

R	13-NOV-1997;	97US-065311P.	PR	01-JUL-1998;	98US-091544P.				
R	24-NOV-1997;	97US-066770P.	PR	02-JUL-1998;	98US-091478P.				
R	25-FEB-1998;	98US-075945P.	PR	02-JUL-1998;	98US-091519P.				
R	20-MAR-1998;	98US-078910P.	PR	02-JUL-1998;	98US-091626P.				
R	28-APR-1998;	98US-083322P.	PR	02-JUL-1998;	98US-091628P.				
R	07-MAY-1998;	98US-084600P.	PR	02-JUL-1998;	98US-091633P.				
R	28-MAY-1998;	98US-087106P.	PR	02-JUL-1998;	98US-091646P.				
R	02-JUN-1998;	98US-087607P.	PR	02-JUL-1998;	98US-091673P.				
R	02-JUN-1998;	98US-087609P.	PR	02-JUL-1998;	98US-091678P.				
R	02-JUN-1998;	98US-087759P.	PR	02-JUL-1998;	98US-091982P.				
R	03-JUN-1998;	98US-087827P.	PR	02-JUL-1998;	98US-092182P.				
R	04-JUN-1998;	98US-088021P.	PR	02-JUL-1998;	98US-092472P.				
R	04-JUN-1998;	98US-088025P.	PR	02-JUL-1998;	98US-093339P.				
R	04-JUN-1998;	98US-088026P.	PR	02-JUL-1998;	98US-093339P.				
R	04-JUN-1998;	98US-088028P.	PR	02-JUL-1998;	98US-094651P.				
R	04-JUN-1998;	98US-088029P.	PR	02-JUL-1998;	98US-095282P.				
R	04-JUN-1998;	98US-088030P.	PR	02-JUL-1998;	98US-095285P.				
R	04-JUN-1998;	98US-088033P.	PR	02-JUL-1998;	98US-095301P.				
R	04-JUN-1998;	98US-088326P.	PR	02-JUL-1998;	98US-095302P.				
R	05-JUN-1998;	98US-088167P.	PR	02-JUL-1998;	98US-095318P.				
R	05-JUN-1998;	98US-088202P.	PR	02-JUL-1998;	98US-095318P.				
R	05-JUN-1998;	98US-088212P.	PR	02-JUL-1998;	98US-095325P.				
R	05-JUN-1998;	98US-088217P.	PR	02-JUL-1998;	98US-095325P.				
R	09-JUN-1998;	98US-088734P.	PR	02-JUL-1998;	98US-095916P.				
R	10-JUN-1998;	98US-088738P.	PR	02-JUL-1998;	98US-095916P.				
R	10-JUN-1998;	98US-088742P.	PR	02-JUL-1998;	98US-095929P.				
R	10-JUN-1998;	98US-088810P.	PR	02-JUL-1998;	98US-096012P.				
R	10-JUN-1998;	98US-088824P.	PR	02-JUL-1998;	98US-096012P.				
R	10-JUN-1998;	98US-088826P.	PR	02-JUL-1998;	98US-096143P.				
R	11-JUN-1998;	98US-088858P.	PR	02-JUL-1998;	98US-096146P.				
R	11-JUN-1998;	98US-088861P.	PR	02-JUL-1998;	98US-096329P.				
R	11-JUN-1998;	98US-088866P.	PR	02-JUL-1998;	98US-096329P.				
R	12-JUN-1998;	98US-089105P.	PR	02-JUL-1998;	98US-096757P.				
R	16-JUN-1998;	98US-089400P.	PR	02-JUL-1998;	98US-096768P.				
R	16-JUN-1998;	98US-089512P.	PR	02-JUL-1998;	98US-096773P.				
R	16-JUN-1998;	98US-089514P.	PR	02-JUL-1998;	98US-096773P.				
R	17-JUN-1998;	98US-089532P.	PR	02-JUL-1998;	98US-096791P.				
R	17-JUN-1998;	98US-089538P.	PR	02-JUL-1998;	98US-096867P.				
R	17-JUN-1998;	98US-089598P.	PR	02-JUL-1998;	98US-096891P.				
R	17-JUN-1998;	98US-089599P.	PR	02-JUL-1998;	98US-096891P.				
R	17-JUN-1998;	98US-089600P.	PR	02-JUL-1998;	98US-096894P.				
R	17-JUN-1998;	98US-089600P.	PR	02-JUL-1998;	98US-096894P.				
R	17-JUN-1998;	98US-089653P.	PR	02-JUL-1998;	98US-096897P.				
R	18-JUN-1998;	98US-089801P.	PR	02-JUL-1998;	98US-096949P.				
R	18-JUN-1998;	98US-089907P.	PR	02-JUL-1998;	98US-096950P.				
R	18-JUN-1998;	98US-089908P.	PR	02-JUL-1998;	98US-096959P.				
R	19-JUN-1998;	98US-089947P.	PR	02-JUL-1998;	98US-096960P.				
R	19-JUN-1998;	98US-089948P.	PR	02-JUL-1998;	98US-097022P.				
R	19-JUN-1998;	98US-089952P.	PR	02-JUL-1998;	98US-097022P.				
R	22-JUN-1998;	98US-090246P.	PR	02-JUL-1998;	98US-097141P.				
R	22-JUN-1998;	98US-090252P.	PR	02-JUL-1998;	98US-097218P.				
R	22-JUN-1998;	98US-090254P.	PR	02-JUL-1998;	98US-097218P.				
R	23-JUN-1998;	98US-090349P.	PR	02-JUL-1998;	98US-097661P.				
R	24-JUN-1998;	98US-090353P.	PR	02-JUL-1998;	98US-097661P.				
R	24-JUN-1998;	98US-090429P.	PR	02-JUL-1998;	98US-097952P.				
R	24-JUN-1998;	98US-090431P.	PR	02-JUL-1998;	98US-097954P.				
R	24-JUN-1998;	98US-090435P.	PR	02-JUL-1998;	98US-097955P.				
R	24-JUN-1998;	98US-090444P.	PR	02-JUL-1998;	98US-097971P.				
R	24-JUN-1998;	98US-090445P.	PR	02-JUL-1998;	98US-097974P.				
R	24-JUN-1998;	98US-090472P.	PR	02-JUL-1998;	98US-097978P.				
R	24-JUN-1998;	98US-090535P.	PR	02-JUL-1998;	98US-097979P.				
R	24-JUN-1998;	98US-090540P.	PR	02-JUL-1998;	98US-097986P.				
R	24-JUN-1998;	98US-090542P.	PR	02-JUL-1998;	98US-098014P.				
R	24-JUN-1998;	98US-090557P.	PR	02-JUL-1998;	98US-098525P.				
R	25-JUN-1998;	98US-090676P.	PR	02-JUL-1998;	98US-100634P.				
R	25-JUN-1998;	98US-090678P.	PR	02-JUL-1998;	98US-100658P.				
R	25-JUN-1998;	98US-090690P.	PR	02-JUL-1998;	98US-113298P.				
R	25-JUN-1998;	98US-090694P.	PR	02-JUL-1998;	98US-113298P.				
R	25-JUN-1998;	98US-090695P.	PR	02-JUL-1998;	98US-123957P.				
R	25-JUN-1998;	98US-090696P.	PR	02-JUL-1998;	98US-123957P.				
R	26-JUN-1998;	98US-090862P.	PR	02-JUL-1998;	98US-141037P.				
R	26-JUN-1998;	98US-090863P.	PR	02-JUL-1998;	98US-141037P.				
R	01-JUL-1998;	98US-091360P.	PR	02-JUL-1998;	98US-143048P.				

Query Match 100.0%; Score 3440; DB 24; Length 653;

Best Local Similarity 100.0%; Pred. No. 6.4e-278; Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MKLLMQVTHHTWNAILLPPVYLTQVWILCAIAAAASAGPQNCPSVCSNQSFKV	60
DB	1	MKLLMQVTHHTWNAILLPPVYLTQVWILCAIAAAASAGPQNCPSVCSNQSFKV	60
QY	61	CTRGLSEVPQIPSNTRYLNLMENNITQADTFRLHLEVLQIGNSIRQIEVCAFN	120
DB	61	CTRGLSEVPQIPSNTRYLNLMENNITQADTFRLHLEVLQIGNSIRQIEVCAFN	120

QY 121 GLASLNTLFLFNLTVIPSGAFYLSKRLWLNPNPIESIPSVAFNRVPSLWELDGE 180
 DB 121 GLASLNTLFLFNLTVIPSGAFYLSKRLWLNPNPIESIPSVAFNRVPSLWELDGE 180
 QY 181 LKLEYISGAFEGFLNLYLNGMNCIKDMNLTPLVGLBELEMSGNHPEIRPGSFHG 240
 DB 181 LKLEYISGAFEGFLNLYLNGMNCIKDMNLTPLVGLBELEMSGNHPEIRPGSFHG 240
 QY 241 LSLKXKLVWNSQVSLIERNAFDGLASLVEELAHNNLSLPHDLFTPLRYLVELLHNN 300
 DB 241 LSLKXKLVWNSQVSLIERNAFDGLASLVEELAHNNLSLPHDLFTPLRYLVELLHNN 300
 QY 301 PNMCDIILWALWLYREYIPTNSTCCGRCHAPMGRGYLVEVDQASFCQSAPFIMDAPR 360
 DB 301 PNMCDIILWALWLYREYIPTNSTCCGRCHAPMGRGYLVEVDQASFCQSAPFIMDAPR 360
 QY 361 DNLISGRVABLKCRTPPNSSLVKNLLPNGTVLSHARHPRISVLDGTLNFSHVLSDTG 420
 DB 361 DNLISGRVABLKCRTPPNSSLVKNLLPNGTVLSHARHPRISVLDGTLNFSHVLSDTG 420
 QY 421 VYTCMVTVNAGNSNASAYLNVSATLNTSNYGFVTTTVEITEISPEDTTRKYKVPVPTS 480
 DB 421 VYTCMVTVNAGNSNASAYLNVSATLNTSNYGFVTTTVEITEISPEDTTRKYKVPVPTS 480
 QY 481 TGYQPAYTSTTVLIQTTTRVPKQVAPADTDDKQOTSLDEVMKTKLIIICFVAVILLA 540
 DB 481 TGYQPAYTSTTVLIQTTTRVPKQVAPADTDDKQOTSLDEVMKTKLIIICFVAVILLA 540
 QY 541 AAMLIYFYKLRKHQRSTVTAARTVEIIQVDEDIPAATSAATAAPSGVSGEGAVLPT 600
 DB 541 AAMLIYFYKLRKHQRSTVTAARTVEIIQVDEDIPAATSAATAAPSGVSGEGAVLPT 600
 QY 601 IHDHINYNTPKPAHGAHWNTENSLGNSLHPTVTITSEPIYIQTHTKDKVQETQI 653
 DB 601 IHDHINYNTPKPAHGAHWNTENSLGNSLHPTVTITSEPIYIQTHTKDKVQETQI 653

RESULT 14
 ABUS58963 standard; Protein; 653 AA.
 XX
 AC ABUS58963;
 XX
 DT 16-APR-2003 (first entry)
 DE Human secreted/transmembrane protein, #93.
 XX
 KW Human; PRO; secreted; transmembrane; signal peptide;
 KW pharmaceutical; diagnostic; biosensor; bioreactor; tumour; therapeutic;
 KW colon cancer; lung cancer; breast cancer;cancer; gene therapy.
 OS Homo sapiens.
 XX
 PN US2002142961-AL.
 XX
 PD 03-OCT-2002.
 XX
 PF 19-NOV-2001; 2001US-0989721.
 XX
 PR 05-NOV-1997; 97WO-US20069.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 15-SEP-1999; 99WO-US21090.
 PR 10-NOV-1999; 99WO-US21547.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 16-DEC-1999; 99WO-US30095.

PR 20-DEC-1999; 99WO-US30911.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 05-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US04520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 13-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.

```

PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-094199Z.
CX
CX (GETH ) GENENTECH INC.
PA
PX Ashkenazi AJ, Baker KP, Botstein D, Deenoyers L, Eaton DJ,
PI Fextara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF,
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI,
PI Zhang Z;
CX WPI; 2003-155950/15.
CX
CX New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
XT PRO361 or PRO846) useful as targets for therapeutic intervention in
XT cancers (e.g. lung or breast cancers), or for diagnosing these cancers
XT .
XX Claim 12; Fig 157; 647pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
XC comprising a sequence without signal peptide and the nucleic acid
XC encoding them. The polypeptides can be used to raise antibodies that
XC specifically bind to the PRO polypeptide, for linking a bioactive
XC molecule to a cell expressing a PRO protein and for modulating at least
XC one biological activity of a cell. The PRO polypeptides or
XC polynucleotides are also useful as pharmaceuticals, diagnostics,
XC biosensors or bioreactors, for detecting or treating e.g. tumours in
XC mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or
XC rabbits as targets for therapeutic intervention in certain cancers (e.g.
XC colon, lung or breast cancers) and diagnostic determination of the
XC presence of these cancers. The PRO polypeptides are also useful as
XC molecular weight markers or for chromosome identification. The PRO genes
XC are useful as hybridisation probes or for screening libraries of human
XC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
XC therapy, particularly for replacing a defective gene. The sequences
XC presented in ABU58900-ABU59046 are the PRO polypeptides of the invention.
XX
XX Sequence 653 AA;
SQ
Query Match 100.0%; Score 3440; DB 24; Length 653;
Best Local Similarity 100.0%; Pred. No. 6.4E-278;
Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Qy 1 MKLLNQVTHHHHTWNAILLPPVYLTAQVWIICAAIAAASAGPCSPVCSCSNQFSKV 60
Db 1 MKLLNQVTHHHHTWNAILLPPVYLTAQVWIICAAIAAASAGPCSPVCSCSNQFSKV 60
Qy 61 CTRRGLSEVPQGIPSNTRYINLMENNIQMIOADTFRLHLHLLEVQLGRNSIRQIEVGAFN 120
Db 61 CTRRGLSEVPQGIPSNTRYINLMENNIQMIOADTFRLHLHLLEVQLGRNSIRQIEVGAFN 120
Qy 121 GLASLNTLELFNDNLTVIPSGAFYLSKLRRLRNPNISIPSYAPNRVPSLMRDLGE 180
Db 121 GLASLNTLELFNDNLTVIPSGAFYLSKLRRLRNPNISIPSYAPNRVPSLMRDLGE 180
Qy 181 LKXLEYISEGAPGLEFNLYALNGMCKDMPNITPLVGLFEELMSGNHPFPIRPSFG 240
Db 181 LKXLEYISEGAPGLEFNLYALNGMCKDMPNITPLVGLFEELMSGNHPFPIRPSFG 240
Qy 241 LSSLKKLWMVNSQVSILIERNAFDGLASIVELMLAHNNLSLPDLFTPLRYLVELHLHN 300
Db 241 LSSLKKLWMVNSQVSILIERNAFDGLASIVELMLAHNNLSLPDLFTPLRYLVELHLHN 300
Qy 301 PWNCCDDIILWLAWLREYIPTNSTCCGRCHAPMHMRGRYLVEVDQAQSFPQSAFIMDAPR 360
Db 301 PWNCCDDIILWLAWLREYIPTNSTCCGRCHAPMHMRGRYLVEVDQAQSFPQSAFIMDAPR 360
Qy 361 DLNISERGMALRKRT?PMWSVKVKNLIPNGTIVLSHASRHFRISVLNDGTVAHSHVILSDTG 420

```

PR 28-JUL-2000; 2000KO-US20710.
 PR 11-AUG-2000; 2000KO-US22031.
 PR 23-AUG-2000; 2000KO-US23522.
 PR 24-AUG-2000; 2000KO-US23328.
 PR 08-NOV-2000; 2000KO-US30352.
 PR 01-DEC-2000; 2000KO-US32678.
 PR 28-FEB-2001; 2001KO-US05520.
 PR 01-JUN-2001; 2001KO-US17800.
 PR 20-JUN-2001; 2001KO-US19692.
 PR 09-JUN-2001; 2001KO-US21066.
 PR 09-JUL-2001; 2001KO-US21735.
 PR 16-JUN-1997; 97US-849787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 26-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088728P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088976P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.
 (GETH) GENENTECH LTD.
 Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 Ferrara N, Fong S, Gerber H, Gerritsen MB, Goddard A, Godowski RJ;
 Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;
 Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WI;
 Zhang Z;
 WPI; 2003-102117/09.
 N-PSDB; ABX64093.

PT Novel secreted and transmembrane polypeptide for modulating biological
 PT activity of cell expressing the polypeptide, identifying agonists or
 PT antagonists of polypeptide, and as molecular weight markers -
 XX Claim 12; Fig 157; 649pp; English.
 XX The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The
 CC PRO polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides are useful for detecting other PRO polypeptides, for
 CC linking bioactive molecules to cells expressing PRO polypeptides,
 CC for modulating biological activities of cells expressing PRO
 CC polypeptides, and for identifying agonists or antagonists.
 CC The polynucleotide sequences encoding PRO polypeptides are useful as
 CC hybridisation probes, in chromosome and gene mapping, in the generation
 CC of antisense RNA and DNA, in the preparation of PRO polypeptides, for
 CC generating transgenic animals or knockout animals, to construct
 CC hybridisation probes for mapping the gene which encodes the PRO
 CC polypeptide, and for the genetic analysis of individuals with genetic
 CC disorders, in gene therapy, for chromosome identification, as
 CC chromosome markers, and for generating probes for PCR, Northern
 CC analysis, Southern analysis and Western analysis. ABU13860-ABU14006
 CC represent the human PRO polypeptides of the invention.
 CC Note: The sequence data for this patent was obtained in electronic
 CC format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipsidentry.html.
 XX Sequence 653 AA;
 SQ
 Query Match 100.0%; Score 3440; DB 24; Length 653;
 Best Local Similarity 100.0%; Pred. No. 6.4e-278;
 Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MKLLKQVTVHHHTWNAILLPVYLTQAQWVILCAATAAASAGPONCPSCVCSNQFSKVV 60
 Db 1 MKLLKQVTVHHHTWNAILLPVYLTQAQWVILCAATAAASAGPONCPSCVCSNQFSKVV 60
 QY 61 CTRRGLSEVPGQIPNTRYLNLMENNIQMIQADTFRHLHLHLVQLQGRNSIRQIEVGAFN 120
 Db 61 CTRRGLSEVPGQIPNTRYLNLMENNIQMIQADTFRHLHLHLVQLQGRNSIRQIEVGAFN 120
 QY 121 GLASLNTLELFDNWLTVTPSGAFYLSKRLRLNRPDIESIPSYAFNRVPSLWLDLGE 180
 Db 121 GLASLNTLELFDNWLTVTPSGAFYLSKRLRLNRPDIESIPSYAFNRVPSLWLDLGE 180
 QY 181 LKKLEYISEGAPEGLFNKLYNLGNCKDKMPNLTPLVGLSELEMSGNHFFPIRPGSFHG 240
 Db 181 LKKLEYISEGAPEGLFNKLYNLGNCKDKMPNLTPLVGLSELEMSGNHFFPIRPGSFHG 240
 QY 241 LSSLKKLWVNSQVSLIERNAPDGLASLVELNLAHNLSLPHDLFTPLRYLVHLHLHN 300
 Db 241 LSSLKKLWVNSQVSLIERNAPDGLASLVELNLAHNLSLPHDLFTPLRYLVHLHLHN 300
 QY 301 PWNCCDILWLAWLREYIPTNSTCCGCHAPMHRGRYLVEVDQASQCSAPIMDAPR 360
 Db 301 PWNCCDILWLAWLREYIPTNSTCCGCHAPMHRGRYLVEVDQASQCSAPIMDAPR 360
 QY 361 DLNISEGRMAELKCRTPPMSVVKMLLPNGTVLSHSHRPRISVLNDGTFLNFSHLLSDTG 420
 Db 361 DLNISEGRMAELKCRTPPMSVVKMLLPNGTVLSHSHRPRISVLNDGTFLNFSHLLSDTG 420
 QY 421 VYTCMVTVNAGNSNASAVLNYSALNTSNTSFFTTVTTEISPEPTTKYKVPVPTS 480
 Db 421 VYTCMVTVNAGNSNASAVLNYSALNTSNTSFFTTVTTEISPEPTTKYKVPVPTS 480
 QY 481 TGYQPAYTSTTVLIQTTRVPRQKQVAVPATDITDKMQTSLDEVMKTKIIICGFVAVTLLA 540
 Db 481 TGYQPAYTSTTVLIQTTRVPRQKQVAVPATDITDKMQTSLDEVMKTKIIICGFVAVTLLA 540
 QY 541 AMLIVFYKLRKHQORSTVTAARTVEIIQVDEIPATSAATAAPSGVSGEGAVLPT 600
 Db 541 AMLIVFYKLRKHQORSTVTAARTVEIIQVDEIPATSAATAAPSGVSGEGAVLPT 600

PT Novel secreted and transmembrane polypeptide for modulating biological
 PT activity of cell expressing the polypeptide, identifying agonists or
 PT antagonists of polypeptide, and as molecular weight markers -
 XX Claim 12; Fig 157; 649pp; English.
 XX The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The
 CC PRO polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides are useful for detecting other PRO polypeptides, for
 CC linking bioactive molecules to cells expressing PRO polypeptides,
 CC for modulating biological activities of cells expressing PRO
 CC polypeptides, and for identifying agonists or antagonists.
 CC The polynucleotide sequences encoding PRO polypeptides are useful as
 CC hybridisation probes, in chromosome and gene mapping, in the generation
 CC of antisense RNA and DNA, in the preparation of PRO polypeptides, for
 CC generating transgenic animals or knockout animals, to construct
 CC hybridisation probes for mapping the gene which encodes the PRO
 CC polypeptide, and for the genetic analysis of individuals with genetic
 CC disorders, in gene therapy, for chromosome identification, as
 CC chromosome markers, and for generating probes for PCR, Northern
 CC analysis, Southern analysis and Western analysis. ABU13860-ABU14006
 CC represent the human PRO polypeptides of the invention.
 CC Note: The sequence data for this patent was obtained in electronic
 CC format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipsidentry.html.

2Y 601 IHDHINYNYKPAHGAHWTEHNSLGHPTVTITISBPYIIOTHTKDKVQETQI 653
 2D IHDHINYNYKPAHGAHWTEHNSLGHPTVTITISBPYIIOTHTKDKVQETQI 653

RESULT 16

ABU10878
 ID ABU10878 standard; Protein, 653 AA.

LC AC

XX ABU10878;

YT 04-FEB-2003 (first entry)

DE Human PRO polypeptide #64.

W Human; PRO; secreted polypeptide; transmembrane polypeptide;
 W toxin; radiolabel; cell death; gene mapping; chromosome mapping;
 W protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
 W antibacterial.

NS Homo sapiens.

W US2002123463-A1.

ND 05-SEP-2002.

XX 19-NOV-2001; 2001US-0989732.

XX 05-NOV-1997; 97WO-US20069.

XX 16-SEP-1998; 98WO-US19330.

XX 17-SEP-1998; 98WO-US19437.

XX 07-OCT-1998; 98WO-US21141.

XX 01-DEC-1998; 98WO-US25108.

XX 05-JAN-1999; 99WO-US00106.

XX 08-MAR-1999; 99WO-US05028.

XX 02-JUN-1999; 99WO-US12252.

XX 15-SEP-1999; 99WO-US21090.

XX 15-SEP-1999; 99WO-US21547.

XX 30-NOV-1999; 99WO-US28313.

XX 01-DEC-1999; 99WO-US28301.

XX 01-DEC-1999; 99WO-US28634.

XX 16-DEC-1999; 99WO-US30095.

XX 20-DEC-1999; 99WO-US30911.

XX 06-JAN-2000; 2000WO-US00219.

XX 06-JAN-2000; 2000WO-US00376.

XX 11-FEB-2000; 2000WO-US03565.

XX 18-FEB-2000; 2000WO-US04341.

XX 22-FEB-2000; 2000WO-US04414.

XX 24-FEB-2000; 2000WO-US04914.

XX 24-FEB-2000; 2000WO-US05004.

XX 02-MAR-2000; 2000WO-US05841.

XX 10-MAR-2000; 2000WO-US06319.

XX 15-MAR-2000; 2000WO-US06884.

XX 30-MAR-2000; 2000WO-US07377.

XX 30-MAR-2000; 2000WO-US08439.

XX 15-MAY-2000; 2000WO-US13358.

XX 17-MAY-2000; 2000WO-US13705.

XX 22-MAY-2000; 2000WO-US14042.

XX 30-MAY-2000; 2000WO-US14941.

XX 02-JUN-2000; 2000WO-US15264.

XX 28-JUL-2000; 2000WO-US20710.

XX 11-AUG-2000; 2000WO-US22031.

XX 23-AUG-2000; 2000WO-US23522.

XX 24-AUG-2000; 2000WO-US23328.

XX 08-NOV-2000; 2000WO-US30952.

XX 01-DEC-2000; 2000WO-US32878.

XX 28-FEB-2001; 2001WO-US06520.

XX 01-JUN-2001; 2001WO-US17800.

XX 20-JUN-2001; 2001WO-US19692.

XX 29-JUN-2001; 2001WO-US21066.

XX 09-JUL-2001; 2001WO-US21735.

XX 15-JUN-1997; 97US-049787P.

XX 17-OCT-1997; 97US-062250P.

PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-065770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087603P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088023P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089400P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH INC.

Askenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
 Ferrara N, Fong S, Gerber H, Gerritsen MG, Goddard A, Godowski PJ,
 Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NP,
 Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WI,
 Zhang Z;

WPI; 2003-065810/06.

N-PSDB; ABX17057.

Novel secreted and transmembrane polypeptide for modulating biological
 activity of cell expressing the polypeptide, identifying agonists or
 antagonists of polypeptide, and as molecular weight markers -

Claim 12; Fig 157; 655pp; English.

The invention relates to a secreted and transmembrane polypeptide, termed
 PRO polypeptide, and the polynucleotide encoding it. The polypeptide is
 useful for detecting PRO polypeptides and for linking a bioactive
 molecule to a cell expressing the above polypeptides, where the bioactive
 molecule is a toxin, radiolabel or an antibody. The bioactive material
 causes the death of the cell. The polypeptide is useful for identifying
 agonists or antagonists of the PRO polypeptide, for preparing variants of

CC PRO, as a molecular weight marker for protein electrophoresis purposes
CC and the PRO polynucleotide is useful for recombinantly expressing those
CC markers. The polynucleotide is also useful as a hybridisation probe, in
CC chromosome and gene mapping, in generation of antisense RNA and DNA, in
CC the preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, to construct hybridisation
CC probes for mapping the gene which encodes PRO and for the genetic
CC analysis of individuals with genetic disorders, in gene therapy, for
CC chromosome identification, as a chromosome marker and for generating
CC probes for PCR, Northern analysis, Southern analysis and Western
CC analysis. This sequence represents a human PRO polypeptide of the
CC invention.

XX Sequence 653 AA;
SQ Query Match 100.0%; Score 3440; DB 24; Length 653;
Best Local Similarity 100.0%; Pred. No. 6.4e-278;
Matches 653; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MKLLAQVTVHHTWNAILLPFVYLTQVWILCAIAAASAGPQNCPSVCSNQSFKVY 60
DB 1 MKLLAQVTVHHTWNAILLPFVYLTQVWILCAIAAASAGPQNCPSVCSNQSFKVY 60
QY 61 CTRGLSVFPGIPENTRYLNMENNIOICADTFRLHLEVLQGRNSTRIQLEVAFN 120
DB 61 CTRGLSVFPGIPENTRYLNMENNIOICADTFRLHLEVLQGRNSTRIQLEVAFN 120
QY 121 GLASLNTLEFDNNLTVIPSGAFYLSKRLWLNNPIESIPYAFNRPVSLMRDLGE 180
DB 121 GLASLNTLEFDNNLTVIPSGAFYLSKRLWLNNPIESIPYAFNRPVSLMRDLGE 180
QY 181 LKLEYISEGAFEGFLNKLNLGNKCNKMPNLTPLVGLSELEMSGNHPPETPGSEFH 240
DB 181 LKLEYISEGAFEGFLNKLNLGNKCNKMPNLTPLVGLSELEMSGNHPPETPGSEFH 240
QY 241 LSSLLKLVWMSQVSLIERNAFDGLASIVELNLAHNNLSLPHDLFTPLRYLVVELHLHN 300
DB 241 LSSLLKLVWMSQVSLIERNAFDGLASIVELNLAHNNLSLPHDLFTPLRYLVVELHLHN 300
QY 301 PNCDCDILNLAWLREYIPNTSCCGRCHAPMNRGRYLVVEVDQASFOCSAPFINDAPR 360
DB 301 PNCDCDILNLAWLREYIPNTSCCGRCHAPMNRGRYLVVEVDQASFOCSAPFINDAPR 360
QY 361 DINTSEGRMAELKCTPMSVSVKLLPNTGTVLSHARPRISVNDGTLNFSVLLSDTG 420
DB 361 DINTSEGRMAELKCTPMSVSVKLLPNTGTVLSHARPRISVNDGTLNFSVLLSDTG 420
QY 421 VYTCMVTNAGNSASAYLVNSTAELNNTSNYSFPTVTVETTEISPDTRKYPVPTTS 480
DB 421 VYTCMVTNAGNSASAYLVNSTAELNNTSNYSFPTVTVETTEISPDTRKYPVPTTS 480
QY 481 TCYQPAYTSTTVLIQTRVPKOVAVPATDTDKQVTSLDEVMKTKIITGCFVAVTLLA 540
DB 481 TCYQPAYTSTTVLIQTRVPKOVAVPATDTDKQVTSLDEVMKTKIITGCFVAVTLLA 540
QY 541 AAMLIVFYKLAKRQQRSTVTAARTVEIIQVDEDIIPAATSAATAAPSGVSGEAVVLP 600
DB 541 AAMLIVFYKLAKRQQRSTVTAARTVEIIQVDEDIIPAATSAATAAPSGVSGEAVVLP 600
QY 601 IHDHINNTYKPAHGAHWTENSLNSLHPTVTIISEPYIIQTHTKDKVQETOI 653
DB 601 IHDHINNTYKPAHGAHWTENSLNSLHPTVTIISEPYIIQTHTKDKVQETOI 653

RESULT 17
AAV28806
ID AAV28806 standard; Protein; 653 AA.
XX
AC AAV28806;
QY 17-JAN-2000 (first entry)
XX

DE cc359_4 secreted protein.
XX clone cc359_4: cc359_4 protein; human adult brain cDNA library;
XX secreted protein; signal peptide; transmembrane domain; leucine zipper;
XX hydrophobic nature; TopPredII computer program; cytokine; tissue growth;
XX nutritional activity; cell proliferation; immune stimulation;
XX chaoptin domain; immune suppression; hematopoiesis regulation;
XX tumour inhibition.
OS Homo sapiens.
XX
XX Location/Qualifiers
XX Key 29..41
XX Peptide /note= "Predicted signal peptide"
XX Protein 42..653
XX /note= "Mature cc359_4 protein"
XX Domain 94..115
XX /label= Chaoptin domain-1
XX /note= "Composed of 41 potentially amphipathic repeats"
XX Domain 118..139
XX /label= Chaoptin domain-2
XX /note= "Composed of 41 potentially amphipathic repeats"
XX Domain 142..163
XX /label= Chaoptin domain-3
XX /note= "Composed of 41 potentially amphipathic repeats"
XX Domain 261..282
XX /label= Chaoptin domain-4
XX /note= "Composed of 41 potentially amphipathic repeats"
XX W09950405-A1.
XX 07-OCT-1999.
XX 30-MAR-1999; 99WO-US06946.
XX 31-MAR-1999; 98US-0080110.
XX 29-MAR-1999; 99US-0280591.
XX (GENY) GENETICS INST INC.
XX Jacobs K, McCooy JM, LaVallie ER, Collins-Racie LA, Evans C;
XX Merberg D, Treacy M, Agostino MJ, Steininger RJ;
XX WPI; 1999-610849/52.
XX N-PSDB; AAX90848.
XX Polynucleotides encoding secreted human proteins, derived from human
XX adult brain, human fetal brain, human fetal kidney, and human adult
XX blood cDNA libraries -
XX Claim 1; Page 97-99; 122pp; English.
XX The present sequence is the cc359_4 secreted protein encoded by the cDNA
XX clone cc359_4. cc359_4 was isolated from a human adult brain cDNA library
XX using methods specific for secreted protein cDNAs. The leader sequence or
XX signal peptide acts as a transmembrane domain due to its hydrophobic
XX nature. The TopPredII computer program predicts five potential
XX transmembrane domains centered around amino acids 20, 410, 490, 530 and
XX 590. This protein has a leucine zipper motif. The polynucleotide and
XX protein may effect nutritional activity, cytokine and cell proliferation,
XX immune stimulation or suppression, hematopoiesis regulation, tissue
XX growth, tumour inhibition etc.
XX Sequence 653 AA;
SQ Query Match 99.7%; Score 3431; DB 20; Length 653;
Best Local Similarity 99.7%; Pred. No. 3.6e-277;
Matches 651; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1 MKLLAQVTVHHTWNAILLPFVYLTQVWILCAIAAASAGPQNCPSVCSNQSFKVY 60
DB 1 MKLLAQVTVHHTWNAILLPFVYLTQVWILCAIAAASAGPQNCPSVCSNQSFKVY 60

2Y 61 CTRRGLSEVPGIPSNTRYLNLMENNIOIADTFRLHLEVLQGRNSIRQIEVGFN 120
 Db 61 CTRRGLSEVPGIPSNTRYLNLMENNIOIADTFRLHLEVLQGRNSIRQIEVGFN 120
 Y 121 GLASLNTLELFDNWLTVIPSGAFYLSKRLWLNRPPIESIPSYAFNRPVPSLMRLDLGE 180
 b 121 GLASLNTLELFDNWLTVIPSGAFYLSKRLWLNRPPIESIPSYAFNRPVPSLMRLDLGE 180
 Y 181 LKLEYISSEGAFFGLFNLYKYNLGMNCIKOMPNTPLVGLLEEMSGNHPPIRPGSFHG 240
 b 181 LKLEYISSEGAFFGLFNLYKYNLGMNCIKOMPNTPLVGLLEEMSGNHPPIRPGSFHG 240
 Y 241 LSSLUKLWVNSQVSLIERNAFDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHEN 300
 b 241 LSSLUKLWVNSQVSLIERNAFDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHEN 300
 Y 301 PWNCDLILWAWLREYIPTNSTCCGRCHAPMHRGRYLVEVDQASFOCSAPFINDAPR 360
 b 301 PWNCDLILWAWLREYIPTNSTCCGRCHAPMHRGRYLVEVDQASFOCSAPFINDAPR 360
 Y 361 DLNISEGRMAELKCRTPPMSSVKWLLPNGTVLHSHRHPRIISVINDGTINFSHVLLSDTG 420
 b 361 DLNISEGRMAELKCRTPPMSSVKWLLPNGTVLHSHRHPRIISVINDGTINFSHVLLSDTG 420
 Y 421 VYTCMTNVAAGNSAYLNVAETLNTSNYSFPTTVEITISPEDTRKYKVPPTTS 480
 b 421 VYTCMTNVAAGNSAYLNVAETLNTSNYSFPTTVEITISPEDTRKYKVPPTTS 480
 Y 481 TGQOPAYTTSVTLIOTTRVPKQVAVPATDTTDMQTSLDVWKTIIIGCFVAVTLLA 540
 b 481 TGQOPAYTTSVTLIOTTRVPKQVAVPATDTTDMQTSLDVWKTIIIGCFVAVTLLA 540
 Y 541 AAMLIYFKLRKHQRSTVTAARTVEIIIOVDSDIPAATAAATAAPSGVSGEAVLPT 600
 b 541 AAMLIYFKLRKHQRSTVTAARTVEIIIOVDSDIPAATAAATAAPSGVSGEAVLPT 600
 Y 601 IHDHINTYKPAHGAHWNTENSLNSLHPTVTTSISEPYIIQHTKDKVOETQI 653
 b 601 IHDHINTYKPAHGAHWNTENSLNSLHPTVTTSISEPYIIQHTKDKVOETQI 653
 RESULT 18
 EG98014
 D ABG98014 standard; Protein; 649 AA.
 X X ABG98014;
 X X
 X X 07-JAN-2003 (first entry)
 X X Human leucine rich repeat domain protein associated protein #1.
 X X Leucine rich repeat; nervous system; human; neural disorder; apoptosis;
 X X renal disorder; immune deficiency syndrome; rheumatoid arthritis;
 X X acquired immunodeficiency syndrome; asthma; AIDS;
 X X haematopoietic disorder; metabolic disease; reproductive disorder;
 X X pulmonary disease; cardiovascular disease; hyperproliferative disorder;
 X X neurodegenerative disease; Alzheimer's disease; Parkinson's disease;
 X X Huntington's disease; developmental disorder; autoimmune disease;
 X X Addison's disease; haemolytic anaemia; antiphospholipid syndrome;
 X X allergic encephalomyelitis; gene therapy.
 X X Homo sapiens.
 X X W0200274959-A2.
 X X 26-SEP-2002.
 X X 20-DEC-2001; 2001WO-US50457.
 X X 03-JAN-2001; 2001US-259479P.
 X X 09-JAN-2001; 2001US-260616P.
 X X (BRIM) BRISTOL-MYERS SQUIBB CO.

XX Ramanathan C, Feder J, Mintier G;
 XX WPI; 2002-750554/81.
 XX New HLRRNS1 nucleic acids and polypeptides, useful for preventing,
 XX treating, or ameliorating e.g. renal disorder, immune, hematopoietic,
 XX metabolic, reproductive, pulmonary, cardiovascular or autoimmune
 XX diseases -
 XX Example 5; Page 412-415; 415pp; English.
 XX The invention describes nucleic acids encoding human leucine-rich repeat
 XX containing proteins expressed in nervous system tissues, HLRRNS1. The
 XX HLRRNS1 polypeptide or the polynucleotide is useful for preventing,
 XX treating, or ameliorating a neural disorder or a disorder related to
 XX aberrant apoptosis modulation (either directly or indirectly), renal
 XX disorder, immune disorder (e.g. arthritis, asthma, acquired
 XX immunodeficiency syndrome (AIDS) or rheumatoid arthritis),
 XX haematopoietic, metabolic, reproductive, pulmonary or cardiovascular
 XX diseases, hyperproliferative disorders, neurodegenerative diseases
 XX (e.g. Alzheimer's disease, Parkinson's disease or Huntington's
 XX disease), developmental disorders, non-infectious disorders, nervous
 XX system diseases and/or disorders, and autoimmune diseases (e.g.
 XX Addison's disease, haemolytic anaemia, antiphospholipid syndrome, or
 XX allergic encephalomyelitis). The polynucleotides are also useful as
 XX chromosome markers, for chromosome identification, gene therapy, and in
 XX identifying organisms from minute biological samples. This is the amino
 XX acid sequence of a peptide associated with the leucine-rich repeat
 XX containing nervous system protein of the invention.
 XX Sequence 649 AA;
 XX
 XX Query Match 99.0%; Score 3407; DB 23; Length 649;
 XX Best Local Similarity 99.2%; Pred No. 3.6e-275;
 XX Matches 648; Conservative 0; Mismatches 1; Indels 4; Gaps 1;
 QY 1 MKLLQVTVVHHHTWNAILLPFVYLTAQWILCAIAAASAGPQNCPSVCSCNQSKV 60
 Db 1 MKLLQVTVVHHHTWNAILLPFVYLTAQWILCAIAAASAGPQNCPSVCSCNQSKV 60
 QY 61 CTRRGLSEVPGIPSNTRYLNLMENNIOIADTFRLHLEVLQGRNSIRQIEVGFN 120
 Db 61 CTRRGLSEVPGIPSNTRYLNLMENNIOIADTFRLHLEVLQGRNSIRQIEVGFN 120
 QY 121 GLASLNTLELFDNWLTVIPSGAFYLSKRLWLNRPPIESIPSYAFNRPVPSLMRLDLGE 180
 Db 121 GLASLNTLELFDNWLTVIPSGAFYLSKRLWLNRPPIESIPSYAFNRPVPSLMRLDLGE 180
 QY 181 LKLEYISSEGAFFGLFNLYKYNLGMNCIKOMPNTPLVGLLEEMSGNHPPIRPGSFHG 240
 Db 181 LKLEYISSEGAFFGLFNLYKYNLGMNCIKOMPNTPLVGLLEEMSGNHPPIRPGSFHG 240
 QY 241 LSSLUKLWVNSQVSLIERNAFDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHEN 300
 Db 241 LSSLUKLWVNSH---ERNAFDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHEN 296
 QY 301 PWNCDLILWAWLREYIPTNSTCCGRCHAPMHRGRYLVEVDQASFOCSAPFINDAPR 360
 Db 297 PWNCDLILWAWLREYIPTNSTCCGRCHAPMHRGRYLVEVDQASFOCSAPFINDAPR 356
 QY 361 DLNISEGRMAELKCRTPPMSSVKWLLPNGTVLHSHRHPRIISVINDGTINFSHVLLSDTG 420
 Db 357 DLNISEGRMAELKCRTPPMSSVKWLLPNGTVLHSHRHPRIISVINDGTINFSHVLLSDTG 416
 QY 421 VYTCMTNVAAGNSAYLNVAETLNTSNYSFPTTVEITISPEDTRKYKVPPTTS 480
 Db 417 VYTCMTNVAAGNSAYLNVAETLNTSNYSFPTTVEITISPEDTRKYKVPPTTS 476
 QY 481 TGQOPAYTTSVTLIOTTRVPKQVAVPATDTTDMQTSLDVWKTIIIGCFVAVTLLA 540
 Db 477 TGQOPAYTTSVTLIOTTRVPKQVAVPATDTTDMQTSLDVWKTIIIGCFVAVTLLA 536

QY 541 AAMLVYFKLRKHQRSTVTAARTVEIIQVDEIDIPAAATSAATAPSGVSGEAVLPT 600
 DB 537 AAMLVYFKLRKHQRSTVTAARTVEIIQVDEIDIPAAATSAATAPSGVSGEAVLPT 596
 QY 601 IHDHINNTYKPAHGHWTENSLGNSLHPTVTITSEPIIIOHTKQKQVETQI 653
 DB 597 IHDHINNTYKPAHGHWTENSLGNSLHPTVTITSEPIIIOHTKQKQVETQI 649

RESULT 19

AAB23033

ID AAB23033 standard; Protein; 694 AA.

XX AC AAB23033;

XX 16-JAN-2001 (first entry)

XX Human SLIT protein-like splice variant, SECX 3352358-1.

KW SECX protein; human; secreted; membrane-associated; cancer;
 KW proliferation regulator; differentiation regulator; non-malignant tumour;
 KW immune disorder; autoimmune disease; transplant rejection; allergy; AIDS;
 KW infection; inflammatory disorder; arthritis; haematopoietic disorder;
 KW skin disorder; cardiovascular disorder; atherosclerosis; restenosis;
 KW neurological disease; Alzheimer's disease; trauma; wound;
 KW spinal cord injury; skeletal disorder; cytostatic; immunosuppressive;
 KW anti-HIV; antiinflammatory; antiarthritic; antiarteriosclerotic;
 KW neuroprotective; vulnerary; antiallergic; antimicrobial; cardiant;
 KW dermatological; gene therapy.

XX OS Homo sapiens.

XX Key Location/Qualifiers

XX Misc-difference 654

XX /label= unknown

XX /note= "Encoded by TGA"

XX WO2000053742-A2.

XX 14-SEP-2000.

XX 09-MAR-2000; 2000WO-US06280.

XX 09-MAR-1999; 99US-0123667.

XX 08-MAR-2000; 2000US-0123667.

XX (CURA-) CURAGEN CORP.

XX Shinkets RA;

XX WPI; 2000-594318/56.

XX N-PSDB; AAA93620.

PT Novel human membrane associated or secreted polypeptides and
 PT polynucleotides useful for diagnosis, prevention and treatment of
 PT pathological states such as cancer, immune, cardiovascular and
 PT neurological disorders

XX Claim 1; Fig 5; 151pp; English.

XX Sequences AAB23029-B23048 represent human SECX proteins. The SECX
 XX proteins of the invention are either secreted or membrane-associated
 XX proteins and act as regulator of cellular proliferation and
 XX differentiation. SECX proteins or nucleotides are useful for diagnosing
 XX the presence of, or predisposition to, a disease associated with altered
 XX levels of SECX proteins and nucleotides. The SECX proteins are also
 XX useful to screen compounds that modulate SECX activity or expression. The
 XX interaction of a SECX protein with other cellular proteins may be useful
 XX to modulate the activity of a partner protein, cellular proliferation,
 XX cellular differentiation and cell survival. SECX nucleotides are useful
 XX for the recombinant expression of SECX protein, and may be used to detect
 XX SECX mRNA or genetic lesions in the SECX gene. They may also be used to
 XX modulate SECX expression (e.g., using antisense oligonucleotides). SECX

CC nucleic acid sequences are also useful for identifying a cell or tissue
 CC type in a biological sample, and in forensic biology. SECX primers or
 CC probes are useful for detecting the presence of SECX nucleotides and for
 CC screening tissue cultures for contamination. Diseases that may be treated
 CC or prevented using SECX proteins or nucleotides include cancer (e.g.,
 CC colorectal carcinoma, prostate cancer), benign tumours, immune disorders
 CC (including autoimmune diseases, transplant rejection, allergies, AIDS),
 CC infections, inflammatory disorders, arthritis, haematopoietic disorders,
 CC skin disorders, cardiovascular disorders, atherosclerosis, restenosis,
 CC neurological diseases (e.g., Alzheimer's disease), trauma (e.g.,
 CC surgical or traumatic wounds, spinal cord injury), and skeletal
 CC disorders.

XX SQ Sequence 694 AA;

Query Watch 99.0%; Score 3407; DB 21; Length 694;

Best Local Similarity 99.2%; Pred. No. 4e-275;

Matches 648; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 MKLLMQVTVHHTWNAILLPFVYLTAAQWILCAIAAASAGPQNCPSVCSNQFSKVV 60
 DB 1 MKLLMQVTVHHTWNAILLPFVYLTAAQWILCAIAAASAGPQNCPSVCSNQFSKVV 60
 QY 61 CTRGSLSEVPQGISNTRYLMENNIOIADTFRLHLEVLQLGNSIRQIEVGFN 120
 DB 61 CTRGSLSEVPQGISNTRYLMENNIOIADTFRLHLEVLQLGNSIRQIEVGFN 120
 QY 121 GLASLSTLELFDNMLTVIPSGAFVLSKRLRLNPNPIESIPSYAFNRVPSLRLDLGE 180
 DB 121 GLASLSTLELFDNMLTVIPSGAFVLSKRLRLNPNPIESIPSYAFNRVPSLRLDLGE 180
 QY 181 LKLEYISSEGAPEGLFNLKYLNLGNCNIKMPNLTPLVGLLEEMSGNHFPETRPFSHG 240
 DB 181 LKLEYISSEGAPEGLFNLKYLNLGNCNIKMPNLTPLVGLLEEMSGNHFPETRPFSHG 240
 QY 241 LSSLKKLWVMSQVSLIERNAPDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHN 300
 DB 241 LSSLKKLWVMSQVSLIERNAPDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHN 300
 QY 301 PWCDCDILWLAWMLREYIPTNSTCCGRCHAPMHRGRYLYVEVDQASFQCSAPFINDAPR 360
 DB 301 PWCDCDILWLAWMLREYIPTNSTCCGRCHAPMHRGRYLYVEVDQASFQCSAPFINDAPR 360
 QY 361 DLNTISEGHWELKCRTPMSSVKLLNGTVLSHARHPRI SVLNDGTAFESHVLLSDTG 420
 DB 361 DLNTISEGHWELKCRTPMSSVKLLNGTVLSHARHPRI SVLNDGTAFESHVLLSDTG 420
 QY 421 VYTCMVTNVAGNSASAYLVNSTAELNLSNYSPFTTVTVEITTEISPDITTRKYKVPFTTS 480
 DB 421 VYTCMVTNVAGNSASAYLVNSTAELNLSNYSPFTTVTVEITTEISPDITTRKYKVPFTTS 480
 QY 481 TGYQPAYTSTTVLIOTTRVPKQVAVPATDITDKQTSLEDEWVKTKIIIGCFVAVTLLA 540
 DB 481 TGYQPAYTSTTVLIOTTRVPKQVAVPATDITDKQTSLEDEWVKTKIIIGCFVAVTLLA 540
 QY 541 AAMLIVFYKLRKHQRSTVTAARTVEIIQVDEIDIPAAATSAATAPSGVSGEAVLPT 600
 DB 541 AAMLIVFYKLRKHQRSTVTAARTVEIIQVDEIDIPAAATSAATAPSGVSGEAVLPT 600
 QY 601 IHDHINNTYKPAHGHWTENSLGNSLHPTVTITSEPIIIOHTKQKQVETQI 653
 DB 601 IHDHINNTYKPAHGHWTENSLGNSLHPTVTITSEPIIIOHTKQKQVETQI 653

RESULT 20

AAU18035

ID AAU18035 standard; Protein; 606 AA.

XX AC AAU18035;

XX DT 07-NOV-2001 (first entry)

XX DE Human immunoglobulin polypeptide SEQ ID No 180.

X	Immunoglobulin; signal transduction pathway protein; cancer;	PR	14-SEP-2000;	2000US-0233064.
W	antitense therapy; gene therapy; neurological disorder; renal disorder;	PR	14-SEP-2000;	2000US-0233065.
W	cardiovascular disorder; gastrointestinal disorder; pulmonary disorder;	PR	21-SEP-2000;	2000US-0234223.
W	reproductive disorder; immune system disorder; proliferative disorder;	PR	21-SEP-2000;	2000US-0234274.
W	muscular disorder.	PR	25-SEP-2000;	2000US-0234997.
S		PR	25-SEP-2000;	2000US-0234998.
X	Homo sapiens.	PR	26-SEP-2000;	2000US-0235484.
N	WO200155315-A2.	PR	27-SEP-2000;	2000US-0235834.
N		PR	27-SEP-2000;	2000US-0235836.
X		PR	29-SEP-2000;	2000US-0236327.
D		PR	29-SEP-2000;	2000US-0236367.
X		PR	29-SEP-2000;	2000US-0236368.
F		PR	29-SEP-2000;	2000US-0236369.
F		PR	29-SEP-2000;	2000US-0236370.
X		PR	02-OCT-2000;	2000US-0236802.
R		PR	02-OCT-2000;	2000US-0237037.
R		PR	02-OCT-2000;	2000US-0237038.
R		PR	02-OCT-2000;	2000US-0237039.
R		PR	02-OCT-2000;	2000US-0237040.
R		PR	13-OCT-2000;	2000US-0239335.
R		PR	13-OCT-2000;	2000US-0239337.
R		PR	20-OCT-2000;	2000US-0240960.
R		PR	20-OCT-2000;	2000US-0241221.
R		PR	20-OCT-2000;	2000US-0241785.
R		PR	20-OCT-2000;	2000US-0241786.
R		PR	20-OCT-2000;	2000US-0241787.
R		PR	20-OCT-2000;	2000US-0241808.
R		PR	20-OCT-2000;	2000US-0241809.
R		PR	20-OCT-2000;	2000US-0241826.
R		PR	01-NOV-2000;	2000US-0244517.
R		PR	08-NOV-2000;	2000US-0246474.
R		PR	08-NOV-2000;	2000US-0246475.
R		PR	08-NOV-2000;	2000US-0246476.
R		PR	08-NOV-2000;	2000US-0246477.
R		PR	08-NOV-2000;	2000US-0246478.
R		PR	08-NOV-2000;	2000US-0246523.
R		PR	08-NOV-2000;	2000US-0246524.
R		PR	08-NOV-2000;	2000US-0246525.
R		PR	08-NOV-2000;	2000US-0246526.
R		PR	08-NOV-2000;	2000US-0246527.
R		PR	08-NOV-2000;	2000US-0246532.
R		PR	08-NOV-2000;	2000US-0246609.
R		PR	08-NOV-2000;	2000US-0246610.
R		PR	08-NOV-2000;	2000US-0246611.
R		PR	08-NOV-2000;	2000US-0246613.
R		PR	17-NOV-2000;	2000US-0249207.
R		PR	17-NOV-2000;	2000US-0249208.
R		PR	17-NOV-2000;	2000US-0249209.
R		PR	17-NOV-2000;	2000US-0249210.
R		PR	17-NOV-2000;	2000US-0249211.
R		PR	17-NOV-2000;	2000US-0249212.
R		PR	17-NOV-2000;	2000US-0249213.
R		PR	17-NOV-2000;	2000US-0249214.
R		PR	17-NOV-2000;	2000US-0249215.
R		PR	17-NOV-2000;	2000US-0249216.
R		PR	17-NOV-2000;	2000US-0249217.
R		PR	17-NOV-2000;	2000US-0249218.
R		PR	17-NOV-2000;	2000US-0249244.
R		PR	17-NOV-2000;	2000US-0249245.
R		PR	17-NOV-2000;	2000US-0249264.
R		PR	17-NOV-2000;	2000US-0249265.
R		PR	17-NOV-2000;	2000US-0249297.
R		PR	17-NOV-2000;	2000US-0249299.
R		PR	17-NOV-2000;	2000US-0249300.
R		PR	01-DEC-2000;	2000US-0250160.
R		PR	01-DEC-2000;	2000US-0250391.
R		PR	05-DEC-2000;	2000US-0251030.
R		PR	05-DEC-2000;	2000US-0251988.
R		PR	05-DEC-2000;	2000US-0256719.
R		PR	06-DEC-2000;	2000US-0251479.
R		PR	08-DEC-2000;	2000US-0251856.
R		PR	08-DEC-2000;	2000US-0251868.

C nucleic acid sequences are also useful for identifying a cell or tissue
C type in a biological sample, and in forensic biology. SEX primers or
C probes are useful for detecting the presence of SEX nucleotides and for
C screening tissue cultures for contamination. Diseases that may be treated
C or prevented using SEX proteins or nucleotides include cancer (e.g.,
C colorectal carcinoma, prostate cancer), benign tumours, immune disorders
C (including autoimmune diseases, transplant rejection, allergies, AIDS),
C infections, inflammatory disorders, arthritis, haematopoietic disorders,
C skin disorders, cardiovascular disorders, atherosclerosis, restenosis,
C neurological diseases (e.g., Alzheimer's disease), trauma (e.g.,
C surgical or traumatic wounds, spinal cord injury), and skeletal
C disorders.

X	Q	Sequence	590 AA;
		Query Match	85.8%; Score 2951; DB 21; Length 590;
		Best Local Similarity	97.8%; Pred. No. 3.5e-237;
		Matches 562; Conservative	4; Mismatches 10; Indels 0; Gaps 0;
Y	1	MKLLQVTVHHHTWNAILLFFVYLTAAQVILCAIAAASAGPQNCPSVCSNCFKVV 60	
b	1	MKLLQVTVHHHTWNAILLFFVYLTAAQVILCAIAAASAGPQNCPSVCSNCFKVV 60	
Y	61	CTRGISEVPGIPSNTRYINLMENNIQIADTFRLHLEVLQIGRNSIRQIEVGAFN 120	
b	61	CTRGISEVPGIPSNTRYINLMENNIQIADTFRLHLEVLQIGRNSIRQIEVGAFN 120	
Y	121	GLASLTLELFDNLVTPISGAFYLSKRLWLNPNPIESIPSAFNRVPSLMLDLGE 180	
b	121	GLASLTLELFDNLVTPISGAFYLSKRLWLNPNPIESIPSAFNRVPSLMLDLGE 180	
Y	181	LKKLEVISGAFGLFNKLYNLGMCNIMKMPNLTPVGLBLEMSGNHFPBIRGSHG 240	
b	181	LKKLEVISGAFGLFNKLYNLGMCNIMKMPNLTPVGLBLEMSGNHFPBIRGSHG 240	
Y	241	LSSLKKLWNSQVSLIERNADGLASLVELNLANNLSSLDHDLFTPLRYLVELLHNN 300	
b	241	LSSLKKLWNSQVSLIERNADGLASLVELNLANNLSSLDHDLFTPLRYLVELLHNN 300	
Y	301	PMKCDICDLWALWREYIPTNSTCCGRCHAPMHMGRYLVEVDQASFCSCAPPIMDAPR 360	
b	301	PMKCDICDLWALWREYIPTNSTCCGRCHAPMHMGRYLVEVDQASFCSCAPPIMDAPR 360	
Y	361	DLNISGRMAELKCRTPPSSSVKXWLPNGTVLSHSHRPRISVINDGTLNFSHLLSDTG 420	
b	361	DLNISGRMAELKCRTPPSSSVKXWLPNGTVLSHSHRPRISVINDGTLNFSHLLSDTG 420	
Y	421	VYTCMTNVAAGNSAYLNVSATLNTSNISGFTTIVTVEITTEISPEDTRKYKVPVPTS 480	
b	421	VYTCMTNVAAGNSAYLNVSATLNTSNISGFTTIVTVEITTEISPEDTRKYKVPVPTS 480	
Y	481	TGQPAYTSTTVLIQTRVPKQVAVPATDITDKMOTSLDEVNKTIIIGCFVAVTLLA 540	
b	481	TGQPAYTSTTVLIQTRVPKQVAVPATDITDKMOTSLDEVNKTIIIGCFVAVTLLA 540	
Y	541	AAMLIYFKLRKHQRSTVTAARTVEIIQVBDIP 576	
b	541	AAMLIYFKLRKHQRSTVTAARTVEIIQVBDIP 576	

RESULT 22
BB10349
D ABB10349 standard; Protein; 553 AA.
X ABB10349;
X 10-JAN-2002 (first entry)
X Human cDNA SEQ ID NO: 657.
X Human; gene therapy; neural disorder; immune system disorder;
X muscular disorder; reproductive disorder; gastrointestinal disorder;
X pulmonary disorder; cardiovascular disorder; renal disorder;

XX proliferative disorder; inflammation.
XX Homo sapiens.
XX WO200154474-A2.
XX 02-AUG-2001.
XX 17-JAN-2001; 2001WO-US01349.
XX 31-JAN-2000; 2000US-179065P.
XX 04-FEB-2000; 2000US-180628P.
XX 24-FEB-2000; 2000US-184664P.
XX 02-MAR-2000; 2000US-186350P.
XX 16-MAR-2000; 2000US-189874P.
XX 17-MAR-2000; 2000US-190076P.
XX 18-APR-2000; 2000US-198123P.
XX 19-MAY-2000; 2000US-205515P.
XX 07-JUN-2000; 2000US-209467P.
XX 28-JUN-2000; 2000US-214886P.
XX 30-JUN-2000; 2000US-215135P.
XX 07-JUL-2000; 2000US-216647P.
XX 07-JUL-2000; 2000US-216880P.
XX 11-JUL-2000; 2000US-217487P.
XX 11-JUL-2000; 2000US-217496P.
XX 14-JUL-2000; 2000US-218290P.
XX 26-JUL-2000; 2000US-220963P.
XX 26-JUL-2000; 2000US-220964P.
XX 14-AUG-2000; 2000US-224518P.
XX 14-AUG-2000; 2000US-224519P.
XX 14-AUG-2000; 2000US-225213P.
XX 14-AUG-2000; 2000US-225214P.
XX 14-AUG-2000; 2000US-225266P.
XX 14-AUG-2000; 2000US-225267P.
XX 14-AUG-2000; 2000US-225268P.
XX 14-AUG-2000; 2000US-225270P.
XX 14-AUG-2000; 2000US-225447P.
XX 14-AUG-2000; 2000US-225757P.
XX 14-AUG-2000; 2000US-225758P.
XX 14-AUG-2000; 2000US-225759P.
XX 18-AUG-2000; 2000US-226279P.
XX 22-AUG-2000; 2000US-226681P.
XX 22-AUG-2000; 2000US-226686P.
XX 22-AUG-2000; 2000US-227182P.
XX 23-AUG-2000; 2000US-227009P.
XX 30-AUG-2000; 2000US-228924P.
XX 01-SEP-2000; 2000US-229287P.
XX 01-SEP-2000; 2000US-229343P.
XX 01-SEP-2000; 2000US-229344P.
XX 01-SEP-2000; 2000US-229345P.
XX 05-SEP-2000; 2000US-229509P.
XX 05-SEP-2000; 2000US-229513P.
XX 06-SEP-2000; 2000US-230437P.
XX 06-SEP-2000; 2000US-230438P.
XX 08-SEP-2000; 2000US-231242P.
XX 08-SEP-2000; 2000US-231243P.
XX 08-SEP-2000; 2000US-231244P.
XX 08-SEP-2000; 2000US-231413P.
XX 08-SEP-2000; 2000US-231414P.
XX 08-SEP-2000; 2000US-232080P.
XX 08-SEP-2000; 2000US-232081P.
XX 12-SEP-2000; 2000US-231968P.
XX 14-SEP-2000; 2000US-232397P.
XX 14-SEP-2000; 2000US-232398P.
XX 14-SEP-2000; 2000US-232399P.
XX 14-SEP-2000; 2000US-232400P.
XX 14-SEP-2000; 2000US-232401P.
XX 14-SEP-2000; 2000US-233063P.
XX 14-SEP-2000; 2000US-233064P.
XX 14-SEP-2000; 2000US-233065P.
XX 21-SEP-2000; 2000US-234223P.
XX 21-SEP-2000; 2000US-234274P.
XX 25-SEP-2000; 2000US-234937P.

PR	25-SEP-2000;	2000US-234988P.	XX	(HUMA-) HUMAN GENOME SCI INC.
PR	26-SEP-2000;	2000US-235484P.	XX	Rosen CA, Barash SC, Ruben SM;
PR	27-SEP-2000;	2000US-235834P.	XX	WPI; 2001-476161/51.
PR	29-SEP-2000;	2000US-235836P.	XX	N-PSDB; ABA06571.
PR	29-SEP-2000;	2000US-236327P.	DR	Isolated nucleic acid molecule encoding an inflammation-associated
PR	29-SEP-2000;	2000US-236367P.	PT	polypeptide is used in preventing, treating or ameliorating a medical
PR	29-SEP-2000;	2000US-236368P.	PT	condition
PR	29-SEP-2000;	2000US-236369P.	XX	Claim 11; SEQ ID NO: 657; 859pp + Sequence Listing; English.
PR	29-SEP-2000;	2000US-236370P.	PS	The present invention provides human cDNAs, proteins and related genomic
PR	02-OCT-2000;	2000US-237038P.	XX	DNA. These can be used in the treatment of neural, immune system,
PR	02-OCT-2000;	2000US-237039P.	CC	muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,
PR	13-OCT-2000;	2000US-239933P.	CC	renal and proliferative disorders and inflammation. The present sequence
PR	13-OCT-2000;	2000US-240960P.	CC	is a protein of the invention.
PR	20-OCT-2000;	2000US-241221P.	XX	Sequence 553 AA;
PR	20-OCT-2000;	2000US-241785P.	XX	Query Match 84.0%; Score 2888; DB 22; Length 553;
PR	20-OCT-2000;	2000US-241786P.	XX	Best Local Similarity 99.8%; Pred. No. 5.7e-232;
PR	20-OCT-2000;	2000US-241787P.	XX	Matches 552; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
PR	20-OCT-2000;	2000US-241808P.	XX	
PR	20-OCT-2000;	2000US-241809P.	XX	
PR	20-OCT-2000;	2000US-241826P.	XX	
PR	01-NOV-2000;	2000US-244617P.	XX	
PR	08-NOV-2000;	2000US-246474P.	QY	101 LEVLQGRNSIRQIEVGAFNGLASLNTLELFDNWLTVIPSGAFEYLSKRLRLRNPIE 160
PR	08-NOV-2000;	2000US-246475P.	DB	1 LEVLQGRNSIRQIEVGAFNGLASLNTLELFDNWLTVIPSGAFEYLSKRLRLRNPIE 60
PR	08-NOV-2000;	2000US-246476P.	QY	161 SIPSVAFNRPVSLMRLDGLGKLEIYSEGAFEGFLNKLKYNLGMKNIKMPNLTPLVGL 220
PR	08-NOV-2000;	2000US-246477P.	DB	61 SIPSVAFNRPVSLMRLDGLGKLEIYSEGAFEGFLNKLKYNLGMKNIKMPNLTPLVGL 120
PR	08-NOV-2000;	2000US-246478P.	QY	221 EELEMSGNHFPFPIRPGSPHGLSSLKLVWNSQVSLIERNAPFGLASIVELNLHNLSS 280
PR	08-NOV-2000;	2000US-246523P.	DB	121 EELEMSGNHFPFPIRPGSPHGLSSLKLVWNSQVSLIERNAPFGLASIVELNLHNLSS 180
PR	08-NOV-2000;	2000US-246524P.	QY	281 LPHDLFTPLRYLVELHLHHPNWCDDILWLAWMLREYIPTNSTCCGRCHAPMGRYL 340
PR	08-NOV-2000;	2000US-246611P.	DB	181 LPHDLFTPLRYLVELHLHHPNWCDDILWLAWMLREYIPTNSTCCGRCHAPMGRYL 240
PR	08-NOV-2000;	2000US-246613P.	QY	341 VEVDQASPCQCAPFIMDAPRDNISSEGMALCKRTPPMSSVKVLLPNTGTVLSHSHPR 400
PR	17-NOV-2000;	2000US-249207P.	DB	241 VEVDQASPCQCAPFIMDAPRDNISSEGMALCKRTPPMSSVKVLLPNTGTVLSHSHPR 300
PR	17-NOV-2000;	2000US-249208P.	QY	401 ISVLNDGTLNFSHLLSDTGYTCMTNNAAGNSASAYLVNSTAELNLSYSPFTTIVE 460
PR	17-NOV-2000;	2000US-249210P.	DB	301 ISVLNDGTLNFSHLLSDTGYTCMTNNAAGNSASAYLVNSTAELNLSYSPFTTIVE 360
PR	17-NOV-2000;	2000US-249211P.	QY	461 TTEISPEDTTRKYKVPVPTTSTGYQPAYTSTTVLIQTRVPKQAVPATDTRDKQTSLD 520
PR	17-NOV-2000;	2000US-249212P.	DB	361 TTEISPEDTTRKYKVPVPTTSTGYQPAYTSTTVLIQTRVPKQAVPATDTRDKQTSLD 420
PR	17-NOV-2000;	2000US-249213P.	QY	521 EVMKTKIIIGCFVAVTLAAAMLIFFVKLRKHQORSTVTAARTVEIIQVDEIDIPAATS 580
PR	17-NOV-2000;	2000US-249244P.	DB	421 EVMKTKIIIGCFVAVTLAAAMLIFFVKLRKHQORSTVTAARTVEIIQVDEIDIPAATS 480
PR	17-NOV-2000;	2000US-249245P.	QY	581 AAATAAPSGVSGEAVLPTTHDHINNYNTPKAGAHWTENSLGNSLHPTVTITSEPVII 640
PR	17-NOV-2000;	2000US-249255P.	DB	481 AAATAAPSGVSGEAVLPTTHDHINNYNTPKAGAHWTENSLGNSLHPTVTITSEPVII 540
PR	17-NOV-2000;	2000US-249257P.	QY	641 QTHTKDKVQETQI 653
PR	17-NOV-2000;	2000US-249259P.	DB	541 QTHTKDKVQETQI 553
PR	17-NOV-2000;	2000US-249260P.	XX	RESULT 23
PR	01-DEC-2000;	2000US-249300P.	XX	ABP66936
PR	01-DEC-2000;	2000US-250160P.	XX	ID ABP66936 standard; Protein; 553 AA.
PR	01-DEC-2000;	2000US-250391P.	XX	AC ABP66936;
PR	05-DEC-2000;	2000US-250391P.	XX	
PR	05-DEC-2000;	2000US-251988P.	XX	
PR	05-DEC-2000;	2000US-256719P.	XX	
PR	06-DEC-2000;	2000US-251479P.	XX	
PR	06-DEC-2000;	2000US-251856P.	XX	
PR	08-DEC-2000;	2000US-251868P.	XX	
PR	08-DEC-2000;	2000US-251869P.	XX	
PR	08-DEC-2000;	2000US-251989P.	XX	
PR	08-DEC-2000;	2000US-251990P.	XX	
PR	11-DEC-2000;	2000US-254037P.	XX	
PR	05-JAN-2001;	2001US-259678P.	XX	

T 09-DEC-2002 (first entry)
X Human polypeptide SEQ ID NO 657.
E
X Human, neotropic; neuroprotective; cytostatic; dermatological; virucide;
W immunosuppressive; anti-inflammatory; anti-HIV; antibacterial; vulnerary;
W antiparkinsonian; antiskilling; antianaemic; antirheumatic; cancer;
W antirheumatic; hepatotropic; cerebroprotective; antiinflammatory;
W antiallergic; antidiabetic; antitumor; anticonvulsant; antifungal;
W antiparasitic; cardiac; immune disorder; cardiovascular disorder;
W neurological disease; infection; nephrotropic; gene therapy; vaccine.
K
K Homo sapiens.
S
V US2002090672-A1.
Y
D 11-JUL-2002.
C
P 17-JAN-2001; 2001US-0764853.
K
K 31-JAN-2000; 2000US-179065P.
R 04-FEB-2000; 2000US-180628P.
R 28-JUN-2000; 2000US-214986P.
R 07-JUL-2000; 2000US-216647P.
R 07-JUL-2000; 2000US-216980P.
R 11-JUL-2000; 2000US-217487P.
R 11-JUL-2000; 2000US-217496P.
R 14-JUL-2000; 2000US-218290P.
R 26-JUL-2000; 2000US-220963P.
R 26-JUL-2000; 2000US-224518P.
R 14-AUG-2000; 2000US-224519P.
R 14-AUG-2000; 2000US-225267P.
R 14-AUG-2000; 2000US-225268P.
R 14-AUG-2000; 2000US-225270P.
R 14-AUG-2000; 2000US-225447P.
R 14-AUG-2000; 2000US-225757P.
R 14-AUG-2000; 2000US-225758P.
R 22-AUG-2000; 2000US-226868P.
R 30-AUG-2000; 2000US-228924P.
R 01-SEP-2000; 2000US-229287P.
R 01-SEP-2000; 2000US-229343P.
R 01-SEP-2000; 2000US-229344P.
R 01-SEP-2000; 2000US-229345P.
R 05-SEP-2000; 2000US-229509P.
R 05-SEP-2000; 2000US-229513P.
R 08-SEP-2000; 2000US-231413P.
R 21-SEP-2000; 2000US-234223P.
R 21-SEP-2000; 2000US-234274P.
R 25-SEP-2000; 2000US-234997P.
R 27-SEP-2000; 2000US-235834P.
R 29-SEP-2000; 2000US-236327P.
R 29-SEP-2000; 2000US-236367P.
R 29-SEP-2000; 2000US-236368P.
R 29-SEP-2000; 2000US-236369P.
R 29-SEP-2000; 2000US-236370P.
R 02-OCT-2000; 2000US-236802P.
R 02-OCT-2000; 2000US-237037P.
R 02-OCT-2000; 2000US-237038P.
R 02-OCT-2000; 2000US-237039P.
R 13-OCT-2000; 2000US-237040P.
R 13-OCT-2000; 2000US-239335P.
R 20-OCT-2000; 2000US-240960P.
R 20-OCT-2000; 2000US-241785P.
R 20-OCT-2000; 2000US-241809P.
R 01-NOV-2000; 2000US-244517P.
R 17-NOV-2000; 2000US-249299P.
R 08-DEC-2000; 2000US-251856P.
R 08-DEC-2000; 2000US-251869P.
R 08-DEC-2000; 2000US-251869P.
A (ROSE/) ROSEN C A.
A (RUBE/) RUBEN S M.

PA (BARA/) BARASH S C.
XX Rosen CA, Ruben SM, Barash SC;
XX WPI; 2002-691727/73.
DR N-PSDB; ABV83908.
XX
XX Novel polypeptide useful for diagnosis, prognosis, prevention, and
XX treatment of immune, hyperproliferative, renal, respiratory, and
XX cardiovascular, reproductive, endocrine, gastrointestinal and
XX neurological disorders -
XX
XX Claim 11; SEQ ID NO 657; 369pp + Sequence Listing; English.
XX
XX The invention relates to novel genes (ABV83682-ABV84101) and proteins
XX (ABP6710-ABP67129) useful for preventing, treating or ameliorating
XX medical conditions e.g. by protein or gene therapy. The genes are
XX isolated from a range of human tissues disclosed in the specification.
XX The nucleic acids, proteins, antibodies and (ant)agonists are useful
XX in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
XX and ovarian cancer and other cancers of the adrenal gland, bone, bone
XX marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
XX (b) immune disorders e.g. Addison's disease, allergies, autoimmune
XX haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
XX disease, multiple sclerosis, rheumatoid arthritis and ulcerative
XX colitis; (c) cardiovascular disorders such as myocardial ischaemias;
XX (d) wound healing; (e) neurological diseases e.g. cerebral anoxia and
XX epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
XX and parasitic infections.
XX Note: The sequence data for this patent did not form part of the
XX printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
XX SQ Sequence 553 AA;

Query Match 84.0%; Score 2888; DB 23; Length 553;
Best Local Similarity 99.8%; Pred. No. 5.7e-232;
Matches 552; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 101 LEVLQIGRNSIRQIEVGAFNGLASLNTLEFDNWLTVIPSGAFYLSKRLRLNNPIE 160
DB 1 LEVLQIGRNSIRQIEVGAFNGLASLNTLEFDNWLTVIPSGAFYLSKRLRLNNPIE 60
QY 161 SIPSVAFNRPVPSLMELDLGELKLEIYISEGAFEGFLNKLNLGMCNKDKPNLTPVLGL 220
DB 61 SIPSVAFNRPVPSLMELDLGELKLEIYISEGAFEGFLNKLNLGMCNKDKPNLTPVLGL 120
QY 221 BELEMSGNHFFPIRPGSFHGLSSLLKLVWMSQVSLIERNAFDGLASIVELNLAHNNLSS 280
DB 121 BELEMSGNHFFPIRPGSFHGLSSLLKLVWMSQVSLIERNAFDGLASIVELNLAHNNLSS 180
QY 281 LPHDLFTPLRYLVLELHLENPNWDCDILWLAWMLREYIPTNSTCCGCHAPMEMRGYRL 340
DB 181 LPHDLFTPLRYLVLELHLENPNWDCDILWLAWMLREYIPTNSTCCGCHAPMEMRGYRL 240
QY 341 VEVDQASQCQSAFFIMDAPDLINISEGRMAELKCRTPPMSSVKWLLPNGTVLSHSHRPR 400
DB 241 VEVDQASQCQSAFFIMDAPDLINISEGRMAELKCRTPPMSSVKWLLPNGTVLSHSHRPR 300
QY 401 ISVLNDGTLNPSHVLISDTGYTCMTNVAGNSASAYLVNSTAEIANTSNYSFETTVTVE 460
DB 301 ISVLNDGTLNPSHVLISDTGYTCMTNVAGNSASAYLVNSTAEIANTSNYSFETTVTVE 360
QY 461 TTEISPEDTTRKYKFPVPTTSTGYQPAYTTTSTVLIQTTRVPEKQAVPATDTTDMQTSLD 520
DB 361 TTEISPEDTTRKYKFPVPTTSTGYQPAYTTTSTVLIQTTRVPEKQAVPATDTTDMQTSLD 420
QY 521 EVMKTKIIIGCFVAVTLAAAMLIVFKLKRKQQRSTVTAARTVHIIQVDEDIIPAATS 580
DB 421 EVMKTKIIIGCFVAVTLAAAMLIVFKLKRKQQRSTVTAARTVHIIQVDEDIIPAATS 480
QY 581 AAATAAPSGVSGEAVLPTLTHDHNNTYKPAHAHNTENSLGNSLHPTVTTSISEVII 640
DB 581 AAATAAPSGVSGEAVLPTLTHDHNNTYKPAHAHNTENSLGNSLHPTVTTSISEVII 640

Db 481 AAATAAPSGVGEAGVVLPTTHDHNINVTYKPAHGAHWHTENSLNHLPTVTITSPYII 540
QY 641 QTHHKVKVQETQI 553
Db 541 QTHHKVKVQETQI 553

RESULT 24
AAB23044
ID AAB23044 standard; Protein; 448 AA.
AC AAB23044;
JT 16-JAN-2001 (first entry)
QX Human SLIT protein-like splice variant, SECX 3352358-S153A.
DE
QX SECX protein; human; secreted; membrane-associated; cancer;
KW proliferation regulator; differentiation regulator; non-malignant tumour;
KW immune disorder; autoimmune disease; transplant rejection; allergy; AIDS;
KW infection; inflammatory disorder; arthritis; haematopoietic disorder;
KW skin disorder; cardiovascular disorder; atherosclerosis; restenosis;
KW neurological disease; Alzheimer's disease; trauma; wounding;
KW spinal cord injury; skeletal disorder; cytostatic; immunosuppressive;
KW anti-HIV; antiinflammatory; antiarthritic; antiarteriosclerotic;
KW neuroprotective; vulnerary; antiallergic; antimicrobial; cardiant;
KW dermatological; gene therapy.
XX Homo sapiens.
OS
XX WO200053742-A2.
XX 14-SEP-2000.
XX 09-MAR-2000; 2000MO-US06280.
XX 09-MAR-1999; 99US-0123667.
XX 08-MAR-2000; 2000US-0123667.
XX (CURA-) CURAGEN CORP.
PA
PI Shimkets RA;
XX WPI; 2000-594318/56.
XX N-PSDB; AAA93631.
DR Novel human membrane associated or secreted polypeptides and
PT polynucleotides useful for diagnosis, prevention and treatment of
PT pathological states such as cancer, immune, cardiovascular and
PT neurological disorders
PS Claim 1; Fig 17B; 151pp; English.
XX
XX Sequences AAB23029-B3048 represent human SECX proteins. The SECX
CC proteins of the invention are either secreted or membrane-associated
CC proteins and act as regulator of cellular proliferation and
CC differentiation. SECX proteins or nucleotides are useful for diagnosing
CC the presence of, or predisposition to, a disease associated with altered
CC levels of SECX proteins and nucleotides. The SECX proteins are also
CC useful to screen compounds that modulate SECX activity or expression. The
CC interaction of a SECX protein with other cellular proteins may be useful
CC to modulate the activity of a partner protein, cellular proliferation,
CC cellular differentiation and cell survival. SECX nucleotides are useful
CC for the recombinant expression of SECX protein, and may be used to detect
CC SECX mRNA or genetic lesions in the SECX gene. They may also be used to
CC modulate SECX expression (e.g., using antisense oligonucleotides). SECX
CC nucleic acid sequences are also useful for identifying a cell or tissue
CC type in a biological sample, and in forensic biology. SECX primers or
CC probes are useful for detecting the presence of SECX nucleotides and for
CC screening tissue cultures for contamination. Diseases that may be treated
CC or prevented using SECX proteins or nucleotides include cancer (e.g.,
CC colorectal carcinoma, prostate cancer), benign tumours, immune disorders
CC (including autoimmune diseases, transplant rejection, allergies, AIDS),

CC infections, inflammatory disorders, arthritis, haematopoietic disorders,
CC skin disorders, cardiovascular disorders, atherosclerosis, restenosis,
CC neurological diseases (e.g., Alzheimer's disease), trauma (e.g.,
CC surgical or traumatic wounds, spinal cord injury), and skeletal
CC disorders.
XX
SQ Sequence 448 AA;
Query Match 69.4%; Score 2389; DB 21; Length 448;
Best Local Similarity 100.0%; Pred. No. 1.8e-190;
Matches 448; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 45 NCPVSCSCSNQFQSVCTRRGLSEVPQGIQADTFRLHLHLEVL 104
Db 1 NCPVSCSCSNQFQSVCTRRGLSEVPQGIQADTFRLHLHLEVL 60
QY 105 QUGRNSIRQIEVGAFNGLASLNTLELFDNMLTVIPSGAFYLSKRLRLWLNPNPIESIPS 164
Db 61 QUGRNSIRQIEVGAFNGLASLNTLELFDNMLTVIPSGAFYLSKRLRLWLNPNPIESIPS 120
QY 165 YAFNRVPSLMRLDGLKLEYISGAFEGFLNLYLNLCMKIKOMPNTLPLVGLLELE 224
Db 121 YAFNRVPSLMRLDGLKLEYISGAFEGFLNLYLNLCMKIKOMPNTLPLVGLLELE 180
QY 225 YSGNHFFPIRPGSFHGLSSKLLKLVWMSQVSLIERNAPDGLASLVELNLAHNNLSLPHD 284
Db 181 YSGNHFFPIRPGSFHGLSSKLLKLVWMSQVSLIERNAPDGLASLVELNLAHNNLSLPHD 240
QY 285 LFTPLRYLVELHLHNPWNCDDILNLAWLREVIPTNSTCCGCHAPMGRGYLVEVD 344
Db 241 LFTPLRYLVELHLHNPWNCDDILNLAWLREVIPTNSTCCGCHAPMGRGYLVEVD 300
QY 345 QASFOCSAPFTMDAPRDLNISEGRMAELKCTPTPMSSVKMLLPNGTVLSHARPRISVL 404
Db 301 QASFOCSAPFTMDAPRDLNISEGRMAELKCTPTPMSSVKMLLPNGTVLSHARPRISVL 360
QY 405 NDGTLNFSHLLSDTGVTTCMTVNVAGNSASAVLNSTAEINTSNYSFPTVTVEI 464
Db 361 NDGTLNFSHLLSDTGVTTCMTVNVAGNSASAVLNSTAEINTSNYSFPTVTVEI 420
QY 465 SPEDTRKYKVPVTTSTGQPAYTTSTT 492
Db 421 SPEDTRKYKVPVTTSTGQPAYTTSTT 448

RESULT 25
AAB43091
ID AAB43091 standard; Protein; 441 AA.
XX
AC AAB43091;
XX
DT 08-FEB-2001 (first entry)
XX
XX Human ORFX ORP2855 polypeptide sequence SEQ ID NO:5710.
DE
XX Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;
KW vulnerary; antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
KW anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;
KW immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
KW hypotensive; dermatological; immunosuppressive; antiinflammatory;
KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
KW antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
KW neurodegenerative disorder; osteoarthritis; graft vs host disease;
KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
KW cholesterol ester storage; systemic lupus erythematosus; infection;
KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
KW bone damage; cartilage damage; antiinflammatory disease; coagulation;
KW thrombosis; contraceptive.
XX
XX Homo sapiens.
OS
XX WO200058473-A2.
PN

X 05-OCT-2000.
D 31-MAR-2000; 2000WO-US08621.
E 31-MAR-1999; 99US-0127607.
F 02-APR-1999; 99US-0127636.
G 05-APR-1999; 99US-0127728.
H 30-MAR-2000; 2000US-0540763.
I (CURA-) CURAGEN CORP.
J Shinkets RA, Leach M;
K WPI; 2000-602362/57.
L N-PSDB; AAC77300.
M Novel nucleic acids and peptides derived from open reading frame X,
N useful for treating e.g. cancers, proliferative open disorders,
O neurodegenerative disorders and cardiovascular disease -
P Claim 11; Page 4877-4878; 5507pp; English.
Q AAC77446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,
R which represent the human ORFX open reading frames 1 to 3161. The ORFX
S sequences have activities such as: cytostatic; hepatotropic; vulnary;
T antiproliferative; antiparkinsonian; neurotropic; neuroprotective;
U osteoprotective; anticonvulsant; antiarthritic; immunosuppressant;
V immunostimulant; cardiant; thrombolytic; coagulant; vasotrophic;
W anti-diabetic; hypotensive; dermatological; immunosuppressive;
X antifungal; antitubercular; antiviral; antifungal; antirheumatic;
Y antithyroid; and antianemic. The sequences can be used for determining
Z the presence of or predisposition to, or preventing or treating
AA pathological conditions associated with an ORFX-associated disorder. The
AB nucleic acids can be used to express ORFX proteins in gene therapy
AC vectors. The proteins and nucleic acids may be used to treat cancers,
AD proliferative disorders, neurodegenerative disorders, osteoarthritis,
AE graft vs host disease, cardiovascular disease, diabetes mellitus,
AF hypertension, hypothyroidism, cholesterol ester storage, systemic lupus
AG erythematosus, severe combined immunodeficiency (SCID), AIDS, viral,
AH bacterial or fungal infection, malaria, autoimmune disorders, asthma,
AI allergies, aplastic anaemia, burns, wounds, bone and cartilage damage,
AJ nocturnal haemoglobinuria, anti-inflammatory disease; to enhance
AK coagulation; to inhibit thrombosis; and as a contraceptive.
AL Sequence 441 AA;
AM
AN Query Match 67.2%; Score 2312; DB 21; Length 441;
AO Best Local Similarity 99.5%; Pred. No. 4.6e-184;
AP Matches 439; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
AQ
AR 213 NLTPLVGLEELMSGNHPPPEIRPGSFHGLSLKLLVWNSQVSLIERNAPDGLASLVELN 272
AS 1 NLTPLVGLEELMSGNHPPPEIRPGSFHGLSLKLLVWNSQVSLIERNAPDGLASLVELN 60
AT 273 LAPNNLSLPHDLFTPLRYLVHLLHNPWNCDDILWLAWLREYIPTNSTCCGRCHAP 332
AU 61 LAPNNLSLPHDLFTPLRYLVHLLHNPWNCDDILWLAWLREYIPTNSTCCGRCHAP 120
AV 333 MEMRGYLVVEVDQASQCSAPPIMDAPDLNISEGRMAELKCRTPPMSSVKKWLLPNTVL 392
AW 121 MEMRGYLVVEVDQASQCSAPPIMDAPDLNISEGRMAELKCRTPPMSSVKKWLLPNTVL 180
AX 393 SHASRHPRIISLVNDGTLNFSHVLLSDTGYTCMTNVNAGNSNAYLNVSFAELNTSNYS 452
AY 181 SHASRHPRIISLVNDGTLNFSHVLLSDTGYTCMTNVNAGNSNAYLNVSFAELNTSNYS 240
AZ 453 FFTVTVTETISPDFTTRKYPVTTSTGTQPAYTSTTVLQITTRVPKQVAPATDTT 512
BA 241 FFTVTVTETISPDFTTRKYPVTTSTGTQPAYTSTTVLQITTRVPKQVAPATDTT 300
BB 513 DKMQTSLDEVMTTKIIIGCFVAVTLLAAAMLIVFYKLRKHQRSTVTAARTVEIIQVD 572

Db 301 DKMQTSLDEVMTTKIIIGCFVAVTLLAAAMLIVFYKLRKHQRSTVTAARTVEIIQVD 360
Qy 573 EDIPAAATSAATAAPSGVSGGAVVLPITHHINVTYKPAHGAHWNTENSIGNSLHPVT 632
Db 361 EDIPAAATSAATAAPSGVSGGAVVLPITHHINVTYKPAHGAHWNTENSIGNSLHPVT 420
Qy 633 TISEPYIIQTHTKDKVQSTQI 653
Db 421 TISEPYIIQTHTKDKVQSTQI 441
RESULT 26
AAE13006
ID AAE13006 standard; Protein; 713 AA.
XX
XX AAE13006;
XX
DT 28-JAN-2002 (first entry)
XX Human leucine-rich repeat (LRR) family member protein.
DE Human leucine-rich repeat (LRR) family member protein.
XX
XX Human; leucine-rich repeat; LRR; 31939 protein; therapy;
KW cell proliferation; differentiation disorder; cancer; neuronal disorder;
KW neurological disorder; demyelinating disease; multiple sclerosis;
KW degenerative disease; Alzheimer's disease; Huntington's disease;
KW spinocerebellar degeneration; nervous system; bone disorder; diabetes mellitus;
KW osteoporosis; immune disorder; rheumatoid arthritis; diabetes mellitus;
KW cardiovascular disorder; liver disorder; viral disease; pain;
KW metabolic disorder; chromosomal mapping; tissue typing; forensic biology;
KW cytostatic; neurotropic; neuroprotective; anticonvulsant; osteopathic;
KW antirheumatic; antiarthritic; virucide; analgesic.
XX Homo sapiens.
OS
XX
FH Key Location/Qualifiers
FT 1..38 /label= Signal_peptide
FT Protein 39..713 /note= "Mature human 31939 protein"
FT Domain 56..85 /label= N-terminal_LRR_domain
FT Domain 87..110 /label= LRR_domain
FT Domain 111..134 /label= LRR_domain
FT Domain 135..158 /label= LRR_domain
FT Domain 159..182 /label= LRR_domain
FT Domain 183..207 /label= LRR_domain
FT Domain 208..229 /label= LRR_domain
FT Domain 230..253 /label= LRR_domain
FT Domain 254..277 /label= LRR_domain
FT Domain 278..301 /label= LRR_domain
FT Domain 311..362 /label= C-terminal_LRR_domain
FT Domain 378..438 /label= Immunoglobulin_domain
FT
XX WO200175105-A2.
XX
XX 11-OCT-2001.
XX
XX 30-MAR-2001; 2001WO-US10380.
XX
XX 31-MAR-2000; 2000US-193919P.
XX
XX (MILL-) MILLENNIUM PHARM INC.
PA

Q Sequence 713 AA;
 Query Match 56.1%; Score 1931; DB 23; Length 713;
 Best Local Similarity 56.3%; Pred. No. 5.8e-152;
 Matches 379; Conservative 94; Mismatches 151; Indels 49; Gaps 9;
 Y 30 ILCAATAAASAGPQNCPSVCSNQFSKVCVTRGLSEVPQIPSNTRYLNLMENNIQM 89
 b 41 VAVTSAAGGSPATSCPVACSCNQASRVICTREDLAEPASIPVNTRYLNQENGIVQ 100
 Y 90 IQADTPRHHLHLEVLQGRNSIQIEVGAFNGLASINTLELFDNWLTVIPSGAFYLSKL 149
 b 101 IRTDTPKHLHLEILQSKNLVKIEVGAFNGLPSTNLELFDNWLTVIPSGAFYLSKL 160
 Y 150 RELMLRNNPIESIPYAFNRVPSLRMLDLGELKLEYISEGAFGLFNLYLNLMGNK 209
 b 161 RELMLRNNPIESIPYAFNRVPSLRMLDLGELKLEYISEGAFGLFNLYLNLMGNK 220
 Y 210 DMENLTPLVLEELSGNHFPPIRPGSFHGLSSKLKLVNNSQVSLIERNAPDGLASLV 269
 b 221 DIPNLTAIVLRELELSGNRLDILRPGSQGLTSRLKWLMAHQVATIERNAFDLKSLE 280
 Y 270 ELNLAHNNLSLPHDLFTFLRYLVELHLHNPWNCDDILMLAWLREYIPTNSTCCGRC 329
 b 281 ELNLSHNNLSLPHDLFTFLHRLERVHLNHPWNCDDVLSWMLKETVPSNTTCCARC 340
 Y 330 HAPMEHRCYLYEVDOASQCSAPTIMDAPRLINSEGMALCKRT-PPMSSVYKLLPN 388
 b 341 HAPAGUKGRIYIGELDQSHFTCYAPVIVEPTDLNTEGMAALCKRTGTSVNVMLTPN 400
 Y 389 GTVLSHASHPRIASVLNDGTLNFSVLLSDTGVTTCWNTNAGNSAGAYLNVSATL-- 446
 b 401 GTLWTHGSYRVRISVLHDGTLNFTAVTQDTGTYTCWNTNAGNTTASATLNVSAVDPA 460
 Y 447 -----NTSNYSFPTVTVTETIEISPDT-----TRKPKVPTT-- 479
 b 461 AGGTGSGGGGPGSGGSGGGGTYFTTFTVTETIEISPDT-----TRKPKVPTT-- 520
 Y 480 -----SRGYOPAVTSTTVLIQTR-VFKQVAVPATDITDKMTSLDVMKTKIIG 531
 b 521 VNGGCPGDAAGPASTTAPAPRSRPTKAPFTVPTDVTENALKDLDDYKTKIIG 580
 Y 532 CFVAVTLAALMIVPKYKQHQRSSTVAARTVEIIVQVEDIPAAAT-----SAATPA 586
 b 581 CFVAITPFAAVMLVAFYKLRQHQHGHGPTRTVEIINVEDLPAASAVSAAVAAS 640
 Y 587 PSVSGEGAVLPTI-HDHINTY-KPAHGAHTENSIGNSL----HPTVTTISEPVII 640
 b 641 GGVGSDSHALPALERDLNHHYVAAFRARYSNPSGGCGKGPPGLNSIHEPLF 700
 Y 641 QTHTKDKVQETQI 653
 b 701 KSGSKENVQETQI 713

RESULT 28
 A091335
 X AAU91335 standard; Protein; 713 AA.
 X AAU91335;
 X 18-JUN-2002 (first entry)
 X Human novel secreted protein LP223(a).
 X Human; secreted protein; cancer; autoimmune disease;
 X arthritis; osteoporosis; Alzheimer's disease; Parkinson's disease;
 X meningitis; encephalitis; neoplasia; trauma; ischaemia; infarction;
 X mania; stroke; cardiovascular disease; atherosclerosis; sepsis; anaemia;
 X rheumatoid arthritis; hypothyroidism; allergic response; liver failure;
 X multiple sclerosis; haemorrhage; paranoia; obsessive compulsive disorder;
 X autism; panic disorder; learning disability; feeding disorder;
 X sleep pattern disorder; balance; perception; Th1-dependent insulinitis;

XX adult respiratory distress syndrome; ARDS.
 XX Homo sapiens.
 XX WO200214358-A2.
 XX 21-FEB-2002.
 XX 30-JUL-2001; 2001WO-US21124.
 XX 11-AUG-2000; 2000US-224642P.
 XX 19-OCT-2000; 2000US-241779P.
 XX (ELIL) LILLY & CO ELI.
 XX Edmonds BT, Micanovic R, Ou W, Su EW, Tschang SR, Wang H;
 XX WPI; 2002-304057/34.
 XX N-PSDB; ABK62087.
 XX Novel polypeptides and polynucleotides of secreted proteins useful for
 XX treating various diseases such as multiple sclerosis, cancer,
 XX autoimmune diseases, osteoporosis, Alzheimer's disease and Parkinson's
 XX disease.
 XX Claim 9; Page 200-203; 235pp; English.
 XX The invention relates to a novel human secreted polypeptide having
 XX sequence 90% identical to the polypeptide sequences of LP105, LP061,
 XX LP224, LP240, LP239(a), LP243(a), LP253(b), LP258, LP218, LP251(a),
 XX LP252, LP239(b), LP223(a), LP255(a), LP244, LP186, LP251(b), LP255(b),
 XX or LP223(b). Also included are the nucleic acids encoding the LP
 XX proteins (including complement, fragments encoding mature forms of the
 XX polypeptide or variant), a vector comprising the nucleic acid, a
 XX host cell comprising the vector, the preparation of the protein,
 XX an anti-LP antibody, ant/agonists of LP and anti-LP-encoding mRNA,
 XX ribozymes. The secreted protein or its agonist is useful in the
 XX manufacture of a medicament for treating a mammal suffering from a
 XX disease (and in diagnosis), condition or disorder associated with
 XX aberrant levels of the secreted protein e.g. cancer, autoimmune diseases,
 XX arthritis, osteoporosis, Alzheimer's disease, Parkinson's disease,
 XX meningitis, encephalitis, neoplasia, trauma, ischaemia and infarction,
 XX mania, stroke, cardiovascular disease, atherosclerosis, rheumatoid
 XX arthritis, hypothyroidism, anaemia, sepsis, allergic responses, multiple
 XX sclerosis, liver failure, haemorrhages, paranoia, obsessive compulsive
 XX disorder, autism, panic disorder, learning disabilities, ALS
 XX (amyotrophic lateral sclerosis) psychoses, disorders in feeding,
 XX sleep patterns, balance, and perception, Th1-dependent insulinitis, adult
 XX respiratory distress syndrome (ARDS). The secreted protein is further
 XX useful for identifying compounds that bind to the secreted protein. The
 XX present sequence represents a novel secreted protein of the invention.

XX Sequence 713 AA;
 Query Match 56.1%; Score 1931; DB 23; Length 713;
 Best Local Similarity 56.3%; Pred. No. 5.8e-152;
 Matches 379; Conservative 94; Mismatches 151; Indels 49; Gaps 9;
 QY 30 ILCAATAAASAGPQNCPSVCSNQFSKVCVTRGLSEVPQIPSNTRYLNLMENNIQM 89
 DB 41 VAVTSAAGGSPATSCPVACSCNQASRVICTREDLAEPASIPVNTRYLNQENGIVQ 100
 QY 90 IQADTPRHHLHLEVLQGRNSIQIEVGAFNGLASINTLELFDNWLTVIPSGAFYLSKL 149
 DB 101 IRTDTPKHLHLEILQSKNLVKIEVGAFNGLPSTNLELFDNWLTVIPSGAFYLSKL 160
 QY 150 RELMLRNNPIESIPYAFNRVPSLRMLDLGELKLEYISEGAFGLFNLYLNLMGNK 209
 DB 161 RELMLRNNPIESIPYAFNRVPSLRMLDLGELKLEYISEGAFGLFNLYLNLMGNK 220
 QY 210 DMENLTPLVLEELSGNHFPPIRPGSFHGLSSKLKLVNNSQVSLIERNAPDGLASLV 269
 DB 221 DIPNLTAIVLRELELSGNRLDILRPGSQGLTSRLKWLMAHQVATIERNAFDLKSLE 280

Qy	270	ELNLAHNNLSLPHDLFTPLRYLYVELHLHHPNCDILWLAKWLEBYIPTMSTCCGRC	329
Dd	281	ELNLSHNLLNSLPDHLFPLRLERLVRHLNHFNHCNCVILWLSGWLKETVPSTTCCARC	340
Qy	330	HAPMHMRGYLYEVDQAQSFCAPSPPINDAPRDLNISGRMAELKCRIT-PPMSYVKWLLPN	388
Dd	341	HAPAGLGKRYIGELDOSHTCYAPVIVPEPPTDLNVTEGMAAELKCRITGSTSVNMLTEN	400
Qy	389	GTVLGHASRRPRISVLNDGTILNFSHLLSDTGVTTCWTVNAGNSNASAVLNYSIAEL--	446
Dd	401	GLIMTHGSYRVVISLADGTILNFNTVQDTICQTCTWTNSAGNTATLASATLVNSAVDPVA	460
Qy	447	-----NTSNYSFFTTVTVEITE:SPEDT-----TRKYKPVEPT--	479
Dd	461	AGGTSGGGGPGGGGGGVGGGVTYFTVTVTETLETCPGEERALQPRGTEKEPPGPTDG	520
Qy	480	-----STGYOPAYTTSTFVLIOCTR-VPKQAVAPATDDTKMQISLDEVMKTKIILG	531
Dd	521	VMGGRGPCDAGPASSSTTAPAPSSRPTEKAFTVPIIDVTENALKDLLDDWKTKIILG	580
Qy	532	CFVAVTLAAAMLIVFYKLKRKHQRSTVTTAARTVEIIQVDEDIPAAT-----SAAATAA	586
Dd	581	CFVAITFWAAVNLVAFYKLRKHQHJHKHGSETRTVEIINVEDELPAASA VSAVAAA AAVAS	640
Qy	587	PSGVSGEGAVVLPTI-HDHINYNY-KPAHGCHWTENS LGNSL----HPTVTITISEPYII	640
Dd	641	GGVGGDGSHALPALERDHLNHHHYVAAFKAHYSSNPSCGGCGKGKPPOLINSIHPLIF	700
Qy	641	QPTHKDKVOEQTI 653	
Dd	701	KSGSKENVQEQTI 713	
RESULT 29			
ABU52381			
ID	ABU52381 standard; Protein; 713 AA.		
XX	AC ABU52381;		
XX	AC AC		
XX	DT DT		
XX	XX XX		
DE	Human GPCR related protein NOV31a.		
XX	Human; NOX; G-protein coupled receptor; GPCR; cancer; cytotstatic.		
XX	Homo sapiens.		
PX	WC200279398-A2.		
PD	10-OCT-2002.		
PF	08-MAR-2002; 2002WO-US07355.		
XX	08-MAR-2001; 2001US-274194P.		
PR	08-MAR-2001; 2001US-274281P.		
PR	08-MAR-2001; 2001US-274322P.		
PR	09-MAR-2001; 2001US-274849P.		
PR	13-MAR-2001; 2001US-275578P.		
PR	13-MAR-2001; 2001US-275579P.		
PR	13-MAR-2001; 2001US-275601P.		
PR	14-MAR-2001; 2001US-276000P.		
PR	16-MAR-2001; 2001US-276776P.		
PR	19-MAR-2001; 2001US-276994P.		
PR	20-MAR-2001; 2001US-277239P.		
PR	20-MAR-2001; 2001US-277327P.		
PR	20-MAR-2001; 2001US-277338P.		
PR	21-MAR-2001; 2001US-277791P.		
PR	22-MAR-2001; 2001US-277833P.		
PR	23-MAR-2001; 2001US-278152P.		
PR	26-MAR-2001; 2001US-278894P.		
PR	27-MAR-2001; 2001US-278999P.		
PR	27-MAR-2001; 2001US-279036P.		

Db 263 FDLQSLVEINLAHNNLTLPHDLFTPLHLHLRHLHHPNPNKNCIDLMLSWIKWAPS 322
 QY 322 NSTCCGRCHAPMGRYLVVDQASFOCSAPFFIMDAPRLINISEGRMAELKCR-TTPMS 380
 Db 323 NTACCARCNTPEMLKGRVIGELDQNYFTCYAPVIVEPPADLVNTEGMAELKCRASLT 382
 QY 381 SVKLLPNTGTVLASHAPRISVLNDGTLNFSVLLSDTGYTCMTNVAAGNSAYLN 440
 Db 383 SVSWITPNTGTVLASHAPRISVLNDGTLNFSVLLSDTGYTCMTNVAAGNSAYLN 442
 QY 441 VSTALNTSNYSFFTTVTVEITEISPED---TTRKYPVP-----TTSTGYQPAYTTST 492
 Db 443 VTAA--TTTPSYESTVTVETMBPSQDEARTDNNVGPFPVWDEITNV-----TTSLT 494
 QY 493 VLIQTR-VPKQAVPATDFTDKMOTSLDEVMKTKIIIGCFVAVTLLAAMLIYFKLR 551
 Db 495 P--QSTRSTKFTIPVTDINSGL-PGIDEVMKTKIIIGCFVAVTLLAAMLIYFKLR 551
 QY 552 KRHOQRSTVTAARTVELIIOVDEDEIPAAATAAPSGVSEGAVALPTI-HDHIN-YNT 609
 Db 552 KQHRQNHAPTRIVEIINVDDEITGTPM-----ESHLPMPALEHEHLNHS 600
 QY 610 YKPAHGAHTENSGLNHLPTVTITISEPYIIQHTKDKVQETQI 653
 Db 601 YKSPFNHTTWTI-NSIH---SSVHEPLLRMSKDNVQETQI 640

RESULT 31

AAW85722
 ID AAW85722 standard; Protein; 640 AA.
 AC AAW85722;
 DT 27-SEP-1999 (first entry)
 XX Novel protein (Clone AS209_1).
 KW Polynucleotide; protein; nutrition; cytokine; cell proliferation;
 KW cell differentiation; immunostimulation; immunosuppression;
 KW haematopoiesis regulation; tissue growth; activin; inhibin;
 KW chemotaxis; chemokinesis; haemostasis; thrombolysis; receptor;
 KW ligand; anti-inflammatory; tumour suppression; gene therapy.
 XS Homo sapiens.
 PN WO9920644-A1.
 PD 29-APR-1999.
 PF 16-OCT-1998; 98WO-US22034.
 PX 18-OCT-1997; 97US-0955557.
 PR (GENY) GENETICS INST INC.
 PA Agostino MJ, Bowman MR, Evans C, Jacobs K, Lavallie ER;
 PI McCoy JM, Merberg D, Racie LA, Spaulding V, Treacy M;
 XX WPI; 1999-288272/24.
 DR N-PSDB; AAX08687.
 XX New polynucleotides encoding secreted human proteins
 PS Claim 26; Page 109-111; 136pp; English.
 XX The new human secreted proteins are encoded by polynucleotides
 CC obtained from human placenta, adult testes, fetal kidney, fetal
 CC brain, adult brain, adult brain and adult blood cDNA libraries.
 CC The polynucleotides and proteins are predicted to have biological
 CC activities which would make them suitable for treating, preventing or
 CC ameliorating medical conditions in humans and animals. Suggested
 CC activities include nutritional activity, cytokine and cell
 CC proliferation/differentiation activity, immune stimulating (e.g. as

CC vaccines) or suppressing activity, haematopoiesis regulating
 CC activity, tissue growth activity, activin/inhibin activity,
 CC chemotactic/chemokinetic activity, haemostatic and thrombotic
 CC activity, receptor/ligand activity, anti-inflammatory activity,
 CC cadherin/tumour invasion suppressor activity, and tumour inhibition
 CC activity. The polynucleotides are also stated to be useful for gene
 CC therapy. The sequences identified by a secretory leader
 CC sequence motif in the polynucleotide and it is thought that the
 CC encoded proteins have biological activity by virtue of their secreted
 CC nature. This polypeptide was encoded by a clone designated AS209_1
 CC (See AAX08687).
 XX
 SQ Sequence 640 AA;
 Query Match 54.2%; Score 1865; DB 20; Length 640;
 Best Local Similarity 56.4%; Pred. No. 1.6e-146;
 Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;
 QY 22 VYLAQWILCAATAAASAGPQPCSVCSNOFSKVCVTRRGLSEVPQGIPTNRYLN 81
 Db 29 VLLALQLLVAGLVRA-----QTCPSVCSNOFSKVICURKMLREVPGISTNRYLN 82
 QY 82 LMENNIQIADTFRHLHLLEVLQLGRLNSIRQISVGFNGLASLNTLELFDNMLTVIPSG 141
 Db 83 LHEMQIILKVNSEFKLHLLEILQLSRNLHRTIEIGAFNGLANLTLELFDNRLTTPNG 142
 QY 142 AFEYLSKRLRLWLNRPESIPSYAFNRPVSLMELDLGELKCLSVTISEGAPEGLNLYL 201
 Db 143 APVYLSKRLWLNRPESIPSYAFNRPVSLMELDLGELKCLSVTISEGAPEGLNLYL 202
 QY 202 NLGMCNTKDMENLTPLVGLBELENSGNHFPPEIRPGSPHGLSSLLKLMWMSQVSLIERNA 261
 Db 203 NLAMCNLRBEINLTPLIKLDELDSLGNLSAIRPGSPHGLMHLQKLMWMSQVSLIERNA 262
 QY 262 FDGLASLVELLAENLSSLPDLFTPLRYLVELHLHHPNPNKNCIDLMLSWIKWAPS 321
 Db 263 FDLQSLVEINLAHNNLTLPHDLFTPLHLHLRHLHHPNPNKNCIDLMLSWIKWAPS 322
 QY 322 NSTCCGRCHAPMGRYLVVDQASFOCSAPFFIMDAPRLINISEGRMAELKCR-TTPMS 380
 Db 323 NTACCARCNTPEMLKGRVIGELDQNYFTCYAPVIVEPPADLVNTEGMAELKCRASLT 382
 QY 381 SVKLLPNTGTVLASHAPRISVLNDGTLNFSVLLSDTGYTCMTNVAAGNSAYLN 440
 Db 383 SVSWITPNTGTVLASHAPRISVLNDGTLNFSVLLSDTGYTCMTNVAAGNSAYLN 442
 QY 441 VSTALNTSNYSFFTTVTVEITEISPED---TTRKYPVP-----TTSTGYQPAYTTST 492
 Db 443 VTAA--TTTPSYESTVTVETMBPSQDEARTDNNVGPFPVWDEITNV-----TTSLT 494
 QY 493 VLIQTR-VPKQAVPATDFTDKMOTSLDEVMKTKIIIGCFVAVTLLAAMLIYFKLR 551
 Db 495 P--QSTRSTKFTIPVTDINSGL-PGIDEVMKTKIIIGCFVAVTLLAAMLIYFKLR 551
 QY 552 KRHOQRSTVTAARTVELIIOVDEDEIPAAATAAPSGVSEGAVALPTI-HDHIN-YNT 609
 Db 552 KQHRQNHAPTRIVEIINVDDEITGTPM-----ESHLPMPALEHEHLNHS 600
 QY 610 YKPAHGAHTENSGLNHLPTVTITISEPYIIQHTKDKVQETQI 653
 Db 601 YKSPFNHTTWTI-NSIH---SSVHEPLLRMSKDNVQETQI 640

RESULT 32

AAV13394
 ID AAV13394 standard; Protein; 640 AA.
 XX AAV13394;
 XX 25-JUN-1999 (first entry)
 XX Amino acid sequence of protein PRO331.
 DE Amino acid sequence of protein PRO331.
 XX

W thyroiditis; Grave's disease; demyelinating disease; multiple sclerosis;
W Crohn's disease; hepatobiliary disease; hepatitis; asthma; human;
W graft-versus-host-disease.

Key	Location/Qualifiers
Modified-site	40..46
Modified-site	/note= "N-myristoylation site"
Modified-site	73..79
Modified-site	/note= "N-myristoylation site"
Modified-site	118..124
Modified-site	/note= "N-myristoylation site"
Modified-site	183..187
Modified-site	/note= "cAMP and cGMP-dependent protein kinase phosphorylation site"
Modified-site	191..197
Modified-site	/note= "N-myristoylation site"
Modified-site	228..234
Modified-site	/note= "N-myristoylation site"
Modified-site	237..243
Modified-site	/note= "N-myristoylation site"
Modified-site	268..272
Modified-site	/note= "Casein Kinase II phosphorylation site"
Modified-site	278..282
Modified-site	/note= "N-glycosylation site"
Modified-site	364..368
Modified-site	/note= "N-glycosylation site"
Modified-site	390..394
Modified-site	/note= "N-glycosylation site"
Modified-site	391..397
Modified-site	/note= "N-myristoylation site"
Modified-site	412..416
Modified-site	/note= "N-glycosylation site"
Modified-site	415..419
Modified-site	/note= "N-glycosylation site"
Modified-site	417..421
Modified-site	/note= "Casein Kinase II phosphorylation site"
Modified-site	422..428
Modified-site	/note= "N-myristoylation site"
Modified-site	433..439
Modified-site	/note= "N-myristoylation site"
Modified-site	434..438
Modified-site	/note= "N-glycosylation site"
Modified-site	442..446
Modified-site	/note= "N-glycosylation site"
Modified-site	465..469
Modified-site	/note= "Casein Kinase II phosphorylation site"
Modified-site	488..492
Modified-site	/note= "N-glycosylation site"
Modified-site	531..537
Modified-site	/note= "N-myristoylation site"
Modified-site	579..583
Modified-site	/note= "Casein Kinase II phosphorylation site"
Modified-site	606..610
Modified-site	/note= "N-glycosylation site"
Modified-site	620..624
Modified-site	/note= "Casein Kinase II phosphorylation site"

DR N-PSDB; RAZ52207.
XX
XX
PT Composition for treatment and diagnosis of immune related diseases e.g.
PT GrA's disease comprises a PRO225 PRO17 PRO301 PRO266 PRO335
PT PRO331 or PRO336 polypeptide or its agonists or antagonists (preferably
XX antibodies) -
XX
PS Example 1; Fig 14; 201bp; English.

Query Match	54.2%	Score 1865;	DB 21;	Length 640;
Best Local Similarity	56.4%;	Pred. No. 1.6e-146;		
Matches 363;	Conservative 107;	Mismatches 130;	Indels 44;	Gaps 14;
QY	22	VYLTAQWILCAAATAAASAGPQPCVSCSNQFSKQVWCTRGSLSEVPQGISPSNRYLN	81	
Db	29	VLLALQLLWVAGLVRA-----QTCPSVCSCSNQFSKVICVRKQLREVPGDISNTRLN	82	
QY	82	LNENMIOMIQADTFPHLHLEVLQLGNSRTOIEVGFAGFGLASIAITLLELPDWLWITVPSG	141	
Db	83	LHENQIQIIKYNVSFKGHUHEIQLGSNNHIRTTEIGAPNGLANLNTLELFDNRLTTIPNG	144	
QY	142	APFYLSKLRLWLNNPIETSPSYAFNRVPSLMRLDLGELKKLEYISEGAFGLPNLKYL	201	
Db	143	APFYLSKLKLWLNNPIETSPSYAFNRIPSLARLDLGLKRLSVISEGAFGLSNRLYL	202	
QY	202	NLCGMNIKDMNLTPLVGLGHELEKSNHFPETPGSPFHGLSSIKKLWVWNSOVSLIERNA	261	
Db	203	NLACNLKRLIFNLTPFLGLDELDLSGNHLSAIPGFSQGLMHLQKLWLIQSOIQVIENA	262	
QY	262	PDGLASLYELNLAHNNLSSLPDHLFTPLRYLVELHLHHPNRCDDCILMLAWLREYIPT	321	
Db	263	FNQLQSLVEIILAHNNLTLPDHLFTPLHLELRIHLHHPNRCNCDILWLSWIIKDMAPS	322	
QY	322	NSTCGCRCHAPMHMRGYLVEVDQASQCSAPPIMDAPRDLMISGRMAELKCR--TPPMS	380	
Db	323	NFACCARCNUTPNLKGRIYIGELQNYFTCYAPVIVPEPPADLVNTEGMAELKCRASLT	382	
QY	381	SVKWLPLNGTVLASHRHPKISVLNDGTINPSSHVLSDGTGVTTGMVTVAGNSNASVYN	440	
Db	383	SVSWITPNTGTVMTGAYKVIKIAVLSDGTINFTVTVQDGTMYTCVNSVGNVTTASATLN	442	
QY	441	VSTALNTSNYSFFTVTVVETHTISPD-----TTRKYKVPV-----TTSYGQFAYTTSTT	492	
Db	443	VTAA--TTPPSYESTVTVETMPSQDBARTDNNVGPVPVWDVETNV-----TTSLT	494	
QY	493	VLIQTR--VPQVAVPATDITDKMOTSLDEWMTKIIIGCVAVTLLAAAMLVPEYKLR	551	
Db	495	P--QSTRSTETFTPTVDINSGI--PGIDDEWMTKIIIGCVFVAILTMAVMLVIFYKMR	551	
QY	552	KKHQORSVTWTAARTVEIIVQDEIDIPAATSAATAAPSGVSGEAGVLPIT--HDHIN--YNT	609	
Db	552	KOHRONHAPTRVETIIVNDDDEITGDTM-----ESHLPMPAIEHHLNHYNS	600	

QY 610 YPAKGAUKWENSLNLSHTPTTISBPIYIQTHTKDKVQTOI 653
DB 601 YKSPFNHTTWTI-NSIH---SSVHEPLLIRMSKDNVQTOI 640

RESULT 35
AAU12355
ID AAU12355 standard; Protein; 640 AA.
AC AAU12355;
XX 24-OCT-2001 (first entry)
XX Human PRO331 polypeptide sequence.

XX Human secretory and transmembrane; PRO; mammalian; cancer; lung;
XX breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
XX cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
XX adipocyte; A-peptide; factor VIIA; gene therapy.
XX Homo sapiens.
XX WO20010466-A2.
XX 07-JUN-2001.
XX 01-DEC-2000; 2000WO-US32678.
XX 01-DEC-1999; 99WO-US28301.
XX 01-DEC-1999; 99WO-US28634.
XX 02-DEC-1999; 99WO-US28551.
XX 02-DEC-1999; 99WO-US28564.
XX 02-DEC-1999; 99WO-US28565.
XX 09-DEC-1999; 99US-0170262.
XX 16-DEC-1999; 99WO-US30095.
XX 20-DEC-1999; 99WO-US30911.
XX 20-DEC-1999; 99WO-US30999.
XX 30-DEC-1999; 99WO-US31243.
XX 06-JAN-2000; 2000WO-US00277.
XX 06-JAN-2000; 2000WO-US00376.
XX 11-FEB-2000; 2000WO-US03565.
XX 18-FEB-2000; 2000WO-US04341.
XX 18-FEB-2000; 2000WO-US04342.
XX 22-FEB-2000; 2000WO-US04414.
XX 24-FEB-2000; 2000WO-US04914.
XX 24-FEB-2000; 2000WO-US05004.
XX 01-MAR-2000; 2000WO-US05601.
XX 20-MAR-2000; 2000WO-US07377.
XX 21-MAR-2000; 2000WO-US07532.
XX 30-MAR-2000; 2000WO-US08439.
XX 17-MAY-2000; 2000WO-US13705.
XX 22-MAY-2000; 2000WO-US14042.
XX 30-MAY-2000; 2000WO-US14941.
XX 02-JUN-2000; 2000WO-US15264.
XX 10-NOV-2000; 2000WO-US30873.
XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood W, Zhang Z;
XX WPI; 2001-408281/43.
XX N-PSDB; AAS21427.

XX Isolated, secretory and transmembrane PRO polypeptide used to detect
XX other PRO polypeptides, link bioactive molecules to cells expressing
XX PRO polypeptides, and detect the presence of mammalian tumours e.g.
XX lung, breast, prostate, cervical -
XX Claim 12; Fig 368; 813pp; English.

CC AAU12172-AAU12446 represent novel human secretory and transmembrane
CC PRO polypeptides. The PRO polypeptides are useful to detect other
CC PRO polypeptides, to link bioactive molecules to cells expressing
CC PRO polypeptides, to modulate biological activities of cells expressing
CC PRO polypeptides, and to detect the presence of mammalian lung, colon,
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC polypeptide expression in a cell sample to that in a control sample.
CC Some of the 275 sequences are also useful to stimulate the release of
CC tumour necrosis factor-alpha (TNF-alpha) from human blood, the
CC proliferation or differentiation of chondrocytes, the proliferation or
CC gene expression in pericyte cells, the release of proteoglycans from
CC cartilage, the proliferation of inner ear utricular supporting cells or
CC of T-lymphocytes, the release of a cytokine from peripheral blood
CC monocytes (PBMCs), or the proliferation of endothelial cells. Some of
CC the PRO polypeptides may modulate glucose or free fatty acid uptake by
CC skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide
CC to factor VIIA. The PRO polypeptides can be used in assays to identify
CC molecules involved in binding interactions. The polynucleotides encoding
CC PRO polypeptides can be used to generate probes, antisense RNA/DNA,
CC transgenic or knock out animals and can be used in gene therapy.
XX
SQ Sequence 640 AA;

Query Match 54.2%; Score 1865; DB 22; Length 640;
Best Local Similarity 56.4%; Pred. No. 1,6e-146;
Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;
QY 22 VYLTAQWILCAAIAAASAGPQNCPSVCSNCSNFSKVVTTRRGLSEVQDQIPNTRYLN 81
DB 29 VLLALQLLVAGLVRA-----QTCPSCVCSNCSNFSKVICVRKNLREYDPDGISTRILN 82
QY 82 IMENNIQMTQADTFERHLEVLQIGRNSIRQIEVGAFLASLNTLLELFONLWTVIPSG 141
DB 83 LHENGIOIIVKNSFXHLRHEILQSRNHIETIEGAFLANLNTLELFONLWTVIPSG 142
QY 142 AFEYLSKLELMRLNNPIESIPSYAFNRVPSLMRLDLGELKLEYISEGAFEGFLNLYL 201
DB 143 AFVYLSKLELMRLNNPIESIPSYAFNRVPSLMRLDLGELKLEYISEGAFEGFLNLYL 202
QY 202 NLGCMKIMKMNLTPLVGLLELEMSGNHFFRPGSFGLSLKGLWMSQVSLIERNA 261
DB 203 NLAMCNLRIPNLTLPLKDELDSGNHLSAIRPGSFGLSLKGLWMSQVSLIERNA 262
QY 262 FDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHNPWNCDCDILWLAWLREYIPT 321
DB 263 FNLQSLVELNLAHNLTLLPHDLFTPLHLEIRHLHNPWNCDCDILWLSWIKDAPS 322
QY 322 NSTCCGRCHAPMHMGRYLVVDQASFOCSAPFINDAPRDLNISEGRVAKLCR-TPPMS 380
DB 323 NTACCACNTPPNLKRGYIGELDONFTCYAPVIVEPPADLNVTEGMAELKCRASLTSLT 382
QY 381 SVKLLPNCGTVLSHASRRHPRISVANDGTINPSHVLSDTVVTCMTNVAGNSASAYLN 440
DB 383 SVSWITPNCGTVMTHGAYKVRIDVLDGGLNFNTVQDTGYTCNVSVNGVNTASATLN 442
QY 441 VSTAELNTSNYSFPTTIVTETTESPED---TTRKYKVPV-----TSTGYQPAVTTSTT 492
DB 443 VTAA--TTTFFSVFSTVTVETMEPSODEARTDNNVGPVVDVETINV-----TTSLT 494
QY 493 VLIQTR-VPKQVAPATDTTDMQTSLEVMKTKIILGCFVAVTLAAAMLIVFYKLR 551
DB 495 P--QSTRSEKTFPTIPVTDINSIGI-PGIDEVMKTKIILGCFVAVTLAAAMLIVFYKLR 551
QY 552 KRHQRSVTVAARTVEIIQVDEDIIPAATAAAPSQVSGEAGVVLPTI-HDHIN-VNT 609
DB 552 KOHRQNHAPRTVEIINVDEITGTPM-----ESHLPMPAIEHEHLNHYNS 600
QY 610 YKPAHAHTEHNSLNSLHPTTITSEPIYIQTHTKDKVQTOI 653
DB 601 YKSPFNHTTWTI-NSIH---SSVHEPLLIRMSKDNVQTOI 640

AAU00826
 AAU00826 standard; Protein; 640 AA.
 AAU00826;
 04-JUL-2001 (first entry)
 Human immune response protein PRO331 (UNQ292).
 Human; PRO331; UNQ292; immune response; osteoarthritis;
 systemic lupus erythematosus; rheumatoid arthritis; systemic sclerosis;
 juvenile chronic arthritis; spondyloarthropathy; Sjogren's syndrome;
 idiopathic inflammatory myopathy; polymyositis; systemic vasculitis;
 sarcoidosis; autoimmune haemolytic anaemia; immune pancytopenia;
 autoimmune thrombocytopenia; idiopathic thrombocytopenic purpura;
 thyroiditis; Grave's disease; Hashimoto's thyroiditis;
 diabetes mellitus; glomerulonephritis; demyelinating disease;
 multiple sclerosis; Guillain-Barre syndrome; hepatobiliary disease;
 chronic inflammatory demyelinating polyneuropathy; infectious hepatitis;
 auto immune chronic active hepatitis; primary biliary cirrhosis;
 granulomatous hepatitis; sclerosing cholangitis; ulcerative colitis;
 inflammatory bowel disease; Crohn's disease; Whipple's disease;
 erythema multiforme; psoriasis; asthma; allergic rhinitis; urticaria;
 food hypersensitivity; eosinophilic pneumonia; graft rejection;
 idiopathic pulmonary fibrosis; graft-versus-host-disease; immunogen;
 antibody.
 Homo sapiens.
 S X
 X X
 H H
 Key Location/Qualifiers
 Peptide 1..44
 Modified-site 40..45 /label= Signal_peptide
 Protein 45..640 /note= "Glycine is N-myristoylated"
 Modified-site 73..79 /label= Mature_PRO331
 Modified-site 118..124 /note= "Glycine is N-myristoylated"
 Region 183..187 /note= "Glycine at 118 is N-myristoylated"
 Modified-site 228..234 /label= Phosphorylation site
 Modified-site 237..243 /note= "CAMP/cGMP dependent protein kinase phosphorylation site"
 Modified-site 278..282 /note= "Glycine at 191 is N-myristoylated"
 Modified-site 288..294 /note= "Glycine is N-myristoylated"
 Modified-site 337..343 /note= "Glycine is N-myristoylated"
 Modified-site 364..368 /note= "Asn is N-glycosylated"
 Modified-site 390..394 /note= "Asn is N-glycosylated"
 Modified-site 391..397 /note= "Asn is N-glycosylated"
 Modified-site 412..416 /note= "Glycine at 391 is N-myristoylated"
 Modified-site 415..419 /note= "Asn is N-glycosylated"
 Modified-site 422..428 /note= "Asn is N-glycosylated"
 Modified-site 433..439 /note= "Glycine is N-myristoylated"
 Modified-site 434..438 /note= "Glycine is N-myristoylated"
 Modified-site 442..446 /note= "Asn is N-glycosylated"
 Modified-site 488..492 /note= "Asn is N-glycosylated"
 Modified-site 528..543 /note= "Asn is N-glycosylated"
 Domain

PT /label= Transmembrane_domain
 FT 531..537 /note= "Glycine is N-myristoylated"
 FT 606..610 /note= "Asn is N-glycosylated"
 XX
 XX WO200119991-A1.
 XX 22-MAR-2001.
 XX 20-MAR-2000; 2000WO-US07377.
 XX 15-SEP-1999; 99WO-US21547.
 XX (GETH) GENENTECH INC.
 PI Fong S, Goddard A, Gurney AL, Hillan KJ, Tumas D, Wood WI;
 DR WPI; 2001-226823/23.
 DR N-PSDB; AAS00162.
 XX Composition for diagnosing and treating immune related diseases, e.g.
 PT rheumatoid arthritis and diabetes mellitus, comprises a PRO
 FT polypeptide, agonist, antagonist or fragment -
 XX
 XX Claim 31; Fig 12; 136pp; English.
 CC The sequence represents Human PRO331 (UNQ292), a protein involved in
 CC the immune response. PRO polypeptides, and (ant)agonists to them, are
 CC used in compositions for modulating infiltration of inflammatory cells
 CC into a tissue, modulating an immune response and modulating proliferation
 CC of T-lymphocytes in response to an antigen. Immune related diseases can
 CC be treated with the compositions, such as, systemic lupus erythematosus,
 CC rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis,
 CC spondyloarthropathies, systemic sclerosis, idiopathic inflammatory
 CC myopathies (e.g. polymyositis), Sjogren's syndrome, systemic vasculitis,
 CC sarcoidosis, autoimmune haemolytic anaemia (e.g. immune pancytopenia),
 CC autoimmune thrombocytopenia (e.g. idiopathic thrombocytopenic purpura),
 CC thyroiditis (e.g. Grave's disease, Hashimoto's thyroiditis), diabetes
 CC mellitus, immune-mediated renal disease (e.g. glomerulonephritis),
 CC demyelinating diseases of the central and peripheral nervous systems e.g.
 CC multiple sclerosis or Guillain-Barre syndrome, and chronic inflammatory
 CC demyelinating polyneuropathy, hepatobiliary diseases such as infectious
 CC hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses),
 CC auto immune chronic active hepatitis, primary biliary cirrhosis,
 CC granulomatous hepatitis, and sclerosing cholangitis, inflammatory bowel
 CC disease (ulcerative colitis, Crohn's disease and Whipple's disease),
 CC autoimmune or immune-mediated skin diseases (e.g. erythema
 CC multiforme or psoriasis), asthma, allergic rhinitis, urticaria,
 CC food hypersensitivity, immunologic diseases of the lung such as
 CC eosinophilic pneumonias, idiopathic pulmonary fibrosis, transplantation
 CC associated diseases including graft-versus-host-disease and graft
 CC rejection. PRO polypeptides can be used to diagnose immune related
 CC diseases, to identify inhibitors, and to stimulate the proliferation of
 CC T lymphocytes. Anti-PRO antibodies can be used to detect PRO and
 CC in diagnosis. PRO polypeptides, antibodies and (ant)agonists can be used
 CC in rational drug design.

XX Sequence 640 AA;

Query Match 54.2%; Score 1865; DB 22; Length 640;
 Best Local Similarity 56.4%; Pred. No. 1.6e-146;
 Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;

QY 22 VYLAQWILCAIAAASAGPQNCSCNPFQKVCRTGRLSEVPQIGIPNRYLN 81
 DB 29 VLLALQLLVAGLVRA-----QTCPSVCSNPFQKVCRTGRLSEVPQIGIPNRYLN 82
 QY 82 LMENNIQIADTPRHLLHLEVLQGRNSIRQIEVAFNGIASINTLELFDNLTIPSG 141
 DB 83 LHENQIQLIKVNSFKHLRHLLEILQLSNHIETIEIGAFNGLANLTLELFDNLTIPSG 142
 QY 142 APFYLSKILRELNRNPISIPSYAFNRVPSLMRLDGLKLELISEGAFGLFNLKYL 201

495 P--QSTRSTKTIPTIPIVDINSGL-PCIDEVMKTKIIIGCFVAITLMAAVMLVIFYKOR 551
 552 KRHOORSTVTAARTVEIIQVDEIPAAATSAATAAPSGVSGAVVLPPI-HDHIN-YNT 609
 552 KQHRQNHAPHTVTEIIVDDITGDTM-----ESLPMPEAIEHEHLNHYNS 600
 610 YKPAHGAHWTEKSLNLSLHPTVTIIEBPYIIQTHVKVQVETQI 653
 601 YKSPFNHTTIVNTI-NSIH---SSVEHPLLIRWNSKDNVQETQI 640

ESULT 38
 AAB5292 standard; Protein; 640 AA.
 AAB65292;

02-APR-2001 (first entry)
 Human PRO331 protein sequence SEQ ID NO:501.
 Human; secreted and transmembrane protein; PRO; cytostatic;
 cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
 diagnostic assay.
 Homo sapiens.
 WO2000073454-A1.
 07-DEC-2000.
 30-MAR-2000; 2000WO-US08439.

02-JUN-1999; 99WO-US12252.
 23-JUN-1999; 99US-0141037.
 07-JUL-1999; 99US-0143048.
 20-JUL-1999; 99US-0144758.
 26-JUL-1999; 99US-0145698.
 28-JUL-1999; 99US-0146222.
 17-AUG-1999; 99US-0149396.
 15-SEP-1999; 99WO-US21547.
 08-OCT-1999; 99US-0158663.
 30-NOV-1999; 99WO-US28313.
 01-DEC-1999; 99WO-US28301.
 16-DEC-1999; 99WO-US30095.
 20-DEC-1999; 99WO-US30911.
 05-JAN-2000; 2000WO-US00219.
 06-JAN-2000; 2000WO-US00376.
 11-FEB-2000; 2000WO-US03565.
 18-FEB-2000; 2000WO-US04341.
 22-FEB-2000; 2000WO-US04414.
 24-FEB-2000; 2000WO-US04914.
 24-FEB-2000; 2000WO-US05004.
 02-MAR-2000; 2000WO-US05841.
 15-MAR-2000; 2000WO-US06884.
 20-MAR-2000; 2000WO-US07377.

(GETH) GENENTECH INC.
 Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 Grimaldi CU, Gurney AL, Kijavini IG, Napier MA, Pan J, Paoni NF;
 Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 Zhang Z;
 WPI: 2001-032160/04.
 N-PSDB; AAF44261.

PRO polynucleotides used to produce polypeptides used to target
 bioactive molecules such as toxins, radiolabels or antibodies, to
 specific cells, to cause targeted cell death -

XX Claim 12; Fig 314; 935pp; English.
 PX The present invention describes human secreted and transmembrane PRO
 CC proteins. The PRO proteins have cytostatic activity. The PRO proteins
 CC can be used for targeted delivery of bioactive molecules, such as
 CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
 CC sequences, and their fragments, can be used as hybridization probes, in
 CC chromosomal and gene mapping, and in the generation of anti-sense RNA
 CC and DNA. They may also be used to produce transgenic animals which are
 CC used to develop and screen therapeutically useful reagents. The PRO
 CC nucleotide and protein sequence can be used for tissue typing and in
 CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
 CC AAF44270 to AAF4470 represent PCR primers and hybridization probes used
 CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and
 CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein
 CC sequences given in the exemplification of the present invention.
 XX Sequence 640 AA;
 SQ
 Query Match 54.2%; Score 1865; DB 22; Length 640;
 Best Local Similarity 56.4%; Pred. No. 1.6e-146;
 Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;
 QY 22 VYTAQWILCAIAAASAGPQNCSPQSCNORQKVVCTRGSLSEVPQGIPTNYLN 81
 DB 29 VLLAQLLVAVGLVRA-----QTCPSVCSQSPKSVCKRKNREVDPGISTNLLN 82
 QY 82 LMENNIQMIQADTFRIHLHLEVLQIARNSIRQIEVGAFNGSLASLNTLELDFNWLTVIPSG 141
 DB 83 LHENQIQIKVNSFKHLHLEILQLSRNIHTTEIGAFNGSLANLNTLELDFNLTTPNG 142
 QY 142 AFYLSKLRHLWLNNDPIESIPYAFNRPVSLRDLGLKLELYISEGAFEGLENLYL 201
 DB 143 AFYLSKLRHLWLNNDPIESIPYAFNRPVSLRDLGLKLELYISEGAFEGLENLYL 202
 QY 202 NLGMCNIKMPNLTPLVGLRELEMSGNHFEIRPGFPHGLSSLKCLWVWNSQVSLIERNA 261
 DB 203 NLAMCNREIPNLTPLIKLDELDSGNLSAIRPGSQGLMHLQKLWMIQSQIQUIERNA 262
 QY 262 FDGLASLVEINLAHNLSLPHDLFTPLRYLVLHLHNPWNCDCOILMLAWLREYIPT 321
 DB 263 FDNQLSLVEINLAHNLSLPHDLFTPLRYLVLHLHNPWNCDCOILMLAWLREYIPT 322
 QY 322 NSTCGGCHAPMHRGELYVEVQASQCSAPFTMDAPDLNISEGRMAELKCR-TTPMS 380
 DB 323 NTACARCNTPPNLKGRYIGELDONIFYCYAPVIVEPPADLVTEGMAELKCEASTSLT 382
 QY 381 SVKMLLPNGTVLSHARHPRIISVLNDGTLNPSHLLSDGTGVTCTMTNVAAGNSAYLN 440
 DB 383 SVSWITPNTGTVMTGAVKVRIVLSDGTLNFTNVTQDTGMYTCWNSVGNNTASATLN 442
 QY 441 VSTAEIATSNYSPTTWTVTETLSPED---TTRKYPVP-----TTSTGYQPAYTSTT 492
 DB 443 VTAA--TTTPESTFTVTETMPEPSQDEARTDNNVGTTPVDWETINV-----TTSLT 494
 QY 493 VLIQTR-VPKQAVAPATDTTDRKMTSLDEVMKTKIIIGCFVAVTLLAAMLVIFVKLR 551
 DB 495 P--QSTRSTKTIPTIPIVDINSGL-PCIDEVMKTKIIIGCFVAVTLLAAMLVIFVKLR 551
 QY 552 KRHOORSTVTAARTVEIIQVDEIPAAATSAATAAPSGVSGAVVLPPI-HDHIN-YNT 609
 DB 552 KQHRQNHAPHTVTEIIVDDITGDTM-----ESLPMPEAIEHEHLNHYNS 600
 QY 610 YKPAHGAHWTEKSLNLSLHPTVTIIEBPYIIQTHVKVQVETQI 653
 DB 601 YKSPFNHTTIVNTI-NSIH---SSVEHPLLIRWNSKDNVQETQI 640

RESULT 39
 AAB53089
 ID AAB53089 standard; Protein; 640 AA.
 XX

AA853089;
28-FEB-2001 (first entry)
Human angiogenesis-associated protein PRO331, SEQ ID NO:137.
Human; angiogenesis-associated protein; PRO; endothelial cell growth;
cardiac hypertrophy; cardiovascular disorder; endothelial disorder;
angiogenic disorder; atherosclerosis; osteoporosis; hypertension;
myocardial infarction; diabetic retinopathy; rheumatoid arthritis;
Crohn's disease; psoriasis; endometriosis; ulcer; wound healing; cancer;
Alzheimer's disease; Huntington's disease; stroke; drug screening;
gene therapy; transgenic animal.
Homo sapiens.
WO200053753-A2.
14-SEP-2000.
05-JAN-2000; 2000WO-US00219.
08-MAR-1999; 99WO-US05028.
12-MAR-1999; 99US-0123957.
14-MAY-1999; 99US-0134287.
02-JUN-1999; 99WO-US12252.
23-JUN-1999; 99US-0141037.
20-JUL-1999; 99US-0144758.
26-JUL-1999; 99US-0145698.
01-SEP-1999; 99WO-US20111.
08-SEP-1999; 99WO-US20594.
15-SEP-1999; 99WO-US21090.
15-SEP-1999; 99WO-US21547.
15-SEP-1999; 99WO-US23089.
30-NOV-1999; 99WO-US28313.
02-DEC-1999; 99WO-US28409.
02-DEC-1999; 99WO-US28564.
02-DEC-1999; 99WO-US28565.
(GETH) GENENTECH INC.
Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Goddard A;
Godowski PJ, Gurney AL, Hillan KJ, Kuo SS, Mark MR, Marsters SA;
Paoni NF, Pitti RM, Watanabe CK, Williams PM, Wood WI;
WPI: 2001-090793/10.
N-PSDB; AAC97475.
New isolated nucleic acid for producing a PRO polypeptide, analyzing
genetic disorders and treating cardiovascular, endothelial or
angiogenic disorders, such as atherosclerosis, wounds or cancer -
Claim 69; Fig 52; 293pp; English.
The invention relates to novel human angiogenesis-associated proteins
designated PRO proteins (AA853064-B53097), and to nucleic acids encoding
PRO proteins. The invention also relates to vectors and host cells
comprising a PRO nucleic acid, the recombinant production of a PRO
protein, PRO antibodies specific for a PRO protein, fusion proteins
comprising a PRO protein, agonists or antagonists of a PRO protein, and
compounds which inhibit the expression of a PRO gene. The invention
additionally encompasses methods of identifying modulators of PRO
expression or activity; diagnosing a cardiovascular, endothelial or
angiogenic disorder, or a susceptibility to such a disorder by detecting
mutations in a PRO gene, or the expression level of a PRO gene within a
particular tissue; treating a cardiovascular, endothelial or angiogenic
disorder via the administration of a PRO protein, PRO nucleic acid, or
PRO agonist or antagonist; a retroviral gene therapy vector comprising a
PRO nucleic acid; and methods of inhibiting or stimulating endothelial
cell growth, cardiac hypertrophy or PRO-induced angiogenesis via the
administration of a PRO protein, or an agonist or antagonist thereof.
PRO nucleic acids, PRO proteins, antibodies against PRO proteins, PRO
agonists and PRO antagonists may be used as therapeutic agents to treat

cardiovascular, endothelial or angiogenic disorders, such as
atherosclerosis, osteoporosis, myocardial infarction, hypertension,
diabetic retinopathy, rheumatoid arthritis, Crohn's disease, psoriasis,
endometriosis, ulcers, wounds, cancer, Alzheimer's disease, Huntington's
disease, or stroke. PRO nucleic acids are additionally useful in the
recombinant production of PRO proteins, as hybridisation probes to
screen libraries to isolate cDNAs with sequence identity to PRO proteins,
to map genes encoding PRO proteins, to analyse genetic disorders and in
gene therapy. PRO nucleic acids can also be used to produce transgenic
animals useful for the development and screening of potential
therapeutic agents. The present sequence represents a PRO protein of the
invention.
XX Sequence 640 AA;
SQ
Query Match 54.2%; Score 1865; DB 22; Length 640;
Best Local Similarity 56.4%; Pred. No. 1.6e-146;
Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;
QY 22 VYLAQVWILCAATAAASAGPQPCSVCSNPFKVVCTVRGLSEVPQIPSENTRYLN 81
DB 29 VLLALQLLVAGLYRA-----QTCPSVCSNPFKVICVRKNLREVPDGLSNTLLN 82
QY 82 LAMENNIQOATFRHLHLVLOLGRNSIQIIVGAFNGLASLNTLEFDMWLTVPESG 141
DB 83 LHENQIQIKVNSFKHLRLBILQSRNHIRTIBIGAFNGLANLNTLEFDMRLTTPNG 142
QY 142 APEYLSKLRELWLRNNPIESIPSAFNRVPSLMDLGLKELKLYISEGAFEGFLNLYL 201
DB 143 AFVYLSKLRELWLRNNPIESIPSAFNRVPSLMDLGLKELKLYISEGAFEGFLNLYL 202
QY 202 NLGMCNIXDMPNLTPVLGLELEMSGNHFFPIRPGSFHGLSSLKULWVMSQVSLIERN 261
DB 203 NLAMCNLREINPTELLKDLDELSGNHLASIRPGSFQGLMHLQKLMWQIQIQUIERNA 262
QY 262 FGLASIVELALAHNLSLSDHDLFTPLRYLVEHLHNPWNCDDILMLAWLREVIPT 321
DB 263 FDMQSLVEINLAHNLTLLPHDLFTPLHLELRLHNPWNCDDILMLSWIKDMAPS 322
QY 322 NSTCCGRCHAPMHMRGYLVEVDQASFOCSAPFINDAPROLNISEGRMAELKCR-TPPMS 380
DB 323 NYACCARCNTPENLAGRYIGELDQNVFTCYAPVIVEPPADLNVTGMAELKCRASLT 382
QY 381 SVKLLPNGTVLASHASRHPRIISVLDGTLNFSVLLSDTGYVTCWTVTNVAGNSAVLYN 440
DB 383 SVSWITPMTGVTMGAYKVRIVAVLSDGTNLNFTNVTVQDTGMTCNVSNGVITASATLN 442
QY 441 VSTAELNTSNVSFFTTVTVEITTEISPED---TTRKYKEVP-----TTSTGYQPAYTTSTT 492
DB 443 VTAA--TTTPFSYFTVTVEITWEPSQDEARTDNNVGTPTVVDWETNV-----TTSLT 494
QY 493 VLIQTR-VFKQVAVPATDTTDXMQTSLDDEVMKTKIIGCFVATLLAAALIVFYKLR 551
DB 495 P--QSTRSEKTFTEFTVDINSGL-PGIDENVKTKIIGCFVATLLAAALIVFYKOR 551
QY 552 XHQQRSTVTAARTVEIIQVDIEDIPAATAAATAAPSGVSGEGAVLPTI-HDHN-YNT 609
DB 552 KQHQNQHAPTRTVEINVDDEITGDTFM-----ESHLPMFAIEHEHLNYSN 600
QY 610 YKPAHGAHWTEISLNSLHPTVTITSEPIYIQTHTYKQVQETQI 653
DB 601 YKSPFNHTTNTNTI-NSIH---SSVHEPLLRIMNSKDNVQETQI 640
RESULT 40
ABU69672
ID ABU69672 standard; Protein; 640 AA.
XX AC ABU69672;
XX AC ABU69672;
XX DT 05-JUN-2003 (first entry)
XX XX Novel human secreted and transmembrane protein PRO331.

X Human; secreted and transmembrane protein; gene therapy; psoriasis;
 W enterocolitis; gastrointestinal ulceration; skin disease;
 W keratinocyte differentiation; epithelial cancer; Alzheimer's disease;
 W squamous cell carcinoma; Parkinson's disease; inflammatory disease;
 W amyotrophic lateral sclerosis; rheumatoid arthritis; asthma;
 W multiple sclerosis; organ failure; atherosclerosis; cardiac injury;
 W infertility; birth defect; premature aging; AIDS; cancer;
 W diabetic complication; wound repair; tissue re-growth.

Homo sapiens.

US2003017463-A1.

23-JAN-2003.

11-JUL-2001; 2001US-0903640.

10-SEP-1998; 98WO-US18824.

14-SEP-1998; 98WO-US19177.

16-SEP-1998; 98WO-US19330.

17-SEP-1998; 98WO-US19437.

01-DEC-1998; 98WO-US25108.

08-SEP-1999; 99WO-US20594.

13-SEP-1999; 99WO-US20944.

15-SEP-1999; 99WO-US21090.

05-OCT-1999; 99WO-US22089.

29-NOV-1999; 99WO-US22814.

30-NOV-1999; 99WO-US28313.

01-DEC-1999; 99WO-US28301.

02-DEC-1999; 99WO-US28564.

16-DEC-1999; 99WO-US30095.

20-DEC-1999; 99WO-US30911.

20-DEC-1999; 99WO-US30999.

05-JAN-2000; 2000WO-US00219.

11-FEB-2000; 2000WO-US03565.

22-FEB-2000; 2000WO-US04414.

24-FEB-2000; 2000WO-US05004.

02-MAR-2000; 2000WO-US05841.

20-MAR-2000; 2000WO-US07377.

30-MAR-2000; 2000WO-US08439.

22-MAY-2000; 2000WO-US14042.

02-JUN-2000; 2000WO-US15264.

28-JUL-2000; 2000WO-US20710.

24-AUG-2000; 2000WO-US23328.

17-SEP-1997; 97US-059113P.

17-SEP-1997; 97US-059115P.

17-SEP-1997; 97US-059117P.

17-SEP-1997; 97US-059119P.

17-SEP-1997; 97US-059121P.

PR 28-OCT-1997; 97US-063550P.
 PR 28-OCT-1997; 97US-063564P.
 PR 29-OCT-1997; 97US-063435P.
 PR 29-OCT-1997; 97US-063704P.
 PR 29-OCT-1997; 97US-063732P.
 PR 29-OCT-1997; 97US-063734P.
 PR 29-OCT-1997; 97US-063735P.
 PR 29-OCT-1997; 97US-063738P.
 PR 31-OCT-1997; 97US-064215P.
 PR 31-OCT-1997; 97US-063870P.
 PR 31-OCT-1997; 97US-064103P.
 PR 03-NOV-1997; 97US-064248P.
 PR 07-NOV-1997; 97US-064809P.
 PR 12-NOV-1997; 97US-065186P.
 PR 17-NOV-1997; 97US-065846P.
 PR 18-NOV-1997; 97US-065893P.
 PR 21-NOV-1997; 97US-066120P.
 PR 21-NOV-1997; 97US-066364P.
 PR 24-NOV-1997; 97US-066453P.
 PR 24-NOV-1997; 97US-066466P.
 PR 24-NOV-1997; 97US-066511P.
 PR 24-NOV-1997; 97US-066770P.
 PR 24-NOV-1997; 97US-066772P.
 PR 25-NOV-1997; 97US-066840P.
 PR 12-DEC-1997; 97US-069425P.
 PR 04-JUN-1998; 98US-088026P.
 PR 10-SEP-1998; 98US-099803P.
 PR 14-SEP-1998; 98US-100262P.
 PR 17-SEP-1998; 98US-100858P.
 PR 13-OCT-1998; 98US-104080P.
 PR 20-NOV-1998; 98US-109304P.
 PR 22-DEC-1998; 98US-113296P.
 PR 07-JUL-1999; 99US-143048P.
 PR 26-JUL-1999; 99US-145698P.
 PR 28-JUL-1999; 99US-146222P.
 PR 18-SEP-2000; 2000US-0665350.

(GETH) GEMENTECH INC.

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams FM, Wood WI;

WPI: 2003-341586/32.

N-PSDB; ACA55048.

XX New PRO polypeptides and nucleic acid molecules, useful in diagnosing
 or treating inflammatory diseases, organ failure, atherosclerosis,
 cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or
 Parkinson's disease -

Claim 12; Fig 104; 473pp; English.

The invention describes sixty one nucleic acids encoding PRO polypeptides
 (secreted and transmembrane). The PRO polypeptides and nucleic acids are
 useful in diagnosing or treating enterocolitis, gastrointestinal
 ulceration, skin diseases associated with abnormal keratinocyte
 differentiation, e.g. psoriasis or epithelial cancers such as squamous
 cell carcinoma, Alzheimer's disease, Parkinson's disease, amyotrophic
 lateral sclerosis, inflammatory diseases, e.g. rheumatoid arthritis,
 asthma or multiple sclerosis, organ failure, atherosclerosis, cardiac
 injury, infertility, birth defects, premature aging, AIDS, cancer,
 diabetic complications, or mutations in general. The polypeptides are
 also useful for wound repair and associated therapies concerned with
 re-growth of tissue. The PRO polypeptides and nucleic acid molecules
 are also useful in gene therapy, and as molecular weight markers for
 protein electrophoresis purposes. The anti-PRO antibodies may be used
 in diagnostic assays for PRO, or for the affinity purification of PRO
 from recombinant cell culture or natural sources. This is the amino
 acid sequence of a novel human PRO polypeptide.

XX

3Q	Sequence	640 AA;
	Query Match	54.2%; Score 1865; DB 24; Length 640;
	Best Local Similarity	56.4%; Pred. No. 1.6e-146;
	Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;	
2Y	22	VYLTAQWILCAIAAASAGPQNCPSVCSNPFKVCWCTRRGLSEVPQGISNTRYLN 81
2b	29	VLLALQLLVAGLVRA-----QTCPSVCSNPFKVCWCTRRGLSEVPQGISNTRYLN 82
2Y	82	LMENNIQWQADTPRHLLHLVLQGLGNSRQTEVGAENGLASLNTLELPDKNLTVIPSG 141
2b	83	LEENQIQIIVKNSPKHRLHLEIQLSNHRTIEIGAFNGLANLNTLELPDKNLTVIPSG 142
2Y	142	AFYLSKLRELMENNIQWQADTPRHLLHLVLQGLGNSRQTEVGAENGLASLNTLELPDKNLTVIPSG 141
2b	143	AFVLSKLRELMENNIQWQADTPRHLLHLVLQGLGNSRQTEVGAENGLASLNTLELPDKNLTVIPSG 141
2Y	202	NLGNCTKMDNLTPLVGLSELSNGHFFPIRPGSPHGLSSLLKLVWNSQVSLTERNA 261
2b	203	NLGNCTKMDNLTPLVGLSELSNGHFFPIRPGSPHGLSSLLKLVWNSQVSLTERNA 261
2Y	262	PDGLASIVELNLAHNNLSLPHDLFTPLRYLVLELHLHNPWNCDCDILMLAWLREYIPT 321
2b	263	PDGLASIVELNLAHNNLSLPHDLFTPLRYLVLELHLHNPWNCDCDILMLAWLREYIPT 321
2Y	322	NSTCGRCHAPMHRGRLVVEVDQASTQCAPFMDAPRDLINISGEMAEKCR-TPPMS 380
2b	323	NSTCGRCHAPMHRGRLVVEVDQASTQCAPFMDAPRDLINISGEMAEKCR-TPPMS 380
2Y	391	SVKMLPNTVLSHARHPRTSVLNDGTLNPSHVLSDTGVTCWTVNAGNSNAYLN 440
2b	393	SVKMLPNTVLSHARHPRTSVLNDGTLNPSHVLSDTGVTCWTVNAGNSNAYLN 440
2Y	441	VSTALNTSNYSFTTVEITEISPD-----TTRKYKVP-----TTSTGYQAYTTSIT 492
2b	443	VSTALNTSNYSFTTVEITEISPD-----TTRKYKVP-----TTSTGYQAYTTSIT 492
2Y	493	VLIOTTR-VPKQVAPATDITDKMOTSIDEVMTKTKIIIGCFVAVTLAAALIVFVKLR 551
2b	495	VLIOTTR-VPKQVAPATDITDKMOTSIDEVMTKTKIIIGCFVAVTLAAALIVFVKLR 551
2Y	552	KRHOORSTVTAARTVEIIVQVDEIPAAATSAATAAPSGVSGEAVLPTI-HDHIN-YNT 609
2b	552	KRHOORSTVTAARTVEIIVQVDEIPAAATSAATAAPSGVSGEAVLPTI-HDHIN-YNT 609
2Y	610	YKPAHCAHTWNSLNSLHPTVTIISSEPIIOTHTKDKVQETQI 653
2b	601	YKSPNHTTNTI-NSIH-----SSVHEPLLRMSKONVQETQI 640
RESULT 41		
ID	ABU71495	ABU71495 standard; Protein; 640 AA.
XX	AC	ABU71495;
XX	DT	10-JUN-2003 (first entry)
XX	DE	Human PRO polypeptide #51.
XX	KW	Human; secreted and transmembrane protein; PRO polypeptide; cancer;
XX	KW	Alzheimer's disease; ischaemia; cytostatic; neurotropic; vasotropic;
XX	KW	neuroprotective.
XX	OS	Homo sapiens.
XX	OS	US2002192659-A1.
XX	PN	19-DEC-2002.
XX	PD	10-JUL-2001; 2001US-0902853.
XX	PF	
XX	XX	

PR	10-SEP-1998;	98WO-US18824.
PR	14-SEP-1998;	98WO-US19177.
PR	16-SEP-1998;	98WO-US19330.
PR	17-SEP-1998;	98WO-US19437.
PR	01-DEC-1998;	98WO-US25108.
PR	08-SEP-1999;	99WO-US20594.
PR	13-SEP-1999;	99WO-US20944.
PR	15-SEP-1999;	99WO-US21050.
PR	15-SEP-1999;	99WO-US21547.
PR	05-OCT-1999;	99WO-US23089.
PR	01-DEC-1999;	99WO-US28301.
PR	02-DEC-1999;	99WO-US28564.
PR	02-DEC-1999;	99WO-US28565.
PR	16-DEC-1999;	99WO-US30911.
PR	20-DEC-1999;	99WO-US30999.
PR	05-JAN-2000;	2000WO-US00219.
PR	11-FEB-2000;	2000WO-US03565.
PR	22-FEB-2000;	2000WO-US04414.
PR	28-JUL-2000;	2000WO-US20710.
PR	24-AUG-2000;	2000WO-US23328.
PR	17-SEP-1997;	97US-059113P.
PR	17-SEP-1997;	97US-059113P.
PR	17-SEP-1997;	97US-059117P.
PR	18-SEP-1997;	97US-059266P.
PR	15-OCT-1997;	97US-062125P.
PR	17-OCT-1997;	97US-062285P.
PR	17-OCT-1997;	97US-062287P.
PR	21-OCT-1997;	97US-063486P.
PR	24-OCT-1997;	97US-062814P.
PR	24-OCT-1997;	97US-062816P.
XX	(GETH) GENENTECH INC.	
XX	PA	
XX	PI	Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI	PI	Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
PI	PI	Godowski PJ, Grimaldi JC, Gurney AL, Hillan KO, Kljavin LJ;
PI	PI	Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI	PI	Williams PM, Wood WI;
XX	XX	WPI: 2003-361832/34.
XX	DR	N-PSDB; ACA59533.
XX	XX	New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or
PT	PT	PRO1866, useful in molecular biology, chromosome and gene mapping, in
PT	PT	generating antisense RNA and DNA, and in gene therapy
XX	XX	Claim 12; Fig 104; 474pp; English.
XX	CC	The present invention relates to the isolation of novel human secreted
CC	CC	and transmembrane proteins (PRO polypeptides), and the polynucleotide
CC	CC	sequences encoding them. The polynucleotide sequences are useful in
CC	CC	molecular biology, as hybridisation probes, in chromosome and gene
CC	CC	mapping, in generating antisense RNA and DNA, and in gene therapy. The
CC	CC	polynucleotide sequences may also be used in preparing PRO polypeptides
CC	CC	by recombinant techniques, and in generating either transgenic animals
CC	CC	or knock-out animals which, in turn, are useful in the development and
CC	CC	screening of therapeutically useful reagents. The PRO polypeptides or
CC	CC	their antibodies are useful in preparing a medicament for treating a
CC	CC	condition responsive to the polypeptide or antibody, such as cancer,
CC	CC	Alzheimer's disease or ischaemia, and in various diagnostic assays.
CC	CC	ABU71445-ABU71505 represent human PRO polypeptides of the invention.
XX	XX	Sequence 640 AA;
XX	XX	Query Match 54.2%; Score 1865; DB 24; Length 640;
XX	XX	Best Local Similarity 56.4%; Pred. No. 1.6e-146;
XX	XX	Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;
QY	22	VYLTAQWILCAIAAASAGPQNCPSVCSNPFKVCWCTRRGLSEVPQGISNTRYLN 81
DB	29	VLLALQLLVAGLVRA-----QTCPSVCSNPFKVCWCTRRGLSEVPQGISNTRYLN 82

Y 82 LMENNIQIADQTERHLEHLEVLQAGRNISROIEVGAFAAGLASLNTLLEFDNWLTVIPSG 141
b 83 LHENQIOLIKVNSFKHLRLELIQSRHIRTIEGAFNGLANLNTLEFDRJTTIPNG 142
Y 142 APEYLSKLELRLRNPIESIPSYAFNPVPSLMRLDLGELKKLYISGAFEGFLNKL 201
C 143 AFVYLSKLELRLRNPIESIPSYAFNPVPSLMRLDLGELKKLYISGAFEGFLNKL 202
Y 202 NLGCMNKDMPNLTPLVLEELGEMSGNHPPEIRPGSFGLSLKLVNNSOVSLIERN 261
C 203 NLAMCNLRIPNLTPLIKLDELDELGNLSAIPRSGFGLHLOKLMQIOIIVIRNA 262
Y 262 FGLASLVLELHNLNLSLPHDLFTPLRYLVLELHNPWNCDCDILWLAWLREYIPT 321
C 263 FDNQSLVEINLAHNNLTPLPHDLFTPLHLEIRIHLHENPWNCCDILWLAWLREYIPT 322
Y 322 NTCGCRCHAPMHMGRIYVVDQAFQSCAPFIMADPRDLNISEGRVAELKCR-TPPMS 380
C 323 NTACCARCNTPNLKGRIYGEIDQNYFTCYAEVVEPPADLNVTGMAELKCRASLSLT 382
Y 381 SVKMLLPNGITVLSHARHPRISVLNDGTLNFSHLLSDTGVVTCVNTVAGNSNAYLN 440
C 383 SVSWITPNTGTVHNGYKRIAVLDGTLNFINVTQTCMTVNSVNGTASATLN 442
Y 441 VSTASLNTSNYFFFTVTVETTEISPED---TTRKYKVPV-----TSTGQPAYTTSTT 492
C 443 VTAA---TTTFVSFTVTVETMEPSQDEARTDNNVGPVVDVMTTIV-----TTSLT 494
Y 493 VLQITR-VPKQVAVPATDTDKMOTSLDEVMKTKIIGCPVAVTLAAAMLIVFYKLR 551
b 495 P--QSTRTEKFTIPVTDINGI-PGIDEVMKTKIIGCPVAVTLAAAMLIVFYKLR 551
Y 552 KRHQCRSTVTAARTVEIIQVDBDIPAAATSAATAAPSGVSGEAVLPTI-HDHN-INT 609
b 552 KQHRQNHAPRTVEIINVDBDITGDEM-----ESHLPMEAISEHNLHNS 600
Y 610 YKPAHAHTENSLNLSLPTTITSEPIIOTHKQKQVETQI 653
b 601 YKSPFNHTTIVATI-NSIH---SSVHEPLIRMSKNVQETQI 640

RESULT 42
BUT1941
D ABUT1941 standard; Protein; 640 AA.
X C ABUT1941;
X T 12-JUN-2003 (first entry)
X E Human secreted/transmembrane protein PRO331.
X W Human; secreted protein; transmembrane protein; PRO;
W gene therapy; chromosome identification; chromosome marker.
X S Homo sapiens.
X N US2003003530-A1.
X D 02-JAN-2003.
X F 11-JUL-2001; 2001US-0904011.
X R 10-SEP-1998; 98WO-US18824.
R 14-SEP-1998; 98WO-US19177.
R 16-SEP-1998; 98WO-US19330.
R 17-SEP-1998; 98WO-US19437.
R 01-DEC-1998; 98WO-US25108.
R 08-SEP-1999; 98WO-US20594.
R 13-SEP-1999; 98WO-US20944.
R 15-SEP-1999; 98WO-US21090.
R 15-SEP-1999; 98WO-US21547.
R 05-OCT-1999; 98WO-US23089.
R 29-NOV-1999; 99WO-US28214.

PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 05-JAN-2000; 2000WO-US00219.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 30-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 22-MAY-2000; 2000WO-US14042.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23328.
PR 17-SEP-1997; 97US-059113P.
PR 17-SEP-1997; 97US-059115P.
PR 17-SEP-1997; 97US-059117P.
PR 17-SEP-1997; 97US-059119P.
PR 17-SEP-1997; 97US-059121P.
PR 17-SEP-1997; 97US-059122P.
PR 17-SEP-1997; 97US-059184P.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 15-OCT-1997; 97US-062125P.
PR 17-OCT-1997; 97US-062285P.
PR 17-OCT-1997; 97US-062287P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-062814P.
PR 24-OCT-1997; 97US-062816P.
PR 24-OCT-1997; 97US-063045P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 24-OCT-1997; 97US-063127P.
PR 24-OCT-1997; 97US-063128P.
PR 27-OCT-1997; 97US-063327P.
PR 27-OCT-1997; 97US-063329P.
PR 28-OCT-1997; 97US-063341P.
PR 28-OCT-1997; 97US-063342P.
PR 28-OCT-1997; 97US-063344P.
PR 28-OCT-1997; 97US-063349P.
PR 28-OCT-1997; 97US-063550P.
PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063732P.
PR 29-OCT-1997; 97US-063734P.
PR 29-OCT-1997; 97US-063735P.
PR 29-OCT-1997; 97US-063738P.
PR 29-OCT-1997; 97US-064215P.
PR 31-OCT-1997; 97US-064370P.
PR 03-NOV-1997; 97US-064403P.
PR 07-NOV-1997; 97US-064248P.
PR 12-NOV-1997; 97US-064809P.
PR 17-NOV-1997; 97US-065186P.
PR 18-NOV-1997; 97US-065846P.
PR 18-NOV-1997; 97US-065853P.
PR 21-NOV-1997; 97US-066120P.
PR 21-NOV-1997; 97US-066364P.
PR 24-NOV-1997; 97US-066453P.
PR 24-NOV-1997; 97US-066466P.
PR 24-NOV-1997; 97US-066511P.
PR 24-NOV-1997; 97US-066770P.
PR 24-NOV-1997; 97US-066772P.
PR 18-SEP-2000; 2000US-0665350.

(GETH) GENENTECH INC.

PA Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;

PI Godowski RJ, Grimaldi JC, Gurney AL, Hillan KJ, Kljavin ID;
PI Mather JP, Pan J, Paoni NF, Roy NA, Stewart RA, Tumas D;
PI Williams PM, Wood WI;
XX
DR WPI: 2003-329602/31.
DR N-PSDB; ACA60240.
XX

XX New transmembrane polypeptides and nucleic acids encoding the
FT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, in generating probes and in tissue typing -
XX
XX Claim 12; Fig 104; 484pp; English.

XX The invention relates to an isolated nucleic acid with at least 80%
XX nucleic acid sequence identity to a nucleotide sequence encoding one of
XX 61 secreted/transmembrane polypeptides, or PRO polypeptides or encoding a
XX PRO protein extracellular domain. Also included are a vector comprising a
XX the PRO nucleic acid, a host cell comprising the vector, producing a PRO
XX polypeptide (by culturing the host cell for the expression of the PRO
XX polypeptide, and recovering the PRO polypeptide from the cell culture),
XX an isolated PRO polypeptide (having at least 80% sequence identity
XX to: (a) an amino acid sequence selected from the 61 PRO proteins;
XX (b) an amino acid sequence encoded by a nucleic acid molecule deposited
XX with an ATCC number (detailed in the specification); or (c) an
XX extracellular domain of a PRO polypeptide or to a PRO polypeptide lacking
XX its associated signal peptide), a chimeric molecule comprising a PRO
XX polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
XX antibody, detecting a PRO245 or PRO1868 in a sample suspected of
XX containing the polypeptide, linking a bioactive molecule to a cell
XX expressing a PRO245 or PRO1868 and modulating at least one biological
XX activity of a cell expressing a PRO245 or PRO1868. Nucleic acids, which
XX encode PRO can be used to generate either transient animals or knock-out
XX animals which may be used in the development and screening of
XX therapeutically useful reagents. The nucleic acids may also be used in
XX gene therapy, in chromosome identification, as chromosome markers, or in
XX for protein electrophoresis, and the isolated nucleic acids may be used
XX for recombinantly expressing those markers. The PRO polypeptides and
XX nucleic acids may also be used in tissue typing. Anti-PRO antibodies
XX are useful in diagnostic assays for PRO, and in affinity purification
XX of PRO from recombinant cell culture or natural sources. The
XX present sequence represents a PRO protein.

XX Sequence 640 AA;
XX
XX Query Match 54.2%; Score 1865; DB 24; Length 640;
XX Best Local Similarity 56.4%; Pred. No. 1.6e-146;
XX Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;

QY 22 VYLAQVWILCAIAAASAGPQNCPSVCSCNPFKVVCTRRGLSEVPPQGPISNRYLN 81
DB 29 VLLALQLLVAGLVRA-----QTFCVSCSCNPFKVVCTRRGLSEVPPQGPISNRYLN 82
QY 82 LVENNIQMIQADTFRHLHLEVLQGRNSIRQIRVGAFAFGLASLNTLBLEFNLWLTVPSPG 141
DB 83 LHENQIQIKVNSFKELRHLLEQLSRHRTETGAFNGLANLNTLBLEFNLWLTVPSPG 142
QY 142 AFYLSKLELWLRNPISISYAFNRPISLWRLDGLKLEVISRGATEGLFNLYL 201
DB 143 AFYLSKLELWLRNPISISYAFNRPISLWRLDGLKLEVISRGATEGLFNLYL 202
QY 202 NLQMCNKMPLNPLTVLGLLEEMSGNPFPEIRPSPGFLSLKLLWYNSQVSLIERNA 261
DB 203 NLQMCNKMPLNPLTVLGLLEEMSGNPFPEIRPSPGFLSLKLLWYNSQVSLIERNA 262
QY 262 FDGLASLVEINLANNLSLPHDLFPLRYLVELHLHNPWNCDCDILWLAWLREYIPT 321
DB 263 FDNLOSLVEINLANNLSLPHDLFPLRYLVELHLHNPWNCDCDILWLAWLREYIPT 322
QY 322 NSTCCGRCIAPMGRGRLVVEVDQAFQCSAPPFIMDAPDLNISGRMAELKCR-TPRMS 380
DB 323 NTACCRCNTPPNLRGKRYIGELDQNYFTCYAPVIVEPPADLANVTGMAELKCRASLT 382

QY 381 SVKLLPENGTVLASHARPRISVLINDGTGLNPSHLLSDTGVTCTMTNVAGNSAGNAYLN 440
DB 383 SVSMITENGTVMTGAYKVAIVLSDGTGLNPSHLLSDTGVTCTMTNVAGNSAGNAYLN 442
QY 441 VSTAEIATNSYSPFTTIVETTELSPED---TTRKYKPPV-----TSTGVPAYTTSTT 492
DB 443 VTAA--TTTPESYFSTVETMPEQDEARTDNNVGTPTVVDWETINV-----TISLT 494
QY 493 VLIOTTR-VPKQAVAPADTDDKMQTSLDEVMKTKIIIGCFVAVTLLAAAMLIVFYKLR 551
DB 495 P--QSTRSEKTFIPVDINSIGI-PGIDVEMKTKIIIGCFVAVTLLAAAMLIVFYKMR 551
QY 552 RHHQORSTVTAARTVEIIQVDEIDIPATSAATAPSGVSGEAGVLPIT-HDHIN-YNT 609
DB 552 RQHQRNHAPTRTVEIINVDEITGTPM-----ESHLPMPALTEHEHMHYNS 600
QY 610 YKPAHGAETNSLGNLSLHPTVTIISPIYIIQTHTKDKVQETQI 653
DB 601 YKSPNNHTTNTI-NSIH---SSVHEPLLIRMSKDNVQETQI 640
RESULT 43
ABU66753
ID ABU66753 standard; Protein; 640 AA.
XX
XX AC ABU66753;
XX
XX DT 23-MAY-2003 (first entry)
XX
XX DE Human PRO polypeptide #184.
XX
XX KW Human; PRO polypeptide; secreted and transmembrane protein;
XX tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
XX differentiation; chondrocyte; tumour; genetic disorder;
XX cytostatic.
XX
XX OS Homo sapiens.
XX
XX PN US2003036180-A1.
XX
XX PD 20-FEB-2003.
XX
XX PF 09-MAY-2002; 2002US-0143114.
XX
XX PR 31-MAR-1997; 97WO-US05230.
XX PR 12-JUN-1998; 98WO-US12456.
XX PR 14-JUL-1998; 98WO-US14552.
XX PR 28-AUG-1998; 98WO-US17888.
XX PR 10-SEP-1998; 98WO-US18824.
XX PR 14-SEP-1998; 98WO-US19093.
XX PR 14-SEP-1998; 98WO-US19094.
XX PR 14-SEP-1998; 98WO-US19177.
XX PR 16-SEP-1998; 98WO-US19330.
XX PR 17-SEP-1998; 98WO-US19437.
XX PR 07-OCT-1998; 98WO-US21141.
XX PR 29-OCT-1998; 98WO-US22992.
XX PR 29-OCT-1998; 98WO-US22992.
XX PR 20-NOV-1998; 98WO-US24855.
XX PR 01-DEC-1998; 98WO-US25108.
XX PR 05-JAN-1999; 99WO-US00106.
XX PR 08-MAR-1999; 99WO-US05028.
XX PR 10-MAR-1999; 99WO-US05190.
XX PR 20-APR-1999; 99WO-US08615.
XX PR 14-MAY-1999; 99WO-US10733.
XX PR 02-JUN-1999; 99WO-US12252.
XX PR 01-SEP-1999; 99WO-US20111.
XX PR 08-SEP-1999; 99WO-US20594.
XX PR 13-SEP-1999; 99WO-US20944.
XX PR 15-SEP-1999; 99WO-US21090.
XX PR 15-SEP-1999; 99WO-US21547.
XX PR 05-OCT-1999; 99WO-US23089.
XX PR 29-NOV-1999; 99WO-US28214.
XX PR 30-NOV-1999; 99WO-US28313.

R 30-NOV-1999; 99WO-US28409.
R 01-DEC-1999; 99WO-US28301.
R 01-DEC-1999; 99WO-US28634.
R 02-DEC-1999; 99WO-US28551.
R 02-DEC-1999; 99WO-US28564.
R 02-DEC-1999; 99WO-US28565.
R 16-DEC-1999; 99WO-US30095.
R 20-DEC-1999; 99WO-US30911.
R 20-DEC-1999; 99WO-US30999.
R 22-DEC-1999; 99WO-US30720.
R 30-DEC-1999; 99WO-US31243.
R 30-DEC-1999; 99WO-US31274.
R 05-JAN-2000; 2000WO-US00219.
R 06-JAN-2000; 2000WO-US00277.
R 06-JAN-2000; 2000WO-US00376.
R 11-FEB-2000; 2000WO-US03565.
R 18-FEB-2000; 2000WO-US04341.
R 18-FEB-2000; 2000WO-US04342.
R 22-FEB-2000; 2000WO-US04414.
R 24-FEB-2000; 2000WO-US04914.
R 24-FEB-2000; 2000WO-US05004.
R 01-MAR-2000; 2000WO-US05601.
R 02-MAR-2000; 2000WO-US05746.
R 02-MAR-2000; 2000WO-US05841.
R 10-MAR-2000; 2000WO-US06319.
R 15-MAR-2000; 2000WO-US06884.
R 20-MAR-2000; 2000WO-US07377.
R 21-MAR-2000; 2000WO-US07532.
R 30-MAR-2000; 2000WO-US08439.
R 17-MAY-2000; 2000WO-US13705.
R 22-MAY-2000; 2000WO-US14042.
R 30-MAY-2000; 2000WO-US14941.
R 02-JUN-2000; 2000WO-US15264.
R 28-JUL-2000; 2000WO-US20710.
R 11-AUG-2000; 2000WO-US22031.
R 23-AUG-2000; 2000WO-US23522.
R 24-AUG-2000; 2000WO-US23328.
R 08-NOV-2000; 2000WO-US30952.
R 10-NOV-2000; 2000WO-US30873.
R 01-DEC-2000; 2000WO-US32878.
R 20-DEC-2000; 2000WO-US34356.
R 28-FEB-2001; 2001WO-US06520.
R 01-MAR-2001; 2001WO-US06666.
R 25-MAY-2001; 2001WO-US17092.
R 01-JUN-2001; 2001WO-US17800.
R 20-JUN-2001; 2001WO-US19692.
R 22-JUN-2001; 2001WO-US20116.
R 29-JUN-2001; 2001WO-US21066.
R 09-JUL-2001; 2001WO-US21735.
R 20-DEC-2000; 2000US-0747259.
R 28-FEB-2001; 2001US-0796498.
R 09-MAR-2001; 2001US-0802706.
R 14-MAR-2001; 2001US-0808689.
R 22-MAR-2001; 2001US-0816744.
R 05-APR-2001; 2001US-0828366.
R 10-MAY-2001; 2001US-0854208.
R 10-MAY-2001; 2001US-0854280.
R 18-MAY-2001; 2001US-0860216.
R 25-MAY-2001; 2001US-0866028.
R 25-MAY-2001; 2001US-0866034.
R 01-JUN-2001; 2001US-0872035.
R 05-JUN-2001; 2001US-0874503.
R 14-JUN-2001; 2001US-0882636.
R 19-JUN-2001; 2001US-0886342.
R 21-JUN-2001; 2001US-0897879.
R 18-JUL-2001; 2001US-0908827.
R 06-AUG-2001; 2001US-0924419.
R 09-AUG-2001; 2001US-0927796.
R 16-AUG-2001; 2001US-0931836.
R 19-DEC-2001; 2001US-0028072.
(GETH) GENENTECH INC.

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-332040/31.
XX N-PSDB; ACA03786.
XX New secreted and transmembrane PRO nucleic acids, useful for gene
PT therapy, in chromosome and gene mapping, as chromosome markers, in
PT tissue typing, and in chromosome identification
XX Claim 12; Fig 368; 660pp; English.
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for
CC linking bioactive molecules to cells expressing PRO polypeptides,
CC for modulating biological activities of cells expressing PRO
CC polypeptides, and for identifying agonists or antagonists.
CC The PRO polypeptides are useful for stimulating the release of
CC tumour necrosis factor (TNF)-alpha from human blood, for stimulating the
CC the proliferation or differentiation of chondrocytes, and detecting the
CC presence of tumours. The polynucleotide sequences encoding PRO
CC polypeptides are useful as hybridisation probes, in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptides, for generating transgenic animals or
CC knockout animals, for the genetic analysis of individuals with genetic
CC disorders, and in gene therapy. AB066570-AB066844 represent the human
CC PRO polypeptides of the invention.
CC Note: The sequence data for this patent was obtained in electronic
CC format directly from the USPTO web site at
CC seqdata.uspto.gov/psipdsIDEntry.html.
XX Sequence 640 AA;

Query Match 54.2%; Score 1865; DB 24; Length 640;
Best Local Similarity 56.4%; Pred. No. 1.6e-146;
Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;

QY 22 VYLTAQVWILCAAIAAAGAGPQNCPSVCSGNSQKSVKVCRRGLSEVPQGPSPNTRYLN 81
DB 29 VLLALQLLVAGLVRA-----QTCFVSCVSCSNQPSKVICVAKNLRVDPGISTNRLN 82
QY 82 LMENNTOMIOADTFRIHLHLVLEVLQGRNIRQLVCAFNGLASLNTLELKNLTVIPGS 141
DB 83 LHENQIQIKVNSFGHLRLEILQLSRNHRTIEIGAFNGLANLNTLELDFNRLTIPNG 142
QY 142 AFVYLSKRLRLNRPPIESIPSYAFNRVPSLMRLDLGLKLEIYSEGAFGLFNLYL 201
DB 143 AFVYLSKRLRLNRPPIESIPSYAFNRVPSLMRLDLGLKLEIYSEGAFGLFNLYL 202
QY 202 NLGMCNIKDMPNLTPLVGLLENGNHPPEIRPGSFHGLSSLKLVWNSQVSLIERNA 261
DB 203 NLAMCNLREIPNLTPLKLDLDSGNHLSAIRPFSFQGLMHLQKLWMTQSQIQUIERNA 262
QY 262 FDGLASIVELNLAHNNLSLPHDLFTPLRVLHLHHPNWCDCILWLAWLREYIPT 321
DB 263 FDNQLSVLEINLAHNNLTLLPHDLFTPLHLHLHHPNWCNCDILWLSWIKWAPS 322
QY 322 NSTCCGRCFAPMNRGRYLYVEVDQASFCSPAFFINDAPDLNISSEGRMAELKCR-TTPMS 380
DB 323 NTACCAECNTPPNLKGRIIGELDNQVPTCVAPVVEPPADLVNTEGMAELKCRASLT 382
QY 381 SVKWLPLNGTVLSHSRHPRIISVINDGTINFSVLLSDTGVTTCMTNVAGNSNAGAYLN 440
DB 383 SVSWITPENGTVMTGAYKVRIVLSDGTINFNTVQDTGMYTCWNSVNGNTIATNLN 442
QY 441 VSTRELNTSNYSFFITVTVETTEISPED---TTRKYKVPD-----TTSYGQPAYTISFT 492
DB 443 VTAA--TTTFPSYESTVTVETMEPSQDEARTDNNVGPFPVVDMEITNV-----TTSLT 494
QY 493 VLIQTTR-VPKQVAVPANDTTDKMQTSLDEWMTKIIIGCFVAVTLLAAAMLIVFKLR 551

T designated as PRO, useful for treating inflammation, organ failure,
T atherosclerosis, cardiac injury, infertility, birth defects, premature
T aging, AIDS, or cancer
X Claim 12; Fig 368; 659pp; English.
X The invention relates to an isolated nucleic acid comprising, or which is
C at least 80% identical to, or the full-length coding sequence of, any of
C the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
C (one of 275 secreted or transmembrane proteins). The nucleic acid
C further comprises the full-length coding sequence of the DNA deposited
C under American Type Culture Collection (ATCC) accession number in a list
C given in the specification. Also included are vectors and host
C cells for producing PRO proteins, PRO fusion proteins, anti-PRO
C antibodies, PRO extracellular domains and mature sequences, methods
C of detecting PRO proteins, methods for stimulating the release of
C TNF-alpha (tumour necrosis factor alpha) from human blood,
C (and the proliferation of differentiation of chondrocyte cells, the
C proliferation of, or gene expression in pericyte cells, the release or
C proteoglycans from cartilage, proliferation of inner ear utricular
C supporting cells, the proliferation of T-lymphocyte cells, the release
C of a cytokine from peripheral blood mononuclear cells (PBMC), or the
C proliferation of endothelial cells), a method for modulating the uptake
C of glucose or free fatty acid (FFA) by skeletal muscle cells,
C a method for inhibiting the binding of A-peptide to factor VIIA,
C or the differentiation of adipocyte cells, a method for detecting the
C presence of a tumour in a mammal and an oligonucleotide probe derived
C from any of the nucleotide sequences cited above. The nucleic acids and
C polypeptides are useful for treating inflammatory diseases, organ
C failure, atherosclerosis, cardiac injury, infertility, birth defects, or
C premature aging, AIDS (acquired immunodeficiency syndrome), cancer, or
C diabetic complications. The nucleic acids are useful as hybridisation
C probes, in chromosome and gene mapping, and in generating antisense RNA
C or DNA. The polypeptides are useful as pharmaceuticals, diagnostics,
C biosensors or bioreactors. Both are useful in tissue typing.
C The present sequence represents a PRO protein of the invention.

X Q Sequence 640 AA;

Query Match 54.2%; Score 1865; DB 24; Length 640;
Best Local Similarity 56.4%; Pred. No. 1.6e-146;
Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;
Y 22 VYLAQVWILCAIAAASAGPQSCNSQPSKQVCTRGSLSEVPQGISNTRYLN 81
b 29 VYLAQLVWAGLVRA-----QTCPSVSCNSQPSKVICVRKLEVPDGLISTWRLLA 82
Y 82 LMENNIQMIQADTFRLHHLHLEVLQGRNSIRQIEVCAFNGLASNTLFLFDNLWTVIPSG 141
b 83 LHENQIQIKVNSFKHLRHLLEILQLSRNRITIEIGAFNGLANLNTLFLDNLRTIIPNG 142
Y 142 AFVLSKRLRLRNPIESIPSYAFNRPVPSLMRLDLGLKXLEYISGAPFGLNLYL 201
b 143 AFVLSKRLRLRNPIESIPSYAFNRPVPSLMRLDLGLKXLEYISGAPFGLNLYL 202
Y 202 NLGMCNKKMPLNPLVGLGLEBSMGNHFFPIRPGSFHGLSSLKXLMVNSQVSLIERNA 261
b 203 NLAMCNLREIPNLTPLKLELDLSENLHLSAIRPGSFQGLMHLQXLMQISQIQUVERNA 262
Y 262 FDGLASVLELANHNLSSPHDLFTPLRYVLEHLPNPNPCDDILMLANWLEYIPT 321
b 263 FDNLSQVLEINLAFNLTLLPHDLFTPLHLEIRHLHPNPNPCDDILWLSWIKMAPS 322
Y 322 NSTCCGRCHAPMEMRGYLVVEVQAFQCSAPFMDAPDLNISEGRMAELKCR-TPPMS 380
b 323 NTACCACNTFPPNKGRIYIGELQDNVFTCYAVIVEPADLVNTEGAAELACRASTISIT 382
Y 381 SVKLLPNGTVLGHASHPHRISVINDGTNLNFSHVLSDTGVTQNTVAGNSNAYLN 440
b 383 SVSMITPNTGVTWTHGAKVRIAVLSLDTLNFTNTVQDTGWTCTWNSVNGVNTASATLN 442
Y 441 VSTALNTSNYSPTTWTVTETTESPED---TTRKYKVPV-----TTSYGQPAYTSTT 492

Db 443 VTAA--TTTFSSYFSTVTVMETPEPSODEARTTNNVGPFPVDMETTV-----TTSUT 494
Qy 493 VLIQTR-VFKQVAVPATDTDKQWQSLDEVMKTKIILGCFVAVTLLAAAMLIVFYKLR 551
Db 495 P-QSIFSEKTEFTIPVDINSGL-PSIDEVMKTKIILGCFVAVTLLMAAVMLVIFYKLR 551
Qy 552 KRUCQSRSTVTAARTVHIIQVDEDIIPAATSAATAAPSGVSGEAVLPFI-HDHIN-YNT 609
Db 552 KQHRQNEHAFTPTVRIINVDDEITGDTM-----ESHLPMPAIEHEHLNHYNS 600
Qy 610 YKPAHGARHTWENSLGNSLHPTVTIIESEPVIIQTHTKDKVQETQI 653
Db 601 YKSEPFNHTTWTI-NSIH---SSVHEPLLIRMSKDNVQETQI 640
RESULT 45
ABU67395
ID ABU67395 standard; Protein; 640 AA.
XX
AC ABU67395;
XX
DT 29-MAY-2003 (first entry)
XX
DE Human secreted protein PRO331.
XX
KW Human; Gene therapy; mucosal lesion; ulcer; enterocolitis; skin disease;
KW psoriasis; cancer; lung cancer; colon cancer; nerve cell disease;
KW Alzheimer's disease; Parkinson's disease; Usher syndrome; angiogenesis;
KW atrophila areata; inflammatory disease; asthma; rheumatoid arthritis;
KW ischaemia.
XX
OS Homo sapiens.
XX
XX US2003023054-A1.
XX
XX 30-JAN-2003.
XX
XX 16-JUL-2001; 2001US-0906742.
XX
PR 10-SEP-1998; 98WO-US18924.
PR 14-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 01-DEC-1998; 98WO-US25108.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23089.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 11-FEB-2000; 2000WO-US03565.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 30-MAR-2000; 2000WO-US07377.
PR 22-MAY-2000; 2000WO-US08439.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 24-AUG-2000; 2000WO-US23128.
PR 17-SEP-1997; 97US-059113P.
PR 17-SEP-1997; 97US-059115P.
PR 17-SEP-1997; 97US-059117P.
PR 17-SEP-1997; 97US-059119P.
PR 17-SEP-1997; 97US-059121P.

[illegible]

24-OCT-1997; 97US-062816P.
 24-OCT-1997; 97US-063045P.
 24-OCT-1997; 97US-063120P.
 24-OCT-1997; 97US-063121P.
 24-OCT-1997; 97US-063127P.
 24-OCT-1997; 97US-063128P.
 24-OCT-1997; 97US-063327P.
 27-OCT-1997; 97US-063329P.
 28-OCT-1997; 97US-063541P.
 28-OCT-1997; 97US-063542P.
 28-OCT-1997; 97US-063544P.
 28-OCT-1997; 97US-063549P.
 28-OCT-1997; 97US-063550P.
 28-OCT-1997; 97US-063564P.
 29-OCT-1997; 97US-063704P.
 29-OCT-1997; 97US-063732P.
 29-OCT-1997; 97US-063734P.
 29-OCT-1997; 97US-063735P.
 29-OCT-1997; 97US-063738P.
 29-OCT-1997; 97US-064215P.
 31-OCT-1997; 97US-063870P.
 31-OCT-1997; 97US-064103P.
 03-NOV-1997; 97US-064248P.
 07-NOV-1997; 97US-064809P.
 12-NOV-1997; 97US-065186P.
 17-NOV-1997; 97US-065846P.
 18-NOV-1997; 97US-065693P.
 21-NOV-1997; 97US-066120P.
 21-NOV-1997; 97US-066364P.
 21-NOV-1997; 97US-066453P.
 24-NOV-1997; 97US-066466P.
 24-NOV-1997; 97US-066511P.
 24-NOV-1997; 97US-066770P.
 24-NOV-1997; 97US-066772P.
 18-SEP-2000; 2000US-0665350.
 (GETH) GENENTECH INC.

Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
 Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini ID;
 Mather JP, Pan J, Paoni NP, Roy MA, Stewart TA, Tumas D;
 Williams PM, Wood WI;
 WPI; 2003-288105/28.
 N-PSDB; ABX96257.

New secreted and transmembrane PRO polypeptides (e.g. PRO533 or PRO245)
 and genes encoding them, useful for detecting or treating e.g.
 hyperplasia, endometriosis, cancers, ischemia, coronary arterial
 disease or inflammations -

Claim 12; Fig 104; 477pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides
 and the nucleic acid encoding them. The polypeptides can be used to
 raise antibodies that specifically bind to the PRO polypeptide, for
 linking a bioactive molecule to a cell expressing a PRO protein and for
 modulating at least one biological activity of a cell. The PRO
 polypeptides or polynucleotides are also useful as pharmaceuticals,
 diagnostics, biosensors or bioreactors, for detecting or treating e.g.
 hyperplasia, endometriosis, cancers (e.g. those involving solid tumours),
 ischaemia, coronary arterial disease, polycystic kidney disease, chronic
 or acute renal failure, or inflammatory responses (e.g. asthma,
 rheumatoid arthritis, psoriasis or multiple sclerosis). The
 PRO genes may also be used in gene therapy, particularly for replacing a
 defective gene. The sequences presented in ABU64499-ABU64559 are the
 PRO polynucleotides of the invention.

Sequence 640 AA;

Query Match 54.2%; Score 1865; DB 24; Length 640;

Best Local Similarity 56.4%; Pred. No. 1.6e-146;
 Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;
 QY 22 VYLTAQWILCAIAAASAGPQNCPSVCSCNQSKVYCTRRGLSEVPQGPISNRYLN 81
 DB 29 VLLALQLLVAGLVRA-----QTCPSVCSCNQSKVLCVKRLREVPDGISTNRLIN 82
 QY 82 LMENNTQADTFRHLHLEVLQGRNSIROIFVGANGLASLNTLELFDNWLTVIPSG 141
 DB 83 LHENQIITIKVNSFKRLHLEITQSRHIRTETGAFNGLANTLLELFDNRLTIPNG 142
 QY 142 APEYLSKRLRLRNPIESIPSYAFNRVPSLMRLDLGELKLEIYISGAFGLFKYL 201
 DB 143 AFVYLSKRLKELMLRNPIESIPSYAFNRIPSLRRLDLGELKELSYISGAFGLSNRLYL 202
 QY 202 NLCMCNIKMPNLTPLVGLLELEMSGNHPETRPSFGLSSKLKLMWNSQVSLIERNA 261
 DB 203 NLAMCNLRREIPNLTLPLKDELDSLGNHLSAIRPSFQGLMELOKLMWISQIOIERNNA 262
 QY 262 FDGLASIVELNLAHNNLSLPHDLFTPLRYLYVELHLHHPNPNCCDILWLAWLREYIPT 321
 DB 263 FDNLQSLVEINLAHNNLTPLPHDLFTPLHLERHLHHPNPNCCDILWLSWKIDMAPS 322
 QY 322 NSTCCORCHAPMRCRYLVEVDQASFOCSAPFIMDAPRDLMSGRMAELKCR-TPPMS 380
 DB 323 NTACCACNTPPNLKGRTYICELDQNYFTCYAFVIVEPPADLVNTEGMAAELKCRASLT 382
 QY 381 SVKWLJPNCTVLSHASHRPRISVLNDGTILNFHLLSDTGVYTCMVNVAGNSNASAYLN 440
 DB 383 SVSWITPENGTVTHGAYKRVIAVLSDGTILNFVTVQDTGMVTCMVNSVGNVTASATLN 442
 QY 441 VSTAELNTSNYSFPTTVVETTEISPED---TTRKYKVPV-----TTSYQYQAVTTSTT 492
 DB 443 VTAA--TTTPFSYFSTVTVETMEPSQDEARTDNNVGPVVDVWETINV-----TISLT 494
 QY 493 VLQOTTR-VPKQVAVPATDITDMQSLDVKMTKIIGCFVAVTLAAAMLIVPKLR 551
 DB 495 P--QSTRSTKTFITPVTINSIGI-PGIDEVWKTTKIIGCFVAVTLAAAMLIVPKLR 551
 QY 552 KRHOQRSTVTAARTVEIIQVDEIDIPAATAAATAAPSGVSGGAVVLPTI-HDHIN-YNT 609
 DB 552 KQHRQNHAPITVELINVDDITGDTM-----ESHLMPAIREHHLNHYNS 600
 QY 610 YKPAHGAHNTENSLGNSLHPVTITISEPVIIQTHTKQKQVETQI 653
 DB 601 YKSPFFNHTTNTI-NSIH---SSVHEPLLIRNNSKDNVQETQI 640

RESULT 48

ABUS9185
 ID ABUS9185 standard; Protein; 640 AA.

XX AC ABUS9185;

XX DT 28-APR-2003 (first entry)

XX DE Novel human secreted or transmembrane protein PRO331.

XX KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
 KW cardiac insufficiency disorder; cancer; tumour; immune response;
 KW adrenal cortical capillary endothelial growth; c-fos induction;
 KW vascular endothelial growth factor inhibition; VEGF inhibition;
 KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
 KW retinal neurons cell survival; rod photoreceptor cell survival;
 KW retinal disorder; retinitis pigmentosa; kidney disease;
 KW mammalian kidney mesangial cell proliferation; Berger disease;
 KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
 KW chondrocyte redifferentiation; sports injury; arthritis.

XX OS Homo sapiens.

XX PN US2002132252-A1.

XX XX

Q Sequence 640 AA;		Query Match		Score 1865; DB 24; Length 640;	
		Best Local Similarity 56.4%; Pred. No. 1,6e-146;			
		Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;			
y	22	VLTAVQWILCAALAAASAGQNCFCSCSNQSFVCTTRGLSRVPGQIPSNTRYLN	81		
	b	29	VLLAQQLLVAGLVRA-----QTCSFSCSNQSFVCTTRGLSRVPGQIPSNTRYLN	82	
y	82	LMENNIQMIQADTFPHLHLEVLQGRNSIRQIEVGAFNGLASLNTLELFDNNLTVIPSG	141		
	b	83	LHZNQIQLKVNPFELRELELQLSRHEITIEIGAFNGLANLNTLELFDNNLTVIPSG	142	
y	142	AFEYLSKRLMLRNPIESIPYAFNVPSELMELDGLKXLEYISEGAPFGLNLYL	201		
	b	143	AFVYLSKRLMLRNPIESIPYAFNVPSELMELDGLKXLEYISEGAPFGLNLYL	202	
y	202	NLGMNCIKOMPMLTFLVGLERLEKSGNFFPEIRPGSPHGLSSLLKLVWNSQVSLTERNA	261		
	b	203	NLGMNCIKOMPMLTFLVGLERLEKSGNFFPEIRPGSPHGLSSLLKLVWNSQVSLTERNA	262	
y	262	FDGLASLVELNLAHNNLSLPHDLFTPLRYLVLEHLHNNPANCDCDILMLAWMLRYIPT	321		
	b	263	FDGLASLVELNLAHNNLSLPHDLFTPLRYLVLEHLHNNPANCDCDILMLAWMLRYIPT	322	
y	322	NSTCCORCHAPMHMGRYLVVEVDQASFOCSAPFIMDAPRDLINISSEGRMAELKCR-TPPMS	380		
	b	323	NSTCCORCHAPMHMGRYLVVEVDQASFOCSAPFIMDAPRDLINISSEGRMAELKCR-TPPMS	382	
y	381	SVKLLPNGTVLSHARHPRISLVNDGHLNFSHVLLSDTVGTCMVTVNAGNSAAYLN	440		
	b	383	SVKLLPNGTVLSHARHPRISLVNDGHLNFSHVLLSDTVGTCMVTVNAGNSAAYLN	442	
y	441	VSTALNTSNVFFTVVETTESPED---TTRKYPVP-----TSTGYQAVTTSIT	492		
	b	443	VSTALNTSNVFFTVVETTESPED---TTRKYPVP-----TSTGYQAVTTSIT	494	
y	493	VLIQTR-VPKQVAVPATDTTRKQMTSLDEVMKTKIIIGCFVAVTLAAAMLVIPYKUR	551		
	b	495	VLIQTR-VPKQVAVPATDTTRKQMTSLDEVMKTKIIIGCFVAVTLAAAMLVIPYKUR	551	
y	552	KHQRSTVTAARTVEIIQVDEDPAAATSAATAAPSGVSGEAGAVLPTI-HDHIN-YNT	609		
	b	552	KHQRSTVTAARTVEIIQVDEDPAAATSAATAAPSGVSGEAGAVLPTI-HDHIN-YNT	609	
y	610	YKPAHGAHWNTENSLNLSHPTVTSISPYIQTHTKDKVQETQI 653			
	b	601	YKSPFNHTTWNIT-NSIH---SSVHPEFLIRMSKDNVQETQI 640		
RESULT 49					
ABU59332					
[D ABU59332 standard; Protein; 640 AA.					
AC ABU59332;					
JT 22-APR-2003 (first entry)					
DE Human secreted/transmembrane protein, #175.					
CW Human; PRO; secreted; transmembrane; pharmaceutical;					
CW diagnostic; biosensor; bioindicator; tumour; therapeutic;					
CW gene therapy; tumour-associated antigenic target; TAT; ADEPT;					
CW antibody-dependent enzyme mediated prodrug therapy; cytostatic.					
DS Homo sapiens.					
SW US2003027162-A1.					
CX 06-FEB-2003.					
PD 15-NOV-2001; 2001US-0997428.					
PF					

XX	05-NOV-1997;	97WO-US20069.
PR	16-SEP-1998;	98WO-US19330.
PR	17-SEP-1998;	98WO-US19437.
PR	07-OCT-1998;	98WO-US21141.
PR	01-DEC-1998;	98WO-US25108.
PR	05-JAN-1999;	99WO-US00106.
PR	08-MAR-1999;	99WO-US05028.
PR	02-JUN-1999;	99WO-US12252.
PR	15-SEP-1999;	99WO-US21090.
PR	15-SEP-1999;	99WO-US21547.
PR	30-NOV-1999;	99WO-US28313.
PR	01-DEC-1999;	99WO-US28301.
PR	01-DEC-1999;	99WO-US28634.
PR	16-DEC-1999;	99WO-US30095.
PR	20-DEC-1999;	99WO-US30911.
PR	05-JAN-2000;	2000WO-US00219.
PR	06-JAN-2000;	2000WO-US00376.
PR	11-FEB-2000;	2000WO-US03565.
PR	18-FEB-2000;	2000WO-US04341.
PR	22-FEB-2000;	2000WO-US04414.
PR	24-FEB-2000;	2000WO-US04514.
PR	24-FEB-2000;	2000WO-US05004.
PR	02-MAR-2000;	2000WO-US05841.
PR	10-MAR-2000;	2000WO-US06319.
PR	15-MAR-2000;	2000WO-US06884.
PR	20-MAR-2000;	2000WO-US07377.
PR	30-MAR-2000;	2000WO-US08439.
PR	15-MAY-2000;	2000WO-US13358.
PR	17-MAY-2000;	2000WO-US13705.
PR	22-MAY-2000;	2000WO-US14042.
PR	30-MAY-2000;	2000WO-US14941.
PR	02-JUN-2000;	2000WO-US15264.
PR	28-JUL-2000;	2000WO-US20710.
PR	11-AUG-2000;	2000WO-US22031.
PR	23-AUG-2000;	2000WO-US23522.
PR	24-AUG-2000;	2000WO-US23328.
PR	08-NOV-2000;	2000WO-US30952.
PR	01-DEC-2000;	2000WO-US32678.
PR	28-DEC-2001;	2001WO-US06520.
PR	01-JUN-2001;	2001WO-US17800.
PR	20-JUN-2001;	2001WO-US19692.
PR	29-JUN-2001;	2001WO-US21066.
PR	09-JUL-2001;	2001WO-US21735.
PR	16-JUN-1997;	97US-049787P.
PR	17-OCT-1997;	97US-062250P.
PR	12-NOV-1997;	97US-065186P.
PR	13-NOV-1997;	97US-065311P.
PR	24-NOV-1997;	97US-066770P.
PR	25-FEB-1998;	98US-075945P.
PR	20-MAR-1998;	98US-078910P.
PR	28-APR-1998;	98US-083222P.
PR	07-MAY-1998;	98US-084600P.
PR	28-MAY-1998;	98US-087106P.
PR	02-JUN-1998;	98US-087607P.
PR	02-JUN-1998;	98US-087609P.
PR	03-JUN-1998;	98US-087759P.
PR	04-JUN-1998;	98US-088021P.
PR	04-JUN-1998;	98US-088025P.
PR	04-JUN-1998;	98US-088026P.
PR	04-JUN-1998;	98US-088028P.
PR	04-JUN-1998;	98US-088029P.
PR	04-JUN-1998;	98US-088030P.
PR	04-JUN-1998;	98US-088033P.
PR	04-JUN-1998;	98US-088326P.
PR	05-JUN-1998;	98US-088167P.
PR	05-JUN-1998;	98US-088202P.
PR	05-JUN-1998;	98US-088212P.
PR	05-JUN-1998;	98US-088217P.
PR	09-JUN-1998;	98US-088655P.
PR	10-JUN-1998;	98US-088734P.
PR	10-JUN-1998;	98US-088738P.

Db 495 P-QSTRSTKTFIPVTDINSIGI-PGIDEVWTKTKIIIGCFVAITLMAAAVLMVIFYOMR 551
Qy 552 KHQORSVTVAARTVEIIQDEIDPAATSAATAPSGVSGEAVLPTI-HDHIN-YNT 609
Db 552 KQHRRQNHAPTRVVEIINVDEITGTFTM-----ESHEPMPAIEHBEHAHNS 600
Qy 610 YKPAHGAHWHTENSIGNSLHPTVTWISBPYIIQTHTKDKVOETQI 653
Db 601 YKSPNHTTNTI-NSIH---SSVHEPLLRWNSKDNVQETQI 640

RESULT 50
ABU59481
ID ABU59481 standard; Protein; 640 AA.
AC ABU59481;
CX 22-APR-2003 (first entry)
CX Novel human secreted or transmembrane protein PRO363.
CX Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
CX cardiac insufficiency disorder; cancer; tumour; immune response;
CX adrenal cortical capillary endothelial growth; c-fos induction;
CX vascular endothelial growth factor inhibition; VEGF inhibition;
CX endothelial cell growth inhibitor; T-lymphocytes stimulation;
CX retinal neurons cell survival; rod photoreceptor cell survival;
CX retinal disorder; retinitis pigmentosa; kidney disorder;
CX mammalian kidney mesangial cell proliferation; Berger disease;
CX dermatitis; herpiformis; Crohn's disease; chondrocyte proliferation;
CX chondrocyte redifferentiation; sports injury; arthritis.
CX Homo sapiens.
CX US2003027985-A1.
CX 06-FEB-2003.
CX 14-NOV-2001; 2001US-0990562.
CX 05-NOV-1997; 97WO-US20069.
CX 16-SEP-1998; 98WO-US19330.
CX 17-SEP-1998; 98WO-US19437.
CX 07-OCT-1998; 98WO-US21141.
CX 01-DEC-1998; 98WO-US25108.
CX 05-JAN-1999; 99WO-US00106.
CX 08-MAR-1999; 99WO-US05028.
CX 02-JUN-1999; 99WO-US12252.
CX 15-SEP-1999; 99WO-US21090.
CX 15-SEP-1999; 99WO-US21547.
CX 30-NOV-1999; 99WO-US28313.
CX 01-DEC-1999; 99WO-US28301.
CX 16-DEC-1999; 99WO-US28634.
CX 20-DEC-1999; 99WO-US30095.
CX 05-JAN-2000; 99WO-US30911.
CX 06-JAN-2000; 2000WO-US00219.
CX 18-FEB-2000; 2000WO-US00376.
CX 11-FEB-2000; 2000WO-US03565.
CX 22-FEB-2000; 2000WO-US04341.
CX 24-FEB-2000; 2000WO-US04414.
CX 24-FEB-2000; 2000WO-US04914.
CX 02-MAR-2000; 2000WO-US05004.
CX 10-MAR-2000; 2000WO-US05841.
CX 15-MAR-2000; 2000WO-US06319.
CX 20-MAR-2000; 2000WO-US06884.
CX 30-MAR-2000; 2000WO-US07377.
CX 17-MAY-2000; 2000WO-US08435.
CX 17-MAY-2000; 2000WO-US13358.
CX 22-MAY-2000; 2000WO-US13705.
CX 30-MAY-2000; 2000WO-US14042.
CX 02-JUN-2000; 2000WO-US14943.
CX 28-JUL-2000; 2000WO-US15264.
CX 28-JUL-2000; 2000WO-US20710.

PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083222P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088467P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 17-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 18-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089947P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 23-JUN-1998; 98US-090349P.
PR 23-JUN-1998; 98US-090355P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090431P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090445P.
PR 24-JUN-1998; 98US-090472P.

PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 24-JUN-1998; 98US-090542P.
PR 24-JUN-1998; 98US-090557P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 25-JUN-1998; 98US-090698P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091519P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091633P.
PR 02-JUL-1998; 98US-091646P.
PR 02-JUL-1998; 98US-091673P.
PR 07-JUL-1998; 98US-091978P.
PR 07-JUL-1998; 98US-091982P.
PR 09-JUL-1998; 98US-092182P.
PR 10-JUL-1998; 98US-092472P.
PR 20-JUL-1998; 98US-093339P.
PR 30-JUL-1998; 98US-094651P.
PR 04-AUG-1998; 98US-095282P.
PR 04-AUG-1998; 98US-095285P.
PR 04-AUG-1998; 98US-095301P.
PR 04-AUG-1998; 98US-095302P.
PR 04-AUG-1998; 98US-095318P.
PR 04-AUG-1998; 98US-095321P.
PR 04-AUG-1998; 98US-095325P.
PR 10-AUG-1998; 98US-095916P.
PR 10-AUG-1998; 98US-095923P.
PR 10-AUG-1998; 98US-096012P.
PR 11-AUG-1998; 98US-096143P.
PR 11-AUG-1998; 98US-096146P.
PR 12-AUG-1998; 98US-096329P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096768P.
PR 17-AUG-1998; 98US-096773P.
PR 17-AUG-1998; 98US-096791P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096894P.
PR 17-AUG-1998; 98US-096895P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096950P.
PR 18-AUG-1998; 98US-096953P.
PR 18-AUG-1998; 98US-096960P.
PR 18-AUG-1998; 98US-097022P.
PR 19-AUG-1998; 98US-097141P.
PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 24-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 26-AUG-1998; 98US-098014P.

Query Match 54.2%; Score 1865; DB 24; Length 640;
Best Local Similarity 56.4%; Pred. No. 1.6e-146;
Matches 363; Conservative 107; Mismatches 130; Indels 44; Caps 14;
QY 22 VYLAQWILCAATAAASAGPQPCSVCSNQFSKVVCVTRGLSEVPQGISNTRYLN 81

Db 29 VLLALQLLVVAGLVRA-----QTCPSCVCSNQFSKVVCVKNLREVPDGDISTNRYLN 82
QY 82 LMENNTOMIQADTFRHLHLVLQLOGRNSIROIEVGAENGASLANTELEFDNMLTVIPSG 141
Db 83 LHENQIQIKVNSFRHLRHLLEIQSRNHRITIEGAFNGLANTELEFDNRLTIIPNG 142
QY 142 AFEYLSKLRELMLRNPIESIPSYAFNRVPSLWRDLGELKLEYISGAFGLNLYL 201
Db 143 AFVYLSKLRELMLRNPIESIPSYAFNRVPSLWRDLGELKLEYISGAFGLNLYL 202
QY 202 NLGCMNKKMNPILTPVGLERLEKSNHPEPRPSGSLSSKLXLMWNSOVSLIENA 261
Db 203 NLAVCNLRIPNLTPLIKDELDSLGNHLSAIRPSFGELMHLQKMLMQSOIQVIERNA 262
QY 262 FDGLASIVELNLAHNNLSLPHDLFTFLFYVELHLHHPNMCDCDIILWLAWLREYIPT 321
Db 263 FDNLQSLIVEINLAHNNLTLLPHDLFTFLHLHLRIHLHHPNMCNCDIILWLSWIKDMAPS 322
QY 322 NSTCCGRCHAPMMRGYLVVEVDQASPOCSAPFIMDAPEDLANISGRMAELKCR-TPPMS 380
Db 323 NTACCARCNTPPNLKGRYIGELDQNYFTCYAPVIEPPADLANVTEGMAELKCRASSTUT 382
QY 381 SVKWLPPNGTVLSHARRHPRIISVLNDGTLNFSHVLSDTGVTTCMVTVNAGNSASAYLN 440
Db 383 SVSWITPENGTVMTGAYKVRIAVLSGTLNFTNVTVDGTGMYTCMVNSVGNVTASATLN 442
QY 441 VSTABLNTSNYPFTTVTVEFTHEISPD---TTRKYKVP-----TTSYGYPAYTTST 492
Db 443 VTAA--TTTFPSYFSTVETWEPQSODEARTDNNVGPTEVVDWETNV-----TTSUT 494
QY 493 VLIQTER-VPKQVAVPATDITDKMOTSLDEVMKTKIIIGCFVAVTLLAAAMLVIFYKLR 551
Db 495 P--QSTRSTKTTTIPVDINSIGI-FGIDEVMKTKIIIGCFVAVTLLAAAMLVIFYKLR 551
QY 552 KRHQQRSTVTAARTVEIIQVDEDIIPAATSAATAAPSGVSGEGAVVLPPI-HDHIN-YMT 609
Db 552 KQHRQRNHAFTRTVEIINVDEITGTPM-----ESHLEMPAIEHHLNHYNS 600
QY 610 YKPAHGAHWTENSIGNSLHPTVTITISEPVIIQHTKDKVQETOI 653
Db 601 YKSPFNHTTTVNTI-NSIH---SSVHEPILIRNNSKDNVQETOI 640

Search completed: February 5, 2004, 15:49:04
Job time : 54 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

M protein - protein search, using sw model

un on: February 5, 2004, 15:47:15 ; Search time 20 Seconds
(without alignments)
3139.907 Million cell updates/sec

icle: US-09-989-279-229

effect score: 3440

sequence: 1 MKLLMQVTHHTWNAILLP.....ISBPYIIQTHYKQVQETQI 653

coring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

searched: 283308 seqs, 96168682 residues

total number of hits satisfying chosen parameters: 283308

inimum DB seq length: 0

aximum DB seq length: 2000000000

ost-processing: Minimum Match 0%

Maximum Match 100%

Listing first 150 summaries

atabase :

PIR 76:*

1: P11:*

2: P12:*

3: P13:*

4: P14:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

result No.	Score	Query Match	Length	ID	Description
1	1158	33.7	421	2	T46266
2	438	12.7	1031	2	A58532
3	414	12.0	1531	2	T42218
4	411.5	12.0	707	2	JC7763
5	391	11.4	1523	2	T13953
6	376	10.9	361	2	A53860
7	355.5	10.3	1469	2	B36665
8	355.5	10.3	1480	2	A36665
9	335.5	9.8	789	2	T28714
10	335.5	9.8	1355	2	T28715
11	331.5	9.6	1535	2	S46224
12	321.5	9.3	907	2	JG0193
13	321	9.3	603	2	JG6128
14	315	9.2	605	2	JG5239
15	310	9.0	603	2	JC1382
16	309	9.0	605	2	A41315
17	309	9.0	1025	2	T42626
18	308.5	9.0	420	2	A53531
19	305.5	8.9	560	2	A60164
20	303.5	8.8	359	1	NBUH08
21	303.5	8.8	907	2	JE0176
22	298	8.7	360	2	S06280
23	293.5	8.5	360	2	I47020
24	286.5	8.4	357	2	S24317
25	286.5	8.3	354	2	S29145
26	279.5	8.1	354	2	A55454
27	268.5	7.8	1389	2	T13852
28	267	7.8	536	2	A34901
29	265	7.7	653	2	T25194

tlr protein - frui
proteoglycan i - m
biglycan precursor
hypothetical prote
biglycan precursor
biglycan precursor
hypothetical prote
hypothetical prote
hypothetical prote
hypothetical prote
hypothetical prote
hypothetical prote
Toll protein precu
Gene trkC protein
hypothetical prote
hypothetical prote
neurotrophin-3 rec
neurotrophin-3 rec
proline- arginine-
neurotrophin-3 rec
neurotrophin-3 rec
oligodendrocyte-my
hypothetical prote
neurotrophin-3 rec
tyrosine kinase C
fibromodulin - chi
RP105 - mouse
hypothetical prote
leucine-rich alpha
fibromodulin preu
chaoptin precursor
oligodendrocyte-my
hypothetical prote
hypothetical prote
folliotropin recept
folliotropin recept
hypothetical prote
fibromodulin preu
hypothetical prote
sp150 protein - fr
garp precursor - h
lumican precursor
cell-surface molec
connectin precuso
follicle stimulat
folliotropin recept
folliotropin recept
lumican precursor
hypothetical prote
Ras-binding protei
hypothetical prote
protein AC7.2 [imp
G protein-coupled
disease resistance
internalin, probab
brain-derived neur
folliotropin recept
densin-180 - rat
disease resistance
gene flightless-1
G protein-coupled
Probable disease r
lumicon, secretory
folliotropin recept
internalin protein
leucine-rich-repae
folliotropin recept
hypothetical prote
protein phosphatas
hypothetical prote
hypothetical prote
lutropin-choriogon

283.5 7.7 1385 2 T13887
369 7.6 369 2 S20811
362.5 7.6 369 2 S32793
362.5 7.6 738 1 T19938
361.5 7.6 368 1 BGHUN
361.5 7.6 369 2 S32559
361.5 7.5 361 2 T23395
254 7.4 603 2 T23315
252.5 7.3 594 2 T23841
250 7.3 575 2 T29972
250 7.3 680 2 T19939
249.5 7.3 610 2 T23836
248.5 7.2 626 1 NBUH1A
247.5 7.2 1097 2 A25943
244 7.1 612 2 I73633
242.5 7.0 562 2 T34319
240 7.0 458 2 T19941
239 6.9 825 2 A55178
239 6.9 839 1 I73632
238 6.9 382 2 I39068
238 6.9 525 1 A58674
235.5 6.8 803 1 S35695
234.5 6.8 440 2 A39613
234.5 6.8 1066 2 T15864
233 6.8 825 1 A40026
227 6.6 852 2 I51259
225.5 6.6 380 2 S71876
225.5 6.6 661 2 I56258
224 6.5 693 2 T24486
223.5 6.5 312 1 NBUH2
220.5 6.4 375 2 S05390
220.5 6.4 1134 1 A29944
219 6.4 440 2 A47530
217 6.3 333 2 T34555
215.5 6.3 695 1 QRUFT
215.5 6.3 695 1 JN0898
215 6.2 1328 2 T23007
212.5 6.2 376 2 S55275
212.5 6.2 224 2 T32185
209.5 6.1 224 2 T31174
208 6.0 1051 2 T13174
208 6.0 662 2 S43799
206 6.0 343 2 A41748
205.5 6.0 682 2 A49121
205.5 6.0 682 2 A43318
203.5 5.9 695 2 I45896
203.5 5.9 694 2 JC4301
201.5 5.9 694 2 JC2327
201.5 5.9 342 2 A46743
199.5 5.8 1134 2 T04587
199 5.8 559 2 T42998
199 5.8 572 2 T30947
199 5.8 613 2 A88684
199 5.8 1115 2 S40241
198 5.8 771 2 T02565
197.5 5.7 646 2 A11174
195 5.7 818 1 S44099
195 5.7 818 2 JCI493
194.5 5.7 695 2 T31434
193 5.6 1495 2 T01105
191 5.6 818 2 S60461
190 5.5 1256 2 JC2033
188.5 5.5 1011 2 S52284
188 5.5 338 2 S52284
186.5 5.4 692 2 A34548
186.5 5.4 1778 2 AF1116
185 5.4 696 2 JC7361
184.5 5.4 1119 2 AD1822
183.5 5.3 864 2 D84740
183 5.3 332 2 S43988
182.5 5.3 800 2 H84740
182 5.3 448 2 T27395
182 5.3 659 1 QRUFT

103 180 5.2 656 2 AB1479 probable cell surf
104 180 5.2 1007 2 C84668 receptor-
105 178.5 5.2 943 2 E84429 probable receptor-
106 178 5.2 549 2 T41744 hypothetical prote
107 178 5.2 1039 2 T42117 hypothetical prote
108 177.5 5.2 822 1 A56853 brain-derived neur
109 177.5 5.2 1025 1 A57676 protein kinase Xa2
110 177 5.1 338 2 S38030 suppressor protein
111 177 5.1 696 2 A41344 lutropin-choriogon
112 176.5 5.1 505 2 A41469 internalin like pr
113 176.5 5.1 1256 2 T71436 probable resistanc
114 176 5.1 790 1 TVRHTT nerve growth facto
115 173 5.0 799 1 TVRHTT nerve growth facto
116 172 5.0 800 2 AB1129 Internalin A limpo
117 171.5 5.0 1079 2 C96772 probable receptor
118 171 5.0 821 1 S06943 brain-derived neur
119 171 5.0 821 1 A39667 brain-derived neur
120 170.5 5.0 477 1 T73631 brain-derived neur
121 170 4.9 808 2 B97303 hypothetical prote
122 169 4.9 800 2 S37387 Internalin A precu
123 168.5 4.9 1237 2 A41583 internalin protein
124 168.5 4.9 1257 2 A88536 protein B0523.5 [i
125 168 4.9 813 2 T04313 protein kinase Xa2
126 168 4.9 874 2 E97302 hypothetical prote
127 168 4.9 1112 2 T10504 disease resistance
128 167.5 4.9 548 2 A41107 internalin H limpo
129 167 4.9 1143 2 T10636 hypothetical prote
130 166.5 4.8 700 2 T74633 lutetizing hormon
131 166.5 4.8 700 2 A49744 lutropin-choriogon
132 166 4.8 2145 2 J04747 adenylyate cyclase
133 165.5 4.8 526 2 C94552 hypothetical prote
134 164.5 4.8 499 2 A11107 internalin E limpo
135 164 4.8 474 1 C39667 brain-derived neur
136 164 4.8 476 1 A35104 brain-derived neur
137 164 4.8 476 1 B39667 brain-derived neur
138 163.5 4.8 821 2 AB1126 internalin, peptid
139 163.5 4.8 1009 2 T45645 receptor kinase-li
140 163 4.7 540 2 T12704 leucine-rich prote
141 163 4.7 700 2 A42395 lutropin receptor
142 163 4.7 1011 2 T45718 receptor-kinase li
143 162.5 4.7 1064 2 B86465 probable Protein k
144 162 4.7 717 2 T33295 hypothetical prote
145 161.5 4.7 612 2 T10727 protein kinase Xa2
146 161 4.7 853 2 T17461 disease resistance
147 161 4.7 2493 2 A55481 adenylyate cyclase
148 160.5 4.7 2088 2 E71436 hypothetical prote
149 160 4.7 2222 2 T13924 skk protein - frui
150 159.5 4.6 1045 2 T41119 internalin- relate

ALIGNMENTS

RESULT 1
T46266
Hypothetical protein DKFp761A179.1 - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 04-Feb-2000 #sequence_revision 04-Feb-2000 #text_change 04-Feb-2000
C:Accession: T46266
Submitted to the Protein Sequence Database, January 2000
R:Blum, H.; Baurerachs, S.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.
A:Reference number: 223034
A:Accession: T46266
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-421 <AAA>
A:Cross-references: EMBL:AL137451
A:Experimental source: adult amygdala; clone DKFp761A179
C:Genetics:
A:Note: DKFp761A179.1
Query Match 33.7%; Score 1158; DB 2; Length 421;
Best Local Similarity 53.6%; Pred. No. 1.9e-73;

Matches 225; Conservative 62; Mismatches 95; Indels 38; Gaps 5;
QY 205 MCNIKDMNLPLVCLGLEMSGNHFFBIRPGSPHGLSSLKCLWVMSQVSLIERNAFDG 264
DB 1 MCNLKIDINLTALVLELESGNLDLIRPGSPHGLSSLKCLWVMSQVSLIERNAFDG 60
QY 265 LASVELMLANNNSSPHDLFTPLRLVLELHLLHNPNWNCDDILWLAWLREVIPTNST 324
DB 61 LKSLFELNLSHNLMSLPHDLFTPLRLVLELHLLHNPNWNCDDILWLAWLREVIPTNST 120
QY 325 CGGRCHAPMHRGVLVEVDQASFOCSAPFIMDAPRLINISEGRMAELKCRTPPMSSVK 383
DB 121 CACRCHAPAGLGRVIGELDSHFTCAPVLVLEPTDLNVTIEGMAELKCRTPMTSVN 180
QY 384 WLLPNTGLVSHASRHRPISVNLDTGLNPSVLLSDTGYTCMTVNVAGNSNAGLAYLNST 443
DB 181 WLPNTGLVTHGSRVRLSVLHDTGLNFTNVQDTGYTCMTVNVAGNSNAGTASATLVSA 240
QY 444 AEL-----NTSNYSPTTAVTVEISPEDT-----TRKYKV 476
DB 241 VDPVAAAGTGGGGGPGGG 300
QY 477 PTT-----STGYOPAYTSTTVLIQTR-VPKQVAVPATDTTKMQTSLDEVNKT 526
DB 301 PTTDGVWCGGRPGDAAGPSSSTTAPAPRSRPEKAPTPTDVTENALKOLDVDMKT 360
QY 527 KIIIGCFVAVTLLAAMLVVFKLRKHQOBSTVTAARTVRILOVDEDIQAATAAATA 586
DB 361 KIIIGCFVAVTLLAAMLVVFKLRKHQOBSTVTAARTVRILOVDEDIQAATAAATA 420
RESULT 2
A58532
glial cell membrane glycoprotein LIG-1 precursor - mouse
C:Species: Mus musculus (house mouse)
C:Date: 11-Apr-1997 #sequence_revision 11-Apr-1997 #text_change 05-Nov-1999
C:Accession: A58532
R:Suzuki, Y.; Sato, N.; Tohyama, M.; Wanaka, A.; Takagi, T.
J. Biol. Chem. 271, 22522-22527, 1996
A:Title: cDNA cloning of a novel membrane glycoprotein that is expressed specifically in
A:Reference number: A58532; MUID:96394313, PMID:8798419
A:Accession: A58532
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-1091 <SUZ>
A:Cross-references: GB:D78572; MID:g1545806; PIDN:BAAL1416.1; PID:g1545807
C:Superfamily: leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan amino-ter
F:36-61/Domain: proteoglycan amino-terminal homology <PAH>
F:71-94/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
F:95-117/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
F:118-141/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
F:142-165/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
F:166-189/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
F:191-213/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
F:214-237/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
F:238-261/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
F:262-285/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
F:286-309/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR10>
F:310-333/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR11>
F:334-357/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR12>
F:358-381/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR13>
F:385-408/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR14>
F:409-432/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR15>
F:440-485/Domain: proteoglycan carboxyl-terminal homology <PCH>
Query Match 12.7%; Score 438; DB 2; Length 1091;
Best Local Similarity 21.0%; Pred. No. 1.8e-22;
Matches 196; Conservative 110; Mismatches 275; Indels 354; Gaps 26;

QY 28 WVILCAIAAASAGPQ-----NCPSCVCSNCFKSVCTRRGLSEVPGQIPSNTRYLNL 82
DB 20 LWLLLLLQWPESAGARPRAPCAACTCAG--NSLDCSGRGLATLPDLPSPWTRSLNL 77

83 M----- 83
 78 SYNRLSEIDSAPELDTNLQEVYNSNELTALPSLTASIGVSWSEFLQHNKILSDGSOL 137
 84 ----- 83
 138 KSVLSLEVLDSNNITEIRSCPPNGLRIRLEINLASNRISLESAGFDGLSRSLTLRL 197
 84 ----- ENNIQMIQADTFRHLHLEVLQLGNSIRIQIEVQAF 119
 198 SKNRITQLPVKAPKPLRLTQDLNRRNRIRLEGLTFQGLDSEVLRLQNRNISRUTDGA 257
 120 NGLASLNTLELFPNWLTVIPSGAFVYLSKRLRLNPNIESIPS-----YA 166
 258 WGLSKRVHLEFVNSVNSGLYGLTALQHLNSNISIRIQDGSFOOKLHELILS 317
 167 FNRVPSLMRLDLCGLK-----EYISGAPEGLFNKLYLMLGNCRITKMPNLT 216
 318 FNNLTRDSSLAELSLSLRLSHNAISHIABGAPKGLKSLRVL----- 363
 217 LVGLELEMSGNHFPPIRPGSFHGLSLKLMVNSQVSLIERNAPDGLASLVELNLAHN 276
 364 ---LDHNEISGT---IEDTSGAFTGLDNLKSLTLFGNKIKSVAKRAPSGLESLEHLNLAGN 418
 277 NLSSLPHDLFTPLRYLVELLHNPWNCDDILWLAWLR----- 316
 419 AIRSVQDPAKMNKLYISSPFLDCQLXWLPFLMGRMLQAFVATCAHPSLKG 478
 317 ---EYIPTNSTC---CGR---CHA---PM----- 333
 479 QSIPLVDFSVCDPFPKQIITQPETWAVGVKDIRFTCSAASSSSPMTFAWKDREV 538
 334 ---HMRG-----RYLVEVDQASFOC----- 350
 539 LANADMENFAVRQDGEVMEYTLHLRVTFGHGRVQCIITNFGSTYSHKARLTWN 598
 351 SAPFINDAPDLNISGRMAELKCRTP---PMSSVKMLLPNGTVLSHSHRPRISVLNDGT 408
 599 VLPSTKIPHDIALRTGTARLECAARGHPNPQIAWKDGGTDFP-AARERRMHWVPDD 657
 409 LNP-SHVLSDGTGVTCTVNVAGNSASAVLNVSTAEINTSYSP---PTTVTVETTEI 464
 658 VFFITDKIDMGVYSCTAQSAGSVSANATLTV---LETPLAVPLEDRVVTVGETVA 713
 465 SPEDTRKPKVPPTTSTGYOP-----AYTTSTTVLIQT 497
 714 PQCATGSPTRITWLKGRPLSTERTHHTPGNQLLVQNVWIDDAGRYTCMSNPLGT 773
 498 TRVPQVAVPATDTDKQKSLDSEVMKTKIIIGCFVAVTLIAAAMLIIVFYKLRKHQR 557
 774 ERAHSQLSILPTPGCRKDGITVG-----IPTIAVVCISIVLTSL--VWVCIIYQTRKXSEY 827
 558 STVTAASATVEIIQVDEDI PAATSAATAAPSGVSGEGAVLPTIHDHINVTYKPAHGAH 617
 828 SVTNTDETI-----VPPDVPSVLSQGT-----LSDROETVVRTEGGH-QANGHIESNGVC 877
 618 WTENSLGNSLHPTTITISEPVIIOHTKD--KVQE 650
 878 LRDPFLPEVDIHSTTCRQPKLCVGYTRPDKVTE 912

RESULT 3

T42218
 A:Alternate names: MEGF4 protein
 A:Species: Rattus norvegicus (Norway rat)
 C:Date: 03-Dec-1999 #sequence_revision 03-Dec-1999 #text_change 16-Aug-2002
 C:Accession: T42218
 R:Nakayama, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Seki, N.; Ohara, O.
 J:Biochem. Biophys. Res. Commun. 287, 257-263, 2001
 A:Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs
 A:Reference number: Z14126; MUID:98360089; PMID:9693030
 A:Accession: T42218

A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-1531 <NA>
 A:Cross-references: EMBL:AB011530; NID:g3449289; PIDN:BAA32460.1; PID:g3449290
 A:Experimental source: strain Sprague-Dawley; brain
 C:Genetics:
 A:Gene: MEGP4
 C:Superfamily: fruit fly slit protein; EGF homology; leucine-rich alpha-2-glycoprotein r

Query Match 12.0%; Score 414; DB 2; Length 1531;
 Best Local Similarity 24.1%; Pred. No. 1.4e-20;
 Matches 139; Conservative 69; Mismatches 166; Indels 202; Gaps 15;
 QY 27 QWILCAATAAASAGPQPCSVCSQSPKSVCTRGSLSEVPOQIPSNRYLMLNEN 86
 DB 17 ELWL---LWAAWRIGATACPALCTCTG--TTVDGHTGLQAIIPKIPNRYLLELNGNN 72
 QY 87 IQMIQADTFRHLHLEVLQLGNSIRIQIEVQAFNGLASLNTLELFDNMLTVIP----- 139
 DB 73 ITRIHKNDPAGLQALVQLMENOIGAVERGAFDDMKELERLRLNRNQLVPELLFQNN 132
 QY 140 -----SCAPEYLSKIRELMRNPP 158
 DB 133 QALSRLDLSNSIQAVPRKAFRGATDLKNLDKNOISIEGAFALRGLEVLTLNANN 192
 QY 159 IESIPSYAFNRVP-----SLMRLD 177
 DB 193 ITTIPVSSFNHMPKGLRFRLESNHLFCDCHLAWLSQWLQRPTIGLFTQCSGSPASLUGLN 252
 QY 178 LGEUKKLEYISGAF-----GLF-----NLK 199
 DB 253 VAEQYSEFSCSGGAAQVPACTLSGSGCPAMCSNGIVDCRGKGLTAIPANLPETMT 312
 QY 200 YLNLGMCNIDMP--NLTPLVGLEELMSGNHPEIRPGSFHGLSLKLMVNSQVSLI 257
 DB 313 EIRLELNGIKSIIPGAFSPYRKLRRIDLSNNQIATAPDAFQGLRSLSLVLYGNKITDL 372
 QY 258 ERNAPDG-----LASVELNLAHNLSLPHDLFTPLRYLV 293
 DB 373 PRGVFGLYTLQILLNANKINCIRPDADFQDLQNLISLYDNKIOSLAKGTTFTSLRAIQ 432
 QY 294 ELHLHHPNWCDDILAWLWLEYIPTN--STCCGRCHAPMEMRGVLYVEVDQASFOCS 351
 DB 433 TLHLAQNPFCDCNKLWLADPLR---TNFIETGARCASPRELANKRIGQIISKAFCS 498
 QY 352 A--PFINDAPDLNISGRMAEL---KCRTP-----PMSVSKWLLP 387
 DB 489 AKQYFIPGTEDYELNSETSDVACPHKCRCEASVWECGLKSKIPERIPQSTTELRIN 548
 QY 388 NGTV-----LSHNR-----HPRISVLNDGT 408
 DB 549 NNEISILEATGLFKLSHLKKNLNKNVSEIBDGT 584

RESULT 4

JC7763
 A:Neuronal leucine-rich repeat protein-3 - rat
 C:Species: Rattus norvegicus (Norway rat)
 C:Date: 01-Feb-2002 #sequence_revision 01-Feb-2002 #text_change 01-Feb-2002
 C:Accession: JC7763
 R:Fukamachi, K.; Matsuo, Y.; Kitanaka, C.; Kuchino, Y.; Teada, H.
 J:Biochem. Biophys. Res. Commun. 287, 257-263, 2001
 A:Title: Rat neuronal leucine-rich repeat protein-3: Cloning and regulation of the gene
 A:Reference number: JC7763; PMID:11549284
 A:Contents: Fibrosarcoma cells
 A:Accession: JC7763
 A:Molecule type: mRNA
 A:Residues: 1-707 <PUK>
 C:Cross-references: GB:AF291437
 C:Comment: This protein, a new member of the neuronal leucine-rich repeat protein family,
 is in protein-protein interaction and functions as a cell adhesion molecule or soluble ligand
 C:Genetics:
 A:Gene: nlrr-3

C:Keywords: cell adhesion

```

Query Match      12.0%; Score 411.5; DB 2; Length 707;
Best Local Similarity 24.0%; Pred. No. 7.3e-21;
Matches 172; Conservative 103; Mismatches 267; Indels 175; Gaps 24;

2Y      30  ILCAIAAAAGAGPO--NCP5VCSCS-----NQFSKVCVCRGLSEVPQIGPSN 76
2b      11  LGLALATLVQAGDKVDPCQLCTEIRPWFTPRSIWBEASTVDCNDGLINFPARLPAD 70

2Y      77  TRYILNMENNYQMIOADTFRLHLHLEVLQGRNSIRQIEVGAENGASLANTLELEFDNWL 136
2b      71  TOILLQTNRIARIEHSTDFEV-NTGLDLSQNNLSVTVINVQKMSQLLSVILEENKIT 129

2Y     137  VTPSGAFEYLSKRELMRLNRPISISPYAFNRPVSLMRDLIDELCKLEYISIEGAFEG 196
2b     130  ELPECKLVGELSNLQELVYNNLLGASIPGAFVGLHNLRLHLNS-NRLQMINSKWF 188

2Y     197  NLKYNILG--MCNIKOMP-----NLT-----PLVGLLELE-----224
2b     189  NLEILMLGDNPIIRIKDWNFOFLKRLASLVIAGINTEVPDDALVGLENLESISFYDN 248

2Y     225  -----MSGNHFPETRPGSFGLSLKCLWY-----249
2b     249  NKVPOVALQAVNLKFLDLKNPINRIRGDFSNMLHLKELGINNMPELVSDSLAVDNL 308

2Y     250  -----MRSQVSLIERNAPDGLASVLELNLAHNNLSLPHDLPTPLRYLVELHLHNN 300
2b     309  POLRKTEATNPRLSYIHPNAPFPLPKLESIMLNSNALSALYHGTTESLPNLEKISIH 368

2Y     301  PKWCCDILWL--AWMLREYIPTNSTCCGRCHAPMHRGRYLVEVDQASFO-----C- 350
2b     369  PIRCDCVIRIWNKNTNIRFMEPSLFCVD-----PPEFGQ---NVRQVHFRDMMEIC 421

2Y     351  -----SAPFMDAPRLNISEGRMAELKCR--TPPMSSVKKLLPNGTIVLSHARPRIS 403
2b     422  LIAPESFPSILDVEADSYVS-----LHCATAPQPEIYITFSGKRLPNTLREKTYV 475

2Y     404  LNDGTILNFSHLLSDTGYVTCQWTVNAGNSNASAYLVNSTAEINTSNYGFFTVVWTE 463
2b     476  HSEGTLDIRGIIPKGGELYTCIATNLVGADLKSMIKVGGFVQDDNGS-----LAI 531

2Y     464  IGPEDTRRYK--PVPTTSYGYOAYTTSTTVLIQTRVPKQAV-----PATD---510
2b     532  IRANSVLVSKANSKILKSSVKMTAFVKTEDSQQAQARIPSPDVKYNTLHLKPTSEY 591

2Y     511  -----TTDKMQTSLDEVWKTTKIIGCFVAVTLLAAMLIVF-----547
2b     592  CIDIPITYOKSRKQCVNVTTSLEHDKENGCKSHTVFVAC-VGGLIGITGVNCLFCT 650

2Y     548  -----YKLRKRHQORSTVTAAR-----TVEIIQVDEDIIPAATSAAATA--AP 591
2b     651  EGCNCEHNSYTVNHCKPTLAPSLEYPLPINLNESSKEKPALEVKATAGVPTGMS 707

```

RESULT 5

MEGFs protein - rat

Ti3953

N:Alternate names: slit protein homolog

C:Species: Rattus norvegicus (Norway rat)

C:Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 16-Aug-2002

C:Accession: Ti3953

R:Nakayama, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Seki, N.; Ohara, O.

Genomics 51, 27-34, 1998

A:Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs

A:Reference number: Z14136; MUID:98360089; PMID:9693030

A:Accession: T13953
A:Status: Preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: mRNA
A:Residues: 1-1523 <NA>
A:Cross-references: EMBL:AB011531; NID:G3449291; PIDN:BA032461.1; PID:G3449292
C:Genetics:
A:Gene: MEGF5

C; Superfamily: fruit fly slit protein; EGF homology; leucine-rich alpha-2-glycoprotein 1

```

Query Match      11.4%; Score 391; DB 2; Length 1523;
Best Local Similarity 24.3%; Pred No. 5.6e-19;
Matches 137; Conservative 56; Mismatches 171; Indels 200; Gaps 14;

QY 31 LCAAJAANAASAGP-QNCSVCSGNSQFSKVCTTRGSLSEVPOGIPSNTRYILNMENNITQM 89
Db 18 LALALATISLGPPAAACPTKCTCS--AASVDCHGLGLRAVPGRIPNABRLDLDNNITR 75
QY 90 IQADTFRLHLHLEVLQCRNSIRQIEVGAFNGLASLNTLELFDNMILVTIIPSGAFYLSKL 149
Db 76 IYKMDPTGLKNLRVLHLEDNOVSVERGAFQDELKQLERLNKNKQLVLPPELLFQSTPKL 135
QY 150 RELWURNPIGSIYSYAFNRPVPSLMRLDLGELKKLEYISEGAFEGLFNLYKYLNLGNCMI- 208
Db 136 TRLDLSEHQIGIGIPKAFRGVIGVKNLQL-DNNHISCI EDGAFRALRDLEIITLNNNIS 194
QY 209 -----KDMNLPPL-----VG----- 219
Db 195 RILVTSFNHMPKIRTLRHSNHLVCDCHLAWLSDMLRQRRTIQGTLCWAPVHLRGFSVA 254
QY 220 ----- 219
Db 255 DVQKXEYVCPGSHSEAPACNANSICPSAGSCSNIVDCRGKGLTEIPANLPEGIVEIRL 314
QY 220 -----LBELEMSGNHPPPEIRPGSPHGLSSLLKLWVMSQVSLIERNA 261
Db 315 EQNSIKSIPAGAFIQYKKLRIDISKQIISDIADAPAQGLKSLTSLVLYGNKITPEKGL 374
QY 262 FGLGASLV-----ELNLAHNLSSLPHDLTPRLYLVELHL 297
Db 375 FGLVSLQLLLLNANKLNCLRWTFQDLQNLNLSLYDNKLOITISKGLFAPLQSIQTLHL 434
QY 298 HNPWNKCDLILWLAWLRSYIPTN--STCCGRCHAPMHRGRYLVVEVDAQFQCSAP-- 353
Db 435 AQMPFVCDLHKWLA---DYLQDNPIETSGARCSPPRLANKRIISQIKSKPKCSGSD 490
QY 354 ----FIMDAPRLNLTSEGRMAELKCRTEPPMSSVKMLLPNGTVL-----SHASHR 398
Db 491 YNRRSSCFMDLVCPF-----KCRG-----EGTIVDCSNQKLSRIPSHLPEV 533
QY 399 PRISVLNDGTLNFSHVLLSDTGVY 422
Db 534 TTDRLNDNDI-----AVLEATGIF 553

```

RESULT 6

A53860

chondroadherin precursor - bovine

N:Alternate names: 38k leucine-rich protein

C:Species: Bos primigenius taurus (cattle)

C:Date: 07-Oct-1994 #sequence_revision 07-Oct-1994 #text_change 05-Nov-1999

C:Accession: A53860

R:Name: P.J.; Sommarin, Y.; Boynton, R.E.; Heinegard, D.

J. Biol. Chem. 269, 21547-21554, 1994

A:Title: The structure of a 38-kDa leucine-rich protein (chondroadherin) isolated from b

A:Reference number: A53860; MUID:94342341; PMID:8063792

A:Accession: A53860

A:Status: Preliminary

A:Molecule type: mRNA

A:Residues: 1-361 <NEA>

A:Cross-references: GB:U08018; NID:G470671; PIDN:AAA21330.1; PID:G470672

C:Superfamily: leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan carboxyl-

C:Keywords: disulfide bond

E:3303-346/ncma: proteoglycan carboxyl-terminal homology <PCH>

```

Query Match      10.9%; Score 376; DB 2; Length 361;
Best Local Similarity 28.3%; Pred. No. 9e-19;
Matches 102; Conservative 67; Mismatches 152; Indels 40; Gaps 9;

QY      20 9FVYLTAQWILCAIIAAASAGPQNCPSVCSNQFSKVVCTRGILSEVPGQIPSTRY 79
      | : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

```

b 4 PMLLSLSGLASLIPALAA-----CPNCHCHSDLOHVICDKVGLQKIPK-VSEKTKL 57
y 80 LNLKNNIOMIQADTERHLEHLEVLQGRNSIRQIEVGAFNGIASLNTLELFDNLWLTIP 139
b 58 LNLQNNFVLATNSFRAMENLWHLQHCQIREVAAGAFGLKQLLYLISHNDIRVL 117
y 140 SGAFYLSKLRLEWLNNPIESPFAVRVPSLRLDLGLBLKLEYISGAFEGFLMLK 199
b 118 AGAFDDLTELTYLDHKNKVTLPRLGLSPLVNLFIQLNN-NKIRELRSGAFQAKDLR 176
y 200 YNLGMCNIK-----DMPN-----LTPVLGLELEMSGNHFFPEI 233
b 177 WLYSENSLSLOPGALDDVENLAKYLDNRNQLSSVPSAALSCLVVEELKLSHPLASI 236
y 234 RPSGFHGLSS-LKKLVWMSQVSLIERNAPDGLASLVELLAEHNLSSLPDLFTPLRYL 292
b 237 PDNAFQSGRYLETMLDNTLNLEKPSDGAFLGVTTLKHVLEHNLRLHQLPSNF--PFDLSL 294
y 293 VELHLEHNNPNCDDILNLWLAWEIYPTNSTCCGCHAPMEGRVYLVVEVDQAFQCSA 352
b 295 ETLTNNPWNKCTCQURGLRWLE---AKTSRDPATCASFAKFGQHINDTD-AFGCKF 350
y 353 P 353
b 351 P 351

RESULT 7
3665
slit protein 2 precursor - fruit fly (Drosophila melanogaster)
C:Species: Drosophila melanogaster
C>Date: 30-Apr-1991 #sequence_revision 30-Apr-1991 #text_change 02-Aug-2002
C:Accession: B3665
R:Rothenberg, J.M.; Jacobs, J.R.; Goodman, C.S.; Artavanis-Tsakonas, S.
Genes Dev. 4, 2169-2187, 1990
A>Title: slit: an extracellular protein necessary for development of midline glia and co
A:Reference number: A3665; MUID:91099665; PMID:2176636
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-1469 <ROT>
A:Cross-references: GB:X53959
Genetics:
A:Gene: FlyBase:slit
A:Cross-references: FlyBase:FBgn0003425
A:Superfamily: fruit fly slit protein; EGF homology; leucine-rich alpha-2-glycoprotein
A:66-91/Domain: proteoglycan amino-terminal homology <PAH1>
A:101-124/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
A:125-148/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
A:149-172/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
A:173-196/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
A:197-220/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
A:228-272/Domain: proteoglycan carboxyl-terminal homology <PCS1>
A:288-313/Domain: proteoglycan amino-terminal homology <PAH2>
A:323-346/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
A:347-376/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
A:371-394/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
A:395-418/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
A:419-442/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR10>
A:450-494/Domain: proteoglycan carboxyl-terminal homology <PCS2>
A:512-537/Domain: proteoglycan amino-terminal homology <PAH3>
A:547-571/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR11>
A:572-595/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR12>
A:596-619/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR13>
A:620-643/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR14>
A:651-695/Domain: proteoglycan carboxyl-terminal homology <PCS3>
A:708-733/Domain: proteoglycan amino-terminal homology <PAH4>
A:743-766/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR15>
A:767-790/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR16>
A:7846-890/Domain: proteoglycan carboxyl-terminal homology <PCS4>
A:1028-1061/Domain: proteoglycan amino-terminal homology <PAH5>
A:1068-1099/Domain: EGF homology <EGF2>
A:1115-1148/Domain: EGF homology <EGF1>

```

```

Query Match 10.3%; Score 355.5; DB 2; Length 1469;
Best local similarity 25.0%; Pred. No. 1.6e-16;
Matches 109; Conservative 53; Mismatches 137; Indels 137; Gaps 8;

QY 46 CPVCSNQSFQVCTRRGLSEVPQGPISNTRYLNLMENNIQMIOADTFRELHLEVLQ 105
Db 73 CPVCSCTG--LNVDCSHRGLTSVPKISADVERLELQGNLTVIYETDFQRLTKRLMLQ 130
QY 106 LGRNSIRQIEVGAFNGIASLNTLELFDNLWLTIPSGAFYLSKLRLEWLNNPIESP 165
Db 131 LTNQIHTIERNFQDLVSLERLDISNNVITTVGRVFKGAQSESLQLDNNQITCLDEH 190
QY 166 AFRVPSLMDLDELKLEYSISGAFEGLEKLYLNLG----- 204
Db 191 AFKGLVELELTLNN--NLTSLPENIFGGLRLRALRLSDNPACDCHLSMLSRFLRSAT 249
QY 205 -----MC-----NKKD----- 210
Db 250 RLAPYTRCQSPSKQGNVADLHDQFKSGLTERHAPMECGAENSCPHPCRCADGIVDCR 309
QY 211 -----MPNLTPLVGLLE----- 222
Db 310 EKSLTSVFTLPDDTTDVRLEQNFITELPKSPSSFRRLRRDLNNSNISRHAHDAISGL 369
QY 223 -----LEMSGNHFFPEIRPGSFHGLSKLKLWVMSQVSLIERNAPDGLASLVELLNLAHNN 277
Db 370 KQLTTIVLYGNKIKDLPSGVFKGLSLRLLLNANEISCIKDAFRLHLSLLSLYDNN 429
QY 278 LSSLPHDLFTPLRYLVELHLEHNNPNCDDILNLWLAWEIYPTN--STCCSCCHAPMEH 335
Db 430 IQSLANGTFPMKSMKTVHLAKNPFICDCNRLWA----DYLHKNPIETSGARCSFKKM 485
QY 336 RGRVYLVVEVDQAFQCS 351
Db 486 HRRRISLSREKFKCS 501

RESULT 8
A3665
slit protein 1 precursor - fruit fly (Drosophila melanogaster)
C:Species: Drosophila melanogaster
C>Date: 30-Apr-1991 #sequence_revision 30-Apr-1991 #text_change 02-Aug-2002
C:Accession: A3665; A31640; S13523
R:Rothenberg, J.M.; Jacobs, J.R.; Goodman, C.S.; Artavanis-Tsakonas, S.
Genes Dev. 4, 2169-2187, 1990
A>Title: slit: an extracellular protein necessary for development of midline glia and co
A:Reference number: A3665; MUID:91099665; PMID:2176636
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-1480 <ROT>
A:Cross-references: GB:X53959; NID:g8614; PIDN:CAA37910.1; PID:g8615
R:Rothenberg, J.M.; Hartley, D.A.; Walther, Z.; Artavanis-Tsakonas, S.
Cell 55, 1047-1059, 1988
A>Title: slit: An EGF-homologous locus of D. melanogaster involved in the development of
A:Reference number: A31640; MUID:89077533; PMID:3144436
A:Accession: A31640
A:Molecule type: DNA
A:Residues: 881-1182, 'G', 1185-1404, 'GT', 1463-1464, 'YHA', <RO2>
A:Cross-references: GB:M23543; NID:g340939; PID:g514357
C:Genetics:
A:Gene: FlyBase:slit
A:Cross-references: FlyBase:FBgn0003425
A:Superfamily: fruit fly slit protein; EGF homology; leucine-rich alpha-2-glycoprotein
A:66-91/Domain: proteoglycan amino-terminal homology <PAH1>
A:101-124/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
A:125-148/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
A:149-172/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
A:173-196/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
A:197-220/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
A:228-272/Domain: proteoglycan carboxyl-terminal homology <PCS1>
A:288-313/Domain: proteoglycan amino-terminal homology <PAH2>
A:323-346/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
A:347-376/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
A:371-394/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
A:395-418/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
A:419-442/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR10>
A:450-494/Domain: proteoglycan carboxyl-terminal homology <PCS2>
A:512-537/Domain: proteoglycan amino-terminal homology <PAH3>
A:547-571/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR11>
A:572-595/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR12>
A:596-619/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR13>
A:620-643/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR14>
A:651-695/Domain: proteoglycan carboxyl-terminal homology <PCS3>
A:708-733/Domain: proteoglycan amino-terminal homology <PAH4>
A:743-766/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR15>
A:767-790/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR16>
A:7846-890/Domain: proteoglycan carboxyl-terminal homology <PCS4>
A:1028-1061/Domain: proteoglycan amino-terminal homology <PAH5>
A:1068-1099/Domain: EGF homology <EGF2>
A:1115-1148/Domain: EGF homology <EGF1>

```

F:228-272/Domain: proteoglycan carboxyl-terminal homology <PCS1>
 F:288-313/Domain: proteoglycan amino-terminal homology <PAH2>
 F:323-346/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR6>
 F:347-370/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR7>
 F:371-394/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR8>
 F:395-418/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR9>
 F:419-442/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR10>
 F:450-494/Domain: proteoglycan carboxyl-terminal homology <PCS2>
 F:512-537/Domain: proteoglycan amino-terminal homology <PAH3>
 F:547-571/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR11>
 F:572-595/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR12>
 F:596-619/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR13>
 F:620-643/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR14>
 F:651-695/Domain: proteoglycan carboxyl-terminal homology <PCS3>
 F:708-733/Domain: proteoglycan amino-terminal homology <PAH4>
 F:743-766/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR15>
 F:767-790/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR16>
 F:791-814/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR17>
 F:815-838/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR18>
 F:846-890/Domain: proteoglycan carboxyl-terminal homology <PCS4>
 F:1028-1061/Domain: EGF homology <EGF>
 F:1068-1099/Domain: EGF homology <EGF2>
 F:1115-1148/Domain: EGF homology <EGF1>

Query Match 10.3%; Score 355.5; DB 2; Length 1480;
 Best Local Similarity 25.0%; Pred. No. 1.6e-16;
 Matches 109; Conservative 53; Mismatches 137; Indels 137; Gaps 8;

QY 46 CPSVCSNQFSKVVCTRGSLSEVPGQIPSTRYINLMENNIMQIADTFRLHLHLVLQ 105
 DB 73 CPVCSCTG--LNVDCSHRGSLTVPRKISADVERLEQGNLTIVITDFTQRLKRLQ 130
 QY 106 LGRNSIRQIEVGAENGLASLNTLELFDNLTVIFSGAFYLSKRLRLNRPDIESIPSY 165
 DB 131 LTDNQIHTIERNFSQDLVSLERLDISNNVITVGRVRFKQAQSLRSLQDNQITCLDEH 190
 QY 166 AFNRVPSLMRLDLGELKLEYISEGAFGLFNLYKLMG----- 204
 DB 191 AFKGLVELEITLNN--NNLTSLPHNIFGGLGRRLALSLNPNFACDCHLSWLSRFLRSAT 249
 QY 205 -----MC-----NKKD----- 210
 DB 250 RLAPVTRQSPSLQKGVADLHDEQFKCKSLGTHAFMECGAENSCPHPCRCADGVDCR 309
 QY 211 -----MPLNLTPLGLEE----- 222
 DB 310 EKSLSVPTVPTDDTVDRLQNTITELPPKSPSSFRRLRIDLSNNISRIADHLSGL 369
 QY 223 -----LEMSGNHFFPIRPGSPFHGLSSLKGLVWMSQVSLIERNAFDGLASLVLNLAHN 277
 DB 370 KQLTTLVLYGNKIKDLPSPGVFKGLSLRLLLNANEISCIRKQAFRLHLSLSLYDNN 429
 QY 278 LSSLPHDLFTPLRYLVELHLHNPKNKCDITLWLAWLREYIPTN--STCCGRCCHAPMEM 335
 DB 430 IGSILANGTFDAKSMKTVHLANKPFICDNLRLWLA----DYLHKNPITSGARCESPKEM 485
 QY 336 RGRYLVEVDQASFQCS 351
 DB 486 HRRRIESLREKFKCS 501

RESULT 9
 T28714
 hypothetical protein T21D12.9a - Caenorhabditis elegans
 C:Species: Caenorhabditis elegans
 C>Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 29-Oct-1999
 C:Accession: T28714
 R:Woessner, J.
 submitted to the EMBL Data library, August 1997
 A:Description: The sequence of C. elegans cosmid T21D12.
 A:Reference number: Z20514
 A:Accession: T28714
 A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA
 A:Residues: 1-789 <WOB>
 A:Cross-references: EMBL:AF016687; PIDN:AAC48096.1; GSPDB:GN00022; CESP:T21D12.9a
 A:Experimental source: strain Bristol N2; Clone T21D12
 C:Genetics:
 A:Gene: CESP:T21D12.9a
 A:Map position: 4
 A:Introns: 38/2; 84/2; 132/2; 204/2; 275/2; 351/2; 519/3; 615/1; 714/1; 758/2

Query Match 9.8%; Score 335.5; DB 2; Length 789;
 Best Local Similarity 23.7%; Pred. No. 1.8e-15;
 Matches 142; Conservative 79; Mismatches 207; Indels 171; Gaps 20;

QY 78 RYLMNMENIUMIQADTFRLHLHLLEVQLGRNSIRQIEVGAENGLASLNTLELFDNLTV 137
 DB 58 RSVDSRLRLISLTPKPTTSKAVNIEKLDLASNITDITGDFSPSFTLVTKLARNHIT 117
 QY 138 IPSGAFYLSKRLRLNRPDIESIPSYAFNRVPSLM-----RLDLG----- 179
 DB 118 LNQFSRLKLESLLDTRNIREVRFLAFNQLPSLQNVSLARNVYRLDDGMEFYACEGL 177
 QY 180 -----ELKKLEYISEGAFGL-----FN-----LKYINLMGNMKD 210
 DB 178 KHLNLSNTRVQAVTEGWMFGLTSLVDLSVYNQTSFPHISSWSHTPKLWLSLHNRIOQ 237
 QY 211 MP--NLTPLVGLLELMSGNHFFPIRPGSTHGLSSLKLV----- 249
 DB 238 LPSGFRVLRQLEELIUSANSIDSLHKFALVGMSSLHKLDSNTLAVCVEDGAVLYNTS 297
 QY 250 -----MNSQVSLIERNAFDGLASLVELNALHNNLSLPHDLFTPLRYLVELHLHN 300
 DB 298 MFPLRLSRLFTNNQLRVIPKRAFERPALBELDLTDNPDIATIHPEAFEPLE-LKRLVNSS 356
 QY 301 PNWCDDITLWLAWLREYIPTNSTCCGRCCHAPMEMRGVLYLVEVDQASFQCSAPFMDAPR 360
 DB 357 SILCQCISWLASWIYRLKDKSIIAKCSYPPPLADLYVVAIDTANLTCH-----NDSPR 412
 QY 361 -----DLNISGRMAELKCRTPPMS--SVKW-LLPNGTVLSHSHRPRISVINDGT- 408
 DB 413 AKIVRQPEVVESTLIGEXARFTCNVYGASPLSIENRVMEG-----QERVLVQDSATF 464
 QY 409 -----LNFSHVLLSDTGVTCMTNVNAGNSNAYLNVAEL 446
 DB 465 LSINRTAVVNGTDFERELAAELLDNVAMTDNSEYQCVAARNRFG-SDFSTHVKLQVYQA 523
 QY 447 NTSNYSFTTIVTETISPEDTTRKYKVPETSTGYQPAYTTSTT-VLIQTTRVPK--- 502
 DB 524 PKFTY-----TPED-----MPLLVGQTAFLCAATGTPPEI 555
 QY 503 -----QVAVPATDTDKMOTSLDE---VMKTKIIIGCP-----VAVTLAAMLI 547
 DB 556 KWAEQIIPFAAEARLYVTPNDHDIYIMNVTKEDOGAYTCHATNVAGOTQASANLIVF 614

RESULT 10
 T28715
 hypothetical protein T21D12.9b - Caenorhabditis elegans
 C:Species: Caenorhabditis elegans
 C>Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 29-Oct-1999
 C:Accession: T28715
 R:Woessner, J.
 submitted to the EMBL Data library, August 1997
 A:Description: The sequence of C. elegans cosmid T21D12.
 A:Reference number: Z20514
 A:Accession: T28715
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-1355 <WOE>
 A:Cross-references: EMBL:AF016687; PIDN:AAC48095.1; GSPDB:GN00022; CESP:T21D12.9b
 A:Experimental source: strain Bristol N2; Clone T21D12
 C:Genetics:
 A:Gene: CESP:T21D12.9b
 A:Map position: 4

.; Introns: 38/2; 84/2; 132/2; 204/2; 275/2; 351/2; 519/3; 615/1; 714/1; 758/2; 786/3; 84

Query Match 9.8%; Score 335.5; DB 2; Length 1355;
Best Local Similarity 23.7%; Pred. No. 3.7e-15;
Matches 142; Conservative 79; Mismatches 207; Indels 171; Gaps 20;

Y 78 RYLNLMENNIQIADTFRLHLEVLQGRNSIRQIEVCAENGLASLNTLELFDNWLTVI 137
b 58 RVDLSRLNLSYLPKPTTSKYNIEKLDLASNSITDGTDESSFTNLTVLKLAENHITT 117
Y 138 IPGAFYLSKRLMLRNPNPIESIPYAFNRVPSLM-----RLDIG----- 179
b 118 LNOFSFRLKLSLDTLRNIREVFLAFNOLPSLQNVSLARNVDYRLDDGWFYACEGL 177
Y 180 -----ELKLEYISEGAFEL-----FN-----LKYNLGMCNIKD 210
b 178 KHLNLSNVRQAVTEGWMFGLTSLEVLDSYQIQSFHSSHSHTPKLXLSHNSRIQS 237
Y 211 MP--NLTPLVGLBELEMSGNHPEIRPGSFHGLSSLUKLWV----- 249
b 238 LPGSGFRVLRLQLEELTILSANSIDSLHKFALVGWSSLHKLDLSNTLAVCVEDGAVLYNTS 297
Y 250 -----MNSOVSLIERNAPDGLASLVEELAHNNLSLPHDLFTPLRYLVELHLHNN 300
b 298 MPFLRSRLFTNNOLRVIPKRAFRFPALSELDTNPITAIHPEAFEPLE-LKRLVMSS 356
Y 301 PMKCDCLILWLAWLREYIPTNSTCCGRCHAPMEGRYLVVDQASFCQSPFTMDAPR 360
b 357 SILDCQISMLASWIVLKLKXSSIIAKSYPPPLADLVVAIDTANLTCH----NDSPR 412
Y 361 -----DLNISEGRMAELKCRTPMS--SVKW-LLPNGTVLSHSHRPRISVLNDGT- 408
b 413 AKIVROPVEVSTLIGEXARFTCNVYGASPLSIEWRMENG-----QPRVLVQDSATF 464
Y 409 -----LNPESHVLLSDTGVYTCMVTVNAGNSNASAYLNIVSTAEL 446
b 465 LSINRTAVNGTDEBELAAELLNDAVNTDENSEVQCVARNRG-SDFSTHVKLVQYQA 523
Y 447 NTENYGFVTVTVEITEISPDTRTKYKVPPTSGYQPAYTST-VLIQTRVPK--- 502
b 524 PKETY-----TPED-----MPLLVGQAKFLCAATGTPREI 555
Y 503 -----QVAVPATDTTKMOTSLDE--VMKTKIILIGCP-----VAVTLAAAMLIYP 547
b 556 KWAFEQIPFPABARRLYTPNDHHIYIMNTKEDOGATCATWVAGTQASANLIYP 614

RESULT 11

46224
eroxidase - fruit fly (Drosophila sp.)
;Species: Drosophila sp.
;Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 24-Oct-2000
;Accession: S46224
;Nelson, R.E.; Fessler, L.I.; Takagi, Y.; Blumberg, B.; Keene, D.R.; Olson, P.P.; Parke
MBO J. 13, 3438-3447, 1994
;Title: Peroxidase: a novel enzyme-matrix protein of Drosophila development.
;Reference number: S46224, MUID:94341255; PMID:8062820
;Accession: S46224
;Status: preliminary
;Molecule type: mRNA
;Residues: 1-1535 <NEL>
;Cross-references: GB:U11052; NID:G531384; PID:AAA61568.1; PID:G531385
;Superfamily: peroxidase; myeloperoxidase homology; proteoglycan amino-terminal homolo
;13-44/Domain: proteoglycan amino-terminal homology <PAH4>
;661-1350/Domain: myeloperoxidase homology <MPX>

Query Match 9.6%; Score 331.5; DB 2; Length 1535;
Best Local Similarity 23.2%; Pred. No. 8.3e-15;
Matches 112; Conservative 72; Mismatches 173; Indels 125; Gaps 14;

Y 21 FVLTAAQVWILCAIAAASAGPON--CPSVCSCNQPSKVCYCTRGUSEVPGQIPSNTR 78
b 3 FMEMLQLLGLLELLLA-----GGVQSVYCPAGCTCLER--TVRCIRAKLSAVPK-LPDQIQ 55

QY 79 YLNLMMENNIQIADTFRLHLEVLQGRNSIRQIEVCAENGLASLNTLELFDNWLTVI 138
Db 56 TLDLRFNHHIEELPAN-----AFSLAQLTFLFINDLAVL 91
QY 139 PSQAFYLSKRLMLRNPNPIESIPYAFNRVPSLMRLDLGLKXLEYISEGAFEGFLNL 198
Db 92 QDGAINGLTALRFVYLNLRNLSRLPATIIFORMPL-----EGIP-- 130
QY 199 KYNLGMCNIKDPNLTPLVGLBELEMSGNHPEIRPGSFHGLSSLUKLWVANSOVSLIE 258
Db 131 -----LENDIWLQPL 140
QY 259 RNADFGLIASLVELNLAHNNLSLPHDLFTPLRYLVELHLHNNPNCDCDI-----LWLAW 314
Db 141 AGLFDNLPLRLNLIIMYNNKLTQLPVDGPNELNKLKELRLDGNALDIDCGVYSLWRWH 200
QY 315 L-----REVIPNTSCGRCHAPMEGRYLVVDQASFCQSPAFIMKADPDNLISEGMAE 371
Db 201 LDVQROLVSLTCA-----APQMLQNGQSFSLGHEHFKCAKPOFLVAPQDAOVAAGEQVE 256
QY 372 LKCRTPPM--SSVKMLLPNGTVLSHSHRPRISVLNDGTINFSHVLLSDTGVYTCMVTV 429
Db 257 LSCVTVGLHRPQITWM--HNTQELGLEBQTAELLPSGSLHRSADTSDMGIYQCIARNE 314
QY 430 AGNSASAYLNIVSTABLSNTSNYSFFTVTVTEITEISPDTRTKY--KPVPTTSTGYQAP 487
Db 315 MGAIRSQPVRLV-----VNGGNHPLDSPIDARNSQVWADAGTTHGATPLPSPSPSHSPH 370
QY 488 TT 489
Db 371 FT 372

RESULT 12

JG0193
G protein-coupled receptor FEX - mouse
;Species: Mus musculus (house mouse)
;Date: 23-Jul-1999 #sequence_revision 23-Jul-1999 #text_change 11-May-2000
;Accession: JG0193
;Hermey, G.; Methner, A.; Schaller, H.C.; Hermans-Borgmeyer, I.
Biochem. Biophys. Res. Commun. 254, 273-279, 1999
;Title: Identification of a novel seven-transmembrane receptor with homology to glycop
;Reference number: JG0193, MUID:99121227; PMID:9920770
;Accession: JG0193
;Status: preliminary
;Molecule type: mRNA
;Residues: 1-907 <HER>

Query Match 9.3%; Score 321.5; DB 2; Length 907;
Best Local Similarity 25.2%; Pred. No. 2e-14;
Matches 108; Conservative 64; Mismatches 155; Indels 101; Gaps 10;

QY 22 VYLTAAQVWILCAIAAASAG-----PONCPSVCSC---SNQFSKVYCTRGUSEVPGQIP 74
Db 6 VHMLLSLLALLQLVAAGSSPGPDATPRGCPCHCELDGRMLLRVDCSLDGLSELSPNL 65
QY 75 SKTRYLNLMENNIQIADTFRLHLEVLQGRNSIRQIEVCAENGLASLNTLELFDNWLTVI 110
Db 66 VFTSYLDLSNNNISQPLASLHRLCPLEBLRAGNALTHIPKGAFTGLSLKVLMLQNNQ 125
QY 111 IRQIEVCAENGLASLNTLELFDNWLTVIPSGAFYLSKRLMLRNPNPIESIPYAFNRV 170
Db 126 LRKVPBEALQNLRLSLQSLDANHSYVPPSCFSLHSLRLHLDNALTDPVQAFSL 185
QY 171 PSLMRDLGELKLEYISEGA-----FEGFLNLYKYLNLGMC 206
Db 186 SALQAMTLA-LANKIHHIADYAFGNLSSLVVLHLHNNRHSLSKGLKCFDGLHSLTDLN 244
QY 207 NIKDMFN-LTPVLVGLBELEMSGNHPEIRPGSFHGLSSLUKLWVANSOVSLIERNAFD-- 263
Db 245 NLDEPTAKTLNLKELGFHNSNIESIPERAFVGNPSLTIHFYDNPFIQFVGSVAFQHL 304

QY 264 -----GLASVELNLAHNNLSLPHDLFTPLRYLVELHLHNPW 302
DB 305 PEERILTLNGASHITEPHLTGTATLESITGAKISLPOAVCDQLPNQVLDLSYH-- 362
QY 303 NCCDILMLAWMLREY:PTNCTCGRCHAPMGRYLVVEVDQASFOCSAPFINDAPRDL 362
DB 363 -----LLEDLSLSGC--QKQKIDLRHNEIYEIKGSTFO-----QLFNLRSL 403
QY 363 NISEGRMA 370
DB 404 NLAWNKIA 411

RESULT 13
JC6128
insulin-like growth factor binding complex
C:Species: Mus musculus (house mouse)
C>Date: 23-Mar-1997 #sequence_revision 09-May-1997 #text_change 05-Nov-1999
R:Accession: JC6128
R:Boisclair, Y.R.; Seto, D.; Hsieh, S.; Hurst, K.R.; Ooi, G.T.
Proc. Natl. Acad. Sci. U.S.A. 93, 10028-10033, 1996
A:Title: Organization and chromosomal localization of the gene encoding the mouse acid
A:Reference number: JC6128; MUID:96413591; PMID:8816745
A:Accession: JC6128
A:Molecule type: DNA
A:Residues: 1-603 <BOI>
A:Cross-references: GB:U66900; NID:gl621612; PIDN:AA817270.1; PID:gl621613
C:Comment: This protein is a serum protein and it is of the ternary complex in the phys
A:Gene: als
A:Map position: 17

Query Match 9.3%; Score 321; DB 2; Length 603;
Best Local Similarity 24.5%; Pred. No. 1.3e-14;
Matches 131; Conservative 69; Mismatches 162; Indels 172; Gaps 16;
QY 36 AAASAGPQNCVSCS-----NQFSKVCTRGSLSEVPQGISNTR----- 78
DB 32 ASADAEQPQ-CPVCTCSDYDDYDELS-VFCSSRLTQDPGIPVSTRALMLOGNLSII 89

QY 79 -----YLMNMENNIOMIQADTFPHLHLE 102
DB 90 PSAAFONLSLDFNLQGSWLSRLPQALLG:QNLVHLHLRLNLLSLAAGLFRHTPSLA 149

QY 103 VLQIGNSNTRQIEVAFNGIASLNTLELFDNLTWIPSGAFB----- 144
DB 150 SLGLGNLLGRLEEGFLRGLSHLDNLGNLSLVLPDTPVQGLGNLHVLVAGNKTYL 209

QY 145 -----VLSKRELWLRNPIESIPSYAFNRVPSLMLRLDLGE-----LKKLE 185
DB 210 QPALLCGLGSELRELDLSRNALSXANVFHLPRLQKLYLDRNLITAVAPRAFLGMKALR 269

QY 186 YIS-----EGAFEGFLNLYINLGMCMKIDMPNLT--PLVGLLELEMSGNHPEI 233
DB 270 WLDLSHNRVAGLLEDTFPGLLGLHLVLRLAHNAITSRLRPTTKDLHFLLEQLGHNRIRQL 329

QY 234 RGSFHGLSSLKLWVMSQVSLIERNAPDGLASLVELNLAHNNLSLPHDLFTPLRYLV 293
DB 330 GEKTFEGQLQVLTLDNQIHEVKGAFPGFLPNVAVMLSGNCLRSIPHFVFGGLGLH 389

QY 294 ELHLHNPKNVCDILMLAWLREVIPNTSCGCHAPM-----MGRYLVVEVDQA 346
DB 390 SLFLEH-----SCLGRIR--LHTFAGLSGLRLFL----- 417

QY 347 SFQCSAPPIDAPDLNIS--EGMAELKCHTTPMSSVKMLLPNGTVLSHSHRPRISV 403
DB 418 -----RNSISIEQSLAGL-----SLELDLDTANQTLHPHQ----- 452

QY 404 LNDGTLNPSHVLSDTGVTVMVNVAGNSASAYLNVSTAEIANTSNYSFTTV 457
DB 453 LFGQLQGVLLSNNQL-TMLEDVGLPQAFWLDLSHNRLETAPAGLFSFL 505

RESULT 14
JC5239
insulin-like growth factor acid-labile chain - baboon
C:Species: Papio sp. (baboon)
C>Date: 17-Apr-1997 #sequence_revision 09-May-1997 #text_change 09-May-1997
C:Accession: JC5239
R:Delhanty, P.; Baxter, R.C.
Biochem. Biophys. Res. Commun. 227, 897-902, 1996
A:Title: The cloning and expression of the baboon acid-labile subunit of the insulin-li
A:Reference number: JC5239; MUID:97040714; PMID:8886027
A:Contents: liver
A:Accession: JC5239
A:Molecule type: mRNA
A:Residues: 1-605
C:Comment: This factor is structurally related to proinsulin and have insuline-like met.

Query Match 9.2%; Score 315; DB 2; Length 605;
Best Local Similarity 32.4%; Pred. No. 3.4e-14;
Matches 94; Conservative 44; Mismatches 118; Indels 34; Gaps 7;
QY 42 GPQNCVSCS-----NQFSKVCTRGSLSEVPQGISNTRYLNLMENNFMQTOAFTFR 96
DB 38 GPA-CPATCACSYDDVENVLS-VFCSSRLTLPDGPQALWLDSDNLSIPPAAFR 95

QY 97 HLHLEVL-----QLG-----RNSIRQIEVCAFNGLASLNTLELFD 132
DB 96 NLSSLAFLNLQGGQSGLEPQALLGLENLCHLHRLNQLRSLAVGTFAITPALALGLSN 155

QY 133 NMLTVIPSGAFYLSKRELWLRNPIESIPSYAFNRVPSLMLRLDLGELKLEYISEGAF 192
DB 156 NLSLEDELGFEGLNLDNLGNLSLAVLPDAAFRGLGLRELVLVAG-NRLAVYQALPF 214

QY 193 EGLFMKLYINLGMCMKIDMPN--LTPLVGLLELEMSGNHPEIRPGSPHGLSSLKLWVM 250
DB 215 SGIALRELDLSRNALRAKANVFAPQLPRQLKLYLDRNLIAAVAPGAPFLGKALRWLDLS 274

QY 251 NSQVSLIERNAPDGLASLVELNLAHNNLSLPHDLFTPLRYLVELHLHNN 300
DB 275 HNRVAGLLEDTFPGLLGLRVLRLSHNAIASLRPTFEDLHFLLEQLGHV 324

RESULT 15
JC1282
insulin-like growth factor-binding protein acid labile chain precursor - rat
C:Species: Rattus norvegicus (Norway rat)
C>Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 21-Jul-2000
C:Accession: JC1282
R:Bai, J.; Baxter, R.C.
Biochem. Biophys. Res. Commun. 188, 304-309, 1992
A:Title: Molecular cloning of the acid-labile subunit of the rat insulin-like growth fa
A:Reference number: JC1282; MUID:93038676; PMID:1384485
A:Accession: JC1282
A:Molecule type: mRNA
A:Residues: 1-603 <DAL>
A:Cross-references: GB:S46785; NID:g258002; PIDN:AA823770.2; PID:g5705934
A:Experimental source: liver
A:Note: the authors translated the codon AAG for residue 63 as Arg, AAA for residue 205
C:Superfamily: leucine-rich alpha-2-glycoprotein repeat homology
F:1-27/Domain: signal sequence #status predicted <SIG>
F:28-603/Product: insulin-like growth factor binding protein, acid labile chain #status
F:267-290/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR>

Query Match 9.0%; Score 310; DB 2; Length 603;
Best Local Similarity 31.2%; Pred. No. 7.5e-14;
Matches 92; Conservative 48; Mismatches 123; Indels 32; Gaps 5;
QY 36 AAASAGPQNCVSCSN-----QFSKVCTRGSLSEVPQGISNTRYLNLMENNIQMIQ 91
DB 32 ASADAEQPQ-CPVACTCSHDDYDELSVFCSSKNLTHLPDDIPVSTRALMLOGNLSIP 90

QY 92 ADTFRHLHLE-----VLQIGNSNTRQIEVAFNGIASLNT 127
DB 91 SAAFONLSLDFNLQGSWLSRLPQALLG:QNLVHLHLRLNLLSLAAGLFRHTPSLA 150

Y 128 LELFDNWLTVIPSGAPEYLSKLELWLRNPIESIPSAFNRVPSIMRLDGLGELAKLEYI 187
b 151 LSLSSNLGLRLEBGLFQGLSHLWDLNGLWNSLVLPDPTVFQGLGNLHVLVLAG-NKLTLY 209
Y 188 SEGAFGLFNLYLNTGCMYKDMFX--ITPLVGLSELEMSGNHFFPEIRPGSFHGLSSLYK 245
b 210 QPALFQGLGELRELDLSRNALRSVKANVFVHLPRQKLYLDRNLITAVAPGAFGLGMKALR 269
Y 246 KLMWMSQVSLIERNAPDGLASIVELNLAHNNLSLPHDLFTPLRYLVVELHLHN 300
b 270 WLDSLNRVAGLMEDTFGLGLGLHVLRLAHNAIASLRPTTFKDLHFLBELQLGHN 324
RESULT 16
41915
;Insulin-like growth factor-binding complex acid-labile chain precursor - human
;Alternate names: Acid-labile Subunit (ALS)
;Species: Homo sapiens (man)
;Date: 31-Dec-1993 #sequence_revision 31-Dec-1993 #text_change 05-Nov-1999
;Accession: A41915
;Leong, S.R.; Baxter, R.C.; Camerato, T.; Dai, J.; Wood, W.I.
ol. Endocrinol. 6, 870-876, 1992
;Title: Structure and functional expression of the acid-labile subunit of the insulin-I
;Reference number: A41915; MUID:92357025; PMID:1379671
;Accession: A41915
;Status: preliminary
;Molecule type: mRNA; protein
;Residues: 1-605 <GB>
;Cross-references: GB:M86926; NID:G184807; PIDN:AAA36047.1; PID:G184808
;Experimental source: liver
;Note: sequence extracted from NCBI backbone (NCBIP:110171)
;Superfamily: leucine-rich alpha-2-glycoprotein repeat homology
;75-92/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR1>
;99-122/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR2>
;123-146/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR3>
;147-170/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR4>
;171-194/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR5>
;195-218/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR6>
;219-242/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR7>
;243-266/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR8>
;267-290/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR9>
;291-314/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR10>
;315-338/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR11>
;339-362/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR12>
;363-386/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR13>
;387-410/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR14>
;411-434/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR15>
;435-458/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR16>
;459-482/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR17>
;483-506/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR18>
;507-529/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR19>
Query Match 9.0%; Score 309; DB 2; Length 605;
Best Local Similarity 23.8%; Pred. No. 8.9e-14;
Matches 121; Conservative 69; Mismatches 154; Indels 168; Gaps 16;
Y 42 GPQPCSVSCS-----NPFKVVCTRRGLSEVPQIPSNTR----- 78
b 38 GPA-CPAACVSYDDADELS-VFCSSRNLTLPDGVPGTQALWLDGNLNSVPPAAAFQ 95
Y 79 -----YNLMENNTQADTFPHLHLEVLQGR 108
b 96 NLSSGLFLNQGGQLSLFPQALLGLENI-CHLERNQRLSALGTFPAHTPALASLGUN 155
Y 109 NSIRQIEVGAFNGLASINTLELFDNWLTVIPSGAPEYLSKLELWLRNPIESIPSAFN 168
b 156 NLRSLREDDGLFEGSLGWDNLNGLWNSLAVPDAAFRGLGSLRELVLNAGNLAYLOPALFS 215
Y 169 RVPSIMRLDGL-----ELKGL-----EYISGAPFGLFNLYLNT-- 203
b 216 GLAELRELDLSRNALRAIKANVFVQLPRQKLYLDRNLITAAVAPGAFGLKALRLDLSH 275

QY 204 -----GMCNIK-----DMPNLT-----LVGLELEMSGNHFFPEIRPGSFH 239
Db 276 NRVAGLELDTFPGLLGLRLVLRSHNAIASLRPTTFKDLHFLBELQLGHNRIQLAESRFE 335
QY 240 GLSSIAKKLWMSQVSLIERNAPDGLASIVELNLAHNNLSLPHDLFTPLRYLVVELHLHH 299
Db 336 GIGQLVFLIDHNLQVEVAGAFGLGTVAVWNLGNCNLRNLPQVFRGLGKLSHL-- 393
QY 300 NPWNCDDILWLAWMLREYIPTNSTCCGRCH-----APMEMRGYLYVEVDQASFQ 349
Db 394 -----EGSCIGRIIRPHFTFTGLSGRLRLFLKONGLVGIBQSILW 431
QY 350 CSAPPI-MDAPRD-----LNISEGRMAELKC-RTPMSSVKVL----- 385
Db 432 GLAELLEGLTNSQLTHLPHRLFOGLGKLEYLLLRNRLAELPADALGLOAFWLDVSH 491
QY 386 -----LPNGTVLASHRHRPRISVLANDGTINFS 412
Db 492 NRLEALPN-SLLAPGLRLAYLSLRNLSLTFT 522
RESULT 17
T42626
;secreted leucine-rich repeat-containing protein SLIT2 - mouse (fragment)
;Alternate names: neurogenic extracellular slit protein
;Species: Mus musculus (house mouse)
;C;Date: 11-Jan-2000 #sequence_revision 11-Jan-2000 #text_change 16-Aug-2002
;Accession: T42626
;R;Holmes, G.P.; Negus, K.; BurrIDGE, L.; Raman, S.; Algar, E.; Yamada, T.; Little, M.H.
Mech. Dev. 79, 57-72, 1998
;A;Title: Distinct but overlapping expression patterns of two vertebrate slit homologs im
;A;Reference number: Z22177; MUID:99279238; PMID:10349621
;Accession: T42626
;A;Status: preliminary; translated from GB/EMBL/DBJ
;Molecule type: mRNA
;A;Residues: 1-1025 <HOL>
;A;Cross-references: EMBL:AF074960; NID:G4151258; PID:G4151259; PIDN:AAD04345.1
;C;Genetics:
;C;Superfamily: fruit fly slit protein; EGF homology; leucine-rich alpha-2-glycoprotein r

Query Match 9.0%; Score 309; DB 2; Length 1025;
Best Local Similarity 23.7%; Pred. No. 1.8e-13;
Matches 111; Conservative 60; Mismatches 155; Indels 142; Gaps 15;
QY 46 CPBVCSCSNQFVKVCTRRGLSEVPQIPSNTRYLNLMENNTQADTFPHLHLEVL 104
Db 2 CPBKCCEG--TVDCSNQRLNKIPDHIPQYTAELRLNNEFTVLEATCIPKLLQLRXI 59
QY 105 QLGRNSIROIEVGAFNGLASINTLELFDNWLTVIPSGAPEYLSKLELWLRNPIESIPS 164
Db 60 NFGNNKITDIEGAFEGASGVNEILLTSNRLNENVOHKNPKGLESLKTLMLRSNRISCVGN 119
QY 165 YAFNRVPSIMRLDGLGKLEYISGAPFGLFNLYLNT-----GMCN----- 207
Db 120 DSFIGLSVRLSLYD-NQITTVAPGAFDXLSLSLTNLNLANPFCNCHLAWLGEWLRRK 178
QY 208 -----IKMP-----NLTPL----- 217
Db 179 RIVTGPNRCQKPYFLKEIRIQDVAIQDFTCDGNDNNSCPLSRCPSECTCLDTXVRCN 238
QY 218 VGLS-----ELEMGNHF-----PEIRPGSFHGLSS 243
Db 239 KGKVLPGKIPKDVLTLYDGNQFTLVPKELSNYKHLTLDLSNNRISTLSNOXFSNWTQ 298
QY 244 LKKLWMSQVSLIERNAPDGLASIVELNLAHNNLSLPHDLFTPLRYLVVELHLHHPN 303
Db 299 LLTLISYNLRICIPRTFDGLKSLRLSLHNGDISVVPPEGAFNDLSALSHLAGNPLY 358
QY 304 CUCDILWLAWLR-EYIPTNSTCCGRCHAPMEMRGYLYVEVDQASFQCSAPFMDAPDL 362
Db 359 CDCNMQLSDWVKSEY---KBPGLAKCAGGEMADKLLLTTPSKKFTCGPM-----DI 409

QY 363 NISEGMBELKCRTPPMSSVKWLLPNGTVLSHASRHRISVLNDGTLN 410
DB 410 TT-----QAKC-NPCTEN-----PCKNDGTCN 430

RESULT 18
A35331
oncofetal trophoblast glycoprotein ST4 precursor - human
N/Alternate names: oncofetal antigen ST4
C/Species: Homo sapiens (man)
C/Date: 27-Jun-1994 #sequence_revision 27-Jun-1994 #text_change 05-Nov-1999
C/Accession: A35331; S40087
R/Myers, K.A.; Rahi-Saund, V.; Davison, M.D.; Young, J.A.; Cheater, A.J.; Stern, P.L.
J. Biol. Chem. 269, 9319-9324, 1994
A/Title: Isolation of a cDNA encoding ST4 oncofetal trophoblast glycoprotein. An antigen
A/Reference number: A35331; MUID:94179356; PMID:8132670
A/Accession: A35331
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-420 <MB>
A/Cross-references: EMBL:229083; NID:G435654; PIDN:CAA82324.1; PID:G435655
C/Superfamily: leucine-rich alpha-2-glycoprotein repeat homolog
C/Keywords: duplication; glycoprotein; transmembrane protein
F/1-31/Domain: signal sequence #status predicted <SIG>
F/32-420/Product: oncofetal trophoblast glycoprotein ST4 #status predicted <MAT>

Query Match 9.0%; Score 308.5; DB 2; Length 420;
Best Local Similarity 29.5%; Pred. No. 5.9e-14;
Matches 98; Conservative 47; Mismatches 136; Indels 51; Gaps 9;

QY 35 IAAASAG---PQNCPSVCSNQPSKVCTRGSLSEVQGPISNTRYLNLMENNIOMIQ 91
DB 48 LASAVSAQPLPDQCFALCECEAAARTKCVNRNLTEVTPDLPAYVRLFLTGQVLAVP 107

QY 92 ADFRHLHLHLVLQGRNSIRQIEGAF---NGLASMTLELFDNMTLTPSPGAFYLSK 148
DB 108 A-----GAFARPPLEAALNLSGRLDEVRAGAFHLPS 143

QY 149 IRELWLRNPNPISPSYAFN-----RVPS-IMRLDGLKLLYIIEG-AFEGFLNLY 200
DB 144 LRQLDLSHNPZLADLFFAFSGSNASVSAPSLVELILNHIVPPEDERQNRSEFGMW-VAA 202

QY 201 LNLGWNKIDKMNPLVGLGLELESGNHFPEIRPGSPHGLSSLKXLMWMSQVSLERN 260
DB 203 LLAGRA-----LQGRLELASNHFVLPDRVLAQLPSLRHLDLSNLSVSTYV 252

QY 261 AFDGLASIVELNAHNLSLPHDLFTPLRYL--VELHLHNPWNCDDILMLAWLREY 318
DB 253 SPFNLTLESLEHLDNALKVLHNGTLABELQGLPHIRVFLDNNPNWVCDCHMADMYTLKET 312

QY 319 IFTNTCCGCRCHAPMGRVLYVEVDQASFOC 350
DB 313 EVVQGRDLTCAYPEKMRNRVLELNSADLDC 344

RESULT 19
A60164
platelet membrane glycoprotein V precursor - human
C/Species: Homo sapiens (man)
C/Date: 12-Jan-1993 #sequence_revision 24-Feb-1994 #text_change 05-Nov-1999
C/Accession: A48030; A60164; A35483; B35483; A60432; A47507; S34329
R/Lanza, F.; Morales, M.; de La Salle, C.; Cazenave, J.P.; Clemetson, K.J.; Shimomura, T.
J. Biol. Chem. 268, 20801-20807, 1993
A/Title: Cloning and characterization of the gene encoding the human platelet glycoprotein
A/Reference number: A48030; MUID:94012616; PMID:8407908
A/Accession: A48030
A/Molecule type: DNA
A/Residues: 1-560 <LA2>
A/Cross-references: EMBL:223091; NID:G312501; PIDN:CAA80637.1; PID:G312502
R/Shimomura, T.; Fujimura, K.; Maehama, S.; Takemoto, M.; Oda, K.; Fujimoto, T.; Oyama,
Blood 75, 2349-2356, 1990
A/Title: Rapid purification and characterization of human platelet glycoprotein V: the a
A/Reference number: A60164; MUID:90275263; PMID:2350580

A/Accession: A60164
A/Molecule type: protein
A/Residues: 365-384, 'X', 386-390, 'X', 392-395, 'X', 397, 188-208, 'I', 210, 27-50, 'X', 52-53, 174-
'XX', 108, 'T', 61-72, 'TX', 75-77, 'V', 56-57, 'G', 479-487, 'X', 489-498, 'X', 500, 'X', 502-503, 'X',
R/Roth, G.J.; Church, T.A.; McMullen, B.A.; Williams, S.A.
Biochem. Biophys. Res. Commun. 170, 153-161, 1990
A/Title: Human platelet glycoprotein V: a surface leucine-rich glycoprotein related to a
A/Reference number: A35483; MUID:90321220; PMID:2372284
A/Accession: A35483
A/Molecule type: protein
A/Residues: 145-166, 'I', 168-169, 'X', 171-172 <RO>
A/Note: this proteolytic fragment was designated peptide M392
A/Accession: B35483
A/Molecule type: protein
A/Residues: 121-123, 'W', 131-135, 466-468, 'X', 470 <RO2>
A/Note: this material was designated peptide M393 but may contain two peptides
A/Accession: C35483
A/Molecule type: protein
A/Residues: 252-266, 'H', 268-272, 'X', 274-279, 'I', 281-284, 'I', 286 <RO3>
A/Note: this proteolytic fragment was designated peptide M401
R/Zafar, R.S.; Walz, D.A.
Thromb. Res. 53, 31-44, 1989
A/Title: Platelet membrane glycoprotein V: characterization of the thrombin-sensitive g
A/Reference number: A60432; MUID:89162331; PMID:2922700
A/Accession: A60432
A/Molecule type: protein
A/Residues: 477-478, 'EX', 481-485, 'E', 487, 'V', 489-492, 'NQ', 495, 'E', 497-498 <ZAF>
R/Hickey, M.J.; Hagen, F.S.; Yagi, M.; Roth, G.J.
Proc. Natl. Acad. Sci. U.S.A. 90, 8327-8331, 1993
A/Title: Human platelet glycoprotein V: characterization of the polypeptide and the rela
A/Reference number: A47507; MUID:93391348; PMID:7690959
A/Accession: A47507
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: mRNA
A/Residues: 1-560 <RES>
A/Cross-references: GB:L11238; NID:G388759; PIDN:AAA03069.1; PID:G388760
C/Comment: This platelet membrane protein is a substrate for thrombin.
C/Comment: The amino end of the intact protein is blocked.
C/Comment: This protein is absent in Bernard-Soulier syndrome.
C/Genetics:
A/Gene: GDB:GPI5
A/Cross-references: GDB:230236; OMIM:173511
A/Map position: 5pter-5qter
C/Superfamily: leucine-rich alpha-2-glycoprotein repeat homology
C/Keywords: blocked amino end; glycoprotein; platelet; tandem repeat; transmembrane prot

Query Match 8.9%; Score 305.5; DB 2; Length 560;
Best Local Similarity 27.6%; Pred. No. 1.4e-13;
Matches 98; Conservative 47; Mismatches 153; Indels 57; Gaps 9;

QY 66 LSEVPOGI---PSNTRYLNLMENNIQIADTFRHLHLHLVLQGRNSIRQIEGAFNGL 122
DB 182 LTHLPKGLGQAQAKLERLLHLSNLSVLSGLNLSGALTQLQPHRNHRSIADPAFDRL 241

QY 123 ASINTELEFDNMTLTPSPGAFYLSKLRMLRNPNPISPSYAFNRPVPSLMRLDLGLK 182
DB 242 PNLSSLTISRNLHAEPLSALFLHSHNLTLTLFNFNLAELFGLVFGEMGGQLQELWLNAR-T 300

QY 183 KLEYISEGAFEGFLNLYLNLMGNKIDKMNPLTFL-----VGLSELE---MSGNHFPPEIR 234
DB 301 QRTLPAAAFNLSRLVGLVTL-----SPRLSALPQGAFOGLGELQVLALHNSGLTALP 355

QY 235 PGSPHGLSSLKXLMWMSQVSLERNAPDGLASIVELNAHNLSLPHDLFTPLRYLYVE 294
DB 356 DGLLRGLGKLRQVSLRRNRALRALFRNLNLSLESVQLDHNQLETLPDGVFGALPLTE 415

QY 295 LHLHNPWNCDDILMLAWLREYI-----PTNSTCCGCRCHAPMGRVLYVEVDQAS 347
DB 416 VILGHNSWRCCDGLGPFGLWLRQHLGLVGGEPP-----RCAGPGAAGLPLNALPGGD 469

QY 348 FCCSAFFINDAPDLNLSIEGRMAELKCRTPPMSSVKWLLPNGTVLSHASRHRIS 402
DB 470 ABCPGP-----RGPPPR-----PAADSSSEAPVHPALA 497


```

F;189,325/Binding site: dermatan sulfate (Ser) (covalent) #status predicted
F;211,262,303/Binding site: carboxydrate (Asn) (covalent) #status predicted

Query Match      8.8%; Score 303.5; DB 1; Length 359;
Best Local Similarity 31.9%; Pred. NO. 1.1e-13;
Matches 84; Conservative 45; Mismatches 123; Indels 11; Gaps 7;

QY 40 SAGPQNCPSVCSCSNQPSKVQCTRRGLSGVPGQIPSNTRYLNLMENNTQMIOADTFRIHL 99
DB 49 SLGFPV-CPRFCQ--HLRVQCSDLGDKVQKPLPDDTLLDLQNNKITEIKDGFKNLK 105

QY 100 HLEVQLGNSIRQIEVGAFNGASLNTLELFDNMLFVIPSGAFYLSK-LRELWRNRP 158
DB 106 NLHALILVNKKISVSPGAFPLVKLELYLSKNQKELP---EKPKTLQELSAHENE 161

QY 159 IESIPSYAFNRVPSLMRLDLG-ELKKLEVISGSAFEGFLNKLKYLNLGMCNTKDMNLTPL 217
DB 162 ITKRVKTFNGLNQMLVIELGTNPLKSSGIENGAFQGMKKLSYIRIADNTITSIPOGLP- 220

QY 218 VGLEHELMGNNHFPRIQPSGHLSLKKLWVMSQVSLIERNAFPGGLASVELMLAHNN 277
DB 221 PSLTELHLGDNKISRVDAASLKLGNLAKLGLSFNSISAVDNGSLANTPHLRELHDNNK 280

QY 278 LGSPLPHDLFTPLRYLVELHLEN 300
DB 281 LTFVPGGL-AEHKYIQVYVLYHNN 302

RESULT 21
JE0176
orphan G protein-coupled receptor precursor - human
C;Species: Homo sapiens (man)
C;Date: 03-Jul-1998 #sequence_revision 10-Jul-1998 #text_change 21-Jul-2000
C;Accession: JE0176
R;McDonald, T.; Wang, R.; Bailey, W.; Xie, G.; Chen, F.; Caskey, C.T.; Liu, Q.
Biochem. Biophys. Res. Commun. 247, 268-270, 1998
A;Title: Identification and cloning of an orphan G protein-coupled receptor of the glyco
A;Reference number: JE0176; MUID:98308104; PMID:9642114
A;Accession: JE0176
A;Molecule type: mRNA
A;Residues: 1-907 «MCD»
A;Cross-references: GB:AF062006; NID:g3366801; PIDN:AAC28019.1; PID:g3366802
C;Comment: This protein is a receptor for a novel class of glycoprotein ligands.

```

Db 188 LOAMTALNKXIHDPVAFGNLSLVLHLLHN-NRIHSIGKKCFDGLHSLTDLNVMNL 246
 QY 209 KMPEN-LPIVGLBELENSGNHFEIRPGSFHGLSSLKLLWVMSQVSLIERNAPD---- 263
 Db 247 DEFFPAITRLNKLGHSHNNIRSIPEKAFVGNPSLITTHFYDNPIDQFVGRSAFOHLP 306
 QY 264 -----GLASIVELNLAHNNLSLPHDLFTPLRYLVHLLHHPNWC 304
 Db 307 LRTEFLNGASQITEPPDLTGTALESLLTCAQISLSLPTQVGNQLPNQLVLDLSYN--- 362
 QY 305 DCDILNLAWLREVIPTNSTCGRCHAPMHRGRLVVEVDQASFOCSAPIMDAPDNI 364
 Db 363 -----LLEDLPFSVC--QKLQKIDURHNEIYEIKVDTFQ-----QLLSRLSLNL 405
 QY 365 SEGRMA 370
 Db 406 ANWKIA 411.

RESULT 22
 decorin precursor - bovine
 N:Alternate names: dermatan sulfate proteoglycan II; proteoglycan core protein II
 C:Species: Bos primigenius taurus (cattle)
 C>Date: 31-Mar-1990 #sequence revision 31-Mar-1990 #text_change 20-Aug-1999
 C:Accession: S06280; B31430; A26545; A20935
 R:Day, A.A.; McQuillan, C.I.; Termini, J.D.; Young, M.R.
 B:Chem. J. 248, 801-805, 1987
 A:Title: Molecular cloning and sequence analysis of the cDNA for small proteoglycan II
 A:Reference number: S06280; MUID:86133946; PMID:3435485
 A:Accession: S06280
 A:Molecule type: mRNA
 A:Residues: 1-360 <DAY>
 A:Cross-references: EMBL:Y00712; NID:9618; PIDN:CA68702.1; PID:9619
 A:Experimental source: bone
 R:Choi, H.U.; Johnson, T.L.; Pal, S.; Tang, L.H.; Rosenberg, L.; Neame, P.J.
 J. Biol. Chem. 264, 2876-2884, 1989
 A:Title: Characterization of the dermatan sulfate proteoglycans, DS-PGI and DS-PGII, from
 A:Reference number: A31430; MUID:89123388; PMID:2914936
 A:Accession: B31430
 A:Molecule type: protein
 A:Residues: 31-33, X', 35-54 <CHO>
 A:Experimental source: cartilage; fetal skin
 R:Coster, L.; Rosenberg, L.C.; van der Rest, M.; Poole, A.R.
 J. Biol. Chem. 262, 3809-3812, 1987
 A:Title: The dermatan sulfate proteoglycans of bovine sclera and their relationship to
 A:Reference number: A26545; MUID:87137687; PMID:3818667
 A:Accession: A26545
 A:Molecule type: protein
 A:Residues: 31-50 <COS>
 A:Experimental source: sclera
 R:Pearson, C.H.; Winterbottom, N.; Fackre, D.S.; Scott, P.G.; Carpenter, M.R.
 J. Biol. Chem. 258, 15101-15104, 1983
 A:Reference number: A20935; MUID:84087911; PMID:6654908
 A:Accession: A20935
 A:Molecule type: protein
 A:Residues: 31-54 <PEA>
 A:Experimental source: skin
 R:Chopra, R.K.; Pearson, C.H.; Pringle, G.A.; Fackre, D.S.; Scott, P.G.
 B:Chem. J. 232, 277-279, 1985
 A:Title: Dermatan sulphate is located on serine-4 of bovine skin proteodermatan sulphate
 nes around glycosylation sites in different proteoglycans.
 A:Reference number: A4700; MUID:86103195; PMID:3936484
 A:Contents: annotation; glycosylation
 C:Superfamily: decorin; leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan
 F:1-15/Domain: signal sequence #status predicted <PRO>
 F:16-30/Domain: propeptide #status predicted <PRO>
 F:31-360/Product: decorin #status predicted <NAT>
 F:49-73/Domain: proteoglycan amino-terminal homology <PAH>
 F:83-106/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
 F:107-130/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
 F:131-151/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>

F:152-175/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
 F:176-199/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
 F:202-222/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
 F:223-245/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
 F:247-270/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
 F:271-293/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
 F:294-308/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
 F:309-360/Domain: proteoglycan carboxyl-terminal homology <PCH>
 F:34/Binding site: dermatan sulfate (Ser) (covalent) #status experimental
 F:190.326/Binding site: dermatan sulfate (Ser) (covalent) #status predicted
 F:212.263.304/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 8.7%; Score 298; DB 2; Length 360;
 Best Local Similarity 30.1%; Pred. No. 2.6e-12;
 Matches 84; Conservative 49; Mismatches 12; Indels 24; Gaps 7;

QY 38 AASAGPON-----CPSCVSCSNQFSKVYCTRRGLSEVPQGIPTNRYLNLM 83
 Db 33 ASGIGPEHFEVPEIPEMGVCFPRQC--HLRVVQCSDLGLEKVPKDLPPDTALLDLQ 90
 QY 84 ENNIQIOADTFRHLLHLEVLQLGNSIRQIEVCAPNGLASLNTLELFDNWLTVPSGAF 143
 Db 91 NKKITEIKDGFKNLKNLHTLILNNKISKISPGAPAPLVKLERLYLSKNQKELP--- 146
 QY 144 EYLSK-LRELRLNNPIESIPSYAFNRVPSLMRLDLG-ELKKLEYISGGAPEGLFNLYL 201
 Db 147 EKMPKTLQELAVHENEITKVKSVFNGNLQMIIVELGTNPKSSGIENGAFQGMKLSYI 206
 QY 202 NMGCMNKDMNPLFVLGLELEMSGHFFPEIRPGSFHGLSSLKLLWVMSQVSLIERN 261
 Db 207 RIADTNITTIPOGLP-FSLTEHLDGKNKITKVDASLKLNLAKLGLSFNSISAVDNGS 265
 QY 262 FDGLASLVELNLAHNNLSLPHDLFTPLRYLVHLLHHPN 300
 Db 266 LANTPLRELHNNLAKVPGCV-ADHKIQVYVLENN 303

RESULT 23
 I47020
 decorin - rabbit
 C:Species: Oryctolagus cuniculus (domestic rabbit)
 C>Date: 04-Sep-1997 #sequence revision 04-Sep-1997 #text_change 20-Aug-1999
 C:Accession: I47020
 R:Zhan, Q.; Burrows, R.; Cintron, C.
 Invest. Ophthalmol. Vis. Sci. 36, 206-215, 1995
 A:Title: Cloning and in situ hybridization of rabbit decorin in corneal tissues.
 A:Reference number: I47020; MUID:95122319; PMID:7822148
 A:Accession: I47020
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-360 <ZHA>
 A:Cross-references: GB:S76584; NID:913374; PIDN:AAB33083.1; PID:9913375
 C:Superfamily: decorin; leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan
 F:49-73/Domain: proteoglycan amino-terminal homology <PAH>
 F:83-106/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
 F:107-130/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
 F:131-151/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
 F:152-175/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
 F:176-199/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
 F:202-222/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
 F:223-245/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
 F:247-270/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
 F:271-293/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
 F:294-308/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
 F:309-360/Domain: proteoglycan carboxyl-terminal homology <PCH>

Query Match 8.5%; Score 293.5; DB 2; Length 360;
 Best Local Similarity 32.2%; Pred. No. 5.3e-13;
 Matches 84; Conservative 44; Mismatches 122; Indels 11; Gaps 7;

QY 42 GPQNCPTSCVSCSNQFSKVYCTRRGLSEVPQGIPTNRYLNLMENNIQIOADTFRHLLH 101
 Db 52 GPV-CFFRCQC--HLRVVQCSDLGLEKVPKDLPPDTLLDLQNNKITEIKDGFANLKL 108

```

Y 102 EVLQGRNSIRQIEVGAFNGLASINTLEFDNMLTVIPSGAFYLSK-LRELWLRNNPTE 160
b 109 HALILVNNKISKISPGAFPLVLERLYLSKXHLKELP-----EKWPKSQELRAHENEIT 164
Y 161 SIFSAYANRVPVSLMRDLG-ELKKLYIYSEGAFGLFNLYLNGCNKIKOMPNTPLVG 219
b 165 KVRKSVFSGNQMIVIELGTNPVSKSGIENGAFQGMKKLSYIRIADTNTITTIPOGLP-PS 223
Y 220 LEELEMSGNHFFPIRPGSPHGLSSLLKGLWMNSQVSLIERNAPFDGLASIVELNLAHNL 279
b 224 LTELHDGKWKITDASSLKLGNLAKLGLSFNDISAVDNGSLANAPHLRELHLDNKL 283
Y 280 SLPHDLFTPLRYLVLELHNN 300
b 284 RVPGGL-ADHKYIQVVYVYLNHN 303

RESULT 24
24317
ecorin precursor - chicken
;Alternate names: corneal chondroitin/dermatan sulfate proteoglycan
;Species: Gallus gallus (chicken)
;Date: 13-Jan-1995 #sequence revision 13-Jan-1995 #text_change 20-Aug-1999
;Accession: S24317, S58474, S22197
;Ref: Li, W.; Vergnes, J.P.; Cornuet, P.K.; Hassell, J.R.
rch. Biochem. Biophys. 296, 190-197, 1992
;Title: cDNA clone to chick corneal chondroitin/dermatan sulfate proteoglycan reveals i
;Reference number: S24317; MUID:92226755; PMID:1605630
;Accession: S24317
;Molecule type: mRNA
;Residues: 1-357 <LIW>
;Cross-references: EMBL:X63797; NID:G62887; PIDN:CAA45318.1; PID:G62888
;Accession: S58474
;Molecule type: protein
;Residues: 31-33,'X','35-39,'X','41-48,'X','50-51 <LIA>
;Superfamily: decorin; leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan
;Keywords: collagen binding; extracellular matrix; glycoprotein
;1-16/Domain: signal sequence #status predicted <SIG>
;17-30/Domain: propeptide #status experimental <PRO>
;31-357/Product: decorin #status predicted <MAT>
;46-70/Domain: proteoglycan amino-terminal homology <PAH>
;80-103/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
;104-127/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
;128-148/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
;149-172/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
;173-196/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
;199-219/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
;220-243/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
;244-267/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
;268-290/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
;291-305/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
;306-357/Domain: proteoglycan carboxyl-terminal homology <PCH>

Query Match 8.4%; Score 287.5; DB 2; Length 357;
Best Local Similarity 32.2%; Pred. No. 1.4e-12;
Matches 84; Conservative 43; Mismatches 123; Indels 11; Gaps 7;

```

```

Qy 280 SLPHDLFTPLRYLVLELHNN 300
Db 281 RVPGGL-GEHKYIQVVYVYLNHN 300

RESULT 25
S29145
decorin precursor - rat
;Alternate names: dermatan sulfate proteoglycan-II
;Species: Rattus norvegicus (Norway rat)
;Date: 13-Jan-1995 #sequence revision 13-Jan-1995 #text_change 20-Aug-1999
;Accession: S29145; I60238; S28517
;Ref: Abramson, S.R.; Woessner Jr., J.F.
Biochim. Biophys. Acta 1132, 225-227, 1992
;Title: cDNA sequence for rat dermatan sulfate proteoglycan-II (decorin).
;Reference number: S29145; MUID:93003331; PMID:1390895
;Accession: S29145
;Status: preliminary
;Molecule type: mRNA
;Residues: 1-354 <ABR>
;Cross-references: EMBL:Z12298; NID:G57549; PIDN:CAA78170.1; PID:G57550
;Ref: Asundi, V.K.; Dreher, K.L.
Eur. J. Cell Biol. 59, 314-321, 1992
;Title: Molecular characterization of vascular smooth muscle decorin: deduced core prot
;Reference number: I60238; MUID:93154359; PMID:1493796
;Accession: I60238
;Status: preliminary; translated from GB/EMBL/DBJ
;Molecule type: mRNA
;Residues: 11-354 <RES>
;Cross-references: EMBL:X59859; NID:G56056; PIDN:CAA42519.1; PID:G56057
;Genetics:
;Gene: DCN
;Superfamily: decorin; leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan
;Keywords: collagen binding; extracellular matrix; glycoprotein
;F:31-354/Product: decorin #status predicted <MAT>
;F:43-67/Domain: proteoglycan amino-terminal homology <PAH>
;F:77-100/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
;F:101-124/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
;F:125-145/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
;F:146-169/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
;F:170-193/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
;F:196-216/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
;F:217-240/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
;F:241-264/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
;F:265-287/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
;F:288-302/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
;F:303-354/Domain: proteoglycan carboxyl-terminal homology <PCH>

Query Match 8.3%; Score 286.5; DB 2; Length 354;
Best Local Similarity 31.3%; Pred. No. 1.6e-12;
Matches 83; Conservative 44; Mismatches 123; Indels 15; Gaps 7;

```

```

Qy 43 PQN-----CPSCVCSNQPSKVCTRGSLSEVPGQIPSNRYLNMENNIMQIADTFRH 97
Db 41 PDNPLTSMCPYRCQC--HLRVQCSDLGLKRVPEFPDPTLLDQNNKITEKSGAFKN 98
Qy 98 LHELEVLQGRNSIRQIEVGAFNGLASINTLEFDNMLTVIPSGAFYLSK-LRELWLRN 156
Db 99 LKDLHTLILVNNKISKISPEAFKPLVLERLYLSKXHLKELP-----EKLPTKLQELRLHD 154
Qy 157 NPTESTPSYAFNRPVSLMRDLG-ELKKLYIYSEGAFGLFNLYLNGCNKIKOMPNT 215
Db 155 NEITKLKSVFNGLNRMIVIELGTNPVSKSGIENGAFQGMKKLSYIRIADTNTITTIPOGL 214
Qy 216 PLVGLBELEMSGNHFFPIRPGSPHGLSSLLKGLWMNSQVSLIERNAPFDGLASIVELNLAH 275
Db 215 P-TSISELHDGKWKITDASSLKLGNLAKLGLSFNDSVAVDNGSLANAPHLRELHLDN 273
Qy 276 NNLSLSPHDLFTPLRYLVLELHNN 300
Db 274 NKLLRVPAGL-AQHKYIQVVYVYLNHN 297

```

RESULT 26

A55454
 decorin precursor - mouse
 X:Alternate names: proteoglycan II
 C:Species: Mus musculus (house mouse)
 C>Date: 24-Feb-1995 #sequence_revision 24-Feb-1995 #text_change 20-Aug-1999
 C:Accession: A55454; S20812
 R:Scholzen, T.; Solursh, M.; Suzuki, S.; Reiter, R.; Morgan, J.L.; Buchberg, A.M.; Siracusa, J. Biol. Chem. 269, 28270-28281, 1994
 A:Title: The murine decorin. Complete cDNA cloning, genomic organization, chromosomal assignment, and expression.
 A:Reference number: A55454; MUID:95050610; PMID:7961765
 A:Accession: A55454
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-354 <SCH>
 A:Cross-references: GB:X53668; PIDN:CAA37876.1; PID:G53669
 R:Naitoh, Y.; Suzuki, S.
 submitted to the EMBL Data Library, July 1990
 A:Description: Nucleotide sequences of cDNAs encoding mouse PGI and PGII.
 A:Reference number: S20811
 A:Accession: S20812
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-354 <NAI>
 A:Cross-references: EMBL:X53668; PIDN:CAA37876.1; PID:G53669
 C:Superfamily: decorin; leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan
 C:Keywords: collagen binding; extracellular matrix; glycoprotein
 F:1-16/Domain: signal sequence #status predicted <Sig>
 F:17-30/Domain: propeptide #status predicted <Pro>
 F:43-67/Domain: proteoglycan amino-terminal homology <PAH>
 F:77-100/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
 F:101-124/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
 F:125-145/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
 F:146-169/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
 F:170-193/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
 F:196-216/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
 F:217-240/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
 F:241-264/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
 F:265-287/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
 F:288-302/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR10>
 F:303-354/Domain: proteoglycan carboxyl-terminal homology <PCH>

Query Match 8.1%; Score 279.5; DB 2; Length 354;
 Best Local Similarity 30.7%; Pred. No. 5e-12;
 Matches 81; Conservative 45; Mismatches 125; Indels 13; Gaps 6;
 QY 43 PON-----CPVCSGCSQFQVCTRRGLSEVPQGIPTNRYLNLMNNTQIQADTPRH 97
 DB 41 PDNPLISMCPYRCQC--HLRVVQCSGLGDKVPWDFPDPTLLDLQNNKITEIKGAFKN 98
 QY 98 LHLLEVLQGRNSIQIEVGAFNGLASLNTLELFDNNLTVIPSGAFYLSKLRELMLNN 157
 DB 99 LKDLHTLLVNNKISKISPEAFKPLVKLERLYLSKNQLKSLPE---KMPRTLQELRVHEN 155
 QY 158 PIESTIPSAFNRVPSLMRLDL-GEKKLEIYISGAFGLFNKLYNLGCMCNKIDMENLTP 216
 DB 156 EITKLRKSDFNGLNVLVIELGPNPLKNGIENGAFQGLSKLSYIRISDNTNIAIPQGLP 215
 QY 217 LVGLEELMSGNHPPIRPSFGHLSLKLKLVNNSOVSLIERNAPDGLASLVELMLAEN 276
 DB 216 -TSLEVEHLDGNKTKVDAPSLKGLNLKSLGLGFSNITWNGSLANVPHLRELHLN 274
 QY 277 NLSSLPDLPFTPLRYLVBLHLHN 300
 DB 275 KLLRVPAGL-AQHKYIQVYVHLNN 297

RESULT 27

T13852
 gene wheeler protein - fruit fly (Drosophila melanogaster)
 C:Species: Drosophila melanogaster

C>Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 17-Nov-2000

C:Accession: T13852
 R:Eldon, E.; Kooyer, S.; D'aveilyn, D.; Duman, M.; Lawinger, P.; Botas, J.; Bellen, H.
 Development 120, 885-899, 1994
 A:Title: The Drosophila 18 wheeler is required for morphogenesis and has striking simile
 A:Reference number: 217796; MUID:95324375; PMID:7600965
 A:Accession: T13852
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-1389 <ELD>
 A:Cross-references: EMBL:L23171; NID:g415682; PID:g1019104; PIDN:AAA79208.1
 C:Genetics:
 A:Gene: wheeler
 A:Cross-references: FlyBase:FBgn0004364

Query Match 7.8%; Score 268.5; DB 2; Length 1389;
 Best Local Similarity 24.3%; Pred. No. 1.9e-10;
 Matches 103; Conservative 62; Mismatches 161; Indels 97; Gaps 11;

QY 80 LNLNENNIQIADTFERHLHLVQLGRNSIRQIEVGAFNGLASLNTLELFDNNLTVIP 139
 DB 338 LNLNNALTRIGSKTFRELPLQLIDVNNNSIGHIEGAFPLYNLHTLNLAEENRLHLD 397
 QY 140 SCAFEYLSKLRELWLRNNPIESIPSYAFNRVPSLMRLDLGELKKLEYISGAFEGFLNK 199
 DB 398 NRIFNGLVLTKLTLNNLVSVESQAFRCSDLKELDLS-NQLTEVPB-AVQDLMLK 455
 QY 200 YNLGCMNIXDMP-----NLTPVGLSELEMSGNHPIRPSFGHLSLKLKLVNNSOV 254
 DB 456 TLDGEMQISFKNNTFRNLNQLTGLRID---NRIGNITVGHFQDLPLSVNLAKNRI 512
 QY 255 SLIERNADFGLASLVELNLNLSLPHDLFTPLRYLVBLHLHNPNWCCDILMAW 314
 DB 513 QSIERGAFDXTETEARLDKCNFLTDI-NGIFATLASLLMLNSEN-----HLVMP 562
 QY 315 LREVIPTNSTCCGCHAPMGRGYLVEVQASQCSAPFIMDAPRLNISEGMAELKC 374
 DB 563 DYAFIPSN----- 570
 QY 375 RTPPMSSVKVLLPNTGTVLSHAREPRI-SVLNQTGLNFSHLLSDTGVYTC-----M 425
 DB 571 -----LKWLDIHGNYIEALGNYVYKQEEIRVTVTLDSHNRIEIGAMSVPSIELLFI 623
 QY 426 VTNVAGNSNAYLN---VSTAEINTSNYSFPTTVVETTEISPEITRKYKVPPTSTG 482
 DB 624 NNNIIGQIQANTFVDKTRLARVDLYANVLSKISLNLRVAPVSAE-----KPVPEPYLG 677
 QY 483 YQP 485
 DB 678 GNP 680

RESULT 28

A34901
 lysine carboxypeptidase (EC 3.4.17.3) 83K chain - human
 C:Species: Homo sapiens (man)
 C>Date: 20-Jul-1990 #sequence_revision 20-Jul-1990 #text_change 05-Nov-1999
 C:Accession: A34901
 R:Tan, F.; Weerasinghe, D.K.; Skidgel, R.A.; Tamei, H.; Kaul, R.K.; Roninson, I.B.; Schi
 J. Biol. Chem. 265, 13-19, 1990
 A:Title: The deduced protein sequence of the human carboxypeptidase N high molecular wei
 A:Reference number: A34901; MUID:90094386; PMID:2378615
 A:Accession: A34901
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-536 <TAN>
 A:Cross-references: GB:J05158; NID:g179935; PIDN:AAA51921.1; PID:g179936
 C:Genetics:
 A:Gene: GDB:ACBP
 A:Cross-references: GDB:127893
 A:Map position: eq25.3-6q26
 C:Superfamily: leucine-rich alpha-2-glycoprotein repeat homology
 C:Keywords: hydrolase; metallo-carboxypeptidase

```

131 FNNLTVIPSGAFYLSKRLBLWL-RNNPIESIPSYAFNRVPSLRLDLGELKKLEYISE 189
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
190 SGNFTITSIEKAFELTSLTIVIGCHENFINETVVEIGRLKALKTKTLDSRADGIFQPE 249
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
190 GAPEGLENLYKNTLGMCMNIKOMPNI-LP-----LVGLESELEMSGNHPEIRPGSFHGLSSL 244
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
250 TLFKPIQIEVLKSGCSI---PTLEFQGFATLKKELDLRVNLINITYAFDGLLES 306
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
245 KKLWNNVQSVLSIERNAPDGLASLYELNLAHNNLSLPHDLFTPLR-YLVELHLHNPWN 303
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
307 TRLSLAGNFISKLEPDVFFGLSSLEELDGLGWEIKTIPTOVFKPLTDKLTISLRNPNIS 366
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
304 -----CDDIILWL-AWMLREVIPTNSCTCGCHAPMHRGRIYVEVDQAS 347
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
367 ELPSTGLGLEKLSAECGFTSISADQLKDYPKLEELDLSKCN-----ISNIVENT 417
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
348 FQCSAPFIMDAPRLDNISEGRMABLKCRTPPMSSVKWLLPNGTVLSHASRHPRIISVLNDG 407
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
418 FENQ----KDSLKLNQKXKLSLNLKLPALLES-----DVSENP----- 457
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
408 TLFNFSHLLSDTGVTTC---MVTWVAGNSNASAVLNIVSTAEIANTSVSPFTTVVETTEI 464
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
458 -----YRCDELGNFVFGVED-----RYKKAERNGN---SFFVANTNETVCD 496
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
465 SP-----EDTRKVKVPPTTS-TCYOPAYTSTTVLIQTT--RVPKQVAVPATDIT 512
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
497 RPYTLRGQILQVEVEKQPYDEKSDITTPASTITTSVETTELKIPDLLVGSRTNDT 556
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
513 -----DKQVSLDEWMT-----TKIIIGCFVAVTLLAAMLIVFYKLRKHQ 555
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
557 LFKESPRDNDVLSKTDQAGVYKQGTYAVPIITIGALVTIVIVAVVLYFKKKK-V 615
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
556 QRSTVTAARTVEIIQVDB 573
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
616 GTETAKGGRSKVVMKED 633
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
n - fruit fly (Drosophila melanogaster)
  Drosophila melanogaster
    -Sep-1999 #sequence_revision 20-Sep-1999 #text_change 17-Nov-2000
    on: T13887
      C.; Beachy, P.A.
      47, 225-239, 1994
      expression of a novel Toll-like gene spans the parasegment boundary and contrib
      e number: Z17805; MUID:95151581; PMID:7848870
    on: T13887
      preliminary; translated from GB/EMBL/DBJ
      type: mRNA
      : 1-1385 <CHI>
      references: EMBL:S76155; NID:G913247; PID:G913248; PIDN:AAB33383.1
      :
      references: FlyBase:PBgn004364
r
  atch 7.7%; Score 263.5; DB 2; Length 1385;
  al Similarity 24.1%; Pred.No.4.2e-10;
  102; Conservative 62; Mismatches 162; Indels 97; Gaps 11;
  80 LNLMMNTQMCATFRHLHLEVLQGRNSIRQIEVGAENGLASLTLELFNNLTVIP 139
      ||| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
  338 LNLNSNLAUTRGSTFKELYFLQLDMMNNSIGHIEGAPLPDYNLHNLMAENLHTID 397
      ||| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
  140 SCAPEYLSKLRELMRNPNIESIPSYAFNRVPSLRLDLGELKKLEYISGAFEGFLNKL 199
      ||| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
  398 NRIFNGLVLYTKLTLNNNLVSVESQAFNCSDLKSLDLS--NQLTEVPBA--QDL$MLK 455
      ||| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
  200 YNLGMCNIKOMP-----NLTPLVGLESELEMSGNHPEIRPGSFHGLSSKLWVNSQV 254
      ||| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
  456 TLDLGENQISBFKNTFRNLNQUTGELID---NRIGNITVGMFQDLPRLSVLNLAKNRI 512
      ||| : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

QY 255 SLIERAFDGLASIVELNLAHNLSLPHDLFTPLRYLVVHLLHHNPNWCDCDILMLAWW 314
 DB 513 QSIERGAFDQTEIEAIRLKKFLTDI-NGIFATLASLMLNSEN-----HLVWF 562
 QY 315 LREYPTNSTCGRCHAPMHRGRVYVEVDQASQCSAPPIMDAPRLNISEGRMAELKC 374
 DB 563 DYAFIPSN----- 570
 QY 375 RTPPSSVKNLLPNSTVLSHASRHPRI-SVLNDGTGLNFSVLLSDTGVYTC-----M 425
 DB 571 -----LKLWDIHGNYIEALGNVYKQEEIRVITVLOASHNRHTEIGAMSVPSNIELFI 623
 QY 426 VTNVAGNSVASAYLN---VSTAELNTSNYSFTVTVTETTSIPEDTRKYKVPYPTTSTG 482
 DB 624 NNNITGOQANTFVDKTRLARVDLYANVLSKISLNARVAPVSAE-----KVPBEPYLG 677
 QY 483 YQP 485
 DB 678 GNP 680
 RESULT 31
 S20811
 proteoglycan I - mouse
 N:Alternate names: biglycan
 C:Species: Mus musculus (house mouse)
 C>Date: 20-Feb-1995 #sequence revision 20-Feb-1995 #text_change 20-Aug-1999
 C:Accession: S20811; A57645; I49534
 R:Naitoh, Y.; Suzuki, S.
 A:Submitted to the EMBL Data Library, July 1990
 A:Description: Nucleotide sequences of cDNAs encoding mouse PGI and PGI1.
 A:Reference number: S20811
 A:Accession: S20811
 A>Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-369 <NAI>
 A:Cross-references: EMBL:X53928; NID:G53666; PIDN:CAA37875.1; PID:G53667
 R:Wegrowski, Y.; Pillarisetti, J.; Danielson, K.G.; Suzuki, S.; Iozzo, R.V.
 Genomics 30, 8-17, 1995
 A:Title: The murine biglycan: complete cDNA cloning, genomic organization, promoter function
 A:Reference number: A57645; MUID:96129295; PMID:8595907
 A:Accession: A57645
 A>Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-67, 'W', 69-369 <WEG>
 A:Cross-references: GB:L20276; NID:G348961; PIDN:AAA64360.1; PID:G348962
 A:Note: authors translated the codon TGG for residue 58 as Cys
 R:Kau, W.; Just, W.; Vetter, U.; Vogel, W.
 Mamm. Genome 5, 395-396, 1994
 A:Title: A dinucleotide repeat in the mouse biglycan gene (EST) on the X chromosome.
 A:Reference number: I49534; MUID:94319093; PMID:8043960
 A:Accession: I49534
 A>Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-67, 'W', 69-369 <RES>
 A:Cross-references: GB:L20276; NID:G348961; PIDN:AAA64360.1; PID:G348962
 C:Genetics:
 A:Gene: Bgn
 C:Superfamily: decorin; leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan
 C:Keywords: chondroitin sulfate proteoglycan; dermatan sulfate; extracellular matrix; g
 F:58-82/Domain: proteoglycan amino-terminal homology <PAH>
 F:92-115/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
 F:116-139/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
 F:140-160/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
 F:161-184/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
 F:185-208/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
 F:210-230/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
 F:231-254/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
 F:255-278/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
 F:279-301/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
 F:302-316/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR>
 F:317-369/Domain: proteoglycan carboxyl-terminal homology <PCH>

Query Match 7.6%; Score 262.5; DB 2; Length 369;
 Best Local Similarity 31.9%; Pred. No. 8.2e-11;
 Matches 82; Conservative 40; Mismatches 124; Indels 11; Gaps 7;
 QY 46 CPVCSGCSNQFSKVYCTRRGLSEVPGQIPSNRYLNMMNNIOMIQADTFRLHLEVLQ 105
 DB 64 CPGCHC--HLRVVQCSDLGLKTVPKESIPDITLLDQNDISELRKDDFKGLQHLVALV 121
 QY 106 LGRNSIRQIEVGAFNGLASLNTLELFDNMLTVIPSGAFEYLSKLRELWLNPNPIESIPSY 165
 DB 122 LVNNKISKIHEKAFSPRLKOKLYISKHLEVEIPP---NLPSSSLVELRIHDNRIRKVPKG 178
 QY 166 AFNRYPSLARLDLGLBLKLEY--ISEGAFEGLEWLYLNLMCMNKKMPNLTPLVLGEEEL 223
 DB 179 VFSGLRNKNCIEMGG-NPLENSGFEPGAFDGL-KLNYLRISSEAKLTGTPKDPET-LNEL 235
 QY 224 EMSGNHFEIRPGSGHGLSSKLKLVWMSOVSLEARNAFDGLASIVELNLAHNLSLPH 283
 DB 236 HLDHNKIQAIIELEDLLRYSKYLRGLGHGHNQRMHENGSLSFPLTIRELHLDNKLKSRVPA 295
 QY 284 DLFTPLRYLVVHLLHNN 300
 DB 296 GL-PDLKLLQVVYLSN 311
 RESULT 32
 S32793
 biglycan precursor - rat
 N:Alternate names: dermatan sulfate proteoglycan I (DS-PGI); proteoglycan I core protein
 C:Species: Rattus norvegicus (Norway rat)
 C>Date: 02-Dec-1993 #sequence revision 01-Sep-1995 #text_change 20-Aug-1999
 C:Accession: S32793
 R:Preher, K.L.; Asundi, V.; Matzura, D.; Cowan, K.
 Eur. J. Cell Biol. 53, 296-304, 1990
 A:Title: Vascular smooth muscle biglycan represents a highly conserved proteoglycan with
 A:Reference number: S32793; MUID:91184222; PMID:2081545
 A:Accession: S32793
 A>Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-369 <DRE>
 A:Cross-references: GB:U17834; NID:G600497; PIDN:AAA58797.1; PID:G600498
 C:Superfamily: decorin; leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan
 C:Keywords: chondroitin sulfate proteoglycan; dermatan sulfate; extracellular matrix; g
 F:1-16/Domain: signal sequence #status predicted <SIG>
 F:17-37/Domain: propeptide #status predicted <PRO>
 F:38-369/Product: biglycan #status predicted <PAH>
 F:58-82/Domain: proteoglycan amino-terminal homology <PAH>
 F:92-115/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
 F:116-139/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
 F:140-160/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
 F:161-184/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
 F:185-208/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
 F:210-230/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
 F:231-254/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
 F:255-278/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
 F:279-301/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
 F:302-316/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR>
 F:317-369/Domain: proteoglycan carboxyl-terminal homology <PCH>
 F:42,48,181,199/Binding site: dermatan sulfate (Ser) (covalent) #status predicted
 F:271,312/Binding site: carboxylate (Asn) (covalent) #status predicted

Query Match 7.6%; Score 262.5; DB 2; Length 369;
 Best Local Similarity 31.9%; Pred. No. 8.2e-11;
 Matches 82; Conservative 40; Mismatches 124; Indels 11; Gaps 7;
 QY 46 CPVCSGCSNQFSKVYCTRRGLSEVPGQIPSNRYLNMMNNIOMIQADTFRLHLEVLQ 105
 DB 64 CPGCHC--HLRVVQCSDLGLKTVPKESIPDITLLDQNDISELRKDDFKGLQHLVALV 121
 QY 106 LGRNSIRQIEVGAFNGLASLNTLELFDNMLTVIPSGAFEYLSKLRELWLNPNPIESIPSY 165
 DB 122 LVNNKISKIHEKAFSPRLKOKLYISKHLEVEIPP---NLPSSSLVELRIHDNRIRKVPKG 178

Y 166 AFNRVSLRDLGELKKLEY--ISGAFEGFLNLYLNGMNCNIDKPNLTPVGLREL 223
b 179 VFSGLENNANCIENG--NPLENGFEGFADGL--KLYLSISAKLTGPKOLFET--LNEEL 235
Y 224 EMSGNHPPRPGSPHGLISLKLWQVSLIERNAPDGLASVELNLAHNNLSLPH 283
b 236 HLDENKIQALEDLARYSKLYLGLGHQIRMIENGSLSLFPTRELHLNKKLSRYP 295
Y 284 DLFTPLRYLYVELLHN 300
b 296 GL--PDLKLLQVVYLSN 311
RESULT 33
19938
Ypothetical protein C44H4.2 - *Caenorhabditis elegans*
;Species: *Caenorhabditis elegans*
;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 18-Feb-2000
;Accession: T19938
;Smye, R.
;Submitted to the EMBL Data Library, August 1996
;Reference number: Z19200
;Accession: T19938
;Status: preliminary; translated from GB/EMBL/DBJ
;Molecule type: DNA
;Residues: 1-738 <WIL>
;Cross-references: EMBL:Z79598; PIDN:CAB01864.1; GSPDB:GN00028; CESP:C44H4.2
;Experimental source: clone C44H4
;Genetics:
;Gene: CESP:C44H4.2
;Map position: X
;Introns: 30/3; 89/3; 125/3; 168/1; 327/3; 453/3; 524/3; 612/2; 680/2
Query Match 7.6%; Score 262.5; DB 2; Length 738;
Best Local Similarity 23.4%; Pred. No. 2.1e-10;
Matches 141; Conservative 79; Mismatches 232; Indels 151; Gaps 22;
Y 71 QGIPSTRYLYLNMENNIOQADTFPHLEHEVLQGRNSIQIIVGAFNGLASLNTLEL 130
b 145 QNVKSIQITNLGHNNWTAVPSSAIRGLXQLQSLHLKRIEQLDALNPLNPLVNLNL 204
Y 131 FDNWLTVPISGAPEYLSKRELWLRNPIETSPVAFNRVPSLMDLDELKLYISEG 190
b 205 AGQIHLEHARQAPNVPISRYLYLSGNKTKLTAYQVQTFQLEMLDLTN-NEIGALPAN 263
Y 191 AFEGLENLYLNGMNCNIDK--PNLTFVLGLELEMSGNHPIRPGSFHGLSLKLW 249
b 264 SLSELQALQLYLAHNKISNISSNAFTNSSIVVYLSNELKTLTAGIISGLPNLQVVF 323
Y 250 MNSQVSLIERNAPDGLASVELNLAHNNLSLPHDLFTPLRYLYVELH----- 296
b 324 RENOIKTINENAFYDAASLVMLDLAKXQLTETI-----APTFLAQNLNLLVDSNKLPK 378
Y 297 -----LHENFWNCDDILMLAWMLREYI-PTNSTCCGR----- 328
b 379 TPYSAFNSRVGTLLKENPLVCTENLHMLQOQGVYVRDSPDIIIGRKPETKPEVLPVI 438
Y 329 -----CHAPMH-MRGVLYVEVDQASFQ-----CSAP-----PI 355
b 439 VTDSLSTQRPALVQIPKQIHNRVHTTTGDOAPQIPSGAFQOQDLGKRSILPRGHSRFI 498
Y 356 MDAPRDLNINSEGRMAELKCRTPMSSVKVLLNGTVLSHSPRI--SVLNDGTLNFSH 413
b 499 LDKPSTREQSVEFTEL-----TPIQI--ILP-----SREDIRQSSWEAGT---SQ 541
Y 414 VLLSDTGVTCTMVTNAGNSASAYLNVSATLNTSNYSFFTTVTVETETISPEPTTKY 473
b 542 ESVEATSQKIPSTTDIDRPNVVLPPVPFLKRGPP---NLSESKVVESTD----- 588
Y 474 KPVTSTGQPAYTSTTVLIQTTVPKQVAPATDTTK-----M 515
b 589 --MPST--QVFTPLPSILIEPGSTPK-VAQPSSTEANIKSEHIDEFALASSNSNEPTL 642

QY 516 QTSLEDEWMTKXII---IGCFVAVTLAAAMLIVFYKLKRHQQ-----RSTVTAARTV 566
Db 643 QPRLKSFFTTIIIFICVGTAVILVWVIAGLCI-----SKERQLQFENTYSDSAAARTS 697
QY 567 EII 569
Db 698 EYI 700
RESULT 34
BGNHUN
biglycan precursor - human
N;Alternate names: cartilage proteoglycan I; dermatan sulfate proteoglycan I (DS-PGI); p
C;Species: *Homo sapiens* (man)
C;Date: 21-Apr-1992 #sequence_revision 26-May-1995 #text_change 28-Jan-2000
C;Accession: A40757; I38706; A32458; S14349; S05639; A28457
R;Fisher, L.W.; Heegaard, A.M.; Vetter, U.; Vogel, W.; Just, W.; Termine, J.D.; Young, M
J. Biol. Chem. 266, 14371-14377, 1991
A;Title: Human biglycan gene. Putative promoter, intron-exon junctions, and chromosomal
A;Reference number: A40757; MUID:91317791; PMID:1860845
A;Accession: A40757
A;Molecule type: DNA
A;Residues: 1-368 <FIS1>
A;Cross-references: GB:M65151; NID:gl79428; GB:M65152; NID:gl79429; GB:M65153; NID:gl794
A;Note: The translated sequence in Genbank entry HUMBGN3, release 113.0, (PIDN:AAA52287;
d not the DNA) and 26 residues inserted after residue 80 (apparently from a misread spli
Hum. Mol. Genet. 3, 2268, 1994
A;Title: Dinucleotide repeat polymorphism at the human biglycan (BGN) locus.
A;Reference number: I38706; MUID:95187185; PMID:7881444
A;Accession: I38706
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 361-368 <JUS>
A;Cross-references: EMBL:U11686; NID:g607862; PIDN:AAC50117.1; PID:g619663
R;Fisher, L.W.; Termine, J.D.; Young, M.F.
J. Biol. Chem. 264, 4571-4576, 1989
A;Title: Deduced protein sequence of bone small proteoglycan I (Biglycan) shows homology
A;Reference number: A32458; MUID:89174714; PMID:2647739
A;Accession: A32458
A;Molecule type: mRNA
A;Residues: 1-138, 'DV', 141-162, 'DV', 165-368 <FIS2>
A;Cross-references: GB:J04599; NID:gl84339
A;Note: Parts of this sequence, including the amino end of the mature protein, were dete
R;Stoecker, J.; Meyer, H.E.; Wagener, C.; Greiling, H.
Biochem. J. 274, 415-420, 1991
A;Title: Purification and N-terminal amino acid sequence of a chondroitin sulphate/derma
A;Reference number: S14349; MUID:91174749; PMID:1848758
A;Accession: S14349
A;Molecule type: protein
A;Residues: 38-57 <STO>
A;Experimental source: aorta
R;Roughley, P.J.; White, R.J.
Biochem. J. 262, 823-827, 1989
A;Title: Dermatan sulphate proteoglycans of human articular cartilage. The properties of
A;Reference number: S05639; MUID:90073579; PMID:2590169
A;Accession: S05639
A;Molecule type: protein
A;Residues: 38-41, 'X', 43-46, 'X', 48-57 <ROU>
R;Fisher, L.W.; Hawkins, G.R.; Tuross, N.; Termine, J.D.
J. Biol. Chem. 262, 9702-9708, 1987
A;Title: Purification and partial characterization of small proteoglycans I and II, bone
A;Reference number: A92656; MUID:87250639; PMID:3597437
A;Accession: A28457
A;Molecule type: protein
A;Residues: 38-41, 'X', 43-62, 'X', 64-66 <FIS3>
A;Experimental source: bone
C;Genetics:
A;Gene: GDB:BGN
A;Cross-references: GDB:119727; OMIM:301870
A;Map position: Xq28-Xq28
A;Introns: 80/1; 117/3; 189/1; 226/1; 257/2; 303/3

C:Superfamily: decorin; leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan
C:Keywords: chondroitin sulfate proteoglycan, dermatan sulfate; duplication; extracellular
F:1-16/Domain: signal sequence #status predicted <SIG>
F:17-37/Domain: propeptide #status predicted <PRO>
F:38-368/Product: biglycan #status predicted <MAT>
F:57-81/Domain: proteoglycan amino-terminal homology <PAH>
F:91-114/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
F:115-138/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
F:139-159/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
F:160-184/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
F:184-207/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
F:209-229/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
F:230-253/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
F:254-277/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
F:278-300/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
F:301-315/Domain: leucine-rich alpha-2-glycoprotein repeat homology #status atypical <LR
F:316-368/Domain: proteoglycan carboxyl-terminal homology <PCH>
F:42,47/Binding site: dermatan sulfate (Ser) (covalent) #status experimental
F:180,198/Binding site: dermatan sulfate (Ser) (covalent) #status predicted
F:270,311/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 7.6%; Score 261.5; DB 1; Length 369;
Best Local Similarity 31.5%; Pred. No. 9.6e-11;
Matches 81; Conservative 41; Mismatches 124; Indels 11; Gaps 7;

QY 46 CPSCVCSNQSKVCTRGSLSEVPGIPSNTRYLNLMENNIMQIQADTFRLHHLVQLQ 105
DB 63 CPFGCHC-HLRVQCSDGLKAVPKISPTDLDLQNDISELRKDDFKGLQHLVALV 120
QY 106 LGRNSIRQIEVGAFNGLASINTLEFDNWLTVIPSGAFYLSKRELWLRNPIESPSY 165
DB 121 LVNKKISKIHEKAFSPRLKQLKLYISKHVLVIPP---NLPSLVELAIHNRIRKVPKG 177
QY 166 AFNRVPSLMRLDGLGELKLEY--ISEGAFEGFLNKLNLGMCNICKMPNLTPLVGLLEL 223
DB 178 VFSGLGNMNCIEMGG-NPLENGSPFGAPDGL-KENYLRISEAKLTGPKLPET-LNEL 234
QY 224 EMSGNHFFPIRPGSPFGLSSLLKLVWMSQVSLIERNAFDGLASIVELNLAHNNLSLPH 283
DB 235 HLDHNNKIQAIELEDLLRYSKLYRLGLGHQNIIRMIENGSLSPFLTREHLHNNKLSRVP 294
QY 284 DLFTPLRYLVELLHNN 300
DB 295 GL-PDLKLLQVYVLTNN 310

RESULT 35
S32559

N:Alternate names: dermatan sulfate proteoglycan I (DS-PGI); proteochondroitin core prot
C:Species: Bos primigenius taurus (cattle)
C:Date: 03-May-1994 #sequence revision 20-Feb-1995 #text change 07-May-1999
C:Accession: S32559; S34229; A33701; A31430; PT0078; S55673; A33137
R:Torok, M.A.; Evans, S.A.S.; Marcum, J.A.
Biochim. Biophys. Acta 1173, 81-84, 1993
A:Title: cDNA sequence for bovine biglycan (PGI) protein core.
A:Reference number: S32559; MUID:93250052; PMID:8485158
A:Accession: S32559
A:Molecule type: mRNA
A:Residues: 1-369 <OR>
A:Cross-references: EMBL:L07953; NID:g162746
A:Experimental source: aortic smooth muscle
R:Marcum, J.A.; Torok, M.; Evans, S.
submitted to the EMBL Data Library, December 1992
A:Reference number: S34229
A:Accession: S34229
A:Molecule type: mRNA
A:Residues: 1-250, 'V', 252-369 <MAR>
A:Cross-references: EMBL:L07953
A:Experimental source: aortic smooth muscle
R:Neame, P.J.; Choi, H.U.; Rosenberg, L.C.
J. Biol. Chem. 264, 8653-8661, 1989
A:Title: The primary structure of the core protein of the small, leucine-rich proteoglyc
A:Reference number: A33701; MUID:89255324; PMID:2656687

A:Accession: A33701
A:Molecule type: protein
A:Residues: 38-187, 'E', 189-367, 'Y' <NEA>
A:Experimental source: Cartilage
R:Choi, H.U.; Johnson, T.L.; Pal, S.; Tang, L.H.; Rosenberg, L.; Neame, P.J.
J. Biol. Chem. 264, 2876-2884, 1989
A:Title: Characterization of the dermatan sulfate proteoglycans, DS-PGI and DS-PGII, fr
A:Reference number: A31430; MUID:89123388; PMID:2914936
A:Accession: A31430
A:Molecule type: protein
A:Residues: 38-41, 'X', 43-47, 'X', 49-63 <CHO>
A>Note: sequences from skin and cartilage were identical
R:Marcum, J.A.; Thompson, M.A.
Biochim. Biophys. Res. Commun. 175, 706-712, 1991
A:Title: The amino-terminal region of a proteochondroitin core protein, secreted by aor
om human bone.
A:Reference number: PT0077; MUID:91207372; PMID:2018513
A:Accession: PT0078
A:Molecule type: protein
A:Residues: 17-24, 'F', 26-30 <MA2>
A:Experimental source: aortic smooth muscle
R:Scott, P.G.; Nakano, T.; Dodd, C.M.
Biochim. Biophys. Acta 1244, 121-128, 1995
A:Title: Small proteoglycans from different regions of the fibrocartilaginous temporoma:
A:Reference number: S55673; MUID:95284073; PMID:7766647
A:Accession: S55673
A:Molecule type: protein
A:Residues: 38-41, 'X', 43-47, 'X', 49-53 <SCO>
C:Superfamily: decorin; leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan
C:Keywords: cartilage; chondroitin sulfate proteoglycan; dermatan sulfate; extracellular
F:1-16/Domain: signal sequence #status predicted <SIG>
F:17-37/Domain: amino-terminal propeptide #status predicted <PRO>
F:38-369/Product: biglycan #status predicted <MAT>
F:58-82/Domain: proteoglycan amino-terminal homology <PAH>
F:92-115/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
F:116-139/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
F:140-160/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
F:161-184/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
F:185-208/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
F:210-230/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
F:231-254/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
F:255-278/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>
F:279-301/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>
F:302-316/Domain: leucine-rich alpha-2-glycoprotein repeat homology #status atypical <LI
F:317-369/Domain: proteoglycan carboxyl-terminal homology <PCH>
F:42,48/Binding site: dermatan sulfate (Ser) (covalent) #status experimental
F:181,199/Binding site: dermatan sulfate (Ser) (covalent) #status predicted
F:271,312/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 7.6%; Score 261.5; DB 2; Length 369;
Best Local Similarity 31.9%; Pred. No. 9.6e-11;
Matches 82; Conservative 40; Mismatches 124; Indels 11; Gaps 7;

QY 46 CPSCVCSNQSKVCTRGSLSEVPGIPSNTRYLNLMENNIMQIQADTFRLHHLVQLQ 105
DB 64 CPFGCHC-HLRVQCSDGLKAVPKISPTDLDLQNDISELRKDDFKGLQHLVALV 121
QY 106 LGRNSIRQIEVGAFNGLASINTLEFDNWLTVIPSGAFYLSKRELWLRNPIESPSY 165
DB 122 LVNKKISKIHEKAFSPRLKQLKLYISKHVLVIPP---NLPSLVELAIHNRIRKVPKG 178
QY 166 AFNRVPSLMRLDGLGELKLEY--ISEGAFEGFLNKLNLGMCNICKMPNLTPLVGLLEL 223
DB 179 VFSGLGNMNCIEMGG-NPLENGSPFGAPDGL-KENYLRISEAKLTGPKLPET-LNEL 235
QY 224 EMSGNHFFPIRPGSPFGLSSLLKLVWMSQVSLIERNAFDGLASIVELNLAHNNLSLPH 283
DB 236 HLDHNNKIQAIELEDLLRYSKLYRLGLGHQNIIRMIENGSLSPFLTREHLHNNKLSRVP 295
QY 284 DLFTPLRYLVELLHNN 300
DB 296 GL-PDLKLLQVYVLTNN 311

RESULT 36

T23395
hypothetical protein K07A12.2 - Caenorhabditis elegans
;Species: Caenorhabditis elegans
;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
;Accession: T23395
;McLay, K.
submitted to the EMBL Data Library, October 1996
;Reference number: Z19735
;Accession: T23395
;Status: preliminary; translated from GB/EMBL/DBJ
;Molecule type: DNA
;Residues: 1-961 <WIL>
;Cross-references: EMBL:Z81098; PIDN: CAB031182.1; GSPDB: GN00019; CESP: K07A12.2
;Experimental source: clone K07A12
;Genetics:
;Gene: CESP: K07A12.2
;Map position: 1
;Introns: 33/3; 97/3; 137/3; 167/2; 285/3; 325/3; 548/3; 898/2

Query Match 7.5%; Score 256.5; DB 2; Length 961;
Best Local Similarity 21.8%; Pred. No. 7.8e-10;
Matches 87; Conservative 63; Mismatches 120; Indels 129; Gaps 11;
29 WILCAATA---AAASAGPQCPS-----VCSCSNQFQKVVCTRGLEVP- 70
3 WLTIAVAHLIAFLSSAEITCPRIPEKDCCKISKSMILSCNGEDVKTIAQTGVTQSUIDE 62
71 -----QGIPSN-TRYLNLMXNNIOMIQADTERHLH-HLEVLQGRNSIROIEVG 117
63 LHIINGTDVKIESLFFNGRLTIALNTLSQSFSTAWRHEATIEHITINGNELKTPV- 121
118 AFNGIASLNTLEFDNMLTVIPSGAFYLSKRLRLMNNPI-----ELKKLYISE- 159
122 -FGNLSTLMNLSNQISSIPDKAFNGLSALTQLRLNNAICDPEPKSLDAVKASLVLL 180
160 -----ESIPSYAFNRVPSLRLDILG-----ELKKLYISE- 189
181 DVSGNCLDAIPAQILRNAANMLYDLGNNISEINNFELMNLFFRELVRQNNLTERRIHP 240
190 -----GAPEGLFNLYKYL-----GMCNKKDMFNLTPL- 217
241 MAFMNVPLQVLYLDNIIISTLDGNRLQGFNFLEVDVSNALVALPSLKLNLAKQVRV 300
218 -----VGLLELESGNHFFPIRPGSPHGLSSLKKLWVNSQVSLIERNA 261
301 DGNLITKTIETLAFSNNENLQIISVQNNNIVQISRNFSFSLDKLWLLVGNNSLAKIERGM 360
262 FDGLASLVELMLAHNNLSLPHDLFTPLRYLVELHLHN 300
361 FDGKNLQQLSIRNNLTALDASSPAQLAHLITLIDLGN 399

RESULT 37

T24315
hypothetical protein T01G9.3 - Caenorhabditis elegans
;Species: Caenorhabditis elegans
;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
;Accession: T24315
;Lennard, N.
submitted to the EMBL Data Library, July 1996
;Reference number: Z19874
;Accession: T24315
;Status: preliminary; translated from GB/EMBL/DBJ
;Molecule type: DNA
;Residues: 1-603 <WIL>
;Cross-references: EMBL:T275713; PIDN: CAB00050.1; GSPDB: GN00019; CESP: T01G9.3
;Experimental source: clone T01G9
;Genetics:
;Gene: CESP: T01G9.3
;Map position: 1
;Introns: 68/3; 346/1; 407/3; 450/3; 486/3

Query Match 7.4%; Score 254; DB 2; Length 603;

Best Local Similarity 20.2%; Pred. No. 6.2e-10;
Matches 128; Conservative 81; Mismatches 188; Indels 238; Gaps 21;
17 ILLPFVYLTAAQWILCAIAAASAGPQCPSVSC-SNQFSKVWCTRRGL-----SEV 69
5 ILLFL-----SFLVLCIS-----ALPSSCNLCEDQNDSSMSVYCRKAIINDTIYAEI 54
70 PQGIPSNTRYLNLM-----ENNIQMIQADTER-----HLHLE 102
55 LNQLPLTLRSLHIQPPNSNGNKLWNNINPAQLRVLRINCOIPAMRSIRLPSLE 114
103 VLQGRNSIROIEVGAFAENGLASLNTLEFDNMLTVIPSGAFYLSKRLRLMNNPIES 162
115 VLDLHNSNIEHATMSNFGPKRLRVLDLSSNLNLTPTGVFTYLRALRSLSLGNNTISDL 174
163 PSYAFNRVPSL--WRDLGELKKLYISE-----GAFGLFN 197
175 STNLLRGLNSLRVLRDRNPI-PIEHINELFTVQSQDLDELNLHNCMLSSIYSLALDRIPQ 233
198 LKYNLNGMCMIKOMP--NLTPLVGLLELESGNHFFPIRPGSF-----HGLSSL 244
234 LRQLGIGGNLKVPTKEARSLPOLSVLDLSHNSIQEITACAFCTNISKLDLSHNLGI 293
245 KK-----LWVNSQVSLIERNAFQ----- 264
294 SKDSPFNEDAFPTPLRLDLSTFNHNDPDSKWLGAQEELTSIALSGNFLKNFESWTY 353
265 -LASLVELNLAHNNLSLPHDLFTPLRY----- 291
354 TKSLIHLELAYNHKIPVQL--PSRYHLISLNTSGNELTYLPDNINTLLPNVKTFDI 411
292 -----LVLEHLHNNPNCDCILWMLWMLREYIPTNSTCCGRCHAPM 333
412 TANRFTPTSHDTLAFNNVBOVYVYDGNPDCSAIQGL-----QV 451
334 HMRGRYLVE--VDQASQCSAPFTMDAPRDINISEGRMABLKCRTPPMSSVKWLLPNGTV 391
452 HRRDYARHILNDYVRCATPSLVEGHSVALTD-----VNDCA 491
392 LSHASRH-----PRISVLNDGTILNFSHVLLSDTG-VYTCMTVNVAGNSASAYLNVTAE 445
492 VLPGARVGLTQTSMLILLAGVLLFAALLMILGCIYFLRERQVKGSVYVTRHSRTPLTM 551
446 LNTSNYSFPT-----VTVETEIS 466
552 ANTHSCSSTNDTRGPLSPFPDFLNVSTETFKATP 586

RESULT 38

T23841
hypothetical protein M88.6b - Caenorhabditis elegans
;Species: Caenorhabditis elegans
;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
;Accession: T23841
;Sulston, J.
submitted to the EMBL Data Library, June 1994
;Reference number: Z19806
;Accession: T23841
;Status: preliminary; translated from GB/EMBL/DBJ
;Molecule type: DNA
;Residues: 1-594 <WIL>
;Cross-references: EMBL:Z34802; PIDN: CAB54282.1; GSPDB: GN00021; CESP: M88.6b
;Experimental source: clone M88
;Genetics:
;Gene: CESP: M88.6b
;Map position: 3
;Introns: 40/3; 60/2; 101/3; 216/2; 290/1; 361/1; 411/3; 455/1; 544/3

Query Match 7.3%; Score 252.5; DB 2; Length 594;
Best Local Similarity 25.1%; Pred. No. 7.8e-10;
Matches 94; Conservative 50; Mismatches 117; Indels 113; Gaps 11;

```

Qy 252 SOVSLIERNAPDGLASIVLNLAH-----NNLSSLPFLPT 287
Db 292 TPISVFNNAFHPHINLIRLEMSAAVDITBERGAFQTPQIAIYLNKNRLSQVRADFFE 351
Qy 288 PLR--YLVEL-----HLH----- 298
Db 352 GLNDLYSIDLQGNRIDNVQPLGFANLPAISHLDISYNLQTMPSNVFQNSFLQPQNDERV 411
Qy 299 -----HNPNMNCDCDILMLAWLREYI-----PTNSTCCGRCHAPMHMGRVYLVEVDQASF 348
Db 412 IVACGNPMWCNSELEWFRTLLRNLNDIDVEXPGCTAVCTSSPMGCFVEGTPLRSYDFCQN 471
Qy 349 QCSA--PFINDAPRLNITSEGSMAELKCRTPPMSSVKWLLPNCVTULSHASRHRISVLNDG 407
Db 472 NERAAQLV-----GR-----ALSMVGWII----- 490
Qy 408 TLNFSHVLLSDTGYTCMVTNVA--GNSNASAYLVNSTAEFLANTSNYSFFTTVT--VETTEIS 465
Db 491 ---LAVIMTILILISICLLAWRVGMSHQK--KQDAEVAEEVHHQTATTSIYNAPIS 544
Qy 466 PEDTTRKYKVPVTTSTGYQPAYT 488
Db 545 VVD--RPYSTVPPVNLDPAAYT 565

RESULT 40
T19939
hypothetical protein C44H4.3 - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 18-Feb-2000
C:Accession: T19939
R:Smyle, R.
submitted to the EMBL Data Library, August 1996
A:Reference number: Z19200
A:Accession: T19939
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-680 <WIL>
A:Cross-references: EMBL:Z79598; PIDN:CAB01865.1; GSPDB:GN00028; CESP:C44H4.3
A:Experimental source: clone C44H4
C:Genetics:
A:Gene: CESP:C44H4.3
A:Map position: X
A:Introns: 36/3; 74/3; 122/3; 216/3; 364/3; 589/3

Query Watch 7.3%; Score 250; DB 2; Length 680;
Best Local Similarity 25.0%; Pred. No. 1.4e-09;
Matches 126; Conservative 64; Mismatches 185; Indels 128; Gaps 21;

```

Qy	54	NOPSKVCTRGSLSEVDPQGPSNTRVNLWE---NNIQMIQADTFRHLHLLEVLQLGNS	110
Db	108	NVMQELSUSENNKEVTPSALAGRLVNLISLKKKNIENITTKAFVNMISLIDVNLGCQ	167
Qy	111	ITQIEVGAF-NGLASLNTLBLEFNWLTVPISGAFYLSKLRELWLRNNPIISIPYAPNR	169
Db	168	ICSMADTFANVKMSLQMLILDNNKMTPEPPSKAVRMNNLIHLKYKKNIAIRQNDPVN	227
Qy	170	VPSLRRLDGLKLELYISEGAFGLFNLYKLNGLMCNTKOMEN--LTPLVGLGELEMSG	227
Db	228	LTSLSMGSLG-NNISIKGGLQNTPNLHYLYLHNNLOTLDNGVLQSQFKQLQVLDLSF	286
Qy	228	NHPEIRPSPHGLSSLUKKLVWMSQVSIUARNFGLASLVELNLAHNNLSLPHDLFT	287
Db	287	NNFTDITKEMPEGLSEIQLHNLDSNRISAVAPCAFAG-----T	324
Qy	288	PLRYLVELLHHPNWCDCDILMAWRELYPTNSTCCGRCHAPMHRGRYLVEDQAS	347
Db	325	PLL-----LLML-----PNN-----C-----LTVSQOT	343
Qy	348	FQCSAFFIMAPRODINTISGERMAELK-----CRTPPMSSVKNLLPMTGLVS-----	393
Db	344	LK-GAPFL---RMVSSNNNRREVHLSFDELPHNLFTLD--LANNKIMSQNTLSGPE	396

```

y 394 ----HARRPRISVLDGTLNFSHVLLSDTGYVTCTMTNAGNSASAVLNVTAEI--- 446
b 397 NLAVRLQENPWCVRKG-----PHVLNAGEAIW---LITNEA-NTICKGEWQATADLCPK 447
y 447 -----NTSNYSFPTTIVTETTESPISDTRTKYKVPVTTSTGYQPAYTSTTTLVLOT 497
b 448 AQRPPIRPVCCSNEITTTTTTTTT-----FTL-----APTITTEKEKETETTE--KV 495
y 498 TRVPKQVAPVATDTTKMQTSLD 520
b 496 TTVGKSKTKATTTTBEPEDD 518

RESULT 41
23836
hypothetical protein M88.6a - Caenorhabditis elegans
;Species: Caenorhabditis elegans
;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
;Accession: T23836
;Sulston, J.
submitted to the EMBL Data Library, June 1994
;Reference number: Z19806
;Accession: T23836
;Status: preliminary; translated from GB/EMBL/DBJ
;Molecule type: DNA
;Residues: 1-610 <WIL>
;Cross-references: EMBL:Z34802; PIDN:CAA84337.1; GSPDB:GN00021; CESP:M88.6a
;Experimental source: clone M88
;Genetics:
;Gene: CESP-M88.6a
;Map position: 3
;Introns: 40/3; 60/2; 101/3; 216/2; 290/1; 427/3; 471/1; 560/3

Query Match 7.3%; Score 249.5; DB 2; Length 610;
Best Local Similarity 22.7%; Pred. No. 1.3e-09;
Matches 121; Conservative 75; Mismatches 172; Indels 165; Gaps 20;

y 29 WILCAIAPAAAGPQNC-----PSVCSNQ--PSKV-----VTRGL 66
b 7 FVLLALARIAISBTRKSCIDIEKGFEBNAHQPVCIADNGIPSTVKGFTIRCESASI 66
y 67 SEYPOGIPS-----NTRVNLNEN-----NIQMIQADTFRHL- 98
b 67 ASVSENLASLNGTGLTIRDSVNVLPQDLFENVFAQVKLRCGLSTLQPSFQSLG 126
y 99 HLEVLQGRNSIRQIEVGAFNGLAGLNTLELPDNLVTPVPGAFEYLSKLELNRNP 158
b 127 GSAELLISLRNRIKLEKGLFTGLSKLTLDLAWNKIQIDVGAPEELKKVEELLNEND 186
y 159 IESTPSVAENRVPSLMELDIBELKLEYISEGAFGLFVLYNLNLMCNK--DMPNLTP 216
b 187 IRVLKGTTPGKMKLKLTLQNC-NLEIQGAFGLNLSLEQLILSNLNENIDWTIFA 245
y 217 LVGLELEMSGNHPFIRPGSPFGLSLKXLMWYMSQ-----VSLIER 259
b 246 LKNLRVLIDLSNKSINVMKSPFKLEKL-----VLNNTIDSMKSKLKLPLSLVALFDR 301
y 260 NAFDGLASL-----VE-LNLANNLSSLPDLPFLVLYVELHLHHPNWCDDCI 308
b 302 NKIESIGDMDFGLTRSDRIETISLARNLSQISPKAFQHTNLITLLQYN----- 353
y 309 LNLAWMLREYIPTNSTCCGRCHAFMRGRYLVEVDQAS-----FQCSAPPIMDAPR 360
b 354 -----QIEELSSRKLTHPIFKKLIFFPFDSPS 380
y 361 DLNISGRMAELKCRTPPMSSVVMKLLPNGTVLSHSHPRISVINDGTL--NPSVILSD 418
b 381 QV-----RTFPFLASKKLIV-----TLQLSSNN--LSVIRSDGLPKSLSLALDH 422
y 419 TGYVTCTMTNAGNSASAVLNVTAEI---FTTIVTETTES 465
b 423 NVISKIARALEGMEIKULYH-----SNKLVLYQGTDSPPKSVAEVDVS 470
```

RESULT 42

NBHUIA

```

Platelet glycoprotein Ib alpha chain precursor - human
N;Alternate names: membrane glycoprotein Ib alpha chain
N;Contains: Glycocalicin
C;Species: Homo sapiens (man)
C;Date: 28-Dec-1987 #sequence_revision 28-Dec-1987 #text_change 22-Jun-1999
C;Accession: A94174; A60435; A94173; S16945; I55355; A27075; A27102
R;Lopez, J.A.; Chung, D.W.; Fujikawa, K.; Hagen, F.S.; Papayannopoulou, T.; Roth, G.J.
Proc. Natl. Acad. Sci. U.S.A. 84, 5615-5619, 1987
A;Title: Cloning of the alpha-chain of human platelet glycoprotein Ib: a transmembrane p
A;Reference number: A94174; MUID:87289655; PMID:3303030
A;Accession: A94174
A;Molecule type: mRNA
A;Residues: 1-626 <LOP>
A;Cross-references: GB:J02940; NID:G183499; PIDN:AAA52595.1; PID:G306793
R;Wicki, A.N.; Walz, A.; Garber-Huber, S.N.; Wenger, R.H.; Vornhagen, R.; Clemetson, K.J.
Thromb. Haemost. 61, 448-453, 1989
A;Title: Isolation and characterization of human blood platelet mRNA and construction of
d cloning of a GPIb coding cDNA insert.
A;Reference number: A60435; MUID:90020160; PMID:2799758
A;Accession: A60435
A;Molecule type: mRNA
A;Residues: 207-467 <WIC>
R;Titani, K.; Takio, K.; Handa, M.; Ruggeri, Z.M.
Proc. Natl. Acad. Sci. U.S.A. 84, 5610-5614, 1987
A;Title: Amino acid sequence of the von Willebrand factor-binding domain of platelet mem
A;Reference number: S16945; MUID:91301149; PMID:2070794
A;Accession: S16945
A;Accession: A94173
A;Molecule type: protein
A;Residues: 17-315 <TIT>
R;Hess, D.; Schaller, J.; Rickli, E.E.; Clemetson, K.J.
Eur. J. Biochem. 199, 389-393, 1991
A;Title: Identification of the disulphide bonds in human platelet glycoprotein Ib.
A;Reference number: S16945; MUID:91301149; PMID:2070794
A;Accession: S16945
A;Status: preliminary
A;Molecule type: protein
A;Residues: 224-227/262-270; 277-282 <HES>
R;Lopez, J.A.; Ludwig, E.H.; McCarthy, B.J.
J. Biol. Chem. 267, 10055-10061, 1992
A;Title: Polymorphism of human glycoprotein Ib alpha results from a variable number of t
ations.
A;Reference number: I55355; MUID:92250564; PMID:1577776
A;Accession: I55355
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 412-427 <RES>
A;Cross-references: GB:S34436; NID:G249176; PIDN:AAB22152.1; PID:G249177
A;Note: variant D
C;Comment: Glycoprotein Ib (GPIb), a surface membrane protein of platelets, participates
C;Comment: Platelet activation apparently involves disruption of the macromolecular comp
C;Comment: Binding sites for von Willebrand factor and thrombin (the latter site with un
C;Comment: Glycocalicin, which is approximately coextensive with the extracellular part
C;Genetics:
A;Gene: GDB:GPIBA; GPIB
A;Cross-references: GDB:118806; OMIM:231200
A;Map position: 17pter-17p12
C;Complex: heterodimer with platelet glycoprotein Ib alpha chain; leucine-rich alpha-2-glycoprotein r
C;Superfamily: platelet glycoprotein Ib alpha chain; glycoprotein; platelet membrane; tandem repe
F;1-16/Domain: signal sequence #status predicted <SIG>
F;148-71/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
F;72-93/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
F;94-116/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
F;117-140/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
F;141-164/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>
F;165-188/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>
F;189-212/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>
F;379-430/Region: proline/threonine-rich 9-residue repeats
F;502-540/Domain: transmembrane #status predicted <TRM>
```

Matches	121;	Conservative	98;	Mismatches	225;	Indels	143;	Gaps	20;
QY	69	VPOGIPENTYILN	---IMENNI	-----	QMIQADYERHLHH	100			
Db	284	LPQGLFOHNLKHLMEVRLMNNRVPLATLPSGLFANQFOELQLERAEGLSCGLDGFHSTQ	343						
QY	101	LEVLIQGENSIROLEVGAFNGLASLNTLFLFONMLTVIPSGAFEYLSKRLWLNENPIE	160						
Db	344	ITNISLGNLLKTLPATLLEHQVNLSSLDLSNNRLTHLPDSLFAHTNLTDLREDNLT	403						
QY	161	SIPSYAFNRVPSLRDLDELKLEVIISGAGEGLFNLKYLNLGMCNTKDPNLTPLVGL	220						
Db	404	GISGDIPSNLGNLAVTWMSR-NKRLTIDSRAFVSTNGRLHLH---	459						
QY	221	BELEMSGNHPEIRPGSFHGLSLKKLWMNSOVSLIERNAPDGLASLVELNLAHNLS	280						
Db	460	MEQTQINSPF---GVMGELTIN---	511						
QY	281	-----LPHDLFTPLRY---	310						
Db	512	LGVEDLAPLSQNLRLHVNMTHKIRIALPEDVHLGEGYNNLVHVLDLNDPNVAVCDCTILM	571						
QY	311	LAWMLR-----EY-----	360						
Db	572	FIQVRGVHKEPQVSROKLTDLVCSQ---PNVLGTPVROQIEPOTLICLPDF-SDDPR	627						
QY	361	DLNISGRMAELKCRTPPMSSVKWLLPNTGLVLSHARHPRISVLNDGTLNFSHV	414						
Db	628	-----ERKC-----	664						
QY	415	-----LLSDT-----	454						
Db	665	HKNQMLHLENNLTLLRLPSANTPGYESVTSIHLGANNLTSIDVDFTNLTHLIDISWN	724						
QY	455	TTVTVETTEISPEDTTKYKPVTTSTGQPAVTTSTVLIQTTRVPK-----QVAVPA	508						
Db	725	HLQMLNATVIGFLNRTWKRSVKLSGNPNWCDCTAKPELLFTQDNFERIGDRNEMCVNA	784						
QY	509	TDTTKMOTSDEVMKTK---IIGCFVAVT-LLAAMLIIFYKLR	551						
Db	785	EMPTRMVELSTNDICPAEKGVFIALAVVIALTGLAGFTAALYIKFQ	831						
RESULT	44								
I73633		gene trkC protein - human							
C:Species:	Homo sapiens (man)								
C:Date:	02-Aug-1996	#sequence_revision	02-Aug-1996	#text_change	21-Jan-2000				
C:Accession:	I73633								
R:Shelton,	D.L.; Sutherland, J.; Gripp, J.; Camerato, T.; Armanini, M.P.; Phillips, H.S.								
J. Neurosci.	15, 477-491, 1995								
A:Title:	Human trks: molecular cloning, tissue distribution, and expression of extracel								
A:Reference number:	156557; MUID:95123473; PMID:7823156								
A:Accession:	I73633								
A:Status:	preliminary; translated from GB/EMBL/DDBV								
A:Molecule type:	mRNA								
A:Residues:	1-612 <RES>								
A:Cross-references:	GB:S76476; NID:G913723; PIDN:AAB33112.1; PID:G913724								
C:Genetics:									
C:Superfamily:	nerve growth factor receptor, high affinity; leucine-rich alpha-2-glycop								
F:79-103/Domain:	leucine-rich alpha-2-glycoprotein repeat homology <LRR>								
Query Match	7.1%; Score 244; DB 2; Length 612;								
Best Local Similarity	23.6%; Pred. No. 3.2e-09;								
Matches	124; Conservative 64; Mismatches 198; Indels 140; Gaps 24;								
QY	206	CNIKDPNLTPLV-GLBLEMSGN-----	243						
Db	45	CRPPDGNLFELLEGQDSNGSNGANINITDSRNITSIHENWR--SLHTLNADVMELY	102						
QY	244	--LKKLWMNSOVSLIERNAPDGLASLVELNLAHNLSLPHDLFTPLRYLVELHLHNP	301						

```
103 TGLQKLTIKNSGLRSTQPRAPAKNPHLRVINSSRLTTLTSLWOLFQTLTSLRELOLQNF 161
302 WNCDCDILWLAWLWREYIPNTSTCCGRCHAPMHMRGRYVEVDQASF-----QCSAP 353
162 FNGSCDIRWQLWQEQ-----GEAKNSQNLICINADGSQLPLFRWNISQCDLP 210
354 FMDAPRDLNISEGRMAELKCR--TPPMSSVKWLLPNGTIVLASHSRH-----PRISVLN 405
211 EISVSHVNLTVRGDNAVITCNGSGPLPDVWIV---TGLQSIHTHONLNTWNTVHAIN 267
406 DGTINFSHVLLDTG-VYTCMTNVAGNSNAGAYLNVSTAEINTSNYSFFTVTVETTEI 464
268 ---LTVNVTSENGTGLTFCIAENVVGNASVALTV-----YPPRVVSLSEPEL 315
465 SPB---DTRKKYKVPVTS-----TGYPQAVTSTTVLIQT----- 497
316 RLEHCIEFVVRGNPPPTLWHLNGOPLRESKIIHVEYIQEISRGCLLFNKPHTYNNGN 375
498 -TRVPKQ-----VAVPATDTTKMOTSLDEVMKTKI11-----GCFV 534
376 YTLIAKNPGLTANOTINGHFLKEPPPESTDNF-ILFDEVSPPTPTVTHKPEEDTFGUSI 434
535 AVTLIAAA--MLIVFYKLKRRHQORSTVTAARTVEIIQVDEIPA-----ATSA 583
435 AVGLAAFAVCVLLVFLWFMINKYGRSKFGKMGCPVAVISGEEDSAPLKHINEGITPSSL 494
584 TRAPSGVSGEAVVLTPIHHDHINYNKYKPAHGAH---WTENSLGN 625
495 DRGPDVTW-IGMTRIPVIE---NPQVFGHCHRPDPTWVFSNIDN 536

RESULT 45
34319
Vpothetical protein K03A1.2 - Caenorhabditis elegans
;Species: Caenorhabditis elegans
;Date: 29-Oct-1999 #sequence_revision 29-Oct-1999 #text_change 29-Oct-1999
;Accession: T34319
;Nhan, M.
;Submitted to the EMBL Data Library, November 1995
;Description: The sequence of C. elegans cosmid K03A1.
;Reference number: Z21505
;Accession: T34319
;Status: preliminary; translated from GB/EMBL/DBJ
;Molecule type: DNA
;Residues: 1-562 <NHA>
;Cross-references: EMBL:U41625; PIDN:AAA83325.1; CESP:K03A1.2
;Gene: CESP:K03A1.2
;Introns: 113/3; 132/3; 171/3; 221/2; 269/2; 301/2; 332/2; 465/2; 497/2; 530/3

Query Match 7.0%; Score 242.5; DB 2; Length 562;
Best Local Similarity 28.9%; Pred. No. 3.6e-09;
Matches 85; Conservative 50; Mismatches 104; Indels 55; Gaps 12;

76 NTFY-LNTAKENNIQIQAOTFPHLHLEVLQCRNISQIEVGAPNGLASLNTLEFDNW 134
229 NTLRLDLGYNRIKKVSDSFTLSKLVSLDGNPIKAWRKEMPKGLDLSLESLDNCN 288
135 LTVIPSGAFYLSKLRLWLRNPIESPSYAFNRVPSLMRLDLGELKKLEYISEGAFEG 194
289 IENLPADIEFYLKVLKLSRENPLEEIPAVVAH--LKSLOIDL--SVTNLTETIRDHAPAG 346
195 LFMILKYLNTGMCKNMPNLTPL-----VGLLEEM-----SGNHPEIRPGSP----- 238
347 DSDLEBIIL-----EKMPFLTVVRDCGFCGLPQLKTLINDNKYLQELHLPNAPGYIKSQP 401
239 -HGLSSLSKLKLVNNSQVSLIERNAPGLASVELNLAHNNLSLPHDLFTPLRLVELHL 297
402 GHKSAITSLQIHNSNISTISEHVD-----YDNLKT-----FQV 436
298 HNNPNWNCDDILWLAWLRE-YIPTNSTCCGRCHAPMHMRGRYVEVDQASFQC 350
437 GGNPNWNCDDTQFM---LEEKFAKQDSVAPKCTSPAGLNGSLTLTV-RASDAC 486
```

RESULT 46

T19941

hypothetical protein C44H4.1 - Caenorhabditis elegans

C;Species: Caenorhabditis elegans

C;Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 18-Feb-2000

C;Accession: T19941

R;Smye, R.

submitted to the EMBL Data Library, August 1996

A;Reference number: Z19200

A;Accession: T19941

A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: DNA

A;Residues: 1-458 <WIL>

A;Cross-references: EMBL:279598; PIDN:CAB01867.1; GSPDB:GN000028; CESP:C44H4.1

A;Experimental source: clone C44H4

C;Genetics:

A;Gene: CESP:C44H4.1

A;Map position: X

A;Introns: 24/3; 157/1; 257/3; 372/3; 425/1

Query Match 7.0%; Score 240; DB 2; Length 458;

Best Local Similarity 28.7%; Pred. No. 4.1e-09;

Matches 92; Conservative 39; Mismatches 102; Indels 88; Gaps 13;

QY 69 VPQ---GIPSTRYLNLMENNLIQIQAOTFRLH---HLEVLQCGENSIQIEVGAFNGL 122

Db 139 IPQGVSVILKQKILSLPDLNLEYVDNAFLSYHSDRLLLKLDLSANNLTATHTPTGLLGL 198

QY 123 ASLNTLEFDNMLTVIPSGAFYLSKLRLWL-----RN-----NPI 159

Db 199 ENLSQLSLDKNLSRIPSOALENIPSLDLSLGVNRIHTISRNLSPLPMLKLSLEVNOI 258

QY 160 ESIPSVAFNRVPSLMRLDLGELKKLEYISEGAFEGFLMKLYLNLCMKIKMPNL----- 214

Db 259 RLIPSDSFSETFLLSYLYLGN-NLETSIDASFHLGGLKVLK---MSNNKDTITSQANGK 315

QY 215 -----TPLVGLLEEMSGNHPEIRPGSHGLSSLSKLKLVNNSQVSL 256

Db 316 LSVQPFKLCICILAFQHAPSLIRLELFCSS---ISRIEP-----KSLQK--VQHIQVIL 364

QY 257 IERN-----APDGLASLVELNLAHNNLSLPHDLF-----TPRLRYLVEIH 296

Db 365 LSRNQITQINAVDDPAFSQPLMTSLDLSNRLSLPSNVIYDLSLMQKKTSPVQR--KLS 422

QY 297 LHEHNPWNCDDILWLAWLRE 317

Db 423 IQNPNRCDKDLNLRKMLRD 443

RESULT 47

A55178

neurotrophin receptor trkC precursor - human

C;Species: Homo sapiens (man)

C;Date: 27-Jan-1995 #sequence_revision 27-Jan-1995 #text_change 18-Jun-1999

C;Accession: A55178

R;McGregor, L.M.; Baylin, S.B.; Griffin, C.A.; Hawkins, A.L.; Nelkin, B.D.

Genomics 22, 267-272, 1994

A;Title: Molecular cloning of the cDNA for human TrkC (NTRK3), chromosomal assignment, a

A;Reference number: A55178; MUID:95104834; PMID:7806211

A;Accession: A55178

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-825 <MCG>

A;Cross-references: GB:U05012; NID:G442389; PIDN:AAA75374.1; PID:G442390

C;Genetics:

A;Gene: GDB:NTRK3

A;Cross-references: GDB:127899; OMIM:191316

A;Map position: 15q24-15q25

C;Superfamily: nerve growth factor receptor, high affinity; leucine-rich alpha-2-glycopr

C;Keywords: alternative splicing; ATP; growth factor receptor

P;79-103/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>

F:104-127/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR2>
F:128-150/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR3>
F:151-162/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR2>
F:151-162/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR3>
F:536-817/Domain: protein kinase homology <KIN>
F:544-552/Region: protein kinase ATP-binding motif

Query Match 6.9%; Score 239; DB 2; Length 825;
Best Local Similarity 23.7%; Pred. No. 1.1e-08;
Matches 122; Conservative 61; Mismatches 195; Indels 136; Gaps 23;

QY 206 CNIKMPNLTPLV-GLEELEMSGN-----HPEIRPGSEHGLSS----- 243
DB 45 CRPPDGNLFLPEEGQDSNGNGNANITDISNITSIHENWR--SLHTLNADVMEY 102
QY 244 --LKLTWVNSQVSLIERNADGLASVELNLAHNLSLPHDLFTPLRYLVELLHHPN 301
DB 103 TGLQKLTIKNSGLRSIQPAPAKNPHLYINLSNRLTTLWSQLFQTLT-LRELQLEQNF 161
QY 302 WNCDCDILWLAWLREYIPTNSTCCGRCHAPMGRGYLVEVDQASF-----QCSAP 353
DB 162 FNCSCDIRWQLWQEQ-----GEAKLSQNLVCINADGSQPLFRMNISQCDLP 210
QY 354 FTMADAPRLNINSEGEAMBLKCR--TPPMSSVKMLLPNGTIVLSHARH-----PRISVLN 405
DB 211 ELSVSHVNLTVREGDNAVITCGSGSLPDPVDWIV---TGLOSINTQTNLNWTNVHAIN 267
QY 406 DGTLPFSHVLLSDTG-VYTCMTVNVAGNSASAYLNSTAEINTSNYSFFTTVETTEI 464
DB 268 ---LTLVNTSDNGFTLTCAENVVGNASVALTV-----YPPRVVSLSEPEL 315
QY 465 SPE---DTRKYKVPVPTS-----TGQPAYTTTSTVLQIQT----- 497
DB 316 RUEHCIEFVVRGNPPTTLHLHNGQLPRESKLIHVEYQGEISEGCLLKNKPTHYNGN 375
QY 498 -TRVPKQ-----VAVPATDITDQKQSLDEWMTTKIII-----CCFV 534
DB 376 YTLIAKNPLGTANQINGHFLKEPPESTDNF-ILFDEVSPPTPIVTHKPEEDTFGVI 434
QY 535 AVTLAA--MLIVFYKLRKHQRSTVTAARTVEIIQVDEDIPA-----ATSA 583
DB 435 AVGLAFAFVLLVLFVWINKYGRSKFGMKGPVAVISGEEDSASPLHHNHGTTFSSL 494
QY 584 TAAPSGVSGEAVLPTTHDHINYNTRYKPAHGAH 617
DB 495 DAGPTTVV-IGWTRIPVIE---NPQYFRQGHCH 524

RESULT 48
173632
neurotrophin-3 receptor precursor - human
N:Alternate names: receptor tyrosine kinase trkC
N:Contains: protein-tyrosine kinase (EC 2.7.1.112)
C:Species: Homo sapiens (man)
C:Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 11-Jun-1999
C:Accession: I73632
R:Shelton, D.L.; Sutherland, J.; Gripp, J.; Camerato, T.; Armanini, M.P.; Phillips, H.S.
J. Neurosci. 15, 477-491, 1995
A:Title: Human trks: molecular cloning, tissue distribution, and expression of extracellular
A:Reference number: I56557; MUID:95123473; PMID:7823156
A:Accession: I73632
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-839 <RES>
A:Cross-references: GB:S76475; NID:9913721; PID:9913722
C:Genetics:
A:Gene: GDB:NTRX3; TRKC
A:Cross-references: GDB:127899; OMIM:191316
A:Map position: 15q24-15q25
C:Function:
A:Description: regulation of nervous system development; receptor for neurotrophin-3
A:Superfamily: nerve growth factor receptor, high affinity; leucine-rich alpha-2-glycoprotein
C:Keywords: ATP; autophosphorylation; brain; glycoprotein; growth factor receptor; phosphatase
F:1-31/Domain: signal sequence #status predicted <SIG>

F:32-839/Product: neurotrophin-3 receptor #status predicted <MAT>
F:32-436/Domain: extracellular #status predicted <EXT>
F:79-103/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR1>
F:104-127/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR2>
F:128-150/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR3>
F:151-162/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR2>
F:151-162/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LR3>
F:437-453/Domain: transmembrane #status predicted <TMN>
F:454-839/Domain: cytosolic #status predicted <CYT>
F:536-831/Domain: protein kinase homology <KIN>
F:544-552/Region: protein kinase ATP-binding motif
F:72-79,133,203,218,232,259,267,272,294,375,388/Binding site: carbohydrate (asn) (cc
F:709/Binding site: phosphate (tyr) (covalent) (by autophosphorylation) #status predicted
F:834/Binding site: phosphate (tyr) (covalent) #status predicted

Query Match 6.9%; Score 239; DB 1; Length 839;
Best Local Similarity 23.7%; Pred. No. 1.1e-08;
Matches 122; Conservative 61; Mismatches 195; Indels 136; Gaps 23;

QY 206 CNIKMPNLTPLV-GLEELEMSGN-----HPEIRPGSEHGLSS----- 243
DB 45 CRPPDGNLFLPEEGQDSNGNGNANITDISNITSIHENWR--SLHTLNADVMEY 102
QY 244 --LKLTWVNSQVSLIERNADGLASVELNLAHNLSLPHDLFTPLRYLVELLHHPN 301
DB 103 TGLQKLTIKNSGLRSIQPAPAKNPHLYINLSNRLTTLWSQLFQTLT-LRELQLEQNF 161
QY 302 WNCDCDILWLAWLREYIPTNSTCCGRCHAPMGRGYLVEVDQASF-----QCSAP 353
DB 162 FNCSCDIRWQLWQEQ-----GEAKLSQNLVCINADGSQPLFRMNISQCDLP 210
QY 354 FTMADAPRLNINSEGEAMBLKCR--TPPMSSVKMLLPNGTIVLSHARH-----PRISVLN 405
DB 211 ELSVSHVNLTVREGDNAVITCGSGSLPDPVDWIV---TGLOSINTQTNLNWTNVHAIN 267
QY 406 DGTLPFSHVLLSDTG-VYTCMTVNVAGNSASAYLNSTAEINTSNYSFFTTVETTEI 464
DB 268 ---LTLVNTSDNGFTLTCAENVVGNASVALTV-----YPPRVVSLSEPEL 315
QY 465 SPE---DTRKYKVPVPTS-----TGQPAYTTTSTVLQIQT----- 497
DB 316 RUEHCIEFVVRGNPPTTLHLHNGQLPRESKLIHVEYQGEISEGCLLKNKPTHYNGN 375
QY 498 -TRVPKQ-----VAVPATDITDQKQSLDEWMTTKIII-----CCFV 534
DB 376 YTLIAKNPLGTANQINGHFLKEPPESTDNF-ILFDEVSPPTPIVTHKPEEDTFGVI 434
QY 535 AVTLAA--MLIVFYKLRKHQRSTVTAARTVEIIQVDEDIPA-----ATSA 583
DB 435 AVGLAFAFVLLVLFVWINKYGRSKFGMKGPVAVISGEEDSASPLHHNHGTTFSSL 494
QY 584 TAAPSGVSGEAVLPTTHDHINYNTRYKPAHGAH 617
DB 495 DAGPTTVV-IGWTRIPVIE---NPQYFRQGHCH 524

RESULT 49
139068
proline- arginine-rich end leucine-rich repeat protein PRELP precursor - human
C:Species: Homo sapiens (man)
C:Date: 01-Mar-1996 #sequence_revision 01-Mar-1996 #text_change 24-Sep-1999
C:Accession: I39068
R:Bengtsson, E.; Neame, P.J.; Heinigard, D.; Sommarin, Y.
J. Biol. Chem. 270, 25639-25644, 1995
A:Title: The primary structure of a basic leucine-rich repeat protein, PRELP, found in
A:Reference number: I39068; MUID:96029653; PMID:7592739
A:Accession: I39068
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-382 <RES>
A:Cross-references: EMBL:U29089; NID:9886135; PIDN:AA050230.1; PID:g886136
C:Genetics:
A:Gene: GDB:PRELP

1;Cross-references: GDB:696218
1;Map position: 1q32.1-1q32.1
2;Superfamily: fibromodulin; leucine-rich alpha-2-glycoprotein repeat homology
3;Keywords: tandem repeat

Query Match 6.9%; Score 238; DB 2; Length 382;
Best Local Similarity 30.1%; Pred. No. 4.9e-09;
Matches 74; Conservative 47; Mismatches 107; Indels 18; Gaps 8;

1; 45 NCPVSCSCNQF-SKVVCVTRGSLSEVPGQIPSTRYLNLMENNIQIADTFPHLHLEV 103
1; 72 DCPRECVCPDPFSPALYCDSENLEKVP-IPRIHYLYLQNNFTELPEVSEFQATGLAW 130
1; 104 LQLGRNSIRQIEVGAFNGLASLTLELFDNWTVPISGAPFYLSKRLWLRNPNIESIP 163
1; 131 INLDNNIRKIDQKRVLEKLPCLVFLYMEKNQLEVPSPALPRNLEQLR--LSQNHISRIIP 187
1; 164 SYAFNRVPSLMRLDLGLKLEIVSEGAFF-----GLFNLYLNLMCMKMPNUTPLV 218
1; 188 PGVTSKLENLLLDLQNR-----LSDGVFPDFFHGLKMLMQLNLAHNIIRKPPRPV-T 242
1; 219 GLELENSGNHFPPIRGSGFHGLSSLLKKLWVMSQVS--LIERNAPDGLASLVELNLAHN 276
1; 243 AIHQLYLDSNKKIETIPNGYFKSPFNLAFLRENTNKLTDRLGPKNSFN-ISKLLVLFSLHN 301
1; 277 NLSSLP 282
1; 302 RISSVP 307

RESULT 50
158674
neutrophin-3 receptor precursor, short splice form - chicken
1;Alternate names: truncated receptor tyrosine kinase trkC
1;Species: Gallus gallus (Chicken)
1;Date: 19-Nov-1997 #sequence_revision 21-Nov-1997 #text_change 21-Nov-1997
1;Accession: A58674
1;Okazawa, H.; Kamei, M.; Kanazawa, I.
1;Title: Molecular cloning and expression of a novel truncated form of chicken trkC.
1;Reference number: S35695; MUID:93359043; PMID:8394830
1;Accession: A58674
1;Molecule type: mRNA
1;Residues: 1-525 <OKA>
1;Note: the authors translated the codon AAC for residue 105 as Val, CTG for residue 108
1;Comment: This form of the receptor is missing the protein kinase domain.
1;Superfamily: nerve growth factor receptor, high affinity; leucine-rich alpha-2-glycop
1;Keywords: alternative splicing; brain; glycoprotein; growth factor receptor; tandem re
1;1-10/Domain: signal sequence #status predicted <SIG>
1;11-525/Product: neurotrophin-3 receptor, short form #status predicted <MAT>
1;11-417/Domain: extracellular #status predicted <EXT>
1;58-82/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>
1;83-106/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>
1;107-129/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>
1;130-141/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>
1;418-434/Domain: transmembrane #status predicted <TMN>
1;435-525/Domain: cytosolic #status predicted <CYT>
1;47,51,58,142,182,197,211,238,246,251,273,354,367/Binding site: carbohydrate (Asn) (cov

Query Match 6.8%; Score 235.5; DB 1; Length 525;
Best Local Similarity 21.5%; Pred. No. 1e-08;
Matches 120; Conservative 75; Mismatches 193; Indels 171; Gaps 23;

1; 165 YAFNRVPSLMRLDLGELKK-----LVISGAFEGFLNLYL-----NLGCMNKMPE 212
1; 9 FASDRLLKVLFTDKINCKPDGNGLPFLLEGQDSGSSNGNTSINITDISNITSIHENWK 68
1; 213 NLTPVLGLELEMSGNHFPPIRGSPHGLSSLLKKLWVMSQVSLIERNAPDGLASLVELN 272
1; 69 NLQTLNAV-DMEL-----YGLQRLTIRNSGLRNQPRAFGNKPHLYID 112
1; 273 LAHFNLSLPHDLFTPIRLVILVELLHHPNWCDCDILWLAWLREYIPTNSTCCGRCHAP 332

Db 113 LSGNRLTTLNQLFQTLR-LFDLRLERNPFNCSDIRWLIQLWQE-----KGEAN 160
QY 333 MEMEGRYLVEVDQASF-----QCSAPFIMDAPDLNISEGRMAELKCR--TPPMSSV 382
Db 161 LQSQQLHGMILDTAVILLRNMTITQCDLPEISVSHVNLTVREGENAVITCNCGSGSLPDV 220
QY 383 KWLIPN-GTVLSHAS--RHPRIISVLNDGTLNFHVLSDTG-VYTCMVTVNAGNSNASAY 438
Db 221 DWTVDLHLSINTHTNLNWTNVAHAIN---LTLNVNVTSEDNGFLTCTIAENVVGMNASVL 277
QY 439 LNV-----441
Db 278 LTVYPPRIILTLEPVLHLEHCIAFAVHGAPATPLHMLHNGQVLRRETIHMFYQOGEV 337
QY 442 -----STAELNTSNYSPTTVTVVETTBISPDITFRK-----YKPVPTTSTGYQFA--Y 487
Db 338 SEGCLLFNKPHTYNGNYTI-----VATNQLGSANQTIKGHFLEKPPPESTDFVSGIDY 392
QY 488 TTSTTVLIQITRVPKQAVPATDTTDMQTSLEBVMKTKIIIGCFVAVTLAAA--MLI 545
Db 393 EVSPTPTITVTKDEE-----DT-----FGVSIAGLAAPACVLLV 428
QY 546 VFYKLRKHQORSTVTAARTVEIIQVDEDIIPAATSAAT-----AAPSGVSGEGAVVL 598
Db 429 VLPIMINKYGRSRSKFGMKGPVAVISGEED-SAAHTSTTDTTRFVTDAGPDTVV-IGWTRI 486
QY 599 PTIHDHINYNTYKPAHGAH 617
Db 487 PVIE---NPQYFROGHNCH 502

Search completed: February 5, 2004, 15:51:01
Job time : 28 secs

GenCore version 5.1.1-6
Copyright (c) 1993 - 2004 Compugen Ltd.

% protein - protein search, using sw model

Run on: February 5, 2004, 15:46:09 ; Search time 17 Seconds

(without alignments)

1806.379 Million cell updates/sec

Title: US-09-989-279-229

Refect score: 3440

Sequence: 1 MKLLAQVTHVHTWNAILLP.....ISEPYIIQTHXDRVQETQI 653

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

searched: 127863 seqs, 47026705 residues

total number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 150 summaries

Database : SwissProt_41.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

result No.	Score	Query Match	Length	DB ID	Description
1	390	11.3	713	1	GAMP HUMAN
2	389	11.3	646	1	FLRI HUMAN
3	385	11.2	649	1	FLR3 HUMAN
4	380.5	11.1	358	1	CHAD MOUSE
5	379.5	11.0	358	1	CHAD RAT
6	379	11.0	581	1	LR15 HUMAN
7	375.5	10.9	1504	1	SLIT DROME
8	375	10.9	361	1	CHAD BOVIN
9	372.5	10.8	473	1	RT4R MOUSE
10	371.5	10.8	578	1	LR15 RAT
11	370	10.8	473	1	RT4R RAT
12	368	10.7	473	1	RT4R MACFA
13	365.5	10.6	359	1	CHAD HUMAN
14	364	10.6	473	1	RT4R HUMAN
15	356.5	10.4	660	1	FLR2 HUMAN
16	338.5	9.8	951	1	LGR4 RAT
17	337	9.8	567	1	GPV RAT
18	334.5	9.7	951	1	LGR4 HUMAN
19	321.5	9.3	907	1	LGR5 MOUSE
20	321	9.3	567	1	GPV MOUSE
21	321	9.3	603	1	ALS MOUSE
22	320	9.3	481	1	NYX HUMAN
23	315	9.2	605	1	ALS PAPHA
24	310	9.0	603	1	ALS RAT
25	309	9.0	605	1	ALS HUMAN
26	305.5	8.9	560	1	GPV HUMAN
27	303.5	8.8	359	1	PGS2 HUMAN
28	303.5	8.8	907	1	LGR5 HUMAN
29	302	8.8	360	1	PGS2 HORSE
30	300	8.7	360	1	PGS2 PIG
31	298	8.7	360	1	PGS2 BOVIN
32	298	8.7	360	1	PGS2 SHEEP
33	297	8.6	360	1	PGS2 CANFA

34	293.5	8.5	360	1	PGS2 RABIT
35	287.5	8.4	357	1	PGS2 CHICK
36	286.5	8.3	354	1	PGS2 RAT
37	284.5	8.3	356	1	PGS2 COTUJA
38	281.5	8.2	1050	1	TLR7 MOUSE
39	279.5	8.1	354	1	PGS2 MOUSE
40	277	8.1	966	1	Y918 HUMAN
41	275.5	8.0	369	1	PGS1 CANFA
42	268	7.8	905	1	TLR3 MOUSE
43	267	7.8	381	1	PRLP BOVIN
44	267	7.8	536	1	CBP8 HUMAN
45	267	7.8	904	1	TLR3 HUMAN
46	263.5	7.7	423	1	OMD RAT
47	262.5	7.6	369	1	PGS1 MOUSE
48	262.5	7.6	369	1	PGS1 RAT
49	262	7.6	1049	1	TLR7 HUMAN
50	261.5	7.6	368	1	PGS1 HUMAN
51	261.5	7.6	369	1	PGS1 SHEEP
52	261.5	7.6	757	1	LGR7 HUMAN
53	260.5	7.6	369	1	PGS1 BOVIN
54	260.5	7.6	372	1	PGS1 HORSE
55	259.5	7.5	368	1	PGS1 XENLA
56	259	7.5	331	1	PLIB AKBL
57	259	7.5	423	1	OMD MOUSE
58	255	7.4	353	1	KERA CHICK
59	255	7.4	353	1	KERA COTUJA
60	254	7.4	977	1	Y848 HUMAN
61	253	7.4	352	1	KERA BOVIN
62	253	7.4	352	1	KERA HUMAN
63	251.5	7.3	422	1	OMD BOVIN
64	248.5	7.2	373	1	ASPN MOUSE
65	248.5	7.2	626	1	GPBA HUMAN
66	247.5	7.2	1097	1	TOLL DROME
67	244.5	7.1	351	1	KERA MOUSE
68	242	7.0	421	1	OMD HUMAN
69	240.5	7.0	347	1	A2GL HUMAN
70	240.5	7.0	754	1	LGR8 HUMAN
71	239.5	7.0	379	1	ASPN HUMAN
72	239	6.9	839	1	TRKC HUMAN
73	238	6.9	382	1	PRLP HUMAN
74	237	6.9	378	1	PRLP MOUSE
75	236	6.9	377	1	PRLP RAT
76	233.5	6.8	440	1	OMGP HUMAN
77	233.5	6.8	1032	1	TLR8 MOUSE
78	233	6.8	825	1	TRKC PIG
79	231	6.7	737	1	LGR8 MOUSE
80	229.5	6.7	782	1	CHAO TRICA
81	229	6.7	828	1	LGR6 HUMAN
82	228.5	6.6	661	1	C180 HUMAN
83	227	6.6	827	1	TRKC CHICK
84	225.5	6.6	380	1	FMOD CHICK
85	225.5	6.6	661	1	C180 MOUSE
86	225	6.5	1041	1	TLR8 HUMAN
87	220.5	6.4	375	1	FMOD BOVIN
88	220.5	6.4	1315	1	CHAO DROME
89	220	6.4	864	1	TRKC RAT
90	219	6.4	440	1	OMGP MOUSE
91	215.5	6.3	695	1	FSHR HUMAN
92	215.5	6.3	695	1	FSHR MACFA
93	215.5	6.3	740	1	CT75 HUMAN
94	214.5	6.2	376	1	FMOD HUMAN
95	214.5	6.2	826	1	TLR4 PAPAN
96	213	6.2	843	1	TLR4 HORSE
97	212.5	6.2	376	1	FMOD MOUSE
98	211.5	6.1	376	1	FMOD RAT
99	211.5	6.1	858	1	TLR5 HUMAN
100	209.5	6.1	859	1	TLR5 MOUSE
101	207.5	6.0	582	1	SHO2 HUMAN
102	207.5	6.0	582	1	SHO2 MOUSE
103	207.5	6.0	781	1	TL22 CHICK
104	206	6.0	662	1	GARP HUMAN
105	205.5	6.0	343	1	LUM CHICK
106	205.5	6.0	343	1	LUM COTUJA

O28888	oryctolagus
O28675	gallus gall
O01129	rattus norv
O9de68	coturnix co
P58681	mus musculus
O28654	mus musculus
O94991	homo sapien
O02678	canis famil
O99mb1	mus musculus
O9gkn8	bos taurus
P22792	homo sapien
O15455	homo sapien
O92187	rattus norv
O28653	mus musculus
P47853	rattus norv
O9nyk1	homo sapien
P21810	homo sapien
O46390	ovis aries
O9hbx9	homo sapien
P21809	bos taurus
O46403	equus cabal
O91b75	xenopus lae
O93233	agkistrodon
O35103	mus musculus
O42235	gallus gall
O9de66	coturnix co
O94933	homo sapien
O62702	bos taurus
O60938	homo sapien
O77742	bos taurus
O99mq4	mus musculus
P07359	homo sapien
P08953	drosophila
O35367	mus musculus
O99983	homo sapien
P02750	homo sapien
O8wxd0	homo sapien
O9bxx1	homo sapien
P16288	homo sapien
O9jks3	mus musculus
O9eqp5	rattus norv
P23515	homo sapien
P58682	mus musculus
P24786	sus scrofa
O91225	mus musculus
P82963	tribolium c
O9hbx8	homo sapien
O99467	homo sapien
O91044	gallus gall
P51887	gallus gall
O62192	mus musculus
O9nr97	homo sapien
P13605	bos taurus
P12024	drosophila
O03351	rattus norv
O63912	mus musculus
P23945	homo sapien
P32212	macaca fasc
O66828	homo sapien
O9tsp2	papio anubi
O9myw3	equus cabal
P50608	mus musculus
P50609	rattus norv
O60602	homo sapien
O9jlf7	mus musculus
O9ug13	homo sapien
O88520	mus musculus
O9dgb6	gallus gall
O14392	homo sapien
P51890	gallus gall
O9de67	coturnix co

107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	1475	1476	1477	1478	1479	1480	1481	1482	1483	1484	1485	1486	1487	1488	1489	1490	1491	1492	1493	1494	1495	1496	1497	1498	1499	1500	1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515	1516	1517	1518	1519	1520	1521	1522	1523	1524	1525	1526	1527	1528	1529	1530	1531	1532	1533	1534	1535	1536	1537	1538	1539	1540	1541	1542	1543	1544	1545	1546	1547	1548	1549	1550	1551	1552	1553	1554	1555	1556	1557	1558	1559	1560	1561	1562	1563	156
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-----

```
128 QLTREDSFAGLSQELYNHLYRIAPRAGSLNLLRLHNLRAIDRWFEEM 187
181 LKLEYISEGA-----FEGFLNLYNLMGNCNIXDMPN----- 213
188 LPMLEILMIGCNKVDAILDMNFPPLANLSLSVLAGNLAIEISDYALEGLOSLESISFYDN 247
214 -----LTPVLGLEEEMSGNHFPFIRPGSFHGLSLKLMWNMSO----- 253
248 QLARVPRALEQVPGKFLDLNKNPLQRPVGFDFANMLKELGLNMMELVSIKFAIV 307
254 -----VSLIERNAPDGLASIVELNLAHNLSSLPDHLFTPLRYLVLEHLH 298
308 NLBELTKLDITNPRFSFIHPRAPHLPOWETLMLNNALSALHQOTVBSLNLVEGLH 367
299 HNPWNCDDILWL-ANWLR-EYIPTNSTCGRCHAPMGRGRLVEVD--QASFOCSAPP 354
368 GNPICDCVIRWANATGTVRFTEPQSTLCAE---PPDLQRLPVRVPPREMTDHC-LPL 423
355 I--WDAPRLNISGRVAELKCR--TPPMSSVKVLLPNCVTLVSHSRHPRISVINDGTIN 410
424 ISPRSPFSLQVAGSGSVLHCSALAPPEFIYVWTFPAGLRTPAHAGRCRCVYPEGTLE 483
411 FSHVLLSDTGVYTCMTYNVAGNSAGAYLNVSFAEL-----NTSNY----- 451
484 LREVTAEEAGLYTCVAQNLVGADTKTVSVVGRALLQPCRDGQGLELRVQETHPHYILL 543
452 SFTTIVVETTESPEDTKRYKXVPTTSTGQPAYTTS--TTVLQTRVDPKQVAVPAT 509
544 SWYTPPTVSTNLT-WSSASSLRGQATALRPRGTHSYNTRELQATYEWACIQVAPA 602
510 DTTDRKQTSIDEVMKTKIIGGFVA-----VTLAAAMLVFVKLRK---HQQRST 559
603 DA---HTQLACVWATKEATSCHRALDRPGLIALALAVLLAAGLAHLGTQCPKRG 658
560 VTAARTVEIIQVDEDIPATSAATAAPSGVGEAVLPTTHDINVTYKPAHGAHWT 619
659 VGGRR-----PLPPAWAFWGSAPSVRVVSAPLVP-----WNP--GRKLP 697
620 ENSIGNSLHPTVT 632
698 RSSEGETLPLPLS 710

ESULT 2
LRL HUMAN STANDARD; PRT; 546 AA.
C QNZUH; 2003 (Rel. 41, Created)
T 28-FEB-2003 (Rel. 41, Last sequence update)
T 15-SEP-2003 (Rel. 42, Last annotation update)
E Leucine-rich repeat transmembrane protein FLRT1 precursor
E Fibronectin-like domain-containing leucine-rich transmembrane protein
E 1).
N FLRT1.
S Homo sapiens (Human).
C Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
C Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
X NCBI_TaxID=9606;
P SEQUENCE FROM N.A. TISSUE SPECIFICITY, AND GLYCOSYLATION.
X MEDLINE=20112755; PubMed=1064439;
Lacy S.E., Bornemann C.G., Suzney E.A., Kunkel L.M.;
T "Identification of FLRT1, FLRT2, and FLRT3: a novel family of
T transmembrane leucine-rich repeat proteins.";
L Genomics 62:417-426(1999).
C -!- FUNCTION: May have a function in cell adhesion and/or receptor
C signaling.
C -!- SUBCELLULAR LOCATION: Type I membrane protein (Probable).
C -!- TISSUE SPECIFICITY: Expressed in kidney and brain.
C -!- PTM: N-glycosylated.
C -!- SIMILARITY: Contains 1 fibronectin type III domain.
C -!- SIMILARITY: Contains 10 leucine-rich (LRR) repeats.
```

```
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement. See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch)
CC -----
DR EMBL; AF169675; AAF28459.1; ALT_INIT.
DR Genew; HGNC:3760; FLRT1.
DR MIM; 604806; .
DR GO; GO:0005887; C: integral to plasma membrane; NAS.
DR GO; GO:0030222; F: adhesive extracellular matrix constituent a. . .; NAS.
DR GO; GO:0005057; F: receptor signaling protein activity; NAS.
DR InterPro; IPR003961; FN_III.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003591; LRR_Typ.
DR Pfam; PF06041; FN3_1.
DR Pfam; PF01462; LRRCT; 1.
DR Pfam; PF01463; LRRNT; 1.
DR SMART; SM00060; FN3_1.
DR SMART; SM00369; LRR_Typ; 1.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR KW Cell adhesion; Repeat; Signal; Transmembrane; Leucine-rich repeat;
KW Glycoprotein.
FT SIGNAL 1 20
FT CHAIN 21 646
FT LEUCINE-RICH REPEAT TRANSMEMBRANE PROTEIN
FT FLRT1.
FT EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 525 545
FT DOMAIN 546 646
FT REPEAT 52 77
FT REPEAT 78 98
FT REPEAT 99 121
FT REPEAT 123 147
FT REPEAT 148 169
FT REPEAT 170 192
FT REPEAT 194 218
FT REPEAT 219 241
FT REPEAT 242 264
FT REPEAT 265 288
FT DOMAIN 407 485
FT CARBOHYD 221 277
FT CARBOHYD 277 277
FT SEQUENCE 646 AA; 71359 MW; FF2BF5DC3CA13C92 CRC64;
Query Match 11.3%; Score 389; DB 1; Length 646;
Best Local Similarity 23.8%; Pred. No. 8.7e-20;
Matches 166; Conservative 93; Mismatches 270; Indels 168; Gaps 22;
QY 29 WI-LCAAIAAAS--AGPNCPSVCSNQSFKVYVCTRGSLSEVPQGIPSNV----- 77
DB 6 WLFCLCYGLAFUFTVIDSTTSCVCRCONGF--IYCNDRGLTSIPADIPDDATTLYLQNN 63
QY 78 -----RYLNLMMNNIQLQADTFRLH 99
DB 64 QINNAGIPQDLTKVNVQVLYIYENDLDEFFNLPRSLREHLQDNVTVTARDSLRIP 123
QY 100 HLEVLQGLRNSIR-QIEVGAFNGLASLNTLFLPNWLTIPSGAFYLSKRLRLNRN 157
DB 124 LLEKMLDMSVTSVIEEDAFADSKQLKLLFLSRNHLSSIPSGLPHTLELR---LDNM 180
QY 158 PTESIPSVAFNRVPSLMRLD--GELKKLEYISEGAFGLFKLVNLMGNCNKPNTLP 216
DB 181 RSTIPLHAFKGLNSLRVLVDGNLANQRIADDTFSRLQNTLSLVRSLSAAP----- 236
QY 217 LVGLELEMSGNHFPFIRPGSFHGLSLKLMWNMSQVSLIERNAPDGLASIVELNLAH 276
```

Db 237 -----LNLPSAH-----LQKLYLQDNALSHIPYNTYLAKMELELERLDLSNN 276
Qy 277 NLSLPHLFTPLRYLVELHHPNCCDILMLAWLREYIPFNCTCGRCHAPWHR 336
Db 277 NLTTLPRGLFDGLNLAQLLRNPNFQCNLMWLRDVKARAAVNVVRLMCGPEKVR 336
Qy 337 GRYLVEVDQAFQOC--SAPFTMDAPRLNISEGRMAELKCKTTPMSSGVKLLPFGTGLSH 394
Db 337 GWAIKDIITSEWDECTGP-----OGGVANAARKTASNEASATTGGSLFTL 394
Qy 395 ASRHPRIISVANDGLNFS-----HV--LLSTGYVTCWNTVA-----430
Db 395 KAKRPGLR-LPDSNIDYPMATDGAKTALHVKALTADSIKITKATLPASSRLSLWRL 443
Qy 431 GNSNASAVLNSTAEINTSNY-----SFTTIVTETTESPDTTRKYKPV--P 477
Db 444 GSPAVGSGTETLVGDKTEYLLTALBPKSTYIICWMTESNAYVADET-----PVCACA 499
Qy 478 TTSYGQYAYTTSTTVTLQITTRVPKQVAPATDITDKMQTSLDEVMKTKIIGCFVAVT 537
Db 500 ETADSYGP-----TTLNQEQNAGPMASLPLAG-----IIGGAVAVL 536
Qy 538 LLAAMLVFYKLRKHQRQSTVTAARTVEIIOVDEIPATSAATAAPSGVSGEAVV 597
Db 537 FLFLVGLAFCWTV---HQAGELLTTERAYNRSGREKUDYMESGTKONSLIRGPGLOM 593
Qy 598 LPTIHDHINYNTPKPAHGAHWTEENSLGNSLHPTVTI 634
Db 594 LP-----INPRAKEEYVHTTIPPSNGSLCKATHI 625

RESULT 3
FLR3_HUMAN
ID FLR3_HUMAN STANDARD; PRT; 649 AA.
AC Q9NZU0; Q96K39; Q96K42; Q96K43; Q9P259;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Leucine-rich repeat transmembrane protein FLRT3 precursor
DE (Fibronectin-like domain-containing leucine-rich transmembrane protein
DE FLRT3 OR KIAA1469.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
[1]
SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.
MEDLINE=20112755; PubMed=10644439;
RA Lacy S.E., Bonnemant C.G., Ruzney E.A., Kunkel L.M.;
RT "Identification of FLRT1, FLRT2, and FLRT3: a novel family of
RT transmembrane leucine-rich repeat proteins."
RL Genomics 62:417-426(1999).
[2]
SEQUENCE FROM N.A.
TISSUE=Brain;
MEDLINE=20277482; PubMed=10819311;
RA Nagase T., Kikuno R., Ishikawa K.-I., Hirosewa M., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes. XVII.
RT The complete sequences of 100 new cDNA clones from brain which code
RT for large proteins in vitro."
RL DNA Res. 7:143-150(2000).
[3]
SEQUENCE FROM N.A.
TISSUE=Embryo, and Teratocarcinoma;
RA Isegawa T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Shiratori A., Sudo H.,
RA Watanabe M., Hosoi T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA Takahashi M., Chiba Y., Ishida S., Murakami K., Ono Y., Takiguchi S.,
RA Watanabe S., Kimura K., Murakami K., Ishii S., Kawai Y., Saito K.,
RA Yamamoto J., Wakamatsu A., Nakamura Y., Nagahara K., Masuho Y.,
RA Ninomiya K., Iwayanagi T.;
RT "NEDO human cDNA sequencing project."

RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
[4]
SEQUENCE FROM N.A.
MEDLINE=21638749; PubMed=11780052;
RA Deloukas P., Matthews L.H., Ashurst J., Burton J., Gilbert J.G.R.,
RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA Clegg S., Cobley V.S., Collier R.E., Connor R.E., Corby N.R.,
RA Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA Graham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.B.,
RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA Huckle B., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA Leharalao M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA Marsh V.I., Martin S.L., McConachie I.J., McEay K., McMurray A.A.,
RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Showkeen R., Sims S.,
RA Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M., Williams S.A.,
RA Whitehead S.L., Whittaker P., Willey D.L., Williams L., Beck S.,
RA Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
Rogers J.;
RT "The DNA sequence and comparative analysis of human chromosome 20.";
RL Nature 414:865-871(2001).
[5]
SEQUENCE FROM N.A.
TISSUE=Kidney;
MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.P., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh L.,
RA Dratchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences".
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[6]
FUNCTION: May have a function in cell adhesion and/or receptor
signaling.
[7]
SUBCELLULAR LOCATION: Type I membrane protein (Probable).
[8]
TISSUE SPECIFICITY: Expressed in kidney, brain, pancreas, skeletal
muscle, lung, liver, placenta, and heart.
[9]
SIMILARITY: Contains 1 fibronectin type III domain.
[10]
SIMILARITY: Contains 10 leucine-rich (LRR) repeats.

This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).

EMBL; AF169677; AAF28461.1; -;
EMBL; AB040902; BAA95993.1; ALT_INIT.

R EMBL; AK027297; BAB55023.1; --
 R ENBL; AK027670; BAB55282.1; ALT INIT.
 R ENBL; AK027694; BAB55303.1; ALT_INIT.
 R ENBL; AL132826; CAB8687.1; --
 R ENBL; BC020870; AHA20870.1; --
 R Genew; HGNC:3762; FLRT3.
 R MIM; 604808; --
 R GO; GO:0005887; C: integral to plasma membrane; NAS.
 R GO; GO:0030022; F: adhesive extracellular matrix constituent a. . .; NAS.
 R GO; GO:004895; F: cell adhesion receptor activity; TAS.
 R GO; GO:0005057; F: receptor signaling protein activity; NAS.
 R GO; GO:0007165; P: signal transduction; TAS.
 R InterPro; IPR003961; FN_III.
 R InterPro; IPR001611; LRR.
 R InterPro; IPR000483; LRR_Cterm.
 R InterPro; IPR000372; LRR_Nterm.
 R InterPro; IPR003591; LRR_Typ.
 R Pfam; PF000641; fn3; 1.
 R Pfam; PF00360; LRR; 10.
 R Pfam; PF01463; LRRCT; 1.
 R Pfam; PF01462; LRRNT; 1.
 R SMART; SM00060; FN3; 1.
 R SMART; SM00369; FN3_Typ; 1.
 R SMART; SM00082; LRRCT; 1.
 R SMART; SM00013; LRRNT; 1.
 K Cell adhesion; Repeat; Signal; Transmembrane; Leucine-rich repeat;
 W Glycoprotein. 1 28 POTENTIAL.
 T CHAIN 29 649 LEUCINE-RICH REPEAT TRANSMEMBRANE PROTEIN
 T SIGNAL FLRT3.
 T DOMAIN 29 528 EXTRACELLULAR (POTENTIAL).
 T TRANSXEM 529 549 POTENTIAL.
 T DOMAIN 550 649 CYTOPLASMIC (POTENTIAL).
 T REPEAT 57 82 LRR 1.
 T REPEAT 83 105 LRR 2.
 T REPEAT 107 126 LRR 3.
 T REPEAT 127 152 LRR 4.
 T REPEAT 154 179 LRR 5.
 T REPEAT 181 197 LRR 6.
 T REPEAT 198 223 LRR 7.
 T REPEAT 224 246 LRR 8.
 T REPEAT 247 269 LRR 9.
 T REPEAT 270 293 LRR 10.
 T DOMAIN 405 485 FIBRONECTIN TYPE-III.
 T CARBOHYD 226 226 N-LINKED (GLCNAC. .) (POTENTIAL).
 T CARBOHYD 282 282 N-LINKED (GLCNAC. .) (POTENTIAL).
 T CARBOHYD 296 296 N-LINKED (GLCNAC. .) (POTENTIAL).
 T CONFLICT 198 198 L -> P (IN REF. 3; BAB55282).
 T CONFLICT 307 307 W -> R (IN REF. 3; BAB55282).
 T CONFLICT 400 400 H -> Q (IN REF. 3; BAB55023).
 T CONFLICT 519 519 K -> G (IN REF. 3; BAB55023).
 T CONFLICT 638 638 D -> G (IN REF. 3; BAB55282).
 Q SEQUENCE 649 AA; 73003 MW, 9EPF666C46181F08 CRC64;

 Query Match 11.24; Score 385; DB 1; Length 649;
 Best Local Similarity 24.7%; Pred. No. 1.7e-19;
 Matches 167; Conservative 94; Mismatches 270; Indels 146; Gaps 21;

 Y 37 AABAGQPCSCVCSNQPSKVCTRGSLSEVPGIPSN----- 76
 b 22 APLSWAKSCPSVCRDAGP--IYCDREFTSIPTGIPEDATLYLQNNQINAGIPSDL 79
 Y 77 -----TRYLNMMNNIQIADTFHLLHLEVLQGRNS 110
 b 80 KULLKVERIYHNSLDEPPTNLPKVKELHQLQNNIRITVDSLSKIPYLBELHLDNS 139
 Y 111 IR-QIEVGAFNGLASLNTLEFDNMLTWIPSCAFYLSKRLRLRNPIESIPAFN 168
 b 140 VSAVSEEGAFRDSNYRLFLRNLHSLTIPWGLPTTIELR---LDDNRISTISPSLIQ 196
 Y 169 RVPSELMLDL--GELKKLEYISSEGAFLFKLYNLGMCKNIKOMP-NLPLVLGLELEMS 226
 b 197 GLTSLKELVLDGNLNNHGLGDKVFNFLNLTSLVRSNLTAAPVNL----- 244

QY 227 GNHFPPIRPSFHGLSSKKLWPNQSVLSLIERNAFDGLASIVELNLAHNLSSLPDLP 286
 DB 245 -----PG-----TNLFKLYLDQNHINRVPNPAFSLRQLYRLDGNNSNLNLPQGI 291
 QY 287 TPLRYLVLEHLHHPNCCDILMLAWLREYIPNISTCCG--RCHAPMHRGRYLVVEDQ 345
 DB 292 DDLDNTQILRLNPNPYCCCKWVRDLQSL--LPKVNVRGLMCOAPEKVRGMAIKDLNA 350
 QY 346 ASFQCSAPTIMDA-----PRDLNISGRMAELKCRTPPMSSVKWLLPNGVTLVSHASRH 398
 DB 351 ELFDCKDSGIVSTIQITTAIPNTVTPAQSQNPAPVTKQPDIKNPKLTKDHQHTSPSRKT 410
 QY 399 PRISV--LNDGTILNFSHVLSDTGYTCMTNVAGNSNASAVLNVTSLRELNTSYSEFTT 456
 DB 411 ITITVKSVTSDTIHISMKL-----ALPMTALRLSWLKLGSFAGSGIT 453
 QY 457 VTVETTEIS-----PEDTTRRYKEVP--TTSTGQPAYTTTTLVLIQTTRVPKQVAPVA 508
 DB 454 ETIVTGERSEYLVTALEPDSPYKVCVPMETSNLY---LFDETPVCIETETAPLWYNPT 510
 QY 509 TDTDKMOTSLDEVMKTKI-----IIGCFVAVTLAAMLVFY-----K 549
 DB 511 T-TINREQEK--EPYKNPLPLAAIIGGAVLVTTALLALVCWYVRNGSLFSRNCAYSK 567
 QY 550 LRKHQQRSTVTAARTVEIIQVDEDIPAATSAATAAPSGVSGEGAVLPTIHDHINYNT 609
 DB 568 GRRKKDYAEAGTKKONSILIRE-----TSQMLPISNEPISKEEFVHTIFFPPNGMNL 622
 QY 610 YKPAHGAHWTEISLGN 626
 DB 623 YKNNHSESSNRSYRDS 639

 RESULT 4
 CHAD MOUSE STANDARD; PRT; 358 AA.
 ID CHAD MOUSE STANDARD; PRT; 358 AA.
 AC OS5226;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DB Chondroaderin precursor (Cartilage leucine-rich protein).
 GN CHAD.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=98126439; PubMed=9465299;
 RA Landgren C., Beier D.R., Faessler R., Heinegaard D., Sommerin Y.;
 RT "The mouse chondroaderin gene: characterization and chromosomal
 localization.";
 RL Genomics 47:84-91(1998).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Salivary gland;
 RX MEDLINE=22388257; PubMed=12477932;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Sherman C.M., Schuler G.D.,
 RA Altschul S.P., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Frange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mulhally S.J.,
 RA Bosak S.A., McSwain P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergran E.J., Lu X., Gibbs R.A.,
 RA Faney J., Helton E., Kettaman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,

RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length
 RT human and mouse cDNA sequences";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 CC -!- FUNCTION: Promotes attachment of chondrocytes, fibroblasts, and
 CC osteoblasts. This binding is mediated (at least for chondrocytes
 CC and fibroblasts) by the integrin alpha(2)beta(1). May play an
 CC important role in the regulation of chondrocyte growth and
 CC proliferation (By similarity).
 CC -!- SUBUNIT: Mostly monomeric. Interacts with collagen type II (By
 CC similarity).
 CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
 CC similarity).
 CC -!- TISSUE SPECIFICITY: Cartilage.
 CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
 CC (SLRP) FAMILY. CLASS IV SUBFAMILY.
 CC -!- SIMILARITY: Contains 11 leucine-rich (LRR) repeats.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 DR EMBL; U96636; AAC39963.1; -;
 DR EMBL; BC012672; AAH12672.1; -;
 DR MGD; MGI:1096866; Chad.
 DR InterPro; IPR001611; LRR.
 DR InterPro; IPR000483; LRR Cterm.
 DR InterPro; IPR000372; LRR Nterm.
 DR InterPro; IPR000351; LRR typ.
 DR Pfam; PF00560; LRR; 10.
 DR Pfam; PF01463; LRRCT; 1.
 DR Pfam; PF01462; LRR; 1.
 DR SMART; SM003169; LRR TYP; 5.
 DR SMART; SM00082; LRRCT; 1.
 DR SMART; SM00013; LRRNT; 1.
 KW Signal; leucine-rich repeat; Repeat; Glycoprotein;
 KW Extracellular matrix.
 FT SIGNAL 1 20 POTENTIAL.
 FT CHAIN 21 358 CHONDROADHERIN.
 FT REPEAT 49 72 LRR 1.
 FT REPEAT 73 96 LRR 2.
 FT REPEAT 97 120 LRR 3.
 FT REPEAT 121 144 LRR 4.
 FT REPEAT 146 168 LRR 5.
 FT REPEAT 170 192 LRR 6.
 FT REPEAT 193 216 LRR 7.
 FT REPEAT 217 240 LRR 8.
 FT REPEAT 242 265 LRR 9.
 FT REPEAT 266 290 LRR 10.
 FT REPEAT 294 317 LRR 11.
 FT DISULFID 22 37 BY SIMILARITY.
 FT DISULFID 303 345 BY SIMILARITY.
 FT DISULFID 305 325 BY SIMILARITY.
 FT CARBOHYD 143 143 O-LINKED (POTENTIAL).
 SQ SEQUENCE 358 AA; 40348 MW; 6A062FCEB84A078 CRC64;
 Query Match 11.1%; Score 380.5; DB 1; Length 358;
 Best Local Similarity 29.0%; Pred. No. 1.6e-19;
 Matches 106; Conservative 65; Mismatches 147; Indels 47; Gaps 10;
 QY 16 ALLPRLVLTQAQWILCAIAAASAGPNCPSVCSNQSFKVCTRGRLSEVPQGIIPS 75
 DB 4 ALLFSLVFLA----ILLPALA-----CPQCHCHGDIQHVICDKVGLQKIPK-VSE 50
 QY 76 NTRYLNLMNNTQMTQADTFRLHLHLEVLQIGRNSIRIOIFVGAFNGLASINTLBLEFNWL 135
 DB 51 TTLLNLRQNNPFLAANSFRTPNVLVSLHLOHCNIREVAAGAFGLKQLLYLSHNDI 110

QY 136 TVIPGAFYLKRLRLMNNPIESIPSYAFNRVPSLRLDLGLKLEKLEYISGAFEG 195
 DB 111 RVLKAGAPDDLTELTYLDHNVKSELPRGLLSPLVNLFIQLAN-NKIRELRAGAFOGA 169
 QY 196 FNEKYL-----NLGMCNFKDMEN-----LTPLVGLLEEMSGNH 229
 DB 170 KDLRLMLYSENALSSLSQGSDDVENLAKFLDKNQLSSYSAALSKLRVVEELKLSNP 229
 QY 230 FPEIRPGSPHGLSS-LKKLWNNVSNQSVLIERNAFDGLASLVELNLAHNNLSLPHDLFTP 288
 DB 230 LKSIDPNAFQSPGRVLETLWLDNTNLEKFSDAAPSGVTTLKHVHLNDRNLNQLPSSP--P 287
 QY 289 LRYLVELHLHHPNWCDDILWAWLREYIPTNSTCCGRCHAPMHRGRVLYVEVDQASF 348
 DB 288 FNNLETLTNNPKCTCOLRGLRWLE---AKASRPDATCSSPAKFGQRIQRTD-ALR 343
 QY 349 QCSAP 353
 DB 344 SCKSP 348
 RESULT 5
 CHAD RAT
 ID CHAD RAT STANDARD; PRT; 358 AA.
 AC O70210;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Chondroaderin precursor (cartilage leucine-rich protein).
 GN CHAD.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [3]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Chondrosarcoma;
 RX MEDLINE=98129774; PubMed=9461555;
 RA Shen Z., Gantcheva S., Maansson B., Heinegaard D., Sommarin Y.;
 RT "Chondroaderin expression changes in skeletal development.";
 RL Biochem J 330:549-557(1998).
 CC -!- FUNCTION: Promotes attachment of chondrocytes, fibroblasts, and
 CC osteoblasts. This binding is mediated (at least for chondrocytes
 CC and fibroblasts) by the integrin alpha(2)beta(1). May play an
 CC important role in the regulation of chondrocyte growth and
 CC proliferation (By similarity).
 CC -!- SUBUNIT: Mostly monomeric (By similarity).
 CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
 CC similarity).
 CC -!- TISSUE SPECIFICITY: Present in femoral head and rib cartilage, as
 CC well as in tendon. Detected in bone marrow.
 CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
 CC (SLRP) FAMILY. CLASS IV SUBFAMILY.
 CC -!- SIMILARITY: Contains 11 leucine-rich (LRR) repeats.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 DR EMBL; AF004953; AAC40060.1; -;
 DR InterPro; IPR001611; LRR.
 DR InterPro; IPR000483; LRR Cterm.
 DR InterPro; IPR000372; LRR Nterm.
 DR InterPro; IPR000351; LRR typ.
 DR Pfam; PF00560; LRR; 9.
 DR Pfam; PF01463; LRRCT; 1.
 DR Pfam; PF01462; LRRNT; 1.
 DR SMART; SM00369; LRR TYP; 5.
 DR SMART; SM00082; LRRCT; 1.

```

RT  *A novel member of the leucine-rich repeat superfamily induced in rat
RT  astrocytes by beta-amyloid.*
RL  Biochem. Biophys. Res. Commun. 290:756-762(2002).
CC  -!- SUBCELLULAR LOCATION: Type I membrane protein (Potential).
CC  -!- TISSUE SPECIFICITY: Brain and placenta.
CC  -!- SIMILARITY: Contains 15 leucine-rich (LRR) repeats.
CC  -----
CC  This SWISS-PROT entry is copyright. It is produced through a collaboration
CC  between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC  the European Bioinformatics Institute. There are no restrictions on its
CC  use by non-profit institutions as long as its content is in no way
CC  modified and this statement is not removed. Usage by and for commercial
CC  entities requires a license agreement (See http://www.isb-sib.ch/announcement/
CC  or send an email to license@isb-sib.ch).
CC  -----
DR  EMBL; AB071037; BAB84587.1; -.
DR  Genew; HGNC:20818; LRRC15.
DR  InterPro; IPR001611; LRR.
DR  InterPro; IPR000483; LRR_Cterm.
DR  InterPro; IPR000372; LRR_Nterm.
DR  InterPro; IPR003591; LRR_Typ.
DR  Pfam; PF00560; LRR; 14.
DR  Pfam; PF01463; LRRCT; 1.
DR  SMART; SM00369; LRR_Typ; 10.
DR  SMART; SM00082; LRRCT; 1.
DR  SMART; SM00013; LRRNT; 1.
KW  Repeat; Leucine-rich repeat; Transmembrane; Signal.
PT  SIGNAL 1 21
PT  CHAIN 22 581
LEUCINE-RICH REPEAT-CONTAINING PROTEIN
FT  DOMAIN 22 538
FT  TRANSMEM 539 559
FT  DOMAIN 560 581
FT  REPEAT 51 75
FT  REPEAT 76 99
FT  REPEAT 100 123
FT  REPEAT 125 147
FT  REPEAT 148 171
FT  REPEAT 173 195
FT  REPEAT 196 219
FT  REPEAT 221 243
FT  REPEAT 244 267
FT  REPEAT 269 291
FT  REPEAT 292 315
FT  REPEAT 317 339
FT  REPEAT 340 363
FT  REPEAT 364 387
FT  REPEAT 389 411
FT  CARBOHYD 75 75
FT  CARBOHYD 369 369
FT  SQ SEQUENCE 581 AA; 64396 MW; 1F381495BD2C854 CRC64;
Query Match 11.0%; Score 379; DB 1; Length 581;
Best Local Similarity 24.4%; Pred. No. 3.8e-19;
Matches 121; Conservative 56; Mismatches 144; Indels 174; Gaps 9;
QY 30 ILCAIAAASAGQNPSCVCSNFOFSKVYCTRGLSVPGQIFSNRYLNENNLIQM 89
DB 9 LLVGCQAWGAGLYHGCPSFECTCS-RASQVECTGARIVAVPTPLFPWNAMSQILNTHTE 67
QY 90 IQADTFRHLHLEVLQGRNSIRQIEVGAFNGLASLNTLEFDNMLTVIPSCAPEYL--- 146
DB 68 LNESPFNLISALIRIRKXNELSRITPGAFRNLGSLRYLSLANNKLQVLPGLQGLDSL 127
QY 147 -----SKRLRLRNNPISPIPSYAFNRVPSLRGLDGLGELKKLE 185
DB 128 ESLILSSNQLIQPAHFSCSNLKEQLHGHLHYIPDGAFDHIVGLTKMLGK-NSLT 186
QY 186 VISGCAPEGLNTKYNLGMCNKIDWP--NLTPLYGLRELEMSGNHPPEIRPGSPHGLSS 243
DB 187 HSPRVFOHNLGNQVLELYENRUTDIPMGTFDGLVNLQELALQQQIQGLISPELFFHNHN 246
QY 244 LKGLWVFN----- 251

```

```

DB 247 LQRLYSNNHISQLPSPFIMQLPOLNRLTLFGNSLKLSLGI FGMPNRLRELYDNHIS 306
QY 252 -----SQVSLIERNAPDGLASIVELN----- 272
DB 307 SLIPDNVFNLRQLQVLILSRNOISFISPCAFNGLTLELSLFTNNAQLDLDGNVFRMLAN 366
QY 273 -----LAHNNLSLPHDLFTPLRYLVELLHLPNPN 303
DB 367 LQNLISLQNNLRQLPCNIFANVNGMLMAIQNNQLENPLGIFDHLGKLCBELYDNEFR 426
QY 304 CDCDILNLAWML-----RYIPTNCTCCGRCHAPHMGGRYL-----VEVD 344
DB 427 CDSIDLPLNWLNLNQLRGTDTVPV-----CSPANVRGQSLLIINNNAVPSVHPV 479
QY 345 QASPOCSAPFIMDAP 359
DB 480 EYVPSYPTFPWYDTP 494

RESULT 7
ID SLIT DROME STANDARD; PRT: 1504 AA.
AC P24014: Q24526; Q9V7F8; Q9V7F9; Q9XV4;
DT 01-MAR-1992 (Rel. 21, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DE 28-FEB-2003 (Rel. 41, Last annotation update)
DE Slit protein precursor.
GN SLI OR CG8355.
OS Drosophila melanogaster (Fruit fly).
CC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
CC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
CC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxId=7227;
RN [1]
RP SEQUENCE FROM N.A. (ISOFORMS A AND B).
RX MEDLINE=9109665; PubMed=2176636;
RA Rothberg J.M., Jacobs J.R., Goodman C.S., Artavanis-Tsakonas S.;
RT "Slit: an extracellular protein necessary for development of midline
RT glia and intracellular axon pathways contains both EGF and LRR
RT domains.";
RL Genes Dev. 4:2169-2187(1990).
RN [2]
RP SEQUENCE FROM N.A. (ISOFORM C).
RX MEDLINE=99200390; PubMed=10102267;
RA Kidd T., Bland K.S., Goodman C.S.;
RT "Slit is the midline repellent for the robo receptor in Drosophila.";
RL Cell 96:785-794(1999).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=Berkely; PubMed=10731132;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Ananides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.-H.C., Blake J.R.G., Champs M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA Abril J.F., Achayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley B.M.,
RA Beeson K.M., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotter P.,
RA Burtis K.C., Busam D.A., Butler H., Cadiou E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablo B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann M.,
RA Fosler C., Gabrielian A.B., Garg N.S., Gelbart W.M., Glasser K.,
RA Glodok A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA Jalali M., Kalush F., Karpis G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,

```

```

RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Pacleb J.M.,
RA Palazotto M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith I.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Svirkas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.-Y., Wasserman D.A., Weinstock G.M., Weissbach J.,
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA Ye J., Yeh R.-P., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster.";
RN Science 287:2185-2195(2000).
RN [4]
RP REVISIONS, AND ALTERNATIVE SPLICING.
RC STRAIN=Berkely; PubMed=12537572;
RX Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochuk S.E.,
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA Bettencourt B.R., Celniker S.E., de Grey A.D.N.J., Drysdale R.A.,
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA Lewis S.E.;
RT "Annotation of the Drosophila melanogaster euchromatic genome: a
RT systematic review.";
RL Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).
RN [5]
RP SEQUENCE OF 898-1435 FROM N.A.
RC STRAIN=Canton-S; PubMed=3144436;
RX MEDLINE=89077533; PubMed=3144436;
RA Rothberg J.M., Hartley D.A., Walthers Z., Artavanis-Tsakonas S.;
RT "Slit: an EGF-homologous locus of D. melanogaster involved in the
RT development of the embryonic central nervous system.";
RL Cell 55:1047-1059(1988).
CC -|- FUNCTION: A short-range repellent, controlling axon crossing of
CC the midline and a long-range chemorepellent, controlling mesoderm
CC migration and patterning away from the midline. May interact with
CC extracellular matrix molecules.
CC -|- SUBCELLULAR LOCATION: Secreted.
CC -|- ALTERNATIVE PRODUCTS:
CC Event-Alternative splicing; Named isoforms=3;
CC Name=C;
CC IsoId=P24014-1; Sequence=Displayed;
CC Name=A;
CC IsoId=P24014-2; Sequence=VSP_001408;
CC Name=B;
CC IsoId=P24014-3; Sequence=VSP_001408, VSP_001409;
CC -|- TISSUE SPECIFICITY: In embryos, highest expression occurs around
CC the midline glia and low expression is observed around CNS axons
CC lateral to the midline.
CC -|- SIMILARITY: Contains 7 EGF-like domains.
CC -|- SIMILARITY: Contains 24 leucine-rich (LRR) repeats.
CC -|- SIMILARITY: Contains 1 C-terminal cysteine knot-like (CTCK) domain.
CC -|- SIMILARITY: Contains 1 laminin G-like domain.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: X53959; CAA37910.1; -
CC EMBL: AL28540; AD28567.1; -
CC EMBL: AB003809; AAF58097.1; -
CC EMBL: AB003809; AAF58098.1; -
CC EMBL: AB003809; AAF70966.1; -

```

DR EMBL; M23543; AAA72722.1; ALT_INIT.
DR HSP; P00740; 1EDM.
DR GO; GO:0005576; C:extracellular; IEP.
DR GO; GO:0045493; F:chemorepellant activity; IMP.
DR GO; GO:0007411; P:axon guidance; IGI.
DR GO; GO:0008347; P:gila cell migration; IMP.
DR GO; GO:0007509; P:mesoderm migration; IMP.
DR GO; GO:0030182; P:neuron differentiation; IMP.
DR InterPro; IPR00152; Asx_hydroxyl.
DR InterPro; IPR006208; Cys_knot.
DR InterPro; IPR006207; Cys_knot_C.
DR InterPro; IPR00742; EGF_2.
DR InterPro; IPR001881; EGF_Ca.
DR InterPro; IPR006209; EGF_like.
DR InterPro; IPR002049; Laminin_EGF.
DR InterPro; IPR001791; Laminin_G.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003591; LRR_typ.
DR Pfam; PF00007; Cys_knot; 1.
DR Pfam; PF00054; laminin_G; 1.
DR Pfam; PF00560; LRR_16.
DR Pfam; PF01463; LRRCT; 4.
DR Pfam; PF01462; LRRNT; 4.
DR PRINTS; PR00011; EGF_LAMININ.
DR PRINTS; PR00019; LEURICHERP.
DR SMART; SM00041; CT; 1.
DR SMART; SM00179; EGF_CA; 2.
DR SMART; SM00282; LamG; 1.
DR SMART; SM00369; LRR_TYP; 9.
DR SMART; SM00082; LRRCT; 4.
DR SMART; SM00013; LRRNT; 4.
DR PROSITE; PS00010; ASX_HYDROXYL; 3.
DR PROSITE; PS01185; CTCK_1; 1.
DR PROSITE; PS01225; CTCK_2; 1.
DR PROSITE; PS00022; EGF_1; 7.
DR PROSITE; PS01186; EGF_2; 5.
DR PROSITE; PS01187; EGF_CA; 2.
DR PROSITE; PS00025; LAM_G_DOMAIN; 1.
DR Neurogenesis; Glycoprotein; Signal; Alternative splicing;
EGF-like domain; Repeat; Leucine-rich repeat.
SIGNAL 1 36
TT CHAIN 37 1504 SLIT PROTEIN.
TT CHAIN 37 1135 SLIT PROTEIN N-PRODUCT (BY SIMILARITY).
TT CHAIN 1136 1504 SLIT PROTEIN C-PRODUCT (BY SIMILARITY).
TT SITE 1135 1136 CLEAVAGE (BY SIMILARITY).
TT REPEAT 99 122 LRR 1.
TT REPEAT 123 146 LRR 2.
TT REPEAT 147 170 LRR 3.
TT REPEAT 171 194 LRR 4.
TT REPEAT 195 218 LRR 5.
TT REPEAT 219 242 LRR 6.
TT REPEAT 244 270 LRR 7.
TT REPEAT 270 298 LRR 8.
TT REPEAT 298 326 LRR 9.
TT REPEAT 326 354 LRR 10.
TT REPEAT 354 382 LRR 11.
TT REPEAT 382 410 LRR 12.
TT REPEAT 410 438 LRR 13.
TT REPEAT 438 466 LRR 14.
TT REPEAT 466 494 LRR 15.
TT REPEAT 494 522 LRR 16.
TT REPEAT 522 550 LRR 17.
TT REPEAT 550 578 LRR 18.
TT REPEAT 578 606 LRR 19.
TT REPEAT 606 634 LRR 20.
TT REPEAT 634 662 LRR 21.
TT REPEAT 662 690 LRR 22.
TT REPEAT 690 718 LRR 23.
TT REPEAT 718 746 LRR 24.

FT DOMAIN 931 968 EGF-LIKE 1.
FT DOMAIN 970 1007 EGF-LIKE 2.
FT DOMAIN 1009 1046 EGF-LIKE 3, CALCIUM-BINDING (POTENTIAL).
Query Match 10.9%; Score 375.5; DB 1; Length 1504;
Best Local Similarity 27.3%; Pred. No. 2.4e-18;
Matches 111; Conservative 51; Mismatches 141; Indels 103; Gaps 8;
QY 46 CPSVCSNQPSKVCTRRGLSEVPGQIPSNTRYLNLMENNMIQADTPRHLLHLEVLQ 105
DB 73 CPRVCSCTG--LNVDCSHRGTSVPRKISADVLELQGNLTVIYETDFQRLTKRLMLQ 130
QY 106 LGRNSIRQIEVGAFNGLASLNTLFLFONWLTVPISGAFYLSKLRLNLRNPNIESIPSY 165
DB 131 LTDNQIHTIERNSFODLVSLERL-----LNNRLKAIPEN 166
QY 166 AFRNVPISLWRLDLAGELKLEIYISGAPEGLFNLYLNGMGNKMDENLTPLVGLEBLEM 225
DB 167 FVTSSASLRLDI----- 179
QY 226 SGNHPEIRPGSFHGLSKLWVNSQVSLIERNADGLASIVELNLAHNNSSLPDL 285
DB 180 SNNVITTVGRVFKGAQSLRSIQLDNNQITCLDEHAFKGLVELEILTNNNLTSLPHNI 239
QY 286 FTPLRYLVELHHPNWCDCDILWLAWLREYIPTNSTCGGCHAPMHEGRYLVVEDQ 345
DB 240 FGLGLRALRLSDNPFACDCHLSWLSRPLRS--ATLAPYTRQSPSQSLKGNVADLHD 297
QY 346 ASFOCS-----APFIMDA---PRDLNISGRMAELKCRTPPMSSVKWLLPNGTV----- 391
DB 298 QEFKCSGLTEHAPMECGAENSCHPFCADG---IVDCREKSLTSVPVTLPPDDTTELRL 354
QY 392 -----LSHASRHPRIISVNDGTLNPSHVLLSDTGVYTCMV 426
DB 355 QNFITELPPKFSFSSFRRLRIDLSNNSNISRIAHDAISGLKQLTLV 400
RESULT 8
CHAD_BOVIN
ID CHAD_BOVIN STANDARD; PRT; 361 AA.
AC Q27972;
GN CHAD.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OC NCBI_taxid=9913;
RN [1]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RC TISSUE=Cartilage;
RX MEDLINE=94342341; PubMed=8063792;
RA Neame P.J., Sommarin Y., Boynton R.B., Heinigaard D.;
RT "The structure of a 38-kDa leucine-rich protein (chondroadherin)
isolated from bovine cartilage".
RL J. Biol. Chem. 269:21547-21554(1994).
RW [2]
RP SEQUENCE OF 25-55 AND 77-97.
RC TISSUE=Bone;
RX MEDLINE=95113864; PubMed=7814406;
RA Hu B., Coulson L., Moyer B., Price P.A.;
RT "Isolation and molecular cloning of a novel bone phosphoprotein
related in sequence to the cystatin family of thiol protease
inhibitors".
RL J. Biol. Chem. 270:431-436(1995).
CC -!- FUNCTION: Promotes attachment of chondrocytes, fibroblasts, and
osteoblasts. This binding is mediated (at least for chondrocytes
and fibroblasts) by the integrin alpha(2)beta(1). May play an
important role in the regulation of chondrocyte growth and

CC proliferation.
 CC -!- SUBUNIT: Mostly monomeric. Interacts with collagen type II (By
 CC similarity).
 CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix.
 CC -!- TISSUE SPECIFICITY: Cartilage.
 CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
 CC (SRP) FAMILY. CLASS IV SUBFAMILY.
 CC -!- SIMILARITY: Contains 11 leucine-rich (LRR) repeats.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: U08018; AAA21330.1; -.
 CC InterPro: IPR001611; LRR.
 CC InterPro: IPR000483; LRR_Cterm.
 CC InterPro: IPR000372; LRR_Nterm.
 CC InterPro: IPR003591; LRR_Typ.
 CC Pfam: PF00560; LRR; 10.
 CC Pfam: PF01463; LRRCT; 1.
 CC Pfam: PF01462; LRRNT; 1.
 CC SMART: SM00369; LRR_Typ; 5.
 CC SMART: SM00082; LRRCT; 1.
 CC SMART: SM00013; LRRNT; 1.
 CC Signal: Leucine-rich repeat; Repeat; Glycoprotein;
 CC Extracellular matrix.
 CC
 CC SIGNAL 1 24 OR 23 (IN SOME ISOFORM(S)).
 CC CHAIN 25 361 CHONDROADHERIN.
 CC CHAIN 25 352 CHONDROADHERIN, MINOR FORM.
 CC REPEAT 52 75 LRR 1.
 CC REPEAT 76 99 LRR 2.
 CC REPEAT 100 123 LRR 3.
 CC REPEAT 124 147 LRR 4.
 CC REPEAT 149 171 LRR 5.
 CC REPEAT 173 195 LRR 6.
 CC REPEAT 196 219 LRR 7.
 CC REPEAT 220 243 LRR 8.
 CC REPEAT 245 268 LRR 9.
 CC REPEAT 269 292 LRR 10.
 CC REPEAT 294 319 LRR 11.
 CC BY SIMILARITY.
 CC
 CC O-LINKED (POTENTIAL).
 CC C -> Y (IN REF. 2).
 CC C -> W (IN REF. 2).
 CC C -> H (IN REF. 2).
 CC C -> L (IN REF. 2).
 CC S -> R (IN REF. 2).
 CC
 CC SEQUENCE 361 AA; 40884 MW; DA79DC98AD3DD1F8 CRC64;
 CC
 CC Query Match 10.9%; Score 375; DB 1; Length 361;
 CC Best Local Similarity 28.3%; Pred. No. 3.9e-19;
 CC Matches 102; Conservative 66; Mismatches 153; Indels 40; Gaps 9;
 CC
 CC 20 PFVYLAQVWILCAALAAASAGPQVCSCSNQFSAVCTRGELSEVPGQIPSNTRY 79
 CC 4 PALLXLSLGLLASLALPALAA-----CPQNCCHSDQLQHVICKVGLQKIPK-VSEKTL 57
 CC
 CC 80 LNMENNIQMIQADTPRHLLHLEVLQGRNSTQIEVGAENGASLNTLELFDNWLTVIP 139
 CC 58 LNLQRNFFVLATNSFRANFLVSLHQCQREVAAGAFGLKQIYLYLSHNDIRYL 117
 CC 140 SGAFVYLSKRLRLNPNPESIPSAFNRVPSLMRLDLGELKLEYISEGAFELNKL 199
 CC 118 AGAFDLDLTLYLDHNKVTLPRLGLLSPLVNLFIQLNN-NKIRELSRGAFOGADLR 176
 CC 200 YNLGLGNCNIK-----DMPN-----LTPVLGLELEMSGNHPEI 233

Db 177 WLILSENSLSLOPGALDDVENLAKFYLDENQISSYPSAALSGLRVVEELKLSHNP LKSI 236
 Qy 234 RPSGFHGLSS-LKKLVWMSQSVSLIERNAPDGLASIVLELNHNNLSLPHDLFTPLRYL 292
 Db 237 PDNAFQSGRYLETLWLDNTNLEKPSDGAFLGVTTLKHVLENNRLHQPSNF--PFDSL 294
 Qy 293 VELHLHNPNWNCDDILMLAWLREYIPNTSCCGCHAPMMRMGRYLYVEVDQASFOCSA 352
 Db 295 ETTLTNNPWKCTCQLRGLRWLE---AKTSRDPDATCASPAKFRGQHIRD TD-AFRGCKP 350
 Qy 353 P 353
 Db 351 P 351
 RESULT 9
 RT4R MOUSE
 ID RT4R MOUSE STANDARD; PRT; 473 AA.
 AC Q99P18;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Reticulon 4 receptor precursor (Nogo receptor) (NGR) (Nogo-66
 DE receptor).
 GN RTN4R OR NOGOR.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OK NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A., AND FUNCTION.
 RC STRAIN=Swiss Webster;
 RX MEDLINE=21069055; PubMed=11201742;
 RA Fournier A.E., Grandpre T., Strittmatter S.M.;
 RT "Identification of a receptor mediating Nogo-66 inhibition of axonal
 RT regeneration.";
 RL Nature 409:341-346 (2001).
 RP [2]
 RP REVIEW.
 RX MEDLINE=21888956; PubMed=11891768;
 RA Ng C.B.L., Tang B.L.;
 RT "Nogose and the Nogo-66 receptor: factors inhibiting CNS neuron
 RT regeneration.";
 RL J. Neurosci. Res. 67:559-565 (2002).
 CC -!- FUNCTION: Receptor for RTN4, OMG and MAG. Mediates axonal growth
 CC inhibition and may play a role in regulating axonal regeneration
 CC and plasticity in the adult central nervous system (By
 CC similarity).
 CC -!- SUBUNIT: Homodimer (By similarity).
 CC -!- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By
 CC similarity).
 CC -!- SIMILARITY: Contains 10 leucine-rich (LRR) repeats.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: AF283462; AA053611.1; -.
 CC MGD; MGI:2326886; Rtn4r.
 CC GO; GO:0005886; C:plasma membrane; IDA.
 CC GO; GO:0007409; P:axogenesis; IDA.
 CC InterPro: IPR001611; LRR.
 CC InterPro: IPR000483; LRR_Cterm.
 CC InterPro: IPR000372; LRR_Nterm.
 CC Pfam: PF00560; LRR; 8.
 CC Pfam: PF01463; LRRCT; 1.
 CC SMART; SM00369; LRR_Typ; 3.
 CC SMART; SM00082; LRRCT; 1.

DR SMART; SM00013; LRRT; 1.
KW Receptor; Signal; GPI-anchor; Repeat; Leucine-rich repeat.
FT SIGNAL 1 26
FT CHAIN 27 447
FT PROPEP 448 473
FT LIPID 447 447
FT REPEAT 56 79
FT REPEAT 81 103
FT REPEAT 105 128
FT REPEAT 129 152
FT REPEAT 153 176
FT REPEAT 178 200
FT REPEAT 202 224
FT REPEAT 225 248
FT REPEAT 250 273
FT REPEAT 316 339
SQ SEQUENCE 473 AA; 50987 MW; 14C5270B5F57E7C CRC64;

Query Match 10.8%; Score 372.5; DB 1; Length 473;
Best Local Similarity 30.1%; Pred. No. 8.3e-19;
Matches 126; Conservative 57; Mismatches 154; Indels 81; Gaps 17;

29 WILCAIAAASAGPQNCPSVCSNPFKVV--CTRRGLSEVPOGIPSNRYLNLMENN 86
14 WVLW--LQAWRVATP--CPGACVCYNE-PKVTTSCPGQGLQAVPTGIPASSQRIFLHGNR 68
87 IQMIOADTFERHLEVLQGLGRSIRQIEVGAFNGLASLNTLLELFDN-WLTVIPSGAPEY 145
69 ISHPVPAASFCRNLTLNLSNALRIDAAAFGLTLEQLDLSNAQLHVVDPTTFPG 128
146 LSKLELRLNRPITESTPSYAFNRVPSIMELDLGELKLEIYISGAFGLFNLKYLNLGM 205
129 LGHLTL-----HLDRCGLREL--GPGLFRGLAALQYLYLQD 163
206 NIYKDMNLT--PLVGLLEEMSGNHPEPTPQSGFLGSLKGLWNNQSVLSIERNAD 263
164 NNLQALPDNTFRDLGNLTHLFLHGNRIPSPVPEAFRGLHSLDLHLHQHVARVPHAFR 223
264 GLASLEVLNLAHNLSSLPDLTPFLRYVELHLHNPWNCDCDILWLAWLREYIPTNS 323
224 DLGLMTLYLFAANNLSMLPAEVLNPLSLQYLRNDNPWCDCRPLWNLQKPGSSS 283
324 TCQGRCHAPMMGRYIUEVDQASFO-----CSAPP-----INDAPRLN----- 363
284 EV--PCNLQRLADRLKRLAASDLGCAVASGFPFRPQTSQLTDBELSLPKCQCPDAA 341
364 -----ISEGRMAE-----LKCRTPMSVKWLLPNGTVLSHSHRPIISVLND-----GTL 409
342 DKASVLEPGRPASGNALKGRVPPGDT-----PPGN--GSGPRH-----INDSPFGTL 387
[1]

RESULT 10
R15 RAT
D LR15 RAT STANDARD; PRT; 578 AA.
C Q8R5M3;
15-SEP-2003 (Rel. 42, Created)
15-SEP-2003 (Rel. 42, last sequence update)
15-SEP-2003 (Rel. 42, last annotation update)
Leucine-rich repeat-containing protein 15 precursor (rLib).
LRRC15 OR L1B.
Rattus norvegicus (Rat).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
NCBI_TaxID=10116;
[1]
SEQUENCE FROM N.A.
C STRAIN=Wistar; TISSUE=Fetal brain;
X MEDLINE=21645900; PubMed=11785964;
A Satoh K., Hata M., Yokota H.;
T "A novel member of the leucine-rich repeat superfamily induced in rat
astrocytes by beta-amyloid."
L Biochem. Biophys. Res. Commun. 290:756-762(2002).
C -I- SUBCELLULAR LOCATION: Type I membrane protein (Potential).

CC -I- INDUCTION: By beta-amyloid.
CC -I- SIMILARITY: Contains 15 leucine-rich (LRR) repeats.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: AB071036; BAB84586.1; --
DR InterPro; IPR001611; LRR.
DR InterPro; IPR004483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003591; LRR_Typ.
DR Pfam; PF00560; LRR; 14.
DR Pfam; PF01463; LRRCT; 1.
DR SMART; SM00369; LRR_Typ; 11.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRT; 1.
KW Repeat; Leucine-rich repeat; Transmembrane; Signal.
FT SIGNAL 1 21
FT CHAIN 22 578
FT LEUCINE-RICH REPEAT-CONTAINING PROTEIN
15.
FT DOMAIN 22 535
FT TRANSMEM 536 556
FT DOMAIN 557 578
FT REPEAT 51 75
FT REPEAT 76 99
FT REPEAT 100 123
FT REPEAT 125 147
FT REPEAT 148 171
FT REPEAT 173 195
FT REPEAT 196 219
FT REPEAT 221 243
FT REPEAT 244 267
FT REPEAT 269 291
FT REPEAT 292 315
FT REPEAT 316 339
FT REPEAT 340 363
FT REPEAT 364 387
FT REPEAT 389 411
FT CARBOHYD 75 75
FT CARBOHYD 369 369
SQ SEQUENCE 578 AA; 64127 MW; 991BD057F5912591 CRC64;

Query Match 10.8%; Score 371.5; DB 1; Length 578;
Best Local Similarity 25.3%; Pred. No. 1.3e-18;
Matches 118; Conservative 57; Mismatches 131; Indels 161; Gaps 11;

QY 27 QVWILCAIAAASAGPQNCPSVCSNPFKVVCTRRGLSEVPOGIPSNRYLNLMENN 78
DB 14 QAWALGLAY-----YGCPSCTCS-RASQVCECTCARIVAMPTPLPWNAWSLQVVNTH 64
QY 79 -----YLNLM-----ENNIOIADTRPHLHLEVLQGLGRSIRQIEVGAFNGL 122
DB 65 ITLPELNLFLNISALIALKMKKSELSTIMPAGFNLGSLRYLSLANNKLMPLPIRVFDV 124
QY 123 ASLNTLELFDNWLTVIPSGAPEYLSKLELRLNRPITESTPSYAFNRVPSIMELDLGELK 182
DB 125 NNLESLLSNQVLQVQPGFQSPQSNLRELQHLGNMLESIPBEAFPHLYGLTYKLNLR-N 183
QY 183 KLEYISGAFGLFNLKYLNLGMNCKMP-----NLTP----- 216
DB 184 SFTHLSPLRFQHLGNLQVLRFLHNRSLSDIPMGFTDALGNLQELALQENQIGTLISPLGFH 243
QY 217 -----LVGLELEMSGNHFPPIRPGSGFGLSSLLKLVWMM- 251
DB 244 NRMQLRYLSNNHISQLPGIFMQLPQLNKLTLFGNSLRLELSPGFGPMPNLKELMYNN 303
QY 252 -----SQVSLIERNAFDGLASLVELN----- 272
[1]

Db 304 HITSLADTFSHLNQVLIHSHNQLTYSFGAFNGLTNLRLSLTNALQDLSNVRS 363
QY 273 -----LANNLSLPHDLFTPLRYLVELLHN 300
Db 364 LANLQNISQSNRLRQPSIFANVGLTIOQNNLENLPGLFDHVNLCLELYDN 423
QY 301 PNMCDIILAWLW---REYPTNSTCCGRCHAPMRGRYLVVD 344
Db 424 PNRCDSDILPHNLLNRLARLGTDLPV--CSSPANVRGSLVIN 468

RESULT 11
RT4R RAT STANDARD; PRT; 473 AA.
AC Q99M75;
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Reticulon 4 receptor precursor (Nogo receptor) (Ngr) (Nogo-66 receptor)
DE RTN4R OR NOGOR.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=101116;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Sprague-Dawley;
RA Jin W.-L., Jia W., Long M., Ju G.;
RT "Identification and preparation of polyclonal antibody against rat Nogo receptor."
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA Oertle T., van der Haar M.E., Bandtlow C.E., Huber A.B., Simonen M., Schreil L., Broesamle C., Schwab M.E.;
RT "Nogo-A: a molecule with two active sites and two membrane topologies."
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP REVIEW.
RX MEDLINE=2188956; PubMed=11891768;
RA Ng C.E.L., Tang B.L.;
RT "Nogos and the Nogo-66 receptor: factors inhibiting CNS neuron regeneration."
RL J. Neurosci. Res. 67:559-565(2002).
RN [4]
RP FUNCTION.
RX MEDLINE=22033691; PubMed=12037567;
RA Grandpre T., Li S., Strittmatter S.M.;
RT "Nogo-66 receptor antagonist peptide promotes axonal regeneration."
RL Nature 417:547-551(2002).
CC -1- FUNCTION: Receptor for RTN4, OMG and MAG. Mediates axonal growth inhibition and may play a role in regulating axonal regeneration and plasticity in the adult central nervous system (By similarity).
CC -1- SUBUNIT: Homodimer (By similarity).
CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By similarity).
CC -1- SIMILARITY: Contains 10 leucine-rich (LRR) repeats.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).
CC
CC EMBL; AY028438; AA020166.1; -
CC EMBL; AF462390; AA046772.1; -
CC InterPro; IPR001611; LRR.
CC InterPro; IPR000483; LRR_Cterm.

DR InterPro; IPR003591; LRR_TYP.
DR Pfam; PF00560; LRR_8.
DR Pfam; PF01463; LRRCT_1.
DR SMART; SM00369; LRR_TYP_3.
KW Receptor; Signal; GPI-anchor; Repeat; Leucine-rich repeat.
FT SIGNAL 1 26 POTENTIAL.
FT CHAIN 27 447 RETICULON 4 RECEPTOR.
FT PROPEP 448 473 REMOVED IN MATURE FORM (POTENTIAL).
FT LIPID 447 447 GPI-ANCHOR (POTENTIAL).
FT REPEAT 56 79 LRR 1.
FT REPEAT 80 103 LRR 2.
FT REPEAT 105 128 LRR 3.
FT REPEAT 129 152 LRR 4.
FT REPEAT 153 176 LRR 5.
FT REPEAT 178 200 LRR 6.
FT REPEAT 202 224 LRR 7.
FT REPEAT 225 248 LRR 8.
FT REPEAT 250 273 LRR 9.
FT REPEAT 316 339 LRR 10.
FT CONFLICT 12 13 FT -> LA (IN REF. 2).
FT CONFLICT 43 43 R -> C (IN REF. 2).
FT CONFLICT 53 53 A -> T (IN REF. 2).
FT CONFLICT 284 284 G -> E (IN REF. 2).
FT CONFLICT 287 287 S -> C (IN REF. 2).
FT CONFLICT 303 303 T -> A (IN REF. 2).
FT CONFLICT 355 355 V -> A (IN REF. 2).
SQ SEQUENCE 473 AA; 50858 MW; FF87A6643F3A0A35 CRC64;

Query Match 10.8%; Score 370; DB 1; Length 473;
Best Local Similarity 30.0%; Pred. No. 1.2e-18;
Matches 130; Conservative 52; Mismatches 152; Indels 100; Gaps 18;

QY 19 LPEVYLTAQVWILCAIAAASAGPQNCPSVCSNPFQKVCTR--RLSEVPQGIEN 76
Db 11 LPTWVWLQAWRV-----ATP--CFGACVCVNE--PKVTTSPQOGLQAVPAGIPAS 58
QY 77 TRYLNLMENNIMQIADTPRHLHLHLVQLGRNSIRQIEVGAFNGLSINTLELFDN-WL 135
Db 59 SQRIPLHGKRIISVYTPAASQSCNLTILWLSNALAGIDAAFTGLTLLEQLDLSNAQL 118
QY 136 TVTPSGAPEYLSKILRELWLRNPIESIPSYAFNRVPSLMRLDLGELKKLEISGAFBGL 195
Db 119 RYVDPTTFRGLGLHTL-----HLDRCGLQEL-----GPGIFRGL 153
QY 196 ENLYNLGNCNIKMPNLT--PLVGLLEEMSGNHFPFIRPGSPHGLSSLLKGLWVWNSQ 253
Db 154 AALQYLYLQNNLQALPDNTFDLGNLTHLFLHGNRIPSVPEHAERGLSLDRLLHQN 213
QY 254 VSLIERNAFDGLASIVELMLAHNNLSLPHDLFTPIRYLVHLHLHNPWNCDCDILWLAW 313
Db 214 VARVHPHAFRDLGRMLTLYLFANNLSMLPAEVLVPLRSLOVLRNLNDNFVWCDCRAPLWA 273
QY 314 WLREY-----IPTNSTCCGRCHAPMRGRYLVVDQASFO-----CSAFP----- 354
Db 274 WLQKFRGSSSGVPSN-----LQFAGRLDKELATSDLEGCAVASGPFPPQTQOLT 325
QY 355 ---IMPAPRLN-----ISEGRMAE---LKRTPPMSSVXWLLPNGTVLSHARRH 398
Db 326 DEELLGLPKCCQDAADKASVLEPGRPASVGNALGRVPEPGDT-----PPGN--GSGPRH 378
QY 399 PRISVLND---GTL 409
Db 379 -----INDSPFGIL 387

RESULT 12
RT4R MACFA STANDARD; PRT; 473 AA.
AC Q9N0E3;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Reticulon 4 receptor precursor (Nogo receptor) (Ngr) (Nogo-66

DE receptor (QcCE-10286).
EN RTW4 OR NOGOR.
DS Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).
DC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
DC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
DC Cercopithecinae; Macaca.
DX NCBI_TaxID=9541;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
CA Osada N., Hida M., Kusuda J., Tanuma R., Iseki K., Hirai M., Terao K.,
CA Suzuki Y., Sugano S., Hashimoto K.;
CA "Isolation of full-length cDNA clones from macaque brain cDNA
CA libraries.";
CA Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
CL [2]
LN REVIEW.
LN MEDLINE=2188956; PubMed=11891768;
LN NG C.E.L., Tang B.L.;
LN "Nogog and the Nogo-66 receptor: factors inhibiting CNS neuron
LN regeneration.";
LN J. Neurosci. Res. 67:559-565(2002).
LN -!- FUNCTION: Receptor for RTN4, OMG and MAG. Mediates axonal growth
LN inhibition and may play a role in regulating axonal regeneration
LN and plasticity in the adult central nervous system (By
LN similarity).
LN -!- SUBUNIT: Homodimer (By similarity).
LN -!- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By
LN similarity).
LN -!- SIMILARITY: Contains 9 leucine-rich (LRR) repeats.
LN
LN This SWISS-PROT entry is copyright. It is produced through a collaboration
LN between the Swiss Institute of Bioinformatics and the EMBL outstation -
LN the European Bioinformatics Institute. There are no restrictions on its
LN use by non-profit institutions as long as its content is in no way
LN modified and this statement is not removed. Usage by and for commercial
LN entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
LN or send an email to license@sib-sib.ch).
LN
LN -----
LN EMBL; AB045387; BAB01569.1; -;
LN InterPro; IPR001611; LRR.
LN InterPro; IPR000483; LRR_Cterm.
LN InterPro; IPR000372; LRR_Nterm.
LN InterPro; IPR003591; LRR_type.
LN Pfam; PF00560; LRR; 8.
LN Pfam; PF01463; LRRCT; 1.
LN SMART; SM00369; LRR_TYP; 2.
LN SMART; SM00062; LRRCT; 1.
LN SMART; SM00013; LRRNT; 1.
LN Receptor; Signal; GPI-anchor; Repeat; Leucine-rich repeat.
LN SIGNAL 1 26
LN CHAIN 27 447
LN PROPEP 448 473
LN DOMAIN 435 442
LN LIPID 447 447
LN REPEAT 56 79
LN REPEAT 81 103
LN REPEAT 104 128
LN REPEAT 129 152
LN REPEAT 153 176
LN REPEAT 178 200
LN REPEAT 202 224
LN REPEAT 225 248
LN REPEAT 250 273
LN SEQUENCE 473 AA; 50644 MW; 53290DE83DB12CB3 CRC64;
Query Match 10.7%; Score 368; DB 1; Length 473;
Best Local Similarity 30.3%; Pred. No. 1.7e-18;
Matches 128; Conserved 50; Mismatches 154; Indels 90; Gaps 16;
Y 28 VTLCAIAAASAGQNCPSVCSNQPSKV--CTRRLSEVPQGISNTRYLNLMEN 85
b 16 LWLQAEWAAP-----CFGACVCYNE-PKVTTSPPQGLQAVPAGIPASSQRIFLHGN 67

QY 86 NIQIQDTPFRLHLEVLQGRNSIRQIEVGAFNGLASINTLELDN-WLVTPSCAPE 144
DB 68 RISHVPAAPFRACRNLTILMHSNVLAIRIDAAAPAGLALLEGDLSDNAQLRSVDPATPH 127
QY 145 YLSKLRELMRNPIESIPSYAFNRVPSLMRLDLGELCKLEYISEGAFEGFLNKLKYLNLG 204
DB 128 GLGLRLTL-----HLDRCGLQEL-----GPGLFRCGLAALQVLYLQ 162
QY 205 MCNIKDPENLT--PLVGLSELEMSGHFFPIRPGSEHGLSSLAKLWYMNISOVSLIERNAF 262
DB 163 DNAQLALPDDTFRDLGNLTHLFLHGNRISSVPERAFRGLHSLDRLLHQRVAVHPAHF 222
QY 263 DGLASLVELNLAHNLSLPHDLFTPLRYLYVLEHLHHPNPNWCDCDILMLAWLREYIPTN 322
DB 223 RDLGRIMTLVLEFRNLSALPAALALQYLRLNDNPVWCDRCARPLWANLQKFRGSS 282
QY 323 STCCGRCHAPNHEGRVLYVEVDQASFO-----CSAPFI 355
DB 283 SEV--PCSLPQLRAGRLKRLAANDLQGCVAATGCPCHPIWTGRATDELLGLPKCCQP-- 338
QY 356 MDAPRDLNISE-GRMAE---LKRTPPMSSVKWLLPNGTVLSHGRHPRISVLND---G 407
DB 339 -DAADKASVLEPGEPASAGNALKGRVPCDS-----PPGN--CSGPRH-----INDSPFG 385
QY 408 TE 409
DB 386 TL 387
RESULT 13
CHAD_HUMAN
ID CHAD_HUMAN STANDARD; PRT; 359 AA.
AC O15335; Q96R05;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Chondroadherin precursor (Cartilage leucine-rich protein).
GN CHAD.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98008928; PubMed=9344663;
RA Grover J., Chen X.-N., Korenberg J.R., Roughley P.J.;
RT "The structure and chromosome location of the human chondroadherin
RT gene (CHAD).";
RL Genomics 45:379-385(1997).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=21413936; PubMed=11445564;
RA Maansson B., Wengelin C., Moergelin M., Saxne T., Heinegaard D.;
RT "Association of chondroadherin with collagen type II.";
RL J. Biol. Chem. 276:32883-32888(2001).
CC -!- FUNCTION: Promotes attachment of chondrocytes, fibroblasts, and
CC osteoblasts. This binding is mediated (at least for chondrocytes
CC and fibroblasts) by the integrin alpha(2)beta(1). May play an
CC important role in the regulation of chondrocyte growth and
CC proliferation (By similarity).
CC -!- SUBUNIT: Mostly monomeric (By similarity). Interacts with collagen
CC type II.
CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
CC similarity).
CC -!- TISSUE SPECIFICITY: Present in chondrocytes at all ages.
CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
CC (SLRP) FAMILY. CLASS IV SUBFAMILY.
CC -!- SIMILARITY: Contains 11 leucine-rich (LRR) repeats.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its

use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

CC	EMBL; U96769; AAC13410.1; --	CC	DB	305	TCQLGRLRWLEAKASRRDPATCA---SPAKFKGQHIRDTD-AFRSCKFP 349
CC	EMBL; U96767; AAC13410.1; JOINED.	CC	RT4R HUMAN	RESULT 14	
CC	EMBL; U96768; AAC13410.1; JOINED.	CC	AC Q92R6;	STANDARD;	PRT; 473 AA.
CC	EMBL; AF371328; AAKS1556.1; --	CC	DT 28-FEB-2003 (Rel. 41, Created)		
CC	Genew; HGNC:1909; CHAD.	CC	DT 15-SEP-2003 (Rel. 42, Last annotation update)		
CC	MIM: 602178; --	CC	DE Reticulon 4 receptor precursor (Nogo receptor) (Ngr) (Nogo-66 receptor)		
CC	GO; GO:0005578; C:extracellular matrix; TAS.	CC	GN RTN4R OR NOGOR.		
CC	GO; GO:0005201; F:extracellular matrix structural constituent; NAS.	CC	OS Homo sapiens (Human).		
CC	GO; GO:0001558; P:regulation of cell growth; NAS.	CC	OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
CC	InterPro; IPR001611; LRR.	CC	OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
CC	InterPro; IPR000483; LRR Cterm.	CC	OX NCBI_TaxID=9606;		
CC	InterPro; IPR00372; LRR Nterm.	CC	RN [1]	SEQUENCE FROM N.A.	
CC	Pfam; PF00560; LRR; 10.	CC	RP	SEQUENCE FROM N.A.	
CC	Pfam; PF01463; LRRCT; 1.	CC	RC TISSUE=Brain;		
CC	Pfam; PF01462; LRRNT; 1.	CC	RK MEDLINE=21069055; PubMed=11201742;		
CC	SMART; SM00369; LRR_TVP; 4.	CC	RA Fournier A.E., GrandPre T., Strittmatter S.M.;		
CC	SMART; SM00082; LRRCT; 1.	CC	RT "Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration."		
CC	SMART; SM00013; LRRNT; 1.	CC	RL Nature 409:341-346(2001).		
KW	Signal, Leucine-rich repeat; Repeat; Glycoprotein;	CC	RN [2]	SEQUENCE FROM N.A.	
FT	Extracellular matrix	CC	RP	SEQUENCE FROM N.A.	
FT	SIGNAL	CC	RC TISSUE=Brain;		
FT	CHAIN	CC	RA Blum H., Bauersachs S., Mewes H.-W., Weil B., Wiemann S.;		
FT	REPEAT	CC	RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.		
FT	REPEAT	CC	RN [3]	SEQUENCE FROM N.A.	
FT	REPEAT	CC	RP	SEQUENCE FROM N.A.	
FT	REPEAT	CC	RA Dunham I., Hunt A.R., Collins J.E., Bruskewich R., Beare D.M.,		
FT	REPEAT	CC	RA Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,		
FT	REPEAT	CC	RA Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,		
FT	REPEAT	CC	RA Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,		
FT	REPEAT	CC	RA Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,		
FT	REPEAT	CC	RA Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,		
FT	REPEAT	CC	RA Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,		
FT	REPEAT	CC	RA Dami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,		
FT	REPEAT	CC	RA Evans K.B., Fey J.M., Fleming K., French L., Garner A.A.,		
FT	REPEAT	CC	RA Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,		
FT	REPEAT	CC	RA Hall R.E., Hall-Tamlyn G., Heathcote R.W., Ho S., Holmes S.,		
FT	REPEAT	CC	RA Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,		
FT	REPEAT	CC	RA Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,		
FT	REPEAT	CC	RA Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,		
FT	REPEAT	CC	RA Mcclay J., McLaren S., McMurray A.A., Milne S.A., Mortimore B.J.,		
FT	REPEAT	CC	RA Odeil C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,		
FT	REPEAT	CC	RA Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,		
FT	REPEAT	CC	RA Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,		
FT	REPEAT	CC	RA Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,		
FT	REPEAT	CC	RA Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.I.,		
FT	REPEAT	CC	RA Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,		
FT	REPEAT	CC	RA Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,		
FT	REPEAT	CC	RA Minoshima A., Sasaki K., Sasaki T., Asakawa S., Kudoh J.,		
FT	REPEAT	CC	RA Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,		
FT	REPEAT	CC	RA Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,		
FT	REPEAT	CC	RA Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,		
FT	REPEAT	CC	RA Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,		
FT	REPEAT	CC	RA Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,		
FT	REPEAT	CC	RA Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,		
FT	REPEAT	CC	RA Zhan M., Zhang G., Chaisoe S., Murray J., Miller N., Minx P.,		
FT	REPEAT	CC	RA Fulton R., Johnson D., Bems G., Bentley D., Bradshaw H., Bourne S.,		
FT	REPEAT	CC	RA Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,		
FT	REPEAT	CC	RA Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,		
FT	REPEAT	CC	RA Scheet P., Walker C., Wamsley A., Wohlmann P., Pepin K., Nelson J.,		
FT	REPEAT	CC	RA Korf I., Bedell J.A., Hillier L., Mardis E., Waterston R., Wilson R.,		
FT	REPEAT	CC	RA Emanuel B.S., Shaikh T., Kurahashi H., Saitta S., Budarf M.L.,		
FT	REPEAT	CC	RA Mcdermid H.E., Johnson A., Wong A.C.C., Morrow B.E., Edelman L.,		
FT	REPEAT	CC	RA Kim U.J., Shizuya H., Simon M.I., Dumanaki J.P., Feyrad M., Kedra D.,		
FT	REPEAT	CC	RA Seroussi E., Fransson I., Tapia I., Bruder C.E., O'Brien K.P.,		
FT	REPEAT	CC	RA Wilkinson P., Bodenteich A., Hartman K., Hu X., Khan A.S., Lane L.,		

RESULT 15
FLR2_HUMAN STANDARD; PRT; 660 AA.
AC O43155;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Leucine-rich repeat transmembrane protein FLRT2 precursor
DE (Fibronectin-like domain-containing leucine-rich transmembrane protein
DE 2).
DE FLRT2 OR KIAA0405.
GN FLRT2
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A., TISSUE SPECIFICITY, AND GYCLOSYLATION.
RP MEDLINE=20112755; PubMed=1064439;
RA Lacy S.E., Bonnemant C.G., Buzney E.A., Kunkel L.M.;
RT "Identification of FLRT1, FLRT2, and FLRT3: a novel family of
FL transmembrane leucine-rich repeat proteins.";
RL Genomics 62:417-426(1999).
RN [2]
SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=98116655; PubMed=945477;
RA Ishikawa K.-I., Nagase T., Nakajima D., Seki N., Ohira M.,
RA Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes. VIII.
RT 78 new cDNA clones from brain which code for large proteins in
RT vitro.";
RL DNA Res. 4:307-313(1997).
CC -!- FUNCTION: May have a function in cell adhesion and/or receptor
CC signaling.
CC -!- SUBCELLULAR LOCATION: Type I membrane protein (Probable).
CC -!- TISSUE SPECIFICITY: Expressed in pancreas, skeletal muscle, brain,
CC and heart.
CC -!- PM: N-glycosylated.
CC -!- SIMILARITY: Contains 1 fibronectin type III domain.
CC -!- SIMILARITY: Contains 10 leucine-rich (LRR) repeats.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL: AF169676; AAF28460.1; -;
CC EMBL: AB007865; BA223701.1; -;
CC Genew; HGNC:3761; FLRT2.
CC MIM: 604807; -;
CC DR GO: 0005887; C: integral to plasma membrane; NAS.
CC DR GO: 0003022; F: adhesive extracellular matrix constituent a. . .; NAS.
CC DR GO: 0005057; F: receptor signaling protein activity; NAS.
CC DR InterPro: IPR003961; FN III.
CC DR InterPro: IPR01611; LRR.
CC DR InterPro: IPR000483; LRR_Cterm.
CC DR InterPro: IPR000372; LRR_Nterm.
CC DR InterPro: IPR003591; LRR_typ.
CC DR Pfam: PF00041; fn3; 1.
CC DR Pfam: PF00560; LRR; 8.
CC DR Pfam: PF01463; LRRCT; 1.
CC DR Pfam: PF01482; LRRNT; 1.
CC DR SMART: SM00060; FN3; 1.
CC DR SMART: SM00069; LRR_TF; 1.
CC DR SMART: SM00082; LRRCT; 1.
CC DR SMART: SM00013; LRRNT; 1.
CC DR Cell adhesion; Repeat; Signal; Transmembrane; Leucine-rich repeat;
CC Glycoprotein.

FT SIGNAL 1 35
FT CHAIN 36 660
FT
FT POTENTIAL.
FT LEUCINE-RICH REPEAT TRANSMEMBRANE PROTEIN
FT FLRT2.
FT EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 542 562
FT DOMAIN 563 660
FT DOMAIN 62 87
FT REPEAT 88 108
FT REPEAT 109 131
FT REPEAT 132 157
FT REPEAT 159 181
FT REPEAT 183 202
FT REPEAT 203 228
FT REPEAT 229 251
FT REPEAT 252 274
FT REPEAT 275 298
FT DOMAIN 420 502
FT CARBOHYD 202 202
FT CARBOHYD 298 298
FT CARBOHYD 433 433
FT CARBOHYD 521 521
FT CARBOHYD 660 AA; 74048 MW; 9815F283B0D5F78 CRC64;
SQ SEQUENCE
Query Match 10.4%; Score 356.5; DB 1; Length 660;
Best Local Similarity 30.1%; Pred. No. 1.7e-17;
Matches 111; Conservative 38; Mismatches 135; Indels 85; Gaps 10;
Qy 46 CPSCVCSKQFQKVVCTRRGLSEVPGI----- 73
Db 36 CPSCVCRDRNF--VYCNERLSVPLGIPGVTVLYLHNNQNNAGFPABLHNVSHTV 93
Qy 74 -----PNTRYLMNENNIQMIQADTFRLHHLHLVQLGNSIRQ--IEVG 117
Db 94 YLYGNQLDFPPNLPKNVAVLHQQNIQTFISRAALQALLKLEHLDDNSTVGVVDG 153
Qy 118 AFNGLASLTLELFDNWLTVISGAPYLSKRLWLNPNPIESPSYAFNVPVSLRLD 177
Db 154 AFPEAISLKLFLSKNHLSPVVG--LPVDLQSLRVVDENRAVISCDAFQNTSLRLI 210
Qy 178 L-GLKXLEYISGAFGLFNKLYLMGMCNKIDMPNLTPLVGLLEELMSGHFFPEIRPG 236
Db 211 VDNGLLTNKGIAAGTFSHLTKLKEFSI-----VRNLSRPPDPLPG 251
Qy 237 SFHGLSLKLLWNSQVSLIERNAPDGLASIVELNLAHNNLSSLPDLFTPLRVIVELH 296
Db 252 -----THLIRLYQDNQIINHILPTAFSNLRKLERLDISNNQLRMUTQGVDFNLSLKQLT 306
Qy 297 LHENPNWCCDILWLAWLREVIPTNSTCCG-RCHAPMHRGRYLVVDQASFQC----- 350
Db 307 ARNPWFCCSINKVTENLK-YIPSSLVNVRGFWCQCPQEVGRGVAYRELNMNLLSPTTTP 365
Qy 351 SAPPIMDAP 359
Db 366 GLPLFTTAP 374

RESULT 16
LGR4_RAT STANDARD; PRT; 951 AA.
ID LGR4_RAT
AC Q922H4;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Leucine-rich repeat-containing G protein-coupled receptor 4 precursor.
GN GPR48 OR LGR4.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
EN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Ovary;
RX MEDLINE=99065210; PubMed=98499958;

the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

```
EMBL; Z69594; CAA93440.1; -
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR Cterm.
DR InterPro; IPR000372; LRR Nterm.
DR InterPro; IPR003591; LRR typ.
DR Pfam; PF00560; LRR; 13.
DR Pfam; PF01463; LRRCT; 1.
DR PRINTS; PRO0019; LEURICHRPT.
DR SMART; SM00369; LRR_TYP; 10.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
KW Platelet; Transmembrane; Glycoprotein; Blood coagulation;
Repeat; Leucine-rich repeat; Cell adhesion; Signal.
FT SIGNAL 1 16
FT CHAIN 17 567
FT DOMAIN 17 522
FT TRANSMEM 523 543
FT DOMAIN 544 567
FT REPEAT 73 96
FT REPEAT 97 120
FT REPEAT 122 144
FT REPEAT 145 168
FT REPEAT 169 192
FT REPEAT 194 216
FT REPEAT 217 240
FT REPEAT 241 264
FT REPEAT 266 288
FT REPEAT 289 312
FT REPEAT 314 337
FT REPEAT 338 361
FT REPEAT 362 385
FT REPEAT 387 409
FT CARBOHYD 51 51
FT CARBOHYD 181 181
FT CARBOHYD 243 243
FT CARBOHYD 298 298
FT CARBOHYD 312 312
FT CARBOHYD 385 385
FT CARBOHYD 498 498
SQ SEQUENCE 567 AA; 63344 MW; CA10708E0D03707F CRC64;

Query Match
Best Local Similarity 9.8%; Score 337; DB 1; Length 567;
Matches 121; Conservative 56; Mismatches 167; Indels 166; Gaps 14;

30 ILCAIAAASAGPQNCPSVCSCNQSKVCTRGSLSEVQ-GIPNTRYLNWENNIQ 88
5 VLLSAVLSVGAQPPECPKTKCVVR-DAVQCSGSAHIAELGLPTNLTHILLFRMDRG 63
89 MQADTFRLHLEVLQGRNRIQIEVGAENGLASANTLELPNLTVP- 139
64 VLQSHFSFGVTLQRLMSDSHISAIDPQTFNDLVKLTLELNKISHLPAILDKRWVL 123
140 -----SGAFEYLSKLELRLNRPNIPESYAFNRPVPSIMLDELG----- 179
124 LEQFLDHNAALDQNLQFQKLLNRLDCLNQNLQSLFPAFLFSSLGKLVLDLRRNLT 183
180 -----ELKKLEYISEGAFEGFLN 197
184 HLPQGLGAGIKLEKLLYSNRLMSLDGLLANLALGALTLELRLNHLRSLAPGAFDSIGN 243
198 LKYLNGMGNKIDMP-----NLT-----PLVGLBELEMSGNH-- 229
244 LSTLTLSGNLLSLPPLAFHVSWLTTRTLFENPUELPEVLFGEMAGRLWLNGTHLR 303
230 -----PFPIRPGSPHGUSLKKLWVMS----- 252
```

RESULT 18

LGR4_HUMAN

ID LGR4_HUMAN STANDARD; PRT; 951 AA.

Q9BXB1; Q9NYDI; AC

28-FEB-2003 (Rel. 41, Created)

DT 28-FEB-2003 (Rel. 41, Last sequence update)

DE 28-FEB-2003 (Rel. 41, Last annotation update)

DE Leucine-rich repeat-containing G protein-coupled receptor 4 precursor

DE (G protein-coupled receptor 4b).

GN GPR48 OR LGR4.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=Pancreas;

RX MEDLINE=21294803; PubMed=11401528;

RA Loh B.D., Broussard S.R., Kolakowski L.F. Jr.;

RT "Molecular characterization of a novel glycoprotein hormone

RT G-protein-coupled receptor.";

RL Biochem. Biophys. Res. Commun. 282:757-764(2001).

CC -! FUNCTION: Orphan receptor.

CC -! SUBCELLULAR LOCATION: Integral membrane protein.

CC -! TISSUE SPECIFICITY: Expressed in multiple steroidogenic tissues:

CC placenta, ovary, testis and adrenal. Expressed also in spinal

CC cord, thyroid, stomach, trachea, heart, pancreas, kidney, prostate

CC and spleen.

CC -! SIMILARITY: BELONGS TO FAMILY 1 OF G-PROTEIN COUPLED RECEPTORS.

CC -! SIMILARITY: Contains 15 leucine-rich (LRR) repeats.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

CC or send an email to license@isb-sib.ch).

CC EMBL; AF346711; AAK31153.1; -

CC EMBL; AF346709; AAK31153.1; JOINED.

CC EMBL; AF346710; AAK31153.1; JOINED.

CC EMBL; AF257182; AAF68989.1; -

CC Genew; HGNC:13299; GPR48.

CC MIM; 606666; -

CC InterPro; IPR000276; GPCR_Rhodpsn.

CC InterPro; IPR001611; LRR.

CC InterPro; IPR000372; LRR Nterm.

CC InterPro; IPR003591; LRR typ.

CC Pfam; PF00001; 7tm 1; 1.

CC Pfam; PF00560; LRR; 15.

CC PRINTS; PRO0237; GPCR_Rhodopsn.

CC PRINTS; PRO0019; LEURICHRPT.

CC SMART; SM00369; LRR_TYP; 4.

CC SMART; SM00013; LRRNT; 1.

CC PROSITE; PS00237; G-PROTEIN RECEPTOR FL1; FALSE_NEG.

CC PROSITE; PS00262; G-PROTEIN RECEPTOR FL2; 1.

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC


```

FT CARBOHYD 96 96 N-LINKED (GLCNAC. . .) (POTENTIAL) .
FT CARBOHYD 368 368 N-LINKED (GLCNAC. . .) (POTENTIAL) .
FT CARBOHYD 515 515 N-LINKED (GLCNAC. . .) (POTENTIAL) .
FT CARBOHYD 578 578 N-LINKED (GLCNAC. . .) (POTENTIAL) .
FT CARBOHYD 586 586 N-LINKED (GLCNAC. . .) (POTENTIAL) .
FT CONFLICT 71 71 G -> S (IN REF. 2) .
SQ SEQUENCE 603 AA; 66959 MW; 4A6223ABC7026BCC CRC64;

Query Match 9.3%; Score 321; DB 1; Length 603;
Best Local Similarity 24.5%; Pred. No. 4.7e-15;
Matches 131; Conservative 69; Mismatches 162; Indels 172; Gaps 16;

QY 36 AAASAGPQPCSPVCSGCS-----NQPSKVCTCRGLSEVPQGISNTR----- 78
DQ 32 ASADAEPQ-CPVTCSCSYDDYDELS-VFCSSRNLTQLPDGPVSTRAWLGNLSSI 89
QY 79 -----YLMENNIOQTQADFRHLHLE 102
DQ 90 PSAAFQNESSLDLFINQGSWLRSLPEQALGLQNLVHLHLERNLRLSLAAGLFRHTPSLA 149
QY 103 VLQGRNSIRQIEVGAFNGLASLNTLELFDNMLTVIPSGAF----- 144
DQ 150 SLSLGNLGLRLBEGFLRGSLHLDNLGNLSLVLPDVFQGLGNLHVLGNKLYVL 209
QY 145 -----VLSKRLRLWLNPNPIPSVAFNRVPSLWRLDGE-----LKKLE 185
DQ 210 QPALLCGELBELDLSRNALRSVXANVFTLPRQLYLDENLITAVAPRAFLGKALR 269
QY 186 VIS-----EGAFEGFLNLYLNLGMCNTKDMENLT--PLVGLRELESGNHFPPI 233
DQ 270 WLDLSHNRVAGLLEDFPGLLGHVLRALNAITSRPTFDKLFHLESLQCHNRIRQL 329
QY 234 RPSGFLGSLKLLWVNSQVSLIERNAFDGLASVELNALNNLSLPHDLFTPLRYLV 293
DQ 330 GEKTFEGLGQLEVLTLNDNQIEHKVGAFFLNFVAVNLGNSLPSLPEHFVQGLGRH 389
QY 294 ELHLHNPWNCDDILWALWLEVIPTNSTCGRCHAPWH-----MEGRYLVEDQA 346
DQ 390 SLHLH-----SCGRIR--LHTFAGLSGRUFL----- 417
QY 347 SFQCSAPFIMDAPDLNLIS---EGRVAELKCRTPPMSVKKLLPNTGVLSHARHPRISV 403
DQ 418 -----RDNSSISIESQSLAGL-----SELLELDLTANQLTHLPRQ----- 452
QY 404 LNDGTLNFSHLVSDGTGVTCMTWNVAGNSASAYLNVSTALNTSNISFFTTV 457
DQ 453 LFQGLGQLEYLLSNQL-TMLSEVDVLGFLQAPWLDLSHNRLETPAEGLFSSL 505

RESULT 22
NYX_HUMAN
ID - NYX_HUMAN STANDARD; PRT; 481 AA.
AC Q9GZUS; Q9H4J0;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Nctalopin precursor.
GN NYX OR CLRP.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Butheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A. TISSUE SPECIFICITY, AND VARIANTS XLCNSB SER-31;
RP I15-101 DEL; I14-GLU-ALA-118 DEL; PRO-143; ARG-175; LYS-187;
RP 207-LEU-LEU-ARG INS; 243-ALA--PRO-246 DEL; PRO-307; SER-312; PRO-347
RP AND VAL-370.
RX MEDLINE=20517341; PubMed=11062472;
RA Pusch C.M., Zeitz C., Brandau O., Pesch K., Achatz H., Feil S.,
RA Scharfe C., Maurer J., Jacobi F.K., Pinckens A., Andreasson S.,
RA Hardcastle A., Wisinger B., Berger W., Weindl A.,
RP "The complete form of X-linked congenital stationary night blindness
RP is caused by mutations in a gene encoding a leucine-rich repeat

```

```

RT protein.";
RL Nat. Genet. 26:324-327(2000).
RN [2]
RP SEQUENCE FROM N.A. TISSUE SPECIFICITY, AND VARIANTS XLCNSB
RP 29-ARG--ALA-36 DEL; LEU-151; 155-SER-VAL-PRO-GLU-ARG-LEU-LEU INS;
RP 184; 207-LEU-LEU-ARG INS; 209-CYS-LEU-ARG INS; GLN-213; SER-216;
RP 232; LYS-264; PRO-285 AND SER-298.
RX MEDLINE=20517340; PubMed=11062471;
RA Bech-Hansen N.T., Naylor M.J., Maybaum T.A., Sparkes R.L., Koop B.,
RA Birch D.G., Bergen A.A.B., Prinsen C.F.M., Polomeno R.C., Gal A.,
RA Dieck A.V., Musarella M.A., Jacobson S.G., Young R.S.L., Weleber R.G.;
RT "Mutations in NYX, encoding the leucine-rich proteoglycan nctalopin,
RT cause X-linked complete congenital stationary night blindness.";
RL Nat. Genet. 26:319-323(2000).
RN [3]
RP SEQUENCE FROM N.A.
RA Pavitt R.;
RL Submitted (OCT-2000) to the EMBL/GenBank/DBJ databases.
CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
CC similarity).
CC -!- TISSUE SPECIFICITY: Expressed in kidney and retina. Also at low
CC levels in brain, testis and muscle. Within the retina, expressed
CC in the inner segment of photoreceptors, outer and inner nuclear
CC layers and the ganglion cell layer.
CC -!- DISEASE: Defects in NYX are the cause of X-linked congenital
CC stationary night blindness (XLCNSB or CSNB1), rare inherited
CC retinal disorder characterized by impaired scotopic vision,
CC myopia, hyperopia, nystagmus and reduced visual acuity. XLCNSB is
CC identified on the basis of electroretinogram responses by the
CC absence of the rod b-wave but largely normal cone amplitudes.
CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
CC (SLRP) FAMILY. CLASS IV SUBFAMILY.
CC -!- SIMILARITY: Contains 11 leucine-rich (LRR) repeats.
CC -!- CAUTION: Ref.3 sequence differs from that shown due to erroneous
CC gene model prediction.
CC -!- DATABASE: NAMB-Mutations of the NYX gene;
CC NOTE=Retina International's Scientific Newsletter;
CC WWW= http://www.retina-international.com/sci-news/nyxmut.htm".

This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).

EMBL; AJ278865; CAC19014.1; -
EMBL; AF254868; AAC42685.1; -
EMBL; Z93015; CAC15115.1; ALT_SEQ.
Genew; HGNC:8082; NYX.
MIM; 300278; -
MIM; 310500; -
GO; GO:0005622; C:intracellular; IEP.
InterPro; IPR001611; LRR.
InterPro; IPR000483; LRR_Cterm.
InterPro; IPR000372; LRR_Nterm.
InterPro; IPR003591; LRR_Typ.
Pfam; PF00560; LRR; 7.
Pfam; PF01483; LRRCT; 1.
Pfam; PF01482; LRRNT; 1.
SMART; SM00369; LRR_Typ; 3.
SMART; SM00082; LRRCT; 1.
SMART; SM00013; LRRNT; 1.
Glycoprotein; Extracellular matrix; Proteoglycan; Signal; Repeat;
Leucine-rich repeat; Disease mutation; Vision.
FT SIGNAL 1 23
FT CHAIN 24 481 NYCTALOPIN.
FT DOMAIN 27 48 CYS-RICH.
FT REPEAT 60 84 LRR 1.
FT REPEAT 85 108 LRR 2.
FT REPEAT 110 133 LRR 3.
FT REPEAT 134 157 LRR 4.

```

```

FT REPEAT 159 180 LRR 5.
FT REPEAT 161 204 LRR 6.
FT REPEAT 205 228 LRR 7.
FT REPEAT 229 252 LRR 8.
FT REPEAT 254 276 LRR 9.
FT REPEAT 277 300 LRR 10.
FT REPEAT 316 338 LRR 11.
FT CARBOHYD 97 97 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 183 183 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 300 300 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 393 393 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 432 432 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 439 439 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT VARIANT 29 36 MISSING (IN CSNB1).
FT VARIANT 31 31 /FTid=VAR_014084.
FT VARIANT 31 31 C -> S (IN XLCNSB).
FT VARIANT 101 101 /FTid=VAR_013867.
FT VARIANT 114 118 MISSING (IN CSNB1).
FT VARIANT 143 143 /FTid=VAR_014086.
FT VARIANT 151 151 /FTid=VAR_013868.
FT VARIANT 155 155 /FTid=VAR_013869.
FT VARIANT 175 175 /FTid=VAR_014087.
FT VARIANT 184 184 /FTid=VAR_013870.
FT VARIANT 187 187 /FTid=VAR_013871.
FT VARIANT 207 207 /FTid=VAR_013872.
FT VARIANT 209 209 /FTid=VAR_014088.
FT VARIANT 213 213 /FTid=VAR_014089.
FT VARIANT 216 216 L -> Q (IN XLCNSB).
FT VARIANT 232 232 /FTid=VAR_013874.
FT VARIANT 243 246 MISSING (IN CSNB1).
FT VARIANT 264 264 /FTid=VAR_014090.
FT VARIANT 285 285 /FTid=VAR_013876.
FT VARIANT 298 298 /FTid=VAR_013877.
FT VARIANT 307 307 /FTid=VAR_013878.
FT VARIANT 312 312 /FTid=VAR_013879.
FT VARIANT 347 347 /FTid=VAR_013880.
FT VARIANT 370 370 /FTid=VAR_013881.
FT SEQUENCE 481 AA; 51999 MW; 77855134DC564515 CRC64;

Query Match
Best Local Similarity 9.38; Score 320; DB 1; Length 481;
Matches 125; Conservativity 25.88; Pred. No. 4.1e-15;
Indels 124; Gaps 18;

34 AIAAAAGPNCPSVCS-NOFSKVCTRGLEVPQIPSNTRYLNLMENNITQ 91
23 AVGACARA----CPAACACSVTCGSCVRCRAGLLRVPAELPCEAVSVDLDRGLRFLG 78
92 ADTRHLHLHLVQLGRNSIRQIEVGAFNGLASINTLELPDNW-LTVIPSGAFVYLSKLR 150
79 ERAFGTLPISLRRLRNHNNSFTTPGAFKGLPLAELRLAHNGDLRYLHARTFAALSLR 138

```

```

QY 151 ELWLRRNPISIP-----SVAFNRVPSLMR-----LDLGLKKLE 185
DB 139 RLDLAACRLFSVPBELLAELPALRELAFAFNLFRVPCALRGLANLTHAHLERG---RIE 195
QY 186 YISCAFEGLNLYKLYNI-----GMGNI-----KDMF--NLTPVIG 219
DB 196 AVASSIQLGLRELRLSLSLQANRVRAVHAGAGDCGVLEHLLNDNLLAELPADAFGLRR 255
QY 220 LEELEMSGNHPEPTEPGSHGLSSKLWVNSOVSLIERNAPDGLASLVELNLAHNLS 279
DB 256 LATMLGNAIDVARAWAFADLALELYLDNLSIAFVEGAFQNLGLLALHNGNRLT 315
QY 280 SLPHDLFTPLRYLVELHHRHWPNCDCDILWLANLREYIPTNSTCCGR-----CHAPMH 334
DB 316 VLAWAFQPGFGLGELFLFRPWCCDNLRLRWMEG-----SGRVTDVPCASFGS 367
QY 335 MGRYLVVDQASQCSAPPFMDAPRLNI---SEGRMAELKCRTPPMSSVKWLLPNGTV 391
DB 368 VAG---LDLSQVTFGRSSDGLCVDPBELNLTTSPGPSPE-----PAATT 409
QY 392 LSHASR-----HRIISV-----LNDGTLNFHVLLSDTGV-----YTCM 425
DB 410 VSRFESSLSKLLAPRVVVEAANTTGGLANASLSDS---LSSRGVGGAGRPWFLLASCL 466
QY 426 VTNVA 430
DB 467 LPSVA 471

RESULT 23
ALS_PAPHA STANDARD; PRT; 605 AA.
AC 002833;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Insulin-like growth factor binding protein complex acid labile chain
DE precursor (ALS).
GN IGFALS OR ALS.
OC Papio hamadryas (Hamadryas baboon).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopitheidae;
OC Cercopitheidae; Papio.
OX NCBI_TaxID=9557;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Liver;
RX MEDLINE=97040714; PubMed=8886027;
RA Delhanty P., Baxter R.C.;
RT "The cloning and expression of the baboon acid-labile subunit of the
RT insulin-like growth factor binding protein complex.";
RL Biochem. Biophys. Res. Commun. 227:897-902(1996).
CC -!- FUNCTION: INVOLVED IN PROTEIN-PROTEIN INTERACTIONS THAT RESULT
CC IN PROTEIN COMPLEXES, RECEPTOR-LIGAND BINDING OR CELL ADHESION.
CC -!- SUBUNIT: FORMS A TERNARY COMPLEX OF ABOUT 140 TO 150 kDa WITH
CC IGF-I OR IGF-II AND IGFBP-3 (BY SIMILARITY).
CC -!- SUBCELLULAR LOCATION: Extracellular.
CC -!- SIMILARITY: Contains 20 leucine-rich (LRR) repeats.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DB EMBL; S83462; AAN86722.1; --
DB InterPro; IPR001611; LRR.
DB InterPro; IPR000483; LRR_Cterm.
DB InterPro; IPR000372; LRR_Nterm.
DB InterPro; IPR003591; LRR_typ.
DB Pfam; PF00560; LRR; 19.

```

```

DR Pfam; PF01463; LRRT; 1.
DR Pfam; PF01462; LRRT; 1.
DR PRINTS; PR00019; LEUCICHRPT.
DR SMART; SM00369; LRR_TYP; 11.
DR SMART; SM00082; LRRT; 1.
DR SMART; SM00013; LRRT; 1.
DR SMART; SM00013; LRRT; 1.
KW Cell adhesion; Repeat; Signal; Leucine-rich repeat; Glycoprotein.
FT SIGNAL 1 27
FT CHAIN 28 605
FT REPEAT 53 73
FT REPEAT 74 96
FT REPEAT 98 120
FT REPEAT 121 144
FT REPEAT 146 168
FT REPEAT 169 192
FT REPEAT 194 216
FT REPEAT 217 240
FT REPEAT 242 264
FT REPEAT 265 288
FT REPEAT 289 312
FT REPEAT 313 336
FT REPEAT 338 360
FT REPEAT 361 384
FT REPEAT 386 408
FT REPEAT 409 432
FT REPEAT 433 456
FT REPEAT 458 480
FT REPEAT 482 504
FT REPEAT 505 530
FT CARBOHYD 64 64
FT CARBOHYD 85 85
FT CARBOHYD 96 96
FT CARBOHYD 368 368
FT CARBOHYD 515 515
FT CARBOHYD 580 580
SQ SEQUENCE 605 AA; 66110 MW; 9D71994625F23652 CRC64;

Query Match 9.2%; Score 315; DB 1; Length 605;
Best Local Similarity 32.4%; Pred. No. 1.3e-14;
Matches 94; Conservative 44; Mismatches 118; Indels 34; Gaps 7;

QY 42 GPONCPSCVSCS-----NPFKSVKVTTRGLSVPOGIESVNTYRLNLMNNIOMIQADTFR 96
DB 38 GPA-CPATACSYDDDEVNELS-VFCSSRLTLDPGIFGGTQALWLDSDNNLSPPAPRA 95
QY 97 HLHLEVL-----QLG-----RNSRIQIEVGAFFNGLASLNTLELFD 132
DB 96 NLSSLAFLNLOGGGLSLEPQALLGLENLCHLHLERNQLRLSLAVGTFTAYTPALALLGLSN 155
QY 133 NMLTVTPSGAFYLSKRLRLNRLNPIESIPSYAFNRVPSLMRLDGLKLEVISGAP 192
DB 156 NLRSLRLEDGLFGLGNLWDLNGLNSLAVLPDPAAPRGLGLRELVLG-NELAVLQPALF 214
QY 193 EGLFNLYNLGNCKIKOMEN--LTPVLGLELEMSGNHFPPIRPGSFHGLSSLKLLWYM 250
DB 215 SGLAEIRLEDLSRNALRAIKANVPAQLPRQLKYLDRNLIAAVAPGFLGLKALRWLDLS 274
QY 251 NQSVLSIERNADGLASVELLHNNLSLPHDLFTPLRLVLELHNN 300
DB 275 HNRVAGLEEDTPGLLGLRLVRLSHNATSLRPTFEDLHFLLELQUGHN 324

RESULT 24
ALS_RAT
ID -ALS_RAT
AC P35859;
DT 01-JUN-1994 (Rel. 29, Created)
DT 01-JUN-1994 (Rel. 29, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Insulin-like growth factor binding protein complex acid labile chain
DE precursor (ALS).
CN IGPALS OR ALS.

```

OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=101116;
 RN [1]
 RP SEQUENCE FROM M.A.
 RC TISSUE=Liver;
 RX MEDLINE=93038676; PubMed=1384485;
 RA Dai J., Baxter R.C.;
 RT "Molecular cloning of the acid-labile subunit of the rat insulin-like
 growth factor binding protein complex.";
 RL Biochem. Biophys. Res. Commun. 188:304-309(1992).
 [2]
 RN [2]
 RP SEQUENCE OF 24-44, AND CHARACTERIZATION.
 RC STRAIN=Wistar; TISSUE=Serum;
 RX MEDLINE=94130835; PubMed=7507839;
 RA Baxter R.C., Dai J.;
 RT "Purification and characterization of the acid-labile subunit of rat
 serum insulin-like growth factor binding protein complex.";
 RL Endocrinology 134:848-852(1994).
 CC -1- FUNCTION: MAY HAVE AN IMPORTANT ROLE IN REGULATING THE ACCESS OF
 CIRCULATING IGFs TO THE TISSUES.
 CC -1- SUBUNIT: FORMS A TERNARY COMPLEX OF ABOUT 140 TO 150 kDa WITH
 IGF-1 OR IGF-II AND IGFEP-3.
 CC -1- SUBCELLULAR LOCATION: Extracellular.
 CC -1- TISSUE SPECIFICITY: BRAIN, KIDNEY, LUNG, HEART, SPLEEN, MUSCLE
 AND LIVER.
 CC -1- SIMILARITY: Contains 21 leucine-rich (LRR) repeats.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See http://www.isb-sib.ch/announce/
 or send an email to license@isb-sib.ch).
 CC
 CC EMBL; S46785; AAB23770.2; -
 DR PIR; JCI282; JCI282.
 DR InterPro; IPR001611; LRR.
 DR InterPro; IPR000483; LRR_Cterm.
 DR InterPro; IPR000372; LRR_Nterm.
 DR InterPro; IPR003591; LRR_typ.
 DR Pfam; PF00560; LRR; 18
 DR Pfam; PF01463; LRRT; 1.
 DR Pfam; PF01462; LRRT; 1.
 DR SMART; SM00369; LRR_TYP; 9.
 DR SMART; SM00082; LRRT; 1.
 DR SMART; SM00013; LRRT; 1.
 KW Cell adhesion; Repeat; Signal; Leucine-rich repeat; Glycoprotein.
 FT SIGNAL 1 23
 FT CHAIN 24 603
 FT REPEAT 52 73
 FT REPEAT 74 96
 FT REPEAT 98 120
 FT REPEAT 121 144
 FT REPEAT 146 168
 FT REPEAT 169 192
 FT REPEAT 194 216
 FT REPEAT 217 240
 FT REPEAT 242 264
 FT REPEAT 265 288
 FT REPEAT 289 312
 FT REPEAT 313 336
 FT REPEAT 337 360
 FT REPEAT 361 384
 FT REPEAT 386 408
 FT REPEAT 409 432
 FT REPEAT 433 456
 FT REPEAT 458 478
 FT REPEAT 479 504
 FT REPEAT 506 529

FT REPEAT 543 566 LRR 21.
FT CARBOHYD 64 64 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 85 85 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 96 96 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 368 368 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 515 515 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 578 578 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 586 586 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 603 AA; 66811 MW; DCD7637D94A5037C CRC64;
Query Match 9.0%; Score 310; DB 1; Length 603;
Best Local Similarity 31.2%; Pred. No. 2.8e-14;
Matches 92; Conservative 48; Mismatches 123; Indels 32; Gaps 5;
2Y 36 AARASAGPQPCVSCSN-----OFSKVCTTRGLSEVPGIPISTNYLMENNQMIO 91
32 ASADAGGQ-CPVACTSHDDYDELVSFCSSKNLTHLPDDIPVSTRALDGNLSSIP 90
2Y 92 ADTFRHLHLB-----VLQGRNSIRQIEVGAFLASLNT 127
91 SAAFQNLSSDFNLQGSWLSLEPQALLGLQNYLYLHLERNLNLAVGLFTHFTSLAS 150
2Y 128 LELFDNMTVPSGAPEVLSKRLRLRNPIESIPSYAFNRVPSLMDLDGLSKLEYI 187
2Y 151 LSLSSNLGRLEELFQGLSHLMDNLGWSLVVLPDTPVQGLGNLHVLVLAG-NKLTYL 209
2Y 188 SEGAPGLNLYNLGNLGNKIMPN--LTPVLGLBLESGNHFPEIRPGSPHGLSLK 245
2Y 210 QPALFCGLGELELDLGNALRSKVNFFVHLPLQLKLYLDRNLITAVAPGFLGKALR 269
2Y 246 KLVNNGQVSLIERNAFDGLASLVELLAHNNLSLPHDLFTLRYLVVLHLLHN 300
2Y 270 WDLDSHRNVLGMDTFFGLGLGLVLRHNAATASLRPTFKDLHFLLEQLQCHN 324

RESULT 25
ALS HUMAN STANDARD; PRT; 605 AA.
AC P35858;
XT 01-JUN-1994 (Rel. 29, Created)
YT 01-JUN-1994 (Rel. 29, Last sequence update)
YT 15-SEP-2003 (Rel. 42, Last annotation update)
2E Insulin-like growth factor binding protein complex acid labile chain precursor (ALS).
NS IGFBP3 OR ALS.
XS Homo sapiens (Human).
XC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
X NCBI_TaxID=9606;
X [1]
P SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
C TISSUE=Liver;
X MEDLINE=92357025; PubMed=1379671;
A Leong S.R., Baxter R.C., Camerato T., Dai J., Wood W.I.;
T "Structure and functional expression of the acid-labile subunit of the insulin-like growth factor-binding protein complex.";
T Mol. Endocrinol. 6:870-876 (1992).
L [2]
P SEQUENCE FROM N.A.
A Frankland J.;
L Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
N [3]
P SEQUENCE OF 28-35.
X MEDLINE=9308584; PubMed=2473065;
A Baxter R.C., Martin J.L., Beniac V.A.;
T "High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum.";
T J. Biol. Chem. 264:11843-11848 (1989).
C -I- FUNCTION. INVOLVED IN PROTEIN-PROTEIN INTERACTIONS THAT RESULT IN PROTEIN COMPLEXES, RECEPTOR-LIGAND BINDING OR CELL ADHESION.
C -I- SUBUNIT. FORMS A TERNARY COMPLEX OF ABOUT 140 TO 155 KDA WITH IGF-I OR IGF-II AND IGFBP-3.

CC -I- SUBCELLULAR LOCATION: Extracellular.
CC -I- TISSUE SPECIFICITY: Plasma.
CC -I- SIMILARITY: Contains 20 leucine-rich (LRR) repeats.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.ebi.ac.uk/ebis-sib.ch/announcement/> or send an email to license@ebi-sib.ch).
CC EMBL; M86826; AAA36047.1; -;
DR EMBL; AL031724; CAC36078.1; -;
DR PIR; A41915; A41915.
DR Genew; HGNC:5468; IGFALS.
DR MIM; 601489; -;
DR GO; GO:0005615; C:extracellular space; TAS.
DR GO; GO:0005625; C:soluble fraction; TAS.
DR GO; GO:0005520; P:insulin-like growth factor binding activity; TAS.
DR GO; GO:0007185; P:signal transduction; TAS.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR003372; LRR_Nterm.
DR InterPro; IPR003591; LRR_typ.
DR Pfam; PF00560; LRR; 19.
DR Pfam; PF01463; LRRCT; 1.
DR Pfam; PF01462; LRRNT; 1.
DR PRINTS; PR00019; LEURICHRPT.
DR SMART; SM00369; LRR_TYP; 11.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
KW Cell adhesion; Repeat; Signal; Leucine-rich repeat; Glycoprotein.
FT SIGNAL 1 27
FT CHAIN 28 605
FT REPEAT 53 73 INSULIN-LIKE GROWTH FACTOR BINDING
FT REPEAT 74 96 PROTEIN COMPLEX ACID LABILE CHAIN.
FT REPEAT 98 120 LRR 1.
FT REPEAT 121 144 LRR 2.
FT REPEAT 145 168 LRR 3.
FT REPEAT 170 192 LRR 4.
FT REPEAT 193 216 LRR 5.
FT REPEAT 217 240 LRR 6.
FT REPEAT 242 264 LRR 7.
FT REPEAT 265 288 LRR 8.
FT REPEAT 289 312 LRR 9.
FT REPEAT 313 336 LRR 10.
FT REPEAT 361 384 LRR 11.
FT REPEAT 386 408 LRR 12.
FT REPEAT 409 432 LRR 13.
FT REPEAT 433 456 LRR 14.
FT REPEAT 458 480 LRR 15.
FT REPEAT 482 504 LRR 16.
FT REPEAT 505 530 LRR 17.
FT CARBOHYD 64 64 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 85 85 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 96 96 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 368 368 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 515 515 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 580 580 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 605 AA; 66034 MW; F6562A23CBE918F6 CRC64;

Query Match 9.0%; Score 309; DB 1; Length 605;
Best Local Similarity 23.6%; Pred. No. 3.3e-14;
Matches 121; Conservative 69; Mismatches 154; Indels 168; Gaps 16;
Oy 42 GPQNCPSVSCS-----NQFSKVCTTRGLSEVPGIPISTNYLMENNQMIO 78
Db 38 GPA-CFAACVCSYDDADELS-VFCSSRLNLTPLDGVPGTQALMDGNLSSVPPAPQ 95
Oy 79 -----YLNLMENNTQIQADTFRHLHLVLQGR 108


```

Db 96 NLSGLFLNQGGQSLSPQALLGLNCHLHLELNQLRSLALGFAHTPALASGLSN 155
Qy 109 NSIRQIEVGAFNGSLANTLEFDNLVTPSGAFYLSKIRELMRNPNPIESIPYAFN 168
Db 156 NLSRLLEDGFEGLGSLDLNLCWNSLAVLPDAAPFGSLGSLRELVLGNRLAYLPALFS 215
Qy 169 RVSRLVRLDGLG-----ELKLL-----EYISGAFEGFLFKYLVNL-- 203
Db 216 GLAELRELDUSRNALRAIKANVFQPLRQKLVLDNRNLAAVAPAGFLGLKALRWLDLSH 275
Qy 204 -----GNCMK-----DMPNLTP-----LVGLELEMSGNHFEIRPGSGFH 239
Db 276 NRVAAGLLEDTFPGGLGLRVLRLSHNAIASLRPTFKDLHFEELQCHNRIPQLAERSPE 335
Qy 240 GLASLKKLVWNSQVSLIERNADGLASVELNLAHNLSSLPDLFTPLRLVRLVHLHH 299
Db 336 GGLGLEVLTLDHNLQLOVQAGAFGLTNAVNLGNCNLRLNLPQVFRGLGKLHSLHL-- 393
Qy 300 NPWNCDDILWLAWLREVFTPTNSTCCGRCH-----APMHRGRYLVEVDQASFO 349
Db 394 -----EGSLGLRIRHTFTGLSLRLFLKONGLVGIEEQSLW 431
Qy 350 CSAPFI-MDAPRD-----LNISGRMAELKC-RTPMSSVKWL----- 385
Db 432 GLAELLELDLTSNQLTHLPHRLFQGLGKLEVLNLSRNLAEPLADALGLQRAFWDVSH 491
Qy 386 ----LPNGTVLSHASRHRPRISVLNDGTNFS 412
Db 492 NRLEALPN-SLLAPGLRLYLSRNNSLTFT 522

RESULT 26
GPV_HUMAN
ID _GPV_HUMAN STANDARD; PRT; 560 AA.
AC P40197;
DT 01-FEB-1995 (Rel. 31, Created)
DI 01-FEB-1995 (Rel. 31, Last sequence update)
DE 28-FEB-2003 (Rel. 41, Last annotation update)
DB Platelet glycoprotein V precursor (GPV) (CD42D).
GN GP5.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Lung;
RX MEDLINE=93391348; PubMed=7690959;
RA Hickey M.J., Hagen F.S., Yagi M., Roth G.J.,
RT "Human platelet glycoprotein V: characterization of the polypeptide
RL and the related Ib-V-IX receptor system of adhesive, leucine-rich
RN glycoproteins.";
RN Proc. Natl. Acad. Sci. U.S.A. 90:8327-8331(1993).
[2]
RP SEQUENCE FROM N.A.
RC TISSUE=Platelet;
RX MEDLINE=94012616; PubMed=8407908;
RA Lanza F., Moraes M., de la Salle C., Cazenave J.-P., Clemetson K.J.,
RT "Cloning and characterization of the gene encoding the human platelet
RL glycoprotein V. A member of the leucine-rich glycoprotein family
RN cleaved during thrombin-induced platelet activation.";
RN J. Biol. Chem. 268:20801-20807(1993).
[3]
RP PARTIAL SEQUENCE.
RC TISSUE=Platelet;
RX MEDLINE=90275263; PubMed=2330580;
RA Shimomura T., Fujimura K., Maehama S., Takemoto M., Oda K.,
RT Fujimoto T., Oyama R., Suzuki M., Ichiara-Tanaka K., Titani K.,
RA Kuramoto A.;
RT "Rapid purification and characterization of human platelet
RN glycoprotein V: the amino acid sequence contains leucine-rich

```

```

RT repetitive modules as in glycoprotein Ib.";
RL Blood 75:2349-2356(1990).
[4]
RN PARTIAL SEQUENCE.
RC TISSUE=Platelet;
RX MEDLINE=90321220; PubMed=2372284;
RA Roth G.J., Church T.A., McMullen B.A., Williams S.A.;
RT "Human platelet glycoprotein V: a surface leucine-rich glycoprotein
RL related to adhesion.";
CC Biochem. Biophys. Res. Commun. 170:153-161(1990).
CC -!- FUNCTION: THE GPIIb-V-IX COMPLEX FUNCTIONS AS THE VON WILLEBRAND
CC FACTOR RECEPTOR AND MEDIATES VON WILLEBRAND FACTOR-DEPENDENT
CC PLATELET ADHESION TO BLOOD VESSELS. THE ADHESION OF PLATELETS TO
CC INJURED VASCULAR SURFACES IN THE ARTERIAL CIRCULATION IS A
CC CRITICAL INITIATING EVENT IN HEMOSTASIS.
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- TISSUE SPECIFICITY: PLATELETS AND MEGAKARYOCYTES.
CC -!- PTM: THE N-TERMINUS IS BLOCKED.
CC -!- SIMILARITY: Contains 14 leucine-rich (LRR) repeats.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC
EMBL; L11238; AAA03069.1; --
EMBL; Z23091; CAA90637.1; --
PIR; A48030; A60164.
HSP; P16473; IXUM.
Genew; HGNC:4443; GP5.
MIM; 173511; --
GO; GO:0005887; C-integral to plasma membrane; TAS.
InterPro; IPR001611; LRR.
InterPro; IPR000483; LRR_Cterm.
InterPro; IPR000372; LRR_Nterm.
InterPro; IPR003591; LRR_Typ.
Pfam; PF00560; LRR; 13.
Pfam; PF01463; LRRCT; 1.
PRINTS; PR00019; LEURICHRPT.
SMART; SM00369; LRR_TYP; 9.
SMART; SM00082; LRRCT; 1.
SMART; SM00013; LRRNT; 1.
SWAT; Transmembrane; Glycoprotein; Blood coagulation;
KW Platelet; Leucine-rich repeat; Cell adhesion; Signal.
KW Repeat; Leucine-rich repeat; POTENTIAL.
FT SIGNAL 1 16
FT CHAIN 17 560 PLATELET GLYCOPROTEIN V.
FT DOMAIN 17 523 EXTRACELLULAR (POTENTIAL).
FT TRANSEM 524 544 POTENTIAL.
FT DOMAIN 545 560 CYTOPLASMIC (POTENTIAL).
FT REPEAT 73 96 LRR 1.
FT REPEAT 97 120 LRR 2.
FT REPEAT 122 144 LRR 3.
FT REPEAT 145 168 LRR 4.
FT REPEAT 169 192 LRR 5.
FT REPEAT 194 216 LRR 6.
FT REPEAT 217 240 LRR 7.
FT REPEAT 241 264 LRR 8.
FT REPEAT 265 288 LRR 9.
FT REPEAT 289 312 LRR 10.
FT REPEAT 314 337 LRR 11.
FT REPEAT 338 361 LRR 12.
FT REPEAT 362 385 LRR 13.
FT REPEAT 386 409 LRR 14.
FT CARBOHYD 51 51 N-LINKED (GLCNAC. . .).
FT CARBOHYD 181 181 N-LINKED (GLCNAC. . .).
FT CARBOHYD 243 243 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 267 267 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 298 298 N-LINKED (GLCNAC. . .).
FT CARBOHYD 312 312 N-LINKED (GLCNAC. . .).
FT CARBOHYD 385 385 N-LINKED (GLCNAC. . .).

```

FT CARBOHYD 499 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CONFLICT 73 MT -> TK (IN REF. 2).
FT CONFLICT 109 K -> T (IN REF. 2).
FT CONFLICT 130 D -> W (IN REF. 3).
FT CONFLICT 136 GID -> PGG (IN REF. 3).
FT CONFLICT 209 L -> I (IN REF. 2).
FT CONFLICT 267 N -> H (IN REF. 3).
FT CONFLICT 327 L -> I (IN REF. 2).
FT CONFLICT 478 P -> G (IN REF. 2).
FT CONFLICT 509 P -> D (IN REF. 2).
IQ SEQUENCE 560 AA; 60959 MW; BICDB04AF8AF7115 CRC64;

Query Match 8.9%; Score 305.5; DB 1; Length 560;
Best Local Similarity 27.6%; Pred. No. 5.3e-14;
Matches 98; Conservative 47; Mismatches 153; Indels 57; Gaps 9;

Y 66 LSEVPOGI---PSNTRYLNLMENNIOIQTDFHLLHVLQGLGNSROIIEVGAFNGI 122
Y 182 LTHPKGLGQAQKLERLLHNSRLVSLDGLNSLGNLTQELPHNHRISAPGFDEL 241
Y 123 ASLNTLEFDNWLTVIPSGAFYVLSKRLRLNRPPIESIPSYAFNRVPSLMELDIGELK 182
Y 242 PNLSSLTSLRNHLAFLPSALFLSHSNLTLLTFENPLAELPGLVFGEMGGLQELNLR-T 300
Y 183 KLEVISGAFEGLENKLVNLCMCMKIMNLTPL-----VGLLELE---MSCNHPEIR 234
Y 301 QRTLPAAAFNLSRLRYLGVTL-----SRLSALPGQAFQGLGELQVLALHNSGUTALP 355
Y 235 PGSPHGLSSLKLMNMSQVSLIERNADFGLASIVELNLAHNLSSLPDLFTPLYLVE 294
Y 356 DGLRLGLKLRQVSLRLNRLRALPRAFLRNLSLSSVQLQHNQLETLPQGVFGALPRLTE 415
Y 295 LALHNPANPCDILALWMLREVI-----PTNSTCCGRCCHAPHHMGRVYLVEVDQAS 347
Y 416 VLLGHNSWRCDGLGPFGLWLRQHLGLVGGEEPP-----RCAGPGAHAGLPLWALPGSD 469
Y 348 FQCSAPPTMDAPRLNTISGRMAELKCRTPMSSVKWLLPNTGVLGHASHRHRPRIS 402
Y 470 AECFGP-----RGPPPR-----PAADSSSEAPVHPALA 497

RESULT 27
*GS2 HUMAN
ID PGS2_HUMAN STANDARD; PRT: 359 AA.
P07585; Q9P0Z1; Q9V5N8; Q9V5N9;
01-APR-1988 (Rel. 07, Created)
01-APR-1988 (Rel. 07, Last sequence update)
15-SEP-2003 (Rel. 42, Last annotation update)
Decorin precursor [Bone proteoglycan II] (PG-S2) (PG40).
DCN.
X Homo sapiens (Human).
X Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
X Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
X NCBI_TaxId=9606;
[1]
N SEQUENCE FROM N.A.
X MEDLINE=87017013; PubMed=3484330;
LA Krusius T., Ruoslahti B.;
"Primary structure of an extracellular matrix proteoglycan core
protein deduced from cloned cDNA.";
Proc. Natl. Acad. Sci. U.S.A. 83:7683-7687(1986).
[2]
N SEQUENCE FROM N.A.
X TISSUE=Lung;
X MEDLINE=93162643; PubMed=8432527;
LA Vetter U., Vogel W., Just W., Young M.F., Fisher L.W.;
"Human decorin gene: intron-exon junctions and chromosomal
localization.";
Genomics 15:161-168(1993).
[3]
N SEQUENCE OF 1-70 FROM N.A.
X MEDLINE=93162642; PubMed=8432526;
LA Danielson K.G., Fazio A., Cohen I.R., Cannizzaro L., Iozzo R.V.;

RT "The human decorin gene: intron-exon organization, discovery of two
alternatively spliced exons in the 5' untranslated region, and
mapping of the gene to chromosome 12q23.";
Genomics 15:146-160(1993).
[4]
RN SEQUENCE FROM N.A. (ISOFORMS A; B; C; D AND E).
RP CS-Szabo G., Glant T.T.;
"Alternative splicing of human decorin.";
Submitted (MAR-1999) to the EMBL/GenBank/DBJ databases.
[5]
RP SEQUENCE FROM N.A., AND VARIANT MET-268.
RA Kieder M.J., Armet T.Z., Carrington D.P., Chung M.-W., Lee K.L.,
Ozuna M., Poel C.E., Toth E.J., Yi Q., Nickerson D.A.;
Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
[6]
RN SEQUENCE FROM N.A.
RP TISSUE=Liver;
RC MEDLINE=22388257; PubMed=12477932;
RX Strausberg R.D., Feingold E.A., Grouse L.H., Derge J.G.,
Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
Stapleton M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,
Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
Bosak S.A., McSwain P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
Richards S.K., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Fahey J., Helton E., Kettawan M., Madan A., Rodriguez S., Sanchez A.,
Whiting M., Maman A., Young A.C., Shevchenko Y., Bouffard G.G.,
Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smallus D.E.,
Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
"Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences.";
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
[7]
RN SEQUENCE OF 31-50.
RX MEDLINE=90073579; PubMed=2590169;
RA Roughley P.J., White R.J.;
"Dermatan sulphate proteoglycans of human articular cartilage. The
properties of dermatan sulphate proteoglycans I and II.";
Biochem. J. 262:823-827(1989).
[8]
RN SEQUENCE OF 31-49.
RP MEDLINE=87250639; PubMed=3597437;
RA Fisher L.W., Hawkins G.R., Tuross N., Termine J.D.;
"Purification and partial characterization of small proteoglycans I
and II, bone sialoproteins I and II, and osteonectin from the mineral
compartment of developing human bone.";
J. Biol. Chem. 262:9702-9708(1987).
CC -!- FUNCTION: May affect the rate of fibrils formation.
CC -!- SUBUNIT: Binds to type I and type II collagen, to fibronectin and
TCP-beta. Forms a ternary complex with MFAP2 and ELN (by
similarity).
CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=5;
CC Name=A;
CC IsoId=P07585-1; Sequence=Displayed;
CC Name=B;
CC IsoId=P07585-2; Sequence=VSP_006172;
CC Name=C;
CC IsoId=P07585-3; Sequence=VSP_006173;
CC Name=D;
CC IsoId=P07585-4; Sequence=VSP_006174;
CC Name=E;
CC IsoId=P07585-5; Sequence=VSP_006175, VSP_006176;
CC -!- PTM: The attached glycosaminoglycan chain can be either
chondroitin sulfate or dermatan sulfate depending upon the tissue
of origin.

CC -1- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN (SLRP)
 CC FAMILY. CLASS 1 SUBFAMILY.
 CC -1- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL: M14219; AAB00774.1; ALT SEQ.
 CC EMBL: L01131; AAS2301.1; JOINED.
 CC EMBL: L01132; AAS2301.1; JOINED.
 CC EMBL: L01126; AAS2301.1; JOINED.
 CC EMBL: L01127; AAS2301.1; JOINED.
 CC EMBL: L01129; AAS2301.1; JOINED.
 CC EMBL: L01130; AAS2301.1; JOINED.
 CC EMBL: M98262; AAB60901.1; -.
 CC EMBL: AF138300; AAD44713.1; -.
 CC EMBL: AF138301; AAF61437.1; -.
 CC EMBL: AF138302; AAD44714.1; -.
 CC EMBL: AF138303; AAF61438.1; -.
 CC EMBL: AF138304; AAD44715.1; -.
 CC EMBL: AF491944; AAL92176.1; -.
 CC EMBL: BC005322; AAO5322.1; -.
 CC PIR: A45016; NBHUC8.
 CC Genew: HGNC:2705; DCN.
 CC MIM: 125255; -.
 CC GO: GO:0007397; P:histogenesis and organogenesis; TAS.
 CC InterPro: IPR001611; LRR.
 CC InterPro: IPR000372; LRR Nterm.
 CC InterPro: IPR003591; LRR_TYP.
 CC Pfam: PF00560; LRR; 8.
 CC Pfam: PF01462; LRR_TYP; 1.
 CC SMART: SM00369; LRR_TYP; 1.
 CC SMART: SM00013; LRRNT; 1.
 CC KW Glycoprotein; Extracellular matrix; Proteoglycan; Repeat;
 CC Leucine-rich repeat; Signal; Signal; Alternative splicing; Polymorphism.
 CC FT SIGNAL 1 16 POTENTIAL.
 CC FT PROSEP 17 30
 CC FT CHAIN 31 359
 CC FT DOMAIN 54 67
 CC FT REPEAT 73 93
 CC FT REPEAT 117 141
 CC FT REPEAT 118 141
 CC FT REPEAT 142 162
 CC FT REPEAT 163 185
 CC FT REPEAT 187 212
 CC FT REPEAT 213 233
 CC FT REPEAT 234 257
 CC FT REPEAT 258 281
 CC FT REPEAT 282 304
 CC FT REPEAT 305 334
 CC FT REPEAT 335 359
 CC FT DISULFID 54 67
 CC FT CARBOHYD 313 346
 CC FT CARBOHYD 34 34
 CC FT CARBOHYD 211 261
 CC FT CARBOHYD 262 262
 CC FT CARBOHYD 303 303
 CC FT VARSPLIC 71 179
 CC FT VARSPLIC 73 219
 CC FT VARSPLIC 109 295
 CC FT VARSPLIC 72 75
 CC FT VARSPLIC 76 359
 CC FT VARSPLIC 268 268
 CC FT VARIANT 268 268
 CC T -> W.

FT VARIANT 273 273 /FTIG=VAR_014351.
 FT FT E -> Q (IN DBSNP:1803344).
 FT CONFLICT 37 37 /FTIG=VAR_011975.
 FT CONFLICT 45 45 G -> A (IN REF. 8).
 FT CONFLICT 45 45 D -> P (IN REF. 8).
 SQ SEQUENCE 359 AA; 39746 MW; FFS11B871A1A52DD CRC64;
 Query Match 8.8%; Score 303.5; DB 1; Length 359;
 Best Local Similarity 31.9%; Pred. No. 46-14;
 Matches 84; Conservative 45; Mismatches 123; Indels 11; Gaps 7;
 QY 40 SAGPQPCVCSNQFQSKVCTRRGLSEVPQIPGIPSNTRYLNLMENNTQMTQADTFRLHL 99
 DB 49 SLGPV-CPPRCQC--HLRVVQCSDLGLDKVPDPDTLLDLQNNKITEIKGDFKNLK 105
 QY 100 HLEVLQGRNSIRQIEVGAFNGLASLNTLELPDNWLTVPISGAFEYLSK-LRELWLRNP 158
 DB 106 NHALILVNNKISKVSPGAPTPVLERLYSKNGKSLP-----EWPXTLQELRAHENE 161
 QY 159 IESIPSYAFNRPVSLMRLDLG-ELKKLEYISGAFEGFLNKLMLGMCNKDMNLTPL 217
 DB 162 ITKRVKVTNGLNQMVIVIELGTNPLKSSGIENGAFQGMKLSYIRIADTNITSIPQGLP- 220
 QY 218 VGLREHEMGNHPPPIRPOSFGLSLKLLWPMNSQVSLIERNADFGLASLVELNLAENN 277
 DB 221 PSLTEHLDCNKISRVDAAASLGLANLAKLGLSFSISAVDNGSLANTPHRLRELDNNK 280
 QY 278 LSSLPHDLFTPLRLYLVELHLHN 300
 DB 281 LTRVPGGL-AEHKYIQVYVHLHN 302
 ID LGR5 HUMAN STANDARD; PRT; 907 AA.
 AC 075473; Q9UP75;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DE Leucine-rich repeat-containing G protein-coupled receptor 5 precursor
 DE Orphan G protein-coupled receptor HG38 (G protein-coupled receptor
 DE 49).
 DE GPR49 OR LGR5 OR GPR67.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OK NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=98308104; PubMed=9642114;
 RA McDonald T., Wang R., Bailey W., Xie G., Chen F., Caskey C.T.,
 RA Liu Q.,
 RA "Identification and cloning of an orphan G protein-coupled receptor of
 RT the glycoprotein hormone receptor subfamily.";
 RL Biochem. Biophys. Res. Commun. 247:266-270(1998).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Placenta;
 RX MEDLINE=99055210; PubMed=9849958;
 RA Han S.Y., Liang S.-G., Hsueh A.J.W.;
 RA "Characterization of two LGR genes homologous to gonadotropin and
 RT thyrotropin receptors with extracellular leucine-rich repeats and a G
 RT protein-coupled, seven-transmembrane region.";
 RT Mol. Endocrinol. 12:1830-1845(1998).
 RL Mol. Endocrinol. 12:1830-1845(1998).
 CC -1- FUNCTION: Orphan receptor. It may be an important receptor for
 CC signals controlling growth and differentiation of specific
 CC embryonic tissues (By similarity).
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein.
 CC -1- TISSUE SPECIFICITY: Expressed in skeletal muscle, placenta, spinal
 CC cord, and various region of brain.
 CC -1- SIMILARITY: BELONGS TO FAMILY 1 OF G-PROTEIN COUPLED RECEPTORS.
 CC -1- SIMILARITY: Contains 17 leucine-rich (LRR) repeats.

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.ebi.ac.uk/announcements> or send an email to license@ebi.ac.uk).

EMBL; AF062006; AAC28019.1; -
PIR; J01176; J01176
Genew; HENC:4504; GPR49.
MIM; 606667; -
HSP; P23945; LXN.
GO; GO:0005887; C: integral to plasma membrane; TAS.
GO; GO:0007186; P: G-protein coupled receptor protein signalin. .; TAS.
InterPro; IPR000276; GPCR_Rhodopsn.
InterPro; IPR001611; LRR.
InterPro; IPR000372; LRR_Nterm.
InterPro; IPR003591; LRR_Typ.
Pfam; PF00001; 7tm_1; 1.
Pfam; PF00560; LRR; 14.
Pfam; PF01462; LRRNT; 1.
PRINTS; PR00237; GPCR_Rhodopsn.
PRINTS; PR00019; LEURICHRPT.
SMART; SM00369; LRR_TYP; 8.
SMART; SM00013; LRRNT; 1.
PROSITE; PS00237; G-PROTEIN RECP F1_1; FALSE_NEG.
PROSITE; PS0262; G-PROTEIN RECP F1_2; 1.
KW G-protein coupled receptor; Signal; Transmembrane; Glycoprotein;
Repeat; Leucine-rich repeat.
FT SIGNAL 1 21
FT CHAIN 22 907
FT DOMAIN 1 561
FT TRANSMEM 562 582
FT DOMAIN 583 593
FT TRANSMEM 594 614
FT DOMAIN 615 638
FT TRANSMEM 639 659
FT DOMAIN 660 682
FT TRANSMEM 683 703
FT DOMAIN 704 722
FT TRANSMEM 723 743
FT DOMAIN 744 767
FT TRANSMEM 768 788
FT DOMAIN 789 802
FT TRANSMEM 803 823
FT DOMAIN 824 907
FT REPEAT 64 88
FT REPEAT 89 112
FT REPEAT 114 136
FT REPEAT 137 160
FT REPEAT 162 184
FT REPEAT 185 208
FT REPEAT 209 232
FT REPEAT 233 256
FT REPEAT 257 279
FT REPEAT 281 303
FT REPEAT 304 327
FT REPEAT 328 350
FT REPEAT 351 375
FT REPEAT 377 396
FT REPEAT 397 420
FT REPEAT 422 444
FT REPEAT 444 464
FT REPEAT 464 484
FT CARBOHYD 63 63
FT CARBOHYD 77 77
FT CARBOHYD 208 208
FT CARBOHYD 500 500
FT CARBOHYD 792 792
FT CARBOHYD 90 90
FT CONFLICT 90 90
FT CONFLICT 212 212
L -> W (IN REF. 2).
R -> H (IN REF. 2).
N-LINKED (GLCNAC. .) (POTENTIAL).
N-LINKED (GLCNAC. .) (POTENTIAL).
N-LINKED (GLCNAC. .) (POTENTIAL).
N-LINKED (GLCNAC. .) (POTENTIAL).
N-LINKED (GLCNAC. .) (POTENTIAL).
R -> H (IN REF. 2).
L -> W (IN REF. 2).

SQ SEQUENCE 907 AA; 99997 MW; 822D5C5E6F0D9092 CRC64;
Query Match 8.8%; Score 303.5; DB 1; Length 907;
Best Local Similarity 26.1%; Pred. No. 1.4e-13;
Matches 111; Conservative 60; Mismatches 156; Indels 99; Gaps 10;
QY 22 VYLAQWILCAATAAASAGP--QNCPSVCSC---SNQFSKVCTRRGLSEVPGQIPSN 76
DB 8 VLLSLPVLQLATGSSPRSGVLLRGCPHCHCEPGRMLLRVDCSDLGLSELSNLSVF 67
QY 77 TRYLNLMENNIQ-----MIQADTFR 96
DB 58 TSYLDLSNNNISQLPNPLPSLRLEBLRAGNALTYIPKGAFTGLYSLKVLMLQNNQLR 127
QY 97 H-----LHLEVLQIGRNSIRQIEVGAFNGIASLNTLELFDNMLTVTPSGAFYVLSK 148
DB 128 HYPTEALQNLASLOSLRDANHSIVPPSCPSGLHSLRHLWLDNALTEIPVQAFRSLSA 187
QY 149 LREELWLRNPIESIPSAFNPVPSIMRLDGLGELKLEVISGAFEGFLNKLKYLNLGMCNI 208
DB 188 LQAMTLALNKIHIPDYAFGNLSSLVVLHLHN-NRIHSLGKKCFDGLHSLLELDLNTNL 246
QY 209 KDMPN-LTFLVGLLELEMSGNHFFPIRPGSPHGLSSLKCLWVNSQVSLIERNAFD--- 263
DB 247 DEFPTAIRTSLNKLGLPHSNIRSIPEKAFVGNPSLTIHFYDNPIQFVGRSAFQHLPE 306
QY 264 -----GLASIVELNLAHNLSLPHDLFTPLRYLVELHLHNPANC 304
DB 307 LATLTLNGASQITFPDITGTANLESITLTAQISSLPTQVNCQLPNLQVLDLSYN--- 362
QY 305 DCDILWLAWLRLREYIPTNSTCCGRCHAPMHRGRLVVEVDAQSPQCSAPFIMDAPRLNI 364
DB 363 -----LLEDLPSPSVC--QKLQKIDLRHNEIYKVDTFQ-----QLLSLSLSNL 405
QY 365 SEGRMA 370
DB 406 AMNKIA 411
RESULT 29
PGS2_HORSE
ID PGS2_HORSE STANDARD; PRT; 360 AA.
AC O46542;
DT 15-JUL-1999 (Rel. 38, Created)
DT 15-JUL-1999 (Rel. 38, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Decorin precursor (Bone proteoglycan II) (PG-82) (Dermatan sulfate proteoglycan II) (DS-PGII).
GN DCM.
OS Equus caballus (Horse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Rutheria; Perissodactyla; Equidae; Equus.
OX NCBI_TaxID=9796;
RN [1]
RP SEQUENCE FROM N.A.
RA Richardson D.W., Dodge G.R.;
RT "Effects of interleukin-1 beta and tumor necrosis factor-alpha on the expression of matrix related genes in cultured equine articular chondrocytes".
RT Submitted (DEC-1997) to the EMBL/GenBank/DBJ databases.
RL -!- FUNCTION: May affect the rate of fibrils formation (By similarity).
CC -!- SUBUNIT: Binds to type I and type II collagen, to fibronectin and TGP-beta. Forms a ternary complex with MFAP2 and ELN (By similarity).
CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By similarity).
CC -!- PTM: The attached glycosaminoglycan chain can be either chondroitin sulfate or dermatan sulfate depending upon the tissue of origin (By similarity).
CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN (SLRP) FAMILY. CLASS I SUBFAMILY.
CC -!- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.

 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AF038127; AAB92652.1; -;
 DR InterPro; IPR001611; LRR.
 DR InterPro; IPR000372; LRR_Nterm.
 DR InterPro; IPR003591; LRR_Typ.
 DR Pfam; PF00560; LRR; 8.
 DR Pfam; PF01462; LRRNT; 1.
 DR SMART; SMO0013; LRRNT; 1.
 KW Glycoprotein; Extracellular matrix; Proteoglycan; Repeat;
 KW Leucine-rich repeat; Signal.
 FT SIGNAL 1 16 POTENTIAL.
 FT PROPEP 17 30 BY SIMILARITY.
 FT CHAIN 31 360 DECORIN.
 FT DOMAIN 55 68 CYS-RICH.
 FT REPEAT 74 94 LRR-S 1.
 FT REPEAT 95 118 LRR-T 1.
 FT REPEAT 119 142 LRR-T 2.
 FT REPEAT 143 163 LRR-S 2.
 FT REPEAT 164 187 LRR-T 3.
 FT REPEAT 188 213 LRR-T 4.
 FT REPEAT 214 234 LRR-S 3.
 FT REPEAT 235 258 LRR-T 5.
 FT REPEAT 259 282 LRR-T 6.
 FT REPEAT 283 305 LRR-S 4.
 FT REPEAT 306 335 LRR-T 7.
 FT REPEAT 336 360 LRR-T 8.
 FT DISULFID 314 347 BY SIMILARITY.
 FT CARBOHYD 34 34 O-LINKED (GLYCOSAMINOGLYCAN) (BY
 FT CARBOHYD 190 190 O-LINKED (GLYCOSAMINOGLYCAN) (BY
 FT CARBOHYD 212 212 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 263 263 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 304 304 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 360 AA; 39939 MW; 2DAB97CDE16F7C45 CRC64;
 Query Match 8.8%; Score 302; DB 1; Length 360;
 Best local Similarity 30.7%; Pred. No. 5.2e-14;
 Matches 86; Conservative 48; Mismatches 120; Indels 26; Gaps 8;
 QY 38 AAGAGPON-----CPSCVSCSNOPSKVCTRRGLSEVPGQIPGNTRYLNLW 83
 DB 33 ASGIGPEDRIHEVLDLEPLGVCVFFRCQC--HLRVVQCSDLGLDKVKKDLPPDTLLDLQ 90
 QY 84 ENNIQMTQADTFHLLHLEVLQGRNSIRQIEVGAFNGLASLNTLELFDNMTVTIPSGAF 143
 DB 91 NNKITEIKDGFKNLXNLHALIWNKKISKISPGFTPLVKLERLYLSKNHLKELP---- 146
 QY 144 EYLSK-LRELWLRNRPSTPSVAFNRVPSLMDLGL-ELKLEYISEGAFGLFNLYL 201
 DB 147 EKPETQLQSLRVHENEITKRVKAVFNGLNQIMVVELGTPLKSSGLENGAFQMKKLSYI 206
 QY 202 NLGMCNKDM-PNLTPLVGLLELEMSGNHPETIRPGSFGLSKLKMWNQSVLSIERN 260
 DB 207 RIADTNTITPPGLPP--SLTELHLDSNKITKVDAAASLRLANLAKLGLSPNSISAVDNG 264
 QY 261 AFDGLASIVLNLAHNNLSLPHDLTPPLRYLYVELLHN 300
 DB 265 SLANTPHRELHLDDNNKLKIKVPGGL-ADHKYIQVYVYLNH 303
 RESULT 30
 PGS2_PIG
 ID PGS2_PIG STANDARD; PRT; 360 AA.

AC Q9XSD9; Q9XGH4;
 DT 30-MAY-2000 (Rel. 39, Created)
 DT 30-MAY-2000 (Rel. 39, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Decerin precursor (Bone proteoglycan II) (PG-S2).
 GN DCM.
 OS Sus scrofa (Pig).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
 CC NCB1_TaxID=9823;
 CC [1]
 CC SEQUENCE FROM N.A. (ISOFORM LONG).
 CC STRAIN=Yorkshire;
 CC Stephenson S., Schnoke M., Vesely I.;
 CC "Cloning of the porcine decorin gene";
 CC Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
 CC [2]
 CC Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.
 CC SEQUENCE FROM N.A. (ISOFORM SHORT).
 CC STRAIN=Yorkshire; TISSUE=Aorta;
 CC Stephenson S., Schnoke M., Vesely I.;
 CC "Alternatively spliced version of the porcine decorin gene";
 CC Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
 CC -!- FUNCTION: May affect the rate of fibrils formation (By
 CC similarity).
 CC -!- SUBUNIT: Binds to type I and type II collagen, to fibronectin and
 CC TGF-beta. Forms a ternary complex with WFAP2 and ELN (By
 CC similarity).
 CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix.
 CC -!- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=2;
 CC Name=Long;
 CC IsoId=Q9XSD9-1; Sequence=Displayed;
 CC Name=Short;
 CC IsoId=Q9XSD9-2; Sequence=VSP_006177;
 CC -!- PTM: The attached glycosaminoglycan chain can be either
 CC chondroitin sulfate or dermatan sulfate depending upon the tissue
 CC of origin (By similarity).
 CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN (SLRP)
 CC FAMILY. CLASS I SUBFAMILY.
 CC -!- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL; AF125537; AAD23578.1; -;
 CC EMBL; AF140270; AAD33862.1; -;
 CC InterPro; IPR001611; LRR.
 CC InterPro; IPR000372; LRR_Nterm.
 CC InterPro; IPR003591; LRR_Typ.
 CC Pfam; PF00560; LRR; 8.
 CC Pfam; PF01462; LRRNT; 1.
 CC SMART; SMO0369; LRR_Typ; 2.
 CC SMART; SMO0013; LRRNT; 1.
 KW Glycoprotein; Extracellular matrix; Proteoglycan; Repeat;
 KW Leucine-rich repeat; Signal; Alternative splicing.
 FT SIGNAL 1 16 POTENTIAL.
 FT PROPEP 17 30 BY SIMILARITY.
 FT CHAIN 31 360 DECORIN.
 FT DOMAIN 55 68 CYS-RICH.
 FT REPEAT 74 94 LRR-S 1.
 FT REPEAT 95 118 LRR-T 1.
 FT REPEAT 119 142 LRR-T 2.
 FT REPEAT 143 163 LRR-S 2.
 FT REPEAT 164 187 LRR-T 3.
 FT REPEAT 188 213 LRR-T 4.
 FT REPEAT 214 234 LRR-S 3.
 FT REPEAT 235 258 LRR-T 5.
 FT REPEAT 259 282 LRR-T 6.

```

FT REPEAT      283 305 LRR-S 4.
FT REPEAT      306 335 LRR-T 7.
FT REPEAT      336 360 LRR-T 8.
FT DISULFID    55 68 BY SIMILARITY.
FT DISULFID    314 347 BY SIMILARITY.
FT CARBOHYD    34 34 O-LINKED (GLYCOSAMINOGLYCAN)
                        (BY SIMILARITY).
FT CARBOHYD    212 212 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD    263 263 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD    304 304 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT VARSPLIC    281 318 Missing (in isoform Short).
FT SEQUENCE    360 AA; 39899 MW; 8573DB8DEBA7509 CRC64;

Query Match      8.7%; Score 300; DB 1; Length 360;
Best Local Similarity 30.1%; Pred. No. 7.2e-14;
Matches 85; Conservative 49; Mismatches 121; Indels 24; Gaps 7;

Y 38 AASAGPON-----CPSCVCSNQPSKVVCTRRGLSEVPOGIPSNRYLNLM 83
b 33 ASGIGPEDRPPEVPELEPLGPMCFRCQ--HLRVQCSDLGLKVKPDLPPDTALLDLQ 90
Y 84 ENNIQMIQADTFRHLHLHLVQLGRNSIRQIEVGAFNGLASLNTLELFNNLTVPISGAP 143
b 91 NKKITEIKOGDFKNLKNLHTLILNNKISKISPGAFAPLVKLERLYLSKNQKELP---- 146
Y 144 EYLSK-LRELWLRNPNPESIPSYAFNRPVPSLMELDLG-ELKKLEYISEGAFGLFNLYL 201
b 147 EKMPTKLQELRVHENEITKVRKAVFNGLANQMI VVELGNTPLKSSGIEGAFQMGKLSYI 206
Y 202 MLCNCKDMENLTPVLEELSGNHPFIRPGSPHGLSSLKLLWVNSQVSLIARNA 261
b 207 RIADNTITTIPOGLP-PSLTELHLGDNKISKVDAISLKLNNLAKLGLGNSISTVDNGS 265
Y 262 FDGLASIVELNLAHNNLSUPLHDTPLRYLYLVELLHNN 300
b 266 LANTPHLELHLNKNLKNKVPGL-AEHKYIQVYVLENN 303

RESULT 31
DGS2_BOVIN STANDARD; PRT; 360 AA.
AC P21793;
YT 01-MAY-1991 (Rel. 18, Created)
YT 01-MAY-1991 (Rel. 18, Last sequence update)
YT 28-FEB-2003 (Rel. 41, Last annotation update)
YE Decorin precursor (Bone proteoglycan II) (PG-S2).
Y DCN.
Y Bos taurus (Bovine).
Y Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Y Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Y Bovidae; Bovinae; Bos.
Y NCBI_TaxID=9913;
Y [1]
Y SEQUENCE FROM N.A.
Y MEDLINE=88133946; PubMed=3435485;
Y Day A.A., McQuillan C.I., Termino J.D., Young M.R.;
Y "Molecular cloning and sequence analysis of the cDNA for small
Y proteoglycan II of bovine bone.";
Y Biochem. J. 248:801-805(1987).
Y [1]
Y SEQUENCE OF 31-54.
Y MEDLINE=89123388; PubMed=2914936;
Y Choi H.U., Johnson T.L., Pal S., Tang L.H., Rosenberg L.C.,
Y Neame P.J.;
Y "Characterization of the dermatan sulfate proteoglycans, DS-PGI and
Y DS-PGII, from bovine articular cartilage and skin isolated by octyl-
Y sepharose chromatography.";
Y J. Biol. Chem. 264:2876-2884 (1989).
Y [3]
Y INTERACTION WITH MFAP2 AND ELN.
Y MEDLINE=21633536; PubMed=11723132;
Y Reinboth B., Hanssen E., Cleary B.G., Gibson M.A.;

```

```

RT "Molecular interactions of biglycan and decorin with elastic fiber
RT components: biglycan forms a ternary complex with tropoelastin and
RT microfibril-associated glycoprotein 1.";
RL J. Biol. Chem. 277:3950-3957(2002).
CC -!- FUNCTION: May affect the rate of fibrils formation.
CC -!- SUBUNIT: Binds to type I and type II collagen, to fibronectin and
CC TGF-beta. Forms a ternary complex with MFAP2 and ELN.
CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix.
CC -!- PTM: The attached glycosaminoglycan chain can be either
CC chondroitin sulfate or dermatan sulfate depending upon the tissue
CC of origin.
CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
CC (SLRP) FAMILY. CLASS I SUBFAMILY.
CC -!- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC -----
CC EMBL; Y00712; CAA68702.1; -.
CC PIR; S06280; S06280.
CC InterPro; IPR001611; LRR.
CC InterPro; IPR000372; LRR_Nterm.
CC Pfam; PF00560; LRR; 9.
CC Pfam; PF01462; LRRNT; 1.
CC SMART; SM00369; LRR_TYD; 2.
CC SMART; SM00013; LRRNT; 1.
CC Glycoprotein; Extracellular matrix; Proteoglycan; Repeat;
CC Leucine-rich repeat; Signal. POTENTIAL.
CC SIGNAL 1 16
CC PROPEP 17 30
CC CHAIN 31 360 DECORIN.
CC DOMAIN 55 68 CYS-RICH.
CC REPEAT 74 94 LRR-S 1.
CC REPEAT 95 118 LRR-T 1.
CC REPEAT 119 142 LRR-T 2.
CC REPEAT 143 163 LRR-S 2.
CC REPEAT 164 187 LRR-T 3.
CC REPEAT 188 213 LRR-T 4.
CC REPEAT 214 234 LRR-S 3.
CC REPEAT 235 258 LRR-T 5.
CC REPEAT 259 282 LRR-T 6.
CC REPEAT 283 305 LRR-S 4.
CC REPEAT 306 335 LRR-T 7.
CC REPEAT 336 360 LRR-T 8.
CC DISULFID 55 68 BY SIMILARITY.
CC DISULFID 314 347 BY SIMILARITY.
CC CARBOHYD 34 34 O-LINKED (GLYCOSAMINOGLYCAN) (BY
CC SIMILARITY).
CC CARBOHYD 212 212 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC CARBOHYD 263 263 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC CARBOHYD 304 304 N-LINKED (GLCNAC. . .) (POTENTIAL).
CC SEQUENCE 360 AA; 39837 MW; 71E84DA2D87552C0 CRC64;

Query Match      8.7%; Score 298; DB 1; Length 360;
Best Local Similarity 30.1%; Pred. No. 9.9e-14;
Matches 84; Conservative 49; Mismatches 122; Indels 24; Gaps 7;

QY 38 AASAGPON-----CPSCVCSNQPSKVVCTRRGLSEVPOGIPSNRYLNLM 83
Db 33 ASGIGPEDRPPEVPELEPLGPMCFRCQ--HLRVQCSDLGLKVKPDLPPDTALLDLQ 90
QY 84 ENNIQMIQADTFRHLHLHLVQLGRNSIRQIEVGAFNGLASLNTLELFNNLTVPISGAP 143
Db 91 NKKITEIKOGDFKNLKNLHTLILNNKISKISPGAFAPLVKLERLYLSKNQKELP---- 146
QY 144 EYLSK-LRELWLRNPNPESIPSYAFNRPVPSLMELDLG-ELKKLEYISEGAFGLFNLYL 201

```

Db 147 EKMPKTLQELRVHENEITKVRKSVFNGLNQMIWVGLTNPVLSKSSGIENGAPQGMKKLSYI 206
 Qy 202 NLGMCNIKOMPNTPLVGLLEEMSGNHFFPEIRPGSEHGLSSKLKLMWNMSOVSLIERNA 261
 Db 207 RIADTNTITPQGLP-PSLTELHLDGKTKITKDDAASLKLGLNNLAKLGLSFSISAVDNGS 265
 Qy 262 FDGLASIVELNAHNNLSLPHDLFTPLRYLYVELHLHNN 300
 Db 266 LANTPHRLHLNNKLAKVPGGV-ADHKYIQVYVYHLNN 303

RESULT 32
 PGS2 SHEEP
 ID PGS2 SHEEP STANDARD; PRT; 360 AA.
 AC QRTT2;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DE 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Decorin precursor (Bone proteoglycan II) (PG-S2) (PG40).
 GN DCN.
 OS Ovis aries (Sheep).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 CC Bovidae; Caprinae; Ovis.
 CC NCBI_TaxID=9940;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Myometrium.
 RX MEDLINE=20113292; PubMed=10644528;
 RA Wu W.X., Zhang Q., Unno N., Derks J.B., Nathanielsz P.W.;
 RT "Characterization of decorin mRNA in pregnant intrauterine tissues of
 the ewe and regulation by steroids.";
 RL Am. J. Physiol. 278:C199-C206(2000).
 CC -i- FUNCTION: May affect the rate of fibrils formation (By
 similarity).
 CC -i- SUBUNIT: Binds to type I and type II collagen, to fibronectin and
 TGF-beta. Forms a ternary complex with MFAP2 and ELN (By
 similarity).
 CC -i- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
 similarity).
 CC -i- PTM: The attached glycosaminoglycan chain can be either
 chondroitin sulfate or dermatan sulfate depending upon the tissue
 of origin (By similarity).
 CC -i- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
 (SLRP) FAMILY. CLASS I SUBFAMILY.
 CC -i- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.

 This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation.
 The European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 or send an email to license@isb-sib.ch).

 DR EMBL; AF125041; AF00585.1; --
 DR HSP; P09661; IAGN.
 DR InterPro; IPR001611; LRR.
 DR InterPro; IPR003372; LRR_Nterm.
 DR InterPro; IPR003591; LRR_Typ.
 DR Pfam; PF00560; LRR; 9.
 DR SMART; PF01462; LRRNT; 1.
 DR SMART; SM00369; LRR_TYP; 2.
 DR SMART; SM00013; LRRNT; 1.
 DR Glycoprotein; Extracellular matrix; Proteoglycan; Repeat;
 KW Leucine-rich repeat; Signal.
 FT SIGNAL 1 16 POTENTIAL.
 FT PROPEP 17 30 BY SIMILARITY.
 FT CHAIN 31 360 DECORIN.
 FT DOMAIN 55 68 CYS-RICH.
 FT REPEAT 74 94 LRR-S 1.
 FT REPEAT 95 118 LRR-T 1.
 FT REPEAT 119 142 LRR-T 2.

FT REPEAT 143 163 LRR-S 2.
 FT REPEAT 164 187 LRR-T 3.
 FT REPEAT 188 213 LRR-T 4.
 FT REPEAT 214 234 LRR-S 3.
 FT REPEAT 235 258 LRR-T 5.
 FT REPEAT 259 282 LRR-T 6.
 FT REPEAT 283 305 LRR-S 4.
 FT REPEAT 306 335 LRR-T 7.
 FT REPEAT 336 360 LRR-T 8.
 FT DISULFID 55 68 BY SIMILARITY.
 FT DISULFID 314 347 O-LINKED (GLYCOSAMINOGLYCAN) (BY
 FT CARBOHYD 34 34 SIMILARITY).
 FT CARBOHYD 212 212 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 263 263 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 304 304 N-LINKED (GLCNAC...) (POTENTIAL).
 SQ SEQUENCE 360 AA; 39972 MW; 0095D0DFDAB8624 CRC64;

Query Match 8.7%; Score 298; DB 1; Length 360;
 Best Local Similarity 30.5%; Pred. No. 9.9e-14;
 Matches 85; Conservative 47; Mismatches 123; Indels 24; Gaps 7;

Qy 38 AASAGQN-----CPSCVCSNPFKVVCTRGSLSEVPQGISNTYILNM 83
 Db 33 ASGIGPEERFHEVPELEPMPVPCRCQC--HLRVVQCSDLGLEKVPKDLPPDTALLDLQ 90
 Qy 84 ENNIQMIQADTFRHLHLHLEVLQIGRNSIRQIEVGAFNGLASLNTLELDNMLTVIPSGAF 143
 Db 91 NNKITEIKGDFKQKLNHLTLILNNKISKISPGAFAPLVKLERLYLSKNQKELP---- 146
 Qy 144 EYLSK-LRELMLRNNPIESIPYANRVPSLMRLDIG-ELKLEYISGAFGLFLNLYL 201
 Db 147 EKMPKTLQELRVHENEITKVRKSVFNGLNQMIWVGLTNPVLSKSSGIENGAPQGMKKLSYI 206
 Qy 202 NLGMCNIKOMPNTPLVGLLEEMSGNHFFPEIRPGSEHGLSSKLKLMWNMSOVSLIERNA 261
 Db 207 RIADTNTITPQGLP-PSLTELHLDGKTKITKDDAASLKLGLNNLAKLGLSFSISAVDNGS 265
 Qy 262 FDGLASIVELNAHNNLSLPHDLFTPLRYLYVELHLHNN 300
 Db 266 LANTPHRLHLNNKLAKVPGGV-ADHKYIQVYVYHLNN 303

RESULT 33
 PGS2 CANFA
 ID PGS2 CANFA STANDARD; PRT; 360 AA.
 AC Q29393;
 DT 15-JUL-1998 (Rel. 36, Created)
 DT 15-JUL-1998 (Rel. 36, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Decorin precursor (Bone proteoglycan II) (PG-S2).
 GN DCN OR DCNIC.
 OS Canis familiaris (Dog).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 CC NCBI_TaxID=9615;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Giant T.T.;
 RL Submitted (DEC-1996) to the EMBL/GenBank/DBSJ databases.
 RN [2]
 RP SEQUENCE OF 244-259 FROM N.A.
 RA Vonta P.J., Brouillette J.A., Yuzbasiyan-Gurkan V., Brewer G.J.;
 RL Submitted (APR-1996) to the EMBL/GenBank/DBSJ databases.
 CC -i- FUNCTION: May affect the rate of fibrils formation (By
 similarity).
 CC -i- SUBUNIT: Binds to type I and type II collagen, to fibronectin and
 TGF-beta. Forms a ternary complex with MFAP2 and ELN (By
 similarity).
 CC -i- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
 similarity).
 CC -i- PTM: The attached glycosaminoglycan chain can be either
 chondroitin sulfate or dermatan sulfate depending upon the tissue

```

CC of origin (By similarity).
CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
CC (SLRP) FAMILY. CLASS I SUBFAMILY.
CC -!- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U83141; AB51245.1; -
CC EMBL; L77684; AA98062.1; -
CC InterPro; IPR001611; LRR.
CC InterPro; IPR003372; LRR_Nterm.
CC InterPro; IPR003591; LRR_Typ.
CC Pfam; PF00560; LRR; 8.
CC Pfam; PF01462; LRRNT; 1.
CC SMART; SM00369; LRR_Typ; 1.
CC SMART; SM00013; LRRNT; 1.
CC Glycoprotein; Extracellular matrix; Proteoglycan; Repeat;
CC Leucine-rich repeat; Signal.
CC SIGNAL 1 16
CC PROPEP 17 30
CC CHAIN 31 360
CC DOMAIN 55 68
CC REPEAT 74 94
CC REPEAT 95 118
CC REPEAT 119 142
CC REPEAT 143 163
CC REPEAT 164 187
CC REPEAT 188 213
CC REPEAT 214 234
CC REPEAT 235 258
CC REPEAT 259 282
CC REPEAT 283 305
CC REPEAT 306 335
CC REPEAT 336 360
CC DISULFID 55 68
CC BY SIMILARITY.
CC BY SIMILARITY.
CC O-LINKED (GLYCOSAMINOGLYCAN) (BY
CC SIMILARITY).
CC N-LINKED (GLCNAC. . .) (POTENTIAL).
CC N-LINKED (GLCNAC. . .) (POTENTIAL).
CC N-LINKED (GLCNAC. . .) (POTENTIAL).
CC SEQUENCE 360 AA; 39980 MW; 99BEE11A9C812906 CRC64;
Query Match 8.6%; Score 297; DB 1; Length 360;
Best Local Similarity 30.5%; Pred. No. 1.2e-13;
Matches 85; Conservative 46; Mismatches 124; Indels 24; Gaps 7;
38 AASAGPON-----CPSCVCSNQFSKVCTRGSLSEVPQGIPTNRYLNLM 83
33 ASGIGPEDRAPMDPELLGVPVCFRCQ--HLVQCSDGLDKVPKLPPTTLLDLQ 90
84 ENNTQMTQDTFRLHLEVLQIGRNSIRIOEVCAFNGLASLNTLEFNLWTVPSGAP 143
91 NNKITEKDGDFKNLKNLHTLILVNNKISKISPCAPTLLKRLYLKRNHLKELP---- 146
144 EYLSK-LRELWLRNNTPESTPSVAFNPVPSLMRLDLQ-ELKLEYISSEGAFLFKYL 201
147 EKMEPTQLCELRAHENETKVKAVFNGNLQMIIVELGTNPLKSGIENGAFQGMKLSVI 206
202 MLGMCNKDMPNLPVLGLBELENGSNHFPPIRPGSPHGLSLLKXLMVMSQVSLIERNA 261
207 RIADNTNTTTPQGLP-PSLTHELHEGNNIKTKVDASLLKGLNLIKGLSPNLSAVDNGT 265
262 FDGLASIVELNLANHNTSSLPDHLFTPLRYLVELHLHNN 300
266 LANTPHRLHLDNKNKLRVPGGL-AEHKTIQVYLHNN 303

```

```

RESULT 34
PGS2 RABIT
ID Q28888; Q28608; STANDARD; PRT; 360 AA.
AC Q28888; Q28608;
DT 15-JUL-1999 (Rel. 38, Created)
DT 15-JUL-1999 (Rel. 38, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Decorin precursor (Bone proteoglycan II) (PG-S2).
GN DCN.
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
RN NCBI_TaxID=9986;
RN [1]
SEQUENCE FROM N.A.
RP TISSUE=Cornea;
RX MEDLINE=95122319; PubMed=7822148;
RA Zhan Q., Burrows R., Cintron C.;
RT "Cloning and in situ hybridization of rabbit decorin in corneal
RL tissues.";
RL Invest. Ophthalmol. Vis. Sci. 36:206-215(1995).
RN [2]
SEQUENCE OF 38-358 FROM N.A.
RP TISSUE=Cartilage;
RA Hering T.M., Kollar J.;
RT "The primary structure of rabbit chondrocyte decorin deduced from
RL nucleotide sequence.";
RL Submitted (NOV-1993) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: May affect the rate of fibrils formation (By
CC similarity).
CC -!- SUBUNIT: Binds to type I and type II collagen, to fibronectin and
CC TGF-beta. Forms a ternary complex with MFAP2 and ELN (By
CC similarity).
CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
CC similarity).
CC -!- PTM: The attached glycosaminoglycan chain can be either
CC chondroitin sulfate or dermatan sulfate depending upon the tissue
CC of origin (By similarity).
CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
CC (SLRP) FAMILY. CLASS I SUBFAMILY.
CC -!- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; S76584; AB33083.1; -
CC EMBL; U03394; AAC04315.1; -
CC PIR; I47020; I47020.
CC InterPro; IPR001611; LRR.
CC InterPro; IPR003372; LRR_Nterm.
CC InterPro; IPR003591; LRR_Typ.
CC Pfam; PF00560; LRR; 8.
CC Pfam; PF01462; LRRNT; 1.
CC SMART; SM00369; LRR_Typ; 1.
CC SMART; SM00013; LRRNT; 1.
CC Glycoprotein; Extracellular matrix; Proteoglycan; Repeat;
CC Leucine-rich repeat; Signal.
CC SIGNAL 1 16
CC PROPEP 17 30
CC CHAIN 31 360
CC DOMAIN 55 68
CC REPEAT 74 94
CC REPEAT 95 118
CC REPEAT 119 142
CC REPEAT 143 163
CC REPEAT 164 187
CC REPEAT 188 213

```



```

PT REPEAT 214 234 LRR-S 3.
FT REPEAT 235 258 LRR-T 5.
FT REPEAT 259 282 LRR-T 6.
FT REPEAT 283 305 LRR-S 4.
FT REPEAT 306 335 LRR-T 7.
FT REPEAT 336 360 LRR-T 8.
FT DISULFID 55 68 BY SIMILARITY.
FT DISULFID 314 347 BY SIMILARITY.
FT CARBOHYD 34 34 O-LINKED (GLYCOSAMINOGLYCAN) (BY
SIMILARITY).
FT CARBOHYD 212 212 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 263 263 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 304 304 N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 360 AA; 339896 MW; 0B50C6756FE02369 CRC64;

Query Match 8.5%; Score 293.5; DB 1; Length 360;
Best Local Similarity 32.2%; Pred. No. 28-13;
Matches 84; Conservative 44; Mismatches 122; Indels 11; Gaps 7;

QY 42 GPONCSVCSCSNQPSKVVCTRRGLSEVPQGPSTNRYLNLMENNIOIQAOTPRHLHL 101
Db 52 GPV-CFPRQC--HLRVQCSDLGLERVPKDPDPDTLLDLQNNKITEKGDFKNKML 108

QY 102 EVLQGRNSIRQIEVGAFNGLASLNTLEFDNWLTVIPSGAFYLSK-LRELWLRNPIE 160
Db 109 HALILVNNKISKISPAFTPLVKLERLYLSKNHLKELP----EKMPKSLQELRAHENEIT 164

QY 161 SPSYAFNRVPSLMRLDLG-ELKLEYISEGAFGLFNKLYLNLMGNCKNKPNTLPLVG 219
Db 165 KVKSVFSGANQIVIELGTNPLKSSGIENGAFQGMKLSYRIADTNITTPQGLP-PS 223

QY 220 LEELEMSGNHPPRPGSPHGLSSKLKLVWMSQVSLIERNAPDGLASIVELNLAHNLS 279
Db 224 LTELHLDGNKTKIDASSLGLNNAKLGLSFNDISAVDNGSLANAPHRELHLDNNKLI 283

QY 280 SLPHDLFTPLRYLVELHLHN 300
Db 284 RVPFGL-ADHKYIQVYVYLNHN 303

RESULT 35
PGS2 CHICK STANDARD; PRT; 357 AA.
ID PGS2_CHICK
AC P28675;
DT 01-DEC-1992 (Rel. 24, Created)
DT 01-DEC-1992 (Rel. 24, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Decorin precursor (Bone proteoglycan II) (PG-S2).
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RC STRAIN=White leghorn; TISSUE=Cornes;
RX MEDLINE=82296795; PubMed=1605630;
RA Li W., Vergnes J.-F., Cornuet P.K., Hassell J.R.;
RT "cDNA clone to chick corneal chondroitin/dermatan sulfate
proteoglycan reveals identity to decorin."
RL Arch. Biochem. Biophys. 296:190-197(1992).
CC -1- FUNCTION: May affect the rate of fibrils formation (By
similarity).
CC -1- SUBUNIT: Binds to type I and type II collagen, to fibronectin and
TCP-beta. Forms a ternary complex with MFAP2 and ELN (By
similarity).
CC -1- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
similarity).
CC -1- PTM: The attached glycosaminoglycan chain can be either
chondroitin sulfate or dermatan sulfate depending upon the tissue
of origin (By similarity).
CC -1- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
(SLRP) FAMILY. CLASS I SUBFAMILY.

```

```

CC -1- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; X63797; CAA45318.1; -.
CC PIR; S24317; S24317.
CC InterPro; IPR001611; LRR
CC InterPro; IPR000372; LRR_Nterm.
CC InterPro; IPR003591; LRR_Typ.
CC Pfam; PF00560; LRR; 10.
CC Pfam; PF01462; LRRNT; 1.
CC SMART; SM00369; LRR_TVP; 2.
CC SMART; SM00013; LRRNT; 1.
CC Glycoprotein; Extracellular matrix; Proteoglycan; Repeat;
KW Leucine-rich repeat; Signal.
FT SIGNAL 1 16
FT PROPEP 17 30
FT CHAIN 31 357 DECORIN.
FT DOMAIN 52 65 CYS-RICH.
FT REPEAT 71 91 LRR-S 1.
FT REPEAT 92 115 LRR-T 1.
FT REPEAT 116 139 LRR-T 2.
FT REPEAT 140 160 LRR-S 2.
FT REPEAT 161 184 LRR-T 3.
FT REPEAT 185 210 LRR-T 4.
FT REPEAT 211 231 LRR-S 3.
FT REPEAT 232 255 LRR-T 5.
FT REPEAT 256 279 LRR-T 6.
FT REPEAT 280 302 LRR-S 4.
FT REPEAT 303 332 LRR-T 7.
FT REPEAT 333 357 LRR-T 8.
FT DISULFID 52 65 BY SIMILARITY.
FT DISULFID 311 344 BY SIMILARITY.
FT CARBOHYD 34 34 O-LINKED (GLYCOSAMINOGLYCAN) (BY
SIMILARITY).
FT CARBOHYD 209 209 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 260 260 N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 357 AA; 39687 MW; 31B104C7C3CD711D CRC64;

Query Match 8.4%; Score 287.5; DB 1; Length 357;
Best Local Similarity 32.2%; Pred. No. 5.3e-13;
Matches 84; Conservative 43; Mismatches 123; Indels 11; Gaps 7;

QY 42 GPONCSVCSCSNQPSKVVCTRRGLSEVPQGPSTNRYLNLMENNIOIQAOTPRHLHL 101
Db 49 GPV-CFPRQC--HLRVQCSDLGLERVPKDPDPDTLLDLQNNKITEKGDFKNKML 105

QY 102 EVLQGRNSIRQIEVGAFNGLASLNTLEFDNWLTVIPSGAFYLSK-LRELWLRNPIE 160
Db 106 HALILVNNKISKISPAFTPLVKLERLYLSKNHLKELP----ENMPKSLQELRAHENEIS 161

QY 161 SPSYAFNRVPSLMRLDLG-ELKLEYISEGAFGLFNKLYLNLMGNCKNKPNTLPLVG 219
Db 162 KLRKAVFNGLNQIVIELGTNPLKSSGIENGAFQGMKLSYRIADTNITTPQGLP-PS 220

QY 220 LEELEMSGNHPPRPGSPHGLSSKLKLVWMSQVSLIERNAPDGLASIVELNLAHNLS 279
Db 221 LTELHLDGNKISKIDAGLSGLTNLAKLGLSTNSISVENGSLNVPHLRELHLDNNELV 280

QY 280 SLPHDLFTPLRYLVELHLHN 300
Db 281 RVPFGL-GEHKYIQVYVYLNHN 300

RESULT 36
PGS2_RAT STANDARD; PRT; 354 AA.
ID PGS2_RAT

```

AC Q01129;
 DT 01-APR-1993 (Rel. 25, Created)
 DT 01-APR-1993 (Rel. 25, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Decorin precursor (Bone proteoglycan II) (PG-S2) (PG40) (Dermatan sulfate proteoglycan-II) (DSPG).
 EN DCN.
 JS Rattus norvegicus (Rat).
 DC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 DX NCBI_TaxID=10116;
 ZN [1]_TaxID=93934;
 RP SEQUENCE FROM N.A.
 RC STRAIN=Sprague-Dawley; TISSUE=Uterus;
 RX MEDLINE=93003331; PubMed=1390895;
 RA Abramson S.R., Woessner J.F.;
 RT "cDNA sequence for rat dermatan sulfate proteoglycan-II (decorin)."; Biochim. Biophys. Acta 1132:225-227(1992).
 ZN [2]
 RP SEQUENCE OF 11-354 FROM N.A.
 RX MEDLINE=93154359; PubMed=1493796;
 RA Asundi V.K., Dreher K.L.;
 RT "Molecular characterization of vascular smooth muscle decorin: deduced core protein structure and regulation of gene expression."; Eur. J. Cell Biol. 59:314-321(1992).
 ZN [3]
 RP SEQUENCE OF 31-48 AND 171-191.
 RC STRAIN=Sprague-Dawley; TISSUE=Uterus;
 RX MEDLINE=89350825; PubMed=2764879;
 RA Kokenyesi R., Woessner J.F.;
 RT "Purification and characterization of a small dermatan sulphate proteoglycan implicated in the dilatation of the rat uterine cervix."; Biochem. J. 260:413-419(1989).
 ZN [4]
 RP FUNCTION: May affect the rate of fibrils formation (By similarity). May be implicated in the dilatation of the rat cervix.
 ZN [5]
 RP SUBUNIT: Binds to type I and type II collagen, to fibronectin and TGF-beta. Forms a ternary complex with MPAP2 and ELN (By similarity).
 ZN [6]
 RP SUBCELLULAR LOCATION: Secreted; extracellular matrix.
 ZN [7]
 RP DEVELOPMENTAL STAGE: The amount of DSPG per cervix increases 4-fold during pregnancy, then falls precipitously within 1 day post partum.
 ZN [8]
 RP PTM: The attached glycosaminoglycan chain can be either chondroitin sulfate or dermatan sulfate depending upon the tissue of origin (By similarity).
 ZN [9]
 RP SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN (SLRP) FAMILY. CLASS I SUBFAMILY.
 ZN [10]
 RP SIMILARITY: Contains 12 leucine-rich (LRR) repeats.
 ZN [11]
 RP This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).
 ZN [12]
 RP EMBL; 212298; CAA78170.1; -
 ZN EMBL; X59859; CAA42519.1; -
 ZN F01; S29145; S29145.
 ZN InterPro; IPR001611; LRR.
 ZN InterPro; IPR003372; LRR_Nterm.
 ZN InterPro; IPR003591; LRR_Typ.
 ZN Pfam; PF00560; LRR; 9.
 ZN Pfam; PF01462; LRRNT; 1.
 ZN SMART; SM00369; LRR_Typ; 2.
 ZN SMART; SM00013; LRRNT; 1.
 ZN Glycoprotein; Extracellular matrix; Proteoglycan; Repeat;
 ZN Leucine-rich repeat; Signal.
 ZN SIGNAL 1 16
 ZN PROPEP 17 30
 ZN POTENTIAL.

FT CHAIN 31 354 DECORIN.
 FT DOMAIN 49 62 CYS-RICH.
 FT REPEAT 68 88 LRR-S 1.
 FT REPEAT 89 112 LRR-T 1.
 FT REPEAT 113 136 LRR-T 2.
 FT REPEAT 137 157 LRR-S 2.
 FT REPEAT 158 181 LRR-T 3.
 FT REPEAT 182 207 LRR-T 4.
 FT REPEAT 208 228 LRR-S 3.
 FT REPEAT 229 252 LRR-T 5.
 FT REPEAT 253 276 LRR-T 6.
 FT REPEAT 277 299 LRR-S 4.
 FT REPEAT 300 329 LRR-T 7.
 FT REPEAT 330 354 LRR-T 8.
 FT DISULFID 49 62 BY SIMILARITY.
 FT DISULFID 308 341 BY SIMILARITY.
 FT CARBOHYD 34 34 O-LINKED (GLYCOSAMINOGLYCAN) (BY SIMILARITY).
 FT CARBOHYD 184 184 O-LINKED (GLYCOSAMINOGLYCAN) (BY SIMILARITY).
 FT CARBOHYD 206 206 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 241 241 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 257 257 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 298 298 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 354 AA; 39805 MW; 152D92F42D9F5A5B CRC64;
 Query Match 8.3%; Score 286.5; DB 1; Length 354;
 Best Local Similarity 31.3%; Pred. No. 6.2e-13;
 Matches 83; Conservative 44; Mismatches 123; Indels 15; Gaps 7;
 QY 43 PQN-----CPSCVCSNQPSKVCTRRGLSEVPQIGIPSNTRYLNLMENNIQIQAOTFRH 97
 DB 41 PDNPLSMCPYRCQC--HLRVVQCSDLGLDKVPWFPPDTLLDLQNNKLTKEKGAFTN 98
 QY 98 LHHLEVLQGNLSIRQIEVGAFNGLASLNTLELPDNMLTVIPSGAFYLSK-LRELWLN 156
 DB 99 LKDLHTLILVNNKISKISPEAFKPLVLERLYLSKNELKELP-----EKLKTLQBLELHD 154
 QY 157 NPISIPSYAFNRVPSLMRLDL-CELKKEIVISGAPGLFNLKYLNLGMCNCKDMENLT 215
 DB 155 NEITYLKSVENGLNRNIVIELGNPLKNSIENGALQGMKGLGYIRISDTNITAIPOGL 214
 QY 216 PLVGLLEHLEMSGNHFFPIRPGSFHLSLKKLWMNSQVSLIERNAPDGLASIVELWIAH 275
 DB 215 P-TGISELHLDGNIKIAKVDAASLKGMSNLKSLGFSNITSITWVNGSLANVPHLRELHLDN 273
 QY 276 NNLSSLPHDLFTPLRYLVELLHNN 300
 DB 274 NKLRLVPAGL-AQHKYVQVYVLENN 297
 RESULT 37
 PGS2_COTJA
 ID PGS2_COTJA STANDARD; PRT; 356 AA.
 AC Q92568;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Decorin precursor (Bone proteoglycan II) (PG-S2).
 EN DCN.
 OS Coturnix coturnix japonica (Japanese quail).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae; OC Coturnix.
 OC NCBI_TaxID=93934;
 ZN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Cornea, and Sclera;
 RX MEDLINE=20556471; PubMed=11102759;
 RA Corpuz L.M., Dunlevy J.R., Hassell J.R., Conrad A.H., Conrad G.W.;
 RT "Molecular cloning and relative tissue expression of decorin and lumican in embryonic quail cornea.";
 RT Matrix Biol. 19:699-704(2000).

CC -!- FUNCTION: May affect the rate of fibrils formation (By
 CC similarity).
 CC -!- SUBUNIT: Binds to type I and type II collagen, to fibronectin and
 CC TGF-beta. Forms a ternary complex with MAP2 and SLN (By
 CC similarity).
 CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
 CC similarity).
 CC -!- PTM: The attached glycosaminoglycan chain can be either
 CC chondroitin sulfate or dermatan sulfate depending upon the tissue
 CC of origin (By similarity).
 CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
 CC (SLRP) FAMILY. CLASS 12 LEUCINE-RICH (LRR) repeats.
 CC -!- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC ENBL: AF125250; AAG48154.1; --
 CC InterPro: IPR001611; LRR.
 CC InterPro: IPR000372; LRR Nterm.
 CC InterPro: IPR003591; LRR_Typ.
 CC Pfam: PF00560; LRR; 10.
 CC SMART: PF01462; LRRNT; 1.
 CC SMART: SM00369; LRR_Typ; 2.
 CC SMART: SM00013; LRRNT; 1.
 CC SMART: SM00013; LRRNT; 1.
 CC GlycoProtein: Extracellular matrix; Proteoglycan; Repeat;
 CC Leucine-rich repeat; Signal.
 CC SIGNAL 1 15 POTENTIAL.
 CC FT PROPEP 16 29 BY SIMILARITY.
 CC FT CHAIN 30 356 DECORIN.
 CC FT DOMAIN 51 64 CYS-RICH.
 CC FT REPEAT 70 90 LRR-S 1.
 CC FT REPEAT 91 114 LRR-T 1.
 CC FT REPEAT 115 138 LRR-T 2.
 CC FT REPEAT 139 159 LRR-S 2.
 CC FT REPEAT 160 183 LRR-T 3.
 CC FT REPEAT 184 209 LRR-T 4.
 CC FT REPEAT 210 230 LRR-S 3.
 CC FT REPEAT 231 254 LRR-T 5.
 CC FT REPEAT 255 278 LRR-T 6.
 CC FT REPEAT 279 301 LRR-S 4.
 CC FT REPEAT 302 331 LRR-T 7.
 CC FT REPEAT 332 356 LRR-T 8.
 CC FT DISULFID 51 64 BY SIMILARITY.
 CC FT CARBOHYD 310 343 O-LINKED (GLYCOSAMINOGLYCAN) (BY
 CC CARBOHYD 33 33 SIMILARITY).
 CC FT CARBOHYD 208 208 N-LINKED (GLCNAC...) (POTENTIAL).
 CC FT CARBOHYD 259 259 N-LINKED (GLCNAC...) (POTENTIAL).
 CC SQ SEQUENCE 356 AA; 39571 MW; BE9583CCARD7DH26 CRC64;
 Query Match 8.3%; Score 284.5; DB 1; Length 356;
 Best Local Similarity 32.2%; Pred. No. 8.6e-13;
 Matches 84; Conservative 43; Mismatches 123; Indels 11; Gaps 7;
 QY 42 GPQPCVCSQSFQSKVCTRGLESEVPGIPSNTRYLNLMENNTQMCAQDFPHLHL 101
 DB 48 GPV-CPPRCQC--HLRVVQCSGLERVPKLPDPTLLDLQNNKITEIRDGDFKNLKNL 104
 QY 102 EVLQGLGNSIQTEVGAFNGLASLNTLELFDNNLTVIPSGAFYLSK-LRELWLRNNPIE 160
 DB 105 HALILVNKISKISQPAFAFKLERLYLSKNKLKLP-----ENPKSQEIRAHENEIS 160
 QY 161 SIPSAYFNRPVPSMRDLG-ELKKLEYISGAEGLFNKLYNLGMCNTKMDPNTPLVG 219
 DB 161 KLRKAVENGINQVTLVBLGTNPLKSSGIENGAFQGMKRLSYTRIDNTNITSPKGLP-PS 219
 QY 220 LEELEMSGNHFPETRFPSFHLGSLKGLWVMSQVSLIERNAPDGLASLVELNLAHNLIS 279

DB 220 LTELHLDEGKISKIDAGSLGSLTNLAKGLSFNSISSVSGSLNNYPHLRELHANNELV 279
 QY 280 SLPHDLFTPLRLYLVELLHLEN 300
 DB 280 RVPISGL-GEHKYIQVYLENN 299
 RESULT 38
 TLR7_MOUSE STANDARD; PRT; 1050 AA.
 AC P5681; Q92311;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, last sequence update)
 DT 28-FEB-2003 (Rel. 41, last annotation update)
 DE Toll-like receptor 7 precursor.
 GN TLR7.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Macrophage;
 RA Heil F.J., Lipford G.B., Wagner H., Bauer S.M.;
 RT 'Molecular cloning of murine Toll-Like-Receptor 7.';
 RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
 CC -!- FUNCTION: Participates in the innate immune response to microbial
 CC agents. Acts via MyD88 and TRAF6, leading to NF-kappa-B
 CC activation, cytokine secretion and the inflammatory response (By
 CC similarity).
 CC -!- SUBUNIT: Binds MyD88 via their respective TIR domains (By
 CC similarity).
 CC -!- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
 CC -!- SIMILARITY: BELONGS TO THE TOLL-LIKE RECEPTOR FAMILY.
 CC -!- SIMILARITY: Contains 1 TIR domain.
 CC -!- SIMILARITY: Contains 28 leucine-rich (LRR) repeats.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC ENBL: AY035889; AAK62676.1; --
 CC MGD; MGI:2176882; Tlr7.
 CC InterPro: IPR004075; Tlr_receptor1.
 CC InterPro: IPR001611; LRR.
 CC InterPro: IPR000483; LRR_Cterm.
 CC InterPro: IPR000372; LRR_Nterm.
 CC InterPro: IPR003591; LRR_Typ.
 CC InterPro: IPR000157; TIR_domain.
 CC Pfam: PF00560; LRR; 11.
 CC Pfam: PF01463; LRRCT; 1.
 CC Pfam: PF01582; TIR; 1.
 CC PRINTS: PR01537; INTRLNRLRP.
 CC PRINTS: PR00019; LEURICHRPT.
 CC SMART: SM00369; LRR_Typ; 3.
 CC SMART: SM00082; LRRCT; 1.
 CC SMART: SM00013; LRRNT; 1.
 CC PROSITE: PS0104; TIR; 1.
 CC Receptor; Immune response; Inflammatory response; Signal;
 CC Transmembrane; Repeat; Leucine-rich repeat; Glycoprotein.
 CC SIGNAL 1 26
 CC FT CHAIN 27 1050 TOLL-LIKE RECEPTOR 7.
 CC FT DOMAIN 27 837 EXTRACELLULAR (POTENTIAL).
 CC FT TRANSMEM 838 858 POTENTIAL.
 CC FT DOMAIN 859 1050 CYTOPLASMIC (POTENTIAL).
 CC FT REPEAT 42 64 LRR 1.
 CC FT REPEAT 65 87 LRR 2.
 CC FT REPEAT 89 111 LRR 3.


```

FT REPEAT 182 207 LRR-T 4.
FT REPEAT 208 228 LRR-S 3.
FT REPEAT 229 252 LRR-T 5.
FT REPEAT 253 276 LRR-T 6.
FT REPEAT 277 299 LRR-S 4.
FT REPEAT 300 329 LRR-T 7.
FT REPEAT 330 354 LRR-T 8.
FT DISULFID 49 62 BY SIMILARITY.
FT DISULFID 308 341 BY SIMILARITY.
FT CARBOHYD 34 34 O-LINKED (GLYCOSAMINOGLYCAN) (BY SIMILARITY).
FT CARBOHYD 206 206 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 241 241 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 257 257 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 298 298 N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 354 AA; 33809 MW; F05B5CC08DCABF6F CRC64;

Query Match 8.1%; Score 279.5; DB 1; Length 354;
Best Local Similarity 30.7%; Pred. No. 1.9e-12;
Matches 81; Conservative 45; Mismatches 125; Indels 13; Gaps 6;

QY 43 PQN-----CPSCVCSNQSKVCTRGISEVPGQIPSNTRYLMNENNIQMIQADTFRH 97
Db 41 PDNPLISMCPYRCQC--HLRVVQCSDGLGDKVPDPDPDTLLDQNNKITEIKGAFKN 98
QY 98 LHLEVLQGRNSIRQIEVGAFNGLASLNTLEFNMLTVIPSGAFVLSKLRRLMLNN 157
Db 99 LKDLHTLILVNNKISKISEAPKPLVKLRILYLSKNQKELPE---KMPRTLOELRVHEN 155
QY 158 PISIPSYAFNRVPSLMRLDL-GELKKLEYISEGAFGLFNKYLNLGMCNKMNPNT 216
Db 156 EITKLRKSPFNGLNVLVIELOGNPLKNSIENGAFQGLKLSYIRISDTNITAIPOGLP 215
QY 217 LVGLELEKSGNHFFPIRPGSHGLSSKLKLMWMSQVSLIERNAPDGLASLVELNLAHN 276
Db 216 -TSLTEVHLGDKNITVDAPSLKGLNLKSLGSPNSIIVMNGSLANVPHLRHLDDNN 274
QY 277 NLSSPLHDLFTPLRYLVLELHNN 300
Db 275 KLLRVPAQL-AQHKYIQVVVLANN 297

RESULT 40
Y918_HUMAN STANDARD; PRT; 966 AA.
ID C94931;
DC 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Hypothetical protein KIAA0918 (Fragment).
GN KIAA0918.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN 1;
RS SEQUENCE FROM N.A.
RP TISSUE=Brain;
RC MEDLINE=99156230; PubMed=10048485;
RA Nagase T., Ishikawa K.-I., Suyama M., Kikuno R., Hirosewa M.,
RA Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes. XII.
RT The complete sequences of 100 new cDNA clones from brain which code
RT for large proteins in vitro."
RL DNA Res. 5:355-364 (1998).
CC -1- SIMILARITY: Contains 11 leucine-rich (LRR) repeats.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/

```

```

or send an email to license@isb-sib.ch).
CC EMBL; AB020725; BAA74941.1; -.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003591; LRR_Typ.
DR Pfam; PF00580; LRR; 8.
DR Pfam; PF01463; LRRCT; 2.
DR Pfam; PF01462; LRRNT; 1.
DR SMART; SM00369; LRR_TVP; 4.
DR SMART; SM00082; LRRCT; 2.
DR SMART; SM00013; LRRNT; 1.
KW Hypothetical protein; Repeat; Leucine-rich repeat.
FT NON_TER 1 1
FT REPEAT 88 111 LRR 1.
FT REPEAT 112 135 LRR 2.
FT REPEAT 136 159 LRR 3.
FT REPEAT 161 183 LRR 4.
FT REPEAT 184 207 LRR 5.
FT REPEAT 209 231 LRR 6.
FT REPEAT 240 263 LRR 7.
FT REPEAT 264 287 LRR 8.
FT REPEAT 288 311 LRR 9.
FT REPEAT 312 335 LRR 10.
FT REPEAT 336 359 LRR 11.
SQ SEQUENCE 966 AA; 108296 MW; AID236413E2B27DF CRC64;

Query Match 8.1%; Score 277; DB 1; Length 966;
Best Local Similarity 20.3%; Pred. No. 1.1e-11;
Matches 130; Conservative 78; Mismatches 173; Indels 260; Gaps 22;

QY 43 PQMCPVCSNQSKVCTRGISEVPGQIPSNTRYLMNENNIQMIQADTFRH 96
Db 379 PLRCPTACSCNQLQISDLGLNVCQERKESIAELQPKVPKPKMYLTENYIAVVRTDFL 438
QY 97 HLHLVLQGRNSIRQIEVGAFNGLASLNTLEFNMLTVIPSGAFVLSKLRRLMLNN 156
Db 439 EATGLDLHLGNRISMIQDRAFGD-----LTLNRLYLNG 474
QY 157 NPIESIPSYAFNRVPSLMRLDLGELKKLEYISEGAFGLFNKYLNLGMCNKMNPNT 216
Db 475 N-----RIERLSPELFYGLQSLQYLFL----- 496
QY 217 LVGLELEKSGNHFFPIRPGSHGLSSKLKLMWMSQVSLIERNAPDGLASLVELNLAHN 276
Db 497 -----QYNLIRIEIQSGTFDPVPENLQLLFLNNLLQAMPQSGVFSGL-TLLRLNLRSN 546
QY 277 NLSSLP-HDLFTPLRYLVLELHNNPNCDCDILAWLWLRVYIPNTSTCCGRCHAPNMG 335
Db 547 HPTSLPVSGLDQLKSLIQIDLDHPDWDCTDIVGNKLVWVQL----- 589
QY 336 RGRYLVEVDQASFCQSAPPFMDAPRDLNISEGRMAELKCRTPPMSSVKWLLPNGTVLSHA 395
Db 590 --KVGVLVDEVI--CKAP-----KKFAETDKRSIK----- 615
QY 396 SRHPRISSVINDGTLNFSVLLSDTGYYTCMTVNVAGNSNAYLNVAELNNTSNYSFT 455
Db 616 -----SELLCPD-----YS 624
QY 456 TVTVETTESIPDITTKKPKVPTTGTGYQPAYTTSTT-VLIQTTTRVPKQV-----AV 506
Db 625 DVVVSF-----PTPSIQVPARTSAVTPAVRLNSTGAPASLGGAGGASSV 669
QY 507 PATDTTDMQTSLDEVMKTKIIIGCFVAVTLAAAMLIVFKLRKQOQSTVTVAARTV 566
Db 670 PLS-----VLISLLLV--FIMSVEFAAGLFLVMKRRKKKQSDHTSTNNSDV 715
QY 567 ELIQVDEIDIPAAATAAPSGVSGEAVLPTIRHDHINY-----TYK 611
Db 716 SSFNMQYSV-----YGGGGGTGG-----HFAHVVHHRGPALPKVKTPAGHVYVI 760
QY 612 PAHGAHWHTENSL-----GNS-----LHPTVTVTISEPIIQ 641

```


CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

DR EMBL; AF163568; AAG23723.1; -
 DR InterPro; IPR001611; LRR.
 DR InterPro; IPR00372; LRR Nterm.
 DR InterPro; IPR003591; LRR typ.
 DR Pfam; PF00560; LRR; 9.
 DR Pfam; PF01462; LRRNT; 1.
 DR PRINTS; PR00019; LEURICHRPT.
 DR SMART; SM00013; LRRNT; 1.
 KW Glycoprotein; Extracellular matrix; Repeat; Leucine-rich repeat;
 KW Signal.
 FT SIGNAL 1 21 POTENTIAL.
 FT CHAIN 22 381 PROLARGIN.
 FT DOMAIN 72 88 CIS-RICH.
 FT REPEAT 94 113 LRR-S 1.
 FT REPEAT 114 137 LRR-T 1.
 FT REPEAT 138 161 LRR-S 2.
 FT REPEAT 162 182 LRR-S 2.
 FT REPEAT 183 206 LRR-T 4.
 FT REPEAT 207 232 LRR-T 4.
 FT REPEAT 233 253 LRR-S 3.
 FT REPEAT 254 277 LRR-T 5.
 FT REPEAT 278 302 LRR-T 6.
 FT REPEAT 303 322 LRR-S 4.
 FT REPEAT 323 361 LRR-T 7.
 FT REPEAT 362 381 LRR-T 8.
 FT DOMAIN 196 201 POLY-LEU.
 FT DISULFID 331 372 BY SIMILARITY.
 FT CARBOHYD 123 123 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 288 288 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 319 319 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 326 326 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 381 AA; 43682 MW; 23DA95C01BB772A0 CRC64;

Query Match 7.8%; Score 267; DB 1; Length 381;
 Best Local Similarity 32.1%; Pred. No. 1.6e-11;
 Matches 79; Conservative 45; Mismatches 104; Indels 18; Gaps 8;
 QY 45 NCPSCVCSNQF-SKVVTRGLSVQPGIPSNTRYLNLMNNTQMIOADTFRLHLELV 103
 DB 71 DCPRECYCPDPFPPSALYCDSENLRKVPV-IPSRHYLYLQNNFTPLDVSFKNATGLRW 129
 QY 104 LQLGRNSIRQIEVGAFNGLASLNTLELFDNNLTVIPSGAFYLSKLRELWLNPNPIESIP 163
 DB 130 INLDNNIRKVRQVRVLEKLPVLFVLEKQLEEVPAALPNLEQLR---LSQNOISRIIP 186
 QY 164 SVAFNVPVSLMRDLGELKKLEYISEG-----AFGLFNLYNLGNLGNLKNLTPLV 218
 DB 187 PGVFSKLENLLLDLQHNK----LSDGVKEDPTFGKLNGLQMLNLAHTLRKPPKVP-S 241
 QY 219 GLEELMSGNFFPEIRPGSFHGLSSKLKLVWNSQVS--LTERNAFDGLASLVLMIAHN 276
 DB 242 AIHQVLYDSNRIEAPSCVPGFNGFNLAIRLNYNQLSDRGLPKNSFN-ISNLLVHLSHN 300
 QY 277 NLSLIP 282
 DB 301 RISSVP 306

RESULT 44
 CBP8_HUMAN
 ID CBP8_HUMAN STANDARD; PRT; 536 AA.
 AC P22792;
 DT 01-AUG-1991 (Rel. 19, Created)
 DT 01-AUG-1991 (Rel. 19, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Carboxypeptidase N 83 kDa chain (Carboxypeptidase N regulatory

DE subunit) (Fragment).
 GN CPN2.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Sutheria; Primates; Catarrhini; Homnidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX TISSUE=Liver;
 RC MEDLINE=90094386; PubMed=2378615;
 RA Tan F., Weerasinghe D.K., Skidgel R.A., Tamei H., Kaul R.K.,
 RA Roninson I.B., Schilling J.W., Erdoes E.G.;
 RT "The deduced protein sequence of the human carboxypeptidase N high
 RT molecular weight subunit reveals the presence of leucine-rich tandem
 RT repeats.";
 RL J. Biol. Chem. 265:13-19(1990).
 RN [2]
 RP PARTIAL SEQUENCE.
 RX MEDLINE=88309120; PubMed=3408501;
 RA Skidgel R.A., Bennett C.D., Schilling J.W., Tan F., Weerasinghe D.K.,
 RA Erdoes E.G.;
 RT "Amino acid sequence of the N-terminus and selected tryptic peptides
 RT of the active subunit of human plasma carboxypeptidase N: comparison
 RT with other carboxypeptidases.";
 RL Biochem. Biophys. Res. Commun. 154:1323-1329(1988).
 CC -!- FUNCTION; THE 83 kDa SUBUNIT BINDS AND STABILIZES THE CATALYTIC
 CC SUBUNIT AT 37 DEGREES CELSIUS AND KEEPS IT IN CIRCULATION. UNDER
 CC SOME CIRCUMSTANCES IT MAY BE AN ALLOSTERIC MODIFIER OF THE
 CC CATALYTIC SUBUNIT.
 CC -!- SUBUNIT: Tetramer of two catalytic chains and two glycosylated
 CC INACTIVE CHAINS.
 CC -!- SUBCELLULAR LOCATION: Secreted
 CC -!- PTM: O-GLYCOSYLATED IN THE SER/THR-RICH REGION (POTENTIAL).
 CC -!- FTM: WHETHER OR NOT ANY CYS RESIDUES PARTICIPATE IN INTRACHAIN
 CC BONDS IS UNKNOWN, BUT THEY DO NOT FORM INTERCHAIN DISULFIDE BONDS
 CC WITH THE 50 kDa CATALYTIC SUBUNIT.
 CC -!- DISEASE: A COMPLETE ABSENCE OF THE ENZYME IS NOT CONSIDERED TO BE
 CC COMPATIBLE WITH LIFE.
 CC -!- SIMILARITY: Contains 13 leucine-rich (LRR) repeats.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

DR EMBL; J05158; AAA51921.1; -
 DR PIR; A34901; A34901.
 DR Genew; HGNC:2313; CPN2.
 DR MIM; 603104; -
 DR GO; GO:0005576; C:extracellular; NAS.
 DR GO; GO:0003234; F:enzyme regulator activity; NAS.
 DR GO; GO:0017028; F:enzyme stabilization activity; NAS.
 DR InterPro; IPR001611; LRR.
 DR InterPro; IPR00372; LRR Nterm.
 DR InterPro; IPR003591; LRR typ.
 DR Pfam; PF00560; LRR; 11.
 DR PRINTS; PR00019; LEURICHRPT.
 DR SMART; SM00369; LRR typ; 10.
 DR SMART; SM00013; LRRNT; 1.
 KW Repeat; Leucine-rich repeat; Glycoprotein.
 FT NON TER 1 1
 FT REPEAT 51 74 LRR 1.
 FT REPEAT 75 98 LRR 2.
 FT REPEAT 99 122 LRR 3.
 FT REPEAT 123 146 LRR 4.
 FT REPEAT 148 170 LRR 5.
 FT REPEAT 171 194 LRR 6.
 FT REPEAT 196 218 LRR 7.
 FT REPEAT 220 242 LRR 8.
 FT REPEAT 243 266 LRR 9.


```
FT REPEAT 268 290 LRR 10.
FT REPEAT 291 314 LRR 11.
FT REPEAT 316 338 LRR 12.
FT REPEAT 339 362 LRR 13.
FT DOMAIN 359 379 SER/THR-RICH.
FT CARBOHYD 53 53 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 90 90 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 98 98 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 207 207 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 245 245 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 327 327 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 338 338 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 495 495 N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 536 AA; 58649 MW; D524011243C9B2A6 CRC64;

Query Match 7.8; Score 267; DB 1; Length 536;
Best Local Similarity 27.7%; Pred. No. 2.5e-11;
Matches 104; Conservative 60; Mismatches 145; Indels 66; Gaps 14;

QY 66 LSEVPOGIPSN--TRYLNLMENNIQIQADTRHLHLEVLQGRNSIRQTEVGAFNGL 122
DB 112 LEALPEGLFOHLAALESHLQGNQQLPRLPQPLTHLKTLMAGNLQAQPEELFHL 171
QY 123 ASLMTLEFDNLWLPVPSGAFYLSKRLRLWLNPNPIESIPYAFNRVPSLMRLDGLK 182
DB 172 TSLQTKLSNNALSGLPGVFGKLSGLQELFLDSNNISBELPPQVPSQLPCLERLWL-QRN 230
QY 183 KLEVISSEGAEGFLNLYNLGNKIKMP-----NLTP-LVGLLEELMSGNHFFPIRQS 237
DB 231 AITHPLISFASGNLTFELSLQWMLRVLPAGLFAHTPCLVG---LSLTHNQLETVTGT 287
QY 238 FHGLSSLLKLVWVNSQSLIERNAFDGLASVLELNLAHNLSSPLDLPTRLYRVLHLL 297
DB 288 FAHLSNLSRLSMLSYNAITHLPGAFIDLEELVLYLGSNNLTALHPALFQNLKLELSL 347
QY 298 HNN-----PNCDCDILWLAWVREVIPTNSTCCG-----RCHAP 332
DB 348 SKNQLATLPEASPTTTCSTWCTVTPGSATAPGLPLQAAVAHRSAPHEPDLRLC--P 405
QY 333 MNRVG-----RYLVEV--DQASFOCSAPFTMDAPR-----DLNISGRMAELKCRTP 377
DB 406 AYLKGQVYHALNEKQLVSVTRDLHLGQVTPW---DESKAGGWDLAQVQ-RAARSQC--- 458
QY 378 PMSVSKWLLNGTVL 392
DB 459 -----TYSNPEGTIV 468

RESULT 45
TIR3_HUMAN STANDARD; PRT; 904 AA.
AC O15455;
DT 28-FEB-2003 (Rel. 41, Created);
DT 28-FEB-2003 (Rel. 41, Last sequence update);
DE 28-FEB-2003 (Rel. 41, Last annotation update);
GN Toll-like receptor 3 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1];
RP SEQUENCE FROM N.A.
RX MEDLINE=98118556; PubMed=9435236;
RA Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F.;
RT "A family of human receptors structurally related to Drosophila
RT Toll.";
RL Proc. Natl. Acad. Sci. U.S.A. 95:588-593 (1998).
CC -I- FUNCTION: Participates in the innate immune response to microbial
CC agents. May be involved in the recognition of ds-RNA. Acts via
CC MyD88 and IRA6, leading to NF-kappa-B activation, cytokine
CC secretion and the inflammatory response (By similarity).
CC -I- SUBUNIT: Binds MyD88 via their respective TIR domains (By
```

```
similarity).
CC -I- SUBCELLULAR LOCATION: Type I membrane protein (By similarity).
CC -I- TISSUE SPECIFICITY: Expressed at high level in placenta and
CC pancreas. Also detected in CD11c+ immature dendritic cells.
CC Only expressed in dendritic cells and not in other leukocytes,
CC including monocyte precursors.
CC -I- SIMILARITY: BELONGS TO THE TOLL-LIKE RECEPTOR FAMILY.
CC -I- SIMILARITY: Contains 1 TIR domain.
CC -I- SIMILARITY: Contains 22 leucine-rich (LRR) repeats.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC EMBL; U88879; AAC34134.1; --
CC Genew: HGNC:11849; TLR3.
CC MIM: 603029;
CC GO: GO:0005897; C: integral to plasma membrane; TAS.
CC GO: GO:0003797; F: antibacterial peptide activity; TAS.
CC GO: GO:0003793; F: defense/immunity protein activity; NAS.
CC GO: GO:0003725; F: double-stranded RNA binding activity; NAS.
CC GO: GO:0004888; F: transmembrane receptor activity; NAS.
CC GO: GO:0007250; P: activation of NF-kappaB-inducing kinase; NAS.
CC GO: GO:0006955; P: immune response; TAS.
CC GO: GO:0045671; P: negative regulation of osteoclast different. . .; NAS.
CC GO: GO:0009597; P: perception of viruses; NAS.
CC GO: GO:0045359; P: positive regulation of interferon-beta bios. . .; IMP.
CC GO: GO:0007165; P: signal transduction; TAS.
CC InterPro: IPR001611; LRR.
CC InterPro: IPR000483; LRR_Cterm.
CC InterPro: IPR000372; LRR_Nterm.
CC InterPro: IPR003591; LRR_Typ.
CC InterPro: IPR000157; TIR_domain.
CC Pfam: PF00560; LRR; 15.
CC Pfam: PF01463; LRRCT; 1.
CC PRINTS: PR00019; LEURICRPT.
CC SMART: SM00369; LRR_Typ; 2.
CC SMART: SM00082; LRRCT; 1.
CC SMART: SM00013; LRRNT; 1.
CC SMART: SM00255; TIR; 1.
CC PROSITE: PS50104; TIR; 1.
KW Receptor; Immune response; Inflammatory response; Signal;
KW Transmembrane; Repeat; Leucine-rich repeat; Glycoprotein.
KW SIGNAL 1 21
FT CHAIN 22 904
FT DOMAIN 22 704
FT TRANSMEM 705 725
FT DOMAIN 726 904
FT REPEAT 50 73
FT REPEAT 75 97
FT REPEAT 98 121
FT REPEAT 123 145
FT REPEAT 147 169
FT REPEAT 170 193
FT REPEAT 196 219
FT REPEAT 247 270
FT REPEAT 273 296
FT REPEAT 298 320
FT REPEAT 354 377
FT REPEAT 379 403
FT REPEAT 406 429
FT REPEAT 431 454
FT REPEAT 455 478
FT REPEAT 480 504
FT REPEAT 505 528
FT REPEAT 530 552
FT REPEAT 561 584
FT REPEAT 586 608
FT TOLL-LIKE RECEPTOR 3.
FT EXTRACELLULAR (POTENTIAL).
FT CYTOPLASMIC (POTENTIAL).
FT LRR 1.
FT LRR 2.
FT LRR 3.
FT LRR 4.
FT LRR 5.
FT LRR 6.
FT LRR 7.
FT LRR 8.
FT LRR 9.
FT LRR 10.
FT LRR 11.
FT LRR 12.
FT LRR 13.
FT LRR 14.
FT LRR 15.
FT LRR 16.
FT LRR 17.
FT LRR 18.
FT LRR 19.
FT LRR 20.
```

FT	REPEAT	610	632	LRR 21.	
FT	REPEAT	634	659	LRR 22.	
FT	DOMAIN	754	896	TIR.	
FT	CARBOHYD	52	52	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	57	57	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	70	70	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	124	124	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	196	196	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	247	247	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	252	252	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	265	265	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	275	275	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	291	291	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	398	398	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	413	413	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	507	507	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	636	636	N-LINKED (GLCNAC. .)	(POTENTIAL).
FT	CARBOHYD	662	662	N-LINKED (GLCNAC. .)	(POTENTIAL).
3Q	SEQUENCE	904 AA;	103828 MW;	034E05ECA7A4D2F7	CRC64;
Query Match					
Best Local Similarity		7.8%; Score 267;		DB 1; Length 904;	
Matches 101; Conservative		48; Mismatches 146;		Indels 32; Gaps 12;	
2Y	51	SCSNQFSKVVC-----	TRRGLSEVPGQIPSNTRYMLMENNIMQIADTFRLHLEVLQ	106	
3B	385	SLNSFTSLRTLNETFVSLAHSPLHI-----	LNLTKNKISKIESDAFSLGHLVLDL	438	
2Y	107	GRNSIQIIEVG-AFNGASLNTLELFONLTVIPSGAFYLSKLRLMLN-----	NPIESI	162	
3B	439	GLNIGELTQEWGRLNENFEIYLSYKYLQTRNSFALVPSLQRLMLRVALKNVDS	498		
2Y	163	PSYAFNRVPSLRMLDLGELKLEYISEGAFGLFNLYMLGMCNIDKM-----	PN----	213	
3B	499	PS-PPQPLRLNLTILDSN-NNIANINDMLEGLEKLBILDQHNLRARLWKEANPGPIY	556		
2Y	214	-LTLVGLGLEELMSGNHFFHPIRPGSFLGLSLKLLWVNSQVSLIERNAPDGLASLVELN	272		
3B	557	FLKGLSHLHILNLSNGFDEIPVVFQDLPKLDIIDLGLNMLNLTLPASVFNQVSLKSLN	616		
2Y	273	LAHNNLSLPHDLFTPL-LRYLVELLHLHNPNWDCD-ILALWKLRE----	YIPNSTCCG	327	
3B	617	LQKNLITSVEKKVGPAPRNLTELDMEFNPFDCESIANFVWVWINTHTNIPELSSHY-	675		
2Y	328	RCHAPMGRVYLVVEVQASQCSAPP	354		
3B	676	LCNTPPHYHGFVRLFTSTSCCKDSAPP	702		
RESULT 46					
XD	OMD_RAT	STANDARD;	PRT;	423 AA.	
AC	Q92IS7;				
YT	28-FEB-2003 (Rel. 41, Created)				
YT	28-FEB-2003 (Rel. 41, Last sequence update)				
YT	28-FEB-2003 (Rel. 41, Last annotation update)				
YE	Osteomodulin precursor (Osteoadherin) (OSAD) (Keratan sulfate				
YE	proteoglycan osteomodulin) (KSPG osteomodulin).				
AN	OMD.				
YS	Rattus norvegicus [Rat].				
YC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
YC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.				
YX	NCBI_TaxID=10116;				
YN	[1]				
YC	SEQUENCE FROM N.A.				
YC	TISSUE=Calvaria;				
XA	MEDLINE=20076689; PubMed=10607915;				
XA	Shen Z., Gantcheva S., Sommarin Y., Heinigaard D.;				
XT	"Tissue distribution of a novel cell binding protein, osteoadherin, in				
XT	the rat.";				
UL	Matrix Biol. 18:533-542(1999).				
XC	FUNCTION: May be implicated in biomineralization processes. Has a				
XC	function in binding of osteoblasts via the alpha(V)beta(3)-				

CC	integrin.				
CC	-!- SUBUNIT: Binds the alpha(V)beta(3)-integrin.				
CC	-!- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By				
CC	similarity).				
CC	-!- TISSUE SPECIFICITY: Osteoblast and odontoblast. Expressed in				
CC	femoral bone and calvaria tissues. Detected in femoral head, rib,				
CC	tendon and bone marrow.				
CC	-!- DEVELOPMENTAL STAGE: In developing molars, it was first detected				
CC	in alveolar bone in 19-day-old embryos. In more mature teeth				
CC	(newborn and 2-day-old rats), the expression starts in the				
CC	polarized odontoblasts and increases in the secretory and mature				
CC	odontoblasts.				
CC	-!- PTM: Binds keratan sulfate chains.				
CC	-!- PTM: Sulfated on tyrosine residue(s) (By similarity).				
CC	-!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN				
CC	(SRP) FAMILY. CLASS II SUBFAMILY.				
CC	-!- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.				
CC	-----				
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration				
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -				
CC	the European Bioinformatics Institute. There are no restrictions on its				
CC	use by non-profit institutions as long as its content is in no way				
CC	modified and this statement is not removed. Usage by and for commercial				
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/				
CC	or send an email to license@isb-sib.ch).				
CC	-----				
DR	EMBL; AF104362; AAD04570.1; --				
DR	InterPro; IPR001611; LRR.				
DR	InterPro; IPR000372; LRR_Nterm.				
DR	InterPro; IPR003591; LRR_Typ.				
DR	Pfam; PF00560; LRR; 9.				
DR	Pfam; PF01462; LRRNT; 1.				
DR	SMART; SM00013; LRRNT; 1.				
KW	Cell adhesion; Glycoprotein; Extracellular matrix; Proteoglycan;				
FT	Repeat; Leucine-rich repeat; Signal; Sulfation.				
FT	SIGNAL	1	20		
FT	CHAIN	21	423		
FT	REPEAT	84	103		
FT	REPEAT	104	127		
FT	REPEAT	128	153		
FT	REPEAT	154	174		
FT	REPEAT	175	198		
FT	REPEAT	199	224		
FT	REPEAT	225	245		
FT	REPEAT	246	269		
FT	REPEAT	270	292		
FT	REPEAT	293	312		
FT	REPEAT	313	342		
FT	REPEAT	343	367		
FT	DOMAIN	385	407		
FT	DISULFID	321	353		
FT	MOD RES	25	25		
FT	MOD RES	31	31		
FT	MOD RES	39	39		
FT	CARBOHYD	113	113		
FT	CARBOHYD	121	121		
FT	CARBOHYD	187	187		
FT	CARBOHYD	242	242		
FT	CARBOHYD	278	278		
FT	CARBOHYD	316	316		
SQ	SEQUENCE	423 AA;	49783 MW;	587D679FD9482B9F	CRC64;
Query Match					
Best Local Similarity		7.7%; Score 263.5;		DB 1; Length 423;	
Matches 83;		Conservative 47;		Mismatches 100;	
				Indels 57; Gaps 12;	
QY	46	CPSVCSNQF-SKVVCTRGSLSEVPGIPSNTRYMLMENNIMQIADTFRLHLEVL	104		
DB	62	CAKSCPCPTNPTSMYCDNRKLTIPD-IPVHQLQNLQFNQFNIEAVTADSFNATLKEI	120		
QY	105	QLGNSTR--QIEVGAFNGLASLNTLELFONLTVIPSGAFYLSKLRLMLNPIESI	162		
DB	121	NLSNKKIKSQIDYGVFAKLSNQLQHLNHNLEFPF---FPLPKSLERLLGNYEISTL	177		

QY 163 PSVAFNRPVPSIMDLGSLKKLYISGAFEG--LPNL-KYNLGMCH--IKDMNLTPL 217
 Db 178 PTHAGDLVNVTLWL-----CYNHLSDSLTKLKLKLAQNLNNRLESMPGLPL 233
 QY 218 VGLEEELMSGNHPEFRPGSFHGLSSIKLVNNSOVSIERNAPDGLASLVELLAHN 277
 Db 234 -----SLMVLSENNISSIPEDYQKPLKHALAISHNK 268
 QY 278 LSSLPDLFTPLRYLVELLHHPNWCDCDILMAWLR--YIPFN 322
 Db 269 LEDIPYDIFN-LSNLIELNVGHK-----LKQAFYIPRN 301

RESULT 47
 PGSI_MOUSE
 ID PGSI_MOUSE STANDARD; PRT; 369 AA.
 AC P28653; Q61355;
 DT 01-DEC-1992 (Rel. 24, Created)
 DT 01-DEC-1992 (Rel. 24, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Biglycan precursor (Bone/cartilage proteoglycan I) (PG-S1).
 GN BGN.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NH Swiss; TISSUE=Fibroblast;
 RA Naïton Y., Suzuki S.;
 RL Submitted (JULY 1990) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NH Swiss; TISSUE=Embryo;
 RX MEDLINE=94319093; PubMed=8043960;
 RA Rau W., Just W., Vetter U., Vogel W.;
 RT "A dinucleotide repeat in the mouse biglycan gene (EST) on the X
 chromosome.";
 RL Mamm. Genome 5:395-396(1994).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Breast, and Kidney;
 RX MEDLINE=22388257; PubMed12477932;
 RA Krausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldi M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Teshigahara S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahy J., Helton E., Kettaman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinska M.I., Skalska U., Smalhus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length
 human and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [4]
 RP SEQUENCE OF 11-152 FROM N.A.
 RC STRAIN=C57BL/6;
 RX MEDLINE=21210929; PubMed=11311118;
 RA Saeemaarten A.-M.K., Salminen H.J., Rantakokko A.J., Heinigaard D.,
 RA Vuorio E.;
 RT "Murine fibromodulin: cDNA and genomic structure, and age-related
 expression and distribution in the knee joint.";
 RL Biochem. J. 355:577-585(2001).

CC -!- FUNCTION: May be involved in collagen fiber assembly (By
 CC similarity).
 CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
 CC similarity).
 CC -!- TISSUE SPECIFICITY: Found in several connective tissues, specially
 CC in articular cartilages.
 CC -!- PTM: The two attached glycosaminoglycan chains can be either
 CC chondroitin sulfate or dermatan sulfate (By similarity).
 CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
 CC (SLRP) FAMILY. CLASS I SUBFAMILY.
 CC -!- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL; X53928; CAA37875.1; -;
 CC EMBL; L20276; AAA64360.1; -;
 CC EMBL; BC005452; AAH05452.1; -;
 CC EMBL; BC019502; AAH19502.1; -;
 CC EMBL; Y11758; CAA72422.1; -;
 CC PIR; S20811; S20811.
 CC M3D; MGI:88158; Bgn.
 CC InterPro; IPR001611; LRR.
 CC InterPro; IPR000372; LRR Nterm.
 CC InterPro; IPR003591; LRR Typ.
 CC Pfam; PF00560; LRR; 9.
 CC Pfam; PF01462; LRRNT; 1.
 CC SMART; SM00013; LRRNT; 1.
 CC Glycoprotein; Extracellular matrix; Proteoglycan; Repeat;
 CC Leucine-rich repeat; Signal. POTENTIAL.
 CC SIGNAL 1 19
 CC PROPEP 20 37
 CC CHAIN 38 369
 CC DOMAIN 64 77
 CC REPEAT 83 103
 CC REPEAT 104 127
 CC REPEAT 128 151
 CC REPEAT 152 172
 CC REPEAT 173 196
 CC REPEAT 197 221
 CC REPEAT 222 242
 CC REPEAT 243 265
 CC REPEAT 267 290
 CC REPEAT 291 313
 CC REPEAT 314 343
 CC REPEAT 344 369
 CC CARBOHYD 42 42
 CC
 CC CARBOHYD 48 48
 CC
 CC CARBOHYD 271 271
 CC CARBOHYD 312 312
 CC DISULFID 64 77
 CC DISULFID 322 355
 CC CONFLICT 68 68
 CC SEQUENCES 369 AA; 41639 MW; 4B57FCC9A1026B6 CRC64;
 SQ
 Query Match 7.6%; Score 262.5; DB 1; Length 369;
 Best Local Similarity 31.9%; Pred. No. 3.2e-11;
 Matches 82; Conservative 40; Mismatches 124; Indels 11; Gaps 7;
 QY 46 CPSCVCSNQFSKVCTRRGLSEVPGQIPSNTRYLNLMENNIMQIQTDFRHLHLVQLQ 105
 Db 64 CPFGCHC--HLRVQCSDLGKTVPKRISPTTLLDQNNDISLRKDDFKGLQHLVAV 121
 QY 106 LGHNSITROIEVGAENGSLASLTLEFDNWLTVIPSGAFEYLSKFLRLNPNPIESIFS 165
 Db 122 LVNKLISKIHEKAPSLPKLQKLYISKKHLVEIPP---NLPSSELVELIHDNRIRKVPKG 178

QY 166 AFNRVPSLRMLDLGELKKLEY--ISEGAFEGFLNLYNLGNCNKMNPNTPLVGLBEL 223
 DB 179 VFSGLRNMCIEGG-NPLENSGFGPAGDGL-KLYLRISSEAKLTGPKDLPET-LNEL 235
 QY 224 ENSGNHFPPIRPGSFHGLSSKLLKWMNSQVSLIERNADFGLASLVELNLAHNLSLPH 283
 DB 236 HLDHNKIQAIIELELDLRYSKLYRLGHLGHQIRMIENGSLSLFTLRHLHLDNKLRSVPA 295
 QY 284 DLFTPLRYLYVELHLHN 300
 DB 296 GL-PDLKLLQVYVLESN 311

RESULT 48
 PGSI_RAT STANDARD; PRT; 369 AA.
 AC P47853;
 DT 01-FEB-1996 (Rel. 33, Created)
 DT 28-FEB-2003 (Rel. 33, Last sequence update)
 DE Biglycan precursor (Bone/cartilage proteoglycan I) (PG-SI).
 GN BGN.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Vascular smooth muscle;
 RX MEDLINE=91184222; PubMed=2081545;
 RA Dreher K.L., Asundi V.K., Matzura D., Cowan K.;
 RT "Vascular smooth muscle biglycan represents a highly conserved
 proteoglycan within the arterial wall.";
 RL Eur. J. Cell Biol. 53:295-304(1990).
 CC -!- FUNCTION: May be involved in collagen fiber assembly (By
 similarity).
 CC -!- SUBUNIT: Forms a ternary complex with WFAP2 and BLN (By
 similarity).
 CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
 similarity).
 CC -!- TISSUE SPECIFICITY: Found in several connective tissues, specially
 in articular cartilages.
 CC -!- PTM: The two attached glycosaminoglycan chains can be either
 chondroitin sulfate or dermatan sulfate (By similarity).
 CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
 (SLRP) FAMILY. CLASS I SUBFAMILY.
 CC -!- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by not-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 or send an email to license@isb-sib.ch).
 CC
 CC EMBL: U17834; AAA58797.1; --
 DR PIR: S32793; S32793.
 DR InterPro: IPR001611; LRR.
 DR InterPro: IPR000372; LRR Nterm.
 DR InterPro: IPR003591; LRR typ.
 DR Pfam: PF00560; LRR; 9.
 DR Pfam: PF01462; LRRNT; 1.
 DR SMART: SM00013; LRRNT; 1.
 KW Glycoprotein; Extracellular matrix; Proteoglycan; Repeat;
 KW Leucine-rich repeat; Signal.
 FT SIGNAL 1 19 POTENTIAL.
 FT PROPEP 20 37
 FT CHAIN 38 369 BIGLYCAN.
 FT DOMAIN 64 77 CIS-RICH.
 FT REPEAT 83 103 LRR-S 1.
 FT REPEAT 104 127 LRR-T 1.
 FT

FT REPEAT 128 151 LRR-T 2.
 FT REPEAT 152 172 LRR-S 2.
 FT REPEAT 173 196 LRR-T 3.
 FT REPEAT 197 221 LRR-T 4.
 FT REPEAT 222 242 LRR-S 3.
 FT REPEAT 243 266 LRR-T 5.
 FT REPEAT 267 290 LRR-T 6.
 FT REPEAT 291 313 LRR-S 4.
 FT REPEAT 314 343 LRR-T 7.
 FT REPEAT 344 369 LRR-T 8.
 FT CARBOHYD 42 42 O-LINKED (GLYCOSAMINOGLYCAN) (BY
 SIMILARITY).
 FT CARBOHYD 48 48 O-LINKED (GLYCOSAMINOGLYCAN) (BY
 SIMILARITY).
 FT CARBOHYD 271 271 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT CARBOHYD 312 312 N-LINKED (GLCNAC. .) (POTENTIAL).
 FT DISULFID 64 77 BY SIMILARITY.
 FT DISULFID 322 355 BY SIMILARITY.
 SQ SEQUENCE 369 AA; 41706 MW; 319DC15117FC604 CRC64;
 Query Match 7.6%; Score 262.5; DB 1; Length 369;
 Best Local Similarity 31.9%; Pred. No. 3.2e-11;
 Matches 82; Conservative 40; Mismatches 124; Indels 11; Gaps 7;
 QY 46 CPVSQCSNQFSKVVCTRGSEVPGGIPSNTRYLNLMNNIOMIQADTFRLHHLVYLQ 105
 DB 64 CPGGCHC--HLRVQCSDLGLKTVPKBISPDITLDLQNNDISELRKDDFKGLQHLVALV 121
 QY 106 LGRNSIRQIEVCAGFNGLASLNTLELFDNMLTVIPSGAFYLSKLPRLWLRNPNIESIPSY 165
 DB 122 LVNNKISKIHEKAFSPRLKQKLYISKHNLVEIIP---NLPSLVELHIDNRIRKKVPRG 178
 QY 166 AFNRVPSLRMLDLGELKKLEY--ISEGAFEGFLNLYNLGNCNKMNPNTPLVGLBEL 223
 DB 179 VFSGLRNMCIEGG-NPLENSGFGPAGDGL-KLYLRISSEAKLTGPKDLPET-LNEL 235
 QY 224 ENSGNHFPPIRPGSFHGLSSKLLKWMNSQVSLIERNADFGLASLVELNLAHNLSLPH 283
 DB 236 HLDHNKIQAIIELELDLRYSKLYRLGHLGHQIRMIENGSLSLFTLRHLHLDNKLRSVPA 295
 QY 284 DLFTPLRYLYVELHLHN 300
 DB 296 GL-PDLKLLQVYVLESN 311

RESULT 49
 TLR7_HUMAN STANDARD; PRT; 1049 AA.
 ID TLR7_HUMAN
 AC Q9NVK1; Q9NRP8;
 DT 28-FEB-2003 (Rel. 41, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 15-SEP-2003 (Rel. 42, Last annotation update)
 DE Toll-like receptor 7 precursor.
 GN TLR7.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RN SEQUENCE FROM N.A.
 RP TISSUE=Placenta;
 RC MEDLINE=20477806; PubMed=11022119;
 RA Du X., Poltorak A., Wei Y., Beutler B.;
 RT "Three novel mammalian Toll-like receptors: gene structure,
 expression, and evolution.";
 RL Eur. Cytokine Netw. 11:362-371(2000).
 RN [2]
 RN SEQUENCE FROM N.A.
 RP TISSUE=Placenta;
 RX MEDLINE=20477807; PubMed=11022120;
 RA Chuang T.-H., Ulevitch R.J.;
 RT "Cloning and characterization of a sub-family of human Toll-like
 receptors: hTLR7, hTLR8 and hTLR9.";

Query Match	7.68; Score 262; DB 1; Length 1049;
Best Local Similarity 23.7%; Pred. No. 1.4e-10;	
Matches 117; Conservative 66; Mismatches 151; Indels 160; Gaps 19;	
QY 80 LNLMMNTMIQADTFRHLHLEVLQIGRNSRQIEVGA-FNGLASLNTLELFDNMLTVI 138	
498 LQLSKNSIFVKKSSDFQHLSCFLNLSGNLSQTLNGSEFQPLAELRYLDFSNRLDLL 557	
QY 139 PSGRFVLSK-----LBELWRNPNP----- 159	
558 HSTAFEEHLKLEVLDISSNSHYFSQSGEITHMLNFTKXVLQKLMNNDSSSTRTME 617	
QY 160 -ESAPSYAF-----NRVPSLMR--LDLCEL-----KCLEYISEGAFGL-FNL 198	
618 SESARTLEFRGNHLDVLWRGDNRYQLQFNLLKLEELDLSKNSLSFLPSGVDFGMPNL 677	
QY 199 KYNLGMCNFKDM--FNLTPVLGLELNSGNHFFPIRPGSPHGLSSLKGLWANSQVSL 256	
678 KNLGLAKNGKLSFSWKQLQCLKLETLDLSHNQLTTPVERLSNCSRSUKNLIENKNOIRS 737	
QY 257 IERNAFDLASLYELNAHNL-----SSLPHDLFTPLRYLVELLHHPNWCDCDILWL 311	
738 LTKYFLODAQLRYLDISSNKIQMTQKTFPENVLNLLKML---LHNRRFLCTCDVWP 794	
QY 312 AWWLRE-----YIPNTSCCGCHAPMEMRGYLVFVVDQASFQ----- 349	
795 VWMYNTFTVPIATDVTCV-----PGAHKQGVISLDTYCELDLNLFLSLISVS 850	

QY 350 -----CSAPPMDAPRDLNISEGRMA 370
 DB 851 LFLVMYMTASHLYPFDWVYIYHFKAKIKGYORLISPDCCYDADIVYDTKDPVATWVLA 910
 QY 371 EL--KCRTPP-----MSSVKWLLPNTGLVSHASRPRIS-----VLND---GTLNPF-- 411
 DB 911 ELVAKLEPREKHFNLCLEERDQ-LPGQVLENLSQISQISKTVFVWTDKYAKTENFKI 969
 QY 412 ----SHVLISDTGV 421
 DB 970 AFYLSHORLMDKV 983
 RESULT 50
 XCSI_HUMAN
 ID PGSI_HUMAN STANDARD; PRT; 368 AA.
 AC 21810; P13247;
 XT 01-JAN-1990 (Rel. 13, Created)
 XT 01-APR-1993 (Rel. 25, Last sequence update)
 XT 15-SEP-2003 (Rel. 42, Last annotation update)
 XE Biglycan precursor (Bone/cartilage proteoglycan I) (PG-S1).
 XN BGN.
 XS Homo sapiens (Human).
 XC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 XC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 XX NCBI_taxID=9606;
 [1]
 XP SEQUENCE FROM N.A.
 XC TISSUE=Bone;
 XA MEDLINE=99174714; PubMed=2647739;
 XA Fisher L.W., Termino J.D., Young M.F.;
 XT "Deduced protein sequence of bone small proteoglycan I (biglycan)
 XT shows homology with proteoglycan II (decorin) and several
 XT nonconnective tissue proteins in a variety of species.";
 XT J. Biol. Chem. 264:4571-4576(1989).
 [2]
 XN SEQUENCE FROM N.A.
 XP MEDLINE=91317791; PubMed=1860845;
 XA Fisher L.W., Heegaard A.M., Vetter U., Vogel W., Just W.,
 XA Termino J.D., Young M.F.;
 XT "Human biglycan gene. Putative promoter, intron-exon junctions, and
 XT chromosomal localization.";
 XT J. Biol. Chem. 266:14371-14377(1991).
 [3]
 XN SEQUENCE FROM N.A.
 XP MEDLINE=20314869; PubMed=10854409;
 XA Mallon A.M., Platzer M., Bates R., Gloeckner G., Botcherby M.,
 XA Nordstrek G., Strivens M.A., Kioschis P., Dangel A., Cunningham D.,
 XA Stray K., Weston P., Hunter C., Gilbert M., Fernando S., Goodall K.,
 XA Kerry G., Greystrong J.S., Clark D., Goerdes M., Blechechmidt K.,
 XA Rump A., Hinzmann S., Mundy C.R., Miller W., Poustka A., Herman G.E.,
 XA Rhodes M., Denny P., Rosenthal A., Brown S.D.M.;
 XT "Comparative genome sequence analysis of the Bpa/Str region in mouse
 XT and man.";
 XT Genome Res. 10:758-775(2000).
 [4]
 XN SEQUENCE FROM N.A.
 XP TISSUE=Brain;
 XC MEDLINE=22388257; PubMed=12477932;
 XA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 XA Klausner R.D., Collins P.S., Wagner L., Shenmen C.M., Schuler G.D.,
 XA Altschul S.E., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 XA Hopkins R.F., Jordan H., Moore T., Max S.L., Wang J., Hsieh F.,
 XA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 XA Skapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 XA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
 XA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,
 XA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 XA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 XA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 XA Feany J., Heiton M., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
 XA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 XA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,

RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,
 RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length
 RT human and mouse cDNA sequences.";
 RT Proc. Natl. Acad. Sci. U.S.A. 99:16999-16903(2002).
 RN [5]
 RP SEQUENCE OF 38-57.
 RX MEDLINE=90073579; PubMed=2590169;
 RA Roughley P.J., White R.J.;
 RT "Dermatan sulphate proteoglycans of human articular cartilage. The
 RT properties of dermatan sulphate proteoglycans I and II.";
 RT Biochem. J. 262:823-827(1989).
 RN [6]
 RP SEQUENCE OF 38-66.
 RX MEDLINE=87250639; PubMed=3597437;
 RA Fisher L.W., Hawkins G.R., Tuross N., Termino J.D.;
 RT "Purification and partial characterization of small proteoglycans I
 RT and II, bone sialoproteins I and II, and osteonectin from the mineral
 RT compartment of developing human bone.";
 RT J. Biol. Chem. 262:9702-9708(1987).
 RN [7]
 RP SEQUENCE OF 361-368 FROM N.A.
 RC TISSUE=Skin;
 RX MEDLINE=95187185; PubMed=7881444;
 RA Just W., Rau W., Muller R., Geerkens C., Vogel W.;
 RT "Dinucleotide repeat polymorphism at the human biglycan (BGN)
 RT locus.";
 RL Hum. Mol. Genet. 3:2268-2268(1994).
 CC -!- FUNCTION: May be involved in collagen fiber assembly (By
 CC similarity).
 CC -!- SUBUNIT: Forms a ternary complex with MPAP2 and ELN (By
 CC similarity).
 CC -!- SUBCELLULAR LOCATION: Secreted; extracellular matrix (By
 CC similarity).
 CC -!- TISSUE SPECIFICITY: Found in several connective tissues, specially
 CC in articular cartilages.
 CC -!- PTM: The two attached glycosaminoglycan chains can be either
 CC chondroitin sulfate or dermatan sulfate (By similarity).
 CC -!- SIMILARITY: BELONGS TO THE SMALL LEUCINE-RICH PROTEOGLYCAN
 CC (SRP) FAMILY. CLASS I SUBFAMILY.
 CC -!- SIMILARITY: Contains 12 leucine-rich (LRR) repeats.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; J04599; AAA36009.1; -;
 DR EMBL; M65153; AAA52287.1; ALT SEQ.
 DR EMBL; M65152; AAA52287.1; JOINED.
 DR EMBL; U82695; -; NOT_ANNOTATED_CDS.
 DR EMBL; BC002416; AAH02416.1; -;
 DR EMBL; BC004244; AAH04244.1; -;
 DR EMBL; U11686; AAC50117.1; -;
 DR PIR; A40757; BGHUN.
 DR Gene; HGNC:1044; BGN.
 DR MIM; 301870; -;
 DR GO; GO:0005778; C:extracellular matrix; NAS.
 DR GO; GO:0005201; F:extracellular matrix structural constituent; NAS.
 DR InterPro; IPR001611; LRR.
 DR InterPro; IPR000372; LRR_Nterm.
 DR InterPro; IPR003591; LRR_typ.
 DR Pfam; PF00560; LRR; 9
 DR Pfam; PF01482; LRRNT; 1.
 DR SMART; SM00013; LRRNT; 1.
 DR GlycoProtein; Extracellular matrix; Proteoglycan; Repeat;
 KW Leucine-rich repeat; Signal.
 FT SIGNAL 1 19 POTENTIAL.
 FT PROPEP 20 37

```

FT CHAIN 38 368 BIGLYCAN.
FT DOMAIN 63 76 CYS-RICH.
FT REPEAT 82 102 LRR-S 1.
FT REPEAT 103 126 LRR-T 1.
FT REPEAT 127 150 LRR-T 2.
FT REPEAT 151 171 LRR-S 2.
FT REPEAT 172 195 LRR-T 3.
FT REPEAT 196 220 LRR-T 4.
FT REPEAT 221 241 LRR-S 3.
FT REPEAT 242 265 LRR-T 5.
FT REPEAT 266 289 LRR-T 6.
FT REPEAT 290 312 LRR-S 4.
FT REPEAT 313 342 LRR-T 7.
FT REPEAT 343 368 LRR-T 8.
FT CARBOHYD 42 42 O-LINKED (GLYCOSAMINOGLYCAN).
FT CARBOHYD 47 47 O-LINKED (GLYCOSAMINOGLYCAN).
FT CARBOHYD 270 270 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 311 311 N-LINKED (GLCNAC. .) (POTENTIAL).
FT DISULFID 63 76 BY SIMILARITY.
FT DISULFID 321 354 BY SIMILARITY.
FT CONFLICT 139 140 KL -> NV (IN REF. 1).
FT CONFLICT 163 164 EL -> DV (IN REF. 1).
SQ SEQUENCE 368 AA; 41654 MW; BF16F304C5CD3B3E CRC64;

Query Match 7.6%; Score 261.5; DB 1; Length 368;
Best Local Similarity 31.5%; Pred No 3.7e-11;
Matches 31; Conservative 41; Mismatches 124; Indels 11; Gaps 7;

QY 46 CPSCVCSNQFSKVCTRGLEVPQGPISNRYLNMENNIMQADTFRLHLEVLQ 105
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
63 CPFGCHC--HLRVQCSDLGKSVKPEISPTDLDLQNNDISELRKDDFKGLQLYALV 120
QY 106 LGENSIROIEVGAFNGLASINTLEFDNLTWIPSCAFEYLSKLELRLNPNIESIPSY 165
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
121 LVNKKISKEHKAFFSPRLKQLKYISKHLEIPP---NLPSSLVELRIHNRIRKVPKG 177
QY 166 AFNRVPSLRLDLGLKLELEY--ISEGAFEGFLNKLNLGMCNIKMPNLTPLVGLLEL 223
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
178 VFGSLRNWNCIENG-G-NPLENSGFEPGADGL-KLNYLRISSEAKLTGIPKDLPET-LNEL 234
QY 224 EMSGNHFPPIRPGSFGLSSLKXKLVWNSQVSLIERNAPDGLASLVELNLAHNLSLPH 283
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
235 HLDHNKIQAIELEDLRYSKLYALGIGHNQIRMIENGSLSLFTLRELHLDNNKLARVPS 294
QY 284 DLFTPLRYLVELLHNN 300
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
295 GL-PDLKLLQVYVLSN 310

```

Search completed: February 5, 2004, 15:49:33
 Job time : 23 secs